<?xml version="1.0" encoding="utf-8"?>
<documents>
  <document>
    <id>328405</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328405]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Commentary on Carbohydrates in Type 2 Diabetes</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,RESEARCH,NUTRITION AND FOOD,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Commentary on Carbohydrates in Type 2 Diabetes&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This commentary on Carbohydrates in Type 2 Diabetes has been written for NHS Evidence - diabetes by Lindsay Oliver, Consultant Dietitian for Northumbria Healthcare Trust and Chair of the &lt;A href="http://www.dmeg.org.uk/" target="_blank"&gt;Diabetes Management and Education Group&lt;/A&gt;, part of the British Dietetic Association.&amp;nbsp; Her commentary focuses on 5 selected references from the 14 citations found in the searches for the 2009 Annual Evidence Update on Diabetes.&amp;nbsp; &lt;A href="nelh:328202:0" name=internalLink&gt;Link here to the list of citations&lt;/A&gt;. &lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Advice about carbohydrate in diabetes has seen a number of ups and downs over the decades and remains an issue of great debate, particularly within type 2 diabetes. Current UK [1] and international guidelines [2] for diabetes state that 45-60% of calories should be derived from carbohydrate with the promotion of a higher proportion of carbohydrate at meals via models such as “The Eat Well Plate”. In addition the concept of the glycaemic index raises issues of quality versus quantity of carbohydrate. &lt;BR&gt;&amp;nbsp;&lt;BR&gt;Two recent meta- analyses [3,4] examined the impact of differing proportions of calories from total fat and carbohydrate on glycaemia and lipid profile. In these studies the total calorie intake and proportions of calories from saturated fat and protein were constant. Both noted no significant difference in glycaemic measures but lipid profile was significantly different. Cao and colleagues [3] compared moderate fat intakes (30-50% of calories from fat) to low fat intakes (18-30% of calories from fat). The lower fat, higher carbohydrate diets were however associated with deterioration in HDL and triglyceride levels. Kodama et al. [4] compared high fat low /carbohydrate diets (40%/40% of calories) with low fat/ high carbohydrate diets (24%/58% of calories) and also found that higher carbohydrate diets were&amp;nbsp; associated with deterioration in HDL and triglycerides as well as&amp;nbsp; fasting insulin levels. Where carbohydrate was replaced with monounsaturated fat, lipid profile improved more significantly highlighting the need to modify the quality of fat in the diet. However the negative effects of higher carbohydrate intake were ameliorated by calorie reduction and weight loss, implying that total calorie intake maybe singularly more important than the proportion of calories from carbohydrates or fat. In conclusion it would appear that controlling calorie intake and the quality of dietary fat appear to be more important than the proportion of fat and carbohydrate consumed.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Dyson [5] has undertaken a comprehensive review of low and reduced carbohydrate diets which she defines as low carbohydrate (&amp;lt; 50 g of carbohydrate) and reduced carbohydrate diets (lower than usual intake). There is however no common definition of these terms in research leading to significant variation in carbohydrate intake in the interventions described. These studies demonstrate that low and reduced carbohydrate diets can promote significant weight loss, at least in the short term, and are associated with improvements in glycaemic control without deterioration in cardiovascular risk factors, renal function or nutritional intake. The impact on weight was completely driven by calorie reduction and interestingly demonstrated that the majority of weight loss was explained by a reduction in body fat rather than fluid loss. This adds to the body of evidence that emphasises on weight loss achieved by some sort of calorie deficit drives improvement in most risk factors for long term diabetes complications, and again suggests the promotion of higher carbohydrate diets may not be helpful for all individuals.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;The other hot topics in relation to carbohydrate are the glycaemic index (GI) and the glycaemic load, both of which can be described as ways of quantifying the impact of dietary carbohydrate on post prandial blood glucose. The ADA Nutritional guidelines [2] state that “with regard to the glycaemic effects of carbohydrate, the total amount of carbohydrate in a meal or snack is more important than the source or type”.&amp;nbsp; However a recent meta- analysis [6] demonstrated that lower GI diets can improve HbA1c by 0.5% but this is contradicted by an earlier studies [7] which shows a smaller benefit of 0.37%. Disappointingly little research has been conducted on glycaemic load, which is a relatively new concept that marries total carbohydrate with Glycaemic index. In practice GI maybe more about fine tuning than mainstay dietary advice.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;The debate will no doubt continue but in terms of up to date evidence based dietetic practice we should probably be promoting a more modest intake of carbohydrate and being less concerned with the proportion of calories from any one macronutrient. Perhaps instead we should be focusing more on total calorie load and as such being more open minded to all sorts of ways that people can achieve and maintain weight loss given that this still remains the holy grail of dietetic therapy in type 2 diabetes. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;1. Nutritional Sub Committee of the Diabetes Care advisory Committee of Diabetes UK. The implementation of nutritional advice for people with diabetes. Diabetic Medicine 2003; 20: 786-807. &lt;A href="http://www.diabetes.org.uk/Documents/Professionals/nutrition_guidelines.pdf" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;2. American Diabetes Association. Nutritional recommendations and interventions for diabetes. Diabetes Care 2008; 31: S61-78.&amp;nbsp;&amp;nbsp;&lt;A href="http://care.diabetesjournals.org/content/31/Supplement_1/S61.full" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;3. Cao Y, Mauger DT, Pelkman CL, Zhao G, Townsend SM, Kris-Etherton PM. Effects of moderate (MF) versus lower fat (LF) diets on lipids and lipoproteins: a meta-analysis of clinical trials in subjects with and without diabetes. Journal of Clinical Lipidology 2009; 3(1):19-32. &lt;A href="http://www.lipidjournal.com/article/S1933-2874(08)00972-0/abstract" target="_blank"&gt;Link to abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;4. Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Sato M et al. Influence of fat and carbohydrate proportions on the metabolic profile in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2009; 32(5):959-65. &lt;A href="http://care.diabetesjournals.org/content/32/5/959.full" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;5. Dyson PA. A review of low and reduced carbohydrate diets and weight loss in type 2 diabetes. Journal of Human Nutrition and Dietetics 2008; 21(6):530-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18759958" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;6. Thomas D, Elliott E J. Low glycaemic index, or low glycaemic load, diets for diabetes mellitus. Cochrane Database of Systematic Reviews 2009(1). &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006296/frame.html" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;7. Opperman AM, Venter CS, Oosthuizen W, Thompson RL, Vorster HH. Meta-analysis of the health effects of using the glycaemic index in meal-planning. British Journal of Nutrition 2004; 92(3):367-81. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12005009571" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328420</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328420]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Commentary on Diabetic Nephropathy</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,NEPHROPATHY,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,CAUSES,RESEARCH,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,PREDISPOSING FACTORS,DIABETES,INTERVENTIONS,DIABETIC METABOLIC CONTROL,ANNUAL EVIDENCE UPDATES,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Commentary on Diabetic Nephropathy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This commentary on Diabetic Nephropathy has been written for NHS Evidence - diabetes by Ed Sharples, Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford.&amp;nbsp; This commentary focuses on 2 selected references from the 4 citations found in the searches for the 2009 Annual Evidence Update on Diabetes and discusses a recent Cochrane review.&amp;nbsp; &lt;A href="nelh:328166:0" name=internalLink&gt;Link here to the list of citations&lt;/A&gt;. &lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Kidney disease develops in 25-40% of diabetic patients, usually 20-25 years after the onset of diabetes. Renal involvement is defined by the appearance of low but abnormal levels of albumin in the urine (30 – 300 mg/day). Microalbuminuria progresses to overt macroproteinuria. Approximately one third of these with diabetic kidney disease will progress to end-stage renal failure, and will require long-term dialysis or transplantation. &lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;U&gt;Role of hyperfiltration in risk and prediction of developing diabetic nephropathy&lt;/U&gt;&lt;BR&gt;Glomerular hyperfiltration is a well established phenomenon which occurs in some patients with diabetes and can predate the development of microalbuminuria. Animal studies show increased single nephron GFR following streptozotocin-induced diabetes [1]. 10 cohort studies including 780 patients were reviewed by Magee et al. [2]. After a median 11.2 years, 130 had developed nephropathy. Hyperfiltration was associated with a 2.71 (CI 1.2-6.1) odds ratio risk of progression to overt nephropathy. The funnel plot was asymmetrical, suggesting an element of publication bias. Further studies to confirm this association and the effect of management of hyperfiltration are required.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;U&gt;Anti-hypertensive agents for primary prevention of diabetic nephropathy&lt;/U&gt;&lt;BR&gt;The Cochrane group [3] reviewed the effects of different anti-hypertensive agents in patients with diabetes on prevention of diabetic nephropathy – encompassing prevention of microalbuminuria, progression to macroproteinuria. ACE inhibitors have been compared to placebo, calcium channel blockers (CCBs) and other agents. Data from 4 trials (1210 patients) showed that ACE inhibitors reduced the development of microalbuminuria when compared to placebo (3840 patients, RR 0.6) or CCBs (relative risk 0.58). All cause mortality and ESRD were not significantly different in these trials, and the meta-analysis is dominated by the micro-HOPE study, possibly because of competing risks of renal outcomes and overall survival. This highlights the use of change in proteinuria, rather than end-stage renal failure or mortality, which is only a surrogate marker of outcomes.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;U&gt;Angiotensin converting enzyme inhibitors and angiotensin II receptor antogonists for preventing the progression of diabetic kidney disease&lt;BR&gt;&lt;/U&gt;The Cochrane group [4] has also systematically reviewed the use of ACE inhibitors and angiotensin II receptor antagonists (ARBs) in the prevention of progressive kidney disease. 49 studies were identified, with seven studies comparing ACE and ARBs directly. There was no significant difference in the risk of all-cause mortality for ACEi versus placebo (RR 0.91, 95% 0.71-1.17) and ARBs versus placebo (RR 0.99, CI 0.85-1.17). Subgroup analysis showed a significant reduction in the risk of all-cause mortality when full dose ACEi regimes were compared to studies using half or less than half maximal tolerable doses of ACEi (RR 0.78, 95% CI .061-0.98), although there is no evidence that this benefit was related to baseline hypertension, type of diabetes or duration of treatment. There is strong evidence for the beneficial effect of ARBs on renal outcomes (22% reduction doubling creatinine or ESRF, 42% increased regression of proteinuria), without evidence of an effect on mortality. There were no significant differences between therapies when studies comparing ACEi and ARBs were reviewed, although the dataset is small.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;1. Hostetter TH, Troy JL and Brenner BM. Glomerular hemodynamics in experimental diabetes mellitus. Kidney International 1981; 19(3): 410-5. &lt;A href="http://www.nature.com/ki/journal/v19/n3/pdf/ki198133a.pdf" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;2. Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F and Fogarty DG. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 2009 Apr; 52(4): 691-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19198800" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&lt;BR&gt;3. Strippoli GF, Craig M, Schena FP, Craig JC. Antihypertensive agents for primary prevention of diabetic nephropathy. Journal of the American Society of Nephrology 2005; 16(10): 3081-3091. &lt;A href="http://jasn.asnjournals.org/cgi/content/full/16/10/3081" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;4. Strippoli GF, Bonifati C, Craig ME, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antoagonists for preventing the progression of diabetic kidney disease.&amp;nbsp; Cochrane Database of Systematic Reviews 2006, Issue 4. &lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006257/frame.html" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328166</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328166]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Complications</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,NEPHROPATHY,DIABETIC FOOT,PAINFUL NEUROPATHIES,SEXUAL DYSFUNCTION,SKIN PROBLEMS,CARDIOVASCULAR,KETOACIDOSIS,HYPOGLYCAEMIA,PSYCHOLOGICAL PROBLEMS,CHRONIC COMPLICATIONS,ACUTE COMPLICATIONS,DENTAL PROBLEMS,AUTONOMIC NEUROPATHY,RESEARCH,EYE DISEASES,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Complications&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp; 'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.phru.nhs.uk/Doc_Links/S.Reviews%20Appraisal%20Tool.pdf" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; ALL OR GENERAL&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Amini M, Parvaresh E. Prevalence of macro- and microvascular complications among patients with type 2 diabetes in Iran: a systematic review. Diabetes Research and Clinical Practice 2009; 83(1):18-25.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19091437" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes 2008; 32(suppl 1):S1-S201. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Delivery of Care, Education, Living with Diabetes, Treatments, Pregnancy and Gestational Diabetes.&lt;/SPAN&gt; &lt;A href="http://www.diabetes.ca/files/cpg2008/cpg-2008.pdf" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Lind M, Oden A, Fahlen M, Eliasson B. A systematic review of HbA1c variables used in the study of diabetic complications. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 2008; 2(4):282-93. &lt;A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B82Y0-4SPSPRN-1&amp;amp;_user=10&amp;amp;_rdoc=1&amp;amp;_fmt=&amp;amp;_orig=search&amp;amp;_sort=d&amp;amp;_docanchor=&amp;amp;view=c&amp;amp;_acct=C000050221&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=10&amp;amp;md5=48c35c08f4d0d6d5d8598f0f554df32d" target="_blank"&gt;Link to abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Naqshbandi M, Harris SB, Esler JG, Antwi-Nsiah F. Global complication rates of type 2 diabetes in Indigenous peoples: A comprehensive review. Diabetes Research and Clinical Practice 2008; 82(1):1-17. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18768236" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5599" target="_blank"&gt;Link to supporting guidelines on chronic complications&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5600" target="_blank"&gt;Link to supporting guidelines on acute complications &lt;/A&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 10pt" class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; CVD&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Boyden TF, Nallamothu BK, Moscucci M, Chan PS, Grossman PM, Tsai TT et al. Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus. American Journal of Cardiology 2007; 99(10):1399-402. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007002054" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG et al. The benefits of statins in people without established cardiovascular disease but&amp;nbsp; with cardiovascular risk factors: meta-analysis of randomised controlled trials. British Medical Journal 2009; 338:b2376. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009106232" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabetic Medicine 2009; 26(2):142-8. &lt;A href="http://www3.interscience.wiley.com/cgi-bin/fulltext/121567674/HTMLSTART" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Geng DF, Jin DM, Wu W, Wang Z, Wang JF. Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: a meta-analysis of randomized controlled trials. Atherosclerosis 2009; 202(2):521-8. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009102732" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Hartweg J, Farmer AJ, Holman RR, Neil A. Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes. Current Opinion in Lipidology 2009; 20 (1):30-8 . &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19133409" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Iijima R, Byrne RA, Dibra A, Ndrepepa G, Spaulding C, Laarman GJ et al. Drug-eluting stents versus bare-metal stents in diabetic patients with ST-segment elevation acute myocardial infarction: a pooled analysis of individual patient data from seven randomized trials. Revista Espanola De Cardiologia 2009; 62(4):354-64. &lt;A href="http://www.revespcardiol.org/cardio_eng/ctl_servlet?_f=60&amp;amp;ident=13136471" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Institute of Health Economics. Exercise testing for the prediction of cardiac events in patients with diabetes. Institute of Health Economics Report 2009. &lt;A href="http://www.ihe.ca/publications/library/2009/exercise-testing-for-the-prediction-of-cardiac-events-in-patients-with-diabetes/" target="_blank"&gt;Link to&amp;nbsp;full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Kamalesh M, Cleophas TJ. Heart Failure Due to Systolic Dysfunction and Mortality in Diabetes: Pooled Analysis of 39,505 Subjects. Journal of Cardiac Failure 2009; 15(4):305-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19398078" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Patti G, Nusca A, Di Sciascio G. Meta-analysis comparison (nine trials) of outcomes with drug-eluting stents versus bare metal stents in patients with diabetes mellitus. American Journal of Cardiology 2008; 102(10):1328-34. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009101545" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373(9677):1765-72. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009105012" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Riche DM, Valderrama R, Henyan NN. Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis. Diabetes Care 2007; 30(2):384-8. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007000939" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5139" target="_blank"&gt;Link to supporting guidelines on Cardiovascular complications&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; DENTAL PROBLEMS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Reichert C, Deschner J, Jager A. Influence of diabetes mellitus on the development and treatment of malocclusions--a case report with literature review. Journal of Orofacial Orthopedics 2009; 70(2):160-75. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19322534" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5618" target="_blank"&gt;Link to supporting guidelines on dental problems&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; DIABETIC FOOT&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Barber C, Watt A, Pham C, Humphreys K, Penington A, Mutimer K et al. Influence of bioengineered skin substitutes on diabetic foot ulcer and venous leg ulcer outcomes. Journal of Wound Care 2008; 17(12):517-27. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19052516" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Barber C, Watt A, Pham C, Maddern G, Penington A, Mutimer K et al. Bioengineered skin substitutes for the management of wounds: a systematic review. Report 2006;&amp;nbsp;118. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007008446" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Blozik E, Scherer M. Skin replacement therapies for diabetic foot ulcers. Diabetes Care 2008; 31 (4):693-4. Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008104717" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Cruciani M, Lipsky BA, Mengoli C, de Lalla F. Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections. Cochrane Database of Systematic Reviews 2009;&amp;nbsp;(3). &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006810/frame.html" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Langer A, Rogowski W. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Services Research 2009; 9:115. &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716319/?tool=pubmed" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Nowakowski PE. A meta-analysis of the diagnostic accuracy of the monofilament in detecting diabetic peripheral neuropathy. State University of New York at Buffalo PhD Dissertation 2008. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009102438" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Smith C, Kumar S, Causby R. The effectiveness of non-surgical interventions in the treatment of Charcot foot. International Journal of Evidence-Based Healthcare 2007; 5:437-49. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;L&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008008023" target="_blank"&gt;ink to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Teng YJ, Wang JW, Wang YJ, Yang KH, Yan X, Tian JH et al. A meta-analysis of tissue engineered skin improved wound closure in diabetic foot ulcers. Chinese Journal of Evidence-Based Medicine 2009; 9(5):584-92. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009105702" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Vardakas KZ, Horianopoulou M, Falagas ME. Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials. Diabetes Research and Clinical Practice 2008; 80(3):344-51.&amp;nbsp;&lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information.&lt;/SPAN&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008104867" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Villela DL, Santos VLC. Evidence of topical use with platelet-rich plasma in diabetic ulcer. 41st Annual Wound, Ostomy and Continence Nurses Annual Conference, St. Louis, Missouri, June 6-10, 2009. Journal of Wound, Ostomy and Continence Nursing 2009; 36:S70-S70. &lt;A href="http://journals.lww.com/jwocnonline/Fulltext/2009/05001/Wound_Evidence_Based_Interventions__3455__EVIDENCE.210.aspx" target="_blank"&gt;Link to abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Wang WP, Yuan NB, Wang C, Wang Y, Yu TT, Wu XY et al. Evidence-based treatment of chronic leg ulcers in a patient with necrobiosis lipoidica diabeticorum. Chinese Journal of Evidence-Based Medicine 2007; 7(11):830-5. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007004186" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5135" target="_blank"&gt;Link to supporting guidelines on diabetic foot&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; DIABETIC KETOACIDOSIS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Mazer M, Chen E. Is subcutaneous administration of rapid-acting insulin as effective as intravenous insulin for treating diabetic ketoacidosis? Annals of Emergency Medicine 2009; 53(2):259-63. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19177639" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5140" target="_blank"&gt;Link to supporting guidelines on diabetic ketoacidosis&lt;/A&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; EYE DISEASES&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;O'Doherty M, Dooley I, Hickey-Dwyer M. Interventions for diabetic macular oedema: a systematic review of the literature. British Journal of Ophthalmology 2008; 92(12):1581-90. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18952646" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Yilmaz T, Weaver CD, Gallagher MJ, Cordero-Coma M, Cervantes-Castaneda RA, Klisovic D et al. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology 2009; 116 (5):902-11; quiz 912-3. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19410949" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Zafar A, Khan GI, Siddiqui MA. The quality of reporting of diagnostic accuracy studies in diabetic retinopathy screening: a systematic review. Clinical and Experimental Ophthalmology 2008; 36(6):537-42. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18954316" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=8694" target="_blank"&gt;Link to supporting guidelines on diabetic eye diseases&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; HYPOGLYCAEMIA&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Fitzpatrick D, Duncan EAS. Improving post-hypoglycaemic patient safety in the prehospital environment: A systematic review. Emergency Medicine Journal 2009; 26(7):472-8. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Treatments &amp;gt; Medication &amp;gt; Sulphonylureas.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://emj.bmj.com/cgi/content/abstract/26/7/472" target="_blank"&gt;Link to abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5141" target="_blank"&gt;Link to supporting guidelines on Hypoglycaemia&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; NEPHROPATHY&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;Please also see the&lt;/SPAN&gt; &lt;A href="nelh:328420:0" name=internalLink&gt;Commentary on Diabetic Nephropathy&lt;/A&gt; &lt;FONT color=#a81400&gt;by Ed Sharples, Consultant in Renal Medicine, Churchill Hospital, Oxford.&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 2009; 52(4):691-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19198800" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Strippoli GF, Craig M, Schena FP, Craig JC. Antihypertensive agents for primary prevention of diabetic nephropathy. Journal of the American Society of Nephrology 2005; 16(10):3081-91. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12006009112" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Wang F, Wu HM. Xuezhikang for diabetic kidney disease: A systematic review of randomized controlled trials. Chinese Journal of Evidence-Based Medicine 2009; 9 (1):63-70. &lt;FONT color=#a81400&gt;The abstract is available in English, but the full text of the article is in Chinese.&lt;/FONT&gt; &lt;A href="http://www.ceps.com.tw/ec/ecjnlarticleView.aspx?jnlcattype=1&amp;amp;jnlptype=5&amp;amp;jnltype=44&amp;amp;jnliid=2574&amp;amp;issueiid=78117&amp;amp;atliid=1511031" target="_blank"&gt;Link to abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Wang H, Zhang GL., Zhang QB, Deng JL. Spironolactone for diabetic nephropathy: A systematic review. Chinese Journal of Evidence-Based Medicine 2009; 9 (1):71-5. &lt;FONT color=#a81400&gt;The abstract is available in English, but the full text of the article is in Chinese.&lt;/FONT&gt; &lt;A href="http://www.ceps.com.tw/ec/ecjnlarticleView.aspx?jnlcattype=1&amp;amp;jnlptype=5&amp;amp;jnltype=44&amp;amp;jnliid=2574&amp;amp;issueiid=78117&amp;amp;atliid=1511084" target="_blank"&gt;Link to abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5133" target="_blank"&gt;Link to supporting guidelines on diabetic nephropathy&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; NEUROPATHY&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Chan YC, Lo YL, Chan ESY. Immunotherapy for diabetic amyotrophy. Cochrane Database of Systematic Reviews 2009;&amp;nbsp;(3). &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006521/frame.html" target="_blank"&gt;Link to&amp;nbsp;full text&amp;nbsp;here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Chou R, Carson S, Chan BKS. Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic Neuralgia: Discrepancies between direct and indirect meta-analyses of randomized controlled trials. Journal of General Internal Medicine 2009; 24(2):178-88. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009102754" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Evans JD, Jacobs TF, Evans EW. Role of acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy. Annals of Pharmacotherapy 2008; 42 (11 ):1686-91. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18940920" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Goodyear-Smith F, Halliwell J. Anticonvulsants for neuropathic pain: Gaps in the evidence. Clinical Journal of Pain 2009; 25(6):528-36. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19542802" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Hurley RW, Lesley MR, Adams MC, Brummett CM, Wu CL. Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis. Regional Anesthesia and Pain Medicine 2008; 33(5):389-94. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18774507" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Li H, Nyland J, Shelton T. Effectiveness of the anodyne therapy system in treating diabetic peripheral neuropathy: a systematic review. Physical Therapy Reviews 2008; 13:395-404. &lt;A href="http://www.ingentaconnect.com/content/maney/ptr/2008/00000013/00000006/art00004?token=005a196d9e64b9e6e7e442f20675d5866342545495b6c2a3163687627504541676249266d656cd3cf1ecc78189" target="_blank"&gt;Link to abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Quilici S, Chancellor J, Lothgren M, Simon D, Said G, Le TK et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurology 2009; 9:6. &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663537/?tool=pubmed" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Vo T, Marcus KB. Ranirestat: A selective aldose reductase inhibitor for diabetic sensorimotor polyneuropathy. Journal of Pharmacy Technology 2008; 24 (6):340-4. &lt;A href="http://jpharmtechnol.com/abstracts/volume24/nov_dec/340.php" target="_blank"&gt;Link to abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5136" target="_blank"&gt;Link to supporting guidelines on diabetic neuropathies&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; PSYCHOLOGICAL &amp;gt; ANXIETY&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Fu AZ, Qiu Y, Radican L. Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes. Current Medical Research and Opinion 2009; 25 (6):1413-20. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt;&amp;nbsp;Medicaiton &amp;gt; Insulin.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19422281" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=14654" target="_blank"&gt;Link to supporting guidelines on anxiety and depression&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; PSYCHOLOGICAL &amp;gt; COGNITIVE FUNCTION&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Kopf D, Frolich L. Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. Journal of Alzheimer's Disease 2009; 16 (4):677-85. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19387104" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Lamport DJ, Lawton CL, Mansfield MW, Dye L. Impairments in glucose tolerance can have a negative impact on cognitive function: a systematic research review. Neuroscience and Biobehavioral Reviews 2009; 33(3):394-413. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19026680" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Naguib JM, Kulinskaya E, Lomax CL, Garralda ME. Neuro-cognitive performance in children with type 1 diabetes--a meta-analysis. Journal of Pediatric Psychology 2009; 34(3):271-82. &lt;A href="http://jpepsy.oxfordjournals.org/cgi/content/full/34/3/271" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;van den Berg E, Kloppenborg RP, Kessels RP, Kappelle LJ, Biessels GJ. Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: A systematic comparison of their impact on cognition. Biochimica Et Biophysica Acta 2009; 1792(5):470-81. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18848880" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=14653" target="_blank"&gt;Link to supporting guidelines on cognitive function&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; PSYCHOLOGICAL &amp;gt; DEPRESSION&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Gonzalez JS, Peyrot M, McCarl LA, Collins EM, Serpa L, Mimiaga MJ et al. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care 2008; 31(12):2398-403. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Treatment Concordance.&lt;/SPAN&gt; &lt;A href="http://care.diabetesjournals.org/content/31/12/2398.long" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008; 31(12):2383-90. &lt;A href="http://care.diabetesjournals.org/content/31/12/2383.long" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&amp;nbsp; &lt;BR&gt;Schram MT, Baan CA, Pouwer F. Depression and quality of life in patients with diabetes: a systematic review from the European depression in diabetes (EDID) research consortium. Current Diabetes Reviews 2009; 5(2):112-9. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Living with Diabetes &amp;gt; Quality of Life.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764861/?tool=pubmed" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=14654" target="_blank"&gt;Link to supporting guidelines on anxiety and depression&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; SEXUAL DYSFUNCTION&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Bekkering GE, Abou-Setta AM, Kleijnen J. The application of quantitative methods for identifying and exploring the presence of bias in systematic reviews: PDE-5 inhibitors for erectile dysfunction. International Journal of Impotence Research 2008; 20(3):264-77.&amp;nbsp;&lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008104519" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5137" target="_blank"&gt;Link to supporting guidelines on sexual dysfunction as a complication of diabetes&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; SKIN PROBLEMS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Bristow IR, Spruce M.C. Fungal foot infection, cellulitis and diabetes: A review. Diabetic Medicine 2009; 26(5):548-51. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19646196" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?catID=5138" target="_blank"&gt;Link to supporting guidelines on skin problems as a complication of diabetes&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; OTHER&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Adami S. Bone health in diabetes: considerations for clinical management. Current Medical Research and Opinion 2009; 25 (5):1057-72. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19292601" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5599" target="_blank"&gt;Link to supporting guidelines on chronic complications&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5600" target="_blank"&gt;Link to supporting guidelines on acute complications &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328202</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328202]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Condition Management</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Condition Management&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.phru.nhs.uk/Doc_Links/S.Reviews%20Appraisal%20Tool.pdf" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; ALL OR GENERAL&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes 2008; 32(suppl 1):S1-S201. (&lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Delivery of Care, Living with Diabetes, Education, Complications, Pregnancy and Gestational Diabetes).&lt;/SPAN&gt; &lt;A href="http://www.diabetes.ca/files/cpg2008/cpg-2008.pdf" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5627" target="_blank"&gt;Link to supporting guidelines on condition management of Type 1 Diabetes&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5633" target="_blank"&gt;Link to supporting guidelines on condition management of Type 2 Diabetes&amp;nbsp; &lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; BARIATRIC SURGERY&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. American Journal of Medicine 2009; 122 (3):248-56.e5. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19272486" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=14785" target="_blank"&gt;Link to supporting guidelines on condition management of obesity&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; DIET&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;FONT color=#a81400&gt;Please also see the&amp;nbsp;&lt;/FONT&gt;&lt;A href="nelh:328405:0" name=internalLink&gt;Commentary on Carbohydrates in Type 2 Diabetes&lt;/A&gt; &lt;FONT color=#a81400&gt;written by Lindsay Oliver, Consultant Dietitian for Northumbria Healthcare Trust and Chair of the Diabetes Management and Education Group, part of the British Dietetic Association.&lt;/FONT&gt;&lt;FONT color=#000066&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;Bartlett HE, Eperjesi F. Nutritional supplementation for type 2 diabetes: a systematic review. Ophthalmic and Physiological Optics 2008; 28(6):503-23. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19076553" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Cao Y, Mauger DT, Pelkman CL, Zhao G, Townsend SM, Kris-Etherton PM. Effects of moderate (MF) versus lower fat (LF) diets on lipids and lipoproteins: a meta-analysis of clinical trials in subjects with and without diabetes. Journal of Clinical Lipidology 2009; 3(1):19-32. &lt;A href="http://www.lipidjournal.com/article/S1933-2874(08)00972-0/abstract" target="_blank"&gt;Link to abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Dyson PA. A review of low and reduced carbohydrate diets and weight loss in type 2 diabetes. Journal of Human Nutrition and Dietetics 2008; 21(6):530-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18759958" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Eakin EG, Lawler SP, Vandelanotte C, Owen N. Telephone interventions for physical activity and dietary behavior change: a systematic review. American Journal of Preventive Medicine 2007; 32(5):419-34. &lt;FONT color=#a81400&gt;This reference is also listed under Condition Management &amp;gt; Exercise and Delivery of Care&lt;/FONT&gt;. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007001689" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Sato M et al. Influence of fat and carbohydrate proportions on the metabolic profile in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2009; 32(5):959-65. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19407076" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Leyva-Moral JM. [Motivational interviewing as an instrument to promote physical activity and dietary adherence among people with diabetes: literature review]. Nure Investigacion 2007; 29:6.&amp;nbsp;&lt;FONT color=#a81400&gt;This reference is also listed under&amp;nbsp;&lt;/FONT&gt;&lt;FONT color=#a81400&gt;Condition Management &amp;gt; Psychological Interventions and Exercise.&lt;/FONT&gt; &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.fuden.es/originales_detalle.cfm?ID_ORIGINAL=106&amp;amp;FilaInicio=1" target="_blank"&gt;Link to abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Livesey G, Taylor R. Fructose consumption and consequences for glycation, plasma triacylglycerol, and&amp;nbsp; body weight: meta-analyses and meta-regression models of intervention studies. American Journal of Clinical Nutrition 2008; 88(5):1419-37. &lt;A href="http://www.ajcn.org/cgi/content/full/88/5/1419" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Opperman AM, Venter CS, Oosthuizen W, Thompson RL, Vorster HH. Meta-analysis of the health effects of using the glycaemic index in meal-planning. British Journal of Nutrition 2004; 92(3):367-81. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12005009571" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Rovner AJ, Nansel TR. Are children with type 1 diabetes consuming a healthful diet?: a review of the current evidence and strategies for dietary change. Diabetes Educator 2009; 35(1):97-107. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19244565" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Salmela S, Poskiparta M, Kasila K, Vahasarja K, Vanhala M. Transtheoretical model-based dietary interventions in primary care: a review of the evidence in diabetes. Health Education Research 2009; 24(2):237-52. &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654060/?tool=pubmed" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Sievenpiper J.L., Kendall C.W.C., Esfahani A., Wong J.M.W., Carleton A.J., Jiang H.Y. et al. Effect of non-oil-seed pulses on glycaemic control: A systematic review and meta-analysis of randomised controlled experimental trials in people with and without diabetes. Diabetologia 2009; 52(8):1479-95. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19526214" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Smith DM, Pickering RM, Lewith GT. A systematic review of vanadium oral supplements for glycaemic control in type 2 diabetes mellitus. QJM: an International Journal of Medicine 2008; 101(5):351-8. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008106792" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Song Y, He K, Levitan EB, Manson JE, Liu S. Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. Diabetic Medicine 2006; 23(10):1050-6. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12006007322" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Thomas Diana, Elliott Elizabeth J. Low glycaemic index, or low glycaemic load, diets for diabetes mellitus. Cochrane Database of Systematic Reviews 2009;&amp;nbsp;(1). &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006296/frame.html" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=8726" target="_blank"&gt;Link to supporting guidelines on diet as a treatment for Type 1 Diabetes&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=8724" target="_blank"&gt;Link to supporting guidelines on diet as a treatment for Type 2 Diabetes&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; EXERCISE&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;Alexander GK, Taylor AG, Innes KE, Kulbok P, Selfe TK. Contextualizing the effects of yoga therapy on diabetes management: a review of the social determinants of physical activity. Family and Community Health 2008; 31 (3):228-40. &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720829/?tool=pubmed" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Eakin EG, Lawler SP, Vandelanotte C, Owen N. Telephone interventions for physical activity and dietary behavior change: a systematic review. American Journal of Preventive Medicine 2007; 32(5):419-34. &lt;FONT color=#a81400&gt;This reference is also listed under Condition Management &amp;gt; Diet and Delivery of Care.&lt;/FONT&gt; &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007001689" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Gordon BA, Benson AC, Bird SR, Fraser SF. Resistance training improves metabolic health in type 2 diabetes: a systematic review. Diabetes Research and Clinical Practice 2009; 83(2):157-75. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009102612" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Leyva-Moral JM. [Motivational interviewing as an instrument to promote physical activity and dietary adherence among people with diabetes: literature review]. Nure Investigacion 2007; 29:6. &lt;FONT color=#a81400&gt;This reference is also listed under Condition Management &amp;gt; Psychological Interventions and Diet.&lt;/FONT&gt; &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information.&lt;/SPAN&gt;&lt;FONT color=#a81400&gt;&amp;nbsp;&lt;/FONT&gt;&lt;A href="http://www.fuden.es/originales_detalle.cfm?ID_ORIGINAL=106&amp;amp;FilaInicio=1" target="_blank"&gt;Link to abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Richardson CR, Newton TL, Abraham JJ, Sen A, Jimbo M, Swartz AM. A meta-analysis of pedometer-based walking interventions and weight loss. Annals of Family Medicine 2008; 6(1):69-77. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information.&lt;/SPAN&gt;&lt;FONT color=#a81400&gt;&amp;nbsp;&lt;/FONT&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008005285" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Wang Y, Simar D, Fiatarone Singh MA. Adaptations to exercise training within skeletal muscle in adults with type 2 diabetes or impaired glucose tolerance: a systematic review. Diabetes/Metabolism Research and Reviews 2009; 25(1):13-40. &lt;A href="http://www3.interscience.wiley.com/cgi-bin/fulltext/121637664/HTMLSTART" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=8727" target="_blank"&gt;Link to supporting guidelines on exercise as a treatment for Type 1 Diabetes&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=8725" target="_blank"&gt;Link to supporting guidelines on exercise as a treatment for Type 2 Diabetes&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; MEDICATION &amp;gt; ALL OR GENERAL&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Archives of Internal Medicine 2008; 168(19):2070-80. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008106508" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7088" target="_blank"&gt;Link to supporting guidelines on medication for Type 1 Diabetes&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7090" target="_blank"&gt;Link to supporting guidelines on medication for Type 2 Diabetes &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; MEDICATION &amp;gt; GLITAZONES&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Clar C, Royle P, Waugh N. Adding pioglitazone to insulin containing regimens in type 2 diabetes: Systematic review and meta-analysis. PLoS One 2009; 4(7). &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701605/" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Lee JY, Ferlyn TML, Chan A. Evaluation of thiazolidinediones on cardiovascular outcomes in patients with type 2 diabetes mellitus: a systematic review. Journal for Nurse Practitioners 2009; 5:176-84. &lt;A href="http://www.npjournal.org/article/S1555-4155(08)00480-7/abstract" target="_blank"&gt;Link to abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. Canadian Medical Association Journal 2009; 180(1):32-9. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009102172" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 2008; 10(12):1221-38. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009101612" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Monami M, Marchionni N, Mannucci E. Winners and losers at the rosiglitazone gamble A meta-analytical approach at the&amp;nbsp; definition of the cardiovascular risk profile of rosiglitazone. Diabetes Research and Clinical Practice 2008; 82(1):48-57. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18775581" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Nagajothi N, Adigopula S, Balamuthusamy S, Velazquez-Cecena JL, Raghunathan K, Khraisat A et al. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials. American Journal of Therapeutics 2008; 15 (6):506-11. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19127132" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Pinelli NR, Cha R, Brown MB, Jaber LA. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. Annals of Pharmacotherapy 2008; 42(11):1541-51. &lt;FONT color=#a81400&gt;This reference is also listed under Medication &amp;gt; Incretins.&lt;/FONT&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18957626" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007; 30(8):2148-53. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information.&lt;/SPAN&gt;&lt;FONT color=#a81400&gt;&amp;nbsp;&lt;/FONT&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008008100" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Waksman JC. Cardiovascular risk of rosiglitazone: another perspective. Journal of Pharmacy and Pharmacology 2008; 60 (12):1573-82. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19000361" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7088" target="_blank"&gt;Link to supporting guidelines on medication for Type 1 Diabetes&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7090" target="_blank"&gt;Link to supporting guidelines on medication for Type 2 Diabetes&amp;nbsp;&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; MEDICATION &amp;gt; INCRETINS&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Croxtall JD, Keam SJ. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2008; 68(16):2387-409. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18973400" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of&amp;nbsp; randomized clinical trials. European Journal of Endocrinology 2009; 160 (6):909-17. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19318378" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Pinelli NR, Cha R, Brown MB, Jaber LA. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. Annals of Pharmacotherapy 2008; 42(11):1541-51. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Medication &amp;gt; Glitazones.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18957626" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Riche DM, East HE, Riche KD. Impact of sitagliptin on markers of beta-cell function: a meta-analysis. American Journal of the Medical Sciences 2009; 337 (5):321-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19322069" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vascular Health and Risk Management 2008; 4(4):753-68. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information.&lt;/SPAN&gt;&lt;FONT color=#a81400&gt;&amp;nbsp;&lt;/FONT&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2597770/?tool=pubmed" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7088" target="_blank"&gt;Link to supporting guidelines on medication for Type 1 Diabetes&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7090" target="_blank"&gt;Link to supporting guidelines on medication for Type 2 Diabetes &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; MEDICATION &amp;gt; INSULIN&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;Brixner DI, McAdam-Marx C. Cost-effectiveness of insulin analogs. American Journal of Managed Care 2008; 14:766-75. &lt;A href="http://www.ajmc.com/media/pdf/AJMC_08Nov_Brixner_766to775.pdf" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Churchill JN, Ruppe RL, Smaldone A. Use of continuous insulin infusion pumps in young children with type 1 diabetes:&amp;nbsp; a systematic review. Journal of Pediatric Health Care 2009; 23(3):173-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19401250" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Fu AZ, Qiu Y, Radican L. Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes. Current Medical Research and Opinion 2009; 25 (6):1413-20. &lt;FONT color=#a81400&gt;This reference is also listed under Complications &amp;gt; Psychological &amp;gt; Anxiety.&lt;/FONT&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19422281" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Gandhi GY, Murad MH, Flynn DN, Erwin PJ, Cavalcante AB, Bay NH et al. Effect of perioperative insulin infusion on surgical morbidity and mortality: systematic review and meta-analysis of randomized trials. Mayo Clinic Proceedings 2008; 83(4):418-30. &lt;FONT color=#a81400&gt;This reference is also listed under Living with Diabetes &amp;gt; Hospital.&lt;/FONT&gt; &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information.&lt;/SPAN&gt;&lt;FONT color=#a81400&gt;&amp;nbsp;&lt;/FONT&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008103064" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Gough SC. A review of human and analogue insulin trials. Diabetes Research and Clinical Practice 2007; 77(1):1-15. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information.&lt;/SPAN&gt;&lt;FONT color=#a81400&gt;&amp;nbsp;&lt;/FONT&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007005854" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Gough S C TJ. Biphasic insulin aspart in type 2 diabetes mellitus: an evidence-based medicine review. Clinical Drug Investigation 2007; 27(5):299-324. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information.&lt;/SPAN&gt;&lt;FONT color=#a81400&gt;&amp;nbsp;&lt;/FONT&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007002007" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Helms KL, Kelley KW. Insulin glulisine: An evaluation of its pharmacodynamic properties and clinical application. Annals of Pharmacotherapy 2009; 43 (4):658-68. &lt;A href="http://www.theannals.com/cgi/content/abstract/aph.1E662v1" target="_blank"&gt;Link to&amp;nbsp;abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. Diabetes, Obesity and Metabolism 2009; 11(1):53-9. &lt;A href="http://www3.interscience.wiley.com/cgi-bin/fulltext/121358222/HTMLSTART" target="_blank"&gt;Link to&amp;nbsp;full text&amp;nbsp;here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Monami M, Lamanna C, Marchionni N, Mannucci E. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis. Experimental and Clinical Endocrinology and Diabetes 2009; 117 (5):220-2. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19301231" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Monami M., Marchionni N., Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes, Obesity and Metabolism 2009; 11(4):372-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19267715" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&amp;nbsp;&lt;BR&gt;Pang TT, Narendran P. Addressing insulin resistance in Type 1 diabetes. Diabetic Medicine 2008; 25(9):1015-24. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19183305" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Pankowska E, Blazik M, Dziechciarz P, Szypowska A, Szajewska H. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatric Diabetes 2009; 10(1):52-8. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009103167" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Potti LG, Haines ST. Continuous subcutaneous insulin infusion therapy: A primer on insulin pumps. Journal of the American Pharmacists Association 2009; 49 (1):e1-13; quiz e14-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19196588" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Qayyum R, Bolen S, Maruthur N, Feldman L, Wilson LM, Marinopoulos SS et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Annals of Internal Medicine 2008; 149(8):549-59. &lt;A href="http://www.annals.org/content/149/8/549.long" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Qayyum R, Wilson LM, Bolen S, Maruthur N, Marinpoulos SS, Feldman L et al. Comparative effectiveness, safety, and indications of insulin analogues in premixed formulations for adults with type 2 diabetes. Report 2008;&amp;nbsp; 111. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008107518" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. Canadian Medical Association Journal 2009; 180(4):385-97. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009102307" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Tran K, Banerjee S, Li H, Cimon K, Daneman D, Simpson SH et al. Long-acting insulin analogues for diabetes mellitus: meta-analysis of clinical outcomes and assessment of cost-effectiveness. Canadian Agency for Drugs and Technologies in Health. Technology Report. 2007;&amp;nbsp; 48. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information.&lt;/SPAN&gt;&lt;FONT color=#a81400&gt;&amp;nbsp;&lt;/FONT&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008104081" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;van Avendonk M.J.P., Rutten G.E.H.M. Insulin therapy in type 2 diabetes: What is the evidence? Diabetes, Obesity and Metabolism 2009; 11(5):415-32. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19175375" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Warren E, Weatherley-Jones E, Chilcott J, Beverley C. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technology Assessment 2004; 8(45):1-72. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information.&lt;/SPAN&gt;&lt;FONT color=#a81400&gt;&amp;nbsp;&lt;/FONT&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12005008061" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7088" target="_blank"&gt;Link to supporting guidelines on medication for Type 1 Diabetes&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7090" target="_blank"&gt;Link to supporting guidelines on medication for Type 2 Diabetes &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; MEDICATION &amp;gt; METFORMIN&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all- cause mortality? Diabetes Care 2008; 31(8):1672-8. &lt;FONT color=#a81400&gt;This reference is also listed under Medication &amp;gt; Sulphonylureas.&lt;/FONT&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2494623/?tool=pubmed" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Zhang JY, Ma B, Yang KH, Cheng WD. Metformin plus roziglitazone versus metformin for type 2 diabetes: a systematic review. Chinese Journal of Evidence-Based Medicine 2009; 9(4):437-45. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009105112" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7088" target="_blank"&gt;Link to supporting guidelines on medication for Type 1 Diabetes&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7090" target="_blank"&gt;Link to supporting guidelines on medication for Type 2 Diabetes&amp;nbsp;&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; MEDICATION &amp;gt; SULPHONYLUREAS&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;/STRONG&gt;Fitzpatrick D., Duncan E.A.S. Improving post-hypoglycaemic patient safety in the prehospital environment: A systematic review. Emergency Medicine Journal 2009; 26(7):472-8. &lt;FONT color=#a81400&gt;This reference is also listed under Complications &amp;gt; Hypoglycaemia.&lt;/FONT&gt;&amp;nbsp;&lt;A href="http://emj.bmj.com/cgi/content/abstract/26/7/472" target="_blank"&gt;Link to abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all- cause mortality? Diabetes Care 2008; 31(8):1672-8. &lt;FONT color=#a81400&gt;This reference is also listed under Medication &amp;gt; Metformin.&lt;/FONT&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2494623/?tool=pubmed" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7088" target="_blank"&gt;Link to supporting guidelines on medication for Type 1 Diabetes&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7090" target="_blank"&gt;Link to supporting guidelines on medication for Type 2 Diabetes &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; MEDICATION &amp;gt; OTHER&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Abdelghaffar Shereen, Attia Abdelhamid M. Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. Cochrane Database of Systematic Reviews 2009; (1). &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006691/frame.html" target="_blank"&gt;Link to&amp;nbsp;full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Baker WL, Baker EL, Coleman CI. The effect of plant sterols or stanols on lipid parameters in patients with type&amp;nbsp; 2 diabetes: a meta-analysis. Diabetes Research and Clinical Practice 2009; 84(2):e33-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19243852" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Balk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care 2007; 30(8):2154-63. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information.&lt;/SPAN&gt;&lt;FONT color=#a81400&gt;&amp;nbsp;&lt;/FONT&gt;&lt;A href="http://care.diabetesjournals.org/content/30/8/2154.long" target="_blank"&gt;Link to&amp;nbsp;full text&amp;nbsp;here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Chen KW, Liu T, Zhang H, Lin Z. An analytical review of the Chinese literature on Qigong therapy for diabetes mellitus. American Journal of Chinese Medicine 2009; 37:439-57.&amp;nbsp;&lt;FONT color=#a81400&gt;Please note that this systematic review includes only chinese literature.&amp;nbsp;&lt;/FONT&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19606506" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Hasani-Ranjbar S, Larijani B, Abdollah M. A systematic review of iranian medicinal plants useful in diabetes mellitus. Archives of Medical Science 2008; 4 (3):285-92. &lt;FONT color=#a81400&gt;Please note that this systematic review includes only articles published in Iran.&lt;/FONT&gt; &lt;A href="http://www.termedia.pl/magazine.php?magazine_id=19&amp;amp;article_id=11201&amp;amp;magazine_subpage=ABSTRACT" target="_blank"&gt;Link to abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Lee MS, Chen KW, Choi TY, Ernst E. Qigong for type 2 diabetes care: A systematic review. Complementary Therapies in Medicine 2009; 17(4):236-42. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19632552" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Nahas R, Moher M. Complementary and alternative medicine for the treatment of type 2 diabetes. Canadian Family Physician 2009; 55(6):591-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694078/?tool=pubmed" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Xin L, Miller YD, Brown WJ. A qualitative review of the role of qigong in the management of diabetes. Journal of Alternative and Complementary Medicine 2007; 13(4):427-33. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information.&lt;/SPAN&gt;&lt;FONT color=#a81400&gt;&amp;nbsp;&lt;/FONT&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007001942" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7088" target="_blank"&gt;Link to supporting guidelines on medication for Type 1 Diabetes&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7090" target="_blank"&gt;Link to supporting guidelines on medication for Type 2 Diabetes &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt;&lt;/STRONG&gt; &lt;STRONG&gt;PSYCHOLOGICAL INTERVENTIONS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Alam R, Sturt J, Lall R, Winkley K. An updated meta-analysis to assess the effectiveness of psychological interventions delivered by psychological specialists and generalist clinicians on glycaemic control and on psychological status. Patient Education and Counseling 2009; 75(1):25-36. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19084368" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Ismail K, Winkley K, Rabe-Hesketh S. Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. Lancet 2004; 363:1589-97. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information.&lt;/SPAN&gt;&lt;FONT color=#a81400&gt;&amp;nbsp;&lt;/FONT&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12004008280" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Leyva-Moral JM. [Motivational interviewing as an instrument to promote physical activity and dietary adherence among people with diabetes: literature review]. Nure Investigacion 2007; 29:6. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Psychological Interventions and Exercise&lt;/SPAN&gt;. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information.&lt;/SPAN&gt;&lt;FONT color=#a81400&gt;&amp;nbsp;&lt;/FONT&gt;&lt;A href="http://www.fuden.es/originales_detalle.cfm?ID_ORIGINAL=106&amp;amp;FilaInicio=1" target="_blank"&gt;Link to abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=8728" target="_blank"&gt;Link to supporting guidelines on psychological interventions&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; TIGHT GLUCOSE CONTROL&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Fatourechi MM, Kudva YC, Murad MH, Elamin MB, Tabini CC, Montori VM. Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. Journal of Clinical Endocrinology and Metabolism 2009; 94(3):729-40. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19088167" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Kao Lillian S, Meeks Derek, Moyer Virginia A, Lally Kevin P. Peri-operative glycaemic control regimens for preventing surgical site infections in adults. Cochrane Database of Systematic Reviews 2009;(3). &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Living with Diabetes &amp;gt; Hospital.&lt;/SPAN&gt; &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006806/frame.html" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; TREATMENT CONCORDANCE&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Gonzalez JS, Peyrot M, McCarl LA, Collins EM, Serpa L, Mimiaga MJ et al. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care 2008; 31(12):2398-403. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Psychological &amp;gt; Depression.&lt;/SPAN&gt; &lt;A href="http://care.diabetesjournals.org/content/31/12/2398.long" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Wens J, Vermeire E, Hearnshaw H, Lindenmeyer A, Biot Y, Van RP. Educational interventions aiming at improving adherence to treatment recommendations in type 2 diabetes: a sub-analysis of a systematic review of randomised controlled trials. Diabetes Research and Clinical Practice 2008; 79(3):377-88. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Patient and Family Education.&lt;/SPAN&gt; &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information.&lt;/SPAN&gt;&lt;FONT color=#a81400&gt;&amp;nbsp;&lt;/FONT&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17643546?dopt=Abstract" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=11832" target="_blank"&gt;Link to supporting guidelines on treatment concordance&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; SELF-MANAGEMENT&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Cochran J, Conn VS. Meta-analysis of quality of life outcomes following diabetes self-management training. Diabetes Educator 2008; 34(5):815-23. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Living with Diabetes &amp;gt; Quality of Life and Patient and Family Education.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18832286" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; SELF-MONITORING&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;McGeoch G, Derry S, Moore RA. Self-monitoring of blood glucose in type-2 diabetes: what is the evidence? Diabetes/Metabolism Research and Reviews 2007; 23(6):423-40. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information.&lt;/SPAN&gt;&lt;FONT color=#a81400&gt;&amp;nbsp;&lt;/FONT&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17538940?dopt=Abstract" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7089" target="_blank"&gt;Link to supporting guidelines on self-monitoring of Type 1 Diabetes&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7091" target="_blank"&gt;Link to supporting guidelines on self-monitoring of Type 2 Diabetes&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; OTHER&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Darre L, Vergnes JN, Gourdy P, Sixou M. Efficacy of periodontal treatment on glycaemic control in diabetic patients: A meta-analysis of interventional studies. Diabetes and Metabolism 2008; 34(5):497-506. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18948050?dopt=Abstract" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Guo B, Corabian P, Harstall C. Islet transplantation for the treatment of type 1 diabetes: an update. Institute of Health Economics Report 2008;&amp;nbsp; 1-78. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009102862" target="_blank"&gt;Link to DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328146</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328146]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Delivery of Care</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Delivery of Care&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.phru.nhs.uk/Doc_Links/S.Reviews%20Appraisal%20Tool.pdf" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Azar M, Gabbay R. Web-based management of diabetes through glucose uploads: has the time come for telemedicine? Diabetes Research and Clinical Practice 2009; 83:9-17. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19056140" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;Barlow J, Singh D, Bayer S, Curry R. A systematic review of the benefits of home telecare for frail elderly people and those with long-term conditions. Journal of Telemedicine and Telecare 2007; 13(4):172-9. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?View=Full&amp;amp;ID=12008102922" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Brod M, Kongso JH, Lessard S, Christensen TL. Psychological insulin resistance: patient beliefs and implications for diabetes management. Quality of Life Research 2009; 18(1):23-32. &lt;FONT color=#a81400&gt;This reference is also listed&amp;nbsp;under&amp;nbsp;Living with Diabetes &amp;gt; Quality of Life.&lt;/FONT&gt; &lt;A href="http://www.springerlink.com/content/28424653px341316/fulltext.html" target="_blank"&gt;Link to full text here&lt;/A&gt;.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes 2008; 32(suppl 1):S1-S201. &lt;FONT color=#a81400&gt;This reference is also listed&amp;nbsp;under Living with Diabetes, Education, Condition Management, Complications, Pregnancy and Gestational Diabetes.&lt;/FONT&gt;&amp;nbsp;&lt;A href="http://www.diabetes.ca/files/cpg2008/cpg-2008.pdf" target="_blank"&gt;Link to full text here&lt;/A&gt;.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Cherrington A, Ayala GX, Amick H, Allison J, Corbie-Smith G, Scarinci I. Implementing the community health worker model within diabetes management: challenges and lessons learned from programs across the United States. Diabetes Educator 2008; 34(5):824-33. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18832287" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Dalton JE. Web-based care for adults with type 2 diabetes. Canadian Journal of Dietetic Practice and Research 2008; 69:185-91. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19063808" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;de Belvis A.G., Pelone F., Biasco A., Ricciardi W., Volpe M. Can primary care professionals' adherence to Evidence Based Medicine tools improve quality of care in Type 2 diabetes mellitus? A systematic review. Diabetes Research and Clinical Practice 2009; 85(2):119-31. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19539391" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;DelliFraine JL, Dansky KH. Home-based telehealth: a review and meta-analysis. Journal of Telemedicine and Telecare 2008; 14(2):62-6. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?View=Full&amp;amp;ID=12008104962" target="_blank"&gt;Link to DARE abstract here&lt;/A&gt;.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Eakin EG, Lawler SP, Vandelanotte C, Owen N. Telephone interventions for physical activity and dietary behavior change: a systematic review. American Journal of Preventive Medicine 2007; 32(5):419-34. &lt;FONT color=#a81400&gt;This reference is also listed&amp;nbsp;under Condition Management &amp;gt; Diet and Exercise.&lt;/FONT&gt;&amp;nbsp;&lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?View=Full&amp;amp;ID=12007001689" target="_blank"&gt;Link to DARE abstract here&lt;/A&gt;.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Ellitt GR, Brien JAE, Aslani P, Chen TF. Quality patient care and pharmacists' role in its continuity - A systematic review. Annals of Pharmacotherapy 2009; 43 (4):677-91. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19336645" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Farmer A, Gibson OJ, Tarassenko L, Neil A. A systematic review of telemedicine interventions to support blood glucose self-monitoring in diabetes. Diabetic Medicine 2005; 22(10):1372-8. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16176199" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Fjeldsoe BS, Marshall AL, Miller YD. Behavior change interventions delivered by mobile telephone short-message service. American Journal of Preventive Medicine 2009; 36 (2):165-73. &lt;A href="http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?View=Full&amp;amp;ID=12009104574" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Fleming E, Gillibrand W. An exploration of culture, diabetes, and nursing in the South Asian community: a&amp;nbsp; metasynthesis of qualitative studies. Journal of Transcultural Nursing 2009; 20(2):146-55. &lt;FONT color=#a81400&gt;This reference is also listed&amp;nbsp;under Ethnicity.&lt;/FONT&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19141638" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Guldberg T.L., Lauritzen T., Kristensen J.K., Vedsted P. The effect of feedback to general practitioners on quality of care for people with type 2 diabetes. A systematic review of the literature. BMC Family Practice 2009; 10:30. &lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2690581" target="_blank"&gt;Link to full text here&lt;/A&gt;.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Hatherly K, Overland J, Smith L, Taylor S, Johnston C. Providing optimal service delivery for children and adolescents with type 1 diabetes: a systematic review. Practical Diabetes International 2009; 26:154-9. &lt;A href="http://www3.interscience.wiley.com/journal/122459241/abstract" target="_blank"&gt;Link to abstract here&lt;/A&gt;.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Wei HP, Tian JH, Zhang L, Guo H, Yang F, Zhang CY, et al. Effect of nursing interventions on medical behavior of diabetic patients in China: A meta-analysis. Chinese Journal of Evidence-Based Medicine 2008; 8(5):328-33. &lt;FONT color=#a81400&gt;Abstract in English, but full text is in chinese.&lt;/FONT&gt; &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.ceps.com.tw/ec/ecjnlarticleView.aspx?jnlcattype=1&amp;amp;jnlptype=5&amp;amp;jnltype=44&amp;amp;jnliid=2574&amp;amp;issueiid=68791&amp;amp;atliid=1230125" target="_blank"&gt;Link to abstract here&lt;/A&gt;.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5147" target="_blank"&gt;Link to supporting guidelines on delivery of care&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328299</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328299]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Diabetes and Comorbidities</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,LIVING WITH DIABETES,RESEARCH,CHRONIC COMORBIDITIES,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Diabetes and Comorbidities&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.phru.nhs.uk/Doc_Links/S.Reviews%20Appraisal%20Tool.pdf" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. Journal of the American Medical Association 2008; 300(23):2754-64. &lt;A href="http://jama.ama-assn.org/cgi/content/full/300/23/2754" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Conwell LJ, Boult C. The effects of complications and comorbidities on the quality of preventive diabetes care: a literature review. Population Health Management 2008; 11(4):217-28. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18942927" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Dretzke J, Cummins C, Sandercock J, Fry-Smith A, Barrett T, Burls A. Autoantibody testing in children with newly diagnosed type 1 diabetes mellitus. Health Technology Assessment 2004; 8(22):1-196.&amp;nbsp;&lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12004008548" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9:88. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3494&amp;amp;itool=Abstract-nondef&amp;amp;uid=19320986&amp;amp;nlmid=100968562&amp;amp;db=pubmed&amp;amp;url=http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=19320986" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Loza E. Systematic review on the safety of concomitant use of hypoglycemia-inducing drugs and non-steroidal anti-inflammatory drugs in patients with musculoskeletal pathology. Reumatologia Clinica 2008; 4(6):232-9. &lt;A href="http://www.reumatologiaclinica.org/reuma_eng/ctl_servlet?_f=45&amp;amp;ident=13134244" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Lu FP, Lin KP, Kuo HK. Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. PLoS One 2009; 4(1):e4144. &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607544/?tool=pubmed" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Mitri J, Castillo J, Pittas AG. Diabetes and risk of Non-Hodgkin's lymphoma: a meta-analysis of observational studies. Diabetes Care 2008; 31(12):2391-7. &lt;A href="http://care.diabetesjournals.org/content/31/12/2391.long" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Osborn DP, Wright CA, Levy G, King MB, Deo R, Nazareth I. Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. BMC Psychiatry 2008; 8:84. &lt;FONT color=#a81400&gt;This reference is also listed under Prevention, Causes and Risk Factors.&lt;/FONT&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570660/?tool=pubmed" target="_blank"&gt;Link to&amp;nbsp;full text&amp;nbsp;here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=9432" target="_blank"&gt;Link to supporting guidelines on diabetes and co-morbidities&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328303</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328303]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Diagnosis</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,DIAGNOSIS,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Diagnosis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Lutgens MW, Meijer M, Peeters B, Poulsen ML, Rutten MJ, Bots ML et al. Easily obtainable clinical features increase the diagnostic accuracy for latent autoimmune diabetes in adults: an evidence-based report. Primary Care Diabetes 2008; 2(4):207-11. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18815086" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5626" target="_blank"&gt;Link to supporting guidelines on diagnosis of Type 1 Diabetes&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5631" target="_blank"&gt;Link to supporting guidelines on diagnosis of Type 2 Diabetes&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328304</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328304]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Economics</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Economics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Salas M, Hughes D, Zuluaga A, Vardeva K, Lebmeier M. Costs of medication nonadherence in patients with diabetes mellitus: A systematic review and critical analysis of the literature. Value in Health 2009; 12(6):915-22. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19402848" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328152</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328152]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Ethnicity</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,PEOPLE FROM ETHNIC MINORITIES,RESEARCH,PEOPLE FROM ETHNIC MINORITIES,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Ethnicity&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Fleming E, Gillibrand W. An exploration of culture, diabetes, and nursing in the South Asian community: a&amp;nbsp; metasynthesis of qualitative studies. Journal of Transcultural Nursing 2009; 20(2):146-55. (This reference is also listed under Delivery of Care). &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19141638" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Whittemore R. Culturally competent interventions for Hispanic adults with type 2 diabetes: a systematic review. Journal of Transcultural Nursing 2007; 18(2):157-66. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17416718?dopt=Abstract" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=12410" target="_blank"&gt;Link to supporting guidelines on condition management of Type 1 diabetes in people of ethnic minorities&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=8197" target="_blank"&gt;Link to supporting guidelines on condition management of Type 2 diabetes in people of ethnic minorities &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328308</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328308]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Genetics</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CAUSES,PEOPLE FROM ETHNIC MINORITIES,RESEARCH,PEOPLE FROM ETHNIC MINORITIES,ANNUAL EVIDENCE UPDATES,CAUSES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Genetics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Four references were identified in the search for systematic reviews and meta-analyses; these references were then reviewed by Professor Andrew Hattersley, Professor of Molecular Medicine and Consultant physician, Peninsula Medical School.&amp;nbsp; Professor Hattersley rejected&amp;nbsp;all four reviews from our results set concluding that these references offer little insight into either the genetics of diabetes or any treatment implications; he&amp;nbsp;has&amp;nbsp;written the following editorial for NHS Evidence - diabetes.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;For more information on how to assess the quality of genetic studies please see the following publication:&amp;nbsp; Hattersley AT, McCarthy MI. What makes a good genetic association study? Lancet 2005; 366(9493):1315-23. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16214603" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Recently genetic studies have involved a single study genomewide analysis of around 300-600,000 genetic variants that account for approximately 80% of common genetic variation in the human genome.&amp;nbsp; To establish that positive results are robust, very low p values are required (p&amp;lt; 5 X 10-8) and most studies include a meta-analysis of multiple further studies.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Examples of high quality studies that include such a meta-analysis that you should be aware of are:&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nature Genetics 2009; May 10. [Epub ahead of print] PubMed PMID: 19430480. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19430480" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. A Common Variant in the FTO Gene Is Associated with Body Mass Index and Predisposes to Childhood and Adult Obesity. Science 2007; 316(5826):889-894.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646098/?tool=pubmed" target="_blank"&gt;Link to full text here&lt;/A&gt;.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, et al. Variants in MTNR1B&amp;nbsp; influence fasting glucose levels. Nature Genetics 2009 Jan; 41(1):77-81. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19060907" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, Furuta H, et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nature Genetics 2008 Sep; 40(9):1092-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18711367" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nature Genetics 2008 May; 40(5):638-45. &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672416/?tool=pubmed" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Also see &lt;A href="http://www.library.nhs.uk/GENETICCONDITIONS/" target="_blank"&gt;NHS Evidence - genetic conditions&lt;/A&gt;, is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects of genetic conditions including both clinical and organisational issues.&amp;nbsp; There is a section specifically on Diabetes in the genetic conditions specialist collection - &lt;A href="http://www.library.nhs.uk/GENETICCONDITIONS/SearchResults.aspx?tabID=290&amp;amp;catID=8465" target="_blank"&gt;link here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;Rejected references:&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Feng RN, Li Y, Sun CH. TNF 308 G/A polymorphism and type 1 diabetes: A meta-analysis. Diabetes Research and Clinical Practice 2009; 85(1):e4-e7.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Luo Y, Wang H, Han X, Ren Q, Wang F, Zhang X. et al. Meta-analysis of the association between SNPs in TCF7L2 and type 2 diabetes in East Asian population. Diabetes Research and Clinical Practice 2009; 85(2):139-46.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Tong Y, Lin Y, Zhang Y, Yang J, Zhang Y, Liu H et al. Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. BMC Medical Genetics 2009; 10:15.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Zhang XM, Wang HY, Luo YY, Ji LN. HLA-DQ, DR allele polymorphism of type 1 diabetes in the Chinese population: A meta-analysis. Chinese Medical Journal 2009; 122(8):980-6.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328307</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328307]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Gestational Diabetes</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES,GESTATIONAL DIABETES,CAUSES,DIAGNOSIS,PROGRESSION TO TYPE 2 DIABETES,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Gestational Diabetes&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Alwan N, Tuffnell DJ, West J. Treatments for gestational diabetes. Cochrane Database of Systematic Reviews 2009;&amp;nbsp;(3). &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003395/frame.html" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009; 373(9677):1773-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19465232" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Bennett WL, Bolen S, Wilson LM, Bass EB, Nicholson WK. Performance characteristics of postpartum screening tests for type 2 diabetes mellitus in women with a history of gestational diabetes mellitus: a systematic review. Journal of Women's Health 2009; 18:979-87. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19575688" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes 2008; 32(suppl 1):S1-S201. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Delivery of Care, Patient Education, Living with Diabetes, Condition Management, Complications and Pregnancy.&lt;/SPAN&gt; &lt;A href="http://www.diabetes.ca/files/cpg2008/cpg-2008.pdf" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;DiNallo JM, Downs DS. The role of exercise in preventing and treating gestational diabetes: a comprehensive review and recommendations for future research. Journal of Applied Biobehavioral Research 2007; 12(3-4):141-77.&amp;nbsp;&lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008105248" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Golden SH, Bennett WL, Baptist-Roberts K, Wilson LM, Barone B, Gary TL et al. Antepartum glucose tolerance test results as predictors of type 2 diabetes mellitus in women with a history of gestational diabetes mellitus: a systematic review. Gender Medicine 2009; 6 Suppl 1:109-22. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19318222" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Haws RA, Yakoob MY, Soomro T, Menezes EV, Darmstadt GL, Bhutta ZA. Reducing stillbirths: screening and monitoring during pregnancy and labour. BMC Pregnancy Childbirth 2009; 9 Suppl 1:S5. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Pregnancy.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2679411/?tool=pubmed" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Nicholson W, Bolen S, Witkop CT, Neale D, Wilson L, Bass E. Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. Obstetrics and Gynecology 2009; 113(1):193-205. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19104375" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Torloni MR, Betran AP, Horta BL, Nakamura MU, Atallah AN, Moron AF et al. Prepregnancy BMI and the risk of gestational diabetes: a systematic review of the literature with meta-analysis. Obesity Reviews 2009; 10(2):194-203. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19055539" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Toulis KA, Goulis DG, Kolibianakis EM, Venetis CA, Tarlatzis BC, Papadimas I. Risk of gestational diabetes mellitus in women with polycystic ovary syndrome: a&amp;nbsp; systematic review and a meta-analysis. Fertility and Sterility 2009; 92 (2):667-77. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18710713" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Wendland EM, Pinto ME, Duncan BB, Belizan JM, Schmidt MI. Cigarette smoking and risk of gestational diabetes: a systematic review of observational studies. BMC Pregnancy Childbirth 2008; 8:53. &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2632653/?tool=pubmed" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Wensel TM. Role of metformin in the treatment of gestational diabetes. Annals of Pharmacotherapy 2009; 43(5):939-43. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19401478" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Witkop CT, Neale D, Wilson LM, Bass EB, Nicholson WK. Active compared with expectant delivery management in women with gestational diabetes: a systematic review. Obstetrics and Gynecology 2009; 113(1):206-17.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19104376" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&amp;nbsp;&lt;BR&gt;&lt;EM&gt;&amp;nbsp;&lt;BR&gt;&lt;/EM&gt;&lt;FONT color=#a81400&gt;The following reference has been selected as a "possible systematic review" according to the abstract of the article, however we are waiting to receive the full text of this article to check this in further detail.&lt;BR&gt;&lt;/FONT&gt;Baptiste-Roberts K, Barone BB, Gary TL, Golden SH, Wilson LM, Bass EB et al. Risk factors for type 2 diabetes among women with gestational diabetes: a systematic review. American Journal of Medicine 2009; 122 (3):207-14.e4 . &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19272478" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;EM&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;/EM&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=14958" target="_blank"&gt;Link to supporting guidelines on gestational diabetes&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328114</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328114]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Home Page</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Home Page&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;STRONG&gt;Published&lt;/STRONG&gt;: 09 November 2009&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;P dir=ltr align=center&gt;&amp;nbsp; 
&lt;TABLE border=0 cellSpacing=0 cellPadding=2 width="70%" align=middle&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P align=center&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID328114/nelhImp_0013_image1_even_smaller.jpg"&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=center&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID328114/nelhImp_0014_WDD-logo-date-EN-2048px_even_smaller.png"&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=center&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID328114/nelhImp_0015_image2_even_smaller.jpg"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;We are pleased to present the results of&amp;nbsp;our third Annual Evidence Update which identifies new&amp;nbsp;systematic reviews&amp;nbsp;on diabetes published between September 2008 and September 2009.&amp;nbsp; This Annual Evidence Update has been published to co-incide with &lt;A href="http://www.worlddiabetesday.org/" target="_blank"&gt;World Diabetes Day&lt;/A&gt;&amp;nbsp;on November 14th 2009. For ease of reference, the results of the evidence update have been classified based on the topic headings found within 'NHS Evidence - diabetes'.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=384860" target="_blank"&gt;Click here&lt;/A&gt; for the first Annual Evidence Update on Diabetes (January 06 to August 07). &lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=386852" target="_blank"&gt;Click here&lt;/A&gt; for the second Annual Evidence Update on Diabetes (August 07 to Sept 08).&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Contents&lt;/STRONG&gt;&lt;/P&gt;
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;P dir=ltr&gt;1. &lt;A href="nelh:328324:0" name=internalLink&gt;Full introduction&lt;/A&gt;&amp;nbsp;by Dr Roger Gadsby&lt;/P&gt;
&lt;P dir=ltr&gt;2. Results of the 2009 Annual Evidence Update on Diabetes&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;UL&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:328332:0" name=internalLink&gt;Results table&lt;/A&gt; showing number of systematic reviews in each topic&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328201:0" name=internalLink&gt;Prediabetic State&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328195:0" name=internalLink&gt;Prevention, Causes and Risk Factors&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328308:0" name=internalLink&gt;Genetics&lt;/A&gt;&amp;nbsp;with commentary from Professor Andrew Hattersley&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328303:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328192:0" name=internalLink&gt;Screening&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328152:0" name=internalLink&gt;Ethnicity&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328202:0" name=internalLink&gt;Condition Management&lt;/A&gt; &lt;BR&gt;(includes bariatric surgery, diet, exercise, all medication, tight glucose control, treatment concordance, self-management, and self-monitoring)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328307:0" name=internalLink&gt;Gestational Diabetes&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328204:0" name=internalLink&gt;Other Types of Diabetes&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328166:0" name=internalLink&gt;Complications&lt;/A&gt; &lt;BR&gt;(acute and chronic&amp;nbsp;complications including psychological)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328199:0" name=internalLink&gt;Pregnancy&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328205:0" name=internalLink&gt;Living with Diabetes&lt;/A&gt;&lt;BR&gt;(includes quality of life studies, school, and inhospital – surgery)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328299:0" name=internalLink&gt;Diabetes and comorbidites&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328146:0" name=internalLink&gt;Delivery of Care&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328304:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328203:0" name=internalLink&gt;Patient and Family Education&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/UL&gt;
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;P&gt;3. &lt;A href="nelh:328420:0" name=internalLink&gt;Commentary on Diabetic Nephropathy&lt;/A&gt;&amp;nbsp;by Dr Edward Sharples&lt;/P&gt;
&lt;P&gt;4. &lt;A href="nelh:328405:0" name=internalLink&gt;Commentary on Carbohydrates in Type 2 Diabetes&lt;/A&gt; by Lindsay Oliver&lt;/P&gt;
&lt;P&gt;5. &lt;A href="nelh:328308:0" name=internalLink&gt;Commentary on the genetic background to diabetes&lt;/A&gt; by Professor Andrew Hattersley&lt;/P&gt;
&lt;P&gt;6. &lt;A href="nelh:328321:0" name=internalLink&gt;Methodology&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7. &lt;A href="nelh:328374:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P dir=ltr&gt;&lt;STRONG&gt;Acknowledgements&lt;BR&gt;&lt;/STRONG&gt;This annual evidence update was researched and presented by the team at 'NHS Evidence - diabetes': Beth Hall, Rachel Court and Roger Gadsby, based at the University of Warwick.&amp;nbsp; We would like to thank Professor Andrew Hattersely, Dr Ed Sharples and Lindsay Oliver for writing editorials for the annual evidence update.&amp;nbsp; We would also like to thank the &lt;A href="http://www.library.nhs.uk/Diabetes/AboutUs.aspx" target="_blank"&gt;reference group&lt;/A&gt; of 'NHS Evidence - diabetes' for their suggestions on improving the methodology for the annual evidence update and for help with promotion of the resource.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;If you would like to comment on or have any questions about this annual evidence update please contact us via &lt;A href="http://www.library.nhs.uk/Diabetes/ContactUs.aspx" target="_blank"&gt;this email form&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328324</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328324]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Introduction</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=328114" target="_blank"&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;We are pleased to present the results of our third Annual Evidence Update which identifies new&amp;nbsp;systematic reviews&amp;nbsp;on diabetes published between September 2008 and September 2009.&amp;nbsp; For ease of reference, the results of the evidence update have been classified based on the topic headings found within NHS Evidence - diabetes.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=384860" target="_blank"&gt;Click here&lt;/A&gt; for the first Annual Evidence Update on Diabetes (January 06 to August 07). &lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;Click here&lt;/A&gt; for the second Annual Evidence Update on Diabetes (August 07 to Sept 08).&amp;nbsp;&amp;nbsp; &lt;BR&gt;&amp;nbsp;&lt;BR&gt;195 systematic reviews have been found in this Annual Evidence Update for 2009, a slight increase in the 172 found last year.&amp;nbsp;&lt;A href="nelh:328321:0" name=internalLink&gt;Link here&lt;/A&gt; for further information on the methodology for the Annual Evidence Update.&amp;nbsp;&amp;nbsp;Please note that none of the citations identified were critically appraised by the Information Specialists or Clinical Lead.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Specific highlights from this year’s Annual Evidence Update include&lt;/STRONG&gt;:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;A meta-analysis of cardiovascular disease risk and hyperglycaemia by Ray et al.&amp;nbsp;[1] that helps in putting into context the results of several recent RCTs, which have shown no benefit in cardiovascular disease risk reduction from glucose lowering to a HBA1c of 6.5%.&lt;/LI&gt;
&lt;LI&gt;Several reviews on diabetes and depression (see &lt;A href="nelh:328166:0" name=internalLink&gt;Complications &amp;gt; Psychological &amp;gt; Depression&lt;/A&gt;)&lt;/LI&gt;
&lt;LI&gt;The ongoing debate about glitazones, fractures and cardiovascular disease risk is dealt with in several reviews (see &lt;A href="nelh:328202:0" name=internalLink&gt;Condition Management &amp;gt; Medication &amp;gt; Glitazones&lt;/A&gt;)&lt;/LI&gt;
&lt;LI&gt;A number of reviews of telemedicine in diabetes care delivery (see &lt;A href="nelh:328146:0" name=internalLink&gt;Delivery of Care&lt;/A&gt;)&lt;/LI&gt;
&lt;LI&gt;Several reviews on &lt;A href="nelh:328307:0" name=internalLink&gt;Gestational Diabetes&lt;/A&gt; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The review that has particular impact on NICE guideline recommendations is Bulugahapitiya et al.&amp;nbsp;[2]. The fact that Type 2 diabetes is not a coronary risk equivalent means that recommendations obtained from extrapolating evidence from secondary prevention, particularly recommendations about the use of aspirin in primary prevention, and the targets for total cholesterol and LDL cholesterol in all people with type 2 diabetes, may need to be reconsidered.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Also new for this year’s Annual Evidence Update, we have editorials and comment from experts in areas of:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:328420:0" name=internalLink&gt;&lt;A href="nelh:328420:1" name=internalLink&gt;Diabetic nephropathy&lt;/A&gt;&lt;/A&gt; (Dr Edward Sharples - Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328405:1" name=internalLink&gt;Carbohydrates in Type 2 Diabetes&lt;/A&gt;&lt;/A&gt; (Lindsay Oliver, Consultant Dietitian for Northumbria Healthcare Trust and Chair of the Diabetes Management and Education Group, part of the British Dietetic Association).&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328308:0" name=internalLink&gt;Genetics&lt;/A&gt; (Professor Andrew Hattersley, Professor of Molecular Medicine and Consultant physician, Peninsula Medical School).&lt;/LI&gt;
&lt;LI&gt;An editorial on what the new evidence on "Delivery of Care" means for Diabetes Nursing is currently being prepared by nurse consultants Sara Da Costa and Theresa Smyth and will be published soon at 'NHS Evidence - diabetes'. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This year's update shows the vast amount of new knowledge being published in the field of Diabetes.&amp;nbsp; Without help it would be easy to drown in this vast sea of information.&amp;nbsp; We hope that you will find this evidence update helpful and of assistance in preventing you from drowning.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;EM&gt;Roger Gadsby, November 2009.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&lt;BR&gt;1. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373(9677):1765-72. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009105012" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;2. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabetic Medicine 2009; 26(2):142-8. &lt;A href="http://www3.interscience.wiley.com/cgi-bin/fulltext/121567674/HTMLSTART" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328205</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328205]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Living with Diabetes</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,LIVING WITH DIABETES,DELIVERY OF CARE,HOSPITAL INPATIENT CARE,PATIENT EDUCATION AND EMPOWERMENT,RESEARCH,ANNUAL EVIDENCE UPDATES,SCHOOL]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Living with Diabetes&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;LIVING WITH DIABETES &amp;gt; QUALITY OF LIFE&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Brod M, Kongso JH, Lessard S, Christensen TL. Psychological insulin resistance: patient beliefs and implications for diabetes management. Quality of Life Research 2009; 18(1):23-32. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Delivery of Care.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19039679" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;Cochran J, Conn VS. Meta-analysis of quality of life outcomes following diabetes self-management training. Diabetes Educator 2008; 34(5):815-23. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Patient and Family Education.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18832286" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;Schram MT, Baan CA, Pouwer F. Depression and quality of life in patients with diabetes: a systematic review from the European depression in diabetes (EDID) research consortium. Current Diabetes Reviews 2009; 5(2):112-9. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Psychological &amp;gt; Depression.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764861/?tool=pubmed" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;LIVING WITH DIABETES &amp;gt; SCHOOL&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Tolbert R. Managing type 1 diabetes at school: an integrative review. Journal of School Nursing 2009; 25:55-61. &lt;A href="http://jsn.sagepub.com/cgi/content/abstract/25/1/55" target="_blank"&gt;Link to abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=50&amp;amp;sort=TITLE&amp;amp;catID=14942" target="_blank"&gt;Link to supporting guidelines on having diabetes at school&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;LIVING WITH DIABETES &amp;gt; HOSPITAL &amp;gt; SURGERY&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes 2008; 32(suppl 1):S1-S201.&amp;nbsp;&lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Delivery of Care, Education, Living with Diabetes, Condition Management, Complications, Pregnancy and Gestational Diabetes.&lt;/SPAN&gt; &lt;A href="http://www.diabetes.ca/files/cpg2008/cpg-2008.pdf" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Gandhi GY, Murad MH, Flynn DN, Erwin PJ, Cavalcante AB, Bay NH et al. Effect of perioperative insulin infusion on surgical morbidity and mortality: systematic review and meta-analysis of randomized trials. Mayo Clinic Proceedings 2008; 83(4):418-30. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Medication &amp;gt; Insulin.&lt;/SPAN&gt; &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008103064" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Kao LS, Meeks D, Moyer VA, Lally KP. Peri-operative glycaemic control regimens for preventing surgical site infections in adults. Cochrane Database of Systematic Reviews 2009;(3). &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Tight Glucose Control and Living with Diabetes &amp;gt; Hospital.&lt;/SPAN&gt; &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006806/frame.html" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=50&amp;amp;sort=TITLE&amp;amp;catID=5617" target="_blank"&gt;Link to supporting guidelines on having diabetes and being in hospital&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328321</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328321]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Methodology</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about&amp;nbsp;and introduction to the Annual Evidence Update&amp;nbsp;and for links to results for&amp;nbsp;each of the&amp;nbsp;topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;'NHS Evidence – diabetes' presents this 2009 Annual Evidence Update on Diabetes; it consists of the results of extensive literature searches carried out to identify systematic reviews relating to diabetes and its treatment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Inclusion criteria&lt;/STRONG&gt;&lt;BR&gt;References were included if they were identified as systematic reviews that are relevant to the subject scope and were published between September 2008 and September 2009 (see the 'Search period' section below for further information about inclusion of DARE abstracts).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Subject scope&lt;/STRONG&gt; &lt;BR&gt;The subject scope reflects that of 'NHS Evidence - diabetes': covering all types of diabetes mellitus and pre-diabetic conditions, as well as complications of diabetes mellitus and other conditions that are closely related to diabetes mellitus.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication types&lt;/STRONG&gt;&lt;BR&gt;Material included was limited to Systematic Reviews because of the high volume of published material in the topic area. Systematic Reviews are regarded as the highest level of evidence to inform clinical practice.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Sources searched (searches carried out on 9th and 10th September 2009)&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;PUBMED&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Embase via NLH Search 2.0&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;CINAHL via EBSCO&lt;/LI&gt;
&lt;LI&gt;The Cochrane Library &lt;/LI&gt;
&lt;LI&gt;Database of Abstracts of Reviews of Effects (DARE) via CRD interface &lt;/LI&gt;
&lt;LI&gt;NHS Evidence – diabetes&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Search period&lt;/STRONG&gt;&lt;BR&gt;1st September 2008 – 9th September 2009.&amp;nbsp; Please note that DARE abstracts were included in the results set that had been added to DARE within the search period (September 2008 to September 2009) even though they may have been published at an earlier date (unless they had already been listed as citations in previous annual evidence updates).&amp;nbsp; The decision was made to include these citaitons in the results set since DARE search a much wider set of sources and databases than we do and these citations would be missed if they were not included at this time.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Search strategy&lt;/STRONG&gt;&lt;BR&gt;The sources listed were systematically searched for publications published within the search period using search terms relevant to the subject scope. Sensitive systematic review search filters were applied to the Medline and Embase searches which were also restricted to exclude animal research. Please &lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=328321" target="_blank"&gt;click here&lt;/A&gt; for full details of the search strategies including search terms and filters used.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Sifting and selection&lt;/STRONG&gt;&lt;BR&gt;All citations found in the searches were sifted by information specialists, by reading the titles and abstracts to initially exclude those papers definitely not relevant to diabetes, then to identify those that were definite or potential systematic reviews. We also checked duplication with last year’s AEU results.&amp;nbsp; This was followed by a sift for subject relevance carried out by the clinical lead. Finally, the remaining titles were once again sifted to include only those that were classified as ‘definite’ systematic reviews. The full text of citations was obtained where this was not evident from the abstract (see the 'Identification of systematic reviews' section below for more information on how we identified the systematic reviews).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Identification of systematic reviews&lt;/STRONG&gt;&lt;BR&gt;We automatically included Cochrane reviews, DARE abstracts and DARE in process records&lt;BR&gt;Other sources:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;We checked the full text where available electronically (either freely, via NHS My Journals or via University of Warwick Library). Where the full text was not available electronically we ordered the full text of those papers where the title and abstract included any suggestion that it might be a systematic review.&lt;/LI&gt;
&lt;LI&gt;We used the &lt;A href="http://www.crd.york.ac.uk/crdweb/html/helpdoc.htm" target="_blank"&gt;DARE criteria&lt;/A&gt; to decide if a paper was a systematic review. Further clarification was defined based on the Centre for Reviews and Dissemination’s working practices:&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 1.&amp;nbsp;Were inclusion/exclusion criteria reported? &lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 2.&amp;nbsp;Was the search adequate?&amp;nbsp;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; a.&amp;nbsp;Papers must have given search terms and listed the database(s) searched in order that the search can be repeated.&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; b.&amp;nbsp;If only one database is searched it must be the appropriate one for the topic.&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 3.&amp;nbsp;Were the included studies synthesised? &lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 4.&amp;nbsp;Was the validity of the included studies assessed?&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 5.&amp;nbsp;Are sufficient details about the individual included studies presented?&lt;BR&gt;Reviews included on DARE meet at least four criteria; criteria 1-3 are mandatory.&lt;/LI&gt;
&lt;LI&gt;No authors were contacted for further methodological details.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;&lt;BR&gt;Following the removal of duplicates, a total of 1295 potential systematic reviews were retrieved and collated in a reference management database. The search strategy was designed to be sensitive so a large number of the citations retrieved were irrelevant. Following sifting by Information scientists for definite systematic reviews and clinical lead for subject relevance, 195 citations were identified as being relevant. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Appraisal&lt;/STRONG&gt;&lt;BR&gt;Please note that none of the citations identified were critically appraised by the Information Specialists or Clinical Lead.&amp;nbsp; The inclusion of citations in the results set does not imply endorsement.&amp;nbsp; NHS Evidence – diabetes does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp; A tool for critical appraisal is available from &lt;A href="http://www.phru.nhs.uk/Doc_Links/S.Reviews%20Appraisal%20Tool.pdf" target="_blank"&gt;CASP&lt;/A&gt;. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328204</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328204]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Other Types of Diabetes</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,OTHER TYPES OF DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Other Types of Diabetes&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;
&lt;BR&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Fabrizi F, Messa P, Martin P, Takkouche B. Hepatitis C virus infection and post-transplant diabetes mellitus among renal transplant patients: a meta-analysis. International Journal of Artificial Organs 2008; 31 (8):675-82. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18825640" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=50&amp;amp;sort=TITLE&amp;amp;catID=5128" target="_blank"&gt;Link to supporting guidelines on other types of diabetes&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328203</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328203]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Patient and Family Education</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,OTHER LIFE STYLE,OTHER LIFE STYLE,MONITORING / SELF-MONITORING,MONITORING / SELF-MONITORING,RESEARCH,NUTRITION AND FOOD,PHYSICAL ACTIVITY,NUTRITION AND FOOD,PHYSICAL ACTIVITY,TREATMENT CONCORDANCE,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Patient and Family Education&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PATIENT EDUCATION&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Alam R, Singleton L, Sturt J. Strategies and effectiveness of diabetes self-management education interventions for Bangladeshis. Diversity in Health and Social Care 2008; 5:269-79. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19084368" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;Albano MG, Crozet C, d'Ivernois JF. Analysis of the 2004-2007 literature on therapeutic patient education in diabetes: results and trends. Acta Diabetologica 2008; 45(4):211-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18633570" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Boren SA, Fitzner KA, Panhalkar PS, Specker JE. Costs and benefits associated with diabetes education: a review of the literature. Diabetes Educator 2009; 35(1):72-96. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19244564" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes 2008; 32(suppl 1):S1-S201. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Delivery of Care, Condition Management, Complications, Pregnancy and Gestational Diabetes. &lt;/SPAN&gt;&lt;A href="http://www.diabetes.ca/files/cpg2008/cpg-2008.pdf" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Cochran J, Conn VS. Meta-analysis of quality of life outcomes following diabetes self-management training. Diabetes Educator 2008; 34(5):815-23. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Living with Diabetes.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18832286" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Duke SS, Colagiuri S, Colagiuri R. Individual patient education for people with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2009;(1).&amp;nbsp;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005268/frame.html" target="_blank"&gt;Link to full text here.&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;Fan L, Sidani S. Effectiveness of diabetes self-management education intervention Elements: A meta-analysis. Canadian Journal of Diabetes 2009; 33 (1):18-26. &lt;A href="http://www.diabetes.ca/documents/about-diabetes/CJD-Fan-March-13-2009.pdf" target="_blank"&gt;Link to full text here&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;Wens J, Vermeire E, Hearnshaw H, Lindenmeyer A, Biot Y, Van RP. Educational interventions aiming at improving adherence to treatment recommendations in type 2 diabetes: a sub-analysis of a systematic review of randomised controlled trials. Diabetes Research and Clinical Practice 2008; 79(3):377-88. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Treatment concordance.&lt;/SPAN&gt; &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008104231" target="_blank"&gt;Link to DARE abstract here.&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;Yamaoka K, Tango T. Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 2005; 28(11):2780-6. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12006003068" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Zabaleta AM, Forbes A. Structured group-based education for type 2 diabetes in primary care. British Journal of Community Nursing 2007; 12(4):158-62. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17505331" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=50&amp;amp;sort=TITLE&amp;amp;catID=5624" target="_blank"&gt;Link to supporting guidelines on patient education&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;FAMILY&amp;nbsp;EDUCATION&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;McBroom LA, Enriquez M. Review of family-centered interventions to enhance the health outcomes of children with type 1 diabetes. Diabetes Educator 2009; 35(3):428-38. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19299519" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328201</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328201]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Prediabetic State</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,PREDIABETIC STATE,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Prediabetic State&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 31:1898-904. &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518368/?tool=pubmed" target="_blank"&gt;Link to&amp;nbsp;full text&amp;nbsp;here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Lilly M, Godwin M. Treating prediabetes with metformin: systematic review and meta-analysis. Canadian Family Physician 2009; 55(4):363-9. &lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=19366942" target="_blank"&gt;Link to full text here.&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;Mannucci E, Dicembrini I, Rotella F, Rotella CM. Orlistat and sibutramine beyond weight loss. Nutrition Metabolism and Cardiovascular Diseases 2008; 18(5):342-8. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008104957" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Nobili V, Alisi A, Panera N, Agostoni C. Low birth weight and catch-up-growth associated with metabolic syndrome: a ten year systematic review. Pediatric Endocrinology Reviews 2008; 6 (2):241-7. &lt;FONT color=#a81400&gt;Caution, this article may not be a systematic review, the search methods are not clear.&lt;/FONT&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19202511" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;Takeuchi M, Okamoto K, Takagi T, Ishii H. Ethnic difference in inter-East Asian subjects with normal glucose tolerance and&amp;nbsp; impaired glucose regulation: a systematic review and meta-analysis focusing on fasting serum insulin. Diabetes Research and Clinical Practice 2008; 82(3):383-90. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18945510" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=50&amp;amp;sort=TITLE&amp;amp;catID=5143" target="_blank"&gt;Link to supporting guidelines on the prediabetic state&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328199</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328199]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Pregnancy</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETES AND PREGNANCY,CONDITION MANAGEMENT,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Pregnancy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes 2008; 32(suppl 1):S1-S201.&amp;nbsp;&lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Delivery of Care, Education, Living with Diabetes, Condition Management, Complications and Gestational Diabetes.&lt;/SPAN&gt; &lt;A href="http://www.diabetes.ca/files/cpg2008/cpg-2008.pdf" target="_blank"&gt;Link to full text here (PDF)&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Haws RA, Yakoob MY, Soomro T, Menezes EV, Darmstadt GL, Bhutta ZA. Reducing stillbirths: screening and monitoring during pregnancy and labour. BMC Pregnancy Childbirth 2009; 9 Suppl 1:S5. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Gestational Diabetes.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2679411/?tool=pubmed" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=50&amp;amp;sort=TITLE&amp;amp;catID=5130" target="_blank"&gt;Link to supporting guidelines on pregnancy and diabetes&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328195</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328195]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Prevention, Causes and Risk Factors</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,OTHER TYPES OF DIABETES,CAUSES,PREVENTION,RESEARCH,ANNUAL EVIDENCE UPDATES,CAUSES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Prevention, Causes and Risk Factors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Chen T, Jia H, Li J, Chen X, Zhou H, Tian H. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies. Transplant International 2009; 22(4):408-15. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19207185" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Chida Y, Hamer M. An association of adverse psychosocial factors with diabetes mellitus: a meta-analytic review of longitudinal cohort studies. Diabetologia 2008; 51(12):2168-78. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18806995" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes. Diabetes Care 2009; 32(4):741-50. &lt;FONT color=#a81400&gt;Caution, this article may not be a systematic review, the search methods are not clear. &lt;/FONT&gt;&lt;A href="http://care.diabetesjournals.org/content/32/4/741.long" target="_blank"&gt;Link to full text here.&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005; 28(9):2261-6. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12005001328" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Harder T, Roepke K, Diller N, Stechling Y, Dudenhausen JW, Plagemann A. Birth weight, early weight gain, and subsequent risk of type 1 diabetes: systematic review and meta-analysis. American Journal of Epidemiology 2009; 169(12):1428-36. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19363100" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Jackson L. Translating the Diabetes Prevention Program into practice: a review of community&amp;nbsp; interventions. Diabetes Educator 2009; 35(2):309-20. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19321809" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Jing Y, Han G, Hu Y, Bi Y, Li L, Zhu D. Tea consumption and risk of type 2 diabetes: A meta-analysis of cohort studies. Journal of General Internal Medicine 2009; 24 (5):557-62. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19308337" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Lee CC, Adler AI, Sandhu MS, Sharp SJ, Forouhi NG, Erqou S et al. Association of C-reactive protein with type 2 diabetes: prospective analysis and&amp;nbsp; meta-analysis. Diabetologia 2009; 52(6):1040-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19326095" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. Journal of the American Medical Association 2009; 302(2):179-88. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009106459" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp; &lt;BR&gt;Osborn DP, Wright CA, Levy G, King MB, Deo R, Nazareth I. Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. BMC Psychiatry 2008; 8:84.&amp;nbsp;&lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Diabetes and Comorbidities.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18817565" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Ramaswamy K, Masand PS, Nasrallah HA. Do certain atypical antipsychotics increase the risk of diabetes: a critical review of 17 pharmacoepidemiologic studies. Annals of Clinical Psychiatry 2006; 18(3):183-94. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12006006299" target="_blank"&gt;Link to DARE abstract here.&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;Steyn N.P., Lambert E.V., Tabana H. Nutrition interventions for the prevention of type 2 diabetes. Proceedings of the Nutrition Society 2009; 68(1):55-70. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19068148" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;Whincup PH, Kaye SJ, Owen CG, Huxley R, Cook DG, Anazawa S et al. Birth weight and risk of type 2 diabetes: a systematic review. Journal of the American Medical Association 2008; 300(24):2886-97. &lt;A href="http://jama.ama-assn.org/cgi/content/full/300/24/2886" target="_blank"&gt;Link to full text here.&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. Journal of Hepatology 2008; 49(5):831-44. &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2642971/?tool=pubmed" target="_blank"&gt;Link to full text here.&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=50&amp;amp;sort=TITLE&amp;amp;catID=5634" target="_blank"&gt;Link to supporting guidelines on prevention of Type 2 Diabetes&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=50&amp;amp;sort=TITLE&amp;amp;catID=5632" target="_blank"&gt;Link to supporting guidelines on causes, risk factors and screening for Type 2 Diabetes &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328332</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328332]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Results Table</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Results Table&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;195 systematic reviews are presented in the 2009 Annual Evidence Update on Diabetes, some citations appear in multiple topics.&amp;nbsp;&lt;A href="nelh:328321:0" name=internalLink&gt;Link here&lt;/A&gt; for further information on the methodolody for the Annual Evidence Update.&amp;nbsp;&amp;nbsp;Please note that none of the citations identified were critically appraised by the Information Specialists or Clinical Lead.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;The citations break up into the subtopics as follows:&lt;/P&gt;
&lt;P&gt;
&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:328201:0" name=internalLink&gt;Prediabetic State&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;5&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:328195:0" name=internalLink&gt;Prevention, Causes and Risk Factors&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;14 &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:328308:0" name=internalLink&gt;Genetics&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;0/4&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:328303:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;1&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:328192:0" name=internalLink&gt;Screening&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;2&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:328152:0" name=internalLink&gt;Ethnicity&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;2&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:328202:0" name=internalLink&gt;Condition Management&lt;/A&gt; &lt;BR&gt;(includes bariatric surgery, diet, exercise, all medication, tight glucose control, treatment concordance, self-management, and self-monitoring)&lt;/TD&gt;
&lt;TD&gt;78&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:328307:0" name=internalLink&gt;Gestational Diabetes&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;13&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:328204:0" name=internalLink&gt;Other Types of Diabetes&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;1&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:328166:0" name=internalLink&gt;Complications&lt;/A&gt; &lt;BR&gt;(acute and chronic&amp;nbsp;complications including psychological)&lt;/TD&gt;
&lt;TD&gt;55 &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:328199:0" name=internalLink&gt;Pregnancy&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;2&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:328205:0" name=internalLink&gt;Living with Diabetes&lt;/A&gt;&lt;BR&gt;(includes quality of life studies, school, and inhospital – surgery)&lt;/TD&gt;
&lt;TD&gt;7&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:328299:0" name=internalLink&gt;Diabetes and comorbidites&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;8&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:328146:0" name=internalLink&gt;Delivery of Care&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;16&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:328304:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;1&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:328203:0" name=internalLink&gt;Patient and Family Education&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;11&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328192</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328192]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Screening</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ SCREENING,ADULT,DIABETES,TYPE 2,DIABETES,CAUSES,RESEARCH,VASCULAR RISK,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Screening&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Bennett CM, Guo M, Dharmage SC. HbA1c as a screening tool for detection of type 2 diabetes: a systematic review. Diabetic Medicine 2007; 24(4):333-43. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information.&lt;/SPAN&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12007001508" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Norris SL, Kansagara D, Bougatsos C, Nygren P, Fu R. Screening for type 2 diabetes mellitus: update of 2003 systematic evidence review for the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality Report 2008;&amp;nbsp; 1-47. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:328321:0" name=internalLink&gt;methodology&lt;/A&gt; for more information.&lt;/SPAN&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009104864" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=50&amp;amp;sort=TITLE&amp;amp;catID=14953" target="_blank"&gt;Link to supporting guidelines on causes, risk factors and screening for Type 1 Diabetes&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=50&amp;amp;sort=TITLE&amp;amp;catID=5632" target="_blank"&gt;Link to supporting guidelines on causes, risk factors and screening for Type 2 Diabetes&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328374</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=328374]]&gt;</url>
    <title>2009 Annual Evidence Update on Diabetes - Uncertainties about the Effects of Treatments</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Diabetes - Uncertainties about the Effects of Treatments&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;09 November 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about&amp;nbsp;and introduction to the Annual Evidence Update&amp;nbsp;and for links to results for&amp;nbsp;each of the&amp;nbsp;topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:328114:0" name=internalLink&gt;Link back to home page for 2009 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The UK Database of Uncertainties about the Effects of Treatments (UK DUETs) has been established in the UK to publish uncertainties about the effects of treatment which cannot currently be answered by referring to reliable up-to-date systematic reviews of existing research evidence.&amp;nbsp; UK DUETs is being developed to make uncertainties explicit and to help those prioritising research in the UK to take account of the information needs of patients, carers and clinicians. The research needed may entail preparation of reliable up-to-date systematic reviews of existing evidence, if these are not available, or research to generate additional evidence if reliable up-to-date systematic reviews make clear that this is necessary.&lt;/P&gt;
&lt;P&gt;During this Annual Evidence Update, the team at NHS Evidence – diabetes have identified the following 8 DUETs after reviewing the “Implications for research” of the 7 Cochrane reviews identified in this update.&amp;nbsp; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=328380" target="_blank"&gt;Delivery methods of education for people with type 2 diabetes&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=328377" target="_blank"&gt;Diagnosis of gestational diabetes&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=328379" target="_blank"&gt;Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=328378" target="_blank"&gt;Immunotherapy for diabetic amyotrophy&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=328382" target="_blank"&gt;Low glycaemic index, or low glycaemic load, diets for diabetes mellitus: long-term effects, quality of life, mortality, morbidity and cost-effectiveness.&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=328375" target="_blank"&gt;Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=328381" target="_blank"&gt;Peri-operative glycaemic control regimens for preventing surgical site infections in adults&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=328376" target="_blank"&gt;Treatments for gestational diabetes&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/duets/SearchResults.aspx?catID=14514" target="_blank"&gt;Link here to all the uncertainties for diabetes listed so far in UK DUETs&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>314357</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/PUBLICHEALTH/ViewResource.aspx?resID=346750]]&gt;</url>
    <title>2010 Annual Evidence Update - Obesity - Childhood obesity: surveillance and prevention</title>
    <publicationDate>2010-04-19T00:00:00</publicationDate>
    <publisher>National Library for Public Health</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ PREVENTION,OBESITY,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;NHS Evidence - National Library for Public Health provide an update on the evidence on childhood obesity surveillance and prevention published from March 2009 to&amp;nbsp;February 2010. An expert editorial is provided by Dr Louisa Ells, Specialist Advisor, National Obesity Observatory, Obesity and Physical Lead, North East Public Health Observatory.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Publication history information: Published on the 19th April 2010.&amp;nbsp; This is the third annual evidence update on this topic.&amp;nbsp; &lt;A href="http://www.library.nhs.uk/PUBLICHEALTH/ViewResource.aspx?resID=311618" target="_blank"&gt;Click here&lt;/A&gt; to view&amp;nbsp;previous annual evidence updates. &lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>397916</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=397916]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Commentary on Diabetes - Education</title>
    <publicationDate>2010-12-21T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Commentary on Diabetes - Education&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;21&amp;nbsp;December 2010.&amp;nbsp;&amp;nbsp;&lt;BR&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:0" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;HR&gt;
&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;This commentary has been written for 'NHS Evidence - diabetes' by Sara Da Costa - Nurse Consultant Diabetes based in the Diabetes Centre Homefield and&amp;nbsp;Visiting Fellow University of Brighton.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;This commentary focuses on selected references from the 6 citations on Patient Education found in the searches for the 2010 Annual Evidence Update on Diabetes. &lt;A href="nelh:392325:0" name=internalLink&gt;Link here to the rest of the citations&lt;/A&gt;. 
&lt;HR&gt;

&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Hawthorne K, Robles Y, Cannings-John R, Edwards A G K. Culturally appropriate health education for type 2 diabetes in ethnic minority groups: A systematic and narrative review of randomized controlled trials. Diabetic Medicine 2010;27(6):613-623. &lt;/STRONG&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20546277" target="_blank"&gt;&lt;STRONG&gt;Link to PubMed abstract here&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;.&lt;/STRONG&gt; &lt;BR&gt;&lt;BR&gt;This unique study reviewed RCT,s with data collected on HbA1c, blood pressure and quality of life measures, although this limited the number of studies included, and made the meta analysis more difficult. HbA1c was shown to improve at 3 months, and knowledge scores improved in the intervention groups. This review demonstrated that culturally appropriate health education was more effective than “usual” health education in improving both HbA1c and knowledge. However, the authors highlighted contextual issues which can affect success of education such as poorer access to healthcare services by ethnic minority groups and poorer outcomes. It would&amp;nbsp; appear that&amp;nbsp; access to services is time and place specific, and varies between countries and type of health care service available for lower income communities. The effects of the educators themselves was not examined, and there was only anecdotal evidence recommending a combination of one to one and group education, suggesting that both issues are worthy of further research.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Williams B, Pace AE. Problem based learning in chronic disease management: A review of the research. Patient Education and Counseling 2009;77(1):14-19. &lt;/STRONG&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19375265" target="_blank"&gt;&lt;STRONG&gt;Link to PubMed abstract here&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;.&lt;/STRONG&gt; &lt;BR&gt;&lt;BR&gt;This structured review&amp;nbsp; is unique, and demonstrated significant changes in cognitive and clinical outcomes amongst people experiencing asthma, diabetes, arthritis and coronary artery disease. Although PBL&amp;nbsp; has been widely used in health science, its use in patient education for chronic disease is relatively limited. Some of the studies included demonstrated improved outcomes using PBL in face to face contact. Problems in using this method included lack of theoretical models guiding interventions, lack of baseline assessments and a stong focus on physiological outcomes at the expense of psychological ones. The authors identified the lack of studies comparing PBL to conventional teaching.&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>398000</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=398000]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Commentary on Diabetes - Technology</title>
    <publicationDate>2010-12-21T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Commentary on Diabetes - Technology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;21 December 2010.&amp;nbsp;&amp;nbsp;&lt;BR&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:0" name=internalLink&gt;&lt;A href="nelh:392291:0" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=392291&amp;amp;pgID=1" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;
&lt;BR&gt;&lt;BR&gt;This commentary has been written for 'NHS Evidence - diabetes' by Theresa Smyth -&amp;nbsp;Nurse Consultant in Diabetes based in&amp;nbsp;Queen Elizabeth and Selly Oak hospitals. &lt;BR&gt;&lt;BR&gt;This is 1 of 3 commentaries focusing on selected references from the 15 citations on Delivery of Care found in the searches for the 2010 Annual Evidence Update on Diabetes. &lt;A href="nelh:392321:0" name=internalLink&gt;Link here to the rest of the citations&lt;/A&gt;. The other commentaries are available here: &lt;A href="nelh:397908:0" name=internalLink&gt;Diabetes Services – Models, Quality&lt;/A&gt;, and &lt;A href="nelh:397910:0" name=internalLink&gt;Diabetes Services – Clinician Interventions and Contributions&lt;/A&gt;.&lt;BR&gt;&lt;STRONG&gt;
&lt;HR&gt;
&lt;/STRONG&gt;
&lt;P&gt;&lt;BR&gt;Technological advances, especially the modern means of mass media and communication, present healthcare practitioners with potentially potent methods of providing health promotion and educational support. Mobile phone text messaging as a means for encouraging and motivating behavioural change, for avoiding the burden of disease and better management for those living with illness, was reviewed in a paper published in the journal Epidemiologic review’&lt;SUP&gt;1&lt;/SUP&gt;. The systematic review reported that 8 of the 9 methodologically suitable and appropriate studies showed persuasive evidence that this way of communicating with patients, which is commonly available, extensive, and relatively inexpensive, warranted further consideration. &lt;BR&gt;&lt;BR&gt;The use of information and communication technology also features in a recent study reported in Diabetes, obesity and metabolism&lt;SUP&gt;2&lt;/SUP&gt;. Home telehealth, where the patient can be more easily supervised and supported by home telemonitoring and telephone advice, education and other information, especially if they live in more remote settings, can have a positive impact on glycaemic control, as defined by lower HbA1c, as well as reducing the need for and number of hospital admissions and in-patient stays of care. &lt;BR&gt;&lt;BR&gt;Further research is required regarding the utilisation of isolated telephone interventions to improve glycaemic control in patients with Type 2 Diabetes Mellitus, according to the findings of the study presented in Advances in Nursing Science&lt;SUP&gt;3&lt;/SUP&gt;. A review of 8 papers published over an 18 year period suggested a less than conclusive picture re the efficacy of the intervention but the authors note that the this means of communication could be a credible and cost effective intercession and methodologically robust studies may confirm the true benefits.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;1. Cole-Lewis, H&amp;nbsp; &amp;amp; Kershaw, T (2010) Text messaging as a tool for behaviour change in disease prevention and management Epidemiologic Reviews 32: 56-69. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20354039" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;2. Polisena, J et al (2009) Home telehealth for diabetes management: a systematic review of the evidence Diabetes, obesity and metabolism 11: 913-930. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010005058" target="_blank"&gt;Link to&amp;nbsp;DARE abstract&amp;nbsp;here&lt;/A&gt;. &lt;BR&gt;&lt;BR&gt;3. Graziano, JA (2009) The effects of isolated telephone interventions on glycaemic control in type 2 diabetes: a literature review Advances in Nursing Science 32(3): E28-41. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009110057" target="_blank"&gt;Link to DARE abstract here&lt;/A&gt;. &lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>397910</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=397910]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Commentary on Diabetes Services - Clinician Interventions and Contributions</title>
    <publicationDate>2010-12-21T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Commentary on Diabetes Services - Clinician Interventions and Contributions&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;21 December 2010.&amp;nbsp;&lt;BR&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:0" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;This commentary has been written for 'NHS Evidence - diabetes' by Sara Da Costa - Nurse Consultant Diabetes based in the Diabetes Centre Homefield and&amp;nbsp;Visiting Fellow University of Brighton.&amp;nbsp;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;This is 1 of 3 commentaries focusing on selected references from the 15 citations on Delivery of Care found in the searches for the 2010 Annual Evidence Update on Diabetes. &lt;A href="nelh:392321:0" name=internalLink&gt;Link here to the rest of the citations&lt;/A&gt;. The other commentaries are available here: &lt;A href="nelh:397908:0" name=internalLink&gt;Diabetes Services – Models, Quality&lt;/A&gt;, and &lt;A href="nelh:398000:0" name=internalLink&gt;Diabetes - Technology&lt;/A&gt;. 
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Armor BL, Britton ML, Dennis VC, Letassy NA. A review of pharmacist contributions to diabetes care in the united states. Journal of Pharmacy Practice 2010;23(3):250-264.&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;This review uses a Medline search of US articles, and summarises the outcomes&amp;nbsp; associated with pharmacist involvement in diabetes care in all practice settings within the US. As in the UK, pharmacists have had their educational requirements increased, and now participate in&amp;nbsp; collaborative drug therapy management in the US. Consequently, many have completed the certified diabetes educator requirements (CDE), or additional study to become a board certified advanced diabetes manager (BC-ADM). All of the authors are either CDE or BC-ADM. This clear multidisciplinary route into standardised diabetes knowledge is not common outside of the US, which may in turn restrict application of the findings of the study to other countries.&lt;BR&gt;&lt;BR&gt;This review demonstrates adds more evidence to support previous studies which identified positive impact of pharmacists providing diabetes care in a variety of settings. However all published interventions which demonstrated positive outcomes involved collaboration with another health care professional. In the absence of RCT’s, it is difficult to attribute positive outcomes to pharmacists alone, and the authors suggest this as an area of future study, which would help decision makers planning and funding health care. They conclude that educated and committed pharmacists who are recognised for their skills/competence in health care, by working in partnership with other clinical colleagues could address the growing economic and health threats of diabetes. Certainly with the exponential increase in people with diabetes it is relevant to examine all such contributors to care, ensure appropriate use and education and involve as part of the diabetes&amp;nbsp; multidisciplinary team. &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Welch G, Garb J, Zagarins S, Lendel I, Gabbay RA. Nurse diabetes case management interventions and blood glucose control: results of a meta-analysis. Diabetes Research &amp;amp; Clinical Practice 2010 Apr;88(1):1-6. Link to &lt;/STRONG&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20116879" target="_blank"&gt;&lt;STRONG&gt;PubMed abstract here&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;. &lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;This US meta analysis reviewed 29 studies which had sufficient data for analysis regarding blood glucose control, and involved 9397 patients. In the majority of these studies (91%) the patient group had Type 2 diabetes.Th aim was to consider strategies that would enhance the primary care physicians management of diabetes care. Results of this meta analysis demonstrated that case management provides a clinically significant improvement in mean blood glucose control as measured by HbAic (mean reduction of 0.89.Subgroup analyses showed clinical setting, team composition and baseline HbA1c were important predictors of effect size, unlike patient education which was either absent or poorly described in most case management interventions that were examined.&amp;nbsp; Based on this meta analysis whose focus was blood glucose control, the authors conclude that nurse led case management provides an effective clinical strategy for poorly controlled diabetes.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Swinnen SG, Devries JH. Contact frequency determines outcome of basal insulin initiation trials in type 2 diabetes. Diabetologia 2009 Nov;52(11):2324-7. &lt;/STRONG&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19756479" target="_blank"&gt;&lt;STRONG&gt;Link to PubMed abstract here&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;. &lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;The aim of this study from the Netherlands was to investigate whether pre arranged contact frequency with the study team and endpoint insulin dose was associated with study outcomes in basal insulin initiation trials in type 2 diabetes. A systematic Medline search was used and contact frequency was plotted against HbA1c reduction and insulin dose at end of study. Face to face contact was seen as important and also analysed. Insulin dose was plotted against HbA1c reduction, hypoglycaemia and weight gain. The authors found significant dose-response relationships between predetermined frequency of contact , endpoint insulin dose and improvement in glycaemic control. However, only contact frequency was an independent predictor of HbA1c reduction. Both frequency of clinical visits and phone contacts showed a significant relationship with HbA1c improvement, but a higher frequency of phone contact was thought to be particularly beneficial. Overall they concluded that in insulin&amp;nbsp; trials, the benefit of frequent patient contact is mainly related to the frequency of insulin dose titration eve nthough they acknowledged other factors such as increased self monitoring, a more ctive coping style and a readiness for change and motivation to do well on insulin.&lt;BR&gt;&lt;BR&gt;The study also reviewed the same factors in relation to DPP4 inhibitors and found that contact frequency did not correlate with HbA1c improvement, which further supports the notion that it was frequent dose titration which occurred during these contacts which was the main reason for HbA1c reduction.&lt;BR&gt;&lt;BR&gt;This study suggests that frequent dose titration once starting onto insulin therapy is highly correlated with improvement in glycaemic control; this has ramifications for clinical practice and how care post insulin start is organised to optimise patient control and outcomes.&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>397908</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=397908]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Commentary on Diabetes Services - Models, Quality</title>
    <publicationDate>2010-12-21T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Commentary on Diabetes Services - Models, Quality&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;21 December&amp;nbsp;2010.&lt;BR&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:0" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;P&gt;
&lt;HR&gt;
&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;This commentary has been written for 'NHS Evidence - diabetes' by Sara Da Costa - Nurse Consultant Diabetes based in the Diabetes Centre Homefield and&amp;nbsp;Visiting Fellow University of Brighton. &lt;BR&gt;&lt;BR&gt;This is 1 of 3 commentaries focusing on selected references from the 15 citations on Delivery of Care found in the searches for the 2010 Annual Evidence Update on Diabetes. &lt;A href="nelh:392321:0" name=internalLink&gt;Link here to the rest of the citations&lt;/A&gt;. The other commentaries are available here: &lt;A href="nelh:397910:0" name=internalLink&gt;Diabetes Services – Clinican Interventions and Contributions&lt;/A&gt;, and &lt;A href="nelh:398000:0" name=internalLink&gt;Diabetes - Technology&lt;/A&gt;.&lt;BR&gt;
&lt;HR&gt;
&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Medical Advisory Secretariat. Community-based care for the management of type 2 diabetes: an evidence-based analysis. Toronto: Medical Advisory Secretariat,Ontario Ministry of Health and Long-Term Care (MAS) 2009;Volume 9,Number 23. &lt;/STRONG&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=32010000128" target="_blank"&gt;&lt;STRONG&gt;Link to full-text here&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;. &lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;Ontario health technology assessments are part of a series where information is gathered in order to determine whether a technology is effective and safe to use in particular clinical population or setting. Evidence is obtained from practicing medical experts and industry, and diffusion into current practice is also indentified and both inform reviews of the provision and delivery of health technology in Ontario, Canada.&lt;BR&gt;&lt;BR&gt;This assessment considers the Diabetes Strategy Evidence project,&amp;nbsp; an evidence based review of literature relating to strategies for successful management and treatment of diabetes. Five areas requiring further evidence were identified, including this topic of community based care as well as insulin pumps, bariatric surgery, behavioural interventions and home telemonitoring.&lt;BR&gt;&lt;BR&gt;Comparison between the efficacy of&amp;nbsp; specialised multidisciplinary community care for type 2 diabetes and usual care was the subject of this review. Specialised MD community care was subdivided into two models ; Model 1 included at least a registered nurse, dietitian and physician, whilst Model 2 included at least a pharmacist and primary care physician. &lt;BR&gt;&lt;BR&gt;Inclusion and exclusion criteria are explicit and a summary of existing evidence and the selected studies used is stated.&lt;BR&gt;&lt;BR&gt;The two models were compared against HbA1c and systolic blood pressure reduction with usual care. Interestingly, Model 1 demonstrated statistically and clinically significant reduction in HbA1c reduction compared to usual care based on moderate quality evidence, but had an uncertain estimate of effect on SBP compared to usual care based on very low quality evidence.&lt;BR&gt;&lt;BR&gt;Model 2 demonstrated a statistically and clinically significant reduction in HbA1c compared to usual care based on high quality evidence, and a similar outcome regarding SBP based on moderate quality evidence.&lt;BR&gt;&lt;BR&gt;For both models, evidence does not suggest a preferred setting for care delivery.&lt;BR&gt;&lt;BR&gt;Although there are differences in health care in Ontario compared to the UK setting, there may be principles from the evidence that could be considered in service redesign and outcome measurement.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Post PN, Wittenberg J, Burgers JS. Do specialized centers and specialists produce better outcomes for patients with chronic diseases than primary care generalists? A systematic review. International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care / ISQua 2009 Dec;21(6):387-96. &lt;/STRONG&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19734175" target="_blank"&gt;&lt;STRONG&gt;Link to PubMed abstract here&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;. &lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;This review from the Netherlands considers evidence regarding treatment by specialists for diabetes mellitus, rheumatoid arthritis and cystic fibrosis in terms of better outcomes. In terms of diabetes, comparisons were made between specialist care and primary care, endocrinologist input vs non endocrinologist input, and subspecialist care versus general internist care. It is worthy of note that only one study was from the UK and this involved children with diabetes.&lt;BR&gt;&lt;BR&gt;Compared to generalist care, subspecialist care resulted in better outcomes in 2 of the five studies, including lower readmission rates. Lower mortality was seen with diabetes care provided by a specialist centre. Limitations of this review included lack of RCT’s,&amp;nbsp; and lack of recognition that specialists generally treat more complex cases which could mask possible superior results.&lt;BR&gt;&lt;BR&gt;In conclusion, the authors recognise that the lack of association between treatment in specialist centres and improved outcomes does not negate the value of specialised centres. It recommends that unpicking specific processes of care that would explain differences in outcomes might be a more powerful tool in improving health care quality.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Chin MH. Quality improvement implementation and disparities: the case of the health disparities collaboratives. Med Care 2010 Aug;48(8):668-75. &lt;/STRONG&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20613665" target="_blank"&gt;&lt;STRONG&gt;Link to PubMed abstract here&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;. &lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;The purpose of this study was to determine the effect of the health disparities collaboratives (HDC’s) effect on clinical processes and outcomes, their financial impact and factors important for successful implementation. Following a systematic review of the literature, they demonstrated that HDC’s improve clinical processes of car over 1-2 years, and clinical processes and outcomes over 2-4 years.&lt;BR&gt;&lt;BR&gt;Analysis of the diabetes collaborative reveals societal cost effectiveness but highlights lack of consistent revenue streams for this initiative. Consequently, lack of resources, time and staff burnout were identified as causing barriers to improvement ( e.g. more funding for direct patient services) They identified low cost ways to increase staff morale an prevent burnout include personal recognition, skills development opportunities, and fair distribution of work. However, policy reforms are necessary to enable sustainable improvements via funded business cases. Although a US study, principles of service change and resourcing will resonate with a UK audience.&lt;BR&gt;&amp;nbsp;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>393494</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=393494]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Commentary on Diabetic Nephropathy</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,NEPHROPATHY,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,CAUSES,RESEARCH,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,PREDISPOSING FACTORS,DIABETES,INTERVENTIONS,DIABETIC METABOLIC CONTROL,ANNUAL EVIDENCE UPDATES,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Commentary on Diabetic Nephropathy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&lt;STRONG&gt;&amp;nbsp;&amp;nbsp;&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp; 
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;This commentary on Diabetic Nephropathy has been written for NHS Evidence - diabetes by Dr Ed Sharples, Consultant Nephrologist, Churchill Hospital, Oxford.&amp;nbsp; This commentary focuses on&amp;nbsp;2 selected references from the&amp;nbsp;16 citations found in the searches for the 2010 Annual Evidence Update on Diabetes.&amp;nbsp; &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=392317" target="_blank"&gt;Link here to the list of citations&lt;/A&gt;. 
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Diabetic nephropathy is a common and serious complication of diabetes, and is an important public health issue because of the increase in the numbers of patients with end-stage renal failure secondary to diabetes, which currently accounts for up to 40% of all dialysis patients in Western societies. The UK renal registry data demonstrates similar trends in the UK compared to America, with 26 % of incident patients having diabetes [1].&lt;/P&gt;
&lt;P&gt;For the 2010 AEU in Diabetic Nephropathy, 16 systematic reviews or meta-analyses were identified from the date of the last update. In this commentary, two of these reviews have been critically appraised and discussed. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation 2010 May;55(5):835-47.&amp;nbsp;[2]&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Current best practice guidelines highlight the role of blockade of the renin-angiotensin system in the management of the patient with diabetes and proteinuria. Thiazolidinediones are oral anti-diabetic compounds that act through stimulation of the nuclear receptor peroxisome proliferator-activated receptor-? (PPAR- ?), and decrease insulin resistance, and may have additional effects on the metabolic syndrome and cardiovascular risk factors. Animal studies have shown beneficial effects on urine protein excretion and development of glomeruloscelerosis. The authors performed a systematic literature search on all studies on the effects of Thiazolidinediones on urine albumin or protein from 1991 to September 2009. Full text of articles identified was reviewed, and inclusion criteria were randomised controlled trials of at least 12 weeks duration, in adult patients, in which the effects of Thiazolidinediones was compared with placebo or another antidiabetic drug. From 38 studies identified for detailed evaluation, 15 ramdomized controlled trials, including 2860 patients, with sufficient data were included in the analysis. Studies with rosiglitazone and pioglitazone were included in the analysis. &lt;/P&gt;
&lt;P&gt;In studies including patients with normoalbuminuria or microabulinuria, the WMD of the proportional change in urinary albumin excretion during follow-up between the Thiazolidinedione and control groups was -64.8% (CI -75.6 - -53.9). Overall there was a significant effect of Thiazolidinediones on the development and progression of microalbuminuria.&amp;nbsp; Only three studies examined the effect of Thiazolidinediones in patients with macroalbuminuria / overt proteinuria. All patients were treated with either ACE inhibitors or angiotensin receptor antagonists. There was a significant treatment effect of Thiazolidinediones on proteinuria, despite some heterogeneity within these studies. This finding was similar to a subanalysis of the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) study [Dagenais GR, 2008]. This study in 5269 individuals with impaired glucose tolerance, randomised to either ramipril/ placebo and rosiglitazone/ placebo in a 2*2 factorial design, showed that rosigitazone significant reduced the incidence of renal outcomes. &lt;/P&gt;
&lt;P&gt;Thiozolidinediones are effective hypoglycaemic agents and this study shows they have an additive, beneficial effect on albuminuria. However, there have been well documented side effects, especially fluid retention and deterioration in heart failure, with rosiglitazone. The FDA has recently announced a restriction on prescribing of rosiglitazone by requiring the drug sponsor to submit a Risk Evaluation and Mitigation Strategy, or REMS. When the REMS for rosiglitazone is implemented, the drug will be available to patients not already taking it only if they are unable to achieve glycemic control using other medications and, in consultation with their health care professional, decide not to take pioglitazone for medical reasons. Current users of rosiglitazone will be able to continue using the medication if they appear to be benefiting from it and they acknowledge that they understand these risks. The European Agency has issued a restriction in its use on September 23rd. &lt;/P&gt;
&lt;P&gt;In summary, and re-assessing the meta-analysis following these announcements, the evidence for the effect of pioglitazone, which was used in 10 of the studies examined, remains strong. Good glycaemic control and the use of pioglitazone may be an additional tool in the prevention of diabetic nephropathy. Further trials looking at a definite renal outcome measure, such as incidence of dialysis, or doubling of creatinine, remain essential.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;Dusing R, Sellers F. ACE inhibitors,angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Current Medical Research and Opinion 2009 Sep;25(9):2287-301. [3]&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The renin-angiotensin system plays a key role in the regulation of blood pressure, body volume homeostasis and glomerular autoregulation to maintain GFR. Inhibitors of this system have been widely used to improve outcomes in hypertension, heart failure, and since the Collaborative Group Study reported in 1993 showing captopril reduced the progression to CKD, several large well conducted RCTs have shown an anti-proteinuric effect of RAAS inhibition and reduction in progression of diabetic nephropathy in patients with proteinuria.&lt;/P&gt;
&lt;P&gt;Small studies using a combination of ACE inhibitors and angiotensin receptor blockers (ARBs) have suggested an additive effect on proteinuria reduction. However, the Ongoing Telimesartan Alone or in combination with Ramipril Global Endpoint Trial (ONTARGET) [4], which assessed the effect on cardiovascular outcomes of telisartan 80mg od plus ramipril 10 mg od combination therapy compared with ramipril alone in 25000 patients with coronary, peripheral or cerebrovascular disease or diabetes with evidence of organ damage. Combined therapy showed no significant benefit versus ramipril alone. Moreover, the combination therapy was associated with more hypotension, renal dysfunction and hyperkalaemia, leading the authors to comment that the adverse effects of combined therapy may outweigh the potential clinical benefit. The authors of this review did a systematic review of the literature to identify all randomized clinical trials involving combination therapy in hypertension, diabetic nephropathy, albuminuria or myocardial infarction, including all trials lasting more than four weeks. Seventy studies were considered appropriate for inclusion. Most studies examined the BP-lowering effect of combination therapy – with limited effectiveness. The review includes the COOPERATE study, which was withdrawn for possible fraud. The review is not particularly focused on the trials in diabetic renal disease, and hence is not very useful when reviewing the case for combination therapy in this area. The published renal outcomes of the ONTARGET study, published in the Lancet, showed that the rates of dialysis combined both acute temporary dialysis as well as patients starting maintenance haemodialysis, increasing the rate in the group given combination ACEi/ARB therapy. It remains unclear which group of patients with diabetes would benefit most from the combination of ACE inhibitors with ARBs, or direct renin antagonsts. Targeted therapy to specific groups may be of benefit.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Ansell D, Feehally J, Fogarty D, Inward C, Tomson CRV, Warwick G, et al. UK Renal registry 2009. Nephron Clinical Practice 114: S1: 10&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation 2010 May;55(5):835-47. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20110146" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Dusing R, Sellers F. ACE inhibitors,angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Current Medical Research and Opinion 2009 Sep;25(9):2287-301. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19635044" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;The ONTARGET investigators. Telmisartan, Ramipril or both in patients at high risk for vascular events. New England Journal of&amp;nbsp;Medicine 2008;358:1547-1559. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18378520" target="_blank"&gt;Link to Pubmed abstract here.&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>393495</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=393495]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Commentary on Vitamin D and Diabetes</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Commentary on Vitamin D and Diabetes&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&lt;STRONG&gt;&amp;nbsp;&amp;nbsp;&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp; 
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This commentary on&amp;nbsp;Vitamin D and Diabetes&amp;nbsp;has been written for NHS Evidence - diabetes by Lindsay Oliver, Consultant Dietitian in Diabetes Care, Northumbria Diabetes Service.&amp;nbsp;Her commentary focuses on&amp;nbsp;3 selected references from the 12 citations found in the searches for the 2009 Annual Evidence Update on Diabetes.&amp;nbsp; Link here to the list of citations.&amp;nbsp; &lt;BR&gt;&lt;BR&gt;
&lt;HR&gt;

&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Vitamin D - Hero or Hype?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Vitamin D deficiency is common, becoming commoner and we are becoming increasingly aware of modest degrees of deficiency. An adequate vitamin D level is defined as a serum level of 25-hydroxy vitamin D of &amp;gt; 30nm/ml.&amp;nbsp; 80% of our Vitamin D comes from exposure to sunlight and 20% from dietary sources.&amp;nbsp; Low Vitamin D levels can result from a range of factors including inadequate sunlight exposure or dietary intake, aging, malabsorption, and liver&amp;nbsp; or kidney impairment. Figures from the US suggest that between 1994 and 2004 the prevalence of Vitamin D deficiency rose from 55% of the population to 77% of the population [1]. &lt;/P&gt;
&lt;P&gt;A number of systematic reviews of cross sectional and cohort studies published this year show that low levels of 25-hydroxyvitamin D (25OHD) are associated with more adverse “cardiometabolic” outcomes [1,2,3], such as hypertension, cardiovascular disease, metabolic syndrome and diabetes. Highest levels of serum 25OHD were associated with a 43% reduction in cardiometabolic disorders [2]. If this relationship proves to be causal then effective interventions aimed at improving Vitamin D status might be able to reduce the rise in both diabetes and cardiovascular diseases.&amp;nbsp; However whether low Vitamin D status causes or simply reflects other risk factors for these conditions (such as lack of outdoor activity, dietary habits, increasing obesity, aging or genetics) is as yet unclear.&lt;/P&gt;
&lt;P&gt;Barengolts [1] reviewed studies that related directly to Vitamin D status and glucose metabolism.&amp;nbsp; She suggested that, although there may be a role for intervention in those with low Vitamin D levels with pre-diabetes, there seemed to be no benefit to populations with either healthy glucose metabolism or with established diabetes.&amp;nbsp; This suggests that there may be different roles for Vitamin D at different stages of glucose tolerance.&amp;nbsp; To add to this uncertainty Pittas et al&amp;nbsp;[3] reported that lower Vitamin D was associated with increased risk of hypertension and cardiovascular disease but showed no clear association with diabetes risk.&lt;/P&gt;
&lt;P&gt;Intervention trials are limited and so far have not shown improvement in outcome from Vitamin D supplements [3] . However a number of confounding factors may be worth considering before dismissing Vitamin D as a potential intervention.&amp;nbsp; In particular most of these studies were of short duration and small sample size; many did not adequately control the non-intervention arm or indeed achieve a clinically significant increase in serum 25OHD in the intervention arm. In addition variables such as obesity, outdoor activity and smoking were not accounted for making it impossible to disentangle other confounding factors. In terms of making Vitamin D supplementation more effective, it is interesting to note that a small study [4] recently showed that levels of serum 25OHD were most effectively improved by ensuring that any Vitamin D supplementation, irrespective of dose, was consumed with the largest meal of the day (usually the evening meal)&lt;/P&gt;
&lt;P&gt;Vitamin D is clearly of interest, however before recommendations can be made on the role of supplementation what is needed is a Randomised Controlled Trail in clearly defined populations, with an effective intervention that is adequately controlled.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References &lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Barengolts E. Vitamin D role and use in prediabetes. Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2010 May-2010 Jun 30;16(3):476-85. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20150028" target="_blank"&gt;Link to PubMed&amp;nbsp;abstract here. &lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Parker J, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala NB, et al. Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas 2010 Mar;65(3):225-36. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20031348" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Annals of Internal Medicine 2010 Mar 2;152(5):307-14. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20194237" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Mulligan B, Licita A. Taking vitamin D with the largest meal improves absorption and results in higher serum levels of 25-hydroxyvitamin D. Journal of&amp;nbsp;Bone and Mineral Research. 2010;25(4):928-30. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20200983" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>392317</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=392317]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Complications</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,NEPHROPATHY,DIABETIC FOOT,PAINFUL NEUROPATHIES,SKIN PROBLEMS,CARDIOVASCULAR,KETOACIDOSIS,HYPOGLYCAEMIA,PSYCHOLOGICAL PROBLEMS,CHRONIC COMPLICATIONS,ACUTE COMPLICATIONS,DENTAL PROBLEMS,AUTONOMIC NEUROPATHY,RESEARCH,EYE DISEASES,ANNUAL EVIDENCE UPDATES,SEXUAL PROBLEMS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Complications&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&lt;STRONG&gt;&amp;nbsp;&amp;nbsp;&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp; 'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; ALL OR GENERAL&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Lu W, Feng B. The-374A allele of the RAGE gene as a potential protective factor for vascular complications in type 2 diabetes: a meta-analysis. The Tohoku Journal of Experimental Medicine 2010;220(4):291-7. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Genetics.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20410680" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Ma J, Yang W, Fang N, Zhu W, Wei M. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD 2009 Nov;19(9):596-603. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Tight Glucose Control.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19819121" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: Evidence from a systematic review of the literature. Diabetes, Obesity and Metabolism 2010;12(4):288-298. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20380649" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5599" target="_blank"&gt;Link to supporting guidelines on chronic complications&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5600" target="_blank"&gt;Link to supporting guidelines on acute complications &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/A&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; CVD&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Anthopoulos PG, Hamodrakas SJ, Bagos PG. Apolipoprotein E polymorphisms and type 2 diabetes: a meta-analysis of 30 studies including 5423 cases and 8197 controls. Molecular Genetics and Metabolism 2010 Jul;100(3):283-91. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Genetics.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20381392" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Brown SH Abdelhafiz AH. Trials review: cardiovascular outcome with intensive glycemic control and implications for patients with type 2 diabetes. Postgraduate Medicine 2009;121(5):31-41. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Tight Glucose Control.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009109835" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Calvin AD, Aggarwal NR, Murad MH, Shi Q, Elamin MB, Geske JB, et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009 Dec;32(12):2300-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19741185" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Chamnan P, Simmons RK, Sharp SJ, Griffin SJ, Wareham NJ. Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia 2009 Oct;52(10):2001-14. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009109390" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19897665" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;De Luca G, Michael Gibson C, Bellandi F, Murphy S, Maioli M, Noc M, et al. Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation. Journal of Thrombosis and Thrombolysis 2009 Oct;28(3):288-98. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009110003" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Dusing R, Sellers F. ACE inhibitors,angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Current Medical Research and Opinion 2009 Sep;25(9):2287-301. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Nephropathy.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19635044" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. Journal of the American College of Cardiology 2010 Mar 30;55(13):1310-7. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Prediabetic State.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20338491" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Annals of Internal Medicine 2009 Sep 15;151(6):394-403. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Tight Glucose Control.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19620144" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Lee MS, Yang T, Dhoot J, Iqbal Z, Liao H. Meta-analysis of studies comparing coronary artery bypass grafting with drug-eluting stenting in patients with diabetes mellitus and multivessel coronary artery disease. The American Journal of Cardiology 2010 Jun 1;105(11):1540-4. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20494658" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutrition,Metabolism,and Cardiovascular Diseases : NMCD 2009 Nov;19(9):604-12. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Tight Glucose Control.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19427768" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Marso SP, Kennedy KF, House JA, McGuire DK. The effect of intensive glucose control on all-cause and cardiovascular mortality,myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes &amp;amp; Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease 2010 Apr;7(2):119-30. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Tight Glucose Control.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20382775" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Martirosyan L, Voorham J, Haaijer-Ruskamp FM, Braspenning J, Wolffenbuttel BH, Denig P. A systematic literature review: prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management. Pharmacoepidemiol Drug Saf 2010 Apr;19(4):319-34. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19960483" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Pierdomenico SD, Cuccurullo F. Ambulatory blood pressure monitoring in type 2 diabetes and metabolic syndrome: a review. Blood Pressure Monitoring 2010 Feb;15(1):1-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20071977" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials. International Journal of Cardiology 2010 May 28;141(2):157-66. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19232762" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Sander D, Kearney MT. Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. Journal of Neurology 2009 Oct;256(10):1603-19. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19399381" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009 Nov;52(11):2288-98. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Tight Glucose Control.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19655124" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Wang AT, McCoy CP, Murad MH, Montori VM. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ 2010;340:c1344.&amp;nbsp;&lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Medication &amp;gt; Glitazones.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20299696" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Webb DR, Davies MJ, Gray LJ, Abrams KR, Srinivasan B, Das S, et al. Searching for the right outcome? A systematic review and meta-analysis of controlled trials using carotid intima-media thickness or pulse wave velocity to infer antiatherogenic properties of thiazolidinediones. Diabetes,Obesity and Metabolism 2010;12(2):124-132. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Medication &amp;gt; Glitazones.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19922476" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Younis N, Williams S, Ammori B, Soran H. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. Expert Opinion on Pharmacotherapy 2010 Jun;11(9):1459-66. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20429671" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Research &amp;amp; Clinical Practice 2010 Feb;87(2):211-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19853947" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Zhang CY, Sun AJ, Zhang SN, Wu CN, Fu MQ, Xia G, et al. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis. Annals of Medicine 2010 May 6;42(4):305-15. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Tight Glucose Control.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20429797" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Zhang F, Dong L, Ge J. Meta-analysis of five randomized clinical trials comparing sirolimus- versus paclitaxel-eluting stents in patients with diabetes mellitus. The American Journal of Cardiology 2010 Jan 1;105(1):64-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20102892" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5139" target="_blank"&gt;Link to supporting guidelines on Cardiovascular complications&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; DENTAL PROBLEMS&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Chavarry NG, Vettore MV, Sansone C, Sheiham A. The relationship between diabetes mellitus and destructive periodontal disease: a meta-analysis. Oral Health &amp;amp; Preventive Dentistry 2009;7(2):107-127. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19583037" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5618" target="_blank"&gt;Link to supporting guidelines on dental problems&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; DIABETIC FOOT&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;Adler AI, Erqou S, Lima TA, Robinson AH. Association between glycated haemoglobin and the risk of lower extremity amputation in patients with diabetes mellitus-review and meta-analysis. Diabetologia 2010 May;53(5):840-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20127309" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Chen M, Zheng H, Yin L-P, Xie C-G. Is oral administration of Chinese herbal medicine effective and safe as an adjunctive therapy for managing diabetic foot ulcers? A systematic review and meta-analysis. Journal of Alternative and Complementary Medicine 2010;16(8):889-898. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20673140" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Dante A, Checchi A. [Implementation of Clinical Pathway in the management of patients with diabetic foot]. International Nursing Perspectives 2008;8(3):109-112. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:392328:0" name=internalLink&gt;&lt;A href="nelh:392328:1" name=internalLink&gt;methodology&lt;/A&gt;&lt;/A&gt; for more information. &lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010001115" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Dorresteijn JA, Kriegsman DM, Assendelft WJ, Valk G D. Patient education for preventing diabetic foot ulceration. Cochrane Database of Systematic Reviews 2010;5:CD001488. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Diabetic Foot.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20464718" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Dorresteijn JA, Kriegsman DM, Valk GD. Complex interventions for preventing diabetic foot ulceration. Cochrane Database of Systematic Reviews 2010;(1):CD007610. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=10000001488" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Edwards J, Stapley S. Debridement of diabetic foot ulcers. Cochrane Database of Systematic Reviews 2010;(1):CD003556. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=10000003556" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Karthikesalingam A, Holt PJE, Moxey P, Jones KG, Thompson MM, Hinchliffe RJ. A systematic review of scoring systems for diabetic foot ulcers. Diabetic Medicine 2010;27(5):544-549. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20536950" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Roukis TS, Schade VL. Percutaneous flexor tenotomy for treatment of neuropathic toe ulceration secondary to toe contracture in persons with diabetes: a systematic review. The Journal of Foot and Ankle Surgery : Official Publication of the American College of Foot and Ankle Surgeons 2009 Nov-2009 Dec 31;48(6):684-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19857826" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Teng YJ, Li YP, Wang JW, Yang KH, Zhang YC, Wang YJ, et al. Bioengineered skin in diabetic foot ulcers. Diabetes,Obesity and Metabolism 2010;12(4):307-315. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010005382" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Villela DL, Santos VL. Evidence on the use of platelet-rich plasma for diabetic ulcer: a systematic review. Growth Factors 2010 Apr;28(2):111-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20001406" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5135" target="_blank"&gt;Link to supporting guidelines on diabetic foot&lt;/A&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;COMPLICATIONS &amp;gt; EYE DISEASES&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Optical coherence tomography for age-related macular degeneration and diabetic macular edema: an evidence-based analysis. Toronto: Medical Advisory Secretariat,Ontario Ministry of Health and Long-Term Care (MAS) 2009;Volume 9,Number 13. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=32009100460" target="_blank"&gt;Link to&amp;nbsp;full-text&amp;nbsp;here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Abhary S, Hewitt AW, Burdon KP, Craig JE. A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes 2009 Sep;58(9):2137-47. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Genetics.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19587357" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Andriolo RB, Puga ME, Belfort R, Atallah AN. Bevacizumab for ocular neovascular diseases: a systematic review. Revista Paulista De Medicina 2009;127(2):84-91. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:392328:0" name=internalLink&gt;&lt;A href="nelh:392328:1" name=internalLink&gt;methodology&lt;/A&gt;&lt;/A&gt; for more information. &lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009110313" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Benbassat J, Polak BC. Reliability of screening methods for diabetic retinopathy. Diabetic Medicine : a Journal of the British Diabetic Association 2009 Aug;26(8):783-90. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19709148" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Gewaily D, Greenberg PB. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database of Systematic Reviews 2009;(1). &lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD007324/frame.html" target="_blank"&gt;Link to full-text here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Jones S, Edwards RT. Diabetic retinopathy screening: A systematic review of the economic evidence. Diabetic Medicine 2010;27(3):249-256. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Economics.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20536486" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Lee CT, Gayton EL, Beulens JW, Flanagan D W, Adler A I. Micronutrients and diabetic retinopathy a systematic review. Ophthalmology 2010 Jan;117(1):71-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19900709" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Parravano M, Menchini F, Virgili G. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database of Systematic Reviews 2009;(4):CD007419. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:392328:0" name=internalLink&gt;&lt;A href="nelh:392328:1" name=internalLink&gt;methodology&lt;/A&gt;&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=10000007419" target="_blank"&gt;Link&amp;nbsp;DARE abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Rodgers M, Hodges R, Hawkins J, Hollingworth W, Duffy S, McKibbin M, et al. Colour vision testing for diabetic retinopathy: a systematic review of diagnostic accuracy and economic evaluation. Health Technology Assessment (Winchester,England) 2009 Dec;13(60):1-160. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010000310" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Rudnisky CJ, Lavergne V, Katz D. Visual acuity after intravitreal triamcinolone for diabetic macular edema refractory to laser treatment: a meta-analysis. Canadian Journal of Ophthalmology 2009 Oct;44(5):587-93. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19789597" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Steijns D, Duijvesz D, Breedijk MA, van der Heijden GJ. Steroid injection in addition to macular laser grid photocoagulation in diabetic macular oedema: a systematic review. Acta Ophthalmol 2010 Jun;88(4):389-93. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20222888" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Wong TY, Mwamburi M, Klein R, Larsen M, Flynn H, Hernandez-Medina M, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 2009 Dec;32(12):2307-13. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19940227" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=8694" target="_blank"&gt;Link to supporting guidelines on diabetic eye diseases&lt;/A&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;COMPLICATIONS &amp;gt; HYPOGLYCAEMIA&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;Barnard K, Thomas S, Royle P, Noyes K, Waugh N. Fear of hypoglycaemia in parents of young children with type 1 diabetes: A systematic review. BMC Pediatrics 2010;10. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Psychological &amp;gt; Anxiety.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20633252" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Davidson JA, Liebl A, Christiansen JS, Fulcher G, Ligthelm RJ, Brown P, et al. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis. Clinical Therapeutics 2009 Aug;31(8):1641-51. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Medication &amp;gt; Insulin.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19808125" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Nehme Z,Cudini D. A review of the efficacy of 10% dextrose as an alternative to high concentration glucose in the treatment of out-of-hospital hypoglycaemia. Journal of Emergency Primary Health Care 2009 Sep;7(3):5p.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5141" target="_blank"&gt;Link to supporting guidelines on Hypoglycaemia&lt;/A&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;COMPLICATIONS &amp;gt; NEPHROPATHY&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Cui W-P, Du B, Jia Y, Xu Z-G, Miao L-N. Statins for early diabetic kidney disease: A systematic review. Chinese Journal of Evidence-Based Medicine 2010;10(1):81-88. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010001839" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Dusing R, Sellers F. ACE inhibitors,angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Current Medical Research and Opinion 2009 Sep;25(9):2287-301. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Cvd.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19635044" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Li J, Wu HM, Zhang L, Zhu B, Dong BR. Heparin and related substances for preventing diabetic kidney disease. Cochrane Database of Systematic Reviews 2010;(9). &lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD005631/frame.html" target="_blank"&gt;Link to full-text here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Long X, Wang F, Huang C-Q. Tongxinluo capsule for diabetic kidney disease: A systematic review. Chinese Journal of Evidence-Based Medicine 2010;10(1):73-80. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010001838" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation 2010 May;55(5):835-47. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Medication &amp;gt; Glitazones.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20110146" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Shi J-Y, Huang J, Tian H-M. Effect of breviscapine on diabetic nephropathy: A systematic review. Chinese Journal of Evidence-Based Medicine 2009;9(10):1099-1109. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009110302" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Wang F, Wang GG, Ge WH, Li XP, Wu YH, Yuan QY, et al. Sodium ferulate for diabetic kidney disease: a systematic review. Chinese Journal of Evidence-Based Medicine 2009;9(6):652-669. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:392328:0" name=internalLink&gt;&lt;A href="nelh:392328:1" name=internalLink&gt;methodology&lt;/A&gt;&lt;/A&gt; for more information. &lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009107244" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Wang H, Deng JL, Yue J, Li J, Hou YB. Prostaglandin E1 for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews 2010;5:CD006872.&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=10000006872" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Wu WH, Wang H, Zhang MP, Huang SM. Effects of tripterygium on diabetic nephropathy: a systematic review. Chinese Journal of Evidence-Based Medicine 2010;10(6):693-699. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010004853" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Zeng Z, Li L, Zhang Z, Li Y, Wei Z, Huang K, et al. A meta-analysis of three polymorphisms in the endothelial nitric oxide synthase gene (NOS3) and their effect on the risk of diabetic nephropathy. Human Genetics 2010;127(4):373-381. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Genetics.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20049477" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Zhang M-X, Cui K, Zhu Y-M, Duan Y-P. Dan hong injection for diabetic nephropathy: A systematic review. Chinese Journal of Evidence-Based Medicine 2009;9(10):1087-1093. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009110300" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Zintzaras E, Papathanasiou AA, Stefanidis I. Endothelial nitric oxide synthase gene polymorphisms and diabetic nephropathy: a HuGE review and meta-analysis. Genetics in Medicine : Official Journal of the American College of Medical Genetics 2009 Oct;11(10):695-706. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Genetics.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19773668" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5133" target="_blank"&gt;Link to supporting guidelines on diabetic nephropathy&lt;/A&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;COMPLICATIONS &amp;gt; NEUROPATHY&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Dros J, Wewerinke A, Bindels PJ, van Weert HC. Accuracy of monofilament testing to diagnose peripheral neuropathy: a systematic review. Annals of Family Medicine 2009 Nov-2009 Dec 31;7(6):555-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19901316" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Jin DM, Xu Y, Geng DF, Yan TB. Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: a meta-analysis of randomized controlled trials. Diabetes Research &amp;amp; Clinical Practice 2010 Jul;89(1):10-15. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010005688" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Kanji JN, Anglin RE, Hunt DL, Panju A. Does this patient with diabetes have large-fiber peripheral neuropathy? JAMA 2010 Apr 21;303(15):1526-32. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20407062" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Kars HJ, Hijmans JM, Geertzen JH, Zijlstra W. The effect of reduced somatosensation on standing balance: a systematic review. Journal of Diabetes Science and Technology 2009;3(4):931-943. &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769946/pdf/dst-03-0931.pdf" target="_blank"&gt;Link to full-text here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database of Systematic Reviews 2009;(4):CD007115. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:392328:0" name=internalLink&gt;&lt;A href="nelh:392328:1" name=internalLink&gt;methodology&lt;/A&gt;&lt;/A&gt; for more information. &lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=10000007115" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Mijnhout GS, Alkhalaf A, Kleefstra N, Bilo HJ. Alpha lipoic acid: a new treatment for neuropathic pain in patients with diabetes? The Netherlands Journal of Medicine 2010 Apr;68(4):158-62.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20421656" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ, Moore M. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009;(3). &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:392328:0" name=internalLink&gt;&lt;A href="nelh:392328:1" name=internalLink&gt;methodology&lt;/A&gt;&lt;/A&gt; for more information. &lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=10000007076" target="_blank"&gt;Link to&amp;nbsp;DARE abstract&amp;nbsp;here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;O'Grady G, Egbuji JU, Du P, Cheng LK, Pullan AJ, Windsor JA. High-frequency gastric electrical stimulation for the treatment of gastroparesis: a meta-analysis. World Journal of Surgery 2009 ;33(8):1693-1701. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009108078" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Pieber K, Herceg M, Paternostro-Sluga T. Electrotherapy for the treatment of painful diabetic peripheral neuropathy: a review. Journal of Rehabilitation Medicine : Official Journal of the UEMS European Board of Physical and Rehabilitation Medicine 2010 Apr;42(4):289-95. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20461329" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Watson CPN, Gilron I, Sawynok J. A qualitative systematic review of head-to-head randomized controlled trials of oral analgesics in neuropathic pain. Pain Research and Management 2010 ;15(3):147-157. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20577657" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Wolff RF, Bala MM, Westwood M, Kessels AG, Kleijnen J. 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Medical Weekly : Official Journal of the Swiss Society of Infectious Diseases,the Swiss Society of Internal Medicine,the Swiss Society of Pneumology 2010 May 29;140(21-22):297-306. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20458651" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5136" target="_blank"&gt;Link to supporting guidelines on diabetic neuropathies&lt;/A&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;COMPLICATIONS &amp;gt; PSYCHOLOGICAL &amp;gt; ANXIETY&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Barnard K, Thomas S, Royle P, Noyes K, Waugh N. Fear of hypoglycaemia in parents of young children with type 1 diabetes: A systematic review. BMC Pediatrics 2010;10. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Hypoglycemia.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20633252" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Concha JB, Kravitz HM, Chin MH, Kelley MA, Chavez N, Johnson TP. Review of type 2 diabetes management interventions for addressing emotional well-being in Latinos. Diabetes Educator 2009;35(6):941-958. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010001410" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;McIntyre RS, Kenna HA, Nguyen HT, Law CW, Sultan F, Woldeyohannes HO, et al. Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: points of pathophysiological commonality with mood disorders? Advances in Therapy 2010 Feb;27(2):63-80. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Psychological &amp;gt; Cognitive Function, Complications &amp;gt; Psychological &amp;gt; Depression.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20390390" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=14654" target="_blank"&gt;Link to supporting guidelines on anxiety and depression&lt;/A&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;COMPLICATIONS &amp;gt; PSYCHOLOGICAL &amp;gt; COGNITIVE FUNCTION&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;McIntyre RS, Kenna HA, Nguyen HT, Law CW, Sultan F, Woldeyohannes HO, et al. Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: points of pathophysiological commonality with mood disorders? Advances in Therapy 2010 Feb;27(2):63-80. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Psychological &amp;gt; Cognitive Function, Complications &amp;gt; Psychological &amp;gt; Depression.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20390390" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity,diabetes,and related disorders. Biological Psychiatry 2010 Mar 15;67(6):505-12. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19358976" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=14653" target="_blank"&gt;Link to supporting guidelines on cognitive function&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;COMPLICATIONS &amp;gt; PSYCHOLOGICAL &amp;gt; DEPRESSION&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Ali S, Stone M, Skinner TC, Robertson N, Davies M, Khunti K. The association between depression and health-related quality of life in people with type 2 diabetes: a systematic literature review. Diabetes/Metabolism Research and Reviews 2010 Feb;26(2):75-89. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Living with Diabetes.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20186998" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;van der Feltz-Cornelis CM, Nuyen J, Stoop C, Chan J, Jacobson AM, Katon W et al. Effect of interventions for major depressive disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review and meta-analysis. General Hospital Psychiatry 2010 Jul 7;32(4):380-395. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010005691" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;McIntyre RS, Kenna HA, Nguyen HT, Law CW, Sultan F, Woldeyohannes HO, et al. Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: points of pathophysiological commonality with mood disorders? Advances in Therapy 2010 Feb;27(2):63-80. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Psychological &amp;gt; Anxiety, Complications &amp;gt; Psychological &amp;gt; Cognitive Function.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20390390" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=14654" target="_blank"&gt;Link to supporting guidelines on anxiety and depression&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>392298</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=392298]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Condition Management</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Condition Management&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; ALL OR GENERAL&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;Chiu C-J, Wray LA, Beverly EA. Relationship of glucose regulation to changes in weight: A systematic review and guide to future research. Diabetes/Metabolism Research and Reviews 2010;26(5):323-335. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20578206" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Yi Y, Philips Z, Bergman G, Burslem K. Economic models in type 2 diabetes. Current Medical Research and Opinion 2010;26(9):2105-2118. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Economics.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20642392" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5627" target="_blank"&gt;Link to supporting guidelines on condition management of Type 1 Diabetes&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5633" target="_blank"&gt;Link to supporting guidelines on condition management of Type 2 Diabetes&amp;nbsp; &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;CONDITION MANAGEMENT &amp;gt; BARIATRIC SURGERY&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;Medical Advisory Secretariat. Bariatric surgery for people with diabetes and morbid obesity: an evidence-based analysis. Toronto: Medical Advisory Secretariat,Ontario Ministry of Health and Long-Term Care (MAS) 2009;Volume 9,Number 22. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=32010000127" target="_blank"&gt;Link to&amp;nbsp;full-text here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technology Assessment (Winchester,England) 2009 Sep;13(41):1-190,215-357, iii-iv. &lt;A href="http://www.hta.ac.uk/1742" target="_blank"&gt;Link to&amp;nbsp;summary here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=14785" target="_blank"&gt;Link to supporting guidelines on condition management of obesity&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; DIET&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;Esposito K, Maiorino MI, Ceriello A, Giugliano D. Prevention and control of type 2 diabetes by Mediterranean diet: A systematic review. Diabetes Research &amp;amp; Clinical Practice 2010;89(2):97-102. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Prevention,Causes And Risk Factors.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20546959" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Sievenpiper JL, Carleton AJ, Chatha S, Jiang HY, de Souza RJ, Beyene J, et al. Heterogeneous effects of fructose on blood lipids in individuals with type 2 diabetes: systematic review and meta-analysis of experimental trials in humans. Diabetes Care 2009 Oct;32(10):1930-7.&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009110333" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;/STRONG&gt;Steyn NP, Lambert EV, Tabana H. Conference on "Multidisciplinary approaches to nutritional problems". Symposium on "Diabetes and health". Nutrition interventions for the prevention of type 2 diabetes. The Proceedings of the Nutrition Society 2009;68(1):55-70. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19068148" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=8726" target="_blank"&gt;Link to supporting guidelines on diet as a treatment for Type 1 Diabetes&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=8724" target="_blank"&gt;Link to supporting guidelines on diet as a treatment for Type 2 Diabetes&lt;BR&gt;&lt;BR&gt;&lt;/A&gt;&lt;STRONG&gt;&lt;BR&gt;CONDITION MANAGEMENT &amp;gt; EXERCISE&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;Aljasir B, Bryson M, Al-Shehri B. Yoga practice for the management of type II diabetes mellitus in adults: A systematic review. Evidence-Based Complementary and Alternative Medicine 2010;7(4):399-408. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18955338" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Irvine C, Taylor NF. Progressive resistance exercise improves glycaemic control in people with type 2 diabetes mellitus: a systematic review. The Australian Journal of Physiotherapy 2009;55(4):237-246. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010001527" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Korkiakangas EE, Alahuhta MA, Laitinen JH. Barriers to regular exercise among adults at high risk or diagnosed with type 2 diabetes: a systematic review. Health Promotion International 2009 Dec;24(4):416-27. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19793763" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Strasser B, Siebert U, Schobersberger W. Resistance training in the treatment of the metabolic syndrome: a systematic review and meta-analysis of the effect of resistance training on metabolic clustering in patients with abnormal glucose metabolism. Sports Medicine (Auckland,N.Z.) 2010 May 1;40(5):397-415. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20433212" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;van Nieuwaal PA, Wittink HM, de Valk HW. [Effectiveness of supervised exercise programmes versus exercise advice in individuals with diabetes mellitus type 2: a systematic review]. Nederlands Tijdschrift Fur Fysioterapie 2009;119(6):198-205. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010002554" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=8727" target="_blank"&gt;Link to supporting guidelines on exercise as a treatment for Type 1 Diabetes&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=8725" target="_blank"&gt;Link to supporting guidelines on exercise as a treatment for Type 2 Diabetes&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; MEDICATION &amp;gt; ALL OR GENERAL&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control,weight gain,and hypoglycemia in type 2 diabetes. JAMA 2010 Apr 14;303(14):1410-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20388897" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Sherifali D,Nerenberg K,Pullenayegum E,Cheng JE,Gerstein HC. The Effect of Oral Antidiabetic Agents on A1C Levels: A systematic review and meta-analysis. Diabetes Care 2010 Aug;33(8):1859-1864. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20484130" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7088" target="_blank"&gt;Link to supporting guidelines on medication for Type 1 Diabetes&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7090" target="_blank"&gt;Link to supporting guidelines on medication for Type 2 Diabetes &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/A&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; MEDICATION &amp;gt; GLITAZONES&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;Chapell R, Gould AL, Alexander CM. Baseline differences in A1C explain apparent differences in efficacy of sitagliptin,rosiglitazone and pioglitazone. Diabetes,Obesity and Metabolism 2009;11(11):1009-1016. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Medication &amp;gt; Incretins.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19614948" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Derosa G, Maffioli P. Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Diabetes Technology &amp;amp; Therapeutics 2010 Jun;12(6):491-501. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Medication &amp;gt; Sulphonylureas.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20470234" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Nissen SE, Wolski K. Rosiglitazone revisited: An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Archives of Internal Medicine 2010;170(14):1191-1201. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:392328:0" name=internalLink&gt;&lt;A href="nelh:392328:1" name=internalLink&gt;methodology&lt;/A&gt;&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010004585" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation 2010 May;55(5):835-47. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Nephropathy.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20110146" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Wang AT, McCoy CP, Murad MH, Montori VM. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ 2010;340:c1344. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Cvd.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20299696" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Webb DR, Davies MJ, Gray LJ, Abrams KR, Srinivasan B, Das S, et al. Searching for the right outcome? A systematic review and meta-analysis of controlled trials using carotid intima-media thickness or pulse wave velocity to infer antiatherogenic properties of thiazolidinediones. Diabetes,Obesity and Metabolism 2010;12(2):124-132. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Cvd.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19922476" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7088" target="_blank"&gt;Link to supporting guidelines on medication for Type 1 Diabetes&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7090" target="_blank"&gt;Link to supporting guidelines on medication for Type 2 Diabetes&amp;nbsp;&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; MEDICATION &amp;gt; INCRETINS&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;Anderson SL, Trujillo JM. Association of pancreatitis with glucagon-like peptide-1 agonist use. The Annals of Pharmacotherapy 2010 May;44(5):904-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20371755" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Chapell R, Gould AL, Alexander CM. Baseline differences in A1C explain apparent differences in efficacy of sitagliptin,rosiglitazone and pioglitazone. Diabetes,Obesity and Metabolism 2009;11(11):1009-1016. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Medication &amp;gt; Glitazones.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19614948" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010 Mar 5-;70(4):489-512. &lt;BR&gt;&lt;BR&gt;Drab SR. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy 2010 Jun;30(6):609-24. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20500049" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Fakhoury WKH, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010;86(1):44-57. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20616619" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Garg SK. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. Diabetes Technology &amp;amp; Therapeutics 2010 Jan;12(1):11-24. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Medication &amp;gt; Insulin.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20082581" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Johnson JT, Golden KL, Braceras R. An update of recent trials with vildagliptin,a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Journal of Pharmacy Technology 2009;25(4):235-243. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009110100" target="_blank"&gt;Link to DARE abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;Logan JK, Escano AK. Saxagliptin: New therapy for type 2 diabetes. Journal of Pharmacy Technology 2010;26(3):123-128. &lt;BR&gt;&lt;BR&gt;Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutrition,Metabolism,and Cardiovascular Diseases : NMCD 2010 May;20(4):224-35. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19515542" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Norris SL, Lee N, Thakurta S, Chan BK. Exenatide efficacy and safety: a systematic review. Diabetic Medicine : a Journal of the British Diabetic Association 2009 Sep;26(9):837-46. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19719703" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technology Assessment (Winchester,England) 2010;14(36):1-248. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Medication &amp;gt; Insulin.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.hta.ac.uk/1743" target="_blank"&gt;Link to&amp;nbsp;summary here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;White J. Efficacy and safety of incretin based therapies: clinical trial data. Journal of the American Pharmacists Association : JAPhA 2009 Sep-2009 Oct 31;49 Suppl 1:S30-40. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19801363" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7088" target="_blank"&gt;Link to supporting guidelines on medication for Type 1 Diabetes&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7090" target="_blank"&gt;Link to supporting guidelines on medication for Type 2 Diabetes &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/A&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; MEDICATION &amp;gt; INSULIN&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technology &amp;amp; Therapeutics 2010 Jun;12 Suppl 1:S101-8. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Economics, Condition Management &amp;gt; Treatment Concordance.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20515297" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Cummins E, Royle P, Snaith A, Greene A, Robertson L, McIntyre L, et al. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technology Assessment (Winchester,England) 2010 Feb;14(11):iii-iv,xi-xvi,1-181. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Economics.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010002837" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Davidson JA, Liebl A, Christiansen JS, Fulcher G, Ligthelm RJ, Brown P, et al. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis. Clinical Therapeutics 2009 Aug;31(8):1641-51. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Hypoglycaemia.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19808125" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Garg SK. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. Diabetes Technology &amp;amp; Therapeutics 2010 Jan;12(1):11-24. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Medication &amp;gt; Incretins.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20082581" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Hagenmeyer EG, Schadlich PK, Koster AD, Dippel F-W, Haussler B. Quality of life and treatment satisfaction in patients being treated with long-acting insulin analogues: Systematic review [German] Lebensqualitat und behandlungszufriedenheit unter therapie mit langwirksamen analoginsulinen: Systematischer review. Deutsche Medizinische Wochenschrift 2009;134(12):565-570. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:392328:0" name=internalLink&gt;&lt;A href="nelh:392328:1" name=internalLink&gt;methodology&lt;/A&gt;&lt;/A&gt; for more information. &lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009105325" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer T W, Plank J, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2009;(4). &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=10000005613" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;IQWiG. Rapid-acting insulin analogues in children and adolescents with diabetes mellitus type 1- follow-up commission. Cologne: Institut Fuer Qualitaet Und Wirtschaftlichkeit Im Gesundheitswesen (IQWiG) 2009. &lt;A href="http://www.iqwig.de/index.789.en.html" target="_blank"&gt;Link to&amp;nbsp;summary here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Jacobsen IB, Henriksen JE, Hother-Nielsen O, Vach W, Beck-Nielsen H. Evidence-based insulin treatment in type 1 diabetes mellitus. Diabetes Research &amp;amp; Clinical Practice 2009 Oct;86(1):1-10. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009109552" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 2009 Oct;52(10):1990-2000. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19644668" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Medical Advisory Secretariat. Continuous subcutaneous insulin infusion (CSII) pumps for type 1 and type 2 adult diabetic populations: an evidence-based analysis. Toronto: Medical Advisory Secretariat, Ontario Ministry of Health and Long-Term Care (MAS) 2009;Volume 9, Number 20. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=32010000125" target="_blank"&gt;Link to&amp;nbsp;full-text here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Misso ML, Egberts KJ, Page M, O'Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database of Systematic Reviews 2010;(1):CD005103. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=10000005103" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Molife C, Lee LJ, Shi L, Sawhney M, Lenox SM. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technology &amp;amp; Therapeutics 2009 Aug;11(8):529-38. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19698067" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Valentine WJ, Pollock RF, Plun-Favreau J, White J. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes. Current Medical Research and Opinion 2010 Jun;26(6):1399-412. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Economics.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20387997" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technology Assessment (Winchester, England) 2010;14(36):1-248. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Medication &amp;gt; Incretins. &lt;/SPAN&gt;&lt;A href="http://www.hta.ac.uk/1743" target="_blank"&gt;Link to&amp;nbsp;summary here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7088" target="_blank"&gt;Link to supporting guidelines on medication for Type 1 Diabetes&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7090" target="_blank"&gt;Link to supporting guidelines on medication for Type 2 Diabetes &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/A&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; MEDICATION &amp;gt; METFORMIN&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;Goergen SK, Rumbold G, Compton G, Harris C. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology 2010;254(1):261-269. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20032157" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2010;4:CD002967. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=10000002967" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia 2010 May;53(5):809-20. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20057994" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7088" target="_blank"&gt;Link to supporting guidelines on medication for Type 1 Diabetes&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7090" target="_blank"&gt;Link to supporting guidelines on medication for Type 2 Diabetes&amp;nbsp;&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; MEDICATION &amp;gt; OTHER&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;Dunican KC, Adams NM, Desilets AR. The role of pramlintide for weight loss. The Annals of Pharmacotherapy 2010 Mar;44(3):538-45.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20164472" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Grant SJ, Bensoussan A, Chang D, Kiat H, Klupp N L, Liu J P, et al. Chinese herbal medicines for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database of Systematic Reviews 2009;(4):CD006690. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Prediabetic State. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:392328:0" name=internalLink&gt;&lt;A href="nelh:392328:1" name=internalLink&gt;methodology&lt;/A&gt;&lt;/A&gt; for more information.&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=10000006690" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;IQWiG. Glinides in the treatment of diabetes mellitus type 2. Cologne: Institut Fuer Qualitaet Und Wirtschaftlichkeit Im Gesundheitswesen (IQWiG) 2009. &lt;A href="http://www.iqwig.de/index.650.en.html" target="_blank"&gt;Link to&amp;nbsp;summary here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Lloret-Linares C Greenfield JR Czernichow S. Effect of weight-reducing agents on glycaemic parameters and progression to type 2 diabetes: a review. Diabetic Medicine 2008;25(10):1142-1150. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Prevention, Causes And Risk Factors. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:392328:0" name=internalLink&gt;&lt;A href="nelh:392328:1" name=internalLink&gt;methodology&lt;/A&gt;&lt;/A&gt; for more information.&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009109343" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Ooi CP, Yassin Z, Hamid TA. Momordica charantia for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2010;2:CD007845. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=10000007845" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7088" target="_blank"&gt;Link to supporting guidelines on medication for Type 1 Diabetes&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7090" target="_blank"&gt;Link to supporting guidelines on medication for Type 2 Diabetes &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/A&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; MEDICATION &amp;gt; SULPHONYLUREAS&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;Derosa G, Maffioli P. Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Diabetes Technology &amp;amp; Therapeutics 2010 Jun;12(6):491-501. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Medication &amp;gt; Glitazones.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20470234" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Liu R-M, Jia P, Tang Y. Glimepiride therapy for type 2 diabetes mellitus: A systematic review. Chinese Journal of Evidence-Based Medicine 2009;9(10):1094-1098. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010001839" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7088" target="_blank"&gt;Link to supporting guidelines on medication for Type 1 Diabetes&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7090" target="_blank"&gt;Link to supporting guidelines on medication for Type 2 Diabetes&amp;nbsp;&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; PSYCHOLOGICAL INTERVENTIONS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Harkness E, Macdonald W, Valderas J, Coventry P, Gask L, Bower P. Identifying psychosocial interventions that improve both physical and mental health in patients with diabetes: a systematic review and meta-analysis. Diabetes Care 2010 Apr;33(4):926-30. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20351228" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Soo H, Lam S. Stress management training in diabetes mellitus. Journal of Health Psychology 2009 Oct;14(7):933-43. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19786520" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=8728" target="_blank"&gt;Link to supporting guidelines on psychological interventions&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; SELF-MANAGEMENT&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;Belendez M, de Wit M, Snoek FJ. Perspectives in practice. Assessment of parent-adolescent partnership in diabetes care: a review of measures. Diabetes Educator 2010 Mar 3;36(2):205. &lt;BR&gt;&lt;BR&gt;Cobden DS, Niessen LW, Barr CE, Rutten FF, Redekop WK. Relationships among self-management, patient perceptions of care, and health economic outcomes for decision-making and clinical practice in type 2 diabetes. Value Health 2010 Jan;13(1):138-47. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Economics.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19695005" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Frei A, Svarin A, Steurer-Stey C, Puhan MA. Self-efficacy instruments for patients with chronic diseases suffer from methodological limitations--a systematic review. Health and Quality of Life Outcomes 2009;7:86. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19781095" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Huisman SD, De Gucht V, Dusseldorp E, Maes S. The effect of weight reduction interventions for persons with type 2 diabetes: a meta-analysis from a self-regulation perspective. Diabetes Educator 2009 Sep-2009 Oct 31;35(5):818-35. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19687258" target="_blank"&gt;Link to PubMed abstract here. &lt;BR&gt;&lt;BR&gt;&lt;/A&gt;Medical Advisory Secretariat. Behavioural interventions for type 2 diabetes: an evidence-based analysis. Toronto: Medical Advisory Secretariat, Ontario Ministry of Health and Long-Term Care (MAS) 2009;Volume 9, Number 21. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=32010000126" target="_blank"&gt;Link to&amp;nbsp;full-text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Minet L, Moller S, Vach W, Wagner L, Henriksen JE. Mediating the effect of self-care management intervention in type 2 diabetes: a meta-analysis of 47 randomised controlled trials. Patient Education &amp;amp; Counseling 2010 Jul;80(1):29-41. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010005378" target="_blank"&gt;Link to DARE abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; SELF-MONITORING&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;Allemann S, Houriet C, Diem P, Stettler C. Self-monitoring of blood glucose in non-insulin treated patients with type 2 diabetes: a systematic review and meta-analysis. Current Medical Research and Opinion 2009 Dec;25(12):2903-13. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19827909" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Boren SA, Clarke WL. Analytical and clinical performance of blood glucose monitors. Journal of Diabetes Science and Technology 2010;4(1):84-97. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20167171" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Clar C, Barnard K, Cummins E, Royle P, Waugh N. Self-monitoring of blood glucose in type 2 diabetes: systematic review. Health Technology Assessment (Winchester, England) 2010 Mar;14(12):1-140. &lt;A href="http://www.hta.ac.uk/1870" target="_blank"&gt;Link to&amp;nbsp;summary here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Currie CJ, Poole CD, Papo NL. An overview and commentary on retrospective, continuous glucose monitoring for the optimisation of care for people with diabetes. Current Medical Research and Opinion 2009 Oct;25(10):2389-400. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19650750" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;IQWiG. Urine and blood glucose self-measurement in diabetes mellitus type 2. Cologne: Institut Fuer Qualitaet Und Wirtschaftlichkeit Im Gesundheitswesen (IQWiG) 2009. &lt;A href="http://www.iqwig.de/index.559.en.html" target="_blank"&gt;Link to&amp;nbsp;summary here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Kleefstra N, Hortensius J, Van Hateren KJJ, Logtenberg SJJ, Houweling ST, Gans ROB, et al. Self-monitoring of blood glucose in noninsulin-treated type 2 diabetes: An overview. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009;2:155-163. &lt;BR&gt;&lt;BR&gt;Poolsup N, Suksomboon N, Rattanasookchit S. Meta-analysis of the benefits of self-monitoring of blood glucose on glycemic control in type 2 diabetes patients: an update. Diabetes Technology &amp;amp; Therapeutics 2009 Dec;11(12):775-84. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20001678" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;St John A, Davis WA, Price CP, Davis TM. The value of self-monitoring of blood glucose: a review of recent evidence. Journal of Diabetes and Its Complications 2010 Mar-2010 Apr 30;24(2):129-41. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19230717" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7089" target="_blank"&gt;Link to supporting guidelines on self-monitoring of Type 1 Diabetes&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=7091" target="_blank"&gt;Link to supporting guidelines on self-monitoring of Type 2 Diabetes&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; TIGHT GLUCOSE CONTROL&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;Brown SH, Abdelhafiz AH. Trials review: cardiovascular outcome with intensive glycemic control and implications for patients with type 2 diabetes. Postgraduate Medicine 2009;121(5):31-41. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Cvd.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009109835" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Annals of Internal Medicine 2009 Sep 15;151(6):394-403. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Cvd.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19620144" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Ma J, Yang W, Fang N, Zhu W, Wei M. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD 2009 Nov;19(9):596-603. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; All Or General.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19819121" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD 2009 Nov;19(9):604-12. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Cvd.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19427768" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Marso SP, Kennedy KF, House JA, McGuire DK. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes &amp;amp; Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease 2010 Apr;7(2):119-30. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Cvd.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20382775" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009 Nov;52(11):2288-98. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Cvd.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19655124" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Wang Q Han P. Intensive glucose control compared with standard therapy in type 2 diabetes: a systemic [sic] review. Chinese Journal of Evidence-Based Medicine 2009;9(7):774-782. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:392328:0" name=internalLink&gt;&lt;A href="nelh:392328:1" name=internalLink&gt;methodology&lt;/A&gt;&lt;/A&gt; for more information.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009107528" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Zhang CY, Sun AJ, Zhang SN, Wu CN, Fu MQ, Xia G, et al. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis. Annals of Medicine 2010 May 6;42(4):305-15. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Cvd.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20429797" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;CONDITION MANAGEMENT &amp;gt; TREATMENT CONCORDANCE&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technology &amp;amp; Therapeutics 2010 Jun;12 Suppl 1:S101-8. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Economics, Condition Management &amp;gt; Medication &amp;gt; Insulin.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20515297" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Hood KK, Peterson CM, Rohan JM, Drotar D. Association between adherence and glycemic control in pediatric type 1 diabetes: a meta-analysis. Pediatrics 2009 Dec;124(6):e1171-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19884476" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Hood KK, Rohan JM, Peterson CM, Drotar D. Interventions With Adherence-Promoting Components in Pediatric Type 1 Diabetes: Meta-analysis of their impact on glycemic control. Diabetes Care 2010 Jul;33(7):1658-1664. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20587726" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;Saini SD Schoenfeld P Kaulback K Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. American Journal of Managed Care 2009;15(6):e22-e33. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:392328:0" name=internalLink&gt;&lt;A href="nelh:392328:1" name=internalLink&gt;methodology&lt;/A&gt;&lt;/A&gt; for more information.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009108184" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=11832" target="_blank"&gt;Link to supporting guidelines on treatment concordance&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>392321</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=392321]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Delivery of Care</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Delivery of Care&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;Armor BL, Britton ML, Dennis VC, Letassy NA. A review of pharmacist contributions to diabetes care in the united states. Journal of Pharmacy Practice 2010;23(3):250-264. &lt;BR&gt;&lt;BR&gt;Boren SA, Puchbauer AM, Williams F. Computerized prompting and feedback of diabetes care: a review of the literature. Journal of Diabetes Science and Technology 2009;3(4):944-950. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:392328:0" name=internalLink&gt;&lt;A href="nelh:392328:1" name=internalLink&gt;methodology&lt;/A&gt;&lt;/A&gt; for more information.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010004072" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Chin MH. Quality improvement implementation and disparities: the case of the health disparities collaboratives. Med Care 2010 Aug;48(8):668-75. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20613665" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Cole-Lewis H, Kershaw T. Text messaging as a tool for behavior change in disease prevention and management. Epidemiologic Reviews 2010;32(1):56-69. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20354039" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Cooper H, Cooper J, Milton B. Technology-based approaches to patient education for young people living with diabetes: a systematic literature review. Pediatr Diabetes 2009 Nov;10(7):474-83. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Patient Education.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19490492" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Dafogianni C, Poli A, Theofanidis D. Nurses knowledge of type 1 diabetes mellitus care in children: A systematic review. Review of Clinical Pharmacology and Pharmacokinetics, International Edition 2009;23(3):157-162.&lt;BR&gt;&lt;BR&gt;Gialamas A, St John A, Laurence CO, Bubner TK. Point-of-care testing for patients with diabetes,hyperlipidaemia or coagulation disorders in the general practice setting: a systematic review. Family Practice 2010 Feb;27(1):17-24. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19969524" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Gibbons MC, Wilson RF, Samal L, Lehman CU, Dickersin K, Lehmann HP, et al. Impact of consumer health informatics applications. Evidence Report/Technology Assessment 2009 Oct;(188):1-546. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20629477" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Graziano JA Gross CR. The effects of isolated telephone interventions on glycemic control in type 2 diabetes: a literature review. Advances in Nursing Science 2009;32(3):E28-E41. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009110057" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Medical Advisory Secretariat. Community-based care for the management of type 2 diabetes: an evidence-based analysis. Toronto: Medical Advisory Secretariat,Ontario Ministry of Health and Long-Term Care (MAS) 2009;Volume 9,Number 23. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:392328:0" name=internalLink&gt;&lt;A href="nelh:392328:1" name=internalLink&gt;methodology&lt;/A&gt;&lt;/A&gt; for more information.&lt;/SPAN&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=32010000128" target="_blank"&gt;Link to full-text here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Home telemonitoring for type 2 diabetes: an evidence-based analysis. Toronto: Medical Advisory Secretariat,Ontario Ministry of Health and Long-Term Care (MAS) 2009;Volume 9,Number 24.&amp;nbsp;&lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:392328:0" name=internalLink&gt;&lt;A href="nelh:392328:1" name=internalLink&gt;methodology&lt;/A&gt;&lt;/A&gt; for more&amp;nbsp;information.&lt;/SPAN&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=32010000129" target="_blank"&gt;Link to full text here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Polisena J, Tran K, Cimon K, Hutton B, McGill S, Palmer K. Home telehealth for diabetes management: A systematic review and meta-analysis. Diabetes,Obesity and Metabolism 2009;11(10):913-930. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010005058" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Post PN, Wittenberg J, Burgers JS. Do specialized centers and specialists produce better outcomes for patients with chronic diseases than primary care generalists? A systematic review. International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care / ISQua 2009 Dec;21(6):387-96. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19734175" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Swinnen SG, Devries JH. Contact frequency determines outcome of basal insulin initiation trials in type 2 diabetes. Diabetologia 2009 Nov;52(11):2324-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19756479" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Welch G, Garb J, Zagarins S, Lendel I, Gabbay RA. Nurse diabetes case management interventions and blood glucose control: results of a meta-analysis. Diabetes Research &amp;amp; Clinical Practice 2010 Apr;88(1):1-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20116879" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5147" target="_blank"&gt;Link to supporting guidelines on delivery of care&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>392319</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=392319]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Diabetes and Comorbidities including Cancer</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,LIVING WITH DIABETES,RESEARCH,CHRONIC COMORBIDITIES,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Diabetes and Comorbidities including Cancer&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&lt;STRONG&gt;&amp;nbsp;&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care 2010 Apr;33(4):931-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20351229" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA. Alanine aminotransferase,-glutamyltransferase,and incident diabetes. Diabetes Care 2009;32(4):741-750.&lt;BR&gt;&lt;BR&gt;Gao C, Yao SK. Diabetes mellitus: a "true" independent risk factor for hepatocellular carcinoma? Hepatobiliary &amp;amp; Pancreatic Diseases International : HBPD INT 2009 Oct;8(5):465-73. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19822488" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Klein OL, Krishnan JA, Glick S, Smith LJ. Systematic review of the association between lung function and Type 2 diabetes mellitus. Diabetic Medicine 2010;27(9):977-987. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20722670" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Shantikumar S, Ajjan R, Porter KE, Scott DJ. Diabetes and the abdominal aortic aneurysm. European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery 2010 Feb;39(2):200-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19948418" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Snyder CF, Stein KB, Barone BB, Peairs KS, Yeh HC, Derr RL, et al. Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate cancer and prostatic diseases 2010 Mar;13(1):58-64. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20145631" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Stein KB, Snyder CF, Barone BB, Yeh HC, Peairs KS, Derr RL, et al. Colorectal cancer outcomes,recurrence,and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis. Digestive Diseases and Sciences 2010 Jul;55(7):1839-51. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19731028" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;van den Borst B, Gosker HR, Zeegers MP, Schols AM. Pulmonary function in diabetes: a metaanalysis. Chest 2010 Aug;138(2): 393-406. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20348195" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=9432" target="_blank"&gt;Link to supporting guidelines on diabetes and co-morbidities&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>392326</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=392326]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Economics</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Economics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technology &amp;amp; Therapeutics 2010 Jun;12 Suppl 1:S101-8. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Treatment Concordance, Condition Management &amp;gt; Medication &amp;gt; Insulin.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20515297" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Cobden DS, Niessen LW, Barr CE, Rutten FF, Redekop WK. Relationships among self-management,patient perceptions of care,and health economic outcomes for decision-making and clinical practice in type 2 diabetes. Value Health 2010 Jan;13(1):138-47. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Self-Management.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19695005" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Cummins E, Royle P, Snaith A, Greene A, Robertson L, McIntyre L, et al. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technology Assessment (Winchester,England) 2010 Feb;14(11):iii-iv,xi-xvi,1-181. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Medication &amp;gt; Insulin.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.hta.ac.uk/1622" target="_blank"&gt;Link to&amp;nbsp;summary&amp;nbsp;here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Jones S, Edwards RT. Diabetic retinopathy screening: A systematic review of the economic evidence. Diabetic Medicine 2010;27(3):249-256. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Eye Diseases.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20536486" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Tarride JE, Hopkins R, Blackhouse G, Bowen JM, Bischof M, Von Keyserlingk C, et al. A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. Pharmacoeconomics 2010 Apr 1;28(4):255-77. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20222752" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Valentine WJ, Pollock RF, Plun-Favreau J, White J. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes. Current Medical Research and Opinion 2010 Jun;26(6):1399-412. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Medication &amp;gt; Insulin.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20387997" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Yi Y, Philips Z, Bergman G, Burslem K. Economic models in type 2 diabetes. Current Medical Research and Opinion 2010;26(9):2105-2118. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; All Or General.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20642392" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>393331</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=393331]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Epidemiology</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Epidemiology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&amp;nbsp;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp; 'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Abubakari AR, Lauder W, Jones MC, Kirk A, Agyemang C, Bhopal RS. Prevalence and time trends in diabetes and physical inactivity among adult West African populations: the epidemic has arrived. Public Health 2009 Sep;123(9):602-14. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19748643" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research &amp;amp; Clinical Practice 2010 Jan;87(1):4-14. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19896746" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>393349</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=393349]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Ethnicity</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PEOPLE FROM ETHNIC MINORITIES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Ethnicity&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&amp;nbsp;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp; 'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Hawthorne K, Robles Y, Cannings-John R, Edwards AGK. Culturally appropriate health education for type 2 diabetes in ethnic minority groups:&amp;nbsp;a systematic and narrative review of randomized controlled trials. Diabetic Medicine 2010;27(6):613-623. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Patient Education.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20546277" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>393573</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=393573]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Foreign Language Articles</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Foreign Language Articles&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about&amp;nbsp;and introduction to the Annual Evidence Update&amp;nbsp;and for links to results for&amp;nbsp;each of the&amp;nbsp;topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;The following articles were identified by the search as being potentially relevant to the AEU, but were not&amp;nbsp;checked further&amp;nbsp;because the full text is in a language other than English. They are included here for interest, and for the sake of completeness.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Beltran DO. Systematic review of the effectiveness and safety of premixed insulin analogues in type 2 diabetes [Spanish] Revision sistematica sobre la efectividad y la seguridad de los analogos de insulina premezclada en la diabetes tipo 2. FMC Formacion Medica Continuada En Atencion Primaria 2009;16(9).&lt;BR&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Spanish&lt;BR&gt;&lt;BR&gt;Gonzalez-Escalada JR, Rodriguez MJ, Camba MA, Portoles A, Lopez R. Recommendations for the treatment of neuropathic pain [Spanish] Recomendaciones para el tratamiento del dolor neuropatico. Revista De La Sociedad Espanola Del Dolor 2009;16(8):445-467.&lt;BR&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Spanish&lt;BR&gt;&lt;BR&gt;Lerch C, Richter B. Combination therapy with insulin and oral antidiabetic drugs in patients with type 2 diabetes mellitus: A systematic review [German] Kombinationstherapie mit insulin und oralen antidiabetika bei diabetes mellitus typ 2: Eine systematische ubersicht. Zeitschrift Fur Allgemeinmedizin 2010;86(1):6-13. &lt;A href="http://www.online-zfa.de/article/Kombinationstherapie_mit_Insulin/originalarbeit-original-papers/2010/01/1" target="_blank"&gt;Link to full-text here.&lt;/A&gt; &lt;BR&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; German&lt;BR&gt;&lt;BR&gt;Nauck MA, El-Ouaghlidi A, Vardarli I. Self-monitoring of blood glucose in diabetes mellitus: arguments for an individualized approach.&amp;nbsp; [German] Blutzuckerselbstkontrolle bei diabetes mellitus: Pladoyer fur ein individuelles selbstkontrollkonzept. Deutsches Ärzteblatt International 2009 Sep;106(37):587-94. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19890425" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; German&lt;BR&gt;&lt;BR&gt;Ng D, Ramli SNB , Chia K-S, Koh D, Tai B-C. Genetic variation at the angiotensin-l converting enzyme locus and the risk for diabetic nephropathy: An update based on 53 studies and 17 791 subjects [Spanish] La variacion genetica en el locus de la enzima convertidora se asocia con riesgo de nefropatia diabetica. Salud (i) Ciencia 2009;16(7):751-754.&lt;BR&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Spanish&lt;BR&gt;&lt;BR&gt;Pare G, Moqadem K, Pineau G, St-Hilaire C. Impacts of telemonitoring in the context of diabetes [French] Effets du telemonitorage dans la prise en charge du diabete. Medecine Des Maladies Metaboliques 2010;4(3):257-262.&lt;BR&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; French&lt;BR&gt;&lt;BR&gt;Pons MB, Badia OA. A systematic review with meta analysis of women with gestational diabetes indicate that they are at risk to suffer diabetes seven times more than normoglycemic women: Commentary [Spanish] Una revision sistematica con metaanalisis en mujeres con diabetes gestacional obtiene un riesgo relativo de sufrir diabetes posterior siete veces mayor que en mujeres normoglucemicas: Comentario. FMC Formacion Medica Continuada En Atencion Primaria 2010;17(3).&lt;BR&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Spanish&lt;BR&gt;&lt;BR&gt;Teixeira CRS, Zanetti ML, Landim CAP, Becker TAC, dos Santos ECB, Franco RC, et al. Self-monitoring blood glucose at home: integrative literature review [Portuguese]. Revista Eletr+¦Nica De Enfermagem 2009 Dec;11(4):1006-1017. &lt;A href="http://www.fen.ufg.br/revista/v11/n4/pdf/v11n4a27.pdf" target="_blank"&gt;Link to full text here.&lt;/A&gt; &lt;BR&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Portuguese&lt;BR&gt;&lt;BR&gt;Vlachioti E, Matziou V. Juvenile diabetes mellitus and psychoemotional disorders [Greek]. Nosileftiki 2010 Jan-2010 Mar 31;49(1):31-39. &lt;A href="http://www.hjn.gr/index.php?page=abstract&amp;amp;id=209" target="_blank"&gt;Link to English abstract here.&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.hjn.gr/actions/get_pdf.php?id=209" target="_blank"&gt;Link to Greek full text here.&lt;/A&gt; &lt;BR&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Greek&lt;BR&gt;&lt;BR&gt;Wild C, Mathis S, Guba B, Gartlehner G. Rheopheresis in patients with age-related macular degeneration, sudden hearing loss or tinnitus, diabetes. Systematic review. Vienna: Ludwig Boltzmann Institut Fuer Health Technology Assessment (LBIHTA) 2008. &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=32009100380" target="_blank"&gt;Link to HTA&amp;nbsp;record here.&lt;/A&gt; &lt;BR&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; German&lt;BR&gt;&lt;BR&gt;Zhang RY, Bai JL, Yi HG, Zhao Y, Lin YD, Zhang TM, et al. [Association between calpain-10 gene polymorphism and risk of type 2 diabetes mellitus: a meta analysis]. Zhonghua Liu Xing Bing Xue Za Zhi 2009 Aug;30(8):850-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20193213" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Chinese&lt;BR&gt;&lt;BR&gt;Zhang S, Zhang P, Huang QY. [Association of the D358A polymorphism of IL6R gene with type 2 diabetes in Hubei Han Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2009 Aug;26(4):452-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20017315" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Chinese&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>392297</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=392297]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Genetics</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CAUSES,PEOPLE FROM ETHNIC MINORITIES,RESEARCH,PEOPLE FROM ETHNIC MINORITIES,ANNUAL EVIDENCE UPDATES,CAUSES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Genetics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt; 08 November 2010.&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:0" name=internalLink&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=392291" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Regarding quality of Genetics studies please see &lt;A href="nelh:328308:1" name=internalLink&gt;commentary from 2009 AEU&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;For more information on how to assess the quality of genetic studies please see the following publication:&amp;nbsp; Hattersley AT, McCarthy MI. What makes a good genetic association study? Lancet 2005; 366(9493):1315-23. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16214603" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;/P&gt;
&lt;HR&gt;
&amp;nbsp;&lt;BR&gt;
&lt;P&gt;Abhary S, Hewitt AW, Burdon KP, Craig JE. A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes 2009 Sep;58(9):2137-47. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Eye Diseases. &lt;/SPAN&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19587357" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Anthopoulos PG, Hamodrakas SJ, Bagos PG. Apolipoprotein E polymorphisms and type 2 diabetes: a meta-analysis of 30 studies including 5423 cases and 8197 controls. Molecular Genetics and Metabolism 2010 Jul;100(3):283-91. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Cvd. &lt;/SPAN&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20381392" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Chen T, Cao X, Long Y, Zhang X, Yu H, Xu J, et al. I27L Polymorphism in hepatocyte nuclear factor-1alpha gene and type 2 diabetes mellitus: A meta-analysis of studies about orient population (Chinese and Japanese). International Journal of Diabetes Mellitus 2010;2(1):28-31.&lt;BR&gt;&lt;BR&gt;Dehwah MAS, Wang M, Huang Q-Y. CDKAL1 and type 2 diabetes: A global meta-analysis. Genetics and Molecular Research 2010;9(2):1109-1120. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20568056" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Feng R, Li Y, Zhao D, Wang C, Niu Y, Sun C. Lack of association between TNF 238 G/A polymorphism and type 2 diabetes: a meta-analysis. Acta Diabetologica 2009 Dec;46(4):339-43. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19367363" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Gong M, Long J, Liu Q, Deng HC. Association of the ADIPOQ rs17360539 and rs266729 polymorphisms with type 2 diabetes: A meta-analysis. Molecular and Cellular Endocrinology 2010;325(1-2):78-83. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20580771" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Gouda HN, Sagoo GS, Harding AH, Yates J, Sandhu MS, Higgins JP. The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. American Journal of Epidemiology 2010 Mar 15;171(6):645-55. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20179158" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Huguenin GV, Rosa G. The Ala allele in the PPAR-gamma2 gene is associated with reduced risk of type 2 diabetes mellitus in Caucasians and improved insulin sensitivity in overweight subjects. The British Journal of Nutrition 2010 Aug;104(4):488-97. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20420754" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Lu W, Feng B. The-374A allele of the RAGE gene as a potential protective factor for vascular complications in type 2 diabetes: a meta-analysis. The Tohoku Journal of Experimental Medicine 2010;220(4):291-7. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; All or General. &lt;/SPAN&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20410680" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Morini E, Prudente S, Succurro E, Chandalia M, Zhang Y-Y, Mammarella S, et al. IRS1 G972R polymorphism and type 2 diabetes: A paradigm for the difficult ascertainment of the contribution to disease susceptibility of 'low-frequency-low-risk' variants. Diabetologia 2009;52(9):1852-1857. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19557384" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Niu W, Qi Y, Gao P, Zhu D. Angiotensin converting enzyme D allele is associated with an increased risk of type 2 diabetes: evidence from a meta-analysis. Endocrine Journal 2010;57(5):431-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20160398" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Rojas-Villarraga A, Botello-Corzo D, Anaya J-M. HLA-Class II in Latin American patients with type 1 diabetes. Autoimmunity Reviews 2010;9(10):666-673. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20561992" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Sookoian S, Gemma C, Pirola CJ. Influence of hepatocyte nuclear factor 4alpha (HNF4alpha) gene variants on the risk of type 2 diabetes: a meta-analysis in 49,577 individuals. Molecular Genetics and Metabolism 2010 Jan;99(1):80-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19748811" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Xi B, Mi J. FTO polymorphisms are associated with obesity but not with diabetes in East Asian populations: a meta-analysis. Biomedical and Environmental Sciences : BES 2009 Dec;22(6):449-57. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20337217" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Zeng Z, Li L, Zhang Z, Li Y, Wei Z, Huang K, et al. A meta-analysis of three polymorphisms in the endothelial nitric oxide synthase gene (NOS3) and their effect on the risk of diabetic nephropathy. Human Genetics 2010;127(4):373-381. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Nephropathy. &lt;/SPAN&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20049477" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Zhou JB, Yang JK, Lu JK, An YH. Angiotensin-converting enzyme gene polymorphism is associated with type 2 diabetes: a meta-analysis. Molecular Biology Reports 2010 Jan;37(1):67-73. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19655271" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Zintzaras E, Papathanasiou AA, Stefanidis I. Endothelial nitric oxide synthase gene polymorphisms and diabetic nephropathy: a HuGE review and meta-analysis. Genetics in Medicine : Official Journal of the American College of Medical Genetics 2009 Oct;11(10):695-706. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Nephropathy. &lt;/SPAN&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19773668" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>392314</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=392314]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Gestational Diabetes</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES,GESTATIONAL DIABETES,CAUSES,DIAGNOSIS,PROGRESSION TO TYPE 2 DIABETES,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Gestational Diabetes&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Devlin HM, Desai J, Walaszek A. Reviewing performance of birth certificate and hospital discharge data to identify births complicated by maternal diabetes. Maternal &amp;amp; Child Health Journal 2009 Sep;13(5):660-666. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Pregnancy.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18766434" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;Horvath K, Koch K, Jeitler K, Matyas E, Bender R, Bastian H, et al. Effects of treatment in women with gestational diabetes mellitus: systematic review and meta-analysis. BMJ 2010;340:c1395.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20360215" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;IQWiG. Screening for gestational diabetes. Cologne: Institut Fuer Qualitaet Und Wirtschaftlichkeit Im Gesundheitswesen (IQWiG) 2009.&amp;nbsp;&lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Screening.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.iqwig.de/index.648.en.html" target="_blank"&gt;Link to summary here.&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=32010000658" target="_blank"&gt; &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Jones EJ, Roche CC, Appel SJ. A review of the health beliefs and lifestyle behaviors of women with previous gestational diabetes. JOGNN: Journal of Obstetric,Gynecologic &amp;amp; Neonatal Nursing 2009 Sep 9;38(5):516-526. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19883473" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;Tieu J, Middleton P, McPhee AJ, Crowther CA. Screening and subsequent management for gestational diabetes for improving maternal and infant health. Cochrane Database of Systematic Reviews 2010;7:CD007222. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Screening.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=10000007222" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;EM&gt;&amp;nbsp;&lt;BR&gt;&lt;/EM&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=14958" target="_blank"&gt;Link to supporting guidelines on gestational diabetes&lt;/A&gt;&lt;STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>392291</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=392291]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Home Page</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Home Page&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;
&lt;P dir=ltr align=center&gt;&amp;nbsp; 
&lt;TABLE border=0 cellSpacing=0 cellPadding=2 width="70%" align=middle&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P align=center&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID328114/nelhImp_0013_image1_even_smaller.jpg"&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=center&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID328114/nelhImp_0014_WDD-logo-date-EN-2048px_even_smaller.png"&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=center&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID328114/nelhImp_0015_image2_even_smaller.jpg"&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;We are pleased to present the results of&amp;nbsp;our&amp;nbsp;fourth Annual Evidence Update which identifies new&amp;nbsp;systematic reviews&amp;nbsp;on diabetes identified since the last update (September 2009).&amp;nbsp; This Annual Evidence Update has been published to co-incide with &lt;A href="http://www.worlddiabetesday.org/" target="_blank"&gt;World Diabetes Day&lt;/A&gt;&amp;nbsp;on 14th November&amp;nbsp;2010. For ease of reference, the results of the evidence update have been classified based on the topic headings found within 'NHS Evidence - diabetes'.&lt;/P&gt;
&lt;P&gt;Links to previous Annual Evidence Updates on diabetes are available below:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=384860" target="_blank"&gt;First&amp;nbsp;(Jan 06 to Aug 07)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;Second&amp;nbsp;(Aug 07 to Sep 08)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=328114" target="_blank"&gt;Third (Sept 08 to Sep 09)&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Contents&lt;/STRONG&gt;&lt;/P&gt;
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;P dir=ltr&gt;1. &lt;A href="nelh:392292:0" name=internalLink&gt;Full introduction&lt;/A&gt;&amp;nbsp;by Dr Roger Gadsby&lt;/P&gt;
&lt;P dir=ltr&gt;2. Results of the 2010 Annual Evidence Update on Diabetes&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;UL&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:392330:0" name=internalLink&gt;Results table&lt;/A&gt; showing number of systematic reviews in each topic&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:392294:0" name=internalLink&gt;Prediabetic State&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:392295:0" name=internalLink&gt;Prevention, Causes and Risk Factor&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:393331:0" name=internalLink&gt;Epidemiology&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:392297:0" name=internalLink&gt;Genetics&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:393346:0" name=internalLink&gt;Screening&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:393349:0" name=internalLink&gt;Ethnicity&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:392298:0" name=internalLink&gt;Condition Management&lt;/A&gt;&amp;nbsp;&lt;BR&gt;(includes all or general, bariatric surgery, diet, exercise, all medication, psychological interventions, tight glucose control, treatment concordance, self-management, self-monitoring and other)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:392314:0" name=internalLink&gt;Gestational Diabetes&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:393424:0" name=internalLink&gt;Other Types of Diabetes&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:392317:0" name=internalLink&gt;Complications&lt;/A&gt; &lt;BR&gt;(includes all or general, CVD, dental problems, diabetic foot, eye diseases, hypoglycaemia, nephropathy, neuropathy, psychological-anxiety, psychological-cognitive function, psychological-depression)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:392318:0" name=internalLink&gt;Pregnancy&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:393427:0" name=internalLink&gt;Living with Diabetes&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:392319:0" name=internalLink&gt;Diabetes and Comorbidites&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;BR&gt;(includes cancer)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:392321:0" name=internalLink&gt;Delivery of Care&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:392325:0" name=internalLink&gt;Patient&amp;nbsp;Education&lt;/A&gt;&lt;A href="nelh:392325:0" name=internalLink&gt; &lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:328304:0" name=internalLink&gt;Economics&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:393573:0" name=internalLink&gt;Foreign Language Articles&lt;/A&gt; &lt;/LI&gt;&lt;/UL&gt;&lt;/UL&gt;
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;P&gt;3. &lt;A href="nelh:393494:0" name=internalLink&gt;Commentary on Diabetic Nephropathy&lt;/A&gt;&amp;nbsp;by Dr Edward Sharples&lt;/P&gt;
&lt;P&gt;4. &lt;A href="nelh:393495:0" name=internalLink&gt;Commentary on Vitamin D and Diabetes&lt;/A&gt; by Lindsay Oliver&lt;/P&gt;&lt;A name=delivery&gt;&lt;/A&gt;
&lt;P&gt;5. Commentary on Delivery of Care and Diabetes Nursing&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;UL&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:397908:0" name=internalLink&gt;&lt;B&gt;&lt;FONT color=#cc0000&gt;&lt;B&gt;&lt;FONT color=#cc0000&gt;NEW! &lt;/FONT&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/B&gt;Commentary on Diabetes Services - Models, Quality&lt;/A&gt; by Sara Da Costa &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:397910:0" name=internalLink&gt;&lt;B&gt;&lt;FONT color=#cc0000&gt;NEW! &lt;/FONT&gt;&lt;/B&gt;Commentary on Diabetes Services - Clinician Interventions and Contributions&lt;/A&gt; by Sara Da Costa &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:397916:0" name=internalLink&gt;&lt;B&gt;&lt;FONT color=#cc0000&gt;NEW! &lt;/FONT&gt;&lt;/B&gt;Commentary on Diabetes - Education&lt;/A&gt; by Sara Da Costa &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:398000:0" name=internalLink&gt;&lt;B&gt;&lt;FONT color=#cc0000&gt;NEW! &lt;/FONT&gt;&lt;/B&gt;Commentary on Diabetes - Technology&lt;/A&gt; by Theresa Smyth&lt;B&gt;&lt;FONT color=#cc0000&gt;&amp;nbsp; &lt;/FONT&gt;&lt;/B&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/UL&gt;
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;P&gt;6.&amp;nbsp;&lt;A href="nelh:392328:0" name=internalLink&gt;Methodology&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. &lt;A href="nelh:392331:0" name=internalLink&gt;Uncertainties&lt;/A&gt; &lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P dir=ltr&gt;&lt;STRONG&gt;Acknowledgements&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P dir=ltr&gt;This annual evidence update was researched and presented by the team at 'NHS Evidence - diabetes':&amp;nbsp;Roger Gadsby,&amp;nbsp;Rachel Court, Anna Brown&amp;nbsp;and Susan Vollmer&amp;nbsp;based at the University of Warwick.&amp;nbsp; We would like to thank Dr Ed Sharples and Lindsay Oliver for writing commentaries for the annual evidence update.&amp;nbsp; We would also like to thank the &lt;A href="http://www.library.nhs.uk/Diabetes/AboutUs.aspx" target="_blank"&gt;reference group&lt;/A&gt; of 'NHS Evidence - diabetes' for their&amp;nbsp;help with promotion of the resource.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;If you would like to comment on or have any questions about this annual evidence update please contact us via &lt;A href="http://www.library.nhs.uk/Diabetes/ContactUs.aspx" target="_blank"&gt;this email form&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;BLOCKQUOTE&gt;&lt;/BLOCKQUOTE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>392292</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=392292]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Introduction</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;We are pleased to present the results of our fourth Annual Evidence Update (AEU)&amp;nbsp;which identifies new systematic reviews on diabetes published between Sept 2009 and Sept 2010. &lt;/P&gt;
&lt;P&gt;Links to previous AEUs on diabetes are available below:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=384860" target="_blank"&gt;First&amp;nbsp;(Jan 06 to Aug 07)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;Second&amp;nbsp;(Aug 07 to Sep 08)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=328114" target="_blank"&gt;Third (Sept 08 to Sep 09)&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;For ease of reference the results of the AEU have been classified based upon the topic headings found within NHS Evidence – diabetes.&lt;/P&gt;
&lt;P&gt;224 systematic reviews meeting the basic search criteria (the same criteria that have been used in all the previous AEUs) have been identified. This is an increase on the 195&amp;nbsp;identified in the AEU published in 2009.&amp;nbsp;One particular area of increase has been&amp;nbsp;in&amp;nbsp;cardiovascular complications up from 11 last year to 23 this year. &lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:392328:1" name=internalLink&gt;Link here&lt;/A&gt; for further information on the methodology for the Annual Evidence Update.&amp;nbsp;&amp;nbsp;Please note that none of the citations identified were critically appraised by the Information Specialists or Clinical Lead.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;New evidence that impacts on current NICE guideline recommendations&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;The reviews that have particular impact on NICE diabetes guideline recommendations (&lt;A href="http://www.nice.org.uk/Guidance/CG66" target="_blank"&gt;CG66&lt;/A&gt;/&lt;A href="http://www.nice.org.uk/CG87" target="_blank"&gt;CG87&lt;/A&gt;) are the ones on aspirin for the primary prevention of cardiovascular&amp;nbsp;disease (CVD) events in diabetes [1-4]. This new evidence has lead the SIGN Diabetes guideline (&lt;A href="http://www.sign.ac.uk/guidelines/fulltext/116/index.html" target="_blank"&gt;SIGN 116&lt;/A&gt;) published in March 2010 to state that low-dose aspirin is NOT recommended for primary prevention of vascular disease in patients with diabetes, in contrast to NICE guidelines which do recommend the use of aspirin.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other&amp;nbsp;highlights from this year’s Annual Evidence Update include&lt;/STRONG&gt;:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;A number of reviews that look at the relationship between tight glycaemic control and&amp;nbsp;CVD events (see &lt;A href="nelh:392317:0" name=internalLink&gt;Complications &amp;gt; CVD&lt;/A&gt;)&lt;/LI&gt;
&lt;LI&gt;Reviews that highlight the on-going debate about the CVD safety of rosiglitazone (which was suspended by the European Medicines Agency in Sept 2010) (see &lt;A href="nelh:392298:0" name=internalLink&gt;Condition Management &amp;gt; Medication &amp;gt; Glitazones&lt;/A&gt;)&lt;/LI&gt;
&lt;LI&gt;Twelve reviews on incretin therapies. The first Incretin therapy was only&amp;nbsp; launched&amp;nbsp; 4 to&amp;nbsp; 5 years ago. Systematic reviews of individual agents or new drug classes are now being published much earlier in the life cycle of a drug or the class. (see &lt;A href="nelh:392298:0" name=internalLink&gt;Condition Management &amp;gt; Medication &amp;gt; Incretins&lt;/A&gt;)&lt;/LI&gt;
&lt;LI&gt;A number of reviews of telemedicine in diabetes care delivery (see &lt;A href="nelh:392321:0" name=internalLink&gt;Delivery of Care&lt;/A&gt;)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Our searching found a &lt;A href="nelh:393573:0" name=internalLink&gt;further 12 reviews&lt;/A&gt; that seemed to fulfil our inclusion criteria but the&amp;nbsp;full text of which was in a foreign language and 1 review [5]&amp;nbsp;that seemed to fulfil our inclusion criteria&amp;nbsp;but the full text was not available via our document supply service. We have not included these in the 224 total quoted above.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Also new for this year’s Annual Evidence Update, we have editorials and comment from experts in areas of:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:393494:0" name=internalLink&gt;Diabetic nephropathy&lt;/A&gt;&lt;/A&gt; (Dr Edward Sharples - Consultant in Nephrology and Transplant Medicine, Churchill Hospital, Oxford)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:393495:0" name=internalLink&gt;Vitamin D and diabetes&lt;/A&gt;&lt;/A&gt; (Lindsay Oliver, Consultant Dietitian for Northumbria Healthcare Trust and member of the British Dietetic Association).&lt;/LI&gt;
&lt;LI&gt;An editorial on what the new evidence on "Delivery of Care" means for Diabetes Nursing is currently being prepared by nurse consultants Sara Da Costa and Theresa Smyth and will be published soon at 'NHS Evidence - diabetes'. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;There is a vast and increasing amount of new evidence published in the field of diabetes each year.&amp;nbsp;This annual evidence update summarises this new evidence, and by limiting our search to systematic reviews that fulfil “basic” criteria, hopefully provides it in a reliable and simplified form. Looking through this AEU should enable healthcare professionals delivering diabetes care to keep up to date with new evidence.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;EM&gt;Roger Gadsby, November 2010.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;EM&gt;&lt;/EM&gt;Calvin AD, Aggarwal NR, Murad MH, Shi Q, Elamin MB, Geske JB, et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009 Dec;32(12):2300-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19741185" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19897665" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Younis N, Williams S, Ammori B, Soran H. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. Expert Opinion on Pharmacotherapy 2010 Jun;11(9):1459-66. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20429671" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Research &amp;amp; Clinical Practice 2010 Feb;87(2):211-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19853947" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Zhou L , Deng W , Zhou L , Fang P , He D , Zhang W , et al. Prevalence, incidence and risk factors of chronic heart failure in the type 2 diabetic population: systematic review. Current Diabetes Reviews 2009 Aug;5(3):171-84. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19689252" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>393427</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=393427]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Living with Diabetes</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,LIVING WITH DIABETES,DELIVERY OF CARE,HOSPITAL INPATIENT CARE,PATIENT EDUCATION AND EMPOWERMENT,RESEARCH,ANNUAL EVIDENCE UPDATES,SCHOOL]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Living with Diabetes&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=392291" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=392291" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Ali S, Stone M, Skinner TC, Robertson N, Davies M, Khunti K. The association between depression and health-related quality of life in people with type 2 diabetes: a systematic literature review. Diabetes/Metabolism Research and Reviews 2010 Feb;26(2):75-89. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Psychological &amp;gt; Depression.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20186998" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Stainsby D, Brunskill S, Chapman CE, Doree C, Stanworth S. Safety of blood donation from individuals with treated hypertension or non-insulin dependent type 2 diabetes- a systematic review. Vox Sang 2010 Apr;98(3 Pt 2):431-40. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19878496" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>392328</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=392328]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Methodology</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about&amp;nbsp;and introduction to the Annual Evidence Update&amp;nbsp;and for links to results for&amp;nbsp;each of the&amp;nbsp;topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;‘NHS Evidence –diabetes’ presents this 2010 Annual Evidence Update on Diabetes. It consists of the results of extensive literature searches carried out to identify systematic reviews (SR's) relating to diabetes and its treatment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Inclusion criteria&lt;BR&gt;&lt;/STRONG&gt;References were included if they were identified as systematic reviews that are relevant to the subject scope and were published between September 2009 and September 2010. (See the 'Search period' section below for further information about inclusion of DARE abstracts).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Subject scope&lt;/STRONG&gt; &lt;BR&gt;The subject scope reflects that of ‘NHS Evidence – diabetes’: covering all types of diabetes mellitus and pre-diabetic conditions, as well as complications of diabetes mellitus and other conditions that are closely related to diabetes mellitus.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication types&lt;BR&gt;&lt;/STRONG&gt;Material included was limited to Systematic Reviews because of the high volume of published material in the topic area. Systematic Reviews are regarded as the highest level of evidence to inform clinical practice.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Sources searched (searches carried out on 14th - 17th September 2010)&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;PUBMED&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Embase via&amp;nbsp;NHS EVIDENCE via Healthcare Databases Advanced Search (HDAS) &lt;/LI&gt;
&lt;LI&gt;CINAHL via EBSCO&lt;/LI&gt;
&lt;LI&gt;The Cochrane Library &lt;/LI&gt;
&lt;LI&gt;Database of Abstracts of Reviews of Effects (DARE) via CRD interface &lt;/LI&gt;
&lt;LI&gt;Health Technology Assessment (HTA) Database via CRD interface&lt;/LI&gt;
&lt;LI&gt;'NHS Evidence – diabetes'&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Search period&lt;BR&gt;&lt;/STRONG&gt;September 2009 – September 2010.&amp;nbsp; Please note that DARE abstracts were included in the results set that had been added to DARE within the search period even though the articles they refer to may have been published at an earlier date (unless they had already been listed as citations in previous annual evidence updates).&amp;nbsp; The decision was made to include these citations in the results set since DARE search a much wider set of sources and databases than we do and these citations would be missed if they were not included at this time.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Search strategies&lt;BR&gt;&lt;/STRONG&gt;The sources listed were systematically searched for publications published within the search period using search terms relevant to the subject scope. Sensitive systematic review search filters were applied to the Medline and Embase searches which were also restricted to exclude animal research. Please &lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=392328" target="_blank"&gt;click here&lt;/A&gt; for full details of the search strategies including search terms and filters used. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Sifting and selection&lt;BR&gt;&lt;/STRONG&gt;All citations found in the searches were sifted by information specialists, by reading the titles and abstracts to initially exclude those papers definitely not relevant to diabetes, then to identify those that were definite or potential systematic reviews. We also checked duplication with previous years’ AEU results.&amp;nbsp; This was followed by a sift for subject relevance carried out by the clinical lead. Finally, the remaining titles were once again sifted to include only those that were classified as ‘definite’ systematic reviews. The full text of citations was obtained where this was not evident from the abstract (see the 'Identification of systematic reviews' section below for more information on how we identified the systematic reviews).&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Identification of Systematic Reviews&lt;BR&gt;&lt;/STRONG&gt;We automatically included Cochrane reviews, DARE abstracts and DARE in process records&lt;BR&gt;Other sources:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;We checked the full text where available electronically (either freely, via NHS My Journals or via the University of Warwick's Library). Where the full text was not available electronically we ordered the full text of those papers where the title and abstract included any suggestion that it might be a systematic review.&lt;/LI&gt;
&lt;LI&gt;We used the &lt;A href="http://www.crd.york.ac.uk/crdweb/html/helpdoc.htm" target="_blank"&gt;DARE criteria&lt;/A&gt; to decide if a paper was a systematic review. Further clarification was defined based on the Centre for Reviews and Dissemination’s working practices:&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 1.&amp;nbsp;Were inclusion/exclusion criteria reported? &lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 2.&amp;nbsp;Was the search adequate?&amp;nbsp;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; a.&amp;nbsp;Papers must have given search terms and listed the database(s) searched in order that the search can be repeated.&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; b.&amp;nbsp;If only one database is searched it must be the appropriate one for the topic.&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 3.&amp;nbsp;Were the included studies synthesised? &lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 4.&amp;nbsp;Was the validity of the included studies assessed?&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 5.&amp;nbsp;Are sufficient details about the individual included studies presented?&lt;BR&gt;Reviews included on DARE meet at least four criteria; criteria 1-3 are mandatory.&lt;/LI&gt;
&lt;LI&gt;No authors were contacted for further methodological details.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;BR&gt;&lt;/STRONG&gt;Following the removal of duplicates, a total of 1374 potential systematic reviews were retrieved and collated in a reference management database. The search strategy was designed to be sensitive so a large number of the citations retrieved were irrelevant. Following sifting,&amp;nbsp;224 citations were identified as being relevant to the subject and systematic reviews. Our searching found a further 12 reviews that seemed to fulfil our inclusion criteria but the&amp;nbsp;full text of which was in a foreign language and 1 review&amp;nbsp;that seemed to fulfil our inclusion criteria&amp;nbsp;but the full text was not available via our document supply service. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Appraisal&lt;BR&gt;&lt;/STRONG&gt;Please note that none of the citations identified were critically appraised by the Information Specialists or Clinical Lead.&amp;nbsp; The inclusion of citations in the results set does not imply endorsement.&amp;nbsp; ‘NHS Evidence – diabetes’ does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp; A tool for critical appraisal is available from &lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>393424</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=393424]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Other Types of Diabetes</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,OTHER TYPES OF DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Other Types of Diabetes&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&amp;nbsp;&lt;/STRONG&gt;08 November 2010.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;
&amp;nbsp; 
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;
&lt;BR&gt;
&lt;P&gt;Montori VM Basu A Erwin PJ Velosa JA Gabriel SE Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002;25(3):583-592. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:392328:0" name=internalLink&gt;&lt;A href="nelh:392328:1" name=internalLink&gt;methodology&lt;/A&gt;&lt;/A&gt; for more information. &lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12002000662" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=50&amp;amp;sort=TITLE&amp;amp;catID=5128" target="_blank"&gt;Link to supporting guidelines on other types of diabetes.&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>392325</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=392325]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Patient Education</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,OTHER LIFE STYLE,OTHER LIFE STYLE,MONITORING / SELF-MONITORING,MONITORING / SELF-MONITORING,RESEARCH,NUTRITION AND FOOD,PHYSICAL ACTIVITY,NUTRITION AND FOOD,PHYSICAL ACTIVITY,TREATMENT CONCORDANCE,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Patient Education&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;Baradaran HR, Shams-Hosseini N, Noori-Hekmat S, Tehrani-Banihashemi A, Khamseh ME. Effectiveness of diabetes educational interventions in Iran: a systematic review. Diabetes Technology &amp;amp; Therapeutics 2010 Apr;12(4):317-31. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20210572" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Cooper H, Cooper J, Milton B. Technology-based approaches to patient education for young people living with diabetes: a systematic literature review. Pediatric diabetes 2009 Nov;10(7):474-83. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Delivery of Care.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19490492" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Dorresteijn JA, Kriegsman DM, Assendelft WJ, Valk GD. Patient education for preventing diabetic foot ulceration. Cochrane Database of Systematic Reviews 2010;5:CD001488. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Diabetic Foot.&lt;/SPAN&gt; &lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12002002091" target="_blank"&gt;Link to DARE abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;Hawthorne K, Robles Y, Cannings-John R, Edwards A G K. Culturally appropriate health education for type 2 diabetes in ethnic minority groups: A systematic and narrative review of randomized controlled trials. Diabetic Medicine 2010;27(6):613-623. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Ethnicity.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20546277" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Simmons D, Voyle J, Rush E, Dear M. The New Zealand experience in peer support interventions among people with diabetes. Family Practice 2010 Jun;27 Suppl 1:i53-61. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19254967" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Williams B, Pace AE. Problem based learning in chronic disease management: A review of the research. Patient Education and Counseling 2009;77(1):14-19. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19375265" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=50&amp;amp;sort=TITLE&amp;amp;catID=5624" target="_blank"&gt;Link to supporting guidelines on patient education&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>392294</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=392294]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Prediabetic State</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,PREDIABETIC STATE,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Prediabetic State&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Barengolts E. Vitamin D role and use in prediabetes. Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2010 May-2010 Jun 30;16(3):476-85. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20150028" target="_blank"&gt;Link to PubMed&amp;nbsp;abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Bertram MY, Vos T. Quantifying the duration of pre-diabetes. Australian and New Zealand Journal of Public Health 2010 Jun;34(3):311-4. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20618275" target="_blank"&gt;Link to PubMed&amp;nbsp;abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. Journal of the American College of Cardiology 2010 Mar 30;55(13):1310-7. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Complications &amp;gt; Cvd.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20338491" target="_blank"&gt;Link to PubMed&amp;nbsp;abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Grant SJ, Bensoussan A, Chang D, Kiat H, Klupp NL, Liu JP, et al. Chinese herbal medicines for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database of Systematic Reviews 2009;(4):CD006690. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Medication &amp;gt; Other.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=10000006690" target="_blank"&gt;Link to&amp;nbsp;DARE&amp;nbsp;abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Yuen A, Sugeng Y, Weiland TJ, Jelinek GA. Lifestyle and medication interventions for the prevention or delay of type 2 diabetes mellitus in prediabetes: a systematic review of randomised controlled trials. Australian and New Zealand Journal of Public Health 2010 Apr;34(2):172-178. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Prevention, Causes and Risk Factors.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://onlinelibrary.wiley.com/doi/10.1111/j.1753-6405.2010.00503.x/abstract" target="_blank"&gt;Link to&amp;nbsp;abstract here.&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=50&amp;amp;sort=TITLE&amp;amp;catID=5143" target="_blank"&gt;Link to supporting guidelines on the prediabetic state&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>392318</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=392318]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Pregnancy</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETES AND PREGNANCY,CONDITION MANAGEMENT,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Pregnancy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;BR&gt;Balsells M, Garcia-Patterson A, Gich I, Corcoy R. Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis. The Journal of Clinical Endocrinology and Metabolism 2009 Nov;94(11):4284-91. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19808847" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Devlin HM, Desai J, Walaszek A. Reviewing performance of birth certificate and hospital discharge data to identify births complicated by maternal diabetes. Maternal &amp;amp; Child Health Journal 2009 Sep;13(5):660-666. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Gestational Diabetes.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18766434" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;Middleton P, Crowther CA, Simmonds L, Muller P. Different intensities of glycaemic control for pregnant women with pre-existing diabetes. Cochrane Database of Systematic Reviews 2010;(9). &lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD008540/frame.html" target="_blank"&gt;Link to full text here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=50&amp;amp;sort=TITLE&amp;amp;catID=5130" target="_blank"&gt;Link to supporting guidelines on pregnancy and diabetes&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>392295</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=392295]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Prevention, Causes and Risk Factors</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,OTHER TYPES OF DIABETES,CONDITION MANAGEMENT,CAUSES,CONDITION MANAGEMENT,RESEARCH,ANNUAL EVIDENCE UPDATES,CAUSES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Prevention, Causes and Risk Factors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=392291" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp;&amp;nbsp;'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Abdullah A, Peeters A, de Courten M, Stoelwinder J. The magnitude of association between overweight and obesity and the risk of diabetes: A meta-analysis of prospective cohort studies. Diabetes Research &amp;amp; Clinical Practice 2010;89(3):309-319. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20493574" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Aune D, Ursin G, Veierod MB. Meat consumption and the risk of type 2 diabetes: a systematic review and meta-analysis of cohort studies. Diabetologia 2009 Nov;52(11):2277-87. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19662376" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Baliunas DO, Taylor BJ, Irving H, Roerecke M, Patra J, Mohapatra S, et al. Alcohol as a risk factor for type 2 diabetes: A systematic review and meta-analysis. Diabetes Care 2009 Nov ;32(11):2123-32. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19875607" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 2010 Feb;33(2):414-20. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19910503" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Cardwell CR, Stene LC, Joner G, Bulsara MK, Cinek O, Rosenbauer J, et al. Maternal age at birth and childhood type 1 diabetes: a pooled analysis of 30 observational studies. Diabetes 2010 Feb;59(2):486-94. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19875616" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Cardwell CR, Stene LC, Joner G, Davis EA, Cinek O, Rosenbauer J, et al. Birthweight and the risk of childhood-onset type 1 diabetes: a meta-analysis of observational studies using individual patient data. Diabetologia 2010 Apr;53(4):641-51. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20063147" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Esposito K, Maiorino MI, Ceriello A, Giugliano D. Prevention and control of type 2 diabetes by Mediterranean diet: A systematic review. Diabetes Research &amp;amp; Clinical Practice 2010;89(2):97-102. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Diet.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20546959" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Huxley R, Lee CM, Barzi F, Timmermeister L, Czernichow S, Perkovic V, et al. Coffee,decaffeinated coffee,and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis. Archives of Internal Medicine 2009 Dec 14;169(22):2053-63. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20008687" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Kastorini CM, Panagiotakos DB. Dietary patterns and prevention of type 2 diabetes: from research to clinical practice; a systematic review. Current Diabetes Reviews 2009 Nov;5(4):221-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19531025" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care 2009 Sep;32(9):1737-42. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19549729" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Lloret-Linares C, Greenfield JR, Czernichow S. Effect of weight-reducing agents on glycaemic parameters and progression to type 2 diabetes: a review. Diabetic Medicine 2008;25(10):1142-1150. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Condition Management &amp;gt; Medication &amp;gt; Other.&amp;nbsp;&lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:392328:0" name=internalLink&gt;&lt;A href="nelh:392328:1" name=internalLink&gt;methodology&lt;/A&gt;&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009109343" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Micha R, Wallace SK, Mozaffarian D. Red and processed meat consumption and risk of incident coronary heart disease,stroke,and diabetes mellitus: a systematic review and meta-analysis. Circulation 2010 Jun 1;121(21):2271-83. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20479151" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Parker J, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala NB, et al. Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas 2010 Mar;65(3):225-36. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20031348" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Annals of Internal Medicine 2010 Mar 2;152(5):307-14. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20194237" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Qin L, Knol MJ, Corpeleijn E, Stolk RP. Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data. European Journal of Epidemiology 2010;25(1):5-12. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19847656" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009 Oct;32(10):1924-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19794004" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Renzaho AM, Mellor D, Boulton K, Swinburn B. Effectiveness of prevention programmes for obesity and chronic diseases among immigrants to developed countries- a systematic review. Public Health Nutrition 2010 Mar;13(3):438-50. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19723366" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010 Feb 27;375(9716):735-42. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20167359" target="_blank"&gt;Link to PubMed abstract here. &lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Walker KZ, O'Dea K, Gomez M, Girgis S, Colagiuri R. Diet and exercise in the prevention of diabetes. Journal of Human Nutrition &amp;amp; Dietetics 2010 Aug;23(4):344-352. &lt;BR&gt;&lt;BR&gt;Yamaoka K Tango T. [Efficacy of lifestyle education in preventing type 2 diabetes: an updated version]. Salud (i) Ciencia 2009;17(1):29-33. &lt;SPAN style="COLOR: #a81400"&gt;Older reference but was published in DARE within the search period, please see the &lt;A href="nelh:392328:0" name=internalLink&gt;&lt;A href="nelh:392328:1" name=internalLink&gt;methodology&lt;/A&gt;&lt;/A&gt; for more information. &lt;/SPAN&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12010000052" target="_blank"&gt;Link to DARE abstract here.&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Yuen A, Sugeng Y, Weiland TJ, Jelinek GA. Lifestyle and medication interventions for the prevention or delay of type 2 diabetes mellitus in prediabetes: a systematic review of randomised controlled trials. Australian and New Zealand Journal of Public Health 2010 Apr;34(2):172-178. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Prediabetic State.&lt;/SPAN&gt; &lt;A href="http://onlinelibrary.wiley.com/doi/10.1111/j.1753-6405.2010.00503.x/abstract" target="_blank"&gt;Link to abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;Zhang X, Gregg EW, Williamson DF, Barker LE, Thomas W, Bullard KM, et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care 2010 Jul;33(7):1665-73. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20587727" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=50&amp;amp;sort=TITLE&amp;amp;catID=5634" target="_blank"&gt;Link to supporting guidelines on prevention of Type 2 Diabetes&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=50&amp;amp;sort=TITLE&amp;amp;catID=5632" target="_blank"&gt;Link to supporting guidelines on causes, risk factors and screening for Type 2 Diabetes&amp;nbsp;&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>392330</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=392330]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Results Table</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Results Table&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=392291" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;224&amp;nbsp;systematic reviews are presented in the 2010 Annual Evidence Update on Diabetes, some citations appear in multiple topics.&amp;nbsp;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=392328" target="_blank"&gt;Link here&lt;/A&gt; for further information on the methodolody for the Annual Evidence Update.&amp;nbsp;&amp;nbsp;Please note that none of the citations identified were critically appraised by the Information Specialists or Clinical Lead.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;The citations break up into the subtopics as follows: &lt;/P&gt;
&lt;P&gt;
&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:392294:1" name=internalLink&gt;Prediabetic State&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;5&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:392295:1" name=internalLink&gt;Prevention, Causes and Risk Factors&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;22&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:393331:1" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;2&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:392297:1" name=internalLink&gt;Genetics&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;17&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:393346:1" name=internalLink&gt;Screening&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;2&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:393349:1" name=internalLink&gt;Ethnicity&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;1&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:392298:1" name=internalLink&gt;Condition management&lt;/A&gt;&lt;BR&gt;(includes all or general, bariatric surgery, diet, exercise, all medication, psychological interventions, tight glucose control, treatment concordance, self-management, self-monitoring and other)&lt;/TD&gt;
&lt;TD&gt;82&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:392314:1" name=internalLink&gt;Gestational diabetes&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;5&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:393424:1" name=internalLink&gt;Other types of diabetes&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;1&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&lt;A href="nelh:392317:1" name=internalLink&gt;Complications&lt;/A&gt;&lt;BR&gt;(includes all or general, CVD, dental problems, diabetic foot, eye diseases, hypoglycaemia, nephropathy, neuropathy, psychological-anxiety, psychological-cognitive function, psychological-depression)&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;79&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:392318:1" name=internalLink&gt;Pregnancy&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;3&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:393427:1" name=internalLink&gt;Living with diabetes&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;2&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:392319:1" name=internalLink&gt;Diabetes and comorbidities including cancer&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;8&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:392321:1" name=internalLink&gt;Delivery of care&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;15&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:392325:1" name=internalLink&gt;Patient education&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;6&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;A href="nelh:392326:1" name=internalLink&gt;Economics&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;7&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>393346</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=393346]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Screening</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ SCREENING,ADULT,DIABETES,TYPE 2,DIABETES,CAUSES,RESEARCH,VASCULAR RISK,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Screening&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;08 November 2010.&amp;nbsp;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about the scope and methods used and for links to results for other topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that the inclusion of citations in this list does not imply endorsement.&amp;nbsp; 'NHS Evidence - diabetes' does not accept responsibility for the content or quality of included or excluded studies.&amp;nbsp;These citations have not been critically appraised.&amp;nbsp; A tool for critical appraisal is available from&amp;nbsp;&lt;A href="http://www.sph.nhs.uk/what-we-do/public-health-workforce/resources/critical-appraisals-skills-programme" target="_blank"&gt;CASP&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;IQWiG. Screening for gestational diabetes. Cologne: Institut Fuer Qualitaet Und Wirtschaftlichkeit Im Gesundheitswesen (IQWiG) 2009. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Gestational Diabetes.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.iqwig.de/index.648.en.html" target="_blank"&gt;Link to&amp;nbsp;summary here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Tieu J, Middleton P, McPhee AJ, Crowther CA. Screening and subsequent management for gestational diabetes for improving maternal and infant health. Cochrane Database of Systematic Reviews 2010;7:CD007222. &lt;SPAN style="COLOR: #a81400"&gt;This reference is also listed under Gestational Diabetes.&lt;/SPAN&gt;&amp;nbsp;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=10000007222" target="_blank"&gt;Link to&amp;nbsp;DARE abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>392331</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=392331]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetes - Uncertainties about the Effects of Treatments</title>
    <publicationDate>2010-11-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetes - Uncertainties about the Effects of Treatments&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;08 November 2010.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please return to the annual evidence homepage for further information about&amp;nbsp;and introduction to the Annual Evidence Update&amp;nbsp;and for links to results for&amp;nbsp;each of the&amp;nbsp;topics.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:392291:1" name=internalLink&gt;Link back to home page for 2010 Annual Evidence Update on Diabetes here&lt;/A&gt;.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The UK Database of Uncertainties about the Effects of Treatments (UK DUETs) has been established in the UK to publish uncertainties about the effects of treatment which cannot currently be answered by referring to reliable up-to-date systematic reviews of existing research evidence.&amp;nbsp; UK DUETs is being developed to make uncertainties explicit and to help those prioritising research in the UK to take account of the information needs of patients, carers and clinicians. The research needed may entail preparation of reliable up-to-date systematic reviews of existing evidence, if these are not available, or research to generate additional evidence if reliable up-to-date systematic reviews make clear that this is necessary.&lt;/P&gt;
&lt;P&gt;During the period covered by this&amp;nbsp;Annual Evidence Update, the team at 'NHS Evidence – diabetes' have identified the following DUETs after reviewing the “Implications for research” of the Cochrane Reviews&amp;nbsp;published in the Cochrane Library&amp;nbsp;in&amp;nbsp;issues 4&amp;nbsp;2009&amp;nbsp;to&amp;nbsp;9 2010.&amp;nbsp; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=334674" target="_blank"&gt;Antiangiogenic therapy with anti-vascular endothelial growth factor (anti-VEGF) modalities to treat diabetic macular oedema&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=334673" target="_blank"&gt;Chinese herbal medicines for people with impaired glucose tolerance or impaired fasting blood glucose and the delay of diabetes onset&lt;/A&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=375008" target="_blank"&gt;Complex interventions for preventing diabetic foot ulceration&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=381154" target="_blank"&gt;Does treatment of periodontal disease improve glycaemic control in people with diabetes?&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=380506" target="_blank"&gt;Effectiveness of debridement of diabetic foot ulcers&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=387895" target="_blank"&gt;Heparin and related substances for preventing diabetic kidney disease&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=381169" target="_blank"&gt;Prostaglandin E1 for preventing the progression of diabetic kidney disease&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=380880" target="_blank"&gt;What are the long-term adverse effects of continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus?&lt;/A&gt; &amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/duets/SearchResults.aspx?catID=14514" target="_blank"&gt;Link here to all the uncertainties for diabetes listed so far in UK DUETs&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387365</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=387365]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetic Retinopathy  - Conventional treatment for diabetic retinopathy: vitrectomy</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,EYES AND VISION,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,EYE DISEASES,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>part of the 2010 Annual Evidence Update on Diabetic Retinopathy</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetic Retinopathy  - Conventional treatment for diabetic retinopathy: vitrectomy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt; 13 September 2010&lt;BR&gt;Originally written by P Scanlon in June 2006, updated annually, &lt;A href="#ref1"&gt;link to further author and publication details here.&lt;/A&gt;&lt;BR&gt;Changes and additions since August 2009 are highlighted in red.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387096" target="_blank"&gt;Link back to home page for 2010 Annual Evidence Update on Diabetic Retinopathy here.&lt;BR&gt;&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387421" target="_blank"&gt;Link to table of abbreviations here.&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID387365/nelhImp_0000_photo10b1-previtrectomy.jpg"&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID387365/nelhImp_0001_photo10b2-post-vitrectomy.jpg"&gt;&lt;/P&gt;
&lt;P align=left&gt;Smiddy [1] wrote an excellent review in 1999 when he noted that, according to the Early Treatment Diabetic Retinopathy Study, at least 5% of eyes receiving optimal medical treatment will still have progressive retinopathy that requires laser treatment and pars plana vitrectomy. He also noted that, although vitrectomy improves the prognosis for a favourable visual outcome, preventive measures, such as improved control of glucose levels and timely application of panretinal photocoagulation, are equally important in the management. Vitrectomy clearly does have a place in the management of diabetic eye disease. Evidence of improving visual results during the last 20 years following vitrectomy have been shown in studies reported by Blankenship [2], Thompson [3-6], Sigurdsson [7], Flynn [8], Nakazawa [9], Karel [10], Harbour [11], Pendergast [12], La Heij [13], Yamamoto [14], Amino [15], Lewis [16], Lahey [17], Treumer [21] Schrey [22] , Diolaiuti [23], Liu [24], Tseng [25], Yorston [26] and Shen[27]. A restriction in driving field has been reported in over two thirds of patients in a small series of patients by Barsam [28]. &lt;BR&gt;&lt;BR&gt;Barzideh [26] reported that, in patients undergoing PPV to repair TRD secondary to PDR reports that persistent subfoveal fluid may take several months to resolve and account for delayed visual recovery.&lt;BR&gt;Two recent studies by Okamoto [27] and Emi [28] have shown that vitrectomy for diabetic retinopathy is effective in increasing the QOL of diabetic retinopathy patients.&lt;BR&gt;&lt;BR&gt;A review by Laidlaw [29] on vitrectomy for diabetic macular oedema concluded that the evidence at present suggests that vitrectomy for Diabetic Macular Oedema should be restricted to those with clinical or OCT signs of traction. &lt;BR&gt;Management of the lens in diabetic eyes undergoing vitrectomy has long been a source of controversy as discussed by Bhatnagar [30].&lt;BR&gt;&lt;BR&gt;There are some early reports (e.g. by Rizzo [31], Yeoh [32], Yang [33], Oshima [34] Ishikawa [35]) of anti VEGF agents being given intravitreally prior to vitrectomy to reduce the active neovascularisation, which the authors believed facilitated the vitrectomy, although the appropriate cases in which to use these agents and the exact timing is not yet clear [35]. There have been some reported complications of anti VEG F agents such as the progression of a previously stable tractional detachment [36] and a deterioration of pre-existing macular ischaemia [37].&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Huang [38] reported results of a study comparing a group of 40 patients with persistent vitreous haemorrhage, given an intravitreal bevacizumab injection (1.25 mg), followed by PRP when visualization of peripheral fundus could be obtained (and a second injection if required after 4-6 weeks), with a historical control group. The vitrectomy rate for non-clearing vitreous haemorrhage after 12 weeks were reduced from 45% in the historical control group to 10% in the study group (P = 0.01).&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;There have been several reports of preoperative VEGF inhibitors improving vitrectomy surgical outcomes:&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;1. Ahmadieh [39] evaluated the effect of preoperative intravitreal bevacizumab (IVB) injection on the rate of early (&amp;lt; or =4 weeks) postvitrectomy hemorrhage in patients with proliferative diabetic retinopathy (PDR). Of 68 eyes, 35 and 33 eyes were in the IVB and control groups, respectively. In the intention-to-treat analysis, the incidence of postvitrectomy hemorrhage 1 week and 1 month after surgery was significantly lower in the IVB group compared with the control group (P = 0.023 and P = 0.001, respectively). Mean BCVA improved from 1.88 logarithm of minimum angle of resolution (logMAR) units in both study groups before surgery to 0.91 logMAR units and 1.46 logMAR units 1 month after vitrectomy in the IVB and control groups, respectively (P = 0.001).&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;2.&amp;nbsp;Modarres [40] evaluated the use of preoperative intravitreal bevacizumab (IVB) injection in patients undergoing pars plana vitrectomy for complications of proliferative diabetic retinopathy (PDR). Eyes of 40 diabetic patients who were candidates for vitrectomy were randomly assigned to receive 2.5 mg IVB 3-5 days before operation (injected group) or no injection before operation (noninjected group). No patient in the injected group developed significant postoperative vitreous hemorrhage obscuring the fundus details, while 7 eyes of noninjected eyes had this complication (p=0.01).&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;3.&amp;nbsp;Yeh [41] studied 41 eyes of 39 patients to evaluate the effects of intravitreal bevacizumab pretreatment in vitrectomy with silicone oil infusion for severe diabetic retinopathy. Multiple regression analyses indicated bevacizumab significantly reduced intra- and postoperative bleeding but there were more cases of subretinal bleeding (P &amp;lt; 0.01) in the group receiving intravitreal bevacizumab pretreatment.&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;4.&amp;nbsp;di Lauro [42] reported the results of 72 eyes of 68 patients affected by vitreous hemorrhage (VH) and tractional retinal detachment (TRD), which occurred as a consequence of active proliferative diabetic retinopathy (PDR), randomly assigned to receive a sham injection or an intravitreal injection of 1.25 mg of bevacizumab, either 7 or 20 days before the vitrectomy. The study concluded that&amp;nbsp; the best surgical results are achieved performing the IVB 7 days before vitrectomy using the outcome measures of reduced surgical mean time, less use of endodiathermy and fewer iatrogenic breaks.&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;5.&amp;nbsp;Hattori [43] studied the use of a single intravitreal injection of bevacizumab (0.16-1.25 mg) 3 days before vitrectomy, measuring whether there was less intraoperative bleeding as recorded by the reduced number of coagulation spots. Numbers of intraoperative coagulation spots differed significantly between the bevacizumab (3.2 +/- 0.8) and nonbevacizumab (5.7 +/- 1.0) groups (P &amp;lt; 0.0001).&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;6.&amp;nbsp;Hernandez-Da Mota [44] evaluated the safety and efficacy of intravitreal injection of bevacizumab in 40 eyes before vitrectomy in advanced proliferative diabetic retinopathy. Effective vitrectomy time was 8.05 minutes in the bevacizumab group vs 16.8 minutes in the non-bevacizumab group. There was less bleeding intraoperatively in the bevacizumab group. Mean final visual acuity in the bevacizumab group was 0.82 logMAR and 2.01 logMAR in the non-bevacizumab group.&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;7.&amp;nbsp;Park [45] retrospectively studied the use of an intravitreal injection of bevacizumab or triamcinolone acetonide in 156 eyes from 139 consecutive patients who underwent pars plana vitrectomy for diabetic vitreous hemorrhage (VH) with or without tractional retinal detachment (TRD). IVB (1.25 mg/0.05 ml) injection was given in 66 eyes (60 patients) and IVT (4 mg/0.1 ml) injection in 33 eyes (31 patients) at the end of vitrectomy, and no injection was given in 57 eyes (48 patients). The rate of early postoperative VH was significantly lower in the IVB and IVT group than the control group (p = 0.002 and 0.006, respectively). There was no difference for BCVA between the three groups at each follow-up period (p &amp;gt; 0.05). In only the IVT group, IOP at postoperative day 1 was higher than IOP preoperatively (p = 0.002).&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;There was one report of complications when used post vitrectomy:&lt;BR&gt;Liu [46] described the development of ghost cell glaucoma within 1 week after intravitreal injection of bevacizumab in three eyes treated for a postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy (PDR) and advised caution in administering an intravitreal injection of bevacizumab for a postoperative vitreous hemorrhage after vitrectomy for PDR.&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;Haller [47] reported the vitrectomy outcomes in 87 eyes with optical coherence tomography (OCT) signs of diabetic macular edema and vitreomacular traction. At baseline, median visual acuity in the 87 eyes was 20/100 and median OCT thickness was 491 microns. At 6 months, median OCT central subfield thickness decreased by 160 microns, with 43% having central subfield thickness &amp;lt;250 microns and 68% having at least a 50% reduction in thickening. Visual acuity improved by &amp;gt; or =10 letters in 38% (95% confidence interval, 28%-49%) and deteriorated by &amp;gt; or =10 letters in 22% (95% confidence interval, 13%-31%). Postoperative complications through 6 months included vitreous hemorrhage (5 eyes), elevated intraocular pressure requiring treatment (7 eyes), retinal detachment (3 eyes), and endophthalmitis (1 eye).&lt;BR&gt;Sakamoto [48] assessed the integrity of the photoreceptor inner and outer segments (IS/OS) line in the fovea, using OCT in relation to their VA and other characteristics after resolution of diabetic macular edema by pars plana vitrectomy. There were no differences in initial VA or in foveal thickness between eyes with or without complete IS/OS at final observation. However, final VA without complete IS/OS was significantly poorer (P = 0.004). VA had improved by more than 2 lines in eight of ten eyes with complete IS/OS and in ten of 27 eyes without complete IS/OS.&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;Tao [49] reported the retina reattached in 158 eyes (94%) after vitrectomy without endotamponade in proliferative diabetic retinopathy with tractional retinal detachment and remained attached until the end of a study period of 7 years.&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;Steel [50] reported the effectiveness of entry site treatment to prevent late recurrent postoperative vitreous cavity hemorrhage after vitrectomy for proliferative diabetic retinopathy. Late recurrent postoperative vitreous cavity hemorrhage occurred in 12 (15%) eyes in the control group compared with five (6%) in the treatment group (p=0.03).&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;Yan [51] studied the reasons for and management of postvitrectomy vitreous hemorrhage in proliferative diabetic retinopathy. Of 315 eyes with PDR and receiving pars plana vitrectomy, 32 eyes had postvitrectomy vitreous hemorrhage. The reasons were fibro vascular ingrowths at sclerotomy sites (9 eyes), residual or recurrent neovascular membrane on the optic nerve (6 eyes), insufficient retinal photocoagulation (7 eyes), residual and recurrent epiretinal proliferative membrane (3 eyes), retinal vein occlusion (2 eyes), postoperative low intraocular pressure (2 eyes), and ocular trauma (3 eyes).&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;The following articles describe the results of vitrectomy for treatment of diabetic eye disease:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;
&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;STRONG&gt;Year&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;STRONG&gt;Author&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;STRONG&gt;Number (n) patients (p) eyes (e)&lt;BR&gt;&lt;/STRONG&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1985&lt;/TD&gt;
&lt;TD&gt;Blankenship [2]&lt;/TD&gt;
&lt;TD&gt;n = 72 e diabetic vitrectomies&lt;BR&gt;42% VA &amp;gt; 6/60 at 10 yrs.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1986&lt;/TD&gt;
&lt;TD&gt;Thompson [3]&lt;/TD&gt;
&lt;TD&gt;n = 1007 e diabetic vitrectomies.&lt;BR&gt;The percentage of eyes achieving final VA &amp;gt; 20/100:&lt;BR&gt;vitreous haemorrhage, 48%; traction detachment, 27%; rhegmatogenous detachment, 24%; and progressive fibrovascular proliferation, 46%. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1987&lt;/TD&gt;
&lt;TD&gt;Thompson [3-6]&lt;/TD&gt;
&lt;TD&gt;Published three further papers describing results and prognostic factors for vitrectomy for diabetic traction-rhegmatogenous retinal detachment7, diabetic traction retinal detachment of the macula6 and diabetic vitreous haemorrhage5.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1988&lt;/TD&gt;
&lt;TD&gt;Sigurdsson [7]&lt;/TD&gt;
&lt;TD&gt;n = 34 e diabetic vitrectomies.&lt;BR&gt;Improvement in VA compared to pre-operative level in 62%.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1992&lt;/TD&gt;
&lt;TD&gt;Flynn [8]&lt;/TD&gt;
&lt;TD&gt;n = 208 (5.6%) of the 3711 patients (243 eyes) in the ETDRS&lt;BR&gt;The risk of a combined end point, severe visual loss or vitrectomy, was low in eyes assigned to deferral (6% at 5 years) and was reduced by early photocoagulation (4% at 5 years).&lt;BR&gt;Before vitrectomy, visual acuity &amp;lt; 5/200 in 66.7% of eyes and &amp;gt; 20/100 in 6.2%. One year after vitrectomy, the visual acuity was &amp;gt; 20/100 in 47.6% of eyes, including 24.0% with visual acuity &amp;gt; 20/40.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1993&lt;/TD&gt;
&lt;TD&gt;Nakazawa [9]&lt;/TD&gt;
&lt;TD&gt;n = 56 e diabetic vitrectomies. 5 yr follow-up.&lt;BR&gt;44.7% eyes maintained improved visual outcome, 19.6% had unchanged visual acuity, and 35.7% were considered failures, as compared to preoperative measurements.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2000&lt;BR&gt;2001&lt;BR&gt;2001&lt;BR&gt;2002&lt;/TD&gt;
&lt;TD&gt;Pendergast [12]&lt;BR&gt;La Heij [13] &lt;BR&gt;Yamamoto [14] &lt;BR&gt;Amino [15]&lt;/TD&gt;
&lt;TD&gt;Other studies that have suggested that there may be some improvement in diabetic macular oedema following vitrectomy&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2001&lt;/TD&gt;
&lt;TD&gt;Lewis [16]&lt;/TD&gt;
&lt;TD&gt;Review of vitrectomy for diabetic macular oedema&lt;BR&gt;Editorial: The author suggested that, on the available data, optical coherence tomography should be performed to test for oedema associated with posterior hyaloid thickening. Vitrectomy should be considered when a shallow macular detachment is found.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2003&lt;/TD&gt;
&lt;TD&gt;Lahey [17]&lt;/TD&gt;
&lt;TD&gt;Retrospective series of 223 p treated with combined phacoemulsification, insertion of posterior chamber intraocular lens (PCIOL), and pars plana vitrectomy for vitreoretinal disorders secondary to diabetic retinopathy. &lt;BR&gt;The average increase in vision was 4.3 Snellen lines.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2006&lt;/TD&gt;
&lt;TD&gt;Treumer [18]&lt;/TD&gt;
&lt;TD&gt;Retrospective series of 111 eyes with combined surgery and 50 eyes with sequential surgery. This article concludes that combined pars plana vitrectomy, phacoemulsification and intraocular lens implantation as well as the two-step procedure are safe and effective. Sequential surgery could be advantageous to minimise the postoperative anterior chamber inflammatory response.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2006&lt;/TD&gt;
&lt;TD&gt;Schrey [19]&lt;/TD&gt;
&lt;TD&gt;Retrospective series of ninety-three eyes of diabetic patients-who underwent PPV with or without intraocular gas tamponade for complications of proliferative diabetic retinopathy. Indication for vitrectomy was vitreous haemorrhage in 80 patients (86.1%), tractional retinal detachment in 3 (3.2%), and vitreous haemorrhage associated with tractional retinal detachment in 10 (10.7%). Four (4.3%) of 93 eyes developed an RRD after vitrectomy.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2006&lt;/TD&gt;
&lt;TD&gt;Diolaiuti [20]&lt;/TD&gt;
&lt;TD&gt;Retrospective series of 117 eyes (91 patients) undergoing combined pars plana vitrectomy, phacoemulsification, and intraocular lens implantation. Follow-up ranged from 8 to 64 months (median = 25 months). Retinal tears were the most frequent intraoperative problems (19%). Limited postoperative fibrin formation occurred in 22% of eyes. Within 6 months, 7% developed glaucoma and 2% showed new anterior segment rubeosis. Overall, 10% underwent secondary surgical procedures as follows: lavage for hemorrhage (n = 3), silicone oil exchange after 7 days for focal rebleeding (n = 1), silicone oil surgery for retinal detachment after gas resorption (n = 1), and lavage for late vitreous hemorrhage (7 to 13 months) (n = 4). Half of the secondary procedures were necessitated within 3 months of the original surgery.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2006&lt;/TD&gt;
&lt;TD&gt;Barsam [25]&lt;/TD&gt;
&lt;TD&gt;This study reported the extent of visual field loss in 20 patients who had required a pars plana vitrectomy secondary to complications of proliferative diabetic retinopathy. 70% of patients had sufficient binocular acuity to drive and of these 71.4% were shown not to have a minimum visual field for safe driving on binocular Esterman field analysis&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2007&lt;/TD&gt;
&lt;TD&gt;Liu [21]&lt;/TD&gt;
&lt;TD&gt;RCT. Fifty-three patients (57 eyes) with PDR, and tractional or tractional-rhegmatogenous retinal detachment. Thirty-three patients (33 eyes) of combined surgery group underwent vitreoretinal surgery and silicone oil tamponade combined with phacoemulsification and foldable intraocular implantation. Twenty patients (24 eyes) of vitrectomy group underwent vitreoretinal surgery and silicone oil tamponade only. The difference in rates of retinal re-attachment was not statistically significant (88% vs 83%) Rates of visual acuity better than 0.1 in combined surgery group was 60.6% vs. 33.3% in vitrectomy group 6 month after operation. The difference in rates of post operative iris neovascularisation similar in both groups.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2007&lt;/TD&gt;
&lt;TD&gt;Tseng [22]&lt;/TD&gt;
&lt;TD&gt;Case review of vitrectomy alone (53 eyes) and vitrectomy combined with phacoemulsification (phacovitrectomy) (31 eyes) and intraocular lens implantation regarding both complications and results in PDR. Postoperative iris and angle NV were found in eight (15.1%) eyes in the first group and no (0%) eyes in the second. The final vision gain of one or more lines was found in 17 (32.1%) and 21 (67.7%) eyes, respectively.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2007&lt;/TD&gt;
&lt;TD&gt;Barzideh [26]&lt;/TD&gt;
&lt;TD&gt;A case note review of 3 patients undergoing PPV to repair TRD secondary to PDR reports that persistent subfoveal fluid may take several months to resolve in patients and account for delayed visual recovery.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Yorston [23]&lt;/TD&gt;
&lt;TD&gt;Prospective study of 174 consecutive vitrectomies for proliferative diabetic retinopathy in 148 patients, with a minimum follow-up of 4 months. 41 (27.7%) patients had a vision of &amp;lt;6/60 in their better eye at presentation. Posterior retinal breaks occurred in 47 (27.0%) eyes. Postoperative complications included vitreous cavity haemorrhage in 37 (22.0%) eyes, retinal detachment in five eyes (3.0%), and rubeotic glaucoma in five eyes (3.0%). 124 (74.7%) eyes improved by at least 0.3 LogMAR units, and 15 (9.0%) worsened by at least 0.3 LogMAR units. 119 (71.7%) eyes had a visual acuity of 6/60 or better, and 27 (16.3%) were counting fingers or worse. 16 (11.1%) patients had a vision of &amp;lt;6/60 in both eyes at latest follow-up. Preoperative vision in both the operated eye and the contralateral eye, macular detachment, and long-acting intraocular tamponade were independent predictors of poor postoperative vision.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Shen [24]&lt;/TD&gt;
&lt;TD&gt;Fifty-four eyes of 45 patients (18 male and 27 female) with PDR who underwent primary vitrectomy with extended SO tamponade for complex RD Anatomic success was achieved in 85.2% after 3 m and 83.3% at last follow up. Breaks with adjacent unreleased traction associated with final anatomic success (OR=0.173, p=0.024). Best-corrected visual acuity (BCVA) improved or remained unchanged in 89% 3m postoperatively and in 78% at last follow-up. Ambulatory vision was achieved in 41% at the third month postoperative and 44% at last follow-up. Preoperative BCVA was associated with final BCVA (p&amp;lt;0.001) (multivariate analysis). Postoperative complications: peri-silicone oil proliferation in 4 eyes, neovascular glaucoma in 4 eyes, oil migration into anterior chamber in 9 eyes, and pupillary-block induced IOP elevation in 5 eyes.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Okamoto [27]&lt;/TD&gt;
&lt;TD&gt;Prospective, interventional, consecutive, comparative case series looking at Vision-Related Quality of Life and Visual Function Following Vitrectomy for Proliferative Diabetic Retinopathy. VFQ-25 was answered by 51 patients with PDR before and 3m after 20-gauge pars plana vitrectomy. VFQ-25 was also administered to 46 age-matched normal controls. The preoperative VFQ-25 significantly lower in the PDR patients than in the normal controls. Vitrectomy significantly improved VFQ-25 composite score. The preoperative VFQ-25 composite score correlated with preoperative logMAR BCVA in the better-seeing eye (P &amp;lt; .001). The postoperative VFQ-25 composite score exhibited significant correlation with post operative logMAR BCVA in either better or worse seeing eye.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Emi [28]&lt;/TD&gt;
&lt;TD&gt;A study of 87 Japanese patients undergoing vitrectomy assessed with NEI VFQ-25 1 month before and 6 months after the procedure showed that vitrectomy for diabetic retinopathy is effective in increasing the QOL of diabetic retinopathy patients&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Rizzo [31]&lt;/TD&gt;
&lt;TD&gt;To evaluate the use of preoperative intravitreal bevacizumab (IVB) in patients undergoing pars plana vitrectomy (PPV) for complications of proliferative diabetic retinopathy (PDR). METHODS: We studied 22 patients with severe PDR. A preoperative complexity score (CS) was recorded. Eleven eyes were treated with IVB, 1.25 mg, 5-7 days before PPV (group 1), and 11 eyes underwent direct PPV (group 2). RESULTS: The average CS was 5.5, and was similar in the two groups. Mean surgical time was 57 minutes in group 1 vs 83 minutes in group 2; mean tool exchanges was 27 vs 53, intraoperative bleeding 5 vs 15, endodiathermy 2 vs 9. No complications were recorded after IVB. Mean pre-operative BCVA was 1.87 logMAR in group 1 and logMAR 2.04 in group 2. Mean pre-operative BCVA was 1.87 logMAR in the bevacizumab group and 2.04 logMAR in group 2, not significantly different (p = 0.7). Mean post-operative BCVA at 6 months was 0.88 logMAR in group 1 and logMAR 2.01 in control group 2, significantly different (p = 0.01). Post-operative BVCA improved in bevacizumab group from pre-operative value (p = 0.15), while in control group there was non-significant increase (p = 0.96). Anatomical attachment was achieved in 11 patients in group 1 vs nine patients in group 2. CONCLUSIONS: IVB administered prior to vitrectomy was well tolerated and reduced active neovascularization, thus facilitating PPV.&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References (including systematic reviews &amp;amp; primary research)&lt;BR&gt;&lt;/STRONG&gt;Links to PubMed abstracts are provided. Free full text may be available from the PubMed link. Where free full text access is not available, NHS staff in England can access full text of a number of journals via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;NHS Evidence &lt;/A&gt;or can request the full text via their &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;1. Smiddy WE, Flynn HW, Jr. Vitrectomy in the management of diabetic retinopathy. Survey of Ophthalmology 1999; 43(6): 491-507. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=Abstract&amp;amp;list_uids=10416792" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;2. Blankenship GW, Machemer R. Long-term diabetic vitrectomy results. Report of 10 year follow-up. Ophthalmology 1985; 92(4): 503-6. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=2582329" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;3. Thompson JT, de Bustros S, Michels RG, Rice TA, Glaser BM. Results of vitrectomy for proliferative diabetic retinopathy. Ophthalmology 1986; 93(12): 1571-4. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=2433657" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;4. Thompson JT, de Bustros S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic traction-rhegmatogenous retinal detachment. Archives of Ophthalmology 1987; 105(4): 503-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2436604" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;5. Thompson JT, de Bustros S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic traction retinal detachment of the macula. Archives of Ophthalmology 1987; 105(4): 497-502. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=Abstract&amp;amp;list_uids=2436603" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;6. Thompson JT, de Bustros S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic vitreous hemorrhage. Archives of Ophthalmology 1987; 105(2): 191-5. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=Abstract&amp;amp;list_uids=3813948" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;7. Sigurdsson H, Baines PS, Roxburgh ST. Vitrectomy for diabetic eye disease. Eye 1988; 2 ( Pt 4): 418-23. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=3075568" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;8. Flynn HW, Jr., Chew EY, Simons BD, Barton FB, Remaley NA, Ferris FL, 3rd. Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1992; 99(9): 1351-7. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=1407968" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;9. Nakazawa M, Kimizuka Y, Watabe T, Kato K, Watanabe H, Yamanobe S, et al. Visual outcome after vitrectomy for diabetic retinopathy. A five-year follow-up. Acta Ophthalmologica (Copenhagen) 1993; 71(2): 219-23. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=8333269" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;10. Karel I, Kalvodova B. Long-term results of pars plana vitrectomy and silicone oil for complications of diabetic retinopathy. European Journal of Ophthalmology 1994; 4(1): 52-8. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=8019122" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;11. Harbour JW, Smiddy WE, Flynn HW, Jr., Rubsamen PE. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. American Journal of Ophthalmology 1996; 121(4): 405-13. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=8604734" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;12. Pendergast SD, Hassan TS, Williams GA, Cox MS, Margherio RR, Ferrone PJ, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. American Journal of Ophthalmology 2000; 130(2): 178-86. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=11004291" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;13. La Heij EC, Hendrikse F, Kessels AG, Derhaag PJ. Vitrectomy results in diabetic macular oedema without evident vitreomacular traction. Graefe's Archive for Clinical and Experimental Ophthalmology 2001; 239(4): 264-70. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=11450490" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;14. Yamamoto T, Akabane N, Takeuchi S. Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. American Journal of Ophthalmology 2001; 132(3): 369-77. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=11530050" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;15. Amino K, Tanihara H. Vitrectomy combined with phacoemulsification and intraocular lens implantation for diabetic macular edema. Japanese Journal of Ophthalmology 2002; 46(4): 455-9. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=12225826" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;16. Lewis H. The Role of Vitrectomy in the Treatment of Diabetic Macular Edema (Editorial). American Journal of Ophthalmology 2001; 131(1): 123-125. &lt;BR&gt;&lt;BR&gt;17. Lahey JM, Francis RR, Kearney JJ. Combining phacoemulsification with pars plana vitrectomy in patients with proliferative diabetic retinopathy: a series of 223 cases. Ophthalmology 2003; 110(7): 1335-9. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=12867387" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;18. Treumer F, Bunse A, Rudolf M, Roider J. Pars plana vitrectomy, phacoemulsification and intraocular lens implantation. Comparison of clinical complications in a combined versus two-step surgical approach. Graefe's Archive for Clinical and Experimental Ophthalmology 2006; 244(7):808-15. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=16328429" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;19. Schrey S, Krepler K, Wedrich A. Incidence of rhegmatogenous retinal detachment after vitrectomy in eyes of diabetic patients. Retina 2006; 26(2):149-52. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=16467669" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;20. Diolaiuti S, Senn P, Schmid MK, Job O, Maloca P, Schipper I. Combined pars plana vitrectomy and phacoemulsification with intraocular lens implantation in severe proliferative diabetic retinopathy. Ophthalmic Surgery, Lasers &amp;amp; Imaging 2006; 37(6):468-74. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=17152540" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;21. Liu DC, Wu H, Guo L. [Vitrectomy combined with phacoemulsification and intraocular lens implantation for treatment of proliferative diabetic retinopathy]. Zhonghua Yan Ke Za Zhi [Chinese Journal of Ophthalmology] 2007; 43(4):346-9. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=%22%5BZhonghua%20yan%20ke%20za%20zhi%5D%20Chinese%20journal%20of%20ophthalmology%22%5BJour%5D%20AND%20346%5Bpage%5D%20AND%20Liu%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;22. Tseng HY, Wu WC, Hsu SY. Comparison of vitrectomy alone and combined vitrectomy, phacoemulsification and intraocular lens implantation for proliferative diabetic retinopathy. Kaohsiung Journal of Medical Sciences 2007; 23(7):339-43. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17606428?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;23. Yorston D, Wickham L, Benson S, Bunce C, Sheard R, Charteris D. Predictive clinical features and outcomes of vitrectomy for proliferative diabetic retinopathy. British Journal of Ophthalmology 2008; 92(3):365-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=365%5Bpage%5D%20AND%20Yorston%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;24. Shen YD, Yang CM. Extended silicone oil tamponade in primary vitrectomy for complex retinal detachment in proliferative diabetic retinopathy: a long-term follow-up study. European Journal of Ophthalmology 2007; 17(6):954-60. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Shen%5Bauthor%5D%20AND%20extended%20silicone" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;25. Barsam A, Laidlaw A. Visual fields in patients who have undergone vitrectomy for complications of diabetic retinopathy. A prospective study. BMC Ophthalmology 2006; 6:5. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=16438726" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;26. Barzideh N, Johnson TM. Subfoveal fluid resolves slowly after pars plana vitrectomy for tractional retinal detachment secondary to proliferative diabetic retinopathy. Retina 2007; 27(6):740-3. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=retina%5BJour%5D%20AND%20740%5Bpage%5D%20AND%20Barzideh%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;27. Okamoto F, Okamoto Y, Fukuda S, Hiraoka T, Oshika T. Vision-Related Quality of Life and Visual Function Following Vitrectomy for Proliferative Diabetic Retinopathy. American Journal of Ophthalmology 2008. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18400203?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;28. Emi K, Oyagi T, Ikeda T, Bando H, Okita T, Kashimoto D, et al. [Influence of vitrectomy for diabetic retinopathy on health-related quality of life]. Nippon Ganka Gakkai Zasshi 2008; 112(2):141-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18318275?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;29. Laidlaw DA. Vitrectomy for diabetic macular oedema. Eye 2008; 22(10):1337-41. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18437175" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;30. Bhatnagar P, Schiff WM, Barile GR. Diabetic vitrectomy: the influence of lens status upon surgical outcomes. Current Opinion in Ophthalmology 2008; 19(3):243-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18408501" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;31. Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefe's Archive for Clinical and Experimental Ophthalmology 2008. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18286296?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;32. Yeoh J, Williams C, Allen P, Buttery R, Chiu D, Clark B, et al. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clinical &amp;amp; Experimental Ophthalmology 2008; 36(5):449-54. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18942219" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;33. Yang CM, Yeh PT, Yang CH, Chen MS. Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. American Journal of Ophthalmology 2008; 146(2):211-217. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18547539" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;34. Oshima Y, Shima C, Wakabayashi T, Kusaka S, Shiraga F, Ohji M, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 2009; 116(5):927-38. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19269033" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;35. Ishikawa K, Honda S, et al. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye 2009; 23(1):108-11. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17891057" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;36. Krishnan R, Goverdhan S, Lochhead J. Intravitreal pegaptanib in severe proliferative diabetic retinopathy leading to the progression of tractional retinal detachment. Eye 2009; 23(5):1238-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18551139" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;37. Jun Lee S, Koh HJ. Enlargement of the foveal avascular zone in diabetic retinopathy after adjunctive intravitreal bevacizumab (avastin) with pars plana vitrectomy. Journal of Ocular Pharmacology and Therapeutics 2009; 25 (2):):173-4. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19284326" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;38. Huang YH, Yeh PT, Chen MS, Yang CH, Yang CM. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage. Retina 2009; 29(8):1134-40. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19672218" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;39. Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology 2009; 116(10):1943-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19699531" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;40. Modarres M, Nazari H, Falavarjani KG, Naseripour M, Hashemi M, Parvaresh MM. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. European Journal of Ophthalmology 2009; 19(5):848-52. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19787608" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;41. Yeh PT, Yang CM, Lin YC, Chen MS, Yang CH. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina 2009; 29(6):768-74. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19516117" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;42. di Lauro R, De Ruggiero P, di Lauro MT, Romano MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology 2010; 248(6):785-91. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20135139" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;43. Hattori T, Shimada H, Nakashizuka H, Mizutani Y, Mori R, Yuzawa M. Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy. Retina 2010; 30(5):761-4. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20453802" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;44. Hernandez-Da Mota SE, Nunez-Solorio SM. Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy. European Journal of Ophthalmology 2010; 20(6):7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20491044" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;45. Park DH, Shin JP, Kim SY. Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study. Graefe's Archive for Clinical and Experimental Ophthalmology 2010; 248(5):641-50. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20012643" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;46. Liu L, Wu WC, Yeung L, Wang NK, Kuo YH, Chao AN, et al. Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy. Ophthalmic surgery, lasers &amp;amp; imaging 2010; 41(1):72-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20128573" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;47. Haller JA, Qin H, Apte RS, Beck RR, Bressler NM, Browning DJ, et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 2010; 117(6):1087-1093 e3. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20299105" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;48. Sakamoto A, Nishijima K, Kita M, Oh H, Tsujikawa A, Yoshimura N. Association between foveal photoreceptor status and visual acuity after resolution of diabetic macular edema by pars plana vitrectomy. Graefe's Archive for Clinical and Experimental Ophthalmology 2009; 247(10):1325-30. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19430805" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;49. Tao Y, Jiang YR, Li XX, Gao L, Jonas JB. Long-term results of vitrectomy without endotamponade in proliferative diabetic retinopathy with tractional retinal detachment. Retina 2010; 30(3):447-51. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20216292" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;50. Steel DH, Connor A, Habib MS, Owen R. Entry site treatment to prevent late recurrent postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. British Journal of Ophthalmology 2010.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19955203" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;51. Yan H, Cui J, Lu Y, Yu J, Chen S, Xu Y. Reasons for and management of postvitrectomy vitreous hemorrhage in proliferative diabetic retinopathy. Current Eye Research 2010; 35(4):308-13. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20373898" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;BR&gt;Further Evidence&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/SearchResults.aspx?catID=5134&amp;amp;searchText=&amp;amp;sort=PUBLICATION_DATE&amp;amp;resultsPerPage=10&amp;amp;summaries=true" target="_blank"&gt;Links to systematic reviews on diabetic retinopathy in&amp;nbsp;NHS Evidence - diabetes&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Guidelines&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5658&amp;amp;searchText=&amp;amp;sort=PUBLISHER&amp;amp;resultsPerPage=10&amp;amp;summaries=true" target="_blank"&gt;Links to supporting Guidelines&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Patient Information&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?tabID=292&amp;amp;catID=5658&amp;amp;sort=PUBLISHER&amp;amp;resultsPerPage=10&amp;amp;summaries=true&amp;amp;" target="_blank"&gt;Links to supporting Patient Information&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Reference Material&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?catID=5134&amp;amp;tabID=290&amp;amp;searchText=&amp;amp;sort=PUBLICATION_DATE&amp;amp;resultsPerPage=10&amp;amp;summaries=true" target="_blank"&gt;Links to supporting reference material&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;Publication details&lt;BR&gt;&lt;/STRONG&gt;Originally written by Peter Scanlon (Consultant Ophthalmologist&amp;nbsp; and National Clinical Director of the English National Screening Programme for Diabetic Retinopathy) in June 2006, since reviewed and updated in June 2007 by P Scanlon, in June 2008 by P Scanlon and Irene Stratton, in June 2009 by P Scanlon, and in August 2010 by P Scanlon.&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387401</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=387401]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetic Retinopathy - Alternative surgical treatment for diabetic retinopathy: intravitreal injection of triamcinolone</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,EYES AND VISION,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,EYE DISEASES,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>part of the 2010 Annual Evidence Update on Diabetic Retinopathy</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetic Retinopathy - Alternative surgical treatment for diabetic retinopathy: intravitreal injection of triamcinolone&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt; 13 September 2010&lt;BR&gt;Originally written by P Scanlon in June 2006, updated annually, &lt;A href="#ref1"&gt;link to further author and publication details here.&lt;/A&gt;&amp;nbsp; &lt;BR&gt;Changes and additions since August 2009 are highlighted in red.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387096" target="_blank"&gt;Link back to home page for 2010 Annual Evidence Update on Diabetic Retinopathy here.&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387421" target="_blank"&gt;Link to table of abbreviations here.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID387401/nelhImp_0000_photo13-diabeticmaculopathy.jpg"&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Promising results in the short term for improving the vision in eyes with chronic diabetic macular oedema unresponsive to conventional laser treatment, reducing macular thickness, and inducing reabsorption of hard exudates, have been described using intravitreal steroids in the following studies:&lt;BR&gt;Ciardella [1], Jonas [2-3] , Lam [4], Massin [5], Micelli Ferrari [6], Ozkiris [7], Sutter [8], Chieh [9], Er [10], Islam [11], Khairallah [12], Negi [13], Ozdemir [14], Patelli [15], Zacks [16], Avci [17] , Spandau [18], Brasil [19], Bardak [20], Lubczynska [21], Paccola [22] and Shimura [23]. One case study did report regression of NVD in addition to the decrease in macular oedema. &lt;BR&gt;&lt;BR&gt;The effects are reported to last for 3 to 8 months. This may be partially dependent on the dose given. The following doses have been used:&lt;BR&gt;Doses as low as 1mg have been reported by Chieh [9]. 4mg is the commonest dose used by Ciardella [1], Lam [4], Massin [5], Er [10], Islam [11], Negi [13], Ozdemir [14], Patelli [15], Avci [17], Brasil [19], Bardak [20], Lubczynska [21], Paccola [22] and Shimura [23], 8 mg by Ozkiris [7], 13mg by Spandau [18] and 20 - 25 mg by Jonas [2-3]. Hauser [24] has suggested that in eyes with refractory diffuse DME with cystic changes, 4 mg IVTA does not appear to be more effective than 1 or 2 mg IVTA.&lt;BR&gt;&lt;BR&gt;Garcia-Arumi [25] recommended that one should reduce the concentration of the solvent agent benzyl alcohol (9.9 mg/ml) from a commercially prepared triamcinolone acetonide (TA) suspension by centrifugation before administering the drug. Oishi [26] developed a new TA injection made of pure TA suspended in 0.5% sodium hyaluronate.&lt;BR&gt;&lt;BR&gt;Cellini [27] suggested, from his study of 14 patients with diffuse cystoid macular oedema in both eyes from diabetic retinopathy, that a parabulbar subtenon approach can be considered a valid alternative to the intravitreal injection.&lt;BR&gt;&lt;BR&gt;A further study [28] described an interventional case series of 9 patients with bilateral proliferative diabetic retinopathy one eye ascribed to intravitreal triamcinolone before PRP and suggested that this may be useful in improving the effects of PRP in eyes with proliferative diabetic retinopathy by reducing neovascularization and macular thickening. &lt;BR&gt;&lt;BR&gt;One of the proponents of intravitreal triamcinolone in diabetic retinopathy (Jonas) has written two review articles [29-30] on the subject.&amp;nbsp; However, the following complications have been reported:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;posterior subcapsular cataract [1, 9, 17, 31- 33]&lt;/LI&gt;
&lt;LI&gt;vitreous haemorrhage [1]&lt;/LI&gt;
&lt;LI&gt;transient rise in intraocular pressure [1, 4, 5, 7, 10, 12, 13, 18, 32 - 34]&lt;/LI&gt;
&lt;LI&gt;early rapid increases in intraocular pressure (IOP) requiring surgical intervention [35]&lt;/LI&gt;
&lt;LI&gt;severe sub conjunctival haemorrhage [36]&lt;/LI&gt;
&lt;LI&gt;culture-negative sterile endophthalmitis [9, 10, 32]&lt;BR&gt;infectious endophthalmitis [8, 32] &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Batioglu [33] reports on 2 year follow-up of 75 eyes of 75 diabetic patients with clinically significant diffuse macular edema that had failed to respond to previous laser photocoagulation after intravitreal injection of triamcinolone acetonide. Intravitreal triamcinolone reduces foveal thickness and improves visual acuity in the short term, but with the extended follow-up, the number of recurrences and steroid-related complications were shown to increase. During the follow-up, 29 (38.7%) eyes received re-injection of intravitreal triamcinolone. 21 (28%) eyes developed intraocular pressure values higher than 21 mmHg, and 18 (24%) eyes developed cataract. 13 (17.3%) eyes required cataract and/or glaucoma surgery.&lt;BR&gt;&lt;BR&gt;In view of the reported complications, extreme caution is advised in the use of this technique. Randomised controlled trials utilising varying doses of steroid are now required to assess the long-term efficacy, safety and to define optimum treatment regimens.&lt;BR&gt;&lt;BR&gt;Margolis [37] has suggested that, from a retrospective case series, the addition of IVTA to PRP in the treatment of eyes with high-risk PDR and CSMO may prevent PRP-induced foveal thickening and loss of vision.&lt;BR&gt;&lt;BR&gt;In a direct comparison between intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema, the Diabetic Retinopathy Clinical Research Network [38] found over a 2-year period, focal/grid photocoagulation is more effective and has fewer side effects than 1-mg or 4-mg doses of preservative-free intravitreal triamcinolone for most patients with DME. Maia [39] has suggested that there may be visual benefits in a combination of laser photocoagulation with IVTA for patients with proliferative DR and clinically significant macular oedema. Sivaprasad [40] demonstrated that the frequency of peri-foveal vitreous detachment occurred more frequently after intravitreal triamcinolone and Wickremasinghe [41] demonstrated a significant narrowing effect on both retinal arteriolar and venular diameters.&lt;BR&gt;&lt;BR&gt;A systematic review of the use of intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema by Yilmaz [42] concluded that intravitreal triamcinolone acetonide injection is effective in improving VA in patients with refractory DME in the short-term, but the benefits do not seem to persist in the long-term.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Gillies [43] describes the 3-year risk of cataract after intravitreal triamcinolone (IVTA) injections for diabetic macular oedema and the outcomes of cataract surgery. Over the 3 years of the study, 15/27 (56%) phakic eyes in the IVTA treated group underwent cataract surgery as compared with 2/25 (8%) initial sham-treated eyes (P &amp;lt; 0.001). Visual outcomes after cataract surgery were generally good, although a small proportion of eyes lost greater than 15 letters over the course of the study.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Takata [44] compared the effectiveness of intravitreal injection (IVT) versus posterior subtenon infusion (STI) of triamcinolone acetonide performed during phacoemulsification cataract surgery in eyes with refractory diffuse diabetic macular edema. Ten patients from the IVT group and 9 patients from the STI group completed the 24-week study visit. A significant improvement in best-corrected visual acuity was observed only in the IVT group at 4 weeks (mean difference +/- standard error, improved to 20/116; P = 0.0437), 8 weeks (20/110; P = 0.0355), and 12 weeks (20/121; P = 0.0471) postoperatively.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Mirshahi [45] reported the results of twenty-three patients diagnosed with both high-risk proliferative diabetic retinopathy (PDR) and clinically significant macular edema (CSME) were enrolled in our prospective, randomized clinical trial study. One eye of each patient was selected to undergo IVTA injection one week before initial panretinal photocoagulation (PRP) and macular photocoagulation (MPC) (IVTA eye), and the other eye was treated with PRP and MPC (control eye) based on block randomization. Combined IVTA plus PRP and MPC in coexisting high-risk PDR and CSME eyes did not have a significant beneficial effect on best-corrected visual acuity improvement and central macular thickness reduction compared with standard treatment.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Haller [46] reported the results of an intravitreous dexamethasone drug delivery system in 171 patients with diabetic macular edema. At day 90, a BCVA improvement of 10 letters or more was seen in more eyes in the 700-microg group (33.3%) and 350-microg group (21.1%) than the observation group (12.3%; P = .007 vs 700-microg group). At day 180, a BCVA improvement of 10 letters or more was seen in 30% of eyes in the 700-microg group, 19% in the 350-microg group, and 23% in the observation group (P &amp;gt; or = .4 for treated vs observed eyes). There were also significantly greater improvements in central retinal thickness and fluorescein leakage in treated eyes than observed eyes (P = .03; day 90).&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Bressler [47] reported an analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. The cumulative probability of progression of retinopathy at 2 years was 31% (laser group), 29% (1-mg group), and 21% (4-mg group) (P = .64 in the 1-mg group and .005 in the 4-mg group compared with the laser group). These differences appeared to be sustained at 3 years. The conclusion of the study was that intravitreal triamcinolone acetonide (4 mg) appeared to reduce the risk of progression of diabetic retinopathy. Given the exploratory nature of this analysis and because intravitreal triamcinolone adverse effects include cataract formation and glaucoma, use of this treatment merely to reduce the rates of progression of proliferative diabetic retinopathy or worsening of the level of diabetic retinopathy does not seem warranted at this time.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Steijns [48] conducted a systematic review of steroid injection in addition to macular laser grid photocoagulation in diabetic macular oedema and concluded that a literature search does not provide sufficiently strong evidence to recommend steroid injection before MLG photocoagulation in DMO.&lt;/SPAN&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;BR&gt;References (including systematic reviews &amp;amp; primary research)&lt;BR&gt;&lt;/STRONG&gt;Links to PubMed abstracts are provided. Free full text may be available from the PubMed link. Where free full text access is not available, NHS staff in England can access full text of a number of journals via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/" target="_blank"&gt;NHS Evidence&lt;/A&gt; or can request the full text via their &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;1. Ciardella AP, Klancnik J, Schiff W, Barile G, Langton K, Chang S. Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study. British Journal of Ophthalmology 2004; 88(9): 1131-6. &lt;A href="http://bjo.bmjjournals.com/cgi/content/full/88/9/1131" target="_blank"&gt;Link to full text here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;2. Jonas JB, Degenring RF, Kamppeter BA, Kreissig I, Akkoyun I. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. American Journal of Ophthalmology 2004; 138(1): 158-60. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=15234306" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;3. Jonas JB, Martus P, Degenring RF, Kreissig I, Akkoyun I. Predictive factors for visual acuity after intravitreal triamcinolone treatment for diabetic macular edema. Archives of Ophthalmology 2005; 123(10): 1338-43. &lt;A href="http://archopht.ama-assn.org/cgi/content/full/123/10/1338" target="_blank"&gt;Link to full text here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;4. Lam DS, Chan CK, Tang EW, Li KK, Fan DS, Chan WM. Intravitreal triamcinolone for diabetic macular oedema in Chinese patients: six-month prospective longitudinal pilot study. Clinical &amp;amp; Experimental Ophthalmology 2004; 32(6): 569-72. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=15575825" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;5. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004; 111(2): 218-24; discussion 224-5. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=15019365" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;6. Micelli Ferrari T, Sborgia L, Furino C, Cardascia N, Ferreri P, Besozzi G, et al. Intravitreal triamcinolone acetonide: valuation of retinal thickness changes measured by optical coherence tomography in diffuse diabetic macular edema. European Journal of Ophthalmology 2004; 14(4): 321-4. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=15309977" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;7. Ozkiris A, Evereklioglu C, Erkilic K, Tamcelik N, Mirza E. Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular edema. European Journal of Ophthalmology 2004; 14(6): 543-9. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=15638105" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;8. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004; 111(11): 2044-9. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=15522370" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;9. Chieh JJ, Roth DB, Liu M, Belmont J, Nelson M, Regillo C, et al. Intravitreal triamcinolone acetonide for diabetic macular edema. Retina 2005; 25(7): 828-34. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=16205559" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;10. Er H, Yilmaz H. Intravitreal cortisone injection for refractory diffuse diabetic macular edema. Ophthalmologica 2005; 219(6): 394-400. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=16286802" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;11. Islam MS, Negi A, Vernon SA. Improved visual acuity and macular thickness 1 week after intravitreal triamcinolone for diabetic macular oedema. Eye 2005; 19(12): 1325-7. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=15578081" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;12. Khairallah M, Zeghidi H, Ladjimi A, Yahia SB, Attia S, Zaouali S, et al. Primary intravitreal triamcinolone acetonide for diabetic massive macular hard exudates. Retina 2005; 25(7): 835-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=16205560" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;13. Negi AK, Vernon SA, Lim CS, Owen-Armstrong K. Intravitreal triamcinolone improves vision in eyes with chronic diabetic macular oedema refractory to laser photocoagulation. Eye 2005; 19(7): 747-51. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15359268" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;14. Ozdemir H, Karacorlu M, Karacorlu SA. Regression of serous macular detachment after intravitreal triamcinolone acetonide in patients with diabetic macular edema. American Journal of Ophthalmology 2005; 140(2): 251-5. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=15992756" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;15. Patelli F, Fasolino G, Radice P, Russo S, Zumbo G, FM DIT, et al. Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macular edema with and without previous macular laser treatment. Retina 2005; 25(7): 840-5. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=16205561" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;16. Zacks DN, Johnson MW. Combined intravitreal injection of triamcinolone acetonide and panretinal photocoagulation for concomitant diabetic macular edema and proliferative diabetic retinopathy. Retina 2005; 25(2): 135-40. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=15689801" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;17. Avci R, Kaderli B, Akalp FD. Intravitreal triamcinolone injection for chronic diffuse diabetic macular oedema. Clinical &amp;amp; Experimental Ophthalmology 2006; 34(1): 27-32. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=16451255" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;18. Spandau UH, Derse M, Schmitz-Valckenberg P, Papoulis C, Jonas JB. Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. British Journal of Ophthalmology 2005; 89(8): 999-1003. &lt;A href="http://bjo.bmjjournals.com/cgi/content/full/89/8/999" target="_blank"&gt;Link to full text here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;19. Brasil OF, Smith SD, Galor A, Lowder CY, Sears JE, Kaiser PK. Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: an optical coherence tomography study. British Journal of Ophthalmology 2007; 91(6):761-5. &lt;A href="http://bjo.bmj.com/cgi/reprint/91/6/761" target="_blank"&gt;Link to full text here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;20. Bardak Y, Cekic O, Sahin Tig U, Bardak H. Alterations in central retinal sensitivity after intravitreal triamcinolone injection for diffuse diabetic macular edema. European Journal of Ophthalmology 2007; 17(5):780-4. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=780%5Bpage%5D%20AND%20Bardak%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;21. Lubczynska A, Kociecki J. [Intravitreal triamcinolone acetonide injections in treatment of cystoid macular edema due to diabetic maculopathy]. Klinika Oczna 2007; 109(4-6):165-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=165%5Bpage%5D%20AND%20Lubczynska%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;22. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Journal of Ophthalmology 2008;92(1):76-80. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=76%5Bpage%5D%20AND%20Paccola%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;23. Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. American Journal of Ophthalmology 2008; 145(5):854-861 e3. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=854%5Bpage%5D%20AND%20Shimura%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;24. Hauser D, Bukelman A, Pokroy R, Katz H, Len A, Thein R, et al. Intravitreal triamcinolone for diabetic macular edema: comparison of 1, 2, and 4 mg. Retina 2008; 28(6):825-30. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18536598" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;25. Garcia-Arumi J, Boixadera A, Giralt J, Martinez-Castillo V, Gomez-Ulla F, Corcostegui B, et al. Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use. British Journal of Ophthalmology 2005; 89(9): 1112-4. &lt;A href="http://bjo.bmjjournals.com/cgi/content/full/89/9/1112" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;26. Oishi M, Maeda S, Nakamura A, Kurokawa N, Ohguro N, Tano Y. Examination of purification methods and development of intravitreal injection of triamcinolone acetonide. Japanese Journal of Ophthalmology 2005; 49(5): 384-7. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=16187038" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;27. Cellini M, Pazzaglia A, Zamparini E, Leonetti P, Campos EC. Intravitreal vs. subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular edema. BMC Ophthalmology 2008; 8:5. &lt;A href="http://www.biomedcentral.com/content/pdf/1471-2415-8-5.pdf" target="_blank"&gt;Link to full text here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;28. Bandello F, Polito A, Pognuz DR, Monaco P, Dimastrogiovanni A, Paissios J. Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy. Archives of Ophthalmology 2006; 124(5):643-50. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16682585&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;29. Jonas JB. Intravitreal triamcinolone acetonide for diabetic retinopathy. Developments in Ophthalmology 2007; 39:96-110. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17245081&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;30. Jonas JB, Schlichtenbrede F. Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases. Eye 2007. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Jonas%5Bauthor%5D%20AND%20Visual%20acuity%20and%20intraocular%20pressure%20" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;31. Jonas JB, Kreissig I, Degenring RF. Cataract surgery after intravitreal injection of triamcinolone acetonide. Eye 2004; 18(4): 361-4. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=15069430" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;32. Selim Kocabora M, Kucuksahin H, Gulkilik G, Taskapili M, Yilmazli C, Engin G. [Treatment of diabetic macular edema with intravitreal triamcinolone acetonide injection: functional and anatomical outcomes]. Journal Français d'Ophtalmologie 2007; 30(1):32-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=32%5Bpage%5D%20AND%20Kucuksahin%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;33. Batioglu F, Ozmert E, Parmak N, Celik S. Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema. International Ophthalmology 2007; 27(5):299-306. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=299%5Bpage%5D%20AND%20Batioglu%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;34. Yamashita T, Uemura A, Kita H, Sakamoto T. Intraocular pressure after intravitreal injection of triamcinolone acetonide following vitrectomy for macular edema. Journal of Glaucoma 2007; 16(2):220-4. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17473734?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;35. Singh IP, Ahmad SI, Yeh D, Challa P, Herndon LW, Allingham RR, et al. Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. American Journal of Ophthalmology 2004; 138(2): 286-7. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=15289140" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;36. Gupta R, Negi A, Vernon SA. Severe sub conjunctival haemorrhage following intravitreal triamcinolone for refractory diabetic oedema. Eye 2005; 19(5): 590-1.&lt;BR&gt;&lt;BR&gt;37. Margolis R, Singh RP, Bhatnagar P, Kaiser PK. Intravitreal triamcinolone as adjunctive treatment to laser panretinal photocoagulation for concomitant proliferative diabetic retinopathy and clinically significant macular oedema. Acta Ophthalmologica (Oxf) 2008; 86(1):105-10. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17608830?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;38. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115(9):1447-9, 1449 e1-10. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18662829" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;39. Maia OO, Jr., Takahashi BS, Costa RA, Scott IU, Takahashi WY. Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial. American Journal of Ophthalmology 2009; 147(2):291-297 e2. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18929352" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;40. Sivaprasad S, Ockrim Z, Massaoutis P, Ikeji F, Hykin PG, Gregor ZJ. Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina 2008; 28(10):1435-42. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18628722" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;41. Wickremasinghe SS, Rogers SL, Gillies MC, Zhu M, Wong TY. Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Invest Investigative Ophthalmology &amp;amp; Visual Science 2008; 49(11):4707-11. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18599569" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;42. Yilmaz T, Weaver CD, Gallagher MJ, Cordero-Coma M, Cervantes-Castaneda RA, Klisovic D, et al. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology 2009; 116(5):902-11; quiz 912-3. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19410949" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;43. Gillies MC, Islam FM, Larsson J, Pasadhika S, Gaston C, Zhu M, et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical &amp;amp; Experimental Ophthalmology 2010; 38(6):605-12. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20528977" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;44. Takata C, Messias A, Folgosa MS, Lucena LR, Lucena DR, Scott IU, et al. Intravitreal injection versus subtenon infusion of triamcinolone acetonide during cataract surgery in patients with refractory diabetic macular edema. Retina 2010; 30(4):562-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20182403" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;45. Mirshahi A, Shenazandi H, Lashay A, Faghihi H, Alimahmoudi A, Dianat S. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema. Retina 2010; 30(2):254-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20057344" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;46. Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Archives of Ophthalmology 2010; 128(3):289-96. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20212197" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;47. Bressler NM, Edwards AR, Beck RW, Flaxel CJ, Glassman AR, Ip MS, et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology 2009; 127(12):1566-71. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20008708" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;48. Steijns D, Duijvesz D, Breedijk MA, van der Heijden GJ. Steroid injection in addition to macular laser grid photocoagulation in diabetic macular oedema: a systematic review. Acta Ophthalmologica 2010; 88(4):389-93. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20222888" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;/SPAN&gt;&lt;STRONG&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;BR&gt;Further Evidence&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/SearchResults.aspx?catID=5134&amp;amp;tabID=289&amp;amp;" target="_blank"&gt;Links to systematic reviews on diabetic retinopathy in&amp;nbsp;NHS Evidence - diabetes&lt;/A&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;Guidelines&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5658&amp;amp;searchText=&amp;amp;sort=PUBLISHER&amp;amp;resultsPerPage=10&amp;amp;summaries=true" target="_blank"&gt;Links to supporting Guidelines&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Patient Information&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?tabID=292&amp;amp;catID=5658&amp;amp;sort=PUBLISHER&amp;amp;resultsPerPage=10&amp;amp;summaries=true&amp;amp;" target="_blank"&gt;Links to supporting Patient Information&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Reference Material&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?catID=5134&amp;amp;tabID=290&amp;amp;searchText=&amp;amp;sort=PUBLICATION_DATE&amp;amp;resultsPerPage=10&amp;amp;summaries=true" target="_blank"&gt;Links to supporting reference material&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN; mso-bidi-language: AR-SA" lang=EN&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;Publication details&lt;BR&gt;&lt;/STRONG&gt;Originally written by Peter Scanlon (Consultant Ophthalmologist&amp;nbsp; and National Clinical Director of the English National Screening Programme for Diabetic Retinopathy) in June 2006, since reviewed and updated in June 2007 by P Scanlon, in June 2008 by P Scanlon and Irene Stratton, in June 2009 by P Scanlon, and in August 2010 by P Scanlon.&lt;/P&gt;&lt;/SPAN&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387406</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=387406]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetic Retinopathy - Alternative surgical treatment for diabetic retinopathy: intravitreal injection of VEGF inhibitors</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,EYES AND VISION,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,EYE DISEASES,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>part of the 2010 Annual Evidence Update on Diabetic Retinopathy</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetic Retinopathy - Alternative surgical treatment for diabetic retinopathy: intravitreal injection of VEGF inhibitors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt; 13 September 2010&lt;BR&gt;Originally written by P Scanlon in June 2006, updated annually, &lt;A href="#ref1"&gt;link to further author and publication details here.&lt;/A&gt;&amp;nbsp; &lt;BR&gt;Changes and additions since August 2009 are highlighted in red.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387096" target="_blank"&gt;Link back to home page for 2010 Annual Evidence Update on Diabetic Retinopathy here.&lt;BR&gt;&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387421" target="_blank"&gt;Link to table of abbreviations here&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;Ocular neovascularisation (angiogenesis) and increased vascular permeability have been associated with Vascular Endothelial Growth Factor (VEGF). Neovascularisation is dependent on the presence of VEGF - expression of VEGF in animal models is sufficient to induce neovascularisation whereas inhibition reduces this effect. In humans ocular VEGF levels have been shown to rise with the growth and leakage of new vessels. This provides a therapeutic rationale for the targeting of VEGF in diabetic retinopathy. &lt;BR&gt;However, there is a concern that VEGF does have a neuroprotective effect and that there might be neurological adverse effects if there is significant systemic absorption of these substances.&lt;/P&gt;
&lt;P align=left&gt;There are three potential VEGF inhibitors:&lt;BR&gt;&lt;STRONG&gt;Macugen (Pegaptanib)&lt;BR&gt;Lucentis (Ranibizumab)&lt;BR&gt;Bevacizumab (Avastin)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;A NICE Technology Appraisal in August 2008 [1] advised the following:&lt;BR&gt;‘Ranibizumab is recommended as a possible treatment for people with wet AMD if all the following apply to their eye. &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;The best possible visual acuity after correction with glasses or contact lenses is between 6/12 and 6/96.&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;There is no permanent damage to the fovea (the part of the eye that helps people to see things in sharp detail).&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;The area affected by AMD is no larger than 12 times the size of the area inside the eye where the optic nerve connects to the retina.&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;There are signs that the condition has been getting worse.&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;Treatment should be stopped if a person's vision gets worse and there are changes inside the eye which show that treatment isn’t working. &lt;BR&gt;The NHS should cover the drug cost of ranibizumab for the first 14 injections in each eye being treated. If people need more than 14 injections per eye, the manufacturer of ranibizumab has agreed to take over the drug cost from the NHS.&lt;BR&gt;&lt;STRONG&gt;Pegaptanib&lt;/STRONG&gt; is not recommended for people with wet AMD. Healthcare professionals should not immediately stop prescribing pegaptanib for people who were already taking it when the guidance was issued. These people should be able to carry on taking pegaptanib until they and their healthcare professionals decide that it is the right time to stop treatment.’&lt;BR&gt;&lt;BR&gt;NICE did not review Avastin because it is unlicensed for treating Wet AMD. Lucentis is derived from bevacizumab (Avastin), which is a full length humanised monoclonal antibody against human VEGF currently used for treatment of several solid organ tumours (colorectal etc). Lucentis is an antibody fragment of Avastin, produced by recombinant antibody production (genetic engineering) techniques.&lt;BR&gt;&lt;BR&gt;These drugs have not been extensively studied in diabetic eye disease and there are only early reports of their use.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;SPAN style="COLOR: #a81400"&gt;Use of intravitreal VEGF inhibitors in conjunction with vitrectomy:&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;There have been reports of preoperative VEGF inhibitors improving vitrectomy surgical outcomes, which have been reported in &lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387365" target="_blank"&gt;section vi(b): Conventional treatment for diabetic retinopathy: vitrectomy&lt;/A&gt;.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;SPAN style="COLOR: #a81400"&gt;Use of intravitreal VEGF inhibitors in the treatment of iris neovascularisation:&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;Thew [2] reported on a patient with severe bilateral proliferative diabetic retinopathy and left rubeotic glaucoma who responded well to adjunctive intravitreal bevacizumab (Avastin) following panretinal photocoagulation.&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Reports by Jiang [3] and Falavarjani [4] found benefits in the treatment of iris neovascularisation or neovascular glaucoma:&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;SPAN style="COLOR: #a81400"&gt;Complications of intravitreal VEGF inhibitors&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;Shima [5] retrospectively reviewed the systemic and ocular complications that developed within 2 months of each intravitreal injection of bevacizumab in 707 patients (1300 injections) with intraocular neovascularization or macular oedema. Nine ocular (1.27%) and eight systemic (1.13%) complications occurred in 707 patients. The ocular complications included corneal abrasion (n = 2), chemosis (n = 2), lens injury (n = 1), ocular inflammation (n = 2), retinal pigment epithelial tear (n = 1) and acute vision loss (n = 1). The systemic complications included cerebral infarction (n = 1), elevation of systolic blood pressure (n = 2), facial skin redness (n = 1), itchy diffuse rash (n = 1) and menstrual irregularities (n = 3). Caution was therefore advised when considering intravitreal injection of this drug.&lt;BR&gt;Chen [6] described a patient who noticed a significant decrease in visual acuity with enlargement of the foveal avascular zone on a fluorescein angiogram and persistent late leakage within 2 days of treatment with intravitreal bevacizumab.&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Liu [7] described the development of ghost cell glaucoma within 1 week after intravitreal injection of bevacizumab in three eyes treated for a postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy (PDR) and advised caution in administering an intravitreal injection of bevacizumab for a postoperative vitreous hemorrhage after vitrectomy for PDR.&lt;BR&gt;Bhavsar [8] reported that that a low rate of endophthalmitis can be achieved by means of a protocol that includes use of topical povidone-iodine, a sterile lid speculum, and topical anesthetic, but does not require topical antibiotics, sterile gloves, or a sterile drape.&lt;BR&gt;Batman [9] described the progression of subretinal fibrosis in 21 eyes of patients with proliferative diabetic retinopathy refractory to panretinal laser photocoagulation.&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;STRONG&gt;Use of intravitreal VEGF inhibitors in the treatment of proliferative DR:&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;Mirshahi [10] conducted a prospective, fellow-eye sham controlled clinical trial on 80 eyes of 40 high-risk characteristic proliferative diabetic retinopathy type II diabetics. The study reported that intravitreal bevacizumab remarkably augmented the short-term response to scatter panretinal laser photocoagulation in high-risk characteristic proliferative diabetic retinopathy but the effect was short-lived, as many of the eyes showed rapid recurrence. A total of 87.5% of bevacizumab-injected eyes and 25% of sham group showed complete regression at week 6 of follow-up (p&amp;lt;0.005). However, at week 16, PDR recurred in a sizable number of the bevacizumab-treated eyes, and the complete regression rate in the two groups became identical (25%; p=1.000); partial regression rates were 70% vs 65%.&lt;/P&gt;
&lt;P align=left&gt;Moradian [11] described the effects of intravitreal Bevacizumab (Avastin) on thirty eight eyes of 38 patients with active progressive proliferative diabetic retinopathy. The treatment caused a significant amount of VH resolution and neovessel regression but two cases showing moderate fibrous proliferation developed traction retinal detachment.&lt;/P&gt;
&lt;P align=left&gt;Arevalo [12] described the effects of intravitreal bevacizumab (Avastin) on retinal neovascularization (RN) in forty-four eyes of 33 patients with proliferative diabetic retinopathy. The article concluded that intravitreal bevacizumab resulted in marked regression of RN in patients with PDR and previous PRP, and rapid resolution of vitreous haemorrhage in three naive eyes. One eye had PDR progression to tractional retinal detachment requiring vitrectomy.&lt;/P&gt;
&lt;P align=left&gt;Krishnan [13] also described two diabetic patients who underwent intravitreal pegaptanib for persistent retinal neovascularisation and developed the progression of a previously stable tractional retinal detachment (TRD). &lt;/P&gt;
&lt;P align=left&gt;Minnella [14] described the use of intravitreal bevacizumab in 15 eyes of 10 patients with bilateral proliferative diabetic retinopathy. All eyes received or completed panretinal photocoagulation (PRP) 1 month after the first injection. The study found no adverse effects and concluded that the intravitreal injections were useful in allowing time for a safe and effective PRP laser treatment to be performed. &lt;/P&gt;
&lt;P align=left&gt;Mason [15] suggested that a single Intravitreal bevacizumab (Avastin) injection given before standard PRP may be beneficial in preventing PRP-induced visual dysfunction and foveal thickening in eyes with severe proliferative diabetic retinopathy and good vision.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Huang [16] reported that the vitrectomy rate for non-clearing vitreous haemorrhage can be reduced by giving intravitreal bevacizumab injection followed by PRP.&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;Gonzalez [17] reported results of a prospective, randomised, controlled exploratory study of twenty subjects with active PDR who were randomly assigned at a 1:1 ratio to receive treatment in one eye either with IVP (0.3 mg) every 6 weeks for 30 weeks or with PRP laser. In 90% of randomised eyes to IVP, retinal NV showed regression by week 3. By week 12, all IVP eyes were completely regressed and maintained through week 36. In the PRP-treated group, at week 36, two eyes demonstrated complete regression, two showed partial regression, and four showed persistent active PDR.&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;Schmidinger [18] evaluated the effect of repeated intravitreal injections of bevacizumab in 11 eyes of 10 diabetic patients with persistent new vessels after previous complete panretinal photocoagulation. At the 1-week follow-up visit, 73% of the treated eyes showed complete regression of retinal new vessels. The mean interval to retreatment up because of the reappearance of retinal new vessels was 2.9 +/- 1.0 months.&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;Cho [19] described the use of intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy. There was significant worsening in best corrected visual acuity BCVA from 0.26 to 0.29 at 1 and 3 months (p=0.031) in the PRP group. In eyes with CSME, there was significant improvement of BCVA from 0.33 to 0.27 at 1 and 3 months (p=0.012) in IVTA group. The proportion of eyes with visual gain and decreased CMT was significantly higher in the IVTA group (75% and 100%, respectively) than in the IVB group (37.5% and 62.5%, respectively).&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;Erdol [20] evaluated the use of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy. After a single dose of bevacizumab, complete resolution rate of neovascularizations was 78.8% at 1 month, 63.6% at 3 months, and 45.4% at 6 months.&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;STRONG&gt;Use of intravitreal VEGF inhibitors in the treatment of diabetic macular edema (DME):&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;Haritoglou [21] reported the results of 51 consecutive patients (26 females and 25 males; mean age, 64 years) with diffuse diabetic macular oedema treated with a 0.05-mL injection containing 1.25 mg of bevacizumab. All patients completed 6 weeks of follow-up; 23 (45%) completed 12 weeks of follow-up. Their results suggested that improvement of visual acuity and decrease of retinal thickness could be observed after intravitreal injection of bevacizumab.&lt;BR&gt;&lt;BR&gt;The Pan-American Collaborative Retina Study Group reported a 6-month study [22] after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME). They reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventy-eight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age of 59.7+/-9.3 years were included in this analysis. They concluded that primary intravitreal bevacizumab at doses of 1.25 to 2.5 mg seem to provide stability or improvement in VA, OCT, and FA in DME at 6 months. However they acknowledged that follow-up is still too short to make any specific treatment recommendations. Evaluation in a multicenter randomised controlled clinical trial with longer follow-up is needed.&lt;BR&gt;&lt;BR&gt;Paccola [23] compared the use of intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema. Central macular thickness was significantly reduced in the intravitreal triamcinolone group compared with the bevacizumab group at weeks 4, 8, 12 and 24 (p&amp;lt;0.05). The article concluded that one single intravitreal injection of triamcinolone may offer certain advantages over bevacizumab in the short-term management of refractory diabetic macular oedema, specifically with regard to changes in central macular thickness. Shimura [24]&amp;nbsp;found that, with the generally used concentration, intravitreal injection of triamcinolone acetonide (4mg) showed better results in reducing DME and in the improvement of VA than that of bevacizumab (1.25mg), suggesting that the pathogenesis of DME is not only attributable to VEGF-dependency, but is also attributable to other mechanisms suppressed by corticosteroid.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;A Cochrane review [25] completed in April 2009 concluded that, at that time, there was not sufficient high quality evidence from large RCTs supporting the use of either single or multiple anti-VEGF intravitreal injections to treat DMO. Results from ongoing studies on several compounds should assess not only treatment efficacy but also, if a benefit is found, the number of injections needed for maintenance and long-term safety.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;Soheilian [26] reported a three-arm clinical trial, 103 eyes of 97 patients with clinically significant DME and no previous treatment. The intravitreal bevacizumab (IVB) group, received 1.25 mg of intravitreal bevacizumab (37 eyes); the IVB/IVT group, received 1.25 mg of intravitreal bevacizumab and 2 mg of intravitreal triamcinolone (33 eyes); and the MPC group, underwent focal or modified grid laser (33 eyes). The primary outcome measure was change in visual acuity. Up to 12 weeks, intravitreal bevacizumab treatment of patients with DME yielded better visual outcome than laser photocoagulation, although it was not associated with a significant decrease in Central Macular Thickness. Further clinical trials with longer follow-up are required to evaluate the long-term visual outcomes and complication profiles after primary treatment with such medications.&lt;BR&gt;&lt;BR&gt;Kook [27] described the use of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. A long-term decrease of central retinal thickness can be observed following repeated intravitreal injections of bevacizumab and in these patients, mean decrease in retinal thickness is aligned with a gain in mean VA. Macular ischemia was not exacerbated as a result of the treatment. Roh [28] and Lam [29] have also reported good results in patients with clinically significant diabetic macular edema.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Querques [30] conducted a retrospective outcome analysis, by optical coherence tomography (OCT) and best-corrected visual acuity (BCVA), of eyes with diabetic macular edema treated with intravitreal pegaptanib sodium. Intravitreal pegaptanib was found to produce significant improvements in mean BCVA (p = 0.019) and reductions in mean central macular thickness (CMT) (p &amp;lt; 0.001) as soon as the 6-week follow-up.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Querques [31] reported the results of 18 eyes that received an intravitreal injection of ranibizumab (0.05 mL/0.5 mg) for treatment of diabetic macular edema. Anatomical and functional improvement, which compared with baseline was evident as soon as the 1-hour follow-up (mean central macular thickness reduction CMT: t= 1.7899, P = 0.045; mean macula pattern fundus perimetry MP-1 sensitivity improvement: t = -1.9891, P 0.0315), and lasted until the 56-day follow-up (mean best-corrected visual acuity BCVA improvement: t= 2.26, P &amp;lt; 0.05; mean CMT reduction: t = 3.61, P &amp;lt; 0.05; MP-1 sensitivity improvement: t = -5.21, P &amp;lt; 0.05).&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Following a question by Kumar [32], Fang reanalysed [33] data and found eleven (29%) of 38 cases of diabetic macular oedema reported in the previously study [34] had a serous macular detachment. The mean height of the serous macular detachment decreased significantly at 3 months after an intravitreal injection of bevacizumab compared to before the injection (197 ± 106 and 76 ± 94 µm, respectively; p = 0.002). The mean central retinal thickness also decreased significantly at 3 months compared to before the injection (578 ± 205 and 394± 175 µm, respectively; p =0.047). However, in four cases (36%), the height of the serous macular detachment still exceeded 150 µm; in six cases (55%), the central retinal thickness still exceeded 300 µm at 3 months. There was no significant difference in the best-corrected visual acuity before the injection and 3 months after the injection. The visual acuity improved more than two lines 3 months after the injection of bevacizumab in only four cases (36%).&lt;/SPAN&gt;&amp;nbsp; &lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Mehta [35] conducted a retrospective review of 60 eyes of 54 consecutive patients who underwent intravitreal bevacizumab therapy for refractory diabetic macular edema. Pretreatment mean visual acuity plus or minus standard deviation was 0.71 +/- 0.28 logarithm of the minimum angle of resolution (LogMAR) Snellen letters. At final follow-up, mean visual acuity had improved to 0.66 +/- 0.30 LogMAR (P = .0543). Mean baseline central retinal thickness CRT was 440 +/- 106 microm, and follow-up mean CRT was 386 +/- 129 microm (P = .008).&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;SPAN style="COLOR: #a81400"&gt;Michaelides [36] reported 12-month data from a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study). A total of 80 eyes of 80 patients with center-involving CSME and at least 1 prior macular laser therapy (MLT) were randomized to either intravitreal bevacizumab ivB (6 weekly; minimum of 3 injections and maximum of 9 injections in the first 12 months) or MLT (4 monthly; minimum of 1 treatment and maximum of 4 treatments in the first 12 months). The bevacizumab group gained a median of 8 ETDRS letters, whereas the laser group lost a median of 0.5 ETDRS letters (P = 0.0002). The study concluded that this provides evidence to support the use of bevacizumab in patients with center-involving CSME without advanced macular ischemia.&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;Nicholson [37] reviewed the clinical trials of anti-VEGF agents for diabetic retinopathy. The review concluded that, despite promising early reports on the safety of these medications, we eagerly await the results of large, controlled trials to substantiate the safety and efficacy of anti-VEGF drugs for diabetic retinopathy. The first of a large controlled trial was published in June 2010:&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;Elman [38], on behalf of the Diabetic Retinopathy Clinical Research Network, reported the results of a multicenter, randomized clinical trial, of 854 eyes of 691 participants that evaluated ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.The main outcome measures were best-corrected visual acuity and safety (systemic events) at 1 year. The 1-year mean change (+/-standard deviation) in the visual acuity letter score from baseline was significantly greater in the ranibizumab + prompt laser group (+9+/-11, P&amp;lt;0.001) and ranibizumab + deferred laser group (+9+/-12, P&amp;lt;0.001) but not in the triamcinolone + prompt laser group (+4+/-13, P=0.31) compared with the sham + prompt laser group (+3+/-13). Reduction in mean central subfield thickness in the triamcinolone + prompt laser group was similar to both ranibizumab groups and greater than in the sham + prompt laser group. In the subset of pseudophakic eyes at baseline (n=273), visual acuity improvement in the triamcinolone + prompt laser group appeared comparable to that in the ranibizumab groups. No systemic events attributable to study treatment were apparent. Three eyes (0.8%) had injection-related endophthalmitis in the ranibizumab groups, whereas elevated intraocular pressure and cataract surgery were more frequent in the triamcinolone + prompt laser group. Two-year visual acuity outcomes were similar to 1-year outcomes. The conclusion of the study was that Intravitreal ranibizumab with prompt or deferred laser is more effective through at least 1 year compared with prompt laser alone for the treatment of DME involving the central macula. Ranibizumab as applied in this study, although uncommonly associated with endophthalmitis, should be considered for patients with DME and characteristics similar to those in this clinical trial. In pseudophakic eyes, intravitreal triamcinolone + prompt laser seems more effective than laser alone but frequently increases the risk of intraocular pressure elevation.&lt;/SPAN&gt;&lt;/P&gt;&lt;SPAN style="COLOR: #a81400"&gt;
&lt;P align=left&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;BR&gt;Links to PubMed abstracts are provided. Free full text may be available from the PubMed link. Where free full text access is not available, NHS staff in England can access full text of a number of journals via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/" target="_blank"&gt;NHS Evidence&lt;/A&gt; or can request the full text via their &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;1. NICE. Technology Appraisal TA155: Pegaptanib and ranibizumab for the treatment of age-related macular degeneration, August 2008.&amp;nbsp; &lt;A href="http://guidance.nice.org.uk/TA155" target="_blank"&gt;Link to full text here&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;2. Thew M. Rapid resolution of severe retinal neovascularisation in proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab (Avastin). Clinical &amp;amp; Experimental Optometry 2009; 92(1):34-7. &lt;A href="http://www3.interscience.wiley.com/cgi-bin/fulltext/121589826/HTMLSTART" target="_blank"&gt;Link to full text here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;3. Jiang Y, Liang X, Li X, Tao Y, Wang K. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. Acta Ophthalmologica 2008. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18803622" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;4. Falavarjani KG, Modarres M, Nazari H. Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy. Eye 2010; 24(4):717-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19407842" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;5. Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmologica 2008; 86(4):372-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18028234" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;6. Chen E, Hsu J, Park CH. Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema. Ophthalmic Surgery, Lasers &amp;amp; Imaging 2009; 40(1):68-70. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19205502" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;7. Liu L, Wu WC, Yeung L, Wang NK, Kuo YH, Chao AN, et al. Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy. Ophthalmic Surgery, Lasers &amp;amp; Imaging 2010; 41(1):72-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20128573" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;8. Bhavsar AR, Googe JM, Jr., Stockdale CR, Bressler NM, Brucker AJ, Elman MJ, et al. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Archives of Ophthalmology 2009; 127(12):1581-3. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20008710" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;9. Batman C, Ozdamar Y. The relation between bevacizumab injection and the formation of subretinal fibrosis in diabetic patients with panretinal photocoagulation. Ophthalmic Surgery, Lasers &amp;amp; Imaging 2010; 41(2):190-5. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20307036" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;10. Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Abdoallahi A, Faghihi H. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: A randomized double-masked clinical trial. European Journal of Ophthalmology 2008; 18(2):263-9. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=263%5Bpage%5D%20AND%20Mirshahi%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;11. Moradian S, Ahmadieh H, Malihi M, Soheilian M, Dehghan MH, Azarmina M. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology 2008; 246(12):1699-705. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18696095" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;12. Arevalo JF, Wu L, Sanchez JG, Maia M, Saravia MJ, Fernandez CF, et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye 2009; 23(1):117-23. &lt;A href="http://www.nature.com/eye/journal/v23/n1/pubmed/6702980a.html" target="_blank"&gt;Link to&amp;nbsp;abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;13. Krishnan R, Goverdhan S, Lochhead J. Intravitreal pegaptanib in severe proliferative diabetic retinopathy leading to the progression of tractional retinal detachment. Eye 2009; 23(5):1238-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18551139" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;14. Minnella AM, Savastano CM, Ziccardi L, Scupola A, Falsini B, Balestrazzi E. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. Acta Ophthalmologica 2008; 86(6):683-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17995986" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;15. Mason JO, 3rd, Yunker JJ, Vail R, McGwin G, Jr. Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy. Retina 2008; 28(9):1319-24. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18667958" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;16. Huang YH, Yeh PT, Chen MS, Yang CH, Yang CM. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage. Retina 2009; 29(8):1134-40. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19672218" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;17. Gonzalez VH, Giuliari GP, Banda RM, Guel DA. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. British Journal of Ophthalmology 2009; 93(11):1474-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19692371" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;18. Schmidinger G, Maar N, Bolz M, Scholda C, Schmidt-Erfurth U. Repeated intravitreal bevacizumab (Avastin(R)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Acta Ophthalmologica 2009. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19747221" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;19. Cho WB, Moon JW, Kim HC. Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy. British Journal of Ophthalmology 2010; 94(7):858-63. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20606024" target="_blank"&gt;Link to PubMed abstract here.&lt;/SPAN&gt;&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;20. Erdol H, Turk A, Akyol N, Imamoglu HI. The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy. Retina 2010; 30(4):570-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20224478" target="_blank"&gt;Link to PubMed abstract here.&lt;/SPAN&gt;&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;21. Haritoglou C, Kook D, Neubauer A, Wolf A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26(9):999-1005. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17151486&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;22. Arevalo JF, Fromow-Guerra J et al, Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007; 114(4): 743-50. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17398322&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;23. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). British Journal of Ophthalmology 2008; 92(1):76-80. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=76%5Bpage%5D%20AND%20Paccola%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;24. Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. American Journal of&amp;nbsp;Ophthalmology 2008; 145(5):854-61. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18328456" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;25. Parravano M, Menchini F, Virgili G. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database of Systematic Reviews 2009;&amp;nbsp;4. Art. No.: CD007419. &lt;A href="http://dx.doi.org/10.1002/14651858.CD007419.pub2" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;26. Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan MH, et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007; 27(9):1187-95. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=1187%5Bpage%5D%20AND%20Soheilian%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;27. Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008; 28(8):1053-60. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18667958" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;28. Roh MI, Byeon SH, Kwon OW. Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema. Retina 2008; 28(9):1314-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18728621" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;29. Lam DS, Lai TY, Lee VY, Chan CK, Liu DT, Mohamed S, et al. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Retina 2009; 29(3):292-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19287286" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;30. Querques G, Bux AV, Martinelli D, Iaculli C, Noci ND. Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema. Acta Ophthalmologica 2009; 87(6):623-30. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19678810" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;31. Querques G, Bux AV, Martinelli D, Iaculli C, Del Curatolo MV, Delle Noci N. Short-term fluctuation of diabetic macular edema after intravitreal ranibizumab injection. Retina 2009; 29(9):1274-81. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19696699" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;32. Kumar V, Ghosh B, Raina U, Goel N. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema - letter to the editor. Acta Ophthalmologica 2010; 88(2):e3 author reply - e4.&lt;/SPAN&gt; &lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;33. Fang X, Sakaguchi H, Gomi F, Oshima Y, Sawa M, Tsujikawa M, et al. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema – authors' reply. Acta Ophthalmologica 2010; 88(2):e4.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;34. Fang X, Sakaguchi H, Gomi F, Oshima Y, Sawa M, Tsujikawa M, et al. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Acta Ophthalmologica 2008; 86(7):800-5. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18547274" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;35. Mehta S, Blinder KJ, Shah GK, Kymes SM, Schlief SL, Grand MG. Intravitreal bevacizumab for the treatment of refractory diabetic macular edema. Ophthalmic Surgery, Lasers &amp;amp; Imaging 2010; 41(3):323-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20507016" target="_blank"&gt;Link to PubMed abstract here.&lt;/SPAN&gt;&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;36. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010; 117(6):1078-1086 e2. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20416952" target="_blank"&gt;Link to PubMed abstract here.&lt;/SPAN&gt;&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;37. Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology 2010; 248(7):915-30. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20174816" target="_blank"&gt;Link to PubMed abstract here.&lt;/SPAN&gt;&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;38. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117(6):1064-1077 e35. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20427088" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;BR&gt;Further Evidence&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/SearchResults.aspx?catID=5134&amp;amp;tabID=289&amp;amp;" target="_blank"&gt;Links to systematic reviews on diabetic retinopathy in&amp;nbsp;NHS Evidence - diabetes&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Guidelines&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5658&amp;amp;searchText=&amp;amp;sort=PUBLISHER&amp;amp;resultsPerPage=10&amp;amp;summaries=true" target="_blank"&gt;Links to supporting Guidelines&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Patient Information&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?tabID=292&amp;amp;catID=5658&amp;amp;sort=PUBLISHER&amp;amp;resultsPerPage=10&amp;amp;summaries=true&amp;amp;" target="_blank"&gt;Links to supporting Patient Information&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Reference Material&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?catID=5134&amp;amp;tabID=290&amp;amp;searchText=&amp;amp;sort=PUBLICATION_DATE&amp;amp;resultsPerPage=10&amp;amp;summaries=true" target="_blank"&gt;Links to supporting reference material&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;Publication details&lt;/STRONG&gt;&lt;BR&gt;Originally written by Peter Scanlon (Consultant Ophthalmologist&amp;nbsp; and National Clinical Director of the English National Screening Programme for Diabetic Retinopathy) in June 2006, since reviewed and updated in June 2007 by P Scanlon, in June 2008 by P Scanlon and Irene Stratton, in June 2009 by P Scanlon, and in August 2010 by P Scanlon.&lt;BR&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387422</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=387422]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetic Retinopathy - Automated assessment of retinopathy</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,EYES AND VISION,CHRONIC COMPLICATIONS,EYE DISEASES,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>part of the 2010 Annual Evidence Update on Diabetic Retinopathy</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetic Retinopathy - Automated assessment of retinopathy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published&lt;/STRONG&gt;: 13 September 2010&lt;BR&gt;Originally written by N Hill in June 2008, updated annually, &lt;A href="#ref1"&gt;link to further author and publication&amp;nbsp;details here.&lt;/A&gt; This section has been substantially re-written for 2010. Changes and additions to text and references since August 2009 are highlighted in red, and &lt;A href="#2010"&gt;a paragraph highlighting the most significant developments in 2009-2010&lt;/A&gt; has been included.&lt;BR&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387096" target="_blank"&gt;Link back to home page for 2010 Annual Evidence Update on Diabetic Retinopathy here&lt;/A&gt;.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387421" target="_blank"&gt;Link to table of abbreviations here&lt;/A&gt;.&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;In England, Scotland, Wales and Northern Ireland the recommendation for retinal screening is to photograph digitally two images per eye in order to detect retinopathy early [1] (in Scotland, screening is conducted using one field). The earlier the retinopathy is detected the easier it is to treat at the appropriate stage [2-3]. The retinal images can be stored and used to follow the progression of the disease. However, the problem remains that these images require the use of a skilled grader or ophthalmologist to diagnose any disease.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;The scale of the management task for handling retinal photographs for the English Screening Programme is huge. There are approximately two million retinal image sets that require grading each year in the UK. The problem with accumulating large numbers of photographic images - either on film or in digital form - is that they all need review and/or grading to allow interpretation that may influence management and reduce the risk of loss of vision.&lt;SPAN style="COLOR: #a81400"&gt;It is not sufficient to grade a subset of these images, as they all require interpretation. &lt;/SPAN&gt;Grading is expensive in terms of staff time and needs to be performed in a timely fashion. One of the problems of reviewing retinal photographs is that the task is both highly skilled and very repetitive. Skilled ophthalmologists do not have the time for laborious photograph examination and the training of graders has, in the past, generally only been undertaken for use in trials - for example the UKPDS grading centre set up by Professor Eva Kohner and Steve Aldington at the Hammersmith Hospital. Graders are difficult to recruit, train and retain because of the nature of the work. Grading occurs in dimly lit rooms, and rest periods need to occur frequently. Computer systems have been proposed and developed by a number of groups to assist or replace the grader. An automated grading process may be more cost effective [4] in the long term.&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;Computers have long been proposed to assist (or automate) the grading process. The systems developed have used varied feature recognition techniques to identify and quantify retinopathy automatically.&lt;/SPAN&gt;The sensitivity and specificity of each of these technologies incrementally advance and may soon meet the sensitivity of 80% and specificity of 95% for diagnosis of retinopathy that is required by the National Institute for Clinical Excellence (NICE) guidelines for clinicians [1].&lt;SPAN style="COLOR: #a81400"&gt;Indeed further improvements in sensitivity of the latest algorithms cannot be differentiated from best clinical practice as the algorithms have now reached the human intra-reader variability limit [5].&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;STRONG&gt;State of the art&lt;/STRONG&gt;&lt;BR&gt;There are numerous methods of approach to the problem of automated assessment of retinopathy. A non-exhaustive list of the major categories of retinal analysis can be seen in Table 1. &lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;STRONG&gt;Morphological detection:&lt;/STRONG&gt; The commonest method of analysis and the detection of micro-aneurysms (MA) is the most common form of computer aided assessment as the appearance of MA’s is a definitive indicator of background retinopathy and is one the earliest sign of diabetic retinopathy detected through retinal screening. Early attempts at automated MA detection have relied on morphological and threshold techniques. However, the threshold needed to achieve high sensitivity comes at the expense of specificity.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;STRONG&gt;Vascular changes:&lt;/STRONG&gt; New features in retinal vasculature have become more apparent as the resolution of the cameras increases. One of the features is tortuosity which has been proposed as a method to predict early diagnosis of diabetes or cardiovascular risk.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;STRONG&gt;Transformation of Image Space:&lt;/STRONG&gt; This is an operation that transforms one complex-valued function of a real variable into another. This transformation may enable information to be examined in a different way or may enhance the information and reduce the noise.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;STRONG&gt;Component Identification:&lt;/STRONG&gt; The retinal architecture of the eye (optic disc, fovea, vessels) is often a precursor for any morphological detection of retinopathy. The latest publications cite sensitivities and specificities now in the high 90’s.&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;STRONG&gt;Reviews:&lt;/STRONG&gt; With the growing number of algorithms, reviews and competitions are being published that attempt to determine which methods and techniques are the most successful.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;STRONG&gt;Cost effectiveness:&lt;/STRONG&gt; With the development of the latest algorithms that can be used in clinical practice the cost effectiveness of replacement or assistance to the retinal grader has been examined.&lt;/SPAN&gt; &lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;STRONG&gt;Computational Intelligence based:&lt;/STRONG&gt; The development of algorithms that allow a system to evolve rules based on empirical data, such as examples of MAs. A learning system can take advantage of these examples to capture characteristics of interest of their unknown underlying characteristics.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;STRONG&gt;Retinal Thickness:&lt;/STRONG&gt; Can be assessed using optical coheherence tomography (OCT). These OCT images are analysed by algorithms in order to determine retinal thickness of the various retinal layers.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;STRONG&gt;Content-based comparison:&lt;/STRONG&gt; This emerging method analyses the actual contents of the image and compares this content to a database of known image types. The term 'content' in this context might refer to retinopathy lesions or retinal architecture.&lt;BR&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;STRONG&gt;Image Databases&lt;/STRONG&gt;&lt;BR&gt;There are two publicly available databases for use with the algorithms developed. DRIVE (&lt;A href="http://www.isi.uu.nl/Research/Databases/DRIVE/" target="_blank"&gt;http://www.isi.uu.nl/Research/Databases/DRIVE/&lt;/A&gt;) a database that has been established to enable comparative studies on segmentation of blood vessels in retinal images. STARE (&lt;A href="http://www.parl.clemson.edu/stare/manifestations.html" target="_blank"&gt;http://www.parl.clemson.edu/stare/manifestations.html&lt;/A&gt;) is a project to automatically segment vascular and lesion structures. However the database they use is freely available for use by other algorithms.&lt;BR&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;STRONG&gt;Common Issues&lt;BR&gt;&lt;/STRONG&gt;The majority of algorithms published often have a small sample size and the power of the study is rarely considered. Without a properly powered non- inferiority study or randomised control trial it is difficult to draw conclusive judgements from these publications. A further issue with emerging algorithms in this field is that as the sensitivity of the automated systems increases specificity is often poor. Sensitivity is more important than specificity in the context of automated analysis. A false negative case might come to harm, if significant retinopathy was not referred. The percentage of people who are correctly identified as not having the retinopathy still remains an important cost factor.&lt;BR&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;STRONG&gt;Clinical Use&lt;/STRONG&gt;&lt;BR&gt;Historically, retinopathy recognition algorithms have performed poorly in trials in a real-life situation/clinical practice by being both complex and non-intuitive [6-7].&amp;nbsp; Recent developments in computing power, storage and networking and development of more sophisticated algorithms have enabled automated assessment to be used clinically [8-9].&lt;/SPAN&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;Traditionally level 1 grading is undertaken manually by junior graders, whose task is to identify retinopathy. They divide images into two groups: group 1 no retinopathy and group 2 those with either any retinopathy or suspected retinopathy.&amp;nbsp; Software developed in Aberdeen is now being used to replace level 1 human grading in&amp;nbsp; grading a single field in the Scottish model.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;An economic forecast model has been published [4] estimating the potential savings for a grade 1 screening algorithm introduced into Scotland. In this small population (approx 160,000 people with diabetes) this model forecast savings of over £200,000 per year.&lt;BR&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;&amp;nbsp;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;A name=2010&gt;&lt;/A&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;STRONG&gt;Developments in 2009-2010&lt;/STRONG&gt; &lt;BR&gt;In 2009-2010, the sensitivity of methods that automate detection of retinopathy has been incrementally advancing. Acharya et al [10] achieved a sensitivity of 82% in 331 fundus images. Sanchez et al [11] achieved 90% sensitivity in 80 images. Garcia et al [12] achieved sensitivity of 92.% in 67 images. Osareh et al [13] achieved 93.5% sensitivity on 300 images. Nayak et al [14] managed a sensitivity of 95% in 350 subjects.. Fleming et al [9] recorded the highest sensitivity of 97% in 7586 fundus images and is the software being considered as level 1 grading in a single field in the Scottish model. &lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;STRONG&gt;&lt;BR&gt;Conclusions&lt;/STRONG&gt;&lt;BR&gt;Whichever approach used, the common aim is to detect progression of retinopathy early enough to avoid visual loss in the future, by seeking to extract and reduce the information in the non-steady state pathological process and investigate suitable timed treatment to prevent the progression of retinopathy. After 50 years of development we are now beginning to be able to consider automating the detection of retinopathy but it is not yet clear the most cost effective method in which automated analysis may assist human grading.&amp;nbsp;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;STRONG&gt;Table 1 &lt;/STRONG&gt;- list of selected publications as examples of types of automated assessment methods&lt;/SPAN&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;BR&gt;
&lt;TABLE style="mso-cellspacing: 1.5pt" class=MsoNormalTable border=1 cellPadding=0 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;STRONG&gt;Assessment category&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Morphological detection&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;[9-31]&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Vascular changes&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;[32-35]&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Transformation of image space&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;[11, 34, 36-37]&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Component identification&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;[29, 37-44]&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Reviews&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;[5, 45-46]&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Cost effectiveness&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;[4, 39]&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Computational intelligence based&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;[17, 47-49]&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Retinal thickness&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;[50-52]&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Content based comparison&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;[53-54]&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Links to PubMed abstracts are provided. Free full text may be available from the PubMed link. Where free full text access is not available, NHS staff in England can access full text of a number of journals via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/" target="_blank"&gt;NHS Evidence&lt;/A&gt; or can request the full text via their &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;1. NICE. Management of Type 2 Diabetes.&amp;nbsp; Retinopathy - screening and early management.&amp;nbsp; 2002 [updated February 2007] &lt;A href="http://guidance.nice.org.uk/CGE/?c=91500" target="_blank"&gt;Link to full text here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;2. Kohner EM, Stratton IM, Aldington SJ, Turner RC, Matthews DR.. Microaneurysms in the development of diabetic retinopathy (UKPDS 42). Diabetologia 1999; 42:1107-12. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10447523" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on development and progression of long term complications in insulin-dependent diabetes melitus. New England Journal of Medicine 1993; 329:977-86. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8366922" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;4. Scotland GS, McNamee P, Philip S, Fleming AD, Goatman KA, Prescott GJ, et al. Cost-effectiveness of implementing automated grading within the national screening programme for diabetic retinopathy in Scotland. British Journal of Ophthalmology 2007; 91(11):1518-23. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=1518%5Bpage%5D%20AND%20Scotland%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;5. Abramoff MD, Reinhardt JM, Russell SR, Folk JC, Mahajan VB, Niemeijer M, et al. Automated early detection of diabetic retinopathy. Ophthalmology 2010; 117(6):1147-54. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20399502" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;BR&gt;6. Ege BM, Hejlesen OK, Larsen OV, Moller K, Jennings B, Kerr D, et al. Screening for diabetic retinopathy using computer based image analysis and statistical classification. Computer Methods and Programs in Biomedicine 2000; 62(3):165-75. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10837904?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;7. Teng T, Lefley M, Claremont D. Progress towards automated diabetic ocular screening: a review of image analysis and intelligent systems for diabetic retinopathy. Medical and Biological Engineering and Computing 2002; 40(1):2-13. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=2%5Bpage%5D%20AND%20Teng%5Bauthor%5D%20AND%20progress" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;8. Philip S, Fleming AD, Goatman KA, Fonseca S, McNamee P, Scotland GS, et al. The efficacy of automated "disease/no disease" grading for diabetic retinopathy in a systematic screening programme. British Journal of Ophthalmology 2007; 91(11):1512-7. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=1512%5Bpage%5D%20AND%20Philip%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;9. Fleming AD, Goatman KA, Philip S, Williams GJ, Prescott GJ, Scotland GS, et al. The role of haemorrhage and exudate detection in automated grading of diabetic retinopathy. British Journal of Ophthalmology 2010; 94(6):706-11. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19661069" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;10. Hatanaka Y, Nakagawa T, Hayashi Y, Hara T, Fujita H. Improvement of automated detection method of hemorrhages in fundus images. IEEE Engineering in Medicine and Biology Society Conference 2008. 2008:5429-32. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19163945" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;11. Sopharak A, Uyyanonvara B, Barman S, Williamson TH. Automatic detection of diabetic retinopathy exudates from non-dilated retinal images using mathematical morphology methods. Computerized medical imaging and graphics. 2008; 32(8):720-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18930631" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;12. Nayak J, Bhat PS, Acharya R, Lim CM, Kagathi M. Automated identification of diabetic retinopathy stages using digital fundus images. Journal of Medical Systems 2008; 32(2):107-15. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18461814" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;13. Bouhaimed M, Gibbins R, Owens D. Automated detection of diabetic retinopathy: results of a screening study. Diabetes Technology and Therapeutics 2008; 10(2):142-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=142%5Bpage%5D%20AND%20Bouhaimed%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;14. Acharya UR, Lim CM, Ng EY, Chee C, Tamura T. Computer-based detection of diabetes retinopathy stages using digital fundus images. Proceedings of the Institution of Mechanical Engineers. Part H. 2009; 223(5):545-53. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19623908" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;15. Sanchez CI, Garcia M, Mayo A, Lopez MI, Hornero R. Retinal image analysis based on mixture models to detect hard exudates. Medical Image Analysis 2009; 13(4):650-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19539518" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;16. Karnowski TP, Govindasamy V, Tobin KW, Chaum E, Abramoff MD. Retina lesion and microaneurysm segmentation using morphological reconstruction methods with ground-truth data. IEEE Engineering in Medicine and Biology Society Conference 2008. 2008:5433-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19163946" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;17. Garcia M, Sanchez CI, Lopez MI, Diez A, Hornero R. Automatic detection of red lesions in retinal images using a multilayer perceptron neural network. IEEE Engineering in Medicine and Biology Society Conference 2008. 2008:5425-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19163944" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;18. Reza AW, Eswaran C, Hati S. Automatic tracing of optic disc and exudates from color fundus images using fixed and variable thresholds. Journal of Medical Systems. 2009; 33(1):73-80. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19238899" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;19. Englmeier KH, Schmid K, Hildebrand C, Bichler S, Porta M, Maurino M, et al. Early detection of diabetes retinopathy by new algorithms for automatic recognition of vascular changes. European Journal of Medical Research 2004; 9(10):473-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=473%5Bpage%5D%20AND%20Englmeier%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;20. Larsen N, Godt J, Grunkin M, Lund-Andersen H, Larsen M. Automated detection of diabetic retinopathy in a fundus photographic screening population. Investigative Ophthalmology and Visual Science 2003; 44(2):767-71. &lt;A href="http://www.iovs.org/cgi/reprint/44/2/767" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;21. Sinthanayothin C, Boyce JF, Williamson TH, Cook HL, Mensah E, Lal S, et al. Automated detection of diabetic retinopathy on digital fundus images. Diabetic Medicine 2002; 19(2):105-12. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=105%5Bpage%5D%20AND%20Sinthanayothin%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;22. Fleming AD, Philip S, Goatman KA, Williams GJ, Olson JA, Sharp PF. Automated detection of exudates for diabetic retinopathy screening. Physics in Medicine and Biology 2007; 52(24):7385-96. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=7385%5Bpage%5D%20AND%20Fleming%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;23. Muller W, Spittel U, Gobel H. First results of the computer-aided classification of electroretinograms. Ophthalmologica. 1986; 192(4):228-33. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/3748556?ordinalpos=18&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;24. Niemeijer M, van Ginneken B, Staal J, Suttorp-Schulten MS, Abramoff MD. Automatic detection of red lesions in digital color fundus photographs. IEEE Transactions on Medical Imaging 2005; 24(5):584-92. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=584%5Bpage%5D%20AND%20Niemeijer%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;25. Walter T, Klein JC, Massin P, Erginay A. A contribution of image processing to the diagnosis of diabetic retinopathy--detection of exudates in color fundus images of the human retina. IEEE Transactions on Medical Imaging 2002; 21(10):1236-43. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12585705?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;26. Hipwell JH, Strachan F, Olson JA, McHardy KC, Sharp PF, Forrester JV. Automated detection of microaneurysms in digital red-free photographs: a diabetic retinopathy screening tool. Diabetic Medicine 2000; 17(8):588-94. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=588%5Bpage%5D%20AND%20Hipwell%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;27. Cree MJ, Olson JA, McHardy KC, Sharp PF, Forrester JV. A fully automated comparative microaneurysm digital detection system. Eye 1997; 11(Pt 5):622-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=622%5Bpage%5D%20AND%20Cree%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;28. Spencer T, Olson JA, McHardy KC, Sharp PF, Forrester JV. An image-processing strategy for the segmentation and quantification of microaneurysms in fluorescein angiograms of the ocular fundus. Computers and Biomedical Research 1996; 29(4):284-302. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8812075?ordinalpos=5&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;29. Spencer T, Phillips RP, Sharp PF, Forrester JV. Automated detection and quantification of microaneurysms in fluorescein angiograms. Graefes Arch Clin Exp Ophthalmol. 1992;230(1):36-41. Graefe's Archive for Clinical and Experimental Ophthalmology 1992; 230(1):36-41. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/1547965?ordinalpos=8&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;30. Usher D, Dumskyj M, Himaga M, Williamson TH, Nussey S, Boyce J. Automated detection of diabetic retinopathy in digital retinal images: a tool for diabetic retinopathy screening. Diabetic Medicine 2004; 21(1):84-90.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14706060?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;31. Staal J, Abramoff MD, Niemeijer M, Viergever MA, van Ginneken B. Ridge-based vessel segmentation in color images of the retina. IEEE Transactions on Medical Imaging 2004; 23(4):501-9. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=501%5Bpage%5D%20AND%20Staal%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;32. Owen CG, Newsom RS, Rudnicka AR, Barman SA, Woodward EG, Ellis TJ. Diabetes and the tortuosity of vessels of the bulbar conjunctiva. Ophthalmology 2008; 115(6):e27-32. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18423868" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;33. Bhuiyan A, Nath B, Ramamohanarao K, Kawasaki R, Wong TY. Automated analysis of retinal vascular tortuosity on color retinal images. Journal of Medical Systems 2010; Jun 18. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20703661" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;34. Kozousek V, Shen Z, Gregson P, Scott RC. Automated detection and quantification of venous beading using Fourier analysis. Canadian Journal of Ophthalmology 1992; 27(6):288-94. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/1451016?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;35. Gregson PH, Shen Z, Scott RC, Kozousek V. Automated grading of venous beading. Computers and Biomedical Research 1995; 28(4):291-304. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=291%5Bpage%5D%20AND%20Gregson%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;36. Acharya UR, Chua CK, Ng EY, Yu W, Chee C. Application of higher order spectra for the identification of diabetes retinopathy stages. Journal of Medical Systems 2008; 32(6):481-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19058652" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;BR&gt;37. Zana F, Klein JC. A multimodal registration algorithm of eye fundus images using vessels detection and Hough transform. IEEE Transactions on Medical Imaging 1999; 18(5):419-28. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=419%5Bpage%5D%20AND%20Zana%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;38. Youssif AR, Ghalwash AZ, Ghoneim AR. Optic disc detection from normalized digital fundus images by means of a vessels' direction matched filter. IEEE Transactions on Medical Imaging 2008; 27(1):11-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18270057" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;39. Scotland GS, McNamee P, Fleming AD, Goatman KA, Philip S, Prescott GJ, et al. Costs and consequences of automated algorithms versus manual grading for the detection of referable diabetic retinopathy. British Journal of Ophthalmology 2010; 94(6):712-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19965826" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;40. Niemeijer M, Abramoff MD, van Ginneken B. Fast detection of the optic disc and fovea in color fundus photographs. Medical Image Analysis 2009;13(6):859-70. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19782633" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;41. Xu L, Luo S. A novel method for blood vessel detection from retinal images. BioMedical Engineering Online 2010; 9:14. &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838898/?tool=pubmed" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;42. Sinthanayothin C, Boyce JF, Cook HL, Williamson TH. Automated localisation of the optic disc, fovea, and retinal blood vessels from digital colour fundus images. British Journal of Ophthalmology. 1999; 83(8):902-10. &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1723142/" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;BR&gt;43. Fleming AD, Goatman KA, Philip S, Olson JA, Sharp PF. Automatic detection of retinal anatomy to assist diabetic retinopathy screening. Physics in Medicine and Biology 2007; 52(2):331-45. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17202618?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;44. Martinez-Perez ME, Hughes AD, Thom SA, Bharath AA, Parker KH. Segmentation of blood vessels from red-free and fluorescein retinal images. Medical Image Analysis 2007; 11(1):47-61. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17204445" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;45. Abramoff MD, Niemeijer M, Suttorp-Schulten MS, Viergever MA, Russell SR, van Ginneken B. Evaluation of a system for automatic detection of diabetic retinopathy from color fundus photographs in a large population of patients with diabetes. Diabetes Care 2008; 31(2):193-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=193%5Bpage%5D%20AND%20Abramoff%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;46. Niemeijer M, van Ginneken B, Cree MJ, Mizutani A, Quellec G, Sanchez CI, et al. Retinopathy online challenge: automatic detection of microaneurysms in digital color fundus photographs. IEEE Transactions on Medical Imaging 2010; 29(1):185-95. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19822469" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;47. Osareh A, Shadgar B, Markham R. A computational-intelligence-based approach for detection of exudates in diabetic retinopathy images. IEEE Transactions on Information Technology in Biomedicine 2009; 13(4):535-45. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19586814" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;48. Garcia M, Sanchez CI, Poza J, Lopez MI, Hornero R. Detection of hard exudates in retinal images using a radial basis function classifier. Annals of Biomedical Engineering 2009; 37(7):1448-63. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19430906" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;49. Nayak J, Bhat PS, Acharya UR. Automatic identification of diabetic maculopathy stages using fundus images. Journal of Medical Engineering &amp;amp; Technology 2009; 33(2):119-29. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19205991" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;50. Taban M, Sharma S, Williams DR, Waheed N, Kaiser PK. Comparing retinal thickness measurements using automated fast macular thickness map versus six-radial line scans with manual measurements. Ophthalmology 2009;116(5):964-70. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19410954" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;51. Asrani S, Zeimer R, Goldberg MF, Zou S. Application of rapid scanning retinal thickness analysis in retinal diseases. Ophthalmology 1997; 104(7):1145-51. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=1145%5Bpage%5D%20AND%20Asrani%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;52. Sadda SR, Tan O, Walsh AC, Schuman JS, Varma R, Huang D. Automated detection of clinically significant macular edema by grid scanning optical coherence tomography. Ophthalmology 2006; 113(7):1187 e1-12. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=1187%5Bpage%5D%20AND%20Sadda%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;53. Chaum E, Karnowski TP, Govindasamy VP, Abdelrahman M, Tobin KW. Automated diagnosis of retinopathy by content-based image retrieval. Retina 2008; 28(10):1463-77. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18997609" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;54. Tobin KW, Abramoff MD, Chaum E, Giancardo L, Govindasamy V, Karnowski TP, et al. Using a patient image archive to diagnose retinopathy. IEEE Engineering in Medicine and Biology Society Conference 2008; 2008:5441-4. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19163948" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;BR&gt;&lt;STRONG&gt;Publication details&lt;/STRONG&gt;&lt;BR&gt;Originally written by Dr Nathan Hill (Oxford Centre for Diabetes and Endocrine Medicine) in June 2008.&amp;nbsp; Reviewed and updated by N Hill in March 2009 and September 2010.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387432</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=387432]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetic Retinopathy - Blindness and visual impairment</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,EYES AND VISION,CHRONIC COMPLICATIONS,EYE DISEASES,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>part of the 2010 Annual Evidence Update on Diabetic Retinopathy</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetic Retinopathy - Blindness and visual impairment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;Published&lt;/STRONG&gt;:&lt;/STRONG&gt; 13 September 2010&lt;BR&gt;Originally written by P Scanlon in June 2006, updated annually, &lt;A href="#ref1"&gt;link to further author and publication details here.&lt;/A&gt;&amp;nbsp; &lt;BR&gt;Changes and additions since August 2009 are highlighted in red.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387096" target="_blank"&gt;Link back to home page for 2010 Annual Evidence Update on Diabetic Retinopathy here.&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387421" target="_blank"&gt;Link to table of abbreviations here.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID387432/nelhImp_0000_photo15-ischaemicmaculacausingvisualimpairment.jpg"&gt;&lt;BR&gt;&lt;BR&gt;The majority of studies recorded below report that sight-threatening diabetic retinopathy and consequent visual impairment are prevalent and are therefore an important public health problem.&lt;BR&gt;In 1980, Ziemianski [1] reported on 85 eyes with severe vitreous haemorrhage on initial visit. Ultimately 68% of the eyes (over a 10 yr follow-up) had a visual acuity of 5/200 or worse. In 1990, the St Vincent Declaration [2] recognised diabetes and diabetic retinopathy to be a major and growing European health problem, a problem at all ages and in all countries. The first of the five-year targets that were unanimously agreed by Government Health Departments and patient organisations from all European countries was to reduce new blindness due to diabetes by one third or more. In 1994, Moss [3] reported on the 10-year incidence of blindness in the WESDR study. 1.8%, 4.0%, and 4.8% in the younger-onset, older-onset taking insulin, and older-onset not taking insulin groups, respectively. Respective 10-year rates of visual impairment were 9.4%, 37.2%, and 23.9%. In 1995, Evans [4] reported on the causes of blindness and partial sight in England and Wales from an analysis of all BD8 forms for the year April 1990 to March 1991. Among people of working age (ages 16-64), diabetes was the most important cause (13.8%) with 11.9% due to diabetic retinopathy. A study of registration data between April 1999 and March 2000 was reported by Bunce [5] in 2006 and confirmed that diabetic retinopathy remained the commonest cause of blindness in the working age group.&lt;BR&gt;&lt;BR&gt;Other reports of blindness due to diabetic eye disease have been by Clark [6], Fong [7], Roy [8], Cormack [9], Prasad [10], Miki [11], Hayward [12] and Scanlon [13].&lt;BR&gt;In 2001, Cunningham [14] reported that 45 million people worldwide fulfill the World Health Organisation's criterion for blindness and the cause of one quarter of all blindness, which affects people in both developed and developing nations, includes diabetic retinopathy and macular degeneration. In 2002, Kocur [15] reported that in people of working age in Europe, diabetic retinopathy is the most frequently reported causes of serious visual loss.&lt;BR&gt;&lt;BR&gt;Zhang [16] reported results from the national health and nutrition examination survey in the USA. People with diabetes were more likely to have uncorrectable VI than those without diabetes.&lt;BR&gt;&lt;BR&gt;Studies by Wu [17] and Matza [18] reported the direct link between visual acuity impairment and vision related quality of life.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Gardner [19] assessed the relationship between visual acuity (VA) and diabetic macular oedema (DMO) in relation to the location of retinal thickening in 584 eyes in 340 placebo-treated patients in the 3-years-long Protein Kinase C Diabetic Retinopathy Study (PKC-DRS2) trial. Sustained moderate visual loss was found in 36 eyes, most commonly associated with DMO at the centre of the fovea in 73% of eyes. There was a strong relationship (p &amp;lt; 0.001) between foveal centre involvement with DMO and mean VA. Mean VA decreased with increasing retinal thickness at the centre (p &amp;lt; 0.001) and increasing duration of centre-involving DMO (p &amp;lt; 0.001).&lt;/SPAN&gt;&amp;nbsp; &lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Hayat [20] undertook a retrospective study of case notes of those patients registered blind or partially sighted due to diabetic retinopathy in the Leeds metropolitan area in the years 2002 and 2005.&amp;nbsp; The main risk factors for registered visual impairment were poor glycaemic control prior to ophthalmic review, no prior retinopathy screening, late presentation with symptomatic visual loss, non-compliance with planned review and laser treatment failure.&lt;/SPAN&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Bamashmus [21] reported the prevalence of blindness among 350 DM patients attending an eye hospital in Sana, Yemen during 2004 was 16%.&lt;/SPAN&gt; &lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Clark [22] reported results of 1331 eye examinations in 920 Aboriginals between 1995 and 2007. There were 246 eyes with vision loss (best-corrected VA &amp;lt; 6/12) in 159 Aboriginals, of whom five were bilaterally blind. The four major known causes of vision loss were cataract (n = 53, 30.1%), DR (n = 44, 25.0%), uncorrected refractive error (n = 31, 17.6%) and trauma (n = 19, 10.8%). Aboriginals who had diabetes were far more likely to have vision loss (odds ratio = 8.5, 95% confidence interval 5.7-12.6, P &amp;lt; 0.0001). Of the 329 Aboriginals with diabetes, 82 (24.9%) had DR, and 32 (9.7%) had vision-threatening retinopathy.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Laitinen [23] surveyed a cross-sectional sample of 7413 Finnish people and found the most prevalent eye diseases in a subgroup with visual impairment&amp;nbsp; (VA &amp;lt; or = 0.25) were ARM (37%), unoperated cataract (27%), glaucoma (22%) and DR (7%).&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Klein [24] reported changes in visual impairment prevalence by period of diagnosis of diabetes using data from the Wisconsin Epidemiologic Study of Diabetic Retinopathy. While controlling for duration of T1DM, there was a lower prevalence of VI for more recent periods of diagnosis of diabetes (odds ratio per category, 0.91; 95% confidence interval, 0.88-0.93; P&amp;lt;0.001). This remained while controlling for glycosylated hemoglobin, blood pressure, and other related factors. More recently diagnosed of type 1 diabetes mellitus (T1DM) was associated with a lower prevalence of visual impairment (VI). It is likely that this is because of the diminishing incidence of proliferative diabetic retinopathy (PDR) and clinically significant macular edema (CSME) resulting from better glycemic control and more timely interventions with photocoagulation for CSME and PDR in those with more recently diagnosed T1DM.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Klein [25] also reported on the 25-year incidence of visual impairment (VI) in type 1 diabetes mellitus the Wisconsin epidemiologic study of diabetic retinopathy. The 25-year cumulative incidences of any VI and severe VI (accounting for competing risk of death) were 13% and 3%, respectively and that that VI may be reduced by better glycemic and blood pressure control and avoidance of smoking.&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;STRONG&gt;Studies reporting the prevalence and incidence of blindness and visual impairment in diabetes:&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;
&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;Year&lt;/TD&gt;
&lt;TD&gt;Author&lt;/TD&gt;
&lt;TD&gt;Number (n) patients (p) eyes (e)&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1980&lt;/TD&gt;
&lt;TD&gt;Ziemianski&amp;nbsp; [1]&lt;/TD&gt;
&lt;TD&gt;n = 85 e with severe vitreous haemorrhage on initial visit&lt;BR&gt;10 yr follow-up: Ultimately 68% of the eyes had a visual acuity of 5/200 or worse.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1990&lt;/TD&gt;
&lt;TD&gt;Report [2]&lt;/TD&gt;
&lt;TD&gt;St Vincent Declaration recognised diabetes and diabetic retinopathy to be a major and growing European health problem, a problem at all ages and in all countries.&lt;BR&gt;The first of the five-year targets that were unanimously agreed by Government Health Departments and patient’s organisations from all European countries was to reduce new blindness due to diabetes by one third or more.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1994&lt;/TD&gt;
&lt;TD&gt;Moss [3]&lt;/TD&gt;
&lt;TD&gt;10-year incidence of blindness in the WESDR study.&lt;BR&gt;Results: 1.8%, 4.0%, and 4.8% in the younger-onset, older-onset taking insulin, and older-onset not taking insulin groups, respectively. Respective 10-year rates of visual impairment were 9.4%, 37.2%, and 23.9%.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1994&lt;/TD&gt;
&lt;TD&gt;Clark&amp;nbsp; [6]&lt;/TD&gt;
&lt;TD&gt;Data from all patients registered blind from diabetic retinopathy in Avon (UK) during a 16 month period n = 471&lt;BR&gt;50% of the patients had no screening for retinopathy and were known to be diabetic, 25% were regularly screened for retinopathy (three-quarters by local opticians) and 22% were newly diagnosed as diabetic at the time of hospital referral. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1995&lt;/TD&gt;
&lt;TD&gt;Evans [4]&lt;/TD&gt;
&lt;TD&gt;Causes of blindness and partial sight in England and Wales from an analysis of all BD8 forms for the year April 1990 to March 1991. &lt;BR&gt;Results: Among people of working age (ages 16-64), diabetes was the most important cause (13.8%) with 11.9% due to diabetic retinopathy. In the older age groups (65 years and older), degeneration of the macula and posterior pole accounted for over half the certifications (54.5%), followed by glaucoma (12.9%), cataract (3.5%) and diabetic retinopathy (2.2%).&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1999&lt;/TD&gt;
&lt;TD&gt;Fong [7]&lt;/TD&gt;
&lt;TD&gt;Severe visual loss occurring in the Early Treatment Diabetic Retinopathy Study (ETDRS) &lt;BR&gt;Incidence: Severe visual loss that persisted developed in 149 eyes of 127 persons.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2000&lt;/TD&gt;
&lt;TD&gt;Roy [8]&lt;/TD&gt;
&lt;TD&gt;n = 725 African Americans type 1&lt;BR&gt;Prevalence: 63.9% any DR and 18.9% PDR. Visual impairment present in 11.0% and legal blindness in 3.1% (90.9% due to DR)&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2001&lt;/TD&gt;
&lt;TD&gt;Cormack [9]&lt;/TD&gt;
&lt;TD&gt;Blindness in the diabetic population of Fife&lt;BR&gt;Incidence and prevalence: The incidence of blindness due to diabetes was 64 (SD 24, 95&amp;amp; CI 49-79) per 100 000 diabetic population/year. The point prevalence of blindness was 210 per 100 000 population.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2001&lt;/TD&gt;
&lt;TD&gt;Prasad [10]&lt;/TD&gt;
&lt;TD&gt;n = 7652 diabetes attending screening in population of 361,050&lt;BR&gt;Prevalence: Of the 181 (2.84%) individuals whose causation significant visual impairment could be established, the majority visual impairment was due to causes other than diabetic retinopathy.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2001&lt;/TD&gt;
&lt;TD&gt;Cunningham [14]&lt;/TD&gt;
&lt;TD&gt;45 million people worldwide fulfil the World Health Organization's criterion for blindness.&lt;BR&gt;Prevalence: More than 90% of all blind and visually disabled people live in the developing world, where common causes of bilateral vision loss include cataract, glaucoma, trachoma, vitamin A deficiency, and onchocerciasis. Additional causes of bilateral vision loss, which together comprise nearly one quarter of all blindness, and which affect people in both developed and developing nations, include diabetic retinopathy and macular degeneration.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2001&lt;/TD&gt;
&lt;TD&gt;Miki [11]&lt;/TD&gt;
&lt;TD&gt;WHO Multinational Study of Vascular Disease in Diabetes&lt;BR&gt;Incidence: Overall the 8.4 year incidence of severe visual impairment was 1.94 %.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2002&lt;/TD&gt;
&lt;TD&gt;Hayward [12]&lt;/TD&gt;
&lt;TD&gt;Estimated the prevalence of blindness and partial sight in the general and diabetic populations in Leicestershire&lt;BR&gt;The prevalence of blindness and partial sight in the general and diabetic populations was estimated to be 51.8/10 000 (CI 50.6-53.0) and 148.8/10 000 (CI 122.1-175.5), respectively. In the diabetic population there was a higher proportion of visually impaired females than males (P &amp;lt; 0.05), with no overall ethnic differences.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2002&lt;/TD&gt;
&lt;TD&gt;Kocur [15]&lt;/TD&gt;
&lt;TD&gt;Review of the causes of visual impairment and blindness in Europe.&lt;BR&gt;In people of working age, diabetic retinopathy is the most frequently reported causes of serious visual loss&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2006&lt;/TD&gt;
&lt;TD&gt;Bunce [5]&lt;/TD&gt;
&lt;TD&gt;Blind and partially-sighted certificates completed by a consultant ophthalmologist in England and Wales during the year April 1999 to March 2000 were examined and the main cause of visual loss was ascertained. 13,788 people were certified as blind, 19107 were certified as partially sighted. The majority of certifications were in the older age groups. The most commonly recorded main cause of certifications for both blindness (57.2 %) and partial sight (56 %) was degeneration of the macula and posterior pole which largely comprises age-related macular degeneration. Glaucoma and diabetic retinopathy were the next most commonly recorded main causes. Overall, the age specific incidence of all three leading causes has increased since 1990-1991--with changes in diabetic retinopathy being the most marked--particularly in the over 65's where figures have more than doubled. The numbers of individuals per 100,000 population being certified blind or partially sighted due to the three leading causes--AMD, diabetic retinopathy and glaucoma have increased since 1990. This may to some extent be explained by improved ascertainment.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Zhang [16]&lt;/TD&gt;
&lt;TD&gt;Using National Health and Nutrition Examination Surveys conducted during 1999-2004, the study estimated the prevalence of presenting correctable and uncorrectable Visual Impairment (VI) among Americans 20 years or older with and without diabetes. Approximately 11.0% of US adults with diabetes had some form of VI (3.8% uncorrectable and 7.2% correctable). Among those without diabetes, 5.9% had some form of VI (1.4% uncorrectable and 4.5% correctable). People with diabetes were more likely to have uncorrectable VI than those without diabetes.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Wu [17]&lt;/TD&gt;
&lt;TD&gt;This report assessed the impact of visual impairment in a subset of the African-origin participants of the population-based Barbados Eye Studies, using the US National Eye Institute's 25-item Visual Functioning Questionnaire (NEI-VFQ-25). Visual impairment was associated with significantly (P 0.01) lower VFQ scores in multidimensional aspects of vision-related quality of life (QOL), including vision-related activities and psychosocial functioning.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Matza [18]&lt;/TD&gt;
&lt;TD&gt;This study characterized the degree of change in health-related quality of life (HRQL) associated with change in visual acuity among 535 patients with diabetic retinopathy&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References (including systematic reviews &amp;amp; primary research)&lt;BR&gt;&lt;/STRONG&gt;Links to PubMed abstracts are provided. Free full text may be available from the PubMed link. Where free full text access is not available, NHS staff in England can access full text of a number of journals via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/" target="_blank"&gt;NHS Evidence&lt;/A&gt; or can request the full text via their &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;1. Ziemianski MC, McMeel JW, Franks EP. Natural history of vitreous hemorrhage in diabetic retinopathy. Ophthalmology 1980; 87(4): 306-12. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=7393537" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;2. Diabetes care and research in Europe: the Saint Vincent declaration. Diabetic Medicine 1990; 7(4): 360.&lt;BR&gt;&lt;BR&gt;3. Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994; 101(6): 1061-70. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=8008348" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;4. Evans J. Causes of blindness and partial sight in England and Wales 1990 - 1991. London: Office of Population Censuses and Surveys - Studies on medical and population subjects - no. 57, 1995:1-29. &lt;BR&gt;&lt;BR&gt;5. Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England &amp;amp; Wales. BMC Public Health 2006; 6:58. &lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=16524463" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;6. Clark JB, Grey RH, Lim KK, Burns-Cox CJ. Loss of vision before ophthalmic referral in blind and partially sighted diabetics in Bristol. British Journal of Ophthalmology 1994; 78(10): 741-4. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=7803348" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;7. Fong DS, Ferris FL, 3rd, Davis MD, Chew EY. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology 1999; 127(2): 137-41. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=10030553" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;8. Roy MS. Diabetic retinopathy in African Americans with type 1 diabetes: The New Jersey 725: I. Methodology, population, frequency of retinopathy, and visual impairment. Arch Ophthalmologica 2000; 118(1): 97-104. &lt;A href="http://archopht.ama-assn.org/cgi/content/full/118/1/97" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;9. Cormack TG, Grant B, Macdonald MJ, Steel J, Campbell IW. Incidence of blindness due to diabetic eye disease in Fife 1990-9. British Journal of Ophthalmology 2001; 85(3): 354-6. &lt;A href="http://bjo.bmjjournals.com/cgi/content/full/85/3/354" target="_blank"&gt;Link to full text here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;10. Prasad S, Kamath GG, Jones K, Clearkin LG, Phillips RP. Prevalence of blindness and visual impairment in a population of people with diabetes. Eye 2001; 15(Pt 5): 640-3. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=11702977" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;11. Miki E, Lu M, Lee ET, Keen H, Bennett PH, Russell D. The incidence of visual impairment and its determinants in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 Suppl 2: S31-6. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=11587048" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;12. Hayward LM, Burden ML, Burden AC, Blackledge H, Raymond NT, Botha JL, et al. What is the prevalence of visual impairment in the general and diabetic populations: are there ethnic and gender differences? Diabetic Medicine 2002; 19(1): 27-34. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=11869300" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;13. Scanlon PH, Foy C, Chen FK. Visual acuity measurement and ocular co-morbidity in diabetic retinopathy screening. British Journal of Ophthalmology 2008; 92(6):775-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18356262" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;14. Cunningham ET, Jr. World blindness--no end in sight. British Journal of Ophthalmology 2001; 85(3): 253. &lt;A href="http://bjo.bmj.com/content/85/3/253.full" target="_blank"&gt;Link to full text here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;15. Kocur I, Resnikoff S. Visual impairment and blindness in Europe and their prevention. British Journal of Ophthalmology 2002; 86(7): 716-22. &lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=12084735" target="_blank"&gt;Link to full text here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;16. Zhang X, Gregg EW, Cheng YJ, Thompson TJ, Geiss LS, Duenas MR, et al. Diabetes mellitus and visual impairment: national health and nutrition examination survey, 1999-2004. Archives of Ophthalmology 2008; 126(10):1421-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18852421" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;17. Wu S, Nemesure B, Hennis A, Leske M. Visual acuity impairment and vision-related quality of life: the Barbados Eye Studies. British Journal of Visual Impairment 2009; 27(1):9-24. &lt;A href="http://jvi.sagepub.com/cgi/content/abstract/27/1/9" target="_blank"&gt;Link to abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;18. Matza LS, Rousculp MD, Malley K, Boye KS, Oglesby A. The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy. Health and Quality of Life Outcomes 2008; 6:95. &lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=18992161" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;19. Gardner T, Larsen M, Girach A, Zhi X. Diabetic macular oedema and visual loss: relationship to location, severity and duration. Acta Ophthalmologica 2009; 87(7):709-713. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19817721" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;20. Hayat H, D Nayak D, AAshiq A, Goyder E, Bodansky H, McKibbin M. Risk factors for visual impairment registration due to diabetic retinopathy in Leeds, 2002–2005. Practical Diabetes International 2009; 26(3):103-106.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;21. Bamashmus MA, Gunaid AA, Khandekar RB. Diabetic retinopathy, visual impairment and ocular status among patients with diabetes mellitus in Yemen: a hospital-based study. Indian Journal of Ophthalmology 2009; 57(4):293-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2712699/" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;22. Clark A, Morgan WH, Kain S, Farah H, Armstrong K, Preen D, et al. Diabetic retinopathy and the major causes of vision loss in Aboriginals from remote Western Australia. Clinical &amp;amp; Experimental Ophthalmology 2010; 38(5):475-82. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20649617" target="_blank"&gt;Link to PubMed abstract here.&lt;/SPAN&gt;&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;23. Laitinen A, Laatikainen L, Harkanen T, Koskinen S, Reunanen A, Aromaa A. Prevalence of major eye diseases and causes of visual impairment in the adult Finnish population: a nationwide population-based survey. Acta Ophthalmologica 2010; 88(4):463-71. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19878108" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;24. Klein R, Lee KE, Knudtson MD, Gangnon RE, Klein BE. Changes in visual impairment prevalence by period of diagnosis of diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 2009; 116(10):1937-42. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19616855" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;25. Klein R, Lee KE, Gangnon RE, Klein BE. The 25-year incidence of visual impairment in type 1 diabetes mellitus: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 2010; 117(1):63-70. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19880184" target="_blank"&gt;Link to PubMed abstract here.&lt;/SPAN&gt;&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;BR&gt;Further Evidence&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/SearchResults.aspx?catID=5134&amp;amp;tabID=289&amp;amp;" target="_blank"&gt;Links to systematic reviews on diabetic retinopathy in&amp;nbsp;NHS Evidence - diabetes&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidelines&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=50&amp;amp;sort=PUBLISHER&amp;amp;catID=5134" target="_blank"&gt;Links to supporting Guidelines&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Patient Information&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?tabID=292&amp;amp;summaries=true&amp;amp;resultsPerPage=50&amp;amp;sort=PUBLISHER&amp;amp;catID=5134&amp;amp;" target="_blank"&gt;Links to supporting Patient Information&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Reference Material&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?catID=5134&amp;amp;tabID=290&amp;amp;searchText=&amp;amp;sort=PUBLICATION_DATE&amp;amp;resultsPerPage=10&amp;amp;summaries=true" target="_blank"&gt;Links to supporting reference material&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication details&lt;/STRONG&gt;&lt;BR&gt;Originally written by Peter Scanlon (Consultant Ophthalmologist&amp;nbsp; and National Clinical Director of the English National Screening Programme for Diabetic Retinopathy) in June 2006, since reviewed and updated in June 2007 by P Scanlon, in June 2008 by P Scanlon and Irene Stratton, in June 2009 by P Scanlon, and in August 2010 by P Scanlon.&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387337</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=387337]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetic Retinopathy - Conventional treatment for diabetic retinopathy: laser</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,EYES AND VISION,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,EYE DISEASES,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>part of the 2010 Annual Evidence Update on Diabetic Retinopathy</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetic Retinopathy - Conventional treatment for diabetic retinopathy: laser&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt; 13 September 2010&lt;BR&gt;Originally written by P Scanlon in June 2006, updated annually, &lt;A href="#ref1"&gt;link to further author and publication details here.&lt;/A&gt;&amp;nbsp;&lt;BR&gt;Changes and additions since August 2009 are highlighted in red.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387096" target="_blank"&gt;Link back to home page for 2010 Annual Evidence Update on Diabetic Retinopathy here.&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387421" target="_blank"&gt;Link to table of abbreviations here.&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID387337/nelhImp_0000_10a123-smaller.jpg"&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Since Spalter [1] described the photocoagulation of circinate maculopathy in diabetic retinopathy, clear evidence for the efficacy of laser treatment for diabetic eye disease has been shown from the Diabetic Retinopathy Study [2-6] and the Early Treatment Diabetic Retinopathy Study [7-15]. In 1976, the organisers of the Diabetic Retinopathy Study [2] modified the trial protocol and recommended treatment for control eyes with ‘high risk characteristics’. In 1979, the Diabetic Retinopathy Study reported [5] four retinopathy factors that increase the two-year risk of developing severe visual loss:&lt;BR&gt;•&amp;nbsp;the presence of vitreous or preretinal haemorrhage;&lt;BR&gt;•&amp;nbsp;the presence of new vessels;&lt;BR&gt;•&amp;nbsp;the location of new vessels on or near the optic disc;&lt;BR&gt;•&amp;nbsp;the severity of new vessels.&lt;BR&gt;&lt;BR&gt;In 1981 they reported [4] that photocoagulation, as used in the study, reduced the two-year risk of severe visual loss by 50% or more.&lt;BR&gt;In 1985, a report [7] from the Early Treatment Diabetic Retinopathy Study showed that focal photocoagulation of "clinically significant" diabetic macular oedema (CSMO) substantially reduced the risk of visual loss.&lt;BR&gt;Further studies that have shown evidence for the efficacy of laser treatment for diabetic eye disease have been reported by Whitelocke [16], British multicentre study [17], Davies [18], Casswell [19], Sullivan [20], Blankenship [21], Bailey [22-24], Chew [25], and these have been reviewed by Mohamed [26].&lt;BR&gt;In 2008, Soliman [27] reported that the bulk of the reduction in retinal thickness and macular volume after macular photocoagulation was manifest after 1 month.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Figueira [28] reported the results of a study of 53 eyes and Vujosevic [29] reported on the results of 62 eyes treated with subthreshold diode micropulse laser for treatment of macular oedema, both concluding no significant difference with conventional laser with these numbers. Luttrull [30] reported on the use of subthreshold diode micropulse panretinal photocoagulation for proliferative diabetic retinopathy, the rationale being questioned by Kumar [31] who considered that the mechanism of action of conventional panretinal photocoagulation was destruction of the ischaemic retina thereby decreasing the angiogenic stimulus. This theory was questioned in a reply by Luttrull [32].&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Gaucher [33] reported effective reduction in diabetic macular oedema (DME) and improvement in vision following panretinal photocoagulation in 17 patients with florid proliferative diabetic retinopathy and severe DME. Kim [34] suggested that classifying diabetic macular oedema structural patterns using optical coherence tomographic might allow visual outcome to be predicted after laser photocoagulation.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Lim [35] found a thinner retinal nerve fiber layer (RNFL) at the optic nerve head in eyes treated with panretinal photocoagulation (PRP) giving rise to an abnormal optic nerve head appearance, sometimes confused with glaucoma. Muqit [36] reported that, despite thinning of the nerve fibre layer of the optic nerve head measured at 6 months post laser, there was no adverse effects on the UK standard driving fields in the 10 eyes in this study.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Mendrinos [37] observed a vasoconstrictive effect on retinal arterioles in patients following panretinal photocoagulation.&lt;/SPAN&gt; &lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;There have been reports from Tinley [38] of single session, indirect panretinal photocoagulation (PRP) for proliferative diabetic retinopathy and comparisons by&amp;nbsp; Brucker [39] and Muqit [40] of treatment in a single session versus multiple sessions in an out patient setting.&amp;nbsp; Tinley [38]&amp;nbsp; reported 14% returned with adverse events within the first 8 weeks.&amp;nbsp; Brucker [39] concluded that clinically meaningful differences are unlikely between the two groups in the study and Muqit [40] found no adverse outcomes (CRT, visual acuity, or visual field) from using multispot single session PRP versus single spot multisession PRP at 12 weeks postlaser.&lt;/SPAN&gt; &lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Nagpal [41] compared 60 patients whose eyes were randomized into panretinal photocoagulation, one eye with 532-nm solid-state green laser (GLX) and the other with a multispot 532-nm pattern scan laser (PASCAL), two sittings per eye. The study concluded that the pattern scan laser showed lesser collateral damage and similar regression of retinopathy compared with GLX. Pattern scan laser treatment was less time consuming and less painful for the patient compared with GLX.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Combinations of laser and intravitreal VEGF inhibitors are discussed in section 8b: Alternative surgical treatment for diabetic retinopathy: intravitreal VEGF inhibitors.&lt;/SPAN&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;B&gt;The following studies reported results of laser treatment in sight-threatening diabetic retinopathy:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;
&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;STRONG&gt;Year&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;STRONG&gt;Author&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;STRONG&gt;Number(n) patients (p) eyes (e)&lt;/STRONG&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1971&lt;/TD&gt;
&lt;TD&gt;Spalter [1]&lt;/TD&gt;
&lt;TD&gt;Described the photocoagulation of circinate maculopathy in diabetic retinopathy. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1976&lt;/TD&gt;
&lt;TD&gt;DRS [2]&lt;/TD&gt;
&lt;TD&gt;Diabetic Retinopathy Study Research Group&lt;BR&gt;The organisers modified the trial protocol and recommend treatment for control eyes with ‘high risk characteristics’.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1979&lt;/TD&gt;
&lt;TD&gt;DRS [5]&lt;/TD&gt;
&lt;TD&gt;Reported four retinopathy factors that increase the two-year risk of developing severe visual loss. &lt;BR&gt;(1) The presence of vitreous or preretinal haemorrhage;&lt;BR&gt;(2) The presence of new vessels;&lt;BR&gt;(3) The location of new vessels on or near the optic disc;&lt;BR&gt;(4) The severity of new vessels. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1979&lt;/TD&gt;
&lt;TD&gt;Whitelocke [16]&lt;/TD&gt;
&lt;TD&gt;Results of photocoagulation in three groups with diabetic maculopathy - focal, cystoid and ischaemic maculopathy.&lt;BR&gt;Of the 24 with focal maculopathy, 38% visual improvement, 62% unchanged and none deteriorated over 2 years.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1981&lt;/TD&gt;
&lt;TD&gt;DRS [4]&lt;/TD&gt;
&lt;TD&gt;Reported that photocoagulation, as used in the study, reduced the risk of severe visual loss by 50% or more. &lt;BR&gt;The two-year risk of severe visual loss without treatment outweighed the risk of harmful treatment effects for two groups of eyes a) eyes with new vessels and preretinal or vitreous haemorrhage b) eyes with new vessels on or within one disc diameter of the optic disc (NVD) equalling or exceeding 1/4 to 1/3 disc area, even in the absence of preretinal or vitreous haemorrhage.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1984&lt;/TD&gt;
&lt;TD&gt;British Study [17]&lt;/TD&gt;
&lt;TD&gt;Xenon-arc photocoagulation for proliferative retinopathy&lt;BR&gt;n = 107 p follow up 5-7 yrs one eye treated, other control.&lt;BR&gt;77 completed the 5 yr follow up.&lt;BR&gt;Visual outcome was significantly better (0.001 &amp;lt; p &amp;lt; 0.05). in the treated than in the control eyes.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1985&lt;/TD&gt;
&lt;TD&gt;ETDRS [7]&lt;/TD&gt;
&lt;TD&gt;n = 754 e assigned to focal argon laser, 1,490 e randomly assigned to deferral&lt;BR&gt;Showed that focal photocoagulation of "clinically significant" diabetic macular oedema (CSMO) substantially reduced the risk of visual loss.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1987&lt;/TD&gt;
&lt;TD&gt;ETDRS [8]&lt;/TD&gt;
&lt;TD&gt;Described the treatment techniques in detail, and defined the concepts of "clinically significant macular oedema" and "treatable lesions".&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1987&lt;/TD&gt;
&lt;TD&gt;DRS[6]&lt;/TD&gt;
&lt;TD&gt;Recommended principles for treatment:&lt;BR&gt;The principal factor influencing prompt treatment is the presence of DRS high-risk characteristics. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1989&lt;/TD&gt;
&lt;TD&gt;Davies [18]&lt;/TD&gt;
&lt;TD&gt;n = 62 e (of 40 p) follow-up 10 years after photocoagulation for diabetic maculopathy.&lt;BR&gt;Of those eyes with baseline VA &amp;gt; 6/12, 60% maintained this level of acuity at ten years.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1990&lt;/TD&gt;
&lt;TD&gt;Casswell [19]&lt;/TD&gt;
&lt;TD&gt;n = 91 e treated by macular grid photocoagulation &lt;BR&gt;At two years, macular oedema had improved equally in both groups, and the visual acuity was unchanged or better in 85% of eyes treated with Argon and in 79.5% of eyes treated with Krypton laser. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1990&lt;/TD&gt;
&lt;TD&gt;Sullivan [20]&lt;/TD&gt;
&lt;TD&gt;n = 140 p (182 e) follow-up 10 years after photocoagulation for PDR. n = 68 alive.&lt;BR&gt;Sixty-nine percent of all patients and 82% of those followed up for 10 years maintained good vision (6/12 or better) in their better eye at the last follow-up.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1991&lt;/TD&gt;
&lt;TD&gt;ETDRS [12]&lt;/TD&gt;
&lt;TD&gt;For eyes with macular oedema, focal photocoagulation was effective in reducing the risk of moderate visual loss but that scatter photocoagulation was not. Focal treatment also increased the chance of visual improvement, decreased the frequency of persistent macular oedema, and caused only minor visual field losses. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1991&lt;/TD&gt;
&lt;TD&gt;Blankenship [21]&lt;/TD&gt;
&lt;TD&gt;15 yr follow-up after photocoagulation for PDR. n = 151 p, 86 died, 14 not located, examined 51.&lt;BR&gt;58% of the initially argon-treated and 41% of the initially xenon-treated eyes had 20/40 or better acuity, and 95% of the initially argon-treated and 82% of the initially xenon-treated eyes had 20/200 or better acuity&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1998&lt;/TD&gt;
&lt;TD&gt;Bailey [22-24] &lt;/TD&gt;
&lt;TD&gt;UK National Diabetic Retinopathy Laser Treatment Audit.&lt;BR&gt;n = 546 p undergoing their first photocoagulation treatment for PDR or maculopathy. 9 month follow-up.&lt;BR&gt;Maculopathy: 9.2% had deterioration in VA equivalent to a doubling of the visual angle, 3.3% of eyes had a VA &amp;lt; 6/60 at follow-up. &lt;BR&gt;Improvement in the macular oedema occurred in 64.6% and exudates in 77.3%.&lt;BR&gt;PDR: Neovascularisation had regressed fully in 50.8%, no change or deterioration in 10.3%. Regression of neovascularisation was associated with greater areas of retinal ablation at the initial treatment session. &lt;BR&gt;VA &amp;lt; 6/60 at follow-up in 8.6% of eyes. There was a poor morphological outcome at follow-up in 7.2%. &lt;BR&gt;The relationship of poor outcome with worse initial disease made the authors recommend earlier detection of retinopathy.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2003&lt;/TD&gt;
&lt;TD&gt;Chew [25]&lt;/TD&gt;
&lt;TD&gt;Follow-up study of 214 surviving patients enrolled at the Johns Hopkins Clinical Centre for the ETDRS.&lt;BR&gt;Of the 71 who were examined 42% had visual acuity &amp;gt; 20/20 and 84% had visual acuity &amp;gt; 20/40 in the better eye.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2007&lt;/TD&gt;
&lt;TD&gt;Mohamed [26]&lt;/TD&gt;
&lt;TD&gt;A systematic review of management of diabetic retinopathy. This review concluded that tight glycaemic and blood pressure control remain the cornerstone in the primary prevention of DR. Pan-retinal and focal retinal laser photocoagulation reduces the risk of visual loss in patients with severe DR and macular oedema, respectively. There is currently insufficient evidence to recommend routine use of other treatments.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Soliman [27]&lt;/TD&gt;
&lt;TD&gt;A prospective, non-controlled, case series study, in which 28 consecutive eyes with previously untreated diffuse DMO underwent fundus photography and OCT at baseline and at 1, 3 and 6 months after treatment. Macular photocoagulation was followed by a significant reduction in retinal thickness in the foveal centre (- 80 microm) and in the foveal subfield (- 65 microm) from baseline to 6 months (p &amp;lt; 0.01). The bulk of the reduction in retinal thickness and macular volume was manifest after 1 month. No significant change in retinal thickness occurred from 1 to 3 months or from 1 to 6 months in any macular subfield (p &amp;gt; 0.05).&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;2008&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Luttrull[30]&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Reported on 99 eyes of 63 patients undergoing subthreshold diode micropulse panretinal photocoagulation for proliferative diabetic retinopathy. Median follow-up was 1.0 year (range of 0.3-2.7 years). Treatment sessions per eye ranged from 1 to 6 (with a median of two sessions per eye). Overall visual acuity remained unchanged. The probability of treatment failure end points at 12 months post-treatment was 12.5% for vitreous haemorrhage and 14.6% for vitrectomy (from Kaplan-Meier survival analysis&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;2009&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Kumar[31]&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Kumar stated that the mechanism of action of laser photocoagulation is thought to be different in treatment for macular oedema as opposed to proliferative diabetic retinopathy. The decrease in macular oedema is supposed to be mediated through the retinal pigment epithelium2 for which even subthreshold energies may be sufficient. However, in proliferative diabetic retinopathy, destruction of the ischaemic retina thereby decreasing the angiogenic stimulus and improved oxygenation of the remaining retina are among the major hypotheses of the mechanism of action.&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;2009&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Luttrull.[32]&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Reply by Luttrull.&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;2009&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Figueira[28]&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Reported results of 84 eyes of 53 patients randomly assigned to sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema and concluded that the two methods were equally effective.&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;2010&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Vujosevic[29]&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Compared subthreshold micropulse diode laser versus modified Early Treatment Diabetic Retinopathy Study photocoagulation. In 62 eyes (50 patients) with untreated, center-involving, clinically significant diabetic macular edema. At 12 months There was no significant difference in either best-corrected visual acuity or central retinal thickness between the 2 treatment groups (P = 0.48 and P = 0.29).&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;2010&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Muqit[36]&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Reported that conventional argon panretinal laser photocoagulation increase the retinal nerve fibre layer thickness of the optic nerve at 10 weeks with thinning of the nerve fibre layer measured at 6 months post laser. The 10 degrees and 24 degrees visual fields improved significantly after laser with no adverse effects on the UK standard driving fields.&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;2010&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Mendrinos[37]&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Studied retinal vessel analyzer measurements of the effect of panretinal photocoagulation on the retinal arteriolar diameter in diabetic retinopathy. The study reported that panretinal photocoagulation has a vasoconstrictive effect on retinal arterioles in patients with severe nonproliferative or proliferative diabetic retinopathy.&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;2009&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Tinley[38]&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Reported on adverse events related to routine, single session, indirect panretinal photocoagulation (PRP) for proliferative diabetic retinopathy. Of 107 patients, 14% returned with adverse events within the first 8 weeks of indirect PRP. One patient with neurotrophic keratopathy developed a persistent epithelial defect, one developed non-progressive macular drag, three transient new or exacerbations of preexisting clinically significant macular oedema, two transient choroidal effusions, two transient anterior uveitis, and two transient visual deteriorations without macular oedema clinically.&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;2009&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Brucker[39]&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Reported differences in central subfield thickness on optical coherence tomography between 84 patients receiving panretinal photocoagulation in one sitting compared to 71 patients receiving panretinal photocoagulation in four sittings. Central subfield thickness was slightly greater in the 1-sitting group (n = 84) than in the 4-sitting group (n = 71) at the 3-day (P = .01) and 4-week visits (P = .003). At the 34-week primary outcome visit, the slight differences had reversed, with the thickness being slightly greater in the 4-sitting group than in the 1-sitting group (P = .06). &lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;2010&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Muqit[40]&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Reported results from 40 eyes randomized to single-session (SS-PRP) vs multiple-session (MS-PRP) pattern scanning laser panretinal photocoagulation in proliferative diabetic retinopathy using the pattern scanning laser (Pascal). The article concluded that there were no adverse outcomes (CRT, visual acuity, or visual field) from using multispot SS-PRP vs single-spot MS-PRP at 12 weeks postlaser.&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;
&lt;P&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/TABLE&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;References (including systematic reviews &amp;amp; primary research)&lt;BR&gt;&lt;/STRONG&gt;Links to PubMed abstracts are provided. Free full text may be available from the PubMed link. Where free full text access is not available, NHS staff in England can access full text of a number of journals via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/" target="_blank"&gt;NHS Evidence &lt;/A&gt;or can request the full text via their &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;1. Spalter HF. Photocoagulation of circinate maculopathy in diabetic retinopathy. American Journal of Ophthalmology 1971; 1(1 Part 2): 242-50. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/5542126" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;2. Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology 1976; 81(4): 383-96. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/944535" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;3. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 1978; 85(1): 82-106. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/345173" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;4. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 1981; 88(7): 583-600. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7196564" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;5. Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study. The Diabetic Retinopathy Study Research Group. Archives of Ophthalmology 1979; 97(4): 654-5. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=426679" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;6. Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics 1987; 27(4): 239-53.&lt;BR&gt;&lt;BR&gt;7. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Archives of Ophthalmology 1985; 103(12): 1796-806. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2866759" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;8. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1987; 94(7): 761-74. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=3658348" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;9. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98(5 Suppl): 823-33. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2062515" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;10. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98(5 Suppl): 807-22. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2062514" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;11. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98(5 Suppl): 786-806. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2062513" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;12. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98(5 Suppl): 766-85. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=2062512" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;13. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98(5 Suppl): 757-65. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2062511" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;14. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 1991; 98(5 Suppl): 741-56. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2062510" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;15. Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98(5 Suppl): 834-40. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2062516" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;16. Whitelocke RA, Kearns M, Blach RK, Hamilton AM. The diabetic maculopathies. Transactions of the ophthalmological societies of the United Kingdom 1979; 99(2): 314-20. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/298436" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;17. Photocoagulation for proliferative diabetic retinopathy: a randomised controlled clinical trial using the xenon-arc. Diabetologia 1984; 26(2): 109-15. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=6201409" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;18. Davies EG, Petty RG, Kohner EM. Long term effectiveness of photocoagulation for diabetic maculopathy. Eye 1989; 3 ( Pt 6): 764-7. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2630360" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;19. Casswell AG, Canning CR, Gregor ZJ. Treatment of diffuse diabetic macular oedema: a comparison between argon and krypton lasers. Eye 1990; 4 ( Pt 5): 668-72. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2282940" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;20. Sullivan P, Caldwell G, Alexander N, Kohner E. Long-term outcome after photocoagulation for proliferative diabetic retinopathy. Diabetic Medicine 1990; 7(9): 788-94. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2148130" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;21. Blankenship GW. Fifteen-year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology 1991; 98(2): 125-8. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=2008268" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;22. Bailey CC, Sparrow JM, Grey RH, Cheng H. The National Diabetic Retinopathy Laser Treatment Audit. I. Maculopathy. Eye 1998; 12 (Pt 1): 69-76. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=9614521" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;23. Bailey CC, Sparrow JM, Grey RH, Cheng H. The National Diabetic Retinopathy Laser Treatment Audit. II. Proliferative retinopathy. Eye 1998; 12 (Pt 1): 77-84. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9614522" target="_blank"&gt;Link to PubMed abstract here.&lt;/SPAN&gt;&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;24. Bailey CC, Sparrow JM, Grey RH, Cheng H. The National Diabetic Retinopathy Laser Treatment Audit. III. Clinical outcomes. Eye 1999; 13 (Pt 2): 151-9. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=10450373" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;25. Chew EY, Ferris FL, 3rd, Csaky KG, Murphy RP, Agron E, Thompson DJ, et al. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology 2003; 110(9): 1683-9. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=13129862" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;26. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. Journal of the American Medical Association 2007; 298(8):902-16. &lt;A href="http://jama.ama-assn.org/cgi/reprint/298/8/902" target="_blank"&gt;Link to full text here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;27. Soliman W, Sander B, Soliman KA, Yehya S, Rahamn MS, Larsen M. The predictive value of optical coherence tomography after grid laser photocoagulation for diffuse diabetic macular oedema. Acta Ophthalmologica 2008; 86(3):284-91. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18005220" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;28. Figueira J, Khan J, Nunes S, Sivaprasad S, Rosa A, de Abreu JF, et al. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. British Journal of Ophthalmology 2009; 93(10):1341-4. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19054831" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;29. Vujosevic S, Bottega E, Casciano M, Pilotto E, Convento E, Midena E. Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina 2010; 30(6):908-16. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20168272" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;30. Luttrull JK, Musch DC, Spink CA. Subthreshold diode micropulse panretinal photocoagulation for proliferative diabetic retinopathy. Eye 2008; 22(5):607-12. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17293791" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;31. Kumar V, Ghosh B, Raina UK, Goel N. Subthreshold diode micropulse panretinal photocoagulation for proliferative diabetic retinopathy. Eye 2009; 23(11):2122-3; author reply 2123.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;32. Luttrull J, Musch D, Spink C. Subthreshold diode micropulse panretinal photocoagulation for proliferative diabetic retinopathy - reply to Dr Kumar et al. Eye 2009; 23(11):2123.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;33. Gaucher D, Fortunato P, LeCleire-Collet A, Bourcier T, Speeg-Schatz C, Tadayoni R, et al. Spontaneous resolution of macular edema after panretinal photocoagulation in florid proliferative diabetic retinopathy. Retina 2009; 29(9):1282-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19629019" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;34. Kim NR, Kim YJ, Chin HS, Moon YS. Optical coherence tomographic patterns in diabetic macular oedema: prediction of visual outcome after focal laser photocoagulation. British Journal of Ophthalmology 2009; 93(7):901-5. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19254904" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;35. Lim MC, Tanimoto SA, Furlani BA, Lum B, Pinto LM, Eliason D, et al. Effect of diabetic retinopathy and panretinal photocoagulation on retinal nerve fiber layer and optic nerve appearance. Archives of Ophthalmology 2009; 127(7):857-62. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19597104" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;36. Muqit MM, Wakely L, Stanga PE, Henson DB, Ghanchi FD. Effects of conventional argon panretinal laser photocoagulation on retinal nerve fibre layer and driving visual fields in diabetic retinopathy. Eye 2010; 24(7):1136-42.&lt;/SPAN&gt; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20019760" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;37. Mendrinos E, Mangioris G, Papadopoulou DN, Dosso AA, Pournaras CJ. Retinal vessel analyzer measurements of the effect of panretinal photocoagulation on the retinal arteriolar diameter in diabetic retinopathy. Retina 2010; 30(4):555-61. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20010452" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;38. Tinley CG, Gray RH. Routine, single session, indirect laser for proliferative diabetic retinopathy. Eye 2009; 23(9):1819-23. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19136919" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;39. Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, Browning DJ, et al. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Archives of Ophthalmology 2009; 127(2):132-40. &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754061/?tool=pubmed" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;40. Muqit MM, Marcellino GR, Henson DB, Young LB, Patton N, Charles SJ, et al. Single-session vs multiple-session pattern scanning laser panretinal photocoagulation in proliferative diabetic retinopathy: The Manchester Pascal Study. Archives of Ophthalmology 2010; 128(5):525-33. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20457972" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;41. Nagpal M, Marlecha S, Nagpal K. Comparison of laser photocoagulation for diabetic retinopathy using 532-nm standard laser versus multispot pattern scan laser. Retina 2010; 30(3):452-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20216293" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;BR&gt;Further Evidence&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/SearchResults.aspx?catID=5134&amp;amp;searchText=&amp;amp;sort=PUBLICATION_DATE&amp;amp;resultsPerPage=10&amp;amp;summaries=true" target="_blank"&gt;Links to systematic reviews on diabetic retinopathy in&amp;nbsp;NHS Evidence - diabetes&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Guidelines&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5658&amp;amp;searchText=&amp;amp;sort=PUBLISHER&amp;amp;resultsPerPage=10&amp;amp;summaries=true" target="_blank"&gt;Links to supporting Guidelines&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Patient Information&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?tabID=292&amp;amp;catID=5658&amp;amp;sort=PUBLISHER&amp;amp;resultsPerPage=10&amp;amp;summaries=true&amp;amp;" target="_blank"&gt;Links to supporting Patient Information&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Reference Material&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?catID=5134&amp;amp;tabID=290&amp;amp;searchText=&amp;amp;sort=PUBLICATION_DATE&amp;amp;resultsPerPage=10&amp;amp;summaries=true" target="_blank"&gt;Links to supporting reference material&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication details&lt;/STRONG&gt;&lt;BR&gt;Originally written by Peter Scanlon (Consultant Ophthalmologist&amp;nbsp; and National Clinical Director of the English National Screening Programme for Diabetic Retinopathy) in June 2006, since reviewed and updated in June 2007 by P Scanlon, in June 2008 by P Scanlon and Irene Stratton, in June 2009 by P Scanlon, and in August 2010 by P Scanlon.&lt;BR&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387222</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=387222]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetic Retinopathy - Epidemiology and progression of diabetic retinopathy</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,EYES AND VISION,CHRONIC COMPLICATIONS,EYE DISEASES,STATISTICS,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS,INCIDENCE AND PREVALENCE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>part of the 2010 Annual Evidence Update on Diabetic Retinopathy</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetic Retinopathy - Epidemiology and progression of diabetic retinopathy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published&lt;/STRONG&gt;: 13 September 2010&lt;/P&gt;
&lt;P align=left&gt;Originally written by P Scanlon in June 2006, updated annually, &lt;A href="#ref1"&gt;link to further author and publication&amp;nbsp;details here.&lt;/A&gt;&amp;nbsp; &lt;BR&gt;Changes and additions since August 2009 are highlighted in red.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387096" target="_blank"&gt;Link back to home page for 2010 Annual Evidence Update on Diabetic Retinopathy here.&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387421" target="_blank"&gt;Link to table of abbreviations here.&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID387222/nelhImp_0000_5-6-7-smaller.jpg"&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=left&gt;In 1981, Palmberg [1] described a study of the natural history of diabetic retinopathy in 461 people with juvenile-onset IDDM. At diagnosis no DR was found, at 7 yrs 50%, at 17-50 yrs 90%. Proliferative Diabetic Retinopathy (PDR) was first seen at 13 yrs, 26% at 26-50 yrs. &lt;BR&gt;&lt;BR&gt;In 1984 and 1989, Klein [2-5] reported on the natural history of Diabetic Retinopathy in the Wisconsin Epidemiological Study (WESDR study). For the 996 insulin-taking younger-onset people with diabetes (given diagnoses of diabetes under 30 yrs), the prevalence of any DR was 17% &amp;lt; 5 yrs, 97.5% &amp;gt; 15yrs. The prevalence of PDR was 1.2% &amp;lt; 10 yrs, 67% &amp;gt; 35yrs. For the 271 people with IDDM diagnosed &amp;lt; 30 yrs with no DR at first visit in WESDR, 59% developed DR after 4 yrs. For the 713 people with IDDM diagnosed &amp;lt; 30 yrs with no PDR at first visit, 11% developed PDR after 4 years. Worsening of DR occurred in 41%, improvement in 7%. Incidence of PDR rose to 14% after 13yrs of diabetes. For the 1,370 patients given diagnoses of diabetes at age 30 years or older the prevalence of any DR was 28.8% &amp;lt; 5 yrs, 77.8% &amp;gt; 15yrs. The prevalence of PDR was 2.0% &amp;lt; 5 yrs, 15.5% &amp;gt; 15yrs. For the 154 people with IDDM diagnosed &amp;gt; 30 yrs with no DR at first visit, 47% developed DR after 4 yrs. For the 418 people with IDDM diagnosed &amp;gt; 30 yrs with no PDR at first visit, 7% developed PDR after 4 years and worsening of DR in 34%. For the 320 non IDDM diagnosed &amp;gt; 30 yrs with no DR at first visit, 34% (developed DR after 4 yrs. For the 486 non IDDM diagnosed &amp;gt; 30 yrs with no PDR at first visit, 2% developed PDR after 4 years and worsening of DR in 25%.&lt;BR&gt;&lt;BR&gt;Further studies that have shown clear evidence that sight-threatening diabetic retinopathy has a recognisable latent or early symptomatic stage have been reported by Frank [6], Klein [7], Burger [8], Kohner [9], ETDRS [10-11], Aldington [12], Klein [13], Danne [14], Klein [15], Ling [16] and Younis [17-18].&lt;BR&gt;&lt;BR&gt;A systematic review published by Williams [19] in 2004 on the epidemiology of diabetic retinopathy and macular oedema concluded that studies of sufficient size to stratify for age and duration of eye disease show an increase in DR in older age groups with long-standing disease.&lt;BR&gt;&lt;BR&gt;In 2006, an article by Leske [20] on long-term incidence among persons of African origin suggested a possible lower risk of severe/proliferative DR than in whites, while CSME incidence seems comparable or higher. &lt;BR&gt;&lt;BR&gt;In 2007 and 2008, Romero-Aroca [21-22] reported on the changes in diabetic retinopathy epidemiology after 14 years in a population of Type 1 and 2 diabetic patients following the new diabetes mellitus diagnosis criteria and stricter control of the blood glucose. &lt;BR&gt;&lt;BR&gt;In 2008 and 2009, Klein [23-24] reported on the 25-year cumulative progression and regression of diabetic retinopathy (DR) and on the 25-year cumulative incidence of macular edema (ME) and clinically significant macular oedema (CSME) in the Wisconsin Epidemiologic Study of Diabetic Retinopathy.&lt;BR&gt;&lt;BR&gt;In 2008, Escariao [25] described regional differences in the prevalence of diabetic retinopathy in Brazil and in 2009, Tam [26] described the incidence and progression of diabetic retinopathy in Hong Kong Chinese with type 2 diabetes mellitus.&lt;BR&gt;&lt;BR&gt;In 2009, Nunes [27] demonstrated that a high microaneurysm formation rate on colorcolour fundus photographs appears to be a good biomarker for DR progression to CSME in type 2 diabetic patients with NPDR.&lt;BR&gt;&lt;BR&gt;In 2009, Wong [28] conducted a systematic review of rates of progression in diabetic retinopathy during different time periods. The article concluded that since 1985, diabetic patients have lower rates of progression to PDR and SVL. These findings may reflect an increased awareness of retinopathy risk factors; earlier identification and initiation of care for patients with retinopathy; and improved medical management of glucose, blood pressure, and serum lipids. &lt;BR&gt;&lt;BR&gt;In 2010, Varma [29] demonstrated that the 4-year incidence and progression of DR and the incidence of ME and CSME among Latinos are high compared to non-Hispanic whites.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;The following studies have observed the natural history of diabetic retinopathy:&lt;/STRONG&gt;&amp;nbsp; 
&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;STRONG&gt;Year&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;STRONG&gt;Author&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;STRONG&gt;Number (n) patients (p) eyes (e)&lt;/STRONG&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1981&lt;/TD&gt;
&lt;TD&gt;Palmberg [1]&lt;/TD&gt;
&lt;TD&gt;n = 461 juvenile-onset IDDM.&lt;BR&gt;At diagnosis no DR, at 7 yrs 50%, at 17-50 yrs 90%.&lt;BR&gt;PDR first seen at 13 yrs, 26% at 26-50 yrs.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1981&lt;/TD&gt;
&lt;TD&gt;Frank [6]&lt;/TD&gt;
&lt;TD&gt;n = 173 juvenile-onset IDDM.&lt;BR&gt;Prevalence: 1% 0-4 years, 25% 5-9 years, 67% 10-16 years after diagnosis.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1984&lt;/TD&gt;
&lt;TD&gt;Klein [2-3]&lt;/TD&gt;
&lt;TD&gt;n = 996 younger-onset IDDM from WESDR.&lt;BR&gt;Prevalence: Any DR 17% &amp;lt; 5 yrs, 97.5% &amp;gt; 15yrs&lt;BR&gt;PDR 1.2% &amp;lt; 10 yrs, 67% &amp;gt; 35yrs.&lt;BR&gt;n = 1,370 diagnosed &amp;gt; 30 yrs.&lt;BR&gt;Prevalence: Any DR 28.8% &amp;lt; 5 yrs, 77.8% &amp;gt; 15yrs&lt;BR&gt;PDR 2.0% &amp;lt; 5 yrs, 15.5% &amp;gt; 15yrs.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1985&lt;/TD&gt;
&lt;TD&gt;Klein [7]&lt;/TD&gt;
&lt;TD&gt;n = 200 IDDM &amp;lt; 26 yrs.&lt;BR&gt;Prevalence: Any DR 9% &amp;lt; 13yrs and 34% &amp;gt; 13 yrs. DR more strongly associated with duration of diabetes after 13 yrs than before.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1986&lt;/TD&gt;
&lt;TD&gt;Burger [8]&lt;/TD&gt;
&lt;TD&gt;n = 231 juvenile-onset IDDM in the Berlin retinopathy study.&lt;BR&gt;Results: 1-6 examinations with fluorescein angiography over 5 years. 47% developed retinal changes, 1/2 classified as minimal (&amp;lt; 5 ma’s). The median individual risk for development of early DR was 9.1 yrs of diabetes duration.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1986&lt;/TD&gt;
&lt;TD&gt;Kohner [9]&lt;/TD&gt;&amp;nbsp; 
&lt;TD&gt;n = 55 IDDM with early DR and fluorescein angiography at 0, 8, and 24 months.&lt;BR&gt;Results: Significant correlations between microaneurysm count and retinopathy level at all three time intervals, (p&amp;lt;0.05-&amp;lt;0.001).&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1989&lt;/TD&gt;
&lt;TD&gt;Klein [4-5]&lt;/TD&gt;
&lt;TD&gt;n = 271 IDDM diagnosed &amp;lt; 30 yrs with no DR at first visit in WESDR, 59% developed DR after 4 yrs. n = 713 with no PDR at first visit, 11% developed PDR after 4 years. Worsening of DR in 41%, improvement in 7%. Incidence of PDR rose to 14% after 13yrs of diabetes.&lt;BR&gt;n = 154 IDDM diagnosed &amp;gt; 30 yrs with no DR at first visit, 47% developed DR after 4 yrs. n = 418 with no PDR at first visit, 7% developed PDR after 4 years and worsening of DR in 34%. &lt;BR&gt;n = 320 non IDDM diagnosed &amp;gt; 30 yrs with no DR at first visit, 34% (developed DR after 4 yrs. n = 486 with no PDR at first visit, 2% developed PDR after 4 years and worsening of DR in 25%.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1991&lt;/TD&gt;
&lt;TD&gt;ETDRS [10-11]&lt;/TD&gt;
&lt;TD&gt;n = 3711. Patients were assigned randomly to either aspirin or placebo. One eye of each patient was assigned randomly to early argon laser or deferral of photocoagulation. &lt;BR&gt;A retinopathy severity scale was developed, which divides DR into 13 levels and can be used to describe overall retinopathy severity and change in severity over time.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1995&lt;/TD&gt;
&lt;TD&gt;Aldington [12]&lt;/TD&gt;
&lt;TD&gt;Two cohorts from the UKPDS, both with no DR or ma’s only at baseline. &lt;BR&gt;No DR, 11% progressed to DR of &amp;gt; ma’s alone by 3 years.&lt;BR&gt;Significant trends existed between ma count at entry and more serious levels of retinopathy at follow-up.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1995&lt;/TD&gt;
&lt;TD&gt;Klein [13]&lt;/TD&gt;
&lt;TD&gt;n = 189 with ma’s only at baseline in WESDR&lt;BR&gt;The increase in the number of ma’s and the ratio of the number of ma’s at the 4-year follow-up to the number at baseline were positively associated with incidence of PDR or CSMO at the 10-year follow-up.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1998&lt;/TD&gt;
&lt;TD&gt;Danne [14]&lt;/TD&gt;
&lt;TD&gt;Review of monitoring for DR in children and adolescents with type 1 diabetes.&lt;BR&gt;In children with an average diabetes onset at 11 yrs of age, the first retinal changes can be expected after a median duration of 9 yrs and clinically relevant background DR after 14 yrs.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1998&lt;/TD&gt;
&lt;TD&gt;Klein [15]&lt;/TD&gt;
&lt;TD&gt;The 14-year rate of progression of retinopathy in type 1 diabetes in the WESDR study was 86%, regression of retinopathy was 17%, progression to proliferative retinopathy was 37%, and incidence of macular oedema was 26%. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2002&lt;/TD&gt;
&lt;TD&gt;Ling [16]&lt;/TD&gt;
&lt;TD&gt;n = 775 p screened by the Exeter Diabetic Retinopathy .&lt;BR&gt;Prevalence: Baseline - background DR 21.4%, PDR 2.8%, and CSMO 6.1%.&lt;BR&gt;Incidence: 2.20% PDR, 4.79% CSMO and 2.25% PDR, 5.18% CSMO respectively in the next two screening rounds.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2003&lt;/TD&gt;
&lt;TD&gt;Younis [17]&lt;/TD&gt;
&lt;TD&gt;n = 501 p with Type 1 (2742 screen events).&lt;BR&gt;For a 95% likelihood of remaining free of STDR, mean screening intervals by baseline status were: NDR 5.7 (95% CI 3.5-7.7) years, BDR 1.3 (0.4-2.0) years and mild PPDR 0.4 (0-0.8) years.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2003&lt;/TD&gt;
&lt;TD&gt;Younis [18]&lt;/TD&gt;
&lt;TD&gt;n = 7231 p with Type 2 (20,570 screen events).&lt;BR&gt;For a 95% probability of remaining free of STDR, mean screening intervals by baseline status were: NDR 5.4 years (95% CI 4.7-6.3), BDR 1.0 years (0.7-1.3), and mild PPDR 0.3 years (0.2-0.5).&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2004&lt;/TD&gt;
&lt;TD&gt;Williams [19]&lt;/TD&gt;
&lt;TD&gt;Epidemiology of diabetic retinopathy and macular oedema: a systematic review.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2006&lt;/TD&gt;
&lt;TD&gt;Leske [20]&lt;/TD&gt;&amp;nbsp; 
&lt;TD&gt;The study provides new data on long-term incidence among persons of African origin. Results suggest a possible lower risk of severe/proliferative DR than in whites, while CSME incidence seems comparable or higher.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2007&lt;/TD&gt;
&lt;TD&gt;Romero-Aroca [21]&lt;/TD&gt;
&lt;TD&gt;Comparison of 1993 and 2005 Spanish cohorts with Type 2 diabetes (n=741 in both). In the first study the incidence was 39.41% while in the present study it was 27.55%. The diabetic macular edema prevalence was similar in both studies (7.15% in the past and 7.90% in the present study). There was also a decrease in the number of blind patients (11.20% in 1993 and 4.90% in the current study). The number of patients treated with laser photocoagulation increased (13.49% in the current study as compared to 6.20% in the previous study).&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Romero-Aroca [22]&lt;/TD&gt;
&lt;TD&gt;Described epidemiological differences between two samples of patients from the same population in Spain, the first in 1993 (741 Type 2 and 76 Type 1 diabetic patients) and the second in 2006 (1157 Type 2 and 93 Type 1 diabetic patients). A decrease in prevalence of DR was observed from 39.41% in the 1993 study to 27.48% in the 2006 study in type 2 patients, but not in Type 1 diabetic patients-35.52% in 1993 to 36.55% in 2006 The difference was considered to be due to stricter glycaemic and B/P control. The diabetic macular edema prevalence is similar in both studies-7.15% in 1993 and 7.86% in 2006 in Type 2 patients, and 11.84-12.90% in Type 1. A decrease in the number of patients with blindness, from 11.20% to 4.90% in Type 2, and from 9.21% to 7.52% in Type 1 patients was observed.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Escariao [25]&lt;/TD&gt;
&lt;TD&gt;Described regional differences in the prevalence of diabetic retinopathy in Brazil in 2,223 diabetic patients (1,568 females and 655 males; mean age 59.3 +/- 12.0 years; mean duration of diabetes 8.1 +/- 6.3 years). Patients living in the interior of Pernambuco state have a higher incidence of diabetic retinopathy (89, 39.4%) and the advanced forms than patients living in Recife (477, 24.2%) and the metropolitan area.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Klein [23]&lt;/TD&gt;
&lt;TD&gt;Described the 25-year cumulative progression and regression of diabetic retinopathy (DR) in the Wisconsin Epidemiologic Study of Diabetic Retinopathy. The 25-year cumulative rate of progression of DR was 83%, progression to proliferative DR (PDR) was 42%, and improvement of DR was 18%. The lower risk of prevalent PDR in more recently diagnosed persons possibly reflects improvement in care over the period of the study.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2009&lt;/TD&gt;
&lt;TD&gt;Klein [24]&lt;/TD&gt;
&lt;TD&gt;Described the 25-year cumulative incidence of macular edema (ME) and clinically significant macular oedema (CSME) in the Wisconsin Epidemiologic Study of Diabetic Retinopathy. The 25-year cumulative incidence was 29% for ME and 17% for CSME.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2009&lt;/TD&gt;
&lt;TD&gt;Tam [26]&lt;/TD&gt;
&lt;TD&gt;Described the Incidence and progression of diabetic retinopathy in Hong Kong Chinese with type 2 diabetes mellitus. The baseline prevalence of DR was 39.2%. On 4-year follow-up, the incidence of DR was 20.3% (43 of 212). In those with baseline DR, 34.7% (42 of 121) progressed by &amp;gt;or=2 steps in ETDRS.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;2009&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Nunes [27]&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;In total, 113 patients/eyes with nonproliferative DR (NPDR) were followed up every 6 months for 2 years as controls of the DR clinical trials, and by conventional general and ophthalmological care for the next 8 years (over a total of 10 years' follow-up). Microaneurysm turnover for the 2 first years was computed using the MA-Tracker. RESULTS: The 17 patients that developed CSME over the 10 years of follow-up presented a microaneurysm formation rate of 9.2 +/- 18.2 microaneurysms/year (mean +/- SD) during the first 2 years, which was statistically higher than the eyes that did not develop CSME (0.5 +/- 1.2 microaneurysms/year, p &amp;lt; 0.001).&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;2009&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Wong [28]&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;This systematic literature review and meta-analysis of prospective studies assesses progression of retinopathy among diabetic patients without treatment for retinopathy at baseline. Studies published between 1975 to February 2008 were identified. A total of 28 studies comprising 27,120 diabetic patients (mean age 49.8 years) were included. After 4 years, pooled incidence rates for proliferative diabetic retinopathy and severe visual loss were 11.0 and 7.2%, respectively.&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;2010&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Varma [29]&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;A population-based, longitudinal study of 4658 self-identified Latinos (primarily Mexican Americans), residing in Los Angeles, examined at baseline (2000-2003) and at 4 years (2004-2008). The 4-year incidence of DR, ME, and CSME was 34.0% (182/535), 5.4% (38/699), and 7.2% (50/699) respectively. Younger persons and those with longer duration of diabetes mellitus had a higher incidence of DR compared to those who were older and had shorter duration of diabetes mellitus.&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;BR&gt;References (including systematic reviews &amp;amp; primary research)&lt;/STRONG&gt;&lt;BR&gt;Links to PubMed abstracts are provided. Free full text may be available from the PubMed link. Where free full text access is not available, NHS staff in England can access full text of a number of journals via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/" target="_blank"&gt;NHS Evidence&lt;/A&gt; or can request the full text via their &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt;. &lt;BR&gt;&lt;BR&gt;1. Palmberg P, Smith M, Waltman S, Krupin T, Singer P, Burgess D, et al. The natural history of retinopathy in insulin-dependent juvenile-onset diabetes. Ophthalmology 1981; 88(7): 613-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7267029" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;2. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Archives of Ophthalmology 1984; 102(4): 520-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/6367724" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;3. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Archives of Ophthalmology 1984; 102(4): 527-32. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/6367725" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;4. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Archives of Ophthalmology 1989; 107(2): 237-43. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2916977" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;5. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Archives of Ophthalmology 1989; 107(2): 244-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2644929?ordinalpos=3392&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;6. Frank RN, Hoffman WH, Podgor MJ, Joondeph HC, Lewis RA, Margherio RR, et al. Retinopathy in juvenile-onset type I diabetes of short duration. Diabetes 1982; 31(10): 874-82. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7152126?ordinalpos=67&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;7. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Retinopathy in young-onset diabetic patients. Diabetes Care 1985; 8(4): 311-5. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/4042795?ordinalpos=86&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;8. Burger W, Hovener G, Dusterhus R, Hartmann R, Weber B. Prevalence and development of retinopathy in children and adolescents with type 1 (insulin-dependent) diabetes mellitus. A longitudinal study. Diabetologia 1986; 29(1): 17-22. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/3956893" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;9. Kohner EM, Sleightholm M. Does microaneurysm count reflect severity of early diabetic retinopathy? Ophthalmology 1986; 93(5): 586-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/3725317" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;10. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98(5 Suppl): 823-33. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2062515" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;11. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 1991; 98(5 Suppl): 741-56. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2062510" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;12. Aldington SJ, Stratton IM, Matthews DR, Kohner EM. Relationship of retinal microaneurysm count to progression of retinopathy over 3 and 6 years in non-insulin dependent diabetes. Diabetic Medicine 1995; 12(Suppl 1): 3. &lt;BR&gt;&lt;BR&gt;13. Klein R, Meuer SM, Moss SE, Klein BE. Retinal microaneurysm counts and 10-year progression of diabetic retinopathy. Archives of Ophthalmology 1995; 113(11): 1386-91. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7487599" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;14. Danne T, Kordonouri O, Enders I, Hovener G. Monitoring for retinopathy in children and adolescents with type 1 diabetes. Acta paediatrica. Supplementum 1998; 425: 35-41. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9822192" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;15. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998; 105(10): 1801-15. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9787347" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;16. Ling R, Ramsewak V, Taylor D, Jacob J. Longitudinal study of a cohort of people with diabetes screened by the Exeter Diabetic Retinopathy Screening Programme. Eye 2002; 16(2): 140-5. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11988813" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;17. Younis N, Broadbent DM, Harding SP, Vora JP. Incidence of sight-threatening retinopathy in Type 1 diabetes in a systematic screening programme. Diabetic Medicine 2003; 20(9): 758-65. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12925058" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;18. Younis N, Broadbent DM, Vora JP, Harding SP. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003; 361(9353): 195-200. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12547541" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;19. Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye 2004; 18(10): 963-83. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15232600" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;20. Leske M, Wu S, Hennis A, Nemesure B, Schachat A, Hyman L, et al. Nine-year incidence of diabetic retinopathy in the Barbados eye studies. Archives of Ophthalmology 2006; 124(2):250-252. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16476895" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;21. Romero-Aroca P, Fernandez-Alart J, Baget-Bernaldiz M, Mendez-Marin I, Salvat-Serra M. [Diabetic retinopathy epidemiology in type II diabetic patients. Effect of the changes in the diagnostic criteria and stricter control of the diabetes between 1993 and 2005 on the incidence of diabetic retinopathy]. Archivos de la Sociedad Española de Oftalmología 2007; 82(4):209-18. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17443425" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;22. Romero-Aroca P, Fernandez-Balart J, Baget-Bernaldiz M, Martinez-Salcedo I, Mendez-Marin I, Salvat-Serra M, et al. Changes in the diabetic retinopathy epidemiology after 14 years in a population of Type 1 and 2 diabetic patients after the new diabetes mellitus diagnosis criteria and a more strict control of the patients. Journal of Diabetes and its Complications 2009; 23(4):229-38. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18439844" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;23. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008; 115(11):1859-68. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19068374" target="_blank"&gt;Link to Pubmed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;24. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009; 116(3):497-503. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19167079" target="_blank"&gt;Link to Pubmed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;25. Escariao PH, Arantes TE, Figueiroa Filho NC, Urgtiga Rde D, Florencio TL, Arcoverde AL. Epidemiology and regional differences of diabetic retinopathy in Pernambuco, Brazil. Arquivos Brasileiros de Oftalmologia 2008; 71(2):172-5. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18516414" target="_blank"&gt;Link to Pubmed abstract here.&lt;/A&gt; &lt;A href="http://www.scielo.br/scielo.php?script=sci_arttext&amp;amp;pid=S0004-27492008000200008&amp;amp;lng=en&amp;amp;nrm=iso&amp;amp;tlng=en" target="_blank"&gt;Link to full text here (non English language).&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;26. Tam VH, Lam EP, et al. Incidence and progression of diabetic retinopathy in Hong Kong Chinese with type 2 diabetes mellitus. Journal of Diabetes and its Complications 2009; 23(3):185-93. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18479945" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;BR&gt;&lt;BR&gt;27. Nunes S, Pires I, Rosa A, Duarte L, Bernardes R, Cunha-Vaz J. Microaneurysm turnover is a biomarker for diabetic retinopathy progression to clinically significant macular edema: findings for type 2 diabetics with nonproliferative retinopathy. Ophthalmologica 2009; 223(5):292-297. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19372723" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;BR&gt;&lt;BR&gt;28. Wong TY, Mwamburi M, Klein R, Larsen M, Flynn H, Hernandez-Medina M, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 2009; 32(12):2307-13. &lt;A href="http://care.diabetesjournals.org/content/32/12/2307.long" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;BR&gt;&lt;BR&gt;29. Varma R, Choudhury F, Klein R, Chung J, Torres M, Azen SP. Four-year incidence and progression of diabetic retinopathy and macular edema: the Los Angeles Latino Eye Study. American Journal of Ophthalmology 2010; 149(5):752-61 e1-3. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20149342" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;STRONG&gt;Further Evidence&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/SearchResults.aspx?catID=5134&amp;amp;tabID=289&amp;amp;" target="_blank"&gt;Links to systematic reviews on diabetic retinopathy in&amp;nbsp;NHS Evidence - diabetes&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Guidelines&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?catID=5134&amp;amp;tabID=288" target="_blank"&gt;Links to supporting Guidelines&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Patient Information&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?catID=5134&amp;amp;tabID=292&amp;amp;" target="_blank"&gt;Links to supporting Patient Information&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Reference Material&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?catID=5134&amp;amp;tabID=290&amp;amp;searchText=&amp;amp;sort=PUBLICATION_DATE&amp;amp;resultsPerPage=10&amp;amp;summaries=true" target="_blank"&gt;Links to supporting reference material&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;Publication details&lt;BR&gt;&lt;/STRONG&gt;Originally written by Peter Scanlon (Consultant Ophthalmologist and National Clinical Director of the English National Screening Programme for Diabetic Retinopathy) in June 2006, since reviewed and updated in June 2007 by P Scanlon, in June 2008 by P Scanlon and Irene Stratton, in June 2009 by P Scanlon, and in August 2010 by P Scanlon.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;&lt;/SPAN&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387096</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=387096]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetic Retinopathy - Home Page</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ SCREENING,ADULT,DIABETES,RETINOPATHY,DIABETIC RETINOPATHY,EYES AND VISION,CHRONIC COMPLICATIONS,DIAGNOSIS,CONDITION MANAGEMENT,CAUSES,EYE DISEASES,SURGERY,SURGERY,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,HEAD &amp; NECK,EYE,RETINA,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Home page of the 2010 Annual Evidence Update on Diabetic Retinopathy</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetic Retinopathy - Home Page&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published&lt;/STRONG&gt;: 13 September 2010&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Images of diabetic retinopathy, screening camera and visual acuity chart, and diabetic maculopathy" src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID322717/nelhImp_0008_3-9-13-mediumsize.jpg" width=550 height=144&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;Diabetic retinopathy is the most common cause of blindness in working age people in the UK.&amp;nbsp; The UK leads the world in diabetic retinopathy screening.&amp;nbsp; The update of the Annual Evidence Update on Diabetic Retinopathy provides an opportunity to present an up-to-date comprehensive collection of information that has been subject to rigorous selection criteria. Coverage has been developed on the basis of topics suggested by UK diabetic retinopathy experts. Information is organised by topic areas and links are provided within each topic to the relevant references (systematic reviews, primary research), guidelines and patient information. &lt;BR&gt;&amp;nbsp;&lt;BR&gt;Changes and additions made since August 2009 are highlighted in the commentary pages in&amp;nbsp;&lt;SPAN style="COLOR: #a81400"&gt;red&lt;/SPAN&gt;.&amp;nbsp;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;&lt;U&gt;Contents:&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P dir=ltr&gt;1. &lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387093" target="_blank"&gt;Introduction&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;2. Commentaries with new evidence highlighted:&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; i.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387173" target="_blank"&gt;Incidence and prevalence of diabetes&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; ii.&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387199" target="_blank"&gt;Prevalence of diabetic retinopathy and sight threatening&amp;nbsp;diabetic retinopathy&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; iii.&amp;nbsp;&amp;nbsp; &lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387222" target="_blank"&gt;Epidemiology and progression of diabetic retinopathy&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; iv.&amp;nbsp;&amp;nbsp; &lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387101" target="_blank"&gt;Risk factors for the development of diabetic retinopathy and sight threatening diabetic retinopathy&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; v.&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387102" target="_blank"&gt;Screening for diabetic retinopathy&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; vi.&amp;nbsp;&amp;nbsp; Conventional treatment for diabetic retinopathy&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; a) &lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387337" target="_blank"&gt;Laser&lt;/A&gt; &lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; b) &lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387365" target="_blank"&gt;Vitrectomy&lt;/A&gt;&amp;nbsp; &lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; vii.&amp;nbsp; &lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387393" target="_blank"&gt;Surgery for cataract and diabetic retinopathy&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; viii. Alternative surgical treatment for diabetic retinopathy &lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; a) &lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387401" target="_blank"&gt;Intravitreal injection of triamcinolone&lt;/A&gt; &lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; b) &lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387406" target="_blank"&gt;Intravitreal injection of VEGF Inhibitors&lt;/A&gt; &lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; ix.&amp;nbsp;&amp;nbsp; &lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387428" target="_blank"&gt;Modern medical therapies&lt;/A&gt;&amp;nbsp;&amp;nbsp; &lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; x.&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387432" target="_blank"&gt;Blindness and visual impairment&lt;/A&gt; &lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; xi.&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387422" target="_blank"&gt;Automated assessment of&amp;nbsp;retinopathy&lt;/A&gt;&amp;nbsp; (written by Dr Nathan Hill)&lt;BR&gt;&lt;BR&gt;3. &lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387099" target="_blank"&gt;Methodology&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;4. &lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387421" target="_blank"&gt;Table of abbreviations&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P dir=ltr&gt;&lt;STRONG&gt;Acknowledgements&lt;/STRONG&gt;&lt;/P&gt;
&lt;P dir=ltr&gt;This annual evidence update was researched and written by Dr Peter Scanlon (Consultant Ophthalmologist, Gloucestershire Eye Unit and Oxford Eye Hospital and&amp;nbsp;Programme Director of the &lt;A href="http://www.retinalscreening.nhs.uk/pages/" target="_blank"&gt;English National Screening Programme for Diabetic Retinopathy&lt;/A&gt;).&amp;nbsp; The project team for NHS Evidence - diabetes, based at the University of Warwick (Roger Gadsby, Rachel Court, Anna Brown and&amp;nbsp;Susan Vollmer) checked the references and prepared the text for web publication.&amp;nbsp; We would like to&amp;nbsp;thank a&amp;nbsp;number of other people involved in&amp;nbsp;the development and publicity of the annual evidence update, including Irene Stratton (Statistician for the English National Screening Programme for Diabetic Retinopathy), Jenny Sykes (Peter Scanlon's Research Assistant), Dr Nathan Hill (Oxford Centre for Diabetes and Endocrine Medicine), Clare Bailey (Royal College of Ophthalmologists)&amp;nbsp;and members of the NHS Evidence - diabetes Reference Group.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;If you would like to comment on or have any questions about this annual evidence update please contact us via &lt;A href="http://www.library.nhs.uk/Diabetes/ContactUs.aspx" target="_blank"&gt;this email form&lt;/A&gt;.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387173</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=387173]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetic Retinopathy - Incidence and Prevalence of Diabetes</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,EYES AND VISION,DATA GATHERING AND AUDIT AND QOF,STATISTICS,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS,INCIDENCE AND PREVALENCE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>part of the 2010 Annual Evidence Update on Diabetic Retinopathy</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetic Retinopathy - Incidence and Prevalence of Diabetes&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Incidence and prevalence of diabetes&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt; 13 September 2010&lt;BR&gt;Originally written by P Scanlon in June 2006, updated annually, &lt;A href="#ref1"&gt;link to further author and publication details here.&lt;/A&gt; &lt;BR&gt;Additions since August 2009 are highlighted in red.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387096" target="_blank"&gt;Link back to home page for 2010 Annual Evidence Update on Diabetic Retinopathy here.&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387421" target="_blank"&gt;Link to table of abbreviations here.&lt;/A&gt;&lt;/P&gt;&lt;EM&gt;
&lt;P align=left&gt;&lt;BR&gt;&lt;FONT color=#000000 size=2 face=Arial&gt;&lt;/FONT&gt;&lt;/EM&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID387173/nelhImp_0000_photo3smaller.jpg"&gt;&lt;BR&gt;&lt;BR&gt;Numerous studies have shown that there is a rising incidence of diabetes and its complications in all age groups, both in the UK and worldwide. &lt;BR&gt;&lt;BR&gt;In 2001, Boyle [1] estimated the number of Americans with diagnosed diabetes is projected to increase from prevalence of 4.0% in 2000 to a prevalence of 7.2% in 2050.&lt;BR&gt;&lt;BR&gt;Other reports describing the rising incidence of diabetes are from Ehtisham [2], Sidibe [3], Feltbower [4], Zimmet [5], Cugati [6], Lipscombe [7] and Evans [8].&lt;BR&gt;&lt;BR&gt;In 2004, Wild [9] suggested that the most important demographic change to diabetes prevalence across the world appears to be the increase in the proportion of people over 65 years of age.&lt;BR&gt;&lt;BR&gt;In 2008, Almdal [10] reported that, in a randomly selected northern European population, more men than women develop type 2 DM and the study related this to a higher prevalence of risk factors for type 2 diabetes mellitus.&lt;BR&gt;&lt;BR&gt;Carstensen [11] reported data from the Danish National Diabetes Register showing rise in the prevalence of diabetes between 1995-2006. Ringborg [12] reported results from a retrospectives study in Uppsala county, Sweden. The crude prevalence of Type 2 diabetes increased from 2.2 to 3.5% between 1996 and 2003 although the crude population incidence was approximately stable after 1997 (3.7 cases/1000 residents in 1997 compared with 3.8/1000 in 2003).&lt;BR&gt;&lt;BR&gt;In 2009, Bell [13] reported that the incidence of type 1 diabetes in Non Hispanic White youth in the U.S. is one of the highest in the world. While type 2 diabetes is still relatively rare in this group, rates are several-fold higher than those reported by European countries. In the same supplement, Lawrence [14] reported on the incidence and prevalence of type 1 and type 2 diabetes in Hispanic youth and Mayer-Davis [15] provided a similar report on African American youth.&lt;BR&gt;&lt;BR&gt;Gonzalez [16] used the Health Improvement Network database in the UK to estimate the incidence and prevalence of type 1 and type 2 diabetes in the UK general population from 1996 to 2005 showing an increase in prevalence from 2.8% in 1996 to 4.3% in 2005.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Mohan [17] reported that, in 1972, the prevalence of diabetes in urban areas of India was 2.1% and this has rapidly climbed to 12-16% representing a 600-800% increase in prevalence rates over a 30 year period. &lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;In 2009, the International Diabetes Federation launched a 5-year programme [18] on education and prevention. Every year there are 4 million deaths worldwide due to diabetes. Today, 285 million people across the world are living with diabetes; an estimated 70% are in low-income and middle-income countries (LMIC). Around 90% of the burden is caused by type 2 diabetes, which is a preventable chronic disease.&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;The Federation's Diabetes Atlas [19] shows that the estimated diabetes prevalence for 2010 has risen to 285 million, representing 6.4% of the world's adult population, with a prediction that by 2030 the number of people with diabetes will have risen to 438 million.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;SPAN style="COLOR: #000000"&gt;Reports of rising incidence of diabetes:&lt;/SPAN&gt;&lt;/STRONG&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;
&lt;TABLE style="mso-cellspacing: 1.5pt" class=MsoNormalTable border=1 cellPadding=0&gt;
&lt;TBODY&gt;
&lt;TR style="mso-yfti-irow: 0; mso-yfti-firstrow: yes"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Year&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Author&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Number (n) patients (p) eyes (e)&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 1"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;2000&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Ehtisham [2]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Reported Type 2 diabetes emerging in &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:country-region w:st="on"&gt;&lt;st1:place w:st="on"&gt;UK&lt;/st1:place&gt;&lt;/st1:country-region&gt; children.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 2"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;2000&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Sidibe [3]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;In &lt;st1:place w:st="on"&gt;Africa&lt;/st1:place&gt;, a rise in complications of diabetes mellitus has gone in hand with the growing disease prevalence.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 3"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;2001&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Boyle [1]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Estimated the number of Americans with diagnosed diabetes is projected to increase 165%, from 11 million in 2000 (prevalence of 4.0%) to 29 million in 2050 (prevalence of 7.2%). &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 4"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;2001&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Zimmet [5]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Review article about global and societal implications of the diabetes epidemic.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 5"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;2002&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Feltbower [4]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Reported an increasing incidence of Type 1 diabetes in south Asians in &lt;st1:place w:st="on"&gt;Bradford&lt;/st1:place&gt;.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 6"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;2004&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Wild [9]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;The prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030. The prevalence of diabetes is higher in men than women, but there are more women with diabetes than men. The urban population in developing countries is projected to double between 2000 and 2030. The most important demographic change to diabetes prevalence across the world appears to be the increase in the proportion of people &amp;gt;65 years of age. &lt;BR&gt;These findings indicate that the "diabetes epidemic" will continue even if levels of obesity remain constant. Given the increasing prevalence of obesity, it is likely that these figures provide an underestimate of future diabetes prevalence.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 7"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;2006&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Cugati [6]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;The Blue Mountains Eye Study examined 3654 residents (82.4% response) aged &amp;gt;49 years in BMES I (1992-1994). Survivors (n = 2335) and newly eligible residents (n = 1174) were examined in BMES II (1997-2000). Diabetes was defined by history or fasting plasma glucose &amp;gt; or =7.0 mmol/L. The overall diabetes prevalence increased from 7.8 to 9.9% (p = 0.002).&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 8"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;2007&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Lipscombe [7]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;The prevalence of diabetes in &lt;st1:place w:st="on"&gt;&lt;st1:City w:st="on"&gt;Ontario&lt;/st1:City&gt;, &lt;st1:country-region w:st="on"&gt;Canada&lt;/st1:country-region&gt;&lt;/st1:place&gt; increased substantially during the past 10 years, and by 2005 already exceeded the global rate that was predicted for 2030. Using population-based data from the &lt;st1:place w:st="on"&gt;&lt;st1:PlaceType w:st="on"&gt;province&lt;/st1:PlaceType&gt; of &lt;st1:PlaceName w:st="on"&gt;Ontario&lt;/st1:PlaceName&gt;&lt;/st1:place&gt;, &lt;st1:country-region w:st="on"&gt;&lt;st1:place w:st="on"&gt;Canada&lt;/st1:place&gt;&lt;/st1:country-region&gt;, age-adjusted and sex-adjusted diabetes prevalence increased from 5.2% of the population in 1995 to 6.9% in 2000 and to 8.8% of the population in 2005.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 9"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;2007&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Evans [8]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;A diabetes clinical information system in &lt;st1:place w:st="on"&gt;&lt;st1:City w:st="on"&gt;Tayside&lt;/st1:City&gt;, &lt;st1:country-region w:st="on"&gt;Scotland&lt;/st1:country-region&gt;&lt;/st1:place&gt;, showed a doubling in incidence and prevalence of type 2 diabetes between 1993 and 2004, with statistically significant increasing trends of 6.3 and 6.7% per year respectively. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 10"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2008&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Almdal [11]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;A total of 14,223 randomly selected men and women were studied from 1976 to 1978. Patients with diabetes (self-reported type 2 DM or non-fasting plasma glucose &amp;gt;11.1 mmol/l) were excluded. Some 6154 women and 4733 men were studied and followed up in 1981-1983 or in 1991-1994. The significance of risk factors was examined by multiple logistic regression analysis. Significantly more men (242, 5.4%) than women (152, 2.5%) developed type 2 DM.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 11"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2008&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Carstensen[12]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;The Danish National Diabetes Register contains records for about 360,000 persons with diabetes; 230,000 were alive at 1 January 2007, corresponding to an overall prevalence of 4.2%. The prevalence increased by 6% per year. In 2004 the incidence rates were 1.8 per 100,000 at age 40 years and 10.0 per 100,000 at age 70 years. The incidence rate increased 5% per year before 2004 and then stabilised.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 12"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2008&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Ringborg [13]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Retrospective population-based study of patients with Type 2 diabetes identified in computerized medical records at 26 county primary care centres. : Crude prevalence of Type 2 diabetes increased from 2.2 to 3.5% between 1996 and 2003. In the population aged &amp;gt; or = 30 years, the age- and sex-adjusted period increase was 53% [odds ratio (OR) 1.53, 95% confidence interval (CI) 1.47-1.58]. Crude population incidence was approximately stable after 1997 (3.7 cases/1000 residents in 1997 compared with 3.8/1000 in 2003).&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 13"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2009&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Bell [14]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;The prevalence of type 1 diabetes (at ages 0-19 years) was 2.00/1,000, which was similar for male (2.02/1,000) and female (1.97/1,000) subjects. The incidence of type 1 diabetes was 23.6/100,000, slightly higher for male compared with female subjects (24.5 vs. 22.7 per 100,000, respectively, P = 0.04). Incidence rates of type 1 diabetes among youth aged 0-14 years in the SEARCH study are higher than all previously reported U.S. studies and many European studies. Few cases of type 2 diabetes in youth aged &amp;lt;10 years were found. The prevalence of type 2 diabetes (at ages 10-19 years) was 0.18/1,000, which is significantly higher for female compared with male subjects (0.22 vs. 0.15 per 1,000, P = 0.01). Incidence of type 2 diabetes was 3.7/100,000, with similar rates for female and male subjects (3.9 vs. 3.4 per 1,000, respectively, P = 0.3).&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 14"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2009&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Lawrence [15]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Reported the 2001 prevalence and 2002-2005 incidence of type 1 and type 2 diabetes in Hispanic American youth and to describe the demographic, clinical, and behavioral characteristics of these youth.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 15"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2009&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Mayer-Davis [16]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Among African American youth aged 0-9 years, prevalence (per 1,000) of type 1 diabetes was 0.57 (95% CI 0.47-0.69) and for those aged 10-19 years 2.04 (1.85-2.26). Among African American youth aged 0-9 years, annual type 1 diabetes incidence (per 100,000) was 15.7 (13.7-17.9) and for those aged 10-19 years 15.7 (13.8-17.8). Among African American youth aged 10-19 years, prevalence (per 1,000) of type 2 diabetes was 1.06 (0.93-1.22) and annual incidence (per 100,000) was 19.0 (16.9-21.3).&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 16; mso-yfti-lastrow: yes"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2009&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Gonzalez [17]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Diabetes prevalence increased from 2.8% in 1996 to 4.3% in 2005. The incidence of diabetes in the UK increased from 2.71 (2.58-2.85)/1000 person-years in 1996 to 4.42 (4.32-4.53)/1000 person-years in 2005. The incidence of type 1 diabetes remained relatively constant throughout the study period; however, the incidence of type 2 diabetes increased from 2.60 (2.47-2.74)/1000 person-years in 1996 to 4.31 (4.21-4.42)/1000 person-years in 2005&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 16; mso-yfti-lastrow: yes"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #a81400"&gt;2009&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #a81400"&gt;Mohan [18]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #a81400"&gt;In 1972, the prevalence of diabetes in urban areas of India was 2.1%. This has rapidly climbed to 12-16% representing a 600-800% increase in prevalence rates over a 30 year period.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;SPAN style="COLOR: #000000"&gt;
&lt;P&gt;&lt;BR&gt;References (including systematic reviews &amp;amp; primary research)&lt;BR&gt;&lt;/STRONG&gt;Links to PubMed abstracts are provided. Free full text may be available from the PubMed link. Where free full text access is not available, NHS staff in England can access full text of a number of journals via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/" target="_blank"&gt;NHS Evidence&lt;/A&gt; or can request the full text via their &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;1. Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001; 24(11): 1936-40. &lt;A href="http://care.diabetesjournals.org/content/24/11/1936.full" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;2. Ehtisham S, Barrett TG, Shaw NJ. Type 2 diabetes mellitus in UK children--an emerging problem. Diabetic Medicine 2000; 17(12): 867-71. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11168330?dopt=Citation" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;3. Sidibe EH. [Main complications of diabetes mellitus in Africa]. Annales de médecine interne (Paris) 2000; 151(8): 624-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11173705?dopt=Citation" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;4. Feltbower RG, Bodansky HJ, McKinney PA, Houghton J, Stephenson CR, Haigh D. Trends in the incidence of childhood diabetes in south Asians and other children in Bradford, UK. Diabetic Medicine 2002; 19(2): 162-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11874434?dopt=Citation" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;5. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414(6865):782-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11742409" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;6. Cugati S, Kifley A, Mitchell P, Wang JJ. Temporal trends in the age-specific prevalence of diabetes and diabetic retinopathy in older persons: Population-based survey findings. Diabetes Research and Clinical Practice 2006; 74(3):301-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16716443" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;7. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet 2007; 369(9563):750-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17336651?ordinalpos=33&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;8. Evans JM, Barnett KN, Ogston SA, Morris AD. Increasing prevalence of type 2 diabetes in a Scottish population: effect of increasing incidence or decreasing mortality? Diabetologia 2007; 50(4):729-32. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17225122" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;9. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047-53. &lt;A href="http://care.diabetesjournals.org/content/27/5/1047.full" target="_blank"&gt;Link to full text here. &lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #000000"&gt;10. Almdal T, Scharling H, et al. Higher prevalence of risk factors for type 2 diabetes mellitus and subsequent higher incidence in men. European Journal of Internal Medicine 2008; 19(1):40-5. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18206600" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;11. Carstensen B, Kristensen JK, et al. The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia 2008; 51(12):2187-96. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18815769" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;12. Ringborg A, Lindgren P, et al. Prevalence and incidence of Type 2 diabetes and its complications 1996-2003--estimates from a Swedish population-based study. Diabetic Medicine 2008; 25(10):1178-86. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19046196" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;13. Bell RA, Mayer-Davis EJ, et al. Diabetes in non-Hispanic white youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009; 32 (Suppl 2):S102-11. &lt;A href="http://care.diabetesjournals.org/content/32/Supplement_2/S102.full" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;14. Lawrence JM, Mayer-Davis EJ, et al. Diabetes in Hispanic American youth: prevalence, incidence, demographics, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009; 32 (Suppl 2):S123-32. &lt;A href="http://care.diabetesjournals.org/content/32/Supplement_2/S123.full" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;15. Mayer-Davis EJ, Beyer J, et al. Diabetes in African American youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009; 32 (Suppl 2):S112-22. &lt;A href="http://care.diabetesjournals.org/content/32/Supplement_2/S112.full" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;16. Gonzalez EL, Johansson S, et al. Trends in the prevalence and incidence of diabetes in the UK: 1996-2005. Journal of Epidemiology and Community Health 2009; 63(4):332-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19240084" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;BR&gt;&lt;BR&gt;17. Mohan V, Pradeepa R. Risk factors for diabetic retinopathy in rural India. Journal of Postgraduate Medicine 2009; 55(2):89-90. &lt;A href="http://dx.doi.org/10.4103/0022-3859.52837" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;BR&gt;&lt;BR&gt;18. Type 2 diabetes epidemic: a global education. Lancet 2009; 374 9702):1654. &lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61974-7/fulltext" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;19. International Diabetes Federation (IDF). 2009. Diabetes Atlas. &lt;/SPAN&gt;&lt;A href="http://www.diabetesatlas.org/" target="_blank"&gt;http://www.diabetesatlas.org/&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;/SPAN&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;A name=ref1&gt;&lt;/A&gt;Reference Material&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/SearchResults.aspx?tabID=290&amp;amp;catID=9423&amp;amp;searchText=&amp;amp;sort=PUBLICATION_DATE&amp;amp;resultsPerPage=10&amp;amp;summaries=true" target="_blank"&gt;Links to supporting reference material&amp;nbsp;&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication details&lt;/STRONG&gt;&lt;BR&gt;Originally written by Peter Scanlon (Consultant Ophthalmologist and National Clinical Director of the English National Screening Programme for Diabetic Retinopathy) in June 2006, since reviewed and updated in June 2007 by P Scanlon, in June 2008 by P Scanlon and Irene Stratton, in June 2009 by P Scanlon, and in August 2010 by P Scanlon.&lt;BR&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387093</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=387093]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetic Retinopathy - Introduction</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,EYES AND VISION,CHRONIC COMPLICATIONS,DIAGNOSIS,CONDITION MANAGEMENT,CAUSES,EYE DISEASES,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Part of the 2010 Annual Evidence Update on Diabetic Retinopathy</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetic Retinopathy - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt; 13 September 2010&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387096" target="_blank"&gt;Link back to home page for 2010 Annual Evidence Update on Diabetic Retinopathy here&lt;/A&gt;.&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387421" target="_blank"&gt;Link to table of abbreviations here.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Images of diabetic retinopathy, screening camera and visual acuity chart, and diabetic maculopathy" src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID322936/nelhImp_0000_3-9-13-mediumsize.jpg" width=550 height=144&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Introduction&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;This year, several new studies report on the prevalence of diabetic retinopathy and the incidence and prevalence of blindness or visual impairment due to diabetic retinopathy in different parts of the world. [Section i, references 17-19; section x, references 19-25]. New epidemiological studies focus particularly on the incidence of diabetic retinopathy and progression rates to proliferative diabetic retinopathy, severe visual loss and clinically significant macular oedema [Section iii, references 27-29] and suggest that, since 1985, diabetic patients have lower rates of progression to proliferative diabetic retinopathy and severe visual loss. Risk factors for diabetic retinopathy discussed in the studies that reported this year include ethnicity, diet, age at onset of Type 1 diabetes, comorbidities (sleep apnoea and non-alcoholic fatty liver disease) and control of blood glucose, blood pressure and serum lipids in type 2 diabetes. [Section iv, references 60-65].&lt;BR&gt;&lt;BR&gt;Recent studies on screening for diabetic retinopathy include a review of studies reporting the reliability of screening methods, reports on a 2006 survey of a screening service in the UK and a workload survey of the British Association of Retinal Screeners, as well as a health technology assessment reviewing the diagnostic accuracy and economic evaluation of colour vision testing (CVT) for diabetic retinopathy, the latter concluding that there is insufficient evidence to support the use of CVT alone, or in combination with retinal photography, as a method for screening for retinopathy in patients with diabetes. A systematic review of the economic evidence relating to diabetic retinopathy screening concluded that systematic screening is cost-effective in terms of sight years preserved compared with no screening. This systematic review and two other recent studies also discuss the issue of optimal screening intervals for diabetic retinopathy. [Section v, references 74-84]&lt;BR&gt;&lt;BR&gt;Two recent studies found no significant difference in treatment with subthreshold diode micropulse laser versus conventional laser treatment for diabetic macular oedema. [Section vi(a), references 28-29] although the number of eyes in these studies was relatively small (53 and 62).&amp;nbsp; Other studies of laser treatment looked at various effects of panretinal photocoagulation, and comparisons of single session versus multiple sessions found no clinically meaningful differences/differences in adverse outcomes between the two groups. [Section vi(a), references 30-41]. Tinley reported that, of 107 patients, 14% returned with adverse events within the first 8 weeks of indirect PRP. &lt;BR&gt;&lt;BR&gt;A number of new references for 2009-2010 report on intravitreal steroid injections for diabetic retinopathy, including a randomised clinical trial that compared intravitreal triamcinolone acetonide with focal/grid photocoagulation. [Section viii(a), references 43-48] Although this study concluded that intravitreal triamcinolone acetonide (4 mg) appeared to reduce the risk of progression of diabetic retinopathy, use of this treatment does not seem warranted at this time due to the exploratory nature of the analysis and the adverse effects of intravitreal triamcinolone. [Section viii(a), reference 47]&amp;nbsp; A systematic review of steroid injection in addition to macular laser grid photocoagulation in diabetic macular oedema concluded that a literature search does not provide sufficiently strong evidence to recommend steroid injection before MLG photocoagulation in DMO. [Section viii(a), reference 48]&lt;BR&gt;&lt;BR&gt;Once again this year, there were many studies looking at the effects of treatment with intravitreal VEGF inhibitors. There were several reports of preoperative VEGF inhibitors improving outcomes of vitrectomy, though an additional paper reported complications (ghost cell glaucoma) when bevacizumab was used post vitrectomy. [Section vi(b), references 39-46]. A Cochrane review completed in April 2009 concluded that, at that time, there was not sufficient high quality evidence from large RCTs supporting the use of either single or multiple anti-VEGF intravitreal injections to treat diabetic macular oedema. [Section 8(b), reference 25]&amp;nbsp; A more recent review of the clinical trials of anti-VEGF agents also concluded that, despite promising early reports on the safety of these medications, we eagerly await the results of large, controlled trials to substantiate the safety and efficacy of anti-VEGF drugs for diabetic retinopathy. [Section 8(b), reference 37]&amp;nbsp; The first report of a randomised, multicentre trial by the Diabetic Retinopathy Clinical Research Network was published in June 2010. [Section 8(b), reference 38]&lt;BR&gt;&lt;BR&gt;New evidence for 2009-2010 on the subject of automated detection of retinopathy shows that the sensitivity of detection methods continues to advance incrementally. [Section xi, references 9-14].&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387099</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=387099]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetic Retinopathy - Methodology</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,EYES AND VISION,CHRONIC COMPLICATIONS,DIAGNOSIS,CONDITION MANAGEMENT,CAUSES,EYE DISEASES,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>part of the 2010 Annual Evidence Update on Diabetic Retinopathy</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetic Retinopathy - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;STRONG&gt;Published&lt;/STRONG&gt;: 13 September 2010&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387096" target="_blank"&gt;Link back to home page for 2010 Annual Evidence Update on Diabetic Retinopathy here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Inclusion criteria&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;All primary research, systematic reviews, meta-analyses, guidelines, guideline reviews, method comparison studies were added if they were English language and relevant to the subject scope.&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Subject scope&lt;/STRONG&gt;&lt;BR&gt;The subject scope covers all aspects of diabetic retinopathy – the incidence and prevalence, epidemiology and progression, risk factors, screening, treatment, complications and care.&amp;nbsp; Peter Scanlon has identified the following terms to cover the evidence in the area of diabetic retinopathy:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Epidemiology&lt;/LI&gt;
&lt;LI&gt;ETDRS&lt;/LI&gt;
&lt;LI&gt;Fields and driving&lt;/LI&gt;
&lt;LI&gt;Fluorescein&lt;/LI&gt;
&lt;LI&gt;Genetic factors DR&lt;/LI&gt;
&lt;LI&gt;Glaucoma&lt;/LI&gt;
&lt;LI&gt;Glaucoma DR&lt;/LI&gt;
&lt;LI&gt;Histopathology&lt;/LI&gt;
&lt;LI&gt;Hyperspectral Imaging&lt;/LI&gt;
&lt;LI&gt;Imaging&lt;/LI&gt;
&lt;LI&gt;Intravitreal injections&lt;/LI&gt;
&lt;LI&gt;Intravitreal injections sub tenons&lt;/LI&gt;
&lt;LI&gt;Laser&lt;/LI&gt;
&lt;LI&gt;Legal&lt;/LI&gt;
&lt;LI&gt;New therapies and modern medical treatment&lt;/LI&gt;
&lt;LI&gt;Natural history DR&lt;/LI&gt;
&lt;LI&gt;Ocular biochemistry cellular changes&lt;/LI&gt;
&lt;LI&gt;Optical Coherence Tomography – retinal thickness analyser&lt;/LI&gt;
&lt;LI&gt;Optical Coherence Tomography&lt;/LI&gt;
&lt;LI&gt;Other eye conditions&lt;/LI&gt;
&lt;LI&gt;Other eye diseases&lt;/LI&gt;
&lt;LI&gt;Paediatric &lt;/LI&gt;
&lt;LI&gt;Photography and screening for diabetic retinopathy&lt;/LI&gt;
&lt;LI&gt;Pregnancy DR&lt;/LI&gt;
&lt;LI&gt;Prevalence of diabetes&lt;/LI&gt;
&lt;LI&gt;Prevalence of diabetic retinopathy&lt;/LI&gt;
&lt;LI&gt;Prevention BP smoking and control&lt;/LI&gt;
&lt;LI&gt;Progression of diabetic retinopathy&lt;/LI&gt;
&lt;LI&gt;Pseudoxanthoma elasticum&lt;/LI&gt;
&lt;LI&gt;Psychology DR&lt;/LI&gt;
&lt;LI&gt;Puberty DR&lt;/LI&gt;
&lt;LI&gt;Public Health Problem&lt;/LI&gt;
&lt;LI&gt;Quality Assurance&lt;/LI&gt;
&lt;LI&gt;Quality of life&lt;/LI&gt;
&lt;LI&gt;Radiation&lt;/LI&gt;
&lt;LI&gt;Renal&lt;/LI&gt;
&lt;LI&gt;Research&lt;/LI&gt;
&lt;LI&gt;Retinal emboli&lt;/LI&gt;
&lt;LI&gt;Scanning laser ophthalmoscope&lt;/LI&gt;
&lt;LI&gt;Screening for diabetic retinopathy&lt;/LI&gt;
&lt;LI&gt;Screening for glaucoma&lt;/LI&gt;
&lt;LI&gt;Screening&lt;/LI&gt;
&lt;LI&gt;Sickle cell disease&lt;/LI&gt;
&lt;LI&gt;Socio-economic factors&lt;/LI&gt;
&lt;LI&gt;St Vincent declaration&lt;/LI&gt;
&lt;LI&gt;Telemedicine&lt;/LI&gt;
&lt;LI&gt;Treatment not laser&lt;/LI&gt;
&lt;LI&gt;Vascular and angiogenic DR&lt;/LI&gt;
&lt;LI&gt;Vision loss mortality blindness&lt;/LI&gt;
&lt;LI&gt;Visual acuity&lt;/LI&gt;
&lt;LI&gt;Vitrectomy&lt;/LI&gt;
&lt;LI&gt;Wisconsin&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Search period&lt;/STRONG&gt; &lt;BR&gt;The annual evidence update is updated annually, searches are being carried out daily&amp;nbsp;by Dr Peter Scanlon and his research assistant.&amp;nbsp;This year new references from July 2009 to August 2010&amp;nbsp; were added.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Search strategy&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;A search was carried out in Proquest, NHS Evidence Health Information Resources, Zetoc, Cochrane and PubMed for publications published within the search period using search terms relevant to the subject scope.&amp;nbsp; This search was also supplemented by a search of a number of particular journals chosen by relevance by Dr Peter Scanlon (journals searched are listed below).&amp;nbsp; For further details on the search strategies used please contact NHS Evidence – diabetes.&amp;nbsp;&amp;nbsp; &lt;A href="http://www.library.nhs.uk/DIABETES/ContactUs.aspx" target="_blank"&gt;Link to contact us form here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Direct Searching of Journals&lt;BR&gt;&lt;/STRONG&gt;The following journals were searched regularly by Peter Scanlon and Jenny Sykes looking for content on the topics of&amp;nbsp; "retinopathy" , "digital" &amp;amp; "imaging" &amp;amp; "eye", "digital" &amp;amp; "imaging" &amp;amp; "ophthalm*", "digital" &amp;amp; "imaging" &amp;amp; "diabet*", "laser" &amp;amp; "eye", "laser" &amp;amp; "ophthalm*", " laser" &amp;amp; "diabet*", " visual" &amp;amp; "acuity", " visual" &amp;amp; "impairment", " blindness" &amp;amp; "diabet*", " diabetic" &amp;amp; "screening", " uptake" &amp;amp; "screening" &amp;amp; "diabet*", " attendance" &amp;amp; "screening" &amp;amp; "diabet*", and " vitrectomy" &amp;amp; "diabet*" in the Title.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Acta Ophthalmologica&lt;/LI&gt;
&lt;LI&gt;American Journal of Ophthalmology&lt;/LI&gt;
&lt;LI&gt;Archives of Ophthalmology&lt;/LI&gt;
&lt;LI&gt;British Journal of Ophthalmology&lt;/LI&gt;
&lt;LI&gt;British Medical Journal&lt;/LI&gt;
&lt;LI&gt;Clinical and Experimental Ophthalmology&lt;/LI&gt;
&lt;LI&gt;Current Opinion in Ophthalmology&lt;/LI&gt;
&lt;LI&gt;Diabetes&lt;/LI&gt;
&lt;LI&gt;Diabetes Care&lt;/LI&gt;
&lt;LI&gt;Diabetes Metabolism Research and Reviews&lt;/LI&gt;
&lt;LI&gt;Diabetes Research and Clinical Practice&lt;/LI&gt;
&lt;LI&gt;Diabetes Technology and Therapeutics&lt;/LI&gt;
&lt;LI&gt;Diabetic Medicine&lt;/LI&gt;
&lt;LI&gt;Diabetoligia&lt;/LI&gt;
&lt;LI&gt;European Journal of Ophthalmology&lt;/LI&gt;
&lt;LI&gt;Eye&lt;/LI&gt;
&lt;LI&gt;Graefe’s Archive for Clinical and Experimental Ophthalmology&lt;/LI&gt;
&lt;LI&gt;Investigative Ophthalmology and Visual Science&lt;/LI&gt;
&lt;LI&gt;Journal of Diabetes and its Complications&lt;/LI&gt;
&lt;LI&gt;Journal of the Eye&lt;/LI&gt;
&lt;LI&gt;Lancet&lt;/LI&gt;
&lt;LI&gt;Ophthalmic Surgery Lasers and Imaging&lt;/LI&gt;
&lt;LI&gt;Ophthalmologica&lt;/LI&gt;
&lt;LI&gt;Ophthalmology&lt;/LI&gt;
&lt;LI&gt;Pediatric&lt;/LI&gt;
&lt;LI&gt;Retina&lt;/LI&gt;
&lt;LI&gt;Survey of Ophthalmology&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Sifting and selection&lt;BR&gt;&lt;/STRONG&gt;The results set was followed by a sift for subject relevance carried out by the clinical expert Dr Peter Scanlon and his research assistant Jenny Sykes.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387428</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=387428]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetic Retinopathy - Modern medical therapies</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,EYES AND VISION,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,EYE DISEASES,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>part of the 2010 Annual Evidence Update on Diabetic Retinopathy</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetic Retinopathy - Modern medical therapies&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt; 13 September 2010&lt;BR&gt;Originally written by P Scanlon in June 2006, updated annually, &lt;A href="#ref1"&gt;link to further author and publication details here.&lt;/A&gt;&amp;nbsp; &lt;BR&gt;Changes and additions since August 2009 are highlighted in red.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387096" target="_blank"&gt;Link back to home page for 2010 Annual Evidence Update on Diabetic Retinopathy here.&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387421" target="_blank"&gt;Link to table of abbreviations here&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID387428/nelhImp_0000_photo14-diabeticretinopathy.jpg"&gt;&lt;BR&gt;&lt;BR&gt;The following articles describe the use of modern medical therapies for treatment of diabetic eye disease:&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;
&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;STRONG&gt;Year&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;STRONG&gt;Author&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;STRONG&gt;Novel therapies for diabetic retinopathy and diabetic macular oedema&lt;/STRONG&gt;&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2003&lt;/TD&gt;
&lt;TD&gt;Ciulla [1]&lt;/TD&gt;
&lt;TD&gt;Several biochemical mechanisms, including protein kinase C-beta activation, increased vascular endothelial growth factor production, oxidative stress, and accumulation of intracellular sorbitol and advanced glycosylation end products, may contribute to the vascular disruptions that characterize DR/DME. The inhibition of these pathways holds the promise of intervention for DR at earlier non-sight-threatening stages.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2005&lt;/TD&gt;
&lt;TD&gt;Joy [2]&lt;/TD&gt;
&lt;TD&gt;Ruboxistaurin mesylate, by inhibiting excessive activation of certain PKC isoforms, has the potential to reduce the burden of microvascular complications for patients with diabetes.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2005&lt;/TD&gt;
&lt;TD&gt;PKC-DRS Study Group [3]&lt;/TD&gt;
&lt;TD&gt;In this multicenter, double-masked, randomized, placebo-controlled study, 252 subjects with moderately severe to very severe nonproliferative diabetic retinopathy (NPDR) received placebo or orally administered protein kinase C (PKC) beta isoform-selective inhibitor ruboxistaurin (RBX 8, 16, or 32 mg/day) for 36-46 months. In multivariable Cox proportional hazard analysis, 32 mg/day RBX significantly reduced the risk of moderate visual loss (MVL) (doubling of the visual angle) compared with placebo (hazard ratio 0.37 [95% CI 0.17-0.80], P = 0.012). In this clinical trial, RBX was well tolerated and reduced the risk of visual loss but did not prevent DR progression.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2006&lt;/TD&gt;
&lt;TD&gt;PKC-DRS Study Group [4]&lt;/TD&gt;
&lt;TD&gt;A further report from the same study group of six hundred eighty-five patients randomized at 70 clinical sites. Effect of oral ruboxistaurin (32 mg/day) on reduction of sustained moderate visual loss (&amp;gt; or =15-letter decrease in ETDRS VA score maintained &amp;gt; or = 6 months) in patients with moderately severe to very severe nonproliferative diabetic retinopathy. RESULTS: Sustained moderate visual loss occurred in 9.1% of placebo-treated patients versus 5.5% of ruboxistaurin-treated patients (40% risk reduction, P = 0.034). Mean VA was better in the ruboxistaurin-treated patients after 12 months.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2007&lt;/TD&gt;
&lt;TD&gt;Keech[5]&lt;/TD&gt;
&lt;TD&gt;The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study was a multinational randomised trial of 9795 patients aged 50-75 years with type 2 diabetes mellitus. Eligible patients were randomly assigned to receive fenofibrate 200 mg/day (n=4895) or matching placebo (n=4900).. Laser treatment was needed more frequently in participants with poorer glycaemic or blood pressure control than in those with good control of these factors, and in those with a greater burden of clinical microvascular disease, but the need for such treatment was not affected by plasma lipid concentrations. The requirement for first laser treatment for all retinopathy was significantly lower in the fenofibrate group than in the placebo group (164 [3.4%] patients on fenofibrate vs 238 [4.9%] on placebo; hazard ratio [HR] 0.69, 95% CI 0.56-0.84; p=0.0002; absolute risk reduction 1.5% [0.7-2.3]). In the ophthalmology substudy, the primary endpoint of 2-step progression of retinopathy grade did not differ significantly between the two groups overall (46 [9.6%] patients on fenofibrate vs 57 [12.3%] on placebo; p=0.19) or in the subset of patients without pre-existing retinopathy (43 [11.4%] vs 43 [11.7%]; p=0.87). By contrast, in patients with pre-existing retinopathy, significantly fewer patients on fenofibrate had a 2-step progression than did those on placebo (three [3.1%] patients vs 14 [14.6%]; p=0.004). An exploratory composite endpoint of 2-step progression of retinopathy grade, macular oedema, or laser treatments was significantly lower in the fenofibrate group than in the placebo group (HR 0.66, 95% CI 0.47-0.94; p=0.022). The results would support a study specifically designed for the purpose.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2007&lt;/TD&gt;
&lt;TD&gt;Hattori [6]&lt;/TD&gt;
&lt;TD&gt;40 Japanese patients with type 2 diabetes were enrolled in a randomised, single-blind controlled trial in which the effects of sulindac (200 mg/day, 100 mg twice a day; n = 16 patients) on the progression of DR were compared to controls (24 patients) for 3 years. All patients were comparable in their age, gender, duration of disease, body mass index, dipstick proteinuria, insulin therapy, glycaemic control, and clinical stages of DR. &lt;BR&gt;RESULTS: Patients in the sulindac group did not develop DR during the course of treatment nor was there progression of pathology in those who began the study with mild non-proliferative DR (NPDR). On the other hand, six patients progressed to mild NPDR in the control group--three at year 1 and three at year 3--and an additional patient progressed to severe NPDR from mild NPDR by year 1 and to proliferative DR by year 2. The findings at year 3 in the sulindac group were significantly (p &amp;lt; 0.05) different from the control group. None of the patients experienced any adverse effects of treatment. The results would support a study specifically designed for the purpose.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Chaturvedi [7]&lt;/TD&gt;
&lt;TD&gt;Results were reported from the DIabetic REtinopathy Candesartan Trials (DIRECT) Programme. Two randomised, double-blind, parallel-design, placebo-controlled trials were done in 309 centres worldwide. Participants with normotensive, normoalbuminuric type 1 diabetes without retinopathy were recruited to the DIRECT-Prevent 1 trial and those with existing retinopathy were recruited to DIRECT-Protect 1, and were assigned to candesartan 16 mg once a day or matching placebo. After 1 month, the dose was doubled to 32 mg.&lt;BR&gt;In the DIRECT-Prevent 1 trial, although candesartan reduces the incidence of retinopathy, no beneficial effect on retinopathy progression was seen.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Sjolie [8]&lt;/TD&gt;
&lt;TD&gt;Reported results of the effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2). 1905 participants (aged 37-75 years) were randomised to candesartan (n=951) or placebo (n=954). 161 (17%) patients in the candesartan group and 182 (19%) in the placebo group had progression of retinopathy by three steps or more on the Early Treatment Diabetic Retinopathy Study scale. The risk of progression of retinopathy was non-significantly reduced by 13% in patients on candesartan compared with those on placebo (hazard ratio [HR] 0.87, 95% CI 0.70-1.08, p=0.20). Regression on active treatment was increased by 34% (1.34, 1.08-1.68, p=0.009).&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Mohamed [9]&lt;/TD&gt;
&lt;TD&gt;Reviewed emerging drugs for diabetic retinopathy. Emerging therapies including inhibition of aldose reductase/polyol pathway, non-enzymatic glycation/advanced glycated end products inhibitors, protein kinase C inhibitors, and reduction of oxidative stress/superoxide induced damage. Newer drugs modulating growth factor and cytokine production (including VEGF, TNF and cytokines such as NF-kB) and newer targeted therapeutics utilising antisense oligonucleotides, and small interfering RNAs are also currently in clinical trials. The article concluded that emerging treatments, possibly used in combination with standard therapy, offer the hope of effective and safe treatment that may allow us to improve visual outcomes and prevent the damaging consequences of DR.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;2009&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Beulens [10]&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Reported results from 1602 patients with type 2 diabetes recruited into the ADVANCE study (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) from 39 centres in 14 countries in Asia, Australia, Europe and North America. The baseline retinopathy level (ETDRS =20) of these patients with type 2 diabetes was 40.1%. Blood pressure lowering or intensive glucose control did not significantly reduce the incidence and progression of retinopathy, although consistent trends towards a benefit were observed, with significant reductions in some lesions observed with both interventions e.g. blood pressure-lowering treatment reduced the occurrence of macular oedema (OR 0.50; 95% CI 0.29-0.88; p = 0.016) and arteriovenous nicking compared with placebo (OR 0.60; 95% CI 0.38-0.94; p = 0.025).&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;2010&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Chew [11]&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;SPAN style="COLOR: #a81400"&gt;Reported from the ACCORD Eye study that, in 10,251 participants with type 2 diabetes, intensive glycemic control and intensive combination treatment of dyslipidemia, but not intensive blood-pressure control, reduced the rate of progression of diabetic retinopathy. At 4 years, the rates of progression of diabetic retinopathy were 7.3% with intensive glycemia treatment, versus 10.4% with standard therapy (adjusted odds ratio, 0.67; 95% confidence interval [CI], 0.51 to 0.87; P=0.003); 6.5% with fenofibrate for intensive dyslipidemia therapy, versus 10.2% with placebo (adjusted odds ratio, 0.60; 95% CI, 0.42 to 0.87; P=0.006); and 10.4% with intensive blood-pressure therapy, versus 8.8% with standard therapy (adjusted odds ratio, 1.23; 95% CI, 0.84 to 1.79; P=0.29).&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References (including systematic reviews &amp;amp; primary research)&lt;/STRONG&gt;&lt;BR&gt;Links to PubMed abstracts are provided. Free full text may be available from the PubMed link. Where free full text access is not available, NHS staff in England can access full text of a number of journals via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/" target="_blank"&gt;NHS Evidence&lt;/A&gt; or can request the full text via their &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;1. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003; 26(9): 2653-64. &lt;A href="http://care.diabetesjournals.org/cgi/content/full/26/9/2653" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;2. Joy SV, Scates AC, Bearelly S, Dar M, Taulien CA, Goebel JA, et al. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications. Annals of Pharmacotherapy 2005; 39(10): 1693-9. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=16160002" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;3. PKC-DRS. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005; 54(7): 2188-97. &lt;A href="http://diabetes.diabetesjournals.org/cgi/content/full/54/7/2188" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;4. Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006; 113(12):2221-30. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16989901&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;5. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370(9600):1687-97. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=pubmed&amp;amp;cmd=Search&amp;amp;term=1687%5Bpage%5D%20AND%20Keech%5Bauthor%5D" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;6. Hattori Y, Hashizume K, Nakajima K, Nishimura Y, Naka M, Miyanaga K. The effect of long-term treatment with sulindac on the progression of diabetic retinopathy. Current Medical Research and Opinion 2007; 23(8):1913-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17621415?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;7. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372(9647):1394-402. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18823656" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;8. Sjolie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008; 372(9647):1385-93. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18823658" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;9. Mohamed Q, Wong TY. Emerging drugs for diabetic retinopathy. Expert Opinion on Emerging Drugs 2008; 13(4):675-94. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19046134" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;10. Beulens JW, Patel A, Vingerling JR, Cruickshank JK, Hughes AD, Stanton A, et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia 2009; 52(10):2027-36. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19633827" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;11. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. New England Journal of Medicine 2010; 363(3):233-44. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20587587" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;BR&gt;&lt;STRONG&gt;Further Evidence&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/SearchResults.aspx?catID=5134&amp;amp;tabID=289&amp;amp;" target="_blank"&gt;Links to systematic reviews on diabetic retinopathy in&amp;nbsp;NHS Evidence - diabetes&lt;/A&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;Guidelines&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5658&amp;amp;searchText=&amp;amp;sort=PUBLISHER&amp;amp;resultsPerPage=10&amp;amp;summaries=true" target="_blank"&gt;Links to supporting Guidelines&lt;/A&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;Patient Information&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?tabID=292&amp;amp;catID=5658&amp;amp;sort=PUBLISHER&amp;amp;resultsPerPage=10&amp;amp;summaries=true&amp;amp;" target="_blank"&gt;Links to supporting Patient Information&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Reference Material&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?catID=5134&amp;amp;tabID=290&amp;amp;searchText=&amp;amp;sort=PUBLICATION_DATE&amp;amp;resultsPerPage=10&amp;amp;summaries=true" target="_blank"&gt;Links to supporting reference material&lt;/A&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;Publication details&lt;/STRONG&gt;&lt;BR&gt;Originally written by Peter Scanlon (Consultant Ophthalmologist&amp;nbsp; and National Clinical Director of the English National Screening Programme for Diabetic Retinopathy) in June 2006, since reviewed and updated in June 2007 by P Scanlon, in June 2008 by P Scanlon and Irene Stratton, in June 2009 by P Scanlon, and in August 2010 by P Scanlon.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387199</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=387199]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetic Retinopathy - Prevalence of diabetic retinopathy and sight threatening diabetic retinopathy</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,EYES AND VISION,CHRONIC COMPLICATIONS,EYE DISEASES,STATISTICS,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS,INCIDENCE AND PREVALENCE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>part of the 2010 Annual Evidence Update on Diabetic Retinopathy</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetic Retinopathy - Prevalence of diabetic retinopathy and sight threatening diabetic retinopathy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt; 13 September 2010&lt;BR&gt;Originally written by P Scanlon in June 2006, updated annually, &lt;A href="#ref1"&gt;link to further author and publication details here.&lt;/A&gt;&amp;nbsp; &lt;BR&gt;Changes and additions since August 2009 are highlighted in red.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387096" target="_blank"&gt;Link back to home page for 2010 Annual Evidence Update on Diabetic Retinopathy here.&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387421" target="_blank"&gt;Link to table of abbreviations here.&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID387199/nelhImp_0000_photo4-diabeticretinopathy.jpg"&gt;&lt;/P&gt;
&lt;P align=left&gt;Three historical studies have given strong evidence that sight-threatening diabetic retinopathy is prevalent and numerous other studies have supported this viewpoint. These three studies are by Klein [1-2], Kohner [3] and Younis [4].&lt;BR&gt;&lt;BR&gt;In 1992, Klein [1] reported results from the Wisconsin Epidemiological Study of Diabetic Retinopathy (WESDR study), which was a population-based study in southern Wisconsin of 996 insulin-taking younger-onset diabetic persons (given diagnoses of diabetes under 30 yrs) and 1,370 patients given diagnoses of diabetes at age 30 years or older who were examined using standard protocols to determine the prevalence and severity of diabetic retinopathy and associated risk variables. Proliferative Diabetic Retinopathy (PDR) was found to be a prevalent complication - 23% in the younger-onset group, 10% in the older-onset group that takes insulin, and 3% in the group that does not take insulin. In 1995 Klein [2] reported the incidence of macular oedema over a 10-year period. This was 20.1% in the younger-onset group, 25.4% in the older-onset group taking insulin, and 13.9% in the older-onset group not taking insulin.&lt;BR&gt;&lt;BR&gt;In 1998, Kohner [3] reported baseline retinopathy levels in 2964 patients with newly diagnosed type 2 diabetes enrolled in the United Kingdom Prospective Diabetes Study (UKPDS). Retinopathy, defined as microaneurysms or worse lesions in at least 1 eye, was present in 39% of men and 35% of women. Marked retinopathy with cotton wool spots or intraretinal microvascular abnormalities was present in 8% of men and 4% of women.&lt;BR&gt;&lt;BR&gt;In 2002, Younis [4] reported baseline results from population screening in Liverpool of 831 people with Type 1 diabetes and 7231 people with Type 2 diabetes. The results showed a baseline for Type 1 of any DR 45.7%, PDR 3.7% and STED 16.4%. Baseline for Type 2 group of any DR 25.3%, PDR 0.5% and STED 6.0%.&lt;BR&gt;&lt;BR&gt;Kernell [5] reported the youngest child in the literature (11.8 years) with pre-proliferative DR. Donaghue [6] reported the youngest child reported in the literature with background diabetic retinopathy - 7.9 yrs (duration 5.6 years, HbA1c 8.9%). Bailey [7] reported high levels of visual symptomatology in patients with sight-threatening diabetic retinopathy.&lt;BR&gt;&lt;BR&gt;Other studies that have reported on the prevalence of diabetic eye disease in different parts of the world have been by Joner [8], Malone [9], West [10], Kullberg [11], Tapp [12], Williams [13], Cugati [14], Wong [15], Knudsen [16], Al-Maskari [17], Ross [18], Shrestha [19], Taylor [20], Rani [21], Blum [22] Massin [23], Al-Adsani [24] and Romero-Aroca [25], Wong [26], Xie [27], Raman [28], Wang [29], Javadi [30] and Salti [31].&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Two studies [32-33] have demonstrated that, if one screens for Type 2 diabetes, the prevalence of diabetic retinopathy in screen positive patients (7.6% and 6.8%) is much lower than the prevalence in the known population of people with diabetes.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Grauslund [34] reported the 25 year incidence of proliferative retinopathy among population-based cohort of 727 type 1 Danish diabetic patients was 42.9%.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Beulens [35] reported that baseline retinopathy levels (ETDRS =20) of 1602 patients with type 2 diabetes in the ADVANCE study was 40.1%.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Dedov [36] reported the prevalence of diabetic retinopathy (DR) and cataract (DC) in 7,186 adult patients with type 1 and type 2 diabetes in Russia. The prevalence of DR and DC was 45.9% and 30.6%, respectively. The prevalence of background, preproliferative and proliferative DR among diabetic patients was 28.1%, 8.1%, and 6.7%, respectively. &lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Studies reporting the prevalence of diabetic retinopathy (DR) and of sight-threatening diabetic retinopathy (STDR) in different populations:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;
&lt;TABLE style="WIDTH: 100%; mso-cellspacing: 1.5pt" class=MsoNormalTable border=1 cellPadding=0 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR style="mso-yfti-irow: 0; mso-yfti-firstrow: yes"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;B&gt;Year&lt;/B&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Author&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Number (n) patients (p) eyes (e)&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 1"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;1992&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Klein[1]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Wisconsin Epidemiological Study of Diabetic Retinopathy (WESDR study).&lt;BR&gt;Prevalence: &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:stockticker w:st="on"&gt;PDR&lt;/st1:stockticker&gt; is a prevalent complication - 23% in the younger-onset group, 10% in the older-onset group that takes insulin, and 3% in the group that does not take insulin.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 2"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;1992&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Joner [8]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;n= 600 Norwegian cohort of Type 1 DM.&lt;BR&gt;Prevalence: Any DR in 32.8% and in 7.3% patients &amp;lt; 13 years.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 3"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;1995&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Klein [2]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;The incidence of macular oedema over a 10-year period.&lt;BR&gt;Incidence: 20.1% in the younger-onset group, 25.4% in the older-onset group taking insulin, and 13.9% in the older-onset group not taking insulin.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 4"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;1997&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Kernell [5]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;n = 780 children and adolescents with IDDM in &lt;st1:country-region w:st="on"&gt;&lt;st1:place w:st="on"&gt;Sweden&lt;/st1:place&gt;&lt;/st1:country-region&gt;.&lt;BR&gt;Prevalence: Any DR in 14.5%. This study reports the youngest child in the literature (11.8 years) with preproliferative DR.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 5"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;1998&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Kohner[3]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: black; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Baseline in the United Kingdom Prospective Diabetes Study (UKPDS), a 23-centre study of 2964 newly diagnosed white NIDDM patients.&lt;BR&gt;Prevalence: Retinopathy, defined as microaneurysms or worse lesions in at least 1 eye, was present in 39% of men and 35% of women. Marked retinopathy with cotton wool spots or intraretinal microvascular abnormalities was present in 8% of men and 4% of women.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 6"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;1999&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Donaghue[6]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;n = 937 children and adolescents aged 6-20 years.&lt;BR&gt;Prevalence: Early DR in 27% (9% &amp;lt; 11 yr). This study has the youngest age reported in the literature of background diabetic retinopathy - 7.9 yrs (duration 5.6 years, HbA1c 8.9%).&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 7"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class="MsoNormal2001&lt;o:p"&gt;&lt;SPAN style="COLOR: #000000"&gt;2001&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Malone [9]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Type 1 &amp;lt; 5 years duration in the Diabetes Control and Complications Trial (DCCT).&lt;BR&gt;Prevalence: 67.1% had retinopathy &amp;lt; 5 years duration.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 8"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2001&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;West [10]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Hispanic &amp;gt; 40 yrs in Arizona.&lt;BR&gt;Prevalence: Any DR 48%, moderate to severe NPDR and &lt;st1:stockticker w:st="on"&gt;PDR&lt;/st1:stockticker&gt; 32%.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 9"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;2002&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Kullberg [11]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;VISS study (Vascular complications in South-east Sweden).&lt;BR&gt;n = 390 of 440 Type 1 onset &amp;lt; 36 yrs.&lt;BR&gt;Any DR 29% no DR 71%.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 10"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;2002&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Younis [4]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;n = 831 Type 1, n = 7231 Type 2.&lt;BR&gt;Baseline Type 1 of any DR 45.7%, &lt;st1:stockticker w:st="on"&gt;PDR&lt;/st1:stockticker&gt; 3.7% and STED 16.4%. Baseline Type 2 group of any DR 25.3%, &lt;st1:stockticker w:st="on"&gt;PDR&lt;/st1:stockticker&gt; 0.5% and STED 6.0%.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 11"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2003&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Spijkerman [32]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;n = 195 screening-detected type 2 in the Hoorn screening study and 60 newly diagnosed in general practice in Holland.&lt;BR&gt;Prevalence: Any DR was 7.6% (95% CI 4.6-12.4) in screening-detected type 2 diabetic patients and 1.9% (0.3-9.8) in patients newly diagnosed.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 12"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2003&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Tapp [12]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Australian Diabetes, Obesity and Lifestyle study (AusDiab) of 11,247 adults &amp;gt; 25 years in 42 randomly selected areas of Australia.&lt;BR&gt;Prevalence: Any DR was 21.9% in those with known type 2 diabetes (KDM) and 6.2% in those newly diagnosed (NDM). &lt;st1:stockticker w:st="on"&gt;PDR&lt;/st1:stockticker&gt; 2.1% in those with KDM.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 13"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2004&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Williams [13]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Epidemiology of diabetic retinopathy and macular oedema: a systematic review.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 14"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2006&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Cugati [14]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;An increased prevalence of diabetes, but decreased prevalence of severe levels of DR, was documented in two survey samples from the same region in the Blue Mountains Eye Study in Australia over 6 years. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 15"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;2006&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Wong [15] &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;In this population of 778 individuals from ages 45 to 85 years with diabetes, the prevalence of any retinopathy was 33.2% and macular edema 9.0%.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 16"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;2006&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;Knudsen [16] &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;The point prevalence of proliferative retinopathy was found to be 0.8% and 0.3% for type 1 and type 2 diabetes. Equivalent prevalence rates of clinically significant macular oedema were 7.9% and 12.8%, respectively. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 17"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2007&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Al-Maskari [17]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;A sample of 513 diabetic patients in United Arab Emirates, were examined for evidence of diabetic retinopathy by ophthalmologist and their fundi were examined using slit lamp examination and fundus photography through dilated pupils. Retinopathy was present in 19% (95% CI: 15.1-23.5%) of the study population. Most patients (74%) were not aware of their condition.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 18"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2007&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Ross [18]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Prevalence rates of DR in type 2 diabetic native and non native Canadian communities in Southern Alberta were identical, with a prevalence rate of 40%. Native subjects with retinopathy tended to have more advanced changes of retinopathy compared to the non native subjects.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 19"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2007&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Shrestha [19]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;371 diabetic subjects in Nepal, mean of 57.4 years (SD 12.0) prevalence of Diabetic Retinopathy was 44.7% (166), non-proliferative Diabetic Retinopathy 85.5% (142),14.5% (24) were proliferative Diabetic Retinopathy. Clinically significant macular edema was found in 19.2% (32).&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 20"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2007&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Taylor [20]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;In 203 subjects in primary care n Nashville, USA, rates of DR higher in non-whites (52% vs 38%) and rates of STDR also higher (15% vs 6%)&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 21"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2007&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Rani [21]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;7716 subjects in southern India. 18%DR in rural areas, 17% in urban areas. Referrable higher in rural areas (6.8% vs 4.6%)&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 22"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2007&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Blum [22]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Of 5596 patients with diabetes with a German public health insurance company with reports from ophthalmologists, mild/moderate DR was reported in 8.3%, Severe NPDR in 1.7%, &lt;st1:stockticker w:st="on"&gt;PDR&lt;/st1:stockticker&gt; in 0.5%.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 23"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2007&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Massin [23]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;504 children aged 10-18 (mean diabetes duration 5 years) with T1DM at summer camp in France assessed with non mydriatic photography. &lt;BR&gt;Mild NPDR in 23 children (4.6%). Longer duration associated with DR.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 24"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2007&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Al-Adsani [24]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Kuwaiti subjects with type 2 diabetes (n=165) between October 2000 and March 2005 were screened. Any diabetic retinopathy was found in 40% while 20.6% had sight threatening retinopathy. Mild NPDR was present in 21.2%, moderate to severe non-proliferative diabetic retinopathy (NPDR) in 7.9%, and proliferative diabetic retinopathy (&lt;st1:stockticker w:st="on"&gt;PDR&lt;/st1:stockticker&gt;) in 3.0%. Maculopathy was present in 10.3% and 7.9% of the patients were photocoagulated.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 25"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2008&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Wong [26]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Results from the Singapore Malay Eye Study. Of the 3261 persons who participated in this study, 757 (23.1%) had diabetes and gradable retinal photographs. In persons with diabetes, the overall prevalence of any retinopathy was 35.0% (95% confidence interval [CI], 28.2-43.4), the overall prevalence of macular edema was 5.7% (95% CI, 3.2-9.9), and the overall prevalence of vision-threatening retinopathy was 9.0% (95% CI, 5.8-13.8).&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 26"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2008&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Xie [27]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;The Beijing Eye Study 2006 is a population-based cross-sectional study that included 3,251 subjects (aged 45+ years). Gradable fundus photographs were available for 362 (95.0%) subjects. Diabetic retinopathy was detected in 101 subjects (27.9%). Most of the diabetic retinopathy was of the mild type (74/101; 73%). Severe non-proliferative or proliferative diabetic retinopathy was present in 16 (16%) subjects, and clinically significant macular edema in four (4%) subjects.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 27"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2009&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Raman [28]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;A population based study in Chennai, India. The prevalence of diabetic retinopathy was 18% in an retinopathy was 18% in an urban population with diabetes mellitus in India.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 28"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2009&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Wang [29]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Results from a rural population in northern China. Of the 6830 eligible individuals participating in the study, 387 participants (6.9%) were diagnosed with diabetes mellitus. For these, gradable photographs were available for 368 subjects (95.1%). The overall prevalence of DR was 43.1% (95% confidence interval, 38.1-48.4) and was higher in persons with KDM (65.2%) than NDM (33.5%). The prevalence of proliferative DR, macular edema, and vision-threatening retinopathy was 1.6%, 5.2%, and 6.3%, respectively, with 12.1% with known diabetes mellitus before the study commenced having untreated vision-threatening DR.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 29"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;2009&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #000000"&gt;Bek [33]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN&gt;&lt;SPAN style="COLOR: #000000"&gt;Reported on the prevalence of diabetic retinopathy in patients with screen-detected type 2 diabetes in Denmark. 763 persons with type 2 diabetes were identified. 670 of these 670 of these had fundus photography. Forty-five (6.8%) of the examined patients had any retinopathy, of which the majority was minimal. No patients had severe non-proliferative or proliferative diabetic retinopathy demonstrating that in this population, screen-detected diabetes have a low prevalence of diabetic retinopathy.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 30"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: red; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #a81400"&gt;2009&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: red; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="COLOR: #a81400"&gt;Javadi [30]&lt;/SPAN&gt;&lt;SPAN style="COLOR: red; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: red; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="COLOR: #a81400"&gt;Reported in a population of 634 patients with diabetes in Tehran, prevalence of any retinopathy was 37.0% (95% CI: 33.2-40.8), including 27.3% (95% CI: 23.7-30.8) (n = 175) with non-proliferative and 9.6% (95% CI: 7.3-11.9) (n = 65) with proliferative diabetic retinopathy. Clinically significant macular edema and vision-threatening retinopathy were detected in 5.8% (95% CI: 4.0-7.7) (n = 38) and 14.0% (95% CI: 11.3-16.7) (n = 95) of patients, respectively.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 31"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: red; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #a81400"&gt;2009&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: red; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="COLOR: #a81400"&gt;Salti [31]&lt;/SPAN&gt;&lt;SPAN style="COLOR: red; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: red; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="COLOR: #a81400"&gt;Reported results from 500 patients with type 2 diabetes seen in a Medical Centre in Beirut. DR was present in 175 patients (35%), 130 (26%), and 45 (9%) having non-proliferative and proliferative DR, respectively. Clinically significant macular edema was present in 42 patients (8%).&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 32"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: red; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #a81400"&gt;2009&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: #a81400"&gt;Grauslund [34]&lt;/SPAN&gt;&lt;SPAN style="COLOR: red; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P style="mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="COLOR: #a81400"&gt;Reported on the prevalence and 25 year incidence of proliferative retinopathy among population-based cohort of 727 type 1 Danish diabetic patients. The median age and duration of diabetes at follow-up were 58.8 and 43 years, respectively. At follow-up, the prevalence of diabetic retinopathy was 97.0%. Non-proliferative retinopathy was found in 45.8%, and 51.2% had proliferative retinopathy. The 25 year incidence of proliferative retinopathy was 42.9%&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'AdvTT3713a231','serif'; COLOR: red; mso-bidi-font-family: AdvTT3713a231; mso-fareast-language: EN-GB"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="mso-yfti-irow: 33; mso-yfti-lastrow: yes"&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: red; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;SPAN style="COLOR: #a81400"&gt;2009&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN style="COLOR: red; mso-bidi-font-family: Arial"&gt;&lt;SPAN style="COLOR: #a81400"&gt;Beulens [35]&lt;/SPAN&gt;&lt;SPAN style="COLOR: red; mso-bidi-font-family: Arial; mso-ansi-language: EN-US" lang=EN-US&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;
&lt;TD style="PADDING-BOTTOM: 0.75pt; PADDING-LEFT: 0.75pt; PADDING-RIGHT: 0.75pt; PADDING-TOP: 0.75pt"&gt;
&lt;P style="mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="COLOR: #a81400"&gt;Reported results from 1602 patients with type 2 diabetes recruited into the ADVANCE study (&lt;SPAN style="COLOR: #a81400"&gt;Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) from 39 centres in 14 countries in Asia, Australia, Europe and North America. The baseline retinopathy level (ETDRS&lt;SPAN style="COLOR: #a81400"&gt;&lt;/SPAN&gt;=20) of these patients with type 2 diabetes was 40.1%.&lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;References (including systematic reviews &amp;amp; primary research)&lt;/STRONG&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #000000"&gt;Links to PubMed abstracts are provided. Free full text may be available from the PubMed link. Where free full text access is not available, NHS staff in England can access full text of a number of journals via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/" target="_blank"&gt;NHS Evidence &lt;/A&gt;or can request the full text via their &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #000000"&gt;1. Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care 1992; 15(12): 1875-91. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7831044?dopt=Citation" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #000000"&gt;2. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995; 102(1): 7-16. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9514482?dopt=Citation" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;3. Kohner EM, Aldington SJ, Stratton IM, Manley SE, Holman RR, Matthews DR, et al. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Archives of Ophthalmology 1998; 116(3): 297-303. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9514482?dopt=Citation" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;4. Younis N, Broadbent DM, Harding SP, Vora JR. Prevalence of diabetic eye disease in patients entering a systematic primary care-based eye screening programme. Diabetic Medicine 2002; 19(12): 1014-21. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12647843?dopt=Citation" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;5. Kernell A, Dedorsson I, Johansson B, Wickstrom CP, Ludvigsson J, Tuvemo T, et al. Prevalence of diabetic retinopathy in children and adolescents with IDDM. A population-based multicentre study. Diabetologia 1997; 40(3): 307-10. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9084969?dopt=Citation" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;6. Donaghue KC, Fairchild JM, Chan A, Hing SJ, Howard NJ, Silink M. Diabetes complication screening in 937 children and adolescents. Journal of Pediatric Endocrinology &amp;amp; Metabolism 1999; 12(2): 185-92. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10392365?dopt=Citation" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;7. Bailey CC, Sparrow JM. Co-morbidity in patients with sight-threatening diabetic retinopathy. Eye 2001; 15(Pt 6): 719-22. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11826989?dopt=Citation" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;8. Joner G, Brinchmann-Hansen O, Torres CG, Hanssen KF. A nationwide cross-sectional study of retinopathy and microalbuminuria in young Norwegian type 1 (insulin-dependent) diabetic patients. Diabetologia 1992; 35(11): 1049-54. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/1473614?dopt=Citation" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;9. Malone JI, Morrison AD, Pavan PR, Cuthbertson DD. Prevalence and significance of retinopathy in subjects with type 1 diabetes of less than 5 years' duration screened for the diabetes control and complications trial. Diabetes Care 2001; 24(3): 522-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11289479" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;10. West SK, Klein R, Rodriguez J, Munoz B, Broman AT, Sanchez R, et al. Diabetes and diabetic retinopathy in a Mexican-American population: Proyecto VER. Diabetes Care 2001; 24(7): 1204-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11423503?dopt=Citation" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;11. Kullberg CE, Abrahamsson M, Arnqvist HJ, Finnstrom K, Ludvigsson J. Prevalence of retinopathy differs with age at onset of diabetes in a population of patients with Type 1 diabetes. Diabetic Medicine 2002; 19(11): 924-31. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12421429?dopt=Citation" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;12. Tapp RJ, Shaw JE, Harper CA, de Courten MP, Balkau B, McCarty DJ, et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care 2003; 26(6): 1731-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12766102?dopt=Citation" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;BR&gt;&lt;BR&gt;13. Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye 2004; 18(10): 963-83. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15232600" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;14. Cugati S, Kifley A, Mitchell P, Wang JJ. Temporal trends in the age-specific prevalence of diabetes and diabetic retinopathy in older persons: Population-based survey findings. Diabetes Research and Clinical Practice 2006; 74(3):301-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16716443" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;15. Wong TY, Klein R, Islam FM, Cotch MF, Folsom AR, Klein BE, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. American Journal of Ophthalmology 2006; 141(3):446-455. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16490489" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;16. Knudsen LL, Lervang HH, Lundbye-Christensen S, Gorst-Rasmussen A. The North Jutland County Diabetic Retinopathy Study: population characteristics. British Journal of Ophthalmology 2006;90(11):1404-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16825278" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;17. Al-Maskari F, El-Sadig M. Prevalence of diabetic retinopathy in the United Arab Emirates: a cross-sectional survey. BMC Ophthalmology 2007; 7:11. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17572909" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;18. Ross SA, McKenna A, Mozejko S, Fick GH. Diabetic retinopathy in native and nonnative Canadians. Experimental Diabetes Research 2007; 2007:76271. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18317512" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;19. Shrestha MK, Paudyal G, Wagle RR, Gurung R, Ruit S, Onta SR. Prevalence of and factors associated with diabetic retinopathy among diabetics in Nepal: a hospital based study. Nepal Medical College Journal 2007; 9(4):225-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18298009" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;20. Taylor CR, Merin LM, Salunga AM, Hepworth JT, Crutcher TD, O'Day DM, et al. Improving diabetic retinopathy screening ratios using telemedicine-based digital retinal imaging technology: the Vine Hill study. Diabetes Care 2007; 30(3):574-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17327323" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;21. Rani PK, Raman R, Sharma V, Mahuli SV, Tarigopala A, Sudhir RR, et al. Analysis of a comprehensive diabetic retinopathy screening model for rural and urban diabetics in developing countries. British Journal of Ophthalmology 2007; 91(11):1425-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17947265" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;22. Blum M, Kloos C, Muller N, Mandecka A, Berner R, Bertram B, et al. [Prevalence of diabetic retinopathy. Check-up program of a public health insurance company in Germany 2002-2004]. Ophthalmologe 2007; 104(6):499-500, 502-4. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17457588" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;23. Massin P, Erginay A, Mercat-Caudal I, Vol S, Robert N, Reach G, et al. Prevalence of diabetic retinopathy in children and adolescents with type-1 diabetes attending summer camps in France. Diabetes &amp;amp; Metabolism 2007; 33(4):284-9.n &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17625942" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;24. Al-Adsani AM. Risk factors for diabetic retinopathy in Kuwaiti type 2 diabetic patients. Saudi Medical Journal 2007; 28(4):579-83. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17457481" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;25. Romero-Aroca P, Fernandez-Balart J, Baget-Bernaldiz M, Martinez-Salcedo I, Mendez-Marin I, Salvat-Serra M, et al. Changes in the diabetic retinopathy epidemiology after 14 years in a population of Type 1 and 2 diabetic patients after the new diabetes mellitus diagnosis criteria and a more strict control of the patients. Journal of Diabetes and its Complications 2008; 23(4): 229-38. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18439844" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;26. Wong TY, Cheung N, Tay WT, Wang JJ, Aung T, Saw SM, et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology 2008; 115(11):1869-75. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18584872" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;27. Xie XW, Xu L, Wang YX, Jonas JB. Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006. Graefe's Archive for Clinical and Experimental Ophthalmology 2008; 246(11):1519-26. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18604548" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;28. Raman R, Rani PK, Reddi Rachepalle S, Gnanamoorthy P, Uthra S, Kumaramanickavel G, et al. Prevalence of diabetic retinopathy in India: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study report 2. Ophthalmology 2009; 116(2):311-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19084275" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;29. Wang FH, Liang YB, Zhang F, Wang JJ, Wei WB, Tao QS, et al. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology 2009; 116(3):461-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19168222" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;BR&gt;&lt;BR&gt;30. Javadi MA, Katibeh M, Rafati N, Dehghan MH, Zayeri F, Yaseri M, et al. Prevalence of diabetic retinopathy in Tehran province: a population-based study. BMC Ophthalmology 2009; 9:12. &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770536/?tool=pubmed" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;BR&gt;&lt;BR&gt;31. Salti HI, Nasrallah MP, Taleb NM, Merheb M, Haddad S, El-Annan J, et al. Prevalence and determinants of retinopathy in a cohort of Lebanese type II diabetic patients. Canadian Journal of Ophthalmology 2009; 44(3):308-13. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19491987" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #000000"&gt;32. Spijkerman AM, Dekker JM, Nijpels G, Adriaanse MC, Kostense PJ, Ruwaard D, et al. Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the hoorn screening study. Diabetes Care 2003; 26(9): 2604-8. &lt;A href="http://care.diabetesjournals.org/content/26/9/2604.full" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;33. Bek T, Lund-Andersen H, Hansen AB, Johnsen KB, Sandbaek A, Lauritzen T. The prevalence of diabetic retinopathy in patients with screen-detected type 2 diabetes in Denmark: the ADDITION study. Acta Ophthalmologica 2009; 87(3):270-4. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18823287" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;34. Grauslund J, Green A, Sjolie AK. Prevalence and 25 year incidence of proliferative retinopathy among Danish type 1 diabetic patients. Diabetologia 2009; 52(9):1829-35. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19593541" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;BR&gt;&lt;BR&gt;35. Beulens JW, Patel A, Vingerling JR, Cruickshank JK, Hughes AD, Stanton A, et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia 2009; 52(10):2027-36. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19633827" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;BR&gt;&lt;BR&gt;36. Dedov I, Maslova O, Suntsov Y, Bolotskaia L, Milenkaia T, Besmertnaia L. Prevalence of diabetic retinopathy and cataract in adult patients with type 1 and type 2 diabetes in Russia. The Review of Diabetic Studies 2009; 6(2):124-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779015/" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;SPAN style="COLOR: #a81400"&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;BR&gt;Further Evidence&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/SearchResults.aspx?catID=5134&amp;amp;tabID=289&amp;amp;" target="_blank"&gt;Links to systematic reviews on diabetic retinopathy in&amp;nbsp;NHS Evidence - diabetes&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Guidelines&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/SearchResults.aspx?tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=50&amp;amp;sort=PUBLICATION_DATE&amp;amp;catID=5134" target="_blank"&gt;Links to supporting Guidelines&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;STRONG&gt;Patient Information&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?catID=5134&amp;amp;sort=PUBLISHER&amp;amp;resultsPerPage=50&amp;amp;summaries=true&amp;amp;tabID=292" target="_blank"&gt;Links to supporting Patient Information&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Reference Material&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?catID=5134&amp;amp;tabID=290&amp;amp;searchText=&amp;amp;sort=PUBLICATION_DATE&amp;amp;resultsPerPage=10&amp;amp;summaries=true" target="_blank"&gt;Links to supporting reference material&lt;/A&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;Publication details&lt;/STRONG&gt;&lt;BR&gt;Originally written by Peter Scanlon (Consultant Ophthalmologist and National Clinical Director of the English National Screening Programme for Diabetic Retinopathy) in June 2006, since reviewed and updated in June 2007 by P Scanlon, in June 2008 by P Scanlon and Irene Stratton, in June 2009 by P Scanlon, and in August 2010 by P Scanlon. &lt;BR&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387101</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=387101]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetic Retinopathy - Risk factors for the development of diabetic retinopathy and sight threatening diabetic retinopathy</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,EYES AND VISION,CHRONIC COMPLICATIONS,CAUSES,EYE DISEASES,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>part of the 2010 Annual Evidence Update on Diabetic Retinopathy</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetic Retinopathy - Risk factors for the development of diabetic retinopathy and sight threatening diabetic retinopathy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published&lt;/STRONG&gt;: 13 September 2010&lt;/P&gt;
&lt;P&gt;Originally written by P Scanlon in June 2006, updated annually, &lt;A href="#ref1"&gt;link to further author and publication&amp;nbsp;details here.&lt;/A&gt;&amp;nbsp;&lt;EM&gt; &lt;BR&gt;&lt;/EM&gt;Changes and additions since August 2009 are highlighted in red.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387096" target="_blank"&gt;Link back to home page for 2010 Annual Evidence Update on Diabetic Retinopathy here.&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387421" target="_blank"&gt;Link to table of abbreviations here.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage8 border=0 name=nelh_tempImage8 alt="Image of: hypertensive retinopathy" src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID321822/nelhImp_0000_photo8-hypertensiveretinopathy.jpg" width=200 height=200&gt;&lt;/P&gt;
&lt;P&gt;Major international epidemiological trials have established that the development of diabetic retinopathy is related to the following modifiable and non-modifiable risk factors:&lt;BR&gt;&lt;BR&gt;&lt;U&gt;Modifiable risk factors are Blood Glucose, Blood Pressure, Lipid Levels and Smoking&lt;BR&gt;&lt;/U&gt;&lt;BR&gt;1. Blood glucose&lt;BR&gt;&lt;BR&gt;In 1976, Cahill [1] wrote that the weight of evidence strongly supports the concept that the microvascular complications of diabetes are decreased by reduction of glucose concentrations. In 1981, Hyman [2] recommended a nationally co-ordinated clinical study of sufficient duration to resolve the issue. Evidence for the link between poor glucose control and greater progression of diabetic retinopathy was provided by Frank [3], Dahl-Jorgensen [4], Brinchmann-Hansen [5], Joner [6], Klein [7], Danne [8], Klein [9], Davis [10], Klein [11, 25-26], Fong [12].&amp;nbsp; More recent studies by Knudsen [13] Pradeepa [14] and Romero-Aroca [15] have also found this correlation.&lt;BR&gt;&lt;BR&gt;The study that changed opinion and confirmed that intensive blood glucose control reduces the risk of new onset DR and slows the progression of existing DR for patients with IDDM was the Diabetes Control and Complications Trial [16-18] (DCCT). The trial included 1441 people with IDDM, 726 with no DR at base line (the primary-prevention cohort), and 715 with mild retinopathy (the secondary-intervention cohort), with mean follow-up of 6.5 years. For the primary-prevention cohort, intensive therapy reduced the mean risk for the development of DR by 76 % (CI 62-85 %), compared with conventional therapy. For the secondary-intervention cohort, intensive therapy slowed the progression of DR by 54 % (CI 39-66 %) and reduced the development of PDR or severe NPDR by 47 % (CI 14-67 %). &lt;BR&gt;&lt;BR&gt;The study that changed opinion and confirmed that intensive blood glucose control reduces the risk of new onset DR and slows the progression of existing DR for patients with NIDDM was the United Kingdom Prospective Diabetes Study [19-22]. This study recruited 3867 with NIDDM and the effect of intensive blood-glucose control with sulphonylureas or insulin was compared with conventional treatment. Compared with the conventional group, there was a 25% risk reduction (7-40, p=0.0099) in the intensive group in microvascular endpoints, including the need for retinal photocoagulation. Patients allocated metformin, compared with the conventional group, had risk reductions of 32% (95% CI 13-47, p=0.002) for any diabetes-related endpoint. &lt;BR&gt;&lt;BR&gt;2. Blood Pressure&lt;BR&gt;&lt;BR&gt;Evidence that control of systemic hypertension reduces the risk of new onset DR and slows the progression of existing DR comes from studies reported by Chase [24], Joner [6], Klein [11, 25-26], UKPDS [22], Stratton [23] and Estacio [27].&lt;BR&gt;Recent studies that have shown the link between hypertension and diabetic retinopathy are those by Al-Maskari [28], Al-Adsani [29] and Shrestha [30].&lt;BR&gt;A study reported in 2008 by Tikellis [31] in a tertiary eye clinic in Melbourne showed that adherence to clinical guidelines for glycaemic and BP control in patients with DR was low, even in a well-developed healthcare system with free ophthalmic care access.&lt;BR&gt;&lt;BR&gt;3. Serum lipids&lt;BR&gt;&lt;BR&gt;Evidence that elevated serum lipids are associated with macular exudates and moderate visual loss and partial regression of hard exudates may be possible by reducing elevated lipid levels comes from studies reported by Chew [32], Fong [12], Klein [33], Sen [34], Cusick [35] and Galetovic [36]. The FIELD study [37] reported by Keech suggested that use of fenofibrate in type 2 diabetes might reduce the need for laser treatment of diabetic retinopathy over a five-year period. However, one needs to be cautious with the interpretation of the results because this was a tertiary outcome of a trial that failed its primary outcome of Coronary Heart Disease death or non-fatal Myocardial Infarction and the numbers of events, particularly in the sub-study, were small. The results would, however, support a study specifically designed for the purpose.&lt;BR&gt;A study by Funatsu [38] from Japan suggest that serum lipoprotein A level is an independent risk factor for the progression of NPDR in Type 2 diabetes patients.&lt;BR&gt;&lt;BR&gt;4. Smoking&lt;BR&gt;&lt;BR&gt;There is some evidence that smoking may be a risk factor in progression of diabetic retinopathy in Type 1 diabetes as described by Muhlhauser [39-40] and Karamanos [41]. However, in Type 2 disease the evidence is controversial and it may protect [23] against the progression of retinopathy in some patients despite the fact that it is an independent risk factor for cardiovascular disease in all patients with diabetes.&lt;BR&gt;&lt;BR&gt;&lt;U&gt;Non-modifiable risk factors for DR are Duration, Age, Genetic predisposition, Ethnicity&lt;BR&gt;&lt;BR&gt;&lt;/U&gt;5. Duration&lt;BR&gt;&lt;BR&gt;The major non-modifiable determinant of progression of diabetic retinopathy is duration [42-43] of diabetes.&lt;BR&gt;&lt;BR&gt;6. Age &lt;BR&gt;&lt;BR&gt;There is a rather complex link with age with the Wisconsin Epidemiological Study [44-46] demonstrating that in those whose age of diagnosis was less than 30 years and who had diabetes of 10 years duration or less, the severity of retinopathy was related to older age at examination, whereas when the age at diagnosis was 30 or more years, the severity of retinopathy was related to younger age at diagnosis. In the UKPDS [23], in those who already had retinopathy, progression was associated with older age.&lt;BR&gt;&lt;BR&gt;7. Genetic predisposition&lt;BR&gt;&lt;BR&gt;Early studies of identical twins with diabetes mellitus suggest familial clustering of diabetic retinopathy. An association between severity of diabetic retinopathy and HLA antigens has been suggested in a number of studies [47-48], although this has not been uniformly been accepted [49]. The majority of candidate genes studied exhibit weak or no association with retinopathy status, and where associations have been detected these results have not been replicated in multiple populations. However, Hietala [50] demonstrated that there is a familial clustering of proliferative retinopathy in patients with type 1 diabetes in Finland, which cannot be accounted for by conventional risk factors, suggesting a genetic component in the pathogenesis of proliferative retinopathy in type 1 diabetes.&lt;BR&gt;&lt;BR&gt;8. Ethnicity&lt;BR&gt;&lt;BR&gt;Emanuele [51] reported a higher prevalence of diabetic retinopathy scores &amp;gt;40 in Hispanics (36%) and African Americans (29%) than for non-Hispanic whites (22%).&lt;BR&gt;Simmons [52] compared ethnic differences in the prevalence of diabetic retinopathy in European, Maori and Pacific peoples with diabetes in Auckland, New Zealand. They demonstrated that that moderate or more severe retinopathy is more common in Polynesians than Europeans. In neither of these two studies could the differences be accounted for by an imbalance in traditional risk factors such as age, duration of diagnosed diabetes, HbA1c, and blood pressure.&lt;BR&gt;Raymond [53] compared prevalence and risk factors for diabetic retinopathy among UK residents of south Asian or white European ethnicity. Patients of south Asian ethnicity had significantly higher prevalence of diabetic retinopathy (DR) and maculopathy, with significantly elevated systolic and diastolic blood pressures, HbA1c and total cholesterol, lower attained age and younger age at diagnosis. &lt;BR&gt;Lim [54] described the prevalence, severity, and associated risk factors of diabetic retinopathy among different racial groups (whites, blacks, Hispanics, and Asians) within an urban, underserved population. In this population of similar socioeconomic status and access to healthcare, race was not an independent predictor of diabetic retinopathy. This suggests that racial differences described in previous studies may be eliminated when social factors are equalized. However, the prevalence of any retinopathy among all diabetics in this study was low at 15.7%.&lt;BR&gt;&lt;BR&gt;&lt;U&gt;A risk factor which has not been placed in the modifiable or non-modifiable category is Pregnancy.&lt;BR&gt;&lt;BR&gt;&lt;/U&gt;9. Pregnancy&lt;BR&gt;&lt;BR&gt;Two studies [55-56] found pregnancy to be independently associated with progression of diabetic retinopathy. &lt;BR&gt;The effects pregnancy are summarised in a review article by Sheth [57] and by the NICE Diabetes in Pregnancy guideline [58], both published in 2008. &lt;BR&gt;&lt;BR&gt;10. Biomarkers&lt;BR&gt;&lt;BR&gt;In 2009, Nunes [59] described a high microaneurysm formation rate on color fundus photographs appears to be a good biomarker for DR progression to CSME in type 2 diabetic patients with NPDR.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Between August 2009 and August 2010, the following studies reported:&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;A study by Brazionis [60] suggested that Greek ethnicity may confer some protection against diabetic retinopathy to Australia's Greek-born migrants, an effect not explained by established risk factors for diabetic retinopathy.&lt;BR&gt;&lt;BR&gt;A study by Hietala [61] concluded that age at onset in type 1 diabetes significantly modifies the long-term risk of proliferative retinopathy. The highest risk is in age-at-onset group 5-14 years, whereas the lowest risk is in age-at-onset group 15-40 years.&lt;BR&gt;&lt;BR&gt;O'Dell [62] reported that in a study of black patients from New Jersey with Type 1 diabetes mellitus, baseline sodium intake was significantly associated with the 6-year progression of DR and the incidence of diabetic macular edema. Baseline total caloric intake was significantly associated with a 6-year risk for progression of DR and the presence of hard exudates.&amp;nbsp; In type 1 diabetes mellitus, blacks with high caloric and sodium intake are at higher risk for progression to severe, vision-threatening forms of DR.&lt;BR&gt;&lt;BR&gt;Targher [63] reported that ultrasound-diagnosed non-alcoholic fatty liver disease in type 1 diabetes is associated, independently of several confounding factors, with a higher prevalence of chronic kidney disease and retinopathy in type 1 diabetic individuals.&lt;BR&gt;&lt;BR&gt;West [64] reported that, in men with Type 2 diabetes, there is a strong association between retinopathy and obstructive sleep apnoea, independent of conventional retinopathy risk factors.&lt;BR&gt;&lt;BR&gt;Chew [65] reported from the ACCORD Eye study that intensive glycemic control and intensive combination treatment of dyslipidemia, but not intensive blood-pressure control, reduced the rate of progression of diabetic retinopathy.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;STRONG&gt;&lt;BR&gt;Summary of Studies referred to:&lt;/STRONG&gt;&lt;/P&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;SPAN style="COLOR: #000000"&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;
&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;STRONG&gt;Year&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;STRONG&gt;Author&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;STRONG&gt;Number (n) patients (p) eyes (e)&lt;/STRONG&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1976&lt;/TD&gt;
&lt;TD&gt;Cahill [1] &lt;/TD&gt;
&lt;TD&gt;Stated that the weight of evidence strongly supports the concept that the microvascular complications of diabetes are decreased by reduction of glucose concentrations. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1981&lt;/TD&gt;
&lt;TD&gt;Hyman [2] &lt;/TD&gt;
&lt;TD&gt;Recommended a nationally co-ordinated clinical study of sufficient duration to resolve the issue.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1982&lt;/TD&gt;
&lt;TD&gt;Frank [3] &lt;/TD&gt;
&lt;TD&gt;n = 173 juvenile-onset IDDM&lt;BR&gt;Retinopathy was also found to be independently associated with diabetic ‘control’, evaluated semi quantitatively but on a masked basis and frequency of daily insulin injections. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1986&lt;/TD&gt;
&lt;TD&gt;Dahl-Jorgensen[4]&lt;/TD&gt;
&lt;TD&gt;N = 45 IDDM in the Oslo study randomised to treatment with continuous subcutaneous insulin infusion (CSII), multiple insulin injections (five or six daily), or conventional twice daily insulin injections. &lt;BR&gt;After two years fewer retinal microaneurysms and haemorrhages had developed in the patients given CSII and multiple injections compared with those given conventional treatment, in whom the number had increased significantly (p&amp;lt;0.01). &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1986&lt;/TD&gt;
&lt;TD&gt;Brinchmann-Hansen [5] &lt;/TD&gt;
&lt;TD&gt;Reported the 7year results of the Oslo study in 1992.&lt;BR&gt;Multiple regression analysis identified four independent variables as indicative of outcome of retinopathy after seven years; HbA1 value at baseline; the change in HbA1 from start to the mean level through the seven years; duration of diabetes; and retinopathy at the start.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1990&lt;/TD&gt;
&lt;TD&gt;Chase [24]&lt;/TD&gt;
&lt;TD&gt;N = 249 Type 1 IDDM (young people).&lt;BR&gt;Prevalence: Retinopathy 63%, hypertension 2%.&lt;BR&gt;The presence of high-normal blood pressure (&amp;gt;90th percentile but &amp;lt; 141/90 mm Hg) resulted in a prospectively higher occurrence of retinopathy and of progression of pre-existing retinopathy.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TR style="COLOR: #000000"&gt;
&lt;TD&gt;1990&lt;/TD&gt;
&lt;TD&gt;Klein [55] &lt;/TD&gt;
&lt;TD&gt;Insulin-taking diabetic women were enrolled; one group was comprised of 171 pregnant women, the other group was comprised of 298 women who were not pregnant. Women were evaluated on referral and again in the postpartum period. 133 pregnant women and 241 non-pregnant women attended and had gradable photographs at both visits. The severity of diabetic retinopathy was based on grading of fundus photographs of seven standard photographic fields. The glycosylated haemoglobin, duration of diabetes, current age, diastolic blood pressure, number of past pregnancies, and current pregnancy status were evaluated as risk factors for progression of diabetic retinopathy. After adjusting for glycosylated haemoglobin, current pregnancy was significantly associated with progression (P &amp;lt; 0.005, adjusted odds ratio 2.3). &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1992&lt;/TD&gt;
&lt;TD&gt;Joner[6]&lt;/TD&gt;
&lt;TD&gt;n = 600 IDDM in Norway.&lt;BR&gt;In a multiple logistic regression model, age, HbA1c, duration of diabetes, and mean arterial blood pressure were found to be significantly associated with retinopathy. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1992&lt;/TD&gt;
&lt;TD&gt;Klein[7] &lt;/TD&gt;
&lt;TD&gt;Hyperglycaemia, longer duration of diabetes and more severe retinopathy at baseline were associated with an increased 4 yr risk of PDR in WESDR and higher blood pressure at baseline in the younger-onset group.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1993&lt;/TD&gt;
&lt;TD&gt;DCCT[16] &lt;/TD&gt;
&lt;TD&gt;The Diabetes Control and Complications Trial Research Group.&lt;BR&gt;n = 1441 IDDM, n = 726 with no DR at base line (the primary-prevention cohort), n = 715 with mild retinopathy (the secondary-intervention cohort).&lt;BR&gt;Both cohorts randomly assigned to intensive therapy administered either with an external insulin pump or by three or more daily insulin injections or to conventional therapy with one or two daily insulin injections. &lt;BR&gt;Follow-up: Mean 6.5 yrs.&lt;BR&gt;Primary-prevention cohort: Intensive therapy reduced the mean risk for the development of DR by 76 % (CI 62-85 %), compared with conventional therapy.&lt;BR&gt;Secondary-intervention cohort: Intensive therapy slowed the progression of DR by 54 % (CI 39-66 %) and reduced the development of PDR or severe NPDR by 47 % (CI 14-67 %).&lt;BR&gt;The chief adverse event associated with intensive therapy was a two-to-threefold increase in severe hypoglycaemia. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1994 &lt;/TD&gt;
&lt;TD&gt;Danne[8] &lt;/TD&gt;
&lt;TD&gt;n = 346 IDDM adolescents in the Berlin Retinopathy Study.&lt;BR&gt;The rate of BDR per 100 patient-years increased with poorer glycaemic control from 0.7 (long-term HbA1c &amp;lt; 7%) to 7.3 (HbA1c &amp;gt; 11%) following an exponential function. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1994&lt;/TD&gt;
&lt;TD&gt;Muhlhauser[39] &lt;/TD&gt;
&lt;TD&gt;Literature relating to the role of cigarette smoking in the prognosis of diabetes.&lt;BR&gt;Review: Cigarette smoking is strongly associated with all-cause mortality and the development and progression of diabetic nephropathy but the association between smoking and retinopathy was less consistent. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1995&lt;/TD&gt;
&lt;TD&gt;DCCT [17] &lt;/TD&gt;
&lt;TD&gt;Cumulative 8.5-year rates of retinopathy progression by three or more steps at two consecutive visits were 54.1% with conventional treatment and 11.5% with intensive treatment in the primary prevention cohort and 49.2% and 17.1% in the secondary intervention cohort. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1996&lt;/TD&gt;
&lt;TD&gt;Chew [32] &lt;/TD&gt;
&lt;TD&gt;Reported an association of elevated serum lipid levels with retinal hard exudates in diabetic patients from the ETDRS. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1996&lt;/TD&gt;
&lt;TD&gt;Muhlhauser[40] &lt;/TD&gt;
&lt;TD&gt;n = 636 Type 1 IDDM prospective multicentre study.&lt;BR&gt;Significant associations between smoking, and retinopathy were found but the relations were variable depending on the statistical model used. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1998&lt;/TD&gt;
&lt;TD&gt;Davis [10] &lt;/TD&gt;
&lt;TD&gt;Two of the baseline characteristics identified as risk factors for high-risk PDR in eyes assigned to deferral of photocoagulation in the ETDRS were increased higher glycosylated haemoglobin, elevated triglycerides. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1998&lt;/TD&gt;
&lt;TD&gt;DCCT [18]&lt;/TD&gt;
&lt;TD&gt;This further report from the DCCT documented the frequency, importance of, and risk factors for "early worsening" of diabetic retinopathy. Early worsening was observed at the 6- and/or 12-month visit in 13.1% of 711 patients assigned to intensive treatment and in 7.6% of 728 patients assigned to conventional treatment (odds ratio, 2.06; P &amp;lt; .001). Recovery had occurred at the 18-month visit in 51% and 55% of these groups, respectively (P = .39). Outcomes in intensively treated patients who had early worsening were similar to or more favorable than outcomes in conventionally treated patients who had not. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1998&lt;/TD&gt;
&lt;TD&gt;Klein [11] &lt;/TD&gt;
&lt;TD&gt;Progression of retinopathy after 14 yrs in WESDR was more likely with higher glycosylated haemoglobin or diastolic blood pressure at baseline, an increase in the glycosylated haemoglobin level, and an increase in diastolic blood pressure level from the baseline to the 4-year follow-up.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1998&lt;/TD&gt;
&lt;TD&gt;Kohner [19] &lt;/TD&gt;
&lt;TD&gt;Reported on the retinopathy prevalence of patients recruited into the UKPDS.&lt;BR&gt;The severity of retinopathy was related in both sexes to higher fasting plasma glucose levels, higher systolic and diastolic blood pressure. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1998&lt;/TD&gt;
&lt;TD&gt;UKPDS [20] &lt;/TD&gt;
&lt;TD&gt;n = 3867.&lt;BR&gt;Described the effect of intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. &lt;BR&gt;Compared with the conventional group, there was a 25% risk reduction (7-40, p=0.0099) in the intensive group in microvascular endpoints, including the need for retinal photocoagulation.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1998&lt;/TD&gt;
&lt;TD&gt;UKPDS [21]&lt;/TD&gt;
&lt;TD&gt;Described the effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes.&lt;BR&gt;Patients allocated metformin, compared with the conventional group, had risk reductions of 32% (95% CI 13-47, p=0.002) for any diabetes-related endpoint.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1998&lt;/TD&gt;
&lt;TD&gt;UKPDS [22] &lt;/TD&gt;
&lt;TD&gt;Described the effect of tight blood pressure control and risk of microvascular complications in type 2 diabetes. &lt;BR&gt;After nine years of follow up the group assigned to tight blood pressure control had a 34% reduction in risk in the proportion of patients with deterioration of retinopathy by two steps (99% confidence interval 11% to 50%) (P=0.0004) and a 47% reduced risk (7% to 70%) (P=0.004) of deterioration in visual acuity by three lines of the early treatment of diabetic retinopathy study (ETDRS) chart. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;1999&lt;/TD&gt;
&lt;TD&gt;Fong [12]&lt;/TD&gt;
&lt;TD&gt;Patients with persistent severe visual loss in the ETDRS had higher mean levels of haemoglobin A1c (10.4% vs. 9.7%; P = .001) and higher levels of cholesterol (244.1 vs. 228.5 mg/dl; P = .0081) at baseline.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2000&lt;/TD&gt;
&lt;TD&gt;Estacio [27] &lt;/TD&gt;
&lt;TD&gt;Reported results from the Appropriate Blood Pressure Control in Diabetes (ABCD) Trial.&lt;BR&gt;n = 470.&lt;BR&gt;Intensive therapy, with follow-up of 5.3 years, demonstrated a lower overall incidence between the intensive and moderate groups with regard to the progression of diabetic retinopathy. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2000&lt;/TD&gt;
&lt;TD&gt;Karamanos[41] &lt;/TD&gt;
&lt;TD&gt;EURODIAB IDDM Complications Study. &lt;BR&gt;In the short duration group of Type 1 IDDM, factors associated with early development of complications were cigarette smoking and a family history of hypertension. Subjects free of microvascular complications in spite of long duration of diabetes had better glycaemic control, lower blood pressure and better lipid profile.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2000&lt;/TD&gt;
&lt;TD&gt;DCCT [56]&lt;/TD&gt;
&lt;TD&gt;Study of 180 women who had 270 pregnancies and 500 women who did not become pregnant during an average of 6.5 years of follow-up .Women assigned to the conventional treatment group were changed to intensive therapy if they were planning pregnancy or as soon as possible after conception. Fundus photography was performed every 6 months. Compared with non-pregnant women, pregnant women had a 1.63-fold greater risk of any worsening of retinopathy from before to during pregnancy (P &amp;lt; 0.05) in the intensive treatment group; the risk was 2.48-fold greater for pregnant vs. not pregnant women in the conventional group (P &amp;lt; 0.001). Although individual patients had transient worsening of retinopathy during pregnancy, which persisted for as long as 12 months post-pregnancy, at the end of the DCCT, mean levels of retinopathy in subjects who had become pregnant were similar to those in subjects who had not become pregnant within each treatment group. Hence it was concluded that because pregnancy in type 1 diabetes induces a transient increase in the risk of retinopathy; increased ophthalmologic surveillance is needed during pregnancy and the first year postpartum. The long-term risk of progression of early retinopathy, however, does not appear in this study to be increased by pregnancy. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2001&lt;/TD&gt;
&lt;TD&gt;Stratton [23] &lt;/TD&gt;
&lt;TD&gt;UKPDS.&lt;BR&gt;Development of retinopathy (incidence) was strongly associated with baseline glycaemia, glycaemic exposure over 6 years, higher blood pressure and with not smoking. In those who already had retinopathy, progression was associated with older age, male sex, hyperglycaemia (as evidenced by a higher HbA1c) and with not smoking.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2002&lt;/TD&gt;
&lt;TD&gt;Klein [33]&lt;/TD&gt;
&lt;TD&gt;The Atherosis Risk in Communities Study&lt;BR&gt;The data suggest that plasma lipids are associated with the presence of hard exudates. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2002&lt;/TD&gt;
&lt;TD&gt;Sen [34] &lt;/TD&gt;
&lt;TD&gt;N = 50.&lt;BR&gt;Fundus fluorescein angiography and color fundus photograph showed improvement in one patient in the simvastatin group, while seven patients showed worsening in the placebo group (P = 0.009). &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2003&lt;/TD&gt;
&lt;TD&gt;Cusick [35]&lt;/TD&gt;
&lt;TD&gt;Described the regression of retinal hard exudates in 2 patients with diabetic maculopathy after correction of dyslipidemia, and reported immunohistologic findings reflecting lipid deposition in the retina. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2007&lt;/TD&gt;
&lt;TD&gt;Knudsen [13] &lt;/TD&gt;
&lt;TD&gt;The risk factors for clinically significant macular oedema in type 2 diabetic subjects (but not Type 1) are duration of diabetes, HbA1c, neuropathy, and increased urinary albumin excretion.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TR style="COLOR: #000000"&gt;
&lt;TD&gt;2007&lt;/TD&gt;
&lt;TD&gt;Simmons[52]&lt;/TD&gt;
&lt;TD&gt;Compared ethnic differences in the prevalence of diabetic retinopathy in European, Maori and Pacific peoples with diabetes in Auckland, New Zealand. They demonstrated that that moderate or more severe retinopathy is more common in Polynesians than Europeans.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Galetovic[36] &lt;/TD&gt;
&lt;TD&gt;A retrospective study of 402 diabetic patients aged 25 to 65. The incidence of diabetic retinopathy is increasing in Split Dalmatia, with nonproliferative form as the most common type. Women suffer more frequently from diabetic retinopathy, those aged 60 being at the highest risk. The genesis of diabetic retinopathy is directly correlated with the type and duration of diabetes. Changes in total cholesterol concentration, especially LDL fraction, and apolipoproteins A and B (especially B) indicate an increased relative risk of developing diabetic retinopathy.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Pradeepa[14] &lt;/TD&gt;
&lt;TD&gt;Chennai Urban Rural Epidemiology Study. Stepwise ordinal logistic regression analysis 1715 subjects showed that male gender (P = 0.041), duration of diabetes (P &amp;lt; 0.0001), glycated haemoglobin (HbA(1c); P &amp;lt; 0.0001), macroalbuminuria (P = 0.0002) and insulin therapy (P = 0.0001) were significantly associated with severity of DR. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Romero-Aroca [15] &lt;/TD&gt;
&lt;TD&gt;Comparison of 1993 and 2005 Spanish cohorts with Type 2 diabetes (n=741 in both). In the first study the incidence was 39.41% while in the present study it was 27.55%. The diabetic macular edema prevalence was similar in both studies (7.15% in the past and 7.90% in the present study). There was also a decrease in the number of blind patients (11.20% in 1993 and 4.90% in the current study). The number of patients treated with laser photocoagulation increased (13.49% in the current study as compared to 6.20% in the previous study).&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TR style="COLOR: #000000"&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Sheth [57] &lt;/TD&gt;
&lt;TD&gt;Pregnancy is associated with an increased risk of development and progression of diabetic retinopathy. The factors associated with its progression include the pregnant state itself, duration of diabetes, amount of retinopathy at conception, blood glucose control, and the presence of coexisting hypertension. Although the rate of regression of diabetic retinopathy at the end of pregnancy or the postpartum period is high, careful monitoring of these patients is necessary to optimize the vision and pregnancy outcomes. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TR style="COLOR: #000000"&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;NICE [58] &lt;/TD&gt;
&lt;TD&gt;Diabetes in Pregnancy Guideline &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TR style="COLOR: #000000"&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Funatsu [38]&lt;/TD&gt;
&lt;TD&gt;One hundred and six patients with NPDR were followed up for 2 years. Multivariate logistic regression analysis showed that HbA(1c) (OR 1.74; 95% CI 1.12-3.21) and Lp(a) level (OR 1.90; 95% CI 1.06-4.33) were significant and independent predictors of the progression of NPDR.&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TR style="COLOR: #000000"&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Raymond[53] &lt;/TD&gt;
&lt;TD&gt;Diabetic retinopathy was detected in 414 (40%) patients, south Asian 189 (45%) vs. white European 225 (37%), P=0.0078. Sight threatening retinopathy was detected in 142 (14%) patients; south Asian 68 (16%) vs. white European 74 (12%); P=0.0597. Patients of south Asian ethnicity had significantly higher systolic (144 vs. 137 mmHg, P&amp;lt;0.0001) and diastolic (84 vs. 74 mmHg, p&amp;lt;0.0001) blood pressures, HbA1c (7.9 vs. 7.5%, P&amp;lt;0.0001) and total cholesterol (4.5 vs. 4.2mmol/L, P&amp;lt;0.0001). After adjustment for confounders, there were significantly elevated risks of any retinopathy and maculopathy for south Asian vs. white European patients. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TR style="COLOR: #000000"&gt;
&lt;TD&gt;2008&lt;/TD&gt;
&lt;TD&gt;Lim [54]&lt;/TD&gt;
&lt;TD&gt;2-field non-mydriatic retinal photographs of each eye were reviewed for 1073 patients referred to the San Francisco General Hospital mobile eye service, the Eye Van, for diabetic retinopathy screening. The prevalence of any retinopathy among all diabetics was 15.7%. There was no statistical difference in the prevalence of retinopathy among the racial groups. Significant independent predictors of presence and severity of retinopathy were longer duration of diabetes, and use of oral hypoglycaemic medication or insulin (P &amp;lt; 0.05). Gender, age, primary language, income, and co-diagnosis of hypertension were not correlated. &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TR style="COLOR: #000000"&gt;
&lt;TD&gt;2009&lt;/TD&gt;
&lt;TD&gt;Nunes [59]&lt;/TD&gt;
&lt;TD&gt;In total, 113 patients/eyes with non proliferative DR (NPDR) were followed up every 6 months for 2 years as controls of the DR clinical trials, and by conventional general and ophthalmological care for the next 8 years (over a total of 10 years' follow-up). Microaneurysm turnover for the 2 first years was computed using the MA-Tracker. Results: The 17 patients that developed CSME over the 10 years of follow-up presented a microaneurysm formation rate of 9.2 +/- 18.2 microaneurysms/year (mean +/- SD) during the first 2 years, which was statistically higher than the eyes that did not develop CSME (0.5 +/- 1.2 microaneurysms/year, p &amp;lt; 0.001). These 17 patients also presented higher HbA(1C) levels at baseline (8.5 +/- 1.2%) compared to the patients who did not develop CSME (7.3 +/- 1.2%, p = 0.001).&lt;/TD&gt;&lt;/TR&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TR style="COLOR: #a81400"&gt;
&lt;TD&gt;2010&lt;/TD&gt;
&lt;TD&gt;Brazionis [60]&lt;/TD&gt;
&lt;TD&gt;Greek ethnicity may confer some protection against diabetic retinopathy to Australia's Greek-born migrants, an effect not explained by established risk factors for diabetic retinopathy.&lt;/TD&gt;&lt;/TR&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TR style="COLOR: #a81400"&gt;
&lt;TD&gt;2010&lt;/TD&gt;
&lt;TD&gt;Hietala [61]&lt;/TD&gt;
&lt;TD&gt;Age at onset in type 1 diabetes significantly modified the long-term risk of proliferative retinopathy. The highest risk was in age-at-onset group 5-14 years, whereas the lowest risk was in age-at-onset group 15-40 years.&lt;/TD&gt;&lt;/TR&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TR style="COLOR: #a81400"&gt;
&lt;TD&gt;2010&lt;/TD&gt;
&lt;TD&gt;O'Dell [62]&lt;/TD&gt;
&lt;TD&gt;In a study of black patients from New Jersey with Type 1 diabetes mellitus, baseline sodium intake was significantly associated with the 6-year progression of DR and the incidence of diabetic macular edema. Baseline total caloric intake was significantly associated with a 6-year risk for progression of DR and the presence of hard exudates.&lt;/TD&gt;&lt;/TR&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TR style="COLOR: #a81400"&gt;
&lt;TD&gt;2010&lt;/TD&gt;
&lt;TD&gt;Targher [63]&lt;/TD&gt;
&lt;TD&gt;Ultrasound-diagnosed non-alcoholic fatty liver disease in type 1 diabetes was associated, independently of several confounding factors, with a higher prevalence of chronic kidney disease and retinopathy in type 1 diabetic individuals.&lt;/TD&gt;&lt;/TR&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TR style="COLOR: #a81400"&gt;
&lt;TD&gt;2010&lt;/TD&gt;
&lt;TD&gt;West [64]&lt;/TD&gt;
&lt;TD&gt;In men with Type 2 diabetes, there is a strong association between retinopathy and obstructive sleep apnoea, independent of conventional retinopathy risk factors.&lt;/TD&gt;&lt;/TR&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TR style="COLOR: #a81400"&gt;
&lt;TD&gt;2010&lt;/TD&gt;
&lt;TD&gt;Chew [65]&lt;/TD&gt;
&lt;TD&gt;ACCORD Eye Study.&lt;BR&gt;Intensive glycemic control and intensive combination treatment of dyslipidemia, but not intensive blood-pressure control, reduced the rate of progression of diabetic retinopathy.&lt;/TD&gt;&lt;/TR&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;References (including systematic reviews &amp;amp; primary research)&lt;BR&gt;&lt;/STRONG&gt;Links to PubMed abstracts are provided. Free full text may be available from the PubMed link. Where free full text access is not available, NHS staff in England can access full text of a number of journals via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/" target="_blank"&gt;NHS Evidence&lt;/A&gt; or can request the full text via their &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;1. Cahill GF, Jr., Etzwiler LD, Freinkel N. Editorial: "Control" and diabetes. New England Journal of Medicine 1976; 294(18): 1004-5. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/1256496" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;2. Hyman BN. The Prevention of Diabetic Retinopathy. Ophthalmology 1981; 88: 35A-37A. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7022305" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;3. Frank RN, Hoffman WH, Podgor MJ, Joondeph HC, Lewis RA, Margherio RR, et al. Retinopathy in juvenile-onset type I diabetes of short duration. Diabetes 1982; 31(10): 874-82. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7152126" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;4. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Ganes T, Kierulf P, Smeland E, et al. Effect of near normoglycaemia for two years on progression of early diaebtic retinopathy, nephropathy, and neuropathy: the Oslo study. British Medical Journal 1986; 293(8 November 1986): 1195-1199. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/3096429" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;5. Brinchmann-Hansen O, Dahl-Jorgensen K, Sandvik L, Hanssen KF. Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo study. British Medical Journal 1992; 304(6818): 19-22. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/1734985" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;6. Joner G, Brinchmann-Hansen O, Torres CG, Hanssen KF. A nationwide cross-sectional study of retinopathy and microalbuminuria in young Norwegian type 1 (insulin-dependent) diabetic patients. Diabetologia 1992; 35(11): 1049-54. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/1473614" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;7. Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care 1992; 15(12): 1875-91. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/1464243" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;8. Danne T, Weber B, Hartmann R, Enders I, Burger W, Hovener G. Long-term glycemic control has a nonlinear association to the frequency of background retinopathy in adolescents with diabetes. Follow-up of the Berlin Retinopathy Study. Diabetes Care 1994; 17(12): 1390-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7882807" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;9. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995; 102(1): 7-16. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7831044" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;10. Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology &amp;amp; Visual Science 1998; 39(2): 233-52. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9477980" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;11. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998; 105(10): 1801-15. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9787347" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;12. Fong DS, Ferris FL, 3rd, Davis MD, Chew EY. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology 1999; 127(2): 137-41. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10030553" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;13. Knudsen LL, Lervang HH, Lundbye-Christensen S, Gorst-Rasmussen A. The North Jutland County Diabetic Retinopathy Study (NCDRS) 2. Non-ophthalmic parameters and clinically significant macular oedema. British Journal of Ophthalmology 2007;91(12):1593-5. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17202201" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;14. Pradeepa R, Anitha B, Mohan V, Ganesan A, Rema M. Risk factors for diabetic retinopathy in a South Indian Type 2 diabetic population-the Chennai Urban Rural Epidemiology Study (CURES) Eye Study 4. Diabetic Medicine 2008;25(5):536-42. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18346159" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;15. Romero-Aroca P, Fernandez-Balart J, Baget-Bernaldiz M, Martinez-Salcedo I, Mendez-Marin I, Salvat-Serra M, et al. Changes in the diabetic retinopathy epidemiology after 14 years in a population of Type 1 and 2 diabetic patients after the new diabetes mellitus diagnosis criteria and a more strict control of the patients. Journal of Diabetes and its Complications 2009;23(4):229-38.&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18439844" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;16. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine 1993; 329(14): 977-86. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8366922" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;17. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Archives of Ophthalmology 1995; 113(1): 36-51. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7826293" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;18. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Archives of Ophthalmology 1998; 116(7): 874-86. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9682700" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;19. Kohner EM, Aldington SJ, Stratton IM, Manley SE, Holman RR, Matthews DR, et al. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Archives of Ophthalmology 1998; 116(3): 297-303. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9514482" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;20. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837-53. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9742976" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;21. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 854-65. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9742977" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;22. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. British Medical Journal 1998; 317(7160): 703-13. &lt;A href="http://www.bmj.com/cgi/content/full/317/7160/703" target="_blank"&gt;Link to full text here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;23. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44(2): 156-63. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11270671" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;24. Chase HP, Garg SK, Jackson WE, Thomas MA, Harris S, Marshall G, et al. Blood pressure and retinopathy in type I diabetes. Ophthalmology 1990; 97(2): 155-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2326002" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;25. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008; 115(11):1859-68. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19068374" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;26. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009; 116(3):497-503. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19167079" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;27. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 Suppl 2: B54-64. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10860192" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;28. Al-Maskari F, El-Sadig M. Prevalence of diabetic retinopathy in the United Arab Emirates: a cross-sectional survey. BMC Ophthalmology 2007; 7:11. &lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1913498" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;29. Al-Adsani AM. Risk factors for diabetic retinopathy in Kuwaiti type 2 diabetic patients. Saudi Medical Journal 2007; 28(4):579-83. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17457481" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;30. Shrestha MK, Paudyal G, Wagle RR, Gurung R, Ruit S, Onta SR. Prevalence of and factors associated with diabetic retinopathy among diabetics in Nepal: a hospital based study. Nepal Medical College Journal 2007; 9(4):225-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18298009" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;31. Tikellis G, Wang S, Wong N, Wang JJ, Alex Harper C, Wong TY. Poor metabolic and blood pressure control in patients with diabetic retinopathy attending a tertiary ophthalmic hospital in Australia. Diabetes Research and Clinical Practice 2008; 80(2):208-12. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18207279" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;32. Chew EY, Klein ML, Ferris FL, 3rd, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology 1996; 114(9): 1079-84. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8790092" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;33. Klein R, Sharrett AR, Klein BE, Moss SE, Folsom AR, Wong TY, et al. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes : the atherosclerosis risk in communities study. Ophthalmology 2002; 109(7): 1225-34. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12093643" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;34. Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Research and Clinical Practice 2002; 56(1): 1-11. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11879715" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;35. Cusick M, Chew EY, Chan CC, Kruth HS, Murphy RP, Ferris FL, 3rd. Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology 2003; 110(11): 2126-33. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14597519" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;36. Galetovic D, Karlica D, Bucan K, Znaor L. [The role of clinical and metabolic factors in the genesis and development of diabetic retinopathy]. Acta Medica Croatica 2008; 62(1):23-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18365496" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;37. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370(9600):1687-97. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17988728" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;38. Funatsu H, Shimizu E, Noma H, Mimura T, Hori S. Association between serum lipoprotein (a) level and progression of non-proliferative diabetic retinopathy in Type 2 diabetes. Acta Ophthalmologica 2008 [Epub ahead of print] &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18700887" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;39. Muhlhauser I. Cigarette smoking and diabetes: an update. Diabetic Medicine 1994; 11(4): 336-43. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8088104" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;40. Muhlhauser I, Bender R, Bott U, Jorgens V, Grusser M, Wagener W, et al. Cigarette smoking and progression of retinopathy and nephropathy in type 1 diabetes. Diabetic Medicine 1996; 13(6): 536-43. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8799657" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;41. Karamanos B, Porta M, Songini M, Metelko Z, Kerenyi Z, Tamas G, et al. Different risk factors of microangiopathy in patients with type I diabetes mellitus of short versus long duration. The EURODIAB IDDM Complications Study. Diabetologia 2000; 43(3): 348-55. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10768096" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;42. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Archives of Ophthalmology 1989; 107(2):237-43. &lt;A href="http://archopht.ama-assn.org/cgi/reprint/107/2/237" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;43. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Archives of Ophthalmology 1989; 107(2):244-9. &lt;A href="http://archopht.ama-assn.org/cgi/reprint/107/2/244" target="_blank"&gt;Link to full text here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;44. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Archives of Ophthalmology 1994; 112(9):1217-28. &lt;A href="http://archopht.ama-assn.org/cgi/reprint/112/9/1217" target="_blank"&gt;Link to full text here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;45. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Archives of Ophthalmology 1984; 102(4):520-6. &lt;A href="http://archopht.ama-assn.org/cgi/reprint/102/4/520" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;46. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Archives of Ophthalmology 1984; 102(4):527-32. &lt;A href="http://archopht.ama-assn.org/cgi/reprint/102/4/527" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;47. Birinci A, Birinci H, Abidinoglu R, Durupinar B, Oge I. Diabetic retinopathy and HLA antigens in type 2 diabetes mellitus. European Journal of Ophthalmology 2002; 12(2):89-93. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12022291" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;48. Mimura T, Funatsu H, Uchigata Y, Kitano S, Shimizu E, Amano S, et al. Glutamic acid decarboxylase autoantibody prevalence and association with HLA genotype in patients with younger-onset type 1 diabetes and proliferative diabetic retinopathy. Ophthalmology 2005; 112(11):1904-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16157380" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;49. Wong TY, Cruickshank KJ, Klein R, Klein BE, Moss SE, Palta M, et al. HLA-DR3 and DR4 and their relation to the incidence and progression of diabetic retinopathy. Ophthalmology 2002; 109(2):275-81. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11825808" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;50. Hietala K, Forsblom C, Summanen P, Groop PH. Heritability of proliferative diabetic retinopathy. Diabetes 2008; 57(8):2176-80. &lt;A href="http://diabetes.diabetesjournals.org/content/57/8/2176.long" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;51. Emanuele N, Sacks J, Klein R, Reda D, Anderson R, Duckworth W, et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care 2005; 28(8):1954-8. &lt;A href="http://care.diabetesjournals.org/content/28/8/1954.long" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;52. Simmons D, Clover G, Hope C. Ethnic differences in diabetic retinopathy. Diabetic Medicine 2007; 24(10):1093-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17725636" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;53. Raymond NT, Varadhan L, Reynold DR, Bush K, Sankaranarayanan S, Bellary S, et al. Higher prevalence of retinopathy in diabetic patients of South Asian ethnicity compared with white Europeans in the community: a cross-sectional study. Diabetes Care 2009; 32(3):410-5. &lt;A href="http://care.diabetesjournals.org/content/32/3/410.long" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;54. Lim A, Stewart J, Chui TY, Lin M, Ray K, Lietman T, et al. Prevalence and risk factors of diabetic retinopathy in a multi-racial underserved population. Ophthalmic Epidemiology 2008; 15(6):402-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19065433" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;55. Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990; 13(1):34-40. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2404715" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;56. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care 2000; 23(8):1084-91. &lt;A href="http://care.diabetesjournals.org/content/23/8/1084.long" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;57. Sheth BP. Does pregnancy accelerate the rate of progression of diabetic retinopathy?: an update . Current Diabetes Reports 2008; 8(4):270-3. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18631438" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;58. NICE. Diabetes in Pregnancy: National Institute for Clinical Excellence, 2008. &lt;A href="http://guidance.nice.org.uk/CG63" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;59. Nunes S, Pires I, et al. Microaneurysm Turnover Is a Biomarker for Diabetic Retinopathy Progression to Clinically Significant Macular Edema: Findings for Type 2 Diabetics with Non proliferative Retinopathy. Ophthalmologica 2009; 223(5):292-297. &lt;A href="http://content.karger.com/produktedb/produkte.asp?typ=fulltext&amp;amp;file=000213639" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;60. Brazionis L, Rowley K, Itsiopoulos C, O'Dea K. Is risk of diabetic retinopathy lower in Australia's Greek-born migrants? Diabetic Medicine 2010; 27(6):660-5. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20546284" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;61. Hietala K, Harjutsalo V, Forsblom C, Summanen P, Groop PH. Age at onset and the risk of proliferative retinopathy in type 1 diabetes. Diabetes Care 2010; 33(6):1315-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20185730" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;62. O'Dell L. Association of dietary nutrient intakes in relation to progression of diabetic retinopathy in blacks with type 1 diabetes mellitus. Optometry 2010; 81(8):383.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;63. Targher G, Bertolini L, Chonchol M, Rodella S, Zoppini G, Lippi G, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia 2010; 53(7):1341-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20369224" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;64. West SD, Groves DC, Lipinski HJ, Nicoll DJ, Mason RH, Scanlon PH, et al. The prevalence of retinopathy in men with Type 2 diabetes and obstructive sleep apnoea. Diabetic Medicine 2010; 27(4):423-30. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20536514" target="_blank"&gt;Link to PubMed abstract here.&lt;/SPAN&gt;&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;65. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. New England Journal of Medicine 2010; 363(3):233-44. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20587587" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;SPAN style="COLOR: #a81400"&gt;
&lt;P&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;STRONG&gt;Further Evidence&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/SearchResults.aspx?catID=5134&amp;amp;tabID=289&amp;amp;" target="_blank"&gt;Links to systematic reviews on diabetic retinopathy in&amp;nbsp;NHS Evidence - diabetes&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Guidelines&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5659&amp;amp;sort=PUBLISHER&amp;amp;resultsPerPage=50&amp;amp;summaries=true&amp;amp;" target="_blank"&gt;Links to supporting Guidelines&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Patient Information&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?tabID=292&amp;amp;catID=5659&amp;amp;sort=PUBLISHER&amp;amp;resultsPerPage=50&amp;amp;summaries=true&amp;amp;" target="_blank"&gt;Links to supporting Patient Information&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Reference Material&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/SearchResults.aspx?tabID=290&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=PUBLICATION_DATE&amp;amp;catID=5659" target="_blank"&gt;Links to supporting reference material&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication details&lt;BR&gt;&lt;/STRONG&gt;Originally written by Peter Scanlon (Consultant Ophthalmologist and National Clinical Director of the English National Screening Programme for Diabetic Retinopathy) in June 2006, since reviewed and updated in June 2007 by P Scanlon, in June 2008 by P Scanlon and Irene Stratton, in June 2009 by P Scanlon, and in August 2010 by P Scanlon.&lt;BR&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387102</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=387102]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetic Retinopathy - Screening for diabetic retinopathy</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,EYES AND VISION,CHRONIC COMPLICATIONS,CAUSES,EYE DISEASES,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>part of the 2010 Annual Evidence Update on Diabetic Retinopathy</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetic Retinopathy - Screening for diabetic retinopathy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt; 13 September 2010&lt;/P&gt;
&lt;P&gt;Originally written by P Scanlon in June 2006, updated annually, &lt;A href="#ref1"&gt;link to further author and publication details here.&lt;/A&gt;&amp;nbsp; &lt;BR&gt;Changes and additions since August 2009 are highlighted in red.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387096" target="_blank"&gt;Link back to home page for 2010 Annual Evidence Update on Diabetic Retinopathy here.&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387421" target="_blank"&gt;Link to table of abbreviations here.&lt;/A&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage9 border=0 name=nelh_tempImage9 alt="Image of: screening camera and visual acuity chart" src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID321866/nelhImp_0000_photo9-screeningcameraandvisualacuitychart.jpg" width=200 height=155&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;In 1989, Rohan [1] published a qualitative assessment of the effect that a screening programme for diabetic retinopathy might have on the prevention of blindness in England and Wales. He estimated that screening and early treatment of retinopathy would prevent deterioration of visual acuity and could reduce the risk of blindness due to diabetic retinopathy by an estimated 56% and prevent 260 new cases of blindness in diabetics under the age of 70 each year in England and Wales. In 1990, the St Vincent Declaration [2] recognised diabetes and diabetic retinopathy to be a major and growing European health problem, a problem at all ages and in all countries. The first of the five-year targets that were unanimously agreed by Government Health Departments and patient’s organisations from all European countries was to reduce new blindness due to diabetes by one third or more.&lt;BR&gt;&lt;BR&gt;In 1995, Kristinsson [3] reported the low prevalence of blindness in people with Type 1 and Type 2 diabetes in Iceland, which he attributed to a screening programme that had been established in 1980. &lt;BR&gt;&lt;BR&gt;In 1996, Bachmann and Nelson [4] produced a report entitled 'Screening for diabetic retinopathy: A quantitative overview of the evidence, applied to the populations of health authorities and boards'. For a total population of half million, about 5000 would have diabetes. If all of these were screened, about 4% would be detected as requiring treatment during an initial screening round, but this yield would decreased to about 2% in subsequent annual screening rounds. Of those treated, the population prevented from going blind would be 6% with a year of treatment and 34% within ten years of treatment. For every 100 patients with treatable disease, the number expected to become blind or severely visually impaired within 10 years would be 55 if none were treated and 13 if all were treated.&lt;BR&gt;&lt;BR&gt;In 1999, the NHS Centre for Reviews produced a bulletin [5] and a journal publication [6] stating that screening can be effectively provided by trained and accredited optometrists or by retinal photographers in a variety of locations.&lt;BR&gt;&lt;BR&gt;In 2000, Garvican [7] and Gillow [8] reported the findings of a group commissioned by the National Screening Committee to develop a model for a comprehensive national risk-reduction programme in the UK. The group proposed the introduction of a systematic national programme based on digital photography.&lt;BR&gt;&lt;BR&gt;In 2000, a review by Hutchinson [9] et al concluded that, based on an assessment of available cohort studies, the most effective strategy for testing is the use of mydriatic retinal photography with the additional use of ophthalmoscopy for cases where photographs are ungradeable.&lt;BR&gt;&lt;BR&gt;In 2000, a review article by Stefansson [10] concluded that from a public health standpoint screening for diabetic eye disease is one of the most cost effective health procedures available. &lt;BR&gt;&lt;BR&gt;In 2002, the Health Technology Board for Scotland [11] recommended that a national diabetic retinopathy screening programme for Scotland should be established to detect referable (sight-threatening) retinopathy using a three-stage process based on non-mydriatic digital cameras, with the use of mydriasis and slit-lamps, where necessary.&lt;BR&gt;&lt;BR&gt;In 2002, the National Institute of Clinical Excellence [12] recommended the eyes of people with type 2 diabetes are screened at the time of diagnosis and at least annually thereafter, &lt;SPAN style="COLOR: #a81400"&gt;and subsequent guideline CG66 [13] retained this recommendation.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;In 2002, the National Service Framework for Diabetes: Delivery Strategy [14] announced the introduction of a National Screening Programme for Sight-Threatening Diabetic Retinopathy in England. &lt;BR&gt;&lt;BR&gt;In 2004, Williams [15] produced a report for the American Academy of Ophthalmology summarising the use of single-field fundus photography for diabetic retinopathy screening.&lt;BR&gt;&lt;BR&gt;In 2004, the National Institute of Clinical Excellence [16] recommended annual screening for people with Type 1 Diabetes by visual acuity and digital photography after mydriasis with tropicamide. &lt;BR&gt;&lt;BR&gt;In the Four Nations there is unequivocal support for the use of digital photography as the best method of screening. The use of selective mydriasis and the number fields captured have been more controversial. The reasons for digital photography being the preferred method are gained from the following studies.&lt;BR&gt;&lt;BR&gt;1. Direct Ophthalmoscopy &lt;BR&gt;Studies of direct ophthalmoscopy against a recognised reference standard of seven-field stereo photography, an ophthalmologist using slit-lamp biomicroscopy or fluorescein angiography showed variable results in studies by Palmberg [17], Sussman [18], Foulds [19], Moss [20], Kleinstein [21], Awh [22], Nathan [23], Pugh [24] and Harding [25]. The results are considered too variable between different professional groups and even in the hands of a specialist registrar in ophthalmology [25] the sensitivity achieved for the detection of sight-threatening retinopathy was only 65% (CI 51-79%).&lt;BR&gt;&lt;BR&gt;2. Optometrist's slit-lamp biomicroscopy&lt;BR&gt;A number of studies have assessed the performance of Optometrists slit-lamp biomicroscopy including those by Hammond [26] Burnett [27], Prasad [28], Hulme [29], Olson [30], Sharp [31], Tu [32] and Warburton [33]. In the best designed study by Olson [30] and Sharp [31], slit-lamp examination by optometrists achieved a sensitivity of 73% (52-88) and a specificity of 90% (87-93) for the detection of sight threatening retinopathy. No technical failure was reported. However, with two-field imaging, manual grading of red-free digital images achieved a sensitivity of 93% (82-98) and a specificity of 87% (84-90). The technical failure rate for digital imaging reported was 4.4% of patients. Slit-lamp bio-microscopy schemes also have the disadvantage that, for Quality Assurance purposes, a percentage of patients require re-examination as opposed to re-examination of the images in a scheme using digital photography.&lt;BR&gt;&lt;BR&gt;3. Mydriatic photography (&amp;lt; 7 fields) using 35 mm film or Polaroid.&lt;BR&gt;Studies of mydriatic photography with 35 mm film or Polaroid against a recognised reference standard of seven-field stereo photography, an ophthalmologist using slit-lamp biomicroscopy or fluorescein angiography showed consistently good results by Kalm [34], Lee [35], Pugh [24], Schachat [36], Aldington [37], Harding [25], Kiri [38], Taylor [39], Broadbent [40], Moller [41], Stellingwerf [42], Pandit [43], Olson [30] &amp;amp; Sharp [31]. These studies have shown that consistently good results can be achieved, with sensitivities of &amp;gt; 80% and high levels of specificity, using mydriatic photography with 35 mm film or Polaroid in screening for referable or sight-threatening diabetic retinopathy. In these studies, specificity does vary depending on whether ungradeable images are regarded as test positive but levels of &amp;gt; 85% are consistently achieved. &lt;BR&gt;&lt;BR&gt;4. Non-mydriatic photography&lt;BR&gt;There have been strong proponents of non-mydriatic photography for many years. In 1993, ungradable image rates were reported as low as 4% by Leese [44]. However, it has been recognised in more recent years, following the publication of studies by Scanlon [45] and Murgatroyd [46] that ungradable image rates for non-mydriatic digital photography in a predominantly white Caucasian population are of the order of 20 - 26% (19.7% and 26% being reported in the two studies). Age is the strongest correlator to poor quality images in non-mydriatic digital photography as shown in the publication by Scanlon [47]. The Health Technology Board for Scotland used data from the Scanlon [45] study in their report [11] and concluded that similar sensitivities and specificities could be achieved by dilating those patients with ungradable images. This relies on the ability of the screener to accurately determine an ungradable image at the time of screening and, in the Scottish system, relies on the assumption that the grading of one field will detect referable retinopathy with the same degree of accuracy as the grading of two fields (giving evidence from Olson’s study [30]). Other proponents of digital photography have attempted to capture 3-fields [48-50], five-fields [51], and remarkably Shiba [52] excluded the over 70 years age group and attempted 9 x overlapping non-mydriatic 450 fields. &lt;BR&gt;Digital camera systems have lower flash intensities than those using Polaroid or 35mm film. Taylor [39] reported a low flash power (10 W vs. 300 W) of one of the earlier digital systems. This has now increased since the modern digital camera backs require more light but not to the level of 35 mm film or Polaroid cameras.&lt;BR&gt;&lt;BR&gt;5. Mydriatic digital photography&lt;BR&gt;Studies of mydriatic digital photography against a recognised reference standard of seven-field stereo photography, an ophthalmologist using slit-lamp biomicroscopy have shown showed consistently good results by Taylor [39], Razvi [53], Rudnisky [54], Olson [30], Sharp [31] and Scanlon [45]. The study by Olson [30] and Sharp [31] demonstrated that, in 586 patients, for the detection of sight-threatening retinopathy, manual grading of two-field red-free digital images achieved a sensitivity of 93% (82-98) and a specificity of 87% (84-90). The reference standard was slit-lamp biomicroscopy by retinal specialists. Digital imaging had an ungradable image rate of 4.4% of patients. The study by Scanlon [45] demonstrated that for mydriatic digital photography, in 1549 patients, for the detection of sight-threatening retinopathy, the sensitivity was 87.8%, specificity was 86.1% and ungradable image rate was 3.7%. The reference standard was slit-lamp biomicroscopy by an experienced ophthalmologist whose examination technique was tested against 7-field stereo-photography in a separate study [55].&lt;BR&gt;&lt;BR&gt;The English Screening Programme for Sight-threatening Diabetic Retinopathy have interpreted the results from the above mentioned studies in their recommendations for a screening programme based on 2-field mydriatic digital photography. In addition the English Screening Programme have used data from the study by Garvican [56] to develop their Quality Assurance Objectives and Standards. These and other information relating to the English Screening Programme are available on the website &lt;A href="http://www.retinalscreening.nhs.uk/" target="_blank"&gt;www.retinalscreening.nhs.uk&lt;/A&gt; &lt;BR&gt;Two review articles from the USA were written in 2006, the first by Chew [57] concluded that, although screening techniques do not replace the eye examination, in populations with poor access to ophthalmic care, screening techniques such as the non-mydriatic camera used in offices of primary care physicians may be useful in identifying lesions of diabetic retinopathy requiring treatment. The second article by Whited [58], which included very few non US based studies, concluded that, based on existing data, tele-ophthalmology appears to be an accurate and reliable test for detecting diabetic retinopathy and macular edema.&lt;BR&gt;&lt;BR&gt;In 2007 - 08, reports of diabetic retinopathy screening were published from Spain [59], France [60-61], the Canary Islands [62], Western Cape [63], and the USA [64]. &lt;BR&gt;&lt;BR&gt;Scanlon [47] and Murgatroyd [65] have shown that age is the commonest predictive factor for unassessable images and cataract the commonest cause. Scanlon [66] reported that the majority of visual loss in a population with diabetes is due to causes other than DR. BCVA alone is not a reliable criterion in predicting STDR.&lt;BR&gt;Garvican [67] described the challenges facing quality assurance of the English Screening Programme.&lt;BR&gt;&lt;BR&gt;Walker [68] described how a limited telephone intervention can improve significantly participation in retinopathy screening in a minority, low-income population. Zhang [69] conducted a systematic literature search of the effectiveness of interventions aimed to increase retinal screening among people with diabetes. &lt;BR&gt;&lt;BR&gt;Scanlon [70] and Leese [71] both demonstrated that uptake of screening was inversely related to socioeconomic deprivation. The Scanlon study also demonstrated that with each increasing quintile of deprivation, the prevalence of sight-threatening diabetic retinopathy among screened patients increased (odds ratio of 0.98), while the prevalence of non-sight-threatening diabetic retinopathy remained unchanged. In the Leese study, poor attendance was not associated distance to retinal screening event, which used a mobile retinal photographic service screening at GP surgeries.&lt;BR&gt;&lt;BR&gt;Lim [72] used one-field non-mydriatic 45 degree photography as a screening tool for diabetic retinopathy resulted in a cohort of 742 patients referred to the Singapore National Eye Centre, of which 38.1% had diabetic retinopathy.&lt;BR&gt;&lt;BR&gt;Arun [73] reported that in a district that has operated retinal screening since 1986, diabetic retinopathy was not the commonest cause of blindness in the working age population, consistent with an effect of systematic annual screening.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;In the last 12 months (Sept 2009 – August 2010):&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Benbassat [74] reviewed studies that reported reliability of diabetic retinopathy screening methods. Reliability is a measure of the agreement between two or more observers using the same method, validity is the agreement between two different methods. The authors suggested that future studies on the effectiveness of methods of screening for DR should include data on their reliability. A study by Patra [75] reported the kappa coefficient of interobserver agreement between primary graders and an expert grader in the Bristol and Weston diabetic retinopathy screening programme was substantial (0.7) for the overall grading results and ranged from moderate to substantial (0.59-0.65) for referable, non-referable and ungradable disease categories.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Nagi [76] reported the results of a UK survey of screening service for diabetic retinopathy conducted in 2006.&amp;nbsp; At the time 48% of programmes had waiting lists for patients identified as needing further assessment and treatment for retinopathy. Shotliff [77] reported the results of a workload survey of members of the British Association of Retinal Screeners (BARS). Sixty-eight (31%) replied and suggested that an average of 14.4 patients were being screened per session on a fixed site programme, and an average of 15.7 per session with a mobile service. A standard morning session was, on average, 3 hours and 23 minutes long on a fixed site and 3 hours and 14 minutes on a mobile site. A standard afternoon session was, on average, 3 hours and 5 minutes long on a fixed site and 2 hours and 44 minutes long on a mobile site. Those undertaking grading as a stand alone activity screened an average of 39.3 patients per session (ranging from 20–75 patients per session).&lt;/SPAN&gt;&amp;nbsp; &lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Dervan [78] described the use of targeted mydriasis using a combination of pupil size and age, which improves the predictive value to 84%.&lt;/SPAN&gt; &lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Jones [79] described a successful telephone intervention to increase the rate of diabetic retinopathy screening for inner-city adults.&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #a81400"&gt;A Health Technology Assessment&amp;nbsp;[80] reviewed the diagnostic accuracy and economic evaluation of colour vision testing for diabetic retinopathy and concluded that there is insufficient evidence to support the use of CVT alone, or in combination with retinal photography, as a method for screening for retinopathy in patients with diabetes. The evidence that is available is limited in quantity and is of generally poor quality. &lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Wilson [81] reported results of a comparative trial of scanning laser ophthalmoscopy against digital photography with a reference standard of a medical retina specialist and a trainee ophthalmologist. The scanning laser ophthalmoscope was reported as having a sensitivity of 83.6 (75.1–92.1), specificity of 89.5 (85.8–93.2), and ungradable image quality of10.8 (9.2–12.4) with a kappa of 0.67 (0.58–0.76). However, if the ungradable images are counted as test positive, as was reported in the studies by Scanlon [45] and Harding [25], this produces a sensitivity of 84.6 (76.6–92.6), specificity of 78.8 (74.2–83.4) and a kappa of 0.51 (0.42–0.60). The study also reported a lower resolution for the detection of microaneurysms (identifying 80.9% versus 95%) and a longer average grading time than digital photography (106 seconds versus 94 or 64 seconds).&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Jones [82] reported a systematic review of the economic evidence relating to diabetic retinopathy screening. The article concluded that systematic screening for diabetic retinopathy is cost-effective in terms of sight years preserved compared with no screening. There is, however, controversy in relation to the economic evidence on optimal screening intervals. Further research is needed to address the issue of optimal screening interval, the opportunities for targeted screening to reflect relative risk and the effect of different screening intervals on attendance or compliance by patients. Misra [83] reported results of 63 622 screening episodes among 20 788 people in Norfolk. The prevalence of referable retinopathy increased from 2.0% in 1991-1993 to 6.7% in 1998-2001, then decreased to 4.7% in 2006. The authors suggest that screening intervals of up to 24 months should be considered for lower risk patients.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Mehlsen [84] described a new model for individualized optimization of the screening interval for diabetic retinopathy, which was tested in 1372 patients first screened during year 2000.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;References (including systematic reviews &amp;amp; primary research)&lt;BR&gt;&lt;/STRONG&gt;Links to PubMed abstracts are provided. Free full text may be available from the PubMed link. Where free full text access is not available, NHS staff in England can access full text of a number of journals via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/" target="_blank"&gt;NHS Evidence&lt;/A&gt; or can request the full text via their &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="mso-ansi-language: EN" lang=EN&gt;1. Rohan TE, Frost CD, Wald NJ. Prevention of blindness by screening for diabetic retinopathy: a quantitative assessment. British Medical Journal 1989; 299(6709): 1198-201. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2513049" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;2. Diabetes care and research in Europe: the Saint Vincent declaration. Diabetic Medicine 1990; 7(4): 360.&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="mso-ansi-language: EN" lang=EN&gt;3. Kristinsson JK, Gudmundsson JR, Stefansson E, Jonasson F, Gislason I, Thorsson AV. Screening for diabetic retinopathy. Initiation and frequency. Acta Ophthalmologica Scandinavica 1995; 73(6):525-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9019377" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="mso-ansi-language: EN" lang=EN&gt;&lt;BR&gt;&lt;BR&gt;4. Bachmann M, Nelson SJ. Screening for Diabetic Retinopathy: A quantitative overview of the evidence, applied to the populations of health authorities and boards. Bristol: Health Care Evaluation Unit, University of Bristol, 1996:1 - 46.&lt;BR&gt;&lt;BR&gt;5. NHS Centre for Reviews and Dissemination. Complications of diabetes: Screening for retinopathy, management of foot ulcers: Effective Health Care 1999; 5(4):1-12. &lt;A href="http://www.york.ac.uk/inst/crd/EHC/ehc54.pdf" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;6. Melville A, Richardson R, McIntosh A, O'Keeffe C, Mason J, Peters J, et al. Complications of diabetes: screening for retinopathy and management of foot ulcers. Quality in Health Care 2000; 9(2): 137-41. &lt;A href="http://qshc.bmj.com/cgi/content/full/9/2/137" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;7. Garvican L, Clowes J, Gillow T. Preservation of sight in diabetes: developing a national risk reduction programme. Diabetic Medicine 2000; 17(9): 627-34. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11051281" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;8. Gillow JT, Gray JA. The National Screening Committee review of diabetic retinopathy screening. Eye 2001; 15(Pt 1): 1-2. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11318268" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;9. Hutchinson A, McIntosh A, Peters J, O'Keeffe C, Khunti K, Baker R, et al. Effectiveness of screening and monitoring tests for diabetic retinopathy--a systematic review. Diabetic Medicine 2000; 17(7): 495-506. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10972578" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="mso-ansi-language: EN" lang=EN&gt;&lt;BR&gt;&lt;BR&gt;10. Stefansson E, Bek T, Porta M, Larsen N, Kristinsson JK, Agardh E. Screening and prevention of diabetic blindness. Acta Ophthalmologica Scandinavica 2000; 78(4):374-85. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10990036" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="mso-ansi-language: EN" lang=EN&gt;&lt;BR&gt;&lt;BR&gt;11. Facey K, Cummins E, Macpherson K, Morris A, Reay L, Slattery J. Organisation of services for diabetic retinopathy screening. Glasgow: Health Technology Board for Scotland 2002. &lt;A href="http://www.ndrs.scot.nhs.uk/Links/Docs/hta1.pdf" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;12. &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:stockticker w:st="on"&gt;NICE&lt;/st1:stockticker&gt;. Management of type 2 diabetes. Retinopathy - screening and early management, 2002. &lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;r=true&amp;amp;o=10910" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;13. NICE. Type 2 diabetes: the management of type 2 diabetes, 2009. &lt;A href="http://www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdf" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;14. Department of Health. National Service Framework for Diabetes: delivery strategy. London, 2002. &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4003246" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="mso-ansi-language: EN" lang=EN&gt;&lt;BR&gt;&lt;BR&gt;15. Williams GA, Scott IU, Haller JA, Maguire AM, Marcus D, McDonald HR. Single-field fundus photography for diabetic retinopathy screening: a report by the American Academy of Opthalmology. Opthalmology 2004; 111(5):1055-1062. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15121388" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="mso-ansi-language: EN" lang=EN&gt;&lt;BR&gt;&lt;BR&gt;16. National Institute for Health and Clinical Excellence. Type 1 diabetes: diagnosis and management of type 1 diabetes in adults. 2004. &lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;r=true&amp;amp;o=10944" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;17. Palmberg P, Smith M, Waltman S, Krupin T, Singer P, Burgess D, et al. The natural history of retinopathy in insulin-dependent juvenile-onset diabetes. Ophthalmology 1981; 88(7): 613-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7267029" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;18. Sussman EJ, Tsiaras WG, Soper KA. Diagnosis of diabetic eye disease. Journal of the American Medical Association 1982; 247(23): 3231-4. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7087063" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;19. Foulds WS, MacCuish A, T B. Diabetic Retinopathy in the West of Scotland: Its Detection and Prevalence, and the Cost-effectiveness of a Proposed Screening Programme. Health Bulletin 1983; 41(6): 318-326.&lt;BR&gt;&lt;BR&gt;20. Moss SE, Klein R, Kessler SD, Richie KA. Comparison between ophthalmoscopy and fundus photography in determining severity of diabetic retinopathy. Ophthalmology 1985; 92(1): 62-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2579361" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;21. Kleinstein RN, Roseman JM, Herman WH, Holcombe J, Louv WC. Detection of diabetic retinopathy by optometrists. Journal of the American Optometric Association 1987; 58(11): 879-82. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/3693777" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;22. Awh CC, Cupples HP, Javitt JC. Improved detection and referral of patients with diabetic retinopathy by primary care physicians. Effectiveness of education. Archives of Internal Medicine 1991; 151(7): 1405-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2064492" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;23. Nathan DM, Fogel HA, Godine JE, Lou PL, D'Amico DJ, Regan CD, et al. Role of diabetologist in evaluating diabetic retinopathy. Diabetes Care 1991; 14(1): 26-33. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/1991432" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;24. Pugh JA, Jacobson JM, Van Heuven WA, Watters JA, Tuley MR, Lairson DR, et al. Screening for diabetic retinopathy. The wide-angle retinal camera. Diabetes Care 1993; 16(6): 889-95. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8100761" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;25. Harding SP, Broadbent DM, Neoh C, White MC, Vora J. Sensitivity and specificity of photography and direct ophthalmoscopy in screening for sight threatening eye disease: the Liverpool Diabetic Eye Study. British Medical Journal 1995; 311(7013): 1131-5. &lt;A href="http://www.bmj.com/cgi/content/full/311/7013/1131" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;26. Hammond CJ, Shackleton J, Flanagan DW, Herrtage J, Wade J. Comparison between an ophthalmic optician and an ophthalmologist in screening for diabetic retinopathy. Eye 1996; 10 ( Pt 1): 107-12. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8763314" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;27. Burnett S, Hurwitz B, Davey C, Ray J, Chaturvedi N, Salzmann J, et al. The implementation of prompted retinal screening for diabetic eye disease by accredited optometrists in an inner-city district of North London: a quality of care study. Diabetic Medicine 1998; 15 Suppl 3: S38-43. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9829768" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;28. Prasad S, Kamath GG, Jones K, Clearkin LG, Phillips RP. Effectiveness of optometrist screening for diabetic retinopathy using slit-lamp biomicroscopy. Eye 2001; 15(Pt 5): 595-601. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11702969" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;29. Hulme SA, Tin UA, Hardy KJ, Joyce PW. Evaluation of a district-wide screening programme for diabetic retinopathy utilizing trained optometrists using slit-lamp and Volk lenses. Diabetic Medicine 2002; 19(9): 741-5. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12207810" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;30. Olson JA, Strachan FM, Hipwell JH, Goatman KA, McHardy KC, Forrester JV, et al. A comparative evaluation of digital imaging, retinal photography and optometrist examination in screening for diabetic retinopathy. Diabetic Medicine 2003; 20(7): 528-34. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12823232" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;31. Sharp PF, Olson J, Strachan F, Hipwell J, Ludbrook A, O'Donnell M, et al. The value of digital imaging in diabetic retinopathy. Health Technology Assessment 2003; 7(30): 1-119. &lt;A href="http://www.hta.ac.uk/execsumm/summ730.htm" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;32. Tu KL, Palimar P, Sen S, Mathew P, Khaleeli A. Comparison of optometry vs digital photography screening for diabetic retinopathy in a single district. Eye 2004; 18(1): 3-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14707956" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;33. Warburton TJ, Hale PJ, Dewhurst JA. Evaluation of a local optometric diabetic retinopathy screening service. Diabetic Medicine 2004; 21(6): 632-5. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15154953" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;34. Kalm H, Egertsen R, Blohme G. Non-stereo fundus photography as a screening procedure for diabetic retinopathy among patients with type II diabetes. Compared with 60D enhanced slit-lamp examination. Acta Ophthalmologica (Copenhagen) 1989; 67(5): 546-53. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2589054" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;35. Lee VS, Kingsley RM, Lee ET, Lu M, Russell D, Asal NR, et al. The diagnosis of diabetic retinopathy. Ophthalmoscopy versus fundus photography. Ophthalmology 1993; 100(10): 1504-12. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8414411" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;36. Schachat AP, Hyman L, Leske MC, Connell AM, Hiner C, Javornik N, et al. Comparison of diabetic retinopathy detection by clinical examinations and photograph gradings. Barbados (West Indies) Eye Study Group. Archives of Ophthalmology 1993; 111(8): 1064-70. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8352689" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;37. Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK. Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia 1995; 38(4): 437-44. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7796984" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;38. Kiri A, Dyer DS, Bressler NM, Bressler SB, Schachat AP. Detection of diabetic macular edema: Nidek 3Dx stereophotography compared with fundus biomicroscopy. American Journal of Ophthalmology 1996; 122(5): 654-62. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8909204" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;39. Taylor DJ, Fisher J, Jacob J, Tooke JE. The use of digital cameras in a mobile retinal screening environment. Diabetic Medicine 1999; 16(8): 680-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10477214" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;40. Sensitivity and specificity of detection of diabetic maculopathy by a modified method. European Association for the Study of Diabetic Eye Complications (EASDec); 2000 26-28 May; Copenhagen, Denmark.&lt;BR&gt;&lt;BR&gt;41. Moller F, Hansen M, Sjolie AK. Is one 60 degrees fundus photograph sufficient for screening of proliferative diabetic retinopathy? Diabetes Care 2001; 24(12): 2083-5. &lt;A href="http://care.diabetesjournals.org/content/24/12/2083.full" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;42. Stellingwerf C, Hardus PL, Hooymans JM. Two-field photography can identify patients with vision-threatening diabetic retinopathy: a screening approach in the primary care setting. Diabetes Care 2001; 24(12): 2086-90. &lt;A href="http://care.diabetesjournals.org/content/24/12/2086.full" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;43. Pandit RJ, Taylor R. Quality assurance in screening for sight-threatening diabetic retinopathy. Diabetic Medicine 2002; 19(4): 285-91. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11942999" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;44. Leese GP, Ahmed S, Newton RW, Jung RT, Ellingford A, Baines P, et al. Use of mobile screening unit for diabetic retinopathy in rural and urban areas. British Medical Journal 1993; 306(6871): 187-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8443485" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;45. Scanlon PH, Malhotra R, Thomas G, Foy C, Kirkpatrick JN, Lewis-Barned N, et al. The effectiveness of screening for diabetic retinopathy by digital imaging photography and technician ophthalmoscopy. Diabetic Medicine 2003; 20(6): 467-74. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12786681" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;46. Murgatroyd H, Ellingford A, Cox A, Binnie M, Ellis JD, MacEwen CJ, et al. Effect of mydriasis and different field strategies on digital image screening of diabetic eye disease. British Journal of Ophthalmology 2004; 88(7): 920-4. &lt;A href="http://bjo.bmj.com/content/88/7/920.full" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;47. Scanlon PH, Foy C, Malhotra R, Aldington SJ. The influence of age, duration of diabetes, cataract, and pupil size on image quality in digital photographic retinal screening. Diabetes Care 2005; 28(10): 2448-53. &lt;A href="http://care.diabetesjournals.org/content/28/10/2448.full" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;48. Bursell SE, Cavallerano JD, Cavallerano AA, Clermont AC, Birkmire-Peters D, Aiello LP, et al. Stereo nonmydriatic digital-video color retinal imaging compared with Early Treatment Diabetic Retinopathy Study seven standard field 35-mm stereo color photos for determining level of diabetic retinopathy. Ophthalmology 2001; 108(3): 572-85. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11237913" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;49. Lim JI, LaBree L, Nichols T, Cardenas I. A comparison of digital non mydriatic fundus imaging with standard 35-millimeter slides for diabetic retinopathy. Ophthalmology 2000; 107(5): 866-70. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10811076" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="mso-ansi-language: EN" lang=EN&gt;&lt;BR&gt;&lt;BR&gt;50. Aptel F, Denis P, Rouberol F, Thivolet C. Screening of diabetic retinopathy: Effect of field number and mydriasis on sensitivity and specificity of digital fundus photography. Diabetes &amp;amp; Metabolism 2008; 34(3):290-3. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18406188" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN lang=EN&gt;&lt;BR&gt;&lt;BR&gt;51. Massin P, Erginay A, Ben Mehidi A, Vicaut E, Quentel G, Victor Z, et al. Evaluation of a new non-mydriatic digital camera for detection of diabetic retinopathy. Diabetic Medicine 2003; 20(8): 635-41. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12873290" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;52. Shiba T, Yamamoto T, Seki U, Utsugi N, Fujita K, Sato Y, et al. Screening and follow-up of diabetic retinopathy using a new mosaic 9-field fundus photography system. Diabetes Research and Clinical Practice 2002; 55(1): 49-59. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11755479" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;53. Razvi FM, Kritzinger EE, Tsaloumas MD, Ryder RE. Use of oral fluorescein angiography in the diagnosis of macular oedema within a diabetic retinopathy screening programme. Diabetic Medicine 2001; 18(12): 1003-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11903401" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;54. Rudnisky CJ, Hinz BJ, Tennant MT, de Leon AR, Greve MD. High-resolution stereoscopic digital fundus photography versus contact lens biomicroscopy for the detection of clinically significant macular edema. Ophthalmology 2002; 109(2): 267-74. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11825807" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;55. Scanlon PH, Malhotra R, Greenwood RH, Aldington SJ, Foy C, Flatman M, et al. Comparison of two reference standards in validating two field mydriatic digital photography as a method of screening for diabetic retinopathy. British Journal of Ophthalmology 2003; 87(10): 1258-63. &lt;A href="http://bjo.bmj.com/content/87/10/1258.full" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;56. Garvican L, Scanlon PH. A pilot quality assurance scheme for diabetic retinopathy risk reduction programmes. Diabetic Medicine 2004; 21(10): 1066-74. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15384952" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;57. Chew EY. Screening options for diabetic retinopathy. Current Opinion in Ophthalmology 2006; 17(6):519-22. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17065919" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;58. Whited JD. Accuracy and reliability of teleophthalmology for diagnosing diabetic retinopathy and macular edema: a review of the literature. Diabetes Technology &amp;amp; Therapeutics 2006; 8(1):102-11. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16472057" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;59. Garcia-Serrano JL, Serrano-Laborda D, Lopez-Pozas M, Cabello-Aparicio C, Castro-Rosales L. [The Granada Diabetic Retinopathy Study. Direct screening of 8,244 patients. I]. Archivos de la Sociedad Española de Oftalmología 2007; 82(11):681-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17979036" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;60. Deb-Joardar N, Germain N, Thuret G, Garcin AF, Manoli P, Defreyn A, et al. Systematic screening for diabetic retinopathy with a digital fundus camera following pupillary dilatation in a university diabetes department. Diabetic Medicine 2007; 24(3):303-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17263768" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;61. Soulie-Strougar M, Charles A, Metral P, Quercia P, Souchier M, Chirpaz L, et al. [Screening diabetic retinopathy in Burgundy with an itinerant nonmydriatic camera]. Journal Français d'Ophtalmologie 2007; 30(2):121-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17318092" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;62. Lopez-Bastida J, Cabrera-Lopez F, Serrano-Aguilar P. Sensitivity and specificity of digital retinal imaging for screening diabetic retinopathy. Diabetic Medicine 2007; 24(4):403-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17298591" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;63. Mash B, Powell D, du Plessis F, van Vuuren U, Michalowska M, Levitt N. Screening for diabetic retinopathy in primary care with a mobile fundal camera--evaluation of a South African pilot project. South African Medical Journal 2007; 97(12):1284-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18264611" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;64. Taylor CR, Merin LM, Salunga AM, Hepworth JT, Crutcher TD, O'Day DM, et al. Improving diabetic retinopathy screening ratios using telemedicine-based digital retinal imaging technology: the Vine Hill study. Diabetes Care 2007; 30(3):574-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17327323" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;65. Murgatroyd H, Cox A, Ellingford A, Ellis JD, Macewen CJ, Leese GP. Can we predict which patients are at risk of having an ungradeable digital image for screening for diabetic retinopathy? Eye 2008; 22(3):344-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17024219" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;66. Scanlon PH, Foy C, Chen FK. Visual Acuity Measurement and Ocular Co-Morbidity in Diabetic Retinopathy Screening. British Journal of Ophthalmology 2008; 92(6):775-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18356262" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;67. Garvican L. Issues regarding quality assurance in the English National Screening Programme for Sight-threatening Diabetic Retinopathy: response to paper by C. Arun et al., 'Establishing ongoing quality assurance in a retinal screening programme'. Diabetic Medicine 2007; 24(6):688-90; author reply 690-1. &lt;A href="http://www3.interscience.wiley.com/journal/117978077/Link%20to%20PubMed%20abstract%20here." target="_blank"&gt;Link to&amp;nbsp;full text&amp;nbsp;here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;68. Walker EA, Schechter CB, Caban A, Basch CE. Telephone intervention to promote diabetic retinopathy screening among the urban poor. American Journal of Preventive Medicine 2008; 34(3):185-91. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18312805" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;69. Zhang X, Norris SL, Saadine J, Chowdhury FM, Horsley T, Kanjilal S, et al. Effectiveness of interventions to promote screening for diabetic retinopathy. American Journal of Preventive Medicine 2007; 33(4):318-35. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17888859" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;70. Scanlon PH, Carter SC, Foy C, Husband RF, Abbas J, Bachmann MO. Diabetic retinopathy and socioeconomic deprivation in Gloucestershire. Journal of Medical Screening 2008; 15(3):118-21. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18927093" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;71. Leese GP, Boyle P, Feng Z, Emslie-Smith A, Ellis JD. Screening uptake in a well-established diabetic retinopathy screening program: the role of geographical access and deprivation. Diabetes Care 2008; 31(11):2131-5. &lt;A href="http://care.diabetesjournals.org/content/31/11/2131.long" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;72. Lim MC, Lee SY, Cheng BC, Wong DW, Ong SG, Ang CL, et al. Diabetic retinopathy in diabetics referred to a tertiary centre from a nationwide screening programme. Annals of the Academy of Medicine, Singapore 2008; 37(9):753-9. &lt;A href="http://www.annals.edu.sg/pdf/37VolNo9Sep2008/V37N9p753.pdf" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;73. Arun C, Al-Bermani A, Stannard K, Taylor R. Long-term impact of retinal screening on significant diabetes-related visual impairment in the working age Population-based study of diabetic retinopathy in Wolfsburg. Diabetic Medicine 2009; 26(5):489-492. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19646188?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;74. Benbassat J, Polak BC. Reliability of screening methods for diabetic retinopathy. Diabetic Medicine 2009; 26(8):783-90. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19709148" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;75. Patra S, Gomm EM, Macipe M, Bailey C. Interobserver agreement between primary graders and an expert grader in the Bristol and Weston diabetic retinopathy screening programme: a quality assurance audit. Diabetic Medicine 2009; 26(8):820-3. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19709153" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;76. Nagi DK, Gosden C, Walton C, Winocour PH, Turner B, Williams R, et al. A national survey of the current state of screening services for diabetic retinopathy: ABCD-diabetes UK survey of specialist diabetes services 2006. Diabetic Medicine 2009; 26(12):1301-5. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20002486" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;77. Shotliff K, Duncan G, Dewhirst R, Dixon L, Ellingford A, Greenwood R, et al. British Association of Retinal Screeners (BARS): survey of workload in UK diabetic retinopathy screening programmes. Practical Diabetes International 2010; 27(4):152-154. &lt;A href="http://www.eyescreening.org.uk/data/ocm/PDF%20files/Shotliff%20BARS%20Original%20Article%20(2).pdf" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;78. Dervan EW, O'Brien PD, Hobbs H, Acheson R, Flitcroft DI. Targeted mydriasis strategies for diabetic retinopathy screening clinics. Eye (London) 2010; 24(7):1207-12. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20139914" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;79. Jones HL, Walker EA, Schechter CB, Blanco E. Vision is precious: a successful behavioral intervention to increase the rate of screening for diabetic retinopathy for inner-city adults. Diabetes Educator 2010; 36(1):118-26. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20044537" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;80. Rodgers M, Hodges R, Hawkins J, Hollingworth W, Duffy S, McKibbin M, et al. Colour vision testing for diabetic retinopathy: a systematic review of diagnostic accuracy and economic evaluation. Health Technology Assessment 2009; 13(60):1-160. &lt;A href="http://www.hta.ac.uk/execsumm/summ1360.htm" target="_blank"&gt;Link to full text here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;81. Wilson PJ, Ellis JD, MacEwen CJ, Ellingford A, Talbot J, Leese GP. Screening for diabetic retinopathy: a comparative trial of photography and scanning laser ophthalmoscopy. Ophthalmologica 2010; 224(4):251-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20145421" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;82. Jones S, Edwards R. Diabetic retinopathy screening: a systematic review of the economic evidence. Diabetic Medicine 2010; 27(3):249-256. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20536486" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;83. Misra A, Bachmann MO, Greenwood RH, Jenkins C, Shaw A, Barakat O, et al. Trends in yield and effects of screening intervals during 17 years of a large UK community-based diabetic retinopathy screening programme. Diabetic Medicine 2009; 26(10):1040-7. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19900237" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;84. Mehlsen J, Erlandsen M, Poulsen PL, Bek T. Individualized optimization of the screening interval for diabetic retinopathy: a new model. Acta Ophthalmologica 2010. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20384605" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;SPAN style="COLOR: #a81400"&gt;&lt;SPAN style="COLOR: #000000"&gt;&lt;STRONG&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;BR&gt;Further Evidence&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/SearchResults.aspx?tabID=289&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=PUBLICATION_DATE&amp;amp;catID=5659&amp;amp;" target="_blank"&gt;Links to systematic reviews on diabetic retinopathy in&amp;nbsp;NHS Evidence - diabetes&lt;/A&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;Guidelines&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5659&amp;amp;sort=PUBLISHER&amp;amp;resultsPerPage=50&amp;amp;summaries=true&amp;amp;" target="_blank"&gt;Links to supporting Guidelines&lt;/A&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;Patient Information&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?tabID=292&amp;amp;catID=5659&amp;amp;sort=PUBLISHER&amp;amp;resultsPerPage=50&amp;amp;summaries=true&amp;amp;" target="_blank"&gt;Links to supporting Patient Information&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Reference Material&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/SearchResults.aspx?tabID=290&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=PUBLICATION_DATE&amp;amp;catID=5659" target="_blank"&gt;Links to supporting reference material&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication details&lt;/STRONG&gt;&lt;BR&gt;Originally written by Peter Scanlon (Consultant Ophthalmologist and National Clinical Director of the English National Screening Programme for Diabetic Retinopathy) in June 2006, since reviewed and updated in June 2007 by P Scanlon, in June 2008 by P Scanlon and Irene Stratton, in June 2009 by P Scanlon, and in August 2010 by P Scanlon.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387393</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=387393]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetic Retinopathy - Surgery for cataract and diabetic retinopathy</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,EYES AND VISION,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,EYE DISEASES,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>part of the 2010 Annual Evidence Update on Diabetic Retinopathy</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetic Retinopathy - Surgery for cataract and diabetic retinopathy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published:&lt;/STRONG&gt; 13 September 2010&lt;BR&gt;Originally written by P Scanlon in June 2006, updated annually, &lt;A href="#ref1"&gt;link to further author and publication details here.&lt;/A&gt;&amp;nbsp; &lt;BR&gt;Changes and additions since August 2009 are highlighted in red.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387096" target="_blank"&gt;Link back to home page for 2010 Annual Evidence Update on Diabetic Retinopathy here&lt;/A&gt;.&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387421" target="_blank"&gt;Link to table of abbreviations here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Diabetes/contentID387393/nelhImp_0000_11-12.jpg"&gt;&lt;/P&gt;
&lt;P&gt;Klein [1] demonstrated that cataract surgery is a relatively frequent occurrence in people with diabetes. Studies by Henricsson [2], Chew [3], Mittra [4], Chung [5], Somaiya [6] and Liao [7] have shown an increased risk of ocular complications in diabetics after cataract surgery but the same studies and those by Dowler [8], Flesner [9], Squirrell [10] and Hauser [11] have shown that modern surgical techniques have minimised them. Macular oedema before surgery is the most common condition that limits post-operative visual recovery [3,5,8]. Thus, pre-operative laser treatment is needed. Photocoagulation of preproliferative or early preproliferative diabetic retinopathy is also advisable, due to the increased risk of iris neovascularisation or retinopathy progression after surgery [3].&lt;BR&gt;&lt;BR&gt;Patients with preoperative NPDR have a greater chance to show postoperative retinopathy progression which was often associated with poor glycaemic control [2,11]. Poor renal function was an additional risk factor [5]. Anterior capsular contraction [12] and posterior capsular opacification [13] were reported to be more common in eyes of patients with diabetes mellitus. However, a more recent study [14] has suggested that diabetes mellitus appears to be associated with a lower long-term incidence and a decreased risk of Nd:YAG capsulotomy. However younger age, pars plana vitrectomy, postoperative inflammation, plate-haptic silicone and PMMA IOLs appear to be associated with a greater risk. Jurecka [15] reported a series of 86 patients; 26 diabetics, who had no clinically detectable diabetic retinopathy preoperatively, and 60 non-diabetic controls. Apart from a significant major increase in retinal thickness in diabetics in all examined areas in month 2 there were no difference in outcome between the controls and those with diabetes. &lt;BR&gt;&lt;BR&gt;A recent report [16] from Cheema has suggested that intravitreal administration of bevacizumab at the time of cataract surgery might be a useful therapeutic option in some patients and another report by Kim [17] suggested that a single intraoperative sub-Tenon injection of triamcinolone acetonide might reduce the progression of diabetic retinopathy and improve visual outcomes after cataract surgery. However, the group of patients that one might consider either of these options for is unclear.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Akinci [18] retrospectively evaluated the records of 31 patients with diabetic clinically significant macular edema and cataract, who underwent phacoemulsification with intravitreal injection of 1.25 mg bevacizumab at the time of surgery. The central macular thickness (CMT) recorded at the first and third months after the surgery were significantly lower than the initial CMT (P &amp;lt; 0.001, P &amp;lt; 0.001).&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Takata [19] compared the effectiveness of intravitreal injection (IVT) versus posterior subtenon infusion (STI) of triamcinolone acetonide performed during phacoemulsification cataract surgery in eyes with refractory diffuse diabetic macular edema. Ten patients from the IVT group and 9 patients from the STI group completed the 24-week study visit. A significant improvement in best-corrected visual acuity was observed only in the IVT group at 4 weeks (mean difference +/- standard error, improved to 20/116; P = 0.0437), 8 weeks (20/110; P = 0.0355), and 12 weeks (20/121; P = 0.0471) postoperatively.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Hong [20] reported the results of 190 patients with diabetes undergoing cataract surgery at an eye clinic in Sydney, Australia, between 2004 and 2006. There were 56 patients with unilateral surgery performed before baseline (mean postoperative duration 3.3+/-3.3 years). The prevalence of DR at baseline was higher in these 56 pseudophakic eyes than in 324 phakic eyes (71.4% vs. 48.2%, respectively, adjusted OR 2.16; 95% CI, 1.16-4.03). Of the 190 patients, 169 were followed for 12+ months postoperatively; 278 eyes were pseudophakic, and 60 eyes remained phakic at 12 months. During the 12-month postoperative period, incident DR developed in 28.2% of pseudophakic eyes and 13.8% of phakic eyes (adjusted OR 2.65; 95% CI, 1.06-6.61). In a paired-eye comparison of 45 patients who remained unilaterally pseudophakic at 12 months and were at risk of DR progression, 35.6% of pseudophakic eyes exhibited DR progression compared with 20.0% of the fellow phakic eyes (adjusted OR 2.21; 95% CI, 0.85-5.71). &lt;BR&gt;Following publication of the article by Hong [20], Goldman [21] pointed out that ‘since cataract development can be advanced by diabetes, it stands to reason that overall diabetic damage to the eye is greater in the more cataractous eye’.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;Fernandez-Rubio [22] studied the conjunctival bacterial pattern of patients with diabetes undergoing cataract surgery and found a significantly higher prevalence of Staphylococcus aureus, Enterococci, certain Streptococci, and Klebsiella sp. than in patients without diabetes. Patients with a blood creatinine level above 105.2 mumol/l also had an increased conjunctival bacterial prevalence.&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;SPAN style="COLOR: #000000"&gt;Although diabetes is a risk factor for the development of cataracts and studies have shown an increased risk of ocular complications in people with diabetes after cataract surgery, modern surgical techniques and appropriate pre-operative laser treatment have led to an overall good visual outcome in the majority of patients.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;References (including systematic reviews &amp;amp; primary research)&lt;BR&gt;&lt;/STRONG&gt;Links to PubMed abstracts are provided. Free full text may be available from the PubMed link. Where free full text access is not available, NHS staff in England can access full text of a number of journals via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/" target="_blank"&gt;NHS Evidence&lt;/A&gt; or can request the full text via their &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;1. Klein BE, Klein R, Moss SE. Incidence of cataract surgery in the Wisconsin Epidemiologic Study of Diabetic Retinopathy. American Journal of Ophthalmology 1995; 119(3): 295-300. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=7872389" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;2. Henricsson M, Heijl A, Janzon L. Diabetic retinopathy before and after cataract surgery. British Journal of Ophthalmology, 1996:780 - 793. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=8942374" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;3. Chew EY, Benson WE, Remaley NA, Lindley AA, Burton TC, Csaky K, et al. Results after lens extraction in patients with diabetic retinopathy; Early Treatment Diabetic Retinopathy Study Report Number 25. Archives of Ophthalmology 1999; 117: 1600-1606. &lt;A href="http://archopht.ama-assn.org/cgi/content/full/117/12/1600" target="_blank"&gt;Link to full text here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;4. Mittra RA, Borrillo JL, Dev S, Mieler WF, Koenig SB. Retinopathy progression and visual outcomes after phacoemulsification in patients with diabetes mellitus. Archives of Ophthalmology 2000; 118(7): 912-7. &lt;A href="http://archopht.ama-assn.org/cgi/content/full/118/7/912" target="_blank"&gt;Link to full text here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;5. Chung J, Kim MY, Kim HS, Yoo JS, Lee YC. Effect of cataract surgery on the progression of diabetic retinopathy. Journal of Cataract and Refractive Surgery 2002; 28(4): 626-30. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=11955902" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;6. Somaiya MD, Burns JD, Mintz R, Warren RE, Uchida T, Godley BF. Factors affecting visual outcomes after small-incision phacoemulsification in diabetic patients. Journal of Cataract and Refractive Surgery 2002; 28(8): 1364-71.&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=12160805" target="_blank"&gt; Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;7. Liao SB, Ku WC. Progression of diabetic retinopathy after phacoemulsification in diabetic patients: a three-year analysis. Chang Gung Medical Journal 2003; 26(11): 829-34. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=14765753" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;8. Dowler JG, Hykin PG, Hamilton AM. Phacoemulsification versus extracapsular cataract extraction in patients with diabetes. Ophthalmology 2000; 107(3): 457-62.&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=10711881" target="_blank"&gt; Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;9. Flesner P, Sander B, Henning V, Parving HH, Dornonville de la Cour M, Lund-Andersen H. Cataract surgery on diabetic patients. A prospective evaluation of risk factors and complications. Acta Ophthalmologica Scandinavica 2002; 80(1): 19-24. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=11906299" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;10. Squirrell D, Bhola R, Bush J, Winder S, Talbot JF. A prospective, case controlled study of the natural history of diabetic retinopathy and maculopathy after uncomplicated phacoemulsification cataract surgery in patients with type 2 diabetes. British Journal of Ophthalmology 2002; 86(5): 565-71. &lt;A href="http://bjo.bmjjournals.com/cgi/content/full/86/5/565" target="_blank"&gt;Link to full text here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;11. Hauser D, Katz H, Pokroy R, Bukelman A, Shechtman E, Pollack A. Occurrence and progression of diabetic retinopathy after phacoemulsification cataract surgery. Journal of Cataract and Refractive Surgery 2004; 30(2): 428-32.&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15030836&amp;amp;query_hl=20&amp;amp;itool=pubmed_docsum" target="_blank"&gt; Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;12. Kato S, Oshika T, Numaga J, Hayashi Y, Oshiro M, Yuguchi T, et al. Anterior capsular contraction after cataract surgery in eyes of diabetic patients. British Journal of Ophthalmology 2001; 85(1): 21-3. &lt;A href="http://bjo.bmjjournals.com/cgi/content/full/85/1/21" target="_blank"&gt;Link to full text here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;13. Hayashi K, Hayashi H, Nakao F, Hayashi F. Posterior capsule opacification after cataract surgery in patients with diabetes mellitus. American Journal of Ophthalmology 2002; 134(1): 10-6.&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=12095802" target="_blank"&gt; Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;14. Elgohary MA, Dowler JG. Incidence and risk factors of Nd:YAG capsulotomy after phacoemulsification in non-diabetic and diabetic patients. Clinical &amp;amp; Experimental Ophthalmology 2006; 34(6):526-34. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Citation&amp;amp;list_uids=16925699" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;15. Jurecka T, Batkova Z, Ventruba J, Synek S. [Macular edema after cataract surgery in diabetic patients without retinopathy]. Ceská a Slovenská Oftalmologie 2007;63(4):274-84. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17682607?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;Link to PubMed abstract here.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;16. Cheema RA, Al-Mubarak MM, Amin YM, Cheema MA. Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy: prospective randomized study. Journal of Cataract and Refractive Surgery 2009; 35(1):18-25. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19101420" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;17. Kim SY, Yang J, Lee YC, Park YH. Effect of a single intraoperative sub-Tenon injection of triamcinolone acetonide on the progression of diabetic retinopathy and visual outcomes after cataract surgery. Journal of Cataract and Refractive Surgery 2008; 34(5):823-6. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18471640" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;18. Akinci A, Batman C, Ozkilic E, Altinsoy A. Phacoemulsification with intravitreal bevacizumab injection in diabetic patients with macular edema and cataract. Retina 2009; 29(10):1432-5. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19898181" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;19. Takata C, Messias A, Folgosa MS, Lucena LR, Lucena DR, Scott IU, et al. Intravitreal injection versus subtenon infusion of triamcinolone acetonide during cataract surgery in patients with refractory diabetic macular edema. Retina 2010; 30(4):562-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20182403" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;20. Hong T, Mitchell P, de Loryn T, Rochtchina E, Cugati S, Wang JJ. Development and progression of diabetic retinopathy 12 months after phacoemulsification cataract surgery. Ophthalmology 2009; 116(8):1510-4. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19501407" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;21. Goldman DA, Trattler WB. Cataract surgery and diabetic retinopathy. Ophthalmology 2010; 117(4):850; author reply 850-1.&lt;/SPAN&gt;&lt;BR&gt;&lt;BR&gt;&lt;SPAN style="COLOR: #a81400"&gt;22. Fernandez-Rubio ME, Rebolledo-Lara L, Martinez-Garcia M, Alarcon-Tomas M, Cortes-Valdes C. The conjunctival bacterial pattern of diabetics undergoing cataract surgery. Eye 2010; 24(5):825-34. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19713978" target="_blank"&gt;Link to PubMed abstract here.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;A name=ref1&gt;&lt;/A&gt;&lt;BR&gt;Further Evidence&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/SearchResults.aspx?catID=5134&amp;amp;tabID=289&amp;amp;" target="_blank"&gt;Links to systematic reviews on diabetic retinopathy in&amp;nbsp;NHS Evidence - diabetes&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Guidelines&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?tabID=288&amp;amp;catID=5658&amp;amp;searchText=&amp;amp;sort=PUBLISHER&amp;amp;resultsPerPage=10&amp;amp;summaries=true" target="_blank"&gt;Links to supporting Guidelines&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Patient Information&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?tabID=292&amp;amp;catID=5658&amp;amp;sort=PUBLISHER&amp;amp;resultsPerPage=10&amp;amp;summaries=true&amp;amp;" target="_blank"&gt;Links to supporting Patient Information&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Reference Material&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/SearchResults.aspx?catID=5134&amp;amp;tabID=290&amp;amp;searchText=&amp;amp;sort=PUBLICATION_DATE&amp;amp;resultsPerPage=10&amp;amp;summaries=true" target="_blank"&gt;Links to supporting reference material&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Publication details&lt;BR&gt;&lt;/STRONG&gt;Originally written by Peter Scanlon (Consultant Ophthalmologist&amp;nbsp; and National Clinical Director of the English National Screening Programme for Diabetic Retinopathy) in June 2006, since reviewed and updated in June 2007 by P Scanlon, in June 2008 by P Scanlon and Irene Stratton, in June 2009 by P Scanlon, and in August 2010 by P Scanlon&lt;/P&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387421</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=387421]]&gt;</url>
    <title>2010 Annual Evidence Update on Diabetic Retinopathy - Table of abbreviations</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,EYES AND VISION,CHRONIC COMPLICATIONS,EYE DISEASES,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>part of the 2010 Annual Evidence Update on Diabetic Retinopathy</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Diabetic Retinopathy - Table of abbreviations&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;STRONG&gt;Published&lt;/STRONG&gt;: 13 September 2010&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387096" target="_blank"&gt;Link back to home page for 2010 Annual Evidence Update on Diabetic Retinopathy here&lt;/A&gt;.&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;ABCD&amp;nbsp;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Appropriate Blood Pressure Control in Diabetes Trial&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;AION&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Anterior Ischaemic Optic Neuropathy&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;ARMD&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Age Related Macular Degeneration&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;AusDiab&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Australian Diabetes, Obesity and Lifestyle Study&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;BCVA&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Best Corrected Visual Acuity&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;BDA&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;British Diabetic Association (now Diabetes UK)&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;BD8 forms&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Blindness registration forms&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;BDR&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Background diabetic retinopathy&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;BMJ&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;British Medical Journal&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;BRVO&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Branch retinal vein occlusion&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;CCD camera&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Charge coupled device&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;CI&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Confidence interval&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;CLBM&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Contact lens biomicroscopy&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;CRAO&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Central Retinal Artery Occlusion&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;CRVO&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Central Retinal Vein Occlusion&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;CSMO&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Clinically significant macular oedema (in American studies referred to as CSME)&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;CWS&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Cotton wool spot&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;DCCT&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Diabetes Control and Complications Trial&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;DH&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Department of Health&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;DMO/DME&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Diabetic macular oedema/edema&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;DR&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Diabetic retinopathy&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;DRSRG&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Diabetic Retinopathy Study Research Group&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;DD&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Disc diameter&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;ETDRS&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Early Treatment Diabetic Retinopathy Study&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;EURODIAB&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;EURODIAB Insulin Dependent Diabetes Mellitus Complications Study&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;FDR&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Florid diabetic retinopathy&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;GDESS&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Gloucestershire Diabetic Eye Screening Service&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;HE&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Hard exudate&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;HL&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Helen Lipinski (Senior Grader at the Retinopathy Grading Centre)&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;HTBS&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Health Technology Board for Scotland&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;IDDM&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Insulin Dependent Diabetes Mellitus&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;IRMA&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Intra retinal microvascular anomaly&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;JISC&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Joint Information Systems Committee&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;JPEG&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Joint Photographic Experts Group compression&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;LogMAR&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Logarithm of the minimum angle of resolution&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;MA&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Microaneurysm&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;MIMAS&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Manchester Information and Associated Services&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;MDI&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Medical Data Index&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;MO/ME&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Macular oedema/edema&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;MRI&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Magnetic Resonance Imaging&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;NOP&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Non-ophthalmic practitioner&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;NSC&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;National Screening Committee&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;NVD&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Neovascularisation of the disc&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;NVE&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Neovascularisation elsewhere&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;NFL&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Nerve fibre layer&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;NICE&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;National Institute for Clinical Excellence&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;NIDDM&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Non-insulin-dependent diabetes mellitus&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;NPDR&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Non-proliferative diabetic retinopathy&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;NSF&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;National Service Framework&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;OFA&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Oral fluorescein angiography&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;OMP&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Ophthalmic Medical Practitioner&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;PAS&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Patient administration system&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;PPDR&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Pre-proliferative diabetic retinopathy&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;PPV&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Pars plana vitrectomy&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;PCIOL&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Posterior chamber intraocular lens&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;PDR&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Proliferative diabetic retinopathy&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;PRP&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Pan retinal photocoagulation&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;QALY&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Quality-adjusted life-year&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;RM&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Raman Malhotra (Specialist Registrar in Ophthalmology)&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;RPE&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Retinal pigment epithelium&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;RTA&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Retinal thickness analyser&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;SIGN&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Scottish Intercollegiate Guidelines Network&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;SPR&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Specialist Registrar&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;STED&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Sight threatening eye disease&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;STDR&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Sight threatening diabetic retinopathy&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;SVL&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Severe visual loss&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;TFT&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Thin film transistor&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;TIFF&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Tagged Image File Format&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;TCT&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Tritan contrast threshold&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;UKPDS&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;United Kingdom Prospective Diabetes Study&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;VB&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Venous beading&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;VA&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Visual acuity&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;VISS&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Vascular complications in South-east Sweden Study&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;WESDR&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Wisconsin Epidemiological Study of Diabetic Retinopathy&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;WHO&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;World Health Organisation&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>385491</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20519665]]&gt;</url>
    <title>2010 Consensus statement on the worldwide standardization of the Hemoglobin A1c measurement</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MONITORING / SELF-MONITORING,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Hanas R, John G on the behalf of the International HBA1c Consensus Committee. 2010 Consensus Statement on the worldwide standardization of the Hemoglobin A1c measurement. Diabetic Medicine. July 2010; 27:7 737-738&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in July 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full-text of this article online requires subscription to the&amp;nbsp;journal. NHS staff please&amp;nbsp;contact&amp;nbsp; &lt;A href="http://www.hlisd.org/" target="_blank"&gt;your local NHS library&lt;/A&gt;&amp;nbsp;for further assistance.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>379547</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/cdrisk/resources/merec_monthly_no27.pdf]]&gt;</url>
    <title>A key message on intensive blood pressure control in type 2 diabetes from ACCORD</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MEDICATION,CARDIOVASCULAR,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,HYPERTENSION,TYPE 2,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This MeReC monthly article considers a recent trial which adds to the evidence that over-intensification of treatment in type 2 diabetes provides limited or no overall benefit, and may increase the risk of adverse events.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Publication history information:&lt;/B&gt; MeReC Monthly No. 27, page 1. Published June 2010. Original article: The Accord Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. New Engl J Med 2010; published online March 14th.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Access:&lt;/B&gt; Available to the general public. Portable Document File/PDF requiring Adobe Acrobat Reader.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>258651</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/cgi/content/full/30/2/389]]&gt;</url>
    <title>A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin</title>
    <publicationDate>2007-02-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CARDIOVASCULAR,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,MEDICATION,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;BR&gt;&lt;/STRONG&gt;Azim S. Gangji, Tali Cukierman, Hertzel C. Gerstein, Charles H. Goldsmith, and Catherine M. Clase. A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007 February&amp;nbsp;30;(2) 389-394. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessing the full text:&lt;BR&gt;&lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>156148</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/cgi/content/full/29/7/1675]]&gt;</url>
    <title>A systematic review of interventions to improve diabetes care in socially disadvantaged populations</title>
    <publicationDate>2006-07-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,ELDERLY PEOPLE,PEOPLE FROM ETHNIC MINORITIES,ELDERLY PEOPLE,ETHNICITY AND HEALTH,DISEASES AND CONDITIONS,DIABETES,SERVICE DELIVERY,SERVICE SECTORS,PRIMARY CARE,PEOPLE FROM ETHNIC MINORITIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;BR&gt;&lt;/STRONG&gt;Glazier RH, Bajcar J, Kennie NR, Willson K. A systematic review of interventions to improve diabetes care in socially disadvantaged populations. Diabetes Care 2006;29:1675-1688.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessing the full text:&lt;BR&gt;&lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385476</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20587727]]&gt;</url>
    <title>A1c level and future risk of diabetes: a systematic review</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DIAGNOSIS,DIAGNOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Zhang X, Gregg EW, Williamson DF et al. A1c Level and Future risk of diabetes: A systematic review Diabetes Care. July 2010;33:1665-1673. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in July 2010. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Access to the full text online requires subscription to the journal.&amp;nbsp;NHS staff please &lt;A href="http://www.hlisd.org/" target="_blank"&gt;contact your local NHS library for further assistance.&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>59966</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band89/b89-2.html]]&gt;</url>
    <title>ACE-inhibitors for renal disease and diabetes?</title>
    <publicationDate>2001-07-01T00:00:00</publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETIC METABOLIC CONTROL,BLOOD PRESSURE,INTERVENTIONS,CHRONIC KIDNEY DISEASE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,KIDNEY DISEASES,DIABETES,CONDITION MANAGEMENT,PREVENTION,CHRONIC COMPLICATIONS,CARDIOVASCULAR,NEPHROPATHY,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier&amp;nbsp;article describes and reviews evidence (4 papers) to consider whether patients with chronic renal disease or diabetes should be taking ACE inhibitors. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Review published in July 2001.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>83745</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.2aida.org/online]]&gt;</url>
    <title>AIDA freeware diabetic software simulator program of blood glucose-insulin interaction</title>
    <publicationDate></publicationDate>
    <publisher>www.2aida.org</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CPD AND PROFESSIONAL EDUCATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P dir=ltr style="MARGIN-RIGHT: 0px"&gt;This freeware software contains a simple model of glucose-insulin interaction in the human body. It is intended for simulating the effects on the blood glucose profile of changes in insulin and diet for a typical type 1 diabetic patient.&amp;nbsp;This software&amp;nbsp;is only intended to be used for educational / teaching / demonstration purposes and the following disclaimer appears on the website:&amp;nbsp;&lt;BR&gt;"Given the complexity of the human glucoregulatory system it is not possible for a simple model, such as that contained within AIDA, to accurately predict an individual patient's blood glucose profile. Therefore the software cannot be used for therapy planning."&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; First made available on the Internet&amp;nbsp;in 1996.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. AIDA's simulations can be run via the web (no downloads or installation required). &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345010</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.trend-uk.org/TREND-UK_Feb%202010.pdf]]&gt;</url>
    <title>An integrated career and competency framework for diabetes nursing</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>Trend-UK</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CPD AND PROFESSIONAL EDUCATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document provides a UK-wide integrated career and competency framework for diabetes nursing. It works in conjunction with the overall RCN core competency framework by providing the specific competencies for diabetes care.&lt;/P&gt;
&lt;P&gt;This document addresses a number of political and professional issues, including:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The documents Agenda for Change: Modernising the NHS Pay System (DH, 1999) and Agenda for Change: National Job Profiles (DH, 2005). 
&lt;LI&gt;The need to demonstrate fitness for purpose and meet service delivery requirements in diabetes nursing. 
&lt;LI&gt;The need for leadership in specialist nursing. 
&lt;LI&gt;The need for the development of professional standards for HCPs. 
&lt;LI&gt;The document The NHS Plan: A Plan for Investment, a Plan for Reform (DH, 2000), and its equivalent in Scotland, Wales and Northern Ireland. 
&lt;LI&gt;An increased focus on work-based, life-long learning and supervision. 
&lt;LI&gt;The focus on professional, rather than academic, accreditation for HCPs. 
&lt;LI&gt;The document Towards a Framework for Post Registration Nursing Careers (DH, 2007).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The Framework focuses specifically on nurses providing diabetes care, but can be used together with other frameworks that highlight core nursing skills and competencies. Many of the specific competencies outlined here are common to the Skills for Health Project, a DH initiative to develop UK-wide, multidisciplinary occupational standards in diabetes care.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published February 2010. Replaces an earlier edition that was published in April 2005.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323755</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcn.org.uk/__data/assets/pdf_file/0011/78572/002011.pdf]]&gt;</url>
    <title>An RCN guide to the National Service Framework for Diabetes</title>
    <publicationDate>2003-04-01T00:00:00</publicationDate>
    <publisher>Royal College of Nursing</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,KEY POLICIES / NSF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The National Service Framework for Diabetes sets 12 national standards for England and aims to improve health care and make it consistent across the country. This RCN guide summarises the standards, offers practical tips on achieving them and outlines the delivery strategy, as well as what is going on elsewhere in the UK.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history:&lt;/STRONG&gt; Published April 2003.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306743</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19084368]]&gt;</url>
    <title>An updated meta-analysis to assess the effectiveness of psychological interventions delivered by psychological specialists and generalist clinicians on glycaemic control and on psychological status</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>Patient Education and Counseling</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,PSYCHOSOCIAL CARE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom line conclusion: &lt;/STRONG&gt;Psychological and general clinicians are similarly effective in delivering psychological interventions, however, effect sizes for all clinicians have reduced since the earlier review.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method: &lt;/STRONG&gt;Systematic review up to March 2007. Data was extracted on the participants, interventions, delivery methods, comparison groups and outcome measures. 35 trials were reviewed and meta-analysis of 19 trials was conducted.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results: &lt;/STRONG&gt;35 trials were reviewed and meta-analysis of 19 trials (n = 1431), reporting HbA1c found a reduction in HbA1c by 0.54% (-0.32; 95% CI: -0.47 to -0.16). In nine trials (n = 832) interventions were delivered by diabetes or general clinicians reducing HbA1c by 0.51% (-0.27; 95% CI: -0.50 to 0.04). In nine trials, interventions (n = 561) were delivered by psychological specialists reducing HbA1c by 0.57% (-0.36; 95% CI: -0.61 to 0.12). Meta-analysis of 13 trials reporting psychological status found psychological status to be lower in the intervention groups -0.56 (95% CI: 1.00 to -0.13). Trial quality for the majority of studies remained poor.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Alam R, et al. An updated meta-analysis to assess the effectiveness of psychological interventions delivered by psychological specialists and generalist clinicians on glycaemic control and on psychological status. Patient Educ Couns (2008), doi:10.1016/j.pec.2008.08.026&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in April 2009. Available online from 11 December 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Abstract available to the general public. Access to the full text online requires subscription to the journal. &lt;/P&gt;
&lt;P&gt;NHS staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library for further assistance.&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>59982</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/booth/painpag/Chronrev/antidc/anticon.html]]&gt;</url>
    <title>Anticonvulsants for diabetic neuropathy and postherpetic neuralgia</title>
    <publicationDate></publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CONDITION MANAGEMENT,DIABETES,CHRONIC COMPLICATIONS,PAINFUL NEUROPATHIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the Bandolier Pain Site describes and reviews a 2000 systematic review concerning antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia. The review focusses on anticonvulsants. 
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=59980&amp;amp;tabID=289" target="_blank"&gt;A separate Bandolier review focusses on antidepressants.&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>59980</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/booth/painpag/Chronrev/antidc/antidep.html]]&gt;</url>
    <title>Antidepressants for diabetic neuropathy and postherpetic neuralgia</title>
    <publicationDate></publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ PAINFUL NEUROPATHIES,CHRONIC COMPLICATIONS,DIABETES,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the Bandolier Pain Site describes and reviews a 2000 systematic review concerning antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia. The review focusses on antidepressants and includes a list of other reviews on neuropathic pain. 
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=59982&amp;amp;tabID=289" target="_blank"&gt;A separate Bandolier review focusses on anticonvulsants.&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>275938</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,174/Itemid,61/]]&gt;</url>
    <title>Approaching the parents of a child with diabetes mellitus (teaching letter no. 31)</title>
    <publicationDate>2005-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CHILDREN AND YOUNG PEOPLE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document deals with some of the issues that arise in involving the parents of a child with diabetes who is undergoing treatment.&lt;/P&gt;
&lt;P&gt;It includes the following topics:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Why approach the parents? 
&lt;LI&gt;Aims and ways of approaching the parents 
&lt;LI&gt;Parents of children with established diabetes&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The letter draws the conclusion that by having a co-operative team, the parents are able to better cope and that their burden is lessened.&lt;/P&gt;
&lt;P&gt;This is one of a series of &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;teaching letters&lt;/A&gt; for doctors and other health care professionals involved in the daily care of patients with diabetes. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>389574</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_monthly_no30.pdf]]&gt;</url>
    <title>Are higher doses of insulin glargine associated with cancer?</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,MEDICATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This MeReC monthly article (on page 1 of the newsletter) discusses a observational study of people with type 2 diabetes that found that higher mean daily doses of insulin glargine, but not other types of insulin, were associated with a five times high relative risk of cancer after adjusting for confounders. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication History Information:&lt;/STRONG&gt; MeReC Monthly No. 30, page 1. Published&amp;nbsp;September 2010. Original article: Mannucci E et al. Doses of insulin and its analogues and cancer occurrence in insulin-treated&amp;nbsp;type 2 diabetic patients. Diabetes Care 2010;33(9):1997-2003. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>397847</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nyrdtc.nhs.uk/docs/dud/DU_65_Aspirin.pdf]]&gt;</url>
    <title>Aspirin for primary prevention of cardiovascular disease</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>Regional Drug and Therapeutics Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CARDIOVASCULAR,CHRONIC COMPLICATIONS,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; "Low dose aspirin (75 mg daily) has an established role in the secondary prevention of cardiovascular disease (CVD). Although guidelines have previously recommended its use in primary prevention, the evidence to support use is less robust, with recent studies showing limited efficacy and an increased risk of both gastrointestinal bleeding and intracerebral haemorrhage. For the primary prevention of CVD, off-license aspirin therapy should only be used after careful consideration of the individual risks and benefits and consultation with the individual patient."&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; This document is intended for use by NHS Healthcare professionals. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in July 2010.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp; &lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>333629</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/content/extract/339/nov06_1/b4596]]&gt;</url>
    <title>Aspirin for primary prevention of vascular disease in people with diabetes</title>
    <publicationDate>2009-11-06T00:00:00</publicationDate>
    <publisher>BMJ Publishing Group</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CARDIOVASCULAR,CHRONIC COMPLICATIONS,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; This editorial comments on the published article: &lt;EM&gt;De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, Nicolucci A. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ, 2009&lt;/EM&gt;.&amp;nbsp; The editorial states that the analysis by De Berardis et al. was limited by the number of trials that reported significant bleeding, but the increased risk of bleeding reported is consistent with other data. The editorial concludes that the question of aspirin in primary prevention remains open and people should be recruited into the on-going trials trying to answer the problem.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Hayes R, Bowman L, Armitage J&amp;nbsp; Aspirin for primary prevention of vascular disease in people with diabetes (editorial) BMJ 339: 1210-11&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published November 2009.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full-text of this&amp;nbsp;article requires subscription to the journal. Full-text online access is available to NHS staff in England via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/Default.aspx" target="_blank"&gt;NHS Evidence&lt;/A&gt;.&amp;nbsp; Other NHS staff should check with your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>59994</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band108/b108-2.html]]&gt;</url>
    <title>Aspirin in high risk patients</title>
    <publicationDate>2003-02-01T00:00:00</publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CARDIOVASCULAR,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier&amp;nbsp;article describes and reviews a 2002 meta-analysis concerning antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Review published&amp;nbsp;February 2003.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>305390</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_monthly_no09.pdf]]&gt;</url>
    <title>Aspirin ineffective for primary prevention in patients</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR,CHRONIC COMPLICATIONS,DIABETES,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This MeReC&amp;nbsp;Monthly article considers a recent study which does not support the use of aspirin for the primary prevention of CV events in patients with diabetes and asymptomatic peripheral arterial disease.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Merec Monthly No. 9.&amp;nbsp; Published&amp;nbsp;December 2008.&amp;nbsp; Original article: &lt;EM&gt;Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840&amp;nbsp;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;:&amp;nbsp; Available to the general public. Portable Document File / PDF requiring Adobe Acrobat Reader.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301325</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,173/Itemid,61/]]&gt;</url>
    <title>Assessing and improving quality in diabetes education (teaching letter no. 30)</title>
    <publicationDate>2004-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aim&lt;/STRONG&gt;: "The aim of this Teaching Letter is to describe the development and implementation of quality schemes into daily education plans. After reading it, health care providers (HCPs) should be able to start an individual pathway to implement a quality system in educational practice".&lt;/P&gt;
&lt;P&gt;It includes the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Definition of quality 
&lt;LI&gt;Stakeholders and their expectancy of quality 
&lt;LI&gt;Dimensions of quality 
&lt;LI&gt;Steps of improvement 
&lt;LI&gt;Standards 
&lt;LI&gt;Methods 
&lt;LI&gt;Further reading&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This is one of a series of &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;teaching letters&lt;/A&gt; for doctors and other health care professionals involved in the daily care of patients with diabetes. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380385</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.guideline.gov/compare/comparison.aspx?file=OBESITY9_Adult.inc]]&gt;</url>
    <title>Assessment and management of obesity and overweight in adults</title>
    <publicationDate>2010-05-07T00:00:00</publicationDate>
    <publisher>National Guideline Clearinghouse</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,OBESITY,CONDITION MANAGEMENT,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Guideline synthesis comparing three UK and US guidelines.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This guideline synthesis compares the recommendations from three guidelines:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;American College of Physicians (ACP). Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005 Apr 5;142(7):525-31. 
&lt;LI&gt;National Collaborating Centre for Primary Care/National Institute for Health and Clinical Excellence (NCCPC/NICE). &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=213116" target="_blank"&gt;Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children&lt;/A&gt;. London (UK): National Institute for Health and Clinical Excellence; 2006 Dec. 
&lt;LI&gt;Department of Veterans Affairs, Department of Defense (VA/DoD). VA/DoD clinical practice guideline for screening and management of overweight and obesity. Washington (DC): Department of Veterans Affairs, Department of Defense; 2006. &lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60170</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;pubmedid=10938048]]&gt;</url>
    <title>Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study</title>
    <publicationDate>2000-08-12T00:00:00</publicationDate>
    <publisher>British Medical Journal</publisher>
    <publicationType>OBSERVATIONAL STUDY</publicationType>
    <topics>&lt;![CDATA[ DIABETES,GROUND-BREAKING ARTICLES,RESEARCH]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;/STRONG&gt;&lt;BR&gt;Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. 
&lt;P&gt;&lt;STRONG&gt;Additional information:&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.dtu.ox.ac.uk/index.php?maindoc=/ukpds/" target="_blank"&gt;Link to the UKPDS website&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60291</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;pubmedid=10938049]]&gt;</url>
    <title>Association of systolic blood pressure with macrovascular and microvascular complications of Type 2 diabetes: prospective observational study (UKPDS 36)</title>
    <publicationDate>2000-08-12T00:00:00</publicationDate>
    <publisher>British Medical Journal</publisher>
    <publicationType>OBSERVATIONAL STUDY</publicationType>
    <topics>&lt;![CDATA[ DIABETES,GROUND-BREAKING ARTICLES,RESEARCH]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;/STRONG&gt;&lt;BR&gt;Adler AI, Stratton IM, Neil HAW, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of Type 2 diabetes: prospective observational study (UKPDS 36). BMJ. 2000 Aug 12;321(7258):412-9. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10938049" target="_blank"&gt;&lt;/A&gt; 
&lt;P&gt;&lt;STRONG&gt;Additional information:&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.dtu.ox.ac.uk/index.php?maindoc=/ukpds/" target="_blank"&gt;Link to the UKPDS website&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>83736</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dvla.gov.uk/medical/ataglance.aspx]]&gt;</url>
    <title>At a glance (guide to the current medical standards of fitness to drive) : chapter 3, diabetes mellitus</title>
    <publicationDate>2010-08-01T00:00:00</publicationDate>
    <publisher>Driver and Vehicle Licensing Agency (DVLA)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,LIVING WITH DIABETES,DRIVING,GENERAL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The chapter on diabetes in&amp;nbsp;'At a glance',&amp;nbsp;a&amp;nbsp;guide for doctors on the current medical standards of fitness to drive,&amp;nbsp;provides information for both group&amp;nbsp;one entitlement (ODL - CAR, M/CYCLE) and group&amp;nbsp;two entitlement (VOC – LGV/PCV) and&amp;nbsp;includes the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Insulin treated 
&lt;LI&gt;Temporary insulin treated 
&lt;LI&gt;Managed by&amp;nbsp;tablets 
&lt;LI&gt;Managed by Exenatide or Gliptins in Combination with a Sulphonylurea 
&lt;LI&gt;Managed by diet alone 
&lt;LI&gt;Diabetic complications 
&lt;UL&gt;
&lt;LI&gt;Frequent hypoglycaemic episodes likely to impair driving 
&lt;LI&gt;Impaired awareness of hypoglycaemia 
&lt;LI&gt;Eyesight complications (affecting visual acuity or fields) 
&lt;LI&gt;Renal disorders 
&lt;LI&gt;Limb disability e.g. peripheral neuropathy&lt;/LI&gt;&lt;/UL&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The guidelines contain the following disclaimer:&lt;BR&gt;"This booklet is for use as guidance only.&amp;nbsp; Whilst it provides some idea of the anticipated outcome of a meical enquiry, the specific medical factors of each case will be considered before an individual licensing decision is reached."&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Reviewed every 6 months. Last reviewed&amp;nbsp;by DVLA in August 2010.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to the general public. Portable Document File / PDF requiring Adobe Acrobat Reader.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345751</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60234-6/fulltext]]&gt;</url>
    <title>Balancing the benefits of statins versus a new risk-diabetes.</title>
    <publicationDate>2010-02-27T00:00:00</publicationDate>
    <publisher>Lancet</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ TYPE 2,DIABETES,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; This editorial comments on the published article: &lt;EM&gt;Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet;375(9716):735-42&lt;/EM&gt;.&amp;nbsp;This commentary article&amp;nbsp; calculates that in the group of 255 patients treated with statin for 4 years producing 1 new case of diabetes, there would be 5.4 less deaths or myocardial infarctions and nearly the same number of strokes or cardiac revascularisation procedures would have been avoided. It&amp;nbsp; says that thus whilst a new risk of statins has been identified the risk seems small and is far outweighed by the benefits of statin.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt;&amp;nbsp;Cannon CP. Balancing the benefits of statins versus a new risk-diabetes. Lancet;375(9716):700-1.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published February 2010.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full text online requires subscription to the journal. NHS Staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library &lt;/A&gt;for further assistance.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>389126</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/rosiglitazone-avandia-drug-suspended-heart-risk.aspx]]&gt;</url>
    <title>Behind the Headlines - Avandia diabetes drug suspended</title>
    <publicationDate>2010-09-24T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,MEDICATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The diabetes drug Avandia, also known as rosiglitazone, has been suspended by UK and European drug watchdogs. The drug, which is used to control blood sugar in type 2 diabetes, has been linked to an increased risk of heart attack and stroke.&lt;/P&gt;
&lt;P&gt;In light of these risks, both the European Medicines Agency (EMA) and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) have recommended that the drug is no longer prescribed. This prescribing ban also applies to Avandamet and Avaglim, two related drugs also containing rosiglitazone.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;BR&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The MHRA’s advice to patients is that:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Those who are prescribed Avandia, Avandamet or Avaglim should not stop taking their treatment. This is because the drugs will still be needed to manage blood sugar levels and there may be some risk in going unmedicated. Instead patients should contact the doctor or nurse supervising their diabetic treatment, who will issue appropriate guidance and an alternative drug for controlling blood sugar. 
&lt;LI&gt;Any fluid retention in the ankles or body that occurs as a result of rosiglitazone is likely to be reversed on stopping the medicine. However, as it is not known for certain by what mechanism rosiglitazone may increase the risk of heart disease, it cannot be said that the risk of heart disease decreases completely when people stop taking rosiglitazone. 
&lt;LI&gt;Patients should be routinely monitored for cardiovascular disease. However, if they have been experiencing shortness of breath, chest pains/tightness, fatigue, increase in weight, or swelling of ankles (or elsewhere), they should arrange to see their doctor or nurse as soon as possible. 
&lt;LI&gt;This guidance refers only to drugs containing rosiglitazone, ie Avandia, Avandamet and Avaglim. It does not apply to other diabetes medications. &lt;BR&gt;Patients can discuss any concerns they have about their treatment with the doctor or nurse looking after their diabetes&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;See the &lt;A href="http://www.nhs.uk/news/2010/09September/Pages/rosiglitazone-avandia-drug-suspended-heart-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>388130</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/biology-of-type-2-diabetes.aspx]]&gt;</url>
    <title>Behind the Headlines - Biology of diabetes explored</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CAUSES,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Type 2 diabetes may be caused by “a chain reaction which destroys vital insulin-producing cells”, BBC News reported. The website said that a “malfunctioning protein” called amyloid could trigger the condition, in which the body loses its ability to control blood sugar levels.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Type 2 diabetes may be caused by “a chain reaction which destroys vital insulin-producing cells”, BBC News reported. The website said that a “malfunctioning protein” called amyloid could trigger the condition, in which the body loses its ability to control blood sugar levels.&lt;BR&gt;&lt;BR&gt;The news is based on a laboratory study that investigated a series of complex chemical reactions affecting cells involved in type 2 diabetes, the more common form of diabetes. It has discovered a series of complex processes that might trigger the formation of amyloid deposits in the cells of the pancreas. These deposits damage the cells that produce insulin, a hormone that the body uses to regulate blood sugar.&lt;BR&gt;&lt;BR&gt;News reports also suggested that it may eventually be possible to interrupt these processes and stop the disease from progressing. Any such developments are a long way off and it is too soon to claim that a cause or cure for diabetes has been found. Nevertheless, this early research is an important exploration of the processes behind type 2 diabetes.&lt;BR&gt;&lt;BR&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This laboratory study has delved deep into the complex associations between different chemicals that have a known link to type 2 diabetes.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/09September/Pages/biology-of-type-2-diabetes.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Masters SL, Dunne A, Subramanian SL et al. &lt;A href="http://www.nature.com/ni/journal/vaop/ncurrent/full/ni.1935.html" target="_blank"&gt;Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1ß in type 2 diabetes&lt;/A&gt;. Nature Immunology, September 12 2010 (published online) &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>398357</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/12December/Pages/can-dairy-cut-diabetes-risk.aspx]]&gt;</url>
    <title>Behind the Headlines - Can dairy cut diabetes risk?</title>
    <publicationDate>2010-12-21T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“A natural substance found in dairy products could help to prevent diabetes,” reported the Daily Express</description>
    <body>&lt;![CDATA[ &lt;P&gt;“A natural substance found in dairy products could help to prevent diabetes,” reported the Daily Express. It said that research has found that people who had high levels of palmitoleic acid, a fatty acid, in their blood were 60% less likely to develop type 2 diabetes than those who had low levels.&lt;/P&gt;
&lt;P&gt;This study found that whole-fat dairy consumption was linked with increasing levels of trans-palmitoleate in the blood and that this, in turn, was associated with lower fat, higher levels of good cholesterol, lower insulin resistance and a reduced risk of diabetes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This large cohort study found an association between levels of trans-palmitoleate acid in the blood and a lower risk of metabolic problems and incidence of diabetes. These links appeared to be independent of a number of lifestyle, clinical and dietary factors.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/12December/Pages/can-dairy-cut-diabetes-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;Mozaffarian D, Cao H, King IB, et al. Trans-Palmitoleic Acid, Metabolic Risk Factors, and New-Onset Diabetes in U.S. Adults. A Cohort Study. Annals of Internal Medicine 2010: 790-799&lt;BR&gt;&lt;BR&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>396257</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/11November/Pages/red-wine-diabetes-claim.aspx]]&gt;</url>
    <title>Behind the Headlines - Confusion over red wine and diabetes</title>
    <publicationDate>2010-11-22T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,LIVING WITH DIABETES,CONDITION MANAGEMENT,CONDITION MANAGEMENT,OTHER LIFE STYLE,OTHER LIFE STYLE,ALCOHOL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Super-food” compounds in wine “can work as well as a daily dose of medication for people with type 2 diabetes,” the Daily Express has claimed. The newspaper says that “drinking a small glass of red wine every day can help treat diabetes”.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Super-food” compounds in wine “can work as well as a daily dose of medication for people with type 2 diabetes,” the Daily Express has claimed. The newspaper says that “drinking a small glass of red wine every day can help treat diabetes”.&lt;/P&gt;
&lt;P&gt;This story is based on laboratory research that looked at how well polyphenol compounds found in red wine can bind to a protein called PPAR?. The protein, which is targeted by the anti-diabetes drug rosiglitazone, plays an important role in glucose and fat metabolism in the body. However, while the research found that these polyphenol compounds were also able to bind to PPAR? in the laboratory, this does not mean they will have the same effects on the body as rosiglitazone. It is important to note that rosiglitazone can no longer be marketed in the EU for the treatment of diabetes as it was found to be associated with an increased risk of certain cardiovascular problems.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This laboratory study has looked at the ability of red wine and its polyphenol compounds to bind to PPAR?, an important protein in glucose and fat metabolism within the body. Some of the compounds were found to be capable of binding to PPAR? with a strength similar to that of the anti-diabetes drug rosiglitazone.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp; &lt;A href="http://www.nhs.uk/news/2010/11November/Pages/red-wine-diabetes-claim.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Zoechling A, Liebner F and Jungbauer A et al. Red wine: A source of potent ligands for peroxisome proliferator-activated receptor ?. Food and Function, 2011, Advance Article&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>333028</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/12December/Pages/type-II-diabetes-pill-danger-concern.aspx]]&gt;</url>
    <title>Behind the Headlines - Diabetes drugs compared</title>
    <publicationDate>2009-12-04T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,MEDICATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Daily Mirror has reported that drugs used to control blood sugar in type 2 diabetes could increase risk of heart failure and death. It said that when taken alone one group of drugs, called sulphonylureas, increased risk of death by 61% and of heart failure by 30% compared to another drug called metformin.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The Daily Mirror has reported that drugs used to control blood sugar in type 2 diabetes could increase risk of heart failure and death. It said that when taken alone one group of drugs, called sulphonylureas, increased risk of death by 61% and of heart failure by 30% compared to another drug called metformin. &lt;/P&gt;
&lt;P&gt;This study looked at data on 92,000 patients with type 2 diabetes, comparing the outcomes in those prescribed&amp;nbsp; a range of different oral medications. It found higher rates of death in people taking sulphonylurea alone than in those combining it with metformin. It is possible that this may be partly explained by differences between these groups that affected their risk of death. For example, people taking sulphonylureas were older than those taking metformin. While the study took many of these factors into account, this may still not have fully removed their influence.&lt;/P&gt;
&lt;P&gt;Importantly, this research compared outcomes of different drugs, but did not compare them to taking no treatment, which is likely to be more dangerous. People should not stop taking diabetes medication as a result of this research as uncontrolled blood sugar can have serious consequences. People with concerns about these medications can get further advice from their GP or diabetes care team.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This thorough study compared the risk levels associated with different medications for type 2 diabetes, and did not compare the different drugs versus no treatment. For this reason people should not stop taking their medication based on this study, as taking no medication is likely to be more dangerous. If people taking sulphonylureas are concerned, they should discuss this with their doctors or diabetes care team, who will be able to advise them.&lt;/P&gt;
&lt;P&gt;It should also be noted that the people taking the drugs were not randomly assigned to which drugs they received and therefore people taking the different drugs may not have been balanced for other factors that could affect the outcome. For example, the people taking sulphonylureas were on average in their 70s, while those taking the other drugs were in their 60s on average. While the study did take many factors, including age, into account the authors acknowledge that this may still not have fully removed their influence.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/12December/Pages/type-II-diabetes-pill-danger-concern.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Tzoulaki I, Molokhia M, Curcin V et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetesdrugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>330376</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/05May/Pages/Diabetesinchildrentodouble.aspx]]&gt;</url>
    <title>Behind the Headlines - Diabetes in children 'to double'</title>
    <publicationDate>2009-05-29T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ INCIDENCE AND PREVALENCE,CAUSES,TYPE 1,DIABETES,DIAGNOSIS,STATISTICS,CHILDREN AND YOUNG PEOPLE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A newspaper has reported that "The increasing popularity of Caesarean births and having children later in life are contributing to a dramatic rise in cases of diabetes in young children".</description>
    <body>&lt;![CDATA[ &lt;P&gt;The increasing popularity of Caesarean births and having children later in life are contributing to a dramatic rise in cases of diabetes in young children,” the Daily Mail reported. The newspaper said that “the number of children under five with type 1 diabetes is likely to double by 2020”. It said that modern lifestyles, children being born to older mothers, caesarean sections and reduced exposure to germs are all contributing factors.&lt;/P&gt;
&lt;P&gt;The Europe-wide study behind these reports found that new cases of type 1 diabetes are increasing annually by an average of 3.9% a year. If the trend continues, there will be a substantial increase in the number of children with the condition, from an estimated 15,000 new cases a year in 2005 to 24,400 in 2020.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This time-trend and modelling study has demonstrated that new cases of type 1 diabetes are increasing across most European countries studied. If this trend continues, the number of new cases in children under five will double between 2005 and 2020. There are several points to bear in mind when interpreting the results of this research. &lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/05May/Pages/Diabetesinchildrentodouble.aspx" target="_blank"&gt;NHS Choices commentary&amp;nbsp;&lt;/A&gt;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Patterson CC, Dahlquist GG, Gyürüs E,&amp;nbsp; Green A, Soltész G the EURODIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989—2003 and predicted new cases 2005—20: a multicentre prospective registration study. The Lancet 2009; Early Online Publication, 28 May &lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>388135</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/type-2-diabetes-begins-pancreas.aspx]]&gt;</url>
    <title>Behind the Headlines - Diabetes 'test' needs more work</title>
    <publicationDate>2010-09-20T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR DISEASES,CAUSES AND RISK FACTORS,DIABETES MELLITUS,DIABETES,TYPE 2,DIAGNOSIS,CAUSES,RECENT ADDITIONS,SEPTEMBER 2010,JUL-SEPT 10]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A simple blood test is being developed that could save thousands of lives every year by predicting a person’s risk of getting heart disease and diabetes, reported the Daily Mail.</description>
    <body>&lt;![CDATA[ &lt;P&gt;A simple blood test is being developed that could save thousands of lives every year by predicting a person’s risk of getting heart disease and diabetes, reported the Daily Mail. According to the newspaper, the test “would revolutionise the diagnosis and treatment of two of Britain’s biggest killers” and may be available in just five years.&lt;BR&gt;&lt;BR&gt;The study behind this and other news reports found that the levels and functioning of five particular chemicals in the blood may act as a marker for the onset of type 2 diabetes and peripheral arterial disease. However, this is early research. The “test”, which involved using levels of these chemicals as a predictor of disease, correctly identified only 10 out of 19 people (52%) who went on to develop diabetes, and needs to be refined and repeated in a larger sample of people.&lt;BR&gt;&lt;BR&gt;Diabetes and peripheral arterial disease affect a large number people in the UK and cost the NHS a lot of money to manage. The findings of this well-conducted study are promising, but the news is optimistic given the early stage of this research.&lt;BR&gt;&lt;BR&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;BR&gt;&lt;BR&gt;&lt;/B&gt;This research has identified a set of microRNAs that are uniquely regulated in people with diabetes, and which could be used to identify the disease or to predict the development of it. Such screening tools are potentially valuable if they can forewarn of the development of a disease in an individual, although more work will need to be done to determine whether this particular approach can be applied to the general population.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/09September/Pages/type-2-diabetes-begins-pancreas.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Citation of original study&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Zampetaki A, Kiechl S, Drozdov I et al. &lt;A href="http://circres.ahajournals.org/cgi/content/abstract/107/6/810" target="_blank"&gt;Plasma MicroRNA Profiling Reveals Loss of Endothelial MiR-126 and Other MicroRNAs in Type 2 Diabetes&lt;/A&gt;. Circulation Research, September 2010, 107: 810 - 817&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>343708</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/02February/Pages/Diabetes-treatment-trialled.aspx]]&gt;</url>
    <title>Behind the Headlines - Diabetes treatment trialled</title>
    <publicationDate>2010-02-05T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEW DEVELOPMENTS,RESEARCH,MONITORING / SELF-MONITORING,MEDICATION,CONDITION MANAGEMENT,TYPE 1,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“An 'artificial pancreas' can be used to regulate blood sugar in children with type 1 diabetes,” BBC News reported.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“An 'artificial pancreas' can be used to regulate blood sugar in children with type 1 diabetes,” BBC News reported.&lt;/P&gt;
&lt;P&gt;This story is based on research on how to optimise devices that can sense glucose levels and adjust the amount of insulin a child with type 1 diabetes receives overnight. This is important in maintaining glucose levels while a child sleeps where standard glucose monitoring is not practical.&lt;/P&gt;
&lt;P&gt;This was a small but well-conducted study that showed promising results for this technology in keeping glucose levels within an acceptable range overnight. However, further research would be needed before a commercially available system were to be available.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study found some evidence that closed loop systems are better at maintaining appropriate glucose levels overnight than continuous insulin infusion in children and adolescents.&lt;/P&gt;
&lt;P&gt;Further larger studies would be useful in assessing and optimising the technology. If the same study were to be carried out in a larger sample of patients, important differences between the two systems might become more apparent.&lt;/P&gt;
&lt;P&gt;This small but well-conducted study is a step forward in managing blood glucose levels overnight, with the potential for improving the quality of life for young patients with type 1 diabetes. Further research would be needed before a commercially available system were made available.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/02February/Pages/Diabetes-treatment-trialled.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Hovorka R, Allen JM, Elleri D et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. The Lancet, [Early Online Publication], February 5 2010.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>378253</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/diabetes-risk-affected-by-rice.aspx]]&gt;</url>
    <title>Behind the Headlines - Does rice affect diabetes risk?</title>
    <publicationDate>2010-06-16T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ COMPLEMENTARY AND ALTERNATIVE MEDICINE,CAUSES,TYPE 2,DIABETES,DIABETES MELLITUS,CONDITIONS D-E,CONDITIONS A-Z,DIETARY AND NUTRITIONAL THERAPIES,JUNE 2010,FOOD AND BEVERAGES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>'Replacing white rice with brown rice and wholemeal bread could cut the risk of diabetes by a third,' the BBC reported.</description>
    <body>&lt;![CDATA[ &lt;P&gt;'Replacing white rice with brown rice and wholemeal bread could cut the risk of diabetes by a third,' the BBC reported.&lt;/P&gt;
&lt;P&gt;This news story is based on a study that found that people who ate white rice more than five times a week had a 17% higher risk of type 2 diabetes than those who ate it less than once a month. The researchers estimated that a person’s diabetes risk was reduced by 16% if a portion of white rice was replaced with brown rice and 36% if it was swapped with wholegrains.&lt;/P&gt;
&lt;P&gt;This well-conducted study has many strengths, but also has several limitations. As a cohort study, it cannot prove causation, but only draw associations. It is possible that other factors are responsible for the difference in risk, although researchers did adjust their findings to account for some of these. Also, the higher risk associated with white rice was based on a high intake (more than five servings a week).&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The study appears to be the first to evaluate white and brown rice intake in relation to diabetes risk among a Western population. Its strengths include its large sample size, high rates of follow-up and that it carried out repeat assessments of the participants’ diets. The fact that all three cohort studies had similar findings means they are unlikely to be due to chance. Also, researchers took into account many established risk factors.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/06June/Pages/diabetes-risk-affected-by-rice.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Sun Q, Spiegelman D, van Dam RM, et al. White Rice, Brown Rice and Risk of Type 2 Diabetes in US Men and Women. Arch Intern Med 2010; 170: 961-969&lt;BR&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>346144</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/03March/Pages/Drugs-for-halting-diabetes-tested.aspx]]&gt;</url>
    <title>Behind the Headlines - Drugs for halting diabetes tested</title>
    <publicationDate>2010-03-15T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TYPE 2,DIABETES,PREVENTION,PREDIABETIC STATE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Two key treatments do not halt diabetes in people with early signs of the disease,” BBC News reported.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Two key treatments do not halt diabetes in people with early signs of the disease,” BBC News reported. The story is based on a large trial assessing the effects of two approved diabetes medications, valsartan and nateglinide, on the development of diabetes and cardiovascular disease in high-risk populations.&lt;/P&gt;
&lt;P&gt;As BBC News reports, the results indicate that neither drug reduced the risk of cardiovascular disease, and there was only a small reduction in the risk of diabetes with valsartan. This trial was in people showing an early warning sign for diabetes, not in people with the disease. Anyone taking these drugs should not change their treatment on the basis of this study.&lt;/P&gt;
&lt;P&gt;There is good evidence that changing diet and exercise are the best ways of reducing the risk of diabetes in those with raised glucose levels, an early indicator of the condition. Systematic reviews in high risk populations have shown that a change in physical activity and diet could reduce the number of new diabetes cases by about 37%. In comparison, this trial found that valsartan reduced diabetes by only 14%.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Overall, this large, industry-funded study found that nateglinide had no effect on the incidence of diabetes or cardiovascular disease in this population and that valsartan had a small effect on diabetes risk but not on cardiovascular outcomes.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/03March/Pages/Drugs-for-halting-diabetes-tested.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Nathan DM.&amp;nbsp;&lt;A href="http://content.nejm.org/cgi/content/full/NEJMe1002322" target="_blank"&gt;Navigating the Choices for Diabetes Prevention.&lt;/A&gt; &lt;EM&gt;NEJM&lt;/EM&gt; [published online] March 14 2010&lt;/P&gt;
&lt;P&gt;The NAVIGATOR Study Group.&amp;nbsp;&lt;A href="http://content.nejm.org/cgi/content/full/NEJMoa1001122" target="_blank"&gt;Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events.&lt;/A&gt; &lt;EM&gt;NEJM&lt;/EM&gt; [published online] March 14 2010&lt;/P&gt;
&lt;P&gt;The NAVIGATOR Study Group.&amp;nbsp;&lt;A href="http://content.nejm.org/cgi/content/full/NEJMoa1001121" target="_blank"&gt;Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events.&lt;/A&gt; &lt;EM&gt;NEJM&lt;/EM&gt; [published online] March 14 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>325925</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/FatnessRunsInFamily.aspx]]&gt;</url>
    <title>Behind the Headlines - Fat mums have fat daughters</title>
    <publicationDate>2009-07-15T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ PREVENTION,OBESITY,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Girls are 10 times more likely to be overweight if their mothers are obese,” the Daily Mail has said. The newspaper also reports that overweight fathers are six times more likely to have obese sons, based on the results of new research.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Girls are 10 times more likely to be overweight if their mothers are obese,” the &lt;EM&gt;Daily Mail&lt;/EM&gt; has said. The newspaper also reports that overweight fathers are six times more likely to have obese sons, based on the results of new research. &lt;/P&gt;
&lt;P&gt;The study&amp;nbsp;investigated whether childhood obesity was related to environmental influences rather than genetic ones, by looking at the BMI’s of 226 five-year-olds and their parents. Researchers found relationships between the BMI of mothers and daughters and between fathers and sons, but not between children and their parent of the opposite gender. The researchers say that this supports an environmental basis for ‘gender-assortative weight gain’ because if this were a gene trait it would be unlikely to be gender selective.&lt;/P&gt;
&lt;P&gt;It is not all that surprising that a parent’s weight, eating habits and lifestyle may influence their young child, but it is unclear why this should be gender-specific. Also, the small study did not assess the contribution of genetics to being overweight, or evaluate the role of other environmental and social factors likely to influence a child’s weight, such as diet and physical activity. The researchers say that it is “important not to over-interpret these findings”, and note that they relate only to pre-pubescent children.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study has aimed to demonstrate that childhood obesity may be related to environmental influences rather than genetic ones by looking at the relationship between the BMI of 226 five-year-old children and their parents.&lt;/P&gt;
&lt;P&gt;The researchers appear to have found a relationship between the BMI of a mother and her daughter and the BMI of a father and his son, but not between the parent–child pairs of opposite genders. This, they say, supports an environmental link for gender-assortative weight gain, as individual gene traits of this kind are unlikely to be gender-specific. &lt;/P&gt;
&lt;P&gt;The researchers suggest that the relationship between the weight of a child and their same-sex parent may be due to the parent acting as a role model for the child. However, this study is not able to shed light on why the environmental influence of obesity and shared eating patterns within a family should only influence a child of the same sex. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/07July/Pages/FatnessRunsInFamily.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Perez-Pastor EM, Metcalf BS, Hosking J, Jeffery AN, Voss LD and Wilkin TJ. Assortative weight gain in mother–daughter and father–son pairs: an emerging source of childhood obesity. Longitudinal study of trios (EarlyBird 43)&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>387460</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/grapefruit-chemical-diabetes-cure.aspx]]&gt;</url>
    <title>Behind the Headlines - 'Grapefruit diabetes cure' unproven</title>
    <publicationDate>2010-08-26T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,MEDICATION,NUTRITION AND FOOD]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Daily Mirror hailed grapefruit as a “fruity 'cure' for diabetes”. The newspaper suggested that the chemical naringenin found in the fruit “can do the same job as two drugs used to treat type-2 diabetes”.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The Daily Mirror today hails grapefruit as a “fruity 'cure' for diabetes”. The newspaper suggests that the chemical naringenin found in the fruit “can do the same job as two drugs used to treat type-2 diabetes”.&lt;/P&gt;
&lt;P&gt;Surprisingly, the research in question only looked at the effects of naringenin on human and rat liver cells in the laboratory. This very preliminary research has certainly not identified a “cure” for diabetes. It only concentrated on how the chemical affected the fat metabolism of cells rather than processes directly related to diabetes. Until clinical trials are carried out in humans, it is not possible to say whether naringenin might be an effective medical treatment or whether it carries side effects. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This complex laboratory research suggests that naringenin can affect proteins and genes involved in fat metabolism in liver cells. Although the effect that it has on the cells is similar to the effects of drugs such as the fibrates and glitazones, this does not necessarily mean that naringenin could be used to treat the same conditions as the fibrates and glitazones. In the body different drugs interact with different subsets of the numerous proteins and molecules in the body in different ways. It is these complex interactions which will determine their overall effects. This study has only assessed interactions of naringenin with a small number of proteins in cells in the laboratory, and cannot tell us what the overall balance of positive and negative effects will be on the whole body.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/08August/Pages/grapefruit-chemical-diabetes-cure.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Goldwasser J, Cohen PY, Yang E et al. &lt;A href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0012399" target="_blank"&gt;Transcriptional Regulation of Human and Rat Hepatic Lipid Metabolism by the Grapefruit Flavonoid Naringenin: Role of PPARa, PPAR? and LXRa&lt;/A&gt;. PLoS One, August 25 2010.&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>385304</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/green-vegetables-and-diabetes-risk.aspx]]&gt;</url>
    <title>Behind the Headlines - Healthy diet 'cuts diabetes risk'</title>
    <publicationDate>2010-08-20T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CAUSES,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,PREDISPOSING FACTORS,DIABETES,INTERVENTIONS,DIABETIC METABOLIC CONTROL,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“A diet rich in green leafy vegetables may reduce the risk of developing diabetes,” reported the BBC. It said that one-and-a-half portions a day “cuts type-2 diabetes risk by 14%”.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“A diet rich in green leafy vegetables may reduce the risk of developing diabetes,” reported the BBC. It said that one-and-a-half portions a day “cuts type-2 diabetes risk by 14%”.&lt;/P&gt;
&lt;P&gt;This news story was based on a systematic review and meta analysis that pooled data from six prospective cohort studies investigating diet and the risk of developing type 2 diabetes. The analysis found that people who ate around 120g of green leafy vegetables per day were 14% less likely to develop the condition than people who ate the least amount of this type of vegetable.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This was a well-conducted systematic review and meta analysis assessing whether fruit and vegetable intake affects the likelihood of developing type 2 diabetes. It found that increased green leafy vegetable intake was associated with a reduced risk of developing type 2 diabetes. One limitation of pooling data from these types of diet cohort studies is that they may have measured diet differently, potentially affecting the results.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2010/08August/Pages/green-vegetables-and-diabetes-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Carter P, Gray LJ, Troughton J, et al. &lt;A href="http://www.bmj.com/cgi/content/full/341/aug18_4/c4229" target="_blank"&gt;Fruit and vegetable intake and incidence of type 2 diabetes mellitus: systematic review and meta-analysis&lt;/A&gt;. &lt;EM&gt;BMJ&lt;/EM&gt; 2010; 341: c4229&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>396959</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/12December/Pages/greater-diabetes-risk-in-south-asians.aspx]]&gt;</url>
    <title>Behind the Headlines - Higher diabetes risk in Asians explored</title>
    <publicationDate>2010-12-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CAUSES,PEOPLE FROM ETHNIC MINORITIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“People of South Asian origin are more prone to diabetes because of the way their muscles burn fat,” BBC News reported.

</description>
    <body>&lt;![CDATA[ &lt;P&gt;This news story is based on research looking at the rates of fat metabolism in 20 men of South Asian origin and 20 white European men. The findings suggest that South Asian men have a lower rate of fat metabolism during exercise than European men. During resting states, fat metabolism was the same. The South Asian men also had a reduced sensitivity to insulin compared with the European group. This indicates a possible tendency towards glucose intolerance and type 2 diabetes.&lt;/P&gt;
&lt;P&gt;This was a small preliminary study and much further research is needed to confirm this association, and to determine how differences in fat metabolism may contribute to the risk of type 2 diabetes. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;These findings suggest that there may be differences in fat metabolism during exercise between South Asian and European men. These differences were associated with a reduced sensitivity to insulin, which may contribute to the higher risk of type 2 diabetes in the South Asian population.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/12December/Pages/greater-diabetes-risk-in-south-asians.aspx" target="_blank"&gt;NHS Choices commentary &lt;/A&gt;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Hall LML, Moran CN, Milne GR, et al. Fat Oxidation, Fitness and Skeletal Muscle Expression of Oxidative/Lipid Metabolism Genes in South Asians: Implications for Insulin Resistance? PLOS One, 2010&lt;/P&gt;
&lt;P&gt;&amp;nbsp; 
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>330375</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/08August/Pages/IsType1diabetesseasonal.aspx]]&gt;</url>
    <title>Behind the Headlines - Is type 1 diabetes seasonal?</title>
    <publicationDate>2009-08-24T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CAUSES,RISK AND FUTURE PROJECTIONS,STATISTICS,DIABETES,TYPE 1]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Newspapers have reported that children are more likely to develop diabetes in winter.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Children are more likely to develop diabetes in winter, newspapers have reported. The Times said that a large international study of 31,000 children from 53 countries suggests there is a correlation between the seasons and type 1 diabetes. It said the trend was more prevalent in boys and older children (5-14 year olds) of both sexes. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The results from this large, well-conducted study confirm what has been seen in previous small studies. However, any interpretation of these findings should take into account several shortcomings that the researchers themselves raise.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/08August/Pages/IsType1diabetesseasonal.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;BR&gt;&lt;/B&gt;Moltchanova EV, Schreier N, Lammi N and Karvonen M. Seasonal variation of diagnosis of Type 1 diabetes mellitus in children worldwide. Diabetic Medicine 2009; 26: 673-678&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>330702</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/05May/Pages/DiabeticSugarControlCutsHeartAttacks.aspx]]&gt;</url>
    <title>Behind the Headlines - Managing diabetes cuts heart attacks</title>
    <publicationDate>2009-05-22T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CONDITION MANAGEMENT,CHRONIC COMPLICATIONS,CARDIOVASCULAR,TYPE 2,DIABETES,PREVENTION,MEDICATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Tighter control of blood sugar levels in people with diabetes may cut their risk of heart problems,” BBC News has reported.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Tighter control of blood sugar levels in people with diabetes may cut their risk of heart problems,” BBC News has reported. The news service said a study pooling data on 33,000 people with type 2 diabetes has shown that intensive control of blood sugar levels cuts heart attacks by 17% and heart disease by 15%.&lt;/P&gt;
&lt;P&gt;This well designed study has shown that medication-based intensive care can reduce the risk of heart attacks, but, unsurprisingly, it also increases the risk of episodes where blood sugar falls too low. Intensive blood sugar control targets may not be appropriate for all patients, and can be difficult to achieve.&lt;BR&gt;&lt;BR&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;BR&gt;&lt;/B&gt;This well designed study has illustrated that if intensive control is used successfully it can reduce the risk of heart attacks. However, there are a number of points to note:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The risk of having a heart attack was quite low in both groups and, therefore, the difference in risk between the groups was also small. If 200 people used intensive treatment for five years, this would prevent three heart attacks compared with if they used standard control over the same period. 
&lt;LI&gt;Two of the included RCTs used drugs called glitazones as part of intensive control treatment. Studies have suggested that these drugs increase the risk of heart failure. Although, overall, this review found no significant increase in heart failure with intensive control, statistical tests showed that the results of the individual trials were significantly different from each other, and that this was likely to be due to an increased risk in heart failure with the glitazones. 
&lt;LI&gt;The studies included in this review used differing methods of intensive control, and it is not possible to say which method is best. Also, with standard treatment it was unclear exactly what medications were being used.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2009/05May/Pages/DiabeticSugarControlCutsHeartAttacks.aspx" target="_blank"&gt;NHS Choices commentary&amp;nbsp;&lt;/A&gt;on this news item. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Citation of original study&lt;BR&gt;&lt;/STRONG&gt;Ray K, Kondapally Seshasai SR, Wijesuriya S et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. The Lancet; Volume 373, Issue 9677, Pages 1765 - 1772&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>325921</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/09September/Pages/Morechildrentakingobesitydrugs.aspx]]&gt;</url>
    <title>Behind the Headlines - More children taking obesity drugs</title>
    <publicationDate>2009-09-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,OBESITY,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The number of children on anti-obesity drugs has risen 15-fold in the last 10 years”, The Daily Telegraph reported.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“The number of children on anti-obesity drugs has risen 15-fold in the last 10 years”, The Daily Telegraph reported. It said that a study of data from GPs between 1999 and 2006 shows up to 1,300 children and teenagers a year could be prescribed the drugs, even though they are not licensed for use by children. The newspaper said that most prescriptions “were for 14-year-olds, although 25 prescriptions were written for children under the age of 12”.&lt;/P&gt;
&lt;P&gt;This research looked at a selection of GP records from practices covering 5% of the population. It is a well-conducted study and the results are likely to be representative of the rest of the UK. It found that the prescribing of unlicensed anti-obesity drugs to children and adolescents has increased significantly in the past eight years.&lt;/P&gt;
&lt;P&gt;Because the data were collected from the time just after orlistat was licensed in the UK, and before sibutramaine was available, it is not surprising that the increase has been so large. However, the estimated absolute number of prescriptions for adolescents (1,300 a year) is large and is another reminder of the growing obesity crises in the UK.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The researchers acknowledge the epidemic of child and adolescent obesity in the UK and say that those who are already obese currently make up 7-10% of the child and adolescent population under 20 years old. This is clearly a problem that needs to be addressed. As a descriptive study, this research sought to identify and describe the problem and not to suggest specific answers.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/09September/Pages/Morechildrentakingobesitydrugs.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Viner RM, Hsia Y, Neubert A, et al. Rise in anti-obesity drug prescribing for children and adolescents in the UK: a population-based study. British Journal of Clinical Pharmacology 2009; Published online: 2 September&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>380145</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/Type-2-diabetes-genes-found.aspx]]&gt;</url>
    <title>Behind the Headlines - More type 2 diabetes genes found</title>
    <publicationDate>2010-06-28T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CAUSES,DIABETES,TYPE 2]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Doctors are closer to building a DNA profile of people who are at risk from diabetes after pinpointing another set of genes associated with the disease,” reported The Daily Telegraph.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Doctors are closer to building a DNA profile of people who are at risk from diabetes after pinpointing another set of genes associated with the disease,” reported &lt;EM&gt;The Daily Telegraph&lt;/EM&gt;.&lt;/P&gt;
&lt;P sizset="96" sizcache="0"&gt;The study behind the news report combined the results from several genome-wide association studies, which compared the DNA of thousands of people with&amp;nbsp;type 2 diabetes to that from people without the disease. In addition to confirming several genetic variants that the previous study had associated with the disease, the research identified 12 new variants, bringing the number of linked genes to 38.&lt;/P&gt;&lt;B&gt;
&lt;P&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is well-conducted, well-reported research that confirmed its initial findings in an independent population, and used accepted methods for this field of research. The researchers discuss possible biological explanations for how each of the newly identified variants might affect disease susceptibility.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/06June/Pages/Type-2-diabetes-genes-found.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Voight BF, Scott LJ, Steinthorsdottir V, et al. &lt;A href="http://www.nature.com/ng/journal/v42/n7/abs/ng.609.html" target="_blank"&gt;Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis&lt;/A&gt;. &lt;EM&gt;Nature Genetics&lt;/EM&gt; 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>325927</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/ObesityDiabetesLinkExplained.aspx]]&gt;</url>
    <title>Behind the Headlines - Obesity and diabetes link explored</title>
    <publicationDate>2009-07-13T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Scientists “may have uncovered a key reason why obese people have a raised risk of health complications such as type 2 diabetes”, BBC News has said. According to the news service, the link is due to ‘pigment epithelium-derived factor’ (PEDF), a protein released from fat cells.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Scientists “may have uncovered a key reason why obese people have a raised risk of health complications such as type 2 diabetes”, BBC News has said. According to the news service, the link is due to ‘pigment epithelium-derived factor’ (PEDF), a protein released from fat cells. &lt;/P&gt;
&lt;P&gt;The results of the study suggest that insulin resistance in obesity, and hence the increased likelihood of diabetes, may be partly caused by PEDF. ‘Obese’ mice, which were resistant to insulin and had elevated blood glucose levels, also had elevated levels of PEDF. When PEDF was injected into ‘lean’ mice, it also reduced their sensitivity to the effects of insulin, as might be seen in type 2 diabetes.&lt;/P&gt;
&lt;P&gt;This is worthy research, which has attempted to understand the possible biological mechanisms that link obesity and the increased risk of diabetes. However, as this is only an animal study, the situation may differ in humans. More research is needed to clarify whether this might have future treatment implications, such as techniques to block the action of PEDF and increase insulin sensitivity. For the general population, a healthy diet and lifestyle with regular exercise remains the best way to avoid obesity and the risk of complications such as type 2 diabetes.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The results suggest that insulin resistance in obesity, and hence the increased likelihood of glucose intolerance and diabetes, may be partly caused by PEDF (pigment epithelium-derived factor) released from fat cells. &lt;/P&gt;
&lt;P&gt;This is worthy and interesting research, which has attempted to understand the possible biological mechanisms behind obesity and the increased risk of diabetes. However, as this is only an animal study, the situation may not be identical in humans.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/07July/Pages/ObesityDiabetesLinkExplained.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Crowe S,&amp;nbsp; Wu LE, Economou C, et al. Pigment Epithelium-Derived Factor Contributes to Insulin Resistance in Obesity. Cell Metabolism 2009; 10:40-47&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>334496</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/Quitting-smoking-and-diabetes-risk.aspx]]&gt;</url>
    <title>Behind the Headlines – Quitting smoking and diabetes risk</title>
    <publicationDate>2010-01-05T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,LIVING WITH DIABETES,CAUSES,SMOKING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>People who give up smoking are prone to developing diabetes because they gain weight,” The Times reported. It said a study has found that quitters are twice as likely as smokers, and 70% more likely than non-smokers, to have type 2 diabetes.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“People who give up smoking are prone to developing diabetes because they gain weight,” The Times reported. It said a study has found that quitters are twice as likely as smokers, and 70% more likely than non-smokers, to have type 2 diabetes.&lt;/P&gt;
&lt;P&gt;This study found that smokers and recent quitters had a greater risk of diabetes compared to those who had never smoked, but that three years after quitting this risk had reduced. The suggestion that this is because quitters are more likely to gain weight is logical, but it cannot be proven by this cohort study.&lt;/P&gt;
&lt;P&gt;The results of this study do not mean that smoking is protective to health. Smokers and former smokers were at greater risk of diabetes than those who had never smoked, and the benefits of giving up far outweigh any temporary increase in risk. Instead, these findings emphasise the importance of an active lifestyle and a healthy balanced diet, and demonstrate the importance of providing quitters with education and support to achieve this.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Smoking is associated with an increased risk of diabetes, and the current study confirms this. However, the effect of quitting smoking on diabetes risk has been unclear until now. This study found that quitting is associated with an increased risk of developing diabetes in the short term, but that this risk decreases over time. When the researchers adjusted their analyses for weight change since quitting this affected the risk.&lt;/P&gt;
&lt;P&gt;This&amp;nbsp;was a well-conducted study that carried out extensive follow-up on a large number of participants. However, there are some points to consider. &lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/01January/Pages/Quitting-smoking-and-diabetes-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Yeh H-C,Duncan BB, Inês Schmidt M, et al. Smoking, Smoking Cessation, and Risk for Type 2 Diabetes Mellitus. Ann Intern Med January 2010: 152; 10-17&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>324049</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/08August/Pages/Stomachstaplinganddiabetes.aspx]]&gt;</url>
    <title>Behind the Headlines - Stomach stapling and diabetes</title>
    <publicationDate>2009-08-28T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CONDITION MANAGEMENT,SEPTEMBER 2009,STOMACH,OBESITY,RECENT ADDITIONS,TYPE 2,DIABETES,OBESITY,CONDITION MANAGEMENT,PREVENTION,COMMON CLINICAL PRESENTATIONS,GASTROENTEROLOGY &amp; LIVER DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Times and other newspapers have reported on a large international study finding that “weight-loss surgery can eliminate the symptoms of type 2 diabetes in nearly eight out of 10 patients”.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The Times and other newspapers have reported on a large international study finding that “weight-loss surgery can eliminate the symptoms of type 2 diabetes in nearly eight out of 10 patients”.&lt;/P&gt;
&lt;P&gt;The news stories are based on a thorough and well-conducted review of the effect of bariatric (weight-loss) surgery on weight and type 2 diabetes. Studies with a total of 4,070 diabetic patients found bariatric surgery to be greatly effective for both reducing weight and improving diabetes, both in the short and long term. There are some limitations to the research, including the fact that it combined studies that used very different methods.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This systematic review and meta-analysis pooled the results of all identified studies that examined the effect of bariatric surgery on weight loss and type 2 diabetes. It found surgery to be effective for both, in the short and long term. There are some limitations to the research, which the authors acknowledge, including:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;the possibility of publication bias in the studies that have been included (those with less favourable results not being published), 
&lt;LI&gt;the variable reporting and measurement of study outcomes, &lt;BR&gt;high loss to follow-up of treated patients, and 
&lt;LI&gt;lack of specific information on subgroups, such as those of different ethnicity.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/08August/Pages/Stomachstaplinganddiabetes.aspx" target="_blank"&gt;NHS Choices commentary &lt;/A&gt;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Buchwald H, Estok R, Fahrbach K, et al. Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis. The American Journal of Medicine 2009; 122: 248-256&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>330725</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/05May/Pages/VitaminDSunshineElderly.aspx]]&gt;</url>
    <title>Behind the Headlines - Sunshine 'the key to long life'</title>
    <publicationDate>2009-05-18T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ PREVENTION,PREVENTION,DIABETES,TYPE 2,TYPE 1]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Daily Telegraph has claimed that “sunbathing could help older people reduce the risk of developing heart disease and diabetes”, while the Daily Express says that “sunshine can add years to your life”.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The Daily Telegraph has claimed that “sunbathing could help older people reduce the risk of developing heart disease and diabetes”, while the Daily Express says that “sunshine can add years to your life”. The Express bases its claims on a study that found that “exposure to sunlight stimulates vitamin D in the skin”.&lt;/P&gt;
&lt;P&gt;It is already well established that the skin produces vitamin D through exposure to sunlight, as well as through diet. This Chinese study reported in the newspapers did not assess exposure to sunlight, but observed low vitamin D levels in a middle-aged to elderly population and found they were associated with a combination of conditions that increase the risk of diabetes and heart disease. However, this study did not actually assess reasons for these low vitamin D levels and many features of the study limit its interpretation. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This large population study has observed an association between having a low vitamin D level and metabolic syndrome, which increases the risk of heart disease and diabetes. &lt;/P&gt;
&lt;P&gt;It is a great leap to conclude from the findings of this study that exposure to sunlight will help to reduce the risk of heart disease and diabetes, or even prolong your life, as some newspapers have claimed. &lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2009/05May/Pages/VitaminDSunshineElderly.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Lu L, Pan AN, Hu FB et al. Plasma 25-hydroxyvitamin D Concentration and Metabolic Syndrome among Middle-aged and Elderly Chinese. Diabetes Care [Published online ahead of print]&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>333435</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/12December/Pages/Tea-coffee-and-diabetes-risk.aspx]]&gt;</url>
    <title>Behind the Headlines - Tea, coffee and diabetes</title>
    <publicationDate>2009-12-15T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Tea and coffee drinkers have a lower risk of developing type 2 diabetes,” reported the BBC, adding that the protection may not be down to caffeine since decaffeinated coffee has the greatest effect.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Tea and coffee drinkers have a lower risk of developing type 2 diabetes,” reported the BBC, adding that the protection may not be down to caffeine since decaffeinated coffee has the greatest effect.&lt;/P&gt;
&lt;P&gt;This story is based on a systematic review and meta-analysis that pooled data from studies of the association between tea and coffee consumption and the risk of developing type 2 diabetes. It found the more tea, coffee or decaffeinated coffee was drunk, the lower the risk of developing diabetes.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This research pooled and analysed data from studies of the association between drinking tea and coffee and the risk of developing type 2 diabetes, and found that these drinks reduced the risk. However, though this type of systematic review is stronger evidence than that from each of its individual components, it still has several limitations that the researchers highlight. &lt;/P&gt;
&lt;P&gt;People should not drink more tea or coffee on the strength of this evidence. The review did not account for diet, exercise and lifestyle, and the studies included were varied. The results do, however, suggest that further research is warranted. Maintaining a healthy weight, choosing a sensible diet and participating in physical activity remain the best ways to protect against type 2 diabetes.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/12December/Pages/Tea-coffee-and-diabetes-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Huxley R, Man Ying Lee C, Barzi F, et al. Coffee, Decaffeinated Coffee, and Tea Consumption in Relation to Incident Type 2 Diabetes Mellitus. Archives of&amp;nbsp;Internal Medicine 2009; 169: 2053-2063.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>331095</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/05May/Pages/VitaminsStopExerciseBenefit.aspx]]&gt;</url>
    <title>Behind the Headlines - Vitamins undo 'benefits of exercise'</title>
    <publicationDate>2009-05-15T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,NUTRITION AND FOOD,PHYSICAL ACTIVITY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Taking vitamins after exercise may undo some of the beneficial effects of the workout,” according to BBC New</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Taking vitamins after exercise may undo some of the beneficial effects of the workout,” according to BBC News. The website says that while some people take antioxidant vitamins, such as vitamin C, to help protect their body from harmful chemical by-products (free radicals), a German study suggests that these substances may in fact be good for us and protect against diabetes. &lt;/P&gt;
&lt;P&gt;The small study behind this article was set up to investigate whether free radical chemicals, an inevitable by-product of muscle use and exercise, play a positive role in the body’s processing of glucose blood sugar. The results suggest free radicals do improve glucose metabolism, and that taking antioxidants may prevent this exercise-related benefit.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;BR&gt;&lt;/STRONG&gt;This small study suggests that exercise-induced free radicals play a role in promoting insulin sensitivity in humans. As the researchers note, the published evidence is ambiguous, with some research finding different results. The authors offer some explanations for the conflict in the evidence, including that some of the other studies assessed the effect of continuous exposure to free radicals, while this one assessed the effects of increases during limited periods of physical exercise.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/05May/Pages/VitaminsStopExerciseBenefit.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;BR&gt;&lt;/B&gt;Ristow M, Zarse K, Oberbach A et al. Antioxidants prevent health-promoting effects of physical exercise in humans. PNAS [Published online before print May 11, 2009] 
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>328298</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/weight-loss-pills-vs-anti-fat-jab.aspx]]&gt;</url>
    <title>Behind the Headlines - Weight loss pills vs anti-fat jab</title>
    <publicationDate>2009-10-23T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,OBESITY,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Patients given a new anti-obesity drug lost more than a stone in weight in five months,” said The Times. The injectable drug, liraglutide, was reported as being almost twice as effective as other treatments in the study. 

The Daily Mail wrongly reports that the drug has been licensed for use in obese patients in the UK since July.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Patients given a new anti-obesity drug lost more than a stone in weight in five months,” said &lt;EM&gt;The Times&lt;/EM&gt;. The injectable drug, liraglutide, was reported as being almost twice as effective as other treatments in the study. &lt;/P&gt;
&lt;P&gt;The &lt;EM&gt;Daily Mail &lt;/EM&gt;wrongly reports that the drug has been licensed for use in obese patients in the UK since July.&lt;/P&gt;
&lt;P&gt;In this high-quality randomised trial, 564 obese or severely obese patients were injected with either 1.2mg to 3.0mg of liraglutide a day, a daily 'dummy' jab, or orlistat pills three times a day. All patients followed a calorie-restricted diet and increased their physical activity.&lt;/P&gt;
&lt;P&gt;Contrary to some newspaper reports, this drug in is only licensed to treat type 2 diabetes in tablet form in Europe, and is not yet licensed in the US.&amp;nbsp;Average weight loss on the highest dose of liraglutide was more than 7.2 kg at 20 weeks, which was 4.4 kg more than placebo. &lt;/P&gt;
&lt;P&gt;This was significantly more than the weight loss achieved on orlistat, and it was clinically important despite the fact that patients were not blinded.&lt;/P&gt;
&lt;P&gt;The researchers acknowledge that the long-term effects of the injection and&amp;nbsp;its safety will need to be understood if the licence for this drug is extended from type 2 diabetes to obesity.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This well-conducted study has confirmed the efficacy of liraglutide and showed a dose response, i.e. higher doses of the drug are associated with larger responses, benefits and harms. &lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/10October/Pages/weight-loss-pills-vs-anti-fat-jab.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Astrup A, Rössner S, Van Gaal L. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. The Lancet, Early Online Publication, October 23 2009 &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>307794</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.biomedcentral.com/gateways/diabetes/]]&gt;</url>
    <title>BioMed Central : diabetes gateway</title>
    <publicationDate></publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ JOURNALS,RESEARCH,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;All original research articles published by BioMed Central are made freely and permanently accessible online immediately upon publication.&lt;/P&gt;
&lt;P&gt;The Diabetes gateway&amp;nbsp;is a collection of content and resources from journals and sites published by BioMed Central, of interest to researchers in the subject of Diabetes.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>373107</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_monthly_no25.pdf]]&gt;</url>
    <title>Blood glucose lowering and mortality in type 2 diabetes: not too little, not too much</title>
    <publicationDate>2010-04-01T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,MEDICATION,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This MeReC monthly article considers a large retrospective cohort study which supports findings from RCTs that intensive blood glucose control in patients with type 2 diabetes may increase the risk of harm.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; MeReC Monthly No. 25. Published April 2010. Original article: Currie CJ, et al. Survival as a function of HbA1 in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481-9.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File/PDF requiring Adobe Acrobat Reader.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>373107</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_monthly_no25.pdf]]&gt;</url>
    <title>Blood glucose lowering and mortality in type 2 diabetes: not too little, not too much</title>
    <publicationDate>2010-04-01T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,MEDICATION,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This MeReC monthly article considers a large retrospective cohort study which supports findings from RCTs that intensive blood glucose control in patients with type 2 diabetes may increase the risk of harm.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; MeReC Monthly No. 25. Published April 2010. Original article: Currie CJ, et al. Survival as a function of HbA1 in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481-9.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File/PDF requiring Adobe Acrobat Reader.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377771</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_extra_no45.pdf]]&gt;</url>
    <title>Blood glucose lowering and mortality in type 2 diabetes: not too little, not too much</title>
    <publicationDate>2010-05-17T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CONDITION MANAGEMENT,DIABETES,TYPE 2,MEDICATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This MeReC&amp;nbsp;Extra article&amp;nbsp;(on page 2 of the newsletter) considers a large retrospective cohort study&amp;nbsp;that supports findings from RCTs that intensive blood glucose control in patients with type 2 diabetes may increase the risk of harm. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; MeReC Extra Issue 45, page 2.&amp;nbsp;Published&amp;nbsp;May 2010. Original article: Currie CJ, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. &lt;EM&gt;Lancet&lt;/EM&gt; 2010;375:481–9 &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;FONT face=ArialMT size=1&gt;&lt;/P&gt;
&lt;P&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377771</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_extra_no45.pdf]]&gt;</url>
    <title>Blood glucose lowering and mortality in type 2 diabetes: not too little, not too much</title>
    <publicationDate>2010-05-17T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CONDITION MANAGEMENT,DIABETES,TYPE 2,MEDICATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This MeReC&amp;nbsp;Extra article&amp;nbsp;(on page 2 of the newsletter) considers a large retrospective cohort study&amp;nbsp;that supports findings from RCTs that intensive blood glucose control in patients with type 2 diabetes may increase the risk of harm. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; MeReC Extra Issue 45, page 2.&amp;nbsp;Published&amp;nbsp;May 2010. Original article: Currie CJ, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. &lt;EM&gt;Lancet&lt;/EM&gt; 2010;375:481–9 &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;FONT face=ArialMT size=1&gt;&lt;/P&gt;
&lt;P&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>177135</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/main.html]]&gt;</url>
    <title>BMJ learning</title>
    <publicationDate></publicationDate>
    <publisher>BMJ Publishing Group</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CPD AND PROFESSIONAL EDUCATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Evidence based learning resource</description>
    <body>&lt;![CDATA[ &lt;P&gt;BMJ learning is an evidence based learning resource in the form of an interactive website. Learning modules&amp;nbsp;cover various clinical specialties&amp;nbsp;including diabetes and obesity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Audience:&lt;/STRONG&gt; The website is designed for postgraduate trainees, general practitioners, hospital doctors, nurses and healthcare professionals to support their personal development, learning and CME needs. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Freely available to BMA members. Registration required. Non BMA members are required to purchase an annual subscription to view the complete&amp;nbsp;resource.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>312086</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19299006?ordinalpos=3&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies</title>
    <publicationDate>2009-03-28T00:00:00</publicationDate>
    <publisher>Lancet</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ DIABETES,OBESITY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Results/Conclusion:&lt;/STRONG&gt; Obesity as measured by BMI is associated with increased total mortality in both men and women and in all age strata from 35-89 years. The increased mortality is due to IHD, stroke, diabetes and liver disease. At a BMI of 30-35 median survival is reduced by 2-4 years. At 40-45 it is reduced by 8-10 years. It also shows that people with a BMI in the low range 16.5-22.5 have an increased risk of death compared with those with BMI of 27.5-30, which is mainly due to smoking related, respiratory disease deaths. The study shows that BMI cannot discriminate CVD risk well in people with intermediate BMI values.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; This is a collaborative analysis of BMI versus mortality in 57 prospective studies with 894576 participants with a mean recruitment age of 46. The first 5 years of follow up were excluded, leaving 66552 deaths of known cause during a mean of 8 years of follow up. The analyses were adjusted for age, sex, smoking status and study.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373(9669):1083-96.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published 28 March 2009&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full text online requires subscription to the journal. NHS Staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library &lt;/A&gt;for further assistance.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307364</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/]]&gt;</url>
    <title>British Medical Journal</title>
    <publicationDate></publicationDate>
    <publisher>British Medical Journal</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The website of the BMJ (British Medical Journal) includes information about the journal and advice to contributors.&amp;nbsp;&amp;nbsp;Sign up for &lt;A href="http://resources.bmj.com/bmj/readers/alerts" target="_blank"&gt;email alerts&lt;/A&gt; of this journal.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; All research articles are&amp;nbsp;freely accessible online. All non-research articles published between 1840 and 2006 are also available free, but they do require registration.&amp;nbsp;&lt;BR&gt;Full access to all content&amp;nbsp;for&amp;nbsp;NHS staff in England is&amp;nbsp;available via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;NHS Evidence&lt;/A&gt;, where (by logging in with your Athens password) you can also receive a table of contents alert via Zetoc, locate items in your local library and create search alerts.&lt;BR&gt;Other NHS staff check with your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323484</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=205]]&gt;</url>
    <title>Building the Capacity to Deliver Structured Education for All People</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Briefing document for SHA Diabetes Leads and PCT Commissioning Leads for Diabetes.&amp;nbsp;The aim of this document&amp;nbsp;is to support SHAs to assess their current position regarding structured education to support diabetes self-care in line with existing policy and evidence.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication information:&lt;/STRONG&gt; Published October 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251173</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=251173]]&gt;</url>
    <title>Can type 2 diabetes be prevented in people with gestational diabetes?</title>
    <publicationDate>2007-03-12T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PREVENTION,GESTATIONAL DIABETES,PROGRESSION TO TYPE 2 DIABETES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Part of the National Knowledge Week for the Prevention of Type 2 Diabetes.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Can type 2 diabetes be prevented in people with gestational diabetes?&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;&lt;FONT color=#666666&gt;Written by&amp;nbsp;R&amp;nbsp;Gadsby&amp;nbsp;March 2007.&lt;BR&gt;&lt;EM&gt;&lt;FONT color=#666666&gt;Reviewed by Dr Roger Gadsby, November 2009&lt;/FONT&gt;&lt;/EM&gt;&lt;/FONT&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387843" target="_blank"&gt;Back to Knowledge Week contents page&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Women who have had gestational diabetes are at an increased risk of developing type 2 diabetes. A systematic review by Case J et al&lt;SUP&gt;1&lt;/SUP&gt; concluded that modification of lifestyle based risk factors including obesity, poor nutrition and lack of exercise can delay or prevent the onset of type 2 diabetes in these women. &lt;BR&gt;Another systematic review&amp;nbsp;by Taylor JS et al&lt;SUP&gt;2&lt;/SUP&gt; looked at breastfeeding and suggested that being breastfed for at least 2 months may lower the risk of developing diabetes in children.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;References and further Information&lt;BR&gt;&lt;/U&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;Systematic reviews&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Systematic reviews from literature search referenced by author:&lt;/P&gt;
&lt;P&gt;1. Case J, Willoughby D, Haley ZV, Maybee P. Preventing type 2 diabetes after gestational diabetes. The&amp;nbsp;Diabetes Educator 2006;&amp;nbsp;32 (6): 877-86. &lt;A href="http://tde.sagepub.com/cgi/content/full/32/6/877" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2. Taylor JS, Kacmar JE, Nothnagle M, Lawrence RA. A&amp;nbsp;systematic review of the literature associating breastfeeding with type 2 diabetes and gestational diabetes. Journal of the&amp;nbsp;American College of Nutrition 2005;&amp;nbsp;24 (5): 320-6. &lt;A href="http://www.jacn.org/cgi/content/full/24/5/320" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Full literature search results &lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=388094" target="_blank"&gt;Systematic reviews and other studies organised by topic&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidelines&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?catID=5634&amp;amp;tabID=288" target="_blank"&gt;Links to supporting guidelines&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient Information&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?catID=5634&amp;amp;tabID=292&amp;amp;" target="_blank"&gt;Links to supporting patient information&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387843" target="_blank"&gt;Back to Knowledge Week contents page&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>301343</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,178/Itemid,61/]]&gt;</url>
    <title>Carbohydrate counting (teaching letter no. 35)</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MONITORING / SELF-MONITORING,MONITORING / SELF-MONITORING,NUTRITION AND FOOD,NUTRITION AND FOOD]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aim&lt;/STRONG&gt;: "The aim of this teaching letter is to help educators make carbohydrate counting one of the main teaching tools used to educate the diabetic patient to achieve controlled blood sugar concentrations. What is carbohydrate counting? Why is it important? When do we use it and how?"&lt;/P&gt;
&lt;P&gt;This is one of a series of &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;teaching letters&lt;/A&gt; for doctors and other health care professionals involved in the daily care of patients with diabetes. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>260999</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=101]]&gt;</url>
    <title>Care planning in diabetes</title>
    <publicationDate>2007-05-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT,KEY POLICIES / NSF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This National Diabetes Support Team (now NHS Diabetes) factsheet&amp;nbsp;explains the concept of Care Planning in diabetes&amp;nbsp;and provides a summary of a report fom the Joint Department of Health and Diabetes UK Care Planning Working Group &lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=212936&amp;amp;tabID=288" target="_blank"&gt;'Care Planning in Diabetes'&lt;/A&gt; published in December 2006.&lt;BR&gt;The factsheet&amp;nbsp;includes the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Introduction 
&lt;LI&gt;Empowerment 
&lt;LI&gt;Principles 
&lt;LI&gt;Components 
&lt;LI&gt;Putting into practice 
&lt;LI&gt;Workforce 
&lt;LI&gt;Further Information&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published May 2007.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60303</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/About_us/Our_Views/Care_recommendations/Folic_acid_supplementation_in_pregnancy/]]&gt;</url>
    <title>Care recommendation : folic acid supplementation in pregnancy</title>
    <publicationDate>2005-06-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETES AND PREGNANCY,CONDITION MANAGEMENT,PRECONCEPTION CARE,GESTATIONAL DIABETES,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Diabetes UK care recommendation covers folic acid supplementation in pregnancy. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>59845</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/About_us/Our_Views/Care_recommendations/Structured_Patient_education/]]&gt;</url>
    <title>Care recommendation: structured patient education</title>
    <publicationDate>2003-03-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Diabetes UK&amp;nbsp;care recommendation&amp;nbsp;covers the structured education of patients in relation to self-management and the maintaining of ‘good control’, i.e. control of blood glucose levels, lipids, blood pressure and body weight, through following a healthy diet, physical activity, moderating alcohol intake and stopping smoking. &lt;BR&gt;It is&amp;nbsp;aimed at health professionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60302</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/About_us/Our_Views/Care_recommendations/The_arm_as_an_injection_site/]]&gt;</url>
    <title>Care recommendation: the arm as an injection site</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MEDICATION,MEDICATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P style="MARGIN-RIGHT: 0px" dir=ltr&gt;This Diabetes UK care recommendation discusses the use of the arm as an injection site. It is aimed at health professionals.&lt;BR&gt;The conclusions drawn are that: 
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;P style="MARGIN-RIGHT: 0px" dir=ltr&gt;"the arms may be used as a site for injection provided the appropriate length of needle, and the correct technique for administration of insulin, is used. This should be individually assessed by the diabetes team. People using their arms should be encouraged to monitor their blood glucose control more regularly, to ensure that their technique is delivering the insulin appropriately. They should also be warned of the risk of hypoglycaemia following injection into the arm. Parents should be encouraged to use the ‘pinch up’ technique if using the arms as a site for their children and should use shorter needles."&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P style="MARGIN-RIGHT: 0px" dir=ltr&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P style="MARGIN-RIGHT: 0px" dir=ltr&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>156705</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/About_us/Our_Views/Care_recommendations/Type-2-diabetes-in-children-and-young-people/]]&gt;</url>
    <title>Care recommendation: type 2 diabetes in children and young people</title>
    <publicationDate>2010-01-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CHILD HEALTH,ENDOCRINOLOGY,GUIDELINES/EBM,DIABETES MELLITUS,SPECIALTIES,DIABETES,TYPE 2,STAFF USE,CHILDREN AND YOUNG PEOPLE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Diabetes UK&amp;nbsp;care recommendation provides information about type 2 diabetes in children and young people. It is&amp;nbsp;aimed at healthcare professionals.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Last reviewed by Diabetes UK in January 2010.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;BR&gt;&lt;BR&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>126163</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/13/40/12/04134012.pdf]]&gt;</url>
    <title>Caring for people with long term conditions:an education framework for community matrons and case managers</title>
    <publicationDate>2006-04-24T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CPD AND PROFESSIONAL EDUCATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document provides a framework for commissioners and providers of education and training for community matrons and case managers. It is designed to help ensure that the education and training these practitioners receive enables them to provide more effective care for people with complex long term conditions. The education framework complements the case management competences framework for the care of people with long term conditions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>266076</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/publications_and_resources/factsheets_and_case_studies/case_studies/]]&gt;</url>
    <title>Case Studies</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,SHARING PRACTICE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Showcase of diabetes good practice.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the&amp;nbsp;NHS Diabetes&amp;nbsp;website lists examples of good practice&amp;nbsp;in diabetes care. Many topics are covered including:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Prevention of Type 2 diabetes 
&lt;LI&gt;Identification of people with diabetes 
&lt;LI&gt;Empowering people with diabetes 
&lt;LI&gt;Clinical care of adults with diabetes 
&lt;LI&gt;Clinical care of children and young people with diabetes 
&lt;LI&gt;Management of diabetic emergencies 
&lt;LI&gt;Care of people with diabetes during admission to hospital 
&lt;LI&gt;Diabetes and pregnancy 
&lt;LI&gt;Detection and management of long-term complications&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301814</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/our_work_areas/children_and_young_people_with_diabetes/]]&gt;</url>
    <title>Children and young people - Work Area - NHS Diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CHILD HEALTH,ENDOCRINOLOGY,DIABETES MELLITUS,DIABETES INSIPIDUS,SPECIALTIES,DIABETES,TYPE 1,TYPE 2,DELIVERY OF CARE,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,CHILDREN AND YOUNG PEOPLE,CHILDREN AND YOUNG PEOPLE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the NHS Diabetes website provides details of the work of the Children's and Young People's Working Group. It provides links to the reports and minutes of this working group.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>387527</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://uk.sitestat.com/diabetes/website-uk/s?templates.GenericContent.aspx%3fid%3d26796%26epslanguage%3den.&amp;ns_type=pdf&amp;ns_url=http://www.diabetes.org.uk/Documents/Reports/Childrens%20Charter%20report-final.pdf]]&gt;</url>
    <title>Children's charter for diabetes</title>
    <publicationDate></publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,LIVING WITH DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT,USER INVOLVEMENT,CHILDREN AND YOUNG PEOPLE,DATA GATHERING AND AUDIT AND QOF,CHILDREN AND YOUNG PEOPLE,DISABILITY AND DISCRIMINATION,SCHOOL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Diabetes UK developed this charter with involvement from children and young people with diabetes, their carers and healthcare professionals, some of whose views were gathered at a policy forum held in 2009. &lt;/P&gt;
&lt;P&gt;It makes bold statements representing what Diabetes UK, children and young people, their families and healthcare professionals believe must happen to ensure high quality care, and to help achieve good physical and emotional wellbeing. &lt;/P&gt;
&lt;P&gt;The report addresses each charter statement in turn, demonstrating why the vision of care and support outlined is important. It identifies what is currently happening, and makes recommendations for how the vision in each statement can be achieved.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in August 2010.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323081</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/our_work_areas/classification_of_diabetes/]]&gt;</url>
    <title>Classification of Diabetes - Work Area - NHS Diabetes</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DELIVERY OF CARE,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,DIAGNOSIS,DIAGNOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the NHS Diabetes website provides details of the work of the&amp;nbsp;Classification of Diabetes&amp;nbsp;Working Group. It also includes links to further information. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>300916</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Professionals/Publications-reports-and-resources/Reports-statistics-and-case-studies/Audit_Reports/Clinical_Audit/]]&gt;</url>
    <title>Clinical Audit</title>
    <publicationDate>2008-12-10T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF,INNOVATION AND IMPROVEMENT,SYSTEMS THINKING,EVALUATION,OUTCOMES,PERFORMANCE INDICATORS,SAFER CARE,CLINICAL SYSTEMS IMPROVEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the&amp;nbsp;Diabetes UK&amp;nbsp;website provides information about&amp;nbsp;clinical audit, a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. It is&amp;nbsp;aimed at healthcare professionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>61072</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.eugms.org/index.php?pid=83]]&gt;</url>
    <title>Clinical guidelines for type 2 diabetes mellitus (older people)</title>
    <publicationDate>2004-05-10T00:00:00</publicationDate>
    <publisher>European Union Geriatric Medicine Society</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,ELDERLY PEOPLE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Aims:&lt;/STRONG&gt; This guideline is concerned with highlighting the special needs of older people with diabetes mellitus. 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Health professionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published May 2004.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/PAGEBODY&gt;&lt;/PAGE&gt;&lt;/ARTICLE&gt;]]&gt;</body>
  </document>
  <document>
    <id>296765</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19183307]]&gt;</url>
    <title>Commentary from Copenhagen on the NICE guideline on management of diabetes and its complications from preconception to the postnatal period</title>
    <publicationDate>2008-10-28T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETES AND PREGNANCY,CONDITION MANAGEMENT,PRECONCEPTION CARE,GESTATIONAL DIABETES,CAUSES,DIAGNOSIS,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full Reference:&lt;/STRONG&gt; &lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;SPAN class=name&gt;&lt;SPAN class=forenames&gt;E. R.&lt;/SPAN&gt; &lt;SPAN class=surname&gt;Mathiesen&lt;/SPAN&gt;&lt;/SPAN&gt; and &lt;SPAN class=name&gt;&lt;SPAN class=forenames&gt;P.&lt;/SPAN&gt; &lt;SPAN class=surname&gt;Damm &lt;/SPAN&gt;&lt;/SPAN&gt;(2008) Commentary from Copenhagen on the NICE guideline on management of diabetes and its complications from preconception to the postnatal period. &lt;I&gt;Diabetic Medicine,&lt;/I&gt; 25 (9)&lt;B&gt;,&lt;/B&gt; 1028-1029.&lt;/SPAN&gt;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;?xml:namespace prefix = o /&gt;&lt;o:p&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; No abstract available. Access to the full text online requires subscription to the journal.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;NHS staff please &lt;A href="http://www.hlisd.org/" target="_blank"&gt;contact your local NHS library for further assistance.&lt;/A&gt;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;This&amp;nbsp;article is&amp;nbsp;a commentary from &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;Copenhagen&lt;/st1:place&gt;&lt;/st1:City&gt;. The authors conclude that the majority of the recommendations are reasonable and based on available research and present tradition. They feel that some of the recommendations are surprising and comment on these specifically. They include the use of metformin as a glucose lowering treatment&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;in pregnancy where they feel that more studies on its safety in pregnancy need to be done. They feel that the guideline could have been more encouraging in the use of long acting insulin analogues and should have given recommendations to use HBA1c measurements in pregnancy. They feel that antenatal cardiotochography should be used as a measure of foetal well being. They conclude that many of the recommendations in the guideline seem sensible but in some places are surprisingly clear cut given the paucity of high-quality evidence. Roger Gadsby, October 08.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>327545</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=560]]&gt;</url>
    <title>Commissioning diabetes without walls</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,COMMISSIONING,COMMISSIONING,DISEASE/CONDITION GROUPS,ENDOCRINE,TYPES OF COMMISSIONING,JOINT COMMISSIONING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report outlines how to support the commissioning of improved quality of diabetes care and patient experience.&amp;nbsp; It&amp;nbsp;includes the following sections: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Aims of the 2009 Diabetes Without Walls Guide 
&lt;LI&gt;Commissioning Diabetes as a long term condition 
&lt;LI&gt;Key Elements of High Quality Diabetes Care 
&lt;LI&gt;Key characteristics of Integrated Diabetes service 
&lt;LI&gt;Commissioning an integrated diabetes service 
&lt;LI&gt;Delivering Diabetes World Class Commissioning 
&lt;LI&gt;Tools to support diabetes commissioning 
&lt;LI&gt;The value of specifying services&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>300914</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Professionals/Education_and_skills/Competencies_-_Feet/]]&gt;</url>
    <title>Competencies - Feet</title>
    <publicationDate>2008-12-10T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETIC FOOT,DELIVERY OF CARE,CHRONIC COMPLICATIONS,DIAGNOSIS,CONDITION MANAGEMENT,CAUSES,PREVENTION,COMMISSIONING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the&amp;nbsp;Diabetes UK&amp;nbsp;website provides information about&amp;nbsp;commissioning of footcare services for people with diabetes. It is&amp;nbsp;aimed at healthcare professionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102943</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[https://tools.skillsforhealth.org.uk/suite/show/id/40]]&gt;</url>
    <title>Competency framework : diabetes</title>
    <publicationDate></publicationDate>
    <publisher>Skills for Health</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CPD AND PROFESSIONAL EDUCATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the provides&amp;nbsp;access to the set of competences for diabetes. &lt;BR&gt;The competences developed by Skills for Health can be used by individuals, employers and education providers for a number of purposes including:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;individual development / appraisal 
&lt;LI&gt;team development 
&lt;LI&gt;role design 
&lt;LI&gt;role re-design 
&lt;LI&gt;service design e.g. new build/service 
&lt;LI&gt;education programme / curriculum design 
&lt;LI&gt;evidence gathering for KSF post outlines&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Further information about what competences are and how they can be used can be found in the&amp;nbsp;&lt;A href="http://www.skillsforhealth.org.uk/competences/competence-faq.aspx" target="_blank"&gt;Frequently Asked Questions &lt;/A&gt;&amp;nbsp;section on the Skills for Health website. &lt;/P&gt;
&lt;P&gt;Skills for Health (SfH)&amp;nbsp;is licenced by DfES as the UK Sector Skills Council (SSC) for health. SfH is part of the NHS,&amp;nbsp;hosted by a Trust, but with its own Board and management. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102945</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[https://tools.skillsforhealth.org.uk/suite/show/id/24]]&gt;</url>
    <title>Competency framework : diabetic retinopathy</title>
    <publicationDate></publicationDate>
    <publisher>Skills for Health</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CPD AND PROFESSIONAL EDUCATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the Skills for Health website provides&amp;nbsp;access to the set of competences for diabetic retinopathy.&amp;nbsp;&lt;BR&gt;The competences developed by Skills for Health can be used by individuals, employers and education providers for a number of purposes including:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;individual development / appraisal 
&lt;LI&gt;team development 
&lt;LI&gt;role design 
&lt;LI&gt;role re-design 
&lt;LI&gt;service design e.g. new build/service 
&lt;LI&gt;education programme / curriculum design 
&lt;LI&gt;evidence gathering for KSF post outlines&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Further information about what competences are and how they can be used can be found in the&amp;nbsp;&lt;A href="http://www.skillsforhealth.org.uk/competences/competence-faq.aspx" target="_blank"&gt;Frequently Asked Questions &lt;/A&gt;&amp;nbsp;section on the Skills for Health website. &lt;/P&gt;
&lt;P&gt;Skills for Health (SfH)&amp;nbsp;is licenced by DfES as the UK Sector Skills Council (SSC) for health. SfH is part of the NHS,&amp;nbsp;hosted by a Trust, but with its own Board and management. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>294788</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2494620/]]&gt;</url>
    <title>Comprehensive Foot Examination and Risk Assessment</title>
    <publicationDate>2008-09-25T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETIC FOOT,CHRONIC COMPLICATIONS,DIAGNOSIS,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full Reference:&lt;/STRONG&gt; Comprehensive Foot Examination and Risk Assessment: A report of the Task Force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists.&amp;nbsp; Boulton et al.&amp;nbsp; Diabetes Care.&amp;nbsp; 2008; 31: 1679-1685.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>287777</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18387076]]&gt;</url>
    <title>Consensus meeting on reporting glycated haemoglobin (HbA1c) and estimated average glucose (eAG) in the UK: report to the National Director for Diabetes, Department of Health</title>
    <publicationDate>2008-04-25T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full Reference:&amp;nbsp; &lt;/STRONG&gt;Barth JH, Marshall SM, Watson ID.&amp;nbsp; Consensus meeting on reporting glycated haemoglobin (HbA1c) and estimated average glucose (eAG) in the UK: report to the National Director for Diabetes, Department of Health.&amp;nbsp; Diabet Med. 2008 Apr;25(4):381-2.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;BR&gt;&lt;/STRONG&gt;Access to the full text online requires subscription to the journal.&lt;/P&gt;
&lt;P&gt;NHS staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt;&amp;nbsp;for further assistance.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301357</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/cgi/content/full/30/9/2399]]&gt;</url>
    <title>Consensus statement on the worldwide standardization of the hemoglobin A1C measurement</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MONITORING / SELF-MONITORING,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;/STRONG&gt;&amp;nbsp;The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation (2007) Consensus Statement on the Worldwide Standardization of the Hemoglobin A1C Measurement. &lt;I&gt;Diabetes Care,&lt;/I&gt; 30&lt;B&gt;,&lt;/B&gt; 2399-2400.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>258900</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.sdo.nihr.ac.uk/files/adhoc/14-research-summary.pdf]]&gt;</url>
    <title>Continuity of care in type 2 diabetes: patients professionals and carers experiences and health outcomes</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>NHS Service Delivery and Organisation Research and Development Programme</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This research summary outlines an investigation of the relevance of continuity in the care of type 2 diabetes. The researchers from King's College London set out to evaluate and measure patients', carers' and providers' experiences of continuity of care in type 2 diabetes and to determine whether continuity of care was associated with improved clinical and patient outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published March 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/?promoid=BUIGO" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>294824</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_extra_no35.pdf]]&gt;</url>
    <title>Controlling blood glucose and reducing the risk of cardiovascular disease in type 2 diabetes</title>
    <publicationDate>2008-09-25T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CARDIOVASCULAR,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,MEDICATION,CAUSES,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This MeReC&amp;nbsp;Extra article&amp;nbsp;considers some key recommendations from the updated NICE guideline on type 2 diabetes with regard to controlling blood glucose and reducing the risk of cardiovascular disease.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; MeReC Extra Issue 35. Published&amp;nbsp;September 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;FONT size=1 face=ArialMT&gt;&lt;/P&gt;
&lt;P&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388847</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20668156]]&gt;</url>
    <title>Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review.</title>
    <publicationDate>2010-08-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CONDITION MANAGEMENT,PREVENTION,CONDITION MANAGEMENT,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Li R, Zhang P, Barker LE, Chowdhury FM, et al. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. August;33(8):1872-94. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in August 2010. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Access to the full text online requires subscription to the journal. NHS staff please contact &lt;A href="http://www.hlisd.org/" target="_blank"&gt;your local NHS library&lt;/A&gt; for further assistance.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60141</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,153/Itemid,61/]]&gt;</url>
    <title>Counselling on late complications (teaching letter no.5)</title>
    <publicationDate>1996-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ ANXIETY AND DEPRESSION,DIABETES,CHRONIC COMPLICATIONS,PSYCHOLOGICAL PROBLEMS,CARDIOVASCULAR,SEXUAL DYSFUNCTION,PAINFUL NEUROPATHIES,DIABETIC FOOT,RETINOPATHY,NEPHROPATHY,PREVENTION,CONDITION MANAGEMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,PREVENTION,PREVENTION,CONDITION MANAGEMENT,PREVENTION,CONDITION MANAGEMENT,PREVENTION,EYE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the counselling of patients with diabetes on the subject of late complications. It covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Knowing the patient 
&lt;LI&gt;The patient without complications 
&lt;UL&gt;
&lt;LI&gt;When does the newly diagnosed diabetic need to hear about late complications? 
&lt;LI&gt;What does the patient need to know? 
&lt;LI&gt;What does the patient need to do?&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;The patient with first symptoms or signs of complications 
&lt;LI&gt;The patient with advanced complications 
&lt;UL&gt;
&lt;LI&gt;Medical responses 
&lt;LI&gt;Social support 
&lt;LI&gt;Psychological support&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Evaluation&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 1996&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>61152</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Professionals/Education_and_skills/Courses/]]&gt;</url>
    <title>Courses</title>
    <publicationDate></publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CPD AND PROFESSIONAL EDUCATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the&amp;nbsp;Diabetes UK&amp;nbsp;website provides information about courses for healthcare professionals, including those for dietitians, community and diabetic nurses, midwives and health visitors. It is&amp;nbsp;aimed at people with diabetes,&amp;nbsp;relatives and carers. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381752</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20546277]]&gt;</url>
    <title>Culturally appropriate health education for type 2 diabetes in ethnic minority groups: a systematic and narrative review of randomized controlled trials</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PEOPLE FROM ETHNIC MINORITIES,ETHNICITY AND HEALTH,DISEASES AND CONDITIONS,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed abstract&lt;BR&gt;"To determine if culturally appropriate health education is more effective than 'usual' health education for people with diabetes from ethnic minority groups living in high- and upper-middle-income countries."&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Methods: &lt;BR&gt;&lt;/STRONG&gt;Taken from PubMed abstract&lt;BR&gt;"A systematic review with meta-analysis, following the methodology of the Cochrane Collaboration. Electronic literature searches of nine databases were made, with hand searching of three journals and 16 author contacts. The criteria for inclusion into the analysis were randomized controlled trials of a specified diabetes health education intervention, and a named ethnic minority group with Type 2 diabetes. Data were collected on HbA(1c), blood pressure, and quality-of-life measures. A narrative review was also performed."&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Results: &lt;BR&gt;&lt;/STRONG&gt;Taken from PubMed abstract&lt;BR&gt;"Few studies fitted the selection criteria, and were heterogeneous in methodologies and outcome measures, making meta-analysis difficult. HbA(1c) showed an improvement at 3 months [weighted mean difference (WMD) -0.32%, 95% confidence interval (CI) -0.63, -0.01] and 6 months post intervention (WMD -0.60%, 95% CI -0.85, -0.35). Knowledge scores also improved in the intervention groups at 6 months (standardized mean difference 0.46, 95% CI 0.27, 0.65). There was only one longer-term follow-up study, and one formal cost-effectiveness analysis."&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed abstract&lt;BR&gt;"Culturally appropriate health education was more effective than 'usual' health education in improving HbA(1c) and knowledge in the short to medium term. Due to poor standardization between studies, the data did not allow determination of the key elements of interventions across countries, ethnic groups and health systems, or a broad view of their cost-effectiveness. The narrative review identifies learning points to direct future research."&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Hawthorne K, Robles Y, Cannings-John R, Edwards AG. Culturally appropriate health education for Type 2 diabetes in ethnic minority groups: a systematic and narrative review of randomized controlled trials. Diabetic Medicine. June 2010;27(6):613-23.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in June 2010.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full-text of this article online requires subscription to the&amp;nbsp;journal. NHS staff please&amp;nbsp;contact&amp;nbsp; &lt;A href="http://www.hlisd.org/" target="_blank"&gt;your local NHS library&lt;/A&gt;&amp;nbsp;for further assistance.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82500</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/09/14/75/04091475.pdf]]&gt;</url>
    <title>Current and future research on diabetes: a review for the Department of Health and the Medical Research Council</title>
    <publicationDate>2002-10-01T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEW DEVELOPMENTS,CPD AND PROFESSIONAL EDUCATION,RESEARCH,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The principal purpose of this review was to identify key opportunities for research in the United Kingdom. A further purpose was to identify opportunities for research to support the implementation by the NHS of the National Service Framework for Diabetes. It was also the intention that the review should be of use to funding agencies which support research on diabetes and to the research community at large.&lt;/P&gt;
&lt;P&gt;The review includes the sections on the following topics:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Pancreatic cell, insulin secretion and action 
&lt;LI&gt;Causes and prevention of diabetes 
&lt;LI&gt;Service organisation and delivery 
&lt;LI&gt;Infrastructure for research&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published 01 Oct 2002.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>389582</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_monthly_no30.pdf]]&gt;</url>
    <title>CV risk reduction in diabetes: law of cumulative benefits, diminishing returns</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CARDIOVASCULAR,CHRONIC COMPLICATIONS,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This MeReC monthly article (on pages 2-3 of the newsletter) discusses a modelling study which illustrates the 'law of cumulative benefits' or conversely the 'law of diminishing returns' with intensification of BP-lowering and lipid-modifying therapy in patients with diabetes.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication History Information:&lt;/STRONG&gt; MeReC Monthly No. 30, pages 2-3. Published&amp;nbsp;September 2010. Original article: Timbie JW, et al. Variationin the net benefit of aggresive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Arch Intern Med 2010; 170:1037-44. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).]]&gt;</body>
  </document>
  <document>
    <id>267565</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/cdrisk/merec_extra_no29.htm]]&gt;</url>
    <title>CV risks of rosiglitazone</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CAUSES,GENERAL/OTHER,CARDIOVASCULAR DISEASES,DISEASE MANAGEMENT,CAUSES AND RISK FACTORS,DIABETES MELLITUS,DIABETES,CARDIOVASCULAR,CHRONIC COMPLICATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of this MeReC&amp;nbsp;Extra article&amp;nbsp;discusses recent research into the cardiovascular risks of rosiglitazone. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published&amp;nbsp;August 2007. MeReC Extra No. 29. 
&lt;P&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309172</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_086052?IdcService=GET_FILE&amp;dID=168944&amp;Rendition=Web]]&gt;</url>
    <title>Delivering care closer to home: meeting the challenge</title>
    <publicationDate>2008-07-08T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ COMMISSIONING,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,KEY POLICIES / NSF,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document is a resource for commissioners and others interested in shifting care closer to home. It aims to share local emerging practice, how national enablers can support shifting care, and highlights new products developed to support local commissioners and providers.&amp;nbsp; Includes information on Year of Care for Diabetes and Community Pharmacy Diabetes Services.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>303733</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19033420]]&gt;</url>
    <title>Depression and diabetes treatment nonadherence: a meta-analysis.</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,PSYCHOLOGICAL PROBLEMS,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MEDICATION,MEDICATION,ADHERENCE / COMPLIANCE,TREATMENT CONCORDANCE,ANXIETY AND DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;BR&gt;&lt;/STRONG&gt;Gonzalez, J. S., Peyrot, M., McCarl, L. A., Collins, E. M., Serpa, L., Mimiaga, M. J. &amp;amp; Safren, S. A. (2008) Depression and Diabetes Treatment Nonadherence: A Meta-Analysis. Diabetes Care, 31, 2398-2403.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: There is a significant association between depression and treatment non adherence in patients with diabetes. Studies that used stronger methodologies had larger effects. Treatment no adherence may represent an important pathway between depression and worse diabetes clinical outcomes.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method&lt;/STRONG&gt;: Meta-analysis of 47 studies which fulfilled the inclusion criteria.&amp;nbsp; Literature search to&amp;nbsp;June 2007.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: Depression is significantly associated with nonadherence to the diabetes treatment regimen (z = 9.97, P &amp;lt; 0.0001). The weighted effect size was near the medium range (r = 0.21, 95% CI 0.17–0.25). Moderator analyses showed that the effect was significantly larger in studies that measured self-care as a continuous versus categorical variable (P = 0.001). Effect sizes were largest for missed medical appointments and composite measures of self-care (r values = 0.31, 0.29). Moderation analyses suggest that effects for most other types of self-care are also near the medium range, especially in studies with stronger methodologies.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Published in December 2008.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessing the full text:&lt;BR&gt;&lt;/STRONG&gt;NHS staff in England: &lt;A href="http://journals.library.nhs.uk/" target="_blank"&gt;available via NLH&lt;/A&gt;&lt;BR&gt;other NHS staff: &lt;A href="http://www.hlisd.org/" target="_blank"&gt;Check with your local NHS library&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>303730</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19033418]]&gt;</url>
    <title>Depression and type 2 diabetes over the lifespan: a meta-analysis</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,PSYCHOLOGICAL PROBLEMS,CHRONIC COMPLICATIONS,ANXIETY AND DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: Depression is associated with a 60% increased risk of diabetes but that type 2 diabetes is associated with only a modest increase in depression.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Method&lt;/STRONG&gt;: Search from 1950-2007 for papers that examine the relationship of diabetes and depression.&amp;nbsp; 42 full text papers reviewed.&amp;nbsp; Seven met criteria for diabetes predicting the onset of depression, representing 6414 incident cases.&amp;nbsp; &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: The pooled relative risk for incident depression associated with baseline diabetes was 1.15 (1.02-1.30) the RR for incident diabetes associated with baseline depression was 1.60 (1.37-1.88).&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Mezuk, B., Eaton, W. W., Albrecht, S. &amp;amp; Golden, S. H. (2008) Depression and Type 2 Diabetes Over the Lifespan: A meta-analysis. Diabetes Care, 31, 2383-2390.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Published in December 2008&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Accessing the full text:&lt;/STRONG&gt;&lt;BR&gt;NHS staff in England: &lt;A href="http://journals.library.nhs.uk/" target="_blank"&gt;available via NLH&lt;/A&gt;&lt;BR&gt;other NHS staff: &lt;A href="http://www.hlisd.org/" target="_blank"&gt;Check with your local NHS library&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>316024</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://wales.gov.uk/topics/health/publications/health/guidance/diabetesconsensus/?lang=en]]&gt;</url>
    <title>Designed for the Management of Adults with Diabetes Mellitus across Wales: Consensus Guidelines</title>
    <publicationDate>2008-10-15T00:00:00</publicationDate>
    <publisher>Welsh Assembly Government</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ HYPEROSMOLAR HYPERGLYCAEMIC STATES,DIABETES,TYPE 1,TYPE 2,ACUTE COMPLICATIONS,CHRONIC COMPLICATIONS,RETINOPATHY,DIABETIC FOOT,NEPHROPATHY,DIABETES AND PREGNANCY,DELIVERY OF CARE,HYPOGLYCAEMIA,PREVENTION,CONDITION MANAGEMENT,PATIENT EDUCATION AND EMPOWERMENT,ORGANISATION OF CARE / CARE PLANNING,KEY POLICIES / NSF,CONDITION MANAGEMENT,PREVENTION,EYE DISEASES,PHYSICAL ACTIVITY,NUTRITION AND FOOD,NUTRITION AND FOOD,PHYSICAL ACTIVITY,OTHER LIFE STYLE,OTHER LIFE STYLE,CPD AND PROFESSIONAL EDUCATION,MONITORING / SELF-MONITORING,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The All Wales Consensus Group have been responsible for the development of these Guidelines designed to provide support and to improve diabetes care across Wales.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>326039</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://wales.gov.uk/docrepos/40382/dhss/guidance/childrens-diabetes-e.pdf;jsessionid=ZXpYKCHdF1z01YydyGH81bQccQ2D1Q0hJKtk55nLJG2bbD7bbwdb!-878747337?lang=en]]&gt;</url>
    <title>Designed for the management of type 1 diabetes in children and young people in Wales</title>
    <publicationDate>2007-05-01T00:00:00</publicationDate>
    <publisher>Welsh Assembly Government</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,CHILDREN AND YOUNG PEOPLE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims&lt;/STRONG&gt;: &lt;BR&gt;"The Diabetes National Service Framework for Wales was published in April 2003 and set a series of 12 standards which provided a vision for the management of diabetes services. Two of the standards (5 and 6) related specifically to children and young people, although all 12 standards related in some way to children and diabetes".&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;U&gt;Standard 5&lt;/U&gt;&lt;/STRONG&gt;&lt;BR&gt;All children and young people with diabetes will receive consistently high quality care and they, with their families and others involved in their day to-day care, will be supported to optimise the control of their blood glucose and their physical, psychological, intellectual, educational and social development.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;Standard 6&lt;/U&gt;&lt;/STRONG&gt;&lt;BR&gt;All young people with diabetes will experience a smooth transition of care from paediatric diabetes services to adult diabetes services, whether hospital or community-based, either directly or via a young people’s clinic. The transition will be organised in partnership with each individual and at an age appropriate to and agreed with them.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;"In order to implement these standards members of the Brecon Group (an all Wales paediatric diabetes interest group/network) met to produce this consensus document which outlines the minimum standards of care for children and young people diagnosed with type 1 diabetes across Wales".&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Published in May 2007.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>258654</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/cdhyper/merec_extra_no27.htm#DEV]]&gt;</url>
    <title>Development of diabetes with thiazides : what are the consequences?</title>
    <publicationDate></publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section (second section) of this MeReC&amp;nbsp;Extra article&amp;nbsp;discusses the development of diabetes in relation to the first-line use of a thiazide diuretic, an angiotensin-converting enzyme (ACE) inhibitor, or a calcium-channel blocker (CCB) for hypertension. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published March 2007. MeReC Extra No. 27.&amp;nbsp; 
&lt;P&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307368</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://diabetes.diabetesjournals.org/]]&gt;</url>
    <title>Diabetes</title>
    <publicationDate></publicationDate>
    <publisher>Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Diabetes is an official journal of the American Diabetes Association. Sign up for &lt;A href="http://diabetes.diabetesjournals.org/cgi/alerts/etoc" target="_blank"&gt;email alerts &lt;/A&gt;of this journal.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; NHS staff in England: full access&amp;nbsp;is available via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;NHS Evidence&lt;/A&gt; where (by logging in with your Athens password) you can also receive a table of contents alert via Zetoc, locate items in your local library and create search alerts.&lt;BR&gt;Other NHS staff: check with your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386455</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://eng.mapofmedicine.com/evidence/map/diabetes1.html]]&gt;</url>
    <title>Diabetes - suspected in adults</title>
    <publicationDate>2010-07-30T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,NEPHROPATHY,DIABETIC FOOT,CARDIOVASCULAR,PREDIABETIC STATE,CHRONIC COMPLICATIONS,DIAGNOSIS,CONDITION MANAGEMENT,DIAGNOSIS,CONDITION MANAGEMENT,EYE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Map of Medicine care pathway.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt; To provide overview care pathways for the diagnosis and management of&amp;nbsp;suspected diabetes in adults.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; The Map of Medicine is a visual representation of evidence-based, practice-informed care pathways. It is designed for use by healthcare professionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; NHS staff in England: England national level pathways are freely available. You can also log on to the Map of Medicine using NHS Athens to gain access to the locally-adapted pathways.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>143971</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.yhpho.org.uk/resource/view.aspx?RID=8872]]&gt;</url>
    <title>Diabetes : key facts</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>Yorkshire and Humber Public Health Observatory (YHPHO)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,STATISTICS,CAUSES,INCIDENCE AND PREVALENCE,RISK AND FUTURE PROJECTIONS,DATA GATHERING AND AUDIT AND QOF,COST / ECONOMIC DATA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document from the Yorkshire and Humber Public Health Observatory (YHPHO) summarises the key facts concerning Diabetes in England. It is written for general public use and is not intended as a systematic review of the evidence base on diabetes. &lt;BR&gt;&lt;BR&gt;The document attempts to answer the following questions: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;How common is diabetes in England? 
&lt;LI&gt;What is the health burden of diabetes? 
&lt;LI&gt;What is the cost of diabetes? 
&lt;LI&gt;What makes people at risk of developing diabetes? 
&lt;LI&gt;What are the increased risks of complications in persons with diabetes? 
&lt;LI&gt;What can be done? 
&lt;LI&gt;What is cost-effective? 
&lt;LI&gt;What is being done?&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history:&lt;/STRONG&gt; published Mar 2006&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>112990</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Professionals/Publications-reports-and-resources/Reports-statistics-and-case-studies/Reports/Diabetes_State_of_the_Nations_2005/]]&gt;</url>
    <title>Diabetes : state of the nations 2005</title>
    <publicationDate>2005-12-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,STATISTICS,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;section of the diabetes UK website provides a summary and links to a report from&amp;nbsp;Diabetes UK&amp;nbsp;and the All Party Parliamentary Group for Diabetes which examines the state of diabetes care across the UK. The report draws together comments from people with diabetes along with government statistics, to show what is happening in diabetes care.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published Dec 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>239523</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Professionals/Publications-reports-and-resources/Reports-statistics-and-case-studies/Reports/Diabetes_State_of_the_Nations_2006/]]&gt;</url>
    <title>Diabetes : state of the nations 2006</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DATA GATHERING AND AUDIT AND QOF,STATISTICS,ORGANISATION OF CARE / CARE PLANNING,DELIVERY OF CARE,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;section of the diabetes UK website provides a summary and links to a report from&amp;nbsp;Diabetes UK&amp;nbsp;and the All Party Parliamentary Group for Diabetes which&amp;nbsp;examines the state of diabetes care across the UK.&lt;/P&gt;
&lt;P&gt;The report is the second of its&amp;nbsp;kind enabling a comparison in the performance of the NHS between 2005 and 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published&amp;nbsp;Jan 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386222</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.scotland.gov.uk/Publications/2010/08/17095311/0]]&gt;</url>
    <title>Diabetes action plan 2010 : quality care for diabetes in Scotland</title>
    <publicationDate>2010-08-20T00:00:00</publicationDate>
    <publisher>The Scottish Government</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DIABETES AND PREGNANCY,NEPHROPATHY,RETINOPATHY,DIABETIC FOOT,CARDIOVASCULAR,KETOACIDOSIS,HYPOGLYCAEMIA,DELIVERY OF CARE,CHRONIC COMPLICATIONS,ACUTE COMPLICATIONS,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,CAUSES,CONDITION MANAGEMENT,PREVENTION,CONDITION MANAGEMENT,HYPERTENSION,DYSLIPIDAEMIA,CONDITION MANAGEMENT,PREVENTION,CONDITION MANAGEMENT,CAUSES,CONDITION MANAGEMENT,PREVENTION,CPD AND PROFESSIONAL EDUCATION,CHILDREN AND YOUNG PEOPLE,MEDICATION,MEDICATION,PEOPLE FROM ETHNIC MINORITIES,PRECONCEPTION CARE,DATA GATHERING AND AUDIT AND QOF,CONDITION MANAGEMENT,CAUSES,PREVENTION,EYE DISEASES,PSYCHOSOCIAL CARE,PSYCHOSOCIAL CARE,CHILDREN AND YOUNG PEOPLE,CONDITION MANAGEMENT,PREVENTION,PEOPLE FROM ETHNIC MINORITIES,GESTATIONAL DIABETES,CAUSES,PROGRESSION TO TYPE 2 DIABETES,CONDITION MANAGEMENT,INSULIN PUMPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This diabetes action plan was informed by a consultation process undertaken between June and August 2009. The 'Better diabetes care' consultation document was widely distributed and made available online. The Scottish Diabetes Group (SDG), also provided funding to Diabetes UK Scotland to drive the consultation process through a national survey of people living with diabetes and a series of local and national events. Implementation of this Action Plan depends on continued collaboration between all groups within the diabetes community and interactions with other national and international organisations.&lt;/P&gt;
&lt;P&gt;The action plan contributes to the Scottish Government's quality strategy, which sets out the measurable and achievable actions that relate to the key drivers of healthcare quality. Each of the actions set out within this plan contains an indication of the 'dimensions of quality' to which it relates, in terms of the care of people with diabetes.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The action plan includes the following sections:&lt;/P&gt;
&lt;P&gt;1. Introduction&lt;/P&gt;
&lt;P&gt;2. Maintaining Health and Wellbeing - Improving the health of people with diabetes in Scotland and reducing health inequalities &lt;/P&gt;
&lt;P&gt;3. Quality Healthcare for All - Improving the quality of healthcare and healthcare experience and developing a mutual NHS - offering the people with diabetes in Scotland a world-class service and a stronger voice in service improvement &lt;/P&gt;
&lt;P&gt;4. Value - Maximising the value of our investment in health services in Scotland &lt;/P&gt;
&lt;P&gt;5. Integration - Integrating health, care and other services &lt;/P&gt;
&lt;P&gt;6. Conclusion&lt;/P&gt;
&lt;P&gt;Appendix 1 - Consultation responses&lt;BR&gt;Appendix 2 - Table of NHS Boards' planned investment in insulin pump therapy&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187929</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/cardiovascular/Page.aspx?pagename=ED20]]&gt;</url>
    <title>Diabetes and cardiovascular disease</title>
    <publicationDate>2006-10-01T00:00:00</publicationDate>
    <publisher>Cardiovascular Diseases Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CAUSES,CARDIOVASCULAR,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,PREVENTION,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Editorial by Roger Gadsby for the Cardiovascular Disease Specialist Library</description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;editorial provides an overview of diabetes and cardiovascular disease and breifly discusses current controversies in diabetes and CHD with links to further key documents.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published October 2006.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>101280</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.cvd.idf.org]]&gt;</url>
    <title>Diabetes and cardiovascular disease : time to act</title>
    <publicationDate>2005-01-01T00:00:00</publicationDate>
    <publisher>International Diabetes Federation (IDF)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CARDIOVASCULAR,CHRONIC COMPLICATIONS,HYPERTENSION,DYSLIPIDAEMIA,CONDITION MANAGEMENT,CAUSES,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This online book from the International Diabetes Federation includes the following chapters:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Diabetes 
&lt;LI&gt;Cardiovascular Disease 
&lt;LI&gt;Double Jeopardy 
&lt;LI&gt;Risk Factors 
&lt;LI&gt;Reducing the Risks 
&lt;LI&gt;Treatment of Cardiovascular Disease 
&lt;LI&gt;The Way Forward 
&lt;LI&gt;Fact File 
&lt;LI&gt;Studies of Diabetes and Cardiovascular Disease 
&lt;LI&gt;Bibliography 
&lt;LI&gt;Glossary&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published 2001. Updated and made available online 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>149119</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band145/b145-5.html]]&gt;</url>
    <title>Diabetes and congenital abnormalities</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CONDITION MANAGEMENT,GESTATIONAL DIABETES,CONDITION MANAGEMENT,DIABETES AND PREGNANCY,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier&amp;nbsp;article describes a study&amp;nbsp;which estimates the frequencies, and tells us some of the problems concerning the risk of mothers with diabetes having children with congenital abnormalities.&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;Publication history information:&lt;/STRONG&gt; Review published March 2006&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323088</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/our_work_areas/pregnancy_and_diabetes/]]&gt;</url>
    <title>Diabetes and Pregnancy - Work Area - NHS Diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETES AND PREGNANCY,DELIVERY OF CARE,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,CONDITION MANAGEMENT,PRECONCEPTION CARE,GESTATIONAL DIABETES,CAUSES,DIAGNOSIS,PROGRESSION TO TYPE 2 DIABETES,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the NHS Diabetes website provides details of the work of the Pregnancy and Diabetes Working Group. It also includes links to further information. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307372</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetesandprimarycare.co.uk/]]&gt;</url>
    <title>Diabetes and Primary Care</title>
    <publicationDate></publicationDate>
    <publisher>Diabetes and Primary Care</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Diabetes and Primary Care is the official journal of the Primary Care Diabetes Society (PCDS). The website includes information on the journal and has links to other related journals.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Full access requires subscription to the journal. NHS staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library &lt;/A&gt;for further details.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>212390</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Documents/Reports/Diabetes_disadvantaged_Nov2006.pdf]]&gt;</url>
    <title>Diabetes and the disadvantaged: reducing health inequalities in the UK</title>
    <publicationDate>2006-11-14T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ ELDERLY PEOPLE,ELDERLY PEOPLE,PEOPLE FROM ETHNIC MINORITIES,OUTCOMES,ENDOCRINE DISORDERS,DIABETES,DISADVANTAGED GROUPS,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,DIABETES,TYPE 1,TYPE 2,PUBLIC HEALTH,PEOPLE FROM ETHNIC MINORITIES,MANAGEMENT &amp; INTERVENTIONS,MANAGEMENT &amp; POLICY,POLICY,POPULATIONS,GROUPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Launched to mark World Diabetes Day 14 November 2006</description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;report from&amp;nbsp;Diabetes UK&amp;nbsp;highlights the issues concerned with diabetes and people at socio economic disadvantage in the UK.&amp;nbsp;The report addresses the range of problems for a variety of groups with diabetes, including: people living in deprived areas or communities, elderly people, people with mental health problems, people from&amp;nbsp;ethnic minorities, prisoners, and homeless people. The report contains key recommendations and examples of practice for reducing inequalities&amp;nbsp; encountered by people in disadvantaged groups.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published 14 November 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring Adobe Acrobat Reader.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>258894</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Documents/Reports/Fire_report_07.pdf]]&gt;</url>
    <title>Diabetes and the fire service: survey report</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EMPLOYMENT,LIVING WITH DIABETES,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report from&amp;nbsp;Diabetes UK&amp;nbsp;looks at how the Fire and Rescue Service has accommodated personnel with diabetes since the Disability Discrimination Act (DDA) was extended to cover the emergency services in October 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published March 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>273540</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=273540]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2007 - complications</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,NEPHROPATHY,DIABETIC FOOT,PAINFUL NEUROPATHIES,SEXUAL DYSFUNCTION,CARDIOVASCULAR,HYPOGLYCAEMIA,LIVING WITH DIABETES,CHRONIC COMPLICATIONS,ACUTE COMPLICATIONS,HOSPITAL INPATIENT CARE,CONDITION MANAGEMENT,CONDITION MANAGEMENT,HYPERTENSION,CONDITION MANAGEMENT,PREVENTION,DIAGNOSIS,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MEDICATION,MEDICATION,CONDITION MANAGEMENT,CONDITION MANAGEMENT,CAUSES,PREVENTION,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'complications' from literature searches carried out for the diabetes annual evidence update 2007 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2007 - complications&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;EM&gt;Please return to the annual evidence update intoduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=384860" target="_blank"&gt;Back to Annual Evidence Update introduction page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;A&amp;nbsp;total of 40 systematic reviews&amp;nbsp;concerning 'complications' were identified from the 2007 Diabetes Annual Evidence Update. The citations are listed here with links to the abstract or full text reference where available.&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;Complications (40)&lt;/U&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Acute complications &amp;gt; Hypoglycemia (3)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;1. Akram K, Pedersen BU,&amp;nbsp;Borch JK,&amp;nbsp;Thorsteinsson, B. Frequency and risk factors of severe hypoglycemia in insulin-treated type 2 diabetes: a literature survey. Journal of Diabetes and its Complications 2006; 20(6):402-408.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17070447&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;2. Kelly, A. M. The case for venous rather than arterial blood gases in diabetic ketoacidosis. EMA - Emergency Medicine Australasia 2006; 18(1):64-67.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;term=18%5Bvolume%5D%20AND%201%5Bissue%5D%20AND%2064%5Bpage%5D%20AND%20Kelly%5Bauthor%5D" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;3. Wild, D et al.&amp;nbsp;&amp;nbsp;A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education. Patient education and counselling 2007; 68(1):10-5.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;term=68%5Bvolume%5D%20AND%201%5Bissue%5D%20AND%2010%5Bpage%5D%20AND%20Wild%5Bauthor%5D" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;&lt;STRONG&gt;Acute complications &amp;gt; Hyperglycemia (4)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;1. Langley J,&amp;nbsp;Adams G. Insulin-based regimens decrease mortality rates in critically ill patients: A systematic review. JA&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;- DIABETES METAB RES REV. 2007; 23(3):184-192.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;term=23%5Bvolume%5D%20AND%203%5Bissue%5D%20AND%20184%5Bpage%5D%20AND%20Langley%5Bauthor%5D" target="_blank"&gt;abstract&lt;/A&gt;]&amp;nbsp; &lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;2. Meijering S et al.&amp;nbsp;&amp;nbsp;Towards a feasible algorithm for tight glycaemic control in critically ill patients: A systematic review of the literature. Critical Care&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;2006; 10(1)&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;term=10%5Bvolume%5D%20AND%201%5Bissue%5D%20AND%20Meijering%5Bauthor%5D" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;3. Pittas AG,&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;Siegel RD,&amp;nbsp;Lau&amp;nbsp;J.&amp;nbsp;&amp;nbsp;Insulin therapy and in-hospital mortality in critically ill patients: systematic review and meta-analysis of randomized controlled trials. JPEN. Journal of parenteral and enteral nutrition 2006; 30(2):164-72.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;term=30%5Bvolume%5D%20AND%202%5Bissue%5D%20AND%20164%5Bpage%5D%20AND%20Pittas%5Bauthor%5D" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;4. Turina M, Christ CM,&amp;nbsp;Polk, Jr HC. Diabetes and hyperglycemia: Strict glycemic control. Critical Care Medicine 2006; 34(SUPPL. 9):S291-S300.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;term=34%5Bvolume%5D%20AND%20S291%5Bpage%5D%20AND%20Turina%5Bauthor%5D" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;&lt;STRONG&gt;Microvascular complications and treatment &amp;gt; Neuropathy (7)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;1. Attal N et al.&amp;nbsp;&amp;nbsp;EFNS guidelines on pharmacological treatment of neuropathic pain. European journal of neurology : the official journal of the European Federation of Neurological Societies 2006; 13(11):1153-69.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17038030&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract]&lt;o:p&gt;&lt;/o:p&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;2. Chaudhry V, Stevens JC, Kincaid J , So YT. Practice advisory: utility of surgical decompression for treatment of diabetic neuropathy. Report of the Therapeutics and Technology Assessment Subcommittee of the &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:place&gt;&lt;st1:PlaceName&gt;American&lt;/st1:PlaceName&gt; &lt;st1:PlaceType&gt;Academy&lt;/st1:PlaceType&gt;&lt;/st1:place&gt; of Neurology. Neurology 2006; 66(12):1805-1808.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16801641&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;3. Eisenberg E, McNicol ED,&amp;nbsp;Carr DB. Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: Systematic review of randomized controlled trials. European Journal of Pain 2006; 10(8):667-676.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16337151&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;4. Gutierrez AAM, Beltrán, Rodríguez J,&amp;nbsp;&lt;st1:City&gt;&lt;st1:place&gt;Moreno CB.&amp;nbsp; &lt;/st1:place&gt;&lt;/st1:City&gt;Antiepileptic drugs in treatment of pain caused by diabetic neuropathy. Journal of pain and symptom management&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;2007; 34(2):201-8.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17572057&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;5. Vardi M, Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. The Cochrane Library 2007; (1)&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002187/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;6. Wong MC, Chung JW Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. British Medical Journal 2007; 335(7610):87-90.&amp;nbsp; [&lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=17562735" target="_blank"&gt;full text&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;&lt;o:p&gt;7. Opioids for neuropathic pain. The Cochrane Library 2006; (Issue 3)&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006146/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;&lt;STRONG&gt;&lt;BR&gt;Microvascular complications and treatment &amp;gt; Nephropathy (4)&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;1. Jennings DL, Kalus JS Coleman CI et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker (ARB) for diabetic nephropathy: a meta-analysis. Diabetic Medicine 2007; 24:486-493.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17367311&amp;amp;ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;2. MacKinnon M et al.&amp;nbsp;&amp;nbsp;Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. American Journal of Kidney Diseases 2006; 48(1):8-20.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16797382&amp;amp;ordinalpos=11&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;3. Strippoli GFM et al.&amp;nbsp;Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. The Cochrane Library 2006; (4)&amp;nbsp;&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006257/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;4. Strippoli GF et al.&amp;nbsp;&amp;nbsp;Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. Journal of the American Society of Nephrology : JASN 2006; 17(Suppl 2):S153-5.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3051&amp;amp;itool=AbstractPlus-def&amp;amp;uid=16565242&amp;amp;db=pubmed&amp;amp;url=http://jasn.asnjournals.org/cgi/pmidlookup?view=long&amp;amp;pmid=16565242" target="_blank"&gt;[full text&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;&lt;STRONG&gt;Microvascular complications and treatment &amp;gt; Foot (8)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;1. Albers M et al.&amp;nbsp;&amp;nbsp;Meta-analysis of popliteal-to-distal vein bypass grafts for critical ischemia. Journal of Vascular Surgery 2006; 43(3):498-503.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16520163&amp;amp;ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;2. Bergin SM, Wraight P. Silver based wound dressings and topical agents for treating diabetic foot ulcers. The Cochrane Library 2006; Issue 1&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005082/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;3. Capriotti G,&amp;nbsp;Chianelli M, Signore A.&amp;nbsp; Nuclear medicine imaging of diabetic foot infection: results of meta- analysis. Nuclear medicine communications 2006; 27(10):757-64.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16969256&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract]&lt;o:p&gt;&lt;/o:p&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;4. Crawford F, &lt;st1:City&gt;&lt;st1:place&gt;Inkster&lt;/st1:place&gt;&lt;/st1:City&gt; M, Kleijnen J,&amp;nbsp;Fahey T. Predicting foot ulcers in patients with diabetes: a systematic review and meta-analysis. QJM : monthly journal of the Association of Physicians 2007; 100(2): 65-86.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17277315&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;5. Kapoor A et al.&amp;nbsp;&amp;nbsp;Magnetic resonance imaging for diagnosing foot osteomyelitis: a meta-analysis. Archives of Internal Medicine 2007; 167:125-132.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17242312&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract]&lt;o:p&gt;&lt;/o:p&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;6. Nelson E A. A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers. Health Technology Assessment 2006; 10(3):iii-iv, ix-x, 1-221. [&lt;A href="http://www.hta.ac.uk/execsumm/summ1012.htm" target="_blank"&gt;full text]&lt;/A&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;7. Nelson EA et al.&amp;nbsp;&amp;nbsp;Systematic review of antimicrobial treatments for diabetic foot ulcers. Diabetic Medicine 2006; 23(4):348-359.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16620262&amp;amp;ordinalpos=4&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;8. O'Meara S et al.&amp;nbsp;&amp;nbsp;Systematic review of methods to diagnose infection in foot ulcers in diabetes. Diabetic Medicine 2006; 23(4):341-347.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16620261&amp;amp;ordinalpos=4&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;&lt;STRONG&gt;Macrovascular complications &amp;amp; treatment &amp;gt; Lipids (2)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;1. Costa J, Borges MDC,&amp;nbsp;Vaz CA.&amp;nbsp;&amp;nbsp;Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. British Medical Journal 2006; 332:1115-24.&amp;nbsp; [&lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=16585050" target="_blank"&gt;full text&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;2. Hartweg J et al.&amp;nbsp;&amp;nbsp;Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia 2007; 50(8):1593-1602.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;term=50%5Bvolume%5D%20AND%208%5Bissue%5D%20AND%201593%5Bpage%5D" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;&lt;STRONG&gt;Macrovascular complications &amp;amp; treatment &amp;gt; Coronary Heart Disease (8)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;1. Allemann S et al.&amp;nbsp;&amp;nbsp;Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials. Current Medical Research and Opinion 2006; 22(3):617-623.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16574044&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;2. &lt;st1:State&gt;&lt;st1:place&gt;Berry&lt;/st1:place&gt;&lt;/st1:State&gt; C, Tardif JC,&amp;nbsp;Bourassa, MG. Coronary Heart Disease in Patients With Diabetes. Part II: Recent Advances in Coronary Revascularization. Journal of the &lt;st1:place&gt;&lt;st1:PlaceName&gt;American&lt;/st1:PlaceName&gt; &lt;st1:PlaceType&gt;College&lt;/st1:PlaceType&gt;&lt;/st1:place&gt; of Cardiology 2007; 49(6):643-656.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17291929&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&amp;nbsp;&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;3. Brohall G, Odén A,&amp;nbsp;Fagerberg, B. Carotid artery intima-media thickness in patients with Type 2 diabetes mellitus and impaired glucose tolerance: A systematic review. Diabetic Medicine 2006; 23(6):609-616.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16759301&amp;amp;ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;[abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;4. El, MAA. Dysrhythmia and electrocardiographic changes in diabetes mellitus: pathophysiology and impact on the incidence of sudden cardiac death. Journal of cardiovascular medicine (&lt;st1:place&gt;&lt;st1:City&gt;Hagerstown&lt;/st1:City&gt; &lt;st1:State&gt;Md.&lt;/st1:State&gt;&lt;/st1:place&gt;) 2006; 7(8):580-5.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16858235&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;5. Huxley R,&amp;nbsp;Barzi F,&amp;nbsp;Woodward, M.&amp;nbsp;&amp;nbsp;Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ (Clinical research ed.) 2006; 332(7533):73-8.&amp;nbsp; [&lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=16371403" target="_blank"&gt;full text&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;6. Koppes LLJ et al.&amp;nbsp;&amp;nbsp;Meta-analysis of the relationship between alcohol consumption and coronary heart disease and mortality in type 2 diabetic patients. Diabetologia 2006; 49(4):648-52.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16463045&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;7. Stettler C et al.&amp;nbsp;&amp;nbsp;Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials. Heart 2006; 92(5):650-657.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16251229&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;8. Stettler C et al.&amp;nbsp;&amp;nbsp;Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. 2006; 152(1):27-38.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16824829&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;&lt;STRONG&gt;Macrovascular complications &amp;amp; treatment &amp;gt; Blood Pressure (1)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;1. McLean DL, Simpson SH, McAlister FA,&amp;nbsp;Tsuyuki RT. Treatment and blood pressure control in 47,964 people with diabetes and hypertension: A systematic review of observational studies. Canadian Journal of Cardiology 2006; 22(10):855-860. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16957803&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;&lt;STRONG&gt;Risk of fracture / Impaired bone healing (3)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;1. Janghorbani M et al.&amp;nbsp;&amp;nbsp;Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. American journal of epidemiology 2007; 166(5):495-505.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17575306&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;2. Kotsovilis S et al.&amp;nbsp;&amp;nbsp;A comprehensive and critical review of dental implant placement in diabetic animals and patients. Clinical oral implants research 2006; 17(5):587-99.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16958701&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;3. Vestergaard, P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2007 ; 18(4):427-44.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17068657&amp;amp;ordinalpos=4&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>273703</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=273703]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2007 - delivery of care</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT,PEOPLE FROM ETHNIC MINORITIES,RESEARCH,PEOPLE FROM ETHNIC MINORITIES,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'delivery of care' from literature searches carried out for the diabetes annual evidence update 2007 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2007 - delivery of care&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;EM&gt;Please return to the annual evidence update intoduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=384860" target="_blank"&gt;Back to Annual Evidence Update introduction page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A&amp;nbsp;total of&amp;nbsp;15 systematic reviews&amp;nbsp;concerning 'delivery of care' were identified from the 2007 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;&lt;STRONG&gt;&lt;U&gt;Delivery of care (15)&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;1. Caban, A Walker, EA. A systematic review of research on culturally relevant issues for Hispanics with diabetes. The Diabetes educator 2006; 32(4):584-95.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16873596&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;2. Clar, C, Waugh, N, and Thomas, S. Routine hospital admission versus out-patient or home care in children at diagnosis of type 1 diabetes mellitus. Cochrane database of systematic reviews (Online) 2007; (2):CD004099.&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004099/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;3. Cooper C,&amp;nbsp; et al.&amp;nbsp;&amp;nbsp;Specialist home-based nursing services for children with acute and chronic illnesses. The Cochrane Library 2006; (4)&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004383/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;4. Glazier RH, Bajcar J Kennie NR Willson K. A systematic review of interventions to improve diabetes care in socially disadvantaged populations. Diabetes Care 2006; 29:1675-1688.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3051&amp;amp;itool=AbstractPlus-def&amp;amp;uid=16801602&amp;amp;db=pubmed&amp;amp;url=http://care.diabetesjournals.org/cgi/pmidlookup?view=long&amp;amp;pmid=16801602" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;5. Jaana, M, Paré, G. Home telemonitoring of patients with diabetes: a systematic assessment of observed effects. Journal of evaluation in clinical practice 2007; 13(2):242-53.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17378871&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;6. &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;Jackson&lt;/st1:place&gt;&lt;/st1:City&gt;, C L et al.&amp;nbsp;&amp;nbsp;A systematic review of interactive computer-assisted technology in diabetes care: Interactive information technology in diabetes care. Journal of General Internal Medicine 2006; 21(2):105-110.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3494&amp;amp;itool=AbstractPlus-nondef&amp;amp;uid=16390512&amp;amp;db=pubmed&amp;amp;url=http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=16390512" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;7. Joshy, G, Simmons, D. Diabetes information systems: a rapidly emerging support for diabetes surveillance and care. Diabetes technology &amp;amp; therapeutics 2006; 8(5):587-97.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17037973&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;8. Kirk, J et al. Disparities in HbA1c levels between African-American and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes care 2006; 29(9):2130-6.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3051&amp;amp;itool=AbstractPlus-def&amp;amp;uid=16936167&amp;amp;db=pubmed&amp;amp;url=http://care.diabetesjournals.org/cgi/pmidlookup?view=long&amp;amp;pmid=16936167" target="_blank"&gt;full text&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;9. Legato, MJ et al.&amp;nbsp;&amp;nbsp;Gender-specific care of the patient with diabetes: review and recommendations. Gender medicine : official journal of the Partnership for Gender-Specific Medicine at Columbia University 2006 ; 3(2):131-58.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16860272&amp;amp;ordinalpos=5&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract]&lt;o:p&gt;&lt;/o:p&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;10. Norris S L,&amp;nbsp; et al.&amp;nbsp; Effectiveness of community health workers in the care of persons with diabetes. Diabetic Medicine 2006; 23(5):544-556.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16681564&amp;amp;ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;11. Paré, G, Jaana, M,&amp;nbsp;Sicotte, C.&amp;nbsp;&amp;nbsp;Systematic review of home telemonitoring for chronic diseases: the evidence base. Journal of the American Medical Informatics Association : JAMIA 2007; 14(3):269-77.&amp;nbsp;&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17329725&amp;amp;ordinalpos=10&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;12. Saxena, SM et al.&amp;nbsp;&amp;nbsp;Systematic review of primary healthcare interventions to improve diabetes outcomes in minority ethnic groups. The Journal of ambulatory care management 2007; 30(3):218-30.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17581434&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;13. Shojania KG, Ranji SR MacDonald KM et al. Effects of quality improvement strategies for type 2 diabetes on glycaemic control : a meta-regression analysis. JAMA 2006; 296(4):427-440.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3051&amp;amp;itool=AbstractPlus-def&amp;amp;uid=16868301&amp;amp;db=pubmed&amp;amp;url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&amp;amp;pmid=16868301" target="_blank"&gt;full text&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;14. Sigurdardottir, AK, Jonsdottir, H, Benediktsson, R. Outcomes of educational interventions in type 2 diabetes: WEKA data- mining analysis. Patient education and counselling 2007; 67(1-2):21-31.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=67%5Bvolume%5D%20AND%2021%5Bpage%5D%20AND%20outcomes" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;15. Tennant, R et al&amp;nbsp;&amp;nbsp;Monitoring patients using control charts: a systematic review. International journal for quality in health care : journal of the International Society for Quality in Health Care / ISQua 2007; 19(4):187-94.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17545672&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>273736</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=273736]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2007 - economics</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,LIVING WITH DIABETES,EMPLOYMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,PREVENTION,RESEARCH,CHILDREN AND YOUNG PEOPLE,GENERAL,ADHERENCE / COMPLIANCE,TREATMENT CONCORDANCE,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'economics' from literature searches carried out for the diabetes annual evidence update 2007 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2007 - economics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;EM&gt;Please return to the annual evidence update intoduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=384860" target="_blank"&gt;Back to Annual Evidence Update introduction page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A&amp;nbsp;total of&amp;nbsp;3 systematic reviews&amp;nbsp;concerning 'economics' were identified from the 2007 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;STRONG&gt;&lt;U&gt;Economics (3)&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;1. Lee, WC et al.&amp;nbsp;&amp;nbsp;Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Managed care interface 2006; 19(7):31-41 .&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16898343&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;2. Milton B, &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;Holland&lt;/st1:place&gt;&lt;/st1:City&gt; P Whitehead M. The social and economic consequences of childhood onset type 1 diabetes across the lifecourse: a systematic review. 2006; 23(8):821-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16911617&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;3. Vijgen, SMC et al&amp;nbsp;&amp;nbsp;Cost effectiveness of preventive interventions in type 2 diabetes mellitus: A systematic literature review. PharmacoEconomics 2006; 24(5):425-441.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16706569&amp;amp;ordinalpos=5&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>273735</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=273735]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2007 - epidemiology</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,ELDERLY PEOPLE,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'epidemiology' from literature searches carried out for the diabetes annual evidence update 2007 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2007 - epidemiology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;EM&gt;Please return to the annual evidence update intoduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=384860" target="_blank"&gt;Back to Annual Evidence Update introduction page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A&amp;nbsp;total of&amp;nbsp;3 systematic reviews&amp;nbsp;concerning 'epidemiology' were identified from the 2007 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;STRONG&gt;&lt;U&gt;&lt;BR&gt;Epidemiology (3)&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;1. Barnett, KN&amp;nbsp;et al.&amp;nbsp;&amp;nbsp;Mortality in people diagnosed with type 2 diabetes at an older age: a systematic review. Age and ageing 2006; 35(5):463-8.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3051&amp;amp;itool=AbstractPlus-def&amp;amp;uid=16679336&amp;amp;db=pubmed&amp;amp;url=http://ageing.oxfordjournals.org/cgi/pmidlookup?view=long&amp;amp;pmid=16679336" target="_blank"&gt;full text&lt;/A&gt;]&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;2. Larsson, SC, Orsini, N, Brismar, K, and Wolk, A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006; 49(12):2819-23.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;term=49%5Bvolume%5D%20AND%2012%5Bissue%5D%20AND%202819%5Bpage%5D" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;3. Larsson, SC, Mantzoros, CS, and Wolk, A. Diabetes mellitus and risk of breast cancer: A meta-analysis. International journal of cancer. Journal international du cancer 2007; 121(4):856-62.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;term=121%5Bvolume%5D%20AND%204%5Bissue%5D%20AND%20856%5Bpage%5D" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>384860</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=384860]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2007 - introduction</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2007 - introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;We are pleased to present the results of our first Annual Evidence Update which identifies new evidence on diabetes published between January 2006 and August 2007.&lt;/P&gt;
&lt;P&gt;For ease of reference, the results of the evidence update have been classified based on the topic headings found within the diabetes specialist library. One new topic has come to light concerning diabetes and bone metabolism. This issue has only become apparent in the past year or so, and there are already 3 systematic reviews (SR's) published on the subject. This is perhaps a measure of the speed at which new SR’s now appear. This increase in the number of SR’s in diabetes is also illustrated in the large number published on glucose lowering therapies. In the past it often took many years, and the publication of many randomised controlled trials&amp;nbsp; before a SR undertaken. Now we are getting SR’s for example, on the Incretins, published within 6 months of their launch in the UK! &lt;/P&gt;
&lt;P&gt;This evidence update illustrates that there is a vast amount of new information being published in the field of diabetes. Without help it would be easy to “drown” in this vast sea of information. We hope that you will find this evidence update helpful and of assistance in preventing you from drowning.&lt;BR&gt;&lt;BR&gt;Roger Gadsby November 2007. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This annual evidence update identified systematic reviews published between January 2006 - August 2007.&amp;nbsp; &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=386852" target="_blank"&gt;Click here &lt;/A&gt;for the second Annual Evidence Update on Diabetes (August 07 to Sept 08).&amp;nbsp; &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=328114" target="_blank"&gt;Click here&lt;/A&gt; for the third Annual Evidence Update on Diabetes (September 08 to September 09). &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Methodology&lt;BR&gt;&lt;/STRONG&gt;The methodology used to carry out the evidence update is outlined here. Please read this for details of the scope and methods used.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Citations&lt;BR&gt;&lt;/STRONG&gt;155 English language citations were identified as being relevant and have been classified as shown in the table below.&lt;BR&gt;Click on a topic to view its search results. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Please note that critical appraisal of these reviews has NOT been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;STRONG&gt;&lt;/P&gt;&lt;/STRONG&gt;
&lt;P&gt;
&lt;TABLE border=1 width="40%" align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Total&lt;/STRONG&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&amp;nbsp;155&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P align=left&gt;&lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=273537" target="_blank"&gt;Treatments&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=left&gt;&amp;nbsp;43&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P align=left&gt;&lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=273540" target="_blank"&gt;Complications&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=left&gt;&amp;nbsp;40&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P align=left&gt;&lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=273589" target="_blank"&gt;Patients&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=left&gt;&amp;nbsp;17&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P align=left&gt;&lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=273699" target="_blank"&gt;Prevention&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=left&gt;&amp;nbsp;16&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P align=left&gt;&lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=273703" target="_blank"&gt;Delivery of care&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=left&gt;&amp;nbsp;15&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P align=left&gt;&lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=273709" target="_blank"&gt;Pregnancy&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=left&gt;&amp;nbsp;10&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P align=left&gt;&lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=273713" target="_blank"&gt;Pre-diabetes including metabolic syndrome&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=left&gt;&amp;nbsp;4&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P align=left&gt;&lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=273718" target="_blank"&gt;Screening&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=left&gt;&amp;nbsp;4&amp;nbsp;&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P align=left&gt;&lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=273735" target="_blank"&gt;Epidemiology&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=left&gt;&amp;nbsp;3&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P align=left&gt;&lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=273736" target="_blank"&gt;Economics&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;
&lt;P align=left&gt;&amp;nbsp;3&lt;/P&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Please &lt;A href="http://www.library.nhs.uk/diabetes/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you have any feedback or comments.&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>384796</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=384796]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2007 - methodology</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2007 - methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;&lt;BR&gt;Please return to the annual evidence homepage for further information about and introduction to the Annual Evidence Update &lt;/EM&gt;&lt;EM&gt;and for links to results for each of the topics.&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=384860" target="_blank"&gt;Back to Annual Evidence Update introduction page&lt;/A&gt;&lt;/P&gt;&lt;BR&gt;
&lt;HR&gt;

&lt;P align=left&gt;The Diabetes Specialist Library's first annual evidence update consists of the results of extensive literature searches carried out to identify systematic reviews (SR's) relating to diabetes and its treatment.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;BR&gt;Inclusion criteria&lt;/STRONG&gt;&lt;BR&gt;References were included if they were identified as English language SR's and relevant to the subject scope.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Subject scope&lt;/STRONG&gt; &lt;BR&gt;The subject scope reflects that of the diabetes specialist library: covering all types of diabetes mellitus and pre-diabetic conditions, as well as complications of diabetes mellitus and other conditions that are closely related to diabetes mellitus.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Publication types&lt;/STRONG&gt;&lt;BR&gt;Material included was limited to Systematic Reviews because of the high volume of published material in the topic area.&lt;BR&gt;Systematic Reviews are regarded as the highest level of evidence to inform clinical practice.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Sources searched&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Medline via Datastar &lt;/LI&gt;
&lt;LI&gt;Embase via Datastar &lt;/LI&gt;
&lt;LI&gt;The Cochrane Library &lt;/LI&gt;
&lt;LI&gt;Database of Abstracts of Reviews of Effects (DARE) via CRD interface &lt;/LI&gt;
&lt;LI&gt;Diabetes Specialist library&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Search period&lt;/STRONG&gt;&lt;BR&gt;January 2006 - August 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Search strategy&lt;/STRONG&gt;&lt;BR&gt;The sources listed were systematically searched for publications published within the search period using search terms relevant to the subject scope.&lt;BR&gt;Sensitive systematic review search filters were applied to the medline and embase searches which were also restricted to exclude animal research.&lt;BR&gt;If you wish to see the full search strategies used please use the &lt;A href="http://www.library.nhs.uk/Diabetes/ContactUs.aspx" target="_blank"&gt;contact us form&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Sifting and selection&lt;BR&gt;&lt;/STRONG&gt;All citations found in the searches were sifted by information specialists, by reading the titles and abstracts to identify those that were definite or potential systematic reviews. This was followed by a sift for subject relevance carried out by the clinical lead. Finally, the remaining titles were once again sifted to include only those that were classified as‘definate’ systematic reviews. The full text of citations was obtained where this was not evident from the abstract.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Identification of Systematic Reviews&lt;/STRONG&gt;&lt;BR&gt;The criteria for classifying a reference as a definite systematic review was based on NLH Specialist Libraries guidance on identifying systematic reviews&lt;SUP&gt;1&lt;/SUP&gt;, in combination with the definition of a systematic review from the &lt;A href="http://www.cochrane.org/resources/glossary.htm" target="_blank"&gt;Glossary of Cochrane Collaboration Terms&lt;/A&gt; on the Cochrane Collaboration website&lt;SUP&gt;2&lt;/SUP&gt;.&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;A reference is classified as a definite systematic review if it contains an explicit statement in the title or abstract where the phrase ‘systematic review’ occurs OR a statement in the title or abstract that a search of one or more source was undertaken. &lt;/LI&gt;
&lt;LI&gt;A systematic review is defined as a review of a clearly formulated question that uses systematic and explicit methods to identify, select, and critically appraise relevant research, and to collect and analyse data from the studies that are included in the review. Statistical methods (meta-analysis) may or may not be used to analyse and summarise the results of the included studies.&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;&lt;BR&gt;Following the removal of duplicates, a total of 953 potential systematic reviews were retrieved and collated in a reference management database. The search strategy was designed to be sensitive so a large number of the citations retrieved were irrelevant. Following sifting by Information scientists for definite systematic reviews and clinical lead for subject relevance, 155 English language citations were identified as being relevant.&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>273589</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=273589]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2007 - patients</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,PSYCHOLOGICAL PROBLEMS,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,CONDITION MANAGEMENT,CHILDREN AND YOUNG PEOPLE,MONITORING / SELF-MONITORING,MONITORING / SELF-MONITORING,ELDERLY PEOPLE,RESEARCH,CHILDREN AND YOUNG PEOPLE,ELDERLY PEOPLE,ADHERENCE / COMPLIANCE,TREATMENT CONCORDANCE,ANNUAL EVIDENCE UPDATES,COGNITIVE FUNCTION,ANXIETY AND DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'patients' from literature searches carried out for the diabetes annual evidence update 2007 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2007 - patients&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;EM&gt;Please return to the annual evidence update intoduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=384860" target="_blank"&gt;Back to Annual Evidence Update introduction page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A&amp;nbsp;total of&amp;nbsp;17 systematic reviews&amp;nbsp;concerning 'patients' were identified from the 2007 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;STRONG&gt;&lt;U&gt;Patient (17)&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;STRONG&gt;Patient &amp;gt; Psychological (8)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;1. Adili F, Larijani B, Haghighatpanah, M. Diabetic patients: Psychological aspects. Annals of the &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:place&gt;&lt;st1:PlaceName&gt;New York&lt;/st1:PlaceName&gt; &lt;st1:PlaceType&gt;Academy&lt;/st1:PlaceType&gt;&lt;/st1:place&gt; of Sciences 2006; 1084:329-49. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;term=1084%5Bvolume%5D%20AND%20329%5Bpage%5D" target="_blank"&gt;abstract]&lt;o:p&gt;&lt;/o:p&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;2. Ali S et al.&amp;nbsp; The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. 2006; 23(11):1165-73.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17054590&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;[abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;3. Barnard KD, Skinner TC Peveler R. The prevalence of co-morbid depression in adults with Type 1 diabetes: systematic literature review. Diabet Med.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;2006; 23(4)::445-8.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16620276&amp;amp;ordinalpos=4&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;4. Jakovljevic M et al.&amp;nbsp; Mental disorders and metabolic syndrome: a fatamorgana or warning reality? Psychiatria Danubina 2007; 19(1-2):76-86.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=19%5Bvolume%5D%20AND%2076%5Bpage%5D%20AND%20mental" target="_blank"&gt;[abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;5. Katon W, Lin, EHB,&amp;nbsp;Kroenke, K.&amp;nbsp;&amp;nbsp;The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. General hospital psychiatry 2007; 29(2):147-55.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17336664&amp;amp;ordinalpos=5&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;6. Knol M J&amp;nbsp; et al.&amp;nbsp;&amp;nbsp;Depression as a risk factor for the onset of type 2 diabetes mellitus A meta-analysis. Diabetologia 2006; 49(5):837-45.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16520921&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;7. McIntyre R S, Soczynska JK, Konarski JZ,&amp;nbsp;Kennedy SH. The effect of antidepressants on glucose homeostatis and insulin sensitivity: Synthesis and mechanisms. Expert Opinion on Drug Safety 2006; 5(1):157-168.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16370964&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;8. Winkley K, Ismail K Landau S Eisler I. Psychological interventions to improve glycaemic control in patients with type 1 diabetes: systematic review and meta-analysis of randomised controlled trials. British Medical Journal 2006; 333:65&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3494&amp;amp;itool=AbstractPlus-nondef&amp;amp;uid=16803942&amp;amp;db=pubmed&amp;amp;url=http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=16803942" target="_blank"&gt;full text&lt;/A&gt;]&amp;nbsp;&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;&lt;o:p&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;BR&gt;&lt;STRONG&gt;Patient &amp;gt; Elderly (2)&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;1. Arvanitakis Z, Wilson RS,&amp;nbsp;Bennett, DA. Diabetes mellitus, dementia, and cognitive function in older persons. Journal of Nutrition, Health and Aging 2006; 10(4):287-291.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16886098&amp;amp;ordinalpos=5&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;2. Biessels GJ et al.&amp;nbsp;&amp;nbsp;Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurology 2006; 5(1):64-74.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16361024&amp;amp;ordinalpos=11&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;STRONG&gt;Patient &amp;gt; Adherence (4)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;1. Hearnshaw H, Lindenmeyer A. What do we mean by adherence to treatment and advice for living with diabetes? A review of the literature on definitions and measurements. Diabetic Medicine 2006; 23:720-728.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16842475&amp;amp;ordinalpos=5&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;2. Heneghan CJ, Glasziou P Perera R. Reminder packaging for improving adherence to self-administered long-term medications. The Cochrane Library 2006; Issue 1&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005025/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;3. Kripalani S, &lt;st1:City&gt;&lt;st1:place&gt;Yao&lt;/st1:place&gt;&lt;/st1:City&gt; X,&amp;nbsp;Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: A systematic review. Archives of Internal Medicine 2007; 167(6):540-550.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;term=167%5Bvolume%5D%20AND%206%5Bissue%5D%20AND%20540%5Bpage%5D" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;4. Lindenmeyer A et al.&amp;nbsp;Interventions to improve adherence to medication in people with type 2 diabetes mellitus: a review of the literature on the role of pharmacists. Journal of clinical pharmacy and therapeutics 2006; 31(5):409-19.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16958818&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;STRONG&gt;Patient &amp;gt; Children and Adolescents (2)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;1. Sherifali Diana,&amp;nbsp;Ciliska D.&amp;nbsp; Parenting children with diabetes and Belsky's Determinants of Parenting Model: literature review. Journal of advanced nursing 2006; 55(5):636-42.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16907796&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;2. Murphy HR, Rayman G Skinner TC. Psycho-educational interventions for children and young people with Type 1 diabetes. Diabetic Medicine 2006; 23(9):935-43.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16922699&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;STRONG&gt;Patient &amp;gt; Monitoring / self monitoring (1)&lt;/STRONG&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;1. Jansen J P. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Current Medical Research and Opinion 2006; 22(4):671-681&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16684428&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>273713</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=273713]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2007 - pre-diabetes including metabolic syndrome</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,PREDIABETIC STATE,OBESITY,RESEARCH,ANNUAL EVIDENCE UPDATES,PREVENTION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'pre-diabetes including metabolic syndrome' from literature searches carried out for the diabetes annual evidence update 2007 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2007 - pre-diabetes including metabolic syndrome&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;EM&gt;Please return to the annual evidence update intoduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=384860" target="_blank"&gt;Back to Annual Evidence Update introduction page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A&amp;nbsp;total of&amp;nbsp;4 systematic reviews&amp;nbsp;concerning 'pre-diabetes including metabolic syndrome' were identified from the 2007 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;November 2008.&amp;nbsp; Please Note: Marketing authorisation has been suspended of Acomplia (rimonabant) as the European Medicines Agency has concluded that the benefits of Acomplia no longer outweigh its risks of psychiatric disorders.&lt;/EM&gt;&lt;U&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;BR&gt;&lt;STRONG&gt;Pre-diabetes including metabolic syndrome (4)&lt;/STRONG&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;1. Chasens, Eileen R. Obstructive sleep apnea, daytime sleepiness, and type 2 diabetes. The Diabetes educator 2007; 33(3):475-82.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17570878&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;2. Curioni C, André C. Rimonabant for overweight or obesity. The Cochrane Library 2006; (4)&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006162/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;3. Thomas DE, Elliott EJ Baur L. Low glycaemic index or low glycaemic load diets for overweight and obesity. The Cochrane Library 2007; 3&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005105/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;4. Van de Laar FA,&amp;nbsp; et al.&amp;nbsp; Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. The Cochrane Library 2006; (4)&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005061/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>273709</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=273709]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2007 - pregnancy</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETES AND PREGNANCY,LIVING WITH DIABETES,CONDITION MANAGEMENT,RESEARCH,ANNUAL EVIDENCE UPDATES,GESTATIONAL DIABETES,CAUSES,PROGRESSION TO TYPE 2 DIABETES,CONTRACEPTION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'pregnancy' from literature searches carried out for the diabetes annual evidence update 2007 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2007 - pregnancy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;EM&gt;Please return to the annual evidence update intoduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=384860" target="_blank"&gt;Back to Annual Evidence Update introduction page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A&amp;nbsp;total of&amp;nbsp;10 systematic reviews&amp;nbsp;concerning 'pregnancy' were identified from the 2007 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;&lt;STRONG&gt;&lt;U&gt;Pregnancy (10)&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;1. Case, J et al.&amp;nbsp;&amp;nbsp;32Preventing type 2 diabetes after gestational diabetes. The Diabetes educator 2006; 32(6):877-86.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17102155&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;2. Ceysens G, Rouiller D, and Boulvain M . Exercise for diabetic pregnant women. The Cochrane Library 2006; (Issue 3)&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004225/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;3. Chu, SY et al.&amp;nbsp;&amp;nbsp;Maternal obesity and risk of gestational diabetes mellitus. Diabetes Care 2007; 30(8):2070-2076.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3051&amp;amp;itool=AbstractPlus-def&amp;amp;uid=17416786&amp;amp;db=pubmed&amp;amp;url=http://care.diabetesjournals.org/cgi/pmidlookup?view=long&amp;amp;pmid=17416786" target="_blank"&gt;full text&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;4. Farrar D, Tuffnell DJ West J. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. The Cochrane Library 2007; (3)&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005542/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;5. Gilbert, C, Valois, M,&amp;nbsp;Koren, G. Pregnancy outcome after first-trimester exposure to metformin: a meta- analysis. Fertility and sterility 2006; 86(3):658-63.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16879826&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;6. Guerin, A, Nisenbaum, R,&amp;nbsp;Ray, JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. Diabetes care 2007; 30(7):1920-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3051&amp;amp;itool=AbstractPlus-def&amp;amp;uid=17446531&amp;amp;db=pubmed&amp;amp;url=http://care.diabetesjournals.org/cgi/pmidlookup?view=long&amp;amp;pmid=17446531" target="_blank"&gt;full text&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;7. Inkster, ME et al.&amp;nbsp;&amp;nbsp;`Poor glycated haemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes mellitus: Systematic review of observational studies. BMC Pregnancy and Childbirth 2006; 6(-)&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3494&amp;amp;itool=AbstractPlus-nondef&amp;amp;uid=17074087&amp;amp;db=pubmed&amp;amp;url=http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=17074087" target="_blank"&gt;full text&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;8. Kim C, Berger DK Chamany S. Recurrence of Gestational Diabetes Mellitus : A systematic review. Diabetes Care 2007; 30:1314-1319.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3051&amp;amp;itool=AbstractPlus-def&amp;amp;uid=17290037&amp;amp;db=pubmed&amp;amp;url=http://care.diabetesjournals.org/cgi/pmidlookup?view=long&amp;amp;pmid=17290037" target="_blank"&gt;full text&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;9. Mukhopadhyay, A, Farrell, T, Fraser, RB, and Ola, B. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials. American Journal of Obstetrics and Gynecology ; 2007 Nov;&lt;SPAN class=volume&gt;197&lt;/SPAN&gt;(&lt;SPAN class=issue&gt;5&lt;/SPAN&gt;):&lt;SPAN class=pages&gt;447-56&lt;/SPAN&gt;. Epub 2007 Aug 6.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17678864&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract]&lt;o:p&gt;&lt;/o:p&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;10. Visser J, Snel M Van Vliet HAAM. Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2. The Cochrane Library 2006; (4)&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003990/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>273699</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=273699]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2007 - prevention</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,PREVENTION,PREVENTION,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'prevention' from literature searches carried out for the diabetes annual evidence update 2007 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2007 - prevention&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;EM&gt;Please return to the annual evidence update intoduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=384860" target="_blank"&gt;Back to Annual Evidence Update introduction page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A&amp;nbsp;total of&amp;nbsp;16 systematic reviews&amp;nbsp;concerning 'prevention' were identified from the 2007 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;STRONG&gt;&lt;U&gt;Prevention (16)&lt;/U&gt;&lt;/STRONG&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;1. Alkhenizan A H, Alswes M A. The role of renin blockers in the prevention of diabetes. Saudi Medical Journal 2007; 28(1):91-95.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17206297&amp;amp;ordinalpos=7&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;2. Andraws, Richard and Brown, David L. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus meta-analysis of randomized trials. The American journal of cardiology 2007; 99(7):1006-12.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17398202&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;3. Beletate V, El Dib RP Atallah AN. Zinc supplementation for the prevention of type 2 diabetes mellitus. The Cochrane Library&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;2007; (1)&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005525/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;4. Cheung BM, Cheung GT Lauder IJ Lau CP Kumana CR. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. Journal of Human Hypertension, 2006; 20(1):37-43.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16121197&amp;amp;ordinalpos=4&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;[abstract]&lt;o:p&gt;&lt;/o:p&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;5. &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:State w:st="on"&gt;&lt;st1:place w:st="on"&gt;Conn&lt;/st1:place&gt;&lt;/st1:State&gt;, V. S., Hafdahl, A. R., Mehr, D. R., LeMaster, J. W., Brown, S. A., and Nielsen, P. J. Metabolic effects of interventions to increase exercise in adults with type 2 diabetes. Diabetologia 2007; 50(5):913-921.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17342472&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;6. Ding, Eric L., Song, Yiqing, Malik, Vasanti S., and Liu, Simin. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA : the journal of the American Medical Association 2006; 295(11):1288-99.&amp;nbsp; [&lt;A href="http://jama.ama-assn.org/cgi/content/full/295/11/1288" target="_blank"&gt;full text&lt;/A&gt;]&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;7. Gilles CL, Abrams KR Lambert PC et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis . British Medical Journal 2007; 334:299&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3494&amp;amp;itool=AbstractPlus-nondef&amp;amp;uid=17237299&amp;amp;db=pubmed&amp;amp;url=http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=17237299" target="_blank"&gt;[full text&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;8. Huang, J. S., Lee, T. A., and Lu, M. C. Prenatal programming of childhood overweight and obesity. Maternal and Child Health Journal 2007; 11(5):461-473.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17006770&amp;amp;ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;9. Jeon CY, Locken RP Hu FB et al. Physical activity of moderate intensity and risk of type 2 diabetes: a systematic review. Diabetes Care 2007; 30;3:744-752.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3051&amp;amp;itool=AbstractPlus-def&amp;amp;uid=17327354&amp;amp;db=pubmed&amp;amp;url=http://care.diabetesjournals.org/cgi/pmidlookup?view=long&amp;amp;pmid=17327354" target="_blank"&gt;full text&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;10. Kuti, E. L., Baker, W. L., and White, C. M. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker. Current Medical Research and Opinion 2007; 23(6):1239-1244.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Kuti%5Bauthor%5D%20AND%20diuretic" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;11. Larsson, S. C. and Wolk, A. Magnesium intake and risk of type 2 diabetes: A meta-analysis. Journal of Internal Medicine 2007; 262(2):208-214.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17645588&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;[abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;12. Nielsen, Paul J., Hafdahl, Adam R., Conn, Vicki S., Lemaster, Joseph W., and Brown, Sharon A. Meta-analysis of the effect of exercise interventions on fitness outcomes among adults with type 1 and type 2 diabetes. Diabetes research and clinical practice 2006; 74(2):111-20.&amp;nbsp;&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16735074&amp;amp;ordinalpos=4&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;13. Owen, Christopher G., Martin, Richard M., Whincup, Peter H., Smith, George Davey, and Cook, Derek G. Does breastfeeding influence risk of type 2 diabetes in later life? A quantitative analysis of published evidence. The American journal of clinical nutrition 2006; 84(5):1043-54.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3051&amp;amp;itool=AbstractPlus-def&amp;amp;uid=17093156&amp;amp;db=pubmed&amp;amp;url=http://www.ajcn.org/cgi/pmidlookup?view=long&amp;amp;pmid=17093156" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;14. Serra, Majem Lluís, Roman, Blanca, and Estruch, Ramón. Scientific evidence of interventions using the Mediterranean diet: a systematic review. Nutrition reviews 2006; 64(2 Pt 2):S27-47.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16532897&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;15. Shaw K, Gennat H O'Rourke P Del Mar C. Exercise for overweight or obesity. The Cochrane Library 2006; (4)&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003817/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;16. Yates, T., Khunti, K., Bull, F., Gorely, T., and Davies, M. J. The role of physical activity in the management of impaired glucose tolerance: a systematic review. Diabetologia 2007; 50(6):1116-26.&amp;nbsp;&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3494&amp;amp;itool=AbstractPlus-nondef&amp;amp;uid=17415549&amp;amp;db=pubmed&amp;amp;url=http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=17415549" target="_blank"&gt;full text&lt;/A&gt;]&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>273718</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=273718]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2007 - screening</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,LIVING WITH DIABETES,CAUSES,RESEARCH,ANNUAL EVIDENCE UPDATES,CONTRACEPTION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'screening' from literature searches carried out for the diabetes annual evidence update 2007 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2007 - screening&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;EM&gt;Please return to the annual evidence update intoduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=384860" target="_blank"&gt;Back to Annual Evidence Update introduction page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A&amp;nbsp;total of&amp;nbsp;4 systematic reviews&amp;nbsp;concerning 'screening' were identified from the 2007 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;STRONG&gt;&lt;U&gt;Screening (4)&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;1. Bennett CM, Guo M Dharmage SC. HbA(1c) as a screening tool for detection of Type 2 diabetes: a systematic review.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;Diabetic Medicine 2007; 24(4):333-43.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17367307&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;2. Elliott W J, Meyer P M.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;Lancet 2007; 369(9557):201-7.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;term=369%5Bvolume%5D%20AND%209557%5Bissue%5D%20AND%20201%5Bpage%5D" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;3. Lopez LM, Grimes DA Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. The Cochrane Library 2007; Issue 2&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006033/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 6pt 0cm 0pt" class=MsoNormal&gt;4. Waugh N, et al. Screening for type 2 diabetes: literature review and economic modelling.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;2007; 11(17) [&lt;A href="http://www.hta.ac.uk/execsumm/summ1117.htm" target="_blank"&gt;full text&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>273537</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=273537]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2007 - treatments</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'treatments' from literature searches carried out for the diabetes annual evidence update 2007 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2007 - treatments&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=left&gt;&lt;EM&gt;Please return to the annual evidenc update intoduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=384860" target="_blank"&gt;Back to Annual Evidence Update introduction page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A&amp;nbsp;total of 43 systematic reviews&amp;nbsp;concerning 'treatments' were identified from the 2007 Diabetes Annual Evidence Update. the citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Glycemic lowering treatment &amp;gt; Medications (37)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;1. Amori RE, Lau J Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298(2):194-206.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;term=298%5Bvolume%5D%20AND%202%5Bissue%5D%20AND%20194%5Bpage%5D" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;2. Gangji&amp;nbsp; AS et al.&amp;nbsp; A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;Diabetes Care&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;2007; (30):389-394 .&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;term=%22Diabetes%20care%22%5BJour%5D%20AND%2030%5Bvolume%5D%20AND%20389%5Bpage%5D" target="_blank"&gt;abstract&lt;/A&gt;]&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;3. Banerjee S et al.&amp;nbsp;&amp;nbsp;Short-acting insulin analogues for diabetes mellitus: meta-analysis of clinical outcomes and assessment of cost-effectiveness. (Technology Report no. 87).&amp;nbsp; Ottowa:&amp;nbsp; Canadian Agency for Drugs and Techonologies&amp;nbsp; in Health;&amp;nbsp;&amp;nbsp;2007.&amp;nbsp;&amp;nbsp;[&lt;A href="http://www.cadth.ca/media/pdf/341A_Insulin_tr_e.pdf" target="_blank"&gt;full text&lt;/A&gt;]&amp;nbsp; &lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;4. Berlie HD,&amp;nbsp;Kalus&amp;nbsp;JS,&amp;nbsp;Jaber LA.&amp;nbsp;&amp;nbsp;Thiazolidinediones and the risk of edeoma: a meta-analysis. Diabetes research and clinical practice 2007; 76(2):279-89.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17055103&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;5. Black C et al.&amp;nbsp;&amp;nbsp;Meglitinide analogues for type 2 diabetes mellitus. The Cochrane Library 2007; Issue 2&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004654/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;6. Bolen, S&amp;nbsp; et al.&amp;nbsp;&amp;nbsp;&amp;nbsp;Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus. Annals of Internal Medicine&amp;nbsp;2007;&amp;nbsp; 147(6):386-9&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;TransSchema=title&amp;amp;term=Bolen%5Bauthor%5D%20AND%20oral%20medications" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;7. Brophy S et al.&amp;nbsp;&amp;nbsp;Interventions for latent autoimmune diabetes (LADA) in adults. The Cochrane Library 2007; 3&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006165/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;8. Campbell RK.&amp;nbsp;&amp;nbsp;Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. The Annals of pharmacotherapy 2007; 41(1):51-60.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17190843&amp;amp;ordinalpos=5&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;9. Ceglia L, Lau J, Pittas AG. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Annals of Internal Medicine 2006; 145(9):665-75.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3051&amp;amp;itool=AbstractPlus-def&amp;amp;uid=17088580&amp;amp;db=pubmed&amp;amp;url=http://www.annals.org/cgi/pmidlookup?view=reprint&amp;amp;pmid=17088580" target="_blank"&gt;full text&lt;/A&gt;]&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;10. Davidson J et al.&amp;nbsp;&amp;nbsp;Biphasic insulin aspart 30: Literature review of adverse events associated with treatment. Clinical Therapeutics 2006; 27(SUPPL. 2):S75-S88.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16781912&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;11. Duckworth W,&amp;nbsp;Davis SN&amp;nbsp;&amp;nbsp;Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. Journal of Diabetes and its Complications 2007; 21(3):196-204.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17493554&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;12. Fonseca, V. The role of basal insulin therapy in patients with type 2 diabetes mellitus. Insulin 2006; 1(2):51-60.&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;13. Halimi S et al.&amp;nbsp;&amp;nbsp;Efficacy of biphasic insulin aspart in patients with type 2 diabetes. Clinical Therapeutics 2006; 27(SUPPL. 2):S57-S74.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16781911&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;14. Horvath K,&amp;nbsp;&amp;nbsp; et al.&amp;nbsp;&amp;nbsp;Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. The Cochrane Library 2007; Issue 2&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005613/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;15. Iltz JL et al.&amp;nbsp;&amp;nbsp;Exenatide: An incretin mimetic for the treatment of type 2 diabetes mellitus. Clinical Therapeutics 2006; 28(5):652-665.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16861088&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;16. Kleppinger EL,&amp;nbsp;Helms K.&amp;nbsp;&amp;nbsp;The role of vildagliptin in the management of type 2 diabetes mellitus. The Annals of pharmacotherapy 2007; 41(5):824-32.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17456545&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;17. Levetan, Claresa. Oral antidiabetic agents in type 2 diabetes. Current medical research and opinion 2007 ; 23(4):945-52. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17407651&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;18. McCullough PA,&amp;nbsp;Lepor NE. The rosiglitazone meta-analysis. Reviews in Cardiovascular Medicine 2007; 8(2):123-126.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17603430&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;19. Meece, J. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. Current medical research and opinion 2007; 23(4):933-44. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17407650&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;20. Natali A,&amp;nbsp;Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 2006; 49(3):434-41.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16477438&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;21. Nissen SE, Wolski K. Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24):2457-71.&amp;nbsp; [abstract]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;22. Nogid A,&amp;nbsp;Pham, DQ.&amp;nbsp;&amp;nbsp;Adjunctive therapy with pramlintide in patients with type 1 or type 2 diabetes mellitus. Pharmacotherapy 2006; 26(11):1626-40.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17064208&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;23. Norris S L, Carson S,&amp;nbsp;Roberts C. Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: A meta-analysis. Current Diabetes Reviews 2007; 3(2):127-140.&amp;nbsp; [&lt;A href="http://warwick.library.ingentaconnect.com/content/ben/cdr/2007/00000003/00000002/art00006" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;24. Phatak HM,&amp;nbsp;Yin, DD. Factors associated with the effect-size of thiazolidinedione TZD therapy on HbA1c: a meta-analysis of published randomized clinical trials. Current medical research and opinion 2006; 22(11):2267-78.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;term=22%5Bvolume%5D%20AND%2011%5Bissue%5D%20AND%202267%5Bpage%5D" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;25. Pratley RE,&amp;nbsp;Salsali A.&amp;nbsp;&amp;nbsp;Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Current medical research and opinion 2007; 23(4):919-31.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17407649&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;26. Qayyum R, Adomaityte J. Meta-analysis of the effect of thiazolidinediones on serum C-reactive protein levels. American Journal of Cardiology 2006; 97(5):655-658.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16490432&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;27. Rex J, Jensen K H,&amp;nbsp;Lawton SA. A review of 20 years' experience with the NovoPen® family of insulin injection devices. Clinical Drug Investigation 2006; 26(7):367-401. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;amp;db=PubMed&amp;amp;cmd=Search&amp;amp;term=%22Clinical%20drug%20investigation%22%5BJour%5D%20AND%20Rex%5Bauthor%5D" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;28. Richter B et al.&amp;nbsp;&amp;nbsp;Pioglitazone for type 2 diabetes mellitus. The Cochrane Library 2006; (4)&amp;nbsp; [&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006060/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;29. Richter B et al.&amp;nbsp;&amp;nbsp;Rosiglitazone for type 2 diabetes mellitus. The Cochrane Library 2007; (3)&amp;nbsp; [&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006063/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;30. Roberts F,&amp;nbsp;Ryan GJ. The safety of metformin in heart failure. Annals of Pharmacotherapy 2007; 41(4):642-646.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17374622&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;31. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus (Cochrane Review). The Cochrane Library 2006; (Issue 1)&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002967/frame.html" target="_blank"&gt;Cochrane review]&lt;o:p&gt;&lt;/o:p&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;32. Setter SM et al.&amp;nbsp;&amp;nbsp;Inhaled dry powder insulin for the treatment of diabetes mellitus. Clinical therapeutics 2007; 29(5):795-813.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17697900&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;33. Siebenhofer A et al.&amp;nbsp;&amp;nbsp;Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus (Cochrane Review). The Cochrane Library 2006; (Issue 2)&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003287/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;34. Singh FD,&amp;nbsp;Robles G,&amp;nbsp;Gazze D. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus. Clinical Therapeutics 2007; 29(4):535-562.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17617279&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;35. Staels, B. Metformin and pioglitazone: Effectively treating insulin resistance. Current Medical Research and Opinion 2006; 22(SUPPL. 2):S27-S37.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16914073&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;36. Stumpf JL,&amp;nbsp;Lin, SW.&amp;nbsp;&amp;nbsp;Effect of glucosamine on glucose control. The Annals of pharmacotherapy 2006; 40(4):694-8.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=16569816&amp;amp;ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;37. Van, De Laar FA et al.&amp;nbsp;&amp;nbsp;Alpha-glucosidase inhibitors for type 2 diabetes mellitus: A systematic review. Chinese Journal of Evidence-Based Medicine 2006; 6(5):335-351.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Glycemic lowering treatment &amp;gt; Diet / Exercise (5)&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;1. Dansinger ML et al.&amp;nbsp;&amp;nbsp;Meta-analysis: the effect of dietary counseling for weight loss. Annals of internal medicine 2007; 147(1):41-50.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17606960&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;2. Nield L et al.&amp;nbsp;&amp;nbsp;Dietary advice for treatment of type 2 diabetes mellitus in adults. Cochrane database of systematic reviews (Online) 2007; (3):CD004097. [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004097/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;3. Snowling NJ, Hopkins WG. .Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;2006; 29(11):2518-27.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3051&amp;amp;itool=AbstractPlus-def&amp;amp;uid=17065697&amp;amp;db=pubmed&amp;amp;url=http://care.diabetesjournals.org/cgi/pmidlookup?view=long&amp;amp;pmid=17065697" target="_blank"&gt;full text]&lt;o:p&gt;&lt;/o:p&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;4. Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus . The Cochrane Library 2006; (Issue 3)&amp;nbsp; [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002968/frame.html" target="_blank"&gt;Cochrane review&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 6pt" class=MsoNormal&gt;5. van, de Laar FA, Akkermans RP,&amp;nbsp;van, Binsbergen JJ.&amp;nbsp;&amp;nbsp; Limited evidence for effects of diet for type 2 diabetes from systematic reviews. European journal of clinical nutrition 2007; 61(8):929-37.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17251927&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Complementary and alternative medicine (1)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;Chang HY,&amp;nbsp;Wallis M,&amp;nbsp;Tiralongo E.&amp;nbsp;&amp;nbsp;Use of complementary and alternative medicine among people living with diabetes: literature review. Journal of advanced nursing 2007; 58(4):307-19.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17442034&amp;amp;ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>297941</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=297941]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2008 - Complications</title>
    <publicationDate>2008-11-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,NEPHROPATHY,RETINOPATHY,DIABETIC FOOT,PAINFUL NEUROPATHIES,CARDIOVASCULAR,KETOACIDOSIS,HYPOGLYCAEMIA,PSYCHOLOGICAL PROBLEMS,CHRONIC COMPLICATIONS,ACUTE COMPLICATIONS,AUTONOMIC NEUROPATHY,RESEARCH,EYE DISEASES,HYPEROSMOLAR HYPERGLYCAEMIC STATES,ANNUAL EVIDENCE UPDATES,COGNITIVE FUNCTION,ANXIETY AND DEPRESSION,GASTROPARESIS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'complications' from literature searches carried out for the diabetes annual evidence update 2008 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2008 - Complications&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;Please return to the annual evidence update introduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/SPAN&gt;&lt;/I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: right; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=right&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;&lt;FONT color=#800080&gt;&lt;EM&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;Back to Annual Evidence Update introduction page&lt;/A&gt;&lt;/EM&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A total of 45 systematic reviews concerning 'complications' were identified from the 2008 Diabetes Annual Evidence Update. The citations are listed here with links to the abstract or full text reference where available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Complications (45)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Acute complications &amp;gt; Hypoglycemia (1)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Amiel S A, Dixon T, Mann R and Jameson K.&amp;nbsp; 2008.&amp;nbsp; Hypoglycaemia in Type 2 diabetes Diabetic Medicine 25(3): 245–254. [&lt;A href="http://www.ingentaconnect.com/content/bsc/dme/2008/00000025/00000003/art00001" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Acute complications &amp;gt; Hyperglycemia (1)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Ovalle F., Vaughan III T.B., Sohn J.E., and Gower B. Catamenial diabetic ketoacidosis and catamenial hyperglycemia: Case report and review of the literature.&amp;nbsp; American Journal of the Medical Sciences 335(4), 298-303. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18414069" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Acute complications &amp;gt; DKA (1)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Pauw R.C., van der Werf T.S., van Dullemen H.M., and Dullaart R.P.F. Mediastinal emphysema complicating diabetic ketoacidosis: Plea for conservative diagnostic approach. Netherlands Journal of Medicine 65(10), 368-371. 2007. [&lt;A href="http://www.njmonline.nl/njm/getpdf.php?t=a&amp;amp;id=10000234" target="_blank"&gt;full text&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Microvascular complications and treatment &amp;gt; Neuropathy (6)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&amp;nbsp; Barrett A.M., Lucero M.A., Le T., Robinson R.L., Dworkin R.H., and Chappell A.S. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: A review. Pain Medicine 8(SUPPL. 2), S50-S62. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17714116" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;&amp;nbsp; Chalk C, Benstead TJ Moore F. (4). 2007.&amp;nbsp; Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database of Systematic Reviews: Reviews 2007 Issue 4 John Wiley &amp;amp; Sons, Ltd Chichester, UK. [&lt;A href="http://www.cochrane.org/reviews/en/ab004572.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;&amp;nbsp; Rolim L.C.D.S.P., De Sa J.R., Chacra A.R., and Dib S.A. Diabetic cardiovascular autonomic neuropathy: Risk factors, clinical impact and early diagnosis. Arquivos Brasileiros de Cardiologia 90(4), e23, e31+e24-e32. 2008. [&lt;A href="http://www.scielo.br/scielo.php?pid=S0066-782X2008000400014&amp;amp;script=sci_arttext&amp;amp;tlng=en" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;&amp;nbsp; Sugumar A., Singh A., and Pasricha P.J. A Systematic Review of the Efficacy of Domperidone for the Treatment of Diabetic Gastroparesis. Clinical Gastroenterology and Hepatology 6(7), 726-733. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18524689" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;&amp;nbsp; Sultan A., Gaskell H., Derry S., and Andrew R.A. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: Systematic review of randomised trials. BMC Neurology 8. 2008. [&lt;A href="http://www.biomedcentral.com/1471-2377/8/29" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;&amp;nbsp; Veves A., Backonja M., and Malik R.A. Painful diabetic neuropathy: Epidemiology, natural history, early diagnosis, and treatment options. Pain Medicine 9(6), 660-674. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18828198" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Microvascular complications and treatment &amp;gt; Nephropathy (4)&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&amp;nbsp; McCormick B.B., Sydor A., Akbari A., Fergusson D., Doucette S., and Knoll G. The Effect of Pentoxifylline on Proteinuria in Diabetic Kidney Disease: A Meta-analysis. American Journal of Kidney Diseases 52(3), 454-463. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18433957" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;&amp;nbsp; Pan Y, Guo LL, and Jin HM. Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition 88(3), 660-6. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18779281" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;&amp;nbsp; Sarafidis P.A., Stafylas P.C.,&amp;nbsp; Kanaki A.I., and Lasaridis A.N. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: An updated meta-analysis. American Journal of Hypertension 21(8), 922-929. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18535536" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;&amp;nbsp; Zintzaras E., Uhlig K., Koukoulis G.N., Papathanasiou A.A., and Stefanidis I. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy: A meta-analysis. Journal of Human Genetics 52(11), 881-890. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17805475" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Microvascular complications and treatment &amp;gt; Foot (8)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&amp;nbsp; Allet L, Armand S, Golay A, Monnin D, de Bie RA, and de Bruin ED. Gait characteristics of diabetic patients: a systematic review. Diabetes/Metabolism Research Reviews 24(3), 173-91. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18232063" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;&amp;nbsp; Berendt A.R., Peters E.J.G., Bakker K., Embil J.M., Eneroth M., Hinchliffe R.J., Jeffcoate W.J., Lipsky B.A., Senneville E., Teh J., and Valk G.D. Diabetic foot osteomyelitis: A progress report on diagnosis and a systematic review of treatment. Diabetes/Metabolism Research and Reviews 24(SUPPL. 1), S145-S161. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18442163" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;&amp;nbsp; Blozik E and Scherer M. Skin replacement therapies for diabetic foot ulcers: systematic review and meta-analysis. Diabetes Care 31(4), 693-4. 2008. [&lt;A href="http://care.diabetesjournals.org/cgi/content/extract/31/4/693" target="_blank"&gt;extract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;&amp;nbsp; Bus S.A., Valk G.D., van Deursen R.W., Armstrong D.G., Caravaggi C., Hlavacek P., Bakker K., and Cavanagh P.R. The effectiveness of footwear and offloading interventions to prevent and heal foot ulcers and reduce plantar pressure in diabetes: A systematic review. Diabetes/Metabolism Research and Reviews 24(SUPPL. 1), S162-S180. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=18442178&amp;amp;tool=MedlinePlus" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;&amp;nbsp; Dinh M.T., Abad C.L., and Safdar N. Diagnostic accuracy of the physical examination and imaging tests for osteomyelitis underlying diabetic foot ulcers: Meta-analysis. Clinical Infectious Diseases 47(4), 519-527. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18611152" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;&amp;nbsp; Hinchliffe R.J., Valk G.D., Apelqvist J., Armstrong D.G. , Bakker K., Game F.L., Hartemann-Heurtier A., Londahl M., Price P.E., van Houtum W.H., and Jeffcoate W.J. A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes/Metabolism Research and Reviews 24(SUPPL. 1), S119-S144. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18442185" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;&amp;nbsp; Noble-Bell G and Forbes A. A systematic review of the effectiveness of negative pressure wound therapy in the management of diabetes foot ulcers. International Wound Journal 5(2), 233-42. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18675559" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;&amp;nbsp; Perrin B and Swerissen H. The behavior and psychological functioning of people at high risk of diabetes-related foot complications. Diabetes Educator 34(3), 493-500. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18535322" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Microvascular complications and treatment &amp;gt; Retinopathy (6)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&amp;nbsp; Grover D, Li TJ Chong CCW. (1). 2008.&amp;nbsp; Grover D, Li TJ, Chong CCW. Intravitreal steroids for macular edema in diabetes. Cochrane Database of Systematic Reviews: Reviews 2008 Issue 1 John Wiley &amp;amp; Sons, Ltd Chichester, UK [&lt;A href="http://www.cochrane.org/reviews/en/ab005656.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;&amp;nbsp; Lopes de Jesus CC, Atallah AN Valente O Moça Trevisani VF. (2). 2008.&amp;nbsp; Pentoxifylline for diabetic retinopathy. Cochrane Database of Systematic Reviews: Reviews 2008 Issue 2 John Wiley &amp;amp; Sons, Ltd Chichester, UK [&lt;A href="http://www.cochrane.org/reviews/en/ab006693.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;&amp;nbsp; Lopes de Jesus CC, Atallah AN Valente O Moça Trevisani VF. (1). 2008.&amp;nbsp; Vitamin C and superoxide dismutase (SOD) for diabetic retinopathy. Cochrane Database of Systematic Reviews: Reviews 2008 Issue 1 John Wiley &amp;amp; Sons, Ltd Chichester, UK [&lt;A href="http://www.cochrane.org/reviews/en/ab006695.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;&amp;nbsp; Virgili G., Menchini F., Dimastrogiovanni A.F., Rapizzi E., Menchini U., Bandello F., and Chiodini R.G. Optical coherence tomography versus stereoscopic fundus photography or biomicroscopy for diagnosing diabetic macular edema: A systematic review. Investigative Ophthalmology and Visual Science 48(11), 4963-4973. 2007. [&lt;A href="http://www.iovs.org/cgi/content/abstract/48/11/4963" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;&amp;nbsp; Wiwanitkit V. Angiotensin-converting enzyme gene polymorphism is correlated to diabetic retinopathy: a meta-analysis. Journal of Diabetes &amp;amp; its Complications 22(2), 144-6. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18280446" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;&amp;nbsp; Zhang X, Norris SL, Saadine J, Chowdhury FM, Horsley T, Kanjilal S, Mangione CM, and Buhrmann R. Effectiveness of interventions to promote screening for diabetic retinopathy. American Journal of Preventive Medicine 33(4), 318-35. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17888859" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Macrovascular complications &amp;amp; treatment &amp;gt; Lipids (3)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&amp;nbsp; Kelley G.A. and Kelley K.S. Effects of aerobic exercise on lipids and lipoproteins in adults with type 2 diabetes: A meta-analysis of randomized-controlled trials. Public Health 121(9), 643-655. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17544042" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;&amp;nbsp; Tkac I. Treatment of dyslipidemia in patients with type 2 diabetes: Overview and meta-analysis of randomized trials. Diabetes Research and Clinical Practice 78(3 SUPPL.), S23-S28. 2007. [&lt;A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B6T5Y-4R2XCGC-2&amp;amp;_user=10&amp;amp;_rdoc=1&amp;amp;_fmt=&amp;amp;_orig=search&amp;amp;_sort=d&amp;amp;view=c&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=10&amp;amp;md5=e0eb721f75e368a73c4646e960f9ba5a" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;&amp;nbsp; Winters SM, Visser H, Steerneman AH, Thomas G, Bots ML, and van der Heijden GJ. Is there a need for dietary measures to further reduce LDL cholesterol in patients with type II diabetes mellitus on statin therapy?. Primary care diabetes 2(1), 51-4. 2008. [&lt;A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B8CX9-4RWHN4S-1&amp;amp;_user=10&amp;amp;_rdoc=1&amp;amp;_fmt=&amp;amp;_orig=search&amp;amp;_sort=d&amp;amp;view=c&amp;amp;_acct=C000050221&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=10&amp;amp;md5=8e625bc0fd433986c8756e0d6b2ff27a" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Macrovascular complications &amp;amp; treatment &amp;gt; Coronary Heart Disease (11)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; 1.&amp;nbsp;&amp;nbsp; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. The Lancet 371(9607), 117-125. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18191683" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; 2.&amp;nbsp;&amp;nbsp; Hartweg J, Farmer AJ, Perera R, Holman RR, and Neil HA. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia 50(8), 1593-602. 2007. [&lt;A href="http://www.springerlink.com/content/a423601u71802314/" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; 3.&amp;nbsp;&amp;nbsp; Kimura M., Mintz G.S., Weissman N.J., Dawkins K.D., Grube E., Ellis S.G., Cannon L.A., Masud Z., Mandinov L., Baim D., and Stone G.W. Meta-analysis of the Effects of Paclitaxel-Eluting Stents Versus Bare Metal Stents on Volumetric Intravascular Ultrasound in Patients With Versus Without Diabetes Mellitus. American Journal of Cardiology 101(9), 1263-1268. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18435955" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; 4.&amp;nbsp;&amp;nbsp; Kirtane A.J., Ellis S.G., Dawkins K.D., Colombo A., Grube E., Popma J.J., Fahy M.,&amp;nbsp; Leon M.B., Moses J.W., Mehran R., and Stone G.W. Paclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus. Pooled Analysis From 5 Randomized Trials. Journal of the American College of Cardiology 51(7), 708-715. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18279734" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; 5.&amp;nbsp;&amp;nbsp; Kumbhani D.J. , Bavry A.A., Kamdar A.R., Helton T.J., and Bhatt D.L. The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: Insights from randomized clinical trials. American Heart Journal 155(4), 640-647. 2008. [&lt;A href="http://content.onlinejacc.org/cgi/content/abstract/51/25/2385" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; 6.&amp;nbsp;&amp;nbsp; Lang CD, Arora RR, Saha SA, and Molnar J. Bayesian meta-analysis of tissue angiotensin-converting enzyme inhibitors for reduction of adverse cardiovascular events in patients with diabetes mellitus and preserved left ventricular function.&amp;nbsp; Journal of the CardioMetabolic Syndrome 3(1), 45-52. 2008. [&lt;A href="http://www3.interscience.wiley.com/cgi-bin/fulltext/119423946/HTMLSTART" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; 7.&amp;nbsp;&amp;nbsp; Mahmud E., Bromberg-Marin G., Palakodeti V., Ang L., Creanga D., and DeMaria A.N. Clinical Efficacy of Drug-Eluting Stents in Diabetic Patients. A Meta-Analysis.&amp;nbsp; Journal of the American College of Cardiology 51(25), 2385-2395. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18565394" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; 8.&amp;nbsp;&amp;nbsp; Nikolsky E, Holmes DR, Mehran R, Dangas G, Schampaert E, Morice MC, Schofer J, Sousa JE, Fahy M, Na Y, Donohoe DJ, Moses JW, and Leon MB. Impact of platelet glycoprotein IIb/IIIa receptor inhibitors on outcomes of diabetic patients undergoing percutaneous coronary interventions using sirolimus-eluting stents. Catheterization &amp;amp; Cardiovascular Interventions 71(7), 896-906. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18498145" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; 9.&amp;nbsp;&amp;nbsp; Saha S.A., Molnar J., and Arora R.R. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: A pooled meta-analysis of randomized placebo-controlled clinical trials. Diabetes, Obesity and Metabolism 10(1), 41-52. 2008. [&lt;A href="http://www3.interscience.wiley.com/journal/119420162/abstract" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp; 10.&amp;nbsp;&amp;nbsp; Sirois C, Poirier P, Moisan J, and Gregoire JP. The benefit of aspirin therapy in type 2 diabetes: what is the evidence?. International Journal of Cardiology 129(2), 172-9. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18495263" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp; 11.&amp;nbsp;&amp;nbsp; Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, De Carlo M, Erglis A, Chechi T, Ortolani P, Schalij MJ, Diem P, Meier B, Windecker S, and Juni P. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 337. 2008. [&lt;A href="http://www.bmj.com/cgi/content/full/337/aug29_3/a1331" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Macrovascular complications &amp;amp; treatment &amp;gt; Blood Pressure (1)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Naik A.D., Issac T.T., Street Jr. R.L., and Kunik M.E. Understanding the quality chasm for hypertension control in diabetes: A structured review of "co-maneuvers" used in clinical trials. Journal of the American Board of Family Medicine 20(5), 469-478. 2007. [&lt;A href="http://www.jabfm.org/cgi/content/abstract/20/5/469" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Fracture Risk (1)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Strotmeyer E.S. and Cauley J.A.&amp;nbsp; Diabetes mellitus, bone mineral density, and fracture risk. Current Opinion in Endocrinology, Diabetes and Obesity 14(6), 429-435. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17982347" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Effect of Diabetes on oral and maxillofacial implant survival rates (1)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Klokkevold PR&amp;nbsp; and Han TJ. How do smoking, diabetes, and periodontitis affect outcomes of implant treatment?. 2007; 22 Suppl,&amp;nbsp; 173-202. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18437796" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Autoantibodies and organ failure (1)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;de Graaff LC; Smit JW, and Radder JK. Prevalence and clinical significance of organ-specific autoantibodies in type 1 diabetes mellitus. 2007; 65, (7): 235-47. [&lt;A href="http://www.zuidencomm.nl/njm/getpdf.php?id=10000195" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;/P&gt;&lt;/SPAN&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>297944</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=297944]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2008 - Delivery of Care</title>
    <publicationDate>2008-11-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'delivery of care' from literature searches carried out for the diabetes annual evidence update 2008 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2008 - Delivery of Care&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN; mso-bidi-font-size: 12.0pt" lang=EN&gt;Please return to the annual evidence update introduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/SPAN&gt;&lt;/I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: right; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=right&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN; mso-bidi-font-size: 12.0pt" lang=EN&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;&lt;FONT color=#800080&gt;&lt;EM&gt;Back to Annual Evidence Update introduction page&lt;/EM&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN; mso-bidi-font-size: 12.0pt" lang=EN&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;
&lt;P style="TEXT-ALIGN: right; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=right&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: right; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=right&gt;&lt;FONT color=#000000 size=2 face=Arial&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;&lt;FONT color=#000000 size=2 face=Arial&gt;
&lt;P&gt;A total of 12 systematic reviews concerning 'delivery of care' were identified from the 2008 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Delivery of care (12)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&amp;nbsp; Angus V.C. and Waugh N. Hospital admission patterns subsequent to diagnosis of type 1 diabetes in children: A systematic review. BMC Health Services Research 7. 2007. [&lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=18053255" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Borgermans LA , Goderis G, Ouwens M, Wens J, Heyrman J, and Grol RP. Diversity in diabetes care programmes and views on high quality diabetes care: are we in need of a standardized framework?. International Journal of Integrated Care [Electronic Resource] 8. 2008. [&lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2387191" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Carey N and Courtenay M. A review of the activity and effects of nurse-led care in diabetes. Journal of Clinical Nursing 16(11C), 296-304. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17931323" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Khunti K, Gadsby R, Millett C, Majeed A, and Davies M. Quality of diabetes care in the UK: comparison of published quality-of-care reports with results of the Quality and Outcomes Framework for Diabetes. Diabetic Medicine 24(12), 1436-41. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17971182" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Kirk J.K., Passmore L.V., Bell R.A., Narayan K.M.V., D'Agostino Jr. R.B., Arcury T.A., and Quandt S.A.&amp;nbsp; Disparities in A1C levels between hispanic and non-hispanic white adults with diabetes: A meta-analysis. Diabetes Care 31(2), 240-246. 2008. [&lt;A href="http://care.diabetesjournals.org/cgi/content/full/31/2/240" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Leykum LK, Pugh J, Lawrence V, Parchman M, Noel PH, Cornell J, and McDaniel RR Jr. Organizational interventions employing principles of complexity science have improved outcomes for patients with Type II diabetes. Implementation Science 2. 2007. [&lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2018702" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Machado M., Bajcar J., Guzzo G.C., and Einarson T.R. Sensitivity of patient outcomes to pharmacist interventions. Part I: Systematic review and meta-analysis in diabetes management. Annals of Pharmacotherapy 41(10), 1569-1582. 2007. [&lt;A href="http://www.theannals.com/cgi/content/abstract/aph.1K151v1" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Peek M.E., Cargill A., and Huang E.S. Diabetes health disparities: A systematic review of health care interventions. Medical Care Research and Review 64(5 SUPPL.), 101S-156S. 2007. [&lt;A href="http://mcr.sagepub.com/cgi/content/abstract/64/5_suppl/101S?rss=1" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. Smiley D. and Umpierrez G.E. Inpatient insulin therapy. Insulin 3(3), 152-166. 2008. [&lt;A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B83WG-4T4J3F8-4&amp;amp;_user=585204&amp;amp;_rdoc=1&amp;amp;_fmt=&amp;amp;_orig=search&amp;amp;_sort=d&amp;amp;view=c&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=585204&amp;amp;md5=2ffe052a97d80cd75de193c7d1af4f0a" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10. Soylemez Wiener R, Wiener DC, and&amp;nbsp; Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA 300(8), 933-44. 2008. [&lt;A href="http://jama.ama-assn.org/cgi/content/abstract/300/8/933" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;11. van Bruggen JA, Gorter KJ, Stolk RP, and Rutten GE. Shared and delegated systems are not quick remedies for improving diabetes care: a systematic review. Primary care diabetes 1(2), 59-68. 2007. [&lt;A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B8CX9-4NRCS37-1&amp;amp;_user=585204&amp;amp;_rdoc=1&amp;amp;_fmt=&amp;amp;_orig=search&amp;amp;_sort=d&amp;amp;view=c&amp;amp;_acct=C000029838&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=585204&amp;amp;md5=78b3a6a0c17f99beedfab49622b1e1ec" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;12. Wubben D.P. and Vivian E.M. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: A systematic review. Pharmacotherapy 28(4), 421-436. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18363526" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: right; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=right&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>297940</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=297940]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2008 – Diabetes and Comorbidites</title>
    <publicationDate>2008-11-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,LIVING WITH DIABETES,RESEARCH,CHRONIC COMORBIDITIES,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'Diabetes and comorbidites' from literature searches carried out for the diabetes annual evidence update 2008 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2008 – Diabetes and Comorbidites&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="MARGIN: 0cm 0cm 0pt" class=NormalWeb7&gt;&lt;EM&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;Please return to the annual evidence update introduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/SPAN&gt;&lt;/EM&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: right; MARGIN: 0cm 0cm 0pt" class=NormalWeb7 align=right&gt;&lt;EM&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-bidi-font-size: 12.0pt; mso-fareast-language: EN-GB" lang=EN&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/Page.aspx?pagename=AEU08" target="_blank"&gt;&lt;FONT color=#800080&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/EM&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-ansi-language: EN; mso-bidi-font-size: 12.0pt; mso-fareast-language: EN-GB" lang=EN&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;&lt;FONT color=#800080&gt;&lt;EM&gt;Back to Annual Evidence Update introduction page&lt;/EM&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=NormalWeb7&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;
&lt;P&gt;A total of&amp;nbsp;4 systematic reviews concerning 'Diabetes and comorbidities' were identified from the 2008 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diabetes and comorbidites (4)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&amp;nbsp; Jeon C.Y. and Murray M.B. Diabetes mellitus increases the risk of active tuberculosis: A systematic review of 13 observational studies. PLoS Medicine 5(7), 1091-1101. 2008. [&lt;A href="http://medicine.plosjournals.org/perlserv/?request=get-document&amp;amp;doi=10.1371/journal.pmed.0050152&amp;amp;ct=1" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;&amp;nbsp; Kloppenborg R.P., van den Berg E., Kappelle L.J., and Biessels G.J. Diabetes and other vascular risk factors for dementia: Which factor matters most? A systematic review. European Journal of Pharmacology 585(1), 97-108. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18395201" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;&amp;nbsp; Promberger R. , Gadenstatter M., Ciovica R., Schwab G., and Neumayer C. Gastroesophageal reflux disease in diabetic patients: A systematic review. European Surgery - Acta Chirurgica Austriaca 39(6), 340-354. 2007. [&lt;A href="http://www.springerlink.com/content/301x2224wgj2637h/" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;&amp;nbsp; Tighe BJ. Long term enteral feeding in diabetes mellitus--a systematic review. Proceedings of the Nutrition Society 67( OCE). 2008. [&lt;A href="http://journals.cambridge.org/action/displayAbstract?fromPage=online&amp;amp;aid=1910988" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=NormalWeb7&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>297945</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=297945]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2008 – Diagnosis/Classification</title>
    <publicationDate>2008-11-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DIAGNOSIS,DIAGNOSIS,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'diagnosis/classification' from literature searches carried out for the diabetes annual evidence update 2008 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2008 – Diagnosis/Classification&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;Please return to the annual evidence update introduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/SPAN&gt;&lt;/I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: right; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=right&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;&lt;FONT color=#800080&gt;&lt;EM&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;Back to Annual Evidence Update introduction page&lt;/A&gt;&lt;/EM&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;
&lt;P style="TEXT-INDENT: -54pt; MARGIN: 0cm 0cm 12pt 54pt; mso-pagination: none; tab-stops: right 9.0pt left 18.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;
&lt;P&gt;A total of 5 systematic reviews concerning 'diagnosis/classification' were identified from the 2008 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Diagnosis/Classification (5)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&amp;nbsp; Balion C.M., Raina P.S., Gerstein H.C., Santaguida P.L., Morrison K.M., Booker L., and Hunt D.L. Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: A systematic review. Clinical Chemistry and Laboratory Medicine 45(9), 1180-1185. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17635074" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;&amp;nbsp; Gerstein H.C. , Santaguida P., Raina P., Morrison K.M., Balion C., Hunt D., Yazdi H., and Booker L. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: A systematic overview and meta-analysis of prospective studies. Diabetes Research and Clinical Practice 78(3), 305-312. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17601626" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;&amp;nbsp; Takeuchi M., Okamoto K., Takagi T., and Ishii H. Ethnic difference in patients with type 2 diabetes mellitus in inter-East Asian populations: A systematic review and meta-analysis focusing on fasting serum insulin. Diabetes Research and Clinical Practice 81(3), 370-376. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18649967" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;&amp;nbsp; Van Deutekom A.W., Heine R.J., and Simsek S. The islet autoantibody titres: Their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus. Diabetic Medicine 25(2), 117-125. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18028440" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;&amp;nbsp; Vazquez G, Duval S, Jacobs DR Jr, and Silventoinen K. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. Epidemiologic Reviews 29, 115-28. 2007. [&lt;A href="http://epirev.oxfordjournals.org/cgi/content/full/29/1/115" target="_blank"&gt;full text&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>297946</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=297946]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2008 - Economics</title>
    <publicationDate>2008-11-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'economics' from literature searches carried out for the diabetes annual evidence update 2008 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2008 - Economics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;Please return to the annual evidence update introduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/SPAN&gt;&lt;/I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: right; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=right&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;&lt;FONT color=#800080&gt;&lt;EM&gt;Back to Annual Evidence Update introduction page&lt;/EM&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;
&lt;P&gt;A total of 2 systematic reviews concerning 'economics' were identified from the 2008 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Economics (2)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&amp;nbsp; Luthy KE, Peterson NE, and Wilkinson J. Cost-efficient treatment for uninsured or underinsured patients with hypertension, depression, diabetes mellitus, insomnia, and gastroesophageal reflux. Journal of the American Academy of Nurse Practitioners 20(3), 136-43. 2008. [&lt;A href="http://www3.interscience.wiley.com/journal/118572466/abstract" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;&amp;nbsp; Stafylas PC, Sarafidis PA, Grekas DM, and Lasaridis AN. A cost-effectiveness analysis of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy. Journal of Clinical Hypertension 9(10), 751-9. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17917502" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>297947</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=297947]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2008 - Epidemiology</title>
    <publicationDate>2008-11-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,RESEARCH,STATISTICS,ANNUAL EVIDENCE UPDATES,CAUSES,INCIDENCE AND PREVALENCE,RISK AND FUTURE PROJECTIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'epidemiology' from literature searches carried out for the diabetes annual evidence update 2008 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2008 - Epidemiology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;Please return to the annual evidence update introduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/SPAN&gt;&lt;/I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: right; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=right&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;&lt;FONT color=#800080&gt;&lt;EM&gt;Back to Annual Evidence Update introduction page&lt;/EM&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;
&lt;P style="TEXT-INDENT: -54pt; MARGIN: 0cm 0cm 12pt 54pt; mso-pagination: none; tab-stops: right 9.0pt left 18.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;
&lt;P&gt;A total of 5 systematic reviews concerning 'epidemiology' were identified from the 2008 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Epidemiology (5)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&amp;nbsp; Abubakari A.R. and Bhopal R.S.&amp;nbsp; Systematic review on the prevalence of diabetes, overweight/obesity and physical inactivity in Ghanaians and Nigerians. Public Health 122(2), 173-182. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18035383" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;&amp;nbsp; Cardwell C.R. , Stene L.C., Joner G., Cinek O., Svensson J., Goldacre M.J., Parslow R.C., Pozzilli P., Brigis G., Stoyanov D., Urbonaite B., Sipetic S., Schober E., Ionescu-Tirgoviste C., Devoti G., De Beaufort C.E., Buschard K., and Patterson C.C. Caesarean section is associated with an increased risk of childhood-onset type 1 diabetes mellitus: A meta-analysis of observational studies. Diabetologia 51(5), 726-735. 2008. [&lt;A href="http://www.ingentaconnect.com/content/klu/125/2008/00000051/00000005/00000941?token=004110dd67232d45237b607a316a4d576b412848743568263c7b9588fc1f26dbe" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;&amp;nbsp; Chao C and Page JH. Type 2 diabetes mellitus and risk of non-Hodgkin lymphoma: a systematic review and meta-analysis. American Journal of Epidemiology 168(5), 471-80. 2008. [&lt;A href="http://aje.oxfordjournals.org/cgi/content/abstract/168/5/471" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;&amp;nbsp; Gupta R. and Kumar P. Global diabetes landscape-type 2 diabetes mellitus in South Asia: Epidemiology, risk factors, and control. Insulin 3(2), 78-94. 2008. [&lt;A href="http://www.insulinjournal.com/Journal/Articles/Volume-3/Issue-2/gupta_4-22_WEB_078.pdf" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;&amp;nbsp; Utz SW. Diabetes care among rural Americans. Annual Review of Nursing Research 26, 3-39. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18709745" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>297950</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=297950]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2008 – Genetics</title>
    <publicationDate>2008-11-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CAUSES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'genetics' from literature searches carried out for the diabetes annual evidence update 2008 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2008 – Genetics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;Please return to the annual evidence update introduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/SPAN&gt;&lt;/I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: right; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=right&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;&lt;FONT color=#800080&gt;&lt;EM&gt;Back to Annual Evidence Update introduction page&lt;/EM&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;
&lt;P&gt;A total of 4 systematic reviews concerning ‘Genetics’ were identified from the 2008 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Genetics (4)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&amp;nbsp; Franks P.W., Rolandsson O., Debenham S.L., Fawcett K.A., Payne F., Dina C., Froguel P., Mohlke K.L., Willer C., Olsson T., Wareham N.J., Hallmans G., Barroso I., and Sandhu M.S. Replication of the association between variants in WFS1 and risk of type 2 diabetes in European populations. Diabetologia 51(3), 458-463. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18040659" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;&amp;nbsp; Li S., Li L., Li K., Qi X., Hoekema D., Liu H., and Yang G. Association of adipose most abundant transcript 1 gene (apM1) with type 2 diabetes mellitus in a Chinese population: A meta-analysis of case-control studies. Clinical Endocrinology 68(6), 885-889. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17980008" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;&amp;nbsp; McAteer JB, Prudente S, Bacci S, Lyon HN, Hirschhorn JN, Trischitta V, Florez JC, and ENPP1 Consortium. The ENPP1 K121Q polymorphism is associated with type 2 diabetes in European populations: evidence from an updated meta-analysis in 42,042 subjects. Diabetes 57(4), 1125-30. 2008. [&lt;A href="http://diabetes.diabetesjournals.org/cgi/content/abstract/57/4/1125" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;&amp;nbsp; Zeggini E., Scott L.J., Saxena R., and Voight B.F. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nature Genetics 40(5), 638-645. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18372903" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386852</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=386852]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2008 - Introduction</title>
    <publicationDate>2008-11-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2008 - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;BR&gt;&lt;BR&gt;We are pleased to present the results of out second Annual Evidence Update which identified new evidence on diabetes published between August 2007 and September 2008.&amp;nbsp; For ease of references, the results of the evidence update have been classified based on the topic headings found within the diabetes specialist library.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;This annual evidence update identified systematic reviews published between August 2007 and September 2008. &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=384860" target="_blank"&gt;Click here&lt;/A&gt; for the first Annual Evidence Update on Diabetes (evidence published January 2006 to August 2007). &lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=328114" target="_blank"&gt;&lt;STRONG&gt;Click here&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt; for the third Annual Evidence Update on Diabetes (September 08 to September 09).&amp;nbsp;&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;172 reviews have been found in this Annual Evidence Update for 2008, a slight increase in the 155 found last year.&amp;nbsp; We have used a similar classification as last years and the reviews are distributed among the topics as per last year.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Within the Treatment section there are a number of reviews of CHD risk in Glitazone therapy.&amp;nbsp; A topic that caused considerable debate over the year.&amp;nbsp;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;This year's update shows the vast amount of new knowledge being published in the field of Diabetes.&amp;nbsp; Without help it would be easy to "drown" in this vast sea of information.&amp;nbsp; We hope that you will find this evidence update helpful and of assistance in preventing you from drowning.&lt;BR&gt;&lt;BR&gt;Roger Gadsby November 2008.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Methodology&lt;BR&gt;&lt;/STRONG&gt;The methodology used to carry out the evidence update is outlined here.&amp;nbsp; Please read this for details of the scope and methods used.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Citations&lt;/STRONG&gt;&lt;BR&gt;172 English language citations were identified as being relevant and have been classified as shown in the table below.&amp;nbsp; Click on a topic to view its search results.&lt;BR&gt;&lt;BR&gt;Please note that critical appraisal of these reviews has NOT been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library. &lt;/P&gt;
&lt;P&gt;
&lt;TABLE border=1 width="50%" align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&lt;STRONG&gt;&amp;nbsp;Total&lt;/STRONG&gt;&lt;/TD&gt;
&lt;TD&gt;&lt;STRONG&gt;&amp;nbsp;172&lt;/STRONG&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=297941" target="_blank"&gt;Complications&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;45&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=297930" target="_blank"&gt;Treatments&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;42&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=297952" target="_blank"&gt;Patients&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;24&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=297944" target="_blank"&gt;Delivery of care&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;12&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=297955" target="_blank"&gt;Prevention&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;12&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=297954" target="_blank"&gt;Pregnancy&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;6&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=297945" target="_blank"&gt;Diagnosis/Classification&lt;/A&gt;&amp;nbsp;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;5&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=297947" target="_blank"&gt;Epidemiology&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;5&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=297953" target="_blank"&gt;Pre-diabetes including metabolic syndrome&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;5&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=297940" target="_blank"&gt;Diabetes and comorbidities&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;4&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=297950" target="_blank"&gt;Genetics&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;4&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=297956" target="_blank"&gt;Psychiatry&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;3&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=297946" target="_blank"&gt;Economics&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;2&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=297957" target="_blank"&gt;Screening&lt;/A&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;2&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=297958" target="_blank"&gt;Type 1 Diabetes and cognitive function&lt;/A&gt; &lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;1&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please &lt;A href="http://www.library.nhs.uk/diabetes/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt; if you have any feedback or comments.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>384883</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=384883]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2008 - Methodology</title>
    <publicationDate>2008-11-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2008 - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial', 'sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal align=left&gt;&lt;EM&gt;&lt;BR&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal align=left&gt;&lt;/SPAN&gt;&lt;/I&gt;&lt;EM&gt;Please return to the annual evidence update introduction page for further information about the scope and methods used and for links to results for other topics.&lt;/EM&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;Return to Diabetes Annual Evidence Update 2008 - Introduction&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P align=left&gt;The Diabetes Specialist Library's annual evidence update consists of the results of extensive literature searches carried out to identify systematic reviews (SR's) relating to diabetes and its treatment.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;Inclusion criteria&lt;BR&gt;&lt;/STRONG&gt;References were included if they were identified as English language SR's and relevant to the subject scope.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Subject scope &lt;BR&gt;&lt;/STRONG&gt;The subject scope reflects that of the diabetes specialist library: covering all types of diabetes mellitus and pre-diabetic conditions, as well as complications of diabetes mellitus and other conditions that are closely related to Diabetes mellitus.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication types&lt;/STRONG&gt;&lt;BR&gt;Material included was limited to Systematic Reviews because of the high volume of published material in the topic area.&lt;BR&gt;Systematic Reviews are regarded as the highest level of evidence to inform clinical practice.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Sources searched&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Medline via NLH Search 2.0&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Embase via NLH Search 2.0&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;The Cochrane Library&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Databse of Abstracts of Reviews of Effects (DARE) via CRD interface&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Diabetes Specialist library&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Search period&lt;BR&gt;&lt;/STRONG&gt;August 2007 – September 2008&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Search strategy&lt;BR&gt;&lt;/STRONG&gt;The sources listed were systematically searched for publications published within the search period using search terms relevant to the subject scope.&lt;BR&gt;Sensitive systematic review search filters were applied to the Medline and Embase searches which were also restricted to exclude animal research.&lt;BR&gt;If you wish to see the full search strategies used please &lt;A href="http://www.library.nhs.uk/diabetes/ContactUs.aspx" target="_blank"&gt;contact the library&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Sifting and selection&lt;BR&gt;&lt;/STRONG&gt;All citations found in the searches were sifted by information specialists, by reading the titles and abstracts to identify those that were definite or potential systematic reviews. This was followed by a sift for subject relevance carried out by the clinical lead. Finally, the remaining titles were once again sifted to include only those that were classified as ‘definite’ systematic reviews. The full text of citations was obtained where this was not evident from the abstract.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Identification of Systematic Reviews&lt;/STRONG&gt;&lt;BR&gt;The criteria for classifying a reference as a definite systematic review was based on:&lt;BR&gt;&lt;BR&gt;NLH Specialist Libraries guidance on identifying systematic reviews1, in combination with the definition of a systematic review from the &lt;A href="http://www.cochrane.org/resources/glossary.htm" target="_blank"&gt;Glossary of Cochrane Collaboration Terms&lt;/A&gt; on the Cochrane Collaboration website2.&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;A reference is classified as a definite systematic review if it contains an explicit statement in the title or abstract where the phrase ‘systematic review’ occurs OR a statement in the title or abstract that a search of one or more source was undertaken. &lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;A systematic review is defined as a review of a clearly formulated question that uses systematic and explicit methods to identify, select, and critically appraise relevant research, and to collect and analyse data from the studies that are included in the review. Statistical methods (meta-analysis) may or may not be used to analyse and summarise the results of the included studies.&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;&lt;BR&gt;Following the removal of duplicates, a total of 1067 potential systematic reviews were retrieved and collated in a reference management database. The search strategy was designed to be sensitive so a large number of the citations retrieved were irrelevant. Following sifting by Information scientists for definite systematic reviews and clinical lead for subject relevance, 172 English language citations were identified as being relevant. &lt;/P&gt;
&lt;P align=right&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;Return to Diabetes Annual Evidence Update 2008 - Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/Page.aspx?pagename=AEU08" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>297952</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=297952]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2008 - Patients</title>
    <publicationDate>2008-11-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,LIVING WITH DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MONITORING / SELF-MONITORING,MONITORING / SELF-MONITORING,RESEARCH,GENERAL,TREATMENT CONCORDANCE,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'patients' from literature searches carried out for the diabetes annual evidence update 2008 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2008 - Patients&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;Please return to the annual evidence update introduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/SPAN&gt;&lt;/I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: right; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=right&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;&lt;FONT color=#800080&gt;&lt;EM&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;Back to Annual Evidence Update introduction page&lt;/A&gt;&lt;/EM&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;A total of 24 systematic reviews concerning 'patients' were identified from the 2008 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient (24)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient &amp;gt; Adherence (3)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Cramer J.A., Benedict A., Muszbek N., Keskinaslan A., and Khan Z.M. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: A review. International Journal of Clinical Practice 62(1), 76-87. 2008. [&lt;A href="http://www3.interscience.wiley.com/journal/119418169/abstract" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Odegard PS and Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educator 33(6), 1014, 29; discussion 1030-1. 2007. [&lt;A href="http://tde.sagepub.com/cgi/content/abstract/33/6/1014" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Wens J, Vermeire E, Hearnshaw H, Lindenmeyer A, Biot Y, and Van Royen P. Educational interventions aiming at improving adherence to treatment recommendations in type 2 diabetes: A sub-analysis of a systematic review of randomised controlled trials. Diabetes Research &amp;amp; Clinical Practice 79(3), 377-88. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17643546" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient &amp;gt; Education (6)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Hawthorne K, Robles Y, Cannings-John R, Edwards A G K.&amp;nbsp; 2008.&amp;nbsp; Culturally appropriate health education for type 2 diabetes mellitus in ethnic minority groups. The Cochrane Library issue 3, 2008. [&lt;A href="http://www.cochrane.org/reviews/en/ab006424.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Loveman E, Frampton G K and Clegg A J. 2008. The clinical effectiveness of diabetes education models for Type 2 diabetes: a systematic review.&amp;nbsp; Health Technology Assessment 2008 vol 12, no. 9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18405469" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Couch R, Jetha M, Dryden DM, Hooten N , Liang Y, Durec T, Sumamo E, Spooner C, Milne A, O'Gorman K, and Klassen TP. Diabetes education for children with type 1 diabetes mellitus and their families. AHRQ Evidence Report/Technology Assessment (166), 1-144. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat1b.chapter.116487" target="_blank"&gt;Full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. O'Brien T and Denham SA. Diabetes care and education in rural regions. Diabetes Educator 34(2), 334-47. 2008. [&lt;A href="http://tde.sagepub.com/cgi/content/full/34/2/334" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Gucciardi E. A systematic review of attrition from diabetes education services: Strategies to improve attrition and retention research. Canadian Journal of Diabetes 32(1), 53-65. 2008. [&lt;A href="http://www.diabetes.ca/files/EGucciardi--MArch112008.pdf" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Khunti K., Camosso-Stefinovic J., Carey M., Davies M.J., and Stone M.A. Educational interventions for migrant South Asians with Type 2 diabetes: A systematic review. Diabetic Medicine 25(8), 985-992. 2008. [&lt;A href="http://www3.interscience.wiley.com/journal/120118943/abstract" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient &amp;gt; Psychological (1)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Duangdao K.M. and Roesch S.C. Coping with diabetes in adulthood: A meta-analysis. Journal of Behavioral Medicine 31(4), 291-300. 2008.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18493847" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Patient &amp;gt; Quality of Life (4)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. El Achhab Y., Nejjari C., Chikri M., and Lyoussi B. Disease-specific health-related quality of life instruments among adults diabetic: A systematic review. Diabetes Research and Clinical Practice 80(2), 171-184. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18279993" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Fisher EB, Thorpe CT, Devellis BM, and Devellis RF. Healthy coping, negative emotions, and diabetes management: a systematic review and appraisal. Diabetes Educator 33(6), 1080, 103; discussion 1104-6. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18057276" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Magwood GS, Zapka J, and Jenkins C. A review of systematic reviews evaluating diabetes interventions: focus on quality of life and disparities. Diabetes Educator 34(2), 242-65. 2008. [&lt;A href="http://tde.sagepub.com/cgi/content/full/34/2/242" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Zhang X, Norris SL, Chowdhury FM, Gregg EW, and Zhang P. The effects of interventions on health-related quality of life among persons with diabetes: a systematic review. Medical Care 45(9), 820-34. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17712252" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient &amp;gt; Monitoring/Self-monitoring (5)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&amp;nbsp; Chetty V.T., Almulla A., Odueyungbo A., and Thabane L. The effect of continuous subcutaneous glucose monitoring (CGMS) versus intermittent whole blood finger-stick glucose monitoring (SBGM) on hemoglobin A1c (HBA1c) levels in Type I diabetic patients: A systematic review. Diabetes Research and Clinical Practice 81(1), 79-87. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18417243" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;&amp;nbsp; Golicki D.T., Golicka D., Groele L., and Pankowska E. Continuous Glucose Monitoring System in children with type 1 diabetes mellitus: A systematic review and meta-analysis. Diabetologia 51(2), 233-240. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18060380" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;&amp;nbsp; McAndrew L, Schneider SH, Burns E, and Leventhal H. Does patient blood glucose monitoring improve diabetes control? A systematic review of the literature. Diabetes Educator 33(6), 991, 1011; discussion 1012-3. 2007. [&lt;A href="http://tde.sagepub.com/cgi/content/full/33/6/991" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;&amp;nbsp; Poolsup N., Suksomboon N., and Jiamsathit W. Systematic review of the benefits of self-monitoring of blood glucose on glycemic control in type 2 diabetes patients. Diabetes Technology and Therapeutics 10(SUPPL. 1), S51-S66. 2008. [&lt;A href="http://www.liebertonline.com/doi/abs/10.1089/dia.2008.0030" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;&amp;nbsp; Towfigh A., Romanova M., Weinreb J.E., Munjas B., Suttorp M.J., Zhou A., and Shekelle P.G. Self-monitoring of blood glucose levels in patients with type 2 diabetes mellitus not taking insulin: A meta-analysis. American Journal of Managed Care 14(7), 468-475. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18611098" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient &amp;gt; Self Management (3)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1. Foster G, Taylor SJC Eldridge SE Ramsay J Griffiths CJ. (4). 2007.&amp;nbsp; Foster G, Taylor SJC, Eldridge SE, Ramsay J, Griffiths CJ. Self-management education programmes by lay leaders for people with chronic conditions. Cochrane Database of Systematic Reviews: Reviews 2007 Issue 4 John Wiley &amp;amp; Sons, Ltd Chichester, UK. [&lt;A href="http://www.cochrane.org/reviews/en/ab005108.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Boren SA, Gunlock TL, Schaefer J, and Albright A. Reducing risks in diabetes self-management: a systematic review of the literature. Diabetes Educator 33(6), 1053, 77; discussion 1078-9. 2007. [&lt;A href="http://tde.sagepub.com/cgi/content/full/33/6/1053" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Hill-Briggs F and Gemmell L. Problem solving in diabetes self-management and control: a systematic review of the literature. Diabetes Educator 33(6), 1032, 50; discussion 1051-2. 2007. [&lt;A href="http://tde.sagepub.com/cgi/content/full/33/6/1032" target="_blank"&gt;full text&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient &amp;gt; Yoga (1)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Innes K.E. and Vincent H.K. The influence of yoga-based programs on risk profiles in adults with type 2 diabetes mellitus: A systematic review. Evidence-based Complementary and Alternative Medicine 5(1). 2008. [&lt;A href="http://ecam.oxfordjournals.org/cgi/content/full/4/4/469" target="_blank"&gt;full text&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient &amp;gt; Health Behaviour Change (1)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Conn VS, Hafdahl AR, Lemaster JW, Ruppar TM, Cochran JE, and Nielsen PJ. Meta-analysis of health behavior change interventions in type 1 diabetes. American Journal of Health Behavior 32(3), 315-29. 2008.&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18067471" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>297953</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=297953]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2008 - Pre-diabetes including metabolic syndrome</title>
    <publicationDate>2008-11-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,PREDIABETIC STATE,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'pre-diabetes including metabolic syndrome' from literature searches carried out for the diabetes annual evidence update 2008 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2008 - Pre-diabetes including metabolic syndrome&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;Please return to the annual evidence update introduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/SPAN&gt;&lt;/I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: right; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=right&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;&lt;FONT color=#800080&gt;&lt;EM&gt;Back to Annual Evidence Update introduction page&lt;/EM&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;
&lt;P&gt;A total of 5 systematic reviews concerning 'pre-diabetes including metabolic syndrome' were identified from the 2008 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Pre-diabetes including metabolic syndrome (5)&lt;BR&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&amp;nbsp; Desilets A.R. , Dhakal-Karki S., and Dunican K.C. Role of metformin for weight management in patients without type 2 diabetes. Annals of Pharmacotherapy 42(6), 817-826. 2008. [&lt;A href="http://www.theannals.com/cgi/content/abstract/aph.1K656v1" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;&amp;nbsp; Freemantle N, Holmes J, Hockey A, and Kumar S. How strong is the association between abdominal obesity and the incidence of type 2 diabetes?. International Journal of Clinical Practice 62(9), 1391-6. 2008. [&lt;A href="http://www3.interscience.wiley.com/journal/120125185/abstract?CRETRY=1&amp;amp;SRETRY=0" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;&amp;nbsp; Gil-Nunez A. The metabolic syndrome and cerebrovascular disease: suspicion and evidence. Cerebrovascular Diseases 24 Suppl 1, 64-75. 2007. [&lt;A href="http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000107380" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4&amp;nbsp;&amp;nbsp; Misra A, Khurana L, Vikram NK, Goel A, and Wasir JS. Metabolic syndrome in children: current issues and South Asian perspective. Nutrition 23(11-12), 895-910. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17936199" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;&amp;nbsp; Xue F and Michels KB. Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. American Journal of Clinical Nutrition 86(3), s823-35. 2007. [&lt;A href="http://www.ajcn.org/cgi/content/abstract/86/3/823S" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>297954</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=297954]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2008 - Pregnancy</title>
    <publicationDate>2008-11-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETES AND PREGNANCY,CONDITION MANAGEMENT,RESEARCH,ANNUAL EVIDENCE UPDATES,GESTATIONAL DIABETES,CAUSES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'pregnancy' from literature searches carried out for the diabetes annual evidence update 2008 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2008 - Pregnancy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;Please return to the annual evidence update introduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/SPAN&gt;&lt;/I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: right; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=right&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;&lt;FONT color=#800080&gt;&lt;EM&gt;Back to Annual Evidence Update introduction page&lt;/EM&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;A total of 6 systematic reviews concerning 'pregnancy' were identified from the 2008 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Pregnancy (6)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&amp;nbsp; Allen VM, Armson BA, Wilson RD, Allen VM, Blight C, Gagnon A, Johnson JA, Langlois S, Summers A, Wyatt P, Farine D, Armson BA, Crane J, Delisle MF , Keenan-Lindsay L, Morin V, Schneider CE, Van Aerde J, and Society of Obstetricians and Gynecologists of Canada. Teratogenicity associated with pre-existing and gestational diabetes. Journal of Obstetrics &amp;amp; Gynaecology Canada: JOGC 29(11), 927-44. 2007. [&lt;A href="http://www.sogc.org/guidelines/documents/guiJOGC200CPG0711.pdf" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;&amp;nbsp; Hillier T.A., Vesco K.K., Pedula K.L., Beil T.L., Whitlock E.P., and Pettitt D.J. Screening for gestational diabetes mellitus: A systematic review for the U.S. preventive services task force. Annals of Internal Medicine 148(10), 766-775. 2008. [&lt;A href="http://www.annals.org/cgi/content/full/148/10/766" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;&amp;nbsp; Moretti M.E., Rezvani M., and Koren G. Safety of glyburide for gestational diabetes: A meta-analysis of pregnancy outcomes. Annals of Pharmacotherapy 42(4), 483-490. 2008. [&lt;A href="http://www.theannals.com/cgi/content/abstract/42/4/483" target="_blank"&gt;abstract]&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;&amp;nbsp; Nicholson WK, Wilson LM, Witkop CT, Baptiste-Roberts K, Bennett WL, Bolen S, Barone BB, Golden SH, Gary TL, Neale DM, and Bass EB. Therapeutic management, delivery, and postpartum risk assessment and screening in gestational diabetes. Evidence Report/Technology Assessment (162), 1-96. 2008. [&lt;A href="http://www.ahrq.gov/downloads/pub/evidence/pdf/gestdiabetes/gestdiab.pdf" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;&amp;nbsp; Tieu Joanna, Crowther Caroline A Middleton Philippa. Dietary advice in pregnancy for preventing gestational diabetes mellitus. Cochrane Issue 2. 2008. [&lt;A href="http://www.cochrane.org/reviews/en/ab006674.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;&amp;nbsp; U.S. Preventive Services Task Force. Screening for gestational diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine 148(10), 759-65. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18490688?dopt=Abstract" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>297955</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=297955]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2008 - Prevention</title>
    <publicationDate>2008-11-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PREVENTION,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'prevention' from literature searches carried out for the diabetes annual evidence update 2008 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2008 - Prevention&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;Please return to the annual evidence update introduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/SPAN&gt;&lt;/I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: right; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=right&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;&lt;FONT color=#800080&gt;&lt;EM&gt;Back to Annual Evidence Update introduction page&lt;/EM&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;BR&gt;&lt;/P&gt;&lt;FONT color=#000000 size=2 face=Arial&gt;
&lt;P&gt;A total of 12 systematic reviews concerning 'prevention' were identified from the 2008 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;November 2008.&amp;nbsp; Please Note: Marketing authorisation has been suspended of Acomplia (rimonabant) as the European Medicines Agency has concluded that the benefits of Acomplia no longer outweigh its risks of psychiatric disorders.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prevention (12)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Bangalore S., Parkar S., Grossman E., and Messerli F.H. A Meta-Analysis of 94,492 Patients With Hypertension Treated With Beta Blockers to Determine the Risk of New-Onset Diabetes Mellitus. American Journal of Cardiology 100(8), 1254-1262. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17920367&amp;amp;dopt=AbstractPlus" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Christensen R, Kristensen P K Bartels E M Bliddal H Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. 370, 1706-1713. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18022033" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Coleman C.I., Reinhart K., Kluger J., and White C.M. The effect of statins on the development of new-onset type 2 diabetes: A meta-analysis of randomized controlled trials. Current Medical Research and Opinion 24(5), 1359-1362. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18384710" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. de Munter JS, Hu FB, Spiegelman D, Franz M, and van Dam RM. Whole grain, bran, and germ intake and risk of type 2 diabetes: a prospective cohort study and systematic review. PLoS Medicine / Public Library of Science 4(8). 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17760498" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Hamer M. and Chida Y. Intake of fruit, vegetables, and antioxidants and risk of type 2 diabetes: Systematic review and meta-analysis. Journal of Hypertension 25 (12), 2361-2369. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17984654" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Leonardo J Orozco, Ana Maria Buchleitner Gabriel Gimenez-Perez Marta Roqué i Figuls Bernd Richter Didac Mauricio.&amp;nbsp; 2008. Exercise or exercise and diet for preventing type 2 diabetes mellitus. The Cochrane Library issue 3, 2008. [&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003054/frame.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Madden SG, Loeb SJ, and Smith CA. An integrative literature review of lifestyle interventions for the prevention of type II diabetes mellitus. Journal of Clinical Nursing 17(17), 2243-56. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18705701" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Priebe MG, van Binsbergen JJ de Vos R Vonk RJ. (1). 2008.&amp;nbsp; Priebe MG, van Binsbergen JJ, de Vos R, Vonk RJ. Whole grain foods for the prevention of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews: Reviews 2008 Issue 1 John Wiley &amp;amp; Sons, Ltd Chichester, UK. [&lt;A href="http://www.cochrane.org/reviews/en/ab006061.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. Salpeter S.R. A systematic review of metformin treatment in persons at risk for diabetes mellitus. Cardiology Review 25(7), 14-18. 2008.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10. Salpeter S.R., Buckley N.S., Kahn J.A., and Salpeter E.E. Meta-analysis: Metformin Treatment in Persons at Risk for Diabetes Mellitus. American Journal of Medicine 121(2), 149-157.e2. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18261504" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;11. Willi C., Bodenmann P., Ghali W.A., Faris P.D., and Cornuz J. Active smoking and the risk of type 2 diabetes: A systematic review and meta-analysis. Journal of the American Medical Association 298(22), 2654-2664. 2007. [&lt;A href="http://jama.ama-assn.org/cgi/content/full/298/22/2654" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;12. Zipitis C.S.&amp;nbsp; and Akobeng A.K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Archives of Disease in Childhood 93(6), 512-517. 2008. [&lt;A href="http://adc.bmj.com/cgi/content/abstract/adc.2007.128579v1" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>297956</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=297956]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2008 - Psychiatry</title>
    <publicationDate>2008-11-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,LIVING WITH DIABETES,RESEARCH,CHRONIC COMORBIDITIES,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'psychiatry' from literature searches carried out for the diabetes annual evidence update 2008 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2008 - Psychiatry&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;Please return to the annual evidence update introduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/SPAN&gt;&lt;/I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: right; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=right&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;&lt;FONT color=#800080&gt;&lt;EM&gt;Back to Annual Evidence Update introduction page&lt;/EM&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;
&lt;P&gt;A total of 3 systematic reviews concerning 'psychiatry' were identified from the 2008 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Psychiatry (3)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&amp;nbsp; Bushe C.J. and Leonard B.E. Blood glucose and schizophrenia: A systematic review of prospective randomized clinical trials. Journal of Clinical Psychiatry 68(11), 1682-1690. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18052561" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;&amp;nbsp; Citrome L.L., Holt R.I.G., Zachry W.M., Clewell J.D., Orth P.A., Karagianis J.L., and Hoffmann V.P. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Annals of Pharmacotherapy 41(10), 1593-1603. 2007. [&lt;A href="http://www.theannals.com/cgi/content/abstract/aph.1K141v1" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;&amp;nbsp; Smith M., Hopkins D., Peveler R.C., Holt R.I.G., Woodward M., and Ismail K. First- V. second-generation antipsychotics and risk for diabetes in schizophrenia: Systematic review and meta-analysis. British Journal of Psychiatry 192(6), 406-411. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18515889" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>297957</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=297957]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2008 - Screening</title>
    <publicationDate>2008-11-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CAUSES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'screening' from literature searches carried out for the diabetes annual evidence update 2008 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2008 - Screening&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;Please return to the annual evidence update introduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/SPAN&gt;&lt;/I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: right; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=right&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;&lt;FONT color=#800080&gt;&lt;EM&gt;Back to Annual Evidence Update introduction page&lt;/EM&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;
&lt;P&gt;A total of 2 systematic reviews concerning 'screening' were identified from the 2008 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Screening (2)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&amp;nbsp; National Coordinating Centre for Health Technology Assessment. Screening for type 2 diabetes: literature review and economic modelling.&amp;nbsp; 146. 2007. [&lt;A href="http://www.hta.ac.uk/execsumm/summ1117.htm" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;&amp;nbsp; Norris S.L., Kansagara D., Bougatsos C., and Fu R. Screening adults for type 2 diabetes: A review of the evidence for the U.S. preventive services task force. Annals of Internal Medicine 148(11), 855-868. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18519931" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>297930</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=297930]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2008 - Treatments</title>
    <publicationDate>2008-11-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MEDICATION,MEDICATION,RESEARCH,NUTRITION AND FOOD,PHYSICAL ACTIVITY,NUTRITION AND FOOD,PHYSICAL ACTIVITY,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'treatments' from literature searches carried out for the diabetes annual evidence update 2008 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2008 - Treatments&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN; mso-bidi-font-size: 12.0pt" lang=EN&gt;Please return to the annual evidence update introduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/SPAN&gt;&lt;/I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: right; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=right&gt;&lt;I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN; mso-bidi-font-size: 12.0pt" lang=EN&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;&lt;FONT color=#800080&gt;Back to Annual Evidence Update introduction page&lt;/FONT&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;A total of 42 systematic reviews concerning 'treatments' were identified from the 2008 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Treatments (42)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Treatments &amp;gt; Glycemic lowering treatment &amp;gt; Medications &amp;gt; Insulin (12)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Bazzano L.A., Lee L.J., Shi L., Reynolds K., Jackson J.A., and Fonseca V. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: A meta-analysis of randomized controlled trials. Diabetic Medicine 25(8), 924-932. 2008. [&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009100340" target="_blank"&gt;Link to DARE abstract here&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Black C, Cummins E, Royle P, Philip S, and Waugh N. The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation. Health Technology Assessment (Winchester, England) 11(33), 1-126. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17767897" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Bradley C and Gilbride CJ. Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine. Diabetes, Obesity &amp;amp; Metabolism 10 Suppl 2, 50-65. 2008. [&lt;A href="http://eprints.rhul.ac.uk/712/" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Dailey G. Developing a pulmonary insulin delivery system for patients with diabetes. Clinical Therapeutics 29(6P), 1271-83. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18046927" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Elrishi M.A. , Jarvis J., Khunti K., and Davies M.J. Insulin glargine and its role in glycaemic management of Type 2 diabetes. Expert Opinion on Drug Metabolism and Toxicology 4(8), 1099-1110. 2008. [&lt;A href="http://www.ingentaconnect.com/content/apl/emt/2008/00000004/00000008/art00007" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Ilag L.L., Kerr L., Malone J.K., and Tan M.H. Prandial Premixed Insulin Analogue Regimens Versus Basal Insulin Analogue Regimens in the Management of Type 2 Diabetes: An Evidence-Based Comparison. Clinical Therapeutics 29(6 PART 1), 1254-1270. 2007. [&lt;A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B6VRS-4R63X2V-3&amp;amp;_user=10&amp;amp;_rdoc=1&amp;amp;_fmt=&amp;amp;_orig=search&amp;amp;_sort=d&amp;amp;view=c&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=10&amp;amp;md5=4f4a9a8050d1711a44ae2cf748276626" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Jeitler K., Horvath K., Berghold A., Gratzer T.W., Neeser K., Pieber T.R., and Siebenhofer A. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: Systematic review and meta-analysis. Diabetologia 51(6), 941-951. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18351320" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Kobeissy A, Zantout MS, and Azar ST. Suggested insulin regimens for patients with type 1 diabetes mellitus who wish to fast during the month of Ramadan. Clinical Therapeutics 30(8), 1408-15. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18803984" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. Monami M, Marchionni N, and Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Research &amp;amp; Clinical Practice 81(2), 184-9. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18495286" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10. Moshe Vardi, Eyal Jacobson Asaph Nini Haim Bitterman.&amp;nbsp; 2008. Intermediate acting versus long acting insulin for type 1 diabetes mellitus.The Cochrane Library.&amp;nbsp; Issue 3, 2008. [&lt;A href="http://www.cochrane.org/reviews/en/ab006297.html" target="_blank"&gt;abstract&lt;/A&gt;] &lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;11. Mullins P., Sharplin P., Yki-Jarvinen H., Riddle M.C., and Haring H.-U. Negative Binomial Meta-Regression Analysis of Combined Glycosylated Hemoglobin and Hypoglycemia Outcomes Across Eleven Phase III and IV Studies of Insulin Glargine Compared with Neutral Protamine Hagedorn Insulin in Type 1 and Type 2 Diabetes Mellitus. Clinical Therapeutics 29(8), 1607-1619. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17919543" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;12. Pickup JC and Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabetic Medicine 25(7), 765-74. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18644063" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Treatments &amp;gt; Glycemic lowering treatment &amp;gt; Medications &amp;gt; Incretins (4)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Elrishi M.A. , Khunti K., Jarvis J., and Davies M.J. The dipeptidyl-peptidase-4 (DPP-4) inhibitors: A new class of oral therapy for patients with type 2 diabetes mellitus. Practical Diabetes International 24(9), 474-482. 2007. [&lt;A href="http://www3.interscience.wiley.com/journal/117355965/abstract" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Pratley RE. Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape journal of medicine 10(7). 2008.&amp;nbsp; [&lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2525460" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Richter B, Bandeira-Echtler E Bergerhoff K Lerch CL. (2). 2008.&amp;nbsp; Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews: Reviews 2008 Issue 2 John Wiley &amp;amp; Sons, Ltd Chichester, UK [&lt;A href="http://www.cochrane.org/reviews/en/ab006739.html" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Zerilli T. and Pyon E.Y. Sitagliptin phosphate: A DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clinical Therapeutics 29(12), 2614-2634. 2007. [&lt;A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B6VRS-4RKMM3V-2&amp;amp;_user=10&amp;amp;_rdoc=1&amp;amp;_fmt=&amp;amp;_orig=search&amp;amp;_sort=d&amp;amp;view=c&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=10&amp;amp;md5=e7d6b51a948834c850ba9546d1bf37bd" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Treatments &amp;gt; Glycemic lowering treatment &amp;gt; Medications &amp;gt; Glitazones (8)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Dahabreh I.J.&amp;nbsp; Meta-analysis of rare events: An update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clinical Trials 5(2), 116-120. 2008. [&lt;A href="http://ctj.sagepub.com/cgi/content/short/5/2/116" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Diamond G.A., Bax L., and Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Annals of Internal Medicine 147(8), 578-581. 2007. [&lt;A href="http://www.annals.org/cgi/content/full/147/8/578" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Doggrell S.A. Does rosiglitazone increase cardiovascular outcomes? Expert Opinion on Pharmacotherapy 8(15), 2665-2669. 2007. [&lt;A href="http://www.ingentaconnect.com/content/apl/eop/2007/00000008/00000015/art00016" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Lago R.M., Singh P.P., and Nesto R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370(9593), 1129-1136. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17905165" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Lincoff A.M. , Wolski K., Nicholls S.J., and Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. Journal of the American Medical Association 298(10), 1180-1188. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17848652" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Monami M, Lamanna C, Marchionni N, and Mannucci E. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 31(7), 1455-60. 2008. [&lt;A href="http://care.diabetesjournals.org/cgi/content/abstract/31/7/1455" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Rizzo M, Christ ER, Rini GB, Spinas GA, and Berneis K. The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?. Expert Opinion on Pharmacotherapy 9(13), 2295-303. 2008. [&lt;A href="http://www.ingentaconnect.com/content/apl/eop/2008/00000009/00000013/art00008?crawler=true" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Singh S., Loke Y.K., and Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. Journal of the American Medical Association 298(10), 1189-1195. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17848653" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Treatments &amp;gt; Glycemic lowering treatment &amp;gt; Medications &amp;gt; Other (11)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;1. Belsey J and Krishnarajah G. Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis. Diabetes, Obesity &amp;amp; Metabolism 10 Suppl 1, 1-7. 2008. [&lt;A href="http://www.ingentaconnect.com/content/bsc/dom/2008/00000010/A00101s1/art00002" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2. Bozkurt O., De Boer A., Grobbee D.E., Heerdink E.R., Burger H., and Klungel O.H. Pharmacogenetics of glucose-lowering drug treatment: A systematic review. Molecular Diagnosis and Therapy 11(5), 291-302. 2007. [&lt;A href="http://www.ingentaconnect.com/content/adis/mdt/2007/00000011/00000005/art00002" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. Eurich D.T., McAlister F.A., Blackburn D.F., Majumdar S.R. , Tsuyuki R.T., Varney J., and Johnson J.A. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: Systematic review. British Medical Journal 335(7618), 497-501. 2007. [&lt;A href="http://www.bmj.com/cgi/content/full/335/7618/497" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4. Johansen O.E. and Birkeland K.I. Defining the role of repaglinide in the management of type 2 diabetes mellitus: A review. American Journal of Cardiovascular Drugs 7(5), 319-335. 2007. [&lt;A href="http://www.ingentaconnect.com/content/adis/acv/2007/00000007/00000005/art00002" target="_blank"&gt;abstract]&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Krentz A.J. Management of type 2 diabetes in the obese patient: Current concerns and emerging therapies. Current Medical Research and Opinion 24(2), 401-417. 2008. [&lt;A href="http://www.ingentaconnect.com/content/libra/cmro/2008/00000024/00000002/art00011?token=00481232376b34272c5f7b3d6d3f4e4b34496e586546244044423847655d236b6c5f6a2c" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6. Leach M.J. Gymnema sylvestre for diabetes mellitus: A systematic review. Journal of Alternative and Complementary Medicine 13(9), 977-983. 2007. [&lt;A href="http://www.liebertonline.com/doi/abs/10.1089/acm.2006.6387" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;7. Monami M, Lamanna C, Marchionni N, and Mannucci E. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. Diabetes Research &amp;amp; Clinical Practice 79(2), 196-203. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17931733/" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;8. Mukai J, Tada H, Watanabe Y, Miura M,&amp;nbsp; Katsuyama S, Shoji T, Mouri K, Eto M, and Suzuki T. Lipids behavior and adverse effects for oral antidiabetic agents in patients with Type 2 diabetes treated with sulfonylureas alone based on systematic review. Yakugaku Zasshi - Journal of the Pharmaceutical Society of Japan 127(10), 1747-56. 2007. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17917433" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9. ten Brinke R , Dekker N, de Groot M, and Ikkersheim D. Lowering HbA1c in type 2 diabetics results in reduced risk of coronary heart disease and all-cause mortality. Primary care diabetes 2(1), 45-9. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18684420" target="_blank"&gt;abstract&lt;/A&gt;] &lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;10. Wang E and Wylie-Rosett J. Review of selected Chinese herbal medicines in the treatment of type 2 diabetes. Diabetes Educator 34(4), 645-54. 2008. [&lt;A href="http://tde.sagepub.com/cgi/content/abstract/34/4/645" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;11. Wang MY, Tsai PS, Chou KR, and Chen CM. A systematic review of the efficacy of non-pharmacological treatments for depression on glycaemic control in type 2 diabetics. Journal of Clinical Nursing 17(19), 2524-30. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;amp;Cmd=ShowDetailView&amp;amp;TermToSearch=17848653" target="_blank"&gt;abstract&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Treatments &amp;gt; Glycemic lowering treatment &amp;gt; Diet / Exercise (6)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&amp;nbsp; Kavookjian J, Elswick BM, and Whetsel T. Interventions for being active among individuals with diabetes: a systematic review of the literature. Diabetes Educator 33(6), 962, 88; discussion 989-90. 2007. [&lt;A href="http://tde.sagepub.com/cgi/content/abstract/33/6/962" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;&amp;nbsp; Kirk, A. F., Barnett, J., and Mutrie, N. 2008.&amp;nbsp; Physical activity consultation for people with Type 2 diabetes.&amp;nbsp; Evidence and guidelines.&amp;nbsp; Diabetic Medicine 24(8), 809-816. 2008.&amp;nbsp; [&lt;A href="http://www3.interscience.wiley.com/journal/117978121/abstract" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;&amp;nbsp; Kirk JK, Graves DE, Craven TE, Lipkin EW, Austin M, and Margolis KL. Restricted-carbohydrate diets in patients with type 2 diabetes: a meta-analysis. Journal of the American Dietetic Association 108(1), 91-100. 2008. [&lt;A href="http://www.adajournal.org/article/S0002-8223(07)01928-1/abstract" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;&amp;nbsp; Livesey G., Taylor R., Hulshof T., and Howlett J. Glycemic response and health - A systematic review and meta-analysis: Relations between dietary glycemic properties and health outcomes. American Journal of Clinical Nutrition 87(1), 258S-268S. 2008. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18175762" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;&amp;nbsp; Povey RC and Clark-Carter D. Diabetes and healthy eating: a systematic review of the literature. Diabetes Educator 33(6), 931, 59; discussion 960-1 . 2007. [&lt;A href="http://tde.sagepub.com/cgi/content/abstract/33/6/931" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;&amp;nbsp; Zhang L.-Y. and Yin C.-C. New development of exercise therapy for type 2 diabetes. Journal of Clinical Rehabilitative Tissue Engineering Research 11(45), 9201-9203. 2007. [&lt;A href="http://adc.bmj.com/cgi/content/extract/92/11/1015" target="_blank"&gt;extract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Treatments &amp;gt; Immunotherapy (1)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Gandhi G.Y.; Murad M.H.; Flynn D.N.; Elamin M.B.; Erwin P.J.; Montori V.M., and Kudva Y.C. Immunotherapeutic agents in type 1 diabetes: A systematic review and meta-analysis of randomized trials. 2008; 69, (2): 244-252. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18194488" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>297958</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=297958]]&gt;</url>
    <title>Diabetes Annual Evidence Update 2008 – Type 1 Diabetes and cognitive function</title>
    <publicationDate>2008-11-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,PSYCHOLOGICAL PROBLEMS,CHRONIC COMPLICATIONS,RESEARCH,ANNUAL EVIDENCE UPDATES,COGNITIVE FUNCTION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The citations retrieved and selected concerning 'type 1 diabetes and cognitive function' from literature searches carried out for the diabetes annual evidence update 2008 are listed here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes Annual Evidence Update 2008 – Type 1 Diabetes and cognitive function&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;Please return to the annual evidence update introduction page for further information about the scope and methods used&amp;nbsp;and for links to results&amp;nbsp;for other topics.&lt;/SPAN&gt;&lt;/I&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: right; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=right&gt;&lt;SPAN style="FONT-SIZE: 10pt; mso-ansi-language: EN" lang=EN&gt;&lt;o:p&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-bidi-font-size: 12.0pt; mso-ansi-language: EN" lang=EN&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=386852" target="_blank"&gt;&lt;FONT color=#800080&gt;&lt;EM&gt;Back to Annual Evidence Update introduction page&lt;/EM&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 10pt; mso-fareast-language: EN-GB; mso-ansi-language: EN" lang=EN&gt;
&lt;P&gt;A total of 1 systematic reviews concerning 'Type 1 Diabetes and cognitive function' were identified from the 2008 Diabetes Annual Evidence Update. The citations are listed here with links to the abstracts or full text reference where available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note that critical appraisal of these reviews has not been carried out and their inclusion does not imply endorsement by the Diabetes Specialist Library.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Type 1 Diabetes and coginitive function (1)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Gaudieri PA; Chen R; Greer TF, and Holmes CS. Cognitive function in children with type 1 diabetes: a meta-analysis. 2008; 31, (9): 1892-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18753668" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>293272</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.yhpho.org.uk/resource/view.aspx?RID=9949]]&gt;</url>
    <title>Diabetes Area Classification for PCTs</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Yorkshire and Humber Public Health Observatory (YHPHO)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ SHARING PRACTICE,DIABETES,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;YHPHO has developed a Diabetes Area Classification for primary Care Trusts.&amp;nbsp; This is a grouping of all PCTs in England based on the main risk factors for diabetes.&amp;nbsp; It allows PCTs to compare and benchmark diabetes services against a group of PCTs that have similar diabetes related characteristics.&amp;nbsp; It also identifies PCTs who may be tackling the same issues and be facing similar challenges.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Also see the "&lt;A href="http://www.yhpho.org.uk/resource/item.aspx?RID=10143" target="_blank"&gt;Where are we now? Diabetes Area Classification Comparison 2009&lt;/A&gt;" tool, which provides PCT level data on a number of diabetes indicators and allows benchmarking against the Diabetes Area Classification.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>224072</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetesaustralia.com.au/en/Resources/Multilingual/]]&gt;</url>
    <title>Diabetes Australia multilingual resource</title>
    <publicationDate>2008-05-16T00:00:00</publicationDate>
    <publisher>Diabetes Australia</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ GENERAL,PEOPLE FROM ETHNIC MINORITIES,NUTRITION AND FOOD,PHYSICAL ACTIVITY,NUTRITION AND FOOD,PHYSICAL ACTIVITY,EYE DISEASES,ALCOHOL,MEDICATION,PEOPLE FROM ETHNIC MINORITIES,MEDICATION,CONDITION MANAGEMENT,TYPE 1,DIABETES,CONDITION MANAGEMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,CARDIOVASCULAR,KETOACIDOSIS,SEXUAL DYSFUNCTION,LIVING WITH DIABETES,DIABETES AND PREGNANCY,TYPE 2,DIABETIC FOOT,PAINFUL NEUROPATHIES,NEPHROPATHY,RETINOPATHY,ACUTE COMPLICATIONS,DRIVING,CHRONIC COMPLICATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This website contains patient information about diabetes in several different languages. &lt;/P&gt;
&lt;P&gt;Please note that&amp;nbsp;the information from this resource reflects Australian based population data. UK based patient information in different languages is also available from &lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=191099&amp;amp;tabID=292&amp;amp;catID=8197" target="_blank"&gt;Diabetes UK&lt;/A&gt; and &lt;A href="http://www.nhs.uk/Pages/homepage.aspx" target="_blank"&gt;NHS Choices&lt;/A&gt;, however this resource contains information in&amp;nbsp;some languages not available from Diabetes UK and NHS direct including Croatian, Greek, Italian, Turkish, Mandarin, Thai and Vietnamese.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>156650</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Professionals/Conferences_and_events/Teaching_aids/Diabetes_awareness_toolkit/]]&gt;</url>
    <title>Diabetes awareness toolkit</title>
    <publicationDate>2005-09-05T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,PEOPLE FROM ETHNIC MINORITIES,PEOPLE FROM ETHNIC MINORITIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the Diabetes UK website provides a toolkit, which includes speaker's notes and slides, designed to assist key workers in holding diabetes awareness days and helping people to understand diabetes and complications involved. The toolkit is specifically aimed at raising awareness in people from diverse and black and ethnic communities.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307377</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/]]&gt;</url>
    <title>Diabetes Care</title>
    <publicationDate></publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ JOURNALS,DIABETES,RESEARCH]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Diabetes Care is an official journal of the American Diabetes Association. Sign up for an &lt;A href="http://care.diabetesjournals.org/cgi/alerts" target="_blank"&gt;email alert&lt;/A&gt; of this journal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;NHS staff: see this journal via the NHS Evidence&amp;nbsp;&lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; page, where (if you log in with your Athens password) you can search for full text, recieve a table of contents alert via Zetoc, locate items in your local library and create search alerts.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; NHS staff in England: full access available &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/Default.aspx" target="_blank"&gt;via NHS Evidence&lt;/A&gt;, other NHS staff: check with your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;General public: Free full text (html) available 3 months after publication, PDFs available 6 months after publication without subcription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311358</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.yhpho.org.uk/diabetesprofiles.aspx]]&gt;</url>
    <title>Diabetes Community Health Profiles</title>
    <publicationDate></publicationDate>
    <publisher>Yorkshire and Humber Public Health Observatory (YHPHO)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF,STATISTICS,INCIDENCE AND PREVALENCE,RISK AND FUTURE PROJECTIONS,DATA GATHERING AND AUDIT AND QOF,COST / ECONOMIC DATA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Diabetes Community Health Profiles&amp;nbsp;bring together a range of data on diabetes and related health issues and diabetes services. A Diabetes Community Health Profile Overview is available for every PCT in England, providing an overview of the key areas of diabetes care (such as prevalence of diabetes, spending on diabetes care, predictive factors for diabetes),&amp;nbsp;and highlighting issues for further investigation. It can be used to benchmark against other PCTs and provides a starting point for needs assessment work. 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/PAGEBODY&gt;&lt;/PAGE&gt;&lt;/ARTICLE&gt;]]&gt;</body>
  </document>
  <document>
    <id>276979</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://yhpho.york.ac.uk/diabetesdd/introddd.asp]]&gt;</url>
    <title>Diabetes data directory</title>
    <publicationDate></publicationDate>
    <publisher>Yorkshire and Humber Public Health Observatory (YHPHO), National Diabetes Support Team (NDST)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF,STATISTICS,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This directory outlines the&amp;nbsp;the range of datasets and tools that are available to support key diabetes professionals in their decision making. &lt;/P&gt;
&lt;P&gt;The aim of the Diabetes Data Directory is to allow improved access and understanding&amp;nbsp;by: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;providing a brief description of the various tools/datasets 
&lt;LI&gt;confirming how these tools can be accessed by linking directly to relevant websites 
&lt;LI&gt;signposting to the various tools/datasets that will provide answers to key headline questions&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published September 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307381</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetesdigestjournal.co.uk/]]&gt;</url>
    <title>Diabetes Digest</title>
    <publicationDate></publicationDate>
    <publisher>Diabetes Digest</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The website includes information on the journal Diabetes Digest, and has links to other diabetes journals.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full access online requires subscription to the journal. NHS staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library &lt;/A&gt;for further assistance.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60160</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/index2.php?option=com_docman&amp;task=doc_view&amp;gid=183&amp;Itemid=61]]&gt;</url>
    <title>Diabetes education and cost control: time to measure (teaching letter no.23)</title>
    <publicationDate>2001-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,DATA GATHERING AND AUDIT AND QOF,COMMISSIONING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the cost-effectiveness of patient education in the field of diabetes and covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Key points 
&lt;LI&gt;Evaluation of efficacy 
&lt;LI&gt;Evaluation of cost 
&lt;LI&gt;Evaluation of efficiency 
&lt;LI&gt;Evaluation of cost-effectiveness 
&lt;LI&gt;Applying these principles to diabetes education 
&lt;LI&gt;Final remarks 
&lt;LI&gt;Further reading&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>258927</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.idf.org/home/index.cfm?node=1554]]&gt;</url>
    <title>Diabetes education modules</title>
    <publicationDate></publicationDate>
    <publisher>International Diabetes Federation (IDF)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ CPD AND PROFESSIONAL EDUCATION,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The education modules available on this page of the IDF website&amp;nbsp;supplement the &lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resID=258926" target="_blank"&gt;International curriculum for diabetes health professional education&lt;/A&gt;&amp;nbsp; and include sections on: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;pathophysiology and classification of diabetes 
&lt;LI&gt;psychological issues and behavioural change 
&lt;LI&gt;nutritional issues 
&lt;LI&gt;physical activity 
&lt;LI&gt;self-management. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The supporting material presented in this package is divided into five sections. A sixth section provides information on group work and case studies to assist course providers in the consistent and appropriate delivery of the information. &lt;/P&gt;
&lt;P&gt;Course facilitators will need to undertake some preliminary work to ensure that they are familiar with the content, and, where relevant, adapt it to meet local needs. A&amp;nbsp;leaflet containing&amp;nbsp;tips and recommendations on how to prepare a course, on how to view and print the slides, and to view sample programmes is provided. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published December 2006&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Microsoft Powerpoint (PPT) files &amp;amp; Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293262</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes-education.net/]]&gt;</url>
    <title>Diabetes Education Network</title>
    <publicationDate>2003-01-01T00:00:00</publicationDate>
    <publisher>The Diabetes Education Network</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Diabetes Education Network started in 2003 as the Type 1 Education Network. It is a national network of diabetes health professionals from all parts of the UK who are committed to developing and delivering structured education programmes for people with type 1 and type 2 diabetes.&lt;/P&gt;
&lt;P&gt;This website provides details of all the activities to date and future work programme, together with resources to help diabetes teams across the UK provide high quality self-management education for their patients. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307384</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://tde.sagepub.com/]]&gt;</url>
    <title>Diabetes Educator</title>
    <publicationDate></publicationDate>
    <publisher>Diabetes Educator</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Diabetes Educator (TDE) is the official journal of the American Association of Di&amp;shy;abetes Educators (AADE). It is a peer-reviewed journal intended to serve as a reference source for the science and art of diabetes management. &lt;BR&gt;&lt;BR&gt;Sign up for an &lt;A href="http://www.sagepub.com/emailAlerts.sp" target="_blank"&gt;email alert&lt;/A&gt; of this journal.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full access online requires subscription to the journal. NHS staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library &lt;/A&gt;for further assistance.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317294</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19470990?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Diabetes in Asia: epidemiology, risk factors and pathophysiology</title>
    <publicationDate>2009-05-27T00:00:00</publicationDate>
    <publisher>Journal of the American Medical Association</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,STATISTICS,INCIDENCE AND PREVALENCE,RISK AND FUTURE PROJECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Narrative literature review with systematic search of medline from January 1980 to March 2009. Meta-analysis, systematic reviews, large surveys and cohort studies were included and the evidence was sythesised.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; This is a review which quotes 46 studies. Their evidence synthesis summary states that the prevalence of diabetes in Asian populations has increased rapidly in recent decades. In 2007, more than 110 million people in Asia were living with diabetes. with a disproportionate burden among the young and middle aged. Similarly, rates of obesity are increasing sharply driven by economic development, nutritional transition, and increasingly sedentary lifestyle. The metabolically obese phenotype (normal body weight with increased abdominal adiposity) is common in Asian populations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access NHS staff in England: available via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;NHS Evidence&lt;/A&gt;.&lt;BR&gt;Other NHS Staff please&amp;nbsp;check with&amp;nbsp;your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library &lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>300742</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.yhpho.org.uk/resource/view.aspx?RID=10113]]&gt;</url>
    <title>Diabetes in England</title>
    <publicationDate>2008-12-08T00:00:00</publicationDate>
    <publisher>Yorkshire and Humber Public Health Observatory (YHPHO), National Diabetes Support Team (NDST)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ COMMISSIONING,RISK AND FUTURE PROJECTIONS,INCIDENCE AND PREVALENCE,COST / ECONOMIC DATA,DATA GATHERING AND AUDIT AND QOF,STATISTICS,DELIVERY OF CARE,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document from the Yorkshire and Humber Public Health Observatory (YHPHO) and the National Diabetes Support Team (NDST) summarises the key facts concerning Diabetes in England. It is written for general public use and is not intended as a systematic review of the evidence base on diabetes. &lt;BR&gt;&lt;BR&gt;The document attempts to answer the following questions: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Children and Young People 
&lt;LI&gt;How common is diabetes in England? 
&lt;LI&gt;What is the health burden of diabetes? 
&lt;LI&gt;What is the cost of diabetes? 
&lt;LI&gt;Who is at risk of developing diabetes? 
&lt;LI&gt;What are the increased risks of complications in people with diabetes? 
&lt;LI&gt;What is being done?&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history:&lt;/STRONG&gt; published Nov 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386460</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://eng.mapofmedicine.com/evidence/map/diabetes_in_pregnancy1.html]]&gt;</url>
    <title>Diabetes in pregnancy</title>
    <publicationDate>2010-01-28T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETES AND PREGNANCY,CONDITION MANAGEMENT,PRECONCEPTION CARE,GESTATIONAL DIABETES,CAUSES,DIAGNOSIS,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Map of Medicine care pathway</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt; To provide overview care pathways for the management of diabetes in pregnancy, including the diagnosis and management of gestational diabetes and&amp;nbsp;preconception, postnatal and neonatal care.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; The Map of Medicine is a visual representation of evidence-based, practice-informed care pathways. It is designed for use by healthcare professionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; NHS staff in England: England national level pathways are freely available. You can also log on to the Map of Medicine using NHS Athens to gain access to the locally-adapted pathways.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>250782</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.cemach.org.uk/getattachment/07707df7-9b29-4e2b-b1cf-5de2f9715af2/Diabetes-in-Pregnancy---Are-we-providing-the-b-(1).aspx]]&gt;</url>
    <title>Diabetes in pregnancy: are we providing the best care? Findings of a National Enquiry: England, Wales and Northern Ireland.</title>
    <publicationDate>2007-02-01T00:00:00</publicationDate>
    <publisher>Confidential Enquiry into Maternal and Child Health (CEMACH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETES AND PREGNANCY,DELIVERY OF CARE,WOMEN'S HEALTH,ORGANISATION OF CARE / CARE PLANNING,CONDITION MANAGEMENT,COMPLICATED PREGNANCY,ANTENATAL PROBLEMS,CO-EXISTING DISEASE,DIABETES,PRECONCEPTION CARE,DATA GATHERING AND AUDIT AND QOF,STATISTICS,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Findings of a National Enquiry: England, Wales and Northern Ireland.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This Confidential Enquiry into Maternal and Child Health (CEMACH) report concerning the impact of clinical care on pregnancy outcome for women with pre-gestational diabetes, describes the findings from the&amp;nbsp;third study in CEMACH’s diabetes programme of work (see below). &lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please also see the post project review report&amp;nbsp;(&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=373582" target="_blank"&gt;link to record here&lt;/A&gt;).&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published February 2007.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CEMACH’s diabetes programme of work&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;The Confidential Enquiry into Maternal and Child Health (CEMACH) initiated a national enquiry programme aimed at improving the quality of maternity care and pregnancy outcomes for women with pre-gestational diabetes in England, Wales and Northern Ireland. This programme of work comprises three linked studies:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;A survey of maternity services for women with type 1 and type 2 diabetes in 2002.&amp;nbsp;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resID=82798" target="_blank"&gt;(Link to the record here)&lt;BR&gt;&lt;/A&gt;&amp;nbsp; 
&lt;LI&gt;A descriptive study on all pregnancies of women with pre-gestational diabetes who delivered or booked between 1 March 2002 and 28 February 2003, with follow up to pregnancy outcome at 28 days after delivery. This study included an audit of standards of care for women with pre-gestational diabetes. (&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resID=104777" target="_blank"&gt;Link to the record here&lt;/A&gt;)&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;A confidential enquiry, consisting of multidisciplinary panel case reviews. This comprises a case–control study into the impact of clinical care on pregnancy outcome and an audit of care during and after pregnancy, for women with pre-gestational diabetes. published in February 2007. (this report)&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>275945</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.cemach.org.uk/getattachment/521f7abe-7fa4-461e-a7c7-16a91a9ac9b2/Diabetes-in-Pregnancy--Caring-for-the-baby-after-b.aspx]]&gt;</url>
    <title>Diabetes in pregnancy: caring for the baby after birth - Findings of a national enquiry</title>
    <publicationDate>2007-09-30T00:00:00</publicationDate>
    <publisher>Confidential Enquiry into Maternal and Child Health (CEMACH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETES AND PREGNANCY,WOMEN'S HEALTH,CONDITION MANAGEMENT,COMPLICATED PREGNANCY,ANTENATAL PROBLEMS,CO-EXISTING DISEASE,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Confidential Enquiry into Maternal and Child Health
Findings of a national enquiry</description>
    <body>&lt;![CDATA[ &lt;P&gt;This Confidential Enquiry into Maternal and Child Health (CEMACH) report concerning caring for babies born to mothers with diabetes describes the findings from the&amp;nbsp;fourth study in CEMACH’s diabetes programme of work (see below). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published September 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;CEMACH’s diabetes programme of work&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;The Confidential Enquiry into Maternal and Child Health (CEMACH) initiated a national enquiry programme aimed at improving the quality of maternity care and pregnancy outcomes for women with pre-gestational diabetes in England, Wales and Northern Ireland. This programme of work comprises three linked studies:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;A survey of maternity services for women with type 1 and type 2 diabetes in 2002.&amp;nbsp;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resID=82798" target="_blank"&gt;(Link to the record here)&lt;BR&gt;&lt;/A&gt;&amp;nbsp; 
&lt;LI&gt;A descriptive study on all pregnancies of women with pre-gestational diabetes who delivered or booked between 1 March 2002 and 28 February 2003, with follow up to pregnancy outcome at 28 days after delivery. This study included an audit of standards of care for women with pre-gestational diabetes. (&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resID=104777" target="_blank"&gt;Link to the record here&lt;/A&gt;)&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;A confidential enquiry, consisting of multidisciplinary panel case reviews. This comprises a case–control study into the impact of clinical care on pregnancy outcome and an audit of care during and after pregnancy, for women with pre-gestational diabetes. published in February 2007. (&lt;A href="http://www.cemach.org.uk/getattachment/ce7b601d-9a14-443e-982c-bcda4fd92ca3/Diabetes-in-Pregnancy.aspx" target="_blank"&gt;Link to the record here&lt;/A&gt;)&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.cemach.org.uk/getattachment/2c4f069c-f293-4b4f-a800-6abccf4c0661/Diabetes-in-Pregnancy.aspx" target="_blank"&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>269674</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=318]]&gt;</url>
    <title>Diabetes in the NHS : commissioning and providing specialist services</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ OBESITY,OUTCOMES,BIOLOGICAL COMPOSITION,ENDOCRINE DISORDERS,DIABETES,POPULATION BASED &amp; PREVENTATIVE SERVICES,SERVICE PROVISION,ENDOCRINE,DISEASE/CONDITION GROUPS,TYPES OF COMMISSIONING,COMMISSIONING,SERVICE SECTORS,PRIMARY CARE SERVICES,ACUTE SERVICES,COMMISSIONING,NHS ACTIVITIES,SERVICE DELIVERY,DIABETES,ORGANISATION OF CARE / CARE PLANNING,DELIVERY OF CARE,HEALTH MANAGEMENT,DETERMINANTS,COMMISSIONING,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,MANAGEMENT &amp; POLICY,SERVICES,MANAGEMENT,SPECIALIST AND TERTIARY CARE,SPECIALIST COMMISSIONING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This booklet provides details of the improved pathways that can be designed for people with diabetes, the governance issues that can be addressed by PCTs and the money that can be saved by acute trusts and commissioners, if the expertise of consultant diabetologists and the teams they work with is used to the full.&lt;/P&gt;
&lt;P&gt;This booklet was written and reviewed by approximately 75 consultants in Diabetes working in England. These individuals have been actively involved in the Specialist Service Liaison Group, in a survey, ‘Diabetes and Diabetologists: A survey of the roles, responsibilities, working practices and job satisfaction of Consultant Diabetologists in England’, or attended one of three Diabetes Development Programmes commissioned by the Specialist Services Liaison Group (SSLG) in partnership with the National Diabetes Support Team and the King’s Fund.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in September 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>260493</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=229]]&gt;</url>
    <title>Diabetes information listening exercise 2007</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT,DELIVERY OF CARE,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This National Diabetes Support Team (now NHS Diabetes)&amp;nbsp;document provides a summary of the results of a survey on how diabetes information is used by the diabetes community.&lt;/P&gt;
&lt;P&gt;The aim of the exercise was to provide an opportunity for healthcare professionals to review the available information and provide feedback, both on the usefulness of current information and what more could be provided. This will be used&amp;nbsp;to inform a&amp;nbsp;planned review of of what information is required to support effective service delivery and meet the NSF standards.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published&amp;nbsp;March 2007.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>61031</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4083867.pdf]]&gt;</url>
    <title>Diabetes information strategy</title>
    <publicationDate>2003-01-01T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DELIVERY OF CARE,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,DIABETES,INFORMATICS,NATIONAL SERVICE FRAMEWORKS,POLICY,NHS ACTIVITIES,HEALTH MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The National Service Framework (NSF) for Diabetes sets out a ten-year programme to improve services for people with and at risk of diabetes. This Diabetes Information Strategy is intended to provide the information infrastructure, systems and services required to deliver these improved services. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published January 2003&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>112988</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band136/b136-3.html]]&gt;</url>
    <title>Diabetes management</title>
    <publicationDate></publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,CONDITION MANAGEMENT,MEDICATION,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier&amp;nbsp;article describes and reviews evidence (3 papers)&amp;nbsp;about&amp;nbsp;interventions aimed at helping people with type 2 diabetes achieve better control and better quality of life. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Review published&amp;nbsp;June 2005.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381756</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20609967]]&gt;</url>
    <title>Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>Lancet</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CAUSES,MEDICATION,MEDICATION,TYPE 2,TYPE 1,DIABETES,CONDITION MANAGEMENT,CONDITION MANAGEMENT,CARDIOVASCULAR,CHRONIC COMPLICATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims: &lt;BR&gt;&lt;/STRONG&gt;Taken from PubMed abstract&lt;BR&gt;"Uncertainties persist about the magnitude of associations of diabetes mellitus and fasting glucose concentration with risk of coronary heart disease and major stroke subtypes. We aimed to quantify these associations for a wide range of circumstances."&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed abstract&lt;BR&gt;"We undertook a meta-analysis of individual records of diabetes, fasting blood glucose concentration, and other risk factors in people without initial vascular disease from studies in the Emerging Risk Factors Collaboration. We combined within-study regressions that were adjusted for age, sex, smoking, systolic blood pressure, and body-mass index to calculate hazard ratios (HRs) for vascular disease."&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed abstract&lt;BR&gt;"Analyses included data for 698 782 people (52 765 non-fatal or fatal vascular outcomes; 8.49 million person-years at risk) from 102 prospective studies. Adjusted HRs with diabetes were: 2.00 (95% CI 1.83-2.19) for coronary heart disease; 2.27 (1.95-2.65) for ischaemic stroke; 1.56 (1.19-2.05) for haemorrhagic stroke; 1.84 (1.59-2.13) for unclassified stroke; and 1.73 (1.51-1.98) for the aggregate of other vascular deaths. HRs did not change appreciably after further adjustment for lipid, inflammatory, or renal markers. HRs for coronary heart disease were higher in women than in men, at 40-59 years than at 70 years and older, and with fatal than with non-fatal disease. At an adult population-wide prevalence of 10%, diabetes was estimated to account for 11% (10-12%) of vascular deaths. Fasting blood glucose concentration was non-linearly related to vascular risk, with no significant associations between 3.90 mmol/L and 5.59 mmol/L. Compared with fasting blood glucose concentrations of 3.90-5.59 mmol/L, HRs for coronary heart disease were: 1.07 (0.97-1.18) for lower than 3.90 mmol/L; 1.11 (1.04-1.18) for 5.60-6.09 mmol/L; and 1.17 (1.08-1.26) for 6.10-6.99 mmol/L. In people without a history of diabetes, information about fasting blood glucose concentration or impaired fasting glucose status did not significantly improve metrics of vascular disease prediction when added to information about several conventional risk factors."&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Conclusions: &lt;BR&gt;&lt;/STRONG&gt;Taken from PubMed abstract&lt;BR&gt;"Diabetes confers about a two-fold excess risk for a wide range of vascular diseases, independently from other conventional risk factors. In people without diabetes, fasting blood glucose concentration is modestly and non-linearly associated with risk of vascular disease."&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S,et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 26 Jun 2010;375(9733):2215-22.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in June 2010.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full-text of this article online requires subscription to the&amp;nbsp;journal. NHS staff please&amp;nbsp;contact&amp;nbsp; &lt;A href="http://www.hlisd.org/" target="_blank"&gt;your local NHS library&lt;/A&gt;&amp;nbsp;for further assistance.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>154855</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=310]]&gt;</url>
    <title>Diabetes network self assessment tool</title>
    <publicationDate>2006-07-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This self assessment tool has been developed by the NDST to assist diabetes networks understand their current stage of development and increase their effectiveness.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published Jun&amp;nbsp;2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>389278</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetesresearchclinicalpractice.com/]]&gt;</url>
    <title>Diabetes Research and Clinical Practice</title>
    <publicationDate></publicationDate>
    <publisher>Diabetes research and clinical practice</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Diabetes research and clinical practice is the official journal of the International Diabetes Federation (IDF).The website includes information about the journal, guidelines for authors and access to tables of content.&lt;/P&gt;
&lt;P&gt;Access: Full access online requires subscription to the journal. NHS staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt; for further assistance.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>105844</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcn.org.uk/development/practice/diabetes/complications]]&gt;</url>
    <title>Diabetes resource : complications</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Royal College of Nursing</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,NEPHROPATHY,RETINOPATHY,DIABETIC FOOT,PAINFUL NEUROPATHIES,SKIN PROBLEMS,CARDIOVASCULAR,CHRONIC COMPLICATIONS,DENTAL PROBLEMS,CAUSES,CAUSES,CAUSES,PREVENTION,AUTONOMIC NEUROPATHY,CAUSES,CAUSES,PREVENTION,EYE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the RCN's diabetes resource starts to highlight areas of associated symptoms that individuals with diabetes may experience or need treatment and care for. There are further links to the sub-sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Complication Risks 
&lt;LI&gt;Resources&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The RCN's diabetes resource offers guidance and help to nurses, people with diabetes, their families and carers.&amp;nbsp; The aim is to improve care for people with diabetes and reduce variations in clinical practice.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The information presented in this resource:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Highlights key issues and current topics. 
&lt;LI&gt;Directs you to policy, national guidelines and other evidence based resources across the four UK countries. 
&lt;LI&gt;Provides examples of how evidence has been incorporated into care. 
&lt;LI&gt;Signposts other key organisations and support services. 
&lt;LI&gt;The structure of the resource enables you to focus easily on a particular aspect of diabetes care or a particular area of practice. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Launched October 2005.&amp;nbsp; Updated November 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>105848</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcn.org.uk/development/practice/diabetes/diagnosis]]&gt;</url>
    <title>Diabetes resource : diagnosis</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Royal College of Nursing</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIAGNOSIS,GESTATIONAL DIABETES,DIABETES,TYPE 2,TYPE 1,DIAGNOSIS,DIAGNOSIS,CAUSES,OTHER TYPES OF DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Diabetes resource : diagnosis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;This section of the&amp;nbsp;RCN's diabetes resource&amp;nbsp;looks at what diabetes is and the different types of diabetes. It presents information on the risk factors for diabetes and identification of Type 2 diabetes.&lt;/P&gt;
&lt;P&gt;The RCN's diabetes resource offers guidance and help to nurses, people with diabetes, their families and carers.&amp;nbsp; The aim is to improve care for people with diabetes and reduce variations in clinical practice. &lt;/P&gt;
&lt;P&gt;The information presented in this resource:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Highlights key issues and current topics. 
&lt;LI&gt;Directs you to policy, national guidelines and other evidence based resources across the four UK countries. 
&lt;LI&gt;Provides examples of how evidence has been incorporated into care. 
&lt;LI&gt;Signposts other key organisations and support services. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The structure of the resource enables you to focus easily on a particular aspect of diabetes care or a particular area of practice. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Launched October 2005.&amp;nbsp; Updated November 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>105853</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcn.org.uk/development/practice/diabetes/good_practice]]&gt;</url>
    <title>Diabetes resource : good practice</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Royal College of Nursing</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DIABETES AND PREGNANCY,NEPHROPATHY,RETINOPATHY,DIABETIC FOOT,SEXUAL DYSFUNCTION,LIVING WITH DIABETES,DELIVERY OF CARE,CHRONIC COMPLICATIONS,HOSPITAL INPATIENT CARE,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,CAUSES,CAUSES,PREVENTION,CONDITION MANAGEMENT,USER INVOLVEMENT,CHILDREN AND YOUNG PEOPLE,ELDERLY PEOPLE,PEOPLE FROM ETHNIC MINORITIES,PRECONCEPTION CARE,EYE DISEASES,CHILDREN AND YOUNG PEOPLE,ELDERLY PEOPLE,DISABILITY AND DISCRIMINATION,ETHNICITY AND HEALTH,DISEASES AND CONDITIONS,DIABETES,SERVICE DELIVERY,CLINICAL PROFESSIONS,NURSES,SHARING PRACTICE,PEOPLE FROM ETHNIC MINORITIES,GESTATIONAL DIABETES,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The purpose of this section of the&amp;nbsp;RCN's diabetes resource&amp;nbsp;is to showcase good practice in the UK. The RCN diabetes resource&amp;nbsp;welcomes input from practitioners who care for people with diabetes.&amp;nbsp; The national frameworks and strategies for each of the four countries highlight the care that people with diabetes should be receiving regardless of setting and it is hoped this resource will help in achieving these goals.&lt;/P&gt;
&lt;P&gt;The&amp;nbsp;RCN diabetes resources is intended to be&amp;nbsp;a living resource which will grow and&amp;nbsp;the&amp;nbsp;RCN&amp;nbsp;invite you&amp;nbsp;to share your examples of good practice with other practitioners around the country.&lt;/P&gt;
&lt;P&gt;The areas of practice and diabetes care in this good practice section are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Black and minority ethnic (BME) groups 
&lt;LI&gt;Children 
&lt;LI&gt;Learning disabilities 
&lt;LI&gt;Older people and footcare 
&lt;LI&gt;Pregnancy 
&lt;LI&gt;Primary care 
&lt;LI&gt;Prisons and special hospitals 
&lt;LI&gt;Renal 
&lt;LI&gt;Residential care 
&lt;LI&gt;Screening for diabetic retinopathy 
&lt;LI&gt;Sexual health 
&lt;LI&gt;Young people 
&lt;LI&gt;Examples of good practice 
&lt;LI&gt;Case studies &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The RCN's diabetes resource offers guidance and help to nurses, people with diabetes, their families and carers.&amp;nbsp; The aim is to improve care for people with diabetes and reduce variations in clinical practice. &lt;/P&gt;
&lt;P&gt;The information presented in this resource:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Highlights key issues and current topics. 
&lt;LI&gt;Directs you to policy, national guidelines and other evidence based resources across the four UK countries. 
&lt;LI&gt;Provides examples of how evidence has been incorporated into care. 
&lt;LI&gt;Signposts other key organisations and support services. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The structure of the resource enables you to focus easily on a particular aspect of diabetes care or a particular area of practice. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Launched October 2005.&amp;nbsp; Updated November 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>300814</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcn.org.uk/development/practice/diabetes/national_service_frameworksstrategy]]&gt;</url>
    <title>Diabetes resource : national frameworks</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Royal College of Nursing</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,KEY POLICIES / NSF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the&amp;nbsp;RCN's diabetes resource&amp;nbsp;provides details about the national service frameworks (NSFs) and strategies relevent to each UK country and provides links to key related documents.&lt;/P&gt;
&lt;P&gt;The RCN's diabetes resource offers guidance and help to nurses, people with diabetes, their families and carers.&amp;nbsp; The aim is to improve care for people with diabetes and reduce variations in clinical practice. &lt;/P&gt;
&lt;P&gt;The information presented in this resource:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Highlights key issues and current topics. 
&lt;LI&gt;Directs you to policy, national guidelines and other evidence based resources across the four UK countries. 
&lt;LI&gt;Provides examples of how evidence has been incorporated into care. 
&lt;LI&gt;Signposts other key organisations and support services. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The structure of the resource enables you to focus easily on a particular aspect of diabetes care or a particular area of practice. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Launched October 2005.&amp;nbsp; Updated November 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>105856</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcn.org.uk/development/practice/diabetes/skill_development]]&gt;</url>
    <title>Diabetes resource : skill development</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Royal College of Nursing</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CPD AND PROFESSIONAL EDUCATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the RCN's diabetes resource focusses on skill development for nurses, with particular reference to diabetes care. It&amp;nbsp;includes the following sub-sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Finding information for diabetes care 
&lt;LI&gt;Clinical guidelines 
&lt;LI&gt;Continuing professional development 
&lt;LI&gt;Health care professional roles 
&lt;LI&gt;Cochrane Library 
&lt;LI&gt;Research&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The RCN's diabetes resource offers guidance and help to nurses, people with diabetes, their families and carers.&amp;nbsp; The aim is to improve care for people with diabetes and reduce variations in clinical practice. &lt;/P&gt;
&lt;P&gt;The information presented in this resource:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Highlights key issues and current topics. 
&lt;LI&gt;Directs you to policy, national guidelines and other evidence based resources across the four UK countries. 
&lt;LI&gt;Provides examples of how evidence has been incorporated into care. 
&lt;LI&gt;Signposts other key organisations and support services. &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The structure of the resource enables you to focus easily on a particular aspect of diabetes care or a particular area of practice. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Launched October 2005.&amp;nbsp; Updated November 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>105849</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcn.org.uk/development/practice/diabetes/treatment_and_lifestyle]]&gt;</url>
    <title>Diabetes resource : treatment and lifestyle</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Royal College of Nursing</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,LIVING WITH DIABETES,DRIVING,EMPLOYMENT,TRAVEL,CONDITION MANAGEMENT,CONDITION MANAGEMENT,OTHER LIFE STYLE,OTHER LIFE STYLE,MEDICATION,MONITORING / SELF-MONITORING,MEDICATION,MONITORING / SELF-MONITORING,NUTRITION AND FOOD,PHYSICAL ACTIVITY,NUTRITION AND FOOD,PHYSICAL ACTIVITY,ALCOHOL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In this section of the resource, ‘key issues’ highlights some topical issues around lifestyle and treatment management in diabetes care. Information is also provided on the following specific aspects of lifestyle and treatment. Within each topic area there is a section signposting evidence based resources which provide further information and support.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Key issues 
&lt;LI&gt;Alcohol 
&lt;LI&gt;Blood glucose monitoring 
&lt;LI&gt;Diet 
&lt;LI&gt;Employment and driving 
&lt;LI&gt;Insulin therapy 
&lt;LI&gt;Oral agents 
&lt;LI&gt;Physical activity 
&lt;LI&gt;Smoking cessation 
&lt;LI&gt;Travel 
&lt;LI&gt;Targets&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The RCN's diabetes resource offers guidance and help to nurses, people with diabetes, their families and carers.&amp;nbsp; The aim is to improve care for people with diabetes and reduce variations in clinical practice. &lt;/P&gt;
&lt;P&gt;The information presented in this resource:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Highlights key issues and current topics. 
&lt;LI&gt;Directs you to policy, national guidelines and other evidence based resources across the four UK countries. 
&lt;LI&gt;Provides examples of how evidence has been incorporated into care. 
&lt;LI&gt;Signposts other key organisations and support services. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;The structure of the resource enables you to focus easily on a particular aspect of diabetes care or a particular area of practice. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Launched October 2005.&amp;nbsp; Updated November 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323485</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcn.org.uk/development/practice/diabetes/patient_involvement]]&gt;</url>
    <title>Diabetes resource: patient involvement</title>
    <publicationDate></publicationDate>
    <publisher>Royal College of Nursing</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ PATIENT EDUCATION AND EMPOWERMENT,DELIVERY OF CARE,DIABETES,USER INVOLVEMENT,PATIENT AND PUBLIC INVOLVEMENT,PPI IN PRACTICE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The involvement of patients, carers and the public in health decision-making is at the heart of the modernisation of the UK’s National Health Service. Active and effective involvement of people with diabetes and their carers is intrinsic to the national frameworks and strategies for diabetes across the UK. The emphasis is on enabling as wide a participation as possible.&lt;/P&gt;
&lt;P&gt;The RCN's diabetes resource offers guidance and help to nurses, people with diabetes, their families and carers.&amp;nbsp; The aim is to improve care for people with diabetes and reduce variations in clinical practice. &lt;/P&gt;
&lt;P&gt;The information presented in this resource:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Highlights key issues and current topics. 
&lt;LI&gt;Directs you to policy, national guidelines and other evidence based resources across the four UK countries. 
&lt;LI&gt;Provides examples of how evidence has been incorporated into care. 
&lt;LI&gt;Signposts other key organisations and support services. &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The structure of the resource enables you to focus easily on a particular aspect of diabetes care or a particular area of practice. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>373585</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Professionals/Publications-reports-and-resources/Reports-statistics-and-case-studies/Reports/]]&gt;</url>
    <title>Diabetes UK reports and statistics</title>
    <publicationDate></publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DATA GATHERING AND AUDIT AND QOF,COMMISSIONING,SHARING PRACTICE,DIABETES,ORGANISATION OF CARE / CARE PLANNING,DELIVERY OF CARE,STATISTICS,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the Diabetes UK website lists all the&amp;nbsp;reports&amp;nbsp;and statistical reports published by Diabetes UK for healthcare professionals.&amp;nbsp; The reports include survey results, workshop reports, working group reports and guidance.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to this webpage is available to the general public.&amp;nbsp; Access to the&amp;nbsp;reports in Portable Document File / PDF format requires Adobe Acrobat Reader.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307395</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www3.interscience.wiley.com/journal/122459774/grouphome/ProductInformation.html]]&gt;</url>
    <title>Diabetes/Metabolism Research and Reviews</title>
    <publicationDate></publicationDate>
    <publisher>Diabetes/Metabolism Research and Reviews</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Diabetes/Metabolism Research and Reviews, formerly known as Diabetes/Metabolism Reviews, is a resource for clinicians and researchers working in the fields of diabetes, endocrinology, metabolism and obesity.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full access requires subscription to the journal. NHS staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library &lt;/A&gt;for further assistance.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307834</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://home2.btconnect.com/innove/Resources/diabetese_fifth_national_report.pdf]]&gt;</url>
    <title>DiabetesE: national reports</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>BT, Innove</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DATA GATHERING AND AUDIT AND QOF,DIABETES,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF,STATISTICS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;DiabetesE is a web-based diabetes care performance improvement tool that supports the implementation of the Diabetes NSF, allowing PCTs to assess their progress in developing their services for people with diabetes. For further information on diabetesE &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=82714" target="_blank"&gt;click here&lt;/A&gt;. This&amp;nbsp;fifth national report analyses results captured on 6th November 2009.&amp;nbsp; Links to previous reports are listed under the "Related Links" section below.&lt;BR&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Published Feb 2010.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public. Portable Document File / PDF requiring Adobe Acrobat Reader.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307400</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabeticfootjournal.co.uk/]]&gt;</url>
    <title>Diabetic Foot</title>
    <publicationDate></publicationDate>
    <publisher>Diabetic Foot</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The website includes information on the journal 'Diabetic Foot' and links to other related journals.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full access online requires subscription to the journal. NHS staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library &lt;/A&gt;for further assistance.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307405</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.wiley.com/bw/journal.asp?ref=0742-3071]]&gt;</url>
    <title>Diabetic Medicine</title>
    <publicationDate></publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Diabetic Medicine is a journal of Diabetes UK. The website includes information about the journal, guidelines for authors and access to tables of content.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Full access online requires subscription to the journal. NHS staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library &lt;/A&gt;for further assistance.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60153</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,161/Itemid,61/]]&gt;</url>
    <title>Diabetic retinopathy and therapeutic education (teaching letter no.16)</title>
    <publicationDate>1999-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ EYE DISEASES,DIABETES,CONDITION MANAGEMENT,DIAGNOSIS,CHRONIC COMPLICATIONS,RETINOPATHY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the management of diabetic retinopathy and covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Facilitating management of the crisis period when retinopathy is diagnosed; as well as management of continuing care. 
&lt;LI&gt;Raising patients' awareness of their need for information and for psychosocial and practical support. 
&lt;LI&gt;Promoting appropriate therapeutic education, with emphasis upon the use of metaphors to explain technical information.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288214</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_083895]]&gt;</url>
    <title>Diabetic retinopathy screening statement</title>
    <publicationDate>2008-04-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CHRONIC COMPLICATIONS,DELIVERY OF CARE,RETINOPATHY,CAUSES,DATA GATHERING AND AUDIT AND QOF,EYE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Data from Local Delivery Plan Returns shows that by December 2007 85.7 percent of people diagnosed with diabetes were offered screening for diabetic retinopathy that met stringent national clinical standards of quality and safety in the previous twelve months 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Published 3 April 2008.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public. Portable Document File / PDF requiring&lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt; Adobe Acrobat Reader.&lt;/A&gt;&lt;/P&gt;&lt;/PAGEBODY&gt;&lt;/PAGE&gt;&lt;/ARTICLE&gt;]]&gt;</body>
  </document>
  <document>
    <id>288214</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_083895]]&gt;</url>
    <title>Diabetic retinopathy screening statement</title>
    <publicationDate>2008-04-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CHRONIC COMPLICATIONS,DELIVERY OF CARE,RETINOPATHY,CAUSES,DATA GATHERING AND AUDIT AND QOF,EYE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Data from Local Delivery Plan Returns shows that by December 2007 85.7 percent of people diagnosed with diabetes were offered screening for diabetic retinopathy that met stringent national clinical standards of quality and safety in the previous twelve months 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Published 3 April 2008.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public. Portable Document File / PDF requiring&lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt; Adobe Acrobat Reader.&lt;/A&gt;&lt;/P&gt;&lt;/PAGEBODY&gt;&lt;/PAGE&gt;&lt;/ARTICLE&gt;]]&gt;</body>
  </document>
  <document>
    <id>288214</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_083895]]&gt;</url>
    <title>Diabetic retinopathy screening statement</title>
    <publicationDate>2008-04-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CHRONIC COMPLICATIONS,DELIVERY OF CARE,RETINOPATHY,CAUSES,DATA GATHERING AND AUDIT AND QOF,EYE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Data from Local Delivery Plan Returns shows that by December 2007 85.7 percent of people diagnosed with diabetes were offered screening for diabetic retinopathy that met stringent national clinical standards of quality and safety in the previous twelve months 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Published 3 April 2008.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public. Portable Document File / PDF requiring&lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt; Adobe Acrobat Reader.&lt;/A&gt;&lt;/P&gt;&lt;/PAGEBODY&gt;&lt;/PAGE&gt;&lt;/ARTICLE&gt;]]&gt;</body>
  </document>
  <document>
    <id>294585</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_083895]]&gt;</url>
    <title>Diabetic Retinopathy Screening Statement</title>
    <publicationDate>2008-04-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,EYES AND VISION,CHRONIC COMPLICATIONS,CAUSES,EYE DISEASES,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Statement from the Department of Health about the national screening programme for diabetic retinopathy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>294585</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_083895]]&gt;</url>
    <title>Diabetic Retinopathy Screening Statement</title>
    <publicationDate>2008-04-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,EYES AND VISION,CHRONIC COMPLICATIONS,CAUSES,EYE DISEASES,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Statement from the Department of Health about the national screening programme for diabetic retinopathy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>294585</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_083895]]&gt;</url>
    <title>Diabetic Retinopathy Screening Statement</title>
    <publicationDate>2008-04-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,EYES AND VISION,CHRONIC COMPLICATIONS,CAUSES,EYE DISEASES,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Statement from the Department of Health about the national screening programme for diabetic retinopathy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296781</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_083895]]&gt;</url>
    <title>Diabetic Retinopathy Screening Statement</title>
    <publicationDate>2008-04-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,DELIVERY OF CARE,CHRONIC COMPLICATIONS,KEY POLICIES / NSF,CAUSES,DATA GATHERING AND AUDIT AND QOF,EYE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;Department of Health&amp;nbsp;document&amp;nbsp;provides information about UK standards, targets and progress.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296781</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_083895]]&gt;</url>
    <title>Diabetic Retinopathy Screening Statement</title>
    <publicationDate>2008-04-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,DELIVERY OF CARE,CHRONIC COMPLICATIONS,KEY POLICIES / NSF,CAUSES,DATA GATHERING AND AUDIT AND QOF,EYE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;Department of Health&amp;nbsp;document&amp;nbsp;provides information about UK standards, targets and progress.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296781</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_083895]]&gt;</url>
    <title>Diabetic Retinopathy Screening Statement</title>
    <publicationDate>2008-04-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,DELIVERY OF CARE,CHRONIC COMPLICATIONS,KEY POLICIES / NSF,CAUSES,DATA GATHERING AND AUDIT AND QOF,EYE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;Department of Health&amp;nbsp;document&amp;nbsp;provides information about UK standards, targets and progress.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307411</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetologia-journal.org/]]&gt;</url>
    <title>Diabetologia</title>
    <publicationDate></publicationDate>
    <publisher>Diabetologia</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Diabetologia is a journal of the European Association for the Study of Diabetes (EASD). Diabetologia publishes original clinical and experimental research within the field of diabetes. The website has information on the journal and a section for authors.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Full access online requires subscription to the journal. NHS staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library &lt;/A&gt;for further assistance.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>347270</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.chimat.org.uk/default.aspx?QN=CHMTDMIT]]&gt;</url>
    <title>Disease Management Information Toolkit</title>
    <publicationDate></publicationDate>
    <publisher>Child and Maternal Health Observatory (ChiMat)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DATA GATHERING AND AUDIT AND QOF,COMMISSIONING,STATISTICS,DATA GATHERING AND AUDIT AND QOF,DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The disease management information toolkit (DMIT) is a good practice toolkit designed to help increase the efficiency of services for children with long-term conditions. It was originally developed by the Department of Health for the NHS to help service providers identify which conditions contribute to high numbers of emergency bed days.&lt;/P&gt;
&lt;P&gt;This toolkit is primarily aimed at primary care trusts (PCTs) and commissioners of children's health and social care services, although it will inform those working with people with long-term conditions at all levels. &lt;/P&gt;
&lt;P&gt;The toolkit presents data that is already in the public domain, and&amp;nbsp;also provides a summary report of key data and information on trends over time and potential cost savings. It includes a Diabetes module.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Free registation is required to access this toolkit.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187554</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=408]]&gt;</url>
    <title>Do once and share (DOaS) diabetes - final report</title>
    <publicationDate>2006-01-04T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report presents the work and findings of the Do Once and Share (DOaS) Diabetes project . The aim of the project was to identify key components of the Electronic Health Record (HER) for people with diabetes and the healthcare professionals they work with, that would enable holistic diabetes care to take place.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published January 2006.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>66507</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_bulletin_vol15_no1.pdf]]&gt;</url>
    <title>Drug management of type 2 diabetes: summary</title>
    <publicationDate></publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ PREVENTION,MEDICATION,CARDIOVASCULAR,CHRONIC COMPLICATIONS,DYSLIPIDAEMIA,HYPERTENSION,CONDITION MANAGEMENT,DIABETES,TYPE 2]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bulletin provides a summary of MeReC Briefing numbers &lt;A href="http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_briefing_no25.pdf" target="_blank"&gt;25&lt;/A&gt; and &lt;A href="http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_briefing_no26.pdf" target="_blank"&gt;26&lt;/A&gt;, which discuss the management of people with type 2 diabetes. 
&lt;P&gt;&lt;STRONG&gt;Publication details:&lt;/STRONG&gt; Bulletin&amp;nbsp;vol 15 no 1 prepared 2004 
&lt;P&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323098</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/our_work_areas/education/]]&gt;</url>
    <title>Education - Work Area - NHS Diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the NHS Diabetes website provides details of the work of the&amp;nbsp;Education Working Group. It also includes links to further information. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>266941</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npci.org.uk/therapeutics/cardio/diabetes1/room_diabetes1.php]]&gt;</url>
    <title>Education materials for type 1 diabetes</title>
    <publicationDate></publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ CPD AND PROFESSIONAL EDUCATION,MEDICATION,DIABETES,TYPE 1,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the National Prescribing Centre website contains several education materials for type 1 diabetes.&amp;nbsp; These include quizzes, case studies, commentaries, patient decision aids and slides.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311626</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npci.org.uk/therapeutics/cardio/diabetes2/room_diabetes2.php]]&gt;</url>
    <title>Education materials for type 2 diabetes</title>
    <publicationDate></publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ CPD AND PROFESSIONAL EDUCATION,MEDICATION,CONDITION MANAGEMENT,TYPE 2,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the National Prescribing Centre website contains several education materials for type&amp;nbsp;2&amp;nbsp;diabetes.&amp;nbsp; These include quizzes, case studies, commentaries, patient decision aids&amp;nbsp;and slides.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344338</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npci.org.uk/therapeutics/therap/wound/room_wound.php]]&gt;</url>
    <title>Education materials for wound care (including diabetic foot)</title>
    <publicationDate></publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ CONDITION MANAGEMENT,CHRONIC COMPLICATIONS,DIABETIC FOOT,DIABETES,CPD AND PROFESSIONAL EDUCATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the National Prescribing Centre website contains several education materials on wound care (including diabetic foot).&amp;nbsp; These include quizzes, case studies, commentaries and slides.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60165</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,169/Itemid,61/]]&gt;</url>
    <title>Education of people with diabetes to the use of hi-tech devices (teaching letter no.26)</title>
    <publicationDate>2003-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MEDICATION,MONITORING / SELF-MONITORING,MEDICATION,MONITORING / SELF-MONITORING,INSULIN PUMPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the education of people with diabetes about continuous subcutaneous insulin infusion (CSII), intraperitoneal insulin therapy (IPII), glucose sensors and other high tech devices. It covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Aims 
&lt;LI&gt;Requirement for successful and safe CSII implementation 
&lt;UL&gt;
&lt;LI&gt;Patient selection 
&lt;LI&gt;Further recommendations&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;How to approach the patient at the start of CSII 
&lt;UL&gt;
&lt;LI&gt;What is an insulin pump? 
&lt;LI&gt;Advantages of CSII&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Are there specific risks associated with CSII? 
&lt;LI&gt;Intraperitoneal insulin with or without and implantable pump 
&lt;LI&gt;Glucose sensors 
&lt;LI&gt;Further sources of information&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 2003&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60154</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,162/Itemid,61/]]&gt;</url>
    <title>Educational approach to the elderly diabetic patient (teaching letter no.17)</title>
    <publicationDate>1999-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,DIABETES,TYPE 1,TYPE 2,ELDERLY PEOPLE,ELDERLY PEOPLE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the educational&amp;nbsp;problems which may be faced by those providing care to elderly diabetic patients with special needs&amp;nbsp;and covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Educational problems in the elderly 
&lt;LI&gt;Educational constraints 
&lt;LI&gt;Adapting therapeutic objectives 
&lt;LI&gt;Conclusion&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/content/blogcategory/20/34/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60177</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9742977]]&gt;</url>
    <title>Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)</title>
    <publicationDate>1998-09-12T00:00:00</publicationDate>
    <publisher>Lancet</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,GROUND-BREAKING ARTICLES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;BR&gt;&lt;/STRONG&gt;UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 Sep 12;352(9131):854-65. 
&lt;P&gt;&lt;STRONG&gt;Accessing the full text:&lt;/STRONG&gt; Access to the full text of this article online requires subscription to the journal. NHS staff please: &lt;A href="http://www.hlisd.org/" target="_blank"&gt;Contact your local NHS library for further assistance.&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Additional information:&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.dtu.ox.ac.uk/index.php?maindoc=/ukpds/" target="_blank"&gt;Link to the UKPDS website&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>266046</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://content.nejm.org/cgi/content/full/356/24/2457]]&gt;</url>
    <title>Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes</title>
    <publicationDate>2007-06-14T00:00:00</publicationDate>
    <publisher>New England Journal of Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CARDIOVASCULAR,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,MEDICATION,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;See also:&lt;/STRONG&gt; &lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=262491&amp;amp;tabID=290&amp;amp;catID=12541" target="_blank"&gt;Interesting new diabetes papers : May 2007&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Full Reference:&lt;/STRONG&gt;&lt;BR&gt;Nissen SE, Wolski K. Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 Jun 14;356(24):2457-71.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessing the full text:&lt;/STRONG&gt;&lt;BR&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>299126</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19046191]]&gt;</url>
    <title>Effect of weight-reducing agents on glycaemic parameters and progression to Type 2 diabetes - a review</title>
    <publicationDate>2008-11-19T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PREDIABETIC STATE,OBESITY,PREVENTION,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;BR&gt;&lt;/STRONG&gt;Lloret-Linares C, Greenfield JR, Czernichow S&lt;STRONG&gt;.&lt;/STRONG&gt;&amp;nbsp; Effect of weight-reducing agents on glycaemic parameters and progression to Type 2 diabetes: a review. Diabetic Medicine, 2008&amp;nbsp;25, 1142-1150.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Access to the full text online requires subscription to the journal.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;NHS staff please &lt;A href="http://www.hlisd.org/" target="_blank"&gt;contact your local NHS library for further assistance.&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>224051</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/cgi/content/full/29/11/2518]]&gt;</url>
    <title>Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis.</title>
    <publicationDate></publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,PHYSICAL ACTIVITY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full Reference:&lt;BR&gt;&lt;/STRONG&gt;Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care. 2006 Nov;29(11):2518-27. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Accessing the full text:&lt;BR&gt;&lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>182000</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://jama.ama-assn.org/cgi/content/full/296/4/427]]&gt;</url>
    <title>Effects of quality improvement strategies for type 2 diabetes on glycaemic control : a meta-regression analysis</title>
    <publicationDate>2006-07-26T00:00:00</publicationDate>
    <publisher>Journal of the American Medical Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,MONITORING / SELF-MONITORING,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;/STRONG&gt;&lt;BR&gt;Shojania KG, Ranji SR, MacDonald KM, et al. Effects of quality improvement strategies for type 2 diabetes on glycaemic control:&amp;nbsp;a meta-regression analysis. JAMA Jul 26&amp;nbsp;2006; 296(4):427-440. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>277116</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18022033]]&gt;</url>
    <title>Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials</title>
    <publicationDate>2007-11-17T00:00:00</publicationDate>
    <publisher>Lancet</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CONDITION MANAGEMENT,OBESITY,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Conclusion: &lt;BR&gt;&lt;/STRONG&gt;Taken from PubMed abstract&lt;BR&gt;"Findings suggest that 20 mg per day rimonabant increases the risk of psychiatric adverse events--ie, depressed mood disorders and anxiety-despite depressed mood being an exclusion criterion in these trials. Taken together with the recent US Food and Drug Administration finding of increased risk of suicide during treatment with rimonabant, we recommend increased alertness by physicians to these potentially severe psychiatric adverse reactions&lt;STRONG&gt;."&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method: &lt;BR&gt;&lt;/STRONG&gt;Taken from PubMed abstract&lt;BR&gt;"We searched The Cochrane database and Controlled Trials Register, Medline via Pubmed, Embase via WebSpirs, Web of Science, Scopus, and reference lists up to July, 2007. We collected data from four double-blind, randomised controlled trials (including 4105 participants) that compared 20 mg per day rimonabant with placebo." &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed abstract&lt;BR&gt;"Patients given rimonabant had a 4.7 kg (95% CI 4.1-5.3 kg; p&amp;lt;0.0001) greater weight reduction after 1 year than did those given placebo. Rimonabant caused significantly more adverse events than did placebo (OR=1.4; p=0.0007; number needed to harm=25 individuals [95% CI 17-58]), and 1.4 times more serious adverse events (OR=1.4; p=0.03; number needed to harm=59 [27-830]). Patients given rimonabant were 2.5 times more likely to discontinue the treatment because of depressive mood disorders than were those given placebo (OR=2.5; p=0.01; number needed to harm=49 [19-316]). Furthermore, anxiety caused more patients to discontinue treatment in rimonabant groups than in placebo groups (OR=3.0; p=0.03; number needed to harm=166 [47-3716])."&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Lancet. 2007 November 17;370(9600):1706-13.Comment in:Lancet. 2007 Nov 17;370(9600):1671-2.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in November 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessing the full text:&lt;/STRONG&gt; &lt;BR&gt;Access to the full text of this article online requires subscription to the journal. NHS staff please &lt;A href="http://www.hlisd.org/" target="_blank"&gt;contact your local NHS library for further assistance&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;November 2008.&amp;nbsp; Please Note: Marketing authorisation has been suspended of Acomplia (rimonabant) as the European Medicines Agency has concluded that the benefits of Acomplia no longer outweigh its risks of psychiatric disorders.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323097</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/our_work_areas/emotional_and_psychological/]]&gt;</url>
    <title>Emotional and Psychological - Work Area - NHS Diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,PSYCHOLOGICAL PROBLEMS,DELIVERY OF CARE,CHRONIC COMPLICATIONS,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,ANXIETY AND DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the NHS Diabetes website provides details of the work of the&amp;nbsp; Emotional and Psychological Support Working Group. It also includes links to further information. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345668</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=1036]]&gt;</url>
    <title>Emotional and psychological support and care in diabetes</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ ANXIETY AND DEPRESSION,CHRONIC COMPLICATIONS,PSYCHOLOGICAL PROBLEMS,DELIVERY OF CARE,KEY POLICIES / NSF,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Report from the emotional and psychological support working group of NHS Diabetes and Diabetes UK.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This NHS Diabetes report explores the many issues relevant to integrating emotional and psychological care within diabetes services.&amp;nbsp;The authors&amp;nbsp;hope that it assists in the development of high quality, sensitive services that meet the emotional and psychological needs of people living with diabetes.&lt;/P&gt;
&lt;P&gt;This report includes the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;1 Introduction&lt;/LI&gt;
&lt;LI&gt;2 Emotional and psychological needs&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; The range and complexity of need&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; The pyramid model&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Evidence supporting the pyramid model&lt;/LI&gt;
&lt;LI&gt;3 Policy context &lt;/LI&gt;
&lt;LI&gt;4 Current provision &lt;/LI&gt;
&lt;LI&gt;5 The evidence base for intervention&lt;/LI&gt;
&lt;LI&gt;6 Commissioning &lt;/LI&gt;
&lt;LI&gt;7 Workforce development and planning&lt;/LI&gt;
&lt;LI&gt;8 Conclusion and next steps&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in March 2010.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public, Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60169</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,171/Itemid,61/]]&gt;</url>
    <title>Emotional intelligence in diabetes care (teaching letter no.28)</title>
    <publicationDate>2004-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CONDITION MANAGEMENT,CONDITION MANAGEMENT,PSYCHOSOCIAL CARE,PSYCHOSOCIAL CARE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the concept of emotional intelligence (EI). It aims to introduce health professionals to the concept and how&amp;nbsp;it can be integrated into everyday diabetes care.&amp;nbsp;It covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Aim 
&lt;LI&gt;Definition and history 
&lt;LI&gt;Why do HCPs need to know about EI? 
&lt;LI&gt;What is "intelligence"? 
&lt;LI&gt;How may EI influence self-care in diabetes? 
&lt;LI&gt;"Pandora's box?" 
&lt;LI&gt;Conclusion 
&lt;LI&gt;References 
&lt;LI&gt;Further reading&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 2004&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>59988</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/booth/booths/erect.html]]&gt;</url>
    <title>Erectile dysfunction and premature ejaculation</title>
    <publicationDate></publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,SEXUAL DYSFUNCTION,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the Bandolier Knowledge Library&amp;nbsp;describes and reviews&amp;nbsp;papers&amp;nbsp;concerning the treatment of men with erectile dysfunction.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82774</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.york.ac.uk/yhpho/documents/diabetes/Diabetes%20models%20template%20v1c.doc]]&gt;</url>
    <title>Estimating diabetes prevalence : comparison of selected models</title>
    <publicationDate></publicationDate>
    <publisher>Yorkshire and Humber Public Health Observatory (YHPHO)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DATA GATHERING AND AUDIT AND QOF,INCIDENCE AND PREVALENCE,DATA GATHERING AND AUDIT AND QOF,STATISTICS,DELIVERY OF CARE,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guide&amp;nbsp;provides&amp;nbsp;a useful comparison&amp;nbsp;of&amp;nbsp;the diabetes prevalence models&amp;nbsp;available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word file.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60161</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,167/Itemid,61/]]&gt;</url>
    <title>Evaluating diabetes education (teaching letter no.24)</title>
    <publicationDate>2002-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the evaluation of therapeutic patient education in the field of diabetes and covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Aim 
&lt;LI&gt;What is evaluation? 
&lt;LI&gt;Certifying evaluation 
&lt;LI&gt;Designing evaluation instruments 
&lt;LI&gt;Guidelines for evaluation 
&lt;UL&gt;
&lt;LI&gt;Knowledge assessment 
&lt;LI&gt;Attitude and psychosocial assessment 
&lt;LI&gt;Decision-making in diabetes 
&lt;LI&gt;Performance 
&lt;LI&gt;Patient satisfaction&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Feedback implementation: completing the educational loop 
&lt;LI&gt;Further reading&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 2002&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60308</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dnsg-easd.org/info/general/Document/get/12/documentId/guida.pdf]]&gt;</url>
    <title>Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus</title>
    <publicationDate>2004-12-01T00:00:00</publicationDate>
    <publisher>Nutrition, Metabolism, and Cardiovascular Diseases</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,NEPHROPATHY,CARDIOVASCULAR,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,CONDITION MANAGEMENT,PREVENTION,CONDITION MANAGEMENT,PREVENTION,CONDITION MANAGEMENT,PREVENTION,NUTRITION AND FOOD,NUTRITION AND FOOD,PUBLIC HEALTH,DETERMINANTS,OUTCOMES,FOOD &amp; NUTRITION,NUTRITION,MANAGEMENT &amp; INTERVENTIONS,ANALYSIS &amp; RESEARCH,ENDOCRINE DISORDERS,DIABETES,METHODS,ANALYSIS,MANAGEMENT &amp; POLICY,FRAMES OF REFERENCE,GUIDELINES,MONTHLY ADDITIONS,2008-JULY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ These recommendations&amp;nbsp;cover nutritional management in diabetics. They include: 
&lt;UL&gt;
&lt;LI&gt;Introduction 
&lt;LI&gt;Energy balance and body weight 
&lt;LI&gt;Protein 
&lt;LI&gt;Dietary fat 
&lt;LI&gt;Carbohydrate 
&lt;LI&gt;Dietary fibre 
&lt;LI&gt;Glycaemic index 
&lt;LI&gt;Sucrose and other free sugars 
&lt;LI&gt;Antioxidant nutrients, vitamins, minerals and trace elements 
&lt;LI&gt;Alcohol 
&lt;LI&gt;Prevention of diabetes 
&lt;LI&gt;Supplements and functional foods&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2004. These recommendations&amp;nbsp;represent an update of those issued in&amp;nbsp;2000 by the &lt;A href="http://www.dnsg-easd.org/" target="_blank"&gt;Diabetes and Nutrition Study Group of the European Association for the Study of Diabetes (EASD). &lt;/A&gt;
&lt;P&gt;&lt;STRONG&gt;Full reference:&lt;/STRONG&gt;&lt;BR&gt;Mann JI, De Leeuw I, Hermansen K, Karamanos B, Karlstrom B, Katsilambros N, et al. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutrition, Metabolism, and Cardiovascular Diseases, 2004, 14, 373-394.&lt;/P&gt;&lt;/PAGEBODY&gt;&lt;/PAGE&gt;&lt;/ARTICLE&gt;]]&gt;</body>
  </document>
  <document>
    <id>59979</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/booth/hliving/Excer2Diab.html]]&gt;</url>
    <title>Exercise and type 2 diabetes</title>
    <publicationDate>1999-10-15T00:00:00</publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PREVENTION,PUBLIC HEALTH,DETERMINANTS,OUTCOMES,INDIVIDUAL BEHAVIOUR,PHYSICAL ACTIVITY,SOCIAL DETERMINANTS,LIFESTYLE,ENDOCRINE DISORDERS,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the Bandolier Knowledge Library&amp;nbsp;describes and reviews a 1999 study concerning the relationship between exercise and incidence of type 2 diabetes.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Describes an article that was published in October&amp;nbsp;1999.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>105378</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=409]]&gt;</url>
    <title>Fact sheets for healthcare professionals working with type 2 diabetes</title>
    <publicationDate>2005-01-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,CONDITION MANAGEMENT,OTHER LIFE STYLE,MEDICATION,MONITORING / SELF-MONITORING,NUTRITION AND FOOD,PHYSICAL ACTIVITY,PSYCHOSOCIAL CARE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;These&amp;nbsp;ten fact sheets&amp;nbsp;are aimed at&amp;nbsp;healthcare professionals working with people with type 2 diabetes. They cover the following&amp;nbsp;subjects:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Good glycaemic control 
&lt;LI&gt;Regular monitoring of glycemia 
&lt;LI&gt;Holistic approach to type 2 diabetes management 
&lt;LI&gt;The role of specialist care units 
&lt;LI&gt;Address the underlying pathophysiology of type 2 diabetes 
&lt;LI&gt;The need for an early and intensive approach 
&lt;LI&gt;Benefits of earlier initiation of combination therapy 
&lt;LI&gt;Treatment of patients with HbA&lt;SUB&gt;1c&lt;/SUB&gt; = 9% at diagnosis 
&lt;LI&gt;Benefits of complementary agents 
&lt;LI&gt;The role of the multidisciplinary team&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>389585</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_monthly_no30.pdf]]&gt;</url>
    <title>Financial conflicts of interest linked to author's views on MI risk with rosiglitazone</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CARDIOVASCULAR,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,MEDICATION,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This MeReC monthly article (on page 3 of the newsletter) discusses a systematic review which found a link between the authors' financial conflicts of interests with pharmaceutical companies and their views on the association of rosiglitazone with increased risk of MI.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication History Information:&lt;/STRONG&gt; MeReC Monthly No. 30, page 3. Published September 2010. Original article: Wang AT, et al. Association industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ 2010; 340: c1344. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).]]&gt;</body>
  </document>
  <document>
    <id>70251</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band128/b128-4.html]]&gt;</url>
    <title>Finding type 2 diabetics in primary care</title>
    <publicationDate></publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier&amp;nbsp;article describes and reviews a 2004 study concerning screening for type 2 diabetes. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Review published&amp;nbsp;October 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>292481</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_087123]]&gt;</url>
    <title>Five years on: delivering the diabetes national service framework</title>
    <publicationDate>2008-08-20T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RETINOPATHY,RETINA,DIABETIC RETINOPATHY,NATIONAL SERVICE FRAMEWORKS (NSFS) AND EYE HEALTH,OUTCOMES,DETERMINANTS,ENDOCRINE DISORDERS,DIABETES,PERFORMANCE &amp; ASSESSMENT FRAMEWORKS,DELIVERY OF CARE,EYES AND VISION,KEY POLICIES / NSF,DIABETES,PUBLIC HEALTH,SOCIAL DETERMINANTS,LIFESTYLE,MANAGEMENT &amp; INTERVENTIONS,INDIVIDUAL BEHAVIOUR,EATING HABITS,PHYSICAL ACTIVITY,FRAMEWORKS,MANAGEMENT &amp; POLICY,MONTHLY ADDITIONS,2008-AUGUST,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The &lt;A href="http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Diabetes/index.htm" target="_blank"&gt;Diabetes National Service Framework&amp;nbsp;(NSF)&lt;/A&gt;&amp;nbsp;set out the first ever set of national standards for the care of people with diabetes. This report highlights progress over the first five years of the NSF Delivery Strategy; marking the half-way point of the implementation period.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published&amp;nbsp;20 August 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_087123" target="_blank"&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310573</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.institute.nhs.uk/option,com_joomcart/Itemid,26/main_page,document_product_info/products_id,373.html]]&gt;</url>
    <title>Focus on: Inpatient care for people with diabetes</title>
    <publicationDate>2008-03-01T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,ORGANISATION OF CARE / CARE PLANNING,DELIVERY OF CARE,LIVING WITH DIABETES,HOSPITAL,ACUTE ILLNESS INCLUDING INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;NHS Institute for Innovation and Improvement state that the “provision of consistent, effective and proactive inpatient care for people with diabetes is still inadequate in the NHS, often leaving patients with a poor experience in terms of their diabetes treatment. Whether they are admitted for emergency or elective treatment we need all NHS staff to think about diabetes care for their patients”.&lt;/P&gt;
&lt;P&gt;This report offers suggestions to care providers and commissioners on how they can optimise their own provision of care.&lt;/P&gt;
&lt;P&gt;This document is one of a series of documents produced by the NHS Institute for Innovation and Improvement as part of the High Volume Care programme. Produced by the Delivering Quality and Value Team, the aim of the Focus on series is to help local health communities and organisations improve the quality and value of the care they deliver.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS staff only, free registration with NHS email address required. Portable Document File/PDF.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310573</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.institute.nhs.uk/option,com_joomcart/Itemid,26/main_page,document_product_info/products_id,373.html]]&gt;</url>
    <title>Focus on: Inpatient care for people with diabetes</title>
    <publicationDate>2008-03-01T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,ORGANISATION OF CARE / CARE PLANNING,DELIVERY OF CARE,LIVING WITH DIABETES,HOSPITAL,ACUTE ILLNESS INCLUDING INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;NHS Institute for Innovation and Improvement state that the “provision of consistent, effective and proactive inpatient care for people with diabetes is still inadequate in the NHS, often leaving patients with a poor experience in terms of their diabetes treatment. Whether they are admitted for emergency or elective treatment we need all NHS staff to think about diabetes care for their patients”.&lt;/P&gt;
&lt;P&gt;This report offers suggestions to care providers and commissioners on how they can optimise their own provision of care.&lt;/P&gt;
&lt;P&gt;This document is one of a series of documents produced by the NHS Institute for Innovation and Improvement as part of the High Volume Care programme. Produced by the Delivering Quality and Value Team, the aim of the Focus on series is to help local health communities and organisations improve the quality and value of the care they deliver.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS staff only, free registration with NHS email address required. Portable Document File/PDF.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>319837</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.institute.nhs.uk/quality_and_value/high_volume_care/focus_on%3a_diabetes.html]]&gt;</url>
    <title>Focus on: inpatient care for people with diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Institute for Innovation and Improvement</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ ORGANISATION OF CARE / CARE PLANNING,HOSPITAL,DELIVERY OF CARE,LIVING WITH DIABETES,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The NHS Institute's diabetes team website includes information on inpatient care in England for people admitted for non diabetes reasons who happen to have diabetes.]]&gt;</body>
  </document>
  <document>
    <id>319837</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.institute.nhs.uk/quality_and_value/high_volume_care/focus_on%3a_diabetes.html]]&gt;</url>
    <title>Focus on: inpatient care for people with diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Institute for Innovation and Improvement</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ ORGANISATION OF CARE / CARE PLANNING,HOSPITAL,DELIVERY OF CARE,LIVING WITH DIABETES,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The NHS Institute's diabetes team website includes information on inpatient care in England for people admitted for non diabetes reasons who happen to have diabetes.]]&gt;</body>
  </document>
  <document>
    <id>60142</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,154/Itemid,61/]]&gt;</url>
    <title>Foot care (teaching letter no.6)</title>
    <publicationDate>1996-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ PREVENTION,CAUSES,CONDITION MANAGEMENT,DIAGNOSIS,DIABETIC FOOT,CHRONIC COMPLICATIONS,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the diabetic foot and covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Causes 
&lt;UL&gt;
&lt;LI&gt;The main contributory factors 
&lt;LI&gt;The neuropathis foot 
&lt;LI&gt;The ischemic foot 
&lt;LI&gt;Trauma 
&lt;LI&gt;Shoe fitting 
&lt;LI&gt;Infection 
&lt;LI&gt;Psychological factors 
&lt;LI&gt;Social factors 
&lt;LI&gt;Orthopedic factors 
&lt;LI&gt;Foot swelling&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Preventing damage - education 
&lt;LI&gt;How to determine the patients at risk 
&lt;LI&gt;Learning objectives 
&lt;UL&gt;
&lt;LI&gt;Older patients or those with a long duration of diabetes, with normal feet 
&lt;LI&gt;Patients at high risk&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Ensuring success 
&lt;UL&gt;
&lt;LI&gt;Reinforcement and evaluation 
&lt;LI&gt;Chain of events for patients already at risk&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Detection 
&lt;LI&gt;Treatment 
&lt;UL&gt;
&lt;LI&gt;Ulcer treatment 
&lt;LI&gt;Role of paramedical personnel&lt;/LI&gt;&lt;/UL&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 1996&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323087</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/our_work_areas/footcare/]]&gt;</url>
    <title>Footcare - Work Area - NHS Diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETIC FOOT,DELIVERY OF CARE,CHRONIC COMPLICATIONS,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,DIAGNOSIS,CONDITION MANAGEMENT,CAUSES,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the NHS Diabetes website provides details of the work of the&amp;nbsp;Footcare Working Group. It also includes links to further information. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298316</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=204]]&gt;</url>
    <title>Getting to Grips with the Year of Care: A Practical Guide</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Diabetes UK, NHS National Diabetes Support Team, Department of Health, Health Foundation</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,COMMISSIONING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This practical guide, published by the Year of Care programme, is designed to help commissioners, clinicians and networks interested in setting up Year of Care programmes locally. 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;The Year of Care programme sets out to learn how routine care can be redesigned and commissioned to provide a personalised approach, including support for self management, for people with long term conditions, starting with diabetes.&lt;/P&gt;
&lt;P&gt;The guide concentrates on what needs to be put in place and&amp;nbsp; particularly the key role commissioning has to play. Each section of the guide provides guidance based on national literature and the experience of the three Year of Care pilots.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>212553</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/cdhyper/merec_extra_no25.htm#GLI]]&gt;</url>
    <title>Glitazones for preventing type 2 diabetes: the DREAM study</title>
    <publicationDate></publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;MeReC&amp;nbsp;Extra article&amp;nbsp;discusses the results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study which aimed to find out whether rosiglitazone or ramipril could prevent the development of type 2 diabetes in people at high risk of developing this condition. This article focuses on the rosiglitazone part of the study. &lt;STRONG&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published November 2006. MeReC Extra No. 25. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public. 
&lt;P&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296975</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=296975]]&gt;</url>
    <title>Glitazones in type 2 diabetes : the PROactive study</title>
    <publicationDate>2008-10-30T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CARDIOVASCULAR,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,MEDICATION,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glitazones in type 2 diabetes : the PROactive study&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;1. MeReC Rapid Review, Published October 2008&lt;BR&gt;&lt;A href="http://www.npci.org.uk/blog/?p=201" target="_blank"&gt;http://www.npci.org.uk/blog/?p=201&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;This MeReC article discusses&amp;nbsp;a re-analysis of secondary endpoint data from the PROactive study.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp; The&amp;nbsp;full reference of the original research article providing the results of the re-analysis is as follows:&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=text_bold_smallm&gt;&lt;SPAN class=text_smallm&gt;Robert Wilcox, Stuart Kupfer, Erland Erdmann, on behalf of the PROactive Study investigators&lt;/SPAN&gt;. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). 2008. &lt;/SPAN&gt;&lt;SPAN class=text_smallm&gt;American Heart Journal 155, Issue 4, Pages 712-717.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;The abstract is available at: &lt;A href="http://www.ahjonline.com/article/S0002-8703(07)00984-2/abstract" target="_blank"&gt;http://www.ahjonline.com/article/S0002-8703(07)00984-2/abstract&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3. MeReC Extra Issue 20, Published January 2006&lt;BR&gt;&lt;A href="http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_extra_no20.pdf" target="_blank"&gt;http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_extra_no20.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;This section of this MeReC&amp;nbsp;Extra article&amp;nbsp;discusses the results of the PROactive randomised controlled trial which aimed to find out whether pioglitazone reduced cardiovascular morbidity and mortality in high risk patients with type 2 diabetes. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>102957</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.idf.org/home/index.cfm?unode=B7462CCB-3A4C-472C-80E4-710074D74AD3]]&gt;</url>
    <title>Global guideline for type 2 diabetes</title>
    <publicationDate>2005-01-01T00:00:00</publicationDate>
    <publisher>International Diabetes Federation (IDF)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,DIABETES AND PREGNANCY,NEPHROPATHY,RETINOPATHY,DIABETIC FOOT,PAINFUL NEUROPATHIES,SEXUAL DYSFUNCTION,CARDIOVASCULAR,PSYCHOLOGICAL PROBLEMS,LIVING WITH DIABETES,DELIVERY OF CARE,CHRONIC COMPLICATIONS,HOSPITAL INPATIENT CARE,PATIENT EDUCATION AND EMPOWERMENT,DIAGNOSIS,CAUSES,CONDITION MANAGEMENT,PREVENTION,CONDITION MANAGEMENT,HYPERTENSION,DIAGNOSIS,CONDITION MANAGEMENT,CAUSES,CAUSES,DIAGNOSIS,CONDITION MANAGEMENT,CAUSES,CONDITION MANAGEMENT,OTHER LIFE STYLE,CHILDREN AND YOUNG PEOPLE,MEDICATION,MONITORING / SELF-MONITORING,PRECONCEPTION CARE,AUTONOMIC NEUROPATHY,DIAGNOSIS,CONDITION MANAGEMENT,PREVENTION,EYE DISEASES,NUTRITION AND FOOD,PHYSICAL ACTIVITY,PSYCHOSOCIAL CARE,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,CHRONIC KIDNEY DISEASE,PREDISPOSING FACTORS,DIABETES,COGNITIVE FUNCTION,ANXIETY AND DEPRESSION,GESTATIONAL DIABETES,CAUSES,DIAGNOSIS,CONDITION MANAGEMENT,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the International Diabetes Federation website provides access to its 'Global guideline for type 2 diabetes'. The following statement is given in the introduction to the guideline:&lt;/P&gt;
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;P&gt;"A global guideline presents a unique challenge. Many national guidelines address one group of people with diabetes in the context of one health-care system, with one level of national and health-care resources. This is not true in the global context where, although every health-care system seems to be short of resources, the funding and expertise available for health care vary widely between countries and even between localities. Published national guidelines come from relatively resource-rich countries, and may be of limited practical use in less well resourced countries. Accordingly we have also tried to develop a guideline that is sensitive to resource and cost-effectiveness issues. Despite the challenges, we hope to be found to have been at least partially successful in that endeavour, which has used an approach that we have termed ‘Levels of care’"&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P dir=ltr&gt;The guideline is divided into the following sections:&lt;/P&gt;
&lt;UL dir=ltr&gt;
&lt;LI&gt;
&lt;DIV&gt;Screening and diagnosis&amp;nbsp; &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;Care delivery&amp;nbsp;&amp;nbsp; &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;Education&amp;nbsp; &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;Psychological care&amp;nbsp; &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;Lifestyle management&amp;nbsp; &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;Glucose control levels&amp;nbsp;&amp;nbsp; &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;Clinical monitoring&amp;nbsp; &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;Self-monitoring&amp;nbsp; &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;Glucose control: oral therapy&amp;nbsp; &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;Glucose control: insulin therapy&amp;nbsp; &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;Blood pressure control&amp;nbsp; &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;Cardiovascular risk protection&amp;nbsp; &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;Eye screening&amp;nbsp; &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;Kidney damage&amp;nbsp; &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;Foot care&amp;nbsp; &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;Nerve damage&amp;nbsp; &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;Pregnancy&amp;nbsp; &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;Children&amp;nbsp; &lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;In-patient care&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P dir=ltr&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2005.&lt;/P&gt;
&lt;P dir=ltr&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345506</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.idf.org/webdata/docs/Pregnancy_EN_RTP.pdf]]&gt;</url>
    <title>Global guideline on pregnancy and diabetes</title>
    <publicationDate>2009-09-16T00:00:00</publicationDate>
    <publisher>International Diabetes Federation (IDF)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ PRECONCEPTION CARE,CONDITION MANAGEMENT,DIABETES AND PREGNANCY,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guideline deals with the means of identifying women who may develop diabetes during pregnancy,&amp;nbsp;and helping these women, as well as women already known to have diabetes, to achieve the desired outcome of&amp;nbsp;a healthy mother and baby.&lt;/P&gt;
&lt;P&gt;The guideline includes the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;1. Introduction&lt;/LI&gt;
&lt;LI&gt;2. Gestational diabetes mellitus (GDM)&lt;/LI&gt;
&lt;LI&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;2.1 Defining the condition&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;2.2 Diagnosis of GDM&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;2.3 Rationale for treating GDM&lt;/LI&gt;
&lt;LI&gt;3. Before pregnancy&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;3.1 General issues for different groups of women&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;3.2 Review of medications&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;3.3 Pre-conception glycaemic control &lt;/LI&gt;
&lt;LI&gt;4. During pregnancy&amp;nbsp;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;4.1 Testing of all or some women for GDM&amp;nbsp;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;4.2 Testing for GDM – a two-stage or one-stage procedure?&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;4.3 Management during pregnancy&lt;/LI&gt;
&lt;LI&gt;5. After pregnancy&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;5.1 Breastfeeding&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 5.2 Follow-up of GDM&amp;nbsp;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 5.3 Prevention of type 2 diabetes in women who developed GDM&lt;/LI&gt;
&lt;LI&gt;6. Recommendations for Standard Care&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Pre-pregnancy counselling&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; At first prenatal visit&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Frequency of subsequent visits &lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Ongoing management of diabetes during pregnancy&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Management of gestational diabetes&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; After delivery&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Breastfeeding&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Follow-up within 6 weeks&lt;/LI&gt;
&lt;LI&gt;7. Implementation&lt;/LI&gt;
&lt;LI&gt;8. Evaluation&lt;/LI&gt;
&lt;LI&gt;9. References&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published in September 2009.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102658</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band134/b134-2.html]]&gt;</url>
    <title>Glucose monitoring in type 2 diabetes</title>
    <publicationDate>2005-04-01T00:00:00</publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier&amp;nbsp;article describes and reviews evidence (3 papers) and other information sources to consider whether blood or urine testing for glucose in patients with type 2 diabetics on oral treatment is worthwhile. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Review published April 2005.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102659</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band134/b134-4.html]]&gt;</url>
    <title>Glucose self monitoring in the UK</title>
    <publicationDate>2005-04-01T00:00:00</publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MONITORING / SELF-MONITORING,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier&amp;nbsp;article describes and reviews&amp;nbsp;evidence (one study)&amp;nbsp;to consider glucose self monitoring in primary care in the UK. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Review published&amp;nbsp;April 2005.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325855</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/content/32/8/1357.short]]&gt;</url>
    <title>Glucose sensing during hypoglycemia: lessons from the lab</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,HYPOGLYCAEMIA,ACUTE COMPLICATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;: An up to date view of the pathophysiology of hypoglycaemia.&amp;nbsp; This article&amp;nbsp;summarises the current&amp;nbsp;understanding of counterregulartory&amp;nbsp;mechanisms that culminate in restoration of circulating glucose concentrations, and discusses&amp;nbsp;how these mechanisms&amp;nbsp;may be initiated and coordinated by central glucose sensing.&amp;nbsp; The article also&amp;nbsp;describes the possible molecular mechanisms of neuronal glucose sensing, and alludes to the defective performance of these mechanisms in insulin-treated diabetes. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Citation&lt;/STRONG&gt;: McCrimmon R. Glucose sensing during hypoglycemia: lessons from the lab. Diabetes Care 2009;32(8):1357-63.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: The full-text of this article online requires subscription to the journal. NHS staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library for further assistance&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>312103</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19317813?ordinalpos=3&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Glucose sensors: a review of current and emerging technology</title>
    <publicationDate>2009-03-26T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MONITORING / SELF-MONITORING,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;: This is an expert review that outlines the important steps that have been made over the last 30 years in measuring glucose in the body. It outlines the different types of sensor and the different techniques that have been used to measure glucose. It concludes that the ideal sensor for glucose remains elusive, but there has been significant progress.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Expert review.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Oliver NS, Tournazou C, Cass, AEG, Johnson DG. Glucose sensors: a review of current and emerging technology. Diabetic Medicine 2009; 26:197-210&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published March 2009&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Access to the full text online requires subscription to the journal. NHS Staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library &lt;/A&gt;for further assistance.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60155</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,163/Itemid,61/]]&gt;</url>
    <title>Group versus individual therapeutic patient education (teaching letter no.18)</title>
    <publicationDate>1999-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,PATIENT EDUCATION AND EMPOWERMENT,DELIVERY OF CARE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the setting of therapeutic patient education and covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Individual education 
&lt;UL&gt;
&lt;LI&gt;Advantages 
&lt;LI&gt;Disadvantages 
&lt;LI&gt;Indications&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Group education 
&lt;UL&gt;
&lt;LI&gt;Advantages 
&lt;LI&gt;Disadvantages 
&lt;LI&gt;Indications&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Mass education 
&lt;UL&gt;
&lt;LI&gt;Advantages 
&lt;LI&gt;Disadvantages 
&lt;LI&gt;Indications&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Warnings (how to avoid some common pitfalls) 
&lt;LI&gt;Recommendations 
&lt;UL&gt;
&lt;LI&gt;Why not start tomorrow?&lt;/LI&gt;&lt;/UL&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 1999&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311655</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpch.ac.uk/doc.aspx?id_Resource=4817]]&gt;</url>
    <title>Growing up with Diabetes: children and young people with diabetes in England</title>
    <publicationDate>2009-03-31T00:00:00</publicationDate>
    <publisher>Royal College of Paediatrics and Child Health (RCPCH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CHILDREN AND YOUNG PEOPLE,REPORTS,STATISTICS,CHILDREN AND YOUNG PEOPLE,OUTCOMES,DIABETES,AGE GROUPS,CHILDREN,YOUNG PEOPLE,ENDOCRINE DISORDERS,SERVICE SECTORS,NHS ACTIVITIES,RESEARCH,PUBLIC HEALTH,TYPE 1,TYPE 2,DIABETES,SPECIALTIES,PUBLICATIONS,DIABETES MELLITUS,DIABETES INSIPIDUS,HEALTH MANAGEMENT,ENDOCRINOLOGY,CHILD HEALTH,PUBLIC HEALTH,MONTHLY ADDITIONS,2009 APRIL,POPULATIONS,GROUPS,DATA GATHERING AND AUDIT AND QOF,INCIDENCE AND PREVALENCE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Full research report describing the results of the 2009 survey of children and young people with diabetes in England.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This survey gives accurate numbers of children and young people under the age of 18 with diabetes of any type in England.&amp;nbsp; The survey has found that almost 23,000 children and young people have diabetes in England, higher than previous estimates.&lt;/P&gt;
&lt;P&gt;The report also shows that (&lt;EM&gt;taken directly from source&lt;/EM&gt;):&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The majority of children and young people have Type 1 diabetes (97%) – this is in contrast to adult populations where numbers of cases of Type 2 far exceed Type 1&amp;nbsp; 
&lt;LI&gt;A very small percentage of children and young people have Type 2 diabetes (1.5%) but prevalence of Type 2 is probably increasing in children as in adults 
&lt;LI&gt;The greatest number of children and young people with diabetes are aged between 10 and 14 years (just under 9,000) 
&lt;LI&gt;There are at least 15,361 children (aged 5 to 15) in schools in England with diabetes 
&lt;LI&gt;There are differences in numbers of cases between Strategic Health Authorities (SHAs). The numbers with Type 1 diabetes are higher than would be expected in the North East and South East Coast SHAs. For Type 2 diabetes, numbers were much higher than average in London, the North East and the West Midlands.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Published in March 2009&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&amp;nbsp; Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311655</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpch.ac.uk/doc.aspx?id_Resource=4817]]&gt;</url>
    <title>Growing up with Diabetes: children and young people with diabetes in England</title>
    <publicationDate>2009-03-31T00:00:00</publicationDate>
    <publisher>Royal College of Paediatrics and Child Health (RCPCH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CHILDREN AND YOUNG PEOPLE,REPORTS,STATISTICS,CHILDREN AND YOUNG PEOPLE,OUTCOMES,DIABETES,AGE GROUPS,CHILDREN,YOUNG PEOPLE,ENDOCRINE DISORDERS,SERVICE SECTORS,NHS ACTIVITIES,RESEARCH,PUBLIC HEALTH,TYPE 1,TYPE 2,DIABETES,SPECIALTIES,PUBLICATIONS,DIABETES MELLITUS,DIABETES INSIPIDUS,HEALTH MANAGEMENT,ENDOCRINOLOGY,CHILD HEALTH,PUBLIC HEALTH,MONTHLY ADDITIONS,2009 APRIL,POPULATIONS,GROUPS,DATA GATHERING AND AUDIT AND QOF,INCIDENCE AND PREVALENCE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Full research report describing the results of the 2009 survey of children and young people with diabetes in England.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This survey gives accurate numbers of children and young people under the age of 18 with diabetes of any type in England.&amp;nbsp; The survey has found that almost 23,000 children and young people have diabetes in England, higher than previous estimates.&lt;/P&gt;
&lt;P&gt;The report also shows that (&lt;EM&gt;taken directly from source&lt;/EM&gt;):&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The majority of children and young people have Type 1 diabetes (97%) – this is in contrast to adult populations where numbers of cases of Type 2 far exceed Type 1&amp;nbsp; 
&lt;LI&gt;A very small percentage of children and young people have Type 2 diabetes (1.5%) but prevalence of Type 2 is probably increasing in children as in adults 
&lt;LI&gt;The greatest number of children and young people with diabetes are aged between 10 and 14 years (just under 9,000) 
&lt;LI&gt;There are at least 15,361 children (aged 5 to 15) in schools in England with diabetes 
&lt;LI&gt;There are differences in numbers of cases between Strategic Health Authorities (SHAs). The numbers with Type 1 diabetes are higher than would be expected in the North East and South East Coast SHAs. For Type 2 diabetes, numbers were much higher than average in London, the North East and the West Midlands.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Published in March 2009&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&amp;nbsp; Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342057</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=986]]&gt;</url>
    <title>Growing up with diabetes: children and young people with diabetes in England</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ INCIDENCE AND PREVALENCE,DATA GATHERING AND AUDIT AND QOF,CHILDREN AND YOUNG PEOPLE,STATISTICS,CHILDREN AND YOUNG PEOPLE,DIABETES,TYPE 2,TYPE 1]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Factsheet from NHS Diabetes summarising findings of the survey of children and young people with diabetes in England.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This factsheet from NHS Diabetes summarises the findings of the 2009 Royal College of Paediatrics and Child Health (RCPCH) survey of&amp;nbsp;children and young people with diabetes in England.&amp;nbsp; &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=311655" target="_blank"&gt;See details of the full survey here&lt;/A&gt;. &lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in September 2009.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public, Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342057</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=986]]&gt;</url>
    <title>Growing up with diabetes: children and young people with diabetes in England</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ INCIDENCE AND PREVALENCE,DATA GATHERING AND AUDIT AND QOF,CHILDREN AND YOUNG PEOPLE,STATISTICS,CHILDREN AND YOUNG PEOPLE,DIABETES,TYPE 2,TYPE 1]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Factsheet from NHS Diabetes summarising findings of the survey of children and young people with diabetes in England.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This factsheet from NHS Diabetes summarises the findings of the 2009 Royal College of Paediatrics and Child Health (RCPCH) survey of&amp;nbsp;children and young people with diabetes in England.&amp;nbsp; &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=311655" target="_blank"&gt;See details of the full survey here&lt;/A&gt;. &lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in September 2009.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public, Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301787</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Documents/News/Fire_service_guidance.pdf]]&gt;</url>
    <title>Guidance on the recruitment and employment of firefighters and control room staff with diabetes</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,LIVING WITH DIABETES,EMPLOYMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims&lt;/STRONG&gt;: This guidance was written in response to the findings of a survey of firefighters and control room staff about the treatment of employees with diabetes. It is intended for managers in the Fire and Rescue Service, to support them in the recruitment and retention of employees with diabetes. It is a guide to best practice, focusing on individual case management. It is not a comprehensive guide to the law on the recruitment, employment and retention of employees with diabetes.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience&lt;/STRONG&gt;: Managers in the fire and rescue service and trainees or existing staff with diabetes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Published September 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345516</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.idf.org/webdata/docs/OralHealth_EN_RTP.pdf]]&gt;</url>
    <title>Guideline on oral health for people with diabetes</title>
    <publicationDate>2009-09-16T00:00:00</publicationDate>
    <publisher>International Diabetes Federation (IDF)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DENTAL PROBLEMS,CHRONIC COMPLICATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In this guideline, the International Diabetes Federation and the World Dental Federation came together under the lead of the IDF Task Force on Clinical Guidelines to assess the evidence base in the area of peridontal disease in people with diabetes, and to make&amp;nbsp;formal recommendations on oral health and diabetes care.&lt;/P&gt;
&lt;P&gt;The guideline includes the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Clinical rationale&lt;/LI&gt;
&lt;LI&gt;Guideline process&lt;/LI&gt;
&lt;LI&gt;Evidence review&lt;/LI&gt;
&lt;LI&gt;Consideration&lt;/LI&gt;
&lt;LI&gt;Recommendations&lt;/LI&gt;
&lt;LI&gt;Implementation&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in September 2009.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345525</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.idf.org/webdata/docs/SMBG_EN2.pdf]]&gt;</url>
    <title>Guideline on self-monitoring of blood glucose in non-insulin treated type 2 diabetes</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>International Diabetes Federation (IDF)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CONDITION MANAGEMENT,DIABETES,TYPE 2,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guideline presents a summary of the findings and recommendations of&amp;nbsp;a&amp;nbsp;workshop held in Amsterdam in October 2008, convened by the IDF clinical guidelines task force and the SMBG working group, related to the use of self-monitoring of blood glucose&amp;nbsp;in non-insulin treated people with Type 2 Diabetes Mellitus.&lt;/P&gt;
&lt;P&gt;The guideline contains the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;1. Introduction&lt;/LI&gt;
&lt;LI&gt;2. Summary of recommendations&lt;/LI&gt;
&lt;LI&gt;3. Background&lt;/LI&gt;
&lt;LI&gt;4. Review of selected evidence&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; Observational studies&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; Randomized controlled trials&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; Studies of costs and cost-eff ectiveness of SMBG&lt;/LI&gt;
&lt;LI&gt;5. Assessment of study limitations&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; Reduced external validity&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; Subject contamination&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; Attrition bias and analytic approach&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; Potential design constraints&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; ‘Study effect’ in behaviour-dependent intervention studies&lt;/LI&gt;
&lt;LI&gt;6. Future SMBG studies and study design&lt;/LI&gt;
&lt;LI&gt;7. Potential uses of SMBG&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; Diabetes education and understanding&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; Behavioural changes&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; Glycaemic assessment&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; Optimization of therapy&lt;/LI&gt;
&lt;LI&gt;8. Recommendations&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; Explanation and rationale&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; Cost implications&lt;/LI&gt;
&lt;LI&gt;9. Summary&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2009.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>283076</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=283076]]&gt;</url>
    <title>Guidelines for the prevention and management of foot problems for people with diabetes</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CAUSES,PREVENTION,DIAGNOSIS,CONDITION MANAGEMENT,CHRONIC COMPLICATIONS,DIABETIC FOOT]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The aim of this guideline is to provide a minimum standard of care for foot problems for people with diabetes. The recommendations in this guideline are endorsed by Foot in Diabetes UK (FDUK).</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Guidelines for the prevention and management of foot problems for people with diabetes&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp;To provide a minimum standard of care for foot problems for people with diabetes. This guideline complements NICE guidance but provides specific advice on podiatry assessments, interventions and referrals. The recommendations in this guideline are endorsed by&amp;nbsp;Foot Diabetes United Kingdom (FDUK).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Clinicians, health professionals. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published March 2005.&amp;nbsp; Version 2 was issued in April 2008.&amp;nbsp; A provisional&amp;nbsp;review date set for this guideline is April 2011.&amp;nbsp;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word file.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>385478</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20636950]]&gt;</url>
    <title>Haemaglobin A1c towards global standardization (editorial)</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MONITORING / SELF-MONITORING,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This editorial provides a discussion of haemaglobin A1&lt;SUB&gt;c &lt;/SUB&gt;(HbA&lt;SUB&gt;1c&lt;/SUB&gt;) methods in routine clinical practice. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; John G. Haemaglobin A1c towards global standardization (editorial). Diabetic Medicine. July 2010; 27:733-734&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in July 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full-text of this article online requires subscription to the&amp;nbsp;journal. NHS staff please&amp;nbsp;contact&amp;nbsp; &lt;A href="http://www.hlisd.org/" target="_blank"&gt;your local NHS library&lt;/A&gt;&amp;nbsp;for further assistance.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>261312</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=17367307]]&gt;</url>
    <title>HbA(1c) as a screening tool for detection of Type 2 diabetes: a systematic review.</title>
    <publicationDate></publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ TYPE 2,DIABETES,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;BR&gt;&lt;/STRONG&gt;Bennett CM, Guo M, Dharmage SC. HbA(1c) as a screening tool for detection of Type 2 diabetes: a systematic review. Diabet Med. 2007 Apr;24(4):333-43. Epub 2007 Mar 15.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full text online requires subscription to the journal.&lt;BR&gt;NHS staff please&amp;nbsp;contact your&lt;A href="http://www.hlisd.org/" target="_blank"&gt; local NHS library&lt;/A&gt;&amp;nbsp;for further assistance&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309817</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=242]]&gt;</url>
    <title>HbA1c Standardisation For Clinical Health Care Professionals</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CONDITION MANAGEMENT,DIABETES,TYPE 1,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ From 1 June 2009, the way in which HbA1c results are reported in the UK is changing. This leaflet explains why and how this will happen.]]&gt;</body>
  </document>
  <document>
    <id>309819</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=243]]&gt;</url>
    <title>HbA1c Standardisation For Laboratory Professionals</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ MONITORING / SELF-MONITORING,TYPE 1,DIABETES,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ From 1 June 2009, the way in which HbA1c results are reported in the UK is changing. This leaflet explains why and how this will happen.]]&gt;</body>
  </document>
  <document>
    <id>312068</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publichealth/Healthimprovement/Obesity/HealthyWeight/index.htm]]&gt;</url>
    <title>Healthy Weight, Healthy Lives</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CONDITION MANAGEMENT,OBESITY,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This section of the Department of Health website contains information about "Healthy weight, healthy lives", a cross-government strategy for England. This section of the website provides access to progress reports and guidance documents.]]&gt;</body>
  </document>
  <document>
    <id>60145</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,180/Itemid,61/]]&gt;</url>
    <title>Help your patients to improve self-management: building a therapeutic chain (teaching letter no.9)</title>
    <publicationDate>1997-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ SELF MANAGEMENT,INDIVIDUAL INVOLVEMENT,DIABETES,TYPE 2,TYPE 1,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,PPI IN PRACTICE,PATIENT AND PUBLIC INVOLVEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the improvement of diabetic patients' self-management through patient education. It covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;The doctor talks of the necessity and advantages of the treatment 
&lt;LI&gt;The patient speaks about his fears and expectations of the treatment 
&lt;LI&gt;Deciding and imposing the treatment plan 
&lt;LI&gt;Proposing and negotiating changes linked to treatment plan 
&lt;LI&gt;Controlling the biological results 
&lt;LI&gt;Recognizing and using the patient's experience 
&lt;LI&gt;Sharing the patient's responsibilities and risks of the treatment&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 1997&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386324</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.yhpho.org.uk/resource/view.aspx?RID=81584]]&gt;</url>
    <title>How many inpatients have diabetes? : an analysis of hospital episode statistics</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>Yorkshire and Humber Public Health Observatory (YHPHO)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,LIVING WITH DIABETES,HOSPITAL INPATIENT CARE,STATISTICS,INCIDENCE AND PREVALENCE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In order to estimate the number and percentage of people in hospital at a given time that have diabetes an analysis of hospital episode statistics was undertaken for the week beginning 22nd September 2008. &lt;/P&gt;
&lt;P&gt;Key findings:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;At a given point in time at least 14% of adults in hospital in England being treated under a medical or surgical speciality have diabetes. 
&lt;LI&gt;In this group of patients approximately 55% are being treated under medical specialities and 45% are being treated under surgical specialities.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60187</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/diabetes1/resources/merec_extra_no08.pdf]]&gt;</url>
    <title>How to achieve the standards set out in the NSF for diabetes</title>
    <publicationDate>2003-03-01T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ DIABETES,ORGANISATION OF CARE / CARE PLANNING,KEY POLICIES / NSF,DELIVERY OF CARE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of this MeReC&amp;nbsp;Extra article&amp;nbsp;draws out key points from the &lt;A href="http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4003246&amp;amp;chk=lKNg9r" target="_blank"&gt;delivery strategy for the NSF for Diabetes&lt;/A&gt;. It includes major deadlines and a link to example of good practice. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published March 2003. MeReC Extra No 8.&lt;BR&gt;&amp;nbsp; 
&lt;P&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60149</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,158/Itemid,61/]]&gt;</url>
    <title>How to improve follow-up in the long term disease (teaching letter no.12)</title>
    <publicationDate>1998-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ TREATMENT CONCORDANCE,DIABETES,PATIENT EDUCATION AND EMPOWERMENT,ORGANISATION OF CARE / CARE PLANNING,DELIVERY OF CARE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns patients' difficulties in adhering to treatment in chronic disease and covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Change in behavior 
&lt;LI&gt;Stagewise achievement via intermediate goals 
&lt;LI&gt;Patient diary 
&lt;LI&gt;Automatic thought patterns interfering with treatment compliance 
&lt;LI&gt;Treatment contract 
&lt;LI&gt;Conclusions&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 1998&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60151</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,181/Itemid,61/]]&gt;</url>
    <title>How to manage the poorly controlled patient (teaching letter no.14)</title>
    <publicationDate>1998-12-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ TYPE 1,TYPE 2,DIABETES,CONDITION MANAGEMENT,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the management of patients with poor diabetes&amp;nbsp;control and covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;From acute to long-term medical care 
&lt;LI&gt;The crisis situation 
&lt;LI&gt;The chronic phase of the disease 
&lt;LI&gt;The patient's attitude towards long-term care 
&lt;LI&gt;Coping with the disease 
&lt;LI&gt;The patient's image of the illness and the treatment 
&lt;LI&gt;Am I controlling my health or is someone else? Internal versus external control 
&lt;LI&gt;New approach in prescription of treatment 
&lt;LI&gt;Conclusions&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 1998&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380679</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.technologyadoptioncentre.nhs.uk/Continuous-Subcutaneous-Insulin-Infusion/executive-summary.html]]&gt;</url>
    <title>How to why to guide: continuous subcutaneous insulin infusion (insulin pump therapy)</title>
    <publicationDate>2010-06-18T00:00:00</publicationDate>
    <publisher>NHS Technology Adoption Centre (NTAC)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,CONDITION MANAGEMENT,MEDICATION,INSULIN PUMPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This online guide informs clinicians, commissioners and managers how to successfully implement insulin pump therapy into routine clinical and operational practice. It includes the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Executive summary 
&lt;LI&gt;Introduction to the technology 
&lt;LI&gt;Evidence base 
&lt;LI&gt;Benefits v barriers 
&lt;LI&gt;Implementation project 
&lt;LI&gt;Procurement 
&lt;LI&gt;Policy 
&lt;LI&gt;Business case (including costing model and business case template) 
&lt;LI&gt;Roadmap 
&lt;LI&gt;Contacts and links&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Access: Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>83758</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/nicemedia/pdf/CG015childrenfullguideline.pdf]]&gt;</url>
    <title>Hypoglycaemia (in children and young people) from the NICE guideline on Type 1 diabetes</title>
    <publicationDate>2004-07-21T00:00:00</publicationDate>
    <publisher>NICE</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CHILD HEALTH,GUIDELINES/EBM,METABOLIC DISEASE,HYPOGLYCAEMIA,SPECIALTIES,DIABETES,HYPOGLYCAEMIA,ACUTE COMPLICATIONS,STAFF USE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;NICE offers guidance for&amp;nbsp;the management&amp;nbsp;of hypoglycaemia in children and young people in Section 5.1 of the guideline entitled 'Type 1 diabetes : diagnosis and management of type 1 diabetes in children and young people' published in&amp;nbsp;July 2004. &lt;/P&gt;
&lt;P&gt;Section 5.1, which starts on page 89 of the guideline, discusses and makes recommendations regarding the management of hypoglycaemia in children and young people with type 1 diabetes.&amp;nbsp;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60139</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,150/Itemid,61/]]&gt;</url>
    <title>Hypoglycaemia (teaching letter no.2)</title>
    <publicationDate>1996-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ HYPOGLYCAEMIA,ACUTE COMPLICATIONS,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the education of patients on the subject of hypoclycaemia. It covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;"Mild" hypoglycemia 
&lt;UL&gt;
&lt;LI&gt;Symptoms of mild hypoglycemia 
&lt;LI&gt;Special cases 
&lt;LI&gt;Fear and avoidance of hypoglycemia 
&lt;LI&gt;Dealing with mild hypoglycemia 
&lt;LI&gt;Teaching patients how to avoid hypoglycemia&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Severe hypoglycemia 
&lt;UL&gt;
&lt;LI&gt;Symptoms and signs 
&lt;LI&gt;Treating severe hypoglycemia 
&lt;LI&gt;Training patients' relatives to inject glucagon 
&lt;LI&gt;Prevention of severe hypoglycemia&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Oral agents 
&lt;LI&gt;Prevention of sulfonylurea-induced hypoglycemia&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 1996&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>284129</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;pubmedid=18215172]]&gt;</url>
    <title>Hypoglycaemia in Type 2 diabetes.</title>
    <publicationDate></publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ DIABETES,HYPOGLYCAEMIA,ACUTE COMPLICATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;/STRONG&gt;&amp;nbsp; Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in Type 2 diabetes. Diabetic Medicine. 2008 Feb 27;25(3):245-254&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325891</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/content/32/8/1364.extract]]&gt;</url>
    <title>Hypoglycemia: from the laboratory to the clinic</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,HYPOGLYCAEMIA,ACUTE COMPLICATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;: An up to date view of the pathophysiology of hypoglycaemia and hypoglycaemia unawareness, their clinical effects and how they can be managed.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Citation&lt;/STRONG&gt;: Amiel SA. Hypoglycemia: from the laboratory to the clinic. Diabetes Care 2009;32(8):1364-71.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: The full-text of this article online requires subscription to the journal. NHS staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library for further assistance&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>375229</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/content/33/4/926.abstract]]&gt;</url>
    <title>Identifying psychosocial interventions that improve both physical and mental health in patients with diabetes: a systematic review and meta-analysis</title>
    <publicationDate>2010-04-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,PSYCHOLOGICAL PROBLEMS,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,CONDITION MANAGEMENT,PHYSICAL ACTIVITY,PHYSICAL ACTIVITY,PSYCHOSOCIAL CARE,PSYCHOSOCIAL CARE,COGNITIVE FUNCTION,ANXIETY AND DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt;&amp;nbsp;"Patients with diabetes suffer high rates of mental health problems, and this combination is associated with poor outcomes. Although effective treatments exist for both diabetes and mental health problems, delivering services for physical and mental health problems separately ignores their interaction and may be inefficient. This systematic review sought to identify psychosocial interventions that could improve both the physical and mental health of patients with diabetes."&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Research design and methods:&lt;/STRONG&gt;&amp;nbsp;"Studies were identified from the following databases: CENTRAL, MEDLINE, Excerpta Medica (EMBASE), Psychinfo, and Cumulative Index to Nursing and Allied Health Literature (CINAHL). The review included randomized controlled trials in patients with type 1 and type 2 diabetes who received psychosocial interventions and where both mental health and physical health outcomes were reported. Data were extracted on study quality, the content and process of interventions, and outcomes."&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Results: "&lt;/STRONG&gt;Eighty-five eligible comparisons were identified, of which 49 reported sufficient data for analysis. Psychosocial interventions modestly improved A1C (standardized mean difference -0.29 [95% CI -0.37 to -0.21]) and mental health outcomes (-0.16 [-0.25 to -0.07]). However, there was a limited association between the effects on A1C and mental health, and no intervention characteristics predicted benefit on both outcomes."&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Conclusions: "&lt;/STRONG&gt;Managing physical and mental health in long-term conditions are increasingly important. The review did not identify types of interventions that consistently provide benefits for both physical and mental health. Developing such interventions remains an important challenge. The findings have implications for understanding the interaction between physical and mental health problems and for the coordination of care." &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full-text of this article online requires subscription to the&amp;nbsp;journal. NHS staff please&amp;nbsp;contact&amp;nbsp; &lt;A href="http://www.hlisd.org/" target="_blank"&gt;your local NHS library&lt;/A&gt;&amp;nbsp;for further assistance.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>260334</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.idf.org/idf-consensus-type-2-diabetes-prevention]]&gt;</url>
    <title>IDF consensus on type 2 diabetes prevention</title>
    <publicationDate>2007-05-01T00:00:00</publicationDate>
    <publisher>International Diabetes Federation (IDF)</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;To address the growing impact of type 2 diabetes, the International Diabetes Federation (IDF) Taskforce on Epidemiology and Prevention convened a consensus workshop in 2006. The resulting consensus paper was published in Diabetic Medicine in May 2007:&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Full reference:&lt;/STRONG&gt;&amp;nbsp;Alberti KGMM, Zimmet P,&amp;nbsp;Shaw J. International Diabetes Federation: a consensus on Type 2 diabetes prevention. Diabetic Medicine 2007 24(5), 451–463.&amp;nbsp; doi:10.1111/j.1464-5491.2007.02157.x &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>389559</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.idf.org/united-nations-resolution-workshops]]&gt;</url>
    <title>IDF Regional Action Plans</title>
    <publicationDate></publicationDate>
    <publisher>International Diabetes Federation (IDF)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Each action plan reflects the demographics, geography, culture and healthcare systems within that region and includes specific responses to local issues.&lt;/P&gt;
&lt;P&gt;Regional Action Plans&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Africa (AFR) (pdf) 
&lt;LI&gt;Europe (EUR) 
&lt;LI&gt;Middle East and North Africa (MENA) (pdf) 
&lt;LI&gt;North America and Caribbean (NAC) (pdf) 
&lt;LI&gt;South and Central America (SACA) (pdf) 
&lt;LI&gt;South-East Asia (SEA) 
&lt;LI&gt;Western Pacific (WP) (pdf)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>93133</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band132/b132-2.html]]&gt;</url>
    <title>Impaired fasting glycaemia</title>
    <publicationDate>2005-02-01T00:00:00</publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PREDIABETIC STATE,PREDIABETES,CONDITION MANAGEMENT,CAUSES,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier&amp;nbsp;article describes and reviews evidence (3 papers) on the subject of impaired fasting glycaemia. It specifically looks at the risk of progressing to diabetes with impaired fasting glycaemia, and about the risk factors, and how to deal with the condition. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Review published February 2005.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>125014</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band140/b140-5.html]]&gt;</url>
    <title>Implementing better diabetes care</title>
    <publicationDate></publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier&amp;nbsp;article describes and reviews a 2005 report of an observational study from Israel concerning improving the delivery of diabetic care. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Review published&amp;nbsp;October 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>59973</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band84/b84-5.html]]&gt;</url>
    <title>Improved diabetic control reduces healthcare costs</title>
    <publicationDate>2011-03-31T00:00:00</publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier&amp;nbsp;article describes and reviews a 2001 study concerning the cost-saving effects of better glycaemic control, mainly in type 2 diabetics. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Review published&amp;nbsp;February 2001.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>143218</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band141/b141-6.html]]&gt;</url>
    <title>Improving care for chronic illness</title>
    <publicationDate>2005-11-01T00:00:00</publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,KEY POLICIES / NSF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier article describes and reviews 1 meta-analysis (of&amp;nbsp;112 studies) to consider if elements of the Chronic Care Model (CCM), used in the USA as a framework for improving chronic disease care in the community, contribute to better care.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Review published Nov 2005.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>143243</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.institute.nhs.uk/option,com_joomcart/Itemid,26/main_page,document_product_info/products_id,265.html]]&gt;</url>
    <title>Improving care for people with long term conditions: a review of UK and international frameworks</title>
    <publicationDate>2006-05-16T00:00:00</publicationDate>
    <publisher>NHS Institute for Innovation and Improvement, University of Birmingham Health Service Management Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,KEY POLICIES / NSF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In January 2005, the government launched a bespoke NHS and Social Care Model designed to help local health and social care organisations improve care for people with long-term conditions.&lt;BR&gt;This evidence review was commissioned as an early part of the NHS Institute’s workplan to help to gain a greater understanding of current international, national, and local thinking about the different approaches in use.&lt;BR&gt;The review has been produced by the &lt;A href="http://www.institute.nhs.uk/" target="_blank"&gt;NHS Institute for Innovation and Improvement&lt;/A&gt; in conjunction with the &lt;A href="http://www.hsmc.bham.ac.uk/" target="_blank"&gt;University of Birmingham Health Service Management Centre&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published 16 May 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82893</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4106716&amp;chk=7v4EyV]]&gt;</url>
    <title>Improving diabetes services : the NSF two years on</title>
    <publicationDate>2005-03-23T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,KEY POLICIES / NSF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The &lt;A href="http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Diabetes/index.htm" target="_blank"&gt;Diabetes National Service Framework&amp;nbsp;(NSF)&lt;/A&gt; set out national standards for the treatment of diabetes to raise the quality of NHS services and reduce unacceptable variations between them. This Department of Health report highlights progress over the two years following the publication of the &lt;A href="http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4003246&amp;amp;chk=lKNg9r" target="_blank"&gt;NSF Delivery Strategy&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published&amp;nbsp;23&amp;nbsp;March&amp;nbsp;2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286972</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=324]]&gt;</url>
    <title>Improving emergency and inpatient care for people with diabetes.</title>
    <publicationDate>2008-03-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ ORGANISATION OF CARE / CARE PLANNING,HOSPITAL,DELIVERY OF CARE,LIVING WITH DIABETES,DIABETES,ACUTE ILLNESS INCLUDING INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report from the National Diabetes Support team pulls together the many strands of work focusing on emergency and in hospital care for people with diabetes.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;It includes:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Top ten things to know about emergency and inpatient diabetes care 
&lt;LI&gt;Introduction and policy context 
&lt;LI&gt;Preventing admissions due to diabetes emergencies 
&lt;LI&gt;People with diabetes in hospital 
&lt;LI&gt;Next steps 
&lt;LI&gt;Annexes: Lay glossary, inpatient experience, audit and quality assurance&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication History:&lt;/STRONG&gt;&amp;nbsp; March 2008&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>331706</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Documents/Reports/Supported_self-management.pdf]]&gt;</url>
    <title>Improving supported self-management for people with diabetes</title>
    <publicationDate>2009-11-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,USER INVOLVEMENT,INNOVATION AND IMPROVEMENT,CHANGE MANAGEMENT,ENGAGEMENT,LEADING IMPROVEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report&amp;nbsp;looks at what&amp;nbsp;Diabetes UK&amp;nbsp;consider are the essential components that make up good supported self-management. The report contains some background to self-management, and discusses results of Diabetes UK surveys where people with diabetes were consulted about what they want&amp;nbsp;to support their self-management.&amp;nbsp; The report goes on to discuss&amp;nbsp;barriers to&amp;nbsp;supporting self-management, and suggests&amp;nbsp;priorities for action.&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in November 2009.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>250520</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=17240286]]&gt;</url>
    <title>Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis</title>
    <publicationDate>2007-05-05T00:00:00</publicationDate>
    <publisher>Lancet</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CAUSES,TYPE 2]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims: &lt;BR&gt;&lt;/STRONG&gt;Taken from PubMed abstract&lt;BR&gt;"The effect of different classes of antihypertensive drugs on incident diabetes mellitus is controversial because traditional meta-analyses are hindered by heterogeneity across trials and the absence of trials comparing angiotensin-converting-enzyme (ACE) inhibitors with angiotensin-receptor blockers (ARB). We therefore undertook a network meta-analysis, which accounts for both direct and indirect comparisons to assess the effects of antihypertensive agents on incident diabetes."&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods: &lt;BR&gt;&lt;/STRONG&gt;Taken from PubMed abstract&lt;BR&gt;"We undertook a systematic review up to Sept 15, 2006, and identified 48 randomised groups of 22 clinical trials with 143,153 participants who did not have diabetes at randomisation and so were eligible for inclusion in our analysis. 17 trials enrolled patients with hypertension, three enrolled high-risk patients, and one enrolled those with heart failure. The main outcome was the proportion of patients who developed diabetes."&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results: &lt;BR&gt;&lt;/STRONG&gt;Taken from PubMed abstract&lt;BR&gt;"Initial drug therapy used in the trials (and the number of patients with diabetes of the total number at risk) included: an ARB (1189 of 14,185, or 8.38%), ACE inhibitor (1618 of 22,941, or 7.05%), calcium-channel blocker (CCB, 2791 of 38,607, or 7.23%), placebo (1686 of 24,767, or 6.81%), beta blocker (2705 of 35,745, or 7.57%), or diuretic (998 of 18,699, or 5.34%). With an initial diuretic as the standard of comparison (eight groups), the degree of incoherence (a measure of how closely the entire network fits together) was small (omega=0.000017, eight degrees of freedom). The odds ratios were: ARB (five groups) 0.57 (95% CI 0.46-0.72, p&amp;lt;0.0001); ACE inhibitor (eight groups) 0.67 (0.56-0.80, p&amp;lt;0.0001); CCB (nine groups): 0.75 (0.62-0.90, p=0.002); placebo (nine groups) 0.77 (0.63-0.94, p = 0.009); beta blocker (nine groups) 0.90 (0.75-1.09, p=0.30). These estimates changed little in many sensitivity analyses." &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions: &lt;BR&gt;&lt;/STRONG&gt;Taken from PubMed abstract&lt;BR&gt;"The association of antihypertensive drugs with incident diabetes is therefore lowest for ARB and ACE inhibitors followed by CCB and placebo, beta blockers and diuretics in rank order."&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Elliott W J, Meyer P M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007 Jan 20:369(9557):201-7.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in May 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessing the full text:&lt;/STRONG&gt;&amp;nbsp;Access to the full text of this article online requires subscription to the journal.&lt;/P&gt;
&lt;P&gt;NHS staff please &lt;A href="http://www.hlisd.org/" target="_blank"&gt;contact your local NHS library for further assistance&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>378442</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20536944]]&gt;</url>
    <title>Incorrect and incomplete coding and classification of diabetes: a systematic review</title>
    <publicationDate>2010-05-01T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,OTHER TYPES OF DIABETES,DIAGNOSIS,DIAGNOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed abstract&lt;BR&gt;“To conduct a systematic review to identify types and implications of incorrect or incomplete coding or classification within diabetes or between diabetes and other conditions; also to determine the availability of evidence regarding frequency of occurrence.”&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed abstract&lt;BR&gt;“Medical Subject Headings (MeSH) and free-text terms were used to search relevant electronic databases for papers published to the end of August 2008. Two researchers independently reviewed titles and abstracts and, subsequently, the full text of potential papers. Reference lists of selected papers were also reviewed and authors consulted. Three reviewers independently extracted data.”&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed abstract&lt;BR&gt;“Seventeen eligible studies were identified, including five concerned with distinguishing between Type 1 and Type 2 diabetes. Evidence was also identified regarding: the distinction between diabetes and no-diabetes, failure to specify type of diabetes, and diagnostic errors or difficulties involving maturity-onset diabetes of the young, latent autoimmune diabetes in adults, pancreatic diabetes, persistence of foetal haemoglobin and acquired immune deficiency syndrome (AIDS). The sample was too heterogeneous to derive accurate information about frequency, but our findings suggested that misclassification occurs most commonly in young people. Implications relating to treatment options and risk management were highlighted, in addition to psychological and financial implications and the potential impact on the validity of quality of care evaluations and research.” &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed abstract&lt;BR&gt;“This review draws attention to the occurrence and implications of incorrect or incomplete coding or classification of diabetes, particularly in young people. A pragmatic and clinically relevant approach to classification is needed to assist those involved in making decisions about types of diabetes.”&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt;&amp;nbsp;Camosso-Stefinovic J, Wilkinson J, de Lusignan S, Hattersley AT, Khunti K. Incorrect and incomplete coding and classification of diabetes: a systematic review.&amp;nbsp;Diabetic Medicine 2010;27(5):491-7.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in May 2010.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full-text of this article online requires subscription to the&amp;nbsp;journal. NHS staff please&amp;nbsp;contact&amp;nbsp; &lt;A href="http://www.hlisd.org/" target="_blank"&gt;your local NHS library&lt;/A&gt;&amp;nbsp;for further assistance.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301813</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/our_work_areas/inequalities/]]&gt;</url>
    <title>Inequalities - Work Area - NHS Diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,ELDERLY PEOPLE,PEOPLE FROM ETHNIC MINORITIES,ELDERLY PEOPLE,PEOPLE FROM ETHNIC MINORITIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the&amp;nbsp;NHS Diabetes&amp;nbsp;website provides details of the work of the Working Group on inequalities.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>347267</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.yhpho.org.uk/resource/view.aspx?RID=73474]]&gt;</url>
    <title>Inequalities in Diabetes and Obesity Prevalence in England</title>
    <publicationDate>2009-11-01T00:00:00</publicationDate>
    <publisher>Yorkshire and Humber Public Health Observatory (YHPHO)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ STATISTICS,OBESITY,INDIVIDUAL BEHAVIOUR,BIOLOGICAL COMPOSITION,OUTCOMES,ENDOCRINE DISORDERS,DIABETES,DISADVANTAGED GROUPS,ETHNIC GROUPS,PUBLIC HEALTH ORGANISATIONS,MONTHLY ADDITIONS,DIABETES,PUBLIC HEALTH,DETERMINANTS,EATING HABITS,SOCIOECONOMIC FACTORS,SOCIAL DETERMINANTS,MEASUREMENT,METHODS,POPULATIONS,ANALYSIS &amp; RESEARCH,AGE GROUPS,ORGANISATIONS,GROUPS,INCIDENCE AND PREVALENCE,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report highlights the pattern of inequality in diabetes prevalence in relation to age, deprivation and ethnic group. It also highlights the distribution of obesity in relation to these factors.&amp;nbsp; This report is based on data from the &lt;A href="http://www.ic.nhs.uk/statistics-and-data-collections/health-and-lifestyles-related-surveys/health-survey-for-england" target="_blank"&gt;Health Survey for England&lt;/A&gt;, the &lt;A href="http://www.ic.nhs.uk/services/national-clinical-audit-support-programme-ncasp/diabetes" target="_blank"&gt;National Diabetes Audit&lt;/A&gt;, and the &lt;A href="http://www.ic.nhs.uk/statistics-and-data-collections/health-and-lifestyles/obesity/national-child-measurement-programme-england-2008-09-school-year" target="_blank"&gt;National Child Measurement Programme&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published&amp;nbsp;November 2009.&amp;nbsp;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>305283</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/14519713]]&gt;</url>
    <title>Infant diets and type 1 diabetes: too early, too late, or just too complicated?</title>
    <publicationDate></publicationDate>
    <publisher>Journal of the American Medical Association</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ CAUSES,PREVENTION,TYPE 1,DIABETES,CHILDREN AND YOUNG PEOPLE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;/STRONG&gt;&lt;BR&gt;Atkinson M, Gale EA. Infant diets and type 1 diabetes: too early, too late, or just too complicated? JAMA. 2003 Oct 1;290(13):1771-2. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; NHS staff in England: available &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;via NHS Evidence.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Other NHS staff please &lt;A href="http://www.hlisd.org/" target="_blank"&gt;check with your local NHS library for further assistance&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301818</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/our_work_areas/information_for_diabetes/]]&gt;</url>
    <title>Information - Work Area - NHS Diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the&amp;nbsp;NHS Diabetes website provides details of the work of the Working Group on information. It gives details of the National Diabetes Audit, the National Diabetes Public Health Information group and the "Do once and share diabetes" project.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323073</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/our_work_areas/inpatient_care/]]&gt;</url>
    <title>Inpatient care - Work Area - NHS Diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,LIVING WITH DIABETES,DELIVERY OF CARE,HOSPITAL INPATIENT CARE,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,ACUTE ILLNESS INCLUDING INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the NHS Diabetes website provides details of the work of the&amp;nbsp; Inpatient Care Working Group. It also includes links to further information. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>258656</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/DH_072777]]&gt;</url>
    <title>Insulin pump services: report of the insulin pumps working group</title>
    <publicationDate>2007-03-08T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,CONDITION MANAGEMENT,MEDICATION,INSULIN PUMPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report sets out the findings of the Insulin Pumps Working Group, which was set up to address variation in access to this therapy across the country. It outlines the group’s conclusions and gives examples of best practice in improving access to pump therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>379548</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/cdrisk/resources/merec_monthly_no27.pdf]]&gt;</url>
    <title>Insulin use may increase mortality in type 2 diabetes</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,MEDICATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This MeReC monthly article (on page 2 of the newsletter) discusses a large observational study in Canada that found a statistically significant association between all-cause mortality and exposure to insulin in people with type 2 diabetes.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Publication history information:&lt;/B&gt; MeReC Monthly No. 27, page 2. Published June 2010. Original article: Gamble J–M, et al. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes, obesity and metabolism 2010;12:47–53.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Access:&lt;/B&gt; Available to the general public. Portable Document File/PDF requiring Adobe Acrobat Reader.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381285</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/documents/reports/integratedcaretfgroupreport_june%202010.doc]]&gt;</url>
    <title>Integrated care for the person with diabetes a report from the diabetes UK integrated care task and finish group May 2010</title>
    <publicationDate>2010-05-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,USER INVOLVEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Diabetes UK and individual people with diabetes should stimulate improved integration of their care by asking to see if there are&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Locally agreed guidelines and protocols for managing people with diabetes, including agreed referral pathways – these should reflect the latest available guidance, including NICE guidance 
&lt;LI&gt;IT systems included as part of the integration process, so that a shared system is used by all professionals involved (including the potential role of the Map of Medicine), underpinned by robust arrangements for the sharing of information 
&lt;LI&gt;Ongoing education and development and training for all professionals involved in caring for people with diabetes, including training in the consultation skills required for effective care planning and easy access for primary care professionals to specialist advice (by email or telephone) 
&lt;LI&gt;Education for all people with diabetes, in a range of formats to suit their needs 
&lt;LI&gt;Enhanced communication with people with diabetes and their carers, e.g. patient held records, letters following clinic consultation written to the patient and copied to the GP, and patients having electronic access to their own care record&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published May 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word file.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>327927</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcn.org.uk/__data/assets/pdf_file/0005/276449/003053.pdf]]&gt;</url>
    <title>Integrated core career and competence framework for registered nurses</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>Royal College of Nursing</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CPD AND PROFESSIONAL EDUCATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The competences developed by the Royal College of Nursing are designed to support the development of registered nurses and to enable them to gain recognition for their knowledge, skills and competence in their daily roles. They reflect all the domains in which registered nurses may be required to practice. The competences apply to all registered nurses regardless of area of employment.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in October 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60250</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9742976]]&gt;</url>
    <title>Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)</title>
    <publicationDate>1998-09-12T00:00:00</publicationDate>
    <publisher>Lancet</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,GROUND-BREAKING ARTICLES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;BR&gt;&lt;/STRONG&gt;UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 Sep 12;352(9131):837-53. 
&lt;P&gt;&lt;STRONG&gt;Accessing the full text:&lt;BR&gt;&lt;/STRONG&gt;Access to the full text online requires subscription to the journal.&amp;nbsp;NHS staff please: &lt;A href="http://www.hlisd.org/" target="_blank"&gt;Check with your local NHS library&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Additional information: &lt;/STRONG&gt;&lt;A href="http://www.dtu.ox.ac.uk/index.php?maindoc=/ukpds/" target="_blank"&gt;Link to the UKPDS website&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323528</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/atrial/resources/merec_monthly_no17.pdf]]&gt;</url>
    <title>Intensive glucose control in type 2 diabetes</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CARDIOVASCULAR,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,MEDICATION,CAUSES,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This MeReC monthly article considers a recent meta-analysis of RCTs which suggest a small benefit of intensive glucose control in people with type 2 diabetes in reducing coronary heart disease.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; MeReC Monthly No. 17. Published August 2009. Original article: &lt;EM&gt;Ray KK, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765–72.&lt;/EM&gt;&amp;nbsp;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File/PDF requiring Adobe Acrobat Reader.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>59983</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band48/b48-5.html]]&gt;</url>
    <title>Intensive insulin treatment and heart attack</title>
    <publicationDate></publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CARDIOVASCULAR,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This Bandolier&amp;nbsp;article describes and reviews a&amp;nbsp;1997 study concerning intensive insulin therapy&amp;nbsp;and long term survival after acute myocardial infarction in patients with diabetes mellitus. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Review published&amp;nbsp;February 1998.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public&lt;/P&gt;&lt;/PAGEBODY&gt;&lt;/PAGE&gt;&lt;/ARTICLE&gt;]]&gt;</body>
  </document>
  <document>
    <id>87481</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=87481]]&gt;</url>
    <title>Interesting new diabetes papers : Apr 2005</title>
    <publicationDate>2005-05-16T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2005,DIABETES,INTERESTING NEW ARTICLES,RESEARCH]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the third in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Apr 2005&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;OBESITY&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;November 2008.&amp;nbsp; Please Note: Marketing authorisation has been suspended of Acompila (rimonabant) as the European Medicines Agency has concluded that the benefits of Acompila no longer outweigh its risks of psychiatric disorders.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Paper 1 &lt;BR&gt;Van Gaal LF, Rissanen AM, Scheen AJ for the RIO-Europe Study Group&lt;BR&gt;Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study Lancet 365; 1389-1397&lt;BR&gt;Paper 2&lt;BR&gt;Pagotto U, Pasquali R Fighting obestity and associated risk factors by antagonising cannabinoid&amp;nbsp; type 1 receptors (Comment) Lancet 365; 1363-4&lt;BR&gt;Summary&lt;BR&gt;Paper 1 is a report of a 1 year blinded randomised clinical trial of rimonabant, the first drug in a new class of compounds cannabinoid type 1 receptor (CB1) antagonists. It randomised 1507 obese subjects of BMI 30 or more or BMI of 27 or more with dyslipidaemia, hypertension or both, to 5mgs rimonabant 5mgs daily, or 20mgs daily or placebo&amp;nbsp; in addition to a mildly hypocaloric diet (600Kcal/day).&amp;nbsp; Those on 20mgs daily of rimonabant had significantly greater improvements than placebo in waist circumference&amp;nbsp; (-8.5cms v -1.5cms), weight reduction, (8.6Kg v 3.6Kg ), HDL cholesterol (+0.32mmol v +0.2mmol), triglycerides –0.24 v – 0.04,&amp;nbsp; and a sustained amelioration of&amp;nbsp; metabolic profile. The 5mg dose were of less clinical significance. The drug was well tolerated&amp;nbsp; with mild transient side effects mainly of nausea and dizziness.&lt;BR&gt;The drugs benefit on lipid parameters appears to be weight-independent and&amp;nbsp; the authors postulate that this may be through a rise in adiponectin.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This interesting report and the commentary on it highlight the importance of obesity management and the emergence of rimonabant as the first CB1 antagonist. The drug is likely to become available in the UK within the next year or so..&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;INSULIN THERAPY &lt;/P&gt;
&lt;P&gt;Paper 3 &lt;BR&gt;Rosenstock J, Dailey G, Massi-Bendetti M et al &lt;BR&gt;Reduced hypoglycaemia risk with insulin glargine&amp;nbsp; Diabetes Care 28; 950-954&lt;BR&gt;Summary&lt;BR&gt;This is a meta analysis of data from 4 open label randomised parallel-group studies. Each compared insulin glargine once daily with NPH insulin given once or twice a day. 2 studies were of 28 weeks, one of 52 weeks and one of 24 weeks. A total of 2304 patients were included in the studies.&lt;BR&gt;There was a consistent significant reduction of hypoglycaemia risk associated with insulin glargine compared to NPH insulin in terms of overall symptomatic and nocturnal hypoglycaemia. The risk of severe hypoglycaemia and severe nocturnal hypoglycaemia were reduced by 46% and 59% respectively.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This meta-analysis confirms that glargine once daily reduces the risk of hypoglycaemia compared to NPH insulin. This can facilitate more aggressive titration of insulin dose to enable a glycaemic target of HBA1c of 7% to be achieved.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;ORAL AGENT THERAPY&lt;/P&gt;
&lt;P&gt;Paper 4&lt;BR&gt;Charbonnel; BH, Matthews DR, Schernthanert G et al on the behalf of the QUARTET study group&amp;nbsp; Diabetes Care 22; 399-405&lt;BR&gt;Summary&lt;BR&gt;In this study 1270 patients with type 2 diabetes who were drug naïve were randomised to pioglitazone up to 45mgs daily or gliclazide up to 160mgs bd in this double-dummy, double blind study. They were followed for 52 weeks. HBA1c levels dropped by the same 1.4% in both groups. Improvements in HDL cholesterol and total cholesterol were greater with pioglitazone than with gliclazide. Frequency of adverse events were similar in the 2 groups, but more hypoglycaemic events were reported in the gliclazide group whereas twice as many patients reported oedema with pioglitazone than with gliclazide.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This result in a head to head comparison shows than both oral agents are equally good at lowering HBA1c but have different side effect profiles. It remains to be seen whether the favourable reductions in lipid parameters with pioglitazone result in improved cardiovascular outcomes.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Paper 5&lt;BR&gt;Kennedy L, Herman WH for the GOAL A1C Study team&lt;BR&gt;Renal status among patients using metformin in a primary care setting&amp;nbsp; Diabetes Care 28; 922 –924&lt;BR&gt;Summary&lt;BR&gt;This paper looked at subjects known to be taking metformin who had a serum creatinine measurement at enrolment in a study looking at point of care HBA1c&amp;nbsp; versus lab HBA1c measurement in the USA. 4838 patients were taking metformin of which 219 (4.5%) had a creatinine above 133 for men and 124 for women. These are the FDA level prescribing guideline upper limits for using metformin. &lt;BR&gt;They also calculated estimated GFR rates&amp;nbsp; and found 17.7% of women and 13.4% of men had an eGFR at or below 60ml/min.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This finding that 4.5% of people on metformin have raised creatinine levels is in keeping with other published studies. The use of&amp;nbsp; eGFR as a more sensitive measure of renal impairment is likely to come into more widespread use in the UK soon.&lt;/P&gt;
&lt;P&gt;Paper 6&lt;BR&gt;Johnson JA, Simpson SH, Toth EL , Majumdar SR &lt;BR&gt;Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes.&amp;nbsp; Diabetic Medicine 22; 497-502&lt;BR&gt;Summary&lt;BR&gt;A retrospective cohort analysis of 12188 new users of oral agent therapies in Canada from 1991 to 1999.&amp;nbsp; Data on deaths or hospitalisation was obtained from hospital coding.&amp;nbsp; The composite endpoint was first non fatal hospitalisation or death.&lt;BR&gt;Metformin monotherpy was associated with a lower risk of the composite endpoint compared with sulphonylurea monotherapy.&amp;nbsp; Combination therapy with metformin and a sulphonylurea was associated with lower mortality than sulphonylurea monotherapy.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This epidemiological study provides further evidence for the beneficial effects of metformin on adverse CHD outcomes as compared to sulphonylurea therapy. It also refutes the suggestion (made from the UKPDS data) that the combination of metformin plus sulphonylurea is associated with increased CHD adverse events.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;DIABETES MANAGEMENT&lt;/P&gt;
&lt;P&gt;Paper 7 &lt;BR&gt;Luzio S, Tovar C, Piehlmeir W et al&amp;nbsp;&amp;nbsp;&amp;nbsp; DIADEM: implementation of a comprehensive disease management programme for type 2 diabetes. &lt;BR&gt;Pract Diab Int 22; 93-97&lt;BR&gt;Summary&lt;BR&gt;This paper reports on pilot feasibility study carried out in Aachen and Cardiff of using an IT based disease management programme. 303 patients with type 2 diabetes received education at one of the 2 clinical centres and then entered self measured data on blood pressure and blood glucose into their own electronic record via a telephone. A common internet based server connected all participants in the trial and for example GP’s could view the data on all their patients,. Every 3 months doctors and patients received structured feedback from a neutral evaluation centre. &lt;BR&gt;Patient responses were positive and HBA1c levels dropped from 7.7 to 7.1% in the Cardiff group.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments &lt;BR&gt;This shows it is feasible to use IT based diabetes management service to improve glycaemic control if convenient pathways for data entry are provided&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;SHORT REPORTS&lt;/P&gt;
&lt;P&gt;Paper 8&amp;nbsp; &lt;BR&gt;Eckel RH, Grundy SC Zimmet P&amp;nbsp; The metabolic Syndrome Lancet 365; 1415-1428&lt;BR&gt;Summary&lt;BR&gt;Expert review article citing 168 references giving fully up to date review of this expanding area.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments &lt;BR&gt;Good expert review&lt;/P&gt;
&lt;P&gt;Paper 9&lt;BR&gt;Stumvoll M, Goldstein BJ, Van Haeften TW Type 2 diabetes: principles of pathogenesis and therapy Lancet 365; 1333-1346&lt;BR&gt;Summary&lt;BR&gt;Expert review citing 156 references giving an up to date review covering many areas including areas of signalling, and candidate genes.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments &lt;BR&gt;Good expert review&lt;/P&gt;
&lt;P&gt;Paper 10 &lt;BR&gt;Boulton AJ, Vinik AI, Arezzo JC et al&amp;nbsp; Diabetic Neuropathies – a statement by the ADA&amp;nbsp; Diabetes Care 28; 956-962&lt;BR&gt;Summary&lt;BR&gt;Review and statements about treatments and screening.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments &lt;BR&gt;ADA statement&lt;/P&gt;
&lt;P&gt;Papers 11 &amp;amp; 12 &lt;BR&gt;Bryer-Ash M, Garber AJ Point: Inpatient glucose management Diabetes Care 28; 973-974&lt;BR&gt;Inzucchi SE, Rosenstock J Counterpoint: Inpatient glucose management Diabetes Care 28; 976-979&lt;BR&gt;Summary&lt;BR&gt;A debate on new position statement from USA endocrinologists on the management of blood glucose in patients in hospital. The initial paper saying ok, the latter on saying it’s too tight control too soon .&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments &lt;BR&gt;Fascinating debate.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Journals reviewed this month:&lt;/STRONG&gt; Diabetes Care , Diabetic Medicine, BMJ, NEJM, BJDVD , Lancet, JAMA, Pract Diab Int&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;May&amp;nbsp;2005. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versios available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of these bulletins is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and generak medical journals in the previous month.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>126192</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=126192]]&gt;</url>
    <title>Interesting new diabetes papers : Apr 2006</title>
    <publicationDate>2006-05-18T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2006,DIABETES,INTERESTING NEW ARTICLES,RESEARCH]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the fifteenth in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Apr 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;DIABETIC FOOT ULCERS&lt;/P&gt;
&lt;P&gt;Paper 1&lt;BR&gt;Nelson EA, O’Meara SO, Golder S on the behalf of the DASIDU Steering Group&lt;BR&gt;Systematic review of antimicrobial treatments for diabetic foot ulcers Diabetic Medicine 23; 348-359&lt;BR&gt;Paper 2&lt;BR&gt;O’Meara SO, Nelson EA, Golder S et al on the behalf of the DASIDU Steering Group &lt;BR&gt;Systematic review of methods to diagnose infection in foot ulcers in diabetes &lt;BR&gt;Diabetic Medicine 23; 341 - 347&lt;BR&gt;Paper 3&lt;BR&gt;Jeffcoate WJ The evidence base to guide the use of antibiotics in foot ulcers is thin, but what are we going to do about it? (editorial)&amp;nbsp; Diabetic Medicine 23; 339-340&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;Paper 1 and paper 2 are based on a&amp;nbsp; Health Technology Assessment report commissioned by the DH which looked at the question of how infection in foot ulcers is confirmed and treated, and paper 3 is an editorial commenting on the 2 papers.&amp;nbsp; In answer to the first question 2762 papers were identified but only 3 were deemed acceptable. After reviewing the 3 papers in detail the conclusion is we don’t know. The best available is probably is probably quantitative tissue biopsy. Comparing this as “gold standard” to surface swabs shows that swabs are hopelessly unreliable, but they are the method most generalists use.&lt;BR&gt;In paper 1 studying treatment of infection 23 papers were selected from 1903 originally considered.. The conclusions were the same as all the previous reviews in this field that trial design is poor, sample sizes are inadequate, and that there was no evidence to recommend one antibiotic and approach against any other.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;These papers are a very good summary of current understanding in this area. &lt;BR&gt;Surface swabs are very unreliable to use to detect infection yet they are the method most people use. A change in behaviour needs to occur. &lt;BR&gt;Which antibiotic to use for how long remain unanswered questions still.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;ASSESSING GLYCAEMIA IN DIABETES&lt;/P&gt;
&lt;P&gt;Paper 4&lt;BR&gt;Saudek CD, Derr RL, Kalyani RR&amp;nbsp; Assessing glycaemia in Diabetes Using Self monitoring blood glucose (SMBG) and HBA1c JAMA 295; 1688-1697&lt;BR&gt;Paper 5&lt;BR&gt;Monnier L, Mas E, Ginet C et al&amp;nbsp; Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycaemia in patients with type 2 diabetes. JAMA 295; 1681-87&lt;BR&gt;Paper 6&lt;BR&gt;Brownlee M Hirsch IB&amp;nbsp; Glycaemic variability: A Haemoglobin A1c independent risk factor for diabetic complications.&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;Paper 4&amp;nbsp; reviews the literature around SMBG and concludes that the evidence supports a positive effect of regular SMBG for improving glycaemia particularly in those treated with insulin. HBA1c measures long&amp;nbsp; term glycaemic control reflecting a time weighted mean over the previous 3-4 months.&lt;BR&gt;In people with diabetes the hour by hour fluctuations of blood glucose may vary 10 fold, whereas in those without glucose they may vary by only 50%.&lt;BR&gt;Clearly it is possible to have an HBA1c level that indicates good control over the previous 3 months and yet experience large fluctuations of blood glucose on an hour by hour basis. There is some epidemiological evidence that high post prandial peaks of glucose may increase CHD risk.&lt;BR&gt;Paper 5 looks at an indicator of free radical production (8 iso prostaglandin F 2 alpha) in people with type 2 diabetes not on insulin and with poor glycaemic control. There was no significant correlation between this measure of free radical production and 24hr mean glucose, fasting glucose or HBA1c level.&amp;nbsp; Levels were however 4 times higher in people with the greatest glycaemic variability compared with the lowest.&lt;BR&gt;Paper 6 is an editorial comment on papers 4 and 5. It suggests that if the results from paper 5 are confirmed there could be enormous clinical implications. Firstly that there should be much more SMBG regardless of HBA1c level to measure glycaemic excursions and that different therapeutic strategies will be needed to minimise them.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;The idea that post prandial glycaemic peaks are a significant risk factor for CHD has been around for a number of years, and has some epidemiological evidence to support it. Paper 5 gives some biochemical explanation of what may be happening but it requires more confirmation and exploration. As the editorial points out if it were proven there would be significant implications for SMBG and therapy.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;BRIEF REPORTS&lt;/P&gt;
&lt;P&gt;Paper 7 – Depression and type 1 diabetes&lt;BR&gt;Barnard KD, Skinner TC, Peveler R&amp;nbsp; The prevalence of co-morbid depression in adults with type 1 diabetes: systematic literature review Diabetic Medicine 23; 445-448&lt;BR&gt;A review of 5 further studies since a previous meta-analysis in 2000 showed the prevalence of diabetes in controlled studies was 12% for people with diabetes compared to 3.2% in control subjects. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt;&amp;nbsp; Diabetic Medicine, BMJ, NEJM, BJGP, Lancet,&amp;nbsp; JAMA, Pract Diab Int&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;April 2006. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp;Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of&amp;nbsp;this series&amp;nbsp;is to inform readers of interesting new papers relevant to diabetes that have appeared in&amp;nbsp;several diabetes and general medical journals in the previous month.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>261308</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=261308]]&gt;</url>
    <title>Interesting new diabetes papers : Apr 2007</title>
    <publicationDate>2007-05-29T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2007,DIABETES,INTERESTING NEW ARTICLES,RESEARCH]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the twenty seventh in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Apr 2007&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;SYSTEMATIC REVIEWS &amp;amp; META-ANALYSIS&lt;/P&gt;
&lt;P&gt;HBA1c&lt;BR&gt;Paper 1&amp;nbsp; Bennett CM, Guo M, Dharmage SC HBA1c as a screening tool for the detection of type 2 diabetes: a systematic review Diabetic Medicine 24; 333-343&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;A systematic&amp;nbsp; review of&amp;nbsp; 9 relevant papers, all using HBA!c for the detection of diabetes with FPG as the comparator and 75gm OGTT as the reference test. Using a HBA1c (DCCT aligned) cut-off of equal to or greater than 6.1% the sensitivity range was 78-81% and the specificity 79-64%. For a FPG cut off at or greater than 6.1mmoles/L the sensitivity ranged from 48-64% and specificity of 94-98%. Both HBA1c and FPG had a low sensitivity to detect IGT.&lt;BR&gt;They conclude that both HBA!c and FPG are equally effective screening tools for detection of type 2 diabetes. &lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Interesting systematic review. HBA1c is not indicated to diagnose diabetes but may have a role as a screening test&lt;BR&gt;&lt;BR&gt;RANDOMISED CONTROLLED TRIALS&lt;/P&gt;
&lt;P&gt;Possible diabetes treatments of the future?&lt;/P&gt;
&lt;P&gt;Paper 2&amp;nbsp;&amp;nbsp; Larsen CM, Faulenbach M, Vaag A et al Interleukin -1 – receptor antagonist in type 2 diabetes N Engl J Med 356; 1517-1526&lt;/P&gt;
&lt;P&gt;Paper 3 Rother KI, Diabetes Treatment – Bridging the divide (editorial) N Engl J Med 356; 1449-1501&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;RCT randomising 34 patients to anakinra (a recombinant human interleukin-1 – receptor antagonist) sc once daily for 13 weeks and 36 to placebo. In the anakinra group there was a 0.46% drop in HBA1c, increased C peptide secretion, and reductions in CRP and interleukin 6. There was no hypoglycaemia and no drug related serious adverse events. Interleukin 1 has been implicated in beta cell damage in diabetes. Interleukin -1-receptor antagonists are licensed to treat RA. There is a “smouldering inflammation “ hypothesis in the pathogenesis of insulin resistance, and the improvement in HBA1c noted could be due to a reduction in insulin resistance or a reduction in beta cell dysfunction. &lt;BR&gt;This new novel treatment approach will need to be subjected to a lot more investigation and development.&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Fascinating new treatment concept&lt;/P&gt;
&lt;P&gt;Paper 4 Voltarelli JC, Couri CEB, Stracieri ABPL et al&amp;nbsp; Autologous Nonmyeloablative Hematopoietic stem cell transplantation (AHSCT)&amp;nbsp; in newly diagnosed type 1 diabetes JAMA 297; 1568-1576&lt;/P&gt;
&lt;P&gt;Paper 5 Skyler JS Cellular therapy for type 1 diabetes – has the time come? (editorial) JAMA 297; 1599-60&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;15 people who had been diagnosed with type 1 DM in previous 6 weeks underwent AHSCT. It involves (1) stem cell mobilisation of peripheral blood CD34+ cells (2) conditioning (immune ablation) of the recipient to eliminate self-reactive lymphocytes within the body, (3) reinfusion of the autologous human stem cells harvested in step 1 which had been stored in liquid nitrogen.&lt;BR&gt;During 7-36 month follow up (mean 18.8 months) 14 patients became insulin free and 1 resumed insulin use after 1 year. 13 out of 14 had an HBA!c of less than 7% . One had a culture negative pneumonia, and 2 had late endocrine dysfunction hypothyroidism or hypogonadism &lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;High risk new therapy idea for type 1 diabetes. This new novel treatment approach will need to be subjected to a lot more investigation and development&lt;BR&gt;&lt;BR&gt;OTHER TYPES OF STUDY&lt;/P&gt;
&lt;P&gt;CKD &amp;amp; Diabetes&lt;/P&gt;
&lt;P&gt;Paper 6&amp;nbsp; New JP, Middleton RJ, Klebe B et al Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetes compared with those without diabetes in general practice&lt;BR&gt;Diabetic Medicine 24; 364-369&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;Study in a GP population of&amp;nbsp; 162113 patients from 17 practices with 5072 people with diabetes.(prevalence 3.1%) In people with diabetes 31% had CKD levels 3-5 (eGFR below 60mls/min&amp;nbsp; compared to 6.9% in those without diabetes. This study shows similar rates of CKD to those in USA&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Further evidence about frequency of CKD in people with diabete&lt;BR&gt;&lt;BR&gt;BREIF REPORTS&lt;/P&gt;
&lt;P&gt;Paper 7&amp;nbsp; Gottschalk M, Danne T, Vlajnic A, Cara JF Glimepride versus metformin as monotherapy in paediatric patients with type 2 diabetes&amp;nbsp; Diabetes Care 30; 790-794&lt;BR&gt;285 children with type 2 diabetes aged 8-17years randomised to metformin or glimeperide. Both dropped HBA1c by similar amount, glimepride caused more wt gain, side effects similar in each group with 1 severe hypo episode in each&lt;/P&gt;
&lt;P&gt;Paper 8 Lipsombe LL, Jamal SA, Booth GL, Hawker GA&amp;nbsp; The risk of hip fracture in older individuals with diabetes Diabetes Care 30; 835-841&lt;BR&gt;Followed 197412 Ontario residents with diabetes aged 66 for mean of 6.1 years and compared them to 401400 without diabetes. Diabetes increased hip fracture risk. People with diabetes were more likely to be on medications that increased their risk of falling.&lt;/P&gt;
&lt;P&gt;Paper&amp;nbsp; 9 Vine AI, Zhang Q Adding insulin glargine versus rosiglitazone health related quality of life impact (HRQOL)&amp;nbsp; in type 2 diabetes Diabetes Care 30; 795-800&lt;BR&gt;In RCT of 217 patients on metformin and sulphonylurea randomised to rosiglitazone or glargine HBA1c falls were similar but the glargine group was associated with greater improvements in HRQOL&lt;/P&gt;
&lt;P&gt;Paper 10 Kulzer B, Hermanns N, Reinecker H, Haak T Effects of self-management training in type 2 diabetes a randomised prospective trial Diabetic Medicine 24; 415-423&lt;BR&gt;Study from Germany in which a didactic training was compared to self management training taught in groups or individually to 181 people with type 2 diabetes. Self management training had a&amp;nbsp; significantly higher medium term efficacy than didactic diabetes education. The group sessions were more effective than an individual approach&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt;&amp;nbsp; BMJ, Lancet,&amp;nbsp; N Eng J Med, Diabetes Care, JAMA, Diabetic Medicine, Primary Care Diabetes, Pract Diab Int, BJDVD, Diabetes and Primary Care&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;April 2007. This series began in 2002 as a bulletin for Warwick Diabetes Care staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>287187</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=287187]]&gt;</url>
    <title>Interesting new diabetes papers : April 2008</title>
    <publicationDate>2008-05-27T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2008,INTERESTING NEW ARTICLES,RESEARCH,DIABETES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the thirty sixth in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : April 2008&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONSENSUS REPORT&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;HBA1c Reporting&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Paper 1 Consensus meeting on reporting glycated haemoglobin (HBA1c) and estimated average glucose (eAG) in the UK.: report to the National Director for Diabetes, Department of Health. Diabetic Medicine 25: 381-382&lt;/P&gt;
&lt;P&gt;Summary&lt;BR&gt;Report of consensus meeting held in Jan 08 with representatives of 18 organisations in UK.&amp;nbsp; They agreed:-&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;HBA1c test results should be standardised using the new International Federation of Clinical Chemistry (IFCC) reference measurement procedure&lt;BR&gt;•&amp;nbsp;An extensive education programme should be developed urgently for all healthcare professionals and people with diabetes to help the understanding and interpretation of the new IFCC units. Provision of this programme will require considerable resource&lt;BR&gt;•&amp;nbsp;HBA1c results should be reported in both IFCC units (mmol/mol) and derived National Glycohaemaglobin Standardization programme (NGSP) units (%) (synonymous with the DCCT) using the IFCC-NGSP master equation for the time being&lt;BR&gt;•&amp;nbsp;There is insufficient experimental evidence to support the introduction of eAG&lt;BR&gt;•&amp;nbsp;Further research into the individual utility of eAG and of its use in all groups of individuals with diabetes is required in order to determine what role reporting of eAG has in clinical practice&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&amp;nbsp;&amp;nbsp;&amp;nbsp;This is a good compromise. We will still get HBA1c results in a form we know and understand until the new IFCC value is understood&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;RCT’s&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;STRONG&gt;Oral hypoglycaemic agents and cardiovascular disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Paper 2 Nissen SE, Nicholls SJ, Wolski K et al Comparison of pioglitazone vs glimepride on progression of coronary atherosclerosis in patients with type 2 diabetes – the PERISCOPE R.C.T.&amp;nbsp; JAMA 299:1561-1573&lt;BR&gt;Paper 3 Steg PG, Marre M Does PERISCOPE provide a new perspective on diabetic treatment (editorial) JAMA 299:1603-4&lt;/P&gt;
&lt;P&gt;Summary&lt;BR&gt;In this RCT of 543 people with type 2 diabetes and Coronary Heart Disease in America (mostly USA some in Canada, Chile and Argentina) were randomised to glimeperide or pioglitazone with titration to max dose of 4mg or 45 mg respectively for 18 months. Atherosclerosis progression was measured by intravascular ultrasonography examination at baseline and at 18 months in 360 patients.&amp;nbsp; The outcome measure was change in % atheroma volume (PAV) from baseline to 18 months.&amp;nbsp; Mean HBA1c was 7.4% at the start and declined by 0.55% in the pio group and 0.36% in the glimepride group.&amp;nbsp; PAV increased 0.73% in the glimepride group and decreased 0.16% in the pio group. &lt;BR&gt;In the editorial it is noted that the ultrasound technique described exquisitely delineates changes in atherosclerosis. That the changes detected look small but are of a similar range to that achieved by high dose statins. That most patients in the study were on statin,&amp;nbsp; renin-angiotensin blockers and aspirin. That there was a high level of non completors. The editorial notes that given that the small differences in glycaemic control and the fact that there is still no evidence that more intensive glycaemic control is associated with CVD benefit the authors ascribe the benefit in the pio group to non glycaemic effects. &lt;BR&gt;&amp;nbsp;&lt;BR&gt;Roger Gadsby’s comments:&lt;BR&gt;These results although they relate to a surrogate endpoint are consistent with the clinical benefit seen with pioglitazone in the PROactive trial.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Insulin Treatment in Type 2 Diabetes&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Paper 4 Bretzel RG, Nuber U, Landgraf W et al One daily basal insulin glargine versus thrice daily prandial lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO) : an open randomised controlled trial Lancet 371: 1073-84&lt;BR&gt;Paper 5 Kudva YC Montori VM&amp;nbsp; Patient centred treatments for type 2 diabetes (comment) Lancet 371: 1047-8 &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Summary&lt;BR&gt;415 people with type 2 diabetes in Europe on oral agents randomised to once daily glargine or thrice daily lispro.&amp;nbsp; Both regimes were equally effective at lowering HBA1c. The glargine group had less hypoglycaemia&amp;nbsp; (5.2 v 24 events per patient per year), fewer injections,&amp;nbsp; less need for smbg and greater patient satisfaction (as measured by the diabetes treatment satisfaction questionnaire DTSQ). &lt;BR&gt;&amp;nbsp;&lt;BR&gt;Roger Gadsby’s Comments.&lt;BR&gt;More evidence that once daily insulin added to oral agents is the best treatment approach for people with type 2 diabetes requiring insulin.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Target for BP and Cholesterol in Diabetes&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Paper 6 Howard BV, Roman MJ, Devereux RB et al Effect of Lower Targets for Blood Pressure&amp;nbsp; and LDL Cholesterol on atherosclerosis in Diabetes : the SANDS randomised trial JAMA 299; 1678-89&lt;BR&gt;Paper 7 Peterson ED, Wang TY The great debate of 2008- How low to go in preventive cardiology? (editorial) JAMA 299: 1718-1720&lt;/P&gt;
&lt;P&gt;Randomised trial in 499 Native Americans aged 40 years and over with type 2 diabetes. One group were treated to aggressive targets of systolic BP of 115 or lower and an LDL cholesterol of 70 or lower, the other to standard targets of BP of 130 or lower and LDL cholesterol of 100 or lower. The outcome measure was atherosclerosis as measured by carotid artery intimal medial thickness (IMT).&amp;nbsp; Secondary outcome measures were other carotid and cardiac scan measures and clinical events.&amp;nbsp;&amp;nbsp; The aggressive treatment targets resulted in&amp;nbsp; regression of carotid IMT and greater decrease in left ventricular mass. Clinical events were lower than expected and did not differ between the groups. Polypharmacy and adverse events were higher in the aggressive targets group.&lt;BR&gt;The excellent editorial concludes that the SANDS trial gives support for the “true believers” (those with a strong a proiri conviction that more aggressive pharmacological treatment will reduce future events) in that the surrogate measures of CVD were reduced in the more aggressive target group. However it also gives support for the “ therapeutic nihilists”&amp;nbsp; (those who require unequivocal proof before acceptance) as clinical events were not altered and the aggressive target group had more adverse events of hypotension and hypokalaemia.&lt;/P&gt;
&lt;P&gt;Roger Gadsby’s comments&lt;BR&gt;Interesting data and excellent commentary in the editorial&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;OTHER TYPES OF STUDY&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;BR&gt;Paper 8 Lloyd CE, Sturt J, Johnson M et al Development of alternative methods of data collection in South Asians with type 2 diabetes Diabetic Medicine 25: 455-462&lt;/P&gt;
&lt;P&gt;Summary&lt;BR&gt;Development of questionnaires using focus groups for 2 South Asian populations whose language is mainly spoken.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;SHORT REPORTS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Adherence:&amp;nbsp; &amp;nbsp;Paper 9 Lawton J, Peel E, Parry O, Douglas M Patients perceptions and experiences of taking oral glucose-lowering agents: a longitudinal qualitative study Diabetic Medicine 25: 491-5&lt;BR&gt;Repeat in depth interviews with 20 patients over 4 years. The findings call for multifaceted strategies to promote adherence.&lt;BR&gt;ARB2 agents to reduce CHD:&amp;nbsp;&amp;nbsp; Paper 10 On target investigators Telmisartan, Ramipril or both in patients at high risk for vascular events N Eng J Med 358: 1537-59&lt;BR&gt;8576 people with vascular disease or high risk diabetes randomised to 10mg ramipril compared to 8542 assigned to telmisartan 80mgs and 8502 to receive both. Outcome was death from CVD causes or hospitalization for heart failure. Telmisartan was equivalent to ramipril and was associated with less angioedema. The combination&amp;nbsp; of the 2 was associated with more adverse events without an increase in benefit.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt;&lt;BR&gt;N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetic Medicine, Pract Diab Int&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; published in&amp;nbsp;February 2008.&amp;nbsp;This series began in 2002 as a bulletin for Diabetes Care Staff.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public.&amp;nbsp; Word and webpage versions available.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>102852</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=102852]]&gt;</url>
    <title>Interesting new diabetes papers : Aug 2005</title>
    <publicationDate>2005-09-27T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,ETHNICITY AND HEALTH,DISEASES AND CONDITIONS,DIABETES,2005]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the seventh in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Aug 2005&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="MARGIN-RIGHT: 0px" dir=ltr align=left&gt;DIABETES CARE&lt;/P&gt;
&lt;P&gt;Paper 1&lt;BR&gt;O’Connor PJ, Desai J Solberg LI et al Randomised trial of Quality Improvement Intervention to Improve Diabetes Care in Primary Care settings&lt;BR&gt;Diabetes Care 28; 1890-1897&lt;BR&gt;Summary&lt;BR&gt;Randomised controlled trial of 12 primary care practices in the USA randomised to intervention or control. Intervention clinic staff were trained in a 7-point quality improvement change process to improve diabetes care. Surveys and medical records review of 754 patients, surveys with 329 clinic staff, interviews with clinic leaders and analysis of training session videos evaluated compliance with and impact of the intervention.&lt;BR&gt;All intervention clinics had broader staff participation in QI activities, used patient registers more often and had better process rates for HBA!c and BP measurements. The intervention did not improve HBA1c, Blood pressure or a&amp;nbsp; composite of these outcomes &lt;BR&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This paper shows how hard it is to get a positive result from an RCT of an intervention to improve care. The authors approached about 100 clinics before getting 12 to agree to take part. The levels of process achievement in both groups for HBA1c were around 70-77%, Bp 90%, cholesterol 45%, creatinine 40%, retinal screening 39%, foot exam 58%, flu vaccination 33% and average HBA1c was&amp;nbsp; around 8%. All these figures are much lower than obtained in the UK GP quality and outcomes framework.&lt;/P&gt;
&lt;P&gt;Paper 2&lt;BR&gt;Wilson C, Curtis J, Lipke S et al&amp;nbsp; Nurse case manager effectiveness and case load in a large clinical practice: implications for workforce development&lt;BR&gt;Diabetic Medicine 22; 1116-1120&lt;BR&gt;Summary&lt;BR&gt;In one clinic providing services to American Indian and Native Alaska people, a retrospective cohort design was used to assess outcomes of patients who did or did not receive case management services from 4 nurse case managers.&lt;BR&gt;1070 patients (out of 4112) met the high adherence profile and were included in the evaluation cohort. 793 had a case manager, 277 did not.&lt;BR&gt;Patients with a case manager were more likely to have had an eye examination, foot examination and nephropathy screening. Process outcomes for these were 80%, 68% and 73% respectively. Those with a case manager had an HBA1c improvement of 0.58% as compared to 0.17% in the control group. The case load used averaged one manager for 365 patients.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;Interesting data from one clinic in Arizona providing free health care to native peoples. Process data even with a case manager lower than that from new GP contract Quality and outcomes framework&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;DEPRESSION &amp;amp; DIABETES&lt;/P&gt;
&lt;P&gt;Paper 3&lt;BR&gt;Engum A, Mykletun A, Midthjell K et al.&amp;nbsp; Depression and Diabetes. A large population based study of sociodemographic, lifestyle, and clinical factors associated with depression in type 1 and type 2 diabetes. Diabetes Care 28; 1904-1909&lt;BR&gt;Summary&lt;BR&gt;In an unselected population study comprising 60,869 individuals in Norway, potential sociodemographic, lifestyle, and clinical factors were investigated in participants with diabetes,&amp;nbsp; (223 with type 1 and 958 with type 2) and without diabetes. The levels of depression were self rated by using the Hospital anxiety and depression scale.&lt;BR&gt;Type 2 diabetes without other chronic somatic diseases did not increase the risk of depression. Factors associated with depression in type1 and type 2 diabetes were shared with the non diabetic population.&lt;BR&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This is a large well conducted study which suggests that it is the burden of co-morbidity rather than type 2 diabetes per se that is associated with depression&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;METABOLIC SYNDROME IN TYPE 1 DIABETES&lt;/P&gt;
&lt;P&gt;Paper 4&lt;BR&gt;Thorn LA, Forsblom C Fagerudd J et al for the FinnDiane study group&lt;BR&gt;Metabolic syndrome in type 1 diabetes&lt;BR&gt;Summary&lt;BR&gt;An analysis of 2415 type 1 diabetes patients in Finland participating in the nationwide Finnish Diabetic Nephropathy (FinnDiane) study.&amp;nbsp; Metabolic syndrome was defined according to the National Cholesterol Education Program criteria.&lt;BR&gt;The prevalence was 38% in men, 40% in women. It increased with advanced diabetic retinopathy and worse glycaemic control&lt;BR&gt;Dr Roger Gadsby’s comments&lt;BR&gt;Metabolic syndrome in type 1 diabetes is just becoming recognised. This provides good data on prevalence.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;SHORT REPORTS&lt;/P&gt;
&lt;P&gt;NEW THERAPIES&lt;/P&gt;
&lt;P&gt;Paper 5 &lt;BR&gt;DeFronzo RA, Bergenstal RM, Cefalu WT et al for the EXUBERA phase 3 study group Efficacy of inhaled insulin in patients with type 2 diabetes not controlled on diet and exercise. Diabetes Care 28; 1922-1928&lt;BR&gt;A 12 week randomised comparative trial in which people not controlled on diet and exercise were randomised to inhaled insulin before meals or rosiglitazone 4mgs bd. &lt;BR&gt;HBA!c lowering was greater with inhaled insulin, but there was greater mild hypoglycaemia.&lt;BR&gt;Dr Roger Gadsby’s comments&lt;BR&gt;Inhaled insulin can be used as initial therapy in type 2.&lt;/P&gt;
&lt;P&gt;Paper 6&lt;BR&gt;Feinglos MN, Saad MF, Pi-Sunyer FX et al on the behalf of the liraglutide dose-response study group. Effects of liraglutide a long acting GLP-1 analogue on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabetic Medicine 22; 1016-1023&lt;BR&gt;Once daily injection of liraglutide improved glycaemic control and weight in a comparable degree to metformin. It appeared to be safe and well tolerated&lt;BR&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This new injection therapy is being developed and is likely to be second to market after exenatide.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;FOOT CARE&lt;/P&gt;
&lt;P&gt;Paper 7&lt;BR&gt;Abbot CA, Garrow AP, Carrington AL et al&amp;nbsp; Foot ulcer risk is lower in South Asian and African-Caribbean compared with European Diabetic patients in the UK &lt;BR&gt;Diabetes Care 28;1869-1875&lt;BR&gt;Data from the Northwest England study group showing that South Asians with diabetes in the UK have about one third of the risk of foot ulcers of Europeans. The lower levels of peripheral arterial disease, insulin usage, neuropathy, and foot deformities account for about half of this reduced ulcer risk. Lower neuropathy is the main contributor to the reduced African-Caribbean ulcer rate, particularly in men. The reasons for these ethnic differences warrant further investigation.&lt;BR&gt;Dr Roger Gadsby’s comments&lt;BR&gt;Interesting findings.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Journals reviewed this month:&lt;/STRONG&gt;&amp;nbsp; Diabetes Care , Diabetic Medicine, BMJ, NEJM, BJDVD , Lancet,&amp;nbsp; Pract Diab Int&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;September 2005. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp;Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of&amp;nbsp;this series&amp;nbsp;is to inform readers of interesting new papers relevant to diabetes that have appeared in&amp;nbsp;several diabetes and general medical journals in the previous month.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>181998</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=181998]]&gt;</url>
    <title>Interesting new diabetes papers : Aug 2006</title>
    <publicationDate>2006-09-19T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2006,DIABETES,INTERESTING NEW ARTICLES,RESEARCH]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the nineteenth in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Aug 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;SYSTEMATIC REVIEWS&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;QUALITY IMPROVEMENT IN TYPE 2 DIABETES&lt;/P&gt;
&lt;P&gt;Paper 1&amp;nbsp; Shojania KG, Ranji SR, MacDonald KM et al Effects of Quality improvement Strategies for type 2 Diabetes on glycaemic control A meta-regression analysis. JAMA 296:427-440&lt;BR&gt;Summary:&lt;BR&gt;Systematic review to assess the impact on glycaemic control of 11 distinct strategies for quality improvement in adults with type 2 diabetes. The 11 were audit and feedback, case management, team changes, electronic patient registry, clinician education, clinician reminders, facilitated relay of info to clinicians, patient education, promoting self management, patient reminder systems, and continuous quality improvement. 66 trials were analysed. HBA1c dropped by 0.42% over a median of 13 months of follow up.&amp;nbsp; The authors conclude that most QI strategies produced small to modest gains in glycaemic control. Team changes and case management showed more robust improvements.&lt;BR&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;Meta-analysis of lots of different QI initiatives, with the sort of conclusion that would be expected.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;SOCIAL &amp;amp; ECONOMIC CONSEQUENCES OF TYPE 1 DIABETES&lt;/P&gt;
&lt;P&gt;Paper 2 Milton B, Holland P, Whitehead M&amp;nbsp; The social and economic consequences of childhood onset type 1 diabetes across the lifecourse: a systematic review Diabetic Medicine 23: 821-829&lt;BR&gt;Summary:&lt;BR&gt;Systematic review of 20 studies of sufficient methodological quality, of 2832 people with type 1 diabetes. The conclude that many children with type 1 diabetes – especially late onset- perform well at school despite increased rates of absence, but it is not yet clear whether specific subgroups are at greater risk of educational under performance. People with childhood onset type 1 diabetes however do appear to experience some disadvantage in adult employment.&lt;BR&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;Interesting findings. An area that more research is needed in.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;OTHER RESEARCH PAPERS&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;EPIDEMIOLOGY OF TYPE 1 DIABETES&lt;/P&gt;
&lt;P&gt;Paper 3 The DIAMOND Project Group Incidence and trends of childhood Type 1 Diabetes worldwide 1990 – 1999 Diabetic Medicine 23:857-866&lt;BR&gt;Summary:&lt;BR&gt;The incidence of type 1 diabetes was analysed in children at or below 14 yrs of age in 112 centres in 57 countries. A total of 43013 cases were diagnosed in the study population of 84 million children. The age adjusted incidence varied from 0.1 per 100,000 in China and Venezuela to 40.9 per 100,000 in Finland. There were statistically significant increases all over the world of 2.8% per year. Data is missing from many countries in Africa and Asia where one in 10 children dies before their 5th birthday.&lt;BR&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;This is the most detailed data on the rising incidence and huge variation in incidence between countries across the world.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;BLOOD GLUCOSE MONITORING&lt;/P&gt;
&lt;P&gt;Paper 4 Karter AJ, Parker MM, Moffet HH et al Longitudinal study of new and prevalent use of self-monitoring of blood glucose&amp;nbsp; Diabetes Care 29: 1757-1763&lt;BR&gt;Summary:&lt;BR&gt;Information from 16091 new users and 15347 ongoing users of SMBG, Kaiser Permanente patients in USA.&amp;nbsp; SMBG was based on pharmacy use and HBA1c was used to monitor glycaemia. Greater SMBG practice frequency was associated with a graded decrease of HBA1c regardless of diabetes therapy. Changes in SMBG frequency among prevalent users was associated with an inverse graded change in HBA1c only among pharmacologically treated patients.&lt;BR&gt;The authors conclude that their observational findings are consistent with short term benefits of initiating SMBG in all patients but continuing benefits only for pharmacologically treated patients&lt;/P&gt;
&lt;P&gt;Paper 5 Davis WA, Bruce DG, Davis TME&amp;nbsp;&amp;nbsp; Is self monitoring of blood glucose appropriate for all type 2 diabetic patients. The freemantle diabetes study&lt;BR&gt;Diabetes Care 29: 1764 -1770&lt;BR&gt;Summary:&lt;BR&gt;This paper reports cross-sectional and longitudinal data from type 2 diabetic participants in the observational community based Freemantle diabetes study who reported SMBG status at the start of the study (n=1286) and annual reviews over 5 years (n=531). There was no difference in HBA1c between SMBG users and non users, and no relationship between SMBG frequency and HBA1c.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;There is still controversy around the value of SMBG in people with type 2 diabetes treated with oral agents other than sulphonylureas and those on diet alone. These papers epitomise the debate. The Freemantle data suggest its of little or no benefit, the large Kaiser study suggests it is of benefit, for everyone to start with and then for those on tablets. The large numbers in the study and the effect size and direction observed both match those reported in 2 recent meta-analyses.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;BRIEF REPORTS&lt;/P&gt;
&lt;P&gt;Paper 6: Ismail H, Wright J, Rhodes P, Scally A Quality of care in diabetic patients attending routine primary care clinics compared with those attending GP specialist clinics&lt;BR&gt;No evidence that patients in specialist clinics do better than patients in routine primary care clinics. Study based in Bradford that has 17 GPSI type community specialist diabetes clinics.&lt;/P&gt;
&lt;P&gt;Paper 7: Zgibor JC, Piatt GA, Ruppert K et al&amp;nbsp; Deficiencies of cardiovascular risk prediction models for type 1 diabetes&amp;nbsp; Diabetes Care 29: 1860-1865&lt;BR&gt;10 year follow up data from a cohort study of 658 subjects with childhood onset type 1 diabetes in Pittsburgh USA. They conclude that currently available CHD models (Framingham and UKPDS) poorly predict events in type 1 diabetes&lt;/P&gt;
&lt;P&gt;Paper 8:&amp;nbsp; Temple RC, Aldridge VJ, Murphy HR&amp;nbsp;&amp;nbsp; Prepregnancy care and pregnancy outcomes in women with type 1 diabetes.&lt;BR&gt;Cohort study of 290 pregnancies in which 110 (38%) had pre pregnancy care which was associated with significant reductions in adverse pregnancy outcome stillbirth neonatal death etc. There was no impact on glycaemic control in later pregnancy and no reduction in macrosomia.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;BMJ, Lancet, JAMA, N Eng J Med, Diabetes Care, Diabetic Medicine, Pract Diab Int, BJDVD, Diabetes and Primary Care&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;September 2006. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp;Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of&amp;nbsp;this series&amp;nbsp;is to inform readers of interesting new papers relevant to diabetes that have appeared in&amp;nbsp;several diabetes and general medical journals in the previous month.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>269513</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=269513]]&gt;</url>
    <title>Interesting new diabetes papers : Aug 2007</title>
    <publicationDate>2007-09-27T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2007,DIABETES,RESEARCH,INTERESTING NEW ARTICLES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the thirty first in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Aug 2007&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;SYSTEMATIC REVIEWS &amp;amp; META-ANALYSIS&lt;/P&gt;
&lt;P&gt;Diabetic Retinopathy&lt;/P&gt;
&lt;P&gt;Paper 1&amp;nbsp; Mohamed Q, Gilles MC, Wong TY Management of Diabetic Retinopathy: A Systematic review JAMA 298; 902-916&lt;/P&gt;
&lt;P&gt;Summary&lt;BR&gt;Systematic review of 44 studies (including 3 meta-analyses) meeting inclusion criteria. Tight glycaemic control and good blood pressure control reduce the incidence and progression of diabetic retinopathy (DR) Pan retinal laser photocoagulation reduces the risk of moderate and severe visual loss by 50% in patients with severe nonproliferative and proliferative retinopathy. Focal laser photocoagulation reduces the risk of moderate visual loss by 50% to 70% in eyes with macular oedema. Early vitrectomy improves visual recovery in patients with proliferative retinopathy and severe vitreous haemorrhage. Intravitreal injections of steroids may be considered in eyes with persistent loss of vision where conventional therapy has failed. There is insufficient evidence for efficacy or safety of lipid lowering therapy, medical interventions or antivascular endothelial growth factors on the incidence or progression of DR&lt;/P&gt;
&lt;P&gt;Roger Gadsby’s comments&lt;BR&gt;Helpful review clearly showing those interventions that have proven benefit and those which at present have insufficient evidence.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;EXPERT REVIEW&lt;/P&gt;
&lt;P&gt;Physical Activity&lt;/P&gt;
&lt;P&gt;Paper 2 Kirk AF, Barnett J, Mutrie N&amp;nbsp; Physical activity consultation for people with type 2 diabetes: Evidence and guidelines Diabetic Medicine 24; 809-816&lt;/P&gt;
&lt;P&gt;Summary&lt;BR&gt;Review of published research but numbers of papers reviewed not stated. It states that the underlying theory of behaviour change for the physical activity consultation is the trans-theoretical model. The review outlines a number of modifiable variables associated with physical activity behaviour change in the population and how these can be addressed within a consultation. Limited by consistent research results highlight the effectiveness of a physical activity consultation for promoting physical activity in people with type 2 diabetes.&lt;/P&gt;
&lt;P&gt;Roger Gadsby’s comments&lt;BR&gt;Not an easy review to read, but interesting summary of information.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;OTHER TYPES OF STUDY&lt;/P&gt;
&lt;P&gt;Rosiglitazone and CHD risk (continued!)&lt;/P&gt;
&lt;P&gt;Paper 3 Rosen CJ&amp;nbsp; The Rosiglitazone Story – Lessons from an FDA Advisory Committee meeting (Editorial) N Eng J Med 30 Aug 2007&lt;/P&gt;
&lt;P&gt;Summary&lt;BR&gt;Fascinating description of the FDA committee meeting written by its chairman in which the committee voted to recommend that rosiglitazone be allowed to continue in the market but with label warnings and extensive educational efforts. It concluded that 3 independently conducted meta-analyses demonstrated an increase in the relative risk of myocardial infarction, angina or sudden death among patients taking rosiglitazone as compared to placebo, metformin or sulphonylurea. It makes the point that clinical outcomes rather than surrogates the primary end-point of trials.&amp;nbsp; Data from 2 large observational studies was presented at the meeting. Both showed no appreciable signal of increased cardiovascular risk. However the weakness of observational studies examining events that are common and whose rates are likely to be increased only slightly by a given drug was highlighted.&lt;/P&gt;
&lt;P&gt;Roger Gadsby’s comments&lt;BR&gt;This gives more discussion in this ongoing debate about the cardiovascular effects of rosiglitazone. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Myocardial infarction and Diabetes&lt;/P&gt;
&lt;P&gt;Paper 4 Mozaffarian D, Marfisi R, Levantesi G et al Incidence on new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors&amp;nbsp; Lancet 370: 667-675&lt;/P&gt;
&lt;P&gt;Paper 5 Opie LH Acute Myocardial infarction and diabetes (editorial) Lancet 370: 634-5&lt;/P&gt;
&lt;P&gt;Summary&lt;BR&gt;Prospective study of 8291 Italian patients with a myocardial infarction who were free of diabetes, who were enrolled in a RCT of fish oil and vitamin E from 1993-1995. They had a clinical examination and fasting bloods at 0.5, 1, 1.5, 2.5 and 3.5 years after their infarct.&lt;BR&gt;They found that compared with population based cohorts, patients with a recent myocardial infarction had a higher incidence rate of IFG 1.8 v 27.5% and diabetes 0.8-1.6% v 3.7%. This suggests that myocardial infarction could be a pre diabetes risk equivalent. Smoking cessation, prevention of weight gain, and consumption of typical Mediterranean foods might lower this risk. This emphasises the importance of lifestyle advice post infarct.&lt;BR&gt;The editorial suggests that the findings further tie the knot between myocardial infarction and diabetes- each causes the other!&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;Interesting data&lt;BR&gt;SHORT REPORTS&lt;/P&gt;
&lt;P&gt;Obstacles to living with Diabetes&lt;/P&gt;
&lt;P&gt;Paper 6&amp;nbsp; Hearnshaw H, Wright K, Dale J et al Development and validation of the Diabetes Obstacles Questionnaire (DOQ) to assess obstacles in living with type 2 diabetes Diabetic Medicine 24: 878-882 &lt;BR&gt;Validation study with 180 people with type 2 diabetes from 22 practices. Respondents also completed the ADDQoL and PAID questionnaires. They conclude that the DOQ with 8 sub scales is a usable valid instrument for both clinical and research settings. It helps to identify in detail the obstacles which an individual finds in living with type 2 diabetes.&lt;/P&gt;
&lt;P&gt;Selenium and Diabetes&lt;/P&gt;
&lt;P&gt;Paper 7 Stranges S, Marshall JR, Natarajan R et al Effects of long term selenium supplementation on the incidence of type 2 diabetes: a randomised controlled trial Ann Intern Med 147: 217-223&lt;/P&gt;
&lt;P&gt;Paper 8 Bleys J, Navas-Acien A, Guallar E Selenium and diabetes: more bad news for Supplements&amp;nbsp; &lt;BR&gt;Findings from the Nutrition Prevention of Cancer Trail show an increased risk for diabetes randomly assigned to receive supplements with 200pg of selenium daily for 7.7 years compared with placebo. More than 1% of the USA population take selenium supplements and 35% take multivitamins supplements that often contain selenium. Most people in the USA get enough selenium in their diet. Taking an extra supplement may increase their risk of diabetes.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt; N Eng J Med, JAMA, Lancet, BMJ, BJGP, An Intern Med Diabetic Medicine&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;September 2007. This series began in 2002 as a bulletin for Warwick Diabetes Care staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>113549</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=113549]]&gt;</url>
    <title>Interesting new diabetes papers : Dec 2005</title>
    <publicationDate>2006-01-20T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2005]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the eleventh in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Dec 2005&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;TYPE 1 DIABETES &amp;amp; CARDIOVASCULAR DISEASE&lt;/P&gt;
&lt;P&gt;Paper 1&lt;BR&gt;The Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group&lt;BR&gt;Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes&amp;nbsp; N Engl J Med 353; 2643-53&lt;BR&gt;Summary &lt;BR&gt;DCCT randomly assigned 1441 people with type 1 diabetes to intensive or conventional therapy treating them for a mean of 6.5 years between 1983 and 1993. 93% were followed up until Feb 2005. Cardiovascular disease defined as non fatal MI, stroke, death from CVD, angina or need for coronary revascularisation was assessed and classified by an independent committee.&lt;BR&gt;During 17 years of follow up 46 CVD events occurred in 31 patients in the intensive DCCT group as compared to 98 events in 52 people who had conventional treatment. Intensive treatment reduced the risk of any CVD event by 42% and the risk of death, stroke or non fatal MI by 57%. The decrease in HBA1c in the intensive group in DCCT was associated with post of the positive effects of intensive treatment on CVD. Microalbuminuria and albuminuria were associated with a significant increase in the risk of CVD.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;The intensive treatment group had a mean HBA1c of 7% as compared to 9% in the conventional group for a mean of 6.5 years.&amp;nbsp; After the study both groups glycaemic control converged to give a mean for both groups of 8% during the 17 years of follow up. This research group have already shown that intensive treatment had a sustained effect on the development of microvascular complications and now show this is the case for macrovascular complications.&lt;BR&gt;They conclude that this study reinforces the original DCCT message that intensive therapy aiming for an HBA1c at or below 7% should be implemented as early as possible in people with type 1 diabetes.&amp;nbsp; The reduction of 57% in death from CVD, stroke and non fatal MI exceeds the reductions in risk achieved by other proven medications such as statins and BP lowering therapies.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;CAN PEOPLE WITH DIABETES RELIABLY ESTIMATE THEIR BLOOD GLUCOSE LEVEL?&lt;/P&gt;
&lt;P&gt;Paper 2&lt;BR&gt;Frankum S, Ogden J&amp;nbsp; Estimation of blood glucose levels by people with diabnetes: a cross sectional study. BJGP 55;944-948&lt;BR&gt;Summary&lt;BR&gt;115 consecutive patients with diabetes aged over 18 attending&amp;nbsp; a GP practice diabetes clinic were invited to estimate their blood glucose level prior to having it routinely measured. 104 made estimates, 43% overestimated and 41 made guesses that fell into the range defined as accurate that is within + or – 1mmol of the lab measured value&lt;BR&gt;They conclude that the majority of people with diabetes in this study could not accurately estimate their blood glucose indicating that home blood glucose monitoring may be a necessary part of diabetes self care&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;Its interesting data, but several caveats need to be applied. Firstly it’s a small study Secondly whether the definition of an accurate estimate needs to be with 1mmol would be open to debate, why couldn’t it be 2mmoles, would most people be classed as accurate then? &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;DO GLITAZONES INCREASE EXERCISE CAPACITY IN PEOPLE WITH TYPE 2 DIABETES?&lt;/P&gt;
&lt;P&gt;Paper 3&lt;BR&gt;Regensteiner JG, Bauer TA, Reusch JEB Rosiglitazone improves Exercise Capacity in Individuals with Type 2 Diabetes Diabetes Care 28;2877-2883&lt;BR&gt;Paper 4&lt;BR&gt;LeBrasseur NK, Ruderman NB&amp;nbsp; Why might&amp;nbsp; Thiazolidinediones Increase Exercise Capacity in Patients with Type 2 Diabetes/ (editorial) Diabetes Care 28; 2975-6&lt;BR&gt;Summary &lt;BR&gt;In this study 20 people with uncomplicated type 2 diabetes were randomly assigned to receive 4mgs rosiglitazone per day or placebo for 4 months. The study showed expected improvements in insulin sensitivity as determined by homeostasis model assessment and hyperinsulinaemic-euglycaemic clamp study.&amp;nbsp; The novel finding was that there was a modest but significant increase in exercise capacity as assessed by graded bicycle testing to measure VO2 max and 3 constant load tests to determine Vo2 kinetics. The authors say that it is possible that the improvement in exercise capacity was due to improvements in insulin sensitivity and/or endothelial function but they could be due to some other unidentified action of glitazones&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This is interesting but preliminary data that needs further confirmation.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;TYPE 2 DIABETES AS A “CORONARY HEART DISEASE EQUIVALET&lt;/P&gt;
&lt;P&gt;Paper 5&lt;BR&gt;Juutilainen A, Lehto S, Ronnemaa T et al Type 2 Diabetes as a “Coronary Heart Disease Equivalent”&lt;BR&gt;Summary &lt;BR&gt;This research group first reported that type 2 diabetic patients without a history of prior myocardial infarction have the same risk of CHD death as nondiabetic subjects with a history of prior myocardial infarction in 1998. Since then 5 studies have supported that view and 8 studies have presented data opposing it. The conclusion of all the studies so far might be that type 2 diabetes might be a CHD equivalent but only in women.&lt;BR&gt;In this paper the research group report&amp;nbsp; a further follow up of their cohort to 18 years. They report that diabetes without prior myocardial infarction and prior myocardial infarction without diabetes indicate a similar risk for CHD death in men and women&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;Further data to add to the debate!&lt;/P&gt;
&lt;P&gt;HYPOGLYCAEMIA &amp;amp; TYPE 2 DIABETES&lt;/P&gt;
&lt;P&gt;Paper 6&lt;BR&gt;Zammitt NN, Frier BM Hypoglycaemia in type 2 Diabetes Diabetes Care 28; 2948-2961&lt;BR&gt;Summary &lt;BR&gt;Expert review with 151 references covering pathophysiology, frequency and effects of different treatment modalities. The paper concludes that it occurs most often with insulin therapy but that sulphonylurea induced hypoglycaemia is a significant problem&lt;BR&gt;Glimeperide and modified release gliclazide and the prandial glucose regulators may limit hypoglycaemia risk&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;Good expert review of this area&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;BRIEF REPORTS&lt;/P&gt;
&lt;P&gt;Screening&lt;BR&gt;Paper 7 &lt;BR&gt;George PM, Valabhji J, Dawood M, Henry JA Screening for type 2 diabetes in the A &amp;amp; E Dept Diabetic Medicine 22;1766-1769&lt;BR&gt;Screened 500 unselected attendees using random capillary glucose of 7 as cut off. 36 had CGB above 7 and had diagnostic testing 13 had diabetes, 8 IFG and 15 were normal&lt;/P&gt;
&lt;P&gt;Pregnancy &amp;amp; type 2 Diabetes&lt;BR&gt;Paper 8 &lt;BR&gt;Roland JM, Murphy HR, Ball V et al The pregnancies of women with type 2 diabetes: poor outcomes but opportunities for improvement Diabetic Medicine 22; 1774-1777&lt;BR&gt;Data from 389 type 1 and 146 type 2 pre gestational diabetic pregnancies from 10 UK hospitals. Type 2 mothers were less likely to have had pre pregnancy counselling, inadequate folic acid supplementation and treatment with oral hypoglycaemic agents all of which may contribute to the serious adverse outcomes affecting 1 in 6 type 2 diabetic pregnancies&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed this month:&lt;/STRONG&gt; Diabetes Care , Diabetic Medicine, BMJ, NEJM, BJGP, Lancet,&amp;nbsp; Pract Diab Int&lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;January 2006. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of these bulletins is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>224608</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=224608]]&gt;</url>
    <title>Interesting new diabetes papers : Dec 2006</title>
    <publicationDate>2007-01-09T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2006,DIABETES,RESEARCH,INTERESTING NEW ARTICLES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the twenty third in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Dec 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;RANDOMISED CONTROLLED TRIALS&lt;/P&gt;
&lt;P&gt;The Adopt study&lt;/P&gt;
&lt;P&gt;Paper 1 Viberti g, Lachin J, Holman R et al&amp;nbsp; A diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 patients in North America and Europe&lt;BR&gt;Diabetic Medicine 23; 1289-1294&lt;/P&gt;
&lt;P&gt;Paper 2 Kahn S, Haffner S, Heise M et al&amp;nbsp; Glycaemic Durability of Rosiglitazone, Metformin or Glyburide monotherapy N Engl J Med 335;2427-43&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;Paper 1 gives the baseline characteristics of 4360 people with type 2 diabetes enrolled into the ADOPT study. Caucasian North American and Euoropean ADOPT patients differed with respect to adiposity, insulin resistance and metabolic syndrome prevalence.&lt;BR&gt;Paper 2 gives the results of the RCT in which these 4360 people were randomised for initial monotherapy to either rosiglitazone titrated up to 8mgs daily, metformin titrated up to 2gms daily or glyburise (glibenclamide) titrated up to 15mgs daily. The patients were treated for 4 years and the primary outcome was time to monotherapy failure defined as&amp;nbsp; a confirmed fasting plasma glucose of more than 10mmoles/l.&lt;BR&gt;The cumulative monotherapy failure at 4 years was 15% for rosiglitazone, 21% for metformin and 34% with glibenclamide. Rosiglitazone was associated with more weight gain and oedema than metformin or glibenclamide but with fewer GIT side effects than metformin and less hypoglycaemia than glibenclamide. &lt;BR&gt;The authors conclude that the potential risks and benefits, the profile of adverse events, and the costs should all be considered to help inform the choice of pharmacology for people with type 2 diabetes.&lt;BR&gt;&lt;BR&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;The side effects seen in this study were those that would have been expected for the 3 drugs. There were no signs of LFT problems with rosiglitazone nor increased levels of CCF although the trial was not designed to evaluate cardiovascular outcomes. There was a small but unexpected increase in the rate of fractures in the rosiglitazone group. The rate of withdrawl of patients from the study was high but was similar in all 3 groups.&lt;BR&gt;The results of this study are unlikely to alter the position of metformin as the initial monotherpay of choice for most people with type 2 diabetes. It may however be interpreted as giving an added boost to the idea of using rosiglitazone second to metformin rather than a sulphonylurea.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;OTHER TYPES OF STUDY&lt;/P&gt;
&lt;P&gt;Paper 3 Kitabchi AE, Umpierrez GE, Murphy MB, Kreisberg RA Hyperglycaemic Crises in Adult Patients with Diabetes A Consensus statement from the American Diabetes Association&lt;BR&gt;&lt;BR&gt;Summary:&lt;BR&gt;An expert review and consensus statement with 81 references looking at Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycaemic state (HHS - usually labelled as HONK in UK) It reviews the pathogenesis, precipitating factors, diagnosis, treatment, complications and prevention. It contains a treatment algorithm for DKA and one for HHS.&lt;BR&gt;&lt;BR&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;This is the definitive document on these conditions for USA practice.&lt;/P&gt;
&lt;P&gt;Ketosis-Prone Diabetes&lt;/P&gt;
&lt;P&gt;Paper 4 Balasubramanyam A, Garza G, Rodriguez L et al Accuracy and Predictive value of classification schemes for Ketosis-Prone Diabetes&amp;nbsp;&amp;nbsp; Diabetes Care 29; 2575-2579&lt;/P&gt;
&lt;P&gt;Paper 5 Umpierrez GE&amp;nbsp;&amp;nbsp; Ketosis-Prone type 2 Diabetes: Time to revise the classification (editorial) Diabetes Care 29; 2755-7&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;Diabetes that is not easily classified as either type 1 or type 2 is increasing worldwide. They include people who are prone to develop ketosis although they lack evidence of autoimmune destruction of beta cells. The ADA classifies them at present as a subset of type 1 – idiopathic type 1 or type 1b. &lt;BR&gt;Paper 4 describes the follow up of 294 patients presenting with ketosis and followed for 12-60 months. They looked at beta cell function and autoimmunity, and propose a new system of classification.&lt;BR&gt;The editorial suggests that in a newly diagnosed patient with ketosis in particular if overweight/obese from an ethnic minority group is more likely to show clinical and immunological features of type 2 rather than type 1 during follow up, and are likely to be able to discontinue insulin therapy. The editorial suggests that the ADA classification be revised to reclassify patients with idiopathic or type 1b diabetes as having “ketosis-prone type 2 diabetes.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments: &lt;BR&gt;Some greater clarity on a fairly rare but important area of&amp;nbsp; diabetes.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;BRIEF REPORTS&lt;/P&gt;
&lt;P&gt;Diabetes Service Delivery &lt;/P&gt;
&lt;P&gt;Paper 6 Young B and Dean JD Navigating services for people with diabetes through the storms of health-care policy development (editorial) Diabetes Care 23; 1277-1280&lt;BR&gt;This editorial reviews&amp;nbsp; policy changes using&amp;nbsp; documents from DH that they feel have influenced diabetes service delivery over the past 10 years or so.&lt;/P&gt;
&lt;P&gt;Paper 7 Baxter M, Toms G, Gadsby R, Griffiths U Empowering primary care practitioners to meet the growing challenge of diabetes care in the community (editorial) BJDVD 6; 245-248&lt;BR&gt;This editorial reviews shifting care from primary to secondary care looking specifically at educating primary care to intitiate insulin in the community&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Telemedicine&lt;/P&gt;
&lt;P&gt;Paper 8 Cho JH, Chang SA, Kwon HS et al Long-term Effect of the internet based glucose monitoring system on HBA1c reduction and glucose stability. Diabetes Care 29; 2625-2631&amp;nbsp; RCT of&amp;nbsp; 80 people in Korea with type 2 diabetes randomised to office visits or an internet based glucose monitoring system which was bidirectional providing a close doctor-patient relationship enhancing feedback and education. Use of the internet based system gave lower HBA1c results.&lt;/P&gt;
&lt;P&gt;Paper 9 Franklin VL, Waller A, Pagliari C and Greene SA A randomised controlled trial of Sweet Talk, a text messaging system to support young people with diabetes. Diabetic Medicine 23; 1332-8&amp;nbsp; An RCT of 126 people 8-18 years with type 1 diabetes. Sweet talk gave daily personalised text messages containing goal specific prompts and messages tailored to the patients age, sex and insulin regime. It did not improve glycaemic control, but 82% felt it improved their self management and 90% wanted to continue to receive the messages. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Clinical Inertia&lt;/P&gt;
&lt;P&gt;Paper 10 Hicks PC, Westfall JM, Van Vorst RF et al Action or inaction? Decision making in patients with diabetes and elevated blood pressure in primary care Diabetes Care 29; 2580-2585 Study from Colorado USA from 26 practices. Questionaire based study looking at clinical action to lower BP.&amp;nbsp; This study found no evidence for patterns of poor care. Providers balanced the clinical circumstances, including how elevated the BP is and issues of polypharmacy, side effects of medications, and costs when determining the best course of action.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;DPP4 Inhibitors&lt;/P&gt;
&lt;P&gt;Paper 11&amp;nbsp; Carbonnel B, Karasik A, Liu J et al Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone Diabetes Care 29; 2638-2643 RCT in 701 patients showing that sitagliptin 100mgs once daily added to metformin monotherapy was well tolerated and&amp;nbsp; efficacious (lowered HBA1c by 0.65%) &lt;/P&gt;
&lt;P&gt;Paper 12 Aschner P, Kipnes MS, Lunceford JK et al Effect of the Dipeptidyl Peptidase-4 inhibitor Sitagliptin as monotherapy on glycaemic control in patients with type 2 diabetes Diabetes Care 29; 2632-2637 RCT in 741 patients randomised to sitagliptin 100 or 200mgs daily or placebo. For 24 weeks. In the study once daily sitagliptin monotherapy improved glycaemic control HBa1c reductions of 0.79% in 100mgs and 0.94% in 200mgs)&amp;nbsp; in fasting and postprandial states, improved measures of beta cell function and was well tolerated.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt;&amp;nbsp; BMJ, Lancet, N Eng J Med, Diabetes Care, Diabetic Medicine, Pract Diab Int, BJDVD, Diabetes and Primary Care&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;January 2007. This series began in 2002 as a bulletin for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>123544</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=123544]]&gt;</url>
    <title>Interesting new diabetes papers : Feb 2006</title>
    <publicationDate>2006-03-22T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2006,RESEARCH,INTERESTING NEW ARTICLES,DIABETES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the thirteenth in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Feb 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;DIABETES &amp;amp; CHD RISK&lt;/P&gt;
&lt;P&gt;Paper 1&lt;BR&gt;Howard BV, Best LG, Golloway JM et al&amp;nbsp; Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors Diabetes Care 29;391-397&lt;BR&gt;Summary:&lt;BR&gt;Should someone with diabetes without CHD be treated the same as&amp;nbsp; someone who already has CHD but does not have diabetes? Various studies in different populations have come to different conclusions on this matter. This paper gives data that explains why.&lt;BR&gt;The authors studied the influence of single and multiple risk factors on the 10 year cumulative incidence of fatal and non fatal CHD and cardiovascular disease CVD, in diabetic and non diabetic men and women, with or without baseline CVD or CHD, in a population of 4.549 people with a high prevalence of diabetes.&lt;BR&gt;Diabetic men and women had a 10 year cumulative incidence of CHD of 25.9 and 19.1% respectively compared with 57.4% and 58.4% for nondiabetic men and women with previous CHD. The pattern was similar when only fatal events were considered.&lt;BR&gt;Diabetic individuals with 1 or 2 risk factors had a 10 year cumulative incidence of CHD that was only 1.4 times higher than that of non diabetic individuals. However the 10 year cumulative incidence of CHD in diabetic subjects with multiple risk factors was greater than 40% and the incidence of fatal CHD was higher in those subjects than in non diabetic subjects with previous CHD. Data for CVD showed a similar pattern as did separate analysis by sex.&lt;BR&gt;They conclude that their results and comparisons with other published data show wide variations in the rate of CHD in diabetes, depending on the population and existing risk factors. Most individuals had a 10 year cumulative incidence of less than 20% but only those with multiple risk factors had a 10 year cumulative incidence that was equivalent to patients with CHD. Until more data is available it may be prudent to consider targets based on the entire risk factor profile rather than just the presence of diabetes&lt;BR&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;This paper helpfully explains why papers have shown conflicting conclusions as to whether diabetes is or is not a risk equivalent for CHD. It clearly shows that it is a risk equivalent in only those with diabetes and multiple other risk factors.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;DIABETES PREVALENCE &lt;/P&gt;
&lt;P&gt;Paper 2&lt;BR&gt;Forouhi NG, Merrick D, Goyder E et al&amp;nbsp; Diabetes prevalence in England 2001 – estimates from an epidemiological model&amp;nbsp; Diabetic Medicine 23; 189-197&lt;BR&gt;Summary:&lt;BR&gt;A epidemiological model was constructed by applying age, sex, ethnic specific prevalence rates to resident populations of England at national, regional and PCT level. The estimated prevalence of total diabetes for all people in England was 4.41% in 2001 equating to 2.168 million people. Type 2 92.3% and Type 1 7.7% (166,000 people)&lt;BR&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;The estimates from the model when compared to QoF data showing the true prevalence of known diabetes give an estimate of numbers yet to be diagnosed.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;GLYCAEMIC CONTROL &amp;amp; MEMORY&lt;/P&gt;
&lt;P&gt;Paper 3&lt;BR&gt;Ryan CM, Freed MI, Rood JA et al Improved metabolic control leads to better working memory in adults with type 2 diabetes&amp;nbsp; Diabetes Care 29; 345-351&lt;BR&gt;A prospective randomised controlled trial in&amp;nbsp; 154&amp;nbsp; people with type 2 diabetes who were randomly allocated to receive rosiglitazone or glibenclamide as add on therapy to metformin.&amp;nbsp; Cognitive function was assessed at baseline and at 24 weeks using 3 standard instruments.&lt;BR&gt;Pretreatment fasting plasma glucose levels were similar in the v2 groups and after 24 weeks both groups showed similar significant reductions. Working memory improved in both treatment groups and was significantly correlated with improved glycaemic control as measured by fpg.&lt;BR&gt;The authors suggest that further work is needed to understand and develop this finding.&lt;BR&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;Fascinating results that need exploring in more research. Gives another reason to encourage good glycaemic control.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;USING METFORMIN AS INITIAL MONOTHERAPY IN DIABETES &lt;/P&gt;
&lt;P&gt;Paper 4&lt;BR&gt;Donnelly LA, Doney ASF, Hattersley AT , Morris AD, Pearson ER The effect of obesity on glycaemic response to metformin or sulphonylurea in type 2 diabetes &lt;BR&gt;Diabetic Medicine 23; 128-133&lt;BR&gt;Summary:&lt;BR&gt;Using the Scottish DARTS database 3856 people with type 2 diabetes were identified who were on monotherapy in 2001. In a linear regression the effect of BMI and other confounders on drug response was assessed in 2064 treatment naïve patients starting sulphonylurea of metformin between 1994 and 2002.&lt;BR&gt;Metformin was more likely to have been used in obese rather than non obese patients. Glycaemic response to sulphonylureas was not influenced by BMI. The HBA1c reduction for metformin was similar in obese and non obese.&lt;BR&gt;The authors conclude that BMI alone should not influence the choice of oral agent monotherapy and that given the non glycaemic benefits of metformin it ought to be used in more non obese people.&lt;BR&gt;Dr Roger Gadsbys comments:&lt;BR&gt;NICE says metformin should be considered in those of normal weight, and this paper supports that.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;DIABETES IN NEW YORK&lt;/P&gt;
&lt;P&gt;Paper 5&lt;BR&gt;Steinbrook R&amp;nbsp; Facing the Diabetes Epidemic- Mandatory reporting of glycosylated haemaglobin values in New York City&amp;nbsp; (Perspective) N Engl J Med 354; 545-548&lt;BR&gt;Summary:&lt;BR&gt;This is a report of the initiative taken by the New York Board of Health in Dec 2005 to instigate mandatory electronic reporting of HBA!c results to the city’s Dept of Health. It has aroused concerns about patient privacy but&amp;nbsp; the city’s health commissioner&amp;nbsp; has said “ we have to get a better handle on what is really the only major health problem in the USA that is getting worse and getting worse rapidly” The prevalence of diabetes in New York is around 9% and rises to 18% in South Bronx.&lt;BR&gt;It will create a register of between 1-2 million tests a year, linked to basic demographic data on the patient and the requesting physician. Starting in July 2007 a pilot intervention programme in South Bronx will write to patients giving them educational and resource materials if their HBA!c is above a certain level. Physicians will also receive details of their patients stratified according to level of HBA1c along with best practice recommendations for diabetes care. Patients will be able to “opt out” of receiving the letters if they wish to.&lt;BR&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;Very interesting development highlighting how important diabetes is as a problem in New York&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;NEW THERAPY AREA – GLP-1&lt;/P&gt;
&lt;P&gt;Paper 6 &lt;BR&gt;Riddle MC Drucker DJ&amp;nbsp; Emerging therapies mimicking the effects of amylin and Glucagon like peptide 1 Diabetes Care 29; 435-449&lt;BR&gt;Dr Roger Gadsby’s comments: Expert review with 186 references covering this new therapy area.&lt;/P&gt;
&lt;P&gt;Paper 7&lt;BR&gt;Levy JC&amp;nbsp; Theraputic intervention in the GLP-1 pathway in type 2 diabetes Diabetic Medicine (Education suppl) 23; 14-19&lt;BR&gt;Dr Roger Gadsby’s comments: Very readable expert review of this new therapy area.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt;&amp;nbsp; Diabetes Care , Diabetic Medicine, BMJ, NEJM, BJGP, Lancet,&amp;nbsp; JAMA, Pract Diab Int&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;March 2006. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp;Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of&amp;nbsp;this series&amp;nbsp;is to inform readers of interesting new papers relevant to diabetes that have appeared in&amp;nbsp;several diabetes and general medical journals in the previous month.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>258645</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=258645]]&gt;</url>
    <title>Interesting new diabetes papers : Feb 2007</title>
    <publicationDate>2007-03-22T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2007,DIABETES,RESEARCH,INTERESTING NEW ARTICLES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the twenty fifth in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Feb 2007&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;SYSTEMATIC REVIEWS &amp;amp; META-ANALYSIS&lt;/P&gt;
&lt;P&gt;Sulphonylureas and hypoglycaemia&lt;/P&gt;
&lt;P&gt;Paper 1&amp;nbsp; Gangji AS, Cukierman T, Gerstein HC et al&amp;nbsp; A Systematic review and meta-analysis of hypoglycaemia and cardiovascular events: a comparison of glyburide and other secretagogues and with insulin&amp;nbsp; Diabetes Care 30; 389-394 &lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;A systematic&amp;nbsp; review of&amp;nbsp; 21 relevant papers. It shows that glyburide (called glibenclamide in UK) was associated with a 52% greater risk of experiencing at least one episode of hypoglycaemia compared to other secretagogues and with 83% greater risk compared with other sulphonylureas. Glyburide was not associated with an increase in cardiovascular events or end of trial weight gain compared with other secretagogues. Limitations included suboptimal reporting of original trials. Loss to follow up exceeded 20% in some studies, and major hypoglycaemia was infrequently reported&lt;BR&gt;&lt;BR&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;In the UK we always thought that glibenclamide produced more hypoglycaemia, and it is not used much as a result. It’s good to have current clinical practice reinforced by a systematic review!&lt;/P&gt;
&lt;P&gt;RANDOMISED CONTROLLED TRIALS&lt;/P&gt;
&lt;P&gt;New treatment for glucose lowering – Data on the DPP-4 inhibitor Vildagliptin&lt;/P&gt;
&lt;P&gt;Paper 2&amp;nbsp;&amp;nbsp; Rosenstock J, Baron MA, Dejager S et al Comparison of Vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes&amp;nbsp; Diabetes Care 30; 217-223&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;A 24 week RCT of vildagliptin 100mgs daily given as equally divided doses (n= 519) or rosiglitazone 8mgs once daily (n=267) in drug naïve patients with type 2 diabetes who had an average HBA1c of 8.7%.&lt;BR&gt;Vildagliptin was well tolerated and produced similar reductions in HBA1c to rosiglitazone of around – 1.1%. The reduction in those with higher HBA1c of above 9% was greater at around -1.8% Wt was unchanged in the vildagliptin group but increased by 1.6Kg in the rosi group.&amp;nbsp; Both agents were well tolerated with no significant hypoglycaemia. The side effect&amp;nbsp;&amp;nbsp; oedema was 4% in the rosi group and 2% in the vildagliptin group.&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;More data on vildagliptin. It is unlikely to be used as monotherapy in the UK as metformin is the established first line therapy for most people. &lt;/P&gt;
&lt;P&gt;OTHER TYPES OF STUDY&lt;/P&gt;
&lt;P&gt;eGFR in Diabetes&lt;/P&gt;
&lt;P&gt;Paper 3 Chudleigh RA, Dunseath G, Evans W et al How reliable is Estimation of glomerular filtration rate at diagnosis of type 2 diabetes. Diabetes Care 30: 300-305&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;The CG and MDRD equations have both been used to determine eGFR in patients. In this study the results using these 2 equations were compared with the “gold standard”&amp;nbsp; isotopic Cr-EDTA method in 292 newly diagnosed treatment naïve people with type 2 diabetes. The equations significantly underestimated GFR, particularly in those with an eGFR at or above 90. &lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;This reinforces the idea&amp;nbsp; that all eGFR’s reported using the now standard MDRD formula that are above 60 can be accepted as “ok” and not much importance should be placed on the precise figure.&lt;/P&gt;
&lt;P&gt;Development of Diabetes in patients with IFG&lt;/P&gt;
&lt;P&gt;Paper 4 Forouhi NG, Luan J, Hennings S, Wareham NJ&amp;nbsp; Incidence of type 2 diabetes in England and its association with baseline impaired fasting glucose (IFG): The Ely study 1990-2000&amp;nbsp; Diabetic Medicine 24;200-207&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;The Ely study has follow 1040 non diabetic adults of ages 45-69 years who has ogtt’s at baseline at 4.5 years and 10 years. This paper reports that the 10 year cumulative incidence of diabetes was 7.3 per 1000 person years. Diabetes incidence was more strongly related to the present WHO definition of IFG as defined as fasting of 6.1 -6.9mmol/l rather than the lower category of 5.6-6.0. &lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Evidence to support the WHO/IDF position to keep IFG defined as 6.1-6.9 rather than lower it to 5.6 as the ADA suggest.&lt;/P&gt;
&lt;P&gt;HBA1c Goals&lt;/P&gt;
&lt;P&gt;Paper 5 Pogach L, Engelgau M, Aron D&amp;nbsp; Measuring Progress towards Achieving Haemoglobin A1c goals in Diabetes Care&amp;nbsp; JAMA 297; 520-523&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Brilliant discussion and analysis. Considers the difference between practical guidelines and performance measures. Discusses 3 questions.&lt;BR&gt;1 Is the generalization of an HBA1c threshold measure of less than 7% to all persons with diabetes justified by currently available evidence and concordant with nationally recognised guidelines? &lt;BR&gt;2 Is achieving and maintaining an HBA!c threshold of less than 7% for most persons with diabetes sufficiently actionable by healthcare systems and by practising physicians to justify its use for public accountability?&lt;BR&gt;3 Are their other approaches to measuring glycaemic control that can accurately assess the benefit to population health, compare plans for public reporting and inform quality improvement?&lt;BR&gt;They conclude that assessing improvement towards optimal HBA1c , rather than a threshold optimal target, is a more precise assessment of individual clinical benefit and achieved improvement in population health. &lt;/P&gt;
&lt;P&gt;BREIF REPORTS&lt;/P&gt;
&lt;P&gt;Paper 6 Gerstein HC Point: if it is important to prevent type 2 diabetes, it is important to consider all proven therapies within a comprehensive approach. Diabetes Care 30: 432-434&lt;BR&gt;&lt;BR&gt;Paper 7 Tuomilehto J Counterpoint: Evidence-based prevention of type 2 diabetes: the power of lifestyle management Diabetes Care 30; 435-438&lt;BR&gt;Debate over drugs or lifestyle. Good review of evidence. Lifestyle wins for me!&lt;BR&gt;&lt;BR&gt;Paper 8 Heeley-Creed D, Brwon K, Hill J Carlisle and District diabetes training in nursing and residential homes Pract Diab Int 24; 15-18&lt;BR&gt;Description of 2 projects targeting care home education needs&lt;BR&gt;&lt;BR&gt;Paper 9 Jones c, Fisher M Intensive insulin treatment in coronary intensive care. Pract Diab Int 24; 42-47.&amp;nbsp; &lt;BR&gt;Good discussion of the evidence&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt;&amp;nbsp; BMJ, Lancet, N Eng J Med, Diabetes Care, Diabetic Medicine, Pract Diab Int, BJDVD, Diabetes and Primary Care&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;March 2007. This series began in 2002 as a bulletin for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>284120</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=284120]]&gt;</url>
    <title>Interesting new diabetes papers : February - March  2008</title>
    <publicationDate>2008-04-29T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2008,DIABETES,RESEARCH,INTERESTING NEW ARTICLES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the thirty fifth in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : February - March  2008&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;SYSTEMATIC REVIEWS &amp;amp; META-ANALYSIS&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Hypoglycaemia in type 2 diabetes&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;/STRONG&gt;Paper 1 Amiel SA, Dixon T, Mann R, Jameson K&amp;nbsp; Hypoglycaemia in type 2 diabetes&amp;nbsp; Diabetic Medicine 25: 245-254&lt;BR&gt;Summary&lt;BR&gt;Review of 53 papers. Concludes that the&amp;nbsp; primary cause of hypoglycaemia in type 2 diabetes is therapy with insulin and therapy with sulphonylureas (SU) The risks of hypoglycaemia is increased in older patients, those with long duration of diabetes, less insulin reserve and perhaps in the drive for strict glycaemic control. Patients taking insulin have the highest rates of self reported severe hypoglycaemia (25% in patients who have been taking insulin for more than 5 years). SU’s are associated with lower rates but large numbers of people in the UK take SU’s and it is estimated that more than 5000 people in the UK will experience a severe event&amp;nbsp; from their SU therapy that will require emergency intervention.&amp;nbsp; Hypoglycaemia has considerable impact in terms of mortality, morbidity and quality of life. It is estimated that each hospital admission for severe hypoglycaemia costs around £1000&amp;nbsp; Hypoglycaemia and fear of hypoglycaemia limit the achievement and maintenance of strict glycaemic control&lt;BR&gt;Dr Roger Gadsby’s comments&amp;nbsp; Very helpful review&lt;/P&gt;
&lt;P&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RANDOMIZED CONTROLLED TRIALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Multifactorial interventions in type 2 d&lt;/STRONG&gt;&lt;STRONG&gt;iabetes to reduce mortality&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Paper 2 Gaede , Lund-Anderson H, Parving H-H, Pedersen O Effect of a Multifactorial Intervention on mortality in type 2 diabetes N Engl J Med 358: 580-591&lt;BR&gt;Summary&lt;BR&gt;This is a follow up from the Steno 2 study in which 160 people with type 2 diabetes and microalbuminuria were randomised to intensive therapy or conventional therapy: the mean treatment period was 7.8 years. Patients were subsequently observed for a further 5.5 years. The primary end point at 13.3 years of follow up was death from any cause. 24 patients in the intensive group died as compared with 40 in the conventional group. Intensive therapy was associated with lower risk of death from CV causes and of cardiovascular events. One person in the intensive arm progressed to end stage renal disease as compared to 6 in the conventional group and there was a reduction in people requiring retinal photocoagulation.&lt;BR&gt;The mean HBA1c in the intensive after 7.8 years was 7.9% and 7.7% after 13.3 years compared to 9% and 8% in the conventional&lt;BR&gt;The BP’s were 131/73 and 140/74 in the intensive and 146/78 and 146/73 in the conventional&lt;BR&gt;The % on statins were 85% and 84% in the intensive and 22% and 85% in the conventional&lt;BR&gt;The % on insulin were 57% and 73% in the intensive and&amp;nbsp; 54% and 92% in the conventional&lt;BR&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This follow up data is fascinating. The conventional group have approached the intensive group in parameters of control during the follow up as the lessons learnt from the initial study were applied to the conventional group. BP seems to be the easiest to control, most were on statins, and few even in the intensive group approached “ideal” HBA1c figures in spite of widespread use of insulin.&lt;BR&gt;The ideal of most people on a statin, BP&amp;nbsp; at or below 130/80 in people with microalbuminuria, and HBA1c below 7.5% have been incorporated into QoF and NICE guidance and similar levels of mortality reduction from CHD can be expected in the UK.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient education&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Paper 3 Davies M, Heller S, Skinner C et al Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes : cluster randomised controlled trial BMJ 336: 491-495&lt;BR&gt;Summary&lt;BR&gt;A cluster randomised trial of 824 patients newly diagnosed with type 2 diabetes in 207 general practices. The intervention was a structured group education programme lasting 6 hours delivered by 2 trained healthcare professionals compared to usual care. &lt;BR&gt;The main outcome measure was HBA1c at 12 months, with weight, smoking and a variety of psycho-social measures as other outcomes.&lt;BR&gt;There was no statistically significant change in HBa1c. There was a statistically significant improvement in weight loss of around 1 Kg and in smoking cessation. There were positive improvements in beliefs about illness.&lt;BR&gt;Dr Roger Gadsby’s Comments.&lt;BR&gt;It is disappointing that this intervention did not reduce HBA1c at 12 months. The improvements in weight and smoking cessation are modest. The improvements in psycho-social measures are interesting.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OTHER TYPES OF STUDY&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Type 1 diabetes &amp;amp; microalbuminuria&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Paper 4 Amin R, Widmer B, Prevost AT et al Risk of microalbuminuria and progression to microalbuminuria in a cohort with child onset type 1 diabetes: prospective observational study BMJ 336: 697-701&lt;BR&gt;Paper 5 Carel J-C, Levy-Marshall C Renal complications of childhood type 1 diabetes (editorial) BMJ 336: 677-8&lt;BR&gt;Summary&lt;BR&gt;Cohort of 527 people with type 1 diabetes diagnosed at a mean age of 8.8 years.&lt;BR&gt;Prevalence of microalbuminuria was about 25% and 50% at 10 and 20 years respectively. The natural course of microalbuminuria was such that about half of patients reverted at least transiently to normoalbuminuria and 13% progressed to macroalbuminuria. The main result of the study is that mean HBA1c is a strong predictor of microalbuminuria and is the only modifiable predictor.&amp;nbsp; The study did not assess whether an HBA!c threshold existed below which the risk of microalbuminuria was minimal. The best controlled group in the study with a mean HBA1c below 8.5% had around a 15% risk of microalbuminuria at the age of 20 years. The mean HBA1c of the cohort was 8.9%&amp;nbsp; which is quite a way above the goals of the ADA of 8.5% for toddlers, 8% for children and 7.5% for adolescents.&lt;BR&gt;Dr Roger Gadsby’s comments&lt;BR&gt;The implications of the study are that better HBA!c control is needed&amp;nbsp; to try to reduce the development of macroalbuminuria.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Retinopathy and fasting glucose&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Paper 6 Wong TY, Liew G, Tapp Ry et al Relation between fasting glucose and retinopathy for diagnosis of diabetes : three population based cross-sectional studies&lt;BR&gt;Lancet 371: 736-743&lt;BR&gt;Paper 7 Mohamed Q, Evans A Retinopathy, plasma glucose and the diagnosis of diabetes (editorial) Lancet 371:700-701&lt;BR&gt;Summary&lt;BR&gt;The current cut-offs for fasting glucose to diagnose diabetes come from studies looking at the prevalence and incidence of diabetes specific microvascular complications such as retinopathy. Previous studies have shown that there is an abrupt glycaemic threshold above which the prevalence of retinopathy increases. These studies led the WHO to reduce the diagnostic level for diabetes from a fasting of 7.8 to 7.0mmoles in the late 1990’s. The cross sectional studies of three adult populations two from Australia, all of whom had multiple retinal photographs suggested a continuous relation with plasma glucose rather than a “cut-off”. Using 7 mmoles or higher gave a sensitivity of less than 40% for detecting retinopathy and a specificity of 80.8%-95.8%.&amp;nbsp; They suggest that the detailed grading of multiple photographs may have disproportionately diagnosed people with isolated lesions such as a couple of micro aneurysms which wouldn’t have been detected in previous studies and which may not be related to diabetes. Minor retinal disease occurs in up to 13% of people without diabetes and may be a non-specific marker of vascular disease. The editorial suggests that we do not rush to change diagnostic criteria for diabetes, but that more research is needed!&lt;BR&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This is fascinating data and debate, but its relevance to diagnostic criteria is at present uncertain.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;SHORT REPORTS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Safety of Tight Glycaemic Control &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;/STRONG&gt;Paper 8 Home P Safety of very tight blood glucose control (editorial) BMJ 336: 458-9&lt;BR&gt;Editorial in response to decision to stop the intensive glucose lowering arm of the ACCORD study 18 months early because of concerns about safety. There were more deaths in the group aiming for HBA1c of 6% or less than in the standard group of 7-7.9%. The cause of this is not known. Until more is known the advice of the editorial is to aim for HBA!c of less than 6.5%, but without using highly intensive treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diabetes &amp;amp; Pregnancy&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Paper 9 The Guideline Development group Management of Diabetes from preconception to the postnatal period: summary of NICE guidance&lt;BR&gt;Summary of the Guideline which was published on 26th March&lt;BR&gt;Paper 10 Griffiths F, Lowe P, Boardman F et al Becoming Pregnant- exploring the perspectives of women living with diabetes BJGP 58:184-190&lt;BR&gt;Qualitative study of 15 women with type 1 diabetes between 20-30 weeks gestation, says that&amp;nbsp; the concept of planned v unplanned pregnancy is unhelpful and that every pregnancy is different&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Inpatient Care&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Paper 11 Flanagan D, Moore E, Baker S et al Diabetic Medicine 25: 147-151. &lt;BR&gt;A team of 5 DSN’s dedicated to inpatient care reduced length of stay for emergency admissions, and for medical admissions but not surgical admissions&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Journals reviewed: &lt;/STRONG&gt;N&lt;/EM&gt;&lt;EM&gt;Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract,&amp;nbsp; Diabetes Care, Diabetic Medicine, Pract Diab Int&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; published in&amp;nbsp;February 2008.&amp;nbsp;This series began in 2002 as a bulletin for Diabetes Care Staff.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public.&amp;nbsp; Word and webpage versions available.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/EM&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79648</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=79648]]&gt;</url>
    <title>Interesting new diabetes papers : Jan &amp; Feb  2005</title>
    <publicationDate>2005-03-11T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2005,INTERESTING NEW ARTICLES,RESEARCH,DIABETES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the first in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Jan &amp; Feb  2005&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;FOOT PROBLEMS&lt;/P&gt;
&lt;P&gt;Paper 1 &lt;BR&gt;Wraight PR, Lawrence SM, Campbell DA, Colman PG&lt;BR&gt;Creation of a Multidisciplinary, evidenced based, clinical guideline for the assessment, investigation and management of acute diabetes related foot complications.&amp;nbsp; Diabetic Medicine 22; 127-136&lt;BR&gt;Summary&lt;BR&gt;There has been no universally accepted, peer reviewed evidence based guideline for the acute diabetic foot. This group from Melbourne Australia did a literature review and found 126 papers that were methodologically sound and clinically relevant. A multidisciplinary expert group used this literature and clinical experience to create a comprehensive, evidenced-based, clinical guideline for the assessment, investigation and management of acute diabetes related foot problems.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This clinical guideline fits with the NICE guideline on the prevention and management of foot problems in people with type 2 diabetes released in Jan 2004.&lt;BR&gt;The one page clinical algorithm is a useful summary that could be displayed in situations where people with acute diabetes related foot problems are being treated to alert healthcare professionals to the steps they need to take.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;INSULIN PUMPS&lt;/P&gt;
&lt;P&gt;Paper 2 &lt;BR&gt;McMahon SK, Airey FL, Marangou DA et al&amp;nbsp; Insulin pump ytherapy in children and adolescents: improvements in key parameters of diabetes care including quality of life Diabetic Medicine 22; 92-96&lt;BR&gt;Summary&lt;BR&gt;Prospective descriptive study of 100 patients from Australia, of mean age 12.5 years when starting pump therapy, who were followed for a mean of 1.4 years. Median HBA1c dropped from 8.3% to 7.8%, episodes of severe hypoglycaemia decreased from 32.9 to 11.4 per 100 patient years, and quality of life&amp;nbsp; scores improved after starting pump therapy.&lt;BR&gt;The authors conclude that pump therapy is proving an effective means of insulin therapy in the young patient that shows promise to improve glycaemic control with a reduction in hypoglycaemic frequency. Quality of life measures suggest that psychosocial outcomes may be improved.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This descriptive study provides data on the safety and efficacy of pump treatment in children with type 1 diabetes.&lt;/P&gt;
&lt;P&gt;Paper 3&lt;BR&gt;Pickup JC, Kidd J, Burmiston S, Yemane N&lt;BR&gt;Effectiveness of continuous subcutaneous insulin infusion in hypoglycaemia-prone type 1 diabetes. Pract Diab Int 22;10-14&lt;BR&gt;Summary&lt;BR&gt;Prospective descriptive study from London on 27 type 1 diabetes patients who had continued to suffer from frequent disabling biochemical hypoglycaemia during multiple insulin injection therapy. On insulin therapy the HBA1c drop was a median of 1.4%. Hypoglycaemia frequency was reduced.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comment&lt;BR&gt;Further data to support use of pumps. The authors conclude that NICE guidelines should explicitly include those with frequent unpredictable biochemical hypoglycaemia&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;TYPE 1 DIABETES IN YOUNGER PEOPLE&lt;/P&gt;
&lt;P&gt;Paper 4 &lt;BR&gt;Silverstein J, Klingensmith G, Copeland K et al&amp;nbsp; Care of children and adolescents with type 1 diabetes : A statement of the American Diabetes association&lt;BR&gt;Diabetes Care 28; 186-212.&lt;BR&gt;This evidenced based statement from the ADA has 237 references and covers all the main areas of care. It includes diagnosis, initial care, education, self management,&amp;nbsp; diabetes care, insulin management, blood glucose monitoring, nutrition, psychological issues, acute and chronic complications, adolescence and risk behaviours, giving recommendations for each section.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This statement covers areas discussed in the NICE type 1 guidelines for children published in July 2004, but from a USA perspective. This differs in some details from that in the UK , but by and large this statement is consistent with and supports the UK guidelines&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;ORAL THERAPY &lt;/P&gt;
&lt;P&gt;Paper 5 &lt;BR&gt;Van de Laar FA, Lucassen PL, Akkermans RP et al&lt;BR&gt;a-glucosidase inhibitors for patients with type 2 diabetes&amp;nbsp;&amp;nbsp; Diabetes Care 28; 154-163&lt;BR&gt;Results from a Cochrane Review and meta-analysis&lt;BR&gt;Summary&lt;BR&gt;Systematic review using Cochrane methodology. Forty one studies were identified, 30 of them on acarbose.&lt;BR&gt;No evidence for effects on morbidity or mortality was found.&amp;nbsp; Compared with placebo acarbose lowered HBA1c by 0.77%. With doses higher than 50mgs tds the effect on HBA1c was the same but side effects increased. It decreased BMI by 0.17, but had no effects on lipids. Compared to sulphonylurea they seemed inferior with respect to glycaemic control. For comparison with other agents, little data was available.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This review provides top level evidence for these agents. They are relatively weak at glucose lowering and do not have effects on lipids.&amp;nbsp; No data on effects on morbidity or mortality was found. Their side effects have limited use in the UK.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed this month:&lt;/STRONG&gt; Diabetes Care (Jan only), Diabetic Medicine, BMJ, NEJM, Lancet, JAMA, Pract Diab Int, Diabetes in Primary Care, Diabetic Foot &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in March 2005. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;The aim of this series is to inform readers of interesting&amp;nbsp; new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>122277</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=122277]]&gt;</url>
    <title>Interesting new diabetes papers : Jan 2006</title>
    <publicationDate>2006-02-25T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2006,RESEARCH,INTERESTING NEW ARTICLES,DIABETES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the twelfth in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Jan 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;IMPROVING CONCORDANCE&lt;/P&gt;
&lt;P&gt;Paper 1&lt;BR&gt;Maier C, Mustapic D, Schuster E at al.&amp;nbsp; Effect of a pocketsize tablet-dispensing device on glycaemic control in type 2 diabetic patients. Diabetic Medicine 23; 40-45&lt;BR&gt;Summary:&lt;BR&gt;This was a prospective randomised open label study with 2 parallel groups of around 1000 people with type 2 diabetes. One group were given a pocket sized tablet dispenser and brief instructions for its use. It could hold one day’s tablets in up to 3 doses. They were told to fill it themselves each day with that days tablets. The other group had no intervention.&amp;nbsp; After 6 months both groups had lowered their HBA1c, by 0.74% in the active group and by 0.53% in the control group, this difference was statistically significant. In the subgroup analysis the effect was more pronounced in patients receiving more medications, in those receiving more diabetes medications, and in younger patients.&lt;BR&gt;The authors conclude that in a large study population in a “realistic” setting. A simple tablet dispensing device led to a significant and clinically relevant improvement in HBA1c levels. Patients with more complex therapy regimes had the greater benefit suggesting that the tablet dispenser device improved adherence to therapy&lt;BR&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;We know from previous studies that many people with type 2 diabetes often do not take the right number of prescribed tablets the right number of times a day. Adherence worsens with increasing numbers of tablets and more frequent daily doses. This simple device seems to improve adherence and HBA1c levels significantly.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;DIABETES &amp;amp; CHD &lt;/P&gt;
&lt;P&gt;Paper 2&lt;BR&gt;Brunner EJ, Shipley MJ, Witte DR et al&amp;nbsp; Relation between blood glucose and coronary mortality over 33 years in the Whitehall study&amp;nbsp; Diabetes Care 29;26-31&lt;BR&gt;Summary:&lt;BR&gt;In the Whitehall study between 1967 – 1969, 17,869 male civil servants aged 40-64 had a 50gm oral glucose tolerance test. There have been 3571 coronary deaths over the 33 plus years of observation.&amp;nbsp; The dose response relationship of blood glucose at 2hrs after the ogtt and all cause cardiovascular and respiratory mortality was best fitted by a single slope above 4.6mmoles/l, there was no dose response relationship below this.&lt;BR&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;People are at increased CHD risk if they have diabetes and lesser degrees of glucose intolerance e.g. IGT. This paper suggests that there is a level of blood glucose 2hrs after a 50gm ogtt below which there is no increase.&lt;/P&gt;
&lt;P&gt;Paper 3&lt;BR&gt;Nishio K, Sakurai M, Kusuyama T et al A randomised comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes Diabetes Care 29; 101-106&lt;BR&gt;Summary:&lt;BR&gt;A prospective randomised controlled trial in 54 people with type 2 diabetes who were randomly allocated to receive pioglitazone 30mgs daily or control and were followed for 6 months.. Those treated with pioglitazone had less insulin resistance and leptin levels. The late luminal loss and in-stent restenosis were significantly less in the pioglitazone treated group than the control group. The authors conclude that pioglitazone reduced leptin levels, which improved insulin resistance and endothelial function with the reduction in insulin. The improved endothelial function affected the reduction of in-stent restenosis.&lt;BR&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;More evidence that glitazones reduce cardiovascular disease.&lt;/P&gt;
&lt;P&gt;Paper 4&lt;BR&gt;Huxley R, Barzi F, Woodward M&amp;nbsp; Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies&amp;nbsp; BMJ 332; 73-76&lt;BR&gt;Summary:&lt;BR&gt;A meta-analysis of 37 studies involving 447,064 patients. The rate of fatal coronary heart disease was higher in people with diabetes than in those without 5.4% v 1.6%. &lt;BR&gt;The relative risk for fatal&amp;nbsp; CHD associated with diabetes was 50% higher in women than in men. This can be explained by more adverse risk profiles in women combined with possible disparities in treatment that favour men.&lt;BR&gt;Dr Roger Gadsbys comments:&lt;BR&gt;This highlights the need to target the treatment of women&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;RETINOPATHY&lt;/P&gt;
&lt;P&gt;Paper 5&lt;BR&gt;Scanlon PH, Martin ML, Bailey C et al&amp;nbsp; Reported symptoms and quality of life impacts in patients having laser treatment for sight threatening retinopathy&lt;BR&gt;Diabetic Medicine 23;60-66&lt;BR&gt;Summary:&lt;BR&gt;This is a qualitative study with&amp;nbsp; 227 interviews of people attending&amp;nbsp; for first laser treatment or first follow up, and in multi-treatment patients with a loss of vision in at least one eye. Patients either had proliferative retinopathy or maculopathy. First time treatment patients reported fewer symptoms than the multi treatment patients.&amp;nbsp; After a pronounced reduction in quality of life impacts after the first treatment, results all demonstrate an increasing impact as patients move from first to multiple treatments.&amp;nbsp; Most patients said that the treatment had less of an impact than they had hoped for, and that they would have the treatment again if needed.&lt;BR&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;Fascinating insight into peoples reaction to laser treatment&lt;/P&gt;
&lt;P&gt;Paper 6 &lt;BR&gt;Liew G, Mitchell P Wang JJ, Wong TY Fundoscopy : to dilate or not to dilate? (editorial) BMJ 332;3&lt;BR&gt;Summary:&lt;BR&gt;Concludes that pupil dilation is important for thorough fundoscopy and that the risk of precipitating acute angle glaucoma is close to zero. Tropicamide 0.5% is a safe agent to be used in primary care&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt;&amp;nbsp; Diabetes Care , Diabetic Medicine, BMJ, NEJM, BJGP, Lancet,&amp;nbsp; Pract Diab Int&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;February 2006. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp;Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of&amp;nbsp;this series&amp;nbsp;is to inform readers of interesting new papers relevant to diabetes that have appeared in&amp;nbsp;several diabetes and general medical journals in the previous month.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>250336</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=250336]]&gt;</url>
    <title>Interesting new diabetes papers : Jan 2007</title>
    <publicationDate>2007-02-16T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2007,INTERESTING NEW ARTICLES,RESEARCH,DIABETES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the twenty fourth in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Jan 2007&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;SYSTEMATIC REVIEWS &amp;amp; META-ANALYSIS&lt;/P&gt;
&lt;P&gt;Paper 1&amp;nbsp; Elliott WJ, Meyer PM&amp;nbsp; Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369; 201-207 &lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;A systematic&amp;nbsp; review of&amp;nbsp; 48 randomised groups of 22 clinical trials with 143153 participants who did not have diabetes at randomisation and so were eligible for inclusion in this analysis.&amp;nbsp; 17 trials enrolled patients with hypertension, 3 enrolled high risk patients and one enrolled people with heart failure.&lt;BR&gt;The results showed that the association of antihypertensive drugs with incident diabetes was lowest for ARB and ACE inhibitors followed by CCB and placebo, beta blockers and diuretics in rank order. These results are consistent with previous meta-analyses but go beyond them. There are several&amp;nbsp; reasons why antihypertensive drugs might have differing effects on the risk of diabetes, with diuretics and beta blockers apparently increasing the likelihood of diabetes and ACE and ARB’s reducing it. These include different effects on insulin release, circulating kinins and the peripheral effects of insulin.&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Useful review of this issue&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;NATIONAL GUIDELINES OR STATEMENTS&lt;/P&gt;
&lt;P&gt;Paper 2 Buse JB, Ginsberg HN, Bakris GL et al Primary Prevention of Cardiovascular Diseases in People with Diabetes;&lt;BR&gt;A Scientific statement from the American Heart Association and the American Diabetes Association Diabetes Care 30; 162-172&lt;/P&gt;
&lt;P&gt;Summary: &lt;BR&gt;This joint statement from 2 Associations in the USA&amp;nbsp; covers:- &lt;BR&gt;1 lifestyle advice (weight and physical activity) &lt;BR&gt;2 blood pressure treating to a target of&amp;nbsp; below130/80 &lt;BR&gt;3 Lipids, if over 40 without overt CHD but with one or more major risk factors aim is LDL cholesterol below 4&lt;BR&gt;4 Glycaemia – HBa1c goal is less than 7% and for individual patients aim to get as near normal (below 6%) without hypoglycaemia&lt;BR&gt;5 Antiplatelet – aspirin 75 mgs in people over 40 with increased CHD risk &lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Interesting to observe what is recommended in USA and compare it to JBS2 and forthcoming NICE guidelines on lipids&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;EXPERT REVIEWS&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;November 2008.&amp;nbsp; Please Note: Marketing authorisation has been suspended of Acompila (rimonabant) as the European Medicines Agency has concluded that the benefits of Acompila no longer outweigh its risks of psychiatric disorders.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Paper 3 Padwal RS, Majumdar SR Drug treatments for obesity: orlistat, sibutramine and rimonabant Lancet 369: 71-77&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;An expert review paper that looks at the published papers on 3 anti obesity drugs now available in the UK. Orlistat, a gastrointestinal lipase inhibitor, reduces weight by around 3kg on average and decreases progression to diabetes in high-risk patients, adverse GIT effects are common. Sibutramine, a monoamine-reuptake inhibitor results in mean weight losses of 4-5kg but is associated with increases in blood pressure and pulse rate. Rimonabant, the first endocannabinoid receptor antagonists., reduces weight by 4-5kg on average and improves waist circumference and concentrations of HDL cholesterol and trglyceride, however an increased incidence of mood-related disorders has been reported.&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Interesting summary of information&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;RANDOMISED CONTROLLED TRIALS&lt;/P&gt;
&lt;P&gt;Preventing Diabetic Foot Ulcer Recurrence&lt;/P&gt;
&lt;P&gt;Paper 4&amp;nbsp; Preventing Diabetic foot ulcer recurrence in high risk patients: Use of temperature monitoring as a self assessment tool Lavery LA, Higgins KR, Lanctot DR et al&amp;nbsp; Diabetes Care 30; 14-20&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;173 people with previous history of foot ulceration were assigned to standard therapy, structured foot examination or enhanced therapy. All groups received footwear, education and regular footcare. Those in structured foot examination did a daily foot examination and wrote their findings in a book. Those in the enhanced therapy group used an infrared skin thermometer to measure temp at 6 foot sites each day. Temperature differences of 4degress F (2.2 degrees C) between l and r corresponding sites triggered patients to contact the study nurse and reduce activity until temperatures normalised. &lt;BR&gt;The enhanced therapy group had fewer foot ulcers than standard and structured foot examination groups. Enhanced 8.5%, standard 29.3%, structured foot 30.4%&lt;BR&gt;They conclude that infrared temperature home monitoring in serving as an “early warning sign” seems to be a simple and useful adjunct in the prevention of diabetic foot ulcerations.&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Fascinating data on a new self management tool. Will need more studies to prove its worth&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;OTHER TYPES OF STUDY&lt;/P&gt;
&lt;P&gt;BRIEF REPORTS&lt;/P&gt;
&lt;P&gt;Obesity and Inactivity as causes of type 2 diabetes &lt;/P&gt;
&lt;P&gt;Paper 5 Rana JS, Li TY, Manson JA, Hu FB&amp;nbsp; Adiposity compared with physical inactivity and risk of type 2 diabetes in women Diabetes Care 30; 5358.&lt;BR&gt;Data from Nurses health study in USA. They conclude that obesity and physical inactivity independently contribute to the development of type 2 diabetes. However the magnitude of the risk contributed by obesity is much greater than that imparted by physical inactivity&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Mortality and eGFR&lt;/P&gt;
&lt;P&gt;Paper 6 Nag R, Bilous R, Kelly S et al All-cause and cardiovascular mortality in diabetic subjects increases significantly with reduced estimated glomerular filtration rate (eGFR) ; 10 years data from the South Tees Mortality study Diabetic Medicine 24; 10-17 &lt;BR&gt;Found that eGFR below 29 mls/min per 1.73m2 CKD stages 4 &amp;amp; 5 had much more death and death from CHD than more normal eGRF . They show that eGFR is inversely related to diabetes mortality.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Education in Type 2 diabetes&lt;/P&gt;
&lt;P&gt;Paper 7 Ko SH, Song KH, Kim SR et al Long term effects of a structured&amp;nbsp; intensive diabetes education programme (SIDEP) in patients with type 2 diabetes; - a 4 year follow up study Diabetic Medicine 24; 55-62&lt;BR&gt;Study from South Korea. SIDEP is an inpatient 30hrs one week course based on the German model.&amp;nbsp; Of completers 73% were followed to 4 years. The mean HBA1c and frequency of hospitalisation related to diabetes per patient per year was lower in the SIDEP group than controls, and they more closely adhered to self care behaviours.. People with type 2 diabetes of longer duration and those treated with insulin had poorer HBA1c at follow up.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;UK Diabetes research network&lt;/P&gt;
&lt;P&gt;Paper 8 Matthews DR, Kennedy ED, Darbyshire JH, Johnston DG The UK Diabetes Research Network – an opportunity and a challenge Diabetic Medicine 24;7-9&lt;BR&gt;A brief over view of the network and its aims&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt;&amp;nbsp; BMJ, Lancet, N Eng J Med, Diabetes Care, Diabetic Medicine, Pract Diab Int, BJDVD, Diabetes and Primary Care&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;February 2007. This series began in 2002 as a bulletin for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>281277</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=281277]]&gt;</url>
    <title>Interesting new diabetes papers : January 2008</title>
    <publicationDate>2008-03-03T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2008,DIABETES,RESEARCH,INTERESTING NEW ARTICLES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the thirty fourth in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : January 2008&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;SYSTEMATIC REVIEWS &amp;amp; META-ANALYSIS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Statin Therapy in Diabetes&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Paper 1 Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371: 117-125&lt;BR&gt;Paper 2 Cheung BMY. Statins for people with diabetes (editorial) Lancet 371: 94-5&lt;BR&gt;Summary:&lt;BR&gt;This meta-analysis benefits from including data on very large numbers of individual trial participants, which enables detailed and pre-specified sub-group analysis. The findings are that there was a 9% proportional reduction in all cause mortality per mmol/L&amp;nbsp; reduction in LDL cholesterol in people with diabetes which was similar to the 13% reduction in those without diabetes. There were significant reductions in the numbers of fatal and non fatal myocardial infarctions, coronary revascularisations and strokes. After 5 years 42 fewer people with diabetes had major vascular events per 100 allocated to statin therapy. The relative risk reduction was similar irrespective of previous history of vascular disease and baseline characteristics. The review did not include 3 recent trials all of which failed to show statistically significant benefit., but including data from 2 of them did not affect the estimated rate ratios. There was no indication of harm from statin therapy in the meta-analysis&lt;BR&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Very helpful review and summary of the trials in this area. &lt;/P&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;BR&gt;Compliance and Therapy&lt;/P&gt;
&lt;P&gt;&lt;/STRONG&gt;Paper 3 Cramer JA, Benedict A, Muszbek N et al&amp;nbsp; The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review&lt;BR&gt;Int J Clin Pract 62: 76-87&lt;BR&gt;Summary:&lt;BR&gt;Review of 139 studies, 32% focused on hypertension, 27% on diabetes and 13% on dyslipidaemia. The remainder covered Cardiovascular disease in general. The most frequently reported measure of compliance was the 12 month medication possession ratio (MPR) . The overall mean MPR was 72% and it did not differ significantly between treatment classes (range 67%-76%). The average proportion of patients with an MPR over 80% was 59% overall, and 58%&amp;nbsp; for oral antidiabetics and 51% for lipid lowering therapy. The average 12 month persistence rate was 63% and was similar across classes. Good compliance had a positive effect on outcome in 73% of the studies examining clinical outcome.&lt;BR&gt;The review concludes that non compliance is a significant problem in chronic disease management. There are around 30% of days on therapy not covered by medication and only 59% of patients taking medication for more than 80% of their days on therapy each year. Good compliance has a positive effect on clinical outcome.&lt;BR&gt;Dr. Roger Gadsby’s comments:Very interesting review. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RANDOMIZED CONTROLLED TRIALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;STRONG&gt;Surgical treatment for obesity&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;Paper 4&amp;nbsp; Dixon JB, O’Brien PE, Playfair J et al Adjustable Gastric Banding and Conventional therapy for type 2 diabetes: A randomised controlled trial JAMA 299: 316-323&lt;BR&gt;Paper 5 Cummings DE, Flum DR Gastrointestinal Surgery as a Treatment for Diabetes (editorial) JAMA 299: 341-343&lt;BR&gt;Summary:&lt;BR&gt;Unblinded randomised study from Australia of 60 obese (BMI 30-40)&amp;nbsp; patients recently diagnosed with type 2 diabetes (Mean baseline HBA1c 7.7%). Half were randomised to conventional diabetes therapy with a focus on weight loss by lifestyle measures, the others to laparoscopic adjustable gastric banding with conventional diabetes care.&lt;BR&gt;Remission of diabetes was defined as fasting glucose below 7mmoles/L and HBA1c below 6.2%. Follow up was for 2 years. Remission&amp;nbsp; was achieved in 73% of the surgical group and 13% in the behaviour group. No serious surgical problems were reported. Wt loss in the surgical group was 20.7% as compared to 1.7% in lifestyle group. The % wt loss needed for diabetes resolution was 10% which was achieved in 86% of surgical patients but only 1 patient in the medical group. Diabetes remission after surgery appeared to be due just to weight loss.&lt;BR&gt;The editorial notes that the lifestyle intervention seeing a healthcare professional every 6 weeks for the 2 years was intensive and unlikely to be achieved in normal practice. It also reports that the team reporting the study are among the most experienced in gastric banding surgery.&lt;BR&gt;In the USA more Roux-en-Y gastric bypass operations are done than gastric banding. These operations cause weight loss and may activate GLP-1 activity so lowering glucose by weight loss and non weight loss mechanisms. After such operations many can stop diabetes medications within a month.&lt;BR&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;This paper reinforces the idea that weight loss is the most important treatment in type 2 diabetes and is the only treatment that can produce remission of diabetes.&amp;nbsp; Around 10% weight loss seems to be needed. It can be achieved by laparoscopic gastric banding but is not easily achievable by lifestyle change in this study.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;SHORT REPORTS&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;HBA1c Reporting&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Paper 6 Twomey PJ, Rayman G, Pledger DR Implications of different DCCT aligned HBA1c methods on GMS clinical indicators Diabetic Medicine 25: 97-100&lt;BR&gt;Uses 2 different analysers the DCA 2000 and Variant 11 analyser, both of which are DCCT aligned to compare HBA1c levels in 164 samples. The mean difference of 6.5% between methods meant that&amp;nbsp; an HBA1c at or below 7.4% occurred by one method in 32 patients (19.5%) versus 63 patients (38.4%) on the other. They conclude that the limitations of the current methods need to be understood by health care professionals and policy makers, as they may have important financial implications&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Insulin in type 2 DM&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Paper 7 Rosenstock J, Ahmann AJ, Colon G Advancing Insulin therapy in Type 2 Diabetes previously treated with glargine plus oral agents Diabetes Care 31: 20-25&lt;BR&gt;374 people with type 2 DM average duration of DM 11 years wt 99Kg, HBA1c 8.8% on glargine plus oral agents randomised to basal bolus adding lispro to each of 3 meals and continuing glargine or three times a day mixed insulin (humalog mix)&lt;BR&gt;Both lowered HBA1c but noninferiority of mixed insulin regime was not achieved over basal bolus, as this lowered HBA1c by more and got more to HBA1c target of 6.5% . Hypo rates and weight gain were similar&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Improving glycaemic control in USA adults&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Paper 8 Hoerger TJ, Segel JE, Gregg EW, Saddine JB Is glycaemic control improving in US adults Diabetes Care 31: 81-86&lt;BR&gt;Using data from 3 waves of the&amp;nbsp; NHANES study says yes!! HBA1c below 7% improved from 37% in 1999/2000 to 549.7% in 2001/2 to 55.7% in 2003/4. Mean HBA1c levels declined from 7.82% in 1999/2000 to 7.47% in 2001/2 and 7.18% in 2003/4. This is based on 403 people in 1999/2000, 448 people in 2001/2 and 482 people in 2003/4&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diabetes Footcare&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Paper 9 Lavery LA, Peters EJG, Williams JR et al Re-evaluating the way we classify the diabetic foot Diabetes Care 31: 154-156&lt;BR&gt;Proposal of new risk classification ( the Texas Foot Risk Classification) as follows&lt;BR&gt;Group 0&amp;nbsp;&amp;nbsp;&amp;nbsp; no neuropathy or peripheral arterial disease&lt;BR&gt;Group 1&amp;nbsp;&amp;nbsp;&amp;nbsp; neuropathy but no peripheral arterial disease or bony deformity&lt;BR&gt;Group 2A&amp;nbsp; Neuropathy and deformity but no peripheral arterial disease&lt;BR&gt;Group 2B&amp;nbsp; Peripheral arterial disease&lt;BR&gt;Group 3A&amp;nbsp; Ulcer history&lt;BR&gt;Group 3B&amp;nbsp;&amp;nbsp; Previous amputation&lt;BR&gt;In this study people in Texas groups 2,3,4 were less than 20% of the study population but comprised 70% of ulcers, and 90% of amputations&lt;/P&gt;
&lt;P&gt;Paper 10 Lavery LA, Barnes SA, Keith Ms et al Prediction of Healing for postoperative diabetic foot wounds based on early wound area progression Diabetes Care 31: 26-29 &lt;BR&gt;Data from a study of 162 patients who had large non ischaemic foot wounds following partial foot amputation. The % of wound area reduction was measured in two dimensions from&amp;nbsp; a bilayered wound tracing&amp;nbsp; by computer software at o, 7, 14, 28, 42, 56, 84 and 112 days. Digital photographs were also taken. Early changes in % of wound area reduction were predictive of wound healing at 16 weeks. Specifically wounds with a 15% or greater&amp;nbsp; wound area reduction at 1 week or a 60% or greater wound area reduction at 4 weeks had a 68% and 77% probability of healing. They conclude that evaluation at 1 week if healing is less than 15% might indicate the need for changing therapy&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Journals reviewed: &lt;/STRONG&gt;N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract,&amp;nbsp; Diabetes Care, Diabetic Medicine, Pract Diab Int&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; published in&amp;nbsp;February 2008.&amp;nbsp;This series began in 2002 as a bulletin for Diabetes Care Staff.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public.&amp;nbsp; Word and webpage versions available.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;EM&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/EM&gt;&lt;/EM&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>101354</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=101354]]&gt;</url>
    <title>Interesting new diabetes papers : Jul 2005</title>
    <publicationDate>2005-08-12T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2005]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the sixth in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Jul 2005&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NUTRITION THERAPY&lt;/P&gt;
&lt;P&gt;Paper 1&amp;nbsp; &lt;BR&gt;Kennedy RL, Chokkalingham K, Farshchi HR&amp;nbsp; Nutrition in patients with type 2 diabetes: are low carbohydrate diets effective, safe or desirable?&lt;BR&gt;Diabetic Medicine 22 821- 832&lt;BR&gt;Summary &lt;BR&gt;This paper is an expert review with 142 references of the whole area of low carbohydrate diets. The authors conclude that it seems reasonable to offer low-carbohydrate diets as an alternative to some patients as a short to medium term intervention. For the moment , experts in the field are agreed that they cannot be recommended for long term treatment. The diets are not recommended in pregnancy because of increased cortisol production and risk of hypertension. They improve glycaemic control and this may retard progression from IGT to diabetes, or may allow patients with diabetes to reduce their drug treatment while they loose weight.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This is a useful expert review on this subject which has been quite contentious. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;BLOOD GLUCOSE MONITORING&lt;/P&gt;
&lt;P&gt;Paper 2 . &lt;BR&gt;Franciosi M, Pellegrini F, DeBerardis G et al for the QuED Study Group – quality of care and outcomes in type 2 diabetes&amp;nbsp; Diabetic Medicine 22;900-906&lt;BR&gt;Summary&lt;BR&gt;This study of 1896 patients assessed the impact of self monitoring of blood glucose (SMBG) on metabolic control over 3 years in patients with type 2 diabetes not treated with insulin.&lt;BR&gt;22% were on diet alone, 78% on oral agents.&amp;nbsp; The analysis of metabolic control according to the frequency of SMBG failed to show any significant impact on HBA1c levels over 3 years. Changes in SMBG frequency were not related to significant changes in HBA1c levels. In this study most patients use SMBG less than once daily. There was no significant education packager given in association with SMBG in this study.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This is the prospective study with the longest duration exploring, under routine clinical practice conditions, the relationship of SSMBG and HBA1c in a large sample of patients with type 2 diabetes not on insulin. Its failure to demonstrate benefit is perhaps not surprising as the patients had not specific education package in association with the SMBG.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;EFFECTS OF GLITAZONES ON LIPIDS&lt;/P&gt;
&lt;P&gt;Paper 3 &lt;BR&gt;Goldberg RB, Kendall DM, Deeg MA et al for the GLAI Study Investigators&lt;BR&gt;A comparison of lipid and glycaemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidaemia&lt;BR&gt;Diabetes Care 28; 1547-1554&lt;BR&gt;Summary&lt;BR&gt;This paper reports on a 24 week&amp;nbsp; randomised double blind study in 802 patients with type 2 diabetes on diet alone or oral monotherapy who were given either pioglitazone 30mgs daily&amp;nbsp; for 12 weeks followed by 45mgs for 12 weeks, or rosiglitazone 4mgs for 12 weeks followed by 4mgs bd for 12 weeks.&lt;BR&gt;It showed that pioglitzone is associated with significant improvements versus rosiglitazone in triglycerides, HDL cholesterol, non HDL cholesterol, and LDL particle size concentrations and LDL particle size, despite similar effects on glycaemic control and surrogate measures of insulin resistance. These results are consistent with prior less well controlled comparison studies.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;More evidence, more conclusive this time, that pioglitazone has more beneficial effects on lipids than does rosiglitazone. It remains to be seen (in Sept 05) whether the improvements that pioglitazone makes in lipids will translate into improved CHD outcomes with its use.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;ERECTILE DYSFUNCTION&lt;/P&gt;
&lt;P&gt;Paper 4&lt;BR&gt;Kalter-Leibovici O, Wainstein J, Ziv A et al for the Israel Diabetes Research Group (IDRG) Investigators&lt;BR&gt;Diabetes Care 28; 1739-1744&lt;BR&gt;Summary&lt;BR&gt;Questionnaire based study of 1040 male patients, of median age 57 years and median diabetes duration&amp;nbsp; 8 years, from 26 diabetes clinics in Israel. Severe erectile dysfunction was reported in 30.1% of the patients, with normal erectile function reported in 13.5%. Erectile dysfunction severity increased with age, diabetes duration, poor glycaemic control, presence of microvascular complications, diuretic treatment, and cardiovascular disease. They found that physical activity and alcohol may be protective.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This paper reinforces the association of ED with age, poor glycaemic control and microvascular complications.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;TELEMEDICINE &amp;amp; DIABETES&lt;/P&gt;
&lt;P&gt;Paper 5 &lt;BR&gt;Gerber BS, Brodsky IG, Lawless KA et al&amp;nbsp;&amp;nbsp; Implementation and evaluation of a low literacy diabetes education computer multimedia application&lt;BR&gt;Diabetes Care 28; 1574-1580&lt;BR&gt;Summary&lt;BR&gt;In this study 5 public clinics in the USA installed computer kiosks in their waiting areas. 204 people with diabetes were randomised to receive supplemental computer multimedia use or standard care. The multimedia package had audio/visual material on self management skills, psychological support, and diabetes information. After 1 year there were no differences in metabolic control , knowledge, self efficacy or self reported medical care. There was an increase in perceived susceptibility to diabetes complications in the intervention group which had its greatest effect in subjects with low health literacy.&lt;/P&gt;
&lt;P&gt;Paper 6&lt;BR&gt;McMahon GT, Gomes HE, Hohne SH et al&amp;nbsp; Web-based care management in patients with poorly controlled diabetes. Diabetes Care 28; 1624-1629&lt;BR&gt;Summary&lt;BR&gt;104 patients with diabetes and HBA1c of 9% or above completed an educational class and then were randomised to usual care or a web based care management in which they had a notebook computer, blood glucose and blood pressure measuring devices and access to a care management website which contained educational modules and accepted uploads from the blood glucose and blood pressure devices.&lt;BR&gt;Those receiving the web package had lower HBA!c over 12 months than standard care. Persistent website users had greater improvements than intermittent users, and larger number of website uploads was associated with a larger decline in HBA1c.&lt;BR&gt;The costs of the package were not discussed.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;These 2 papers give a flavour of the research being carried out to assess the potential of computers and the internet in diabetes education.&amp;nbsp; The results are interesting, but the cost effectiveness of the interventions has not usually been analysed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed this month:&lt;/STRONG&gt;&amp;nbsp; Diabetes Care , Diabetic Medicine, BMJ, NEJM, BJDVD , Lancet,&amp;nbsp; Pract Diab Int&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;August 2005. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage version available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this series is to inform readers of interesting&amp;nbsp; new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>156144</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=156144]]&gt;</url>
    <title>Interesting new diabetes papers : Jul 2006</title>
    <publicationDate>2006-08-16T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2006,DIABETES,RESEARCH,INTERESTING NEW ARTICLES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the eighteenth in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Jul 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;PSYCHOLOGICAL INTERVENTIONS IN TYPE 1 DIABETES &lt;/P&gt;
&lt;P&gt;Paper 1&lt;BR&gt;De Beaufort C, Swift P. Support for young people with diabetes (editorial) BMJ 333: 55-56&lt;BR&gt;Paper 2&lt;BR&gt;Winkley K, Landau S, Eisler I, Ismail K. Psychological interventions to improve glycaemic control in patients with type 1 diabetes: systematic review and meta-analysis of randomised controlled trials. BMJ 333 65-68&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;The systematic review included 29 trials and the meta-analysis 21 trials. They found that in the 10 studies in children and adolescents, the mean % of glycated haemaglobin was significantly reduced in those who had received a psychological intervention compared with those in the control group equivalent to a 0.48% absolute reduction in HBA1c. In the studies in adults the pooled standardised mean difference was 0.22%. Psychological distress was significantly lower in the intervention groups in children and adolescents, but not in adults.&lt;BR&gt;Most of the psychological interventions used variants of cognitive behaviour therapy. &lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;This highlights the importance of psychological support for children and adolescents with diabetes and their family and carers.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;ADHERENCE TO TREATMENT&lt;/P&gt;
&lt;P&gt;Paper 3&lt;BR&gt;Hearnshaw H, Lindenmeyer A. What do we mean by adherence to treatment and advice for living with diabetes? A review of the literature on definitions and measurements. Diabetic Medicine 23: 720-728&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;Systematic review of 26 papers including definitions of adherence and 46 which described measurements of adherence. Definitions and measurements fell into 5 categories: coincidence of behaviour with professional advice, relationship as part of the process of care, outcome and process targets, taking the medication as prescribed and others. No single definition of adherence emerged. Many authors did not provide a definition of adherence.&amp;nbsp; HBA1c was the most common measurement of adherence, although this can raise problems.&lt;BR&gt;The conclusion was that research which claims to show an intervention has, or has not improved adherence must be interpreted cautiously. Interventions which appear to fail may actually succeed in aspects of adherence which were not defined or measured in the study. Clinicians and researchers could use clear definitions and measurements, such as the ones presented in this paper.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;This is a good review of the literature with clear recommendations, from our own research team!&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;DIABETES CARE IN SOCIALLY DISADVANTAGED POPULATIONS&lt;/P&gt;
&lt;P&gt;Paper 4&lt;BR&gt;Glazier RH, Bajcar J, Kennie NR, Willson K. A systematic review of interventions to improve diabetes care in socially disadvantaged populations. Diabetes Care 29: 1675-1688&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;Systematic review of 17 studies, 11 of which had positive results. Features that appeared to have the most consistent positive effects included cultural tailoring of the intervention, community educators or lay people leading the intervention, one-on-one interventions with individualised assessment and reassessment, incorporating treatment algorithms, focusing on behaviour related tasks, providing feedback, and high intensity interventions delivered over a long duration. Interventions that were consistently associated with negative outcomes included those that mainly used didactic teaching or that focused only on diabetes knowledge.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;This review confirms our view at WDC about what sort of programmes are likely to have a positive effect and which are unlikely to have much effect.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;DIABETES &amp;amp; PREGNANCY&lt;/P&gt;
&lt;P&gt;Paper 5 &lt;BR&gt;Macintosh MCM, Fleming KM, Bailey JA et al. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales and Northern Ireland: population based study BMJ 333: 177-180&lt;BR&gt;Paper 6 &lt;BR&gt;Macfarlane A, Tuffnell D. Diabetes and pregnancy (editorial) BMJ 333: 157-8&lt;/P&gt;
&lt;P&gt;This paper is based on the CEMACH (Confidential Enquiry into Maternal And Child Health) report of 2359 pregnancies in women with diabetes in the England Wales and Northern Ireland from 1 March 2002 to 28 Feb 2003. Perinatal mortality was similar in type 1 and type 2 and was four times higher than general population. Congenital abnormalities were more than double that of the general population.&lt;BR&gt;The editorial points out that this data shows women with type 2 diabetes need the same level of care in pregnancy as those with type 1.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;This data shows how much improvement is needed to achieve the St Vincent Target of reducing risks of pregnancy in women with diabetes to those levels seen in the general population.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;BRIEF REPORTS&lt;/P&gt;
&lt;P&gt;Paper 7 – Peripheral Neuropathy in type 2 diabetes&lt;BR&gt;Davies M, Brophy S, Willams R, Tayor A. The prevalence, severity, and impact of painful diabetic neuropathy in type 2 diabetes Diabetes Care 29: 1518-1522&lt;BR&gt;Questionnaire study of 326 people in a Welsh GP. Then 269 attended and were assessed. Prevalence of 26.4% , having PDPN was associated with negative effect on quality of life&lt;/P&gt;
&lt;P&gt;Paper 8 - Community Interventions to reduce inactivity&lt;BR&gt;Jenum AK, Anderssen SA, Birkeland KI, et al. Promoting Physical Activity in a low income multiethnic district: effects of a community intervention study to reduce risk factors for type 2 diabetes and cardiovascular disease Diabetes Care 29: 1605-1612&lt;BR&gt;Work from Oslo where leaflets, local meetings local publicity, biannual fitness tests with individual counselling, organised walking groups, and group indoor activity sessions at no cost were provided.&amp;nbsp; The found increased levels of physical activity, reduced wt gain and beneficial effects on risk factors for DM and CHD in 1766 people.&lt;/P&gt;
&lt;P&gt;Paper 9 – Visual acuity and Quality of Life&lt;BR&gt;Clarke PM, Simon J, Cull CA, Holman RR. Assessing the impact of visual acuity on quality of life in individuals with type 2 diabetes using the short form –36 Diabetes Care 29: 1506-1511&lt;BR&gt;In 4051 individuals enrolled in the lipids in diabetes study reduced visual acuity is negatively associated with quality of life. &lt;/P&gt;
&lt;P&gt;Paper 10 – Glucose variability and complications&lt;BR&gt;Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes &lt;BR&gt;Analysis of 1441 individuals from DCCT with pre and post prandial 7 point glucose profiles quarterly. Glucose variability does not appear to be an additional factor in the development of microvascular complications.&lt;/P&gt;
&lt;P&gt;Paper 11 – Age and CHD &lt;BR&gt;Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population based retrospective cohort study. Lancet 368: 29-35&lt;BR&gt;Population based retrospective cohort study. Diabetes confers an equivalent risk to ageing 15 years. However in general younger people with diabetes under 40 do not seem to be at high risk of CVD.&lt;/P&gt;
&lt;P&gt;Papers 12 &amp;amp; 13 Metabolic Syndrome does it exist?&lt;BR&gt;Grundy SM. Does the metabolic syndrome exist Diabetes Care 29: 1689-1692&lt;BR&gt;Kahn R The metabolic syndrome (Emperor) Wears no clothes Diabetes Care 29: 1693-1696&lt;BR&gt;Good debate highlighting the issues.&lt;/P&gt;
&lt;P&gt;Paper 14 Glargine or oral agents?&lt;BR&gt;Gerstein HC, Yale J-F, Harris SB, et al. A randomised trial adding insulin glargine vs avoidance of insulin in people with type 2 diabetes on either no oral glucose lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin glargine for Hyperglycaemia Treatment) Study&amp;nbsp; Diabetic Medicine 23: 736-742&lt;BR&gt;206 given glargine 199 on oral agents. Adding insulin glargine is more likely to achieve a lower HBA1c than conventional therapy with oral agents.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt; Diabetes Care, Diabetic Medicine, BMJ, NEJM, BJGP, Lancet,&amp;nbsp; JAMA, Pract Diab Int, Diabetic foot, BJDVD&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;August 2006. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp;Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of&amp;nbsp;this series&amp;nbsp;is to inform readers of interesting new papers relevant to diabetes that have appeared in&amp;nbsp;several diabetes and general medical journals in the previous month.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>267569</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=267569]]&gt;</url>
    <title>Interesting new diabetes papers : Jul 2007</title>
    <publicationDate>2007-08-16T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2007,DIABETES,INTERESTING NEW ARTICLES,RESEARCH]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the thirtieth in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Jul 2007&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;SYSTEMATIC REVIEWS &amp;amp; META-ANALYSIS&lt;/P&gt;
&lt;P&gt;Incretins&lt;/P&gt;
&lt;P&gt;Paper 1&amp;nbsp; Amori RE, Lau J, Pittas AG&amp;nbsp; Efficacy and safety of Incretin therapy in type 2 diabetes :Systematic review and meta-analysis JAMA 298: 194-206 &lt;/P&gt;
&lt;P&gt;Summary&lt;BR&gt;Systematic review of 29 papers meeting inclusion criteria. Incretins lowered HBA1c compared with placebo with a weighted mean difference of 0.97% for GLP-1 analogues and 0.74% for DPP4 inhibitors and they were non inferior to other hypoglycaemic agents.&lt;BR&gt;GLP-1 analogues resulted in weight loss of 1.4Kg against placebo and 4.8Kg against insulin while DPP4 inhibitors were wt neutral. GLP-1 analogues had more GIT side effects of nausea and vomiting, DPP4 inhibitors had an increased risk of infection eg nasopharyngitis and UTI and headache. All but 3 of the 29 trials included were 30weeks or shorter so long term safety and efficacy could not be evaluated&lt;/P&gt;
&lt;P&gt;Roger Gadsby’s comments&lt;BR&gt;Helpful review of the effects of these emerging new therapies&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Painful Neuropathy&lt;/P&gt;
&lt;P&gt;Paper 2 Wong M-C,&amp;nbsp; Chung JWY, Wong TKS Effects of treatments for symptoms of painful diabetic neuropathy: systematic review&amp;nbsp; BMJ 335: 87-90&lt;/P&gt;
&lt;P&gt;Paper 3 Jude EB, Schaper N Treating Painful Neuropathy (editorial) BMJ 335: 57-58&lt;/P&gt;
&lt;P&gt;Summary&lt;BR&gt;Systematic review of 25 papers meeting inclusion criteria. Clinical success was defined as a 50% reduction in pain, withdrawal due to adverse events was a secondary outcome. The review found that tricyclic antidepressants were most effective in reducing pain. However even for the most efficacious drug, amitriptiline, 3 people need to be treated to achieve a 50% reduction in pain score for one person.&amp;nbsp; Adverse events were frequent. For the painkiller tramadol the odds ratio for withdrawal due to adverse events was higher than the odds ratio for 50% pain reduction. Duration of the trials examined was fairly short, and some trials had very small numbers in them. The review suggests that after tricyclics the next best treatment group are traditional anticonvulsants and the next are new generation anticonvulsants. The authors of the editorial however say that the traditional convulsant category is based on widely differing drugs with different actions and if they are considered separately the number of studies for each is small and efficacy is not convincing. The authors of the editorial therefore suggest that if tricyclic antidepressant eg amitrypitiline is not effective,&amp;nbsp; then one of gabapentin, pregabalin or duloxetine be tried.&lt;/P&gt;
&lt;P&gt;Roger Gadsby’s comments&lt;BR&gt;Interesting review and editorial. In my opinion amitryptiline first and then gabapentin, pregabalin or duoxetine is the treatment pathway most people agree with.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;RCT’S&lt;/P&gt;
&lt;P&gt;Self Monitoring of blood glucose&lt;/P&gt;
&lt;P&gt;Paper 4 Farmer A, Wade A, Goyder E et al on the behalf of the Diabetes Glycaemic Education and Monitoring Trial Group (DiGEM) BMJ 335:132-136&lt;/P&gt;
&lt;P&gt;Paper 5 Heller S Self monitoring of blood glucose in type 2 diabetes (editorial) BMJ 335: 105-106&lt;/P&gt;
&lt;P&gt;Summary&lt;BR&gt;453 people with type 2 diabetes treated with oral agents with mean age 65.7 years were randomised into one of three groups. One had standardised usual care with 3 monthly HBA1c but no self monitoring n =152. Another group had usual care plus blood glucose self monitoring (SMBG) with advice to contact their doctors for interpretation of results n=150 and a third group had usual care, SMBG and additional training in interpretation and application of the results to enhance motivation and maintain adherence to a healthy lifestyle.&lt;BR&gt;The main outcome was HBA1c at 12 months. It was not statistically different between the 2 groups. The authors and the editorial conclude that in people with established diabetes relatively well controlled by oral drugs little is gained by promoting SMBG even in conjunction with an education programme. It does not&amp;nbsp; answer the question as to whether it might be useful at diagnosis.&lt;BR&gt;The conclusion supports other randomised trials which show inconclusive benefits, in contrast to large observational studies that showed benefit.&lt;BR&gt;SMBG costs the NHS over £100 million per year. It is vital for people treated with insulin. This study suggests it should not be encouraged in people with type 2 diabetes treated with oral agents who are relatively well controlled and who are being regularly monitored by HBA1c measurements.&lt;/P&gt;
&lt;P&gt;Roger Gadsby’s comments&lt;BR&gt;These results in my opinion are what I would have expected. People with type 2 diabetes who are well controlled on oral agents will get very little benefit from routine SMBG as they can do very little with the results, most of which will probably be within a reasonably normal range!&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Rosiglitazone and CHD risk (continued!)&lt;/P&gt;
&lt;P&gt;Paper 6 Home PD, Pocock SJ, Beck-Nielson H et al for the RECORD study group Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis&lt;BR&gt;N Engl J Med 357:28-38&lt;/P&gt;
&lt;P&gt;Paper 7 Drazen JM, Morrisey S, Curfman GD Rosiglitazone – continued uncertainty about safety (editorial) N Engl J Med 357: 63-64&lt;/P&gt;
&lt;P&gt;Paper 8 Nathan D Rosiglitazone and cardiotoxicity – weighing the evidence (editorial) N Engl J Med 357:64-66&lt;/P&gt;
&lt;P&gt;Paper 9 Psaty BM Furberg CD&amp;nbsp; The Record on Rosiglitazone and risk of myocardial infarction (editorial) n Engl J Med 357: 67-69&lt;/P&gt;
&lt;P&gt;Summary&lt;BR&gt;Paper 6 reports an unplanned interim analysis of this randomised multicentre open-label non inferiority trial involving 4447 people with type 2 diabetes in which 2220 patients were assigned to receive rosiglitazone in addition to metformin or sulphonylurea and 2227 received metformin plus sulphonylurea. Mean follow up was 3.75 years and the primary end point was hospitalization or death from cardiovascular causes. A total of 217 in the rosiglitazone group and 202 in the control, group had the adjudicated end point. There were no statistically significant differences between the rosiglitazone and control groups regarding myocardial infarction and death from CHD causes or any cause. The conclusion was that the interim analysis was inconclusive regarding the effect of rosiglitazone on the primary endpoint.&lt;BR&gt;This unplanned interim analysis was conducted in response to the meta-analysis published by Nissen and Wolski (see bulletin May 2007) which hinted at possible increased cardiovascular risk from taking rosiglitazone.&lt;BR&gt;In the editorials the authors state several weaknesses in the RECORD study design. These include the fact it was open label, had an unusual composite primary endpoint, had a loss to follow up of 3% (instead of the 2% suggested at the design stage) and most importantly has a very low event rate (2.5% per year rather than the 11% that went into the sample size calculation). Nathan in his editorial concludes that “considering the low power of the study and the trend to more cardiovascular outcomes in the rosiglitazone- treated group in the interim analysis, it is highly unlikely that the study will ever establish a cardiovascular benefit for rosiglitazone”.&lt;BR&gt;The RECORD study is continuing and is due to report in 2009. &lt;BR&gt;The other editorial concludes that patients should not stop treatment on their own, but if they have concerns they should consult their physicians. Together patients and physicians can decide whether they wish to suspend the use of rosiglitazone.&lt;BR&gt;The Advisory panel of the Federal Drugs Agency (FDA)&amp;nbsp; in the USA on the 30th July voted that the data they had reviewed suggested some ischaemic risk with rosiglitazone. They voted to keep the medicine available to patients in the USA.&lt;/P&gt;
&lt;P&gt;Roger Gadsby’s comments&lt;BR&gt;More data and discussion in this ongoing debate about the cardiovascular effects of rosiglitazone &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;SHORT REPORTS&lt;/P&gt;
&lt;P&gt;Educational toolkit for Prediabetes&lt;/P&gt;
&lt;P&gt;Paper 10&amp;nbsp; Evans PH, Greaves C, Winder R et al. Development of an educational toolkit for health professionals and their patients with prediabetes: The WAKEUP study (Ways of Addressing Knowledge Education and Understanding in Pre-Diabetes) Diabetic Medicine 24:770-777&lt;BR&gt;Mixed qualitative methodology within an action research framework. Key messages of seriousness of condition, preventability of progress to diabetes and need for &lt;BR&gt;lifestyle change were identified. A “toolkit” was developed and successfully piloted.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Incretin levels after gastric bypass surgery&lt;/P&gt;
&lt;P&gt;Paper 11&amp;nbsp; Laferrere B, Heshka S, Wang K et al Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes&amp;nbsp; Diabetes Care 30 1709-1716&lt;BR&gt;The study showed that incretin levels and incretin effect are markedly increased 1 month after Roux-en-Y gastric bypass surgery. The magnitude of the incretin release may be specific to the anatomical changes in the gut resulting from the operation. &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt; N Eng J Med, JAMA, Diabetes Care, Lancet, BMJ, BJGP, Diabetic Medicine, Pract Diab Int.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;August 2007. This series began in 2002 as a bulletin for Warwick Diabetes Care staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>93924</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=93924]]&gt;</url>
    <title>Interesting new diabetes papers : Jun 2005</title>
    <publicationDate>2005-07-13T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2005,DIABETES,INTERESTING NEW ARTICLES,RESEARCH]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the fifth in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Jun 2005&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;INSULIN THERAPY&lt;/P&gt;
&lt;P&gt;Paper 1&amp;nbsp; &lt;BR&gt;Davies M, Storms F, Shulter S et al for the AT.LANTUS Study Group&lt;BR&gt;Improvement in glycaemic control in subjects with poorly controlled type 2 diabetes&amp;nbsp; Diabetes Care 28; 1282-1288&lt;BR&gt;Summary&lt;BR&gt;This paper reports a prospective multicentre 24 week randomised trial in 4961 people with type 2 diabetes who were suboptimally controlled. Some were on tablets only, others tablets and insulin. The study compared 2 treatment algorithms for initiation and titration of insulin glargine, one investigator led, the other patient led.&lt;BR&gt;The patient led treatment algorithm resulted in a greater drop of HBA1c of 1.22% compared to 1.08% in the investigator led one, with no difference in hypoglycaemia..&lt;BR&gt;The paper concludes that insulin glargine is safe and effective in improving glycaemic control in a large diverse population with longstanding type 2 diabetes. A simple subject-administered titration algorithm conferred significantly improved glycaemic control with a low incidence of severe hypoglycaemia compared with a physician-managed titration.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This is the largest study of insulin initiation in type 2 diabetes and shows that once daily insulin glargine plus tablets with dose titration’s up by the patient&amp;nbsp; is safe and effective.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;BLOOD GLUCOSE MONITORING&lt;/P&gt;
&lt;P&gt;Paper 2 &lt;BR&gt;Welschen L, Bloemendal E, Nijpels G et al Self-Monitoring of blood glucose in Patients with type 2 Diabetes Who are not using insulin&lt;BR&gt;Diabetes Care 28; 1510-1517&lt;BR&gt;Paper 3 &lt;BR&gt;Ipp E, Aquino RL, Christenson P Point: Serlf monitoring of Blood glucose in Type 2 Diabetic Patients not receiving insulin : the sanguine approach Diabetes Care 28; 1528-30&lt;BR&gt;Paper 4 &lt;BR&gt;Davidson M&amp;nbsp; Counterpoint: Self monitoring of blood glucose in type 2 Diabetic patients not receiving insulin; a waste of money Diabetes Care 28; 1531-1533&lt;BR&gt;Summary&lt;BR&gt;Paper 2 is a good quality systematic review following Cochrane methodology. It identified 6 relevant RCT’s. The overall effect in those trials was for SMBG to lower HBA1c by 0.39%. There were a number of limitations in the studies reported. They also found 7 non randomised studies, in which 2 report HBA1c reductions.&lt;BR&gt;They conclude that more high quality research is needed.&lt;BR&gt;Papers 3 and 4 debate the subject given the lack of conclusive evidence in the literature. One supports its use, the other feels it’s a waste of money&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;The debate continues due to the lack of conclusive evidence. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;GESTATIONAL DIABETES&lt;/P&gt;
&lt;P&gt;Paper 5 &lt;BR&gt;Crowther C, Hiller J, Moss JR et al for the Australian Carbohydrate Intolerance Study in Pregnant women&amp;nbsp; (ACHOIS) Trial Group &lt;BR&gt;Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes&lt;BR&gt;N Eng J Med 352; 2477 - 86&lt;BR&gt;Summary&lt;BR&gt;A randomised clinical trial in which 510 women&amp;nbsp; between 24 and 34 weeks with Gestational diabetes received routine care and 490 women received dietary advice, blood glucose monitoring and insulin therapy as needed. ( intervention group)&lt;BR&gt;The rate of serious perinatal complications was significantly lower among the infants in the intervention group&amp;nbsp; (1% v 4%) LSCS rates were similar in the 2 groups but there was a high rate of induction of labour in the intervention group and children were more likely to be admitted to the neonatal nursery. .£ months after delivery data on mood and quality of life from 573 women revealed lower rates of depression and higher scores, consistent with improved health status in the intervention group.&lt;BR&gt;The authors conclude that treatment of gestational diabetes reduces serious perinatal morbidity and may also improve the womanise health-related quality of life.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;There has been a lack of evidence as to whether diagnosing and treating gestational diabetes was worthwhile. As a result different hospitals have different policies. This good quality randomised trial clearly indicates a benefit from treatment and is therefore likely to change policy and management&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;WALKING &amp;amp; TYPE 2 DIABETES&lt;/P&gt;
&lt;P&gt;Paper 6 &lt;BR&gt;Di Loreto C, Fanelli C, Lucidi P at al&amp;nbsp; Make your diabetic patients walk&lt;BR&gt;Diabetes Care 28; 1295 – 1302&lt;BR&gt;Paper 7&amp;nbsp; &lt;BR&gt;Hill JO (editorial) Walking and type 2 diabetes Diabetes Care 28; 1524-1525&lt;BR&gt;Summary&lt;BR&gt;The paper reports a Post Hoc analysis of long term effects of different amounts of increased energy expenditure through voluntary aerobic activity in 179 diabetic subjects randomised to a physical activity counselling intervention&lt;BR&gt;Results from the study suggest that you can get impressive improvements in health and reductions in health care costs just by getting people to make modest increases in physical activity. A second message is that you can produce these increases in physical activity in a large proportion of your patients with a simple counselling programme that requires only a modest commitment of time and effort.&lt;BR&gt;The paper measures physical activity in MET’s metabolic equivalents. A rise of 11 Mets per week provides health benefits, a rise of 27 mets a week is a good target for sedentary patients with type 2. The editorial translates this into walking. 11 Mets is walking 1.2mls/day or 2400 steps, 27 is 3.2 mls/day or 6400 steps. &lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This gives healthcare professionals more evidence to support the encouragement of walking, and some idea as to the amount that is needed for health benefit. The use of pedometers as step counters is clearly valuable&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;BRIEF REPORTS&lt;/P&gt;
&lt;P&gt;Paper 8 &lt;BR&gt;Rutten G&amp;nbsp; Diabetes Patient Education; Time for a new era (Editorial) Diab Med 22 671-3&lt;BR&gt;Dr Roger Gadsby’s comments: Good summary of current thinking &lt;/P&gt;
&lt;P&gt;Paper 9 &lt;BR&gt;Weinger K, Butler HA, Welch G Measuring Diabetes Self Care Diabetes Care 28; 1346-1352&lt;BR&gt;Dr Roger Gadsby’s comments: A new instrument, the self care inventory revised SCI-R&lt;/P&gt;
&lt;P&gt;Paper 10&lt;BR&gt;Schinner S, Scherbaum WA, Bornstein SR and Barth el A Molecular mechanisms of insulin resistance Diab Med 22, 674-682&lt;BR&gt;Dr Roger Gadsby’s comments: Expert review with 98 refs, covering this important area&lt;/P&gt;
&lt;P&gt;Paper 11 &lt;BR&gt;Janka HU&amp;nbsp;&amp;nbsp; Initiation of insulin in patients with type 2 diabetes failing oral therapy.&lt;BR&gt;Dr Roger Gadsby’s comments: Letter from the author of the glargine study outlining reasons for why his study and that of Raskin (both Feb Diabetes Care see March bulletin) come to different conclusions. &lt;BR&gt;Clearly stated view that once daily glargine plus tabs is better than bd pre mix.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed this month:&lt;/STRONG&gt; Diabetes Care, Diabetic Medicine, BMJ, NEJM, BJDVD, Lancet, JAMA, Pract Diab Int&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in July 2005. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this series is to inform readers of interesting&amp;nbsp; new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>149128</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=149128]]&gt;</url>
    <title>Interesting new diabetes papers : Jun 2006</title>
    <publicationDate>2006-07-18T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2006,DIABETES,RESEARCH,INTERESTING NEW ARTICLES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the seventeenth in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Jun 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;PREVENTING DIABETES &lt;/P&gt;
&lt;P&gt;Paper 1&lt;BR&gt;Teutsch S Preventing Diabetes- The Time is now (editorial) Diabetes Care 29;1447-8&lt;BR&gt;Paper 2&lt;BR&gt;&amp;nbsp;Johnson RF, Manjunath R, Mansfield CA et al High-Risk individuals willingness to pay for a Diabetes Risk-Reduction Programms Diabetes Care 29; 1351-1356&lt;BR&gt;Paper 3&lt;BR&gt;Ackermann R, Marrero DG, Hicks KA&amp;nbsp; An Evaluation of Cost sharing to finance a diet and physical activity intervention to prevent diabetes Diabetes Care 29; 1237-1241&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;These papers discuss funding prevention in the context of the USA healthcare system and provide very interesting insights for the NHS. The editorial concludes that DPP like programmes provide economic value, target behaviours that contribute in large measure to the leading causes of death and health care costs, and now demand that we find realistic ways to deliver them in real world settings.&amp;nbsp; Public funding of prevention is a potential approach.&lt;BR&gt;Paper 3 uses novel economic modelling techniques to demonstrate the financial consequences of paying for a behavioural programme to delay or prevent the development of diabetes. What is clear is that such a DPP programme starting at age 50 is much more effective at reducing progression to diabetes than delaying the intervention to age 65.&lt;BR&gt;Paper 2 looks at patients willingness to self fund DPP programmes. Their model is hypothetical and the findings unremarkable. Patients prefer programmes that reduce the risk of diabetes substantially, induce large amounts of weight loss, and have few dietary restrictions. Those who perceive themselves at high risk are more willing to participate and to pay more to reduce that risk. &lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;This discussion reflects the problems of the USA healthcare system .&amp;nbsp; Preventing diabetes is possible and cost effective. Public funding of such schemes is an answer that is applicable in the UK&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;PHYSICAL ACTIVITY AND TYPE 2 DIABETES&lt;/P&gt;
&lt;P&gt;Paper 4&lt;BR&gt;Sigal RJ, Kenny GP, Wasserman DH et al ADA CONSENSUS STATEMENT – Physical activity/exercise and type 2 diabetes Diabetes Care 29 1433-1438&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;Recommends levels of activity to prevent diabetes, and then to improve glycaemic control, to reduce CHD risk and to maintain weight loss in type 2 diabetes. There are recommendations for resistance exercise and the prevention of glycaemia &lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;This is a&amp;nbsp; good&amp;nbsp; review of the literature with clear recommendations&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;CHD RISK TABLES AND TYPE 2 DIABETES&lt;/P&gt;
&lt;P&gt;Paper 5&lt;BR&gt;Donnan PT, Donnelly L, New JP, Morris AD&lt;BR&gt;Derivation and Validation of a Prediction Score for Major Coronary Heart Disease events in a UK type 2 Diabetic population Diabetes Care 29; 1231-1236&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;The use of algorithms to estimate the risk of cardiovascular disease in diabetes is controversial. Most are based on Framingham data which included only 337 people with diabetes in their cohort of around 5000. The one based on UKPDS was based on a trial population with age restrictions and exclusions for co-morbidities. It is not recommended for people over the age of 65. There is therefore a need for a robust algorithm in an UK population with type 2 diabetes.&lt;BR&gt;This paper developed an algorithm from the Tayside dataset in Scotland from 1995-2004 in which 243 subjects had a fatal or non-fatal MI. Validation of the algorithm was performed on an independent dataset from Salford.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;Another algorithm to determine CVD risk in type 2 diabetes. Likely to be the most accurate. It will be interesting to see if it becomes widely used&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;BRIEF REPORTS&lt;/P&gt;
&lt;P&gt;Paper 6 &amp;amp; 7 – Insulin pumps in type 1 diabetes&lt;BR&gt;Pickup J Are insulin pumps under utilised in type 1 diabetes? Yes (editorial) Diabetes Care 29; 1449-1452&lt;BR&gt;Schade D, Valentine V&amp;nbsp; Are insulin pumps under utilised in type 1 diabetes? No (editorial) Diabetes Care 29; 1453 –1455&lt;BR&gt;Interesting point and counterpoint debate&lt;/P&gt;
&lt;P&gt;Paper 8- Glitazones in triple therapy&lt;BR&gt;Tran MT, Navar MD, Davidson MB Comparison of glycaemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes Diabetes Care 29; 1395-1396&lt;BR&gt;Pioglitazone or rosiglitazone added to metformin and sulphonylurea both gave similar levels of added glycaemic benefit of around 1.8%.&lt;/P&gt;
&lt;P&gt;Paper 9 – Chronic wounds and delayed healing in diabetes&lt;BR&gt;Blakytny R, Jude E The molecular biology of chronic wounds and delayed healing in diabetes Diabetic Medicine 23; 594-608&lt;BR&gt;Expert review with 221 references &lt;/P&gt;
&lt;P&gt;Paper 10 – IDF Global Guideline for type 2 Diabetes&lt;BR&gt;IDF Clinical Guidelines Taskforce Group&amp;nbsp; Global Guidelines for type 2 Diabetes: recommendations for standard, comprehensive and minimal care &lt;BR&gt;Diabetic Medicine 23; 579-593&lt;BR&gt;The recommendations section of the IDF guideline now in Diabetic Medicine&lt;/P&gt;
&lt;P&gt;Paper 11 – Diabetes complications in Adolescents with diabetes&lt;BR&gt;Eppens MC, Craig ME Cusumano J et al&amp;nbsp; Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes Diabetes Care 29; 1300-1306&lt;BR&gt;Adolescents with type 2 diabetes have significantly higher rates of microalbuminuria and hypertension than their peers with type 1 diabetes despite shorter diabetes duration and lower HBA1&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt; Diabetes Care, Diabetic Medicine, BMJ, NEJM, BJGP, Lancet,&amp;nbsp; JAMA, Pract Diab Int, Diabetic foot, BJDVD&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;July 2006. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp;Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of&amp;nbsp;this series&amp;nbsp;is to inform readers of interesting new papers relevant to diabetes that have appeared in&amp;nbsp;several diabetes and general medical journals in the previous month.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>266402</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=266402]]&gt;</url>
    <title>Interesting new diabetes papers : Jun 2007</title>
    <publicationDate>2007-07-18T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2007,INTERESTING NEW ARTICLES,RESEARCH,DIABETES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the twenty ninth in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Jun 2007&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;SYSTEMATIC REVIEWS &amp;amp; META-ANALYSIS&lt;/P&gt;
&lt;P&gt;Type 2 DM in young people :complications&lt;/P&gt;
&lt;P&gt;Paper 1&amp;nbsp; Pinhas-Hamiel O Zeitler P Acute and chronic complications of type 2 diabetes mellitus in children and adolescents Lancet 369;1823-1832 &lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;This review of the literature concludes that substantial morbidity and mortality has been reported in children and adults with type 2 diabetes. Microvascular complications can be present at the time of diagnosis and their rate of progression might be higher than in young people with type 1 diabetes&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;It has been said of young people being diagnosed with type 2 that this will be a group of people who are likely to die before their parents!&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;EXPERT REVIEWS&lt;/P&gt;
&lt;P&gt;DPP-4 Inhibitors&lt;/P&gt;
&lt;P&gt;Paper 2 Ahren B Dipeptidyl Peptidase-4 inhibitors: Clinical data and clinical implications Diabetes Care 30;1344-1350&lt;/P&gt;
&lt;P&gt;Paper 3 Drucker DJ Dipeptidyl peptidase- 4 Inhibition and the treatment of type 2 diabetes : Preclinical biology and mechanisms of action Diabetes Care 30; 1335-1343&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;2 good summaries of the current data on DPP-4 inhibitors&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Useful references&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;RCT’S&lt;/P&gt;
&lt;P&gt;Insulin Initiation in Type 2&lt;/P&gt;
&lt;P&gt;Paper 4 Yki-Jarvinen H, Juurinen L, Alvarsson M et al Initiate insulin by aggressive titration and education (INITIATE) Diabetes Care 30: 1364-1369&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;121 people with type 2 diabetes on metformin and sulphonylurea were randomised to initiate in groups of 4-8 persons or individually. They conclude that similar glycaemic control and treatment satisfaction can be achieved by initiating insulin in groups or individually. Starting insulin in groups takes one half as long as individual initiation&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;This paper uses an insulin initiation programme similar to the one taught in the WDC programme and shows that group starts are as effective as individual starts and may be more cost-effective&lt;/P&gt;
&lt;P&gt;Exenatide Once weekly&lt;/P&gt;
&lt;P&gt;Paper 5 Kim D, MacConell L, Zhuang D Effects of once weekly dosing of a long acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes Diabetes Care 30: 1487-1493&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;Study on 45 people given a once weekly long acting formulation of exenatide (0.8 or 2mgs) or placebo for 15 weeks. HBa1c reduction in the 2.0mg group was 1.7% and wt reduction was 3.8Kg. Mild nausea was the most frequent adverse event.&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Impressive HBA1c reduction with weight reduction, a unique combination!&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;OTHER TYPES OF STUDY&lt;/P&gt;
&lt;P&gt;ACE use in DM&lt;/P&gt;
&lt;P&gt;Paper 6 Chaturvedi N, Bilous R, Hardy R et al Misleading meta-analysis: a need to look beyond headlines Diabetic Medicine 24; 587-591&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;A detailed critique of a meta-analysis which appeared in the Lancet and said that there was little evidence of the superiority of ACE and ARB drugs over other therapies to treat hypertension in people with diabetes.&amp;nbsp; They conclude that the meta-analysis should have concluded that in patients with renal disease there is clear cut evidence for a specific renal protection effect of ACE/ARB therapy that exceeds the benefits expected on the basis of blood pressure reductions alone.&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Meta-analysis isn’t always right!&lt;/P&gt;
&lt;P&gt;Inpatient diabetes &lt;/P&gt;
&lt;P&gt;Paper 7 Sampson MJ, Brennan C, Dhatariya K et al A national survey of in-patient diabetes services in the United Kingdom&amp;nbsp; Diabetic Medicine 24: 643-649&lt;BR&gt;Post survey of 239 (out of 262 ) UK acute hospitals. They conclude that it highlighted substantial gaps in in-patient diabetes care. The rapid increase in DISN numbers indicates increasing attention to in-patient diabetes care in UK hospitals&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Important information&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;SHORT REPORTS&lt;/P&gt;
&lt;P&gt;Diabetes &amp;amp; Qof&lt;/P&gt;
&lt;P&gt;Paper 8&amp;nbsp;&amp;nbsp; Calvert M, MacManus RJ, Freemantle N Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in Primary Care BJGP 57: 455-460&lt;BR&gt;Retrospective cohort study of 154 practices from 1995 and 2005 in DIN-Link database. It concludes that many people received inadequate monitoring and had poor glycaemic control.&lt;BR&gt;NB the June issue of BJGP contains a number of editorials and&amp;nbsp; articles about QoF , several of which are about diabetes.&lt;/P&gt;
&lt;P&gt;Thiazolidinediones&lt;/P&gt;
&lt;P&gt;Paper 9 Schwartz AV, Sellmeyer DE Thiazolidinedione therapy gets complicated (editorial) Diabetes Care 30 1670-1671&lt;BR&gt;Is bone loss the price of improved insulin resistance. A review of the fracture data and bone mineral loss data, concludes that more data is needed and that at present osteoporosis screening is not recommended for people being considered for TZD therapy&lt;/P&gt;
&lt;P&gt;Paper 10 &amp;amp; 11&lt;BR&gt;Kahn SE, Zinman B Point: recent long term clinical studies support an enhanced role for TZD’s in the management of type 2 diabetes&lt;BR&gt;Al-Ozairi E, Sibal L, Home P Counterpoint: A Diabetes outcome Progression trial (ADOPT) Good for sulphonylureas?&lt;BR&gt;Debate about the results of PROactive, ADOPT and DREAM studies and the implications of TZD therapy. Written before the meta-analysis about rosiglitazone and risk of myocardial infarcts.&lt;BR&gt;adjusted prevalence’s of&amp;nbsp; coronary (26.6% v 18.3%) cerebrovascular ( 20 v 13.3%) and peripheral (15.4% v 10%) vascular disease&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt; N Eng J Med, JAMA, Diabetes Care, Lancet, BMJ, Diabetic Medicine, Pract Diab Int.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;July 2007. This series began in 2002 as a bulletin for Warwick Diabetes Care staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>291654</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=291654]]&gt;</url>
    <title>Interesting new diabetes papers : June 2008</title>
    <publicationDate>2008-08-06T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the thirty eighth in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : June 2008&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;RCTs&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;GLYCAEMIC TARGETS &amp;amp; CARDIOVASCULAR DISEASE&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 1 The ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;diabetes &lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;N Engl J Med 358: 2560-2572&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 2 The Action to Control Cardiovascular Risk in Diabetes Study (ACCORD) Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358:&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;2545-2559&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 3 Dluhy RG, McMahon GT Intensive Glycaemic Control in the ACCORD and ADVANCE trials (editorial) N Engl J Med 358: 2630-2633&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 4 Cefalu WT Glycaemic Targets and Cardiovascular Disease (editorial) N Engl J Med 358: 2633-2635&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 5 McGrane D, Fisher M Struck by ACCORD (Leader) Pract Diab Int 25: 127-129&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 6 Narendran P Glycaemic control in type 2 diabetes – not for sidelining (review) Diabetic Medicine 25: 639-642 &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Summary- ADVANCE Paper1&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;11140 people with type 2 diabetes were randomised to undergo either standard glucose control or intensive glucose control defined as the use of gliclazide mr plus other drugs to achieve an HBA1c of 6.5% or less. Primary end points were composites of major macrovascular and microvascular events assessed both jointly and separately.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;After a median of 5 years follow up the HBA1c in the intensive group was 6.5% and 7.3% in the standard group. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Intensive control reduced the combined macrovascular and microvascular endpoint by 10% primarily as a consequence of&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;a 21% relative reduction in nephropathy. There was no effect on macrovascular events. Severe hypoglycaemia was uncommon but more common in the intensive group&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Summary – ACCORD&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;Paper 2&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;10251 people with type 2 diabetes with mean HBA1c of 8.1% of mean age 62.2 years, were randomised to an intensive group targeting an HBA1c of below 6% or standard group targeting an HBA1c from 7-7.9%. &lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;The primary outcome was a macrovascular composite of CVD death, or non fatal stroke or myocardial infarct. More died in the intensive group so the trial was stopped after 3.5 years. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;At 1 year the HBA1c was stable in the intensive group at 6.4% and in the standard group at 7.5%. During 3.5 years of follow up the primary endpoint occurred in 352 people in the intensive group and 371 in the standard group but 257 in the intensive group died as compared to 203 in the standard group.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Comment&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;The strengths of these 2 trials are the large number of participants with typical baseline characteristics. About one third in each trial had pre-existing macrovascular disease so the trials assessed the benefit of glycaemic control in those with and without pre existing CVD. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;In the ADVANCE trial nonglycaemic CVD risk factors were not optimally controlled as only about half were on statin at the end of follow up. In ACCORD the figures were 75% -88%.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;The most compelling message from both studies is that near normal glucose control (HBA1c 6.4-6.5%) for 3.5 to 5 years does not reduce CVD events. However the ADVANCE trial reconfirmed the predicted reductions in new onset nephropathy.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;The troubling finding is of an increased death rate in the ACCORD study in the intensive group. The reasons for this are not clear. 19 of the 41 excess deaths from CVD in the study were attributed to unexplained or presumed CVD which could have been related to hypoglycaemia. There was more rosiglitazone use in the intensive arm 92% v 58% in the standard (cf 17%v11% in ADVANCE) but the investigators analysis did not suggest that rosiglitazone was a factor. Many people in the intensive arm of ACCORD were on 3-5 oral agents plus insulin.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;The mean wt gain of 3.5Kg in ACCORD may be related to use of insulin plus glitazone. (28% gained more than 10kg). Wt gain in ADVANCE was negligible.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Although in both trials the intensive group got to similar HBA1c levels the rate of reduction in HBA1c in the 2 trials was different. In ACCORD the intensive group had a very rapid reduction in HBA1c by 1.4% within 4 months, in the ADVANCE trial it was 0.6% at 12 months.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;The editorials suggest that there is no need to alter the ADA HBA1c target from its present 7%, and that intensive glycaemic control to lower CVD risk does not seem to work.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Roger Gadsby’s comments&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;These trials have engendered considerable debate. There is clearly no benefit in these studies for reducing HBA1c to near normal levels to reduce &lt;/SPAN&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;CVD&lt;/SPAN&gt;&lt;/st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; risk. The new &lt;/SPAN&gt;&lt;st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;NICE&lt;/SPAN&gt;&lt;/st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; guideline on type 2 diabetes gives a target HBA1c of 6.5% for people on diet and metformin and sulphonylurea but a target of 7.5% for those on more complex regimes. This view is justified by these studies. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;The ACCORD protocol which meant that people on 3 glucose lowering agents with an HBA1c of 6.5% received additional therapy to intensify glycaemic control is not concordant with the vast majority of clinical practice across the world and has been shown to be dangerous. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;The use of statin therapy and good blood pressure control remains the mainstay of &lt;/SPAN&gt;&lt;st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;CVD&lt;/SPAN&gt;&lt;/st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; risk reduction in type 2 diabetes. Good glycaemic control with HBA1c targets of 6.5% (on simple glucose lowering regimes) or 7.5% (with more complex regimes) will benefit microvascular complications, and therefore glucose lowering is still very important.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;DIABETES EDUCATION&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 7 Sturt JA, Whitlock S, Fox C et al Effects of the Diabetes Manual 1:1 structured education in primary care Diabetic Medicine 25: 722-731&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Summary&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;A cluster randomised trial of an intervention group (23 practices, 114 people with type 2 diabetes) and a delayed intervention group (25 practices with 131 participants) using the diabetes manual.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;This intervention is a work book for people with diabetes to use independently with practice nurse telephone support. It is underpinned by self efficacy theory with component parts designed to develop confidence in self care and reduce diabetes related distress.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;There was no difference in HBA!c between the intervention and control group at 6 months, but small improvements in patient diabetes related distress and confidence to self care.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Roger Gadsby’s comments&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;The NICE guideline for type 2 diabetes recommends group education as the education intervention of choice for people with newly diagnosed diabetes. Not everyone will accept group education. NICE says that in that case they should be offered 1:1 education of similar quality. This paper gives data on the diabetes manual which allows this intervention to be assessed and used where group education is not acceptable.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;SHORT REPORTS&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Specialist Diabetes care in the &lt;/SPAN&gt;&lt;/B&gt;&lt;st1:country-region&gt;&lt;st1:place&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;UK&lt;/SPAN&gt;&lt;/B&gt;&lt;/st1:place&gt;&lt;/st1:country-region&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 8 Winocour PH, Gosden C, Walton C et al Association of British Clinical Diabetologists (ABCD) and Diabetes-UK survey of specialist diabetes services in the UK 2006. 1 The consultant physician perspective&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Diabetic Medicine 25: 643-650&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;All 592 &lt;/SPAN&gt;&lt;st1:country-region&gt;&lt;st1:place&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;UK&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:country-region&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; consultant diabetologists were invited to take part in an one line survey. A 49% response rate was achieved. Continuing disparities in specialist service provision were found. A “well resourced service score” had not improved since 2000&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Aliskiren in type 2 diabetes and nephropathy &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 9 Parving H-H, Persson F, Lewis J et al. N Engl J Med 358: 2433-2346 &lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Aliskiren is direct rennin inhibitor the first of a new class of blood pressure lowering medication. In this study 599 people with type 2 diabetes, hypertension and nephropathy on losartan 100mgs daily were randomised to 150 mgs aliskiren daily for 3 months followed by 300mgs for 3 months, or placebo. The outcome measure was reduction in Alb: creatinine ratio at 6 months.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;The aliskiren group had a bp drop of 2/1 mm Hg at 6 months versus placebo. They had a reduction of 20% in mean urinary alb: creatinine ratio &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;The authors conclude that aliskiren may have &lt;/SPAN&gt;&lt;st1:City&gt;&lt;st1:place&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Reno&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:City&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; protective effects that are independent of bp lowering in patients with type 2 diabetes hypertension and nephropathy who are already receiving the recommended &lt;/SPAN&gt;&lt;st1:City&gt;&lt;st1:place&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Reno&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:City&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; protective treatment&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt;&lt;BR&gt;N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetic Medicine, Pract Diab Int&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; published in&amp;nbsp;February 2008.&amp;nbsp;This series began in 2002 as a bulletin for Diabetes Care Staff.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public.&amp;nbsp; Word and webpage versions available.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;EM&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>83533</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=83533]]&gt;</url>
    <title>Interesting new diabetes papers : Mar 2005</title>
    <publicationDate>2005-04-12T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2005,DIABETES,INTERESTING NEW ARTICLES,RESEARCH]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the second in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Mar 2005&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;FOOT PROBLEMS&lt;/P&gt;
&lt;P&gt;Paper 1 &lt;BR&gt;Katz IA, Harlan A, Miranda –Palma B et al&amp;nbsp; A Randomised trial of 2 irremovable off-loading devices in the management of plantar neuropathic diabetic foot ulcers&amp;nbsp; Diabetes care 28; 555-559&lt;BR&gt;Paper 2 &lt;BR&gt;Armstrong DG, Lavery LA, Wu S, Boulton AJM Evaluation of Removable and non removable cast walkers in the healing of diabetic foot wounds&lt;BR&gt;Summary&lt;BR&gt;Off loading is one of the main cornerstones of treatment to get foot ulcers healed. Various devices can be used to achieve this. One reason for their lack of success can be that people don’t wear them all the time that they are supposed to. The gold standard off loading device is the total contact cast. Unfortunately, for many reasons, including fear of complications, cost, and lack of expertise it is under utilised in clinical practice. In these two papers the authors compare their “instant total contact cast iTCC” which is a removable cast walker made irremovable by wrapping it with a single layer of fibreglass casting material with total contact cast in paper 1 and a removable cast walker in paper 2.&lt;BR&gt;Paper 1 shows that the iTCC gives similar healing rates to the total contact cast, but is easier to use and less expensive.&lt;BR&gt;Paper 2 shows that a higher proportion of ulcers heal with the iTCC than with the removable cast walker.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;These papers show that a device that increases patient adherence, but does not require the expertise of total contact casting works.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;INITIAL INSULIN THERAPY IN TYPE 2 DIABETES&lt;/P&gt;
&lt;P&gt;Paper 3&lt;BR&gt;Janka HU, Plewe G, Riddle MC et al Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes Diabetes Care 28; 254-259&lt;BR&gt;Summary&lt;BR&gt;This paper reports the results of a 24 week trial in 371 insulin naïve people with type 2 diabetes. One group had their oral agents stopped and were given bd mixed insulin, the other continued on their oral agents of sulphonylurea and metformin and had once daily insulin glargine added.&lt;BR&gt;Mean HBA1c decease from baseline was more pronounced and more patients reached an HBA1c target of 7% or less without nocturnal hypoglycaemia in the glargine group than the bd premix group.&lt;BR&gt;Paper 4&lt;BR&gt;Raskin P, Allen E, Hollander P et al Initiating insulin therapy in type 2 diabetes – A comparison of biphasic and basal insulin analogues&amp;nbsp; Diabetes Care 28; 260 – 265&lt;BR&gt;This paper reports a trial on 233 insulin naïve type 2 patients who were randomised into a group that continued on oral agents but were given once daily glargine, and another group who continued on oral agents and were given bd novomix insulin.&lt;BR&gt;The bd novomix group had a greater reduction in HBA1c and more achieved the target than those on once daily glargine. Weight gain, daily insulin dose and minor hypoglycaemic episodes were greater in the bd novomix group.&lt;BR&gt;Paper 5 &lt;BR&gt;Davidson M Starting insulin therapy in type 2 diabetic patients – does it really matter how? (Editorial) Diabetes Care 28; 494-495&lt;BR&gt;The editorial writer gives his own views on why the statistically significant small differences that in his opinion probably will not affect clinical outcomes very much, might have occurred in the two trials. He gives his own practice which is to use 3 oral medications and then add once daily insulin.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;In the UK it always used to be the policy to initiate insulin in type 2 diabetes by stopping oral agents and using bd premixed insulin. Paper 4 reinforces the developing view that this is inferior to continuing on sulphonylurea and metformin and adding once daily glargine insulin.&lt;BR&gt;The debate over whether this is better than, worse than or non inferior to continuing oral agents and using novomix, which requires two insulin injections a day, continues.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;DIABETES PREVENTION&lt;/P&gt;
&lt;P&gt;Paper 6&amp;nbsp; &lt;BR&gt;Padwal R, Majumdar SR, Johnson JA et al A systematic review of drug therapy to delay or prevent type 2 diabetes&amp;nbsp; Diabetes Care28; 736-744&lt;BR&gt;Summary&lt;BR&gt;Systematic review with robust methodology reviewed 25 studies.&amp;nbsp; In the largest studies metformin, acarbose, troglitazone and orlistat have all been shown to decrease diabetes compared with placebo.&amp;nbsp; Current evidence for statins, fibrates, antihypertensive agents, and oestrogen is inconclusive. In addition the critical question of whether drugs are preventing or simply delaying the onset of diabetes remains unresolved.&lt;BR&gt;They conclude that currently no single agent can be definitively recommended for diabetes prevention.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This is an important review of this subject.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;DIABETES MANAGEMENT&lt;/P&gt;
&lt;P&gt;Paper 7 &lt;BR&gt;Grant RW, Buse JB, Meigs JB et al Quality of Diabetes Care in US Academic Medical Centres&amp;nbsp; Diabetes Care 28; 337-442&lt;BR&gt;Summary&lt;BR&gt;Retrospective cohort study from 2000 – 2002 looking at 30 centres who contributed data from 44 clinics (27 Primary care 17 diabetes/endocrinology clinics). Assessed management on 1765 patients with diabetes (both type1 and 2). It was an ethnically and economically diverse cohort. Annual testing rates were very high 97.4% for HbA1c 96.6% for Bp, 87.6% for total cholesterol. Few were at targets 34% HBA1c 7% or lower, 33% Bp of 130/80 or lower. At the most recent clinic visit 40% of patients with HBA1c above target, 10% with BP above target&amp;nbsp; had intensification of treatment.&lt;BR&gt;They conclude that high rates of risk factor testing do not necessarily translate to effective metabolic control. Low rates of medication adjustment among patients with levels above target suggest a specific and novel target for quality improvement.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments &lt;BR&gt;Even in leading academic centres professionals don’t usually adjust medication when someone presents with rosin factors above target. This therapeutic inertia means that people with diabetes are not getting optimal management.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;SHORT REPORTS&lt;/P&gt;
&lt;P&gt;Paper 8 &lt;BR&gt;Tidman MJ, Duncan C The treatment of necrobiosis lipoidica &lt;BR&gt;BJDVD 5; 37-48 &lt;BR&gt;Dr Roger Gadsby’s comments: not many papers published on this subject. Expert review paper on treatment options. 68 references.&lt;/P&gt;
&lt;P&gt;Paper 9 &lt;BR&gt;Hermanns N, Kulzer B Krichbaum M et al Affective and anxiety disorders in a German sample of diabetic patients: prevalence, comormidity and risk factors. Diabetic Medicine 22; 293-300&lt;BR&gt;Dr Roger Gadsby’s comments: Survey of 420 type 1 and 2 diabetic patients., showed a twofold increase in prevalence of affective disorders, whereas anxiety disorders was not increased.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed this month:&lt;/STRONG&gt; Diabetes Care (Feb &amp;amp; March), Diabetic Medicine, BMJ, NEJM, BJDVD , Lancet, JAMA, Pract Diab Int, Diabetes in Primary Care, Diabetic Foot &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in April&amp;nbsp;2005. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for Diabetes Care staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this series is to inform readers of interesting&amp;nbsp; new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>124902</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=124902]]&gt;</url>
    <title>Interesting new diabetes papers : Mar 2006</title>
    <publicationDate>2006-04-19T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2006,DIABETES,RESEARCH,INTERESTING NEW ARTICLES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the fourteenth in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Mar 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;DIABETES, PREGNANCY&amp;nbsp; &amp;amp; METFORMIN&lt;/P&gt;
&lt;P&gt;Paper 1&lt;BR&gt;Hughes RC, Rowan JA. Pregnancy in women with type 2 diabetes: who takes metformin and what is the outcome. Diabetic Medicine 23; 318-322.&lt;BR&gt;Paper 2&lt;BR&gt;Hughes RC, Gardiner SJ, Begg EJ, Zhang M. Effect of pregnancy on the pharmokinetics of pregnancy. Diabetic Medicine 23; 323-326.&lt;BR&gt;Paper 3&lt;BR&gt;Hawthorne G. Metformin use and diabetic pregnancy – has its time come? (Commentary). Diabetic Medicine 23; 223-227.&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;Paper 1 is an audit paper reviewing 214 pregnancies in&amp;nbsp; women with type 2 diabetes in which metformin was taken by 93 with the remaining 121 pregnancies as controls. Metformin was taken to delivery in 32. There was no difference in outcomes between the metformin treated and control groups.&lt;BR&gt;Paper 2 is a study of 7 women with type 2 diabetes taking metformin in pregnancy showing that clearance of metformin increases as the result of enhanced renal elimination.. It suggests that metformin dose adjustments might be appropriate in late pregnancy to maintain therapeutic effect.&lt;BR&gt;Paper 3 is a commentary. It cites evidence that metformin can safely be taken in mothers breastfeeding. It concludes that on the basis of small non randomised and non blinded studies metformin appears to be safe and non teratogenic during pregnancy.&amp;nbsp; Metformin treatment may be useful in managing women with type 2 diabetes in pregnancy and gestational diabetes. It says that a proper RCT is needed.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;These papers especially the commentary paper provide a good overview of the developing role of metformin in managing gestational diabetes and type 2 diabetes and pregnancy.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;WHAT PEOPLE WITH DIABETES&amp;nbsp; THINK&lt;/P&gt;
&lt;P&gt;Paper 4&lt;BR&gt;Farmer A, Kinmonth A-L, Sutton S. Measuring beliefs about taking hypoglycaemic medication among people with type 2 diabetes. Diabetic Medicine 23; 265-270.&lt;BR&gt;Summary:&lt;BR&gt;A postal questionnaire study of people with type 2 diabetes over age 40 in 3 general practices. 121 people (61.7% of those contacted) returned their questionnaires after 2 reminders. Negative beliefs about taking medications that they would cause “unpleasant side effects” and&amp;nbsp; would “lead to weight gain “ were held by 24% and 14% of responders. Two beliefs were associated with reduced medication adherence “changes to my daily routine would make it more difficult to take my diabetes medications regularly and “ if I were to take my diabetes medications regularly this would lead to my gaining weight”.&lt;BR&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;This highlights the importance of exploring concerns about weight gain and how to keep taking tablets when routines change.&lt;/P&gt;
&lt;P&gt;Paper 5&lt;BR&gt;Brown K, Dyas J, Chahal P et al. Discovering the research priorities of people with diabetes in a multicultural community.&amp;nbsp; BJGP 56; 206-213.&lt;BR&gt;Summary:&lt;BR&gt;This is a qualitative project with 39 adults in 6 focus groups carried out in the participants preferred language and analysed using the constant comparative&amp;nbsp; method.&lt;BR&gt;9 themes emerged of which information and awareness, service delivery and primary prevention of diabetes were the main three. There were no science-based topics and there was more emphasis on culturally influenced research questions, which differed from DH diabetes research priorities.&lt;BR&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;People with diabetes have very different research priorities to published DH research priorities and Diabetes UK research strategy.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;QUALITY OF DIABETES CARE IN THE USA&lt;/P&gt;
&lt;P&gt;Paper 6 &lt;BR&gt;Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes 1999-2002. Diabetes Care 29; 531-537.&lt;BR&gt;Summary:&lt;BR&gt;This paper uses data on 998 adults from the 1999-2002 National Health and Nutrition examination survey (NHANES) and compares their achievement of process and quality standards compared to ADA recommendations.&lt;BR&gt;49.8% had HBA1c below 7%, 40% met BP recommendations, 66% had normal renal function. Achievement of ADA clinical practice recommendations was affected by race, age, duration of diabetes and education.&lt;BR&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;This paper provides some data with which to compare the UK QoF&amp;nbsp; diabetes results.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;CARE HOME DIABETES&lt;/P&gt;
&lt;P&gt;Paper 7&lt;BR&gt;Aspray TJ, Nesbit K, Cassidy TP et al. Diabetes in British Nursing and Residential Homes. Diabetes Care 29; 707-8.&lt;BR&gt;Summary:&lt;BR&gt;This looked at data from 1275 residents of homes in Newcastle upon Tyne, to compare fasting glucose with 2 hour post prandial glucose measured by Haemocue analyser . They found 105 with undiagnosed diabetes 8.2%, which with the known diabetes gives a prevalence of 19.9% in this population. They found high levels of diabetes among residents with dementia.&lt;BR&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;This study shows again the high prevalence of diabetes in residents of Care homes and also highlights the co-morbidity of dementia with diabetes.&lt;/P&gt;
&lt;P&gt;BRIEF REPORTS&lt;/P&gt;
&lt;P&gt;Paper 8 - Comorbidities&lt;BR&gt;Piette JD, Kerr EA.. The impact of co-morbid chronic conditions on diabetes care.&lt;BR&gt;Diabetes Care 29; 725-731.&lt;BR&gt;Very good expert review developing the typology of :&lt;BR&gt;1. Clinically dominant conditions defined as comorbid chronic conditions that are so complex and serious that they eclipse the management of other health problems e.g. terminal cancer, severe dementia, severe CCF etc.&lt;BR&gt;2. Concordant versus discordant chronic conditions. E.g. concordant with diabetes hypertension, discordant asthma.&lt;BR&gt;3. Symptomatic versus asymptomatic chronic conditions&lt;BR&gt;symptomatic&amp;nbsp; - depression, RA etc&lt;BR&gt;asymptomatic – hypertension, hyperlipidaemia &lt;/P&gt;
&lt;P&gt;Paper 9 – Oral treatment escalation&lt;BR&gt;Nichols GA, Alexander CM, Girman CJ et al. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care 29; 504-509.&lt;BR&gt;This paper concludes that whether defined by adding/switching to another drug or by reaching an HBA1c of 8% secondary failure is inversely associated with the reduction in HBA1c achieved within the first year of metformin monotherapy.&lt;/P&gt;
&lt;P&gt;Paper 10 – mechanism of glitazone weight gain&lt;BR&gt;Basu A, Jensen MD, McCann F et al. Effects of pioglitazone versus glipizide on body fat distribution, body water content and haemodynamics in type 2 diabete.s Diabetes Care 29; 510-514. &lt;BR&gt;Study of 19 people using state of the art techniques. When pioglitazone and glipizide are given in doses sufficient to achieve equivalent glycaemic control in people with type 2 diabetes, pioglitazone increases total body water, thereby accounting for the majority of weight gain, tended to decrease visceral and abdominal fat content and blood pressure. And reduces systemic vascular resistance.&lt;/P&gt;
&lt;P&gt;Paper 11 – Triple therapy in type 2 diabetes&lt;BR&gt;Rosenstock J, Sugimoto D, Strange P et al. Triple therapy in type 2 diabetes. Diabetes Care 29; 554-9.&lt;BR&gt;Low dose insulin glargine combined with a sulphonylurea and metformin resulted in similar HBA!C improvements except for greater reductions in HBA1c when baseline was at or above 9.5% compared with add on rosiglitazone. Further insulin glargine was associated with more hypoglycaemia but less wt gain, no oedema, and salutary lipid changes at a lower cost of therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt;&amp;nbsp; Diabetes Care , Diabetic Medicine, BMJ, NEJM, BJGP, Lancet,&amp;nbsp; JAMA, Pract Diab Int&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;April 2006. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp;Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of&amp;nbsp;this series&amp;nbsp;is to inform readers of interesting new papers relevant to diabetes that have appeared in&amp;nbsp;several diabetes and general medical journals in the previous month.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>259459</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=259459]]&gt;</url>
    <title>Interesting new diabetes papers : Mar 2007</title>
    <publicationDate>2007-04-10T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2007,DIABETES,RESEARCH,INTERESTING NEW ARTICLES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the twenty sixth in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Mar 2007&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;SYSTEMATIC REVIEWS &amp;amp; META-ANALYSIS&lt;/P&gt;
&lt;P&gt;Physical Activity&lt;/P&gt;
&lt;P&gt;Paper 1&amp;nbsp; Jeon CY, Locken RP, Hu FB, Van Dam RM&amp;nbsp; Physical Activity of Moderate intensity and risk of Type 2 Diabetes ; a systematic review Diabetes Care 30;744-752&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;A systematic&amp;nbsp; review of&amp;nbsp; 10 relevant papers, totalling 301,221 participants and 9367 incident cases of diabetes. 5 of the studies specifically investigated the role of walking. The summary risk reduction of type 2 diabetes was 0.69 for regular participation in physical activity of moderate intensity as compared with being sedentary. Similarly the risk reduction was 0.70 for regular walking at or greater than 2.5hours/week of brisk walking as compared with almost no walking. The associations remained significant after adjustment for BMI, and occurred in both men and women in the USA and Europe.&lt;BR&gt;The review concludes that adherence to recommendations to participate in physical activities of moderate intensity such as brisk walking can substantially reduce the risk of type 2 diabetes.&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Good systematic review reinforcing the importance of physical activity&lt;BR&gt;&lt;BR&gt;RANDOMISED CONTROLLED TRIALS&lt;/P&gt;
&lt;P&gt;Dressings for Foot ulcers in People with Diabetes&lt;/P&gt;
&lt;P&gt;Paper 2&amp;nbsp;&amp;nbsp; Jude EB, Apelqvist J, Spraul M, Martini J and the Silver Dressing Study Group. Prospective randomised controlled study of Hydrofiber dressing containing ionic silver or calcium alginate dressings in non-ischaemic diabetic foot ulcers&amp;nbsp; Diabetic&amp;nbsp; Medicine 24; 280-288&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;Patients stratified by antibiotic use on enrolment were randomly assigned to similar protocols including off loading and 67 to silver dressings and 67 to calcium alginate primary dressings for 8 weeks or until healing. Mean time to healing was 53 days in silver and 58 days in alginate group. There was more overall ulcer improvement and less deterioration in the silver subjects, particularly in the subset initially using antibiotics.&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;This is the first randomised good quality study to report the&amp;nbsp; clinical effects of a primary wound dressing containing silver on diabetic foot ulcer (DFU)&amp;nbsp; healing. All previous studies of dressings have shown no difference and guideline recommendations in the past have always suggested using the cheapest.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;OTHER TYPES OF STUDY&lt;/P&gt;
&lt;P&gt;Incretins&lt;/P&gt;
&lt;P&gt;Paper 3&amp;nbsp; Todd JF, Bloom SR&amp;nbsp; Incretins and other peptides in the treatment of diabetes&lt;BR&gt;Diabetic Medicine 24; 223-232&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;Expert review with 97 references summarising the field. They conclude that both the approach of using GLP analogues and that of using DPP-4 inhibitors have demonstrated remarkable efficacy in both animal models and human clinical studies. Both are well tolerated and appear to have advantages over current therapies for type 2 diabetes particularly on pancreatic beta cell restoration and potential weight loss&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;Useful review of the subject&lt;BR&gt;&lt;BR&gt;Pregnancy outcome in women with type 2 diabetes&lt;BR&gt;&lt;BR&gt;Paper 4&amp;nbsp; Ekpebegh CO, Coetzee EJ, Van de Merwe L, Levitt NS A 10 year retrospective analysis of pregnancy outcome in pregestational type 2 diabetes: comparison of insulin and oral glucose lowering agents Diabetic Medicine 24;253-258&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;This study considered 379 pregnancies in women with type 2 diabetes from 1991 to 2000 in Groote Shuur hospital in South Africa. There were 3 groups, those on oral hypoglycaemic agents metformin or glibenclamide, those changed from orals to insulin, and those on insulin alone or changed from diet alone to insulin. Mean HBA1c was similar in all groups at booking and throughout pregnancy. Conversion from orals to insulin was protective for perinatal mortality compared with orals alone. No perinatal mortality was observed in women on metformin alone.&lt;BR&gt;They conclude that the data suggest that metformin and glibenclamide are not tetragenic but that it is advisable to replace glibenclamide with insulin when women book for pregnancy care&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;There have been few reports on type 2 diabetes and pregnancy. South Africa is one of the few places that has used oral agents in pregnancy. This is very interesting data. There are more women with type 2 diabetes being diagnosed at younger ages now in the UK, so more pregnancies in women with type 2 diabetes will be seen here.&lt;BR&gt;&lt;BR&gt;Depression and Diabetes&lt;/P&gt;
&lt;P&gt;Paper 5&amp;nbsp; Fisher L, Skaff MM, Mullan JT et al Clinical Depression versus Distress among patients with type 2 Diabetes&amp;nbsp; Diabetes Care 30: 542-548&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;An assessment of 506 diabetic patients for major depressive disorder by a structured interview, questionnaires (CESD and Diabetes Distress Scale) and 4 behavioural management measures. They conclude that most patients with diabetes and high levels of depressive symptoms are not clinically depressed. The CESD may be more reflective of general emotional and diabetes specific distress and clinical depression. Most treatment of distress however is based on the depression literature, which suggests the need to consider different interventions for distressed but not clinically depressed people with diabetes&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Very interesting data in the light of QoF and the need to ask the 2 screening questions for depression in people with diabetes. &lt;BR&gt;&lt;BR&gt;BREIF REPORTS&lt;/P&gt;
&lt;P&gt;Paper 6 Lipscombe LL, Hux JE Trends in diabetes prevalence, incidence and mortality in Ontario, Canada 1995-2005: a population based study Lancet 369; 750-56. &lt;BR&gt;Large increase in prevalence due to rising incidence and declining mortality&lt;BR&gt;&lt;BR&gt;Paper 7 Skyler JS, Jovanovic L, Klioze S et al Two year safety and efficacy of inhaled insulin (exubera) in Adult Patients with type 1 Diabetes Diabetes Care 30; 579-584 &lt;BR&gt;Treatment group differences, between inhaled and sc injected insulin, in lung function in adult patients with type 1 diabetes are small, develop early and are non progressive for up to 2 years of therapy&lt;BR&gt;&lt;BR&gt;Paper 8&amp;nbsp; Vermeire E, Hearnshaw H, Ratsep A et al Obstacles to adherence in living with type 2 diabetes: An international qualitative study using meta-ethnography (EUROBSTACLE) Primary Care Diabetes 1:25-33 &lt;BR&gt;Warwick involvement in this paper published in a new journal&lt;BR&gt;&lt;BR&gt;Paper 9 Wens J, Dirven K, Mathieu C et al&amp;nbsp; Quality indicators for type 2 diabetes care in practice guidelines: An example from six European Countries&amp;nbsp; Primary Care Diabetes 1; 17-23 &lt;BR&gt;Five “mini” lists of highly valuable indicators for optimal treatment in the field of type 2 diabetes could be drawn up&lt;BR&gt;&lt;BR&gt;Paper 10 Lai WA, Chie WC, Lew-Ting CY How diabetic patients ideas of illness course affect non-adherent behaviour; a qualitative study BJGP 57;296-302&lt;BR&gt;Interview and focus group study from Taiwan&lt;BR&gt;&lt;BR&gt;Paper 11 Landon BE, Hicks LS, O’Malley AJ et al Improving the management of Chronic Disease at Community Health Centers N Engl J Med 256; 921-934&lt;BR&gt;A controlled preintervention and intervention study of centers participating in&amp;nbsp; quality improvement collaboratives for the care of people with asthma, diabetes or hypertension. Improved care for asthma and diabetes not for hypertension&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Journals reviewed: &lt;/STRONG&gt;BMJ, Lancet,&amp;nbsp; N Eng J Med, Diabetes Care, JAMA, Diabetic Medicine, Primary Care Diabetes, Pract Diab Int, BJDVD, Diabetes and Primary Care&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;April 2007. This series began in 2002 as a bulletin for Warwick Diabetes Care staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>89407</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=89407]]&gt;</url>
    <title>Interesting new diabetes papers : May 2005</title>
    <publicationDate>2005-06-23T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2005,RESEARCH,INTERESTING NEW ARTICLES,DIABETES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the fourth in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : May 2005&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;STATIN THERAPY&lt;/P&gt;
&lt;P&gt;Paper 1&amp;nbsp; &lt;BR&gt;Sever PS, Poulter NR, Dahlof B et al for the ASCOT –LLA investigators Reduction in cardiovascular events with atorvastatin in 2532 patients with type 2 diabetes.&amp;nbsp; Diabetes Care 28; 1151-1157&lt;BR&gt;Summary&lt;BR&gt;In this lipid lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial 10,305 hypertensive patients with no history of coronary heart disease were randomly assigned to receive 10mgs of atorvastatin or placebo. Effects on total cardiovascular outcomes in 2532 patients with type 2 diabetes at randomisation were compared.&lt;BR&gt;During median follow up of 3.3 years, levels of total cholesterol and LDL cholesterol were 1mmol lower in atorvastatin group. There were 116 major events in the atorvastatin group and 151 in the placebo group, a 23% risk reduction. For the individual components of this composite end point the number of events was small and reductions did not reach statistical significance.&lt;BR&gt;Allocation to atorvastatin prevented 9 diabetic participants from suffering a first major cardiovascular event or procedure for every 1000 treated for 1 year.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;These results support those from other statin trials. They extend the data to groups with hypertension and no history of CHD. The authors conclude that it seems reasonable to recommend that all patients with type 2 diabetes and hypertension&amp;nbsp; should be routinely considered for statin therapy&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;COST EFFECTIVENESS OF STATINS&lt;/P&gt;
&lt;P&gt;Paper 2&lt;BR&gt;Heart Protection Study Collaborative Group. Cost-effectiveness of simvastatin at different levels of vascular disease risk: economic analysis of a randomised trial in 20536 individuals.&amp;nbsp; Lancet 365; 1779-1785&lt;BR&gt;Paper 3 &lt;BR&gt;Imai K, Zhang P Integrating economic analysis into clinical trials&lt;BR&gt;Lancet 365; 1749-50 (editorial)&lt;BR&gt;Summary&lt;BR&gt;Paper 1 is a cost –effectiveness analysis from the Heart Protection Study. Using 2001 prices they calculate that the cost of preventing a major vascular event ranges from £4500 to those with the highest risk (a 42% 5 year risk)&amp;nbsp; to £31000 in those with more modest risk a 12%&amp;nbsp; 5 year rate). The cost of preventing a vascular death ranges from £20700 in patients with the highest risk to £296300 in those with a more modest risk.&lt;BR&gt;They conclude that statin therapy is cost effective for a wider range of individuals with vascular disease or diabetes than previously recognised. It would be appropriate to consider reducing the estimated level of vascular event risk at which statin therapy is recommended.&lt;BR&gt;Paper 2 is an editorial in which the problems of integrating economic analysis into clinical trial is discussed. One problem identified is the need to use standardised units to measure health interventions such as life-years or QUALY’s. The paper uses major vascular events. This measure is difficult to use – how do we compare interventions to prevent major vascular events with those that prevent other conditions, such as kidney failure.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;The paper demonstrates that therapy with simvastatin 40 in the HPS trial is cost effective across a wide range of people. The editorial points out that the measure used makes its cost-effectiveness&amp;nbsp; difficult to compare&amp;nbsp; with other treatments for other conditions.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;INSULIN THERAPY &lt;/P&gt;
&lt;P&gt;Paper 4&amp;nbsp; &lt;BR&gt;Rave K,&amp;nbsp; Bott S, Heinman L et al Time-Action Profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin&lt;BR&gt;Diabetes Care 28; 1077-1082&lt;BR&gt;Summary&lt;BR&gt;Study in 17 healthy volunteers showing that inhaled insulin (exubera) had a faster onset of action that either of the sc injected insulins and a duration of action longer than lispro and comparable to regular human insulin.&lt;BR&gt;The authors conclude that these characteristics make inhaled insulin&amp;nbsp; suitable for prandial insulin supplementation in patients with diabetes.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This is important pharmacological data to inform the use of inhaled insulin&lt;/P&gt;
&lt;P&gt;Paper 5&amp;nbsp; &lt;BR&gt;Douek IF, Allen SE, Ewing P et al for the metformin trial group&lt;BR&gt;Continuing metformin when starting insulin in patients with type 2 diabetes: a double blind randomised placebo controlled trial&amp;nbsp;&amp;nbsp; Diabetic Medicine 22;634-640&lt;BR&gt;Summary&lt;BR&gt;183 patients on max tolerated doses of oral agents&amp;nbsp; received placebo or metformin titrated up to max of 2gms/day, with insulin started according to local practice in this study from Bristol. Over 12 months the metformin group had less weight gain, a greater reduction in HBA1c and lower insulin requirements. Treatment satisfaction scores improved more in the metformin group.&lt;BR&gt;They conclude that metformin should be continued in patients with type 2 diabetes who transfer onto insulin&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This paper gives further support to the current practice of continuing metformin&lt;BR&gt;when starting insulin in type 2 diabetes.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;ORAL AGENT THERAPY &lt;/P&gt;
&lt;P&gt;Paper 6&lt;BR&gt;Cook MI, Girman CJ Stein P et al Glycaemic control continues to deteriorate after sulphonylureas are added to metformin among people with type 2 diabetes Diabetes Care 28; 995-1000&lt;BR&gt;Summary&lt;BR&gt;This papers reports a retrospective analysis of electronic records using the UK General Practice Research Database. 2220 patients treated with metformin monotherapy for at least 90 days before starting metformin plus SU combination therapy between 1998 and 2004 were studied. &lt;BR&gt;At 6 months post SU initiation, median HBA1c resumed deterioration at a somewhat comparable rate to that observed on metformin monotherapy.&amp;nbsp; Median HBA1c was 9.5% when therapy was intensified. HBA1c at or above 8% was estimated to occur in 85% of patients 4 years after initiation of SU.&lt;BR&gt;The high proportion of patients remaining on Metformin plus SU despite having HBA1c above 8%.sugests there are considerable barriers to starting insulin or adding a third agent when treatment goals are not being achieved with Met plus SU combination&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This shows that there were many people in the community poorly controlled. This may have improved now that the Quality &amp;amp; outcomes framework of the nGMS contract is in place.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;BRIEF REPORTS&lt;/P&gt;
&lt;P&gt;Paper 7&amp;nbsp;&amp;nbsp; &lt;BR&gt;Barrosa I&amp;nbsp;&amp;nbsp; Genetics of type 2 diabetes&amp;nbsp;&amp;nbsp; Diabetic Medicine 22, 517-535&lt;BR&gt;Dr Roger Gadsby’s comments: Comprehensive (257 references) expert review of this difficult area.&lt;/P&gt;
&lt;P&gt;Paper 8&amp;nbsp; &lt;BR&gt;Klonoff DC&amp;nbsp; Continuous Glucose monitoring&amp;nbsp;&amp;nbsp;&amp;nbsp; Diabetes Care 28; 1231-1238&lt;BR&gt;Dr Roger Gadsby’s comments: Expert review article (85 references) of this evolving subject&lt;/P&gt;
&lt;P&gt;Paper 9 &lt;BR&gt;ADA workgroup on hypoglycaemia&amp;nbsp; Defining and Reporting Hypoglycaemia in Diabetes&amp;nbsp;Diabetes Care 28; 1245-1249&lt;BR&gt;Dr Roger Gadsby’s comments: Interesting information on definitions and reporting of hypoglycaemia&lt;/P&gt;
&lt;P&gt;Paper 10 &lt;BR&gt;Greenhalgh T, Collard A, Begum N&amp;nbsp;Narratiive based medicine. Pract Dab Nit 22; 125-129&lt;BR&gt;Dr Roger Gadsby’s comments: An action research project to develop group education and support for bilingual health advocates and elderly South Asian patients with diabetes. Fascinating report.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed this month:&lt;/STRONG&gt; Diabetes Care, Diabetic Medicine, BMJ, NEJM, BJDVD, Lancet, JAMA, Pract Diab Int&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;June&amp;nbsp;2005. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this series is to inform readers of interesting&amp;nbsp; new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>143016</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=143016]]&gt;</url>
    <title>Interesting new diabetes papers : May 2006</title>
    <publicationDate>2006-06-09T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2006,DIABETES,RESEARCH,INTERESTING NEW ARTICLES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the sixteenth in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : May 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;STATINS AND DIABETES&lt;/P&gt;
&lt;P&gt;Paper 1&lt;BR&gt;Costa J, Borges M, David C, Vaz Carneiro A Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials&amp;nbsp; BMJ 332; 1115-8&lt;BR&gt;Paper 2&lt;BR&gt;Reckless JPD Diabetes and lipid lowering : where are we? (Editorial)&lt;BR&gt;BMJ 332;1103-4&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;Paper 1 is a meta analysis of 12 trials of lipid lowering. The risk reduction in primary and secondary prevention was 21% in diabetic patients and 23% in non-diabetic patients. When results were adjusted for baseline risk diabetic patients benefited more in both primary and secondary prevention. Blood lipids were reduced to a similar degree in both groups.&lt;BR&gt;The editorial points out that this meta-analysis confirms what guidelines are saying – that all patients with type 2 diabetes should be considered for, and the vast majority should receive statin treatment.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;This meta-analysis as gold standard evidence confirms what we already know and are putting into practice through guideline recommendations about the use of statins in type 2 diabetes.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;PREGNANCY &amp;amp; DIABETES&lt;/P&gt;
&lt;P&gt;Paper 3&lt;BR&gt;Casson IF Pregnancy in women with diabetes-after the CEMACH report, what now?&lt;BR&gt;Diabetic Medicine 23; 481-4&lt;BR&gt;Paper 4&lt;BR&gt;Cutchie WA, Cheung NW, Simmons D&amp;nbsp; Comparison of International and New Zealand Guidelines for the care of pregnant women with diabetes&amp;nbsp; Diabetic Medicine 23; 460-468&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;Paper 3 reports on the CEMACH (confidential Enquiry into Maternal and Child Health) study on 3808 pregnancies of women with diabetes. Stillbirth, prenatal mortality were 4-5 times higher and congenital abnormalities twice as high as non-diabetic pregnancies. The paper concludes that the need to educate, motivate and bring about improved pre-pregnancy care in women with diabetes is a prority.&lt;BR&gt;Paper 4 is a literature review of national and international guidelines for the care of women with diabetes during pregnancy 8 guidelines for pre-pregnancy diabetes and 10 guidelines for gestational diabetes were identified. The paper concludes that International guidelines remain fragmented and inconsistent, especially around gestational diabetes. The development of one set of guidelines based around the consensus of best international practice could overcome many of the misconceptions associated with diabetes in pregnancy.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;These papers confirm what we already know. A NICE guideline for the UK on Diabetes &amp;amp; Pregnancy is being developed. Perhaps the IDF needs to take on the task of an international guideline&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;IFG/IGT&lt;/P&gt;
&lt;P&gt;Paper 5&lt;BR&gt;Abdul-Ghani MA, Tripathy D, DeFronzo RA Contributions of beta cell Dysfunction and Insulin Resistance to the pathogenesis of Impaired Glucose Tolerance and Impaired Fasting Glucose Diabetes Care 29; 1130-1139&lt;BR&gt;Papers 6 &amp;amp; 7&lt;BR&gt;Shaw JF, Zimmet PZ, Alberti GMM Point: Impaired Fasting Glucose: The Case for the new American Diabetes association Criterion Diabetes Care 29; 1170-1172&lt;BR&gt;Dekker JM, Balkau B Counterpoint: Impaired Fasting Glucose the case against the new ADA guidelines&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;Paper 5 is a review of the pathophysiology of IFG/IGT pointing out that the 2 categories describe 2 distinct populations with only partial overlap. Insulin resistance in IGT seems to be mostly muscle with only mild hepatic insulin resistance, whereas in IFG there is severe hepatic bit near normal muscle insulin resistance. In both IFG and IGT there is a reduction in first phase insulin, while in IGT there is impaired late phase insulin. The distinct metabolic features present in subjects with IFG and IGT may require different therapeutic interventions to prevent their progress to diabetes i.e. in IFG use metformin in IGT use glitazones with GLP-1 analogue!!&lt;BR&gt;The ADA are considering lowering the lower limit of IFG from 6 to 5.6. The point paper says that 6 wasn’t based on good evidence and that 5.6 provides the best cut off to predict future diabetes. The counterpoint paper argues that by lowering it to 5.6 you label one third of most populations at high risk of diabetes, but most will not develop diabetes. In fact those most likely to will be in the range 6.1 –6.9! People with FPG between 5.6 and 6 do not have an increased risk of CVD.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;DIABETES EDUCATION&lt;/P&gt;
&lt;P&gt;Paper 8&lt;BR&gt;Knight KM, Dornan T, Bundy C&amp;nbsp; The diabetes educator: trying hard, but must concentrate more on behaviour Diabetic Medicine 23; 485-501&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;This is a review of 37 RCT’s in the literature since 1990. They say that there is a widespread assumption that transferring knowledge will improve health outcomes, but there is little empirical support for this assertion. Knowledge and behaviour are poorly correlated.&amp;nbsp; Single interventions give disappointing results so they advocate that educational interventions should have multiple interventions to improve self-efficacy and empowerment.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s&amp;nbsp; comments:&lt;BR&gt;This paper confirms what we know and need to practice.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;BRIEF REPORTS&lt;/P&gt;
&lt;P&gt;Paper 9 – Effectiveness of&amp;nbsp; community health workers in the care of persons with diabetes&lt;BR&gt;Norris SL, Chowdhury FM, Van Le K, et al&amp;nbsp; Diabetic Medicine 23; 544-556&lt;BR&gt;A systematic review of 18 studies, mostly in minority populations in the USA. There is some data demonstrating improvements in participant knowledge and behaviour. Much additional research is needed&lt;/P&gt;
&lt;P&gt;Paper 10- Mortality of people with Type 2 diabetes in the UK&lt;BR&gt;Mulnier HE, Seaman HE, Raleigh VS et al Diabetic Medicine 23;516-521&lt;BR&gt;Using data from General Practice Research Database paper reports&amp;nbsp; a doubling of mortality rate of those with diabetes than those without. The relative risk decreases with age, and obesity and smoking contribute to the risk of all-cause mortality&lt;/P&gt;
&lt;P&gt;Paper 11 – Diabetic ketoacidosis in infants, children and adolescents&lt;BR&gt;Wolfsdorf J, Glaser n, Sperling MA Diabetes Care 29;1150-1159&lt;BR&gt;ADA Consensus statement&lt;/P&gt;
&lt;P&gt;Paper 12 – Metabolic Syndrome – a new world-wide definition. A consensus statement from the International Diabetes Federation&lt;BR&gt;Alberti GMM, Zimmet P Shaw J&amp;nbsp; Diabetic Medicine 23; 469-480&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt;&amp;nbsp; Diabetes Care, Diabetic Medicine, BMJ, NEJM, BJGP, Lancet,&amp;nbsp; JAMA, Pract Diab Int&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;June 2006. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp;Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of&amp;nbsp;this series&amp;nbsp;is to inform readers of interesting new papers relevant to diabetes that have appeared in&amp;nbsp;several diabetes and general medical journals in the previous month.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>262491</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=262491]]&gt;</url>
    <title>Interesting new diabetes papers : May 2007</title>
    <publicationDate>2007-06-21T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2007,RESEARCH,INTERESTING NEW ARTICLES,DIABETES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the twenty eighth in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : May 2007&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;SYSTEMATIC REVIEWS &amp;amp; META-ANALYSIS&lt;/P&gt;
&lt;P&gt;Rosiglitazone and CHD Risk&lt;/P&gt;
&lt;P&gt;NB This controversy has arisen in papers that have been released electronically in May but have yet to be published in hard copy.&lt;/P&gt;
&lt;P&gt;Paper 1&amp;nbsp; Nissen SE, Wolski K Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356;2457-71&lt;BR&gt;Paper 2 Psaty BM, Furberg CD Rosiglitazone and cardiovascular risk (editorial) N Engl J Med &lt;BR&gt;Paper 3 anonymous Rosiglitazone: seeking a balanced perspective (editorial) Lancet &lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;Paper 1 is a meta-analysis of 42 trials with 15560 people treated with rosiglitazone compared with 12283 people treated with placebo or other oral agents.&amp;nbsp; In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (86 people having infarcts in the rosi group&amp;nbsp; against 72&amp;nbsp; in the comparator group)&amp;nbsp; and for deaths from cardiovascular causes the odds ratio was 1.64 39 deaths from cardiovascular causes in the rosi group as compared to 22 deaths in the comparator group) The authors conclude by stating that rosiglitazone was associated with a significant risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance.&lt;BR&gt;The editorial went further and questioned the whole rationale for prescribing rosiglitazone, and whether the procedures of the USA drug licensing authority the FDA, were robust enough.&lt;BR&gt;In contrast the Lancet editorial suggests that a calmer and more measured approach to the safety of rosiglitazone is needed. It says that alarmist headlines and confident declarations help nobody, and that we can reasonably wait for the results of RECORD a trial designed specifically to study cardiovascular outcomes.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;Very controversial meta-analysis and editorial which has produced alarmist headlines. Further data is promised to try to clarify the situation. More publications and discussion is expected over the next weeks.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Gestational Diabetes&lt;/P&gt;
&lt;P&gt;Paper 4&amp;nbsp; Kim C, Berger DK, Chamany S&amp;nbsp; Recurrence of Gestational Diabetes Mellitus : A systematic review&amp;nbsp; Diabetes Care 30; 1314-1319&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;Systematic review with 13 inclusion articles on the recurrence rates of GDM among women with a history of GDM.&amp;nbsp; After the index pregnancy rates varied between 30 and 84%.&amp;nbsp; Lower rates were found in non Hispanic whites (30-37%) and higher rates in minority populations (52-69%)&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Useful information&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;ACE &amp;amp; ARB used together&lt;/P&gt;
&lt;P&gt;Paper 5 Jennings DL, Kalus JS, Coleman CI et al Combination therapy with an ACE inhibitor and an angiotensin receptor blocker(ARB)&amp;nbsp; for diabetic nephropathy: a meta-analysis Diabetic Medicine 24; 486-493&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;A meta-analysis of 10 included trials in which 156 patients had ACE +ARB and 159 had ACE alone. Most studies were 8-12 weeks duration. The results show that ACE+ARB reduces 24hr proteinuria to a greater extent than ACE alone. This benefit was associated with small effects on GFR, creatinine, potassium and blood pressure. The results need to be interpreted with caution as most were short studies and the few 12 month studies have not shown benefit.&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;More research is needed as this meta-analysis only covers very small numbers of people.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;OTHER TYPES OF STUDY&lt;/P&gt;
&lt;P&gt;Cognitive impairment in type 1 Diabetes&lt;/P&gt;
&lt;P&gt;Paper 6&amp;nbsp; The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study research group&lt;BR&gt;Long term effects of Diabetes and its treatment on Cognitive Function&lt;BR&gt;N Eng J Med 356; 1842-1852&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;A total of 1144 people with type 2 diabetes enrolled in the DCCT study and followed up in the EDIC study had a battery of cognitive tests at entry into the DCCT study at mean age 27 years and 18 years later. 40% reported at least one hypoglycaemic coma or fit. They conclude that there was no evidence of substantial long term decline in cognitive function in a large group of patients with type 1 diabetes who were followed for 18 years and who had relatively high rates of recurrent severe hypoglycaemia.&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Very reassuring data&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;CHD in people with type 2 diabetes&lt;/P&gt;
&lt;P&gt;Paper 7&amp;nbsp; Avogaro A, Giorda C, Magginini M et al Incidence of Coronary Heart Disease (CHD) in Type 2 Diabetic Men &amp;amp; Women&amp;nbsp;&amp;nbsp; Diabetes Care 30; 1241-1247&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;Italian study looking at nearly 12000 people with type 2 diabetes free of CVD. They found that risk of first CHD event depends on sex, geographical location, and presence of microvascular disease. Hyperglycaemia and hypertension, particularly in men and dyslipidaemia particularly in women are modifiable risk factors.&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Further data showing the multiplicity of factors affecting CHD rates in people with type 2 diabetes.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;SHORT REPORTS&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Metformin and eGFR&lt;/P&gt;
&lt;P&gt;Paper 8&amp;nbsp;&amp;nbsp; Warren RE, Strachen MWJ, Wild S, McKnight JA Introducing estimated glomerular filtration rate (eGFR) into clinical practice: implications for the use of metformin&amp;nbsp; Diabetic Medicine 24; 494-497&lt;BR&gt;Current guidelines suggest stopping metformin if creatinine rises above 150. In this paper the authors looked at a database of nearly 20000 Scottish people with type 2 diabetes and suggest that an eGFR cut off for metformin of 36 would allow a similar number to continue as at present.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Diabetes Prevention&lt;/P&gt;
&lt;P&gt;Paper 9 Alberti KGMM, Zimmet M, Shaw J International Diabetes Federation: a consensus on Type 2 diabetes prevention Diabetic Medicine 24; 451-463&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;The IDF consensus&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Non Alcoholic Fatty Liver Disease&lt;/P&gt;
&lt;P&gt;Paper 10&amp;nbsp; Targher G, Bertolini L, Padovani R et al Prevalence of Nonalcoholic Fatty liver disease (NAFLD) and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30; 1212-1218&lt;BR&gt;Screened 2839 people with type 2 diabetes attending Italian diabetes OPD for fatty liver using ultrasound. The unadjusted prevalence was 69.5%. Those with NAFLD compared with those without, had higher age and sex adjusted prevalence’s of&amp;nbsp; coronary (26.6% v 18.3%) cerebrovascular ( 20 v 13.3%) and peripheral (15.4% v 10%) vascular disease.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Type 2 DM in Children in UK&lt;/P&gt;
&lt;P&gt;Paper 11 Haines L, Wan KC, Lynn R et al Rising incidence of type 2 diabetes in children in UK Diabetes Care 30; 1097-1101&lt;BR&gt;From monthly reports of British Paediatric Surveillance Unit from 2665 consultant paediatricians in UK and republic of Ireland for year from 1 Oct 2004.&amp;nbsp; 168 were non type 1, 67 were type 2 (40%) MODY were 17 (10%) Secondary diabetes were 37 (22%) 13 were part of a recognised syndrome (8%) and 34 (20%) were unclassified.&lt;BR&gt;The frequency of type 2 is increasing, and incidence is far higher in ethnic minorities than in whites. Increasing adiposity and family history of type 2 are strong associations.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Telemedicine&lt;/P&gt;
&lt;P&gt;Paper 12&amp;nbsp; Bu D, Pan E, Walker J, et al Benefits of Information Technology –Enabled Diabetes Management&amp;nbsp; Diabetes Care 30: 1137-1142&lt;BR&gt;Computer modelling to project impact of IT enabled disease management on care processes, clinical outcomes and medical costs for people with type 2 DM over age 25 in USA. Estimates of improvements were derived from published literature. The model suggested that over 10 years diabetes registries saved $14.5 billion, Decision support $10.7 billion, payer-cantered technologies $7.1 remote monitoring $326 million, self management $286 million and integrated provider-patient systems saved $16.9 billion.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;BMJ, Lancet,&amp;nbsp; N Eng J Med, Diabetes Care, JAMA, Diabetic Medicine, Primary Care Diabetes, Pract Diab Int, BJDVD, Diabetes and Primary Care&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;June 2007. This series began in 2002 as a bulletin for Warwick Diabetes Care staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>291647</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=291647]]&gt;</url>
    <title>Interesting new diabetes papers : May 2008</title>
    <publicationDate>2008-08-05T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the thirty seventh in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : May 2008&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;MAJOR GUIDELINES&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;TYPE 2 DIABETES&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:stockticker&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;NICE&lt;/SPAN&gt;&lt;/B&gt;&lt;/st1:stockticker&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; Guideline on Type 2&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;Diabetes&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Available from&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;:- &lt;A href="http://www.nice.org.uk/" target="_blank"&gt;&lt;FONT color=#0066cc&gt;www.nice.org.uk&lt;/FONT&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;This guideline is an update an amalgamation of the inherited guidelines from &lt;/SPAN&gt;&lt;st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;NICE&lt;/SPAN&gt;&lt;/st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; in 2002. The foot aspects were updated in the &lt;/SPAN&gt;&lt;st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;NICE&lt;/SPAN&gt;&lt;/st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; diabetes and footcare guideline of 2004 so this one mainly concentrates on glycaemic control, bp and lipid control, kidney and neuropathy. Retinopathy screening is dealt with by the national retinopathy screening advisory committee so this guideline defers to their guidance.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;It is available in the full version of 279 pages, a 19 page quick reference guide with the recommendations given in diagram and algorithm form, an understanding &lt;/SPAN&gt;&lt;st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;NICE&lt;/SPAN&gt;&lt;/st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; guidance form written for patients and a &lt;/SPAN&gt;&lt;st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;NICE&lt;/SPAN&gt;&lt;/st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; version of 44 pages which lists the 131 recommendations.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 1 Home P, Mant J, Diaz J, Turner C for the Guideline development group Management of type 2 diabetes: summary of updated &lt;/SPAN&gt;&lt;st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;NICE&lt;/SPAN&gt;&lt;/st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; guidance&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;BMJ 336: 1306-8&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;This summarises the main recommendations&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;DIABETES &amp;amp; PREGNANCY&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;st1:stockticker&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;NICE&lt;/SPAN&gt;&lt;/B&gt;&lt;/st1:stockticker&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; guideline on diabetes &amp;amp; Pregnancy&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Available from &lt;A href="http://www.nice.org.uk/" target="_blank"&gt;&lt;FONT color=#0066cc&gt;www.nice.org.uk&lt;/FONT&gt;&lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Is available in the different formats as outlined above&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;This is the first &lt;/SPAN&gt;&lt;st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;NICE&lt;/SPAN&gt;&lt;/st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; guideline on diabetes and pregnancy. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 2 Guideline Development Group. Management of diabetes from preconception to the postnatal period.: summary of &lt;/SPAN&gt;&lt;st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;NICE&lt;/SPAN&gt;&lt;/st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; guidance BMJ 336: 714-717&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;RCT’s&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;DIABETES &amp;amp; PREGNANCY&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 3 Rowan JA, Hague WM, Gao W et al for the &lt;/SPAN&gt;&lt;st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;MIG&lt;/SPAN&gt;&lt;/st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; trial investigators&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Metformin versus insulin for the treatment of gestational diabetes N Engl J Med 358: 2003-2015&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Summary&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; &lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;751 women with gestational diabetes at 20-33 weeks were randomly assigned to open treatment with metformin (with supplemental insulin if required) or insulin. The primary outcome was a composite of neonatal hypoglycaemia, respiratory distress, need for phototherapy, birth trauma, 5 min Apgar score less than 7, or prematurity.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Of 363 women assigned to metformin 92.6% continued to receive metformin until delivery and 46.3% received supplemental insulin. The rate of the composite primary outcome was 32% in the metformin and 32.2% in the insulin only group. There were no serious adverse events associated with the use of metformin.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;The authors conclude that metformin alone or with supplemental insulin is not associated with increased perinatal complications as compared to insulin. The women preferred metformin to insulin treatment.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Roger Gadsby’s comments&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;This landmark paper opens the way for metformin to be used as a treatment for GDM.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;The &lt;/SPAN&gt;&lt;st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;NICE&lt;/SPAN&gt;&lt;/st1:stockticker&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; pregnancy and diabetes guideline (see above) recommends this. The summary of product characteristics for metformin still says not to be used in pregnancy. &lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 4 The HAPO research study group. Hyperglycaemia and Adverse Pregnancy Outcomes &lt;/SPAN&gt;&lt;st1:place&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;N Engl&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; J Med 358: 1991-2002&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Summary&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;In this observational study 25,505 pregnant women at 15 centres in 9 countries underwent a 75gm oral GTT at 24-32 weeks. Data remained blinded if the fasting was less than 5.8 and the 2 hr less than 11.1. Data on a variety of birth and perinatal outcomes was collected. For the 23316 participants with blinded data calculated adjusted odds ratios were determined for adverse pregnancy outcomes associated with an increase of fpg of 1 standard deviation =0.4mmoles/l, an increase in the 1 or 2 hr plasma glucose of 1 SD = 1.7mmoles/l. The results indicate strong continuous associations of maternal glucose levels below those diagnostic of diabetes with increased birth weight and increased cord-blood serum c peptide levels&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Roger Gadsby’s comments&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;The implication of this paper is that diagnostic thresholds for GDM will need to be lowered. The problem is that adverse outcomes seem to be continuous and so any lower cut-off will have to be “ plucked out of the air”. An international conference is being held in summer 2008 to address this and try to reach a consensus&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;DIABETES IN SOUTH ASIANS&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 5 Bellamy S, O’Hare JP, Raymond NT et al for the UKADS study group Enhanced diabetes care to patients of south asian ethnic origin (The UKADS Study): a cluster randomised controlled trial Lancet 371: 1769-1775&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 6 Chowdhury TA, Hitman G Diabetes care for south Asians: a special case (editorial) Lancet 371: 1728-1730&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Summary&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;21 inner city practices in &lt;/SPAN&gt;&lt;st1:City&gt;&lt;st1:place&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Coventry&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:City&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; and &lt;/SPAN&gt;&lt;st1:City&gt;&lt;st1:place&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Birmingham&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:City&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; were randomised to the intervention (9 practices n=868) and control 12 practices n=618. All adults of south asian origin with type 2 diabetes were eligible. The intervention was enhanced care including more time with practice nurse and support from a link worker and DSN. Control was standard care. The trial over 2 years showed small benefits in diastolic bp and mean arterial pressure in the intervention group, but none in total cholesterol, systolic bp or HBA1c.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;There were decreases across all the populations (control and intervention) in systolic and diastolic bp and cholesterol with a small but non significant increase in HBA1c. Economic analysis showed that the nurse led intervention was not cost effective at £28,933 per QUALY gained&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Roger Gadsby’s comments&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;The editorial suggested that the failure of the intervention could have been due to the failure to include structured patient education or be due to the enhanced achievements in control across both groups from QoF or it may not have addressed some of the cultural barriers. The study emphasises the difficulty in improving HBA1c in this population&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;OTHER TYPES OF STUDY&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 7 Harjutsalo V, Sjoberg L, Tuomilehto J Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study Lancet 371 :1777-1782&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 8 Myers M, Zimmet P Halting the accelerating epidemic of type 1 diabetes (editorial) Lancet 371: 1730-31&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Summary&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;st1:country-region&gt;&lt;st1:place&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Finland&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:country-region&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; has the highest incidence of type 1 diabetes worldwide reaching 40 per 100000 people in the 1990’s. In this paper data from the national registry show that the incidence of type 1 diabetes in Finnish children is rising faster than before. The average age standardised incidence in 2005 was 64.2 per 100000 per year.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;The editorial states that the case for an environmental contribution to the cause of type 1 diabetes is compelling, but we don’t know what it is. The editorial states that Finnish children have a lot of root vegetables, 16% receive them as their first solid food, and questions whether toxins from Streptomyces might be involved&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;SHORT REPORTS&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Nurse led clinics in &lt;/SPAN&gt;&lt;/B&gt;&lt;st1:place&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Africa&lt;/SPAN&gt;&lt;/B&gt;&lt;/st1:place&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 8 Gill GV, Price C, Shandu D et al An effective system of nurse-led clinics in rural Africa Diabetic Medicine 25: 606-611 Nurse led protocol and education for clinics in Kwazulu Natal in &lt;/SPAN&gt;&lt;st1:country-region&gt;&lt;st1:place&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;South Africa&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:country-region&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;, showing good results following up 284 enrolled patients for 18 months.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Diabetes and RTA’s &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 9 Lonnen KF, Powell RJ, &lt;/SPAN&gt;&lt;st1:Street&gt;&lt;st1:address&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Taylor D et al Road&lt;/SPAN&gt;&lt;/st1:address&gt;&lt;/st1:Street&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; Traffic Accidents and Diabetes : Insulin does not determine risk Diabetic Medicine 25:578-584 Historical cohort combined information from Devon &amp;amp; Cornwall police database on RTA’s with retinal screening database. Accident rates were compared in the people with diabetes and compared to rates in non diabetic populations. The estimated overall accident rate was 1469 per 100000 in non diabetics and 856 in diabetics. Stratifying for age within the insulin treated group there was no significant difference in the rate compared to non diabetics&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Biochemistry of &lt;/SPAN&gt;&lt;/B&gt;&lt;st1:stockticker&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;CVD&lt;/SPAN&gt;&lt;/B&gt;&lt;/st1:stockticker&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt; risk &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 10 Mazzone T, Chait A, Plutzky J Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;Lancet 371: 1800-1809 Excellent biochemical/pathopysiological review of the subject&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Measuring Cholesterol &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;Paper 11 Glasziou P, Irwig L, Heritier S et al Monitoring Cholesterol levels: measurement error or true change Ann Int Med 148:656-661Concludes that the signal of a small increase in cholesterol value is difficult to detect against the background of a short term variability of 7%, so that in annual checks of adherent patients, many apparent increases in cholesterol may be false positive.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Journals reviewed: &lt;/STRONG&gt;N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetic Medicine, Pract Diab Int&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; published in August 2008. This series began in 2002 as a bulletin for Diabetes Care Staff.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public.&amp;nbsp; Word and webpage versions available.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/SPAN&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>112620</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=112620]]&gt;</url>
    <title>Interesting new diabetes papers : Nov 2005</title>
    <publicationDate>2006-01-03T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2005]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the tenth in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Nov 2005&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;USING FIBRATE THERAPY IN PEOPLE WITH DIABETES&lt;/P&gt;
&lt;P&gt;Paper 1&lt;BR&gt;The Field Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366; 1849-61&lt;BR&gt;Paper 2&lt;BR&gt;Colhoun H&amp;nbsp; After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes? Lancet 366; 1829-30&lt;BR&gt;Summary &lt;BR&gt;Multinational prospective randomised controlled trial in&amp;nbsp; 9795 patients with type 2 diabetes, aged 50-75 years who were not taking statin therapy at study entry. 2131 had previous CVD 7664 had none. They were randomised to placebo or fenofibrate 200mgs daily. The primary outcome was coronary events, coronary heart disease death and non fatal myocardial infarction, and prespecified subgroup analysis was for total cardiovascular events.&lt;BR&gt;During the study 17% of placebo and 8% of fenofibrate group began statin therapy.&lt;BR&gt;288 on placebo and 256 on fenofibrate had a coronary event, a non significant relative risk reduction of 11%. Total cardiovascular events were significantly reduced from 13.9% in placebo arm to 12.5% in the fenofibrate arm.&lt;BR&gt;The auuthors interpretation of the results is that fenofibrate did not reduce the risk of the primary outcome. It did reduce total cardiovasdcular events, mainly due to fewer non-fatal myocardial infarctions and revbascularisations. The higher rate of starting statin therapy in the placebo group might have masked a moderately larger treatment benefit.&lt;BR&gt;The editorial commentary concludes that the results from this well executed trial do not warrant a recommendation for increased fenofibrate use in patients with diabetes, nor do they provide convincing evidence for the benefit of fenofibrate therapy in patients already at target serum LDL cholesterol.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This was a well executed placebo controlled, study with a large number of subjects. It does not show a significant benefit of fenofibrate. A number of studies published since FIELD began recruiting have shown the benefit of statin therapy which has become a standard CHD prevention therapy for both primary and secondary prevention in type 2 diabetes. The important question is whether the addition of fibrates to statins gives added CHD benefit. The answer to this question should be given by the ACCORD trial, but this is not due to report till 2010.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;LIFESTYLE EDUCATION TO PREVENT TYPE 2 DIABETES&lt;/P&gt;
&lt;P&gt;Paper 3&lt;BR&gt;Yamoka K, Tango T Efficacy of Lifestyle Education tp Prevent type 2 Diiabetes Diabetes Care 28; 2780-86&lt;BR&gt;Summary&lt;BR&gt;This is a meta-analysis of&amp;nbsp; papers of lifestyle education for preventing type 2 diabetes in individuals at high risk (IGT or IFG) 8 studies met strict inclusion criteria for 2hr glucose ,measurements and 5 for incidence of diabetes. In the meta-analysis lifestyle education reduced 2hr ogtt glucoise by 0.84mmoles/l compared with controls. The I year incidence of diabetes was reduced by around 50% compared with controls.&lt;BR&gt;They conclude that lifestyle is effective at preventing diabetes.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;Two high quality RCT’s already showed this, but the meta-analysis of those 2 plus 6 others adds to the confidence in the conclusion&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;DIABETIC FOOT PROBLEMS&lt;/P&gt;
&lt;P&gt;The majority of the Lancet edition 12-18th Nov was dedicated to the diabetic foot, in recognition of&amp;nbsp; the focus of world diabetes day 14 Nov which is “putting feet first”&lt;/P&gt;
&lt;P&gt;3 major review articles are listed below plus 3 editorials&lt;/P&gt;
&lt;P&gt;Paper 4&lt;BR&gt;Boulton AJM, Vileikyte L, Ragnarson-Tennvall, Apelqvist J&amp;nbsp; The global burden of diabetic foot disease Lancet 366; 1719-1724&lt;BR&gt;Expert review on epidimeology and health economics&lt;BR&gt;Paper 5&lt;BR&gt;Falanga V&amp;nbsp; Wound healing and its impairment&amp;nbsp; in the diabetic foot Lancet 366; 1736-43&lt;BR&gt;Expert review of patho-physiology of wound healing in diabetes&lt;BR&gt;Paper 6&lt;BR&gt;Cavanagh PR, Lipsky BA, Bradbury AW, Botek G Treatment of diabetic foot ulcers Lancet 366; 1725-1735&lt;BR&gt;Expert review covering classification, ischaemia, infection, off loading and surgery&lt;BR&gt;EDITORIALS &lt;BR&gt;Urbancic-Rovan V&amp;nbsp; Causes of Diabetic foot lesions Lancet 366; 1675-76&lt;BR&gt;Reiber G E, Raugi GJ Preventing foot ulcers and amputations in diabetes Lancet 366; 1676-77&lt;BR&gt;Van Houtum WH&amp;nbsp; Barriers to the Delivery of diabetic foot care&amp;nbsp; Lancet 366; 1678-9&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;There is a wealth of footcare information in this issue&lt;/P&gt;
&lt;P&gt;SHORT REPORTS&lt;/P&gt;
&lt;P&gt;Paper 7&lt;BR&gt;Diabetes Screening and Anxiety&lt;BR&gt;Skinner TC, Davies MJ, Farooqi AM, Jarvis J, Tringham JR, Khunti K Diabetes screening anxiety and beliefs&amp;nbsp; Diabetic Medicine 22; 1497-1502&lt;BR&gt;Data from Leicester screening research replicating results from previous studies showing that screening for diabetes does not induce significant anxiety&lt;/P&gt;
&lt;P&gt;Paper 8 &lt;BR&gt;Metabolic Syndrome IDF definition in the USA&lt;BR&gt;Ford E Prevalence of the Metabolic Syndrome defined by the International Diabnetes Federation (IDF) among adults in the USA&lt;BR&gt;Using the IDF definition leads to a higher prevalence in the USA using NHNES data &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed this month:&lt;/STRONG&gt;&amp;nbsp; Diabetes Care, Diabetic Medicine, BMJ, NEJM, Lancet,&amp;nbsp; Pract Diab Int.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;December 2005. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this series is to inform readers of interesting&amp;nbsp; new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>223824</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=223824]]&gt;</url>
    <title>Interesting new diabetes papers : Nov 2006</title>
    <publicationDate>2006-12-19T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2006,DIABETES,INTERESTING NEW ARTICLES,RESEARCH]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the twenty second in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Nov 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;SYSTEMATIC REVIEWS &amp;amp; META-ANALYSIS&lt;/P&gt;
&lt;P&gt;Paper 1 Ali S, Stone MA, Peters JL, Davies MJ, Khunti K&amp;nbsp; The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis&lt;BR&gt;Diabetic Medicine 23;1165-1173 &lt;BR&gt;Summary:&lt;BR&gt;A review of 10 papers including 51331 people with type 2 diabetes. The prevalence of depression was significantly higher in people with type 2 diabetes than those without 17.6% v 9.8%. However in most studies patients with diabetes differed from those without on variables known to be associated with an increased risk of depression. Failure to report potential confounders prevented a more rigorous meta-analysis of risk. There is a need for well-controlled and better-reported studies to inform the development of effective treatments for depression in these patients&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;There are increased rates of depression in people with type 2 diabetes, but better research is still needed on the reasons for this and treatment&lt;/P&gt;
&lt;P&gt;Paper 2 Snowling NJ, Hopkins WG&amp;nbsp; Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients. Diabetes Care 29; 2518-2527&lt;BR&gt;Summary:&lt;BR&gt;A review of 27 trials including 1003 people with type 2 diabetes age 55 years + or – 7years for 5 -104 weeks. &lt;BR&gt;Differences among the effects of aerobic, resistance and combined training on HBA1c were trivial for training lasting 12 weeks. The overall effect was a small beneficial reduction in HBA1c of 0.8% + or – 0.3%. There were generally small to moderate benefits for other measures of glucose control.. For other risk factors there were either small benefits or effects were trivial and unclear, although combined training was generally superior to aerobic and resistance training.&lt;BR&gt;The review concludes that all forms of exercise training produce small benefits in HBA1c the main measure of glucose control. The effects are similar to those of dietary, drug and insulin treatments. The clinical importance of combining these treatments needs further research&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;All forms of exercise are beneficial in lowering HBA1c. This is a useful review of the evidence&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;RANDOMISED CONTROLLED TRIALS&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Triple therapy with insulin glargine or rosiglitazone&lt;BR&gt;Paper 3 Triplitt C, Glass L, Miyazaki Y et al Comparison of glargine Insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulphonylurea&amp;nbsp; Diabetes Care 29; 2371-2377&lt;BR&gt;Summary:&lt;BR&gt;Small RCT n=10, of insulin glargine uptitration versus 8mgs daily of rosiglitazone. Triple therapy with insulin glargine or rosiglitazone similarly reduced HBA1c, primarily by suppressing basal endogenous glucose production. (EGP) glargine did it by increasing plasma insulin levels, rosiglitazone&amp;nbsp; decreased basal hepatic glucose production by improving hepatic insulin sensitivity &lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;Both triple therapies drop HBA1c by same amount through different actions&lt;/P&gt;
&lt;P&gt;OTHER TYPES OF STUDY&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Diabetes in older people in USA&lt;BR&gt;Paper 4 Selvin E, Coresh J, Brancati FL&amp;nbsp; The burden and treatment of Diabetes in Elderly Individuals in USA Diabetes Care 29; 2415-2419&lt;BR&gt;Summary:&lt;BR&gt;Data from 2809 individuals from National Health and Nutrition Examination Survey (NHANES) 1999-2002. Among adults at or over 65 the prevalence of diagnosed diabetes was 15.3%. Diabetes was classified as middle age onset if diagnosed at 40-64 years and old age onset if at or above 65 years.&amp;nbsp; There were high rates of poor glycaemic control in all populations. Elderly individuals with middle age onset had worse glycaemic control than elderly onset. They conclude that future studies of diabetes in elderly individuals may need to consider stratification based on age at diagnosis&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments &lt;BR&gt;Interesting ideas&lt;/P&gt;
&lt;P&gt;Preventing type 2 Diabetes, - follow up data from Finish Diabetes Prevention Study&lt;BR&gt;Paper 5&amp;nbsp; Lindstom J, Ilanne-Parikka P, Peltonen M et al&amp;nbsp; Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow up of the Finnish Diabetes Prevention Study.&amp;nbsp; Lancet 368;1673-1679&lt;BR&gt;Follow up of those who hadn’t developed diabetes at the end of the 4 year intervention period of the original Finnish Diabetes Prevention Study. They were followed up for a median of a further 3 years. There was a incidence of diabetes was 4.3 and 7.4 per 100 person years in what were the intervention and control groups, a 43% reduction in the relative risk. Beneficial lifestyle changes achieved by participants in the intervention group were maintained after discontinuation of the intervention.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;Lifestyle change works to prevent diabetes and the beneficial behaviours that were learnt persist&lt;/P&gt;
&lt;P&gt;Paper 6&lt;BR&gt;Scheen AJ, Finer N, Hollander P et al Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368; 1660-1672&lt;BR&gt;Summary:&lt;BR&gt;1047 overweight or obese people with type 2 diabetes on metformin or sulphonylurea monotherapy were given diet and exercise advice then randomised to placebo, or rimonobant 5mgs daily or 20mgs daily. 692 completed 1 year follow up, with equal numbers in each group. Wt loss was greater in both rimonobant groups than placebo, (placebo – 1.4kg, rim 5 -2.3 Kg, rim 20mg -5.3Kg) Adverse events that lead to discontinuation were slightly greater in rim 20 group, mainly due to depressed mood disorders, nausea and dizziness.&lt;BR&gt;They conclude that rimonobant 20mgs daily with diet and exercise can produce clinically significant reductions in weight and also improve HBA1c (lower by 0.7%) and a number of cardiovascular and metabolic risk factors .&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;November 2008.&amp;nbsp; Please Note: Marketing authorisation has been suspended of Acompila (rimonabant) as the European Medicines Agency has concluded that the benefits of Acompila no longer outweigh its risks of psychiatric disorders.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments &lt;BR&gt;Interesting data on rimonabant in people with diabetes.&lt;/P&gt;
&lt;P&gt;BRIEF REPORTS&lt;/P&gt;
&lt;P&gt;The Lancet on 11 November was a themed issue for World Diabetes Day. It contained a number of&amp;nbsp; papers (2 of which are listed above) and a number of editorials. These included:&lt;BR&gt;Lefebvre P, Silink M&amp;nbsp; Diabetes Fights for Recognition Lancet 368; 1625-6&lt;BR&gt;The background to proposed UN resolution on diabetes&lt;BR&gt;Gale E Dying of Diabetes Lancet 368; 1626-8&lt;BR&gt;The commonest cause of death in a child with diabetes on a global perspective is lack of access to insulin. This discusses possible answers to this dilemma&lt;BR&gt;Mbanya JC, Kenge AP, Assah F Diabetes Care in Africa Lancet 368; 1628-9&lt;BR&gt;Discusses the problems in Africa&lt;BR&gt;Rigby N, Baillie K&amp;nbsp; Challenging the future: the Global Prevention Alliance Lancet 368:1629-30 &lt;BR&gt;Explains about the Global Alliance for the Prevention of obesity and related chronic diseases&lt;BR&gt;Avendano M, Mackenbach JP&amp;nbsp; Blood glucose levels: facing a global crisis Lancet 368; 1631-2&lt;BR&gt;This comments on a paper in the same issue entitled Global and regional mortality from ischaemic heart disease and stroke attributable to higher than optimum blood glucose concentration : comparative risk assessment by Danaei G, Lawes CMM, Hoorn SV et al Lancet 368; 1651-9 . This computes that higher than optimum blood glucose is a leading cause of cardiovascular mortality in most world regions.&lt;BR&gt;Cleland SJ Sattar N Does rimonabant pull its weight for type 2 diabetes Lancet 368; 1632-34.&lt;BR&gt;Comments on paper 6, saying longer term studies with hard CHD outcomes, cost effectiveness studies and further research is needed&lt;BR&gt;Goldberg R Lifestyle interventions to prevent diabetes Lancet 368;1634-6&lt;BR&gt;Comments on paper 5 above&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt;&amp;nbsp; BMJ, Lancet, JAMA, N Eng J Med, Diabetes Care, Diabetic Medicine, Pract Diab Int, BJDVD, Diabetes and Primary Care&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in December 2006. This series began in 2002 as a bulletin for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>276637</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=276637]]&gt;</url>
    <title>Interesting new diabetes papers : Oct &amp; Nov 2007</title>
    <publicationDate>2007-12-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2007]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the thirty third in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Oct &amp; Nov 2007&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;SYSTEMATIC REVIEWS &amp;amp; META-ANALYSIS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Glitazones and CHD Risk&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;Paper 1 Diamond G, Bax L, Kaul Uncertain effects of Rosiglitazone on the risk for myocardial infarction and cardiovascular death Ann Int Med 147: 578-581&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;The original Nissen meta-analysis which began this controversy (see Bulletin May 2007) had a number of academic limitations. These are spelt out clearly in this paper. These authors sought to overcome the limitations by re-analysing the data set of the 42 trials used in the Nissen paper using a variety of statistical techniques. They conclude that the risk of myocardial infarction and death from cardiovascular disease for diabetic patients taking rosiglitazone is uncertain. Neither increased risk or decreased risk is established.&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments&lt;BR&gt;The uncertainty continues! &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Efficacy and safety of Rimonabant&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;November 2008.&amp;nbsp; Please Note: Marketing authorisation has been suspended of Acompila (rimonabant) as the European Medicines Agency has concluded that the benefits of Acompila no longer outweigh its risks of psychiatric disorders.&lt;/EM&gt;&lt;BR&gt;&lt;BR&gt;Paper 2 Christensen R, Kristensen PK, Bartels EM et al Efficacy and safety of the weight loss drug rimonabant: a meta-analysis of randomised trials Lancet 370: 1706-1713&lt;BR&gt;Paper 3 Mitchell PB, Morris MJ&amp;nbsp; Depression and anxiety with rimonabant (editorial) Lancet 370: 1671-2&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;A meta-analysis of&amp;nbsp; 4 RCT’s&amp;nbsp; (including 4105 participants) that compared rimonabant 20mgs daily with placebo particularly looking at adverse events.&lt;BR&gt;Those on rimonabant had a 4.7Kg weight reduction at 1 year compared to placebo. It caused more adverse events (OR 1.4 Number needed to harm (nnh)&amp;nbsp; =25) and more serious adverse events (OR 1.4 nnh =59) These were&amp;nbsp; depressed mood (OR 2.5 nnh= 49). Anxiety caused more people to discontinue treatment (OR 3.00 nnh =166)&lt;BR&gt;They conclude that rimonabant 20mgs daily increases the risk of psychiatric adverse events, despite depressed mood being an exclusion criteria in these 4 trials.&lt;BR&gt;The Federal Drugs Administration (FDA) in the USA have also released a report raising major concerns about rimonabant and serious psychiatric problems including suicide.&lt;BR&gt;The editorial considers these findings and relates them to the physiological actions of the endo-cannabinoid system. &lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;There are real concerns about the risk of psychiatric adverse events in people taking rimonabant&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;RANDOMIZED CONTROLLED TRIALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Insulin initiation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Paper 4 Addition of Biphasic, Prandial or Basal Insulin to oral therapy in type 2 diabetes Lancet 2007 370:1716-1730&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;This is a multicentre, controlled, open label study in which 708 people with type 2 diabetes with suboptimal glycaemic control (HBa1c 7-10%) on maximally tolerated doses of metformin and sulphonylurea were randomly assigned to receive bd mixed insulin (novomix), prandial insulin three times a day (novorapid) or basal insulin once (or twice in 34%) daily (detemir). Outcome measure at one year was HBA1c, hypoglycaemia and wt gain.&lt;BR&gt;At 1 year HBA1c was 7.3% in prandial and bd mixed group and 7.6% in basal group.. There were more hypos and weight gain in prandial and bd mixed group compared with the basal. The prandial had more wt gain and hypos than the bd mixed. &lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;This is an interesting study and the first to compare 3 different methods of insulin initiation in people with type 2 diabetes sub optimally controlled on 2 oral agents. It was sponsored by NovoNordisk and used only their insulins. The conclusion reached by most commentators is that the results suggest that&amp;nbsp; basal is the best regime as it has the lowest wt gain and level of hypoglycaemia with only a slightly inferior HBA1c drop. However twice daily basal was required by 34%. Some commentators suggest that using once daily insulin glargine as the basal insulin might result in everyone being able to manage on one injection. The trial is being continued for a further 2 years.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Fenofibrate for Diabetic Retinopathy&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Paper 5&amp;nbsp; Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD) study : a randomised controlled trial&amp;nbsp; Keech AC, Summanen PA, O’Day J et al for the FIELD study investigators&lt;BR&gt;Lancet 370: 1687-1697&lt;BR&gt;&lt;BR&gt;Paper 6 Simo R, Hernandez C Fenofibrate for diabetic retinopathy&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;The FIELD trial was an RCT of 9795 people with type 2 diabetes randomised to fenofibrate 200mgs daily or placebo. The primary endpoint related to CVD protection was not achieved. Treatment with laser therapy was asked about at each clinic visit and in a sub study of 1012 people retinal photographs were obtained . In the fenofibrate group laser for macular oedema was reduced by 31% and for proliferative retinopathy by 30%. In the sub study fenofibrate reduced the risk of first laser treatment by more than 70%. However numbers were small with only 28 patients in the placebo group and 5 in the fenofibrate needing treatment.&lt;BR&gt;The conclusion made from the study is that fenofibrate reduces the need for laser treatment although the mechanism of action does not seem to be related to plasma concentrations of lipids.&lt;BR&gt;The editorial points out the limitations of the study, including the fact that retinal photographs were not taken routinely as part of the protocol and that the criteria for giving laser at the different centres was not defined. It also says that the mechanism by which fenofibrate exerts its reported benefits is far from being elucidated. It suggests that further studies are needed before fenofibrate can be launched as a new tool in the management of diabetic retinopathy&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;SHORT REPORTS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Paper 7 Hirst United for Diabetes: the route to the UN resolution Diabetic Medicine 24:1060-1&lt;/P&gt;
&lt;P&gt;On 16th Dec 2006 UN resolution 61/1225 to make diabetes a global priority was passed. This is the first UN resolution on any specific disease. The article outlines the background&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;BR&gt;Journals reviewed: &lt;/STRONG&gt;N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Diabetic Medicine, Pract Diab Int&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;December 2007. This series began in 2002 as a bulletin for Warwick Diabetes Care staff.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions available.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>106198</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=106198]]&gt;</url>
    <title>Interesting new diabetes papers : Oct 2005</title>
    <publicationDate>2005-11-18T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2005]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the ninth in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Oct 2005&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;CVD PROTECTION WITH PIOGLITAZONE&lt;/P&gt;
&lt;P&gt;Paper 1&lt;BR&gt;Dormandy JA, Charbonnel B, Eckland A et al on the behalf of the PROactive investigators&amp;nbsp; Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial in macroVasular Events): a randomised controlled trial. Lancet 366; 1279-1289&lt;BR&gt;Paper 2&lt;BR&gt;Yki-Jarvinen H&amp;nbsp; The PROactive study:some answers, many questions (editorial) Lancet 366;1241-1242&lt;BR&gt;Summary &lt;BR&gt;Prospective randomised controlled trial in 5238 patients with type 2 diabetes who had evidence of macrovasular disease. People were given poiglitazone titrated from 15 to 45mgs or placebo in addition to all other treatments. The primary endpoint was a composite including endovascular or surgical intervention, and the predefined secondary endpoint was death plus non fatal stroke or myocardial infarction.&lt;BR&gt;Average time of observation was 34.5 months. There were 514 in the pioglitazone group and 572 in the placebo group who had at least one event in the primary composite endpoint. This reduction in the primary endpoint of 9% did not reach statistical significance. The reduction of 16% in the secondary endpoint did reach statistical significance. The safety and tolerability of pioglitazone was good. 6% of the pio group and 4% of the placebo group were admitted to hospital with heart failure, mortality rates for heart failure did not differ between the groups. There was a 47% reduction in the numbers beginning to use insulin in the pio group.&lt;BR&gt;The editorial points out that oedema and heart failure were greater in the pio group than placebo. The increase in heart failure reporting was at least partly caused by a diagnostic bias because of increased oedema.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This was a well executed placebo controlled study with a large number of subjects in a high risk population. The hard endpoint of death plus non fatal stoke and myocardial infarction reached statistical significance. I think the data on reduced need to start insulin in the pioglitazone group is also interesting and important. The subjects studied were similar to those seen in UK general practice and the results are therefore generalisable. &lt;BR&gt;The reductions in risk in the active group were perhaps less impressive than had been hoped. More oedema and wt gain occurred in the pio group, as did heart failure although some of this may have just been oedema.&lt;BR&gt;However I do feel that this study does give hard endpoint data to promote the use of pioglitazone,&amp;nbsp; as the first addition to metformin montherapy, instead of a using a sulphonylurea, which is known not to lower cardiovascular risk, in the people I look after who have type 2 diabetes.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;METFORMIN &amp;amp; HEART FAILURE&lt;/P&gt;
&lt;P&gt;Paper 3&lt;BR&gt;Eurich DT, Majumdar SR, McAlister FA et al&amp;nbsp; Improved clinical outcomes associated with metformin in patients with diabetes and heart failure Diabetes Care 28; 2345-2351&lt;BR&gt;Paper 4&lt;BR&gt;Inzucchi SE Metformin and heart failure (editorial) Diabetes Care 288; 2585-2587&lt;BR&gt;Summary&lt;BR&gt;In the USA, because of the perceived increased risk of lactic acidosis in people with heart failure, package inserts for metformin assert that it is absolutely contraindicated in heart failure. Paper 3 is a large database survey of patients in Canada who were on oral agents and who had a heart failure diagnosis. They found that metformin alone or in combination, in subjects with heart failure was associated with lower morbidity and mortality as compared with sulphonylurea monotherapy.&lt;BR&gt;The editorial suggests that in heart failure metformin should be considered innocent until proven guilty&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;In the UK we say that metformin can be used in people with stable heart failure but not in acute failure. These papers support that position&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;FOOT ULCERATION&lt;/P&gt;
&lt;P&gt;Paper 5&lt;BR&gt;Pound N, Chipchase S, Treece K et al&amp;nbsp; Ulcer-free survival following management of foot ulcers in diabetes Diabetic Medicine 22;1306-1309&lt;BR&gt;Paper 6&lt;BR&gt;Edmonds M, Foster A Ulcer-free survival in diabetic foot patients Diabetic Medicine 22; 1293-1294&lt;BR&gt;Summary&lt;BR&gt;This paper and editorial, develop and comment on the concept of ulcer-free survival of patients attending a diabetic foot clinic. It is a new and interesting composite outcome measure that depends on 3 ideas. Firstly to get ulcers healed as quickly as possible, secondly to prevent recurrence and thirdly to get good medical care to the patients so as to treat all of their co-morbidities such as coronary and cerebro-vascular disease, and thus preserve life. It is a meaningful outcome measure for the patient and the foot clinic, and could be used to compare performance between different clinics.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This is an interesting new outcome measure for diabetic foot disease&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;SHORT REPORTS&lt;/P&gt;
&lt;P&gt;Paper 7 - Telemedicine&lt;BR&gt;Farmer A, Gibson OJ, Tarassenko L, Neil A A systematic review of telemedicine interventions to support blood glucose self monitoring in diabetes Diabetic Medicine 22; 1372-1378&lt;BR&gt;32 papers identified, pooled results from 9 RCT’s did not provide evidence that the interventions were effective in reducing HBA1c&lt;/P&gt;
&lt;P&gt;Paper 8 – Doing systematic reviews&lt;BR&gt;Boyle PL, Bain L, Waugh NR Sources of evidence for systematic reviews of interventions in diabetes. Diabetic Medicine 22;1386-1393&lt;BR&gt;A search of only the Medline database is insufficient for systematic reviews in diabetes, because in about 34% of reviews the missed trials could affect the results of the meta-analysis. It is recommended that CENTRAL on the Cochran library is also searched.&lt;/P&gt;
&lt;P&gt;Paper 9 – Neuropathy &amp;amp; Depression&lt;BR&gt;Vileikyte L, Leventhal H Gonzalez et al Diabetic Peripheral Neuropathy and Depressive Symptoms Diabetes Care 28; 2378-2383&lt;BR&gt;Measured depression using HADS scale in 494 patients with neuropathy. Findings establish a relationship between neuropathy and depressive symptoms.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed this month:&lt;/STRONG&gt;&amp;nbsp; Diabetes Care , Diabetic Medicine, BMJ, NEJM, Lancet,&amp;nbsp; Pract Diab Int&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;November 2005. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this series is to inform readers of interesting&amp;nbsp; new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>212730</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=212730]]&gt;</url>
    <title>Interesting new diabetes papers : Oct 2006</title>
    <publicationDate>2006-11-30T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2006,DIABETES,INTERESTING NEW ARTICLES,RESEARCH]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the twenty first in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Oct 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;RANDOMISED CONTROLLED TRIALS&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;PREVENTING DIABETES&lt;/P&gt;
&lt;P&gt;Paper 1&amp;nbsp; The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone medication ) Trial Investigators&amp;nbsp; Effects of rosiglitazone on the frequency of diabetes in patients with impasired glucose tolerance or impaired fasting glucose: a randomised controlled trial Lancet 368; 1096-1105&lt;BR&gt;Paper 2&amp;nbsp; The DREAM trial investigators Effect of Ramipril on the incidence of diabetes N Eng J Med 355; 1551-1562&lt;BR&gt;Paper 3&amp;nbsp; Tuomilehto J, Wareham N&amp;nbsp; Glucose lowering and diabetes prevention: are they the same (editorial) Lancet 368; 1218-1219&lt;BR&gt;Summary:&lt;BR&gt;The DREAM study is a double blind, randomised clinical trial with a 2 by 2 factorial design. 5269 subjects with IGT but no cardiovascular disease were given ramipril up to 15mgs/day or placebo or rosiglitazone or placebo and were followed for a median of 3 years. Those given rosiglitazone reduced their development of diabetes by 60%, those given ramipril were no different to placebo. The rosiglitazone group had more weight gain and a 7 times more heart failure. &lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;Rosiglitazone impressively reduces transfer to diabetes. It is not licensed for this indication (neither is metformin) and in view of the adverse events of weight gain and cardiac failure it may need to seek such a licence. Weight loss and exercise remain therefore the main treatments for people with prediabetes (IFG &amp;amp; IGT) to prevent transfer to diabetes&lt;/P&gt;
&lt;P&gt;OTHER TYPES OF STUDY&lt;/P&gt;
&lt;P&gt;Paper 4 Basker V, Venugopal H, Holland MR, Singh BM.&amp;nbsp; Clinical Utility of estimated glomerular filtration rates in predicting renal disease in a district diabetes population Diabetic Medicine 23; 1057-1060&lt;BR&gt;Paper 5 New JP, O’Donoghue DJ, Middleton RJ, et al&amp;nbsp; Time to move from serum creatinine to eGFR (editorial) Diabetic Medicine 23; 1047-1049&lt;BR&gt;Summary:&lt;BR&gt;Paper 4 is a cross sectional study of 4548 patients with diabetes attending the diabetes centre in Wolverhampton. They compared the numbers diagnosed as having significant renal impairment found by using eGFR measurements compared with serum creatinine measurement and microalbuminuria estimation using an albumin:creatinine ratio (ACR). Of those with clinically meaningful renal disease with eGFR below 60 mls/min only 42% and 45% were identified by serum creatinine and ACR individually, and 38% of those with eGFR below 60 would have been missed by using both together.&lt;BR&gt;They conclude that eGFR with ACR, creatinine and blood pressure are all needed to assess renal function in adults with diabetes.&lt;BR&gt;The editorial points out that the relationship between rising serum creatinine and reduction in eGFR is not linear. Some with normal serum creatinine have reduced eGFR. They state that eGFR needs to be measured by the Modified Diet in Renal Disease Formula (MDRD).&amp;nbsp; It is not applicable under age of 18, and it needs to be multiplied by 1.21 in Afro Caribbean subjects. Stages of CKD have been defined as follows:-&lt;BR&gt;CKD stage 1 is Kidney damage with normal or high eGFR at or above 90 &lt;BR&gt;CKD stage 2 is kidney damage with mild reduction in eGFR between 60-89&lt;BR&gt;CKD stage 3 is kidney damage with moderate reduction in eGFR 30-59&lt;BR&gt;CKD stage 4 is kidney damage with severe reduction in eGFR 15-29&lt;BR&gt;CKD stage 5 is kidney failure eGFR below 15&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;eGFR measurements are being introduced and levels of CKD are being&amp;nbsp; assessed in primary care from April 2006 as part of QoF. This editorial and paper shows why.&lt;/P&gt;
&lt;P&gt;BRIEF REPORTS&lt;/P&gt;
&lt;P&gt;Paper 6&amp;nbsp;&amp;nbsp; Thoolen BJ, De Ridder DT, Bensing JM et al Psychological outcomes of patients with screen detected diabetes Diabetes Care c29; 2257-2262&lt;BR&gt;Study of 196 patients. They did not experience much difficulty with their condition in the first few years but early intensive treatment can influence patients psychological outcomes, leading to relatively more anxiety and less self-efficacy. This suggests that intensive treatment confronts patients with their diabetes early.&lt;/P&gt;
&lt;P&gt;Paper 7&amp;nbsp; Schofield CJ, Libby G, Brennan GM et al&amp;nbsp; Mortality and hospitalization in patients asfter amputation. Diabetes Care 29; 2252-2256&lt;BR&gt;Data from Darts/Memo collaborative in Scotland showing that after lower limb amputation patients with diabetes have an increased risk of death compared to non diabetic patients&lt;/P&gt;
&lt;P&gt;Paper 8&amp;nbsp;&amp;nbsp;&amp;nbsp; Iannotti RJ, Nansel TR, Schneider S et al Assessing regimen adherence of adolescents with type 1 diabetes. Diabetes Care 29; 2263-2267&lt;BR&gt;Used 2 measures with 146 people aged 11-18 with type 1. The diabetes self management profile, (DSMP) an interview instrument and the Diabetes Behaviour rating scale (DBRS) a self administered survey. Both measures exhibited good psychometric properties and good criterion validity but varied in terms of respondent and interviewer burden.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt;&amp;nbsp; BMJ, Lancet, JAMA, N Eng J Med, Diabetes Care, Diabetic Medicine, Pract Diab Int, BJDVD, Diabetes and Primary Care&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;November 2006. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp;Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of&amp;nbsp;this series&amp;nbsp;is to inform readers of interesting new papers relevant to diabetes that have appeared in&amp;nbsp;several diabetes and general medical journals in the previous month.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>105005</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=105005]]&gt;</url>
    <title>Interesting new diabetes papers : Sep 2005</title>
    <publicationDate>2005-10-19T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2005]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the eighth in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Sep 2005&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;METABOLIC SYNDROME&lt;/P&gt;
&lt;P&gt;Paper 1&lt;BR&gt;Alberti GM, Zimmet P, Shaw J for the IDF Epidemeiology Task Force Consensus Group&amp;nbsp; The Metabolic Syndrome – a new world-wide definition Lancet 366;1059-1061&lt;BR&gt;Paper 2&lt;BR&gt;Kahn R, Buse J, Ferrannini E, Stern M&amp;nbsp; The Metabolic Syndrome : Time for a critical appraisal&amp;nbsp; Diabetes Care 28; 2289-2304&lt;BR&gt;Summary&lt;BR&gt;There is still a lot of controversy about the metabolic syndrome. There have been at least 2 definitions one from the WHO in 1999 and another from the US National Cholesterol Education Programme&amp;nbsp; Adult treatment panel (ATP 3). Paper 2 is a critical review including 168 references, which asks, is it a syndrome as the cause is unclear, does it serve a useful purpose? and is it labelling (and medicalising) people unnecessarily?&amp;nbsp; Additionally it has been suggested that its recognition has been driven by industry to create new markets.&lt;BR&gt;Paper 1 is an editorial outlining the new IDF definition. They feel that the term metabolic syndrome serves a useful purpose to focus on people in both community and clinical settings who are at high risk of developing CVD and type 2 diabetes. The main treatment for it must focus on lifestyle change, and on individual components of the syndrome if this fails.&lt;BR&gt;The new definition is &lt;BR&gt;An increased waist circumference with ethnicity specific definitions ( for europids men equal to or over 94cms, women equal to&amp;nbsp; or over 80cms, for South Asians men 90, women 80)&lt;BR&gt;Plus any 2 from&lt;BR&gt;(a) Raised Triglycerides (Above 150 mg/dl or 1.7 mmol/l)&lt;BR&gt;Specific treatment for this lipid abnormality&lt;BR&gt;(b) Reduced HDL Cholesterol ( below 40mg/dl&amp;nbsp; (1.03mmol/l in men)&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; ( below 50mg/dl, 1.29mmol/l in women)&lt;BR&gt;Specific treatment for this lipid abnormality&lt;BR&gt;(c) Raised blood pressure equal to or greater than 130/85&lt;BR&gt;Treatment of previously diagnosed hypertension&lt;BR&gt;(d) Raised fasting plasma glucose equal to or greater than 100mg/dl, 5.6mmol/l&lt;BR&gt;Previously diagnosed type 2 diabetes&lt;BR&gt;If above 5.6 ogtt is strongly recommended but is not necessary to define presence of the syndrome&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;I think this new definition is the one likely to gain widespread acceptance and use. The authors stress its not the final word on the subject but that hopefully it will help to identify people at increased risk and through further research will lead to more accurate predictive indices.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;EPIDEMIOLOGY – MORTALITY ATTRIBUTABLE TO DIABETES&lt;/P&gt;
&lt;P&gt;Paper 3 &lt;BR&gt;Roglic G, Unwin N, Bennett P et al The Burden of Mortality from Diabetes : realistic estimates for the year 2000&amp;nbsp; Diabetes Care 28; 2130-2135&lt;BR&gt;Paper 4&lt;BR&gt;Boyko EJ&amp;nbsp; Progress in the Estimation of Mortality due to Diabetes (editorial)&lt;BR&gt;Diabetes Care 28; 2320-2321&lt;BR&gt;Summary&lt;BR&gt;Paper 3 is based on a model of mortality attributable to diabetes based on estimates of age and sex specific diabetes prevalence, relative risk of death from diabetes, all cause mortality rates and population structure. The excess global mortality attributable to diabetes in the year 2000 was estimated to be 2.9million deaths, equivalent to 5.2% of all deaths. Excess mortality attributable to diabetes accounted for 203% of deaths in poorest countries and over 8% of deaths in USA, Canada, &amp;amp; the Middle East. From these estimates diabetes is likely to be the fifth leading cause of death world-wide.&lt;BR&gt;These results are some three times as high as a prior estimate from the WHO in 2002.&lt;BR&gt;The editorial says that previous estimates were based on death certificate data which is very unreliable. Modelling is likely to give more accurate figures&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;Important data showing the significance of diabetes&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;ETHNICITY ISSUES&lt;/P&gt;
&lt;P&gt;Paper 5&lt;BR&gt;Lanting LC, Joung IMA, Mackenbach JP et al&amp;nbsp; Ethnic differences in Mortality, End Stage Complications, and Quality of Care Among Diabetic Patients&amp;nbsp; Diabetes Care 28;2280-2288&lt;BR&gt;Summary&lt;BR&gt;A systematic review of 51 studies, mainly from USA and UK. In general after adjusting for confounders many ethnic differences disappear. Nevertheless blacks and Hispanics in the USA and Asians in the UK have an increased risk of end stage renal failure, and blacks and Hispanics in the USA have an increased risk of retinopathy. In the USA process of care was worse in blacks.&lt;BR&gt;Paper 6&lt;BR&gt;McElduff P, Edwards R, Burns JA, et al&amp;nbsp; Comparison of processes and intermediate outcomes between South Asians and European patients with diabetes in Blackburn, North west England&amp;nbsp; Diabetic Medicine 22;1226-1233&lt;BR&gt;Summary&lt;BR&gt;Longitudinal study of all patients on the diabetes information system from 1995-2001. 2070 Europeans and 820 South Asians were studied. Processes of care were similar in the 2 groups. South Asians had a higher level of HBA1c throughout the study period. South Asians had lower levels of BP and cholesterol in 1995 but differences diminished or were abolished over time.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;Important review paper and interesting data from Blackburn&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;SHORT REPORTS&lt;/P&gt;
&lt;P&gt;Paper 7&lt;BR&gt;Al-Arouj M, Bouguerra R, Buse J et al&amp;nbsp; Recommendations for management of diabetes during Ramadan Diabetes Care 28; 2305-2311&lt;BR&gt;Dr Roger Gadsby’s comments&lt;BR&gt;Comprehensive expert review and recommendations.&lt;/P&gt;
&lt;P&gt;Paper 8&lt;BR&gt;Danne T, Becker RHA, Heise T et al&amp;nbsp; Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 28; 2100-2105&lt;BR&gt;Insulin glulisine a new short acting analogue works and is safe and well tolerated in children and adolescents&lt;BR&gt;Dr Roger Gadsby’s comments&lt;BR&gt;Glulisine now launched in UK&lt;/P&gt;
&lt;P&gt;Paper 9&lt;BR&gt;Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ&amp;nbsp; Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of type 1 diabetes in the UK&amp;nbsp; Diabetic Medicine 22; 1239-1245&lt;BR&gt;Improvements in glycaemic control with pumps led to improvement in QALE owing to reduced incidence of diabetes related complication. Pumps were associated with an incremental cost effectiveness ratio of £25,648 per QALY gained versus injections&lt;/P&gt;
&lt;P&gt;Paper 10&lt;BR&gt;Hauber BA, JohnsonFR, Sauriol L, Lescrauwaet B&amp;nbsp; Risking health to avoid injections Diabetes Care 28; 2243-2245&lt;BR&gt;Questionnaire study (50% response) of Canadians with type 2 diabetes asked about relative importance placed on short term treatment outcomes and frequency of injections. They said that reducing injections to once daily was as important as improving glucose levels from suboptimal to optimal.&lt;BR&gt;Insulin experienced patients place more value on improving glucose control and less on reducing frequency of injections&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Journals reviewed this month:&lt;/STRONG&gt;&amp;nbsp; Diabetes Care, Diabetic Medicine, BMJ, NEJM, BJDVD , Lancet,&amp;nbsp; Pract Diab Int.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;October 2005. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this series is to inform readers of interesting&amp;nbsp; new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>187420</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=187420]]&gt;</url>
    <title>Interesting new diabetes papers : Sep 2006</title>
    <publicationDate>2006-10-20T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2006,DIABETES,INTERESTING NEW ARTICLES,RESEARCH]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the twentieth in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Sep 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;SYSTEMATIC REVIEWS&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;PSYCHO-EDUCATIONAL INTERVENTIONS FOR CHILDREN AND YOUNG PEOPLE WITH TYPE 1 DIABETES&lt;/P&gt;
&lt;P&gt;Paper 1&amp;nbsp; Murphy HR, Rayman G, Skinner TC&amp;nbsp; Psycho- educational interventions for children and young people with type 1 diabetes. Diabetic Medicine 23; 935-943&lt;BR&gt;Summary:&lt;BR&gt;Systematic review of diabetes education programmes developed for children, young people and their families in past 5 years. 27 articles were found describing the evaluation of 24 interventions. The conclusion is that although there has been an improvement in the quality and quantity of educational research in the last 5 years it has not resulted in the improved effectiveness of interventions. There is still insufficient evidence to recommend adoption of a particular educational programme and there is no programme that has been proven effective in randomised studies for those with poor glycaemic control. &lt;BR&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;No interventions proven in an RCT yet/. More research needed!!&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;RANDOMISED CONTROLLED TRIALS&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;STRUCTURED EDUCATION FOR TYPE 2 DIABETES&lt;/P&gt;
&lt;P&gt;Paper 2 Deakin TA, Cade JE, Williams R, and Greenwood DC Structured patient education: the Diabetes x-PERT programme makes a difference Diabetic Medicine 23; 944-954&lt;BR&gt;Paper 3 Skinner TC. What does make the difference (editorial) Diabetic Medicine 23: 933-934 &lt;BR&gt;Summary:&lt;BR&gt;Adults with type 2 diabetes from Lancashire were randomised to either individual appointments (control n= 157) or the X PERT group education programme, a 2hrs a week for 6 weeks structured group education programme delivered by a diabetes research dietitian&amp;nbsp; (intervention n= 157). The theoretical models underpinning the programme are empowerment and discovery learning.&lt;BR&gt;82% in the intervention group attended 4 or more sessions. By 14 months the intervention group showed a drop of 0.6% in HBA1c compared with control. The NNT for preventing diabetes medication increase was 4 and the NNT for reducing diabetes medication was 7. The intervention group showed statistically significant improvements in weight, BMI, activity levels, knowledge of diabetes, self empowerment, and treatment satisfaction.&lt;BR&gt;The editorial suggests that the trial design is more robust than many others in the field but criticises it over problems in the theoretical modelling underlying the programme and problems with the control group. The editorial suggests that there was not a psychological equivalent placebo group. It concludes that the data provide compelling evidence that when enthusiastic and motivated health care professionals invest more time with patients in a structured way to help them manage their diabetes we see improved biomedical outcome.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;Despite the caveats in the editorial this does provide evidence for the X –PERT programme, in a way. &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;OTHER RESEARCH PAPERS&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;ADHERENCE TO MEDICATIONS&lt;/P&gt;
&lt;P&gt;Paper 4 Walker EA, Molitch M, Kramer KM et al for the Diabetes Prevention Program&amp;nbsp; (DPP) Research Group Adherence to Preventive Medications. Diabetes Care 29: 1997-2002&lt;BR&gt;Summary:&lt;BR&gt;Within the DPP research programme data on adherence was collected by counting numbers of tablets of metformin or placebo dispensed and returned.&amp;nbsp; It was documented as either above or below 80% of the prescribed dose at each quarterly visit. Adherence was promoted using a brief 5 item structured interview. Adherence was better in people over 60 years of age 70.6% than 25-44 years 65.9%. The most frequent barrier to adherence reported was “ forgetting” . The authors conclude that their results are unique in primary prevention for a chronic disease in a large multiethnic sample. The finding that adherence was associated with risk reduction for diabetes supports the development of brief interventions in clinical settings where medication adherence is a challenge.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;Very interesting data on adherence in a large prevention RCT. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;BRIEF REPORTS&lt;/P&gt;
&lt;P&gt;Paper 5 Hamman RF, Wing RR, Edelstein for the DPP Research Group Diabetes Care 29: 2102-2107&lt;BR&gt;In DPP it was the weight reduction that was the most important part of the intervention to prevent diabetes&lt;/P&gt;
&lt;P&gt;Paper 6 Venkat Narayan KM, Boyle JP, Geiss LS et al Impact of Recent increase in incidence on future diabetes burden Diabetes Care 29: 2114-2116&lt;BR&gt;Previous studies predicted there would be 39 million with diabetes in USA in the year 2050. This has been now adjusted upwards to be 48.3 million. They are 95% certain that&amp;nbsp; the estimate will fall between 45 – 51.5 million&lt;/P&gt;
&lt;P&gt;Paper 7 Wang J, Williams DE,&amp;nbsp; Venkat Nayan KM, Geiss LS Declining death rates from hyperglycaemic crises among adults with diabetes US 1985-2002 Diabetes Care 29: 2018-2022&lt;BR&gt;Deaths calculated from national morbidity data.&amp;nbsp; Deaths dropped from 2989 in 1985 to 2459 in 2002. One fifth of deaths occurred at home or on arrival at hospital. They conclude that there is scope for improvement still!&lt;/P&gt;
&lt;P&gt;Paper 8 Sampson MJ, Crowle T , Dhatariya K et al&amp;nbsp; Trends in bed occupancy for inpatients with diabetes before and after the introduction of a diabetes inpatient specialist nurse Diabetic Medicine 23; 1008-1015&lt;BR&gt;Study in Norwich hospital from 1998 – 2004. 9.7% of inpatients had diabetes. They accounted for 12.4% of occupied bed days Diabetes excess bed occupancy was concentrated in patients under 75 years and this was reduced noticeably following the introduction of a DSN service.&lt;/P&gt;
&lt;P&gt;Paper 9 Marshall SM, Flyvberg A Prevention and early detection of vascular complications of diabetes BMJ 333; 475-480&lt;BR&gt;Expert review giving clear overall information.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt;&amp;nbsp; BMJ, Lancet, JAMA, N Eng J Med, Diabetes Care, Diabetic Medicine, Pract Diab Int, BJDVD, Diabetes and Primary Care&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;October 2006. This series began in 2002&amp;nbsp;as&amp;nbsp;a&amp;nbsp;bulletin&amp;nbsp;for &lt;A href="http://www2.warwick.ac.uk/fac/med/study/cpd/subject_index/diabetes/wdc/" target="_blank"&gt;Warwick Diabetes Care&lt;/A&gt; staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp;Word and webpage versions available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of&amp;nbsp;this series&amp;nbsp;is to inform readers of interesting new papers relevant to diabetes that have appeared in&amp;nbsp;several diabetes and general medical journals in the previous month.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>271179</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=271179]]&gt;</url>
    <title>Interesting new diabetes papers : Sep 2007</title>
    <publicationDate>2007-10-25T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2007,DIABETES,INTERESTING NEW ARTICLES,RESEARCH]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the thirty second in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers : Sep 2007&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;SYSTEMATIC REVIEWS &amp;amp; META-ANALYSIS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Glitazones and CHD Risk&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Paper 1&amp;nbsp; Singh S, Loke,YK, Furberg CD Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis JAMA 2007 298:1189-1195&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;The original Nissen meta-analysis which began the controversy (see Bulletin May 07) included many short trials which were not designed to look at CHD endpoints, and as a result it was criticised. This meta-analysis included only studies of at least 12 months duration that prospectively collected data on cardiovascular events. The study reports a 42% increase in risk of myocardial infarction. In addition the review notes a more than doubling of the risk of heart failure, but no significantly increased risk of cardiovascular mortality&lt;/P&gt;
&lt;P&gt;Paper 2 Lincoff AM, Wolski K, Nicholls SJ, Nissen SE Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes: a meta-analysis of randomised controlled trials JAMA 2007 298: 1180-1188&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;This review is a pooled analysis of cardiovascular events using patient level data from 19 RCT’s comparing pioglitazone with a range of alternative regimes. Among patients randomised to receive pioglitazone, the rate of death, myocardial infarction or stroke was reduced by 18% compared with controls. There was an increased risk of heart failure&lt;/P&gt;
&lt;P&gt;Paper 3 Solomon DH, Winkelmayer WC Cardiovascular risk and the thiazolidinediones Déjà vu all over again? (editorial) JAMA 298: 1216-8&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;The editorial comments that the rosiglitazone meta-analysis is in line with the Nissen one, that rosiglitazone increases the risk of myocardial infarction. The results of the pioglitazone meta-analysis show a clear difference in that pioglitazone reduces CHD risk by 18%. &lt;/P&gt;
&lt;P&gt;Paper 4 Bilous R Rosiglitazone and myocardial infarction: cause for concern or mis-leading meta-analysis? (editorial)&amp;nbsp; Diabetic Medicine 2007 24:931-933 &lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;This editorial looks at the controversy from a UK perspective&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;The evidence from meta-analyses is&amp;nbsp; showing that there is a difference between rosiglitazone, which increases the risk of myocardial infarction and pioglitazone which decreases CHD risk. Paper 4 also suggests that overall the papers show that CHD risk has reduced overall in people with diabetes since the 1990’s&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Glitazones and CCF&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Paper 5 Lago RM, Singh PP, Nesto RW Congestive cardiac failure and cardiovascular death in patients with pre-diabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised controlled clinical trials Lancet 2007 370: 1129-1136&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;A meta-analysis of 7 RCT’s in which 360 of 20191 patients developed CCF, 214 in those treated with TZD’s and 146 with comparators. This indicates an increased risk for the development of CCF in people treated with TZD’s across a wide background of cardiac risk. By contrast the risk of cardiovascular death was not increased with either of the two TZD’s . The authors conclude that CCF in people on TZD’s may not carry the risks usually associated with CCF caused by progressive systolic or diastolic dysfunction of the left ventricle&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;This confirms the increased risk of CCF without increase in CHD death in people taking TZD’s&lt;/P&gt;
&lt;P&gt;Oral agents in people with diabetes abd heart failure&lt;/P&gt;
&lt;P&gt;Paper 6 Eurich DT, McAllister FA, Blackburn DF et al Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review&lt;BR&gt;BMJ 2007 335: 497-501&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;A review of 8 studies. 3 out of 4 studies found that insulin was associated with increased risk of all cause mortality. Metformin was associated with a significantly reduced all cause mortality in two studies when compared with other oral agents and insulin. Metformin was not associated with increased hospital admission for any cause or for heart failure. In 4 studies TZD use was associated with reduced all cause mortality but increased risk of admission for heart failure. 2 studies of sulphonylurea had conflicting results. The authors conclude that metformin is the only glucose lowering therapy not associated with harm in patients with diabetes and heart failure&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments:&lt;BR&gt;Metformin was traditionally thought of as being contra- indicated in people with heart failure. This review suggests it is the only agent with evidence of benefit!&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Efficacy and safety of Oral agents for type 2 diabetes&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Paper 7 Bolen S, Feldman L, Vassy J et al Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes. Ann Int Med 2007 147: 386-399&lt;/P&gt;
&lt;P&gt;Summary&lt;BR&gt;A systematic review of 216 trials and cohort studies and 2 systematic reviews. They found that evidence on major clinical outcomes such as CHD mortality was inconclusive. The review was therefore limited to studies of intermediate outcomes.. They conclude that most oral agents (TZD’s, metformin, repaglinide) lower HBA1c to the same degree as sulphonylureas (about 1% ) and that netaglinide and acarbose may have slightly weaker effects. TZD’s were the only ones to benefit&amp;nbsp; HDL cholesterol levels. Most agents apart from metformin increased body weight by between 1-5Kg. Sulphonylureas and repaglinide were associated with a greater risk of hypoglycaemia, TZD’s with a greater risk of heart failure and metformin with a greater risk of GIT symptoms. Lactic acidosis was no more common in metformin recipients without co-morbid conditions than in recipients of other oral agents.&lt;/P&gt;
&lt;P&gt;Dr Roger Gadsby’s comments&lt;BR&gt;Review of large number of papers with no unexpected conclusions&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RANDOMIZED CONTROLLED TRIALS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;BP Lowering&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Paper 8 Advance Collaborative Group Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in people with type 2 diabetes (the ADVANCE trial) a randomised controlled trial Lancet 2007 370:829-840&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;A large muticentre (215) multicountry (20) trial of 11140 people with type 2 diabetes randomised to fixed dose combination of perindopril/indapamide or placebo. After a mean of 4.3 years of follow up 73% remained on active treatment or placebo. In the active arm BP was lowered by mean of 5.6/2.2. The relative risk of a major macrovasular or microvascular event was reduced by 9% (861 events v 938 events)&lt;BR&gt;The relative risk of death from CHD was reduced by 18% and all cause death by 14%.&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsby’s comments :&lt;BR&gt;Large study showing benefits.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Exercise&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Paper 9 Sigal RJ, Kenny GP, Boule NG et al Effects of aerobic training, resistance training or both on glycaemic control in type 2 diabetes. A randomised controlled trial Ann Int Med 2007 147: 357-369&lt;/P&gt;
&lt;P&gt;Paper 10 Kraus WE, Levine BD Exercise training for diabetes: The “strength” of the evidence (editorial) Ann Int Med 2007 147: 423-424&lt;/P&gt;
&lt;P&gt;Summary:&lt;BR&gt;An RCT in which 251 people with type 2 DM of mean BMI 35 aged 39-70 years were randomised to 1 of 4 exercise programmes either aerobic training, resistance training, both combined or no training. There was no nutrition programme and weight loss was minimal in all groups. It was a 22 week study, participants exercised 3 days a week. HBA!c drop was outcome . Both the aerobic and resistance groups dropped 0.5% compared with no exercise. The combined group dropped 1%&lt;BR&gt;The editorial concludes that an inexpensive pill that lowered HBA1c by 1% reduced CHD death by 12% and improved functional capacity would be quickly taken up by all guidelines! So exercise should be taken up!&lt;/P&gt;
&lt;P&gt;Dr. Roger Gadsbys comments:&lt;BR&gt;Very interesting paper&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;SHORT REPORTS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Work of Diabetologist&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Paper 11 MacLeod K, Carter M, Asprey A et al&amp;nbsp; Diabetic Medicine 24: 946-954 &lt;BR&gt;Report based on semi-structured interviews with 92 consultant diabetologists about their work and opinions&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Cost Effectiveness of Pioglitazone&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Paper 12 Valentine WJ, Bottomley JM, Palmer AJ et al PROActive 06 : Cost effectiveness of pioglitazone in type 2 Diabetes in UK&lt;BR&gt;A Cost effectiveness analysis using data from the PROActive study concludes that addition of pioglitazone to existing therapy in patients with type 2 diabetes at high risk of further CHD events is cost effective and represents good value for money.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;BMJ edition 8th Sept focused on diabetes&lt;/STRONG&gt;&lt;BR&gt;It contained editorials on screening for diabetes and self management of diabetes. It contained articles on patients experiences of screening and qualitative aspects of self monitoring of blood glucose&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;EM&gt;Journals reviewed:&lt;/EM&gt;&lt;/STRONG&gt;&lt;EM&gt; N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Diabetic Medicine&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published in&amp;nbsp;October 2007. This series began in 2002 as a bulletin for Warwick Diabetes Care staff.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word and webpage versions available.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/EM&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>314598</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=314598]]&gt;</url>
    <title>Interesting new diabetes papers: April 2009</title>
    <publicationDate>2009-05-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2009,DIABETES,INTERESTING NEW ARTICLES,RESEARCH]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 48th in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: April 2009&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;REVIEW &amp;amp; META_ANALYSIS&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;QUALITY OF LIFE MEASUREMENT&lt;/STRONG&gt;&lt;BR&gt;Paper 1 Speight J, Reaney MD, Barnard KD &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=314605&amp;amp;tabID=289&amp;amp;catID=5146" target="_blank"&gt;Not all roads lead to Rome- a review of quality of life measurements in adults with diabetes&lt;/A&gt; Diabetic Medicine 26: 315-327&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;This is systematic literature review to identify the 10 most frequently used measures to assess quality of life (QoL) in diabetes research from 1995 – March 2008. 6085 abstracts were identified and the 10 most used measures identified. Of the 10 only 3 actually measure QoL, the WHOQOL, DQOL and ADDQoL. The other 7 ( Sf-36, EQ-5D, DTSQ, Beck Depression Inventory, HADS, W-BQ, and&amp;nbsp; PAID more accurately measure health status. The authors state that if QoL is valued it must be measured by an appropriate instrument&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments:&lt;/STRONG&gt; This&amp;nbsp; review highlights an important issue. If QoL is measured with an inappropriate instrument conclusions may be flawed&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;OTHER SORTS OF STUDY&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;PREDICTING RISK OF DIABETES &lt;BR&gt;&lt;/STRONG&gt;Paper 2 Hippisley-Cox J, Coupland C, Robson J et al Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore&amp;nbsp; BMJ 338: 812-816&lt;BR&gt;Paper 3 Schwarz PEH, Li J, Bornstein SR Screening for type 2 diabetes in primary care (editorial) BMJ 338:782&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;This is a prospective open cohort study using routinely collected data from 355 practices to develop the score and from 176 different practices to validate the score.&lt;BR&gt;The QDScore that has been developed is unique in that it considers social deprivation and ethnicity in a standardised algorithm. It uses routinely collected data from clinical computing systems and does not require laboratory tests. Predicted and observed risk correlated well (97%) It could be used in practices to identify people at an increased risk of diabetes who then could receive a test of glucose.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments: &lt;/STRONG&gt;It will be interesting to see how this informs the NHS vascular risk strategy&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;HYPOGLYCAEMIA &amp;amp; DEMENTIA&lt;/STRONG&gt;&lt;BR&gt;Paper 4 Whitmer RA, Karter AJ, Yaffe K et al Hypoglycaemic episodes and risk of dementia in older patients with type 2 diabetes JAMA 301:1565-1572 &lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;A longitudinal cohort study from 1980-2007 of 16667 patients with mean age of 65 years from Kaiser Permanente in Calafornia. Hypoglycaemic events from 1980-2002 were collected from hospital discharge and emergency department diagnoses. People were followed for a diagnosis of dementia till 2007. At least one episode of hypoglycaemia was diagnosed in 1465 patients (8.8%) and dementia diagnosed in 1822 patients (11%) during follow up. Compared with patients with no hypoglycaemia, patients with a single or multiple episodes had a graded increase in risk of dementia.&lt;BR&gt;The authors conclude that among older patients with type 2 diabetes a history of severe hypoglycaemic episodes was associated with a greater risk of dementia. Whether minor hypoglycaemic episodes increase the risk of dementia remains unknown.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments:&lt;/STRONG&gt;&lt;BR&gt;Further reason not to intensify therapy to lower HBA1c inappropriately in older people&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;TIGHT CONTROL OF GLUCOSE&lt;/STRONG&gt;&lt;BR&gt;Paper 5 Lehman R, Krumhotz HM Tight control of blood glucose in long standing type 2 diabetes (editorial) BMJ 338: 901-2&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;A further discussion of the results from the&amp;nbsp; ADVANCE, VADT and ACCORD trials in relation to the change in QoF clinical indicators for HBA1c reduction in the UK which came in on 1 April 2009. They say that reducing HBA1c below 7% is not supported by evidence and may even be harmful and call for the change in QoF target from 7.5% to 7% to be withdrawn.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments:&lt;/STRONG&gt;&lt;BR&gt;Quite a strong view on the potential harm from the QoF changes&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;U&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/U&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;U&gt;&lt;STRONG&gt;SHORT REPORTS&lt;/STRONG&gt;&lt;/U&gt;&lt;/P&gt;&lt;U&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;BR&gt;&lt;/U&gt;&lt;STRONG&gt;Prevalence of Diabetes in older people&lt;BR&gt;&lt;/STRONG&gt;Paper 6 Hewitt J, Smeeth L, Bulpitt CJ, Fletcher AE The prevalence of type 2 diabetes and its associated health problems in a community-dwelling elderly population Diabetic Medicine 26: 370-376&lt;BR&gt;Data from 15095 community dwelling people aged 75 or over recruited in an MRC trial of assessment and management of older people in the community giving prevalence rates of 7.8% for men and 6.8% for women, lowering than some other studies and estimates. Diabetes was a contributory factor to a number of health problems&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Road Traffic Accidents and Diabetes&lt;/STRONG&gt;&lt;BR&gt;Paper 7 Skurtveit S, Strom H, Skrivarhaug J et al Road traffic accident risk in patients with diabetes receiving blood glucose-lowering drugs. Prospective follow up Diabetic Medicine 26: 404-408 &lt;BR&gt;Data from all Norwegians from 18-69 years (3.1 million) from 2004-2006 when there were 20494 RTA’s with personal injuries. 183 RTA’s were in insulin users and 219 for users of oral glucose lowering drugs. They conclude that a slightly increased risk of being involved in an RTA was observed for drivers prescribed insulin while no increased risk was observed for drivers prescribed oral glucose lowering drugs&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Type 1 Diabetes and substance abuse&lt;BR&gt;&lt;/STRONG&gt;Paper 8 Lee P, Greenfield JR Campbell LV Managing young people with type 1 diabetes in a “rave” new world: metabolic complications of substance abuse in type 1 diabetes &lt;BR&gt;An expert review article on this important subject in adolescent diabetes. It reviews the effects of a number of designer drugs and the mechanisms of their drug effects in diabetes&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;JAMA edition of 15th April is dedicated to diabetes.&lt;/STRONG&gt; It contains a number of original articles including paper 4 mentioned above. It has a number of useful commentaries including ones on&amp;nbsp; Bariatric surgery and Diabetes 1593-5, Glucose control in type 2 diabetes 1590-2 (compare with paper 5 above) Can diabetes be cured? 1588-1589 Islet transplantation 1521-25, and the artificial pancreas 1525-27&lt;BR&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed&lt;/STRONG&gt;&lt;BR&gt;N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract,&amp;nbsp; Diabetic Medicine, Pract Diab Int&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;&lt;EM&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; Published in&amp;nbsp;February 2009.&amp;nbsp;This series began in 2002 as a bulletin for Diabetes Care Staff.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public.&amp;nbsp; Word and webpage versions available.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>374355</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=374355]]&gt;</url>
    <title>Interesting new diabetes papers: April 2010</title>
    <publicationDate>2010-05-19T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 60th in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: April 2010&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;U&gt;&lt;STRONG&gt;SYSTEMATIC&amp;nbsp; REVIEWS&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/U&gt;&lt;STRONG&gt;PSYCHOSOCIAL&amp;nbsp; INTERVENTIONS&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 1 Harkness E, MacDonald W, Valderas J et al &lt;/EM&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=375229&amp;amp;code=1eb14de9c10e6ea0362dc11d0e14107d" target="_blank"&gt;&lt;EM&gt;Identifying Psychosocial Interventions that improve both Physical &amp;amp; Mental health in patients with diabetes &lt;BR&gt;&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;Diabetes Care 33:926-930&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;This meta-analysis is from 49 randomised controlled trials in patients with type 1 and type 2 diabetes who received psychosocial interventions and where both mental health and physical outcomes were reported. Psychosocial interventions modestly improved HBA1c by -0.29% and mental health outcomes. However there was a limited association between the effects on HBA1c and mental health and no intervention characteristics predicted benefit on both outcomes. The review did not identify types of interventions that consistently provide benefits for both physical and mental health.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Previous reviews have suggested that psychological therapy can improve both diabetes and mental health outcomes.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;U&gt;RCT’s&lt;BR&gt;&lt;BR&gt;&lt;/U&gt;&lt;/STRONG&gt;&lt;STRONG&gt;BLOOD PRESSURE &amp;amp; LIPID THERAPY IN TYPE 2 DIABETES – FURTHER&amp;nbsp; RESULTS FROM THE ACCORD TRIAL&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 2 The ACCORD Study Group Effects of Combination therapy in type 2 diabetes&lt;BR&gt;N Eng J Med 362: 1563 – 1574&lt;BR&gt;Paper 3The ACCORD Study Group Effects of Intensive Blood-Pressure Control in type 2 Diabetes Mellitus N Eng J Med 362: 1575-1585 &lt;BR&gt;Paper 4 Nilsson PM&amp;nbsp; ACCORD and Risk-Factor Control in type 2 Diabetes (editorial)&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;The ACCORD study, as well as randomising people with type 2 diabetes to intensive and less intensive glucose control, randomised to intensive and less intensive blood pressure control and in a lipid sub study to simvasatin 40mgs plus fenofibrate (usually 160mgs daily) or placebo.&lt;BR&gt;&amp;nbsp;In the lipid study 5518 patients who were treated with open label simvastatin 40mgs daily were randomised to receive masked fenofibrate or placebo. The primary outcome was first occurrence of non fatal stroke or myocardial infarction or death from cardiovascular causes. The mean follow up was 4.7years.&lt;BR&gt;The annual rate of the primary outcome was 2.2% in the fenofibrate group and 2.4% in the placebo group. There was also no significant differences between the two study groups with respect to any secondary outcome. &lt;BR&gt;In the blood pressure study 4733 people were randomised to intensive therapy targeting a systolic blood pressure of less than 120mm Hg or a standard therapy group targeting a systolic below 140. It had the same primary outcome and follow up was again 4.7 years. After 1 year the mean systolic bp in the intensive group was 119.3 and in the standard group 133.5. The annual rate of primary outcome was 1.87% in the intensive and 2.09% in the standard which were not statistically significantly different, nor were there differences in pre specified secondary outcomes.&lt;BR&gt;Serious adverse events attributed to antihypertensive treatment were 3.3% in the intensive and 1.3% in standard.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;BR&gt;&lt;/STRONG&gt;Neither of these ACCORD studies showed benefit in more intensive treatment of blood pressure or lipids with fenofibrate. They therefore do not suggest we should change any of the present NICE recommendations for BP or Lipid control in type 2 diabetes.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;PREVENTING DIABETES – THE NAVIGATOR TRIAL&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 5 The Navigator Study Group.&amp;nbsp; Effect of Nateglinide on the incidence of diabetes and cardiovascular events N Engl J Med 362: 1463-1476&lt;BR&gt;Paper 6 The Navigator Study Group. Effect of Valsartan on the incidence of cardiovascular events N Engl J Med 362: 1477-1490&lt;BR&gt;Paper 7 Nathan DM Navigating the choices for diabetes prevention (editorial) N Engl J Med 362:1533-4&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;In this double blind randomized clinical trial with a two by two factorial design 9306 people with impaired glucose tolerance and established cardiovascular disease or cardiological risk factors were assigned to receive valsartan (up to 160mgs daily) or placebo or netaglinide (up to 60mgs tds) or placebo or&amp;nbsp; both active drugs or double placebo. The follow up was 5 years. All participants were given a lifestyle ontervention programme. The primary outcomes were development of diabetes or&amp;nbsp; composite cardiovascular outcomes&amp;nbsp; (CVD). The rationale for using netaglinide is that it reduces post prandial glycaemia.&lt;BR&gt;The results were largely negative. Neither drug ( nor the combination) reduced the two coprimary CVD disease outcomes. Netaglinide did not reduce the incidence of diabetes. The only positive outcome was a weak albeit statistically significant reduction in the incidence of diabetes with valsartan. The relative reduction of 14% and the absolute reduction of 3.7% in incident diabetes with valsartan, as compared to placebo, over a mean follow up of 5 years makes valsartan the weakest of drugs studied to date.&amp;nbsp; It did not answer the question of post prandial glycaemia because the mean glucose levels 2hrs after glucose load in the annual ogtt’s was higher in the netaglinide group than placebo. The authors describe this paradoxical finding as a rebound effect since netaglinide was not given on the mornings of the ogtt, suggesting that on the other 364 days of the year when netaglinide was given postprandial glucose levels were lower. &lt;BR&gt;The editorial suggests that for the prevention of diabetes it is best to use lifestyle interventions and in selected people add metformin.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Largely negative trials and no change in policy for diabetes prevention as a result.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;PATIENT EDUCATION&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 8 Trento M, Gamba S, Gentile L et al for the ROMEO investigators Rethink Organization to iMprove Education and Outcomes (ROMEO)&amp;nbsp; Diabetes Care 33:745-747&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt; &lt;BR&gt;This was a 4 year two armed, multi centered study in 13 hospital based diabetes clinics in Italy. A total of 815 non insulin treated people under 80 years of age who had type 2 diabetes for 1 year or more were randomised to group or individual care. Group care sessions and individual visits were 3 monthly. The group sessions were 7 of 1 hr spread over two years and then repeated. The curriculum was that already published in the Turin study.&lt;BR&gt;After 4 years patients in group care had lower HBA1c (7.3% v 8.8%) , lower lipids, blood pressure BMI and creatinine than control subjects receiving individual care despite similar pharmacological prescriptions. Health behaviours, quality of life and knowledge of diabetes had become better in group care subjects than in control subjects. The authors conclude that the favourable clinical, cognitive and psychological outcomes of group care (seen in the original Turin study papers) can be reproduced in different clinical settings.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;The Turin study produced the best biosocial outcomes of any diabetes patient education programme. ROMEO shows that these outcomes can be reproduced in other centres.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;U&gt;OTHER SORTS OF STUDY&lt;BR&gt;&lt;BR&gt;&lt;/U&gt;SCREENING FOR DIABETES&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 9 Kahn R, Alperin P, Eddy D et al Age at initiation and frequency of screening to detect type 2 diabetes: a cost effectiveness analysis Lancet 375:1365-1374&lt;BR&gt;Paper 10 Rutten G Screening for type 2 diabetes – where are we now (comment) Lancet 375:1324-5&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;Mathmatical modelling using the Archimedes model to compare cost effectiveness of 8 simulated screening strategies for type 2 diabetes with a non screening control strategy. In the US population screening for type 2 diabetes is cost effective when started between the ages of 30 and 45 years with screening repeated every 3-5 years&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;BR&gt;&lt;/STRONG&gt;The paper provides further evidence that screening for diabetes should be combined with screening for hypertension and lipid tests.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;U&gt;SHORT REPORTS&lt;BR&gt;&lt;BR&gt;&lt;/U&gt;Effect of Guidelines&lt;/STRONG&gt;&amp;nbsp; &lt;BR&gt;&lt;EM&gt;Paper 11 Huang EA, Zdon GS, Moore RJ et al The impact of publishing medical speciality society guidelines on subsequent adoption of best practices: a case study with type 2 diabetes Int J Clin Pract 64: 558-561&lt;/EM&gt;&lt;BR&gt;The paper suggest that publication of the ADA/EASD glycaemia algorithm caused a significant acceleration in early metformin monotherapy use in the USA&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;GLP-1 VERSUS DPP4&lt;/STRONG&gt;&amp;nbsp; &lt;BR&gt;&lt;EM&gt;Paper 12 Pratley RE, Nauck M, Bailey T et al Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin : a 26 week randomised parallel group open label trial Lancet 375: 1447-1456&lt;BR&gt;&lt;/EM&gt;Liraglutide 1.2mgs daily&amp;nbsp; was superior to sitagliptin 100mgs daily for reduction in HBA1c (-1.24 v 0.9%) and was well tolerated with minimum risk of hypoglycaemia (5% in both groups) &lt;BR&gt;&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt; N Eng J Med,&amp;nbsp; Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int&lt;BR&gt;&lt;/EM&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>294606</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=294606]]&gt;</url>
    <title>Interesting new diabetes papers: August 2008</title>
    <publicationDate>2008-09-23T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the fortieth in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: August 2008&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;GUIDELINES&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 1 Boulton AJM, Armstrong DG, Albert SF et al Comprehensive Foot Examination and Risk Assessment Diabetes Care 31: 1679-1685&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Summary&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;This is the report of the Task Force of the Foot Care Interest Group of the American Diabetes association, with endorsement by the American Association of Clinical Endocrinologists. It recommends inspection of the skin of the foot &amp;amp; a foot musculo skeletal inspection. Neurological assessment with the 10g nylon monofilament plus one other of vibration using tuning fork, pinprick, ankle reflexes or VPT, and vascular assessment by checking foot pulses. It recommends using the 10g nylon monofilament on 6 sites per foot. These recommendations are in line with the NICE guideline on Type 2 Diabetes: prevention and management of foot problems 2004 &lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Dr &lt;/B&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:PersonName&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Roger Gadsby&lt;/B&gt;&lt;/st1:PersonName&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;’s comments&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;Useful summary of views from the &lt;st1:country-region&gt;&lt;st1:place&gt;USA&lt;/st1:place&gt;&lt;/st1:country-region&gt; which are in line with NICE guidelines in the &lt;st1:country-region&gt;&lt;st1:place&gt;UK&lt;/st1:place&gt;&lt;/st1:country-region&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=center&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;o:p&gt;&lt;SPAN style="TEXT-DECORATION: none"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;SYSTEMATIC REVIEWS &amp;amp; META_ANALYSIS&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 2 Bazzano LA, Lee LJ, Shi L et al Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 Diabetes: a meta-analysis of randomised controlled trials&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;Diabetic Medicine 25: 924-932&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Summary&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;This is a review and meta-analysis of 12 studies with a total of 4385 participants. The mean net change for HBA1c and body weight for people treated with NPH insulin as compared with glargine was 0.08% and -0.33Kg respectively. More participants experienced symptomatic and nocturnal hypoglycaemia on NPH than on glargine, but there was no significant difference in confirmed or severe episodes. The authors conclude that they identified no difference in glucose lowering between glargine and NPH insulin, but less patient reported hypoglycaemia with glargine and slightly less weight gain with NPH insulin.&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Dr &lt;/B&gt;&lt;st1:PersonName&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Roger Gadsby&lt;/B&gt;&lt;/st1:PersonName&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;’s comments&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;Data that is in line with what would have been expected&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;OTHER SORTS OF STUDY&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;HBA1c &amp;amp; ESTIMATED AVERAGE GLUCOSE&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 3 Nathan DM, Kuenen J, Borg R et al Translating the A1C Assay into Estimated Average Glucose Values Diabetes Care 31: 1473-1478&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 4 Kahn R, Fonseca V Translating the A1C Assay (editorial) Diabetes Care 31: 1704-1707&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 5 Home PD HBA1c: the case for using estimated average glucose (eAG) Diabetic Medicine 25: 895-898&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 6 Kilpatrick ES Estimated average glucose (eAG) : fit for purpose?&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I style="mso-bidi-font-style: normal"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;Diabetic Medicine 25:899-901&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Summary&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;Paper 3 is an international study of 268 people with type 1 diabetes, 159 with type 2 diabetes and 80 without diabetes. A lab measured HBA1c at the end of 3 months was compared with average glucose levels calculated by combining weighted results from at least 2 days of continuous glucose monitoring performed 4 times, with 7 point daily self-monitoring of capillary glucose performed at least 3 days per week. About 2700 glucose readings were obtained by each subject. Linear regression analysis allowed calculation of an estimated average glucose for HBA1c value.&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;The editorial comments that the strengths of the study are that it looked at a range of HBA1c from 5-13%, in large numbers of people, and had large numbers of glucose estimations per person. There is a less than perfect correlation with 16-19% of the variation unaccounted for, but given that there is a measurement error of 2-5% in HBA1c and a larger coefficient of variation in the measurement of glucose of 10-20%&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;the constraints imposed by the methodologies explain the residual variation. The editors conclude that the study reinforces the simple explanation that HBA1c reflects the average blood glucose over the past few months.&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;The 2 papers in Diabetic Medicine are a debate. In the first the author explains and defends average daily glucose and in the second Dr Kilpatrick looks critically at some of the results in paper 3.&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;st1:PersonName&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Roger Gadsby&lt;/B&gt;&lt;/st1:PersonName&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;’s comments&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;It is likely that in the future HBA1c levels with their current units and normal range will remain the same. An average estimated glucose result (based on the HBA1c) will also be given. This eAG may be easier to explain to people with diabetes and may convey more meaning and purpose to glucose control. Whatever instrument or assay is used in the clinical laboratory to measure HBA1c will remain the same, but the reference method used for calibration will be more precise.&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;QOF REPORTING &lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 7 Doran T, Fullwood C, Kontopantelis E, Reeves D Effect of financial incentives on inequalities in the delivery of primary clinical care in &lt;/I&gt;&lt;st1:country-region&gt;&lt;st1:place&gt;&lt;I style="mso-bidi-font-style: normal"&gt;England&lt;/I&gt;&lt;/st1:place&gt;&lt;/st1:country-region&gt;&lt;I style="mso-bidi-font-style: normal"&gt;: analysis of clinical activity indicators for the quality and outcomes framework Lancet 372: 728-736&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 8 Starfield B Quality and Outcomes framework: patient centred? (commentary) Lancet 372: 692-694&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Summary&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;QoF data from 7637 practices, data from the &lt;st1:country-region&gt;&lt;st1:place&gt;UK&lt;/st1:place&gt;&lt;/st1:country-region&gt; census and data from the 2006 general medical statistics database was analysed. Practices were grouped into equal sized quintiles on the basis of area deprivation in their locality. The authors calculated overall levels of achievement, defined as the proportion of patients who were deemed eligible by the practices for whom the targets were achieved for 48 clinical activity indicators (15 of them for diabetes) during the first 3 years of the QoF incentive scheme.&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;Median overall reported achievement was 85.1% in year 1, 89.3% in year 2 and 90.8% in year 3. In year 1 area deprivation was associated with lower levels of achievement, with median achievement ranging from 86.8% for the least deprived quintile to 82.8% in the most. Between years 1 and 3 median achievement increased by 4.4% in the least deprived quintile and by 7.6% in the most, and the gap in median achievement narrowed from 4.4% to 0.8% during this period. The results suggest that financial incentive schemes have the potential to make a substantial contribution to the reduction of inequalities in the delivery of clinical care related to area deprivation.&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Dr &lt;/B&gt;&lt;st1:PersonName&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Roger Gadsby&lt;/B&gt;&lt;/st1:PersonName&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;’s comments&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;Very interesting data showing another benefit of the QoF scheme.&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;SHORT REPORTS&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Cost effectiveness of Steno 2 &lt;/B&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper &lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/B&gt;9 &lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;Gaede P, Valentine WJ, Palmer AJ et al Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes Diabetes Care 31: 1510-1515&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/I&gt;Intensive therapy is more cost effective than conventional&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Variability of lipids in patients with type 2 diabetes taking statin&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/B&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 10 Sathyapalan T, Atkin SL, Kilpatrick ES Variability of lipids in patients with type 2 diabetes taking statin: implications for target setting Diabetic Medicine 25: 909-915&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;This study shows that values for total cholesterol can vary by 15% in the same individual on treatment while that of LDL can vary by 24% before any laboratory analytical variability is also taken into consideration. The levels needed to always remain&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;below a target are much lower than the target itself. Thus to achieve a total under 5 the mean values need to be 4.3-4.4, and an LDL under 3 they need to be 2.4-2.5. This means that the existing NICE lipid guideline targets may not be far removed from the current evidence than the values of 5 and 3 suggest.&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;SGLT2 DRUGS&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 11 Jabbour SA, Goldstein BJ Sodium glucose co-transporter 2 inhibitors (SGLT2) blocking renal tubular reabsorbtion of glucose to improve glycaemic control in patients with diabetes Int J Clin Prac 8: 1279-1284&lt;/I&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;Good summary of this emerging new drug group.&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;NB (a) The August edition of BJGP contains a number of papers on diabetes including one on the results of the Counterweight programme&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;(b) The August edition of Diabetic Medicine contains a supplement of papers celebrating 30 years of the UKPDS study &lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;U&gt;&lt;/U&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;U&gt;&lt;/U&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;U&gt;Journals reviewed&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetic Medicine, Pract Diab Int&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; published in&amp;nbsp;September 2008.&amp;nbsp;This series began in 2002 as a bulletin for Diabetes Care Staff.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public.&amp;nbsp; Word and webpage versions available.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;EM&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;/o:p&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>325845</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=325845]]&gt;</url>
    <title>Interesting new diabetes papers: August 2009</title>
    <publicationDate>2009-09-28T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 52nd in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: August 2009&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;GUIDELINES &amp;amp; REPORTS.&lt;/U&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;REPORTING SYSTEMATIC REVIEWS &amp;amp; META-ANALYSIS&lt;/STRONG&gt;&lt;BR&gt;Paper 1 Moher D, Liberati A, Tetzlaff J et al and the PRISMA group.&amp;nbsp; &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=325849" target="_blank"&gt;Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement&lt;/A&gt;.&amp;nbsp;Ann Int Med 151: 264-269&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;This article outlines the PRISMA statement for reporting systematic reviews and meta-analysis. It is a 27 item checklist. It is a revision and expansion of the QUORUM checklist. &lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Use of this checklist will now define what goes into making a good quality literature review&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;EXPERT REVIEWS&lt;/U&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;HYPOGLYCAEMIA&lt;/STRONG&gt;&lt;BR&gt;Paper 2 McCrimmon R &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=325855" target="_blank"&gt;Glucose Sensing During Hypoglycaemia: Lessons from the Lab&lt;/A&gt; Diabetes Care 32:1357-1363&lt;BR&gt;Paper 3 Amiel SA &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=325891" target="_blank"&gt;Hypoglycaemia: From the Laboratory to the Clinic&lt;/A&gt;&amp;nbsp;Diabetes Care 32:1364-71&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;These two papers provide an up to date view of the pathophysiology of hypoglycaemia and hypoglycaemia unawareness, their clinical effects and how they can be managed &lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;These are very helpful summary papers of the latest thinking on hypoglycaemia.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RETINOPATHY&lt;/STRONG&gt;&lt;BR&gt;Paper 4 Simo R Hernandez C Advances in the Medical Treatment of Diabetic Retinopathy&amp;nbsp; Diabetes Care 32:1556-1561&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;The article summarises new data on the benefits of fenofibrate, candasartan and anti-VEGF agents for diabetic retinopathy treatment. It concludes that ophthalmologists and physicians should be aware of the potential usefulness of these agents and work together not only in future research but also in establishing clinical guidelines that will include these newer medical treatments for diabetic retinopathy.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;BR&gt;&lt;/STRONG&gt;Good up to date summary&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;RCT’s&lt;BR&gt;&lt;/U&gt;EXERCISE TO IMPROVE GLUCOSE TOLERANCE&lt;/STRONG&gt;&lt;BR&gt;Paper 5 Yates T, Davies M, Gorely T et al Effectiveness of a Pragmatic Education Program designed to Promote Walking Activity in individuals with impaired glucose tolerance (IGT)&amp;nbsp; Diabetes Care 32: 1404-1410&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;103&amp;nbsp; overweight or obese adults with IGT from Leicester UK were randomised to control (n=34) the PREPARE 3 hr education programme (n = 31) and PREPARE plus a pedometer (n=33). Results from 87 were analysed. At 12 months significant reductions in fasting and 2hr challenge glucose were seen in the PREPARE plus pedometer group compared with control group. No significant improvements were seen in the PREPARE group versus control group. They conclude that a structured education programme to increase walking that includes a pedometer to measure number of steps taken is effective in improving glucose tolerance in people with IGT&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Interesting data. Clearly the pedometer is vital. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;SHORT REPORTS&lt;/U&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;Decreasing amputation rates in diabetes&lt;/STRONG&gt; Paper 6 Schofield CJ, Yu N, Jain AS, Leese P Decreasing amputation rates in patients with diabetes – a population based study Diabetic Medicine 26: 733-777. Data from DARTS database in Scotland showing that the incidence of major amputations fell from 5.1 to 2.9 per 100 patients with diabetes between the years 2000 and 2007&lt;BR&gt;&lt;STRONG&gt;GDM treatment&lt;/STRONG&gt; Paper 7 Balani J, Hyer SL, Rodin DA Shehata H Pregnancy outcomes in women with gestational diabetes treated with metformin or insulin: case control study&amp;nbsp; Diabetic Medicine 26: 798-802 A comparison of 100 women with GDM&amp;nbsp; treated with metformin to 100 women with GDM treated with insulin matched for age, weight and ethnicity. Those treated with metformin had less weight gain and improved neonatal outcomes compared with those treated with insulin.&lt;BR&gt;&lt;STRONG&gt;Urinary Incontinence in diabetic women&lt;/STRONG&gt; Paper 8 Phelan S, Kanaya AM, Subak LL et al on the behalf of the Look AHEAD research group Diabetes Care 32: 1391-1397&lt;BR&gt;Concludes that among overweight and obese women with type 2 diabetes (2994 studied) urinary incontinence is highly prevalent (27%) and far exceeds the prevalence of other diabetes complications. Increasing obesity (BMI at or above35) was the strongest modifiable risk factor.&lt;BR&gt;&lt;STRONG&gt;Insulin resistance of aging&lt;/STRONG&gt; Paper 9 Amati F, Dube JJ, Coen PM et al Physical inactivity and obesity underlie the insulin resistance of aging Diabetes Care 32: 1547-1549&amp;nbsp; Concludes that insulin resistance may not be characteristic of aging but rather associated with obesity and physical inactivity &lt;BR&gt;&lt;STRONG&gt;Hypoglycaemia Unawareness in older people with diabetes&lt;/STRONG&gt;&amp;nbsp; Paper 10 Bremer JP, Jauch-Chara K Hallschmid M et al Hypoglycaemic unawareness in older compared with middle-aged patients with type 2 diabetes Diabetes Care 32: 1513-1517&lt;BR&gt;Concludes that&amp;nbsp; their data indicate marked subjective unawareness of hypoglycaemia in older type 2 diabetic patients that does not depend on altered neuroendocrine counter regulation and which may contribute to the increased probability of severe hypoglycaemia frequently reported in these patients. The joint occurrence of hypoglycaemia unawareness and deteriorated cognitive function is a critical factor to be carefully considered in the treatment of older patients.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed&lt;/STRONG&gt;&amp;nbsp; N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>388833</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=388833]]&gt;</url>
    <title>Interesting new diabetes papers: August 2010</title>
    <publicationDate>2010-09-30T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: August 2010&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;U&gt;&lt;STRONG&gt;SYSTEMATIC&amp;nbsp; REVIEWS&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;/U&gt;&lt;STRONG&gt;HBA1c reduction with oral agents&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 1 Sherifali D, Nerenberg K, Pullenayegum E et al &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=388844" target="_blank"&gt;The effect of oral antidiabetic agents on A1C levels.&lt;/A&gt; Diabetes Care 33:1859-1864&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;This is a systematic review of 61 studies reporting 103 comparisons which fulfilled the inclusion criteria and which had a total of&amp;nbsp; 26367 participants, 15760 randomised to an intervention drug and 10607 to placebo. They conclude that the benefit of initiating an oral antidiabetic drug is most apparent within the first 4 to 6 months, with HBA1c levels unlikely to fall more than 1.5% on average. Pretreated HBA1c levels have a modest effect on the fall of HBA1c in response to treatment&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments: &lt;/STRONG&gt;Interesting review with predictable results &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Cost effectiveness interventions in Diabetes&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 2 Li P, Zhang P, Barker LE et al &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=388847" target="_blank"&gt;Cost effectiveness of Interventions to Prevent and control Diabetes Mellitus: A systematic review.&lt;/A&gt;&amp;nbsp; Diabetes Care 33:1872-1894&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;This is a systematic review of 56 studies from 20 countries which met the inclusion criteria. The studies reported on the cost-effectiveness of diabetes interventions recommended by the ADA. They found strong evidence to classify the following interventions as cost saving:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;ACE inhibitor therapy for intensive hypertension control compared with standard hypertension control&lt;/LI&gt;
&lt;LI&gt;ACE or ARB therapy to prevent end stage renal disease compared with no ACE or ARB treatment&lt;/LI&gt;
&lt;LI&gt;Early irbesartan therapy at the microalbuminuria stage, to prevent end stage renal disease compared with late treatment at the microalbuminuria stage&lt;/LI&gt;
&lt;LI&gt;Comprehensive foot care to prevent ulcers compared with usual care&lt;/LI&gt;
&lt;LI&gt;Multi-component interventions for diabetes risk factor control and early detection of complications compared with conventional insulin therapy for people with type 1 diabetes&lt;/LI&gt;
&lt;LI&gt;Multi-component interventions for diabetes risk factor control and early detection of complications compared with standard glycaemic control for persons with type 2 diabetes&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;They found evidence to classify the following interventions as very cost effective:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Intensive lifestyle interventions to prevent type 2 diabetes in people with IGT compared with standard lifestyle recommendations&lt;/LI&gt;
&lt;LI&gt;Universal opportunistic screening for undiagnosed type 2 diabetes in African Americans between 45 and 54 years old&lt;/LI&gt;
&lt;LI&gt;Intensive glycaemic control as implemented in UKPDS in persons with newly diagnosed type 2 DM compared with conventional glycaemic control&lt;/LI&gt;
&lt;LI&gt;Statin therapy for secondary prevention of CVD compared with no statin therapy&lt;/LI&gt;
&lt;LI&gt;Counselling and treatment for smoking cessation compared with none&lt;/LI&gt;
&lt;LI&gt;Annual screening for diabetic retinopathy and ensuring treatment in people with type 1&amp;nbsp; compared with no screening and &lt;/LI&gt;
&lt;LI&gt;Annual screening for diabetic retinopathy and ensuring treatment in people with type 2 diabetes&amp;nbsp; compared with no screening&lt;/LI&gt;
&lt;LI&gt;Immediate vitrectomy to treat diabetic retinopathy compared with differed vitrectomy&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments: &lt;/STRONG&gt;Important review with implications for diabetes commissioning &lt;/P&gt;&lt;U&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;BR&gt;SHORT REPORTS&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/U&gt;&lt;STRONG&gt;Diabetes Health Economics&lt;/STRONG&gt; &lt;BR&gt;&lt;EM&gt;Paper 3&amp;nbsp; Currie CJ, Gale EAM, Poole CD Estimation of primary care treatment costs and treatment efficacy for people with type 1 and type 2 diabetes in the UK from 1997-2007 Diabetic Medicine 27:938-948&lt;/EM&gt;&amp;nbsp; Uses data from The Health Improvement Network and concludes that over the 10 year period to 2007 diabetes related primary care costs increased considerably wheress HBA1c values did not&lt;BR&gt;&lt;EM&gt;Paper 4 Kristensen T, Laudicella M, Ejersted C, Street A Cost variation in diabetes care delivered in English hospitals Diabetic Medicine 27:949-957&lt;/EM&gt; Used Hospital Episode Statistics and reference costs for the financial year 2005/6 and concludes that Healthcare Resource Groups and diagnostic markers are significant patient related cost drivers in diabetes care. Costs are not lower in hospitals with a high volume of patients and where diabetes is concentrated in a few specialities&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;Type 2 Diabetes and dog walking&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 5 Peel E, Douglas M, Parry O Lawton J&amp;nbsp; Type 2 diabetes and dog walking.&lt;BR&gt;BJGP 60: 570-577&lt;/EM&gt; A qualitative study of 20 patients. Encouraging dog walking or identifying another interest that promotes a regular commitment to undertake physical activity may yield long term benefits.&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;Ramadan – ADA Statement&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 6 Al-Arouj M, Assaad-Khlil S, Buse J et al Recommendations for Management of Diabetes during Ramadan Diabetes Care 33:1895-1902&lt;/EM&gt; ADA statement update 2010&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;Rosiglitazone&lt;/STRONG&gt; &lt;BR&gt;&lt;EM&gt;Paper 7 Rosen CJ Revisiting the Rosiglitazone story – Lessons learnt N Eng J Med 363:803-806&lt;/EM&gt;&amp;nbsp; Reports on the FDA advisory board in July &lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;Postprandial Glucose levels&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 8 Ceriello A.&amp;nbsp; Point: postprandial glucose levels are an important treatment target Diabetes Care 33:1905-07&lt;/EM&gt; &lt;BR&gt;&lt;EM&gt;Paper 9 Davidson M Counterpoint: postprandial glucose levels are not&amp;nbsp; an important treatment target Diabetes Care 33:1908-09&lt;/EM&gt; Good debate on the issue &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Journals reviewed&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp; N Eng J Med, Lancet, JAMA&amp;nbsp; BMJ, BJGP,&amp;nbsp; Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int&lt;/EM&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>303674</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=303674]]&gt;</url>
    <title>Interesting new diabetes papers: December 2008</title>
    <publicationDate>2009-01-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 44th in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: December 2008&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;REVIEW &amp;amp; META-ANALYSIS&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DIABETES &amp;amp; DEPRESSION&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 1 Mezuk B, Eaton WW, Albrecht S, Golden SH &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=303730" target="_blank"&gt;Depression and type 2 diabetes over the lifespan. A meta-analysis &lt;/A&gt;Diabetes Care 31: 2383-2390&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;Search from 1950- 2007 for papers that examine the relationship of diabetes and depression. 42 full text papers reviewed. 13 met eligibility for depression predicting onset of diabetes, representing 6916 incident cases. Seven met criteria for diabetes predicting the onset of depression, representing 6414 incident cases. The pooled relative risk for incident depression associated with baseline diabetes was 1.15 (1.02-1.30) the RR for incident diabetes associated with baseline depression was 1.60 ( 1.37-1.88). The conclusion is that depression is associated with a 60% increased risk of diabetes but that type 2 diabetes is associated with only a modest increase in depression.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;This is a helpful meta-analysis of the relationship of depression and diabetes.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DEPRESSION &amp;amp; DIABETES TREATMENT NONADHERENCE&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 2 Gonzalez JE, Peyrot M, McCarl LA et al &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=303733" target="_blank"&gt;Depression and Diabetes Treatment Nonadherence: A meta-analysis &lt;/A&gt;Diabetes Care 31: 2398-2403&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary &lt;BR&gt;&lt;/STRONG&gt;This is a&amp;nbsp; review of 47 studies which fulfilled the inclusion criteria. They conclude that there is a significant association between depression and treatment non adherence in patients with diabetes. Studies that used stronger methodologies had larger effects. Treatment no adherence may represent an important pathway between depression and worse diabetes clinical outcomes&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;The conclusions are in line with what we expected&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DIABETIC FOOT ULCERS&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 3 Jeffcoate W, Lipsky BA, Berendt AR et al on the behalf of the three systematic review working parties of the International working group on the Diabetic Foot.&amp;nbsp; &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=303734" target="_blank"&gt;Unresolved issues in the management of ulcers of the foot in diabetes&lt;/A&gt;.&amp;nbsp; Diabetic Medicine 25: 1380-1389&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;This paper collates the results of the 3 review working parties on soft tissue infection, osteomyelitis, offloading and other interventions designed to promote ulcer healing. It was written to demonstrate the extent and quality of the evidence currently available and the unresolved issues that remain. There is a strong plea for more sound clinical studies to be performed&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;This is a very useful summary of the current “state of play” in diabetic foot disease&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;U&gt;RCT’s&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DIET &amp;amp; DIABETES&lt;/STRONG&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 4&amp;nbsp; Jenkins DJ, Kendall C W, McKeown-Eyssen G et al Effect of a low-glycaemic index or a high cereal fiber diet on type 2 diabetes JAMA 300: 2742-2753&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;A RCT with 210 subjects with type 2 diabetes treated with oral agents with pre trial HBA1c in the 6.5-8% range, randomised to one of two diet treatments for 6 months. &lt;BR&gt;The low glycaemic index diet emphasised low glycaemic index breads and breakfast cereals, pasta, rice, peas lentils and nuts. The high cereal fibre diet emphasised whole grain breakfast cereals, brown rice, potatoes in their skins and whole wheat bread. The main outcome measure was drop in HBA1c. In the intention to treat analysis that HBA1c drop in the high cereal fibre group was -).18% and in the low glycaemic index group was – 0.5%&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;This is a high quality RCT of comparing two sorts of diet therapy recommended to be used in people with type 2 diabetes. The low glycaemic index diet was more beneficial in lowering HBA1c. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DIABETES CARE&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 5 Cleveringa FGW, Gorter KJ, Van Den Donk M, Rutten G Combined task delegation, computerised decision support, and feedback cardiovascular risk for type 2 diabetic patients A cluster randomised trial in primary care Diabetes Care 31: 2273-2275&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;Study of 26 intervention practices with 1699 people with type 2 diabetes and 29 control practices of 1692 patients with type 2 diabetes in the Netherlands. The intervention practices received the Diabetes Care protocol of task delegation to a practice nurse, computerised decision support and feedback every 3 months.&lt;BR&gt;After 1 year the HBA1c was not different in the two groups whereas the total cholesterol, LDL cholesterol and BP improved significantly more in the intervention group. The 10 year coronary heart disease risk estimate of the UKPDS improved 1.4% more in the intervention group. ; this may explain why no change was seen. &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Paper 6 Peterson KA, Radosevich DM, O’Connor PJ et al Improving Diabetes Care, Findings from the TRANSLATE trial Diabetes Care 31: 2238-2243&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;TRANSLATE was a group-randomised controlled trial in 24 primary care practices in USA. The intervention covered several domains of the chronic care model. It included a computer register, graphically presented results data showing whether people had achieved targets, contacting people to ensure they attended for clinic visits, audit data that was discussed at monthly meetings, and a local clinical champion. Over 24 months 69,965 visits from 8405 adults with type 2 diabetes from 238 health care providers in 24 practices from 17 health systems were recorded.&amp;nbsp; There was an increase in process measures in the intervention practices. Mean HBA!c decreased significantly in intervention practices. At 12 months intervention practices had significantly greater improvements in achieving recommended clinical values for systolic bp, HBA1c, and LDL cholesterol than control clinics&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;&amp;nbsp; &lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;I style="mso-bidi-font-style: normal"&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt; &lt;/I&gt;&lt;I style="mso-bidi-font-style: normal"&gt;N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int&lt;/I&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; Published in&amp;nbsp;December 2008.&amp;nbsp;This series began in 2002 as a bulletin for Diabetes Care Staff.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public.&amp;nbsp; Word and webpage versions available.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>342187</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=342187]]&gt;</url>
    <title>Interesting new diabetes papers: December 2009</title>
    <publicationDate>2010-01-27T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 56th in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: December 2009&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;SYSTEMATIC&amp;nbsp; REVIEWS&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RETINOPATHY&lt;/STRONG&gt;&lt;BR&gt;Paper 1 Wong TY, Mwamburi M, Klein R et al &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=342201" target="_blank"&gt;Rates of Progression of Diabetic Retinopathy During different time periods. A systematic review and meta-analysis&lt;/A&gt;. Diabetes Care 32: 2307-2313&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;A meta-analysis of 28 studies, which included 27120 patients of mean age 49.8 years. The study looked at proliferative retinopathy (PR)&amp;nbsp; and/or severe visual loss (SVL) . Pooled baseline characteristics and outcome measures were summarized using weighted averages of counts and means. Baseline characteristics and outcomes were compared between 2 periods 1975-1985 and 1986-2008. After 4 years pooled incidence rates for proliferative retinopathy were 11% and for severe visual loss 7.2%. Rates were lower in 1986 -2008 than in 1975-1985. Participants in 1986-2008 had lower proportions of PR and SVL at all time points than participants in the 1975-1985 studies. The paper concludes that these findings may reflect an increased awareness of retinopathy risk factors, earlier identification and initiation of care for patients with retinopathy and improved medical management of glucose, blood pressure and serum lipids&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments: &lt;/STRONG&gt;It is good to see these improvements in the amount of retinopathy&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;RCT’s&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;LITERACY &amp;amp; NUMERACY&lt;/STRONG&gt;&lt;BR&gt;Paper 2 Cavanaugh K, Wallston KA, Gebretsadik T et al Addressing Literacy and numeracy to improve diabetes care. Two randomised controlled trials. Diabetes Care 32: 2149-2155&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;In two RCT’s 198 adult patients with diabetes were randomised to receive an enhanced program that addressed numeracy and literacy&amp;nbsp; using a Diabetes&amp;nbsp; Literacy and Numeracy&amp;nbsp; Education toolkit from educators that had received&amp;nbsp; 1 or 2 training sessions on literacy and numeracy. The control group received usual care&amp;nbsp; from existing enhanced diabetes care programmes. &lt;BR&gt;After 3 months those in the control group dropped HBA1c by 0.8% and by -1.5% in the intervention group. At 6 months there were no differences in HBA1c. Self efficacy improved in both groups from baseline. &lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments: &lt;/STRONG&gt;Literacy and numeracy are important factors in trying to improve diabetes care.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;OTHER SORTS OF STUDY&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DRIVING&lt;/STRONG&gt;&lt;BR&gt;Paper 3 Cox DJ, Ford DF, Gonder-Frederick L et al Driving Mishaps among individuals with type 1 diabetes. Diabetes Care 32: 2177-2180&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;Information was obtained from 452 drivers from 3 centres in the USA who prospectively kept datasheets and who reported monthly on driving “mishaps” including collisions, citations, losing control, automatic driving, someone else taking over driving, and moderate or severe hypoglycaemia during driving.&lt;BR&gt;Over 12 months 52% reported at least one hypoglycaemia related “mishap” and 5% reported 6 or more. These “mishaps” were related to mileage driven, history of severe hypoglycaemia and use of insulin pump therapy..&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments: &lt;/STRONG&gt;Rather concerning USA data.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CVD &amp;amp; DIABETES&lt;/STRONG&gt;&lt;BR&gt;Paper 4 Greenfield S, Billimek J, Pelligrini F et al Co-morbidity affects the relationship between glycaemic control and CVD outcomes in Diabetes. Ann Int Med 151:854-860&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;Longitudinal observational study of 2613 patients with type 2 diabetes in 205 practices in Italy. Patients were categorized into high or low co-morbidity subgroups using the total illness burden index, a validated patient reported measure of co morbidity. Patients were recruited randomly from hospital diabetes opd clinics or practices and followed for 5 years. Outcomes were total mortality and incident CVD events. Attaining a level of HBA1c of 6.5% or less at baseline was associated with lower 5 year incidence of CVD events in the low to moderate co-morbidity group but not in the high co morbidity group. Similarly attaining a baseline HBA1c of 7% predicted fewer CVD events in the lower to moderate co-morbidity groups but not in the high co morbidity subgroup.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments: &lt;/STRONG&gt;Co-morbidity is important&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;SHORT REPORTS&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Retinopathy screening in the UK&lt;/STRONG&gt;&amp;nbsp; Paper 5 Nagi DK, Gosden C, Walton C et al National survey of the current state of screening for diabetic retinopathy: ABCD-Diabetes UK survey of specialist diabetes services 2006. Diabetic Medicine 26:1301-1305&lt;BR&gt;On line survey of 73 questions with responses from 68 out of 105 screening programmes in England (64.8% response) There was a survey in 2000 and the 2006 survey shows progress.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Care Delivery&lt;/STRONG&gt; Paper 6 Guthrie B, Emslie-Smith A, Morris AD Which people with type 2 diabetes achieve good control of intermediate outcomes? Population database study in a UK region. Diabetic Medicine 26(12): 1269-1276&lt;BR&gt;Study of 10191 people with type 2 diabetes in 59 Tayside practices looking at 4 process measures of diabetes QoF, recording of HBA1c, BP, cholesterol and smoking and 4 intermediate outcomes, HBA1c below 7.4%, bp below 140/80, cholesterol at or below 5 and not smoking. Process was 95%, Intermediate outcomes were 50% but only 16% achieved all 4 outcome targets. Process and outcome targets were consistently worse for those under 55years.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt;&amp;nbsp; N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>309537</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=309537]]&gt;</url>
    <title>Interesting new diabetes papers: February 2009</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2009,DIABETES,INTERESTING NEW ARTICLES,RESEARCH]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 46th in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: February 2009&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;REVIEW &amp;amp; META_ANALYSIS&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;IS DIABETES A CORONARY RISK EQUIVALENT?&lt;BR&gt;&lt;/STRONG&gt;Paper 1 Bulugaahapitiya U, Siyambalapitiya S, Sithole J, Idris 1 &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=309620&amp;amp;tabID=289&amp;amp;catID=5139" target="_blank"&gt;Is diabetes a coronary risk equivalent? Systematic review and meta-analysis &lt;/A&gt;Diabetic Medicine 26:142-148&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;Search from 1966- 2007 for relevant papers. These included cohort studies or observational studies. Thirteen papers involving 45108 patients met the pre specified quality criteria. The duration of follow up was from 5-25 years (mean of 13.4 years) and the age range was 25-84 years. They found that patients with diabetes without prior myocardial infarction have a 43% lower risk of developing total CHD events compared to patients without diabetes with previous myocardial infarction.&lt;BR&gt;They conclude that this meta-analysis did not support the idea that diabetes is a “coronary risk equivalent”. They say that public health decisions to initiate cardio-protective drugs in patients with diabetes for primary prevention should therefore be based on appropriate patients CHD risk estimates rather than a blanket approach of treatment.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments: &lt;/STRONG&gt;This is a fascinating review. Its results are reflected in the lipid recommendations for the NICE guideline on type 2 diabetes (CG66)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;HDL CHOLESTEROL LEVELS &amp;amp; CHD RISK&lt;BR&gt;&lt;/STRONG&gt;Paper 2 Briel M, Ferreira-Gonzalez I, You JJ et al &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=316822" target="_blank"&gt;Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis &lt;/A&gt;BMJ 338:522-526&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;They included 108 randomised controlled trials involving 299,310 participants. With all trials included, change in HDL cholesterol explained almost no variability in any of the outcomes studied. &lt;BR&gt;They conclude that simply increasing the amount of circulating HDL cholesterol does not reduce the risk of coronary heart disease events, coronary heart disease deaths or total deaths. The results support reduction in LDL cholesterol as the primary goal for lipid modifying interventions.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments:&amp;nbsp;&amp;nbsp;&lt;/STRONG&gt;This is an interesting review.&amp;nbsp; It suggests that therapies designed specifically to raise HDL cholesterol may not be effective in lowering CHD risk. It isn’t specific for diabetes, but a number of the participants included are likely to have had diabetes&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;RCT’s&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;U&gt;&lt;/U&gt;&lt;BR&gt;&lt;STRONG&gt;DIETS TO LOOSE WEIGHT&lt;BR&gt;&lt;/STRONG&gt;Paper 3 Sacks F, Bray GA, Carey VJ et al Comparison of weight-loss diets with different compositions of fat, protein and carbohydrate N Engl J Med 360: 859-873&lt;BR&gt;Paper 4 Katan MB Weight-loss diets for the prevention and treatment of obesity (editorial) N Engl J Med 360: 923-925&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;In this RCT 811 overweight adults were randomly assigning to one of 4 diets which were high or low in fat, protein or carbohydrate, using similar foods. Participants were offered group and individual instructional sessions.&amp;nbsp; It lasted 2 years, the drop out rate was low, and compliance was assessed. The diet goals were only partly achieved in that protein intake was intended to differ by 10% of energy by the actual difference was only 1-2%. . Extreme carbohydrate intakes proved hard to achieve. It was hoped to get 30% of energy difference, it turned out to be 6%.&lt;BR&gt;Wt loss at 6 months was 6Kg. At 12 months subjects started to regain weight. Final wt loss averaged 3-4 Kg after 2 years. Participants who lost more weight attended more counselling sessions and adhered more closely to their diets. The authors conclude that it is behavioural factors rather than macronutrient composition are the main influences on weight loss&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;BR&gt;&lt;/STRONG&gt;The conclusion must be that sticking to a diet, any diet, is the most important thing.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;OTHER SORTS OF STUDY&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;
&lt;P&gt;Paper 5 Johannesson A, Larsson G-U, Ramstrand N et al Incidence of lower limb amputation in the diabetic and non diabetic general population Diabetes Care 32: 275-280&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;A ten year population based cohort study of initial unilateral and contra lateral amputations and re amputations from a region in Sweden. The rates of initial amputation per 100,000 person years were 192 for diabetic women, 197 for diabetic men, 22 for non diabetic women and 24 for non diabetic men. They conclude that in a general population aged 45 and over the incidence of lower leg amputation at or proximal to the Tran metatarsal level is 8 times higher in diabetic than in diabetic individuals. They found that one in four amputees may require contra lateral amputation and/or reamputation&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Clear data on amputation rates&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;SHORT REPORTS&lt;/U&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Mortality after amputation &lt;BR&gt;Paper 6 Hambleton IR, Jonnalagadda R, Davis CR et al.&amp;nbsp; All cause mortality after diabetes related amputation in Barbados. A prospective case-control study. Diabetes Care 32: 306-307. There were 205 amputations. The 1 and 5 year survival rates were 69% and 44% compared to 97% and 82% in the non diabetic case controls. These are the highest mortality rates reported worldwide.&lt;BR&gt;Managing Diabetes Care&lt;BR&gt;Davidson M How our current medical care system fails people with diabetes (editorial) Diabetes Care 32:370-372&lt;BR&gt;In this editorial Mayer Davidson commends the management system where people with diabetes see specially trained nurses or pharmacists, under appropriate supervision, with authority to make changes in treatment without consulting a doctor, as long as the changes fall within appropriate treatment algorithms. He says this has been shown to work as the main barrier in other systems is lack of timely appropriate clinical decisions due to lack of physician time with the patient.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed&lt;/STRONG&gt;&lt;BR&gt;N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int.&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;&lt;EM&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; Published in&amp;nbsp;February 2009.&amp;nbsp;This series began in 2002 as a bulletin for Diabetes Care Staff.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public.&amp;nbsp; Word and webpage versions available.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345735</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=345735]]&gt;</url>
    <title>Interesting new diabetes papers: February 2010</title>
    <publicationDate>2010-03-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 58th in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: February 2010&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;SYSTEMATIC&amp;nbsp; REVIEWS&lt;BR&gt;&lt;/U&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;STATINS &amp;amp; DIABETES&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 1 Sattar N, Preiss D, Murray HM et al &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=361183" target="_blank"&gt;Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials&lt;/A&gt; Lancet 375:735-742&lt;/EM&gt;&lt;BR&gt;&lt;EM&gt;Paper 2 Cannon CP &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=345751" target="_blank"&gt;Balancing the benefits of statins versus a new risk – diabetes (comment)&lt;/A&gt; Lancet 375:700-701&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;A meta-analysis of 13 trials, with 91140 participants of whom 4278 (2226 assigned statins and 2052 assigned control treatment) developed diabetes during a mean of 4 years. Statin therapy was associated with a 9% increased risk for incident diabetes (OR 1.09 CI 1.02-1.17) with little heterogeneity between trials. Treatment of 255 people with statin for 4 years resulted in one extra case of diabetes. The paper concludes by saying that statin therapy is associated with a slightly increased risk of developing diabetes, but the risk is low both in absolute terms and when compared with the reduction in coronary events. Clinical practice in patients with moderate or high cardiovascular risk or existing cardiovascular disease should not change.&lt;BR&gt;The commentary article&amp;nbsp; calculates that in the group of 255 patients treated with statin for 4 years producing 1 new case of diabetes, there would be 5.4 less deaths or myocardial infarctions and nearly the same number of strokes or cardiac revascularisation procedures would have been avoided. It&amp;nbsp; says that thus whilst a new risk of statins has been identified the risk seems small and is far outweighed by the benefits of statin.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;No need to change any clinical guidance on this information&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PERIDONTAL TREATMENT AND GLYCAEMIC CONTROL&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 3 Teeuw WJ, Gerdes VEA, Loos BG &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=374766" target="_blank"&gt;Effects of periodontal treatment on glycaemic control of diabetic patients: a systematic review and meta-analysis&lt;/A&gt;&amp;nbsp; Diabetes Care 33: 421-427&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;This is a&amp;nbsp; meta-analysis of 5 articles with 371 patients with periodontitis as the predictor and absolute change in HBA1c as outcome. The duration of follow up was 3-9 months. All studies described a population of people with type 2 diabetes in whom glycaemic control improved after periodontal therapy compared with a control group, with a mean difference of -0.4% in HBA1c. Nevertheless this improvement must be interpreted with care due to limited robustness as evidenced by heterogeneity among studies (59.5%)&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;BR&gt;&lt;/STRONG&gt;This is further evidence for the link between good oral health and good glycaemic control&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;OTHER SORTS OF STUDY&lt;BR&gt;&lt;/U&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;HBA1c AND MORTALITY&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 4 Currie CJ, Peters JR, Tynan A et al Survival as a function of HBA1c in people with type 2 diabetes: a retrospective cohort study Lancet 375: 481- 489&lt;/EM&gt;&lt;BR&gt;&lt;EM&gt;Paper 5 Balkau B, Simon D Survival in people with type 2 diabetes as a function of HBA1c (comment) Lancet 375:438-439&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;This study generated two cohorts of patients aged 50 and over with type 2 diabetes from the UK general practice research database from Nov 1986 to November 2008.&amp;nbsp; The first cohort was of 27965 people changed from oral monotherapy to combination oral therapy with metformin and a sulphonylurea. The second was of 20005 people changed onto regimes that included insulin. Mean follow up was 4.5 years in cohort 1 and 5.2 years in cohort 2.&amp;nbsp; All cause mortality was the primary outcome. Confounding factors were identified and Cox survival models were adjusted for these factors accordingly. &lt;BR&gt;The main result was that the 10% of patients with the lowest HBA1c values (below 6.7%) had a higher death rate than all but those in the top 10% who had a HBA1c of 9.9% or higher. Furthermore cardiovascular disease was more frequent in this low HBA1c group than in any decile. The results overall show a U shaped association with the lowest hazard ratio for death at an HBA1c of 7.5%. The hazard ratio for all cause mortality in people given insulin based regimes (2834 deaths) versus those given combination oral agents (2035 deaths) was 1.49. The U shaped pattern was sufficiently similar in the 2 treatment cohorts to suggest that risk of mortality with respect to HBA1c was independent of treatment regime. The commentary says that this study although it supports the results of RCT’s such as ACCORD cannot show as causal relationship between HBA1c and mortality. However the results are consistent with the idea that premature death may be related to hypoglycaemia.&lt;BR&gt;This study supports the notion that in people with type 2 diabetes on insulin secretagogues or insulin itself the HBA1c target of 7.5% corresponds to the lowest death rate and the lowest event rate for large vessel disease. The comment says that priority should be given to insulin sensitizer therapy to lower HBA1c for as long as possible in people with type 2 diabetes because these drugs allow a low HBA1c to be targeted without any risk of hypoglycaemia. &lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Interesting study that may have implications for HBA1c targets and the use of insulin sensitizers (metformin and glitazone therapies) as the first two treatment choices for glycaemic lowering therapy. Also see Roger Gadsby's discussion in the &lt;A href="http://www.evidence.nhs.uk/aboutus/Documents/EoE12.pdf" target="_blank"&gt;"Eyes on Evidence" newsletter&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;SHORT REPORTS&lt;BR&gt;&lt;/U&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Incretin Based Therapies&lt;/STRONG&gt;&amp;nbsp; &lt;BR&gt;&lt;EM&gt;Paper 6&amp;nbsp; Drucker DJ, Sherman SI, Gorelick FS et al Incretin based therapies for the treatment of type 2 diabetes: evaluation of risks and benefits (Review) Diabetes Care 33:428-433&lt;/EM&gt;&amp;nbsp; &lt;BR&gt;This review concludes that the available evidence supports the use of incretin based therapies for patients requiring effective control of glycaemia and body weight whilst minimising the risk of hypoglycaemia. &lt;BR&gt;&lt;EM&gt;Paper 7 Butler PC, Dry S, Elashoff R GLP-1 based therapy for diabetes: what you do not know can hurt you. (editorial)&amp;nbsp; Diabetes Care 33: 453-455&lt;/EM&gt; &lt;BR&gt;This says that they believe it is premature to conclude that the GLP-1 class has been established as having a good safety record and is appropriate for relatively early choice of therapy in type 2 diabetes. They feel that this class of drugs may induce asymptomatic pancreatitis and, over time, in some individuals induce pancreatic cancer. &lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Kidney and Glucose Homeostatis&lt;/STRONG&gt; &lt;BR&gt;&lt;EM&gt;Paper 8 Gerich JE Role of the Kidney in normal glucose homeostasis and in hyperglycaemia of diabetes mellitus: therapeutic implications.(review)&amp;nbsp; Diabetic Medicine 27: 136-142&lt;/EM&gt; &lt;BR&gt;Good background review setting the scene for the SGLT2 class of drugs which are coming to market in the next few years.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Thiazides to treat raised BP in people with diabetes &lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 9 Siebenhofer A, Jeitler K, Rakovac , Hovath K Diuretics and diabetes incidence – an appeal against the reluctance to prescribe a medication that is safe and proven. Diabetic Medicine 27:130-135.&lt;BR&gt;&lt;/EM&gt;It states that there are no long term studies which address the issue of whether the negative hyperglycaemic effect observed with diuretic use overcomes the cardioprotective effect in the long run. In the report of German NICE on therapies for hypertension the best results in according to patient relevant outcomes were for the thiazide class. The seemingly important differences in diabetes incidence with thiazides is just a magnification of only a small increase of around 0.28mmoles/l of glucose &lt;BR&gt;&lt;EM&gt;Paper 10 Cruickshank JK Low dose thiazide diuretics in and around diabetes – definitely yes and how do they compare with other interventions (Guest Editorial)) Diabetic Medicine 27: 127-129.&lt;/EM&gt;&amp;nbsp; &lt;BR&gt;The author says that paper 9 is to be applauded and welcomed. He argues that the slight increase in glucose in those on thiazides labels more people as having diabetes but the good bp control they give is vital.&lt;BR&gt;In those with diabetes thiazides should be used as they are excellent at reducing blood pressure and reducing microvascular risk and the small increase in HBA1c they give is of no consequence for macrovascular disease.&lt;BR&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;NOTE&lt;/STRONG&gt; &lt;BR&gt;The Jan-Feb edition of Diabetes &amp;amp; Vascular&amp;nbsp; disease&amp;nbsp; (Vol 11 issue 1) has a number of articles about hypoglycaemia including ones on its relation to cardiovascular disease. (see papers 4 &amp;amp; 5) &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt;&amp;nbsp; N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>306832</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=306832]]&gt;</url>
    <title>Interesting new diabetes papers: January 2009</title>
    <publicationDate>2009-02-20T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2009,RESEARCH,INTERESTING NEW ARTICLES,DIABETES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 45th in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: January 2009&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;U&gt;&lt;STRONG&gt;GUIDELINES&lt;/STRONG&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;GLYCAEMIC MANAGEMENT &lt;BR&gt;&lt;/STRONG&gt;Paper 1 Nathan DM, Buse JB, Davidson MB et al &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=306912&amp;amp;tabID=288" target="_blank"&gt;Medical Management of Hyperglycaemia in Type 2 Diabetes: A consensus algorithm for the initiation and adjustment of therapy &lt;BR&gt;&lt;/A&gt;A consensus statement from ADA/EASD Diabetes Care 32: 193-203&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;This updates the 2006 consensus guideline. It begins with a Tier 1 (well validated core therapies)&amp;nbsp; of lifestyle plus metformin then adds either basal insulin or sulphonylurea. It also gives a&amp;nbsp; Tier 2 (Less well validated therapies) which are lifestyle + metformin add pioglitazone or lifestyle + metformin add GLP-1 agonist. It also mentions triple oral therapy of metformin+ sulphonylurea + pioglitazone It has a brief section on DPP4 inhibitors but doesn’t include them in the algorithm!&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;BR&gt;&lt;/STRONG&gt;This guideline differs from the NICE type 2 guideline published in May 2008, and is likely to be different to the rapid update of the glycaemic section of this guideline due for publication in March 2009. In the UK these NICE guidelines are likely to be the ones that influence management.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;INSULIN PUMP THERAPY&lt;/STRONG&gt;&lt;BR&gt;Paper 2 Pickup JC, Hammond P &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=306917&amp;amp;tabID=290&amp;amp;catID=7088" target="_blank"&gt;NICE Guidance on continuous insulin infusion (CSII) 2008: review of the technology appraisal guidance &lt;/A&gt;(editorial) Diabetic Medicine 26:1-4&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;This NICE TA updates the 2003 guidance. There are 2 major policy changes in this new publication. The first is the introduction of a new category of patients with type 1 diabetes who may be suitable for a trial of CSII: those with persistenly elevated HBA1c at or above 8.5% during best attempts to control their diabetes with multiple dose injections (MDI) The second is the recommendation that children no longer need to have “failed on MDI” before undertaking a trial of CSII.&lt;BR&gt;These changes are discussed and the cost effectiveness arguments are outlined&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;This is an important TA and this editorial helpfully discusses the issues and changes&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;REVIEWS &amp;amp; META-ANALYSES&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;U&gt;&lt;/U&gt;&lt;BR&gt;&lt;STRONG&gt;BARIATRIC SURGERY &amp;amp; DIABETES&lt;/STRONG&gt;&lt;BR&gt;Paper 3 Vetter ML, Cardillo S, Rickets MR, Iqbal N &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=306960&amp;amp;tabID=289&amp;amp;catID=5604" target="_blank"&gt;Narrative Review : Effect of Bariatric Surgery on type 2 diabetes &lt;/A&gt;Ann Intern Med 150:94-103&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;Search from 1967- 2008 for relevant papers These included RCT’s, cohort studies, case controlled studies and large case series. They conclude that bariatric surgery produces substantial and durable weight reduction. Nearly 30% of patients in the studies had type 2 diabetes. For many of them the diabetes resolves after surgery. The rates of resolution are 84%-98% for bypass type of bariatric surgery and 48%-68% for restrictive procedures (banding).&amp;nbsp; Glycaemic control improves in part because of calorie restriction, but also because gut peptide secretion changes. Bariatric surgery, (particularly bypass procedures) alters the secretion of gut hormones (eg GLP-1 GIP, ghrelin, peptide YY) which result in enhanced insulin secretion and sensitivity.&lt;BR&gt;&lt;STRONG&gt;&amp;nbsp;Dr Roger Gadsby’s comments:&lt;/STRONG&gt; This is a fascinating review&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;RCT’s&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;U&gt;&lt;/U&gt;&lt;BR&gt;&lt;STRONG&gt;GLYCAEMIC CONTROL &amp;amp; CVD EVENTS&lt;/STRONG&gt;&lt;BR&gt;Paper 4&amp;nbsp; Duckworth W, Abraira C, Moritz T et al Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360: 129-139&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;A RCT of 1791 military veterans (ie mostly men) of mean age 60.4 years, who had had diabetes for a mean of 11.5 years, 40% had already had a cardiovascular event. One group had standard therapy&amp;nbsp; (mean HBA1c obtained was 8.4%) the other intensive therapy (mean HBA1c obtained 6.9%) Mean follow up was 5.6 years. The main outcome measure was time from randomization to first major CVD event (a composite of MI, death from CVD cause, CCF, etc.) The primary outcome occurred in 264 patients in standard therapy and 235 in intensive therapy, a non significant difference. There was no difference between the groups in microvascular complications&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;This gives similar results to the ACCORD and ADVANCE trials in that intensive glucose control had no effect on CVD events.&lt;BR&gt;Paper 5 Janssen PGH, Gorter KJ, Stolk RP, Rutten G Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen detected type 2 diabetes BJGP 59:43-48&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;People with screen detected type 2 diabetes were randomised to intensified treatment (n=255) or routine treatment (n=243) and followed for 1 year. Intensified treatment aimed to get HBa1c below 7%, BP below 135/85 and cholesterol below 5. The differences in these measures intensive v standard at 1 year were were systolic bp -33 mmhg v – 19, diastolic -12 v -7, HBA1c -1.1 v 0.9%, total chol -1.2v -0.5. Health related quality of life (as measured by HRQoL) was no different in the 2 groups.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Risk factors can be reduced. Does doing that reduce mortality? This remains to be seen, the full study reports in 2010. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;SHORT REPORTS&lt;/U&gt;&lt;/STRONG&gt;&lt;BR&gt;Diabetes Medication Satisfaction Tool&amp;nbsp; Paper 6 Anderson RT, Girman CJ, Pawaskar MD et al Diabetes Medication Satisfaction Tool Diabetes Care 32 :51-53. This tool it concludes offers a comprehensive assessment of patient acceptability with diabetes therapy&lt;BR&gt;Health Beliefs Paper 7 The importance of health belief models in determining self-care behaviour in diabetes; a Review Diabetic Medicinme 26:5-13 This review aims to summarize developments in this area of psychological theory in past 20 years&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed&lt;BR&gt;&lt;/STRONG&gt;N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;&lt;EM&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; Published in January 2009.&amp;nbsp;This series began in 2002 as a bulletin for Diabetes Care Staff.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public.&amp;nbsp; Word and webpage versions available.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345556</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=345556]]&gt;</url>
    <title>Interesting new diabetes papers: January 2010</title>
    <publicationDate>2010-03-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2010,INTERESTING NEW ARTICLES,RESEARCH,DIABETES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 57th in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: January 2010&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;OTHER SORTS OF STUDY&lt;BR&gt;&lt;/U&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;HYPOGLYCAEMIA &amp;amp; DEATH IN THE ACCORD STUDY&lt;/STRONG&gt;&lt;BR&gt;Paper 1 Bonds D, Miller ME, Bergenstal RM et al&amp;nbsp; The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study BMJ 340:137&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;Retrospective epidemiological analysis of 10194 participants in the ACCORD study with an average length of follow up of 3.5 years. The study question was “Did participants in the ACCORD study who experienced 1 or more episodes of symptomatic, severe hypoglycaemia have an increased risk of death. The answer was that symptomatic, severe hypoglycaemia was associated with and increased risk of death in both the intensive glucose control arm and the standard glucose control arm. However among participants who experienced at least 1 episode of hypoglycaemia the risk of death was lower in the intensive arm than in the standard arm.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;This shows that people experiencing severe hypoglycaemia are at increased risk of death, regardless of the intensity of glucose control.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;BR&gt;MORTALITY AND CVD &lt;BR&gt;&lt;/STRONG&gt;Paper 2 Tzoulaki I, Molokhia M, Curcin V et al Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetic drugs: retrospective cohort study using UK general practice research database&lt;BR&gt;BMJ 2009:339:b4731 Published 2 Jan 2010 vol 340&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;Retrospective audit study from UK research database from 1990-2005 of 91521 people with diabetes. 3588 incident cases of myocardial infarction, 6900 of congestive cardiac failure and 18548 deaths occurred. Person time intervals for drug treatment were categorised by drug class, excluding non-drug intervals and intervals for insulin. Compared with insulin, monotherapy with sulphonylureas was associated with a significant 24% to 61% excess risk for all cause mortality. Pioglitazone was associated with a significant 31% to 39% lower risk of all cause mortality compared with metformin. Rosiglitazone was associated with a 34% to 41% higher risk of all cause mortality compared to pioglitazone. &lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;This study tried to account for as many confounders as possible, but is still open to the criticism that residual confounding or cofounding by indication( differences in prognostic factors between drug groups) may have influenced the results. However the unfavourable risk of sulphonylurea compared to metformin is striking, as is the favourable risk of pioglitazone compared to metformin, and the favourable risk of pioglitazone compared to rosiglitazone.&amp;nbsp; Pioglitazone comes off patent in around 12 months and then may reduce in price to around the cost of generic sulphonylurea. Given this evidence of its favourable risk profile one wonders if it might replace sulphonylurea as the recommended agent to be added second to metformin. Also see Roger Gadsby's&amp;nbsp;discussion in the &lt;A href="http://www.evidence.nhs.uk/aboutus/Documents/EoE10.pdf" target="_blank"&gt;"Eyes on Evidence" newsletter&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;SHORT REPORTS&lt;BR&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;Insulin glargine in Pregancy&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp; &lt;BR&gt;Paper 3 Pollex EK, Feig DS, Lubetsky A et al Insulin glargine safety in Pregnancy Diabetes Care 33:29-33 This was a transplacental transfer study. It showed that insulin glargine when used at therapeutic concentrations is not likely to cross the placenta. &lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Diabetes Care in Black Patients &lt;BR&gt;&lt;/STRONG&gt;Paper 4 Sequist TD, Fitzmaurice DM, Marshall R et al Cultural competency training and performance reports to improve diabetes care for black patients Ann Intern Med 2010 152: 40-46 The combination of cultural competency training and monthly race stratified performance reports increased clinician awareness of racial disparities in diabetes care but did not improve clinical outcomes among black patients.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Depression&lt;/STRONG&gt; &lt;BR&gt;Paper 5 Fisher L, Mullan JT, Arean P et al Diabetes distress but not clinical depression or depressive symptoms is associated with glycaemic control in both cross sectional and longitudinal analyses Diabetes Care 33:23-28&lt;BR&gt;They conclude that what has been called depression among people with type 2 diabetes may really be two conditions major depressive disorder and diabetes distress with only the latter displaying significant associations with HBA1c&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Metabolic Syndrome&lt;/STRONG&gt; &lt;BR&gt;Paper 6 Eckel RH, Alberti KGMM, Grundy SM Zimmet PZ Metabolic Syndrome (comment) Lancet 375: 181-183 Further discussion and debate around new IDF definition&lt;BR&gt;HBA1c in Diagnosis Paper 7 Carson AP, Reynolds K, Fonseca VA, Muntner P Comparison of HBA1c and Fasting glucose criteria to diagnose diabetes among US adults Diabetes Care 33:95-97 HBA1c at or greater than 6.5% demonstrates reasonable agreement with fasting glucose for diagnosing diabetes among US adults using data from 6890 adults from 1999-2006 national health and nutrition examination survey (NHANES).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt;&amp;nbsp; N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>294605</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=294605]]&gt;</url>
    <title>Interesting new diabetes papers: July 2008</title>
    <publicationDate>2008-09-23T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the thirty ninth in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: July 2008&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;SYSTEMATIC REVIEWS &amp;amp; META_ANALYSIS&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 1 Pickup JC Sutton AJ Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin (MDI)&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;injections compared with continuous subcutaneous insulin infusion (CSII)&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;Diabetic Medicine 25: 765-774&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Summary&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;This is a review and meta-analysis of 22 studies from 21 reports of RCT’s and before/after studies of 6months or more duration of CSII (Insulin pumps) and with a severe hypoglycaemia frequency of more than 10 episodes/100 patient years on MDI&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;In the reports severe hypoglycaemia during MDI was related to diabetes duration and was greater in adults than children. Severe hypoglycaemia was reduced during CSII as compared to MDI with a rate ratio of 2.89 for RCTs and 4.34 for before/after studies.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;The mean difference in HBA1c between treatments was less for RCT’s (0.21%) than before/after studies (0.72%) &lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;The severe hypoglycaemia rate in type 1 diabetes was markedly less during CSII than MDI, with the greatest reduction in those with most severe hypoglycaemia on MDI and with those with the longest duration of diabetes. The biggest improvement in HBA1c was in those with the highest HBA1c on MDI&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Dr &lt;/B&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:PersonName&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Roger Gadsby&lt;/B&gt;&lt;/st1:PersonName&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;’s comments&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;Helpful data that is in line with what would have been expected&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;OTHER SORTS OF STUDY&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;ADHERENCE&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 2 Donnelly A, Doney ASF, Morris AD et al Long term adherence to statin treatment in diabetes Diabetic Medicine 25: 850-855&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Summary&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;A retrospective study of 6462 people with diabetes started on statin between 1999-2003 in Tayside region of Scotland using the DARTS database and prescription linkage. The outcome measure was % of days covered (PDC) with statin calculated at regular intervals, established from prescription encashment. The pattern of adherence observed in the study, a sharp decline in the first 6 months with PDC of 61% in the first and second quarters, followed by a more gradual decline over time, is consistent with other studies of BP lowering adherence. In this study only 41% of people were taking more than 80% of their statin therapy after 5 years. This is very different to the adherence rates in RCT’s of statin therapy&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;Predictors of poor long term adherence were younger age, higher HBA1c no CVD history at baseline, and occurrence of CVD after starting statin.&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;st1:PersonName&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Roger Gadsby&lt;/B&gt;&lt;/st1:PersonName&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;’s comments&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;The adherence rates reported here are very low. The beneficial effect of statins seen in trials with high adherence rates will not be apparent to the same extent in the real world with these adherence rates.&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;QOF EXCEPTION REPORTING &lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 3 Doran T, Fullwood C, Reeves D et al Exclusion of patients from pay-for-performance targets by English physicians &lt;/I&gt;&lt;st1:place&gt;&lt;I style="mso-bidi-font-style: normal"&gt;N Eng&lt;/I&gt;&lt;/st1:place&gt;&lt;I style="mso-bidi-font-style: normal"&gt; J Med 359: 274-284&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Summary&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;In this paper data from 8105 GP’s in &lt;st1:country-region&gt;&lt;st1:place&gt;England&lt;/st1:place&gt;&lt;/st1:country-region&gt; (96% of all practices) was analysed for the rate of exception reporting for 65 clinical activities.&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;A median of 5.3% of patients were excluded from the quality calculations. Physicians were more likely to exclude patients for indicators that were related to providing treatments and achieving target levels of intermediate outcomes. They were least likely to exclude patients from indicators that were related to routine checks and measurements and to offers of treatment.&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;For the diabetes indicators,&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;the exclusion rates for measurement and review were 4.1%, for offer of treatment 3.2% provision of treatment 12.6% and achievement of intermediate outcome 9.4%. For the individual diabetes indicators exclusion rates varied from mean of 1.55% for indicator 11 BP recorded to&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;mean of 12.57% for indicator 6 HBA1c of 7.4% or less.&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;The authors conclude that rates of exception reporting appear low with little evidence of&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;widespread gaming&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;SHORT REPORTS&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Rosiglitazone use in Canada &lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/B&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 4 Shah BR, Juurlink DN, Austin PC, Mamdani MM New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;Diabetic Medicine 25: 871 - 874&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;Using data from prescription records in &lt;st1:State&gt;&lt;st1:place&gt;Ontario&lt;/st1:place&gt;&lt;/st1:State&gt; &lt;st1:country-region&gt;&lt;st1:place&gt;Canada&lt;/st1:place&gt;&lt;/st1:country-region&gt; between Jan – Dec 2007 the authors describe a sudden decline in new users of rosiglitazone mirrored by a nearly identical but transient increase in new users of pioglitazone. There was also a net decline in new users of&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;TZD’s as a&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;class. The number of new users of other glucose lowering medications did not change&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;U&gt;&lt;o:p&gt;&lt;SPAN style="TEXT-DECORATION: none"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;U&gt;&lt;o:p&gt;&lt;SPAN style="TEXT-DECORATION: none"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;U&gt;&lt;/U&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;U&gt;&lt;/U&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;U&gt;Journals reviewed&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetic Medicine, Pract Diab Int&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;&lt;o:p&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; published in&amp;nbsp;September 2008.&amp;nbsp;This series began in 2002 as a bulletin for Diabetes Care Staff.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public.&amp;nbsp; Word and webpage versions available.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;EM&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;/o:p&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>323115</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=323115]]&gt;</url>
    <title>Interesting new diabetes papers: July 2009</title>
    <publicationDate>2009-08-21T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 51st in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: July 2009&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;GUIDELINES &amp;amp; REPORTS&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;DIAGNOSING DIABETES USING HBA1c&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;Paper 1 The International Expert Committee&amp;nbsp;&amp;nbsp; &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=323116&amp;amp;tabID=290&amp;amp;catID=5626" target="_blank"&gt;The International Expert Committee Report on the Role of A1c Assay in the diagnosis of Diabetes&lt;/A&gt; Diabetes Care 32: 1327-1334&lt;BR&gt;Paper 2 Fonesca V, Inzucchi SE, Ferrannani E &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=323116&amp;amp;tabID=290&amp;amp;catID=5626" target="_blank"&gt;Redefining the Diagnosis of Diabetes using Glycated Hemoglobin &lt;/A&gt;Diabetes Care 32: 1344-5&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;This report recommends that the diagnosis of diabetes is made if the HBA1c level is 6.5% or above. Diagnosis should be confirmed with a repeat HBa1c test unless clinical symptoms and glucose levels of above 11.1mmoles/l are present. If HBA1c testing is not possible owing to patient factors that preclude its interpretation (e.g. haemaglobinopathy) previously recommended diagnostic glucose levels should be used. The diagnosis of diabetes during pregnancy, when changes in red cell turnover make the HBA1c assay problematical will continue to require glucose measurements. &lt;BR&gt;The report states that individuals with a HBA1c at or above 6% but below 6.5% are likely at the highest risk for progression to diabetes, but this range should not be considered an absolute threshold at which preventative measures are initiated.&lt;BR&gt;The editorial comments that debate and concerns from theses recommendations are likely to revolve around the lack of an HBA1c value for a formal definition of prediabetes, and the fact that the ADA guideline treatment target is 7% .&amp;nbsp; &lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;These recommendations await endorsement by the ADA/EASD and IDF. This may occur at the IDF conference in Oct 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;RCT’s&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;LIRAGLUTIDE&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;Paper 3 Buse JB, Rosenstock J, Sesti G et al Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26 week randomised, parallel group multinational open label study (LEAD 6) Lancet 374: 39-45&lt;BR&gt;Paper 4 De Block CEM, Van Gaal LF GLP-1 receptor agonists for type 2 diabetes (comment)&lt;BR&gt;Lancet 374: 4-6&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;Adults with inadequately controlled type 2 diabetes on maximally tolerated doses of metformin, sulphonylurea or both received Liraglutide 1.8mgs daily (n= 233) or exenatide 10 micrograms twice daily (n= 231) for 26 weeks. The mean baseline HBA1c was 8.2%. Liraglutide reduced it by -1.12% and exenatide by -0.79%. Both drugs reduced weight by a similar amount Liraglutide by -3.24kg exenatide by -2.87 kg. Nausea was less persistent and minor hypoglycaemia less frequent with Liraglutide. Treatment satisfaction was greater in patients on Liraglutide than exenatide.&lt;BR&gt;The editorial concludes that Liraglutide provides greater improvements in glycaemic control and is better tolerated than exenatide: therefore this novel GLP-1 analogue might be a good option for the treatment of type 2 diabetes&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Interesting data from a head to head comparison study&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;ACE &amp;amp; ARB DRUGS &amp;amp; MICROVASCULAR COMPLICATIONS&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Paper 5 Bilous R, Chaturvedi N, Sjolie AK, et al Effect of Candasartan on microalbuminuria and albumin excretion rate in Diabetes Three randomised trials&lt;BR&gt;&amp;nbsp;Ann Int Med 151: 11-20&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;3326 people with type 2 diabetes and 1905 people with type 1 diabetes with normal albuminuria most of whom were normotensive were given candasartan 16 mgs daily rising to 32 mgs daily or placebo. The median follow up was 4.7 years. The data was from the 3 DIRECT (Diabetic Retinopathy Candasartan Trials) which were powered to capture retinal and not renal endpoints. The overall study population had a low rate of microalbuminuria.&lt;BR&gt;The results showed that candasartan 32 mgs daily had little effect on risk for microalbuminuria. Pooled results showed that the annual rate of change of albuminuria was 5.53% lower with candasartan than placebo.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;This negative result on the development of microalbuminuria is perhaps unexpected.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Paper 6 Mauer M, Zinman B, Gardiner R et al Renal and retinal effects of enalapril and losartan in type 1 diabetes N Eng J Med 361: 40-51&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;285 normotensive patients with type 1 diabetes and normoalbuminuria were randomly assigned to losartan 100mgs daily, enalapril 20mgs daily or placebo and followed for 5 years in this multi centre study.&amp;nbsp; Renal biopsy data was available on 90% of the subjects.&lt;BR&gt;As compared with placebo retinopathy progression by 2 steps on the scale was reduced by 65% by enalapril and 70% by losartan. There was no effect on nephropathy progression by either enalapril or losartan nor was there any significant treatment benefits on any biopsy assessed structural variables.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Further negative results on nephropathy progression, but very positive benefits on retinopathy progression&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OTHER SORTS OF STUDY&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;Paper 7 Campbell SM, Reeves D, Kontopantelis E et al&amp;nbsp; Effects of Pay for Performance on the Quality of Primary Care in England N Engl J Med 361: 368-378&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;Study based on data collected from 42 representative general practices before the introduction of the Quality and Outcomes framework (QoF)&amp;nbsp; in 1998 and 2003 and after QoF in 2005 and 2007. The quality of Care for diabetes was improving at an average rate of 1.8% per annum before Qof, and showed an accelerated rate of growth after the introduction of QoF. After 2005 the rate of growth fell back to the pre-introduction&amp;nbsp; level &lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;BR&gt;&lt;/STRONG&gt;Further information on the effect of QoF for diabetes&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;SHORT REPORTS&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;Screening for Gestational Diabetes Paper 8 Moses RG Wah Cheung N Point: Universal Screening for Gestational Diabetes Care 32: 1349-51 Paper 9 Berger H Sermer M Counterpoint: Selective screening for gestational diabetes Diabetes Care 32: 1352-3 This form of “debate” highlights the issues very well &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed&lt;/STRONG&gt;&amp;nbsp; N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>385387</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=385387]]&gt;</url>
    <title>Interesting new diabetes papers: July 2010</title>
    <publicationDate>2010-08-25T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: July 2010&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;GUIDELINES &amp;amp; INTERNATIONAL CONSENSUS STATEMENTS&lt;BR&gt;HBA1c Standardization&lt;BR&gt;&lt;/U&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 1 &lt;BR&gt;Hanas R, John G on the behalf of the International HBA1c Consensus Committee&amp;nbsp;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=385491" target="_blank"&gt;2010 Consensus Statement on the worldwide standardization of HBA1c measurement&lt;/A&gt; Diabetic Medicine 27: 737-738&lt;BR&gt;Paper 2 &lt;BR&gt;John G &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=385478" target="_blank"&gt;Haemaglobin A1c towards global standardization (editorial)&lt;/A&gt; Diabetic Medicine 27: 733-734&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;Statements in summary are:-&lt;BR&gt;1 HBA1c should be standardised worldwide 2 The IFCC reference range represents the only valid anchor to implement standardization 3 HBA1c results to be reported in SI units mmole/mole (which have been called IFCC units) and NGSP units (which have been called DCCT aligned HBA1c as %)&amp;nbsp; 4 HBA1c conversion tables to SI units and from SI units to % HBA1c should be easily accessible 5 editors of journals&amp;nbsp; require manuscripts to report in both units 6 reportable term is HBA1c 7 the above recommendations should apply till the subject is discussed again in IDF Dubai in Dec 2011&lt;/P&gt;&lt;STRONG&gt;&lt;U&gt;
&lt;P&gt;&lt;BR&gt;SYSTEMATIC&amp;nbsp; REVIEWS&lt;BR&gt;&lt;/U&gt;HBA1c &amp;amp; Future risk of Diabetes&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 3 &lt;BR&gt;&lt;/EM&gt;&lt;EM&gt;Zhang X, Gregg EW, Williamson DF et al &lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=385476" target="_blank"&gt;A1c Level and Future risk of diabetes: A systematic review&lt;/A&gt; Diabetes Care&amp;nbsp;33:1665-1673&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;This is a systematic review of 16 studies which fulfilled the inclusion criteria and which had a total of&amp;nbsp; 44203 participants with follow up averaging 5.6 years. Annualized diabetes incidence ranged from 0.1% at HBA1c less than 5% to 54% at HBA1c at or greater than 6.1%. Findings from 7 studies that examined incident diabetes across a broad range of HBA1c categories showed (1) risk of incident diabetes increased steeply across the range 5%-6.5%. (2) the range 6-6.5% was associated with a highly increased risk of incident diabetes ( 25-50% incidence over 5 years) (3) 5.5% -6% was associated with a moderately increased risk (9-25%) and 5-5.5% was associated with an increased incidence relative to HBA1c below 5% but the absolute incidence of diabetes was less than 9% over 5 years.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;BR&gt;&lt;/STRONG&gt;Important information that will inform screening for diabetes as HBA1c becomes the preferred measurement &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;BR&gt;RCT’s&lt;/U&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;Nutritional interventions&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 4 &lt;BR&gt;Coppell KJ, Kataoka M, Williams SM et al Nutritional intervention in patients with type 2 diabetes who are hyperglycaemic despite optimal drug treatment – Lifestyle over and above drugs in diabetes (LOADD) study : randomised controlled trial BMJ 341:237&lt;BR&gt;Paper 5 &lt;BR&gt;Clifton P Nutrition in people with poorly controlled type 2 diabetes (editorial) BMJ 341: 209-210&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;A study of 93 people with type 2 diabetes from the community aged under 70 years who were given usual treatment or intensive dietary advice plus usual treatment and followed for 6 months. Physical activity advice was the same in both groups. Those given intensive dietary advice dropped their HBA1c by 0.4% , BMI by 0.5%, systolic bp by 1.4mmhgand waist circumference by 1.6cms. The editorial points out that the intervention with trained dietitians is expensive and that nutrition interventions that can be delivered without dietitians, doctors or psychologists and look at results over longer time periods are needed&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Interesting data&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;School based intervention to lower obesity&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 6 &lt;BR&gt;The HEALTHY Study group A School –Based Intervention for Diabetes risk reduction N Eng J Med 363:443-453&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;A school based 3 year multi component programme in 21 schools in USA with 21 schools as controls with a total of 4603 students. There was a decrease in the primary outcome of combined prevalence of obesity plus overweight in both intervention and control schools, with no significant difference between school groups. The intervention schools had greater reductions in secondary outcomes of % of students with waist circumference above 90th centile, fasting insulin levels and prevalence of obesity.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;The reductions in secondary outcomes may reduce the risk of childhood onset type 2 diabetes&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;BR&gt;OTHER SORTS OF STUDY&lt;/U&gt;&lt;BR&gt;Glitazones and CVD risk &lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 7 &lt;BR&gt;Graham DJ, Ouellet-Hellstrom R, MaCurdy TE et al Risk of Acute myocardial infarction, Stroke, Heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone JAMA 304: 411-418&lt;BR&gt;Paper 8 &lt;BR&gt;Juurlink DN Rosiglitazone and the case for safety over certainty (editorial) JAMA 304: 469-471&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;Observational study of 227571 medicare beneficiaries aged 65 or older (mean age 74.4years) who had glitazone treatment initiated between 2006-2009 who were followed for 3 years, with 8667 endpoints observed during the study. The attributable risk for&amp;nbsp; the composite endpoint of AMI, stroke, heart failure and death was 1.68 excess events per 100 person years of treatment with rosiglitazone compared to pioglitazone. The corresponding number needed to harm was 60. &lt;BR&gt;The editorial concludes that rosiglitazone confers no therapeutic advantage over pioglitazone and that accumulating concerns about rosiglitazone make it difficult to advance a cogent argument regarding why exactly a patient might to receive the drug or why a physician would choose to prescribe it when there is an available and quite possibly safer alternative.&lt;/P&gt;
&lt;P&gt;&lt;U&gt;&lt;STRONG&gt;&lt;BR&gt;SHORT REPORTS&lt;/STRONG&gt;&lt;BR&gt;&lt;/U&gt;&lt;STRONG&gt;Costs of glucose lowering therapies in UK &lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 9 &lt;BR&gt;Currie CJ, Peters JR, Evans M Dispensing patterns and financial cost of glucose lowering therapies in the UK from 200-2008 Diabetic Medicine 27: 744-752&lt;/EM&gt;&lt;BR&gt;Costs rose markedly between 200 and 2008 to represent an annual cost of £708 million. Costs increased at a higher rate than volume. Insulin costs rose from £128 million to £286 million&lt;BR&gt;Diabetes &amp;amp; Cancer&lt;BR&gt;&lt;EM&gt;Paper 10 &lt;BR&gt;Giovannucci E, Harlan DM, Archer MC et al Diabetes &amp;amp; Cancer an ADA consensus report Diabetes Care 33:1674-1685&lt;/EM&gt; Epidemiologic evidence suggests than cancer incidence is associated with diabetes as well as certain diabetes risk factors and treatments. This expert panel report reviews this data.&lt;BR&gt;BP Control and CVD events &lt;BR&gt;&lt;EM&gt;Paper 11 &lt;BR&gt;Cooper- DeHoff RM, Gong Y, Handberg EM Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease JAMA 304: 61-68&lt;/EM&gt; Observational subgroup analysis of 6400 (out of 22576) in the INVEST trial. Conclusion is that tight blood pressure control (systolic bp below 130) among patients with diabetes and coronary artery disease is not associated with improved cardiovascular outcomes compared with usual control (systolic bp 130- less than 140)&lt;BR&gt;Retinopathy&lt;BR&gt;&lt;EM&gt;Paper 12 &lt;BR&gt;The ACCORD Study group and ACCORD eye study group Effects of medical therapies on retinopathy progression in type 2 diabetes N Engl J Med 363:233-244 &lt;/EM&gt;Intensive glycaemic control and intensive combination treatment of dyslipidaemia (simvastatin and fenofibrate 160mgs daily) but not intensive blood pressure control reduced the rate of progression of diabetic retinopathy&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;BR&gt;Journals reviewed:&lt;/STRONG&gt;&amp;nbsp;N Eng J Med,&amp;nbsp; Lancet, JAMA&amp;nbsp; BMJ, BJGP,&amp;nbsp; Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int&lt;/EM&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>324489</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=324489]]&gt;</url>
    <title>Interesting new diabetes papers: June 2009</title>
    <publicationDate>2009-09-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 50th in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: June 2009&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;RCT’s&lt;/U&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;ROSIGLITAZONE AND CVD OUTCOMES&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;Paper 1&lt;/STRONG&gt; Home PD, Pocock SJ, Beck-Nielsen H et al Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD) a multicentre, randomised, open-label trial Lancet 373:2125 - 2135&lt;BR&gt;&lt;STRONG&gt;Paper 2&lt;/STRONG&gt; Retnakaran R, Zinman B Thiazolidinediones and clinical outcomes in type 2 diabetes (comment) Lancet 373: 2088-2090&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;Study of 4447 people with type 2 diabetes on metformin or sulphonylurea were randomised to rosiglitazone 8mgs daily or metformin plus sulphonylurea. They were followed for a mean of 5.5 years. The primary outcome was CVD death or hospitalisation. 321 in the rosiglitazone group and 323 in the control group experienced the primary outcome. Heart failure causing admission to hospital occurred in 61 in the rosiglitazone group and 29 in the control group. There were 185 fractures in the rosiglitazone group and 118 in the control group. The increase was mainly upper and distal limb fractures in women.&lt;BR&gt;The conclusion is that although the data are inconclusive about any possible effects on myocardial infarction, rosiglitazone does not increase the risk of overall CVD mortality compared to standard glucose lowering drugs.&lt;BR&gt;The comment article mentions that there were much lower event rates in the study than expected and that there was a non statistically significant increase in myocardial infarctions in the rosiglitazone group. Rosiglitazone was associated with higher LDL Cholesterol levels leading to an increased use of statins in the group. In view of the data from the PROActive study for pioglitazone the ADA/EASD recommend the use of pioglitazone rather than rosiglitazone.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;This study does not give data to change the ADA/EASD view that when a glitazone treatment is needed pioglitazone should be chosen.&lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DIABETES &amp;amp; CVD&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;Paper 3&lt;/STRONG&gt; The BARI 2D study group. A Randomised trial of therapies for type 2 diabetes and coronary artery disease N Eng J Med 360:2503-2515&lt;BR&gt;Paper 4 Boden WE, Taggart DP Diabetes and Coronary Disease – a moving target and evolving therapies (editorial) N Engl J Med 360:2570-2572&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;2368 people with both type 2 diabetes were randomised to undergo either prompt revascularisation (CABG or percutanous coronary intervention PCI) with intensive medical treatment or intensive medical treatment alone and to undergo either insulin sensitization or insulin provision therapy. The primary outcome was death and death plus myocardial infarct plus stroke. At 5 years the rates of survival did not differ between the revascularisation group and the medical group or between the insulin sensitization or insulin provision group. There was more severe hypos in the insulin provision group.&lt;BR&gt;The editorial notes that although the primary outcomes were negative two pre-specified analyses of a secondary composite outcome of death myocardial infarct and stroke provided potentially important insights. First insulin sensitising therapy was associated with fewer secondary endpoints than insulin provision especially in people undergoing CABG. Secondly as compared to medical therapy people who had CABG (but not PCI) had fewer major cardiac events, mainly non fatal infarcts.&lt;BR&gt;&lt;STRONG&gt;Roger Gadsbys comments&lt;/STRONG&gt;&lt;BR&gt;The study gives no clear outcomes but supports the concept that optimal medical therapy rather than any intervention is an excellent first line strategy. When revascularization is necessary the study supports CABG as the preferred approach.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;OTHER SORTS OF STUDY&lt;/U&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;PREDICTING THE ONSET OF TYPE 2 DIABETES&lt;BR&gt;Paper 5&lt;/STRONG&gt; Tabak AG, Jakela M, Akbaraly N et al Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall 11 study Lancet 373:2215-2221&lt;BR&gt;Paper 6 Impending type 2 diabetes (comment) Matthews&amp;nbsp; DR, Levy JC Lancet 373:2178-2179&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;This longitudinal study has biochemical data available from people who subsequently developed diabetes n =505 and those that did not n= 6538 during a median follow up of 9.7 years. The data shows a slow deterioration in fasting glucose from 13 years before diagnosis with a marked upwards inflexion 2 years before onset from whence the fasting glucose rises rapidly from 5.7mmoles/L to greater than 7. The post load glucose shows a deterioration 3 years earlier. The data on fasting insulin allows beta cell function and insulin sensitivity to be assessed. &lt;BR&gt;For those who did not develop diabetes, whose fasting glucose was, on modelled average 5.3mmoles/L&amp;nbsp; during 13 years of observation nevertheless showed declining insulin sensitivity of around 15% due doubtless to progressive inactivity and middle-aged spread. Those who went on to develop diabetes were 35% more insulin resistant a decade before diabetes onset, and had a 4 year acceleration of resistance leading up to the onset of diabetes. The beta cell function of those who did not develop diabetes remained invariate during the decade. By contrast those who eventually developed diabetes had a higher initial compensatory beta cell function and 2-3 years before diabetes onset had a further last ditch increase in beta cell function before this collapsed to 60% of normal and diabetes ensued.&lt;BR&gt;The editorial says that we cannot as yet use these findings to detect those who are about to get diabetes as the sensitivity and specificity of the forward predictions would be poor.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;BR&gt;&lt;/STRONG&gt;This is interesting data helping us to understand what is going on before someone develops type 2 diabetes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;SHORT REPORTS&lt;/U&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;HBA1c Reporting Changes&lt;BR&gt;Paper 7&lt;/STRONG&gt; Collier A, Ghosh S, Davidson DF, Kilpatrick ES&amp;nbsp; HBA1c “the old order changeth” (editorial) Diabetic Medicine 26:573-576 Good summary and explanation of&amp;nbsp; the standardization of HBA1c and the new IFCC units&lt;BR&gt;Obstructive Sleep Apnoea &amp;amp; Type 2 Diabetes&lt;BR&gt;&lt;STRONG&gt;Paper 8&lt;/STRONG&gt; Foster GD, Sanders MH, Millman R et al Obstructive sleep apnoea among obese patients with type 2 diabetes. Unattended polysomnography was performed on 306 obese (BMI mean 36) subjects who had not complained of OSA. Over 86% had it on testing and 23% had severe OSA. The main predictor was waist circumference.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed&lt;/STRONG&gt;&amp;nbsp; N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>381702</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=381702]]&gt;</url>
    <title>Interesting new diabetes papers: June 2010</title>
    <publicationDate>2010-07-28T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 62nd in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: June 2010&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;SYSTEMATIC&amp;nbsp; REVIEWS&lt;BR&gt;&lt;/U&gt;&lt;BR&gt;GLUCOSE &amp;amp; CVD&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 1 The Emerging Risk Factors Collaboration.&amp;nbsp; &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=381756" target="_blank"&gt;Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.&lt;/A&gt; Lancet 375:2215-2222&lt;BR&gt;Paper 2 Gerstein H C&amp;nbsp; More insights on the dysglycaemia-cardiovascular connection (comment) Lancet 375: 2195-2196&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;This is a comprehensive meta-analysis of 102 studies including almost 700,000 people without previous vascular disease. After accounting for other risk factors diabetes more than doubled the risk of coronary heart disease and ischaemic stroke, and that the diabetes related risk was higher in women than men. Diabetes also increased the risk of haemorrhagic stroke by about 56%. It also shows that in people without diabetes (a) fasting glucose in the normal range of 3.9-5.6mmole/l was not related to CV risk (b) fasting glucose in the range 5.6-6.1 independently increased the CV risk by 11% (c) fasting glucose in the range 6.1-7.0 independently increased the CV risk by 17% (d) every 1mmol higher fasting glucose above 5.6 increased the CV risk by 12%. This explicit demonstration of a basement to a graded relation of fasting glucose to increased CV risk and the fact that this basement comprises normal glucose concentrations is an important contribution to new knowledge&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Important information&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;CULTURALLY APPROPRIATE HEALTH EDUCATION&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 3 &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=381752" target="_blank"&gt;Culturally appropriate health education for type 2 diabetes in ethnic minority groups: a systematic and narrative review of randomised controlled trials.&amp;nbsp;&lt;/A&gt; Diabetic Medicine 27: 613-623&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;Review of 12 eligible studies which were heterogeneous in methodologies and outcome measures making meta-analysis difficult. HBA1c showed improvement at 3 months (-32%) and at 6 months (-0.6%) post intervention. Knowledge scores improved at 6 months. There was only 1 longer term follow up and one cost-effectiveness study.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Interesting study&lt;BR&gt;&lt;STRONG&gt;&lt;U&gt;&lt;BR&gt;&lt;BR&gt;RCT's&lt;BR&gt;&lt;BR&gt;&lt;/U&gt;SGLT2 INHIBITOR&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 4 Bailey CJ, Gross JL, Bastein A, List JF Effect of dapagliflozin in patients with type 2 diabetes who have inadequate control with metformin: a randomised, double blind, placebo controlled trial Lancet375: 2223-2233&lt;BR&gt;Paper 5 Hanefield M Forst T Dapagliflozin, a SGLT2 inhibitor, for diabetes (comment) Lancet 375: 2196-2197&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;A study of 534 people with T2DM not fully controlled on&amp;nbsp; metformin therapy were randomised to dapagliflozin 2.5, 5 or 10mgs once daily&amp;nbsp; or placebo and followed for 24 weeks. There was a dose dependant reduction in HBA1c in people treated with dapa with a reduction of -0.84% in the 10mg group, compared to a reduction of 0.3% in the placebo group. Dapa also reduced bodyweight, and decreased systolic and diastolic bp, with no increase in UTI’s but a slightly higher rate of genital infections&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Interesting data on what is likely to be the first SGLT2 agent to be launched&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;B12 &amp;amp; METFORMIN&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 6 De Jager J, Kooy A, Lehert P et al Long term treatment with metformin and risk of vitamin B12 deficiency: randomised placebo controlled trial BMJ 340: 1177&lt;BR&gt;Paper 7 Vidal-Alaball Butler C Reduced serum vitamin B12 in people taking metformin (editorial) BMJ 340:1147&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;Study of 390 people with T2DM on insulin and either Metformin 850mgs tds or placebo tds,&amp;nbsp; with B12 measurements at 4,17,30, 43 and 52 months. In the placebo group vit b12 levels increased by 0.2 pmol whereas in the metformin group it was reduced by 89.8 pmol. At baseline 3&amp;nbsp; in metformin&amp;nbsp; group and 4 in placebo group had levels below 150pmol. At follow up after 4.3 years this had increased to 19 and 5 respectively. There is no robust research underpinning the assumption that people with Vit B12 below 150pmol are indeed vit b12 deficient. The editorial concludes that until the clinical importance is clear, simple dietary advice could solve the problem. &lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;More research is needed before any routine surveillance of b12 levels in people with metformin is mandated.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;U&gt;&lt;BR&gt;SHORT REPORTS&lt;BR&gt;&lt;BR&gt;&lt;/U&gt;&lt;/STRONG&gt;&lt;STRONG&gt;Diabetic Neuropathy&lt;/STRONG&gt;&amp;nbsp; &lt;EM&gt;Paper 8 Abbott CA, Chaturvedi N, Malik R et al Explanations for the lower rates of neuropathy in Indian Asians versus Europeans Diabetes Care 33:1325-1330.&lt;/EM&gt; &lt;BR&gt;Asians with diabetes have substantially less large and small fibre neuropathy than Europeans despite comparable traditional risk factors, which is due to better skin microvascularization.&lt;BR&gt;&lt;STRONG&gt;Exenatide once weekly&lt;/STRONG&gt;&amp;nbsp;&lt;EM&gt;Paper 9&amp;nbsp; Buse JB, Drucker DJ, Taylor KL, et al Duration -1 Exenatide once weekly produces sustained glycaemic control and weight loss over 52 weeks Diabetes Care 33: 1255-1261.&lt;/EM&gt; &lt;BR&gt;Exenatide once weekly versus exenatide twice daily. Those on once weekly continued for further 22 those on bd were switched to once weekly. Those continuing maintained HBA1c -2% at 52 weeks, those switched had further HBA1c reductions. Body weight dropped by -4Kg&lt;BR&gt;&lt;EM&gt;Paper 10 Diamant M, Van Gaal L, Stranks S et al Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (Duration-3) an open label randomised trial Lancet 375: 2234-2243.&lt;/EM&gt; HBA1c reduction at 26weeks was -1.5% in exenatide group and -1.3% in glargine group. 12 in exenatide group discontinued due to adverse events (nausea and injection site problems, 2 discontinued in glargine group.&lt;BR&gt;&lt;STRONG&gt;Liraglutide&lt;/STRONG&gt;&amp;nbsp;&lt;EM&gt;Paper 11 Buse JB, Sesti G, Scmidt WE et al for the LEAD 6 study group&amp;nbsp; Switching to one daily Liraglutide from twice daily further improves glycaemic control in patients with type 2 diabetes using oral agents.&lt;/EM&gt; &lt;BR&gt;After 26 weeks in LEAD 6 those randomised to exenatide were switched to Liraglutide uptitrated to 1.8mgs and showed further HBA1c reduction -32%, further weight reduction – 0.9kg and further bp drop -3.8mmhg systolic.&lt;BR&gt;&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Journals reviewed&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;N Eng J Med,&amp;nbsp; Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int&lt;/EM&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>312082</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=312082]]&gt;</url>
    <title>Interesting new diabetes papers: March 2009</title>
    <publicationDate>2009-04-16T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2009,DIABETES,RESEARCH,INTERESTING NEW ARTICLES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 47th in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: March 2009&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;REVIEW &amp;amp; META_ANALYSIS&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBESITY &amp;amp; MORTALITY&lt;/STRONG&gt;&lt;BR&gt;Paper 1 &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=312086&amp;amp;tabID=289" target="_blank"&gt;Prospective Studies Collaborative&amp;nbsp; Body-mass index and cause specific mortality in 900,000 adults: collaborative analysis of 57 prospective studies&lt;BR&gt;&lt;/A&gt;Lancet 373:1083-1096&lt;BR&gt;Paper 2 Lopez-Jimenez F&amp;nbsp; Speakable and unspeakable facts about BMI and mortality (comment) Lancet 373:1055-56&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;This is a collaborative analysis of BMI versus mortality in 57 prospective studies with 894576 participants with a mean recruitment age of 46. The first 5 years of follow up were excluded, leaving 66552 deaths of known cause during a mean of 8 years of follow up. The analyses were adjusted for age, sex, smoking status and study. It shows that obesity as measured by BMI is associated with increased total mortality in both men and women and in all age strata from 35-89 years. The increased mortality is due to IHD, stroke, diabetes and liver disease. At a BMI of 30-35 median survival is reduced by 2-4 years. At 40-45 it is reduced by 8-10 years. It also shows that people with a BMI in the low range 16.5-22.5 have an increased risk of death compared with those with BMI of 27.5-30, which is mainly due to smoking related, respiratory disease deaths. The comment article also says that the study shows that BMI cannot discriminate CVD risk well in people with intermediate BMI values. It says that two people with a total cholesterol of 4.79 may have very different CVD risk depending on levels of LDL, HDL etc.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments:&lt;/STRONG&gt; This is an important review that confirms the results of smaller studies that obesity as defined by BMI imposes a substantial toll on life expectancy&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;GLUCOSE SENSORS&lt;BR&gt;&lt;/STRONG&gt;Paper 3 Oliver NS, Tournazou C, Cass, AEG, Johnson DG &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=312103&amp;amp;tabID=290" target="_blank"&gt;Glucose sensors: a review of current and emerging technology &lt;/A&gt;Diabetic Medicine 26:197-210&lt;BR&gt;Paper 4 Flanagan DE The future of glucose sensors – using the technology within a clinical service (editorial) Diabetic Medicine 26: 195-6&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;This is an expert review that outlines the important steps that have been made over the last 30 years in measuring glucose in the body. It outlines the different types of sensor and the different techniques that have been used to measure glucose. It concludes that the ideal sensor for glucose remains elusive, but there has been significant progress.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments:&lt;/STRONG&gt;&amp;nbsp; This is useful review of the history and techniques of blood glucose monitoring technology&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;RCT’s&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;LIRAGLUTIDE&lt;/STRONG&gt;&lt;BR&gt;Paper 5 Marre M, Shaw J, Brandle M et al Liraglutide, a once daily human GLP-1 analogue, added to sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (Lead1 –SU) Diabetic Medicine 26: 268-278&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;Study of 1041 adults with type 2 diabetes with mean HBA1c of 8.4% participated in a 5 arm, 26 week, double dummy, randomised trial. Liraglutide at 1.2 or 1.8mg doses&amp;nbsp; dropped HBA1c by -1.1`% compared with placebo whereas rosiglitazone dropped HBA1c by a mean of -0.4% when either was added to glimeperide.&lt;BR&gt;The changes in body weight were Liraglutide 1.8mg dose -0.2kg, Liraglutide 1.2 +0.3kg, rosiglitazone +2.1kg. Main adverse effects were minor hypoglycaemia, nausea and vomiting.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;&lt;/STRONG&gt;Liraglutide works better to lower glucose when added to glimepiride than does rosiglitazone.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;OTHER SORTS OF STUDY&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;QoF&lt;/STRONG&gt; &lt;BR&gt;Paper 6 Millet, C, Netuveli G, Saxena S, Majeed A Impact of pay for performance on ethnic disparities in intermediate outcomes for diabetes: a longitudinal study Diabetes Care 32:404-409&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;It uses a longitudinal model of 1968 adults with type 2 diabetes in South West London. There were&amp;nbsp; 744 British,&amp;nbsp; 658 Black, 199 South Asian and 339 other ethnic groups patients. They looked at mean HBA1c and BP values yearly from 2000 to 2005 using GP records. They found that the introduction of pay for performance was associated with improvements in&amp;nbsp; BP greater than those predicted by the underlying trend (from years 2000-2003) in the white black and south asian groups, and that HBA1c reductions were greater than those predicted by the underlying trend in the white group but not in the black or south asian.&lt;/P&gt;
&lt;P&gt;Paper 7 Vagela P, Ashworth M, Schofield P, Guliiford MC Population intermediate outcomes of diabetes under pay for performance incentives in England from 2004-2008 Diabetes Care 32: 427-429 &lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;Uses QoF data from 98% of practices, and looks at HBA1c at or below 7.5%, BP at or below 145/85 and total cholesterol at or below 5mmoles. It reports as medians&amp;nbsp; : -&lt;BR&gt;Year&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; HBA1C target&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; BP target&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Chol target&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Excluded from HBA1c target&lt;BR&gt;2004/5&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 59.1&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 70.9&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 72.6&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 9.4&lt;BR&gt;2005/6&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 61.7&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 75.7&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 79.8&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 10.0&lt;BR&gt;2006/7&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 67.6&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 79.6&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 83.7&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 9.9&lt;BR&gt;2007/8&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 66.7&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 80.2&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 83.6&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 8.7&lt;BR&gt;It defined low performing practices if they achieved less than the 25th centile for the HBA1c target across all practices in 2006/7. There were 57% of practices thus classified as low performing in 2004, 47.4% in 2005/6, 25% in 2006/7 and 26% in 2007/8. There were more low performing practices in London than other areas in each year.&lt;BR&gt;They conclude that the introduction of pay-for-performance may be one factor contributing to the achievement of targets and reducing problems of low performance.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;&lt;/STRONG&gt;Fascinating data from QoF&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;SOUTH ASIAN DIABETES&lt;BR&gt;&lt;/STRONG&gt;Paper 8 Raymond NT, Varadhan V, Reynold D et al on the behalf of the UKADS study group. Higher Prevalence of Retinopathy in Diabetic Patients of South Asian Ethnicity compared with White Europeans in the Community Diabetes Care 32: 410-415&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;A community based cross sectional study of 421 South Asian and 614 white patients with type 2 diabetes.&amp;nbsp; They found that patients with south asian ethnicity had a significantly higher prevalence of diabetic retinopathy and maculopathy with elevated systolic and diastolic bp, HBA1c and total cholesterol, lower attained age and younger age at diagnosis.&lt;BR&gt;They conclude by saying that the earlier age of&amp;nbsp; onset of disease and higher levels of modifiable risk factors make early detection of diabetes, retinal screening and intensive risk factor management key elements in addressing health inequality.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments:&lt;BR&gt;&lt;/STRONG&gt;Important findings summarising the problems of diabetes in south Asians&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;U&gt;SHORT REPORTS&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;U&gt;&lt;/U&gt;&lt;BR&gt;&lt;STRONG&gt;Metabolic Syndrome&lt;/STRONG&gt;&lt;BR&gt;Paper 9 Cameron AJ, Zimmet PZ, Shaw JE, Alberti KGMM The Metabolic Syndrome: in need of a Global Mission Statement Diabetic Medicine 26:306-309&lt;BR&gt;They authors argue for the recognition of obesity as being a crucial element within the metabolic syndrome but perhaps even more important, before its development. They feel that metabolic syndrome does have a risk prediction tool.&lt;BR&gt;&lt;STRONG&gt;SMBG&lt;/STRONG&gt;&lt;BR&gt;Paper 10 Belsey JD, Pittard JB, Rao S et al Self blood glucose monitoring in type 2 diabetes. A financial impact analysis based on UK primary care Int J Clin Pract 63:439-448&lt;BR&gt;They calculate mean national expenditure on SMBG was £73.64p per patient per year for&amp;nbsp; 2006/7. The estimated mean weekly strip use by treatment type was 2.5 for diet, 2.6 for glitazone monotherapy, 3.1 metformin monotherapy, 3.5 sulphonylurea monotherapy, combination therapy was 3.3-4.1.&lt;BR&gt;They estimate that savings of £17 million could be made if guidelines were followed more closely&lt;/P&gt;
&lt;P&gt;Journals reviewed&lt;BR&gt;N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;&lt;EM&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; Published in&amp;nbsp;March 2009.&amp;nbsp;This series began in 2002 as a bulletin for Diabetes Care Staff.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public.&amp;nbsp; Word and webpage versions available.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>372218</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=372218]]&gt;</url>
    <title>Interesting new diabetes papers: March 2010</title>
    <publicationDate>2010-04-21T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2010,INTERESTING NEW ARTICLES,RESEARCH,DIABETES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 59th in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: March 2010&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;GUIDELINES &amp;amp; CONSENSUS STATEMENTS&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/U&gt;&lt;/STRONG&gt;&lt;STRONG&gt;GESTATIONAL DIABETES (GDM)&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 1 International Association of Diabetes &amp;amp; Pregnancy Study Groups Consensus Panel (IADPSG) . &lt;A href="nelh:372584:0" name=internalLink&gt;International Association of Diabetes &amp;amp; Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycaemia in Pregnancy&lt;/A&gt;.&amp;nbsp;&amp;nbsp; Diabetes Care 33: 676-682&lt;BR&gt;Paper 2 Moses R G &lt;A href="nelh:372585:0" name=internalLink&gt;New consensus Criteria for GDM, Problem solved or Pandora’s box?&lt;/A&gt; (editorial) Diabetes Care 33: 690-691&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;The HAPO study (2008) using a two hour 75gm glucose load with no preliminary screening based on either risk factors or a challenge test showed a continuum of risk for maternal glucose levels and adverse pregnancy outcomes. After the publication of this study a group designated IADPSG was set up to formulate recommendations. Given the continuum of risk these recommendations are of necessity based on a consensus around an arbitrary decision about odds ratios, but an international panel have reached a consensus.&lt;BR&gt;The diagnostic levels to diagnose overt diabetes in pregnancy are still fasting plasma glucose at or above 7mmoles/l a random at or above 11.1 mmoles/l or an HBA1c at or above 6.5%.&lt;BR&gt;To diagnose GDM the group say FPG at or above 5.1, a one hour plasma glucose (after 75gm glucose load) at or above 10mmoles/l and a 2hr plasma glucose (after 75gm glucose load) at or above 8.5mmoles/l&lt;BR&gt;Using these figures around 18% of all women in pregnancy will be diagnosed as having GDM. The group recommend a first test of FPG, HBA1c or random glucose at first prenatal visit to detect overt diabetes or GDM early (using the diagnostic criteria outlined above on all or only high risk women (the group concluded there was insufficient data to say whether to test all or high risk only)&lt;BR&gt;If DM or GDM was not diagnosed earlier they recommend a 2hr ogtt at 24-28 weeks&amp;nbsp; to diagnose overt DM and GDM using the above criteria.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;New recommendations which when implemented will increase testing and numbers diagnosed with GDM&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;SYSTEMATIC&amp;nbsp; REVIEWS&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 3 DeFronzo RA, Stonehouse AH, Han J, Wintle ME &lt;A href="nelh:372604:0" name=internalLink&gt;Relationship of baseline HBA1c and efficacy of glucose lowering therapies: a meta-analysis of randomised clinical trials&lt;/A&gt; Diabetic Medicine 27: 309-317&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;This meta-analysis is from 59 clinical trials of glucose lowering therapies from all classes of oral agents and insulin ranging in duration from 26 to 52 weeks in which baseline and change in HBA1c were reported. The relationship between baseline and change in HBA1c was analysed by a weighted least-square model accounting for intention to treat population and variance of HBA1c change. The results demonstrate a positive relationship between baseline HBA1c and the magnitude of HBA1c change across 10 categories of glucose lowering therapies, irrespective of class or mode of action. The higher the baseline HBA1c the greater reduction there is in HBA1c in the trial.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;BR&gt;&lt;/STRONG&gt;It is good to have this level of support for something that we all thought was true&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;U&gt;OTHER SORTS OF STUDY&lt;BR&gt;&lt;BR&gt;&lt;/U&gt;&lt;/STRONG&gt;&lt;STRONG&gt;PREVALENCE OF DIABETES IN CHINA&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 4 Yang W, Lu J, Weng J et al Prevalence of diabetes among men and women in China&amp;nbsp;&amp;nbsp; N Eng J Med 362: 1090 -1101&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;A nationally representative sample of 46,239 adults, 20 years of age or older, from 14 provinces and municipalities who underwent an oral glucose tolerance test in which fasting and 2hr levels of glucose were used to identify undiagnosed diabetes and pre-diabetes. Previously diagnosed diabetes was determined on the basis of self-report.&lt;BR&gt;The study reported that total diabetes (previously diagnosed plus diagnosed in the study) was 9.7%, and prediabetes was 15.5%, accounting for 92.4 million adults with diabetes and 148.2 adults with pre diabetes. The prevalence of diabetes increased with age to 20.4% in those 60 and above, and rose with increasing body mass index. It was higher in urban residents than in rural residents. The authors conclude that diabetes has become a major public health problem in China.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;There is a lot of diabetes and prediabetes in China! &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;U&gt;SHORT REPORTS&lt;BR&gt;&lt;BR&gt;&lt;/U&gt;&lt;/STRONG&gt;&lt;STRONG&gt;Preconception Counselling&lt;/STRONG&gt;&amp;nbsp; &lt;BR&gt;&lt;EM&gt;Paper 5 Tripathi A, Rankin J Aarvold J et al Preconception Counselling in women with diabetes Diabetes Care 33:586-588. &lt;BR&gt;&lt;/EM&gt;This is a study from North of England from 2001-4 of 588 people with diabetes (77% with type 1) about half had pre conception counselling and half did not . Preconception counselling was associated with better glycaemic control before conception and in first trimester, higher uptake of pre conception folic acid and reduced risk of adverse pregnancy outcome &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Metformin monotherapy failure&lt;/STRONG&gt; &lt;BR&gt;&lt;EM&gt;Paper 6 Brown J, Connor C, Nichols GA Secondary failure of metformin monotherapy in clinical practice&amp;nbsp;&amp;nbsp; Diabetes Care 33: 501-506&lt;/EM&gt;&amp;nbsp; &lt;BR&gt;Study of 1799 adults from Kaiser Permenante North West&amp;nbsp; who between 2004 and 2006 lowered their HBA1c to 7% or below with metformin monotherapy. HBA1c values were observed for 2-5 years of follow up. Secondary failure was defined as HBA1c at or above 7.5% or addition or substitution of another glucose lowering therapy. 42% experienced monotherapy failure, the mean failure rate was 17% per year. However those who initiated metformin with 3 months&amp;nbsp; of diagnosis failed at a rate of 12.3% per year.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;QoF data&lt;/STRONG&gt; &lt;BR&gt;&lt;EM&gt;Paper 7 Oluwatowoju I, Abu E, Wild SH, Byrne CD Improvements in glycaemic control and cholesterol concentrations associated with the QoF framework: a regional 2 year audit Diabetic Medicine 27: 354-359&lt;/EM&gt; &lt;BR&gt;Study of 8997 adults who had HBA1c and cholesterol levels measured in 2006 and again in 2008&lt;BR&gt;39.7% had an HBA1c at or below 7.5% in 2006 and 52.1% in 2008. Those with HBA1c at or above 10% were 11.8% in 2006 and 10.1 % in 2008. Those achieving this&amp;nbsp; HBA1c level and cholesterol at or below 5 was 30.2% in 2006 and 43.7% in 2008&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;BR&gt;Journals reviewed:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp; N Eng J Med,&amp;nbsp; Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int&lt;BR&gt;&lt;/P&gt;&lt;/EM&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>317193</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=317193]]&gt;</url>
    <title>Interesting new diabetes papers: May 2009</title>
    <publicationDate>2009-06-11T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2009,DIABETES,RESEARCH,INTERESTING NEW ARTICLES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 49th in a monthly series written by Dr Roger Gadsby.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: May 2009&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;GUIDELINES&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;BR&gt;Paper 1 NICE Clinical Guideline CG87 Type 2 Diabetes: Newer Agents &lt;A href="http://www.nice.org.uk/" target="_blank"&gt;www.nice.org.uk&lt;/A&gt;&amp;nbsp; Summary:-&amp;nbsp; Adler AI, Shaw EJ, Stokes T et al Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance. BMJ 338: 1328-1329&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;The rapid update of the glycaemic control section of the NICE CG 66 guideline was published on 27th May 2009 as NICE Clinical Guideline CG 87, and is summarised in the BMJ paper. The new recommendations cover DPP-4 inhibitors (sitagliptin, vildagliptin), thiazolidinediones (pioglitazone, rosiglitazone), exenatide and insulin.&lt;BR&gt;It places the new DPP4 therapies as an option at level 2 and in triple oral therapy. It places exenatide as an option at level 3 in people with a BMI at or above 35.&lt;BR&gt;The new guideline gives discontinuation recommendations for certain therapies. It says that DPP4 inhibitors&amp;nbsp; should only be continued if there is a 0.5% HBA1c drop in 6 months, and thiazolidinedione should only be continued if there is a 0.5% HBA1c drop in 6 months.&lt;BR&gt;It also says that exenatide should only be continued if the person has an HBA1c drop of 1% and a drop of 3% or more of initial body weight in 6 months&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;:&amp;nbsp; In my opinion the guideline does not contain any recommendations that are particularly surprising or controversial. They place the new DPP4 agents for consideration in limited circumstances at level 2 along with thiazolidinediones whilst suggesting that for the majority of people metformin plus sulphonylurea be the usual option. These generic therapies at around £2/3 a month are far cheaper than the newer glucose lowering therapies, and are therefore likely to be most cost effective.&lt;BR&gt;At level three the options of adding&amp;nbsp; insulin or thiazolidinedione or DPP4 or exenatide (in people with a BMI at or above 35) are all considered. Patient preference, after a thorough discussion of the benefits and disadvantages of each option with a healthcare professional will determine which option needs to be used. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;REVIEW &amp;amp; META_ANALYSIS&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;DM &amp;amp; CVD OUTCOMES&lt;BR&gt;&lt;/STRONG&gt;Paper 2 Kay KK, Seshasai SRK, Wijesurlya R et al &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=316825&amp;amp;tabID=289" target="_blank"&gt;Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials &lt;/A&gt;Lancet 373: 1765-1772&lt;BR&gt;Paper 3 Mazzone T Hyperglycaemia and coronary heart disease: the meta picture (comment) Lancet 373:1737-1738&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;Several recent RCT’s have shown no benefit on CVD outcomes from reducing HBA1c to 6.5% (from around 7.3%) and one the ACCORD trial showed that intensive management killed more people than standard management. In this meta-analysis. Five RCT’s&amp;nbsp; (ACCORD, ADVANCE, VADT, UKPDS, &amp;amp; PROactive) fulfilled their quality criteria. Data from&amp;nbsp; 33040 patients in these 5 studies was used . They conclude that it shows that intensive glucose lowering has cardiovascular benefit compared with standard treatment . During about 5 years of treatment reduction of HBA1c by 0.9% resulted in a significant 17% reduction in events of non-fatal myocardial infarction, a significant 15% reduction in events of coronary heart disease and a non significant 7% reduction in stroke. Intensive treatment did not significantly affect all cause mortality, in contrast to statin treatment and blood pressure lowering treatment which has been shown to reduce all cause mortality. The number needed to treat (0.9% HBA1c reduction from around 7.8%) over 5 years for non fatal MI is 87 and for coronary heart disease event is 69. Intense glucose control was associated with adverse effects of 2.5Kg wt gain and double the severe hypo rates compared with standard treatment&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments:&lt;/STRONG&gt;&amp;nbsp; This meta-analysis suggests a benefit on CVD outcomes&amp;nbsp; in contrast to the 3 recent RCT results. There was no effect on total mortality. Its conclusions confirm the need to treat CVD risk holistically by giving statin, lowering raised blood pressure and treating HBA1c to realistic targets.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RISKS OF TYPE 2 DIABETES AFTER GESTATIONAL DIABETES&lt;/STRONG&gt;&lt;BR&gt;Paper 4 Bellamy L, Casas J-P, Hingorani AD, Williams D &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=317291&amp;amp;tabID=289&amp;amp;catID=5632" target="_blank"&gt;Type 2 diabetes after gestational diabetes: a systematic review and meta-analysis&lt;BR&gt;&lt;/A&gt;Paper 5 Bentley-Lewis R Gestational Diabetes Mellitus : an opportunity of a lifetime ( comment) Lancet 373: 1738-1739&lt;BR&gt;Summary&lt;BR&gt;This is a meta-analysis of 20 cohort studies of 675,455 women and 10,858 cases of type 2 diabetes. They report a nearly 7.5 fold increased risk of developing diabetes for women who had gestational diabetes during a pregnancy. Women within 5 years of a pregnancy complicated by gestational diabetes had a relative risk of 4.69 which more than doubled to 9.34 in those who were examined more than 5 years post partum. &lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments:&lt;/STRONG&gt;&amp;nbsp; This is good review that needs to become the main reference in this area.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DIABETES IN ASIA&lt;BR&gt;&lt;/STRONG&gt;Paper 6 Chan JCN, Malik V, Jia W et al &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=317294&amp;amp;tabID=289&amp;amp;catID=9423" target="_blank"&gt;Diabetes in Asia, Epidemiology, Risk factors and path physiology&lt;/A&gt; JAMA 301: 2129-2140&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;This is a review which quotes 46 studies but does not give full details of its inclusion/exclusion criteria. Their evidence synthesis summary states that the prevalence of diabetes in Asian populations has increased rapidly in recent decades. In 2007, more than 110 million people in Asia were living with diabetes. with a disproportionate burden among the young and middle aged. Similarly, rates of obesity are increasing sharply driven by economic development, nutritional transition, and increasingly sedentary lifestyle. The metabolically obese phenotype (normal body weight with increased abdominal adiposity) is common in Asian populations.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments:&lt;/STRONG&gt; This is an interesting review&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;ASPIRIN AND CVD &lt;BR&gt;&lt;/STRONG&gt;Paper 7 Antithrombotic Trialists (ATT) Collaboration. &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=319494&amp;amp;tabID=289" target="_blank"&gt;Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials &lt;/A&gt;Lancet 373: 1849-1860&lt;BR&gt;Paper 8 Algra A, Greving JP Aspirin in primary prevention: sex and baseline risk matter (comment)&amp;nbsp; Lancet 373: 1821-1822&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;A meta-analysis of serious vascular events (MI, stroke, or vascular death) and major bleeds in 6 primary prevention trials (95,000 individuals with 3554 serious vascular events) and 16 secondary prevention trials (17000 individuals and 3306 serious vascular events. They conclude that in primary prevention without previous CVD disease aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds. Further trials are in progress which should help to clarify matters.&lt;BR&gt;The comment suggests that there may be a difference in risk: benefit in men and women which the ATT writers do not feel is true when adjustment for multiple comparisons is made. The writers of the comment also introduce data on cost effectiveness and suggest aspirin may be cost effective in older people from 60 -79 in high risk groups&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments:&lt;/STRONG&gt;&amp;nbsp; This data does not refer to people just with diabetes, but people with diabetes will have made up some of the trial participants. It is another nail in coffin of the guidelines recommendation that everyone with diabetes needs aspirin for primary protection.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;U&gt;&lt;/U&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;OTHER SORTS OF STUDY&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;QoF &lt;BR&gt;&lt;/STRONG&gt;Paper 9 Calvert MJ, Shankar A, McManus RJ et al Effect of the quality and outcomes framework on diabetes care in the United Kingdom : retrospective cohort study BMJ 338: 1366-1369&lt;BR&gt;Summary &lt;BR&gt;Retrospective cohort study of 147 practices, between 2001 to 2007 . Significant improvements in process and intermediate outcome measures were observed during the six year period.&lt;BR&gt;Dr Roger Gadsby’s comments&amp;nbsp; Further analysis of QoF&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;SHORT REPORTS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Acute Pancreatitis &amp;amp; Diabetes Paper 10 Noel RA, Braun DK, Patterson RE, Bloomgren GL Increased risk of acute pancreatitis and bilary disease observed in patients with type 2 diabetes Diabetes Care 32: 834-838 The increased risk was 2.83 in this cohort of 337067 people with diabetes in a US health care claims database&lt;/P&gt;
&lt;P&gt;The 23 May edition of the Lancet was a diabetes theme issue on diabetes. It contained the following important expert reviews&lt;BR&gt;Pancreas Transplantation&amp;nbsp; Paper 11 White SA, Shaw JA, Sutherland&amp;nbsp; Pancreas Transplantation Lancet 373: 1808-1814&lt;BR&gt;Gestational Diabetes Paper 12 Reece EA, Leguizamon G, Wizniter A Gestational Diabetes: the need for a common ground&lt;BR&gt;Stress Hyperglycaemia Paper 13 Dungan KM, Braithwaite SS, Prieser J-C Stress hyperglycaemia Lancet 373: 1798-1807 &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed&lt;/STRONG&gt;&lt;BR&gt;N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;&lt;EM&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; Published in&amp;nbsp;February 2009.&amp;nbsp;This series began in 2002 as a bulletin for Diabetes Care Staff.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public.&amp;nbsp; Word and webpage versions available.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>378444</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=378444]]&gt;</url>
    <title>Interesting new diabetes papers: May 2010</title>
    <publicationDate>2010-06-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 61st in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: May 2010&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;U&gt;&lt;STRONG&gt;SYSTEMATIC&amp;nbsp; REVIEWS&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/U&gt;&lt;STRONG&gt;DM &amp;amp; POLYCYSTIC OVARY SYNDROME&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 1 Tomlinson J, Millward A, Stenhouse E Pinkey J &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=378435" target="_blank"&gt;Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome (PCOS) : what are the risks and can they be reduced?&lt;/A&gt; Diabetic Medicine 27: 498-515&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;Extensive review concluding that PCOS has important metabolic associations, and short term interventions reduce risk factors for T2DM and CVD , data on prevalence and incidence of T2DM &amp;amp; CVD are poor. There is need for a clear definition of PCOS, for diabetes screening protocols and for long term studies to see if risks can be reduced.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Through review&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;MISCLASSIFICATION &amp;amp; CODING OF DIABETES&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 2 Stone MA, Camosso-Stefinovic J, Wilkinson J et al &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=378442" target="_blank"&gt;Incorrect and Incomplete coding and classification of diabetes: systematic review&lt;/A&gt; Diabetic Medicine 27:491-497&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;Review of 17 eligible studies. The sample was too heterogeneous to derive accurate information about frequency, but findings suggest that misclassification occurs more commonly in young people, which has implications for treatment and risk management. Types of misclassification were labelling as type 1 when type 2, missing LADA or MODY etc.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Interesting&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;U&gt;RCT’s&lt;BR&gt;&lt;BR&gt;&lt;/U&gt;&lt;/STRONG&gt;&lt;STRONG&gt;METFORMIN &amp;amp; VIT B12&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 3 de Jagger J, Kooy A, Lehert P et al Long term treatment with metformin in patients with type 2 diabetes and risk of Vit b12 deficiency: randomised placebo controlled trial BMJ 340:1177&lt;BR&gt;Paper 4 Vidal-Alaball J, Butler CC Reduced serum vitamin B12 in patients taking metformin (editorial) BMJ 340:1147-1148&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;A study of 390 people with T2DM on insulin randomised to metformin 850 tds or placebo for a mean of 4.3 years. At baseline 3 in metformin group and 4 in placebo group had B12 levels below 150pmol/L after 4.3 years it was 19 and 5. B12 levels in the metformin group dropped by a mean of 19%.&lt;BR&gt;The editorial points out that the trial did not look at Quality of life, neurological status or measures of fatigue. It was also in people on insulin and involved a large dose of metformin.&lt;BR&gt;The mechanism of the association is unclear but might be simply due to dietary changes. The editorial suggests more studies are needed before routine vit b12 monitoring is needed for all on metformin.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;I support the view of the editorial of more research and no action on these findings at present&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;ACCORD &amp;amp; CVD DEATH&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 5 Riddle MC, Ambrosius WT, Brillon DJ et al for the ACCORD Investigators &lt;BR&gt;Epidemiological relationships between HBA1c and all cause mortality during a median 3.4 year follow up of glycaemic treatment in the ACCORD trial Diabetes Care 33:983-990&lt;BR&gt;Paper 6 Boyko EJ ACCORD Glycaemia results continue to puzzle (Editorial) Diabetes Care 33:1149-1150&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;This paper reports on an observational post hoc analysis of the ACCORD trial results to see if features of glucose control explain the higher death rate in the intensively treated group. It found that higher HBA1c on treatment was a stronger predictor of mortality than was the HBA1c for the last interval of follow up or the decrease in the first year. The editorial points out that a possible clue might lie in the higher mortality associated with resistance to&amp;nbsp; glucose control and suggests that it may be unhelpful to pursue intensive treatment in people in whom no improvement in HBA1c is seen&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;BR&gt;&lt;/STRONG&gt;It still is not clear exactly what caused the increased mortality in people in the intensive arm of ACCORD&lt;BR&gt;&lt;BR&gt;&lt;U&gt;&lt;STRONG&gt;OTHER SORTS OF STUDY&lt;BR&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/U&gt;&lt;STRONG&gt;SCREENING FOR DIABETES&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 7&amp;nbsp; Bao Y, Ma X, Li H et al HBA1c for Diagnosing diabetes in a Chinese population: cross sectional epidemiological study BMJ 340:1178&lt;BR&gt;Paper 8 Yang W Diagnosing Diabetes using HBA1c BMJ 340: 1148&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;A cross sectional survey of 4900 Chinese adults with no history of diabetes comparing HBA1c with ogtt. They found that a HBA1c cut off of 6.3% to diagnose diabetes had a higher sensitivity than fasting glucose of 7mmoles/L or HBA1c of 6.5%&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;BR&gt;&lt;/STRONG&gt;This implies that we may need to use different cut offs for different ethnic groups if we use HBA1c to diagnose diabetes&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;CO-MORBIDITIES &amp;amp; FUNCTIONAL DISABILTY&lt;/STRONG&gt; &lt;BR&gt;&lt;EM&gt;Paper 9 Kalyani RR, Saudek CD, Brancati FL, Selvin E Association of Diabetes, Co-morbidities, and A1c with Functional Disability in Older Adults Diabetes Care 33: 1055-1060&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;Data on 6087&amp;nbsp; adults aged 60 and over from the National Health And Nutrition Examination Survey (NHANES) 1999-2006 in USA. Diabetes and co-morbidities were self reported. Disability was defined by asking 19 questions about the degree of difficulty in performing physical tasks. Diabetes was associated with 2 to 3 times increased odds of disability across functional groups. Co-morbidities, mostly CVD, obesity and poor glycaemic control ( defined as HBA1c at or above 8%) explained up to 85% of the excess odds of disability whereas poor glycaemic control alone explained only about 10% of the excess odds. Adjustment for co-morbidities, HBA1c and diabetes duration fully attenuated the associations of diabetes with disability in all functional groups suggesting that aggressive management of CV risk factors, and obesity may reduce the burden of disability&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;U&gt;SHORT REPORTS&lt;BR&gt;&lt;/U&gt;&lt;BR&gt;Taspoglutide&lt;/STRONG&gt;&amp;nbsp; &lt;EM&gt;Paper 10 Ratner R, Nauck M, Kapitza C et al Safety and tolerability of high doses of taspoglutide, a weekly human GLP-1 analogue, in diabetic patients with metformin: a randomised double blind placebo controlled study&lt;/EM&gt; &lt;BR&gt;Phase 2 trial of 129 subjects on metformin with either placebo or taspoglutide 20, or uptitrated to 30 or 40 mgs weekly. Taspoglutide was well tolerated at high doses and was efficacious for lowering HBA1c . Uptitration of dose was not associated with a worsening AE profile&lt;BR&gt;&lt;STRONG&gt;Diabetes &amp;amp; Clinical Depression&lt;/STRONG&gt;&amp;nbsp; &lt;EM&gt;Paper 11 Fisher L, Glasgow RE, Strycker LA The relationship between diabetes distress and clinical depression with glycaemic control among patients with type 2 diabetes. &lt;/EM&gt;Diabetes Care 33: 1034-1036 The lack of association between depression and glycaemic control is not due to the use of a binary measure of depression. &lt;BR&gt;&lt;STRONG&gt;Informed choice &amp;amp; screening for DM&lt;/STRONG&gt;&amp;nbsp; &lt;EM&gt;Paper 12 Marteau TM, Mann E, Prevost AT et al Impact of an informed choice invitation on uptake of screening for diabetes in primary care (DICISION) randomised trial.&lt;/EM&gt; Providing information to support choice did not affect attendance for diabetes screening&lt;BR&gt;&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Journals reviewed&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp; N Eng J Med,&amp;nbsp; Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int&lt;/EM&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>301580</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=301580]]&gt;</url>
    <title>Interesting new diabetes papers: November 2008</title>
    <publicationDate>2008-12-18T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 43rd in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: November 2008&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;RCTs&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;o:p&gt;&lt;SPAN style="TEXT-DECORATION: none"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;/U&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;ASPIRIN FOR PRIMARY PREVENTION IN PEOPLE WITH DIABETES&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 1 Ogawa H, Nakayama M, Marimoto T et al Low dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;JAMA 300: 2134-2141&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 2 Nicolucci A Aspirin for Primary Prevention of Cardiovascular Events in Diabetes :Still an open question (editorial) JAMA 300:2180-1&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 3 Belch J, Macuish A, Campbell I et al The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 337:1030-1034&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 4 Hiatt WR Aspirin for prevention of cardiovascular events is only effective in established cardiovascular disease (editorial) BMJ 337:1005-6&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Summary &lt;/B&gt;The use of aspirin for primary prevention of cardiovascular events in people with diabetes is widely recommended by existing guidelines based on extrapolated data from other high risk groups. Studies on primary prevention in people with diabetes have been negative.&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;In paper 1 the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial 2539 people with type 2 diabetes but CHD were randomised to low dose aspirin (80-100mgs daily)&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;or a non aspirin control group. After a mean of 4.37 years aspirin therapy was associated with a non significant reduction in the risk of a composite CHD endpoint. No differences in total mortality among the groups was noted. Aspirin therapy was associated with an increased risk of GIT bleeding and retinal haemorrhage . 4 patients in the aspirin group needed blood transfusions and none did in control group. &lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;The trial was underpowered because of a lower than expected event rate in the trail population&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;The estimate was 52 events per 1000 and the observed rate was 13.6-17.&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;In paper 3 the PROPADAD trial 1276 adults with either type 1 or 2 diabetes aged 40 or more with no symptomatic CHD but an ankle brachial pressure index of 0.99 or less were randomised to aspirin 100mgs daily plus antioxidant capsule, aspirin plus placebo capsule, placebo plus antioxidant or placebo plus placebo. They were followed for 8 years. Those in the aspirin group had 116 fatal and non fatal CHD events compared to 117 in the control group. No differences were seen in the events in the antioxidant group compared to placebo.&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;The two editorials take slightly different positions. Paper 2 says more studies are needed and that the decision to prescribe aspirin should be made on an individual basis. Paper 4 is much more definite and says aspirin should only be used in people with established symptomatic CVD.&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Dr &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:PersonName w:st="on"&gt;Roger Gadsby&lt;/st1:PersonName&gt;’s comments&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/B&gt;Further trials are being carried out to get more data but at present there is no direct evidence for the use of aspirin in primary prevention of CHD in people with diabetes&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;o:p&gt;&lt;SPAN style="TEXT-DECORATION: none"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;/U&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;IMPROVING GLYCAEMIC CONTROL IN TYPE1 DIABETES&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 5 Ismail K, Thomas SM, Maissi E et al Motivational enhancement therapy with or without cognitive behaviour therapy to treat type 1 diabetes Ann Int Med 149:708-719&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Summary &lt;/B&gt;344 adults with poorly controlled type 1 diabetes were randomised to a nurse delivered motivational enhancement therapy, motivational enhancement therapy (MET) plus cognitive behaviour therapy (CBT) or usual care. Outcomes were change in&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;a range of biomedical and psycho-social measures at 12 months.&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;Hba1c in the combined intervention was -0.46% and in the motivational interviewing alone -0.19% compared with usual care. The study concludes that nurse delivered MET plus CBT is feasible and that this combined with MET gives better drops than MET alone. However the CBT plus MET intervention was more intensive and of greater duration than the MET alone. Also they screened 1699 people to find 507 eligible subjects of who 344 participated.&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Dr &lt;st1:PersonName w:st="on"&gt;Roger Gadsby&lt;/st1:PersonName&gt;’s comments &lt;/B&gt;Talking therapies can help poorly controlled adults with type 1 diabetes. The more time is spent the better the improvement.&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;o:p&gt;&lt;SPAN style="TEXT-DECORATION: none"&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;/U&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;OTHER SORTS OF STUDY&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;STRONG&gt;LATENT AUTOIMMUNE DIABETES (LADA) &lt;o:p&gt;&lt;/o:p&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;I style="mso-bidi-font-style: normal"&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;Paper 6 Davies H, Brophy S, Fielding A et al Latent Autoimmune Diabetes (LADA) in adults in &lt;st1:place w:st="on"&gt;South Wales&lt;/st1:place&gt;: incidence and characterisation Diabetic Medicine 25: 1354-1357&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;STRONG&gt;Summary&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;LADA is a slowly progressive type 1 diabetes resulting from autoimmune destruction of pancreatic beta cells usually leading to absolute insulin deficiency within 2-6 years. It is often diagnosed and treated as type 2 diabetes , but can be distinguished from it by the presence of antibodies to glutamic acid decarboxylase (GAD) The proportion of type 2 people with GAD antibodies varies with the selection criteria and country of study. In UKPDS it was 13% of 25-65 year olds of whom 94% required insulin within 6 years.&lt;/SPAN&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;In this study 32 practices recruited people with type 2 diabetes for GAD testing and found 28 out of 683 tested =4% Those positive for GAD were more likely to have a lower BMI, to have higher HBA1c and to be symptomatic.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;STRONG&gt;Dr &lt;st1:PersonName w:st="on"&gt;Roger Gadsby&lt;/st1:PersonName&gt;’s comment&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;Interesting data&lt;/SPAN&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;o:p&gt;&lt;SPAN style="TEXT-DECORATION: none"&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;STRONG&gt;&lt;U&gt;SHORT REPORTS&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;STRONG&gt;RISK OF LACTIC ACIDOSIS&lt;o:p&gt;&lt;/o:p&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;I style="mso-bidi-font-style: normal"&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;Paper 7 Bodmer M, Meier C, Krahenbuhl S et al Metformin, sulphonylurea,, or other antidiabetic drugs and the risk of lactic acidosis or hypoglycaemia. Diabetes Care 31: 2086-2091&lt;/SPAN&gt;&lt;/I&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;In this nested case-control analysis of 50048 diabetic subjects from the UK GP research database. 6 cases of lactic acidosis were found. Use of sulphonylurea was associated with a materially elevated risk of hypoglycaemia. Lactic acidosis was very rare and was associated with concurrent co morbidity&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;&lt;I style="mso-bidi-font-style: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;STRONG&gt;SCREENING UPTAKE IN DIABETIC RETINOPATHY&lt;o:p&gt;&lt;/o:p&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;I style="mso-bidi-font-style: normal"&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;Paper 8 Leese GP, Boyle P, Feng Z et al Screening uptake in a well established diabetic retinopathy screening programme. Diabetes Care 31: 2131-2135&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;Data from Tayside in &lt;st1:country-region w:st="on"&gt;&lt;st1:place w:st="on"&gt;Scotland&lt;/st1:place&gt;&lt;/st1:country-region&gt; . Social derivation was strongly associated with poor attendance at screening events but time travelled to get there was not.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;STRONG&gt;PREVENTING TYPE 1 DIABETES&lt;o:p&gt;&lt;/o:p&gt;&lt;/STRONG&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;I style="mso-bidi-font-style: normal"&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;Paper 9 Nanto-Salonen K, Kupila A, Simell S et al Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and auto antibodies conferring increased risk of disease: a double blind randomised controlled trail Lancet 372: 1746-55&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;It didn’t! Short acting human insulin was given for 1.8years in a dose of 1unit per Kg body weight -intranasal&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;I style="mso-bidi-font-style: normal"&gt;&lt;STRONG&gt;Journals reviewed:&lt;/STRONG&gt; &lt;/I&gt;&lt;I style="mso-bidi-font-style: normal"&gt;N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int&lt;/I&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; published in&amp;nbsp;November 2008.&amp;nbsp;This series began in 2002 as a bulletin for Diabetes Care Staff.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public.&amp;nbsp; Word and webpage versions available.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/EM&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P class=MsoTitle style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: left" align=left&gt;&lt;SPAN style="FONT-WEIGHT: normal; TEXT-DECORATION: none; text-underline: none"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>333627</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=333627]]&gt;</url>
    <title>Interesting new diabetes papers: November 2009</title>
    <publicationDate>2009-12-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 55th in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: November 2009&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;SYSTEMATIC&amp;nbsp; REVIEWS&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;ASPIRIN FOR PRIMARY PREVENTION OF VASCULAR DISEASE IN DIABETES&lt;/STRONG&gt; &lt;BR&gt;Paper 1 De Berardis G, Sacco M, Strippoli GFM et al&amp;nbsp; &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=331886" target="_blank"&gt;Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials&lt;/A&gt;&amp;nbsp; BMJ 339: 1238&lt;BR&gt;Paper 2 Hayes R, Bowman L, Armitage J&amp;nbsp; &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=333629" target="_blank"&gt;Aspirin for primary prevention of vascular disease in people with diabetes&lt;/A&gt; (editorial) BMJ 339: 1210-11&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;A meta-analysis of 6 studies, which included 10117 patients.&amp;nbsp; When aspirin was compared with placebo there was no significant reduction in the risk of major cardiovascular events, cardiovascular mortality or all cause mortality. Evidence relating to harms was inconsistent. The weakness of the study was the paucity of high quality RCT’s. They conclude that there study indicates either low efficacy of aspirin in people with diagnosis or insufficient evidence on this matter.&lt;BR&gt;The editorial states that the analysis was limited by the number of trials that reported significant bleeding, but the increased risk of bleeding reported is consistent with other data. The editorial concludes that the question of aspirin in primary prevention remains open and people should be recruited into the on going trials trying to answer the problem. Other primary prevention strategies such as statin therapy and good glucose control should be instituted before thinking about aspirin. Guidelines need to acknowledge the current equipoise and not recommend a treatment without evidence.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Interesting meta-analysis, that could be interpreted as “ don’t use aspirin in primary prevention in people with diabetes at present”&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;RCT’s&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBESITY TREATMENT WITH GLP-1 AGONIST&lt;/STRONG&gt;&lt;BR&gt;Paper 3 Astrup A, Rossner S, Van Gall L et al Effects of Liraglutide in the treatment of obesity: a randomised, double blind, placebo controlled study. Lancet 374:1606-1616&lt;BR&gt;Paper 4 Bray GA Gastrointestinal hormones and weight management (comment) Lancet 374:1570-71&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;564 individuals with BMI between 30-40 were randomised to Liraglutide 1.2, or 1.8, or 2.4 or 3mgs or placebo by sc injection daily for 20 weeks, or to orlistat 120mgs tds orally. All individuals had a 500 Kcal per day energy deficit diet and increased physical activity. Outcome was weight change.&lt;BR&gt;Mean wt loss on Liraglutide was 4.8Kg at 1.2mgs, 5.5Kg at 1.8 mgs, 6.3Kg at 2.4kg and 7.2Kg at 3mg compared to 2.8 with placebo and 4.1 with orlistat. 76% of individuals on Liraglutide 3mgs lost more than 5% weight, as compared to 44% on orlistat and 30% on placebo. Liraglutide reduced bp at all doses, and reduced fasting glucose and HBA1c . Nausea and vomiting occurred more often in people on Liraglutide than on placebo, but adverse events were mainly transient and rarely led to discontinuation of treatment. The study concludes that Liraglutide treatment over 20 weeks is well tolerated, induces weight loss, improves certain obesity related risk factors and reduces prediabetes.&lt;BR&gt;The comment article says that the orlistat placebo subtracted weight reductions in the trial were lower than reported in other studies, but that we can be optimistic that the promise of the GLP-1 agonists for the treatment of obesity will be fulfilled.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;The weight reductions in this study at 20 weeks are impressive. The max wt loss is on the max dose of Liraglutide which may be expensive as the 1.2mg dose used to treat diabetes costs around £80 per month and the 1.8mg dose around £117 per month.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;OTHER SORTS OF STUDY&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PREVENTION OF TYPE 2 DIABETES&lt;/STRONG&gt;&lt;BR&gt;Paper 5 Diabetes Prevention Program Research Group 10 year follow up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study Lancet 374 1677-86&lt;BR&gt;Paper 6 Misra A Prevention of type 2 diabetes: the long and winding road (comment) Lancet 374: 1655-56&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;After the completion of the DPP study 88% of subjects enrolled for a median additional follow up of 5.7years. Those from all initial 3 groups&amp;nbsp; (Intensive lifestyle, metformin and placebo) were offered group implementation lifestyle intervention. &lt;BR&gt;Outcome was development of diabetes.&lt;BR&gt;After the completion of the DPP those in the intensive lifestyle regained some weight,&amp;nbsp; so that at 10 years their weight was similar to the metformin group who maintained their modest weight loss. In the follow up period the diabetes incidence rates were similar across all 3 groups, but the cumulative incidence of diabetes throughout the DPP study period and the follow up (around 10 years in total)&amp;nbsp; remained lowest in the lifestyle group a reduction of 34% compared with the placebo group and 18% in the metformin group. They conclude that prevention or delay of diabetes with lifestyle intervention or metformin can persist for at least 10 years.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;The benefit of intensive lifestyle intervention in reducing development of diabetes in a high risk group of people with IGT persists to 10 years.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;SHORT REPORTS&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;How do we define cure of diabetes.&lt;/STRONG&gt; Paper 7 Buse J, Caprio S, Cefalu WT et al How do we define cure of diabetes (consensus statement)&amp;nbsp; Diabetes Care 32: 2133-2135&lt;BR&gt;Expert group felt that remission was a better word to use rather than cure. For first 5 years screen for complications as per diabetes, after 5 years screen less frequently.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Pregnancy Outcomes in type 1 diabetes.&lt;/STRONG&gt;&amp;nbsp;Paper 8&amp;nbsp; Persson M, Norman M, Hanson U Obstetric and Perinatal Outcomes in type 1 diabetic pregnancies Diabetes Care 32: 2005-2009&lt;BR&gt;Population based study from whole of Sweden from 1991-2003. 5089 type 1 diabetic pregnancies and 1260207 control pregnancies. In the type 1 pregnancies pre-eclampsia was higher (OR 4.47),&amp;nbsp; as was LSCS (OR 5.31), Stillbirth (OR 3.34), perinatal mortality (OR 3.29) major malformations (OR 2.5), very preterm birth (OR 3.08) and foetal macrosomia (OR 11.55) They conclude that type 1 diabetes in pregnancy is still&amp;nbsp; associated with considerably increased rates of adverse obstetric and peri natal complications.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed&lt;/STRONG&gt;&amp;nbsp; N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>299122</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=299122]]&gt;</url>
    <title>Interesting new diabetes papers: October 2008</title>
    <publicationDate>2008-11-19T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2008,INTERESTING NEW ARTICLES,RESEARCH,DIABETES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 42nd in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: October 2008&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;GUIDELINES&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;POSTMEAL GLUCOSE&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 1 Ceriello A Colagiuri S International Diabetes Federation Guideline for management of postmeal glucose: a review of recommendations.&amp;nbsp; Diabetic Medicine 25: 1151-1156&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;This is a summary of the full guideline from the IDF (available from &lt;A href="http://www.idf.org/" target="_blank"&gt;www.idf.org&lt;/A&gt;)&lt;BR&gt;This guideline was based on a literature review of 1600 papers and sought to answer 4 questions. Is postprandial hyperglycaemia harmful, is treatment of postmeal glycaemia beneficial, which therapies are effective in controlling postmeal plasma glucose and what are the targets for postmeal glucose and how should they be assessed? &lt;BR&gt;They conclude that it is important to try and control postmeal glucose and that a target of below 7.8mmoles/l 2hrs after a meal is both reasonable and achievable.&lt;BR&gt;Dr Roger Gadsby’s comments&lt;BR&gt;This is the definitive statement on postmeal glucose in the world.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;WEIGHT-REDUCING MEDICATIONS &amp;amp; PROGRESSION TO DIABETES&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 2 Lloret-Linares C, Greenfield JR, Czernichow S Effect of weight-reducing agents on glycaemic parameters and progression to Type 2 diabetes: a review&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt; &lt;BR&gt;This is a&amp;nbsp; review of 23 studies which fulfilled the inclusion criteria, 15 of which included people who did not have diabetes. The&amp;nbsp; author’s state that in non-diabetic subjects weight loss agents led to a significant improvement in fasting glucose, fasting insulin and insulin resistance. In the diabetic population HBA1c decreased by 0.28%-1.1% with orlistat, 0.6% with sibutramine and rimonobant.&amp;nbsp; Orlistat reduces progression to diabetes in patients with glucose intolerance treated for 4 years (risk reduction of 45%).&amp;nbsp; They conclude that despite leading to only modest weight loss after 12 months, agents promoting weight loss have beneficial effects on glycaemic parameters, glycaemic control and progression to diabetes.&lt;BR&gt;Dr Roger Gadsby’s comments&lt;BR&gt;The conclusions are in line with what we expected&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PREMIXED INSULIN ANALOGUES&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 3 Qayyum R, Bolen S, Maruther N et al Systematic Review: Comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes Ann Intern Med 149: 549-559&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;A review 45 studies, 43 of which were RCT’s, The median duration of follow up was 16 weeks. The trials enrolled a total of 14603 patients. Meta-analysis was performed when data was sufficient.&amp;nbsp; 16 studies compared premixed insulin analogues with premixed human insulin and found similar effects on lowering HBA1c with similar wt gain and similar hypoglycaemia rates.&lt;BR&gt;In trials of premixed insulin analogues versus long acting analogues, the premixed were better at decreasing HBA1c with slightly more weight gain and hypoglycaemia.&lt;BR&gt;In 10 studies comparing premixed analogues with non insulin antidiabetic agents the premixed insulin were more effective at lowering HBA1c&amp;nbsp; with more wt gain and minor hypoglycaemia.&lt;BR&gt;No studies were specifically designed to evaluate micro or macro vascular outcomes and death.&lt;BR&gt;Dr Roger Gadsby’s comments&lt;BR&gt;These results are in line with what would be expected&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;RCT’s&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RETINOPATHY&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 4 Chaturvedi N, Porta M, Klein R et al for the DIRECT Programme Study Group Effect of Candasartan on prevention (DIRECT-Prevent1) and Progression (DIRECT-Protect 1 ) of retinopathy in type 1 diabetes: randomised placebo controlled trials&amp;nbsp; Lancet 372: 1394-1401&lt;/EM&gt;&lt;BR&gt;&lt;EM&gt;Paper 5 Sjolie AK, Klein R, Porta M et al for the DIRECT Programme Study Group Effect of candasartan on progression and regression of retinopathy in type 2 diabetes (DIRECT –Protect 2) a randomised placebo controlled trial Lancet 372: 1385- 1393&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;In DIRECT Prevent 1 1421 people with type 1 diabetes with no microalbuminuria and&amp;nbsp; no retinopathy were randomised to candastartan (16mgs then up to&amp;nbsp; 32 mgs/daily) or placebo. Retinopathy was measured from retinal photographs assessed on the ETDRS scale. Incidence of retinopathy, defined as a 2 step increase in the EDTRS scale&amp;nbsp; was 25% in candastartan group and 31% in placebo group after 4 years.&lt;BR&gt;In&amp;nbsp; DIRECT- Protect 1 1905 people with type 1 diabetes and mild retinopathy were randomised to candastartan and placebo as above. Progression of retinopathy defined as a 3 step increase on the EDTRS scale was 13% in the candastartan group and 13% in the placebo group.&lt;BR&gt;The authors conclude that although candasartan reduces the incidence of retinopathy, we did not see a beneficial effect on retinopathy progression.&lt;BR&gt;In DIRECT – Protect 2 1905 people with type 2 diabetes who were normoalbuminuric were randomised to candasartan (16mgs for 1 month then 32mgs) or placebo and followed for 4 years. Progression was defined as 3 step or more change on the EDTRS scale. Progression occurred in 19% on placebo and 17% in candasartan group. This is a non significant risk reduction of 13%. &lt;BR&gt;The authors conclude that treatment with candasartan in type 2 diabetic patients with mild to moderate retinopathy might induce improvement in retinopathy.&lt;BR&gt;In all the trials there was no increase in adverse events in the candastartan group.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;These results are not as impressive as could have been hoped. The trials were well conducted.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;EXENATIDE ONCE WEEKLY&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 6 Drucker D, Buse JB, Taylor K et al for the DURATION-1 Study group&lt;BR&gt;Exenatide once weekly versus twice daily for the treatment of type 2 diabetes a randomised open label non inferiority study Lancet 372: 1240-1249&lt;BR&gt;Paper 7 Scheen AJ&amp;nbsp; Exenatide once weekly in type 2 diabetes (comment) Lancet 372: 1197-98&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;295 people with type 2 diabetes who were drug naïve or on one or more oral agents with median HBA1c of 8.3%&amp;nbsp; were randomised to either 2mgs long acting exenatide&amp;nbsp; or 10 micrograms twice daily. &lt;BR&gt;At 30 weeks those on once weekly had a significantly lower HBA1c of -1.9% than those on twice daily who had -1.5%. There was no increased risk of hypoglycaemia. lower occurrence of nausea and similar reductions in weight. There was a higher incidence of pruritus at the injection site and increased circulating antibodies in the once weekly group&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Very interesting results.&amp;nbsp; A once weekly injection may overcome some of the reluctance of injected products.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OTHER SORTS OF STUDY&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;TYPE 2 DIABETES &amp;amp; CARDIOVASCULAR DISEASE&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 8 Holman RR, Paul SK, Bethel MA, Mathews D, Neil HAW 10-year follow up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359: 854-865&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;In the UKPDS study people newly diagnosed with type 2 diabetes were randomised to intensive control (HBA1c=7%) or standard control (HBA1c =7.9%) The intensive group had on average&amp;nbsp; 24% reduction in risk of microvascular complications and a 16% risk reduction in myocardial infarction which was “on the boundary of conventional statistical significance”&lt;BR&gt;Once the trial stopped the between group differences in HBA1c disappeared within 1 year. However the relative risk reductions in microvascular disease of 24% were maintained after 10 years of follow up and risk reductions for myocardial infarction of 15% and death from any cause emerged over time.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comment&lt;/STRONG&gt;&lt;BR&gt;The concept of “metabolic memory” was coined by people reporting on the DCCT follow up study&amp;nbsp; to explain their similar findings. This UKPDS data suggests metabolic memory for a period of good glucose control occurs in type 2 diabetes too&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;EM&gt;Paper 9 Holman RR, Paul SK, Bethel MA et al Long-term follow up after tight control of blood pressure in type 2 diabetes N Engl J Med 359:1565-1576&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;In the UKPDS trial 1148 people with type 2 diabetes were randomised to tight or less tight blood pressure control. 884 patients underwent post trial monitoring. For the first 5 years this was in UKPDS clinics and from years 6-10 it was by annual questionnaires to GP’s. Differences in the blood pressure between the 2 groups disappeared with 2 years of end of trial. Significant relative risk reductions found during the trial for any diabetes related endpoint, diabetes related death, microvascular disease, and stroke in the group receiving tight, as compared to less tight were not sustained during the post trial follow up. &lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comment&lt;/STRONG&gt;&lt;BR&gt;It appears that good blood pressure control must be continued if the benefits are to be maintained.&lt;BR&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;U&gt;Journals reviewed&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetic Medicine, Pract Diab Int&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; published in&amp;nbsp;October 2008.&amp;nbsp;This series began in 2002 as a bulletin for Diabetes Care Staff.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public.&amp;nbsp; Word and webpage versions available.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;EM&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>330517</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=330517]]&gt;</url>
    <title>Interesting new diabetes papers: October 2009</title>
    <publicationDate>2009-11-18T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 54th in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: October 2009&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;SYSTEMATIC&amp;nbsp; REVIEWS&lt;BR&gt;&lt;/U&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;STATINS &amp;amp; RISK OF DEVELOPING DIABETES &lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 1 Rajpathak SW Kumbhani DJ, Crandall J et al &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=330523" target="_blank"&gt;Statin therapy and Risk of Developing type 2 Diabetes: a Meta-Analysis&lt;/A&gt; Diabetes Care 32: 1924-1929&lt;/EM&gt;&lt;BR&gt;&lt;EM&gt;Paper 2 Belalcazar LM, Raghavan VA, Ballantyne CM Statin-Induced diabetes: will it change practice (editorial) Diabetes Care 32:1941-43&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;A meta-analysis of 6 studies, which included 57593 patients with a mean follow up of 3.9 years during which 2082 incident diabetes cases accrued. There was a small increase in diabetes risk (RR 1.13 95% CI 1.03-1.23) with no evidence of heteregeneity across trials. However this estimate was no longer statistically significant when data from the hypothesis generating WOSCOPS trial was included.&lt;BR&gt;The authors conclude that although statin therapy greatly lowers vascular risk, including among those with and at risk from diabetes, the relationship of statin therapy to incident diabetes remains uncertain.&lt;BR&gt;The editorial states that as with other meta-analyses the results of this one are only hypothesis generating because they rely on data published previously and thus are inherently observational. It states that little is known about the effects of statins on microvascular complications of diabetes. It concludes that if statins reduce macrovascular and microvascular morbidity and mortality, any associated modest increase in glycaemia will no longer be an issue of concern&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;BR&gt;&lt;/STRONG&gt;Interesting meta-analysis, but will not change clinical practice&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;RCT’s&lt;BR&gt;&lt;/U&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;INSULIN IN TYPE 2 DIABETES&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 3 Holman RR, Farmer AJ, Davies MJ et al for the 4T study group. Three year efficacy of complex insulin regimes in type 2 diabetes N Engl J Med 361: 1736-1747&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;In the first year of the 4T study people with type 2 diabetes not controlled on metformin plus sulphonylurea were randomised to either prandial short acting insulin (novorapid) three times a day, twice daily mixed insulin (novomix 30) or once daily basal insulin (detemir, in 30% of cases given bd). The results of this part of the trial were published in 2007. &lt;BR&gt;After the first year those on tds prandial had basal insulin added, those on basal had tds&amp;nbsp; prandial added and those on bd mixed had lunchtime prandial added.&amp;nbsp; The results after 3 years showed that all regimes had similar HBa1c levels, although prandial was slightly higher. Hypoglycaemia was lowest in the basal, higher in the biphasic and highest in the prandial, and wt gain was higher in the biphasic than either the basal or prandial&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;In my opinion the 4T study confirms that the most appropriate way to begin insulin in someone with type 2 diabetes uncontrolled on 2 oral agents is to continue the oral agents and add basal insulin. If basal insulin alone is insufficient to control glycaemia a dose of prandial rapid acting insulin should be added with the main meal.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;TRIPLE ORAL THERAPY&lt;/STRONG&gt; &lt;BR&gt;&lt;EM&gt;Paper 4 Scheen AJ, Tan MH, Betteridge DJ et al on the behalf of the PROactive investigators Long term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PrROactive 17) Diabetic Medicine 26: 1033-1039&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;SUMMARY&lt;/STRONG&gt;&lt;BR&gt;Post hoc analysis of people in PROactive comparing the effects of pioglitazone 45mgs or placebo on HBA1c, concomitant changes in medications and initiation of permanent insulin. It concludes that intensifying an existing dual oral therapy of metformin plus sulphonylurea by adding pioglitazone results in sustained improvements in glycaemic control and reduced progression to insulin (31.1% in placebo compared with 16.1% in the pioglitazone group)&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsbys comment&lt;/STRONG&gt;&lt;BR&gt;Evidence for the effectiveness of this sort of triple oral therapy. &lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OTHER SORTS OF STUDY&lt;BR&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;POSTPRANDIAL AND FASTING GLUCOSE CONTRIBUTIONS TO HYPERGLYCAEMIA&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 5 Peter R, Dunseath G, Luzio SD et al Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HBA1c in subjects with Type 2 diabetes Diabetic Medicine 26: 974-980&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;12 hour plasma glucose profiles were determined in 52 subjects with type 2 diabetes in response to 3 serial identical test meals. &lt;BR&gt;They confirmed previous research in finding that in people with&amp;nbsp; HBa1c levels of 8% and above the fasting glucose is the main driver.&amp;nbsp; Postprandial glucose is the main driver when HBa1c is at or below 7.3% &lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;BR&gt;&lt;/STRONG&gt;This study sheds light on the treating “fasting or postprandial glucose” debate&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;SHORT REPORTS&lt;BR&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;New GLP-1&amp;nbsp;&amp;nbsp; Paper 6&amp;nbsp; Rosenstock J, Reusch J, Bush M et al&amp;nbsp; Potential of Albiglutide, a long acting GLP-1 receptor agonist, in type 2 diabetes Diabetes Care 32: 1880-1886&amp;nbsp; Phase 2 study of 356 patients on lifestyle alone or metformin monotherapy given albiglutide (a GSK drug) weekly, biweekly or monthly or exenatide. The drug is a fusion of two GLP-1 molecules to human albumin with a single amino acid substitution to render the molecule resistant to DPP4 . Albiglutide reduced HBA1c by similar amounts given weekly or biweekly or monthly with similar wt loss GI symptoms at 30mg weekly was less than observed at higher biweekly or monthly doses.&lt;BR&gt;Aliskiren compared with irbesartan or both in combination&amp;nbsp; Paper 7 Persson F, Rossing P, Reinhard H et al Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension and albuminuria. Aliskerin (a direct rennin inhibitor)&amp;nbsp; lowered albuminuria by similar amount as irbesartan (48% v 58%) but both together lowered it by 71%&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed&lt;/STRONG&gt;&amp;nbsp; N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>395152</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=395152]]&gt;</url>
    <title>Interesting new diabetes papers: September &amp; October 2010</title>
    <publicationDate>2010-11-30T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: September &amp; October 2010&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;GUIDELINES &amp;amp; POLICY&lt;BR&gt;&lt;BR&gt;&lt;/U&gt;Suspension of Marketing Authorisation for Rosiglitazone by European Medicines Agency (EMA)&lt;/STRONG&gt;&amp;nbsp;&lt;STRONG&gt;on 23 September 2010 &lt;BR&gt;&lt;/STRONG&gt;In a press release on 23 Sept the EMA stated that the benefits of rosiglitazone no longer outweigh its risks and so it suspended its marketing authorisation. Articles in the BMJ of 11 September recommended that rosiglitazone be withdrawn &lt;EM&gt;e.g Cohen D&amp;nbsp; Rosiglitazone what went wrong BMJ N341: 530-534,&amp;nbsp;Freemantle N What can we learn from the continuing regulatory focus on the thiazolidinediones BMJ 341:535&lt;BR&gt;&lt;/EM&gt;The situation in the USA was discussed by Woodcock J, Sharfstein JM, Hamburg M &lt;BR&gt;&lt;EM&gt;Regulatory action on Rosiglitazone by the US Food and Drug Administration N Eng J Med 363: 1489-1491&lt;BR&gt;&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;&lt;U&gt;RCT’s&lt;BR&gt;&lt;BR&gt;&lt;/U&gt;Lifestyle Interventions&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 1 The Look AHEAD research Group.&amp;nbsp; Long Term effects of a Lifestyle Intervention on weight and Cardiovascular Risk Factors in Individuals with Type 2 Diabetes Mellitus Arch Int Med 170: 1566-1575&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;5145 people with type 2 diabetes, aged 45 -76,&amp;nbsp; were randomised to an intensive lifestyle intervention (ILI) or a control group given a diabetes support and education programme (DSE) The intensive group were seen weekly for the first 6 months, 3 times a month for second 6 months with a combination of group and individual contacts. During years 2 to 4 the ILI group were seen individually at least once a month, had a further email/phone contact once a month and offered a variety of further group sessions. The DSE group were invited to 3 group sessions per year.&lt;BR&gt;Averaged over 4 years ILI participants had a greater wt loss than DSE group&amp;nbsp; (-6.15% v -0.88%)&amp;nbsp; and greater improvements in treadmill fitness, HBA1c (0.36% v -0.09%) systolic BP (-5.33 v -2.97) . The participants are being followed to see if these differences translate into reductions in CVD events.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;BR&gt;&lt;/STRONG&gt;The improvements are impressive but the intensity of the intervention is huge, and unlikely to be able to be replicated outside of a research programme.&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;OTHER SORTS OF STUDY&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 2 Saaristo T, Moilanen L, Korpi-Hyovalti E, et al&amp;nbsp; Lifestyle Intervention for the Primary Prevention of Type 2 Diabetes in Primary Healthcare : One year follow up of the Finnish National Diabetes Prevention Programme (FIN-D2D) Diabetes Care 33:2146-2151&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;10149 individuals at high risk for diabetes were identified using the Finnish Diabetes Risk Score (FINDRISC) in primary care practices, pharmacies, at public health events and through advertising, by having a history of IFG or IGT , having CVD or GDM. One year follow up data was available on 2798 participants who were non diabetic at baseline. They were referred to FIN-2D2 programme. Intervention visits were either individual counselling or group sessions, and averaged 2.9 visits per person during the one year follow up. The average wt loss was 1.3kg in men and 1.1 in women, with&amp;nbsp; BP and lipids decreasing. 17.5% lost at or above 5kg at this was accompanied by a 69% reduction in risk of diabetes over 1 year compared to the subjects who maintained their weight.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;BR&gt;&lt;/STRONG&gt;The FIN-2D2 is an amazing national programme that has shown that methods for recruiting high risk subjects are simple and easy to use. Moderate wt loss was effective in reducing the risk of diabetes&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Severe Hypoglycaemia&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper32 Zoungas S, Patel A, Chalmers J et al for the ADVANCE Collaborative group Severe Hypoglycaemia and risks of Vascular Events and Death&amp;nbsp; N Eng J Med 363: 1410-1418&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;An examination of the association between severe hypoglycaemia and adverse events in 11140 patients with type 2 diabetes in the ADVANCE trial. During the median follow up of 5 years 231 people had at least one severe hypo, 150 in the intensive control group and 81 in the standard control group. Severe hypoglycaemia was associated with a significant increase in the adjusted risk of major macrovascular events major microvascular events, death from a CVD cause and death from any cause. The analysis indicate that it is possible that severe hypoglycaemia contributes to adverse outcomes but it is possible that hypoglycaemia is just as likely to be a marker of vulnerability to such events.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;BR&gt;&lt;/STRONG&gt;Hypoglycaemia is not good news.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;OTHER SORTS OF STUDY&lt;BR&gt;HBA1c in Screening&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 4 Mann DM, Carson AP, Shimbo D et al Impact of A1C Screening criterion on the Diagnosis of Pre-diabetes among US adults Diabetes Care 33:2190-2195 &lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;Using data from 7029 US adults without diabetes from the NHANES survey 1999-2006 classified as having pre-diabetes by fasting glucose criteria and HBA1c criteria (using the range 5.7-6.4%) . Only 7.7% had prediabetes using both criteria, Using HBA1c alone would reclassify 37.6 million Americans with IFG to not having pre-diabetes using HBA1c criteria and 8.9 million without IFG to&amp;nbsp; having pre-diabetes using HBA1c criteria.&lt;BR&gt;&lt;EM&gt;Paper 5 Olson DE, Rhee MK, Herrick K et al Screening for Diabetes and Pre-Diabetes with Proposed A1c based Diagnostic Criteria Diabetes Care 33: 2184-2189&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;3 datasets with a total of 4706 subjects in the USA were used to compare diabetes and pre-diabetes identified by HBA1c and ogtt results. Ogtt revealed pre diabetes in 35.8%&amp;nbsp; and diabetes in 5.2% of the combined study subjects. The proposed ADA criteria for pre-diabetes of 5.7% - 6.4% HBA1c missed 82-94% with pre-diabetes, with significant discrepancy in different ethnic groups&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;BR&gt;&lt;/STRONG&gt;Further evidence of disagreement between different methods of diagnosing pre-diabetes!&lt;BR&gt;&lt;EM&gt;Paper 6 Takahashi O, Farmer AJ, Shimbo T et al A1c to detect Diabetes in Health Adults; when should we recheck?&lt;BR&gt;&lt;/EM&gt;&lt;STRONG&gt;Summary&lt;BR&gt;&lt;/STRONG&gt;Data from 16313 healthy Japanese adults not on glucose lowering medications at baseline with annual measures of HBA1c. In those the HBA1c below 6% rescreening at intervals shorter than 3 years identifies few individuals with an HBA1c at or greater than 6.5% (i.e. diabetes) &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;U&gt;SHORT REPORTS&lt;BR&gt;&lt;BR&gt;&lt;/U&gt;&lt;/STRONG&gt;&lt;STRONG&gt;CVD risk in Type 2 Diabetes &lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 7 Cano JF, Baena-Diez J, Franch J et al Long-term cardiovascular Risk in type 2 Diabetes compared with non-diabetic first acute myocardial infarction patients&amp;nbsp; Diabetes Care 33:2004-2009&lt;BR&gt;&lt;/EM&gt;Data from 4410 people in Spain showing risk of CVD and CVD mortality are significantly lower in people with diabetes than in myocardial infarction people. This paper provides further evidence against the idea of coronary risk equivalence for people with diabetes versus those without diabetes who have already had an infarct.&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;Cost effectiveness of Bariatric Surgery in people with Diabetes&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 8 Hoerger TJ, Zhang P, Siegel JEet al Cost Effectiveness of Bariatric Surgery for Severely Obese Adults with Diabetes.&amp;nbsp;&amp;nbsp; Diabetes Care 33:1933-1939&lt;BR&gt;Paper 9 Laiteerapong N, Huang ES The public health Implications of the Cost-Effectiveness of Bariatric Surgery for Diabetes (editorial) Diabetes Care 33: 2126-2128&lt;BR&gt;&lt;/EM&gt;Using a simulation model gastric bypass and gastric banding are cost effective methods of reducing mortality and diabetes complications in severely obese adults with diabetes. The editorial suggests that widespread adoption of bariatric surgery may be limited by increases in overall costs, limited numbers of bariatric surgeons and uncertain public health support. &lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;Cares role in older adults with diabetes&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;Paper 10 Sinclair AJ, Armes DG, Randhawa G, Bayer AJ Caring for older adults with diabetes mellitus: characteristics of carers and their prime roles and responsibilities&amp;nbsp; Diabetic Medicine 27: 1055-1059&lt;BR&gt;&lt;/EM&gt;Structured interviews with 98 diabetes patients and 83 carers. A substantial unmet need in relation to domestic activities and diabetes care was highlighted. Primary carers were mostly female relatives not in paid employment. 27 carers (33%) provided 35hours or more caring per week. 11 carers (14%) felt overwhelmed and lacked adequate support.&lt;BR&gt;&lt;BR&gt;&lt;U&gt;Journals reviewed&lt;/U&gt;&amp;nbsp;N Eng J Med, Lancet, JAMA&amp;nbsp; BMJ, BJGP,&amp;nbsp; Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>296760</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=296760]]&gt;</url>
    <title>Interesting new diabetes papers: September 2008</title>
    <publicationDate>2008-10-28T00:00:00</publicationDate>
    <publisher>Diabetes Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ 2008,RESEARCH,INTERESTING NEW ARTICLES,DIABETES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 41st in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: September 2008&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;GUIDELINES&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;PREGNANCY &amp;amp; DIABETES&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 1 Walker JD NICE guidance on diabetes in pregnancy :management of diabetes and its complications from preconception to the postnatal period: NICE clinical guideline 63 &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;London&lt;/st1:place&gt;&lt;/st1:City&gt; March 2008 Diabetic Medicine 25: 1025-1027&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 2 Mathiesen ER Damn P Commentary from &lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;Copenhagen&lt;/st1:place&gt;&lt;/st1:City&gt; on the NICE guideline on management of diabetes and its complications Diabetic Medicine 25: 1028-1029&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Summary&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;Paper 1 is a description of the guideline, and its main recommendations with the conclusion that it is a helpful guideline that has been well received.&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;Paper 2 is a commentary from &lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;Copenhagen&lt;/st1:place&gt;&lt;/st1:City&gt;. The authors conclude that the majority of the recommendations are reasonable and based on available research and present tradition. They feel that some of the recommendations are surprising and comment on these specifically. They include the use of metformin as a glucose lowering treatment&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;in pregnancy where they feel that more studies on its safety in pregnancy need to be done. They feel that the guideline could have been more encouraging in the use of long acting insulin analogues and should have given recommendations to use HBA1c measurements in pregnancy. They feel that antenatal cardiotochography should be used as a measure of foetal well being. They conclude that many of the recommendations in the guideline seem sensible but in some places are surprisingly clear cut given the paucity of high-quality evidence&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Dr &lt;st1:PersonName w:st="on"&gt;Roger Gadsby&lt;/st1:PersonName&gt;’s comments&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;Paper 1 is very supportive of the guideline, paper 2 suggests areas where some European experts may disagree with them! &lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;OTHER SORTS OF STUDY&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 3 Holt RIG The Hyperglycaemia and Adverse Pregnancy Outcomes Trail (HAPO) answers but still more questions about the management of gestational diabetes(editorial)&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;Diabetic Medicine 25 1013-1014&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Summary&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;This is an editorial on the HAPO study which was reported in the May 2008 issue of interesting papers. The HAPO study is an observational study of 25505 women in 9 countries to clarify the risks associated with varying degrees of maternal hyperglycaemia. The women underwent an ogtt at 24-28 weeks and provided the fasting glucose was less than 5.8 and the 2hr less than 11.1 the healthcare professionals were blinded to the results. Pregnancy outcomes were finally assessed in 23316 women. The results showed a strong continuous association between maternal glucose and a number of important pregnancy outcomes across a whole range of blood glucose levels with no obvious threshold. The strongest association with adverse outcomes was with fasting glucose but the editorial says that the ogtt should not be abandoned without further discussion and research.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;The conclusion of the editorial is that at present the clinical implications of the HAPO results are unclear and that further high quality studies are needed to assess whether intervention at lower levels of glucose (below those investigated in the ACHIOS study) are associated with improved outcomes &lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;st1:PersonName w:st="on"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Roger Gadsby&lt;/B&gt;&lt;/st1:PersonName&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;’s comments&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;A thought provoking editorial&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 4 Goldfine AS Assessing the Cardiovascular safety of Diabetes Therapies&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;I style="mso-bidi-font-style: normal"&gt;N Engl J Med 359: 1092-1095&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Summary&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;This is a discussion paper on the issue from someone who sits on relevant section of the Food and Drug Administration (FDA) in the &lt;st1:country-region w:st="on"&gt;&lt;st1:place w:st="on"&gt;USA&lt;/st1:place&gt;&lt;/st1:country-region&gt; who have been debating this subject. At present it is sufficient for a new diabetes drug to lower glycaemia&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;and cardio-vascular outcome trials (which take a long time and are expensive) are not required at the time of approval. The recent debate over whether rosiglitazone might actually increase cardiovascular risk although it lowers glucose, has raised some questions. &lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;This paper suggests that information for the initial assessment of cardiovascular risk could be improved through the development of an integrated trial design for all phase 2 and 3 pre approval trials incorporating prespecified procedures that standardise the collection and analysis of data. The use of an independent adjudication committee for the blinded assessment of cardiovascular events would facilitate the identification of safety signals and help rule out a large excess of CV risk. Setting an upper limit for the hazard ratio in an integrated set of data from pre approval trials would provide an important safety measure.&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;Then the FDA could require manufactures to submit a design for a cardiovascular safety trial and ongoing progress reports to obtain and maintain a drugs approval status.&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;Dr &lt;st1:PersonName w:st="on"&gt;Roger Gadsby&lt;/st1:PersonName&gt;’s comments&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;Very interesting discussion paper.&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;SHORT REPORTS&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;U&gt;Internet based Learning&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;I style="mso-bidi-font-style: normal"&gt;Paper 5 Cook DA, Levinson AJ, Garside S et al Internet-Based Learning in the Health Professions – A meta-analysis JAMA 300:1181-1196&lt;o:p&gt;&lt;/o:p&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;A meta-analysis of 201 eligible studies. It concludes that internet based learning is associated with large positive effects compared to no intervention. In contrast effects compared with non-internet instructional methods are heterogeneous and generally small suggesting effectiveness similar to traditional methods.&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;U&gt;&lt;/U&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;U&gt;Journals reviewed&lt;o:p&gt;&lt;/o:p&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetic Medicine, Pract Diab Int&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp; published in&amp;nbsp;September 2008.&amp;nbsp;This series began in 2002 as a bulletin for Diabetes Care Staff.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to the general public.&amp;nbsp; Word and webpage versions available.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; The aim of this series is to inform readers of interesting new papers relevant to diabetes that have appeared in several diabetes and general medical journals in the previous month.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>327354</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=327354]]&gt;</url>
    <title>Interesting new diabetes papers: September 2009</title>
    <publicationDate>2009-10-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,INTERESTING NEW ARTICLES,2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This bulletin is the 53rd in a monthly series written by Dr Roger Gadsby</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Interesting new diabetes papers: September 2009&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;U&gt;&lt;STRONG&gt;SYSTEMATIC&amp;nbsp; REVIEWS&lt;/STRONG&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;EXENATIDE EFFICACY AND SAFETY: A SYSTEMATIC REVIEW&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 1 &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=379074" target="_blank"&gt;Norris SL, Lee N, Thakurta S Chan BKS Exenatide efficacy and safety: a systematic review Diabetic Medicine 26:837-846&lt;/A&gt;&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;A review of 17 studies, concludes that in subjects with poorly controlled diabetes, exenatide was associated with a reduction in HBA1c of around 1% that was similar to introducing another oral agent or insulin. Nausea was the most common adverse event. Weight loss may be an advantage with exenatide. Long term studies in diverse and unselected populations are needed to clarify the benefit v harm profile of this drug&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Useful review&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;GLUCOSE CONTROL AND CARDIOVASCULAR DISEASE&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 2 &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=327030" target="_blank"&gt;Kelly TN, Bazzano LA, Fonseca V et al Systematic Review: Glucose control and cardiovascular disease in type 2 diabetes&amp;nbsp; Ann Int Med 151:394-403&lt;/A&gt;&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;Review of 5 trials, (UKPDS main and metformin sub study, ADVANCE, ACCORD and VADT) with 27802 adults, the latter 3 trials had lower intensive glucose targets HBA1c of 6.5% or below rather than 7%) . They conclude that intensive glucose control reduced the risk for some CVD outcomes such as non fatal myocardial infarction, did not reduce the risk for cardiovascular death or all cause mortality and increased the risk of severe hypoglycaemia.&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Good&amp;nbsp; summary&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;RCT’s&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DIET IN NEWLY DIAGNOSED TYPE 2 DIABETES&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 3 Esposito K, Maiorino MI,&amp;nbsp; Ciotola M et al Effects of a Mediterranean style diet on the need for antihyperglycaemic drug therapy in patients with newly diagnosed type 2 diabetes Ann Int Med 151: 306-314&lt;/EM&gt; &lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;215 Italian people newly diagnosed with type 2 diabetes randomised to Mediterranean diet with less than 50% of daily calories from carbohydrate or low fat diet with less than 30% of calories from fat. The primary outcome measure start of&amp;nbsp; glucose lowering therapy defined by HBA1c greater than 7%. After 4 years 44% of people in Mediterranean group and 70% in&amp;nbsp; low fat group required treatment. The people in the Med. Group lost more weight and experienced greater improvements in some glycaemic control and coronary risk measures than those in low fat diet group&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;Interesting data.&amp;nbsp; Mediterranean diet for all!!?&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;OTHER SORTS OF STUDY&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;GLITAZONES AND CVD RISK&lt;/STRONG&gt;&lt;BR&gt;&lt;EM&gt;Paper 4 Juurlink DN, Gomes T, Lipscombe LL et al Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study BMJ 339:b2942doi:10.1136/bmj.b2942&lt;/EM&gt;&lt;BR&gt;&lt;EM&gt;Paper 5 de Vries CS, Russell-Jones DL Rosiglitazone or Pioglitazone in type 2 diabetes? (editorial) BMJ 339:b3076&lt;/EM&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;&lt;BR&gt;Retrospective cohort study of 39736 people aged 66 or over started on poiglitazone or rosiglitazone between 2001 and 2008 in Canada. The outcome was a composite of death or hospital admission for either acute myocardial infarction or heart failure. The outcome occurred in 895 taking pioglitazone and 1563 taking rosiglitazone. Secondary analyses revealed a lower risk of death and heart failure but no significant difference in acute myocardial infarction. The authors conclude that among older patients with diabetes pioglitazone is associated with a significantly lower risk of heart failure and death than is rosiglitazone. Given that rosiglitazone lacks a distinct clinical advantage over pioglitazone, continued use of rosiglitazone may not be justified.&lt;BR&gt;The editorial wonders whether the results are confounded by differences in disease severity among the 2 groups and says that the study reinforces the message that glitazones should be avoided in heart failure&lt;BR&gt;&lt;STRONG&gt;Dr Roger Gadsby’s comments&lt;/STRONG&gt;&lt;BR&gt;This study may provide further evidence to prefer pioglitazone over rosiglitazone&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;SHORT REPORTS&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Inflammatory biomarkers in type 2 diabetes&lt;/STRONG&gt;&amp;nbsp; &lt;EM&gt;Paper 6 Pradhan AD, Everitt BM, Cook NR et al Effects of initiating insulin and metformin on glycaemic control and inflammatory biomamarkers among people with type 2 diabetes The LANCET randomised controlled trial JAMA 302:1186-1193&lt;/EM&gt; Treatment with insulin or metformin did not reduce inflammatory biomarkers inspire of improving glucose control&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Saxagliptin&lt;/STRONG&gt; &lt;EM&gt;Paper 7 De Fronzo RA, Hissa MN, Garber AJ et al The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 32: 1649-1655&lt;/EM&gt;&lt;BR&gt;743 people given either 2.5, 5 0r 10mgs saxagliptin&amp;nbsp; (a new DPP4 inhibitor) daily or placebo . HBA1c drops at 24 weeks were -0.59%, 0.69% , 0.58% and plus 0.13%. Side effects in treated groups were same as placebo&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Dapagliflozin&lt;/STRONG&gt;&amp;nbsp; &lt;EM&gt;Paper 8 Wilding JPH, Norwood P, T’joen C et al A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers Diabetes Care 32: 1656-1662&lt;/EM&gt; A study of a SGLT2 blocker dapagliflozin 10mgs or 20mgs daily or placebo added to insulin sensitizers and 50% of daily insulin dose in 71 people . At 12 weeks HBA1c drops were 0.7% (10mgs) or 0.78% (20mgs) from baseline versus placebo. Wt loss was -1.9Kg with placebo, -4.5kg with 10mgs and -4.3kg with 20mgs. Adverse events were similar across all groups but more genital infections occurred in 20mg group&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Journals reviewed&lt;/STRONG&gt;&amp;nbsp; N Eng J Med, JAMA, Lancet, BMJ, BJGP, Ann Int Med, Int J Clin Pract, Diabetes Care, Diabetic Medicine, Pract Diab Int&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>372584</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/content/33/3/676.extract?sid=0c91868a-a051-49fd-b249-1e399e19370d]]&gt;</url>
    <title>International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,GESTATIONAL DIABETES,DIAGNOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; This report provides details of a consensus reached by&amp;nbsp;the IADPSG group&amp;nbsp;concerning recommendations on the diagnosis and classification of hyperglycaemia in pregnancy. The new recommendations include&amp;nbsp; a two phase strategy for diagnosis and classification of hyperglycemia in pregnancy that consists of early screening for overt diabetes, and implementation of&amp;nbsp; a 75 -gram glucose oral glucose tolerance test OGTT for the diagnosis of gestational diabetes (GDM).&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; International Association of Diabetes and Pregnancy Study Groups Consensus Panel (IADPSG), International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy, Diabetes Care. 2010;33(3):676-82.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in March 2010&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full-text of this article online requires subscription to the&amp;nbsp;journal. NHS staff please&amp;nbsp;contact&amp;nbsp; &lt;A href="http://www.hlisd.org/" target="_blank"&gt;your local NHS library&lt;/A&gt;&amp;nbsp;for further assistance.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>258926</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.idf.org/home/index.cfm?node=503]]&gt;</url>
    <title>International curriculum on diabetes health education</title>
    <publicationDate></publicationDate>
    <publisher>International Diabetes Federation (IDF)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CPD AND PROFESSIONAL EDUCATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Curriculum has been developed as a step towards implementing a model of care for diabetes that is supported by skilled multidisciplinary teams. It is aimed to be adapted to meet the different and particular needs of local health professionals, institutions and organisations. It can be used to facilitate the training of health professionals from a variety of disciplines and at different levels. The Curriculum is set out in modular format.&amp;nbsp; Each module contains:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;An overview of the topic 
&lt;LI&gt;Learning Objectives 
&lt;LI&gt;Teaching goals and strategies 
&lt;LI&gt;A suggested timeframe 
&lt;LI&gt;Suggestions as to who should teach the module 
&lt;LI&gt;Evaluation tools 
&lt;LI&gt;A list of references 
&lt;LI&gt;Sample programs&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This curriculum is supplemented by a further modular resource:&amp;nbsp;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resID=258927" target="_blank"&gt;Diabetes education modules&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published 2002&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323116</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/content/32/7/1327.extract]]&gt;</url>
    <title>International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DIAGNOSIS,DIAGNOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This report recommends that the diagnosis of diabetes is made if the HBA1c level is 6.5% or above. Diagnosis should be confirmed with a repeat HBa1c test unless clinical symptoms and glucose levels of above 11.1mmoles/l are present. If HBA1c testing is not possible owing to patient factors that preclude its interpretation (e.g. haemaglobinopathy) previously recommended diagnostic glucose levels should be used. The diagnosis of diabetes during pregnancy, when changes in red cell turnover make the HBA1c assay problematical will continue to require glucose measurements. &lt;BR&gt;The report states that individuals with a HBA1c at or above 6% but below 6.5% are likely at the highest risk for progression to diabetes, but this range should not be considered an absolute threshold at which preventative measures are initiated.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citiation:&lt;/STRONG&gt;The International Expert Committee, The International Expert Committee Report on the Role of A1c Assay in the diagnosis of Diabetes, Diabetes Care 32: 1327-1334.&lt;/P&gt;
&lt;P&gt;Also see the comment on this report in the same journal issue. &lt;BR&gt;Fonesca V, Inzucchi SE, Ferrannani E, Redefining the Diagnosis of Diabetes using Glycated Hemoglobin, Diabetes Care 32: 1344-5. [&lt;A href="http://care.diabetesjournals.org/content/32/7/1344.extract" target="_blank"&gt;link to extract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history:&lt;/STRONG&gt; Published in July 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;NHS staff in England: available via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;NHS Evidence 'My Journals'&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Other NHS staff: check with your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307414</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.blackwellpublishing.com/ijcp_enhanced/]]&gt;</url>
    <title>International Journal of Clinical Practice</title>
    <publicationDate></publicationDate>
    <publisher>International Journal of Clinical Practice</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;IJCP publishes clinically focused material for a global audience, in the form of outcomes research, therapeutic use studies, Phase IV and Phase III research (including subanalysis and followup), Phase II and Phase I research, educational review and discussion of topical clinical concerns (including meta-analyses), consensus statements, and opinion pieces.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full access online requires subscription to the journal. NHS staff please contact your&lt;A href="http://www.hlisd.org/" target="_blank"&gt; local NHS library &lt;/A&gt;for further assistance.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Some &lt;A href="http://www.blackwellpublishing.com/ijcp_enhanced/free.asp" target="_blank"&gt;free texts&lt;/A&gt; are available to the general public without subscription. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>78345</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band129/b129-4.html]]&gt;</url>
    <title>Internet diabetes monitoring</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier&amp;nbsp;article describes and reviews a 2004 study concerning the use of the Internet for blood glucose monitoring by people with type 2 diabetes. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Review published&amp;nbsp;November 2004.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251169</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=251169]]&gt;</url>
    <title>Introduction : what are the main drivers of the increase in numbers in adults?</title>
    <publicationDate>2007-03-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PREVENTION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Part of the National Knowledge Week for the Prevention of Type 2 Diabetes.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction : what are the main drivers of the increase in numbers in adults?&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;&lt;FONT color=#666666&gt;Written by&amp;nbsp;S Kumar&amp;nbsp;March 2007.&lt;BR&gt;Reviewed by Dr Roger Gadsby, November 2009&lt;/FONT&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387843" target="_blank"&gt;Back to Knowledge Week contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Just over 100 years ago, Type 2 diabetes was a rare disease. Less than 25 years ago, it was rare in developing countries. In a relatively short time span in human history we are observing a dramatic change in the incidence of Type 2 diabetes in most populations across the world.&amp;nbsp; Although it is recognised that there are genetic factors that are predispose to diabetes, it is clear that what has changed to account for the rapid increase in the risk for diabetes is the change in the environment.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Firstly, increasing prevalence of overweight and obesity has been shown to be strongly associated with the risk for the development of type-2 diabetes.&amp;nbsp; Indeed, there is a progressive increase in risk for diabetes with obesity whether measured as body mass index or as percentage ideal body weight.&amp;nbsp; The increase in risk for diabetes with each kilogram weight gain has been estimated to be between 4.5–9%.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;A number of dietary factors have been shown to increase risk for diabetes.&amp;nbsp; Diet with low fibre content, low unsaturated:saturated fat ratio, high in trans-fat and with a high glycaemic load are all associated with an increase in risk for Type 2 diabetes.&amp;nbsp; Clearly, some of the excess risk could be attributable to the excess energy intake with high fat diets, however this is not true of all fats.&amp;nbsp; For example, substituting polyunsaturated fats for trans-fat in diet has been estimated to lower risk for diabetes by about 40%.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Physical activity is another key factor that determines risk for diabetes.&amp;nbsp; The relative risk of women who take vigorous exercise at least once a week is 0.67 compared to those women who do no exercise at all.&amp;nbsp; Indeed, it is better to be overweight and physically active rather than normal weight and inactive.&lt;/P&gt;
&lt;P&gt;Whilst the above factors may be modifiable, another key factor that accounts for increasing rates for diabetes is aging.&amp;nbsp; People are living longer than ever before and it is clear that there is increase in risk of diabetes with age.&amp;nbsp; It appears to peak at increased risk of 16% for men and 12% for women aged 75-84.&amp;nbsp; It has been estimated by the year 2036, 20% of increase in diabetes will be related to the aging population in the UK. In view of the increase in longevity, it is important to try and delay the onset of diabetes as much as possible as it may help reduce morbidity in old age.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;U&gt;References and further Information&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Full literature search results &lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=388094" target="_blank"&gt;Systematic reviews and other studies organised by topic&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidelines&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?catID=5634&amp;amp;tabID=288" target="_blank"&gt;Links to supporting guidelines&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient Information&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?catID=5634&amp;amp;tabID=292&amp;amp;" target="_blank"&gt;Links to supporting patient information&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387843" target="_blank"&gt;Back to Knowledge Week contents page&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>309620</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19236616?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Is diabetes a coronary risk equivalent?</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CARDIOVASCULAR,CHRONIC COMPLICATIONS,CAUSES,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; This meta-analysis did&amp;nbsp;not support the idea that diabetes is a “coronary risk equivalent”. Public health decisions to initiate cardio-protective drugs in patients with diabetes for primary prevention should therefore be based on appropriate patients CHD risk estimates rather than a blanket approach of treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Search from 1966- 2007 for relevant papers. These included cohort studies or observational studies. Thirteen papers involving 45108 patients met the pre specified quality criteria. The duration of follow up was from 5-25 years (mean of 13.4 years) and the age range was 25-84 years.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Patients with diabetes without prior myocardial infarction have a 43% lower risk of developing total CHD events compared to patients without diabetes with previous myocardial infarction.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Bulugaahapitiya U, Siyambalapitiya S, Sithole J, Idris 1 Is diabetes a coronary risk equivalent? Systematic review and meta-analysis Diabetic Medicine 2009 Feb 26:142-148&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published February 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full text of this article requires online subscription to the journal. NHS staff: please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS Library &lt;/A&gt;for further assistance.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>294989</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18632013]]&gt;</url>
    <title>Is prevention of Type-2 diabetes feasible and efficient in primary care? A systematic PubMed review.</title>
    <publicationDate>2008-09-29T00:00:00</publicationDate>
    <publisher>Primary Care Diabetes</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;/STRONG&gt;&amp;nbsp; Lauritzen, Torsten; Borch-Johnsen, Knut, and Sandbmk, Annelli. Is prevention of Type-2 diabetes feasible and efficient in primary care?: A systematic PubMed review. Primary Care Diabetes. 2007 Feb; 1(1):5-11.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessing the full text&lt;/STRONG&gt;:&amp;nbsp; NHS staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307418</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.thejournalofdiabetesnursing.co.uk/]]&gt;</url>
    <title>Journal of Diabetes Nursing</title>
    <publicationDate></publicationDate>
    <publisher>Journal of Diabetes Nursing</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The website contains information on the Journal of Diabetes Nursing. It includes articles ordered under different key topics and links to other related journals.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full access online requires subscription to the journal. NHS staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library &lt;/A&gt;for further assistance.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307423</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://jama.ama-assn.org/]]&gt;</url>
    <title>Journal of the American Medical Association</title>
    <publicationDate></publicationDate>
    <publisher>Journal of the American Medical Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Journal of the American Medical Association (JAMA), has been published continuously since 1883. It is an international peer-reviewed general medical journal and is published 48 times per year. The website contains information on the journal, a patients page and a 'readers respond' section.&lt;BR&gt;&lt;BR&gt;Sign up for an &lt;A href="http://pubs.ama-assn.org/misc/alerts.dtl" target="_blank"&gt;email alert &lt;/A&gt;of this journal.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; NHS staff in England: available via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;NHS Evidence. &lt;/A&gt;&lt;BR&gt;NHS staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library &lt;/A&gt;for further assistance.&lt;BR&gt;&lt;BR&gt;Some &lt;A href="http://pubs.ama-assn.org/help/home_help.dtl#features_and_access" target="_blank"&gt;free texts&lt;/A&gt; are available to the general public without subscription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>61108</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Healthcare/Diabetes/DH_4015717]]&gt;</url>
    <title>Key papers and reports on diabetes</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT,USER INVOLVEMENT,DATA GATHERING AND AUDIT AND QOF,SHARING PRACTICE,COMMISSIONING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the Department of Health website provides details of key papers and reports on diabetes. It is divided into the following sections: 
&lt;UL&gt;
&lt;LI&gt;NSF guidance and delivery strategy 
&lt;LI&gt;Toolkits 
&lt;LI&gt;Education 
&lt;LI&gt;Insulin supplies and services 
&lt;LI&gt;Annual reports 
&lt;LI&gt;Other diabetes publications&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>182728</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=300]]&gt;</url>
    <title>Levels of Care: a new language for service planning and design</title>
    <publicationDate>2006-09-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ COMMISSIONING,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guide from the National Diabetes Support Team&amp;nbsp;describes the background of the levels of care language and how it was developed and provides descriptions of four different ‘levels of care’ and what each level consists of.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>149082</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band144/b144-5.html]]&gt;</url>
    <title>Lifestyle interventions to prevent diabetes</title>
    <publicationDate>2006-02-01T00:00:00</publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PREDIABETIC STATE,PREDIABETES,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier&amp;nbsp;article describes a systematic review and meta-analysis which looks at the question of whether a lifestyle education programme compared with conventional education improves glucose levels or incidence of diabetes in people at high risk of developing type 2 diabetes 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Review published&amp;nbsp;February 2006.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>305397</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/cdlipids/resources/merec_bulletin_vol19_no3.pdf]]&gt;</url>
    <title>Lipid-modifying treatment</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ PREVENTION,CONDITION MANAGEMENT,DIABETES,CHRONIC COMPLICATIONS,CARDIOVASCULAR]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This MeReC Bulletin summarises the NICE guidance on lipid modification and statin therapy.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: MeReC&amp;nbsp;Bulletin Volume 19, Number 3.&amp;nbsp; Published December 2008.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;:&amp;nbsp; Available to the general public. Portable Document File / PDF requiring Adobe Acrobat Reader.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318098</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.pharmacy.ac.uk/fileadmin/documents/News/Living_with_Plenty.pdf]]&gt;</url>
    <title>Living with Plenty: Meeting the Challenge of Diabetes</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>The School of Pharmacy, University of London</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ COST / ECONOMIC DATA,STATISTICS,MEDICATION,MEDICATION,TYPE 1,TYPE 2,DIABETES,PREVENTION,CONDITION MANAGEMENT,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The twenty first century role of pharmacy and pharmaceutical innovation in the prevention and treatment of diabetes mellitus.&lt;/P&gt;
&lt;P&gt;The primary objectives of this report are to promote the further development of pharmacy based care as a cost effective part of the support available to people with diabetes and to highlight the importance of pharmaceutical innovation alongside that of facilitating relevant forms of health behaviour change.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82501</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PolicyAndGuidance/HumanResourcesAndTraining/ModernisingWorkforcePlanningHome/CGWTLongTerm/fs/en]]&gt;</url>
    <title>Long Term Conditions Care Group Workforce Team (LTC CGWT)</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ COMMISSIONING,HEALTH MANAGEMENT,DIABETES,WORKFORCE,HEALTH AND SOCIAL CARE,SERVICE SECTORS,NHS ACTIVITIES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,KEY POLICIES / NSF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This section of the Department of Health website concentrates on the work of Care Group Workforce Teams, set up to identify national staffing issues affecting particular services and form plans on how they ought to be addressed. Reports on access, cancer, children, heart disease, long-term conditions including diabetes, mental health and services for older people can be found here.]]&gt;</body>
  </document>
  <document>
    <id>299108</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Documents/Reports/Making_all_children_matter_REPORT.pdf]]&gt;</url>
    <title>Making all children matter: Support for children with diabetes in schools</title>
    <publicationDate>2008-11-19T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,LIVING WITH DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,CHILDREN AND YOUNG PEOPLE,SCHOOL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Diabetes UK report looks at children with Type 1 Diabetes in England and looks at the following questions:&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. Why does support in school matter?&lt;BR&gt;2. What do we know about the experience of children and parents?&lt;BR&gt;3. Is there an adequate legal framework to ensure school support?&lt;BR&gt;4. Is there Government policy and guidance to ensure school support?&lt;BR&gt;5. Is there an effective performance and inspection framework?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Published November 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public. Portable Document File / PDF requiring Adobe Acrobat Reader.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>260310</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.inispho.org/publications/makingdiabetescountasystematicapproachtoestimatingpopulationprevalenceontheislandofirel]]&gt;</url>
    <title>Making diabetes count. A systematic approach to estimating population prevalence on the island of Ireland in 2005</title>
    <publicationDate>2006-04-01T00:00:00</publicationDate>
    <publisher>Institute of Public Health, Ireland</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,STATISTICS,INCIDENCE AND PREVALENCE,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report on the prevalence of diabetes (diagnosed and undiagnosed) on the island of Ireland in 2005, is based on an application of the PBS Population Diabetes Prevalence Model. Ireland and Northern Ireland’s Population Health Observatory (INIsPHO) in the Institute of Public Health in Ireland undertook this study in order to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;provide the best available estimates of the population prevalence of diabetes (diagnosed and undiagnosed) on the island at national and sub-national level 
&lt;LI&gt;promote a more systematic approach to the development of such estimates 
&lt;LI&gt;make recommendations to tackle inadequacies in existing research and data.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=289824&amp;amp;tabID=290" target="_blank"&gt;PBS Population Diabetes Prevalence Model &lt;/A&gt;was developed by Yorkshire and Humber Public Health Observatory (YHPHO), Brent NHS Primary Care Trust, and University of Sheffield School of Health and Related Research (ScHARR). The model estimates the total number of diabetes cases (diagnosed and undiagnosed combined) in resident populations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published April 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to the general public. Portable Document File / PDF requiring Adobe Acrobat Reader.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>83751</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/cgi/content/full/27/2/553]]&gt;</url>
    <title>Management of diabetes and hyperglycemia in hospitals</title>
    <publicationDate>2004-02-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,LIVING WITH DIABETES,HOSPITAL INPATIENT CARE,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MEDICATION,MONITORING / SELF-MONITORING,MEDICATION,MONITORING / SELF-MONITORING,ACUTE ILLNESS INCLUDING INFLUENZA,NUTRITION AND FOOD,NUTRITION AND FOOD]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV&gt;
&lt;P&gt;&lt;STRONG&gt;Authors' conclusions:&lt;/STRONG&gt; "Based on limited interventional studies in selected settings, aggressive control of blood glucose in the hospital may provide an opportunity to improve patient outcomes. Clinical trials are needed to answer these questions. The target blood glucose threshold to optimize outcomes in the hospital is not clearly defined but may be lower than previously thought. From a cost perspective, research and strategies targeting glucose control and diabetes care in the hospital have the potential to translate to substantial cost savings". &lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Method: &lt;BR&gt;&lt;/STRONG&gt;Literature Review. &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;Diabetes Care&amp;nbsp;gives the following information about their&amp;nbsp;technical reviews:&lt;BR&gt;"A balanced review and analysis of the literature on a scientific or medical topic related to diabetes. The technical review provides a scientific rationale for a position statement and undergoes peer review before submission to the Professional Practice Committee for approval. In some cases, in place of a technical review, original research publications, conference proceedings, or other comprehensive review articles are used as a basis for a position statement."&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Full reference:&lt;BR&gt;&lt;/STRONG&gt;Clement S, Braithwaite SS, Magee MF, Ahmann A, Smith EP, Schafer RG, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004; 27: 553-591.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>269664</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://jama.ama-assn.org/cgi/content/full/298/8/902]]&gt;</url>
    <title>Management of diabetic retinopathy : a systematic review</title>
    <publicationDate>2007-08-22T00:00:00</publicationDate>
    <publisher>Journal of the American Medical Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,EYE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: Tight glycemic and blood pressure control remains the cornerstone in the primary prevention of DR. Pan-retinal and focal retinal laser photocoagulation reduces the risk of visual loss in patients with severe DR and macular edema, respectively. There is currently insufficient evidence to recommend routine use of other treatments.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Method&lt;/STRONG&gt;: Systematic review of all English-language articles, retrieved using a keyword search of MEDLINE (1966 through May 2007), EMBASE, Cochrane Collaboration, the Association for Research in Vision and Ophthalmology database, and the National Institutes of Health Clinical Trials Database, and followed by manual searches of reference lists of selected major review articles. All English-language randomized controlled trials (RCTs) with more than 12 months of follow-up and meta-analyses were included. Delphi consensus criteria were used to identify well-conducted studies.&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;Results&lt;/STRONG&gt;: Forty-four studies (including 3 meta-analyses) met the inclusion criteria. Tight glycemic and blood pressure control reduces the incidence and progression of DR. Pan-retinal laser photocoagulation reduces the risk of moderate and severe visual loss by 50% in patients with severe nonproliferative and proliferative retinopathy. Focal laser photocoagulation reduces the risk of moderate visual loss by 50% to 70% in eyes with macular edema. Early vitrectomy improves visual recovery in patients with proliferative retinopathy and severe vitreous hemorrhage. Intravitreal injections of steroids may be considered in eyes with persistent loss of vision when conventional treatment has failed. There is insufficient evidence for the efficacy or safety of lipid-lowering therapy, medical interventions, or antivascular endothelial growth factors on the incidence or progression of DR. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Full reference: &lt;/STRONG&gt;Mohamed Q, Gilles MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA 2007;298(8):902-916.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Published in August 2007.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Access to the full text of this article requires online subscription to the journal. NHS staff in England: available via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/" target="_blank"&gt;NHS Evidence&lt;/A&gt;.&amp;nbsp; Other NHS staff: please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt; for further assistance.&lt;STRONG&gt;&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309891</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4088755.pdf]]&gt;</url>
    <title>Management of medicines: a resource to support implementation of the wider aspects of medicine management for the National Service Framework for Diabetes, Renal Services and Long-Term Conditions</title>
    <publicationDate>2004-07-01T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DELIVERY OF CARE,KEY POLICIES / NSF,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This document, published by the Department of Health, is intended for organisations to implement the medicines management of the three NSFs - diabetes, renal and long-term conditions. It also provides examples of innovative practice which PCTs and NHS Trusts may want to implement.]]&gt;</body>
  </document>
  <document>
    <id>378216</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.guideline.gov/Compare/comparison.aspx?file=MICRODIABETES1.inc]]&gt;</url>
    <title>Management of microvascular complications of type 2 diabetes mellitus</title>
    <publicationDate>2010-06-14T00:00:00</publicationDate>
    <publisher>National Guideline Clearinghouse</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,NEPHROPATHY,RETINOPATHY,DIABETIC FOOT,PAINFUL NEUROPATHIES,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,AUTONOMIC NEUROPATHY,CONDITION MANAGEMENT,EYE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Guideline synthesis comparing three UK and US guidelines.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This guideline synthesis compares the recommendations from three guidelines:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;American Association of Clinical Endocrinologists (AACE). American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus: microvascular complications. Endocrine Practice 2007 May-Jun;13(Suppl 1). 
&lt;LI&gt;National Collaborating Center for Chronic Conditions/National Institute for Health and Clinical Excellence (NCCCC/NICE). &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=287242" target="_blank"&gt;Type 2 diabetes: the management of type 2 diabetes&lt;/A&gt;. London, UK: National Institute for Health and Clinical Excellence (NICE); 2009 May. (Clinical guideline; no. 87). 
&lt;LI&gt;University of Michigan Health System (UMHS). Management of type 2 diabetes mellitus. Ann Arbor, MI: University of Michigan Health System; 2008 Jan.&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;The synthesis was prepared by ECRI Institute on 17 February&amp;nbsp;2010, and the information was verified by University of Michigan Health System (UMHS) on 17 March 2010.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386249</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://guideline.gov/syntheses/synthesis.aspx?f=rss&amp;id=16402]]&gt;</url>
    <title>Management of overweight and obesity in children and adolescents</title>
    <publicationDate>2010-08-03T00:00:00</publicationDate>
    <publisher>National Guideline Clearinghouse</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ BIOLOGICAL COMPOSITION,INDIVIDUAL BEHAVIOUR,OBESITY,CHILDREN,YOUNG PEOPLE,MONTHLY ADDITIONS,OBESITY,DIABETES,PUBLIC HEALTH,DETERMINANTS,PHYSICAL ACTIVITY,EATING HABITS,CONDITION MANAGEMENT,AGE GROUPS,POPULATIONS,GROUPS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Guideline synthesis comparing three UK and US guidelines.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This guideline synthesis compares the recommendations from three guidelines:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Massachusetts Department of Public Health (MDPH). Expert panel on weight loss surgery executive report. Boston, MA: Massachusetts Department of Public Health; 2007 Dec. 
&lt;LI&gt;Scottish Intercollegiate Guidelines Network (SIGN). &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=345069" target="_blank"&gt;Management of obesity&lt;/A&gt;. A national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network (SIGN); 2010 Feb. (SIGN publication; no. 115). 
&lt;LI&gt;The Endocrine Society (TES). Prevention and treatment of pediatric obesity: an Endocrine Society clinical practice guideline based on expert opinion. Journal of Clinical Endocrinology &amp;amp; Metabolism 2008 Dec;93(12):4576-99. &lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;This synthesis was originally prepared by ECRI on 2 March 2005 and updated most recently in May 2010. The information was verified by SIGN on August 3, 2010. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60146</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,156/Itemid,61/]]&gt;</url>
    <title>Managing the patient with excess weight and diabetes (teaching letter no.10)</title>
    <publicationDate>1997-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ NUTRITION AND FOOD,NUTRITION AND FOOD,PHYSICAL ACTIVITY,PHYSICAL ACTIVITY,OBESITY,BIOLOGICAL COMPOSITION,OUTCOMES,ENDOCRINE DISORDERS,DIABETES,GUIDELINES,GOOD PRACTICE,TYPE 2,TYPE 1,DIABETES,CONDITION MANAGEMENT,CONDITION MANAGEMENT,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,FRAMES OF REFERENCE,MEDICAL TREATMENT,MANAGEMENT &amp; POLICY,HEALTHCARE &amp; HEALTH SERVICES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the management of patients with excess weight and diabetes and covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Obesity and diabetes: a major risk for cardiovascular and long-term diabetic complications 
&lt;LI&gt;Weight gain and weight loss: two major survival mechanisms 
&lt;LI&gt;Some biochemical mechanisms of obesity which interfere with blood glucose metabolism 
&lt;LI&gt;Controlling the "diabetes-obesity" syndrome: a major therapeutic task for physicians 
&lt;LI&gt;Cardinal problems with overeating 
&lt;LI&gt;dietary balance 
&lt;LI&gt;Tips for fat reduction 
&lt;LI&gt;The caloric load of alcohol 
&lt;LI&gt;Some tips for the physician when starting a weight-reduction program for a patient 
&lt;LI&gt;Some tips for the patient who initiates a weight reduction program 
&lt;LI&gt;General recommendations for a successful weight reduction program 
&lt;LI&gt;Maintaining weight loss 
&lt;LI&gt;Relapse prevention 
&lt;LI&gt;Some ideas to maximize use of this letter by the medical team&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 1997&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82798</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.cemach.org.uk/getattachment/8af39ba1-1cab-476b-ad8e-b9393fd35aed/Pregnancy-in-women-with-type-1-and-type-2-diab-(1).aspx]]&gt;</url>
    <title>Maternity services in 2002 for women with type 1 and type 2 diabetes</title>
    <publicationDate>2004-04-01T00:00:00</publicationDate>
    <publisher>Confidential Enquiry into Maternal and Child Health (CEMACH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETES AND PREGNANCY,DELIVERY OF CARE,WOMEN'S HEALTH,ORGANISATION OF CARE / CARE PLANNING,CONDITION MANAGEMENT,COMPLICATED PREGNANCY,CO-EXISTING DISEASE,PRECONCEPTION CARE,DATA GATHERING AND AUDIT AND QOF,STATISTICS,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Confidential Enquiry into Maternal and Child Health (CEMACH) report describes the findings from the first study in CEMACH’s diabetes programme of work (see below).&amp;nbsp; It&amp;nbsp;provides feedback on the findings of a survey concerned with the organisation of maternity services for women with type 1 and type 2 diabetes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published Apr 2004. Survey undertaken in 2002.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CEMACH’s diabetes programme of work&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;The Confidential Enquiry into Maternal and Child Health (CEMACH) initiated a national enquiry programme aimed at improving the quality of maternity care and pregnancy outcomes for women with pre-gestational diabetes in England, Wales and Northern Ireland. This programme of work comprises three linked studies:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;A survey of maternity services for women with type 1 and type 2 diabetes in 2002. (This report)&lt;BR&gt;&amp;nbsp; 
&lt;LI&gt;A descriptive study on all pregnancies of women with pre-gestational diabetes who delivered or booked between 1 March 2002 and 28 February 2003, with follow up to pregnancy outcome at 28 days after delivery. This study included an audit of standards of care for women with pre-gestational diabetes. (&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resID=104777" target="_blank"&gt;Link to the record here&lt;/A&gt;)&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;A confidential enquiry, consisting of multidisciplinary panel case reviews. This comprises a case–control study into the impact of clinical care on pregnancy outcome and an audit of care during and after pregnancy, for women with pre-gestational diabetes. published in February 2007. (&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resID=250782" target="_blank"&gt;Link to the record here&lt;/A&gt;)&lt;/LI&gt;&lt;/OL&gt;]]&gt;</body>
  </document>
  <document>
    <id>156545</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Documents/Measure%20up/Info_sheet_hcp.pdf]]&gt;</url>
    <title>Measure up: Information sheet for healthcare professionals</title>
    <publicationDate>2006-01-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Recommendations about who should be screened for type 2 diabetes and how</description>
    <body>&lt;![CDATA[ &lt;P&gt;This document from&amp;nbsp;the&amp;nbsp;health professionals section of the Diabetes UK&amp;nbsp;website provides recommendations about who should be screened for type 2 diabetes and how.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication Information&lt;/STRONG&gt;: Published in 2006&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306912</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/cgi/content/abstract/32/1/193?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;author1=nathan&amp;andorexactfulltext=and&amp;searchid=1&amp;FIRSTINDEX=0&amp;sortspec=relevance&amp;volume=32&amp;resourcetype=HWCIT]]&gt;</url>
    <title>Medical management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,MEDICATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;/STRONG&gt; Nathan DM, Buse JB, Davidson MB et al Medical Management of Hyperglycaemia in Type 2 Diabetes: A consensus algorithm for the initiation and adjustment of therapy &lt;BR&gt;A consensus statement from ADA/EASD Diabetes Care 32: 193-203&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method&lt;/STRONG&gt;: It begins with a Tier 1 (well validated core therapies)&amp;nbsp; of lifestyle plus metformin then adds either basal insulin or sulphonylurea. It also gives a&amp;nbsp; Tier 2 (Less well validated therapies) which are lifestyle + metformin add pioglitazone or lifestyle + metformin add GLP-1 agonist.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion/results:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The guidelines and treatment algorithm presented here emphasize &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;achievement and maintenance of normal glycemic goals; 
&lt;LI&gt;initial therapy with lifestyle intervention and metformin; 
&lt;LI&gt;rapid addition of medications, and transition to new regimens, when target glycemic goals are not achieved or sustained; and 
&lt;LI&gt;early addition of insulin therapy in patients who do not meet target goals.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; NHS staff in England: &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/" target="_blank"&gt;available via NLH.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Other NHS staff: &lt;A href="http://www.hlisd.org/" target="_blank"&gt;check with your local NHS library&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>316032</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Documents/Reports/Minding_the_Gap_psychological_report.pdf]]&gt;</url>
    <title>Minding the gap - The provision of psychological support and care for people with diabetes in the UK</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ TYPE 1,TYPE 2,DIABETES,CONDITION MANAGEMENT,CONDITION MANAGEMENT,PSYCHOSOCIAL CARE,PSYCHOSOCIAL CARE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;It is estimated that some 41% of people with diabetes suffer with poor psychological well-being and there is consistent evidence of elevated rates of depression and anxiety disorders. For example, the rate of depression is doubled in people with diabetes compared with controls. Over and above the severe impact of these psychological problems in their own right, the ‘costs’ of untreated depression in diabetes are high. This is due to its negative impact on diabetes self-care and medication adherence, leading to hyperglycaemia and increased complications and healthcare costs, lost productivity and increased mortality. Other specific psychological conditions such as eating disorders, needle phobias and fear of self-injecting also lead to poor glycaemic control and subsequent complications.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>267576</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band159/b159-7.html]]&gt;</url>
    <title>Moderate activity reduces diabetes risk</title>
    <publicationDate>2007-05-01T00:00:00</publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,PREVENTION,TYPE 2]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier&amp;nbsp;article describes and reviews&amp;nbsp;a systematic review of observational studies, which&amp;nbsp;links moderate periods of moderate intensity exercise with reduced risk of developing type 2 diabetes in adults. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Review published&amp;nbsp;May 2007 Bandolier 159&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to general public. Portable Document File/PDF&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>294714</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=410]]&gt;</url>
    <title>Monogenic Diabetes</title>
    <publicationDate>2008-07-11T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ DIABETES,OTHER TYPES OF DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P style="TEXT-ALIGN: justify"&gt;The National &lt;SPAN class=highlightedSearchTerm&gt;Diabetes&lt;/SPAN&gt; Support Team have published the first in the new series of &lt;B&gt;“&lt;SPAN class=highlightedSearchTerm&gt;Diabetes&lt;/SPAN&gt; &lt;SPAN class=highlightedSearchTerm&gt;Bulletin&lt;/SPAN&gt;&lt;/B&gt;”.&amp;nbsp; The &lt;SPAN class=highlightedSearchTerm&gt;Bulletin&lt;/SPAN&gt; is a one page digest on a topic of the moment intended for all busy healthcare professionals who want a quick and comprehensive update on an important area.&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify"&gt;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify"&gt;The first of these &lt;SPAN class=highlightedSearchTerm&gt;bulletin&lt;/SPAN&gt;’s looks at &lt;SPAN class=highlightedSearchTerm&gt;Monogenic&lt;/SPAN&gt; &lt;SPAN class=highlightedSearchTerm&gt;Diabetes&lt;/SPAN&gt; which is caused by a change in a single gene and affects 20,000 - 40,000 people in the UK or 1-2% of cases of &lt;SPAN class=highlightedSearchTerm&gt;diabetes&lt;/SPAN&gt;. &amp;nbsp;The majority of cases are initially misdiagnosed as type 1 or type 2. &amp;nbsp;Genetic testing can now be used to accurately diagnose &lt;SPAN class=highlightedSearchTerm&gt;monogenic&lt;/SPAN&gt; types of &lt;SPAN class=highlightedSearchTerm&gt;diabetes&lt;/SPAN&gt;. &amp;nbsp;This is important as the specific diagnosis helps to guide treatment, predict the clinical course, and enable genetic counselling of the family.&amp;nbsp; &lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify"&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published on the 11th July 2008.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify"&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify"&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>373135</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_monthly_no25.pdf]]&gt;</url>
    <title>More data suggest aspirin is ineffective for primary prevention in patients with diabetes</title>
    <publicationDate>2010-04-01T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CARDIOVASCULAR,CHRONIC COMPLICATIONS,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This MeReC monthly article considers&amp;nbsp;the results&amp;nbsp;of a&amp;nbsp;meta-analysis findings of Aspirin for primary prevention of cardiovascular events in people with dibaetes. &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; MeReC Monthly No. 25. Published April 2010. Original article: De. Berardis G, et al. Asprin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531. &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File/PDF requiring Adobe Acrobat Reader.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60150</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,159/Itemid,61/]]&gt;</url>
    <title>Motivating the diabetic patient (teaching letter no.13)</title>
    <publicationDate>1998-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,DIABETES,TYPE 2,TYPE 1]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the motivation of patients with diabetes to help them follow their treatment. It covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Defining simple tasks of objectives for the patient 
&lt;LI&gt;Getting to know and understand how patients cope with their disease 
&lt;LI&gt;Using the patient's inner motivation 
&lt;LI&gt;Applying extrinsic motivation 
&lt;LI&gt;Essential attitudes of the diabetes care team 
&lt;LI&gt;Evaluation 
&lt;LI&gt;Conclusions&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 1998&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>59993</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/booth/cardiac/HPS.html]]&gt;</url>
    <title>MRC/BHF Heart Protection Study</title>
    <publicationDate></publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CARDIOVASCULAR,CHRONIC COMPLICATIONS,DYSLIPIDAEMIA,CONDITION MANAGEMENT,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This section of the Bandolier Knowledge Library&amp;nbsp;describes and reviews the MRC/BHF Heart Protection Study. The aims of this large&amp;nbsp;study were to assess reliably the effects of cholesterol-lowering therapy and antioxidant vitamin supplementation on morbidity and mortality in patients with a wide range of different categories of high risk.]]&gt;</body>
  </document>
  <document>
    <id>60252</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12814710]]&gt;</url>
    <title>MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial</title>
    <publicationDate>2003-06-14T00:00:00</publicationDate>
    <publisher>Lancet</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,GROUND-BREAKING ARTICLES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;BR&gt;&lt;/STRONG&gt;Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003 Jun 14;361(9374):2005-16.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Access to the full text online requires subscription to the journal. NHS staff please &lt;A href="http://www.hlisd.org/" target="_blank"&gt;contact your local NHS library for&amp;nbsp;further assistance&lt;/A&gt;.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Additional information: &lt;/STRONG&gt;&lt;A href="http://www.ctsu.ox.ac.uk/~hps/" target="_blank"&gt;Link to the&amp;nbsp;Heart Protection Study&amp;nbsp;website&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60270</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://content.nejm.org/cgi/content/full/348/5/383]]&gt;</url>
    <title>Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes</title>
    <publicationDate>2003-01-30T00:00:00</publicationDate>
    <publisher>New England Journal of Medicine</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,GROUND-BREAKING ARTICLES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; A target-driven, long-term, intensified intervention aimed at multiple risk factors in patients with type 2 diabetes and microalbuminuria reduces the risk of cardiovascular and microvascular events by about 50 percent. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;BR&gt;Method:&lt;/STRONG&gt; The primary end point of this open, parallel trial was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, revascularization, and amputation. Eighty patients were randomly assigned to receive conventional treatment in accordance with national guidelines and 80 to receive intensive treatment, with a stepwise implementation of behavior modification and pharmacologic therapy that targeted hyperglycemia, hypertension, dyslipidemia, and microalbuminuria, along with secondary prevention of cardiovascular disease with aspirin. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;BR&gt;Results:&lt;/STRONG&gt; The mean age of the patients was 55.1 years, and the mean follow-up was 7.8 years. The decline in glycosylated hemoglobin values, systolic and diastolic blood pressure, serum cholesterol and triglyceride levels measured after an overnight fast, and urinary albumin excretion rate were all significantly greater in the intensive-therapy group than in the conventional-therapy group. Patients receiving intensive therapy also had a significantly lower risk of cardiovascular disease (hazard ratio, 0.47; 95 percent confidence interval, 0.24 to 0.73), nephropathy (hazard ratio, 0.39; 95 percent confidence interval, 0.17 to 0.87), retinopathy (hazard ratio, 0.42; 95 percent confidence interval, 0.21 to 0.86), and autonomic neuropathy (hazard ratio, 0.37; 95 percent confidence interval, 0.18 to 0.79). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;BR&gt;Citation: &lt;/STRONG&gt;Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of&amp;nbsp;Medicine 2003 Jan 30;348(5):383-93. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;BR&gt;Publication history information:&lt;/STRONG&gt; Published in January 2003.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;BR&gt;Access: &lt;/STRONG&gt;Available to the general public. 
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;BR&gt;Additional information: &lt;/STRONG&gt;&lt;A href="http://www.stenodiabetescenter.com/documents/home_page/document/index.asp" target="_blank"&gt;Link to the Steno Diabetes Center website&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306960</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.annals.org/cgi/content/abstract/150/2/94]]&gt;</url>
    <title>Narrative review: Effect of bariatric surgery on type 2 diabetes</title>
    <publicationDate>2009-01-20T00:00:00</publicationDate>
    <publisher>Annals of Internal Medicine</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CONDITION MANAGEMENT,CONDITION MANAGEMENT,TYPE 2,OBESITY,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: Bariatric surgery produces substantial and durable weight reduction.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Search from 1967 - 2008 for relevant papers. These included RCT's, cohort studies, case controlled studies and large case series.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Nearly 30% of patients in the studies had type 2 diabetes. For many of them the diabetes resolves after surgery. The rates of resolution are 84%-98% for bypass type of bariatric surgery and 48%-68% for restrictive procedures (banding).&amp;nbsp; Glycaemic control improves in part because of calorie restriction, but also because gut peptide secretion changes. Bariatric surgery, (particularly bypass procedures) alters the secretion of gut hormones (eg GLP-1 GIP, ghrelin, peptide YY) which result in enhanced insulin secretion and sensitivity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation&lt;/STRONG&gt;: Vetter ML, Cardillo S, Rickets MR, Iqbal N Narrative Review : Effect of Bariatric Surgery on type 2 diabetes Ann Intern Med 150:94-103&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Published 20 January 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; NHS staff in England: full text &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/" target="_blank"&gt;available via NLH&lt;/A&gt;, other NHS staffL: check with your local &lt;A href="http://www.hlisd.org/" target="_blank"&gt;NHS library for further assistance.&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82756</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/services/national-clinical-audit-support-programme-ncasp/diabetes]]&gt;</url>
    <title>National clinical audit support programme (NCASP) : diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,QUALITY AND MONITORING,DIABETES,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF,QUALITY IMPROVEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the&amp;nbsp;NHS Health and Social Care Information Centre website provides information about the national clinical audit for diabetes, managed by the National Clinical Audit Support Programme (NCASP).&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82549</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Aboutus/ministersanddepartmentleaders/nationalclinicaldirectors/DH_083359]]&gt;</url>
    <title>National clinical director for diabetes</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,KEY POLICIES / NSF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the Department of Health website&amp;nbsp;provides information about the National Clinical Director for Diabetes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Last modified 03 September 2010.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>379534</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/National_Diabetes_Audit_Executive_Summary_2008_2009.pdf]]&gt;</url>
    <title>National diabetes audit executive summary 2008-2009: key findings about the quality of care for people with diabetes in England and Wales</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DATA GATHERING AND AUDIT AND QOF,DELIVERY OF CARE,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the sixth annual report of the National Diabetes Audit (NDA) presenting the key national findings from 2008-2009. The NDA includes data from both primary and secondary care participants and provides overall, sequential and comparative information at GP, hospital, PCT, regional and national levels.&lt;/P&gt;
&lt;P&gt;The National Diabetes Audit (NDA) is commissioned and sponsored by the Healthcare Quality Improvement Partnership (HQIP) following advice to the Department of Health from the National Clinical Audit Advisory Group (NCAAG).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>300739</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=97]]&gt;</url>
    <title>National Diabetes Audit Summary- 2003/4 to 2005/6</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This factsheet&amp;nbsp;gives a summary of the findings of the National Diabetes Audit (NDA) from 2003/4 to 2005/6&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published Nov 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307726</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/19040607%20IC%20Diabetes-PaediatricReport.FV.pdf]]&gt;</url>
    <title>National diabetes audit: key findings about the quality of care for children and young people with diabetes in England and Wales. Paediatric report for the audit period 2005/06</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DATA GATHERING AND AUDIT AND QOF,CHILDREN AND YOUNG PEOPLE,DELIVERY OF CARE,DIABETES,TYPE 2]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The National Diabetes Audit (NDA) is a national audit service, sponsored by the Healthcare Commission, that supports the implementation of the Diabetes NSF and aims to improve the quality of patient care for all people with diabetes in England and Wales.&lt;BR&gt;&lt;BR&gt;This report presents the main findings from the&amp;nbsp;third year of the National Diabetes Audit of paediatric specialist units. It also provides recommendations for both national and local organisations based on the analysis of the audit data.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; &lt;SPAN class=detail_dataText&gt;Published &lt;/SPAN&gt;in 2007.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307733</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/Diabetes/6846_Paedriatric%20Report_v4%20(2).pdf]]&gt;</url>
    <title>National diabetes audit: key findings about the quality of care for children and young people with diabetes in England and Wales. Paediatric report for the audit period 2006/07</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,PUBLICATIONS,SPECIALTIES,DIABETES MELLITUS,DIABETES INSIPIDUS,CHILD HEALTH,ENDOCRINOLOGY,TYPE 2,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF,CHILDREN AND YOUNG PEOPLE,POLICY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The National Diabetes Audit (NDA) is a national audit service, sponsored by the Healthcare Commission, that supports the implementation of the Diabetes NSF and aims to improve the quality of patient care for all people with diabetes in England and Wales.&lt;BR&gt;&lt;BR&gt;This report presents the main findings from the&amp;nbsp;fourth year of the National Diabetes Audit of paediatric specialist units. It also provides recommendations for both national and local organisations based on the analysis of the audit data.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2008.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>319705</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/7189_Paediatric_Report_final.pdf]]&gt;</url>
    <title>National diabetes audit: key findings about the quality of care for children and young people with diabetes in England and Wales. Paediatric report for the audit period 2007/08</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DATA GATHERING AND AUDIT AND QOF,CHILDREN AND YOUNG PEOPLE,REPORTS,CHILDREN AND YOUNG PEOPLE,ENDOCRINOLOGY,CHILD HEALTH,DIABETES MELLITUS,DIABETES INSIPIDUS,PUBLICATIONS,SPECIALTIES,DIABETES,TYPE 2,TYPE 1,DELIVERY OF CARE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This NDA children and young peoples report presents the key findings from the fifth year of the National Diabetes Audit (NDA). It provides recommendations for paediatric units based on the analysis of the audit data.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;See related links for the data tables.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>182410</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/NDAReport-Paeds-2004-2005.pdf]]&gt;</url>
    <title>National diabetes audit: key findings about the quality of care for children and young people with diabetes in England, incorporating registrations from Wales.  Paediatric report for the audit period 2004/05</title>
    <publicationDate>2006-01-01T00:00:00</publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CHILD HEALTH,ADOLESCENCE,ENDOCRINOLOGY,DIABETES MELLITUS,SPECIALTIES,PUBLICATIONS,DIABETES,TYPE 2,DELIVERY OF CARE,REPORTS,CHILDREN AND YOUNG PEOPLE,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The National Diabetes Audit (NDA) is a national audit service, sponsored by the Healthcare Commission, that supports the implementation of the Diabetes NSF and aims to improve the quality of patient care for all people with diabetes in England.&lt;BR&gt;&lt;BR&gt;This report presents the main findings from the second year of the National Diabetes Audit of paediatric specialist units. It also provides recommendations for both national and local organisations based on the analysis of the audit data.]]&gt;</body>
  </document>
  <document>
    <id>307723</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/NDAReport-Paeds-2003-2004.pdf]]&gt;</url>
    <title>National diabetes audit: key findings about the quality of care for children and young people with diabetes in England. Paediatric report for the audit period 2003/04</title>
    <publicationDate>2005-10-01T00:00:00</publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF,CHILDREN AND YOUNG PEOPLE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The National Diabetes Audit (NDA) is a national audit service, sponsored by the Healthcare Commission, that supports the implementation of the Diabetes NSF and aims to improve the quality of patient care for all people with diabetes in England.&lt;BR&gt;&lt;BR&gt;This report presents the main findings from the National Diabetes Audit of paediatric specialist units. It also provides recommendations for both national and local organisations based on the analysis of the audit data.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in October 2005.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; &lt;SPAN class=detail_dataText&gt;Available &lt;/SPAN&gt;to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307732</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/05070107-IC%20Diabetes-ExecutiveSummary.FV.pdf]]&gt;</url>
    <title>National diabetes audit: key findings about the quality of care for people with diabetes in England and Wales.  Executive summary for the audit period 2005/06</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DATA GATHERING AND AUDIT AND QOF,DELIVERY OF CARE,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;The National Diabetes Audit (NDA) is a national audit service, sponsored by the Healthcare Commission, that supports the implementation of the Diabetes NSF and aims to improve the quality of patient care for all people with diabetes in England and Wales.&amp;nbsp; This report summarises the main findings and recommendations.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2007.&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307734</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/6851_Diabetes%20Exec%20Summary_FINALinclWales.pdf]]&gt;</url>
    <title>National diabetes audit: key findings about the quality of care for people with diabetes in England and Wales.  Executive summary for the audit period 2006/07</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DATA GATHERING AND AUDIT AND QOF,DELIVERY OF CARE,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;The National Diabetes Audit (NDA) is a national audit service, sponsored by the Healthcare Commission, that supports the implementation of the Diabetes NSF and aims to improve the quality of patient care for all people with diabetes in England and Wales.&amp;nbsp; This report summarises the main findings and recommendations.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2008.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>319699</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/7121_National%20Diabetes%20Audit_final.pdf]]&gt;</url>
    <title>National diabetes audit: key findings about the quality of care for people with diabetes in England and Wales.  Executive summary for the audit period 2007/08</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DELIVERY OF CARE,DIABETES,ACUTE SERVICES,SERVICE DELIVERY,NHS ACTIVITIES,SERVICE SECTORS,PRIMARY CARE SERVICES,QUALITY AND MONITORING,HEALTH MANAGEMENT,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the fifth annual report of the National Diabetes Audit (NDA) presenting the key findings from 2007-2008. The NDA collects data from both primary and secondary care sectors, including specialist paediatric units providing care for children and young people with diabetes.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;See related links for the 2007-08 NDA Dashboard.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307727</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/19040707%20IC%20Diabetes-%20AbridgedReport.FV.pdf]]&gt;</url>
    <title>National diabetes audit: key findings about the quality of care for people with diabetes in England and Wales. Abridged report for the audit period 2005/06</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;The National Diabetes Audit (NDA) is a national audit service, sponsored by the Healthcare Commission, that supports the implementation of the Diabetes NSF and aims to improve the quality of patient care for all people with diabetes in England and Wales.&lt;BR&gt;&lt;BR&gt;This report presents the main findings from the&amp;nbsp;third year of the audit for people with diabetes. It also provides recommendations for both national and local organisations based on the analysis of the audit data.&amp;nbsp; &lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2007.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320536</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/19040507%20IC%20Diabetes-MainReport.FV.pdf]]&gt;</url>
    <title>National diabetes audit: key findings about the quality of care for people with diabetes in England and Wales. Report for the audit period 2005-2006</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt" lang=EN-GB&gt;&lt;SPAN class=765231913-18042005&gt;&lt;FONT size=2 face=Arial&gt;The &lt;/FONT&gt;&lt;FONT size=2 face=Arial&gt;National Diabetes Audit&lt;/FONT&gt;&lt;FONT size=2 face=Arial&gt;, carried out on behalf of the Healthcare Commission by The Information Centre for Health and Social Care, is an ongoing audit designed to monitor care and assure consistent quality in services for people with diabetes across the country.&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;]]&gt;</body>
  </document>
  <document>
    <id>182403</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/NDAReport-abridged-2004-2005.pdf]]&gt;</url>
    <title>National diabetes audit: key findings about the quality of care for people with diabetes in England incorporating registrations from Wales. Abridged report for the audit period 2004/05</title>
    <publicationDate>2006-01-01T00:00:00</publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DATA GATHERING AND AUDIT AND QOF,DIABETES,DELIVERY OF CARE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT size=3 face=Humanist777BT-LightB&gt;
&lt;P align=left&gt;&lt;/FONT&gt;The National Diabetes Audit (NDA) is a national audit service, sponsored by the Healthcare Commission, that supports the implementation of the Diabetes NSF and aims to improve the quality of patient care for all people with diabetes in England.&lt;BR&gt;&lt;BR&gt;This report presents the main findings from the second year of the audit for people with diabetes. It also provides recommendations for both national and local organisations based on the analysis of the audit data.&amp;nbsp; The main finding of the national audit is that one in five people expected to have diabetes remain undiagnosed and efforts to tackle the problem are proving more successful in some areas than others. &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to general public. Portable Document File/PDF&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307725</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/NDAReport-FullReport-2004-2005.pdf]]&gt;</url>
    <title>National diabetes audit: key findings about the quality of care for people with diabetes in England, incorporating registrations from Wales. Report for the audit period 2004-2005</title>
    <publicationDate>2006-01-01T00:00:00</publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The National Diabetes Audit, carried out on behalf of the Healthcare Commission by The Information Centre for Health and Social Care, is an ongoing audit designed to monitor care and assure consistent quality in services for people with diabetes across the country.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2006.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307722</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/NDAReport-FullReport-2003-2004.pdf]]&gt;</url>
    <title>National diabetes audit: key findings about the quality of care for people with diabetes in England.  Report for the audit period 2003-2004</title>
    <publicationDate>2005-08-01T00:00:00</publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DATA GATHERING AND AUDIT AND QOF,DELIVERY OF CARE,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The National Diabetes Audit, carried out on behalf of the Healthcare Commission by The Information Centre for Health and Social Care, is an ongoing audit designed to monitor care and assure consistent quality in services for people with diabetes across the country.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in August 2005.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307724</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/NDAReport-abridged-2003-2004.pdf]]&gt;</url>
    <title>National diabetes audit: key findings about the quality of care for people with diabetes in England. Abridged report for the audit period 2003/04</title>
    <publicationDate>2005-08-01T00:00:00</publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DATA GATHERING AND AUDIT AND QOF,DELIVERY OF CARE,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;The National Diabetes Audit (NDA) is a national audit service, sponsored by the Healthcare Commission, that supports the implementation of the Diabetes NSF and aims to improve the quality of patient care for all people with diabetes in England.&lt;BR&gt;&lt;BR&gt;This report presents the main findings from the audit for people with diabetes. It also provides recommendations for both national and local organisations based on the analysis of the audit data.&amp;nbsp; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>379543</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/NDA_Paediatric_Report_2008_2009.pdf]]&gt;</url>
    <title>National diabetes paediatric report 2008-2009: key findings about the quality of care for children and young people with diabetes in England and Wales</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,TYPE 1,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF,CHILDREN AND YOUNG PEOPLE,CHILDREN AND YOUNG PEOPLE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the sixth report prepared by the National Diabetes Audit (NDA) team, on behalf of the project board, based on information submitted by paediatric units in England and Wales. This report presents the main findings from analysis of the 2008–2009 paediatric audit.&lt;/P&gt;
&lt;P&gt;The National Diabetes Audit (NDA) is commissioned and sponsored by the Healthcare Quality Improvement Partnership (HQIP)&amp;nbsp;following advice to the Department of Health from the National Clinical Audit Advisory Group (NCAAG).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>387843</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=387843]]&gt;</url>
    <title>National Knowledge Week for Prevention of Type 2 Diabetes</title>
    <publicationDate>2007-03-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PREVENTION,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Prevention of Type 2 Diabetes&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Introduction &lt;BR&gt;&lt;/STRONG&gt;Type 2 diabetes is becoming increasingly common in the UK. The NHS is striving to reduce the risk of developing Type 2 diabetes in the population as a whole, and to reduce the inequalities in the risk of developing it. The National Library for Health’s (NLH) Diabetes Specialist Library is therefore carrying out a systematic up-to-date review of the literature in this important area of interest for healthcare professionals.&lt;BR&gt;The launch of the Prevention of Type 2 Diabetes National Knowledge Week provides an opportunity to present a comprehensive collection of up-to-date information that has been subject to rigorous selection criteria. Coverage has been developed on the basis of topics suggested by acknowledged UK experts. Information is organised by topic areas and links are provided within each topic to the relevant references (systematic reviews, primary research), guidelines and patient information. &lt;BR&gt;&lt;BR&gt;After you have browsed the knowledge week pages, please take a moment to send us your &lt;A href="http://www.library.nhs.uk/diabetes/ContactUs.aspx" target="_blank"&gt;feedback.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;STRONG&gt;Topics &lt;BR&gt;&lt;/STRONG&gt;Expert summaries are available under the following sub topics:&lt;BR&gt;&lt;BR&gt;1. &lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=251169" target="_blank"&gt;Introduction - What are the main drivers of the increase in numbers in adults?&lt;BR&gt;&lt;/A&gt;2. &lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=251175" target="_blank"&gt;Why are some teenagers developing type 2 diabetes?&lt;/A&gt;&lt;BR&gt;3. &lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=251151" target="_blank"&gt;What are the best ways for identifying those at risk?&lt;BR&gt;&lt;/A&gt;4.1 &lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=251158" target="_blank"&gt;What are the proven interventions at individual level? – lifestyle&lt;/A&gt;&lt;BR&gt;4.2 &lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=250833" target="_blank"&gt;What are the proven interventions at individual level? - pharmacological&lt;BR&gt;&lt;/A&gt;5. &lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=251171" target="_blank"&gt;What are the proven interventions at population level? - obesity prevention (diet)&lt;/A&gt;&lt;BR&gt;6. &lt;A href="http://www.library.nhs.uk/diabetes/ViewResource.aspx?resID=251173" target="_blank"&gt;Can type 2 diabetes be prevented in people with gestational diabetes?&lt;BR&gt;&lt;/A&gt;&lt;STRONG&gt;&lt;BR&gt;Further Information&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/Page.aspx?pagename=PT2DSEARCH" target="_blank"&gt;Summary of methods / Literature search strategy&lt;BR&gt;&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/diabetes/Page.aspx?pagename=PT2DLIT" target="_blank"&gt;Literature search results&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;STRONG&gt;Acknowledgments&lt;/STRONG&gt; &lt;BR&gt;The Project Team, based at the University of Warwick (Roger Gadsby, Rachel Lancaster and Suzette Aniyi) would like to acknowledge the contribution made by our panel of experts: &lt;BR&gt;&lt;BR&gt;&lt;A href="http://www2.warwick.ac.uk/fac/med/staff/kumar/" target="_blank"&gt;Prof. Sudhesh Kumar&lt;/A&gt; MD FRCP Professor of Medicine Diabetes and Metabolism, Clinical Sciences Research Institute, University of Warwick&lt;BR&gt;&lt;A href="http://www2.warwick.ac.uk/fac/med/staff/matyka/" target="_blank"&gt;Dr. Krystyna Matyka&lt;/A&gt; Senior Clinical Lecturer, Clinical Sciences Research Institute, University of Warwick&lt;BR&gt;&lt;A href="http://www.sahf.org.uk/Members.aspx?id=24" target="_blank"&gt;Dr. Wasim Hanif&lt;/A&gt; Consultant Physician with a Specialist interest in Diabetes, University Hospital Birmingham&lt;BR&gt;&lt;A href="http://www2.warwick.ac.uk/fac/med/staff/patel/" target="_blank"&gt;Dr. Vinod Patel&lt;/A&gt; Consultant Physician in Endocrinology and Diabetes George Eliot Hospital, NHS Trust in Nuneaton, Warwickshire, Associate Professor (Reader) in Clinical Skills, University of Warwick&lt;BR&gt;&lt;A href="http://www.mrc-hnr.cam.ac.uk/about/People/senior-staff.html#Susan" target="_blank"&gt;Dr. Susan Jebb&lt;/A&gt; Head of the Nutrition and Health group and Nutrition Communication group at Medical Research Council Human Nutrition Research centre (HNR)&lt;BR&gt;&lt;A href="http://www.tonisteer.com/" target="_blank"&gt;Dr. Toni Steer&lt;/A&gt; Nutritionist, Medical Research Council Human Nutrition Research centre (HNR)&lt;BR&gt;&lt;BR&gt;Our thanks also go to a number of other people in the development and publicising of the knowledge week, including members of our &lt;A href="http://www.library.nhs.uk/diabetes/AboutUs.aspx#ref" target="_blank"&gt;Reference Group&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; 12th - 17th March 2007. Reviewed November 2009&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>388094</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=388094]]&gt;</url>
    <title>National Knowledge Week for Prevention of Type 2 Diabetes: Literature search results</title>
    <publicationDate>2007-03-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PREVENTION,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Prevention of Type 2 Diabetes: Literature search results&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387843" target="_blank"&gt;Back to knowledge week contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Please note that the inclusion of citations in this list does not imply endorsement. The NLH Diabetes Specialist Library does not accept responsibility for the content or quality of included studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;All topics&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic reviews&lt;/STRONG&gt;&lt;BR&gt;Listed by date, then author (most recent first)&lt;BR&gt;&lt;BR&gt;Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. British Medical Journal 2007 Feb 10; 334 (7588): 299. [&lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=17237299" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Burnet DL, Elliott LD, Quinn MT, Plaut AJ, Schwartz MA, Chin MH. Preventing diabetes in the clinical setting. Journal of General Internal Medicine : Official Journal of the Society for Research and Education in Primary Care Internal Medicine 2006; 21 (1): 84-93. [&lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=16423130" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Current Drug Targets 2006; 7 (2): 211-28. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16475962&amp;amp;query_hl=2&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Vijgen SMC, Hoogendoorn M, Baan CA, De Wit GA, Limburg W, Feenstra TL. Cost effectiveness of preventive interventions in type 2 diabetes mellitus: A systematic literature review. PharmacoEconomics 2006; 24 (5): 425-41. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16706569&amp;amp;query_hl=7&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Yamaoka K, Tango T. Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 2005; 28 (11): 2780-6. [&lt;A href="http://care.diabetesjournals.org/cgi/content/full/28/11/2780" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;RCTs&lt;/STRONG&gt;&lt;BR&gt;Listed by date, then author (most recent first)&lt;BR&gt;&lt;BR&gt;Lindström J, Ilanne PP, Peltonen M, Aunola S, Eriksson JG, Hemiö K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368 (9548): 1673-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=17098085&amp;amp;query_hl=1&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Strategies to identify adults at high risk for type 2 diabetes: the Diabetes Prevention Program. Diabetes Care 2005; 28 (1): 138-44. [&lt;A href="http://care.diabetesjournals.org/cgi/content/full/28/1/138" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Hernan WH, Brandle M, Zhang P, Williamson DF, Matulik MJ, Ratner RE, et al. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care 2003; 26 (1): 36-47. [&lt;A href="http://care.diabetesjournals.org/cgi/content/full/26/1/36" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Knowler WC, Barrett CE, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine 2002; 346 (6): 393-403. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=11832527&amp;amp;query_hl=7&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group. Diabetes Care 2000; 23 (11): 1619-29. [&lt;A href="http://care.diabetesjournals.org/cgi/reprint/23/11/1619" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999; 22 (4): 623-34. [&lt;A href="http://care.diabetesjournals.org/cgi/reprint/22/4/623" target="_blank"&gt;full text&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;2. Why are some teenagers developing type 2 diabetes?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic reviews&lt;/STRONG&gt;&lt;BR&gt;Listed by date, then author (most recent first)&lt;BR&gt;&lt;BR&gt;See also 'All topics' above.&lt;BR&gt;&lt;BR&gt;Fisher D, Baird J, Payne L, Lucas P, Kleijnen J, Roberts H, et al. Are infant size and growth related to burden of disease in adulthood? A systematic review of literature. International Journal of Epidemiology 2006; 35 (5): 1196-210. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16845132&amp;amp;query_hl=17&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Owen CG, Martin RM, Whincup PH, Smith GD, Cook DG. Does breastfeeding influence risk of type 2 diabetes in later life? A quantitative analysis of published evidence. The American Journal of Clinical Nutrition 2006; 84: 1043-54. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?itool=abstractplus&amp;amp;db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=abstractplus&amp;amp;list_uids=17093156" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Vivian Eva M. Type 2 diabetes in children and adolescents--the next epidemic? Current Medical Research and Opinion 2006; 22 (2): 297-306. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16466601&amp;amp;query_hl=29&amp;amp;itool=pubmed_DocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Summerbell CD, Waters E, Edmunds LD, Kelly S, Brown T, Campbell KJ. Interventions for preventing obesity in children. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD001871. DOI: 10.1002/14651858.CD001871.pub2. [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001871/frame.html" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Taylor JS, Kacmar JE, Nothnagle M, Lawrence RA. A systematic review of the literature associating breastfeeding with type 2 diabetes and gestational diabetes. Journal of the American College of Nutrition 2005; 24 (5): 320-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16192255&amp;amp;query_hl=33&amp;amp;itool=pubmed_DocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;3. What are the best ways for identifying those at risk?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic reviews&lt;/STRONG&gt;&lt;BR&gt;Listed by date, then author (most recent first)&lt;BR&gt;&lt;BR&gt;See also 'All topics' above.&lt;/P&gt;
&lt;P&gt;Hartemink N, Boshuizen HC, Nagelkerke NJD, Jacobs MAM, Van Houwelingen HC. Combining risk estimates from observational studies with different exposure cutpoints: A meta-analysis on body mass index and diabetes type 2. American Journal of Epidemiology 2006; 163(11):1042-52. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16611666&amp;amp;query_hl=35&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RCTs&lt;/STRONG&gt;&lt;BR&gt;Listed by date, then author (most recent first)&lt;BR&gt;&lt;BR&gt;See also 'All topics' above.&lt;BR&gt;&lt;BR&gt;Strategies to identify adults at high risk for type 2 diabetes: the Diabetes Prevention Program. Diabetes Care 2005; 28 (1): 138-44. [&lt;A href="http://care.diabetesjournals.org/cgi/content/full/28/1/138" target="_blank"&gt;full text&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;4.1. What are the proven interventions at individual level? - Lifestyle&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic reviews&lt;/STRONG&gt;&lt;BR&gt;Listed by date, then author (most recent first)&lt;BR&gt;&lt;BR&gt;See also 'All topics' above.&lt;BR&gt;&lt;BR&gt;Mann JI. Nutrition recommendations for the treatment and prevention of type 2 diabetes and the metabolic syndrome: an evidence-based review. Nutrition Reviews 2006; 64 (9): 422-7.&lt;BR&gt;&lt;BR&gt;Patrick LJ. Review: lifestyle education programmes lower glucose concentrations and reduce the incidence of type 2 diabetes. Evidence-Based Nursing 2006; 9 (3): p.75.&lt;BR&gt;&lt;BR&gt;Serra ML, Roman B, Estruch R. Scientific evidence of interventions using the Mediterranean diet: a systematic review. Nutrition Reviews 2006; 64 (2): S27-47. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16532897&amp;amp;query_hl=44&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Shaw K, Gennat H, O'Rourke P, Del Mar C. Exercise for overweight or obesity. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD003817. DOI: 10.1002/14651858.CD003817.pub3. [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003817/frame.html" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Long-term non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD005270. DOI: 10.1002/14651858.CD005270. [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005270/frame.html" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;van Dam RM, Hu FB. Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA : the Journal of the American Medical Association 2005; 294 (1): 97-104. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15998896&amp;amp;query_hl=46&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;RCTs&lt;/STRONG&gt;&lt;BR&gt;Listed by date, then author (most recent first)&lt;BR&gt;&lt;BR&gt;See also 'All topics' above.&lt;BR&gt;&lt;BR&gt;Crandall J, Schade D, Ma Y, Fujimoto WY, Barrett CE, Fowler S. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A Biological Sciences and Medical Sciences 2006; 61 (10): 1075-81. [&lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=17077202" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006; 29 (9): 2102-7. [&lt;A href="http://care.diabetesjournals.org/cgi/content/full/29/9/2102" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Lindström J, Ilanne PP, Peltonen M, Aunola S, Eriksson JG, Hemiö K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368 (9548): 1673-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=17098085&amp;amp;query_hl=1&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;McAuley KA, Smith KJ, Taylor RW, McLay RT, Williams SM, Mann JI. Long-term effects of popular dietary approaches on weight loss and features of insulin resistance. International Journal of Obesity 2006; 30 (2): 342-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16158081&amp;amp;query_hl=4&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Nelson MS, Robbins AS, Thornton JA. An intervention to reduce excess body weight in adults with or at risk for type 2 diabetes. Military Medicine 2006; 171 (5): 409-14. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16761891&amp;amp;query_hl=8&amp;amp;itool=pubmed_DocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Oldroyd JC, Unwin NC, White M, Mathers JC, Alberti KGMM. Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice 2006; 72 (2): 117-27. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16297488&amp;amp;query_hl=10&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Ostman EM, Frid AH, Groop LC, Björck IME. A dietary exchange of common bread for tailored bread of low glycaemic index and rich in dietary fibre improved insulin economy in young women with impaired glucose tolerance. European Journal of Clinical Nutrition 2006; 60 (3): 334-41. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16234828&amp;amp;query_hl=12&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49 (2): 289-97. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16391903&amp;amp;query_hl=14&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Brekke HK, Jansson PA, Lenner RA. Long-term (1- and 2-year) effects of lifestyle intervention in type 2 diabetes relatives. Diabetes Research and Clinical Practice 2005; 70 (3): 225-34. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15885845&amp;amp;query_hl=16&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;O'Donovan G, Kearney EM, Nevill AM, Woolf MK, Bird SR. The effects of 24 weeks of moderate- or high-intensity exercise on insulin resistance. European Journal of Applied Physiology 2005; 95 (5-6): 522-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16151830&amp;amp;query_hl=20&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Mayer Davis EJ, Sparks KC, Hirst K, Costacou T, Lovejoy JC, Regensteiner JG, et al. Dietary intake in the diabetes prevention program cohort: baseline and 1-year post randomization. Annals of Epidemiology 2004; 14 (10): 763-72. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15573453&amp;amp;query_hl=22&amp;amp;itool=pubmed_DocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Treviño RP, Yin Z, Hernandez A, Hale DE, Garcia OA, Mobley C. Impact of the Bienestar school-based diabetes mellitus prevention program on fasting capillary glucose levels: a randomized controlled trial. Archives of Pediatrics &amp;amp; Adolescent Medicine 2004; 158 (9): 911-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?itool=abstractplus&amp;amp;db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=abstractplus&amp;amp;list_uids=15351759" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Janket Sok J, Manson JE, Sesso H, Buring JE, Liu S. A prospective study of sugar intake and risk of type 2 diabetes in women. Diabetes Care 2003; 26 (4): 1008-15. [&lt;A href="http://care.diabetesjournals.org/cgi/content/full/26/4/1008" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Lindström J, Eriksson JG, Valle TT, Aunola S, Cepaitis Z, Hakumäki M. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the&amp;nbsp; Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology: JASN 2003; 14 (7 Suppl 2): S108-13. [&lt;A href="http://jasn.asnjournals.org/cgi/content/full/14/suppl_2/S108" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Tate DF, Jackvony EH, Wing RR. Effects of Internet behavioral counseling on weight loss in adults at risk for type 2 diabetes: a randomized trial. JAMA : the Journal of the American Medical Association 2003; 289 (14): 1833-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?itool=abstractplus&amp;amp;db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=abstractplus&amp;amp;list_uids=12684363" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Delahanty LM, Meigs JB, Hayden D, Williamson DA, Nathan DM. Psychological and behavioral correlates of baseline BMI in the diabetes prevention program (DPP). Diabetes Care 2002; 25 (11): 1992-8. [&lt;A href="http://care.diabetesjournals.org/cgi/content/full/25/11/1992" target="_blank"&gt;full text&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;4.2. What are the proven interventions at individual level? - Pharmacological&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic reviews&lt;/STRONG&gt;&lt;BR&gt;Listed by date, then author (most recent first)&lt;BR&gt;&lt;BR&gt;See also 'All topics' above.&lt;BR&gt;&lt;BR&gt;Cheung BMY, Cheung GTY, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. Journal of Human Hypertension 2006; 20 (1): 37-43. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16121197&amp;amp;query_hl=39&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Curioni C, André C. Rimonabant for overweight or obesity. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD006162. DOI: 10.1002/14651858.CD006162.pub2. [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006162/frame.html" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Gutknecht DR. Candesartan prevented development of diabetes mellitus in heart failure. ACP Journal Club 2006 Jan-Feb; (1): 11.&lt;BR&gt;&lt;BR&gt;Leiter LA. Can thiazolidinediones delay disease progression in type 2 diabetes? Current Medical Research and Opinion 2006; 22 (6): 1193-201. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16846552&amp;amp;query_hl=43&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Mann JI. Nutrition recommendations for the treatment and prevention of type 2 diabetes and the metabolic syndrome: an evidence-based review. Nutrition Reviews 2006; 64 (9): 422-7.&lt;BR&gt;&lt;BR&gt;Van de Laar FA, Lucassen PLBJ, Akkermans RP, Van de Lisdonk EH, De Grauw WJC. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD005061. DOI: 10.1002/14651858.CD005061.pub2. [&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005061/frame.html" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006; 48 (2): 219-24. [&lt;A href="http://hyper.ahajournals.org/cgi/content/full/48/2/219" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. Journal of the American College of Cardiology 2005; 46 (5): 821-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16139131&amp;amp;query_hl=48&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Anderson Douglas C Jr. Pharmacologic prevention or delay of type 2 diabetes mellitus. The Annals of Pharmacotherapy 2005; 39 (1): 102-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15562143&amp;amp;query_hl=51&amp;amp;itool=pubmed_DocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005; 28 (9): 2261-6. [&lt;A href="http://care.diabetesjournals.org/cgi/content/full/28/9/2261" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;RCTs&lt;BR&gt;&lt;/STRONG&gt;Listed by date, then author (most recent first)&lt;BR&gt;&lt;BR&gt;See also 'All topics' above.&lt;BR&gt;&lt;BR&gt;Bonds DE, Lasser N, Qi L, Brzyski R, Caan B, Heiss , et al. The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial. Diabetologia 2006; 49 (3): 459-68. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16440209&amp;amp;query_hl=56&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Conlon D. DREAM - A diabetes prevention study. British Journal of Diabetes and Vascular Disease 2006; 6 (5): 230-4. [&lt;A href="http://dvd.sagepub.com/cgi/content/abstract/6/5/230" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;DREAM Trial Investigators; Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, et al. Effect of ramipril on the incidence of diabetes. The New England Journal of Medicine 2006; 355 (15): 1551-62. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16980380&amp;amp;query_hl=59&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Eriksson JG, Lehtovirta M, Ehrnström B, Salmela S, Groop L. Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance. Journal of Internal Medicine 2006; 259 (6): 553-60. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16704555&amp;amp;query_hl=65&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368 (9541): 1096-105. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16997664&amp;amp;query_hl=68&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Julius Stevo, Weber Michael A, Kjeldsen Sverre E, McInnes Gordon T, Zanchetti Alberto, Brunner Hans R, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006; 48 (3): 385-91. [&lt;A href="http://hyper.ahajournals.org/cgi/content/full/48/3/385" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Kirkman MS, Shankar RR, Shankar S, Shen C, Brizendine E, Baron A, et al. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program. Diabetes Care 2006; 29 (9): 2095-101. [&lt;A href="http://care.diabetesjournals.org/cgi/content/full/29/9/2095" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. Journal of Hypertension 2006; 24 (7): 1405-12. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16794491&amp;amp;query_hl=74&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Liebl A, Lüddeke HJ, Kotowa W, Maclaine G, Evers T. Cost-effectiveness of acarbose treatment in patients with impaired glucose tolerance. Gesundheitsokonomie Und Qualitatsmanagement 2006; 11 (2): 105-11.&lt;BR&gt;&lt;BR&gt;Liu S, Lee IM, Song Y, Van Denburgh M, Cook NR, Manson JE, et al. Vitamin E and risk of type 2 diabetes in the women's health study randomized controlled trial. Diabetes 2006; 55 (10): 2856-62. [&lt;A href="http://diabetes.diabetesjournals.org/cgi/content/full/55/10/2856" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112 (9): 1339-46. [&lt;A href="http://circ.ahajournals.org/cgi/content/full/112/9/1339" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Knowler C, Hamman RF, Edelstein SL, Barrett Conner E, Ehrmann DA, Walker EA, et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54 (4): 1150-6. [&lt;A href="http://diabetes.diabetesjournals.org/cgi/content/full/54/4/1150" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Mayer Davis EJ, Sparks KC, Hirst K, Costacou T, Lovejoy JC, Regensteiner JG, et al. Dietary intake in the diabetes prevention program cohort: baseline and 1-year post randomization. Annals of Epidemiology 2004; 14 (10): 763-72. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15573453&amp;amp;query_hl=89&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D, et al. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. European Heart Journal 2005; 26 (19): 2032-8. [&lt;A href="http://eurheartj.oxfordjournals.org/cgi/content/full/26/19/2032" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB&amp;nbsp; et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005; 112 (1): 48-53. [&lt;A href="http://circ.ahajournals.org/cgi/content/full/112/1/48" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia 2004; 47 (6): 969-75; discussion 976-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15164169&amp;amp;query_hl=92&amp;amp;itool=pubmed_docsum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 2003; 26 (4): 977-80. [&lt;A href="http://care.diabetesjournals.org/cgi/content/full/26/4/977" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Saloranta C, Guitard C, Pecher E, De Pablos VP, Lahti K, Brunel P, et al. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population. Diabetes Care 2002; 25 (12): 2141-6. [&lt;A href="http://care.diabetesjournals.org/cgi/content/full/25/12/2141" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, et al. Ramipril and the development of diabetes. JAMA : the Journal of the American Medical Association 2001; 286 (15): 1882-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=11597291&amp;amp;query_hl=98&amp;amp;itool=pubmed_DocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;5. What are the proven interventions at Population level?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic reviews&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;See also 'All topics' above.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;RCTs&lt;/STRONG&gt;&lt;BR&gt;Listed by date, then author (most recent first)&lt;BR&gt;&lt;BR&gt;See also 'All topics' above.&lt;BR&gt;&lt;BR&gt;Delahanty LM, Conroy MB, Nathan DM. Psychological predictors of physical activity in the diabetes prevention program. Journal of the American Dietetic Association 2006; 106 (5): 698-705. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?itool=abstractplus&amp;amp;db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=abstractplus&amp;amp;list_uids=16647327" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;van Sluijs EMF, van Poppel MNM, Twisk JWR, Chin A Paw MJ, Calfas KJ, van Mechelen W. Effect of a tailored physical activity intervention delivered in general practice settings: results of a randomized controlled trial. American Journal of Public Health 2005; 95 (10): 1825-31. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?itool=abstractplus&amp;amp;db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=abstractplus&amp;amp;list_uids=16186461" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Williams Kate. The ProActive trial protocol - a randomised controlled trial of the efficacy of a&amp;nbsp; family-based, domiciliary intervention programme to increase physical activity among individuals at high risk of diabetes. BMC public health 2004; 4: 48. [&lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=15491494" target="_blank"&gt;full text&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;6. Can type 2 diabetes be prevented in people with Gestational diabetes?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic reviews&lt;BR&gt;&lt;/STRONG&gt;Listed by date, then author (most recent first)&lt;BR&gt;&lt;BR&gt;See also 'All topics' above.&lt;BR&gt;&lt;BR&gt;Case J, Willoughby D, Haley Zitlin V, Maybee P. Preventing type 2 diabetes after gestational diabetes. The Diabetes Educator 2006; 32 (6): 877-86. [&lt;A href="http://tde.sagepub.com/cgi/content/full/32/6/877" target="_blank"&gt;full text&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Malcolm JC, Lawson ML, Gaboury I, Lough G, Keely E. Glucose tolerance of offspring of mother with gestational diabetes mellitus in a low-risk population. Diabetic Medicine 2006; 23 (5): 565-70. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16681566&amp;amp;query_hl=9&amp;amp;itool=pubmed_DocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;BR&gt;&lt;BR&gt;Taylor JS, Kacmar JE, Nothnagle M, Lawrence RA. A systematic review of the literature associating breastfeeding with type 2 diabetes and gestational diabetes. Journal of the American College of Nutrition 2005; 24 (5): 320-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16192255&amp;amp;query_hl=14&amp;amp;itool=pubmed_DocSum" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387843" target="_blank"&gt;Back to knowledge week contents&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>388098</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=388098]]&gt;</url>
    <title>National Knowledge Week for Prevention of Type 2 Diabetes: search strategy</title>
    <publicationDate>2007-03-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Prevention of Type 2 Diabetes: search strategy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387843" target="_blank"&gt;Back to knowledge week contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The Library's information specialists ran three separate subject searches on MEDLINE and then adapted and ran them in EMBASE and CINAHL. Appropriate methodological (study type) search filters designed for the respective databases were also used. All searches were limited to papers added to the databases since 1st January 2006.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The first aimed to pick up Systematic Reviews or RCTs about prevention of type 2 diabetes. &lt;/LI&gt;
&lt;LI&gt;The second aimed to pick up Systematic Reviews about causes of type 2 diabetes in children &lt;/LI&gt;
&lt;LI&gt;The third aimed to pick up Systematic Reviews about risk engines for type 2 diabetes.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The tested methodological search filters used were at least 90% sensitive. In order to make the amount of papers manageable to sift, the most highly sensitive tested filters available were not used. In total, 849 titles and abstracts were sifted, 157 of which went to the Library's Clinical Lead to further sift for relevance. The &lt;A href="http://www.library.nhs.uk/cancer/Page.aspx?pagename=DCQCINDEX" target="_blank"&gt;DC-QC index&lt;/A&gt; developed by NLH's Cancer Specialist Library was used to identify Systematic Reviews.&lt;BR&gt;&lt;BR&gt;The Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects (DARE) and the Diabetes Specialist Library were also searched for any relevant systematic reviews from the last 2 years (2005, 2006) missed by the above searches.&lt;BR&gt;&lt;BR&gt;Full details of search terms and filters used are available by &lt;A href="http://www.library.nhs.uk/diabetes/ContactUs.aspx" target="_blank"&gt;contacting&lt;/A&gt; the Library's information specialists.&lt;/P&gt;
&lt;P align=right&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387843" target="_blank"&gt;Back to knowledge week contents&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386348</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=1532]]&gt;</url>
    <title>National service framework for children, young people and maternity services - type 1 diabetes in childhood and adolescence</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,POLICY,SERVICE SECTORS,PRIMARY CARE SERVICES,ACUTE SERVICES,DIABETES,TYPE 1,LIVING WITH DIABETES,DELIVERY OF CARE,HOSPITAL INPATIENT CARE,KEY POLICIES / NSF,PATIENT EDUCATION AND EMPOWERMENT,DIAGNOSIS,CONDITION MANAGEMENT,CHILDREN AND YOUNG PEOPLE,GENERAL,SCHOOL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>An exemplar patient journey to support the national service framework.</description>
    <body>&lt;![CDATA[ &lt;P&gt;An exemplar patient journey, published to support the National Service Framework (NSF) for Children, Young People and Maternity Services. It follows a patient, Tom, and his family, from diagnosis at age 3 through overcoming obstacles including injections, hospitalisation and&amp;nbsp;bullying at school, to the transition to adult services.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The primary audience for this exemplar is professionals from a broad range of backgrounds including education, the NHS, social services and the voluntary sector.&amp;nbsp;It will also be of interest to parents, children and young people.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The exemplar may be useful in a number of ways, for example to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;highlight further references, including key clinical guidelines 
&lt;LI&gt;stimulate local debate and assist multi-agency partners to re-evaluate the way they collaborate on, commission and deliver children’s services 
&lt;LI&gt;provide an aid to examining and improving local clinical and non-clinical governance 
&lt;LI&gt;provide a multi-disciplinary training tool for staff working with children and young people to raise awareness of specific issues and&lt;BR&gt;stimulate discussion 
&lt;LI&gt;canvass the views of children and families on specific children’s issues (for example via focus groups), providing a non-threatening mechanism to open discussion 
&lt;LI&gt;provide a starting point or template for debate, prior to development of new local strategies for managing complex childhood conditions.&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in July 2010.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document Format / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>83788</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.psnc.org.uk/publications_download.php/93/Diabetes_Book_tna4s.pdf]]&gt;</url>
    <title>National service framework for diabetes : a guide for community pharmacists</title>
    <publicationDate>2004-01-01T00:00:00</publicationDate>
    <publisher>Pharmaceutical Services Negotiating Committee (PSNC)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,HEALTH MANAGEMENT,NHS ACTIVITIES,POLICY,NATIONAL SERVICE FRAMEWORKS,PHARMACY,DELIVERY OF CARE,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT size=2&gt;
&lt;P&gt;&lt;/FONT&gt;Building on the 2002 PSNC publication 'Diabetes – a guide for community pharmacists' which looked at the Diabetes National Service Framework (NSF)&amp;nbsp;standards, this publication also includes information on the later NSF service specifications and updated information on related NHS policy and publications. Sections covering practical guidance include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Primary prevention 
&lt;LI&gt;Medicine/Disease management 
&lt;LI&gt;Reducing complications 
&lt;LI&gt;Integration into the diabetes team&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published 2004.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82548</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/ContactUs/ContactDetailsList/DH_072317]]&gt;</url>
    <title>National service framework for diabetes : contacts</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,KEY POLICIES / NSF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Department of Health page provides a contact email address for team&amp;nbsp;responsible for the &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=83894&amp;amp;tabID=288" target="_blank"&gt;National Service Framework for diabetes&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82547</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4079281&amp;chk=QbeAKX]]&gt;</url>
    <title>National service framework for diabetes : one year on</title>
    <publicationDate>2004-04-08T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,KEY POLICIES / NSF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Department of Health&amp;nbsp;report describes the progress made in the first year on&amp;nbsp;the &lt;A href="http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Diabetes/index.htm" target="_blank"&gt;National Service Framework for diabetes&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published&amp;nbsp;8 April&amp;nbsp;2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82551</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4105361?IdcService=GET_FILE&amp;dID=22908&amp;Rendition=Web]]&gt;</url>
    <title>National service framework for long-term (neurological) conditions</title>
    <publicationDate>2005-03-10T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ STROKE,ISCHAEMIC STROKE,REHABILITATION,GENERAL/OTHER,KEY POLICIES AND RELATED PUBLICATIONS,DISEASE MANAGEMENT,SECONDARY PREVENTION,TRANSIENT ISCHAEMIC ATTACK,DISEASE MANAGEMENT,DISEASE MANAGEMENT,DISEASE MANAGEMENT,HAEMORRHAGIC STROKE,APR-JUN 08,POLICY,NATIONAL SERVICE FRAMEWORKS,DIABETES,HEALTH MANAGEMENT,DELIVERY OF CARE,KEY POLICIES / NSF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The&amp;nbsp;National Service Framework (NSF)&amp;nbsp;for Long Term Conditions sets 11 quality requirements to transform the way health and social care services support people with long-term neurological conditions to live as independently as possible. Although the NSF focuses on people with long-term neurological conditions, much of the guidance it offers can apply to anyone living with a long-term condition.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published 10 Mar 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>239581</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/cgi/content/full/31/Supplement_1/S97]]&gt;</url>
    <title>National standards for diabetes self-management education</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,PATIENT AND PUBLIC INVOLVEMENT,PPI IN PRACTICE,INDIVIDUAL INVOLVEMENT,SELF MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; (Taken from the original document)&lt;BR&gt;"Diabetes self-management education (DSME) is a critical element of care for all people with diabetes and is necessary in order to improve patient outcomes. The National Standards for DSME are designed to define quality diabetes self-management education and to assist diabetes educators in a variety of settings to provide evidence-based education. Because of the dynamic nature of health care and diabetes-related research, these Standards are reviewed and revised approximately every 5 years by key organizations and federal agencies within the diabetes education community.&lt;/P&gt;
&lt;P&gt;The Task Force was charged with reviewing the current DSME standards for their appropriateness, relevance, and scientific basis. The Standards were then reviewed and revised based on the available evidence and expert consensus".&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Health Service (USA)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published January 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Full reference:&lt;/STRONG&gt; Funnell, M. M., Brown, T. L., Childs, B. P., Haas, L. B., Hosey, G. M., Jensen, B., Maryniuk, M., Peyrot, M., Piette, J. D., Reader, D., Siminerio, L. M., Weinger, K. &amp;amp; Weiss, M. A. (2008) National Standards for Diabetes Self-Management Education. &lt;I&gt;Diabetes Care,&lt;/I&gt; 31, S97-104.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82746</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.cqc.org.uk/_db/_documents/Diabetes_survey_2006_summary.pdf]]&gt;</url>
    <title>National survey of people with diabetes</title>
    <publicationDate></publicationDate>
    <publisher>Care Quality Commission</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DATA GATHERING AND AUDIT AND QOF,DIABETES,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF,STATISTICS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report presents the results of a national survey of people with diabetes carried out in autumn 2006. The survey assessed whether people with diabetes are receiving the care, treatment and information they need to manage their diabetes well and reduce the risk of complications.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>331504</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/our_work_areas/networks/]]&gt;</url>
    <title>Networks - Work Area - NHS Diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the NHS Diabetes website provides details on how NHS Diabetes works with the regional networks. It also includes a link to further information to support the running of successful networks.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372585</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/content/33/3/690.extract]]&gt;</url>
    <title>New consensus criteria for GDM, problem solved or pandora’s box?</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,GESTATIONAL DIABETES,DIAGNOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;FONT face="arial, helvetica"&gt;&lt;FONT face="arial, helvetica"&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; This editorial discusses another article in this issue of Diabetes Care - International Association of Diabetes and Pregnancy Study Groups Consensus Panel (IADPSG), &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=372584" target="_blank"&gt;International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy&lt;/A&gt;, Diabetes Care. 2010;33(3):676-82.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Moses Robert G. New consensus criteria for GDM, problem solved or pandora’s box? Diabetes Care 2010;33(3):690-1.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in March 2010&lt;BR&gt;&lt;BR&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Access to the full-text of this article online requires subscription to the&amp;nbsp;journal. NHS staff please&amp;nbsp;contact&amp;nbsp; &lt;A href="http://www.hlisd.org/" target="_blank"&gt;your local NHS library&lt;/A&gt;&amp;nbsp;for further assistance.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386329</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/project/1743.asp]]&gt;</url>
    <title>Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation</title>
    <publicationDate>2010-08-12T00:00:00</publicationDate>
    <publisher>NIHR Health Technology Assessment programme</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,MEDICATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>HTA Technology Assessment Report</description>
    <body>&lt;![CDATA[ &lt;P&gt;Although economic analyses are subject to considerable uncertainty, the findings&amp;nbsp;of this&amp;nbsp;study support recent NICE clinical guidelines that NPH should be the preferred first line choice of insulin in type 2 diabetes. This finding is driven by much the higher costs and limited clinical advantage of the comparators long acting insulin analogues glargine and detemir. Exenatide appeared clinically and cost effective as an alternative to starting insulin immediately on failure of oral therapy for glucose lowering. Sitagliptin and vildagliptin had similar clinical effectiveness as glitazone but this was achieved at lower cost and side effects.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technology&amp;nbsp;Assessment 2010;14(36). &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346709</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/publications_and_resources/reports_and_guidance/]]&gt;</url>
    <title>NHS Diabetes - reports and guidance</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DIABETIC FOOT,KETOACIDOSIS,HYPOGLYCAEMIA,DELIVERY OF CARE,CHRONIC COMPLICATIONS,ACUTE COMPLICATIONS,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,PREVENTION,USER INVOLVEMENT,MEDICATION,MEDICATION,MONITORING / SELF-MONITORING,PEOPLE FROM ETHNIC MINORITIES,DATA GATHERING AND AUDIT AND QOF,PSYCHOSOCIAL CARE,PSYCHOSOCIAL CARE,STATISTICS,PEOPLE FROM ETHNIC MINORITIES,COMMISSIONING,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the NHS Diabetes website lists important reports and guides published by NHS Diabetes and other organisations. &lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;NHS Diabetes is part of NHS Diabetes and Kidney Care, a national team that works with frontline staff in both the diabetes and kidney communities to implement the respective National Service Frameworks. &lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to this webpage is available to the general public.&amp;nbsp; Access to the current&amp;nbsp;reports in Portable Document File / PDF format requires &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&amp;nbsp; Requests for&amp;nbsp;reports or guides&amp;nbsp;which have been archived can be made to &lt;A href="mailto:enquiries@diabetes.nhs.uk" target="_blank"&gt;enquiries@diabetes.nhs.uk&lt;/A&gt;. &amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346708</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/publications_and_resources/factsheets_and_case_studies/factsheets/]]&gt;</url>
    <title>NHS Diabetes factsheets</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,OTHER TYPES OF DIABETES,DIABETES AND PREGNANCY,RETINOPATHY,DIABETIC FOOT,PSYCHOLOGICAL PROBLEMS,DELIVERY OF CARE,CHRONIC COMPLICATIONS,ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT,CAUSES,DATA GATHERING AND AUDIT AND QOF,EYE DISEASES,CHILDREN AND YOUNG PEOPLE,STATISTICS,COMMISSIONING,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the NHS Diabetes website lists all the factsheets published by NHS Diabetes. These factsheets bring together the most important facts and information on a selected subject. They can also take the form of a summary of key points from a report, helping to condense the most relevant information.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;NHS Diabetes is part of NHS Diabetes and Kidney Care, a national team that works with frontline staff in both the diabetes and kidney communities to implement the respective National Service Frameworks. &lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to this webpage is available to the general public.&amp;nbsp; Access to the current factsheets in Portable Document File / PDF format requires &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&amp;nbsp; Requests for factsheets which have been archived can be made to &lt;A href="mailto:enquiries@diabetes.nhs.uk" target="_blank"&gt;enquiries@diabetes.nhs.uk&lt;/A&gt;. &amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318301</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/CARDIOVASCULAR/SearchResults.aspx?catID=700]]&gt;</url>
    <title>NHS Evidence - cardiovascular</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,HYPERTENSION,DYSLIPIDAEMIA,CARDIOVASCULAR,CHRONIC COMPLICATIONS,PREVENTION,CAUSES,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of&amp;nbsp; NHS Evidence - cardiovascular includes information on cardiovascular diseases and diabetes.&lt;/P&gt;
&lt;P&gt;NHS Evidence - cardiovascular is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects of cardiovascular diseases including both clinical and organisational issues. The website includes a 'What's New' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318424</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/CHILDHEALTH/SearchResults.aspx?catID=1560]]&gt;</url>
    <title>NHS Evidence - child health</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CHILDREN AND YOUNG PEOPLE,CHILDREN AND YOUNG PEOPLE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of NHS Evidence - child health includes information on child health and diabetes.&lt;/P&gt;
&lt;P&gt;NHS Evidence - child health&amp;nbsp;is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects of child health&amp;nbsp;including both clinical and organisational issues. The website includes a 'What's New' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;
&lt;P&gt;This specialist collection also covers &lt;A href="http://www.library.nhs.uk/CHILDHEALTH/SearchResults.aspx?tabID=288&amp;amp;catID=1563" target="_blank"&gt;Hypoglycaemia in children&lt;/A&gt;, &lt;A href="http://www.library.nhs.uk/CHILDHEALTH/SearchResults.aspx?tabID=288&amp;amp;catID=1565" target="_blank"&gt;Obesity in children&lt;/A&gt;, &lt;A href="http://www.library.nhs.uk/CHILDHEALTH/SearchResults.aspx?tabID=288&amp;amp;catID=14644" target="_blank"&gt;Neonatal endocrinology&lt;/A&gt;, &lt;A href="http://www.library.nhs.uk/CHILDHEALTH/SearchResults.aspx?tabID=289&amp;amp;catID=1077" target="_blank"&gt;Nutrition/Diet for children&lt;/A&gt;, &lt;A href="http://www.library.nhs.uk/CHILDHEALTH/SearchResults.aspx?tabID=289&amp;amp;catID=1072" target="_blank"&gt;Metabolic disorders in children&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318433</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/COMMISSIONING/SearchResults.aspx?catID=13404]]&gt;</url>
    <title>NHS Evidence - commissioning</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DELIVERY OF CARE,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of NHS Evidence - commissioning includes information on commissioning and edocrine, nutritional and metabolic problems.&lt;/P&gt;
&lt;P&gt;NHS Evidence -&amp;nbsp;commissioning is a unique resource aimed at supporting&amp;nbsp;all those involved in commissioning for health and wellbeing&amp;nbsp;by providing high quality information, such as examples of good practice, policy and data to support high quality commissioning. The website includes a 'What's New' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318434</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/cam/SearchResults.aspx?catID=11117]]&gt;</url>
    <title>NHS Evidence - complementary and alternative medicine</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MEDICATION,MEDICATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of NHS Evidence - complementary and alternative medicine includes information on complementary and alternative medicine and&amp;nbsp;diabetes.&lt;/P&gt;
&lt;P&gt;NHS Evidence -&amp;nbsp;complementary and alternative medicine&amp;nbsp;is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects of&amp;nbsp;complementary and alternative medicine&amp;nbsp;including both clinical and organisational issues. The website includes a 'What's New' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318435</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/EMERGENCY/SearchResults.aspx?catID=1853]]&gt;</url>
    <title>NHS Evidence - emergency and urgent care</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ HYPEROSMOLAR HYPERGLYCAEMIC STATES,HYPOGLYCAEMIA,KETOACIDOSIS,ACUTE COMPLICATIONS,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of NHS Evidence - emergency and urgent care includes information on diabetes and emergency and urgent&amp;nbsp;care.&lt;/P&gt;
&lt;P&gt;NHS Evidence -&amp;nbsp;emergency and urgent care&amp;nbsp;is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects of&amp;nbsp;emergency and urgent care&amp;nbsp;including both clinical and organisational issues. The website includes a 'What's New' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318426</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/Ethnicity/SearchResults.aspx?catID=11552&amp;tabID=289&amp;]]&gt;</url>
    <title>NHS Evidence - ethnicity and health</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ PEOPLE FROM ETHNIC MINORITIES,PEOPLE FROM ETHNIC MINORITIES,TYPE 2,TYPE 1,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of NHS Evidence - ethnicity and health includes information on ethnicity and diabetes.&lt;/P&gt;
&lt;P&gt;NHS Evidence -&amp;nbsp;ethnicity and health&amp;nbsp;is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects of&amp;nbsp;ethnicity and health&amp;nbsp;including both clinical and organisational issues. The website includes a 'What's New' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318302</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/EYES/SearchResults.aspx?catID=10543]]&gt;</url>
    <title>NHS Evidence - eyes and vision</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ EYE DISEASES,OTHER,CHRONIC COMPLICATIONS,RETINOPATHY,DIAGNOSIS,CONDITION MANAGEMENT,CAUSES,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of NHS Evidence - eyes and vision includes information on diabetic retinopathy.&lt;/P&gt;
&lt;P&gt;NHS Evidence -&amp;nbsp;eyes and vision&amp;nbsp;is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects of&amp;nbsp;eyes and vision,&amp;nbsp;including both clinical and organisational issues. The website includes a 'What's New' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>319363</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/Gastroliver/SearchResults.aspx?catID=10587]]&gt;</url>
    <title>NHS Evidence - gastroenterology and liver diseases</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROPARESIS,DIABETES,CHRONIC COMPLICATIONS,AUTONOMIC NEUROPATHY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of&amp;nbsp; NHS Evidence -&amp;nbsp;gastroenterology and liver diseases&amp;nbsp;includes information on gastroparesis.&lt;/P&gt;
&lt;P&gt;NHS Evidence -&amp;nbsp;gastroenterology and liver diseases&amp;nbsp;is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects&amp;nbsp;of gastroenterology and liver&amp;nbsp;diseases including both clinical and organisational issues. The website includes a 'What's New' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>319370</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/geneticconditions/SearchResults.aspx?catID=8465]]&gt;</url>
    <title>NHS Evidence - genetic conditions</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CAUSES,OTHER TYPES OF DIABETES,CAUSES,DIABETES,TYPE 2,TYPE 1]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of&amp;nbsp; NHS Evidence -&amp;nbsp;genetic conditions&amp;nbsp;includes information on diabetes mellitus.&lt;/P&gt;
&lt;P&gt;NHS Evidence -&amp;nbsp;genetic conditions&amp;nbsp;is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects of&amp;nbsp;genetic conditions&amp;nbsp;including both clinical and organisational issues. The website includes a 'What's New' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318440</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/healthManagement/]]&gt;</url>
    <title>NHS Evidence - health management</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ SHARING PRACTICE,COMMISSIONING,DIABETES,KEY POLICIES / NSF,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The aim of the health management specialist collection is to provide timely and efficient access to high quality information resources for health managers, clinical managers and leaders, and those involved in commissioning health services. The website includes a 'Hot Topics' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322981</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/improvement/]]&gt;</url>
    <title>NHS Evidence - innovation and improvement</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ COMMISSIONING,SHARING PRACTICE,DATA GATHERING AND AUDIT AND QOF,USER INVOLVEMENT,DIABETES,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT,DELIVERY OF CARE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The aim of NHS Evidence - innovation and improvement is to provide timely and efficient access to high quality information resources for those involved in the innovation and improvement of health and social care services. Content will cover both theory and practice and will include best available evidence, tools and techniques, measurement, case-studies and policy on all aspects of innovation and improvement.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320058</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/KIDNEY/SearchResults.aspx?catID=12081]]&gt;</url>
    <title>NHS Evidence - kidney diseases and male urogenital disorders: Diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,NEPHROPATHY,CHRONIC COMPLICATIONS,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of NHS Evidence - kidney diseases and male urogenital disorders covers diabetes as a predisposing factor to chronic kidney disease.&lt;/P&gt;
&lt;P&gt;The kidney diseases and male urogenital disorders specialist collection is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in these areas&lt;/P&gt;
&lt;P&gt;The focus of the specialist collection is on kidney diseases affecting adults and children in the UK, disorders affecting the male urogenital system, and male sexual health. There is also information on renal tract and male urogenital cancers. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320057</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/KIDNEY/SearchResults.aspx?catID=12124]]&gt;</url>
    <title>NHS Evidence - kidney diseases and male urogenital disorders: Diabetic metabolic control</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CONDITION MANAGEMENT,CHRONIC COMPLICATIONS,NEPHROPATHY,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of&amp;nbsp;NHS Evidence - kidney diseases and male urogenital disorders covers Diabetic metabolic control as an intervention to manage chronic kidney disease.&lt;/P&gt;
&lt;P&gt;The kidney diseases and male urogenital disorders specialist collection is for busy health professionals, providing them with high quality information and keeping them up to date with the latest research and developments in these areas&lt;/P&gt;
&lt;P&gt;The focus of the specialist collection is on kidney diseases affecting adults and children in the UK, disorders affecting the male urogenital system, and male sexual health. There is also information on renal tract and male urogenital cancers. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>319560</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/learningdisabilities/]]&gt;</url>
    <title>NHS Evidence - learning disabilities</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DISABILITY AND DISCRIMINATION,DIABETES,LIVING WITH DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;NHS Evidence -&amp;nbsp;learning disabilities&amp;nbsp;is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects of&amp;nbsp;learning disabilities&amp;nbsp;including both clinical and organisational issues. The website includes a 'What's New' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318312</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/MENTALHEALTH/]]&gt;</url>
    <title>NHS Evidence - mental health</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ COGNITIVE FUNCTION,ANXIETY AND DEPRESSION,DIABETES,PSYCHOLOGICAL PROBLEMS,CHRONIC COMPLICATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;NHS Evidence -&amp;nbsp;mental health&amp;nbsp;is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects of mental health including both clinical and organisational issues. The website includes a 'What's New' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318317</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/neurological/SearchResults.aspx?tabID=289&amp;catID=12348]]&gt;</url>
    <title>NHS Evidence - neurological conditions</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CHRONIC COMPLICATIONS,DIABETIC FOOT,PAINFUL NEUROPATHIES,DIABETES,CAUSES,CONDITION MANAGEMENT,DIAGNOSIS,AUTONOMIC NEUROPATHY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of NHS Evidence includes information on endocrine and metabolic disorders.&lt;/P&gt;
&lt;P&gt;NHS Evidence -&amp;nbsp;neurological conditions&amp;nbsp;is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects of neurological conditions including both clinical and organisational issues. The website includes a 'What's New' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318444</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/ppi/]]&gt;</url>
    <title>NHS Evidence - patient and public involvement</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,USER INVOLVEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;NHS Evidence - patient and public involvement aims to support the implementation of patient, user, carer and public involvement in health care by providing access, to the best information which is freely available on the Web. The patient and public involvement specialist collection does not contain patient information on individual medical conditions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Please note&lt;/STRONG&gt; &lt;STRONG&gt;(May 2010):&amp;nbsp;&lt;/STRONG&gt;A decision has been made not to continue NHS Evidence - patient and public involvement as a separate collection but to incorporate relevant material into other specialist collections. Work is under way to migrate the majority of relevant content from NHS Evidence - patient and public involvement into NHS Evidence - commissioning, with some content also going into NHS Evidence - health management and NHS Evidence - innovation and improvement. As a result the information on this site will be maintained but will not be updated.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318448</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/SCREENING/SearchResults.aspx?tabID=289&amp;catID=5525&amp;]]&gt;</url>
    <title>NHS Evidence - screening - diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CAUSES,DIABETES,TYPE 2,TYPE 1,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of NHS Evidence - screeing includes information on diabetes and screening.&lt;/P&gt;
&lt;P&gt;NHS Evidence -&amp;nbsp;screening is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects of&amp;nbsp;screening. The website includes a 'What's New' section, links to&amp;nbsp;NHS Screening Programmes&amp;nbsp;and to other relevant organisations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318449</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/screening/SearchResults.aspx?catID=5526]]&gt;</url>
    <title>NHS Evidence - screening - diabetic retinopathy</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CAUSES,RETINOPATHY,CHRONIC COMPLICATIONS,DIABETES,EYE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of NHS Evidence - screening includes information on screening and diabetic retinopathy.&lt;/P&gt;
&lt;P&gt;NHS Evidence - screening is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects of screening. The website includes a 'What's New' section, links to NHS Screening Programmes and to other relevant organisation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318322</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/SKIN/SearchResults.aspx?tabID=288&amp;catID=8421]]&gt;</url>
    <title>NHS Evidence - skin disorders</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,SKIN PROBLEMS,CHRONIC COMPLICATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of NHS Evidence - skin disorders includes information on skin disorders and diabetes.&lt;/P&gt;
&lt;P&gt;NHS Evidence -&amp;nbsp;skin disorders&amp;nbsp;is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects of&amp;nbsp;skin disorders&amp;nbsp;including both clinical and organisational issues. The website includes a 'What's New' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318323</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/stroke/SearchResults.aspx?catID=13191]]&gt;</url>
    <title>NHS Evidence - stroke</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CHRONIC COMPLICATIONS,CARDIOVASCULAR,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of NHS Evidence - stroke includes information on stroke and diabetes.&lt;/P&gt;
&lt;P&gt;NHS Evidence -&amp;nbsp;stroke is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects of&amp;nbsp;stroke including both clinical and organisational issues. The website includes a 'What's New' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343711</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/TRAUMA_ORTHOPAEDICS/SearchResults.aspx?catID=11063]]&gt;</url>
    <title>NHS Evidence - trauma and orthopaedics : Diabetic foot</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CONDITION MANAGEMENT,DIAGNOSIS,PREVENTION,CHRONIC COMPLICATIONS,DIABETIC FOOT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of NHS Evidence - trauma and orthopaedics covers condition management and treatments for&amp;nbsp;Diabetic foot.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;NHS Evidence - Trauma and Orthopaedics exists primarily to support the work of NHS health professionals in the field of trauma and orthopaedics in the UK.&amp;nbsp; This electronic resource covers the management of orthopaedic trauma after the first 24 hours post injury. &lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318422</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/VASCULAR/SearchResults.aspx?tabID=289&amp;catID=13898&amp;]]&gt;</url>
    <title>NHS Evidence - vascular</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETIC FOOT,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,DIAGNOSIS,CAUSES,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of NHS Evidence - vascular includes information on diabetic foot disease.&lt;/P&gt;
&lt;P&gt;NHS Evidence - vascular is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects of&amp;nbsp;vascular diseases&amp;nbsp;including both clinical and organisational issues. The website includes a 'What's New' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318432</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/womenshealth/SearchResults.aspx?catID=6816&amp;tabID=289&amp;]]&gt;</url>
    <title>NHS Evidence - women's health</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CONDITION MANAGEMENT,GESTATIONAL DIABETES,CAUSES,DIABETES,CONDITION MANAGEMENT,DIABETES AND PREGNANCY,PRECONCEPTION CARE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of NHS Evidence - women's health includes information on pregnancy and diabetes.&lt;/P&gt;
&lt;P&gt;NHS Evidence -&amp;nbsp;women's health&amp;nbsp;is a unique resource aimed at supporting healthcare professionals by providing high quality information on all aspects of&amp;nbsp;women's health&amp;nbsp;including both clinical and organisational issues. The website includes a 'What's New' section, newsfeeds and links to other relevant organisations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323090</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/our_work_areas/nhs_health_check/]]&gt;</url>
    <title>NHS Health Check - Work Area - NHS Diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CAUSES,ORGANISATION OF CARE / CARE PLANNING,KEY POLICIES / NSF,CAUSES,DELIVERY OF CARE,CHRONIC COMPLICATIONS,TYPE 2,CARDIOVASCULAR,DIABETES,TYPE 1,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the NHS Diabetes website provides details of the work of the&amp;nbsp;NHS Health Check&amp;nbsp;Working Group. It also includes links to further information. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>266077</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/statistics-and-data-collections/audits-and-performance/the-quality-and-outcomes-framework]]&gt;</url>
    <title>NHS Information Centre - quality and outcomes framework (QOF)</title>
    <publicationDate></publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF,STATISTICS,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This page on the NHS Information Centre for Health and Social Care website provides&amp;nbsp;information&amp;nbsp;concerning the NHS quality and outcomes framework (QOF).&lt;/P&gt;
&lt;P&gt;The Quality and Outcomes Framework (QOF) is the annual reward and incentive programme detailing GP practice achievement results.&lt;/P&gt;
&lt;P&gt;QOF is a voluntary process for all surgeries in England and was introduced as part of the GP contract in 2004. &lt;/P&gt;
&lt;P&gt;QOF awards surgeries achievement points for: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;managing some of the most common chronic diseases e.g. asthma, diabetes 
&lt;LI&gt;how well the practice is organised 
&lt;LI&gt;how patients view their experience at the surgery 
&lt;LI&gt;the amount of extra services offered such as child health and maternity services. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298281</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=977]]&gt;</url>
    <title>NICE and Diabetes: a summary of relevant guidelines</title>
    <publicationDate>2009-11-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DIABETES AND PREGNANCY,DIABETIC FOOT,DELIVERY OF CARE,CHRONIC COMPLICATIONS,PATIENT EDUCATION AND EMPOWERMENT,DIAGNOSIS,CONDITION MANAGEMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,OTHER LIFE STYLE,MEDICATION,MONITORING / SELF-MONITORING,PRECONCEPTION CARE,NUTRITION AND FOOD,PHYSICAL ACTIVITY,CHILDREN AND YOUNG PEOPLE,PUBLIC HEALTH,OUTCOMES,MANAGEMENT &amp; INTERVENTIONS,ENDOCRINE DISORDERS,DIABETES,MANAGEMENT &amp; POLICY,FRAMES OF REFERENCE,GUIDELINES,MONTHLY ADDITIONS,2008-DECEMBER,GESTATIONAL DIABETES,CAUSES,DIAGNOSIS,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp;NHS Diabetes&amp;nbsp;has produced this summary, which brings together all Clinical Guidelines, Health Technology Appraisals and Interventional Procedures from NICE that involve diabetes care.&amp;nbsp; 
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; healthcare professionals&lt;BR&gt;&lt;FONT face=Frutiger-Light color=#231f20 size=3&gt;&lt;/P&gt;&lt;/FONT&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; First published in July 2006, updated in October 2008, and updated in November 2009 to incorporate the Type 2 guidance released in May 2009.&amp;nbsp;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>124080</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/cdlipids/resources/merec_extra_no21.pdf]]&gt;</url>
    <title>NICE appraises statins</title>
    <publicationDate></publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CARDIOVASCULAR,CHRONIC COMPLICATIONS,DIABETES,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of this MeReC Extra bulletin&amp;nbsp;summarises and discusses the &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=113928&amp;amp;tabID=288" target="_blank"&gt;(NICE) technology appraisal of statins&lt;/A&gt; for the prevention of cardiovascular events. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Merec Extra Issue no&amp;nbsp;21. Published March 2006. 
&lt;P&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306917</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19125753?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>NICE guidance on continuous subcutaneous insulin infusion 2008: review of the technology appraisal guidance</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,CONDITION MANAGEMENT,MEDICATION,INSULIN PUMPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; This article reviews the new (July 2008) NICE technology appraisal guidance on continuous subcutaneous insulin infusion.&amp;nbsp; There are 2 major policy changes in the new NICE technology appraisal. The first is the introduction of a new category of patients with type 1 diabetes who may be suitable for a trial of CSII: those with persistently elevated HBA1c at or above 8.5% during best attempts to control their diabetes with multiple dose injections (MDI) The second is the recommendation that children no longer need to have “failed on MDI” before undertaking a trial of CSII.&amp;nbsp; The authors of this review conclude that the additional clinical indication of an elevated HbA1c on MDI and the new recommendations for children should ensure that many more people with Type 1 diabetes who stand to benefit from CSII are offered a trial of this therapy. The authors state that the challenge will now be to implement the Guidance and to reduce the variability in access to CSII that has occurred throughout the UK in recent years. The authors suggest that commissioners of diabetes services should read the guidance in conjunction with the NICE Costing Template for CSII and the recent Department of Health and Diabetes UK Insulin Pump Working Group Report, which offers valuable advice on organizing insulin pump services.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Pickup JC, Hammond P NICE Guidance on continuous insulin infusion (CSII) 2008: review of the technology appraisal guidance (editorial) Diabetic Medicine 26:1-4&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history:&lt;/STRONG&gt; Published January 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; The full-text of this article online requires subscription to the journal. NHS staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library for further assistance.&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296763</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19183306]]&gt;</url>
    <title>NICE guidance on diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period. NICE clinical guideline 63. London, March 2008</title>
    <publicationDate>2008-10-28T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETES AND PREGNANCY,CONDITION MANAGEMENT,PRECONCEPTION CARE,GESTATIONAL DIABETES,CAUSES,DIAGNOSIS,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;&lt;?xml:namespace prefix = o /&gt;&lt;o:p&gt;&lt;A href="http://www.hlisd.org/" target="_blank"&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Full Reference&lt;/STRONG&gt;: J. D. Walker (2008) NICE guidance on diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period. NICE clinical guideline 63. London, March 2008. &lt;EM&gt;Diabetic Medicine&lt;/EM&gt;, 25 (9), 1025-1027.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Access to the full text online requires subscription to the journal.&amp;nbsp; NHS staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt; for further assistance.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/o:p&gt;&lt;/SPAN&gt;]]&gt;</body>
  </document>
  <document>
    <id>182399</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=411]]&gt;</url>
    <title>Non medical prescribing in diabetes part one: early findings</title>
    <publicationDate>2006-05-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DELIVERY OF CARE,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MEDICATION,MEDICATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This summary reports on work commissioned by Skills for Health on behalf of the Diabetes Workforce Executive Group. The scope of the project was to describe the current legislation on non medical prescribing as it relates to nurses, allied health professionals, community pharmacists and other healthcare professionals, identify and map current practice around non medical prescribing in diabetes and consult on the issues and problems associated with this, and on the basis of this work, identify recommendations for the Diabetes Workforce Executive Group.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published May 2006.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328549</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/prescribers/sharing_practice/long-term.htm]]&gt;</url>
    <title>Non-medical prescribing - sharing practice examples - long term conditions</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,SHARING PRACTICE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This page of the National Prescribing Centre website contains examples of non-medical prescribing implementation for long-term conditions.&amp;nbsp; The National Prescribing Centre have created this database of examples of good practice for sharing with the wider NHS to aid learning and to support development of non-medical prescribing policies and clinical governance frameworks.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314605</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19388959?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Not all roads lead to Rome - a review of quality of life measurements in adults with diabetes</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; The authors state that if QoL is valued then it must measured by an appropriate instrument.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A systematic literature search was conducted to identify the ten measures most frequently used to assess QoL in diabetes research (including clinical trials) from 1995 to March 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; 6085 abstracts were identified and the 10 most used measures identified. Of the 10, only 3 actually measure quality of life (QoL), the WHOQOL (World Health Organization Quality of Life), DQOL (Diabetes Quality of Life) and ADDQoL (Audit of Diabetes-Dependent Quality of Life). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Speight J, Reaney M D, Barnard K D. Not all roads lead to Rome - a review of quality of life measurement in adults with diabetes. Diabetic Medicine 26: 315-327 (2009)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published 24 January 2009&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full text of this article requires online subscription to the journal. NHS staff: please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS Library&lt;/A&gt; for further assistance.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301340</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,177/Itemid,61/]]&gt;</url>
    <title>Nutrition for the child and adolescent with diabetes (teaching letter no. 34)</title>
    <publicationDate>2006-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,NUTRITION AND FOOD,CHILDREN AND YOUNG PEOPLE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aim&lt;/STRONG&gt;: "The aim of this Teaching Letter is to provide basic recommendations on nutritional education that will make “diet” as acceptable as possible. It intends to emphasize that nutritional education can lead to a healthier way of eating with long-term benefits for the child with diabetes, his/her family, and the general population at large. While encouraging the family to adopt healthy eating habits, particularly if changes are advised, emphasis should be placed on the need to preserve the pleasure of eating and the social function of meals. In this connection, it is usually necessary to find compromises between set dietary guidelines and the acceptability of the food plan by the child and his/her family.".&lt;/P&gt;
&lt;P&gt;It includes the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Nutritional Needs 
&lt;LI&gt;Specific Problems 
&lt;LI&gt;Educational Aspects&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This is one of a series of &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;teaching letters&lt;/A&gt; for doctors and other health care professionals involved in the daily care of patients with diabetes. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>126175</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/Obesity/fs/en]]&gt;</url>
    <title>Obesity</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,OBESITY,CONDITION MANAGEMENT,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the Department of Health website provides information to support the government priority of tackling obesity. The section includes links to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Information and statistics on obesity 
&lt;LI&gt;The Healthy Weight, Healthy Lives government strategy 
&lt;LI&gt;The Change4Life social marketing campaign 
&lt;LI&gt;Useful links&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>126140</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4134408&amp;chk=Sq/wNd]]&gt;</url>
    <title>Obesity care pathway and your weight, your health</title>
    <publicationDate>2006-05-04T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,OBESITY,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the Department of Health website comprises a comprehensive package of materials for health professionals as well as information to be given to patients. It includes Obesity Care Pathways for adults and children and a supporting booklet with detailed information for health professionals. In addition, there are tools to help GPs raise the rather sensitive issue of weight opportunistically with both adults and children.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>333020</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.obesitylearningcentre-nhf.org.uk/]]&gt;</url>
    <title>Obesity Learning Centre (OLC)</title>
    <publicationDate></publicationDate>
    <publisher>Obesity Learning Centre (OLC)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,OBESITY,PUBLIC HEALTH,DETERMINANTS,BIOLOGICAL COMPOSITION,EDUCATION,OBESITY,EDUCATION,POPULATIONS,ORGANISATIONS,NATIONAL ORGANISATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This portal is designed as a support tool to share best practice and to provide information, training and data&amp;nbsp;on obesity. This website has been developed to support those people who work, either directly or indirectly, on promoting a healthy weight and tackling obesity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328290</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/Theatres/SearchResults.aspx?catID=11342]]&gt;</url>
    <title>Obesity Surgery from NHS Evidence - surgery, anaesthesia, perioperative and critical care</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence - surgery, anaesthesia, perioperative and critical care</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,OBESITY,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;NHS Evidence - surgery, anaesthesia, perioperative and critical care&lt;/STRONG&gt; provides efficient access to current, quality assured, evidence based resources to support the team providing high quality perioperative and critical care.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This section of the specialist collection contains guidelines, evidence, reference materials and patient information on Obesity Surgery.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323086</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/our_work_areas/older_people/]]&gt;</url>
    <title>Older People - Work Area - NHS Diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DELIVERY OF CARE,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,ELDERLY PEOPLE,ELDERLY PEOPLE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the NHS Diabetes website provides details of the work of the Care of Older People with Diabetes Working Group. It also includes links to further information.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60138</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,149/Itemid,61/]]&gt;</url>
    <title>Oral agents (teaching letter no.1)</title>
    <publicationDate>1996-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,MEDICATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the education of patients with type 2 diabetes on the subject of oral agents. It covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Evaluating patients and what they know about diabetes 
&lt;LI&gt;What information should be given initially? 
&lt;LI&gt;Future control measures 
&lt;LI&gt;Changing therapy 
&lt;LI&gt;Points to remember when teaching 
&lt;LI&gt;Conclusion&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 1996&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286967</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=75]]&gt;</url>
    <title>Partners in Care - A guide to implementing a care planning approach to diabetes care</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ COMMISSIONING,SHARING PRACTICE,USER INVOLVEMENT,DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,KEY POLICIES / NSF,PATIENT EDUCATION AND EMPOWERMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Diabetes care is a team effort. This guide is appropriate for anyone involved in diabetes services -&amp;nbsp; users,&amp;nbsp;commissioners,&amp;nbsp;network managers, clinicians,&amp;nbsp;health care assistants or technicians.&lt;/P&gt;
&lt;P&gt;It includes:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;What is care planning? 
&lt;LI&gt;What needs to be in place to make a care planning approach happen? 
&lt;LI&gt;What does a care planning consultation look like? 
&lt;LI&gt;Further reading, resources and contacts 
&lt;LI&gt;Appendices :&amp;nbsp; Results sharing sheet, Consequent care plan, Action planning proforma&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication History&lt;/STRONG&gt;:&amp;nbsp; February 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to general public. Portable Document File/PDF&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>113001</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=401]]&gt;</url>
    <title>Passionate about workforce</title>
    <publicationDate>2005-11-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Skills for Health / National Diabetes Support Team report highlights issues around workforce in diabetes care. The report contains information about what the Diabetes Workforce Executive has been doing and details about phase two of the project.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published 2005.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>156677</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Documents/Reports/Patient_choice.pdf]]&gt;</url>
    <title>Patient choice: what does ‘choice’ mean to people with diabetes?</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,PATIENT AND PUBLIC INVOLVEMENT,USER INVOLVEMENT,PPI IN PRACTICE,INDIVIDUAL INVOLVEMENT,PATIENT CHOICE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;Diabetes UK report looks at what choice means to people with diabetes and what information these people need to effectively make their choices.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published&amp;nbsp;May 2005. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring Adobe Acrobat Reader.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301335</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,176/Itemid,61/]]&gt;</url>
    <title>Patient education issues and diabetes in pregnancy (teaching letter no. 33)</title>
    <publicationDate>2006-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETES AND PREGNANCY,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,PRECONCEPTION CARE,GESTATIONAL DIABETES,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aim&lt;/STRONG&gt;: "The aim of this Teaching Letter is to describe the development and implementation of quality schemes into daily education plans. After reading it, health care providers (HCPs) should be able to start an individual pathway to implement a quality system in educational practice.&amp;nbsp; This Teaching Letter (TL) is aimed at health care professionals (HCPs) looking after women with diabetes in pregnancy. It concentrates on education methods and teaching/learning opportunities. It is not a guideline or a protocol for diabetes care in pregnancy (which exist elsewhere), although reference is made to good practice. It also discusses lessons for education in type 1 diabetes mellitus (DM), type 2 DM, and states of impaired glucose tolerance (IGT) and insulin-requiring gestational diabetes mellitus (GDM).".&lt;/P&gt;
&lt;P&gt;It includes the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Diabetes education in pregnancy: for which target groups? 
&lt;LI&gt;What are the aims of diabetes education in pregnancy? 
&lt;LI&gt;What are the teaching and learning opportunities? 
&lt;LI&gt;Education methods in diabetes in pregnancy 
&lt;LI&gt;Good practice in diabetes in pregnancy&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This is one of a series of &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;teaching letters&lt;/A&gt; for doctors and other health care professionals involved in the daily care of patients with diabetes. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60143</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/index2.php?option=com_docman&amp;task=doc_view&amp;gid=179&amp;Itemid=61]]&gt;</url>
    <title>Patient education: a lifelong process necessary for quality of treatment (teaching letter no.7)</title>
    <publicationDate>1997-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns patient education as a lifelong process and covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Requirements for a successful continuing education program 
&lt;UL&gt;
&lt;LI&gt;Contact: create a new dynamic process with your patient 
&lt;LI&gt;Assessment of educational needs 
&lt;LI&gt;Justify the reasons for the educational program 
&lt;LI&gt;Set common educational objectives with patients 
&lt;LI&gt;Actively involve your patients 
&lt;LI&gt;Evaluate 
&lt;LI&gt;Continuing education is mandatory for staff who are teaching patients&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Practical organization of an educational program centered on therapy for patients 
&lt;UL&gt;
&lt;LI&gt;Contact with patients 
&lt;LI&gt;Assessment - content 
&lt;LI&gt;Therapeutic education of patients: a timely process 
&lt;LI&gt;Who should teach patients?&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Conclusions&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 1997&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>59999</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/booth/mgmt/patcent.html]]&gt;</url>
    <title>Patient-centred diabetes care</title>
    <publicationDate>2007-04-01T00:00:00</publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,PATIENT AND PUBLIC INVOLVEMENT,USER INVOLVEMENT,PPI IN PRACTICE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This section of the Bandolier Knowledge Library&amp;nbsp;describes and reviews a 1998 study concerned with patient-centred care of diabetes in primary care.]]&gt;</body>
  </document>
  <document>
    <id>317005</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhsbsa.nhs.uk/PrescriptionServices/Documents/PPDPCTReports/pctreport_20071.pdf]]&gt;</url>
    <title>PCT Prescribing Report - Type 2 Diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Prescribing Services</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CONDITION MANAGEMENT,DIABETES,TYPE 2,MEDICATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Primary Care Trusts (PCT) prescribing reports are provided electronically to all PCTs on a quarterly basis. Each discussion section examines an area of prescribing which has been identified as a current area of concern or driver of growth for primary care. This report, published in May 2009, covers prescribing for Type 2 diabetes.]]&gt;</body>
  </document>
  <document>
    <id>156150</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1513435/]]&gt;</url>
    <title>Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales and Northern Ireland: population based study</title>
    <publicationDate>2006-07-22T00:00:00</publicationDate>
    <publisher>British Medical Journal</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETES AND PREGNANCY,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Perinatal mortality and prevalence of congenital anomalies are high in the babies of women with type 1 or type 2 diabetes. The rates do not seem to differ between the two types of diabetes.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; National population based pregnancy cohort. The setting was&amp;nbsp;231 maternity units in England, Wales, and Northern Ireland. The participants were 2359 pregnancies to women with type 1 or type 2 diabetes who delivered between 1 March 2002 and 28 February 2003. The main outcome measures were: stillbirth rates; perinatal and neonatal mortality; prevalence of congenital anomalies.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Results: &lt;/STRONG&gt;Of 2359 women with diabetes, 652 had type 2 diabetes and 1707 had type 1 diabetes. Women with type 2 diabetes were more likely to come from a Black, Asian, or other ethnic minority group (type 2, 48.8%; type 1, 9.1%) and from a deprived area (type 2, 46.3% in most deprived fifth; type 1, 22.8%). Perinatal mortality in babies of women with diabetes was 31.8/1000 births. Perinatal mortality was comparable in babies of women with type 1 (31.7/1000 births) and type 2 diabetes (32.3/1000) and was nearly four times higher than that in the general maternity population. 141 major congenital anomalies were confirmed in 109 offspring. The prevalence of major congenital anomaly was 46/1000 births in women with diabetes (48/1000 births for type 1 diabetes; 43/1000 for type 2 diabetes), more than double that expected. This increase was driven by anomalies of the nervous system, notably neural tube defects (4.2-fold), and congenital heart disease (3.4-fold). Anomalies in 71/109 (65%) offspring were diagnosed antenatally. Congenital heart disease was diagnosed antenatally in 23/42 (54.8%) offspring; anomalies other than congenital heart disease were diagnosed antenatally in 48/67 (71.6%) offspring.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Macintosh MCM, Fleming KM, Bailey JA, et al. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales and Northern Ireland: population based study. BMJ 2006;333:177-180.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2006.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.]]&gt;</body>
  </document>
  <document>
    <id>105620</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band135/b135-7.html]]&gt;</url>
    <title>Pharmacist case management of type 2 diabetes</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier&amp;nbsp;article describes and reviews a 2005 randomised trial concerning&amp;nbsp;input from a clinical pharmacist&amp;nbsp;into the care of&amp;nbsp;patients with poorly controlled type 2 diabetes. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Review published&amp;nbsp;May 2005.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60166</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,170/Itemid,61/]]&gt;</url>
    <title>Physical Activity and Diabetes (teaching letter no.27)</title>
    <publicationDate>2003-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ PHYSICAL ACTIVITY,PHYSICAL ACTIVITY,OUTCOMES,DIABETES,ENDOCRINE DISORDERS,CHILDREN,ADULTS,YOUNG PEOPLE,POPULATION BASED &amp; PREVENTATIVE SERVICES,OLDER PEOPLE,CONDITION MANAGEMENT,CONDITION MANAGEMENT,DIABETES,TYPE 1,TYPE 2,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,SOCIAL DETERMINANTS,LIFESTYLE,PHYSICAL ACTIVITY,INDIVIDUAL BEHAVIOUR,MANAGEMENT &amp; POLICY,SERVICES,INFORMATION,AGE GROUPS,GROUPS,POPULATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns physical activity and diabetes. Its aim is to outline the steps required to help integrate physical activity into the everyday life of the person with diabetes.&amp;nbsp;It covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Motivation 
&lt;LI&gt;Medical screening 
&lt;UL&gt;
&lt;LI&gt;The cardiovascular system 
&lt;LI&gt;The eyes 
&lt;LI&gt;The peripheral nervous system and feet&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Exercise prescription 
&lt;UL&gt;
&lt;LI&gt;Type 2 diabetes 
&lt;LI&gt;Type 1 diabetes 
&lt;LI&gt;Special populations&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Monitoring and maintenance 
&lt;UL&gt;
&lt;LI&gt;Type 2 diabetes 
&lt;LI&gt;Type 1 diabetes&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Recommended reading&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>259452</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/cgi/content/full/30/3/744]]&gt;</url>
    <title>Physical activity of moderate intensity and risk of type 2 diabetes: a systematic review</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ OUTCOMES,DIABETES,ENDOCRINE DISORDERS,TYPE 2,DIABETES,PREVENTION,PUBLIC HEALTH,DETERMINANTS,LIFESTYLE,SOCIAL DETERMINANTS,INDIVIDUAL BEHAVIOUR,PHYSICAL ACTIVITY,IMPACT ASSESSMENT,ANALYSIS,METHODS,ANALYSIS &amp; RESEARCH]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;BR&gt;&lt;/STRONG&gt;Jeon CY, Locken RP, Hu FB et al. Physical activity of moderate intensity and risk of type 2 diabetes: a systematic review. Diabetes Care. March 2007; 30;3 744-752 &lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;Accessing the full text:&lt;BR&gt;&lt;/STRONG&gt;Available to the general public.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>149099</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/cgi/content/full/29/6/1433]]&gt;</url>
    <title>Physical activity/exercise and type 2 diabetes</title>
    <publicationDate>2006-06-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ PHYSICAL ACTIVITY,OUTCOMES,DIABETES,ENDOCRINE DISORDERS,CONDITION MANAGEMENT,PREVENTION,DIABETES,TYPE 2,DETERMINANTS,PUBLIC HEALTH,PHYSICAL ACTIVITY,INDIVIDUAL BEHAVIOUR,ANALYSIS,METHODS,IMPACT ASSESSMENT,ANALYSIS &amp; RESEARCH]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A review&amp;nbsp;on physical&amp;nbsp;activity/exercise and type 2 diabetes; summarising recent advances (up to publication of review in 2006)&amp;nbsp;and the recommendations that follow from these. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Full reference:&lt;BR&gt;&lt;/STRONG&gt;Sigal RJ, Kenny GP, Wasserman DH et al. Physical activity/exercise and type 2 diabetes :&amp;nbsp;A consensus statement from the&amp;nbsp;American Diabetes Association. Diabetes Care. 2006;29(6):1433-1438.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessing the full&lt;/STRONG&gt; &lt;STRONG&gt;text:&lt;BR&gt;&lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>276648</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://jama.ama-assn.org/cgi/content/full/298/10/1180]]&gt;</url>
    <title>Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes : a meta-analysis of randomized trials.</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>Journal of the American Medical Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CARDIOVASCULAR,CHRONIC COMPLICATIONS,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; Pioglitazone is associated with a significantly lower risk of death, myocardial infarction, or stroke among a diverse population of patients with diabetes. Serious heart failure is increased by pioglitazone, although without an associated increase in mortality. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Method&lt;/STRONG&gt;: A database containing individual patient-level time-to-event data collected during pioglitazone clinical trials was transferred from the drug's manufacturer for independent analysis. Trials were included if they were randomized, double-blinded, and controlled with placebo or active comparator. The primary outcome was a composite of death, myocardial infarction, or stroke. Secondary outcome measures included the incidence of serious heart failure. A fixed-effects approach was used to combine the estimates across the duration strata and statistical heterogeneity across all the trials was tested with the I2 statistic. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: A total of 19 trials enrolling 16 390 patients were analyzed. Study drug treatment duration ranged from 4 months to 3.5 years. Death, myocardial infarction, or stroke occurred in 375 of 8554 patients (4.4%) receiving pioglitazone and 450 of 7836 patients (5.7%) receiving control therapy (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.72-0.94; P = .005). Progressive separation of time-to-event curves became apparent after approximately 1 year of therapy. Individual components of the primary end point were all reduced by a similar magnitude with pioglitazone treatment, with HRs ranging from 0.80 to 0.92. Serious heart failure was reported in 200 (2.3%) of the pioglitazone-treated patients and 139 (1.8%) of the control patients (HR, 1.41; 95% CI, 1.14-1.76; P = .002). The magnitude and direction of the favorable effect of pioglitazone on ischemic events and unfavorable effect on heart failure was homogeneous across trials of different durations, for different comparators, and for patients with or without established vascular disease. There was no evidence of heterogeneity across the trials for either end point (I2 = 0%; P = .87 for the composite end point and I2 = 0%; P = .97 for heart failure). &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Full reference: &lt;/STRONG&gt;Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007 Sep 12;298(10):1180-8.&amp;nbsp; Comment in:&amp;nbsp;&amp;nbsp;JAMA. 2007 Sep 12;298(10):1216-8.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Published in August 2007.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>122388</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/About_us/Our_Views/Position_statements/Retinal_screening/]]&gt;</url>
    <title>Position statement : retinal screening</title>
    <publicationDate>2005-08-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,CHRONIC COMPLICATIONS,CAUSES,EYE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;Diabetes UK&amp;nbsp;document&amp;nbsp;provides: details of&amp;nbsp;Diabetes UK's position on&amp;nbsp;retinal screening; information about UK standards and targets; and a checklist for retinal screening programmes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>156755</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/About_us/Our_Views/Position_statements/Fish_and_fish_oils/]]&gt;</url>
    <title>Position statement: fish and fish oils</title>
    <publicationDate></publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CONDITION MANAGEMENT,CONDITION MANAGEMENT,NUTRITION AND FOOD,NUTRITION AND FOOD,PUBLIC HEALTH,DETERMINANTS,OUTCOMES,FOOD &amp; NUTRITION,DIETARY SUPPLEMENTS,MANAGEMENT &amp; INTERVENTIONS,ENDOCRINE DISORDERS,DIABETES,MANAGEMENT &amp; POLICY,FRAMES OF REFERENCE,GUIDELINES,MONTHLY ADDITIONS,2008-JULY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This position statement gives Diabetes UK's recommendations on the use of fish and fish oils in diet.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>59849</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/About_us/Our_Views/Position_statements/Involving_people_-_with_diabetes_in_health_care_planning_and_service_development/]]&gt;</url>
    <title>Position statement: involving people with diabetes in healthcare planning and service development</title>
    <publicationDate>2006-04-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT,PATIENT AND PUBLIC INVOLVEMENT,USER INVOLVEMENT,PPI IN PRACTICE,TECHNIQUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This position statement gives Diabetes UK's recommendations on involving people with diabetes in local planning and decision making.&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>59890</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/About_us/Our_Views/Position_statements/Islet_cell_transplantation_research_in_the_UK_/]]&gt;</url>
    <title>Position statement: islet cell transplantation research in the UK</title>
    <publicationDate>2001-02-15T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,NEW DEVELOPMENTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;document&amp;nbsp;outlines Diabetes UK's&amp;nbsp;position on Islet cell transplantation research in the UK.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published Feb 2001.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>59891</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/About_us/Our_Views/Position_statements/Patient_Held_Records/]]&gt;</url>
    <title>Position statement: patient held records</title>
    <publicationDate>2003-01-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT,PATIENT AND PUBLIC INVOLVEMENT,PPI IN PRACTICE,INVOLVEMENT MECHANISM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document&amp;nbsp;states Diabetes UK's position on the issue of patient held records. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history&lt;/STRONG&gt;: Updated Jan 2003.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60306</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Documents/Professionals/Structured_education_PS_0406.doc]]&gt;</url>
    <title>Position statement: structured education for people with diabetes</title>
    <publicationDate>2006-04-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,PATIENT AND PUBLIC INVOLVEMENT,PPI IN PRACTICE,TECHNIQUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;position statement&amp;nbsp;gives Diabetes UK's recommendations on structured education&amp;nbsp;and support for people with diabetes to enable them to manage their own diabetes. &lt;SPAN style="mso-ansi-language: EN-US" lang=EN-US&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published April 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word file.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>59894</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/About_us/Our_Views/Position_statements/Sweeteners2/]]&gt;</url>
    <title>Position statement: sweeteners</title>
    <publicationDate>2002-11-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CONDITION MANAGEMENT,CONDITION MANAGEMENT,NUTRITION AND FOOD,NUTRITION AND FOOD,PUBLIC HEALTH,DETERMINANTS,FOOD &amp; NUTRITION,BEVERAGES,FOOD,FOOD STANDARDS,MANAGEMENT &amp; INTERVENTIONS,MANAGEMENT &amp; POLICY,FRAMES OF REFERENCE,GUIDELINES,MONTHLY ADDITIONS,2008-JULY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the Diabetes UK's website covers the charity's advice on sugar and sweeteners for people with diabetes. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published November 2002. Last reviewed by Diabetes UK July 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>373582</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.cmace.org.uk/Projects/Maternal-and-Perinatal-Health/Diabetes-in-Pregnancy.aspx]]&gt;</url>
    <title>Post project review report - diabetes in pregnancy</title>
    <publicationDate>2010-04-01T00:00:00</publicationDate>
    <publisher>Centre for Maternal and Child Enquiries</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETES AND PREGNANCY,DELIVERY OF CARE,WOMEN'S HEALTH,ORGANISATION OF CARE / CARE PLANNING,CONDITION MANAGEMENT,COMPLICATED PREGNANCY,ANTENATAL PROBLEMS,DIABETES,PRECONCEPTION CARE,DATA GATHERING AND AUDIT AND QOF,STATISTICS,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Confidential Enquiry into Maternal and Child Health (CEMACH) initiated a national enquiry programme aimed at improving the quality of maternity care and pregnancy outcomes for women with pre-gestational diabetes in England, Wales and Northern Ireland. This programme of work comprised of&amp;nbsp;three linked studies:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;A survey of maternity services for women with type 1 and type 2 diabetes in 2002.&amp;nbsp;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resID=82798" target="_blank"&gt;(Link to the record here)&lt;BR&gt;&lt;/A&gt;&amp;nbsp; 
&lt;LI&gt;A descriptive study on all pregnancies of women with pre-gestational diabetes who delivered or booked between 1 March 2002 and 28 February 2003, with follow up to pregnancy outcome at 28 days after delivery. This study included an audit of standards of care for women with pre-gestational diabetes. (&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resID=104777" target="_blank"&gt;Link to the record here&lt;/A&gt;)&lt;BR&gt;
&lt;LI&gt;A confidential enquiry, consisting of multidisciplinary panel case reviews. This comprises a case–control study into the impact of clinical care on pregnancy outcome and an audit of care during and after pregnancy, for women with pre-gestational diabetes. published in February 2007. Entitled "Diabetes in pregnancy: are we providing the best care? Findings of a National Enquiry: England, Wales and Northern Ireland." (&lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=250782&amp;amp;tabID=290" target="_blank"&gt;Link to the record here&lt;/A&gt;)&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;This report presents findings of a post project review on the national confidential enquiry into diabetes in pregnancy. The aim of this report is to provide an assessment of how the diabetes report and recommendations have been received and put into practice and also to explore any potential barriers to implementation. The outcome of this review will assist CMACE in developing future reports and recommendations with the aim of improving maternal and child health in the UK. This report comprises findings from a post project review survey questionnaire conducted over the summer of 2009 and a summary of dissemination activities undertaken in relation to the diabetes project findings by CMACE between April 2007 and November 2009.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in April 2010.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307447</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www3.interscience.wiley.com/journal/70003726/home]]&gt;</url>
    <title>Practical Diabetes International</title>
    <publicationDate></publicationDate>
    <publisher>Practical Diabetes International</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The website includes information on the journal 'Practical Diabetes International'.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Full access online requires subscription to the journal. NHS staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library &lt;/A&gt;for further assistance&lt;STRONG&gt;.&lt;/STRONG&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>59984</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/booth/hliving/precondi.html]]&gt;</url>
    <title>Preconception care lowers risk of abnormalities in infants of diabetics</title>
    <publicationDate></publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ PRECONCEPTION CARE,DIABETES,DIABETES AND PREGNANCY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the Bandolier Knowledge Library&amp;nbsp;describes and reviews a&amp;nbsp;2001 meta-analysis concerning preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325849</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.annals.org/content/151/4/264.full]]&gt;</url>
    <title>Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement</title>
    <publicationDate>2009-08-18T00:00:00</publicationDate>
    <publisher>Annals of Internal Medicine</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;: Systematic reviews and meta-analyses have become increasingly important in health care. As with other publications, the reporting quality of systematic reviews varies, limiting readers' ability to assess the strengths and weaknesses of those reviews. In 1996, to address the suboptimal reporting of meta-analyses, an international group developed a guidance called the QUOROM Statement (QUality Of Reporting Of Meta-analyses), which focused on the reporting of meta-analyses of randomized, controlled trials.&amp;nbsp;This article&amp;nbsp;summarizes a revision of these guidelines, renamed PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses), which have been updated to address several conceptual and practical advances in the science of systematic reviews. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Citation&lt;/STRONG&gt;: Moher D, Liberati A, Tetzlaff J, Altman DG, the PG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Ann Intern Med 2009;151(4):264-269.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to&amp;nbsp;the general&amp;nbsp;public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>104777</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.cemach.org.uk/getattachment/8af39ba1-1cab-476b-ad8e-b9393fd35aed/Pregnancy-in-women-with-type-1-and-type-2-diab-(1).aspx]]&gt;</url>
    <title>Pregnancy in women with type 1 and type 2 diabetes in 2002-2003, England, Wales and Northern Ireland</title>
    <publicationDate>2005-10-11T00:00:00</publicationDate>
    <publisher>Confidential Enquiry into Maternal and Child Health (CEMACH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETES AND PREGNANCY,DELIVERY OF CARE,WOMEN'S HEALTH,ORGANISATION OF CARE / CARE PLANNING,CONDITION MANAGEMENT,COMPLICATED PREGNANCY,ANTENATAL PROBLEMS,CO-EXISTING DISEASE,DIABETES,PRECONCEPTION CARE,DATA GATHERING AND AUDIT AND QOF,STATISTICS,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P style="MARGIN-RIGHT: 0px" dir=ltr&gt;This Confidential Enquiry into Maternal and Child Health (CEMACH) report on women with diabetes and pregnancy&amp;nbsp;describes the findings from the second study in CEMACH’s diabetes programme of work (see below).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CEMACH’s diabetes programme of work&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;The Confidential Enquiry into Maternal and Child Health (CEMACH) initiated a national enquiry programme aimed at improving the quality of maternity care and pregnancy outcomes for women with pre-gestational diabetes in England, Wales and Northern Ireland. This programme of work comprises three linked studies:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;A survey of maternity services for women with type 1 and type 2 diabetes in 2002.&amp;nbsp;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resID=82798" target="_blank"&gt;(Link to the record here)&lt;BR&gt;&lt;/A&gt;&amp;nbsp; 
&lt;LI&gt;A descriptive study on all pregnancies of women with pre-gestational diabetes who delivered or booked between 1 March 2002 and 28 February 2003, with follow up to pregnancy outcome at 28 days after delivery. This study included an audit of standards of care for women with pre-gestational diabetes. (This report)&lt;BR&gt;&lt;BR&gt;
&lt;LI&gt;A confidential enquiry, consisting of multidisciplinary panel case reviews. This comprises a case–control study into the impact of clinical care on pregnancy outcome and an audit of care during and after pregnancy, for women with pre-gestational diabetes. published in February 2007. (&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resID=250782" target="_blank"&gt;Link to the record here&lt;/A&gt;)&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication&lt;/STRONG&gt; history information:&amp;nbsp;Published 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383061</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/prescribing-for-diabetes-in-england-2004-05-to-2009-10]]&gt;</url>
    <title>Prescribing for diabetes in England : 2004/05 to 2009/10</title>
    <publicationDate>2010-07-30T00:00:00</publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MEDICATION,MEDICATION,DATA GATHERING AND AUDIT AND QOF,STATISTICS,DATA GATHERING AND AUDIT AND QOF,COST / ECONOMIC DATA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This publication reports on prescribing trends for medicines prescribed in primary care for the treatment of diabetes for the period April 2004 to March 2010. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>275546</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.yhpho.org.uk/resource/view.aspx?RID=9711]]&gt;</url>
    <title>Prescribing for diabetes in England : an analysis of volume, expenditure and trends</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Yorkshire and Humber Public Health Observatory (YHPHO)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MEDICATION,MEDICATION,DATA GATHERING AND AUDIT AND QOF,STATISTICS,DATA GATHERING AND AUDIT AND QOF,COST / ECONOMIC DATA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report from the Yorkshire and Humber Public Health Observatory (YHPHO)&amp;nbsp; provides an overview of prescribing for diabetes in England. Data and intelligence are provided on prescribing for diabetes in primary care and secondary care.&lt;BR&gt;The following key messages and points for consideration are identified:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Diabetes Prevalence and the Impact of Obesity 
&lt;LI&gt;Prescribing for Diabetes in Primary Care 
&lt;LI&gt;Insulins 
&lt;LI&gt;Oral Anti-Diabetic Drugs 
&lt;LI&gt;Diagnostic and Monitoring Agents 
&lt;LI&gt;Prescribing for Diabetes in Secondary Care&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history:&lt;/STRONG&gt; published&amp;nbsp;June 2009&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;See also the following &lt;A href="http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/prescribing-for-diabetes-in-england:-supplement--january-2002-to-march-2009" target="_blank"&gt;Supplement - January 2002 to March 2009&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>104776</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/chp/chronic_disease_report/full_report.pdf]]&gt;</url>
    <title>Preventing chronic diseases : a vital investment</title>
    <publicationDate>2005-10-05T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This WHO global report makes the case for urgent action to halt and turn back the growing threat of chronic diseases. It presents a guide to effective and feasible interventions, and provides practical suggestions for how countries can implement these interventions to respond successfully to the growing epidemics.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published 5 October 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>177110</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/content/extract/333/7566/475]]&gt;</url>
    <title>Prevention and early detection of vascular complications of diabetes</title>
    <publicationDate></publicationDate>
    <publisher>British Medical Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,NEPHROPATHY,RETINOPATHY,DIABETIC FOOT,CARDIOVASCULAR,CHRONIC COMPLICATIONS,DIAGNOSIS,CONDITION MANAGEMENT,CAUSES,PREVENTION,DIAGNOSIS,CONDITION MANAGEMENT,CAUSES,PREVENTION,CONDITION MANAGEMENT,CAUSES,PREVENTION,EYE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;BR&gt;&lt;/STRONG&gt;Marshall S M. Prevention and early detection of vascular complications of diabetes.&amp;nbsp;BMJ&amp;nbsp; 2006;333:475-480.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full journal online requires subscription to the journal.&lt;/P&gt;
&lt;P&gt;NHS staff please &lt;A href="http://www.hlisd.org/" target="_blank"&gt;contact your local NHS library for further assistance&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>83798</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://content.nejm.org/cgi/content/full/344/18/1343]]&gt;</url>
    <title>Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance</title>
    <publicationDate>2001-05-03T00:00:00</publicationDate>
    <publisher>New England Journal of Medicine</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,GROUND-BREAKING ARTICLES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Type 2 diabetes can be prevented by changes in the lifestyles of high-risk subjects.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; 522 middle-aged, overweight subjects (172 men and 350 women; mean age, 55 years; mean body-mass index [weight in kilograms divided by the square of the height in meters], 31) with impaired glucose tolerance were randomly assigned to either the intervention group or the control group. Each subject in the intervention group received individualized counseling aimed at reducing weight, total intake of fat, and intake of saturated fat and increasing intake of fiber and physical activity. An oral glucose-tolerance test was performed annually; the diagnosis of diabetes was confirmed by a second test. The mean duration of follow-up was 3.2 years.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The mean (±SD) amount of weight lost between base line and the end of year 1 was 4.2±5.1 kg in the intervention group and 0.8±3.7 kg in the control group; the net loss by the end of year 2 was 3.5±5.5 kg in the intervention group and 0.8±4.4 kg in the control group (P&amp;lt;0.001 for both comparisons between the groups). The cumulative incidence of diabetes after four years was 11 percent (95 percent confidence interval, 6 to 15 percent) in the intervention group and 23 percent (95 percent confidence interval, 17 to 29 percent) in the control group. During the trial, the risk of diabetes was reduced by 58 percent (P&amp;lt;0.001) in the intervention group. The reduction in the incidence of diabetes was directly associated with changes in lifestyle.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Tuomilehto J, Lindstrom MS, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.&amp;nbsp;N Engl J Med, 2001 May 3; 344(18): 1343-1350. &lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2001.&lt;BR&gt;&amp;nbsp;&amp;nbsp; 
&lt;P&gt;&lt;STRONG&gt;Access:&amp;nbsp;&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/STRONG&gt;]]&gt;</body>
  </document>
  <document>
    <id>279009</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Documents/Reports/PCTandLHB2007AtaGlanceReport.pdf]]&gt;</url>
    <title>Primary care organisation progress survey 2007: Access to healthcare services at a glance</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,STATISTICS,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Diabetes UK survey aims to identify what and how services are being delivered in primary care and, where possible, track changes from 2006.&lt;BR&gt;The&amp;nbsp;survey adressed the following Diabetes UK care priorities:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;early identification 
&lt;LI&gt;education 
&lt;LI&gt;retinal screening 
&lt;LI&gt;emotional and psychological support 
&lt;LI&gt;children’s services&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring Adobe Acrobat Reader.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309980</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.endo-society.org/guidelines/final/upload/Metabolic-Syndrome-Guideline-Standalone.pdf]]&gt;</url>
    <title>Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an Endocrine Society clinical practice guideline</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>The Endocrine Society</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CARDIOVASCULAR,CHRONIC COMPLICATIONS,PREVENTION,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Objective: &lt;/STRONG&gt;To develop clinical practice guidelines for the primary prevention of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Healthcare professionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published by the Endocrine Society in October 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>122766</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15325833&amp;query_hl=7&amp;itool=pubmed_docsum]]&gt;</url>
    <title>Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.</title>
    <publicationDate>2004-08-21T00:00:00</publicationDate>
    <publisher>Lancet</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,GROUND-BREAKING ARTICLES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;Atorvastatin 10 mg daily is safe and efficacious in reducing the risk of first cardiovascular disease events, including stroke, in patients with type 2 diabetes without high LDL-cholesterol. No justification is available for having a particular threshold level of LDL-cholesterol as the sole arbiter of which patients with type 2 diabetes should receive statins. The debate about whether all people with this disorder warrant statin treatment should now focus on whether any patients are at sufficiently low risk for this treatment to be withheld.&lt;BR&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; 2838 patients aged 40-75 years in 132 centres in the UK and Ireland were randomised to placebo (n=1410) or atorvastatin 10 mg daily (n=1428). Study entrants had no documented previous history of cardiovascular disease, an LDL-cholesterol concentration of 4.14 mmol/L or lower, a fasting triglyceride amount of 6.78 mmol/L or less, and at least one of the following: retinopathy, albuminuria, current smoking, or hypertension. The primary endpoint was time to first occurrence of the following: acute coronary heart disease events, coronary revascularisation, or stroke. Analysis was by intention to treat.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The trial was terminated 2 years earlier than expected because the prespecified early stopping rule for efficacy had been met. Median duration of follow-up was 3.9 years (IQR 3.0-4.7). 127 patients allocated placebo (2.46 per 100 person-years at risk) and 83 allocated atorvastatin (1.54 per 100 person-years at risk) had at least one major cardiovascular event (rate reduction 37% [95% CI -52 to -17], p=0.001). Treatment would be expected to prevent at least 37 major vascular events per 1000 such people treated for 4 years. Assessed separately, acute coronary heart disease events were reduced by 36% (-55 to -9), coronary revascularisations by 31% (-59 to 16), and rate of stroke by 48% (-69 to -11). Atorvastatin reduced the death rate by 27% (-48 to 1, p=0.059). No excess of adverse events was noted in the atorvastatin group.&amp;nbsp;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004 Aug 21-27;364(9435):685-96.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2004.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Access to the full text online requires subscription to the journal. NHS staff please &lt;A href="http://www.hlisd.org/" target="_blank"&gt;contact your local NHS library for further assistance&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187538</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16922699]]&gt;</url>
    <title>Psycho-educational interventions for children and young people with Type 1 diabetes.</title>
    <publicationDate>2006-09-01T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CHILD HEALTH,ENDOCRINOLOGY,MENTAL HEALTH,DIABETES MELLITUS,TREATMENT METHODS,SPECIALTIES,DIABETES,TYPE 1,STAFF USE,CHILDREN AND YOUNG PEOPLE,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Progress in the quality and quantity of educational research has not resulted in improved effectiveness of interventions. There is still insufficient evidence to recommend adaptation of a particular educational programme and no programme that has been proven effective in randomized studies for those with poor glycaemic control. To develop a range of effective educational interventions, further research involving larger sample sizes with multicentre collaboration is required.&lt;BR&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A comprehensive review of the literature identified 27 articles describing the evaluation of 24 psycho-educational interventions. Data summary tables compare the key features of these, and comparisons are made between individual, group and family-based interventions. Effect sizes are calculated for nine of the randomized studies. Three research questions are posed: firstly has the recent literature addressed the problems highlighted in the previous review; secondly is there sufficient evidence to recommend adaptation of a particular programme; and, finally, what do we still need to do?&lt;STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Murphy HR, Rayman G, Skinner TC. Psycho-educational interventions for children and young people with Type 1 diabetes. Diabetic Medicine 2006 Sep;23(9):935-43. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2006.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Access to the full text online requires subscription to the journal. NHS staff please &lt;A href="http://www.hlisd.org/" target="_blank"&gt;contact your local NHS library for further assistance.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82637</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/guidance/index.jsp?action=byTopic&amp;o=7376]]&gt;</url>
    <title>Public health (smoking, physical activity, obesity)</title>
    <publicationDate></publicationDate>
    <publisher>National Institute for Health and Clinical Excellence (NICE)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,LIVING WITH DIABETES,OBESITY,CONDITION MANAGEMENT,CONDITION MANAGEMENT,OTHER LIFE STYLE,OTHER LIFE STYLE,PHYSICAL ACTIVITY,PHYSICAL ACTIVITY,PUBLIC HEALTH,DETERMINANTS,BIOLOGICAL COMPOSITION,OBESITY,INDIVIDUAL BEHAVIOUR,EATING HABITS,PHYSICAL ACTIVITY,SMOKING,TOBACCO USE,SOCIAL DETERMINANTS,LIFESTYLE,MANAGEMENT &amp; INTERVENTIONS,HEALTHCARE &amp; HEALTH SERVICES,MANAGEMENT &amp; POLICY,SERVICES,HEALTH SERVICES,FRAMES OF REFERENCE,POPULATION BASED &amp; PREVENTATIVE SERVICES,QUALITY,GOOD PRACTICE,GUIDELINES,SMOKING CESSATION,CONDITION MANAGEMENT,PREVENTION,SMOKING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the National Institute for Health and Clinical Excellence (NICE) website provides links to documents and information about clinical guidelines, technology appraisals, public health interventions and public health programmes in areas of public health including: smoking, obesity, and physical activity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>57268</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,152/Itemid,61/]]&gt;</url>
    <title>Putting a patient on a diet (teaching letter no.4)</title>
    <publicationDate>1996-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CONDITION MANAGEMENT,CONDITION MANAGEMENT,NUTRITION AND FOOD,NUTRITION AND FOOD]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the education and advice given to&amp;nbsp;patients with diabetes on the subject of diet and nutrition. It&amp;nbsp;covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Possible approaches to teaching a food plan 
&lt;UL&gt;
&lt;LI&gt;Who can teach? 
&lt;LI&gt;Prerequisites: getting to know your patient 
&lt;LI&gt;Goals&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;How to do it 
&lt;UL&gt;
&lt;LI&gt;Stimulating a patient's demand for information that will enable him to diversify his meal plan 
&lt;LI&gt;Learning to make correct decisions by analyzing the contents of different menus 
&lt;LI&gt;Learning by choosing 
&lt;LI&gt;Experiencing real-life situations 
&lt;LI&gt;Interaction and group discussion&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Suggestions on the content of a teaching program 
&lt;LI&gt;Evaluation 
&lt;LI&gt;Conclusion&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 1996&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346705</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=1063]]&gt;</url>
    <title>Putting feet first - and fast: commissioning specialist services for the management and prevention of foot disease in hospitals</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETIC FOOT,DELIVERY OF CARE,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,PREVENTION,COMMISSIONING,COMMISSIONING,DISEASE/CONDITION GROUPS,ENDOCRINE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Factsheet from NHS Diabetes</description>
    <body>&lt;![CDATA[ &lt;P&gt;This factsheet summarises the key points of the report published in 2009 by Diabetes UK and NHS Diabetes entitled "Putting Feet First".&amp;nbsp; &lt;A href="http://www.library.nhs.uk/Diabetes/ViewResource.aspx?resID=319969" target="_blank"&gt;Click here&lt;/A&gt; to read the full text of the report.&amp;nbsp; The focus of that report was on the skills and resources to which each patient with diabetes should have access in hospital.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in February 2010.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public, Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317009</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhsemployers.org/Aboutus/Publications/Documents/QOF_Guidance_2009_final.pdf]]&gt;</url>
    <title>Quality and Outcomes Framework guidance for GMS contract 2009/10</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>General Medical Services</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,KEY POLICIES / NSF,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document lists Quality and Outcomes Framework (QOF) indicators as part of the new General Medical Services (GMS) contract. GP practices are awarded points according to the number of indicators they meet and they receive funding accordingly. For Diabetes Mellitus indicators, scroll to page 10.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the General Public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>333501</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/qualityandproductivity/SearchResults.aspx?catID=15069]]&gt;</url>
    <title>Quality and productivity examples : Long-term conditions</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence – quality and productivity</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,SHARING PRACTICE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'NHS Evidence - quality and productivity' includes&amp;nbsp;examples of innovative practices that can be shared with all staff. The examples of improvements range from one-off studies in single organisations to robustly tested large scale changes that have been replicated in multiple organisations and have had results published in academic journals.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This section of 'NHS Evidence - quality and productivity' includes&amp;nbsp;examples relevant to long-term conditions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318477</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.health.org.uk/document.rm?id=1022]]&gt;</url>
    <title>Quality of healthcare in England, Wales, Scotland, Northern Ireland: an intra-UK chartbook</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>The Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DATA GATHERING AND AUDIT AND QOF,DIABETES ATTRIBUTABLE DEATHS,INCIDENCE AND PREVALENCE,STATISTICS,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This chartbook brings together publicly available data from across the four home nations of the UK and presents an intra-UK picture of quality.&lt;/P&gt;
&lt;P&gt;Following the NHS Next Stage Review with its emphasis on quality measurement and increased reporting on outcomes, this chartbook is an illustration of how currently available data can be used to create a coherent picture of quality and performance across these domains in each of the UK countries.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring Adobe Acrobat Reader.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82848</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,172/Itemid,61/]]&gt;</url>
    <title>Quality of life, an outcome of diabetes education (teaching letter no.29)</title>
    <publicationDate>2004-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns quality of life as an outcome of diabetes patient eduction and covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;First step: assessment of patient's quality of life 
&lt;LI&gt;Second step: improving or at least maintaining the patient's quality of life 
&lt;LI&gt;Which educational tools can be used? 
&lt;LI&gt;Conclusion 
&lt;LI&gt;Reference&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 2004&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342201</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19940227]]&gt;</url>
    <title>Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,CAUSES,EYE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed abstract&lt;BR&gt;"Since 1985, diabetic patients have lower rates of progression to PDR and SVL. These findings may reflect an increased awareness of retinopathy risk factors; earlier identification and initiation of care for patients with retinopathy; and improved medical management of glucose, blood pressure, and serum lipids. Differences in baseline characteristics, particularly in the prevalence and severity of retinopathy, could also have contributed to these temporal differences".&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed abstract&lt;BR&gt;"This systematic literature review and meta-analysis of prospective studies assesses progression of retinopathy among diabetic patients without treatment for retinopathy at baseline. Studies published between 1975 to February 2008 were identified. Outcomes of interest were rates of progression to PDR and/or SVL. Pooled baseline characteristics and outcome measures were summarized using weighted averages of counts and means. Baseline characteristics and outcomes were compared between two periods: 1975-1985 and 1986-2008". &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed abstract&lt;BR&gt;"A total of 28 studies comprising 27,120 diabetic patients (mean age 49.8 years) were included. After 4 years, pooled incidence rates for PDR and SVL were 11.0 and 7.2%, respectively. Rates were lower among participants in 1986-2008 than in 1975-1985. After 10 years, similar patterns were observed. Participants in 1986-2008 studies had lower proportions of PDR and non-PDR at all time points than participants in 1975-1985 studies". &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Wong TY, Mwamburi M, Klein R, Larsen M, Flynn H, Hernandez-Medina M, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 2009;32(12):2307-13.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in December 2009. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full-text online access of this article requires subscription to the journal.&amp;nbsp; Full-text online access is available to NHS staff in England via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/Default.aspx" target="_blank"&gt;NHS Evidence&lt;/A&gt;.&amp;nbsp; Other NHS staff should check with &lt;A href="http://www.hlisd.org/" target="_blank"&gt;your local NHS library&lt;/A&gt;.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>300339</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nature.com/ejcn/journal/v54/n4/pdf/1600962a.pdf]]&gt;</url>
    <title>Recommendations for the nutritional management of patients with diabetes mellitus</title>
    <publicationDate>2000-04-01T00:00:00</publicationDate>
    <publisher>The Diabetes and Nutrition Study Group of the European Association for the Study of Diabetes</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,NEPHROPATHY,CARDIOVASCULAR,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,CONDITION MANAGEMENT,CONDITION MANAGEMENT,PREVENTION,CONDITION MANAGEMENT,PREVENTION,NUTRITION AND FOOD,NUTRITION AND FOOD]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; Nutritional management aims to help optimize glycaemic control and reduce risk factors for cardiovascular disease and nephropathy. The quality of life of the individual person must be considered when designing nutritional objectives and health care providers must achieve a balance among the demands of metabolic control, risk factor management, patient well-being and safety. All nutritional programmes should be adapted to the specific needs of the individual person, which may change with time. 
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt;&amp;nbsp; Dietitians, doctors and other health professionals 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published 2000 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>266049</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/content/30/5/1314.abstract]]&gt;</url>
    <title>Recurrence of gestational diabetes mellitus : a systematic review</title>
    <publicationDate>2007-05-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,GESTATIONAL DIABETES,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Recurrence of Gestational Diabetes Mellitus was common and may vary most significantly by non-Hispanic white versus minority race/ethnicity.&amp;nbsp;&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt;&amp;nbsp;A systematic literature review of articles published between January 1965 and November 2006, in which recurrence rates of GDM among women with a history of GDM were reported. Factors abstracted included recurrence rates, time elapsed between pregnancies, race/ethnicity, diagnostic criteria, and, when available, maternal age, parity, weight or BMI at the initial and subsequent pregnancy, weight gain at the initial or subsequent pregnancy and between pregnancies, insulin use, gestational age at diagnosis, glucose tolerance test levels, baby birth weight and presence of macrosomia, and breast-feeding.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Of 45 articles identified, 13 studies were eligible for inclusion. After the index pregnancy, recurrence rates varied between 30 and 84%. Lower rates were found in non-Hispanic white (NHW) populations (30–37%), and higher rates were found in minority populations (52–69%). Exceptions to observed racial/ethnic variations in recurrence were found in cohorts that were composed of a significant proportion of both NHW and minority women or that included women who had subsequent pregnancies within 1 year. No other risk factors were consistently associated with recurrence of GDM across studies. The rates of future preexisting diabetes in pregnancy, socioeconomic status, postpartum diabetes screening rates after the index pregnancy, and the average length of time between pregnancies were generally not reported.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Kim C, Berger DK, Chamany S. Recurrence of Gestational Diabetes Mellitus : A systematic review.&amp;nbsp;Diabetes Care 2007 May;30:1314-1319&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2007&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full-text online access of this&amp;nbsp;article requires subscription to the journal.&amp;nbsp; Full-text online access is available to&lt;STRONG&gt; &lt;/STRONG&gt;NHS staff in England via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/Default.aspx" target="_blank"&gt;NHS Evidence&lt;/A&gt;.&amp;nbsp; Other NHS staff should check with &lt;A href="http://www.hlisd.org/" target="_blank"&gt;your local NHS library&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>83809</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://content.nejm.org/cgi/content/full/346/6/393]]&gt;</url>
    <title>Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin</title>
    <publicationDate>2002-02-07T00:00:00</publicationDate>
    <publisher>New England Journal of Medicine</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,GROUND-BREAKING ARTICLES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;/STRONG&gt;&lt;BR&gt;Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.&amp;nbsp;New England Journal of Medicine. 2002 Feb 7; 346(6): 393-403. 
&lt;P&gt;&lt;STRONG&gt;Accessing the full text:&lt;/STRONG&gt; Available to the general public.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372604</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www3.interscience.wiley.com/journal/123305421/abstract]]&gt;</url>
    <title>Relationship of baseline HBA1c and efficacy of glucose lowering therapies: a meta-analysis of randomised clinical trials</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MEDICATION,MEDICATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;SPAN class=h5-inline&gt;&lt;SPAN class=h5-inline&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; "Baseline glycated haemoglobin (HbA1c) concentrations vary between clinical trials of glucose-lowering agents and this may affect interpretation of clinical efficacy. The objective of this study is to quantify the relationship between baseline HbA1c and reduction of HbA1c in clinical trials."&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; "PubMed literature searches from 1991 to 2007. Randomized controlled studies with placebo-controlled or comparator arms [= 9 patients in the intent-to-treat (ITT) population] ranging in duration from 23 to 52 weeks, in which baseline and change in glycated haemoglobin (HbA1c) were reported. The relationship between baseline HbA1c and change in HbA1c was analysed by a weighted least-squared regression model accounting for ITT population and variance of HbA1c change. Fourteen per cent of independently abstracted studies met the selection criteria."&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; "Meta-analysis from 59 clinical trials (8479 patients) produced weighted R2 of 0.35 (P &amp;lt; 0.0001) for the association of baseline HbA1c and absolute change in HbA1c. Subanalysis of eight metformin clinical trials demonstrated a stronger association [weighted R2 of 0.67 (P = 0.0130)]. Exclusion of metformin clinical trials from the overall meta-analysis (n = 51) yielded a weighted R2 of 0.31 (P &amp;lt; 0.0001). Subanalyses of clinical trials of glucose-lowering therapies predominantly targeting fasting (n = 37) or postprandial (n = 22) blood glucose produced weighted R2 values of 0.27 (P &amp;lt; 0.001) and 0.42 (P &amp;lt; 0.005), respectively."&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; "These data demonstrate a positive relationship between baseline HbA1c and the magnitude of HbA1c change across 10 categories of glucose-lowering therapies, irrespective of class or mode of action. These observations should be considered when assessing clinical efficacy of diabetes therapies derived from clinical trials."&lt;BR&gt;&lt;BR&gt;&lt;/SPAN&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Defronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HBA1c and efficacy of glucose lowering therapies: a meta-analysis of randomised clinical trials. Diabetic Medicine 2010; 27: 309–317.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published online in&amp;nbsp;March 2010.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full-text of this article online requires subscription to the&amp;nbsp;journal. NHS staff please&amp;nbsp;contact&amp;nbsp; &lt;A href="http://www.hlisd.org/" target="_blank"&gt;your local NHS library&lt;/A&gt;&amp;nbsp;for further assistance.&amp;nbsp;&lt;/P&gt;&lt;/SPAN&gt;]]&gt;</body>
  </document>
  <document>
    <id>323082</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/our_work_areas/research_and_evaluation/]]&gt;</url>
    <title>Research and Evaluation - Work Area - NHS Diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,RESEARCH]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the NHS Diabetes website provides details of the work of the Research and Evaluation Working Group. It also includes links to further information. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>122038</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Documents/Shared%20practice/cypresourcesdocpdf%20updated%20april%2006.pdf]]&gt;</url>
    <title>Resources to support the delivery of care for children and young people with diabetes</title>
    <publicationDate>2005-11-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CHILD HEALTH,ENDOCRINOLOGY,PATIENT INFORMATION,DIABETES MELLITUS,DIABETES INSIPIDUS,SPECIALTIES,PUBLICATIONS,DIABETES,TYPE 1,TYPE 2,LIVING WITH DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,REPORTS,STAFF USE,CHILDREN AND YOUNG PEOPLE,DATA GATHERING AND AUDIT AND QOF,CHILDREN AND YOUNG PEOPLE,STATISTICS,SCHOOL,INCIDENCE AND PREVALENCE,RISK AND FUTURE PROJECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;Diabetes UK&amp;nbsp;report aims to support the implementation of the various current UK guidelines and frameworks for the care of children and young people with diabetes. The report contains the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Statistics 
&lt;UL&gt;
&lt;LI&gt;Prevalence 
&lt;LI&gt;Risk factors for developing diabetes 
&lt;LI&gt;Risk factors for developing complications&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Justification for Specialist Services for young people with diabetes 
&lt;UL&gt;
&lt;LI&gt;Paediatric expertise 
&lt;LI&gt;The current situation 
&lt;LI&gt;National diabetes frameworks/plans 
&lt;LI&gt;Integrating paediatric diabetes services into local planning 
&lt;LI&gt;Local planning mechanisms&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Importance of Audit 
&lt;UL&gt;
&lt;LI&gt;Overview 
&lt;LI&gt;National audit programmes&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Principles of good practice 
&lt;UL&gt;
&lt;LI&gt;Recommendations to achieve good practice objectives 
&lt;LI&gt;Personnel 
&lt;LI&gt;Access to insulin pump therapy 
&lt;LI&gt;Education 
&lt;LI&gt;Psychological and social issues 
&lt;LI&gt;Peer support 
&lt;LI&gt;Transition care&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Schooling, Disability Living Allowance and the Disability 
&lt;LI&gt;Discrimination Act 1995 
&lt;LI&gt;Appendix 
&lt;UL&gt;
&lt;LI&gt;A: Additional resources&lt;/LI&gt;&lt;/UL&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published November 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323089</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/our_work_areas/retinopathy/]]&gt;</url>
    <title>Retinopathy - Work Area - NHS Diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,DELIVERY OF CARE,CHRONIC COMPLICATIONS,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,DIAGNOSIS,CONDITION MANAGEMENT,CAUSES,EYE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the NHS Diabetes website provides details of the work of the&amp;nbsp;Retinal Screening&amp;nbsp;Working Group. It also includes links to further information. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60152</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,160/Itemid,61/]]&gt;</url>
    <title>Right from the start... education at the time of diagnosis (teaching letter no.15)</title>
    <publicationDate>1999-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ CONDITION MANAGEMENT,DIAGNOSIS,CONDITION MANAGEMENT,DIAGNOSIS,DIABETES,TYPE 2,TYPE 1,CHILDREN AND YOUNG PEOPLE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns&amp;nbsp;patient education&amp;nbsp;at the time of diagnosis&amp;nbsp;and covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Start a good relationship with the patient 
&lt;LI&gt;Give the news as positively as you can 
&lt;LI&gt;Assess the patient's reaction 
&lt;LI&gt;Explain what diabetes is 
&lt;LI&gt;Introduce the team approach 
&lt;LI&gt;Highlight educational priorities 
&lt;UL&gt;
&lt;LI&gt;Type 1 diabetes 
&lt;LI&gt;type 2 diabetes&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Follow-up&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 1999&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>382857</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.healthcareea.co.uk/nhsdiabetes]]&gt;</url>
    <title>Safe use of insulin e-learning course</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ MEDICATION,MEDICATION,CPD AND PROFESSIONAL EDUCATION,DIABETES,TYPE 1,TYPE 2,CONDITION MANAGEMENT,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This free online training course&amp;nbsp;has been designed by NHS Diabetes for all health professionals who need to administer insulin for patients with diabetes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Registration with the Healthcare e-Academy website is required. Please note that you will need to enable pop-ups in your browser in order to view all the content.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>347274</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetesinscotland.org.uk/Publications/Scottish%20Diabetes%20Survey%202009.pdf]]&gt;</url>
    <title>Scottish diabetes survey 2009</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>Diabetes in Scotland</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DATA GATHERING AND AUDIT AND QOF,INCIDENCE AND PREVALENCE,STATISTICS,DATA GATHERING AND AUDIT AND QOF,DELIVERY OF CARE,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report presents the results of the 2009 Scottish Diabetes Survey. The Scottish Diabetes Survey provides data on the number of people with diabetes, the effects on their health, and the progress being made to improve the delivery and outcomes of care for diabetes.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in March 2010.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>390064</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/project/1840.asp]]&gt;</url>
    <title>Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee</title>
    <publicationDate>2010-09-30T00:00:00</publicationDate>
    <publisher>NIHR Health Technology Assessment programme</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,WOMEN'S HEALTH,NORMAL PREGNANCY,ANTENATAL CARE,SCREENING,GESTATIONAL DIABETES,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This updating review concludes that the case for screening for raised blood glucose in pregnancy has strengthened, partly because changes in maternal age and weight are increasing the prevalence of gestational diabetes. There is also evidence that metformin and glibenclamide can be used before insulin. However the threshold of blood glucose at which treatment should start remains uncertain. Screening with HbA1c at booking clinic should be considered.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Waugh N, Royle P, Clar C, Henderson R, Cummins E, et al. Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee. Health Technol Assess 2010;14(45). &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60316</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://whqlibdoc.who.int/hq/2003/WHO_NMH_MNC_03.1.pdf]]&gt;</url>
    <title>Screening for type 2 diabetes : report of a World Health Organization and International Diabetes Federation meeting</title>
    <publicationDate>2003-01-01T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ VASCULAR RISK,DIABETES,CAUSES,TYPE 2,DIABETES,ADULT,SCREENING,NOT ROUTINELY OFFERED,PRIMARY CARE,MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report covers the following topics: 
&lt;UL&gt;
&lt;LI&gt;The background and aims of&amp;nbsp;the WHO/IDF meeting 
&lt;LI&gt;Terminology - what is screening 
&lt;LI&gt;Evaluating screening tests and programmes 
&lt;LI&gt;The current evidence base 
&lt;LI&gt;Formulating policies about screening for type 2 diabetes 
&lt;LI&gt;Widening the evidence base 
&lt;LI&gt;Implementing policies about screening for type 2 diabetes 
&lt;LI&gt;Conclusions and recommendations&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2003.&lt;BR&gt;&amp;nbsp; 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp; 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>122761</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16214598&amp;query_hl=1&amp;itool=pubmed_docsum]]&gt;</url>
    <title>Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.</title>
    <publicationDate>2005-10-01T00:00:00</publicationDate>
    <publisher>Lancet</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,GROUND-BREAKING ARTICLES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;Pioglitazone reduces the composite of all-cause mortality, non-fatal myocardial infarction, and stroke in patients with type 2 diabetes who have a high risk of macrovascular events.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A prospective, randomised controlled trial in 5238 patients with type 2 diabetes who had evidence of macrovascular disease.&amp;nbsp;Patients were recruited from primary-care practices and hospitals. Patients were assigned to oral pioglitazone titrated from 15 mg to 45 mg (n=2605) or matching placebo (n=2633), to be taken in addition to their glucose-lowering drugs and other medications. The primary endpoint was the composite of all-cause mortality, non fatal myocardial infarction (including silent myocardial infarction), stroke, acute coronary syndrome, endovascular or surgical intervention in the coronary or leg arteries, and amputation above the ankle. Analysis was by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN NCT00174993.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Two patients were lost to follow-up, but were included in analyses. The average time of observation was 34.5 months. 514 of 2605 patients in the pioglitazone group and 572 of 2633 patients in the placebo group had at least one event in the primary composite endpoint (HR 0.90, 95% CI 0.80-1.02, p=0.095). The main secondary endpoint was the composite of all-cause mortality, non-fatal myocardial infarction, and stroke. 301 patients in the pioglitazone group and 358 in the placebo group reached this endpoint (0.84, 0.72-0.98, p=0.027). Overall safety and tolerability was good with no change in the safety profile of pioglitazone identified. 6% (149 of 2065) and 4% (108 of 2633) of those in the pioglitazone and placebo groups, respectively, were admitted to hospital with heart failure; mortality rates from heart failure did not differ between groups.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt;&amp;nbsp;Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005 Oct 8;366(9493):1279-89. &lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Access to the full text online requires subscription to the journal. NHS staff please &lt;A href="http://www.hlisd.org/" target="_blank"&gt;contact your local NHS library for further assistance&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187712</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/ethnicity/SearchResults.aspx?tabID=289&amp;catID=11552&amp;searchText=&amp;sort=PUBLISHER&amp;resultsPerPage=50&amp;summaries=true]]&gt;</url>
    <title>Selected research studies relating to diabetes and people from ethnic minorities</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence - ethnicity and health</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,PEOPLE FROM ETHNIC MINORITIES,PEOPLE FROM ETHNIC MINORITIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of &lt;A href="http://www.library.nhs.uk/ethnicity/" target="_blank"&gt;NHS Evidence - ethnicity and health&lt;/A&gt;&amp;nbsp;provides links to selected&amp;nbsp;research studies&amp;nbsp;within ethnic health relating to diabetes.&lt;/P&gt;
&lt;P&gt;NHS Evidence - ethnicity and health state that: "Since the specialism of ‘ethnic health’ is relatively new, there are currently few high quality systematic reviews and publications based on randomised controlled trials or meta-analyses.&amp;nbsp; We have attempted, using a panel of experts, to select the best available evidence relevant to minority ethnic groups and cultures present in Britain in significant numbers.&amp;nbsp; This means that we do not always reference overseas research."&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; available to the general public. 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345384</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=1023]]&gt;</url>
    <title>Self monitoring of blood glucose in non-insulin-treated type 2 diabetes</title>
    <publicationDate>2010-03-02T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This NHS Diabetes report examines the practice of self monitoring of blood glucose (SMBG) in people with non-insulin-treated Type 2 diabetes. This&amp;nbsp;report:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;provides recommendations regarding the place of SMBG in the management of non-insulin treated Type 2 diabetes in England&lt;/LI&gt;
&lt;LI&gt;summarises existing guidelines regarding SMBG in the management of non-insulin-treated Type 2 diabetes&lt;/LI&gt;
&lt;LI&gt;Discusses the results of a commissioned systematic review of SMBG in&lt;BR&gt;non-insulin-treated Type 2 diabetes&lt;/LI&gt;
&lt;LI&gt;Identifies gaps in the evidence and makes recommendations for future research&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in March 2010.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public, Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102939</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.kingsfund.org.uk/document.rm?id=5682]]&gt;</url>
    <title>Self-management for long-term conditions : patients' perspectives on the way ahead</title>
    <publicationDate>2005-07-01T00:00:00</publicationDate>
    <publisher>King's Fund</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,PATIENT AND PUBLIC INVOLVEMENT,USER INVOLVEMENT,PPI IN PRACTICE,INDIVIDUAL INVOLVEMENT,SELF MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This paper from the King's Fund reviews patients’ perceptions about managing their own conditions, and identifies how primary care trusts and other health and social care providers can support them, in line with their individual needs.&lt;/P&gt;
&lt;P&gt;The King's Fund is an independent charitable foundation working for better health, especially in London.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published July 2005. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>57264</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,151/Itemid,61/]]&gt;</url>
    <title>Self-monitoring (teaching letter no.3)</title>
    <publicationDate>1996-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MONITORING / SELF-MONITORING,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the education of patients on the subject of self-monitoring of blood glucose. It covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Setting goals for self-monitoring 
&lt;LI&gt;The educational program 
&lt;LI&gt;Training patients in self-monitoring 
&lt;LI&gt;Reinforcement of self-monitoring skills 
&lt;LI&gt;Misleading results 
&lt;LI&gt;Cost-effectiveness 
&lt;LI&gt;Suggested guidelines for a self-monitoring program&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 1996&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>154829</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.cqc.org.uk/aboutcqc/howwedoit/involvingpeoplewhouseservices/patientsurveys/servicesfordiabetes.cfm]]&gt;</url>
    <title>Services for people with diabetes</title>
    <publicationDate></publicationDate>
    <publisher>Care Quality Commission</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This page on the Care Quality Commission website provides information and links to related documents about a review to assess the quality of healthcare services for people with diabetes.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>294802</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=18644063]]&gt;</url>
    <title>Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion.</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,HYPOGLYCAEMIA,ACUTE COMPLICATIONS,CONDITION MANAGEMENT,MEDICATION,INSULIN PUMPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Conclusion&lt;/STRONG&gt;: The severe hypoglycaemia rate in Type 1 diabetes was markedly less during CSII than MDI, with the greatest reduction in those with most severe hypoglycaemia on MDI and those with the longest duration of diabetes. The biggest improvement in HbA(1c) was in those with the highest HbA(1c) on MDI.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method&lt;/STRONG&gt;: Databases and literature (1996-2006) were searched for randomized controlled trials (RCTs) and before/after studies of &amp;gt; or = 6 months' duration CSII and with severe hypoglycaemia frequency &amp;gt; 10 episodes/100 patient years on MDI. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;: In 22 studies (21 reports), severe hypoglycaemia during MDI was related to diabetes duration (P = 0.038) and was greater in adults than children (100 vs. 36 events/100 patient years, P = 0.036). Severe hypoglycaemia was reduced during CSII compared with MDI, with a rate ratio of 2.89 (95% CI 1.45 to 5.76) for RCTs and 4.34 (2.87 to 6.56) for before/after studies [rate ratio 4.19 (2.86 to 6.13) for all studies]. The reduction was greatest in those with the highest initial severe hypoglycaemia rates on MDI (P &amp;lt; 0.001). The mean difference in glycated haemoglobin (HbA(1c)) between treatments was less for RCTs [0.21% (0.13-0.30%)] than in before/after studies [0.72% (0.55-0.90%)] but strongly related to the initial HbA(1c) on MDI (P &amp;lt; 0.001). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Pickup and A. J. Sutton. (2008) Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabetic Medicine, 25, 765-774.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information&lt;/STRONG&gt;: Published in&amp;nbsp;July 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessing the full text:&lt;BR&gt;&lt;/STRONG&gt;NHS staff in England: available via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;NHS Evidence&lt;BR&gt;&lt;/A&gt;other NHS staff: &lt;A href="http://www.hlisd.org/" target="_blank"&gt;Check with your local NHS library&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>125075</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Professionals/Shared_Practice/]]&gt;</url>
    <title>Sharing your practice</title>
    <publicationDate>2006-07-19T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,KEY POLICIES / NSF,SHARING PRACTICE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the&amp;nbsp;Diabetes UK&amp;nbsp;website&amp;nbsp;is aimed at sharing examples of practice in diabetes care to stimulate debate, encourage improvements in service delivery and promote good practice. This section includes pages on:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Shared Practice Award for Person Centred Care 
&lt;LI&gt;About Shared Practice Database 
&lt;LI&gt;Shared Practice Feedback 
&lt;LI&gt;A - Z of examples 
&lt;LI&gt;Submit Your Example 
&lt;LI&gt;Care Topics: 
&lt;UL&gt;
&lt;LI&gt;Black and Minority Ethnic Communities (including Maslaha, Khush Dil, Somali storybook, Apnee Sehat, Coping with Diabetes, Toolkit to support the&amp;nbsp;running of diabetes awareness events for the South Asian community)&amp;nbsp;&amp;nbsp; 
&lt;LI&gt;Children and Young People (including Flexible Adjustment of Basal Bolus (FABB), Frankie's leap, MICK&amp;amp;YS, Children's diabetes services, Getting Sorted, Young Persons services, innovative education, homecare service, Register, diabetes education, Transition, Sweet Talk, FACTS) 
&lt;LI&gt;Commissioning 
&lt;LI&gt;Diabetes Care in Schools 
&lt;LI&gt;Early identification 
&lt;LI&gt;Emotional and Psychological support 
&lt;LI&gt;Eye screening 
&lt;LI&gt;Innovative care (projects on: reaching the hard to reach, residential homes, pain clinic, hyperglycaemia, inpatient care, coronary heart disease) 
&lt;LI&gt;Integrated Care 
&lt;LI&gt;Patient education (including SNACCS, Diabetes in Pregnancy, X-PERT, DEAL, BERTIE, ASPIRE, READ, TIFA, LAY, DAFNE, DESMOND, XPERT and&amp;nbsp;Tools to assess quality of life and diabetes)&amp;nbsp; 
&lt;LI&gt;Patient held records and care planning 
&lt;LI&gt;Physical activity 
&lt;LI&gt;Pregnancy (Gestational Diabetes and Diabetes in Pregnancy) 
&lt;LI&gt;Sharps Disposal 
&lt;LI&gt;User involvement 
&lt;LI&gt;Weight Management&lt;/LI&gt;&lt;/UL&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Resource launched April 2006.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344339</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_112511.pdf]]&gt;</url>
    <title>Six years on: delivering the diabetes national service framework</title>
    <publicationDate>2010-02-16T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,SERVICE SECTORS,QUALITY AND MONITORING,PRIMARY CARE SERVICES,ACUTE SERVICES,DIABETES,DELIVERY OF CARE,EYES AND VISION,KEY POLICIES / NSF,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,COMMISSIONING,ASSESSMENT AND PLANNING,SERVICE PROVISION,QUALITY IMPROVEMENT,COMMISSIONING PROCESS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The &lt;A href="http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Diabetes/index.htm" target="_blank"&gt;Diabetes National Service Framework&amp;nbsp;(NSF)&lt;/A&gt;&amp;nbsp;set out the first ever set of national standards for the care of people with diabetes. This report highlights progress over the six years since the publication of the NSF.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published&amp;nbsp;16 February 2010.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_087123" target="_blank"&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>250768</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band154/b154-2.html]]&gt;</url>
    <title>SMBG and glycaemic control</title>
    <publicationDate></publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CONDITION MANAGEMENT,CONDITION MANAGEMENT,TYPE 1,TYPE 2,DIABETES,MONITORING / SELF-MONITORING,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier&amp;nbsp;article describes and reviews&amp;nbsp;a 2006 observational study on self monitoring of blood glucose in people with diabetes. Its results add to the evidence which&amp;nbsp;show&amp;nbsp;that increased use of self-monitoring of blood glucose (SMBG) results in better glycaemic control. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Review published&amp;nbsp;December 2006 Bandolier 154&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>235786</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band148/b148-3.html]]&gt;</url>
    <title>SMBG in type 2 diabetes</title>
    <publicationDate>2006-06-01T00:00:00</publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier&amp;nbsp;article describes and reviews a 2006 epidemiological cohort study which adds to the available evidence pointing to better clinical outcomes with self-monitoring of blood glucose (SMBG). &lt;BR&gt;&lt;STRONG&gt;&amp;nbsp;&lt;BR&gt;Publication history information:&lt;/STRONG&gt; Review published&amp;nbsp;June 2006 Bandolier 148&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82646</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ash.org.uk/files/documents/ASH_128.pdf]]&gt;</url>
    <title>Smoking and diabetes</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Action on Smoking and Health (ASH)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ OTHER LIFE STYLE,OTHER LIFE STYLE,EYE DISEASES,CAUSES,CAUSES,PREVENTION,OUTCOMES,PATIENTS,GENERAL PUBLIC,CIRCULATORY DISEASES,ENDOCRINE DISORDERS,DIABETES,TYPE 1,TYPE 2,LIVING WITH DIABETES,CARDIOVASCULAR,DIABETIC FOOT,PAINFUL NEUROPATHIES,RETINOPATHY,NEPHROPATHY,DIABETES,CONDITION MANAGEMENT,CONDITION MANAGEMENT,CHRONIC COMPLICATIONS,CAUSES,CAUSES,CAUSES,DETERMINANTS,PUBLIC HEALTH,INDIVIDUAL BEHAVIOUR,TOBACCO USE,SMOKING,LIFESTYLE,SOCIAL DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,INFORMATION,MANAGEMENT &amp; POLICY,GROUPS,POPULATIONS,SMOKING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;factsheet&amp;nbsp;on the&amp;nbsp;Action on Smoking and Health (ASH)&amp;nbsp;website provides information about smoking and diabetes. It includes an introduction to diabetes and&amp;nbsp;the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Links between smoking and diabetes 
&lt;LI&gt;Insulin Resistance 
&lt;LI&gt;Smoking, diabetes and premature death 
&lt;LI&gt;The effect of smoking on complications of diabetes 
&lt;LI&gt;Benefits of smoking cessation&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;ASH factsheets provide referenced facts, statisitics&amp;nbsp;and information about smoking and health.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published June 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>259378</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ash.org.uk/files/documents/ASH_132.pdf]]&gt;</url>
    <title>Smoking and eye disease</title>
    <publicationDate>2005-09-01T00:00:00</publicationDate>
    <publisher>Action on Smoking and Health (ASH)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ OTHER LIFE STYLE,OTHER LIFE STYLE,EYE DISEASES,GENERAL,OUTCOMES,GENERAL PUBLIC,EYE DISORDERS,ENDOCRINE DISORDERS,DIABETES,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,CONDITION MANAGEMENT,CAUSES,DIABETES,TYPE 2,TYPE 1,RETINOPATHY,LIVING WITH DIABETES,PUBLIC HEALTH,DETERMINANTS,TOBACCO USE,SMOKING,INDIVIDUAL BEHAVIOUR,MANAGEMENT &amp; INTERVENTIONS,INFORMATION,MANAGEMENT &amp; POLICY,GROUPS,POPULATIONS,SMOKING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This factsheet on the action on smoking and health (ASH) website contains a section on smoking and diabetic retinopathy.&lt;/P&gt;
&lt;P&gt;ASH factsheets provide referenced facts, statisitics&amp;nbsp;and information about smoking and health.&lt;/P&gt;
&lt;P&gt;Information includes:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Benefits of stopping smoking 
&lt;LI&gt;Cataract 
&lt;LI&gt;Age-related macular degeneration (AMD) 
&lt;LI&gt;Smoking and diabetic retinopathy 
&lt;LI&gt;Thyroid eye disease 
&lt;LI&gt;Optic neuropathy 
&lt;LI&gt;Passive smoking and eye disease 
&lt;LI&gt;Education campaigns&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published September 2005&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330523</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/content/32/10/1924.abstract]]&gt;</url>
    <title>Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; Although statin therapy greatly lowers vascular risk, including among those with and at risk for diabetes, the relationship of statin therapy to incident diabetes remains uncertain. Future statin trials should be designed to formally address this issue. &lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A systematic literature search for randomized statin trials that reported data on diabetes through February 2009 was conducted using specific search terms. In addition to the hypothesis-generating data from WOSCOPS, hypothesis-testing data were available from the Heart Protection Study (HPS), the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study, the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), and the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA), together including 57,593 patients with mean follow-up of 3.9 years during which 2,082 incident diabetes cases accrued. Weighted averages were reported as risk ratios (RRs) with 95% CIs using a random-effects model. Statistical heterogeneity scores were assessed with the Q and I2 statistic.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; In the meta-analysis of the hypothesis-testing trials, we observed a small increase in diabetes risk (RR 1.13 [95% CI 1.03–1.23]) with no evidence of heterogeneity across trials. However, this estimate was attenuated and no longer significant when the hypothesis-generating trial WOSCOPS was included (1.06 [0.93–1.25]) and also resulted in significant heterogeneity (Q 11.8 [5 d.f.], P = 0.03, I2 = 57.7%).&amp;nbsp; &lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Rajpathak SW Kumbhani DJ, Crandall J et al Statin therapy and Risk of Developing type 2 Diabetes: a Meta-Analysis Diabetes Care 32: 1924-1929&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history:&lt;/STRONG&gt; Published in October 2009.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full-text online access of this article requires subscription to the journal.&amp;nbsp; Full-text online access is available to NHS staff in England via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/Default.aspx" target="_blank"&gt;NHS Evidence&lt;/A&gt;.&amp;nbsp; Other NHS staff should check with &lt;A href="http://www.hlisd.org/" target="_blank"&gt;your local NHS library&lt;/A&gt;.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Also see this comment:&lt;/STRONG&gt; &lt;A href="http://care.diabetesjournals.org/content/32/10/1941" target="_blank"&gt;Belalcazar LM, Raghavan VA, Ballantyne CM Statin-Induced diabetes: will it change practice (editorial) Diabetes Care 32:1941-43&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60000</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/booth/cardiac/statdiab.html]]&gt;</url>
    <title>Statin use in diabetics</title>
    <publicationDate>2007-04-01T00:00:00</publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ PREVENTION,DYSLIPIDAEMIA,CARDIOVASCULAR,CHRONIC COMPLICATIONS,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This section of the Bandolier Knowledge Library&amp;nbsp;describes and reviews&amp;nbsp;a 2003 paper concerning cholesterol-lowering with simvastatin in people with diabetes. The paper analysed results from the MRC/BHF Heart Protection Study.]]&gt;</body>
  </document>
  <document>
    <id>300938</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Professionals/Publications-reports-and-resources/Reports-statistics-and-case-studies/Reports/Structured-Education-Self-Assessment-Toolkit/]]&gt;</url>
    <title>Structured education self assessment toolkit</title>
    <publicationDate>2008-01-16T00:00:00</publicationDate>
    <publisher>Diabetes UK, NHS National Diabetes Support Team, Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;toolkit to support the assessment of structured education programmes for people with diabetes has been developed by Diabetes UK, the Department of Health and the National Diabetes Support Team.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>93131</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/11/31/97/04113197.pdf]]&gt;</url>
    <title>Structured patient education in diabetes : report from the Patient Education Working Group</title>
    <publicationDate>2005-06-15T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,KEY POLICIES / NSF,PATIENT EDUCATION AND EMPOWERMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The report on the Department of Health website sets out in detail the necessary ingredients for developing a high-quality patient education programme. It highlights best practice to enable local services to meet the recommendations outlined in the Diabetes NSF and NICE Health Technology Appraisal on Patient education models.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Also available:&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4113213&amp;amp;chk=NtfDpo" target="_blank"&gt;Patient information leaflet&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187551</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=16922700]]&gt;</url>
    <title>Structured patient education: the diabetes X-PERT Programme makes a difference</title>
    <publicationDate>2006-09-01T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ RESEARCH,GROUND-BREAKING ARTICLES,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed abstract&lt;BR&gt;"Participation in the X-PERT Programme by adults with Type 2 diabetes was shown at 14 months to have led to improved glycaemic control, reduced total cholesterol level, body weight, BMI and waist circumference, reduced requirement for diabetes medication, increased consumption of fruit and vegetables, enjoyment of food, knowledge of diabetes, self-empowerment, self-management skills and treatment satisfaction."&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed abstract&lt;BR&gt;"Adults with Type 2 diabetes (n = 314), living in Burnley, Pendle or Rossendale, Lancashire, UK were randomized to either individual appointments (control group) (n = 157) or the X-PERT Programme (n = 157). X-PERT patients were invited to attend six 2-h group sessions of self-management education. Outcomes were assessed at baseline, 4 and 14" months."&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed abstract&lt;BR&gt;"One hundred and forty-nine participants (95%) attended the X-PERT Programme, with 128 (82%) attending four or more sessions. By 14 months the X-PERT group compared with the control group showed significant improvements in the mean HbA1c (- 0.6% vs. + 0.1%, repeated measures anova, P &amp;lt; 0.001). The number needed to treat (NNT) for preventing diabetes medication increase was 4 [95% confidence interval (CI) 3, 7] and NNT for reducing diabetes medication was 7 (95% CI 5, 11). Statistically significant improvements were also shown in the X-PERT patients compared with the control patients for body weight, body mass index (BMI), waist circumference, total cholesterol, self-empowerment, diabetes knowledge, physical activity levels, foot care, fruit and vegetable intake, enjoyment of food and treatment satisfaction."&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Deakin TA, Cade JE, Williams R, Greenwood DC. Structured patient education: the diabetes X-PERT Programme makes a difference. Diabetic Medicine 2006 Sep;23(9):944-54.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full text online requires subscription to the journal. NHS staff please &lt;A href="http://www.hlisd.org/" target="_blank"&gt;contact your local NHS library for further assistance.&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309843</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=185]]&gt;</url>
    <title>Supporting diabetes care</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ USER INVOLVEMENT,DATA GATHERING AND AUDIT AND QOF,DIABETES,DELIVERY OF CARE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The NHS Information Centre has published a brochure looking at the information on diabetes provided through the NHS Information Centre, and also about the National Diabetes Information&amp;nbsp;Service (NDIS)&amp;nbsp;which will bring together all diabetes data and resources from a variety of sources and organisations.&lt;/P&gt;
&lt;P&gt;Sections include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;What is the National Diabetes Information Service? 
&lt;LI&gt;What is the National Diabetes Audit? 
&lt;LI&gt;Prescribing for diabetes 
&lt;LI&gt;Children with diabetes 
&lt;LI&gt;About the Diabetes Patient Experience Project 
&lt;LI&gt;How you can support the National Diabetes Information Service&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293247</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/our_work_areas/supporting_self_care/]]&gt;</url>
    <title>Supporting self care of diabetes  - Work Area - NHS Diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,PATIENT AND PUBLIC INVOLVEMENT,PPI IN PRACTICE,INDIVIDUAL INVOLVEMENT,SELF MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This section of the NHS Diabetes website provides details of the work of the Working Group on Supporting self care of diabetes and includes links to other resources.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the NHS Diabetes&amp;nbsp;website provides details of the work of the Working Group on Supporting self care of diabetes and includes links to other resources.&lt;/P&gt;
&lt;P&gt;Self Care work is being supported and delivered by NHS Diabetes through a number of work streams which include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Patient education 
&lt;LI&gt;Year of Care and care planning 
&lt;LI&gt;Emotional and Psychological support 
&lt;LI&gt;Self-monitoring blood glucose&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>66431</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;pubmedid=12623912]]&gt;</url>
    <title>Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes</title>
    <publicationDate></publicationDate>
    <publisher>British Medical Journal</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CARDIOVASCULAR,CHRONIC COMPLICATIONS,DYSLIPIDAEMIA,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV&gt;
&lt;P&gt;&lt;STRONG&gt;Full reference:&lt;BR&gt;&lt;/STRONG&gt;Gami AS, Montori VM, Erwin PJ, Khan MA, Smith SA. Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes. British Medical Journal. 2003: 326 (7388); 528-529.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>299132</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.annals.org/cgi/content/full/149/8/549]]&gt;</url>
    <title>Systematic Review: Comparative Effectiveness and Safety of Premixed Insulin Analogues in Type 2 Diabetes</title>
    <publicationDate>2008-11-19T00:00:00</publicationDate>
    <publisher>Annals of Internal Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,MEDICATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Premixed insulin analogues provide glycemic control similar to that of premixed human insulin and may provide tighter glycemic control than long-acting insulin analogues and noninsulin antidiabetic agents.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; The authors searched MEDLINE, EMBASE, CINAHL, and the Cochrane Central Register of Controlled Trials from inception to February 2008 and sought unpublished data from the U.S. Food and Drug Administration, European Medicines Agency, and industry. Studies with control groups that compared premixed insulin analogues with another antidiabetic medication in adults with type 2 diabetes. Two reviewers using standardized protocols performed serial abstraction.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Evidence from clinical trials was inconclusive for clinical outcomes, such as mortality. Therefore, the review focused on intermediate outcomes. Premixed insulin analogues were similar to premixed human insulin in decreasing fasting glucose levels, hemoglobin A1c levels, and the incidence of hypoglycemia but were more effective in decreasing postprandial glucose levels (mean difference, -1.1 mmol/L; 95% CI, -1.4 to -0.7 mmol/L [-19.2 mg/dL; 95% CI, -25.9 to -12.5 mg/dL]). Compared with long-acting insulin analogues, premixed insulin analogues were superior in decreasing postprandial glucose levels (mean difference, -1.5 mmol/L; CI, -1.9 to -1.2 mmol/L [-27.9 mg/dL; CI, -34.3 to -21.5 mg/dL]) and hemoglobin A1c levels (mean difference, -0.39% [CI, -0.50% to -0.28%]) but were inferior in decreasing fasting glucose levels (mean difference, 0.7 mmol/L; CI, 0.3 to 1.0 mmol/L [12.0 mg/dL; CI, 6.0 to 18.1 mg/dL]) and were associated with a higher incidence of hypoglycemia. Compared with noninsulin antidiabetic agents, premixed insulin analogues were more effective in decreasing fasting glucose levels (mean difference, -1.1 mmol/L; CI, -1.7 to -0.6 mmol/L [-20.5 mg/dL; CI, -29.9 to -11.2 mg/dL]), postprandial glucose levels (mean difference, -2.1 mmol/L; CI, -3.4 to -0.8 mmol/L [-37.4 mg/dL; CI, -61.0 to -13.7 mg/dL]), and hemoglobin A1c levels (mean difference, -0.49% [CI, -0.86% to -0.12%]) but were associated with a higher incidence of hypoglycemia.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Qayyum, R., Bolen, S., Maruthur, N., Feldman, L., Wilson, L. M., Marinopoulos, S. S., Ranasinghe, P., Amer, M. &amp;amp; Bass, E. B. (2008) Systematic Review: Comparative Effectiveness and Safety of Premixed Insulin Analogues in Type 2 Diabetes. &lt;I&gt;Annals of Internal Medicine,&lt;/I&gt; 149&lt;B&gt;,&lt;/B&gt; 549-559.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2008.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325899</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/Eyes/ViewResource.aspx?resID=320369]]&gt;</url>
    <title>Systematic reviews on diabetic retinopathy 1997-to-date</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,CHRONIC COMPLICATIONS,DIAGNOSIS,CONDITION MANAGEMENT,CAUSES,EYE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The eyes and vision specialist collection has searched for and quality appraised, using a tool based on QUORUM criteria, all the systematic reviews relevant to eye health care, that have been published since 1997.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;New systematic reviews will be identified and appraised on a half yearly basis.&amp;nbsp; Our 'new content' RSS feed will be updated when new reviews are added to the collection.&amp;nbsp;&amp;nbsp; &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;This page lists all the systematic reviews, relevant to diabetic retinopathy, that have been published since 1997.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>124023</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nao.org.uk//idoc.ashx?docId=d643e345-940d-452a-b7e1-3c3e11ccc206&amp;version=-1]]&gt;</url>
    <title>Tackling child obesity : first steps</title>
    <publicationDate>2006-02-28T00:00:00</publicationDate>
    <publisher>National Audit Office</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CHILDREN AND YOUNG PEOPLE,BIOLOGICAL COMPOSITION,OBESITY,CHILDREN,OBESITY,PREVENTION,DIABETES,TYPE 2,PUBLIC HEALTH,DETERMINANTS,PREVENTION,CONDITION MANAGEMENT,AGE GROUPS,POPULATIONS,GROUPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This joint report from the Healthcare Commission, the National Audit Office and the&amp;nbsp;Audit Commission examines the efficiency and effectiveness of the delivery chain to reduce child obesity. The target 'to halt the increase in obesity among children under the age of 11 by 2010' was set in 2004 as a Public Service Agreement in response to a jump in the growth of childhood obesity. The report concludes that there is a risk that the government's target (jointly held by DH, DfES and DCMS) may not be met unless the departments provide clear leadership and guidance.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published 28 February 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60137</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/]]&gt;</url>
    <title>Teaching Letters</title>
    <publicationDate></publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT,CPD AND PROFESSIONAL EDUCATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The Diabetes Education Study Group (DESG)&amp;nbsp;has produced a series of &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;Teaching Letters&lt;/A&gt; for doctors and other health care professionals involved in the daily care of patients with diabetes. This section of their website gives some background information to the series.]]&gt;</body>
  </document>
  <document>
    <id>82713</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.audit-commission.gov.uk/SiteCollectionDocuments/AuditCommissionReports/NationalStudies/nrdiabet.pdf]]&gt;</url>
    <title>Testing times : a review of diabetes services in England and Wales</title>
    <publicationDate>2000-04-12T00:00:00</publicationDate>
    <publisher>Audit Commission</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,SERVICE DELIVERY,NHS ACTIVITIES,HEALTH MANAGEMENT,ORGANISATION OF CARE / CARE PLANNING,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;Audit Commission&amp;nbsp;report describes the state of diabetes services in 2000 and also considers the possible future direction of diabetes services, in the light of increasing demand. The report was based on research conducted at nine hospitals throughout the country, surveys of general practitioners, health authorities and patients. It includes the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Understanding diabetes 
&lt;LI&gt;Planning services 
&lt;LI&gt;Delivering effective care 
&lt;LI&gt;Meeting the challenges of the 21st Century&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published 2000.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307451</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://dvd.sagepub.com/]]&gt;</url>
    <title>The British Journal of Diabetes and Vascular Disease</title>
    <publicationDate></publicationDate>
    <publisher>The British Journal of Diabetes and Vascular Disease</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The British Journal of Diabetes &amp;amp; Vascular Disease is a bi-monthly, peer reviewed journal that disseminates topical and practical information to the diabetes care team.&lt;/P&gt;
&lt;P&gt;Sign up for an &lt;A href="http://dvd.sagepub.com/cgi/alerts" target="_blank"&gt;email alert &lt;/A&gt;of this journal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;NHS staff: see this journal via the NLH My Journals page, where (if you log in with your Athens password) you can search for full text, recieve a table of contents alert via Zetoc, locate items in your local library and create search alerts.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: NHS staff in England: full text &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/Default.aspx" target="_blank"&gt;available via NHS Evidence&lt;/A&gt;, other NHS staff: check with your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307457</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcgp.org.uk/publications/bjgp.aspx]]&gt;</url>
    <title>The British Journal of General Practice</title>
    <publicationDate></publicationDate>
    <publisher>The British Journal of General Practice</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The British Journal of General Practice is an international journal publishing articles of interest to family practitioners worldwide.&lt;BR&gt;&lt;BR&gt;NHS staff: see this journal via the NHS Evidence&amp;nbsp;My Journals page, where (if you log in with your Athens password) you can search for full text, receive a table of contents alert via Zetoc, locate items in your local library and create search alerts.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; NHS staff in England: full access available via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/Default.aspx" target="_blank"&gt;NHS Evidence 'My Journals' page&lt;/A&gt;, other NHS staff: check with your l&lt;A href="http://www.hlisd.org/" target="_blank"&gt;ocal NHS library&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>260989</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Documents/News/Heartache_report07.pdf]]&gt;</url>
    <title>The diabetes heartache: the hard reality of cardiovascular care for people with diabetes</title>
    <publicationDate></publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CAUSES,CHRONIC COMPLICATIONS,CARDIOVASCULAR,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;report from&amp;nbsp;Diabetes UK&amp;nbsp;discusses the cardiovascular risk associated with&amp;nbsp;diabetes and&amp;nbsp;reports that many people with diabetes are not receiving the recommended care and treatment to reduce their cardiovascular disease risk.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published May 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>154840</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.abpi.org.uk/%2Fpublications%2Fpdfs%2Fdiabetes%5Fjigsaw%2Epdf]]&gt;</url>
    <title>The diabetes information jigsaw : report investigating information access for people with diabetes</title>
    <publicationDate>2006-07-01T00:00:00</publicationDate>
    <publisher>Association of the British Pharmaceutical Industry (ABPI)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report published jointly by Diabetes UK, the Association of the British Pharmaceutical Industry (ABPI) and Ask About Medicines,&amp;nbsp;supports the use of a personalised information provision&amp;nbsp;approach for people with diabetes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published Jul&amp;nbsp;2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346703</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=1064]]&gt;</url>
    <title>The Diabetes UK and NHS Diabetes workforce database of United Kingdom Diabetes Specialist Nurses and Nurse Consultants</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ COMMISSIONING,DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This factsheet from NHS Diabetes summarises the results of a survey&amp;nbsp;carried out in September 2009 to gather information on:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;How many DSNs and Nurse Consultants there are working in the UK&lt;/LI&gt;
&lt;LI&gt;What the work setting of DSNs and Nurse Consultants is&lt;/LI&gt;
&lt;LI&gt;What roles DSNs and Nurse Consultants are carrying out&lt;/LI&gt;
&lt;LI&gt;What qualifications DSNs and Nurse Consultants have gained&lt;/LI&gt;
&lt;LI&gt;What band level DSNs and Nurse Consultants have been awarded&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in February 2010.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public, Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60182</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://content.nejm.org/cgi/content/full/329/14/977]]&gt;</url>
    <title>The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus</title>
    <publicationDate>1993-09-30T00:00:00</publicationDate>
    <publisher>New England Journal of Medicine</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,GROUND-BREAKING ARTICLES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;/STRONG&gt;&lt;BR&gt;The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;BR&gt;&lt;STRONG&gt;&lt;BR&gt;Additional information:&lt;BR&gt;&lt;/STRONG&gt;Link to the &lt;A href="http://diabetes.niddk.nih.gov/dm/pubs/control/index.htm" target="_blank"&gt;Diabetes Control and Complications Trial (DCCT) pages &lt;/A&gt;on the National Diabetes Information Clearinghouse (NDIC) website&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388844</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20484130]]&gt;</url>
    <title>The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis.</title>
    <publicationDate>2010-08-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MEDICATION,MEDICATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Sherifali D, Nerenberg K, Pullenayegum E, et al. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care. August;33(8):1859-64. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in August 2010. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Access to the full text online requires subscription to the journal. NHS staff please contact &lt;A href="http://www.hlisd.org/" target="_blank"&gt;your local NHS library &lt;/A&gt;for further assistance.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60157</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,165/Itemid,61/]]&gt;</url>
    <title>The function of psycho-social support in diabetes education (teaching letter no.20)</title>
    <publicationDate>2000-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PSYCHOLOGICAL PROBLEMS,DELIVERY OF CARE,CHRONIC COMPLICATIONS,PATIENT EDUCATION AND EMPOWERMENT,CONDITION MANAGEMENT,PSYCHOSOCIAL CARE,ANXIETY AND DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the function of psycho-social support in diabetes patient education and covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Aims of this letter 
&lt;LI&gt;Introduction 
&lt;LI&gt;Clues to psychosocial conditions 
&lt;LI&gt;How to provide support 
&lt;UL&gt;
&lt;LI&gt;Requirements 
&lt;LI&gt;Timing&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Target groups 
&lt;LI&gt;A guide for evaluation 
&lt;UL&gt;
&lt;LI&gt;Practical example&lt;/LI&gt;&lt;/UL&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307429</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.thelancet.com/]]&gt;</url>
    <title>The Lancet</title>
    <publicationDate></publicationDate>
    <publisher>Lancet</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Lancet publishes medical news, original research, and reviews on all aspects of clinical medicine and public health. They seek to publish high-quality clinical trials that will alter medical practice.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full access online requires subscription to the journal. NHS staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library &lt;/A&gt;for further assistance.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307433</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://content.nejm.org/]]&gt;</url>
    <title>The New England Journal of Medicine</title>
    <publicationDate></publicationDate>
    <publisher>New England Journal of Medicine</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The New England Journal of Medicine, published by the Massachusetts Medical Society is a peer-reviewed medical journal. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Full access online requires subscription to the journal. Full-text online access is available to NHS staff in England via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/Default.aspx" target="_blank"&gt;NHS Evidence&lt;/A&gt;.&amp;nbsp; Other NHS staff should check with your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322257</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/aboutnice/qof/qof.jsp]]&gt;</url>
    <title>The NICE QOF Indicator Programme</title>
    <publicationDate>2009-08-10T00:00:00</publicationDate>
    <publisher>NICE</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DELIVERY OF CARE,DIABETES,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the NICE website explains NICE's role in QOF.&amp;nbsp; In summary: NICE's role is to manage the process to develop the clinical and health improvement indicators for the QOF. This involves prioritising areas for new indicator development, developing and selecting indicators, and ensuring consultation with individuals and stakeholder groups.&lt;BR&gt;&lt;BR&gt;NICE&amp;nbsp;will also recommend whether existing indicators should continue to be part of the QOF. For example, where the activity being measured has become part of standard clinical practice, there would no longer be a need to provide a financial incentive.&lt;/P&gt;
&lt;P&gt;This section of the NICE website&amp;nbsp;provides links to&amp;nbsp;further details on: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;What is QOF 
&lt;LI&gt;The process for developing the QOF indicators 
&lt;LI&gt;NICE menu of indicators 
&lt;LI&gt;Why NICE is involved in QOF 
&lt;LI&gt;What NICE adds to QOF 
&lt;LI&gt;Partner organisations that are involved&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383358</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.sdo.nihr.ac.uk/projdetails.php?ref=08-1809-249]]&gt;</url>
    <title>The organisation &amp; delivery of diabetes services in the UK: a scoping exercise</title>
    <publicationDate>2010-07-27T00:00:00</publicationDate>
    <publisher>NHS Service Delivery and Organisation Research and Development Programme</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A research report from the NIHR Service Delivery and Organisation (SDO) programme.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Diabetes is one of the most important diseases confronting the United Kingdom's (UK) health care system. Therefore, understanding how best to organise diabetes services is vital area if the health system is going to cope with the expansion in both the demand for and cost of diabetes care. &lt;BR&gt;This scoping exercise aims to provide an overview of current developments in the organisation and delivery of diabetes services in the UK.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346673</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=1065]]&gt;</url>
    <title>The organisation and delivery of diabetes services in the UK: a scoping exercise of research gaps and priorities</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A factsheet from NHS Diabetes.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This factsheet from NHS Diabetes summarises the findings of a&amp;nbsp;scoping exercise by NHS Diabetes that was designed to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Provide an overview of current issues and developments in the organisation and delivery of diabetes services. 
&lt;LI&gt;Produce a synthesis of the evidence and give examples. 
&lt;LI&gt;Detail stakeholder concerns. 
&lt;LI&gt;Recommend further research and type of approach.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in February 2010.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public, Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342741</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.sdo.nihr.ac.uk/projdetails.php?ref=08-1504-111]]&gt;</url>
    <title>The POSEIDON trial: promoting collaborative support and education in diabetes for minority ethnic groups</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>NHS Service Delivery and Organisation Research and Development Programme</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PATIENT EDUCATION AND EMPOWERMENT,DELIVERY OF CARE,PEOPLE FROM ETHNIC MINORITIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This research report describes&amp;nbsp;the POSEIDON trial which sought to promote collaborative support and education in diabetes for minority ethnic groups. &lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;To measure the impact of BHA-led diabetes story-sharing groups for minority ethnic groups with diabetes on clinical, biochemical and psychosocial outcomes. 
&lt;LI&gt;To explore process aspects of the intervention, especially the mechanism by which the group experience leads (or fails to lead) to improved diabetes outcomes. 
&lt;LI&gt;To document and develop the organisational component, especially the patient pathway, human resource issues, data/informatics issues, costs, and sustainability. &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Type and location of research:&lt;/STRONG&gt; Pilot randomised controlled trial with in-depth process evaluation, in an inner London district general hospital (Newham University Hospital NHS Trust). &lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt;&amp;nbsp;The population is 240 people with diabetes aged over 18, referred (or self-referred) for diabetes education, who speak one of the languages in which story-sharing groups are offered - that is, Urdu, Sylheti, Tamil, Somali, or English (for African-Caribbeans). &lt;BR&gt;The intervention will has three components: &lt;BR&gt;1. Professional development groups for BHAs using a validated ‘learning set’ model (in which stories about clients with diabetes form the basis of facilitated group discussion). &lt;BR&gt;2. Story-sharing groups led by BHA with support from diabetes specialist nurse (DSN). Stories about living with diabetes will form the basis of group discussions. &lt;BR&gt;3. Organisational support for establishing these groups, including development and mainstreaming of patient pathways, data management, and information systems. &lt;BR&gt;The comparison will be referral to traditional NHS education sessions (e.g. routine nurse led education groups in either primary or secondary care, or one to one education via GP or in hospital clinic) with an interpreter if needed to accompany them.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Published July 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/?promoid=BUIGO" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>149125</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16620276]]&gt;</url>
    <title>The prevalence of co-morbid depression in adults with Type 1 diabetes: systematic literature review.</title>
    <publicationDate>2006-04-01T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ ANXIETY AND DEPRESSION,DIABETES,PSYCHOLOGICAL PROBLEMS,CHRONIC COMPLICATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;BR&gt;&lt;/STRONG&gt;Barnard KD, Skinner TC, Peveler R. The prevalence of co-morbid depression in adults with Type 1 diabetes: systematic literature review. Diabet Med. 2006 Apr;23(4):445-8.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Access to the full text online requires subscription to the journal.&lt;BR&gt;NHS staff please &lt;A href="http://www.hlisd.org/" target="_blank"&gt;contact your local NHS library for further assistance.&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>224050</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17054590?dopt=Abstract]]&gt;</url>
    <title>The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis.</title>
    <publicationDate>2006-11-01T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,PSYCHOLOGICAL PROBLEMS,CHRONIC COMPLICATIONS,ANXIETY AND DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full Reference:&lt;BR&gt;&lt;/STRONG&gt;Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis.Diabet Med.2006 Nov;23(11):1165-73.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full text online requires subscription to the journal.&lt;/P&gt;
&lt;P&gt;NHS staff please &lt;A href="http://www.hlisd.org/" target="_blank"&gt;contact your local NHS library for further assistance.&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>266398</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/diabetes1/resources/merec_bulletin_vol17_no4_summary.pdf]]&gt;</url>
    <title>The role of newer insulins in diabetes: summary</title>
    <publicationDate></publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CONDITION MANAGEMENT,CONDITION MANAGEMENT,TYPE 1,TYPE 2,DIABETES,MEDICATION,MEDICATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;MeReC&amp;nbsp;bulletin considers the evidence supporting the use of the newer insulins and their role in patients with type 1 and type 2 diabetes.&amp;nbsp; In particular, the rapid-acting and long-acting insulin analogues are discussed, but some attention is also given to inhaled insulin. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;Vol 17 No 4&amp;nbsp;June 2007&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281717</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;pubmedid=17983433]]&gt;</url>
    <title>The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>International Journal of Clinical Practice</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,CARDIOVASCULAR,CHRONIC COMPLICATIONS,HYPERTENSION,DYSLIPIDAEMIA,TREATMENT CONCORDANCE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Non-compliance with cardiovascular and antidiabetic medication is a significant problem, with around 30% of days ‘on therapy’ not covered by medication and only 59% of patients taking medication for more than 80% of their days ‘on therapy’ in a year. Good compliance has a positive effect on clinical outcome, suggesting that the management of CVD may be improved by improving patient compliance.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; English language papers published between January 2000 and November 2005 investigating patient compliance/persistence with cardiovascular or antidiabetic medication were identified through searches of the MEDLINE and EMBASE databases. Definitions and measurements of compliance/persistence were compared across therapeutic areas using contingency tables.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Of the 139 studies analysed, 32% focused on hypertension, 27% on diabetes and 13% on dyslipidaemia. The remainder covered coronary heart disease and cardiovascular disease (CVD) in general. The most frequently reported measure of compliance was the 12-month medication possession ratio (MPR). The overall mean MPR was 72%, and the MPR did not differ significantly between treatment classes (range: 67–76%). The average proportion of patients with an MPR of &amp;gt; 80% was 59% overall, 64% for antihypertensives, 58% for oral antidiabetics, 51% for lipid-lowering agents and 69% in studies of multiple treatments, again with no significant difference between treatment classes. The average 12-month persistence rate was 63% and was similar across therapeutic classes. Good compliance had a positive effect on outcome in 73% of the studies examining clinical outcomes.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Cramer JA, Benedict A, Muszbek N et al.&amp;nbsp;&amp;nbsp;The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review.&amp;nbsp; Int J Clin Pract 62: 76-87.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in 2008&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=17983433" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>182001</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;Cmd=ShowDetailView&amp;TermToSearch=16911617&amp;ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>The social and economic consequences of childhood onset type 1 diabetes across the lifecourse : a systematic review</title>
    <publicationDate></publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GENERAL,LIVING WITH DIABETES,EMPLOYMENT,DIABETES,TYPE 1,CHILDREN AND YOUNG PEOPLE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;BR&gt;&lt;/STRONG&gt;Milton B, Holland P, Whitehead M.&amp;nbsp; The social and economic consequences of childhood onset type 1 diabetes across the lifecourse: a systematic review. Diabetic Medicine Aug 2006;&amp;nbsp;23(8):821-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full text online requires subscription to the journal.&lt;/P&gt;
&lt;P&gt;NHS staff please &lt;A href="http://www.hlisd.org/" target="_blank"&gt;contact your local NHS library for further assistance&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>258658</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_072812]]&gt;</url>
    <title>The way ahead: the local challenge improving diabetes services (NSF four years on)</title>
    <publicationDate>2007-03-08T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RETINOPATHY,RETINA,DIABETIC RETINOPATHY,CONDITIONS,DIABETES,EYES AND VISION,DELIVERY OF CARE,KEY POLICIES / NSF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The diabetes national service framework (NSF) set out the first ever set of national standards for the treatment of diabetes to raise the quality of NHS services and reduce unacceptable variations between them. This report highlights progress over the first four years following the publication of the &lt;A href="http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4003246&amp;amp;chk=lKNg9r" target="_blank"&gt;NSF Delivery Strategy&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>121185</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=413]]&gt;</url>
    <title>The white paper : our health, our care, our say: a new direction for community services : what this means for diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ COMMISSIONING,DIABETES,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT,DELIVERY OF CARE,USER INVOLVEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This National Diabetes Support Team&amp;nbsp;briefing&amp;nbsp;is concerned with&amp;nbsp;the white paper &lt;A href="http://www.library.nhs.uk/DIABETES/ViewResource.aspx?resID=114351" target="_blank"&gt;'Our health, our care, our say'&lt;/A&gt;. It&amp;nbsp;provides a brief introduction to the main points for the diabetes community, and how they link with some of the other work already going on to support the delivery of the Diabetes NSF. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published&amp;nbsp;February 2006.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60156</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,164/Itemid,61/]]&gt;</url>
    <title>Therapeutic diabetes education in camp settings (teaching letter no.19)</title>
    <publicationDate>2000-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the camp setting&amp;nbsp;for therapeutic diabetes education and covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Definition 
&lt;LI&gt;General Objectives 
&lt;LI&gt;Objectives for specific groups 
&lt;UL&gt;
&lt;LI&gt;For children from age 6 to 12 
&lt;LI&gt;For adolescents and young adults 
&lt;LI&gt;For parents 
&lt;LI&gt;For adults, especially those with type 2 diabetes 
&lt;LI&gt;For the team&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Pedagogical principles and structure 
&lt;UL&gt;
&lt;LI&gt;Suggested practical methods&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;The education team 
&lt;UL&gt;
&lt;LI&gt;The team involved should include 
&lt;LI&gt;Basic characteristics and requirements of educators 
&lt;LI&gt;Training&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Organization 
&lt;LI&gt;Evaluation 
&lt;UL&gt;
&lt;LI&gt;Knowledge 
&lt;LI&gt;Self-management and skills 
&lt;LI&gt;Psychological aspects 
&lt;LI&gt;Lifestyle 
&lt;LI&gt;For the team&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Conclusion&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 2000&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60158</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,182/Itemid,61/]]&gt;</url>
    <title>Therapeutic education: what a diabetes centre should provide (teaching letter no.21)</title>
    <publicationDate>2000-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,PATIENT EDUCATION AND EMPOWERMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns diabetes centres and what therapeutic education they should provide. It covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Minimum prerequisites for an educational program 
&lt;UL&gt;
&lt;LI&gt;Evaluation of patients 
&lt;LI&gt;Staff 
&lt;LI&gt;A team approach 
&lt;LI&gt;Psychological aspects&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Content of the educational program 
&lt;LI&gt;Teaching methods 
&lt;UL&gt;
&lt;LI&gt;Individual teaching 
&lt;LI&gt;Group teaching&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Education of Health Professionals 
&lt;UL&gt;
&lt;LI&gt;Organization of professional education 
&lt;LI&gt;Education in the community&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Conclusion&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 2000&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60144</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,155/Itemid,61/]]&gt;</url>
    <title>Therapeutics and education: the added value of therapy (teaching letter no.8)</title>
    <publicationDate>1997-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns therapeutics and education of people with diabetes. Along with a substantial introduction, it&amp;nbsp;describes&amp;nbsp;the process&amp;nbsp;of helping patients to learn how to manage their treatment using the following four steps (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;To explain - to listen and to reformulate what the patient has said 
&lt;LI&gt;Scholerly language - common language 
&lt;LI&gt;Know-how linked to treatment 
&lt;LI&gt;Using the mistake&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 1997&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60281</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;pubmedid=9732337]]&gt;</url>
    <title>Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38)</title>
    <publicationDate>1998-09-12T00:00:00</publicationDate>
    <publisher>British Medical Journal</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,GROUND-BREAKING ARTICLES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed&lt;BR&gt;"Tight blood pressure control in patients with hypertension and type 2 diabetes achieves a clinically important reduction in the risk of deaths related to diabetes, complications related to diabetes, progression of diabetic retinopathy, and deterioration in visual acuity."&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;BR&gt;&lt;/STRONG&gt;Taken from PubMed&lt;BR&gt;&lt;STRONG&gt;"&lt;/STRONG&gt;Randomised controlled trial comparing tight control of blood pressure aiming at a blood pressure of &amp;lt;150/85mmHg (with the use of an angiotensin converting enzyme inhibitor captopril or a ß blocker atenolol as main treatment) with less tight control aiming at a blood pressure of &amp;lt;180/105mm Hg."&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed&lt;BR&gt;"Mean blood pressure during follow up was significantly reduced in the group assigned tight blood pressure control (144/82mm Hg) compared with the group assigned to less tight control (154/87mm Hg) (P&amp;lt;0.0001). Reductions in risk in the group assigned to tight control compared with that assigned to less tight control were 24% in diabetes related end points (95% confidence interval 8% to 38%) (P=0.0046), 32% in deaths related to diabetes (6% to 51%) (P=0.019), 44% in strokes (11% to 65%) (P=0.013), and 37% in microvascular end points (11% to 56%) (P=0.0092), predominantly owing to a reduced risk of retinal photocoagulation. There was a non-significant reduction in all cause mortality. After nine years of follow up the group assigned to tight blood pressure control also had a 34% reduction in risk in the proportion of patients with deterioration of retinopathy by two steps (99% confidence interval 11% to 50%) (P=0.0004) and a 47% reduced risk (7% to 70%) (P=0.004) of deterioration in visual acuity by three lines of the early treatment of diabetic retinopathy study (ETDRS) chart. After nine years of follow up 29% of patients in the group assigned to tight control required three or more treatments to lower blood pressure to achieve target blood pressures."&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ. 1998 Sep 12;317(7160):703-13. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in September 1998&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to the general public. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Additional information: &lt;/STRONG&gt;&lt;A href="http://www.dtu.ox.ac.uk/index.php?maindoc=/ukpds/" target="_blank"&gt;Link to the UKPDS website&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>300941</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Professionals/Publications-reports-and-resources/Reports-statistics-and-case-studies/Reports/Tools-to-measure-quality-of-life-emotional-and-psychological-need-for-people-with-diabetes/]]&gt;</url>
    <title>Tools to measure quality of life, emotional and psychological needs of people with diabetes – patient reported outcomes</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,PSYCHOLOGICAL PROBLEMS,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,CONDITION MANAGEMENT,PSYCHOSOCIAL CARE,PSYCHOSOCIAL CARE,ANXIETY AND DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the&amp;nbsp;Diabetes UK&amp;nbsp;website provides information about tools to measure quality of life, emotional and psychological needs of people with diabetes. It is&amp;nbsp;aimed at&amp;nbsp;healthcare professionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310550</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Healthcare/Children/Transitionfromchildrenstoadultservices/index.htm]]&gt;</url>
    <title>Transition from children's to adult services</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CHILDREN AND YOUNG PEOPLE,CHILDREN AND YOUNG PEOPLE,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,TYPE 2,TYPE 1,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Many children and young people now survive into adult life with complex conditions that previously would have been fatal in infancy. This section of the Department of Health website explains how this transition should be planned and managed as a process.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>112987</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band136/b136-2.html]]&gt;</url>
    <title>Treating type 2 diabetes : how are we doing?</title>
    <publicationDate></publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,ORGANISATION OF CARE / CARE PLANNING,CONDITION MANAGEMENT,DELIVERY OF CARE,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier&amp;nbsp;article describes and reviews evidence (1 paper) to consider how well type 2 diabetes is treated in the UK. 
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Review published June 2005.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>143212</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4136141&amp;chk=uS4XxF]]&gt;</url>
    <title>Turning the corner: improving diabetes care (NSF three years on)</title>
    <publicationDate>2006-06-13T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,EYES AND VISION,KEY POLICIES / NSF,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Department of Health report highlights progress over the first three years following the&amp;nbsp;implementation of the &lt;A href="http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Diabetes/index.htm" target="_blank"&gt;Diabetes National Service Framework (NSF)&lt;/A&gt;&amp;nbsp;and publication of the &lt;A href="http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4003246&amp;amp;chk=lKNg9r" target="_blank"&gt;NSF Delivery Strategy&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386464</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://eng.mapofmedicine.com/evidence/map/type_1_diabetes_mellitus_in_children_and_adolescents1.html]]&gt;</url>
    <title>Type 1 diabetes mellitus in children and adolescents - suspected diabetes</title>
    <publicationDate>2010-07-29T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,KETOACIDOSIS,HYPOGLYCAEMIA,ACUTE COMPLICATIONS,DIAGNOSIS,CONDITION MANAGEMENT,CHILDREN AND YOUNG PEOPLE,DIAGNOSIS,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Map of Medicine care pathway</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt; To provide overview care pathways for the diagnosis and management of&amp;nbsp;type 1 diabetes in children and adolescents.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; The Map of Medicine is a visual representation of evidence-based, practice-informed care pathways. It is designed for use by healthcare professionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; NHS staff in England: England national level pathways are freely available. You can also log on to the Map of Medicine using NHS Athens to gain access to the locally-adapted pathways.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>61404</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_briefing_no25.pdf]]&gt;</url>
    <title>Type 2 diabetes (part 1): the management of blood glucose</title>
    <publicationDate></publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ OTHER LIFE STYLE,MEDICATION,NUTRITION AND FOOD,PHYSICAL ACTIVITY,DIABETES,TYPE 2,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Briefing (part one) provides an introduction to type 2 diabetes and focuses on lifestyle interventions and drug management of blood glucose levels. 
&lt;P&gt;This MeReC&amp;nbsp;Briefing is one of&amp;nbsp;two on the subject of&amp;nbsp;the management of people with type 2 diabetes&amp;nbsp;and it should be read together with &lt;A href="http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_briefing_no26.pdf" target="_blank"&gt;MeReC Briefing issue number 26&lt;/A&gt;. 
&lt;P&gt;The MeReC Bulletin&amp;nbsp;&lt;A href="http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_bulletin_vol15_no1.pdf" target="_blank"&gt;'Drug management of type 2 diabetes: summary'&lt;/A&gt; provides a summary of both Briefings. 
&lt;P&gt;Briefing&amp;nbsp;prepared:&amp;nbsp;Aug 2004 
&lt;P&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>61405</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_briefing_no26.pdf]]&gt;</url>
    <title>Type 2 diabetes (part 2): the management of cardiovascular risk factors</title>
    <publicationDate></publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DYSLIPIDAEMIA,HYPERTENSION,CHRONIC COMPLICATIONS,CARDIOVASCULAR,TYPE 2,DIABETES,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Briefing (part two)&amp;nbsp;focuses on&amp;nbsp;the drug management of cardiovascular risk factors, particularly blood pressure and blood lipids. 
&lt;P&gt;This MeReC&amp;nbsp;Briefing is&amp;nbsp;the second&amp;nbsp;of&amp;nbsp;two on the subject&amp;nbsp;of the management of people with type 2 diabetes and it should be read together with &lt;A href="http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_briefing_no25.pdf" target="_blank"&gt;MeReC Briefing issue number 25&lt;/A&gt;. 
&lt;P&gt;The MeReC Bulletin&amp;nbsp;&lt;A href="http://www.npc.co.uk/ebt/merec/cardio/diabetes2/resources/merec_bulletin_vol15_no1.pdf" target="_blank"&gt;'Drug management of type 2 diabetes: summary'&lt;/A&gt; provides a summary of both Briefings. 
&lt;P&gt;Briefing&amp;nbsp;prepared:&amp;nbsp;Aug 2004 
&lt;P&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>378435</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20536945]]&gt;</url>
    <title>Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced?</title>
    <publicationDate>2010-05-01T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed abstract&lt;BR&gt;"Polycystic ovary syndrome (PCOS) is a risk factor for Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD), but these risks are poorly defined.&amp;nbsp;This study aimed to evaluate the evidence for these risks and whether screening and risk reduction are feasible."&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed abstract&lt;BR&gt;"Medline reviews and data quality analysis were used using standard tools."&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed abstract&lt;BR&gt;"Results showed that (i) polycystic ovary syndrome is a risk factor for T2DM but the magnitude of risk is uncertain, (ii) fasting plasma glucose is an inadequate screening test forT2DM in this population and the oral glucose tolerance test is superior, (iii) the identification of women with PCOS for diabetes screening is constrained by current diagnostic criteria for PCOS; however, women with oligomenorrhoea and those with diagnosed PCOS and obesity or a family history of T2DM are at highest risk, (iv) risk factors for T2DM are improved by weight loss interventions and by metformin. However, no studies have determined whether T2DM incidence is reduced, (v) polycystic ovary syndrome is associated with cardiovascular disease (CVD) risk factors but data on CVD incidence are weak, (vi) risk factors for CVD are improved by the same interventions and statins and (vi) no studies have evaluated whether CVD incidence is reduced." &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; &lt;BR&gt;Taken from PubMed abstract&lt;BR&gt;"While PCOS has important metabolic associations, and short-term interventions reduce risk factors for T2DM and CVD, data on prevalence and incidence of T2DM and particularly CVD are poor. There is a need for a clear definition of PCOS, for diabetes screening protocols and for long-term studies to determine whether risks can be reduced."&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Tomlinson J, Millward A, Stenhouse E, Pinkney J.Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced? Diabetic Medicine 2010;27(5):498-515.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in May 2010.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full-text of this article online requires subscription to the&amp;nbsp;journal. NHS staff please&amp;nbsp;contact&amp;nbsp; &lt;A href="http://www.hlisd.org/" target="_blank"&gt;your local NHS library&lt;/A&gt;&amp;nbsp;for further assistance.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>83741</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Documents/Reports/obesity_0305.doc]]&gt;</url>
    <title>Type 2 diabetes and obesity : a heavy burden</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ OUTCOMES,BIOLOGICAL COMPOSITION,OBESITY,DIABETES,ENDOCRINE DISORDERS,POPULATION BASED &amp; PREVENTATIVE SERVICES,PREVENTION,OBESITY,DIABETES,TYPE 2,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,SERVICES,PREVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;report from&amp;nbsp;Diabetes UK looks at diabetes and obesity and covers the following:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The scale of the problem, the increases in prevalence and projections for the future.&amp;nbsp; 
&lt;LI&gt;How and why the two conditions are linked. 
&lt;LI&gt;Diabetes prevention studies that have been conducted in the past. 
&lt;LI&gt;Practical information on lifestyle changes which could help individuals to delay or prevent the onset of Type 2 diabetes. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt;&amp;nbsp;published March 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Word file.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as parents, families and carers. There is also a section of their website specifically for health professionals.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>61070</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/cgi/content/full/27/7/1798]]&gt;</url>
    <title>Type 2 diabetes in the young : the evolving epidemic: the international diabetes federation consensus workshop</title>
    <publicationDate>2004-07-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CHILDREN AND YOUNG PEOPLE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;/STRONG&gt;&lt;BR&gt;Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M, et al. Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care. 2004 Jul;27(7):1798-811. 
&lt;P&gt;&lt;STRONG&gt;Accessing the full&lt;/STRONG&gt; &lt;STRONG&gt;text:&lt;BR&gt;&lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317291</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19465232?ordinalpos=3&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Lancet</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CAUSES,GESTATIONAL DIABETES,PROGRESSION TO TYPE 2 DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; Women with gestational diabetes have an increased risk of developing type 2 diabetes compared with those who had normoglycaemic pregnancy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Method:&lt;/STRONG&gt; Meta-analysis of 20 cohort studies of 675,455 women and 10,858 cases of type 2 diabetes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Results:&lt;/STRONG&gt; They report a nearly 7.5 fold increased risk of developing diabetes for women who had gestational diabetes during a pregnancy. Women within 5 years of a pregnancy complicated by gestational diabetes had a relative risk of 4.69 which more than doubled to 9.34 in those who were examined more than 5 years post partum. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Citation:&lt;/STRONG&gt; Bellamy L, Casas J-P, Hingorani AD, et al Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis, Lancet 373:1738-40&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Publication history:&lt;/STRONG&gt; Published May 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Access:&lt;/STRONG&gt; Access to the full text online requires subscription to the journal. NHS Staff please contact your &lt;A href="http://www.hlisd.org/" target="_blank"&gt;local NHS library&lt;/A&gt; for further assistance.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>277100</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://annals.org/cgi/content/full/147/8/578]]&gt;</url>
    <title>Uncertain effects of Rosiglitazone on the risk for myocardial infarction and cardiovascular death</title>
    <publicationDate>2007-10-16T00:00:00</publicationDate>
    <publisher>Annals of Internal Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CARDIOVASCULAR,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT,MEDICATION,CAUSES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;/STRONG&gt; Diamond G, Bax L, Kaul S.&amp;nbsp; Uncertain effects of Rosiglitazone on the risk for myocardial infarction and cardiovascular death.&amp;nbsp; Ann Int Med 147: 578-58&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>303734</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19046235]]&gt;</url>
    <title>Unresolved issues in the management of ulcers of the foot in diabetes</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DIABETIC FOOT,CHRONIC COMPLICATIONS,CONDITION MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;BR&gt;&lt;/STRONG&gt;W. J. Jeffcoate, B. A. Lipsky, A. R. Berendt, P. R. Cavanagh,&amp;nbsp;S. A. Bus, E. J. Peters,&amp;nbsp;W. H. van Houtum, G. D. Valk, K. Bakker; International Working Group on the Diabetic&amp;nbsp;Foot&amp;nbsp;(2008) Unresolved issues in the management of ulcers of the foot in diabetes. Diabetic Medicine, 25, 1380-1389.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Summary&lt;/STRONG&gt;: This article collates the results of the 3 review working parties on soft tissue infection, osteomyelitis, offloading and other interventions designed to promote ulcer healing. It was written to demonstrate the extent and quality of the evidence currently available and the unresolved issues that remain. There is a strong plea for more sound clinical studies to be performed.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Access to the full text online requires subscription to the journal.&lt;BR&gt;&lt;BR&gt;NHS staff please contact your local NHS library for further assistance.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102660</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band134/b134-3.html]]&gt;</url>
    <title>Urine glucose testing is a waste of time</title>
    <publicationDate>2005-04-01T00:00:00</publicationDate>
    <publisher>Bandolier Journal</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,CONDITION MANAGEMENT,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Bandolier&amp;nbsp;article describes and reviews evidence (1 paper) to consider newly diagnosed type 2 diabetic patients' perceptions of self-monitoring. 
&lt;P&gt;&lt;STRONG&gt;Publication&amp;nbsp;history information:&lt;/STRONG&gt;&amp;nbsp;published&amp;nbsp;April 2005.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60162</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,168/Itemid,61/]]&gt;</url>
    <title>Use, misuse and abuse of audiovisual aids (teaching letter no.25)</title>
    <publicationDate>2002-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This teaching letter concerns the use of audiovisual aids in patient education and covers the following topics (taken from the document itself): 
&lt;UL&gt;
&lt;LI&gt;Selection of good audiovisual aids or programs 
&lt;UL&gt;
&lt;LI&gt;Necessary educational qualities 
&lt;LI&gt;Desirable technical qualities&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;How to use AV aids - if, for who, how, when, and where? 
&lt;LI&gt;Three important points 
&lt;LI&gt;The misuse of AV aids and programs&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It&amp;nbsp;is one of a &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;series of teaching letters &lt;/A&gt;for doctors and other health care professionals involved in the daily care of patients with diabetes. 
&lt;P&gt;Last updated: 2002&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301820</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/our_work_areas/user_involvement/]]&gt;</url>
    <title>User involvement - Work Area - NHS Diabetes</title>
    <publicationDate></publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT AND PUBLIC INVOLVEMENT,USER INVOLVEMENT,PPI IN PRACTICE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the National Diabetes Support Team website provides details of the work of the Working Group on user involvement, focussing on the importance of the relationship between health care professionals and people with diabetes. It includes information on direct consultation, strategic development, operational development and outcomes.&lt;BR&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>277039</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=292]]&gt;</url>
    <title>User involvement and diabetes services  - involving voices that are not normally heard</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT AND PUBLIC INVOLVEMENT,USER INVOLVEMENT,HOW DO I INVOLVE...?]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report is also described as "Involving the Uninvolved; The role of users in improving diabetes care" in the foreword. &lt;/P&gt;
&lt;P&gt;It covers&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Identifying who you want to reach 
&lt;LI&gt;Identifying the barriers 
&lt;LI&gt;Setting objectives 
&lt;LI&gt;Working with particular groups e.g. disadvantaged communities, people with disabilities, teenagers, frail older people&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published October 2007.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>284923</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=207]]&gt;</url>
    <title>User involvement and diabetes services - adults don’t always know best: involving children and young people in diabetes services</title>
    <publicationDate>2008-03-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DELIVERY OF CARE,DIABETES,SPECIALTIES,DIABETES MELLITUS,CHILD HEALTH,ENDOCRINOLOGY,PATIENT AND PUBLIC INVOLVEMENT,USER INVOLVEMENT,CHILDREN,HOW DO I INVOLVE...?]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report&amp;nbsp;from the National Diabetes Support Team (NDST) deals with&amp;nbsp; how&amp;nbsp;the NHS can provide better diabetic services to young people.&lt;/P&gt;
&lt;P&gt;It includes:&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;• Why involving children and young people is important &lt;BR&gt;• Key factors in success &lt;BR&gt;• Developing a strategy &lt;BR&gt;• Planning activities &lt;BR&gt;• Art and creative media projects &lt;BR&gt;• Questionnaires and surveys &lt;BR&gt;• Focus and discussion groups &lt;BR&gt;• Open meetings &lt;BR&gt;• Forums and reference groups &lt;BR&gt;• Young people as experts &lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;&lt;STRONG&gt;Publication History:&lt;/STRONG&gt; March 2008&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>277038</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=293]]&gt;</url>
    <title>User involvement and diabetes services - making a difference</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT AND PUBLIC INVOLVEMENT,USER INVOLVEMENT,HOW DO I INVOLVE...?]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This booklet from the National Diabetes Support Team (NDST) gives details on how users can help the NHS provide better diabetic services.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;It covers: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;finding out more and giving feedback 
&lt;LI&gt;planning better services 
&lt;LI&gt;working with others 
&lt;LI&gt;helping to monitor services 
&lt;LI&gt;getting involved at national level&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published October 2007.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>277037</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=294]]&gt;</url>
    <title>User involvement and diabetes services - self assessment checklist</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT AND PUBLIC INVOLVEMENT,USER INVOLVEMENT,DATA GATHERING AND AUDIT AND QOF,HOW DO I INVOLVE...?]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is a self-assessment tool to help diabetes networks, NHS managers and others including GPs and users to assess how service users are involved.&amp;nbsp;&amp;nbsp; &lt;BR&gt;There is advice on preparation for use of the tool and help on how to develop an action plan.&lt;/P&gt;
&lt;P&gt;The main sections of the report deal with:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;policy and strategy 
&lt;LI&gt;working with others 
&lt;LI&gt;engaging with communitiesworking with service users 
&lt;LI&gt;staff training and development 
&lt;LI&gt;action plan 
&lt;LI&gt;further information&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Publication history information:&lt;/STRONG&gt; Published October 2007.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>277036</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=295]]&gt;</url>
    <title>User involvement and diabetes services - training toolkit for primary care trusts</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT AND PUBLIC INVOLVEMENT,USER INVOLVEMENT,EDUCATION FOR PPI,MATERIALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report from the National Diabetes Support team (NDST)&amp;nbsp;gives details of the training programme covering:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;how to use the toolkit 
&lt;LI&gt;aims and objectives 
&lt;LI&gt;who the programme is for (both staff and service users) 
&lt;LI&gt;the role of facilitators 
&lt;LI&gt;delivering the programme - 4 sessions over one day or two half days 
&lt;LI&gt;reporting back &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Materials for the following four sessions are provided:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;why involve users? 
&lt;LI&gt;developing an action plan 
&lt;LI&gt;assessing the impact of user involvement 
&lt;LI&gt;setting up a user group&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published October 2007.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301354</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.desg.org/component/option,com_docman/task,doc_download/gid,184/Itemid,61/]]&gt;</url>
    <title>Visualized Discussion: What it is and how it can be used in diabetes education (teaching letter no. 36)</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Education Study Group (DESG) of the European Association for the Study of Diabetes (EASD)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,PATIENT EDUCATION AND EMPOWERMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P style="MARGIN-RIGHT: 0px" dir=ltr&gt;&lt;STRONG&gt;Aim&lt;/STRONG&gt;: "The aim of this Teaching Letter is to describe the method of Visualized Discussion as a tool for an interactive discussion about a chosen topic of interest to all participants. After reading this letter, health care providers (HCPs) should be able to:&lt;/P&gt;
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;P style="MARGIN-RIGHT: 0px" dir=ltr&gt;1. Take part in a Visualized Discussion group as a participant, contributing to the work of the group.&lt;BR&gt;2. Understand their interaction with other group members.&lt;BR&gt;3. Observe the working role of the facilitator. &lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P style="MARGIN-RIGHT: 0px" dir=ltr&gt;After a period of practice (several sessions), HCPs should be able to:&lt;/P&gt;
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;P style="MARGIN-RIGHT: 0px" dir=ltr&gt;1. Act as a rapporteur of the group’s work in a plenary session.&lt;BR&gt;2. Act as a facilitator in a Visualized Discussion work group.&lt;BR&gt;3. Organize a Visualized Discussion session, choosing a convenient and pertinent question (title) to be addressed by HCPs and/or patients.&lt;BR&gt;4. Moderate a plenary discussion between the groups attending the session.&lt;BR&gt;5. Produce a document reporting the contents of the Visualized Discussion session. The distribution and use of the final report of the working group must be agreed upon by participants from the beginning of the training process."&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;This is one of a series of &lt;A href="http://www.desg.org/component/option,com_docman/task,cat_view/gid,43/Itemid,61/" target="_blank"&gt;teaching letters&lt;/A&gt; for doctors and other health care professionals involved in the daily care of patients with diabetes. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>282031</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3051&amp;itool=AbstractPlus-def&amp;uid=18339654&amp;db=pubmed&amp;url=http://adc.bmj.com/cgi/pmidlookup?view=long&amp;pmid=18339654]]&gt;</url>
    <title>Vitamin D supplementation in early childhood and risk of type 1 diabetes : a systematic review and meta-analysis</title>
    <publicationDate>2008-03-13T00:00:00</publicationDate>
    <publisher>Archives of Disease in Childhood</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ SYSTEMATIC REVIEWS,CAUSES,PREVENTION,DIABETES,TYPE 1,DIABETES MELLITUS,SPECIALTIES,CHILD HEALTH,ENDOCRINOLOGY,STAFF USE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt;&amp;nbsp;The authors conclude that&amp;nbsp;"there is evidence from observational studies that vitamin D supplementation in infancy might be protective against the development of type 1 diabetes. Despite limitations, the Hill criteria for causality&lt;SUP&gt;38&lt;/SUP&gt; seem to be fulfilled. However, for concrete conclusions to be reached, adequately powered, randomised controlled trials with long periods of follow-up would be required to establish causality and the best formulation, dose, duration and period of supplementation."&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Full reference&lt;/STRONG&gt;:&amp;nbsp; Zipitis CS, Akobeng AK.&amp;nbsp; Vitamin D Supplementation in Early Childhood and Risk of Type 1 diabetes: a Systematic Review and Meta-analysis.&amp;nbsp; Arch Dis Child. 2008 Mar 13 [Epub ahead of print]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251151</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=251151]]&gt;</url>
    <title>What are the best ways for identifying those at risk?</title>
    <publicationDate>2007-03-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PREVENTION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Part of the National Knowledge Week for the Prevention of Type 2 Diabetes.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;What are the best ways for identifying those at risk?&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;&lt;EM&gt;&lt;FONT color=#666666&gt;Written by&amp;nbsp;R&amp;nbsp;Gadsby&lt;EM&gt;,&amp;nbsp;W Hanif &amp;amp; V Patel&lt;/EM&gt;&amp;nbsp;March 2007.&lt;BR&gt;&lt;EM&gt;&lt;FONT color=#666666&gt;Reviewed by Dr Roger Gadsby, November 2009&lt;/FONT&gt;&lt;/EM&gt;&lt;/FONT&gt;&lt;/EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387843" target="_blank"&gt;Back to Knowledge Week contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;A&amp;nbsp;systematic review from observational studies (Hartemink et al&lt;SUP&gt;1&lt;/SUP&gt;) and other observational studies (Glümer et al&lt;SUP&gt;2&lt;/SUP&gt;, Rathmann et al&lt;SUP&gt;3&lt;/SUP&gt;, Franciosi et al&lt;SUP&gt;4&lt;/SUP&gt;) confirm the following risk factors:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Obesity; having a waist circumference greater or equal to 94cm in men and 80 cm in women is associated with at least doubling of diabetes. &lt;/LI&gt;
&lt;LI&gt;Family history of diabetes; having a parent, brother or sister with diabetes is likely to mean that your chances of developing diabetes is 20% unless you are normal weight.&lt;/LI&gt;
&lt;LI&gt;Ethnicity: Some ethnic groups are associated with increased prevalence and rates of diabetes and this includes Indian, Pakistani, Bangladeshi, Afro-Caribbean and Greek Cypriot.&lt;/LI&gt;
&lt;LI&gt;Having high blood pressure and being on treatment. &lt;/LI&gt;
&lt;LI&gt;Having any condition causing furring of blood vessels and this includes heart attacks, strokes and angina.&lt;/LI&gt;
&lt;LI&gt;Age greater than 50 years.&lt;/LI&gt;
&lt;LI&gt;Diabetes during pregnancy.&lt;/LI&gt;
&lt;LI&gt;Lack of exercise.&lt;/LI&gt;
&lt;LI&gt;Low socio-economic status.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The concept of combining risk factors into ‘risk scores’ has been demonstrated by Schmidt et al&lt;SUP&gt;5&lt;/SUP&gt; and Franciosi et al&lt;SUP&gt;4&lt;/SUP&gt;.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;U&gt;References and further Information&lt;/U&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic reviews&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Systematic reviews from literature search referenced by authors:&lt;/P&gt;
&lt;P&gt;1. Hartemink N, Boshuizen HC, Nagelkerke NJD, Jacobs MAM, Van Houwelingen HC. Combining&amp;nbsp;risk&amp;nbsp;estimates&amp;nbsp;from observational studies with different exposure&amp;nbsp;cutpoints:&amp;nbsp;A&amp;nbsp;meta-analysis on body mass index and diabetes type 2. American&amp;nbsp;Journal&amp;nbsp;of Epidemiology&amp;nbsp;2006;&amp;nbsp;163 (11): 1042-1052. &lt;A href="http://aje.oxfordjournals.org/cgi/content/full/163/11/1042" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other studies&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Observational studies&amp;nbsp;referenced by authors:&lt;BR&gt;&lt;BR&gt;2.&amp;nbsp;Glümer C, Vistisen D, Borch J K, Colagiuri S. Risk scores for type 2 diabetes can be applied in some populations but not all. Diabetes Care Feb 2006; 29 (2): 410-4.&amp;nbsp;&lt;A href="http://care.diabetesjournals.org/cgi/content/full/29/2/410" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3. Rathmann W, Haastert B, Icks A, Giani G, Holle R, Meisinger C, et al. Sex differences&amp;nbsp;in the&amp;nbsp;associations&amp;nbsp;of&amp;nbsp;socioeconomic status with undiagnosed diabetes&amp;nbsp;mellitus&amp;nbsp;and impaired glucose tolerance in the elderly population: The KORA Survey 2000. European Journal of Public Health 2005;&amp;nbsp;15 (6): 627-633. &lt;A href="http://eurpub.oxfordjournals.org/cgi/content/full/15/6/627" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Franciosi M, De Berardis G, Rossi MCE, Sacco M, Belfiglio M, Pellegrini F, et al. Use&amp;nbsp;of the&amp;nbsp;Diabetes Risk Score&amp;nbsp;for&amp;nbsp;opportunistic&amp;nbsp;screening&amp;nbsp;of undiagnosed diabetes and&amp;nbsp;impaired&amp;nbsp;glucose tolerance:&amp;nbsp;the&amp;nbsp;IGLOO (Impaired&amp;nbsp;Glucose&amp;nbsp;Tolerance&amp;nbsp;and&amp;nbsp;Long-Term&amp;nbsp;Outcomes Observational) study. Diabetes&amp;nbsp;Care 2005 May; 28 (5): 1187-94. &lt;A href="http://care.diabetesjournals.org/cgi/content/full/28/5/1187" target="_blank"&gt;[full text]&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;5. Schmidt MI, Duncan BB, Bang H, Pankow JS, Ballantyne CM, Golden SH, et al. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study.&amp;nbsp;Diabetes&amp;nbsp;Care 2005&amp;nbsp;Aug; 28 (8): 2013-8. &lt;A href="http://care.diabetesjournals.org/cgi/content/full/28/8/2013" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Full literature search results &lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=388094" target="_blank"&gt;Systematic reviews and other studies organised by topic&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidelines&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?catID=5634&amp;amp;tabID=288" target="_blank"&gt;Links to supporting guidelines&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient Information&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?catID=5634&amp;amp;tabID=292&amp;amp;" target="_blank"&gt;Links to supporting patient information&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387843" target="_blank"&gt;Back to Knowledge Week contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>251158</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=251158]]&gt;</url>
    <title>What are the proven interventions at individual level? – lifestyle</title>
    <publicationDate>2007-03-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PREVENTION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Part of the National Knowledge Week for the Prevention of Type 2 Diabetes.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;What are the proven interventions at individual level? – lifestyle&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;&lt;FONT color=#666666&gt;Written by&amp;nbsp;R&amp;nbsp;Gadsby&amp;nbsp;March 2007.&lt;BR&gt;&lt;EM&gt;&lt;FONT color=#666666&gt;Reviewed by Dr Roger Gadsby, November 2009&lt;/FONT&gt;&lt;/EM&gt;&lt;/FONT&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387843" target="_blank"&gt;Back to Knowledge Week contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Two&amp;nbsp;systematic reviews&lt;SUP&gt;1,2&lt;/SUP&gt;&amp;nbsp;of randomised controlled trials (RCTs)&amp;nbsp;of lifestyle interventions in individuals at high risk of developing diabetes confirm the effectiveness of reducing weight and increasing physical activity in reducing the risk of developing diabetes.&lt;/P&gt;
&lt;P&gt;Analysis of evidence from one of the RCTs of lifestyle interventions, the Diabetes Prevention Program, suggests that it is the weight reduction element that is the most important (Hamman et al&lt;SUP&gt;3&lt;/SUP&gt;).&lt;/P&gt;
&lt;P&gt;Further evidence from another of the RCTs&lt;SUP&gt;4&lt;/SUP&gt; of lifestyle interventions, the Finnish Diabetes Prevention study, showed that beneficial lifestyle changes achieved by participants in the intervention group were maintained after the discontinuation of the intervention.&lt;/P&gt;
&lt;P&gt;&lt;U&gt;&lt;STRONG&gt;References and further Information&lt;/STRONG&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic reviews&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Systematic reviews from literature search referenced by author:&lt;STRONG&gt;&lt;U&gt;&lt;/P&gt;&lt;/U&gt;&lt;/STRONG&gt;
&lt;P&gt;1.&amp;nbsp;Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT,&amp;nbsp;et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. British&amp;nbsp;Medical&amp;nbsp;Journal 2007 Feb 10; 334 (7588): 299. &lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=17237299" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2. Patrick LJ. Review: lifestyle&amp;nbsp;education&amp;nbsp;programmes lower glucose concentrations and reduce the incidence of type 2 diabetes. Evidence-Based Nursing 2006; 9 (3): 75. [&lt;A href="http://ebn.bmj.com/cgi/content/full/9/3/75" target="_blank"&gt;full text&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other&amp;nbsp;Studies&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Other&amp;nbsp;studies from literature search referenced by author:&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006;&amp;nbsp;29 (9): 2102-7. &lt;A href="http://care.diabetesjournals.org/cgi/content/full/29/9/2102" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4. Lindström J, Ilanne PP, Peltonen M, Aunola S, Eriksson JG, Hemiö K, et al. Sustained&amp;nbsp;reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;&amp;nbsp;368 (9548): 1673-9. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=17098085&amp;amp;query_hl=1&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Full literature search results &lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=388094" target="_blank"&gt;Systematic reviews and other studies organised by topic&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidelines&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?catID=5634&amp;amp;tabID=288" target="_blank"&gt;Links to supporting guidelines&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient Information&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?catID=5634&amp;amp;tabID=292&amp;amp;" target="_blank"&gt;Links to supporting patient information&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387843" target="_blank"&gt;Back to Knowledge Week contents page&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>250833</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=250833]]&gt;</url>
    <title>What are the proven interventions at individual level? - pharmacological</title>
    <publicationDate>2007-03-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PREVENTION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Part of the National Knowledge Week for the Prevention of Type 2 Diabetes.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;What are the proven interventions at individual level? - pharmacological&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;&lt;FONT color=#666666&gt;Written by&amp;nbsp;R&amp;nbsp;Gadsby&amp;nbsp;March 2007.&lt;BR&gt;&lt;EM&gt;&lt;FONT color=#666666&gt;Reviewed by Dr Roger Gadsby, November 2009&lt;/FONT&gt;&lt;/EM&gt;&lt;/FONT&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387843" target="_blank"&gt;Back to Knowledge Week contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Can type 2 Diabetes be prevented with Pharmacological therapy? Yes, is the answer from&amp;nbsp;two well conducted systematic reviews published in the past year. One systematic review&lt;SUP&gt;1&lt;/SUP&gt; of lifestyle and pharmacotherapy concluded that there was evidence the drugs acarbose (three trials), metformin (three trials) and orlistat (two trials) reduced the rate of progression to type 2 diabetes in people with impaired glucose tolerance. They excluded the trials of troglitazone as this drug has been withdrawn due to hepatic toxicity.&lt;BR&gt;A further systematic review&lt;SUP&gt;2&lt;/SUP&gt; again concludes that metformin, troglitazone, acarbose and orlistat have been shown to reduce the risk of progression to diabetes in patients at risk for developing diabetes. The acarbose trials have also been the subject of a Cochrane review&lt;SUP&gt;3&lt;/SUP&gt;.&lt;/P&gt;
&lt;P&gt;The observation that Angiotensin-converting enzyme (ACE)&amp;nbsp;inhibitors&amp;nbsp;and Angiotensin receptor blockers (ARBs)&amp;nbsp;may reduce the occurrence of new onset diabetes has been the subject of a review and pooled analysis of 13 studies&lt;SUP&gt;4&lt;/SUP&gt; which concluded that although the data showed a reduction in new onset diabetes this needed confirmation by randomized controlled trials with the frequency of diabetes as the primary endpoint. A further review of pooled data on the ARB trials&lt;SUP&gt;5&lt;/SUP&gt; confirmed this view.&lt;/P&gt;
&lt;P&gt;The DREAM RCT&lt;SUP&gt;6 7&lt;/SUP&gt;&amp;nbsp; published in Lancet and New England Journal of&amp;nbsp;Medicine in September 2006 which looked at the onset of diabetes in people at high risk of developing the condition showed that glitazone, rosiglitazone, but not the ACE inhibitor ramipril, prevents onset of type 2 diabetes in high risk individuals.&lt;BR&gt;&lt;BR&gt;SUMMARY&lt;/P&gt;
&lt;P&gt;For the busy clinician the one paper that best sums up the knowledge to date to answer the question is Gilles et al&lt;SUP&gt;1&lt;/SUP&gt;. The DREAM RCT&lt;SUP&gt;6&lt;/SUP&gt; suggests that rosigltiazone is an additional pharmacotherapy that can reduce the development of diabetes. The controversy around whether or not ACE and ARB drugs can reduced incident diabetes is well discussed in the McCall&amp;nbsp;review&lt;SUP&gt;4&lt;/SUP&gt;. However its findings are refuted by the DREAM RCT&lt;SUP&gt;7&lt;/SUP&gt;.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;&lt;U&gt;References and further Information&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic reviews&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Systematic reviews from literature search referenced by author:&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT,&amp;nbsp;et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. British&amp;nbsp;Medical&amp;nbsp;Journal 2007 Feb 10; 334 (7588): 299. &lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=17237299" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Anderson DC Jr. Pharmacologic prevention or delay of type 2 diabetes mellitus. The&amp;nbsp;Annals of Pharmacotherapy 2005;&amp;nbsp;39 (1): 102-9. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15562143&amp;amp;query_hl=51&amp;amp;itool=pubmed_DocSum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Van de Laar FA, Lucassen PLBJ, Akkermans RP, Van de Lisdonk EH, De Grauw WJC. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD005061. DOI: 10.1002/14651858.CD005061.pub2.&amp;nbsp;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005061/frame.html" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Cheung BMY, Cheung GTY, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. Journal&amp;nbsp;of Human Hypertension 2006; 20 (1): 37-43. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16121197&amp;amp;query_hl=39&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other studies&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Other studies&amp;nbsp;referenced by author:&lt;/P&gt;
&lt;P&gt;4. McCall KL, Craddock D, Edwards K. Effect&amp;nbsp;of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis. Pharmacotherapy 2006; 26 (9): 1297-306. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?itool=abstractplus&amp;amp;db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=abstractplus&amp;amp;list_uids=16945052" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6. The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone medication) trial investigators. The effects of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006, 368: 1096-1105. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16997664&amp;amp;query_hl=36&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7. DREAM Trial Investigators; Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G,&amp;nbsp;et al. Effect of ramipril on the incidence of diabetes. The New&amp;nbsp;England Journal&amp;nbsp;of&amp;nbsp;Medicine 2006;&amp;nbsp;355 (15): 1551-62. &lt;A href="http://content.nejm.org/cgi/content/full/355/15/1551" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Full literature search results &lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=388094" target="_blank"&gt;Systematic reviews and other studies organised by topic&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidelines&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?catID=5634&amp;amp;tabID=288" target="_blank"&gt;Links to supporting guidelines&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient Information&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?catID=5634&amp;amp;tabID=292&amp;amp;" target="_blank"&gt;Links to supporting patient information&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387843" target="_blank"&gt;Back to Knowledge Week contents page&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>251171</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=251171]]&gt;</url>
    <title>What are the proven interventions at population level? - obesity prevention (diet)</title>
    <publicationDate>2007-03-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ OBESITY,OUTCOMES,BIOLOGICAL COMPOSITION,ENDOCRINE DISORDERS,DIABETES,STRATEGY,PREVENTION,OBESITY,DIABETES,TYPE 2,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,MANAGEMENT &amp; POLICY,DECISION MAKING,NATIONAL,GEOGRAPHY,PREVENTION,SETTINGS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Part of the National Knowledge Week for the Prevention of Type 2 Diabetes.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;What are the proven interventions at population level? - obesity prevention (diet)&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;&lt;FONT color=#666666&gt;Written by&amp;nbsp;S Jebb &amp;amp; T Steer&amp;nbsp;March 2007.&lt;BR&gt;&lt;EM&gt;&lt;FONT color=#666666&gt;Reviewed by Dr Roger Gadsby, November 2009&lt;/FONT&gt;&lt;/EM&gt;&lt;/FONT&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387843" target="_blank"&gt;Back to Knowledge Week contents page&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The prevalence of obesity in the UK is increasing. Data from the Health Survey for England shows that in men and women obesity increased from about 13% and 16% respectively in 1993 to just under 24% in both sexes in 2004&lt;SUP&gt;1&lt;/SUP&gt;. Even at modest degrees of overweight the risk of diabetes increases. For example, women with a BMI of just 25kg/m&lt;SUP&gt;2&lt;/SUP&gt; have over a 5-fold increased risk, whilst those with a BMI of over 35kg/m&lt;SUP&gt;2&lt;/SUP&gt; have more than a 50-fold increased risk&lt;SUP&gt;2&lt;/SUP&gt;.&lt;/P&gt;
&lt;P&gt;Given the scale of the problem, population level interventions to stabilise, then reverse obesity trends is a key factor in reducing the incidence of Type 2 diabetes. In the UK, the importance of obesity prevention was recognised in 2004 with the publication of the Government’s White Paper ‘Choosing Health’&lt;SUP&gt;3&lt;/SUP&gt;. As a result a new Public Service Agreement (PSA) target was set which aims to halt the year-on-year rise in obesity among children under 11 years by 2010, within the context of a broader population strategy. Recent NICE guidance on the management of obesity&lt;SUP&gt;4&lt;/SUP&gt; recommends implementing changes within the NHS, at the local authority level and within the pre-school, school and workplace settings to help prevent obesity.&lt;/P&gt;
&lt;P&gt;However, the evidence base for the prevention of obesity in both adults and children is small and shows a limited impact. Recent population level approaches to obesity prevention have not yet been fully evaluated, these include: initiatives such as the recent introduction of front of pack labelling for food, restrictions on the promotion of advertising of certain foods to children and the implementation of National Healthy Schools Standards which promotes a ‘whole school approach’ to healthy eating. A recent review using a modelling approach to estimate population impact used by Haby and colleagues&lt;SUP&gt;5&lt;/SUP&gt;, suggested that a reduction of TV advertising of high fat/high sugar foods would result in a BMI reduction of 0.17 per child. In contrast to the impact of walking to school schemes that would results in a BMI reduction of 0.03 per child. However, the evidence base for this type of modelling is very limited. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;U&gt;References and further Information&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;References from author:&lt;/P&gt;
&lt;P&gt;1. Health Survey for England (2005). London: Department of Health. &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/PublishedSurvey/HealthSurveyForEngland/index.htm" target="_blank"&gt;[Health Survey for England section of&amp;nbsp;DH website]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2. Chan J, Rimm E, Colditz G, Stampfer M, Willett W. Obesity, fat distribution and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17: 961-969. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=7988316&amp;amp;query_hl=39&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3. Department of Health (2004). Choosing Health: Making Healthier Choices Easier. London: The Stationery Office. &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4094550" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4. NICE (National Institute for Health and Clinical Excellence) (2006). Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. London: NICE. &lt;A href="http://guidance.nice.org.uk/CG43/?c=296726" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5. Haby M, Vos T, Carter R, Moodie M, Markwick A, Magnus A, Tay-Teo K-S, Swinburn B. A new approach to assessing the health benefit from obesity interventions in children and adolescents: the assessing cost-effectiveness in obesity project. International Journal of&amp;nbsp;Obesity 2006; 30: 1463-75. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=17003807&amp;amp;query_hl=43&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Full literature search results &lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=388094" target="_blank"&gt;Systematic reviews and other studies organised by topic&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidelines&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?catID=5634&amp;amp;tabID=288" target="_blank"&gt;Links to supporting guidelines&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient Information&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?catID=5634&amp;amp;tabID=292&amp;amp;" target="_blank"&gt;Links to supporting patient information&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387843" target="_blank"&gt;Back to Knowledge Week contents page&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>156145</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=16842475&amp;query_hl=7&amp;itool=pubmed_docsum]]&gt;</url>
    <title>What do we mean by adherence to treatment and advice for living with diabetes? A review of the literature on definitions and measurements</title>
    <publicationDate></publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 1,TYPE 2,CONDITION MANAGEMENT,CONDITION MANAGEMENT,ADHERENCE / COMPLIANCE,TREATMENT CONCORDANCE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;BR&gt;&lt;/STRONG&gt;Hearnshaw H, Lindenmeyer A. What do we mean by adherence to treatment and advice for living with diabetes? A review of the literature on definitions and measurements. Diabetic Medicine 23: 720-728.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;BR&gt;&lt;/STRONG&gt;Access to the full text online requires subscription to the journal.&lt;/P&gt;
&lt;P&gt;NHS staff please &lt;A href="http://www.hlisd.org/" target="_blank"&gt;contact your local NHS library for further assistance&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82759</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/Other%20related%20documents/142832%20IC%206pp%20Diabetes.pdf]]&gt;</url>
    <title>What is the national diabetes audit?</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>NHS Health and Social Care Information Centre</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,DATA GATHERING AND AUDIT AND QOF]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;factsheet from the&amp;nbsp;NHS Health and Social Care Information Centre website provides information about the national clinical audit for diabetes, managed by the National Clinical Audit Support Programme (NCASP). &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; published 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>60001</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/diabetes1/resources/merec_bulletin_vol13_no1.pdf]]&gt;</url>
    <title>When and how should patients with diabetes mellitus test blood glucose?</title>
    <publicationDate></publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,TYPE 1,CONDITION MANAGEMENT,CONDITION MANAGEMENT,MONITORING / SELF-MONITORING,MONITORING / SELF-MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This MeReC Bulletin summarizes the evidence for monitoring of blood glucose by patients with diabetes (excluding people with asymptomatic hypoglycaemia and pregnant women). It compares blood testing with urine testing, and explores the evidence for frequency of monitoring. 
&lt;P&gt;&lt;STRONG&gt;Publication History Information:&lt;/STRONG&gt; Bulletin prepared July 2002.&amp;nbsp; MeReC Bulletin&amp;nbsp;Volume 13 No. 1.&amp;nbsp; 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://get.adobe.com/uk/reader/" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;BR&gt;
&lt;P&gt;MeReC Publications are produced by the National Prescribing Centre (NPC) and are funded by the National Institute for Clinical Excellence (NICE).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251175</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//diabetes/ViewResource.aspx?resID=251175]]&gt;</url>
    <title>Why are some teenagers developing type 2 diabetes?</title>
    <publicationDate>2007-03-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - diabetes</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ DIABETES,TYPE 2,PREVENTION,CHILDREN AND YOUNG PEOPLE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Part of the National Knowledge Week for the Prevention of Type 2 Diabetes.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Why are some teenagers developing type 2 diabetes?&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;&lt;FONT color=#666666&gt;Written by&amp;nbsp;K Matyka&amp;nbsp;March 2007.&lt;BR&gt;&lt;EM&gt;&lt;FONT color=#666666&gt;Reviewed by Dr Roger Gadsby, November 2009&lt;/FONT&gt;&lt;/EM&gt;&lt;/FONT&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387843" target="_blank"&gt;Back to Knowledge Week contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Type 2 diabetes has long been regarded a disease of adult middle age. Yet recent data from North America and South East Asia have suggested that type 2 diabetes is increasing in prevalence in childhood and can occur in children as young as five years of age&lt;SUP&gt;1&lt;/SUP&gt;. It is felt that the rising tide of type 2 diabetes in childhood is due to the dramatic rise in childhood obesity. Data from a number of sources suggest that the majority of children with Type 2 diabetes are obese&lt;SUP&gt;1 2&lt;/SUP&gt;. They are also likely to come from ethnic backgrounds especially Hispanics and South Asians. &lt;/P&gt;
&lt;P&gt;Recent data which show the extent of the problem of obesity are extremely frightening&lt;SUP&gt;3&lt;/SUP&gt;. An analysis of the National Childhood Obesity Database (2005-2006) suggest that 12.3% of girls and 13.4% of boys in reception year are overweight, and 9.2% of girls and 10.7% of boys in the same year group were found to be obese. Of children in year 6, 13.8% of boys and girls were overweight, and 15.4% of girls and 18.9% of boys were obese&lt;SUP&gt;3&lt;/SUP&gt;. Not all of these children will develop Type 2 diabetes yet if even a significant minority of these children did this would create a huge burden for the NHS. &lt;/P&gt;
&lt;P&gt;It is likely that both genetic and environmental influences are important in the development of Type 2 diabetes. Type 2 diabetes has a very strong pattern of familial inheritance. Yet people living in the same family will share the same food and have also been shown to share the same approach to physical activity. It is possible that changes in nutrition and patterns of activity could increase the risk of diabetes per se irrespective of the presence of obesity. There are few data in childhood but studies of adults suggest that physical activity does improve insulin sensitivity and may decrease the risk of developing diabetes even with no impact on weight loss&lt;SUP&gt;4&lt;/SUP&gt;. Other studies suggest that nutrition, especially in early childhood and especially breast feeding impact on the development of diabetes and obesity&lt;SUP&gt;5&lt;/SUP&gt;. However, those families who have a healthy approach to eating from the start are likely to continue in this way and it is difficult to know if any ‘deficiencies’ in early life can be remedied by a healthier lifestyle later on.&amp;nbsp; Even earlier life may be important with studies of maternal health during pregnancy suggesting that maternal diabetes can predispose to diabetes in the child in later life&lt;SUP&gt;6&lt;/SUP&gt;.&lt;/P&gt;
&lt;P&gt;It is likely therefore that an unhealthy lifestyle in someone who has a genetic predisposition will lead to diabetes, possibly during childhood. Type 2 diabetes in childhood appears to be extremely difficult to manage with depressingly poor outcomes in young adult life. Finding a successful way of preventing obesity, and hence diabetes, in childhood is essential if we are to protect the lives of future generations of children. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;U&gt;&lt;BR&gt;References and further Information&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Systematic Reviews&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Systematic reviews&amp;nbsp;referenced by author:&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;Vivian Eva M. Type 2 diabetes in children and adolescents--the next epidemic? Current Medical&amp;nbsp;Research and Opinion 2006; 22: 297-306. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16466601&amp;amp;query_hl=29&amp;amp;itool=pubmed_DocSum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Owen CG, Martin RM, Whincup PH,&amp;nbsp;Smith GD, Cook DG. Does&amp;nbsp; breastfeeding influence risk of type 2 diabetes in later life? A quantitative analysis of published evidence. The&amp;nbsp;American&amp;nbsp;Journal&amp;nbsp;of&amp;nbsp;Clinical&amp;nbsp;Nutrition 2006; 84: 1043-54. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?itool=abstractplus&amp;amp;db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=abstractplus&amp;amp;list_uids=17093156" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other&amp;nbsp;Studies&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Other&amp;nbsp;studies&amp;nbsp;referenced by author:&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Ehtisham S, Kirk J, McEvilly A, Shaw N, Jones S, Rose S, et al. Prevalence of type 2 diabetes in children in Birmingham. BMJ 2001; 322: 1428. &lt;A href="http://www.bmj.com/cgi/content/full/322/7299/1428/b" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Review of National Child Obesity Database. Department of Health; National Height and Weight Programme; Project Support Team. 2006. &lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH_4139029" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Knowler WC, Barrett CE, Fowler SE, Hamman RF, Lachin JM, Walker EA,&amp;nbsp;et al. Reduction in the&amp;nbsp;incidence&amp;nbsp;of&amp;nbsp;type&amp;nbsp;2&amp;nbsp;diabetes&amp;nbsp;with&amp;nbsp;lifestyle intervention or metformin. The&amp;nbsp;New England Journal of Medicine 2002;&amp;nbsp;346 (6): 393-403. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=11832527&amp;amp;query_hl=7&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Fetita LS, Sobngwi E, Serradas P, Calvo F, Gautier JF. Consequences of fetal exposure to maternal diabetes in offspring. The&amp;nbsp;Journal&amp;nbsp;of&amp;nbsp;Clinical&amp;nbsp;Endocrinology&amp;nbsp;and&amp;nbsp;Metabolism 2006; 19: 3718-3724. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16849402&amp;amp;query_hl=21&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Full literature search results &lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=388094" target="_blank"&gt;Systematic reviews and other studies organised by topic&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidelines&lt;BR&gt;&lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?catID=5634&amp;amp;tabID=288" target="_blank"&gt;Links to supporting guidelines&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient Information&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/diabetes/SearchResults.aspx?catID=5634&amp;amp;tabID=292&amp;amp;" target="_blank"&gt;Links to supporting patient information&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/diabetes/viewResource.aspx?resid=387843" target="_blank"&gt;Back to Knowledge Week contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>270572</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/document.php?o=213]]&gt;</url>
    <title>Workforce planning and development in diabetes</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,COMMISSIONING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Diabetes Workforce Strategy&amp;nbsp;aims to ensure that diabetes services across England are supported to deliver high quality patient care.&amp;nbsp;This means having sufficient numbers of people with the appropriate skills and competences who have access to relevant training and education opportunities. &lt;BR&gt;The&amp;nbsp;document is aimed at diabetes networks, commissioners of services and provider organisations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published&amp;nbsp;September 2007&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public. Portable Document File / PDF requiring &lt;A href="http://www.adobe.com/products/acrobat/readstep2.html" target="_blank"&gt;Adobe Acrobat Reader&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>334506</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.cfwi.org.uk/intelligence/previous-projects/workforce-summaries/diabetes-and-endocrinology/at_download/attachment1]]&gt;</url>
    <title>Workforce Summary – Diabetes and Endocrinology</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>NHS Workforce Review Team</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,ORGANISATION OF CARE / CARE PLANNING,COMMISSIONING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Workforce Review Team have reviewed the current workforce in the areas of endocrinology and diabetes in England.&amp;nbsp; This document summarises the findings of this analysis&amp;nbsp;and includes dicussion points and data on: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;the pattern of training 
&lt;LI&gt;the current workforce including age profile 
&lt;LI&gt;demand drivers 
&lt;LI&gt;workforce supply&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public, the link provided here takes you to the workforce review list, please select the Diabetes and Endocrinology summary from the list.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>341989</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.cfwi.org.uk/intelligence/previous-projects/workforce-summaries/retinal-screeners/at_download/attachment1]]&gt;</url>
    <title>Workforce Summary – Retinal Screeners</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>NHS Workforce Review Team</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RETINOPATHY,DELIVERY OF CARE,CHRONIC COMPLICATIONS,ORGANISATION OF CARE / CARE PLANNING,EYE DISEASES,COMMISSIONING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Workforce Review Team have reviewed the current retinal screening workforce in England.&amp;nbsp; This document summarises the findings of this analysis&amp;nbsp;and includes dicussion points and data on: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;the pattern of training 
&lt;LI&gt;the current workforce including age profile 
&lt;LI&gt;demand drivers 
&lt;LI&gt;workforce supply&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public, the link provided here takes you to the workforce review list, please select the Diabetes and Endocrinology summary from the list.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346725</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_074702]]&gt;</url>
    <title>Working together for better diabetes care : clinical case for change</title>
    <publicationDate>2007-05-16T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ SELF MANAGEMENT,INDIVIDUAL INVOLVEMENT,PPI IN PRACTICE,PATIENT AND PUBLIC INVOLVEMENT,ORGANISATION OF CARE / CARE PLANNING,DELIVERY OF CARE,DIABETES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The national director for diabetes sets out how services are changing to meet the needs of patients, and how they need to change in the future. Clinicians in primary and secondary care need to work together and work in partnership with patients to improve care for people with diabetes.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published on 16th May 2007.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>83820</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://care.diabetesjournals.org/cgi/content/full/27/1/155]]&gt;</url>
    <title>XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study : a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients</title>
    <publicationDate>2004-01-01T00:00:00</publicationDate>
    <publisher>Diabetes Care, American Diabetes Association</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,RESEARCH,GROUND-BREAKING ARTICLES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Full reference:&lt;BR&gt;&lt;/STRONG&gt;Torgerson JS, Hauptman J, Boldrin M, Sjostrom L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.&amp;nbsp;Diabetes Care.&amp;nbsp;2004 Jan; 27(1): 155-61. 
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377754</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.org.uk/Professionals/Service-improvement/Year-of-Care/]]&gt;</url>
    <title>Year of Care (information for health professionals)</title>
    <publicationDate>2008-12-10T00:00:00</publicationDate>
    <publisher>Diabetes UK</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the&amp;nbsp;Diabetes UK&amp;nbsp;website provides information about&amp;nbsp;the Year of Care, a new way of providing care to people with long-term conditions. It is&amp;nbsp;aimed at health professionals.&amp;nbsp; It contains the sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Year of Care concept 
&lt;LI&gt;Year of Care programme 
&lt;LI&gt;Support for Year of Care 
&lt;LI&gt;Keeping in touch with Year of Care&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;Diabetes UK is a charity which provides information about diabetes. Their website's&amp;nbsp;intended audience is people with diabetes, as well as health professionals, parents, families and carers.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296779</id>
    <name>&lt;![CDATA[ Diabetes]]&gt;</name>
    <rootDirectory>/diabetes</rootDirectory>
    <url>&lt;![CDATA[http://www.diabetes.nhs.uk/year_of_care/]]&gt;</url>
    <title>Year of Care for diabetes - NHS Diabetes</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>NHS Diabetes</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DIABETES,DELIVERY OF CARE,KEY POLICIES / NSF,ORGANISATION OF CARE / CARE PLANNING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This section of the&amp;nbsp;NHS Diabetes&amp;nbsp;website provides details of the Year of Care programme for diabetes.&amp;nbsp; A description of the background to the Year of Care concept is provided including details of who is involved and what the project is hoping to achieve.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
</documents>